<SEC-DOCUMENT>0001628280-22-026728.txt : 20221020
<SEC-HEADER>0001628280-22-026728.hdr.sgml : 20221020
<ACCEPTANCE-DATETIME>20221020100043
ACCESSION NUMBER:		0001628280-22-026728
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		23
FILED AS OF DATE:		20221020
DATE AS OF CHANGE:		20221020

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Biohaven Ltd.
		CENTRAL INDEX KEY:			0001935979
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-267928
		FILM NUMBER:		221320199

	BUSINESS ADDRESS:	
		STREET 1:		215 CHURCH STREET
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203-404-0410

	MAIL ADDRESS:	
		STREET 1:		215 CHURCH STREET
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Biohaven Research Ltd.
		DATE OF NAME CHANGE:	20220629
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>biohavenltd-sx1a1.htm
<DESCRIPTION>S-1/A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibbeb41436b1c46838ddd18c39bc90b9a_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">As filed with the U.S. Securities and Exchange Commission on October 20, 2022</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registration No. 333-267928</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT NO. 1</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TO </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM S-1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">REGISTRATION STATEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">UNDER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">THE SECURITIES ACT OF 1933</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">British Virgin Islands</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2834</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Not Applicable</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation or organization)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Primary Standard Industrial Classification Code Number)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification Number)</font></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">c&#47;o Biohaven Pharmaceuticals, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">215 Church Street</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">New Haven, Connecticut 06510</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(203) 404-0410</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Vlad Coric, M.D.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Biohaven Ltd.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">215 Church Street</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">New Haven, Connecticut 06510</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(203) 404-0410</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Copies of Communications to&#58;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Robert W. Downes</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Sullivan &#38; Cromwell LLP</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">125 Broad Street</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">New York, NY 10004</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(212) 558-4000</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">William Michener</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Ropes &#38; Gray LLP</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Prudential Tower</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">800 Boylston Street</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Boston, MA 02199</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(617) 951-7000</font></div></td></tr></table></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approximate date of commencement of proposed sale to the public&#58; As soon as practicable after the effective date of this registration statement.</font></div></td></tr></table></div><div style="margin-bottom:4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933 check the following box. &#9744;</font></div><div style="margin-bottom:4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</font></div><div style="margin-bottom:4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</font></div><div style="margin-bottom:4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</font></div><div style="margin-bottom:3pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Large accelerated filer &#9744;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accelerated filer &#9744;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Non-accelerated filer&#160;&#9746;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Smaller reporting company &#9746;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Emerging growth company &#9746;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9746;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section&#160;8(a), may determine.</font></div></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font><br></font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_4"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#f1665f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBJECT TO COMPLETION, DATED OCTOBER 20, 2022</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(a British Virgin Islands business company)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">20,000,000 Shares</font></div><div style="margin-bottom:12pt;text-align:center"><img alt="picture1.jpg" src="picture1.jpg" style="height:57px;margin-bottom:5pt;vertical-align:text-bottom;width:327px"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Common Shares</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biohaven Ltd. is selling 20,000,000 of its common shares in this offering. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our shares trade on The New York Stock Exchange under the symbol &#8220;BHVN.&#8221; On October&#160;19, 2022, the last sale price of the shares as reported on the New York Stock Exchange was $12.40 per share.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing in our common shares involves risks that are described in the &#8220;Risk Factors&#8221; section beginning on page&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> of this prospectus.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Per Share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public offering price</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$          </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$            </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underwriting discounts and commissions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$          </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$            </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds before expenses</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$          </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$            </font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) We have agreed to reimburse the underwriters for certain expenses in connection with this offering. See &#8220;Underwriting.&#8221;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters may also exercise their option to purchase up to an additional&#160;3,000,000&#160;common shares from us, at the public offering price, less the underwriting discount, for 30 days after the date of this prospectus.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vlad Coric, our Chief Executive Officer, Matthew Buten, our Chief Financial Officer, and certain of our directors and their affiliated funds have indicated an interest in purchasing approximately $100 million, in the aggregate, of our common shares in this offering at the public offering price. Dr. Coric and Mr. Buten have indicated an interest in purchasing approximately $10 million and $1 million of those common shares, respectively. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no shares to each of Dr. Coric, Mr. Buten or our directors and their affiliated funds, and any of such persons or their affiliated funds could determine to purchase more, fewer or no shares in this offering.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common shares will be ready for delivery on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2022.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">J.P. Morgan</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2022.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_10" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PROSPECTUS SUMMARY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_10" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">RISK FACTORS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_22" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_22" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">56</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">INDUSTRY AND MARKET DATA</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">58</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_28" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">USE OF PROCEEDS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_28" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">59</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DIVIDEND POLICY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">60</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">CAPITALIZATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_37" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DILUTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_37" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">62</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">71</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">BUSINESS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">90</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">MANAGEMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">137</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_64" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EXECUTIVE COMPENSATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_64" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">145</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_67" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_67" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">156</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_70" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PRINCIPAL SHAREHOLDERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_70" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">158</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DESCRIPTION OF SHARES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">160</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">SHARES ELIGIBLE FOR FUTURE SALE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">170</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_79" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_79" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">171</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_82" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">UNDERWRITING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_82" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">177</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">VALIDITY OF THE SECURITIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">189</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EXPERTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">189</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_91" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">WHERE YOU CAN FIND ADDITIONAL INFORMATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_91" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">190</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_94" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">INDEX TO COMBINED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_94" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_94" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental publications, reports by market research firms or other independent sources. Some data are also based on our good faith estimates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not authorized, and the underwriters have not authorized, anyone to provide you with information other than the information contained in this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any information that others may give you. The information contained in this prospectus is accurate only as of the date hereof, regardless of the time of delivery of this prospectus or of any sale of our common shares. It is important for you to read and consider all information contained in this prospectus in making your investment decision. You should also read and consider the information in the documents to which we have referred you in the sections entitled &#8220;Where You Can Find Additional Information&#8221; in this prospectus.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are offering to sell, and seeking offers to buy, our common shares only in jurisdictions where offers and sales are permitted. The distribution of this prospectus and the offering of the common shares in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering of the common shares and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS SUMMARY</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common shares. You should read this entire prospectus carefully, including the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and our combined financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless expressly indicated or the context requires otherwise, the terms &#8220;Biohaven,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; in this prospectus refer to Biohaven Ltd., a business company limited by shares incorporated under the laws of the British Virgin Islands (&#8220;BVI&#8221;), and its subsidiaries, including as a business of Biohaven Pharmaceutical Holding Company Ltd. (the &#8220;Former Parent&#8221;) to the extent the context requires. All references to &#8220;Pfizer&#8221; refer to Pfizer Inc., a Delaware corporation. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spin-Off from Biohaven Pharmaceutical Holding Company Ltd.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biohaven Ltd. was incorporated on May&#160;2, 2022 as a direct, wholly owned subsidiary of the Former Parent. On October 3, 2022, the Former Parent completed the distribution (the &#8220;Distribution&#8221;) to holders of its common shares of all of the outstanding common shares of the Company and the spin-off of Biohaven from the Former Parent (the &#8220;Spin-Off&#8221;) was completed. Immediately following the Spin-Off, the Former Parent and Pfizer Inc. (&#8220;Pfizer&#8221;) consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 9, 2022 (the &#8220;Merger Agreement&#8221;), by and among the Former Parent, Pfizer and a wholly owned subsidiary of Pfizer, pursuant to which Pfizer acquired the Former Parent (the &#8220;Merger&#8221;). Each holder of Former Parent common shares received one common share of Biohaven for every two Former Parent common shares held of record as of the close of business, New York City time, on September 26, 2022. In the Distribution, an aggregate of 35,832,557 Biohaven common shares were issued. The aggregate number of common shares issued in connection with the Distribution did not include 2,611,478 common shares to be issued in connection with Former Parent stock options that were exercised on October 3, 2022 and 924,093 common shares to be issued in connection with Former Parent Restricted Stock Units that vested on October 3, 2022. As of October 14, 2022, an aggregate of 39,375,944 Biohaven common shares were issued and outstanding. As of October 3, 2022, we had approximately $257.8 million in cash.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Distribution, we now own clinical stage assets, including the Kv7 ion channel activators, glutamate modulation and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure previously owned by the Former Parent (the &#8220;Biohaven Business&#8221;) and have proprietary rights to a number of trademarks used in this prospectus which are important to our business, including the Biohaven logo.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biohaven Ltd. is a business company limited by shares incorporated under the laws of the BVI. We are a clinical-stage biopharmaceutical company that combines a deep understanding of neuroscience, immunology, disease-related biology, advanced chemistry and expertise in global clinical trials to advance novel therapies for patients. Our experienced management team brings with it a proven track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia, and our research programs, built on a deep understanding of disease-related biology and neuropharmacology, are advancing novel therapies with target indications, including epilepsy, mood disorders, Obsessive-Compulsive Disorder (&#8220;OCD&#8221;), Spinocerebellar Ataxia (&#8220;SCA&#8221;), Spinal Muscular Atrophy (&#8220;SMA&#8221;) and pain disorders. Our neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7 ion channels (&#8220;Kv7&#8221;), glutamate receptors, myostatin, and transient receptor potential (&#8220;TRP&#8221;) channels. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing our broad and diverse pipeline with at least five clinical trials currently underway or expected to start by the end of 2022. We have built a highly experienced team of senior leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with capabilities in drug discovery and development. In addition, we have several preclinical assets in our early discovery program, targeting neuroscience and immunology indications.</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses for the fiscal years ended December 31, 2021 and 2020 were $213.8 million and $118.7 million, respectively. Our net losses for the six months ended June 30, 2022 and 2021 were $300.3 million and $107.5 million, respectively. Our net losses reflect the early-stage (pre-revenue) nature of our core clinical-stage biopharmaceutical business.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Candidates</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes some of our key clinical programs in addition to upcoming potential clinical development milestones for our product candidates. We hold the worldwide rights to all of our product candidates. See the section entitled &#8220;Business&#8221; included in this prospectus for an in-depth discussion of our development programs and product candidates.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="octoberswimlane.jpg" src="octoberswimlane.jpg" style="height:162px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to develop innovative therapies for neurological and immunological diseases that have the potential to change current treatment paradigms. The key elements of our strategy to achieve this goal include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Establish our position as a leader in neuroscience drug discovery and development through the advancement of a diverse and innovative pipeline, including our Kv7 targeting and glutamate modulating platforms. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We leverage our differentiated understanding of neuroscience as well as our proven innovative clinical trial design and execution to develop our assets across multiple indications. In addition, we are investing in future areas of neuroscience and immunoscience research, including the discovery and development of compounds with disease-modifying potential.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Rapidly develop our clinical-stage neurology and neuropsychiatry assets, with at least five clinical trials either underway or expected to start by the end of 2022. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Focus development efforts on our recently acquired Kv7 platform by advancing BHV-7000 to at least one Phase 2&#47;3 registrational trial in 2023. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Phase 1 study with BHV-7000 is currently underway and we expect results by the first half of 2023. If our Phase 1 study with BHV-7000 is successfully completed, we expect to initiate at least one pivotal trial in patients with epilepsy in the second half of 2023.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Advance our early discovery portfolio across multiple neuroscience and immunoscience indications.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our preclinical pipeline includes molecular degraders of extracellular proteins, CD38 targeting antibody recruiting molecules (ARMs), TRP channels, TDP-43 targeting small molecules, and other undisclosed targets, including those with disease-modifying potential. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Efficiently allocate capital to maximize the impact of our assets.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We seek to efficiently allocate capital with the goal of step-wise value creation&#58; driving speed to proof-of-principle, speed to proof-of-concept and speed to market. For example, our early-stage clinical trials are designed to elucidate the potential of our compounds and inform future clinical trials, thereby strengthening our probability of success and our efficiency in bringing our therapies to patients. We aim to be resource- and capital-efficient in the development of our product candidates by selectively accessing complementary expertise and infrastructure through strategic partnerships or other collaborations. We believe that our drug development team with particular experience in neuroscience and immunoscience have a differential ability to identify high-</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential assets for acquisition or in-licensing to unlock their full value. We plan to opportunistically pursue such assets from time to time and strategically expand our portfolio.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Opportunistically match sources and uses of capital.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our broad portfolio both requires and provides a basis for diverse financing options. We will seek to maximize growth opportunities, which may include raising additional capital through a combination of private or public equity offerings, debt financings, collaborations, strategic alliances, marketing, distribution or licensing arrangements with third parties or through other sources of financing. By matching sources and uses of capital, we can maximize our value creation opportunities while mitigating operational risk through partnerships.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Maximize the commercial potential of our product candidates and bring new therapies to underserved patient populations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development and commercialization strategy will be driven by our understanding of existing treatment paradigms along with patient, physician and payor needs. We expect to build a focused and efficient medical affairs and commercial organization to maximize the commercial potential of our portfolio. Our current plan is to commercialize our product candidates, if approved, in the United States and international markets, either alone or in collaboration with others.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Team</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled a seasoned management team with expertise in clinical research, development, regulatory affairs, medical affairs, operations, manufacturing, commercialization and financing. Our team includes industry veterans who have collectively driven numerous drug approvals, with prior experience at large pharmaceutical companies and a demonstrated ability to operate in smaller, more efficient organizations to drive value for investors. We have an experienced research and development team focused on utilizing our differentiated understanding of the complexity of human drug development including an advanced understanding of neuroscience and immunoscience, receptor pharmacology and genetics that underlie many diseases. This allows us to develop investigational agents with target selectivity and indication-appropriate pharmacology, which we believe are key to enhancing activity and improving tolerability in the treatment of these diseases. We believe that the distinctive combination of our proven management team and our existing pipeline has the potential to bring to patients the next generation of transformative neuroscience therapies.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in our common shares is subject to a number of risks, including risks related to our product candidates, risks related to our business and risks related to our common shares. The following list of risk factors is not exhaustive. Please read the information in the section captioned &#8220;Risk Factors&#8221; for a more thorough description of these and other risks.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Development of Our Product Candidates</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend entirely on the success of a limited number of product candidates.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trials are very expensive, time consuming and difficult to design and implement, involve uncertain outcomes and may not be predictive of results of future trials. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory approval processes in the U.S. and foreign jurisdictions are lengthy, time consuming and unpredictable.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates may fail to demonstrate safety and efficacy in clinical trials, or may cause serious adverse or unacceptable side effects.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may become exposed to costly and damaging liability claims, which may not be covered by insurance.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have never commercialized a product candidate and may lack the necessary expertise, personnel and resources to successfully commercialize any product candidate that may receive regulatory approval.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We operate in a highly competitive and rapidly changing industry.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to obtain or maintain adequate coverage and reimbursement for our approved product candidates could limit our ability to market those products and decrease our ability to generate revenue.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates, if approved, will be subject to ongoing regulatory oversight.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our approved product candidates may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history, have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An inability to raise capital when needed or on terms favorable to us could force us to curtail our planned operations and growth strategy.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct our preclinical studies and clinical trials and to supply, manufacture and distribute clinical drug supplies for our product candidates, which may expose our business to risks.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not establish or maintain collaborations with third parties to develop or commercialize product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Regulatory Compliance</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business operations and relationships with investigators, health care professionals, consultants, third-party payors and customers are subject to federal and state healthcare and other laws. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not obtain or maintain orphan drug designation or exclusivity for our product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We could lose market exclusivity earlier than expected.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we were unable to obtain licenses from third parties on commercially reasonable terms or lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing our product candidates.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patent terms may not provide exclusivity for our product candidates for an adequate amount of time to realize sufficient commercial benefits.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties may seek to invalidate our patents.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Business Operations, Employee Matters and Managing Growth</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future growth and ability to compete depend on, among other things, retaining key personnel and recruiting additional qualified personnel and on our ability to penetrate foreign markets.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Laws and regulations governing our international operations may preclude us from developing, manufacturing and selling certain product candidates and products outside of the United States and require us to develop and implement costly compliance programs.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing our growth, which could disrupt our operations.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs and vendors may engage in improper activities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Shares</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Substantially all of our total outstanding shares may be sold freely into the market. This could cause the market price of our common shares to drop significantly, even if our business is doing well.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because we do not expect to pay dividends on our common shares in the foreseeable future, capital appreciation, if any, would be your sole source of gain.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trading price of our common shares may be volatile and may fluctuate.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are or become a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. holders.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our historical financial results as a part of Former Parent and our unaudited pro forma combined financial statements may not be representative of our results as a separate, stand-alone company.</font></div><div style="margin-bottom:9pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to this Offering</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have broad discretion in the use of net proceeds from this offering.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You will experience dilution as a result of this offering, which may adversely affect the per share trading price of our common shares.</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Information</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a business company limited by shares incorporated under the laws of the BVI. Our registered office is located at Kingston Chambers, P.O. Box 173, Road Town, Tortola, British Virgin Islands. Our U.S. office is located at 215 Church Street, New Haven, CT 06510 with additional facilities in Yardley, PA, Pittsburgh, PA, and New Haven, CT. Our telephone number is (203) 404&#8209;0410 and our website address is www.biohaven.com. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in making an investment decision regarding our common shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solely for convenience, the trademarks and trade names in this prospectus are referred to without the &#174; and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implications of Being an Emerging Growth Company</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We qualify as an emerging growth company as defined in the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;), enacted in 2012. As an emerging growth company, we expect to take advantage of reduced reporting requirements otherwise applicable to public companies. These provisions include, but are not limited to&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to comply with the auditor attestation requirements of Section 404 of the&#160;Sarbanes&#8209;Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;)&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely on the relief provided by these provisions until the last day of our fiscal year following the fifth anniversary of the completion of the Distribution. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), our annual gross revenues exceed $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our shareholders may be different than you might receive from other public reporting companies in which you hold equity interests.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 107 of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implications of Being a Smaller Reporting Company</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Rule 12b-2 under the Exchange Act. As such, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not smaller reporting companies, including, but not limited to, reduced disclosure obligations regarding executive compensation. We will continue to be a smaller reporting company as long as either (i) the market value of our common shares held by non-affiliates is less than $250 million as of the last business day of our most recently completed second fiscal quarter or (ii) our annual revenue is less than $100 million during the most recently </font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completed fiscal year and the market value of our common shares held by non-affiliates is less than $700 million as of the last business day of our most recently completed second fiscal quarter.</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:0.50pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE OFFERING</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biohaven Ltd.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares outstanding before this offering</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,375,944 shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares offered by us</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000,000 shares (or 3,000,000 common shares if the underwriters exercise in full their option to purchase additional common shares).</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares to be outstanding immediately after this offering</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,375,944 shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (or 62,375,944 common shares if the underwriters exercise in full their option to purchase additional common shares).</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Use of proceeds</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We estimate that our net proceeds from this offering will be approximately $233.1 million (or approximately $268.1 million if the underwriters exercise their option to purchase additional common shares in full), after deducting the underwriting discount and prior to paying any offering expenses, based on an offering price of $12.40 per share (the closing price for our common shares on the New York Stock Exchange (&#8220;NYSE&#8221;) on October&#160;19, 2022).</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We intend to use the net proceeds that we receive in this offering for general corporate purposes.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See &#8220;Use of Proceeds&#8221; for further details.</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend policy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We do not expect to pay any cash dividends on our common shares in the foreseeable future. All decisions regarding the payment of dividends will be made by our Board of Directors (our &#8220;Board&#8221;) from time to time in accordance with applicable law.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insider participation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vlad Coric, our Chief Executive Officer, Matthew Buten, our Chief Financial Officer, and certain of our directors and their affiliated funds have indicated an interest in purchasing approximately $100 million, in the aggregate, of our common shares in this offering at the public offering price. Dr. Coric and Mr. Buten have indicated an interest in purchasing approximately $10 million and $1 million of those common shares, respectively. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no shares to each of Dr. Coric, Mr. Buten or our directors and their affiliated funds, and any of such persons or their affiliated funds could determine to purchase more, fewer or no shares in this offering.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk factors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Please read the section entitled &#8220;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Risk Factors</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; beginning on page&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of this prospectus for a discussion of some of the factors you should carefully consider before deciding to invest in our common shares.</font></div></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160; The number of shares is based on the number outstanding as of October 14, 2022 and does not include&#58;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:15.2pt">9,110,000 common shares issuable upon the exercise of stock options outstanding as of October 14, 2022, at an exercise price of $7 per share&#59;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:15.2pt">80,000 common shares reserved for future issuance of awards under our 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;)&#59; and</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:15.2pt">393,769 common shares reserved for future issuance under our 2022 Employee Share Purchase Plan (the &#8220;ESPP&#8221;).</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:0.50pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY HISTORICAL AND UNAUDITED PRO FORMA COMBINED FINANCIAL DATA</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our summary historical and unaudited pro forma combined financial data as of the dates and for the periods presented. The summary historical combined financial data of the Company as of and for the years ended December 31, 2021 and 2020, were derived from the audited combined financial statements of the Company, which are included elsewhere in this prospectus. We derived the summary historical combined financial data as of and for the six months ended June 30, 2022 from our unaudited condensed combined financial statements included elsewhere in this prospectus. The summary combined financial data presented below should be read in conjunction with the audited and unaudited combined financial statements and related notes included elsewhere in this prospectus, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results Operations&#8221; and &#8220;Unaudited Pro Forma Combined Financial Information.&#8221; </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary historical combined financial data does not necessarily reflect what our results of operations and financial position would have been if we had operated as a separate publicly traded entity during all periods presented, including changes that will occur in our operations and capitalization as a result of the Distribution. Accordingly, the historical results should not be relied upon as an indicator of our future performance.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited pro forma combined statement of operations data for the year ended December 31, 2021 and the six months ended June 30, 2022 assumes that the Spin-Off and Distribution occurred as of January 1, 2021. The unaudited pro forma combined balance sheet as of June 30, 2022 gives effect to the Spin-Off and the Distribution as if it had occurred on June 30, 2022. The unaudited transaction accounting and autonomous entity adjustments are based on assumptions that management believes are reasonable under the circumstances and given the information available at this time. The summary unaudited pro forma combined financial information is for illustrative and informational purposes only and does not purport to represent what the financial position or results of operations would have been if the Company had operated as an independent company during the periods presented or if the transactions described therein had actually occurred as of the date indicated, nor does it project the financial position at any future date or the results of operations for any future period. See the notes to the unaudited pro forma combined financial statements included elsewhere in this prospectus for a discussion of adjustments reflected in the unaudited pro forma combined financial statements.</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pro Forma</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Historical</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Statement of Operations Data&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands)</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,172&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,486&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,460&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,223&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,414&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,046&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,829)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,796)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,668)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pro Forma</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Historical</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Statement of Operations Data&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands)</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,884&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,183&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,695&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,522&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,700&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,830&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314,322)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300,319)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,545)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:0.50pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pro Forma</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Historical</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Balance Sheet Data&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands)</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,799&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,209&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,131&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,099)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,810&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,220&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,582&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,222&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We define working capital as current assets less current liabilities.</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In connection with any investment decision with respect to our securities, you should carefully consider the risk factors described below, as well as general economic and business risks and the other information contained in this prospectus. The occurrence of any of the events or circumstances described below or other adverse events could have a material adverse effect on our business, results of operations and financial condition and could cause the trading price of our common shares to decline. Additional risks or uncertainties not presently known to us or that we currently deem immaterial may also harm our business.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history and have never generated any product revenues, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated on May 2, 2022 as a direct, wholly-owned subsidiary of Former Parent. Our operations to date have been largely focused on organizing and staffing, raising capital and in-licensing the rights to, and advancing the development of, our product candidates, including conducting preclinical studies and clinical trials. We have not yet demonstrated an ability to obtain marketing approvals for any product candidates, manufacture products on a commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. We will need to eventually transition from a company with a research and development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays, and may not be successful in such a transition.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since our inception as a business of Former Parent and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception as a business of Former Parent, we have incurred significant operating losses. Our net loss was&#160;$213.8 million&#160;for the year ended&#160;December&#160;31, 2021 and $300.3 million for the six months ended June 30, 2022. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. None of our product candidates has been approved for marketing in the United States, or in any other jurisdiction, and may never receive such approval. It could be several years, if ever, before we have a commercialized product that generates significant revenues. As a result, we are uncertain when or if we will achieve profitability and, if so, whether we will be able to sustain it. The net losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate, continue, or complete planned or ongoing clinical trials of our current product candidates, including related support activities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to initiate and progress other supporting studies required for regulatory approval of our product candidates, including long-term safety studies, drug-drug interaction studies, preclinical toxicology and carcinogenicity studies&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make required milestone and royalty payments under the license agreements by which we acquired some of the rights to our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate preclinical studies and clinical trials for any additional indications for our current product candidates and any future product candidates that we may pursue&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to build our portfolio of product candidates through the acquisition or in-license of additional product candidates or technologies&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to develop, maintain, expand and protect our intellectual property portfolio&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue regulatory approvals for our current and future product candidates that successfully complete clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ultimately establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, medical, commercial, and development personnel&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional legal, accounting and other expenses in operating as a public company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must develop and eventually commercialize one or more product candidates with significant market potential. This will require us to be successful in a range of challenging activities, including completing clinical trials of our product candidates, developing commercial scale manufacturing processes, obtaining marketing approval, manufacturing, marketing and selling any current and future product candidates for which we may obtain marketing approval, and satisfying any post-marketing requirements. We are only in the preliminary stages of most of these activities and, in some cases, have not yet commenced certain of these activities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may never succeed in any or all of these activities and, even if we do, we may never generate sufficient revenue to achieve profitability.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of expenses or when, or if, we will obtain marketing approval to commercialize any of our product candidates. If we are required by the United States Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory authorities such as the European Medicines Agency (&#8220;EMA&#8221;) to perform studies and trials in addition to those currently expected, or if there are any delays in the development, or in the completion of any planned or future preclinical studies or clinical trials of our current or future product candidates, our expenses could increase and profitability could be further delayed.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding to pursue our business objectives. If we are unable to raise capital when needed or on terms favorable to us, we could be forced to curtail our planned operations and the pursuit of our growth strategy.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue to develop our product candidates. Our expenses could increase beyond our current expectations if the FDA requires us to perform clinical trials and other studies in addition to those that we currently anticipate. For example, for our troriluzole clinical program, we are conducting a Phase&#160;2&#47;3 clinical trial in SCA incorporating feedback from the FDA in response to discussion that we had with the FDA regarding proposed modifications to the scale for assessment and rating of Ataxia, the primary endpoint in the trial. If the FDA requires us to conduct additional clinical trials of troriluzole, or any of our other product candidates, we would incur substantial additional, unanticipated expenses in order to obtain regulatory approval of those product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our product candidates, if approved, may not achieve commercial success. Our revenue, if any, will be derived from sales of products that we do not expect to be commercially available for a number of years, if at all. Additionally, if we obtain marketing approval for our product candidates, we expect to incur significant expenses related to manufacturing, marketing, sales and distribution and, with respect to certain of our product candidates, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment of milestone and royalty fees. Furthermore, we expect to incur additional costs associated with operating as a public company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;October 3, 2022, we had approximately $257.8 million in cash. We expect that our existing cash will be sufficient to fund our planned operating expenses, financial commitments and other cash requirements for at least 12 months from the date of filing of this report. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect. Changes may occur beyond our control that would cause us to consume our available capital before that time, including changes in and progress of our development activities and changes in regulation. Our future capital requirements will depend on many factors, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of our ongoing and planned preclinical studies and clinical trials for our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amount of milestone and royalty payments we are required to make under our license agreements&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we in-license or acquire other product candidates and technologies&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and development requirements of other product candidates that we may pursue, and other indications for our current product candidates that we may pursue&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including drug manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish strategic collaborations for the development or commercialization of some of our product candidates&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims brought by third parties against us.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require additional capital to complete our planned clinical development programs for our current product candidates to seek regulatory approval. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. Any additional capital-raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future product candidates, if approved.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot guarantee that future financing will be available on a timely basis, in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders and the issuance of additional securities by us, whether equity or debt, or the market perception that such issuances are likely to occur, could cause the market price of our common shares to decline. As a result, we may not be able to access the capital markets as frequently as comparable U.S. companies. If we are unable to obtain funding on a timely basis on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidates, if approved, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our intellectual property or future revenue streams.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we can generate substantial product revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings and license and development agreements in connection with any future collaborations. We do not have any committed external source of funds. In the event we seek additional funds, we may raise additional capital through the sale of equity or convertible debt securities. In such an event, our existing shareholders may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of the holders of our common shares. Debt financing, if available, could result in increased fixed payment obligations and may involve agreements that include restrictive covenants, such as limitations on our ability to incur additional debt, make capital expenditures, acquire, sell or license intellectual property rights or declare dividends, and other operating restrictions that could hurt our ability to conduct our business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if we raise additional capital through collaborations, strategic alliances, or marketing, distribution, licensing or funding arrangements with third parties, we may have to relinquish valuable rights to our intellectual property future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development of Our Product Candidates</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current business depends entirely on the success of a limited number of product candidates, which are in clinical development. If we do not obtain or are delayed in obtaining regulatory approval for and successfully commercialize one or more of our product candidates, our business, financial condition and results of operations could be materially impacted and we may never become profitable.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk. We do not have any products that have received regulatory approval, and therefore we have never generated any revenue from product sales, and we may never be able to develop product candidates that receive regulatory approval or are successfully commercialized after regulatory approval is received. Consequently, the revenue-generating potential of our business is unproven and uncertain. We expect that a substantial portion of our efforts and expenses over the next few years will be devoted to the development of our product candidates&#59; specifically, completion of our Phase&#160;3 clinical trials of troriluzole in OCD, execution of clinical trials for BHV-7000, including late-stage studies in epilepsy and mood disorders, completion of a Phase 2&#47;3 clinical trial of troriluzole in glioblastoma, and completion of a Phase 3 clinical trial of BHV-2000 in SMA. As a result, our business currently depends heavily on the successful development, regulatory approval and, if approved, commercialization of these product candidates. We cannot be certain that we will be able to submit a new drug application (&#8220;NDA&#8221;), biologics license application (&#8220;BLA&#8221;) or comparable applications in other jurisdictions for any of our product candidates within the timeframes we expect, or that any NDA, BLA or similar application we submit will be accepted by the FDA or comparable foreign regulators for filing in a timely manner or at all. The research, testing, manufacturing, safety, efficacy, labeling, approval, sale, marketing and distribution of our product candidates are, and will remain, subject to comprehensive regulation by the FDA and similar foreign regulatory authorities. The success of our product candidates will depend on various factors, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing clinical trials that demonstrate our product candidates&#8217; efficacy and safety&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receiving marketing approvals from applicable regulatory authorities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing any post-marketing studies required by applicable regulatory authorities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching commercial sales, marketing and distribution operations&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse events experienced with our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our product candidates by patients, the medical community and third-party payors&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety profile following approval&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining healthcare coverage and adequate reimbursement for our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing effectively with other therapies, including with respect to the sales and marketing of our product candidates, if approved&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">qualifying for, maintaining, enforcing and defending our intellectual property rights and claims.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of these factors are beyond our control, including the time needed to adequately complete clinical testing, the regulatory submission process, potential threats to our intellectual property rights and changes in the competitive landscape. Our failure to achieve one or more of these factors in a timely manner or at all could materially harm our business, financial condition and results of operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials are very expensive, time-consuming and difficult to design and implement and involve uncertain outcomes. Furthermore, results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical trials.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and delay or failure can occur at any time during the clinical trial process.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in September 2021, we reported negative topline results from our Phase 3 clinical trial evaluating verdiperstat compared to placebo for the treatment of participants with MSA. In September 2022, we reported negative topline results from the Phase 2&#47;3 HEALEY ALS Platform trial evaluating verdiperstat compared to placebo for the treatment of participants with ALS. At this time, we have no plans to continue development of verdiperstat in ALS, and we are evaluating whether or not to pursue any additional clinical trials evaluating other disease indications.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the results generated to date in preclinical studies or clinical trials for our product candidates do not ensure that later preclinical studies or clinical trials will demonstrate similar results. Further, we have limited clinical data for many of our product candidates. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical and earlier stage clinical trials. In later-stage clinical trials, we will likely be subject to more rigorous statistical analyses than in completed earlier stage clinical trials. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in clinical trial procedures set forth in protocols, differences in the size and type of the patient populations, adherence to the dosing regimen, and the rate of dropout among clinical trial participants. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to produce positive results in our planned preclinical studies or clinical trials of any of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, would be materially adversely affected.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim topline or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our reputation and business prospects.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in drug discovery and drug development.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we in-licensed some of our investigational agents from other companies, including BHV-5000 and verdiperstat from AstraZeneca, we were not involved in and had no control over the preclinical and clinical development of these product candidates prior to entering into these in-license agreements. In addition, we are relying on the other companies from which we licensed our investigational agents to have conducted such research and development in accordance with the applicable protocol, legal, regulatory and scientific standards, accurately reported the results of all clinical trials conducted prior to our acquisition of the applicable product candidate, and correctly collected and interpreted the data from these studies and trials. To the extent any of these has not occurred, our expected development time and costs may be increased, which could adversely affect our prospects for marketing approval of, and receiving any future revenue from, these product candidates.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials may be delayed, suspended or terminated for many reasons, which will increase our expenses and delay the time it takes to develop our product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in our ongoing or future preclinical studies or clinical trials, and we do not know whether future preclinical studies or clinical trials need to be redesigned, enroll an adequate number of patients on time or begin or be completed on schedule, if at all. The commencement and completion of clinical trials for our clinical product candidates may be delayed, suspended or terminated as a result of many factors, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulators disagreeing as to the design, protocol or implementation of our clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the delay or refusal of regulators (including the FDA) or institutional review boards (&#8220;IRBs&#8221;) to authorize us to commence a clinical trial&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators (including the FDA), IRBs, ethics committees of the institutions at which trials are being conducted or the data safety monitoring board for such trials requiring that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements (including the FDA&#8217;s current Good Clinical Practice (&#8220;GCP&#8221;) regulations) or our clinical protocols, safety concerns, adverse side effects, or lack of adequate funding to continue the clinical trial, among others&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements, policies and guidelines&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or failure to reach agreement on acceptable terms with prospective clinical research organization (&#8220;CROs&#8221;) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#59; delays in patient enrollment and variability in the number and types of patients available for clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to enroll a sufficient number of patients in trials, particularly in orphan indications, to observe statistically significant treatment effects in the trial&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">having clinical sites deviate from the trial protocol or dropping out of a trial&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results from ongoing preclinical studies or clinical trials, which may require us to conduct additional preclinical studies or clinical trials or to abandon projects that we expect to be promising&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety or tolerability concerns (including due to reports from testing of similar therapies) that could cause us to suspend or terminate a trial if we find that the participants are being exposed to unacceptable health risks&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or IRBs requiring that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or safety concerns, among others&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower than anticipated retention rates of patients and volunteers in clinical trials&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CROs or clinical trial sites failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, deviating from the protocol or dropping out of a trial&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays relating to adding new clinical trial sites&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in maintaining contact with patients after treatment, resulting in incomplete data&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in establishing the appropriate dosage levels&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the quality or stability of the product candidate falling below acceptable standards&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to produce or obtain sufficient quantities of the product candidate to commence or complete clinical trials&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exceeding budgeted costs due to difficulty in accurately predicting costs associated with clinical trials.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenue from product sales. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign regulatory agencies are lengthy, time-consuming and unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither we nor any future collaborator is permitted to market any of our product candidates in the United States or abroad until we receive regulatory approval of an NDA or BLA from the FDA or approval from the EMA, NMPA or other applicable foreign regulatory agency. The time required to obtain approval by the FDA is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including those beyond our control, such as the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval is generally uncertain, may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining approval to commercialize a product candidate in any jurisdiction, we must demonstrate to the satisfaction of the FDA, EMA, NMPA or any comparable foreign regulatory agency, that such product candidates are safe and effective for their intended uses. The FDA, EMA, NMPA or any comparable foreign regulatory agency can delay, limit or deny approval of our product candidates or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, EMA, NMPA or the applicable foreign regulatory agency&#8217;s disagreement with the number, design, conduct or implementation of our preclinical studies and clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA, EMA, NMPA or any comparable foreign regulatory agency for approval&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to demonstrate to the satisfaction of the FDA, EMA, NMPA or the applicable foreign regulatory agency that our product candidates are safe and effective for their proposed indications, or that the clinical and other benefits of our product candidates outweigh any safety or other perceived risks&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s, EMA&#8217;s, NMPA&#8217;s or the applicable foreign regulatory agency&#8217;s disagreement with the interpretation of data from preclinical studies or clinical trials&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the CROs that we retain to conduct our preclinical studies and clinical trials, which are outside of our control and that materially adversely impact our preclinical studies and clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s, EMA&#8217;s, NMPA&#8217;s or the applicable foreign regulatory agency&#8217;s disagreement regarding the formulation, labeling or the specifications of our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s, EMA&#8217;s, NMPA&#8217;s or the applicable foreign regulatory agency&#8217;s failure to approve the manufacturing processes or facilities of third-party manufacturers with which we contract&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential for approval policies or regulations of the FDA, EMA, NMPA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, with respect to our randomized, controlled clinical trial of troriluzole for the treatment of SCA, we undertook discussions with the FDA regarding the acceptability of the primary endpoint and necessary secondary endpoints, including our proposal to use a modified SARA scale. In our first Phase&#160;2&#47;3 clinical trial, the FDA stated that while certain items measured by the SARA scale appeared capable of reflecting a clinically meaningful benefit for patients depending on how the scoring of those items is defined, the use of the SARA scale was not appropriate as a primary endpoint in the trial. Based on our post-hoc analyses of data from the open-label extension phase of the trial, we proposed modifications to the SARA scale that we believe may address some of these shortcomings. Based on feedback received from the FDA, we incorporated trial design modifications that include utilization of a modified SARA scale. However, notwithstanding the feedback that we have received from the FDA, there remains substantial risk that the FDA or any foreign regulatory agency may nevertheless conclude that results obtained using the modified SARA scale would not be an adequate basis for approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in our Phase 3 clinical trial evaluating the efficacy and safety of troriluzole in adult patients with SCA, the primary endpoint, change from baseline to week 48 on the modified SARA scale, did not reach statistical significance in the overall SCA population as there was less than expected disease progression over the course of the study. Post-hoc analysis of efficacy measures by genotype suggests a treatment effect in patients with the SCA Type 3 (&#34;SCA3&#34;) genotype. There is substantial risk that the FDA, EMA, NMPA or the applicable foreign regulatory agency may disagree with the interpretation of our data, and there can be no assurance that any such regulatory agency will find the data sufficient to support approval, or that we will not be required to conduct additional testing on the safety and efficacy of troriluzole.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to interact with the FDA and&#47;or EMA in the first half of 2023 but have not yet decided on the format of such an interaction. We could seek advice through various formal or informal interactions with regulatory agencies or we could choose to submit an NDA if we believe that is warranted from the results of our ongoing post-hoc analyses. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally plan to seek regulatory approval to commercialize our product candidates in the United States, the European Union and other key global markets, which requires compliance with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing and distribution of our product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdiction. Failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. If we fail to obtain approval in any jurisdiction, the geographic market for our product candidates could be limited. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, even if we were to obtain approval to market any product candidate we develop, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may fail to demonstrate safety and efficacy in clinical trials, or may cause serious adverse or unacceptable side effects that could prevent or delay regulatory approval and commercialization, limit the commercial profile of an approved label, increase our costs, necessitate the abandonment or limitation of the development of some of our product candidates or result in significant negative consequences following marketing approval, if any.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication, and failures can occur at any stage of testing. Clinical trials often fail to demonstrate efficacy or safety of the product candidate studied for the target indication.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in September 2021 we reported negative topline results from a Phase 3 clinical trial to evaluate the efficacy and safety of verdiperstat in participants with MSA. Results of the trial showed that verdiperstat did not statistically differentiate from placebo on the prespecified primary efficacy measure, nor on the key secondary efficacy measures. In September 2022, we reported negative topline results from the Phase 2&#47;3 HEALEY ALS Platform trial evaluating verdiperstat compared to placebo for the treatment of participants with ALS. At this time, we do not have plans to pursue any additional clinical trials evaluating verdiperstat in ALS but we are evaluating its potential in other disease indications.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label, the limitation of commercial potential or the delay or denial of regulatory approval by the FDA or a foreign regulatory agency. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Accordingly, we may need to abandon the development of certain product candidates or limit development to certain uses or sub-populations in which such side effects are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in preclinical or early-stage testing have later been found to cause side effects that restricted their use and prevented further development of the compound in the tested indication.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Occurrence of serious treatment-related side effects could impede subject recruitment and clinical trial enrollment or the ability of enrolled patients to complete the trial, delay the clinical trial, and prevent receipt of regulatory approval from the FDA and other regulators. They could also adversely affect physician or patient acceptance of our product candidates or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials of our product candidates by their nature are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have monitored the subjects in our studies for certain safety concerns and we have not seen evidence of significant safety concerns in our clinical trials. However, if one or more of our product candidates receives regulatory approval, and we, or others, later discover that they are less effective than previously believed, or cause undesirable side effects that had not previously been identified, a number of potentially significant negative consequences could result, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal or limitation by regulatory authorities of approvals of such product&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seizure of the product by regulatory authorities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall of the product&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing of the product or the manufacturing process for any component thereof&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirement by regulatory authorities of additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirement that we implement a REMS or similar program or create a medication guide outlining the risks of such side effects for distribution to patients&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commitment to expensive additional safety studies prior to approval or post-marketing studies required by regulatory authorities of such product&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of regulatory investigations and government enforcement actions&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of legal action against us to hold us liable for harm caused to patients&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">harm to our reputation and resulting harm to physician or patient acceptance of our products.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, financial condition, and results of operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on enrollment of patients in our clinical trials for our product candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts could be adversely affected.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. If we are unable to enroll a sufficient number of patients in our clinical trials, our timelines for recruiting patients, conducting clinical trials and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our technology or termination of our clinical trials altogether. We cannot predict how successful we will be at enrolling patients in future clinical trials. Patient enrollment is affected by other factors including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the eligibility criteria for the trial in question&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived risks and benefits of the product candidate in the trial&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating or drugs that may be used off-label for these indications&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition for patients for competitive product candidates undergoing clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts to facilitate timely enrollment in clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design of the trial&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to obtain and maintain patient consents&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients with the indication being studied&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited financial and managerial resources. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. The current and future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such products. In addition, we have agreed to indemnify the licensors of the intellectual property related to our product candidates against certain intellectual property infringement claims. Any claims against us, or with respect to which we are obligated to provide indemnification, regardless of their merit, could be difficult and costly to defend or settle, and could compromise the market acceptance of our product candidates or any prospects for commercialization of our product candidates, if approved.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects or identify patients who should not use our product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all our liabilities. We may need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. As the expense of insurance coverage is increasing, we may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If serious adverse events or other undesirable side effects are identified during the use of our product candidates in investigator-sponsored trials, it may adversely affect our development of such product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt nonclinical studies and clinical trials, or could make it more difficult for us to enroll patients in our clinical trials. If serious adverse events or other undesirable side effects or unexpected characteristics of our product candidates are observed in investigator-sponsored trials, further clinical development of such product candidate may be delayed or we may not be able to continue development of such product candidate at all, and the occurrence of these events could have a material adverse effect on our business. Undesirable side effects caused by our product candidates could also result in the delay or denial of regulatory approval by the FDA or other regulatory authorities or in a more restrictive label than we expect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never commercialized a product candidate and we may lack the necessary expertise, personnel and resources to successfully commercialize any of our products that receive regulatory approval on our own or together with suitable collaborators.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never commercialized a product candidate. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, acquiring the rights to our product candidates and undertaking preclinical studies and clinical trials of our product candidates. We currently have no sales force, marketing or distribution capabilities. To achieve commercial success of our product candidates, if any are approved, we will have to develop our own sales, marketing and supply capabilities or outsource these activities to a third party.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may affect our ability to commercialize our product candidates on our own include&#58; recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our product candidates, and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment, is time-consuming and could delay the launch of our product candidates. We may not be able to build an effective sales and marketing organization in the United States, the European Union or other key global markets. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may have difficulties generating revenue from such product candidates or be able to achieve or sustain profitability.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution of any approved product, our product revenue may be lower than if we directly marketed or sold such product. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third-party collaborators, which may not be successful and are generally not within our control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in a highly competitive and rapidly changing industry. Failure to compete successfully could adversely affect our business, financial condition and results of operations.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biopharmaceutical product development is highly competitive and subject to rapid and significant technological advancements. Our success is highly dependent upon our ability to in-license, acquire, develop and obtain regulatory approval for new and innovative products on a cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large, fully integrated, well-established pharmaceutical companies who already possess a large share of the market, specialty pharmaceutical and biopharmaceutical companies, academic institutions, government agencies and other private and public research institutions in the United States, the European Union and other jurisdictions.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to troriluzole, which we are currently developing for the treatment of ataxias and other neurologic disorders, with SCA as our initial indication, there are currently no approved drug treatments for spinocerebellar ataxias in the United States. We are also developing troriluzole for the potential treatment of OCD and other indications. If we continue to pursue these indications, we would face substantial competition from companies that develop or sell products that treat OCD. With respect to BHV-5000, which we are developing for the treatment of neuropsychiatric conditions the market size and competition will depend on each indication. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies which we are competing with or which we may compete with in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the biopharmaceutical industry could result in even more resources being concentrated among our competitors.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may further increase as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in the biopharmaceutical industry. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, products that are more effective or less costly than any product candidates that we may develop.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Established biopharmaceutical companies may invest heavily to accelerate research and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, and in discovering, developing, receiving FDA approval for or commercializing drugs before we do, which would have an adverse impact on our business and results of operations.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of our competitors&#8217; products could limit the demand and the price we are able to charge for any product candidates we commercialize, if any. The inability to compete with existing or subsequently introduced drugs would harm our business, financial condition and results of operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of certain of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and adequacy of coverage and reimbursement by governmental healthcare programs, such as Medicare and Medicaid, private health insurers and other third-party payors, are essential for most patients to be able to afford products such as our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by third-party payors will have an effect on our ability to successfully commercialize our product candidates, if approved, and attract additional collaboration partners to invest in the development of our product candidates. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and adequate reimbursement in the United States, the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that becomes available may be decreased or eliminated in the future.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. Our competitors may offer their products and services on a less expensive basis to gain coverage and reimbursement from third-party payors. It is possible that a third-party payor may consider our product candidates as substitutable by less expensive therapies and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing drugs may limit the amount we will be able to charge for our product candidates, once approved. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such devices or therapies. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining reimbursement status is time-consuming and costly. No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules&#160;and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules&#160;and regulations are likely.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for any products for which we may obtain regulatory approval&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price that we believe is fair for our products&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain coverage and adequate reimbursement approval for a product&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval for our product candidates, they will remain subject to ongoing regulatory oversight.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for any of our product candidates, they will be subject to extensive and ongoing regulatory requirements for manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promoting, sampling and record-keeping. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing practices (&#8220;cGMP&#8221;) regulations and GCPs, for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase&#160;4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. We may not be able to adapt to changes in existing requirements or the adoption of new requirements or policies. If there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuing warning or untitled letters&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeking an injunction or imposing civil or criminal penalties or monetary fines&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or imposition of restrictions on operations, including product manufacturing&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seizure or detention of products, refusal to permit the import or export of products, or requesting that we initiate a product recall&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of our marketing authorizations&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of any ongoing clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to applications submitted by us&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to permit the import or export of products&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expenses to comply with regulatory requirements, which could adversely affect our business, financial condition and results of operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA approves the marketing of any product candidates that we develop, physicians, patients, third-party payors or the medical community may not accept or use them. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our product candidates. If any of our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue or any profits from operations. Because we expect sales of our product candidates, if approved, to generate substantially all of our product revenue for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing. The degree of market acceptance of our product candidates that are approved for commercial sale will depend on a variety of factors, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy, cost, convenience and ease of administration, and other potential advantages compared to alternative treatments, including any similar generic treatments&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectiveness of sales and marketing efforts&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement, and patients&#8217; willingness to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products, if approved, together with other medications.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the potential market opportunity for our product candidates is difficult to estimate precisely. Our estimates of the potential market opportunity are predicated on several key assumptions such as industry knowledge </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and publications, third-party research reports and other surveys. While we believe that our internal assumptions are reasonable, these assumptions may be inaccurate. If any of the assumptions proves to be inaccurate, then the actual market for our product candidates could be smaller than our estimates of the potential market opportunity, our revenue from product sales may be limited and we may be unable to achieve or maintain profitability.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA or comparable foreign regulatory authorities approve generic versions of any of our products that receive marketing approval, or such authorities do not grant our products sufficient periods of exclusivity before approving generic versions of our products, the sales of our products could be adversely affected.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA is approved, the product covered thereby becomes a &#8220;reference listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; commonly known as the Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of abbreviated new drug applications (&#8220;ANDAs&#8221;) in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference listed drug has expired. The U.S. Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) provides a period of five years of non-patent exclusivity for a new drug containing a new chemical element (&#8220;NCE&#8221;). Specifically, in cases where such exclusivity has been granted, an ANDA may not be submitted to the FDA until the expiration of five years unless the submission is accompanied by a Paragraph&#160;IV certification that a patent covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference listed drug.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that troriluzole, a prodrug of riluzole will be treated as NCEs under current FDA interpretations and, therefore, if approved, should be afforded five years of data exclusivity, the FDA may disagree with that conclusion and may approve generic products after a period that is less than five years. Manufacturers may seek to launch these generic products following the expiration of the applicable marketing exclusivity period, even if we still have patent protection for our product.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition that our products may face from generic versions of our products could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our preclinical studies and clinical trials and if these third parties perform in an unsatisfactory manner, our business could be substantially harmed.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically conducted, and we intend to continue to conduct our clinical trials using our own clinical resources, while also leveraging expertise and assistance from medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research organizations (&#8220;CROs&#8221;) as appropriate. We are reliant upon such third parties to assist us in conducting GCP-compliant clinical trials on our product candidates properly and on time, and may not currently have all of the necessary contractual relationships in place to do so. Once we have established contractual relationships with such third-parties, we will have only limited control over their actual performance of these activities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CROs and other vendors are required to comply with cGMP, GCP and good laboratory practices (&#8220;GLP&#8221;), which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Union and any comparable foreign regulatory authorities for all of our product candidates in preclinical and clinical development. Regulatory authorities enforce these regulations through periodic inspections </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of trial sponsors, principal investigators, clinical trial sites and other contractors. Although we rely on CROs to conduct any current or planned GLP-compliant preclinical studies and GCP-compliant clinical trials and have limited influence over their actual performance, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. If we or any of our CROs or vendors fail to comply with applicable regulations, the data generated in our preclinical studies and clinical trials may be deemed unreliable and the FDA, EMA or any comparable foreign regulatory agency may require us to perform additional preclinical studies and clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory agency, such regulatory agency will determine that all of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP requirements. Our failure to comply with these requirements may require us to repeat clinical trials, which would delay the regulatory approval process.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we will have agreements governing their activities, we are not, and will not be able to control whether or not our CROs devote sufficient time and resources to our future preclinical and clinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our business. If our CROs do not successfully carry out their contractual duties or obligations, or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, the clinical data generated in our clinical trials may be deemed unreliable, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our relationships with these CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus, and could delay development and commercialization of our product candidates. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business and financial condition.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely completely on third-party contractors to supply, manufacture and distribute clinical drug supplies for our product candidates, including certain sole-source suppliers and manufacturers&#59; we intend to rely on third parties for commercial supply, manufacturing and distribution if any of our product candidates receive regulatory approval&#59; and we expect to rely on third parties for supply, manufacturing and distribution of preclinical, clinical and commercial supplies of any future product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we plan to acquire, the internal infrastructure or capability to supply, manufacture or distribute preclinical, clinical or commercial quantities of drug substances or products.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop our product candidates depends and our ability to commercially supply our products will depend, in part, on our ability to successfully obtain the active pharmaceutical ingredients (&#8220;APIs&#8221;) and other substances and materials used in our product candidates from third parties and to have finished products manufactured by third parties in accordance with regulatory requirements and in sufficient quantities for preclinical and clinical testing and commercialization. If we fail to develop and maintain supply relationships with these third parties, we may be unable to continue to develop or commercialize our product candidates. In addition, our results of operations and cash flows could be adversely impacted by any inability to obtain favorable terms from our suppliers, including any acceleration of payment terms to our suppliers and&#47;or the imposition of more restrictive credit terms and other contractual requirements.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have auditing rights with all our current manufacturing counterparties, we do not have direct control over the ability of our contract suppliers and manufacturers to maintain adequate capacity and capabilities to serve </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our needs, including quality control, quality assurance and qualified personnel. Although we are ultimately responsible for ensuring compliance with regulatory requirements such as cGMPs, we are dependent on our contract suppliers and manufacturers for day-to-day compliance with cGMPs for production of both APIs and finished products. Facilities used by our contract suppliers and manufacturers to produce the APIs and other substances and materials or finished products for commercial sale must pass inspection and be approved by the FDA and other relevant regulatory authorities. Our contract suppliers and manufacturers must comply with cGMP requirements enforced by the FDA through its facilities inspection program and review of submitted technical information. If our contract suppliers or manufacturers fail to achieve and maintain compliance with applicable laws and regulatory requirements, our business could be adversely affected in a number of ways, and cause, among other things&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to initiate or continue clinical trials of our product candidates under development&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in submitting regulatory applications, or receiving regulatory approvals, for our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjecting third-party manufacturing facilities or our own facilities to additional inspections by regulatory authorities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to cease distribution or to recall batches of our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of manufacturing of our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revocation of obtained approvals&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to meet commercial demands for our product candidates in the event of approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if the safety of any product or product candidate or component is compromised due to a failure to adhere to applicable laws and regulatory requirements, or for other reasons, we may not be able to successfully commercialize or obtain regulatory approval for the affected product or product candidate, and we may be held liable for injuries sustained as a result. Any of these factors could cause a delay or termination of preclinical studies, clinical trials or regulatory submissions or approvals of our product candidates, and could entail higher costs or result in our being unable to effectively commercialize our approved products on a timely basis, or at all.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely on certain third parties as the sole source of the materials they supply or the finished products they manufacture. We may also have sole-source suppliers for one or more of our other product candidates. Some of the APIs and other substances and materials used in our product candidates are currently available only from one or a limited number of domestic or foreign suppliers and foreign manufacturers and certain of our finished product candidates are manufactured by one or a limited number of contract manufacturers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event an existing supplier or manufacturer fails to supply or manufacture, as applicable, product on a timely basis or in the requested amount, fails to meet regulatory requirements or our specifications, becomes unavailable through business interruption or financial insolvency or loses its regulatory status as an approved source, or if we or our manufacturers are unable to renew current supply agreements when such agreements expire and we do not have a second supplier, we likely would incur added costs and delays in identifying or qualifying replacement suppliers, manufacturers and materials and there can be no assurance that replacements would be available to us on a timely basis, on acceptable terms or at all. In certain cases, we may be required to get regulatory approval to use alternative suppliers and manufacturers, and this process of approval could delay production of our products or development of product candidates indefinitely. We and our manufacturers do not currently maintain inventory of these APIs and other substances and materials. Any interruption in the supply of an API or other substance or material or in the manufacture of a finished product could have a material adverse effect on our business, financial condition, operating results and prospects.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these contract manufacturers are or may be engaged with other companies to supply and manufacture materials or products for such companies, which also exposes our suppliers and manufacturers to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may also affect the regulatory clearance of a contract supplier&#8217;s or manufacturer&#8217;s facility. If the FDA or a comparable foreign regulatory agency does not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approve these facilities for the supply or manufacture of our product candidates, or if it withdraws its approval in the future, we may need to find alternative supply or manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval of or market our product candidates, if approved.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to depend on third-party contract suppliers and manufacturers for the foreseeable future, but supply and manufacturing arrangements do not guarantee that a contract supplier or manufacturer will provide services adequate for our needs. We and our contract suppliers and manufacturers may attempt to improve production processes, certain aspects of which are complex and unique, and we may encounter difficulties with new or existing processes. While we attempt to build in certain contractual obligations on such third-party suppliers and manufacturers, we may not be able to ensure that such third parties comply with these obligations. Depending on the extent of any difficulties encountered, we could experience an interruption in clinical or commercial supply, with the result that the development, regulatory approval or commercialization of our product candidates may be delayed or interrupted. In addition, third-party suppliers and manufacturers may have the ability to increase the price payable by us for the supply of the APIs and other substances and materials used in our product candidates, in some cases without our consent.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, any damages to or destruction of our third-party manufacturers&#8217; or suppliers&#8217; facilities or equipment may significantly impair our ability to have our product candidates manufactured on a timely basis. Furthermore, if a contract manufacturer or supplier becomes financially distressed or insolvent, or discontinues our relationship beyond the term of any existing agreement for any other reason, this could result in substantial management time and expense to identify, qualify and transfer processes to alternative manufacturers or suppliers, and could lead to an interruption in clinical or commercial supply.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the manufacturing facilities of certain of our suppliers are located outside of the United States. This may give rise to difficulties in importing our products or product candidates or their components into the United States or other countries as a result of, among other things, regulatory agency approval requirements or import inspections, incomplete or inaccurate import documentation or defective packaging.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, or third-party manufacturers on whom we rely, may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we prepare for later-stage clinical trials and potential commercialization, we will need to take steps to increase the scale of production of our product candidates, which may include transferring production to new third-party suppliers or manufacturers. In order to conduct larger or late-stage scale clinical trials for our product candidates and supply sufficient commercial quantities of the resulting drug product and its components, if that product candidate is approved for sale, our contract manufacturers and suppliers will need to produce our product candidates in larger quantities, more cost effectively and, in certain cases, at higher yields than they currently achieve. We, or our manufacturers, may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities because of the inherent properties of a product candidate itself or of a product candidate in combination with other components added during the manufacturing and packaging process, or during shipping and storage of the APIs or the finished product. If we, or any of our manufacturers, are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. If we are unable to obtain or maintain third-party manufacturing for commercial supply of our product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may in the future enter into collaborations with third parties to develop and commercialize our product candidates. If these collaborations are not successful, or if we are not able to establish or maintain these collaborations, our business could be harmed.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development programs and the potential commercialization of our product candidates will require substantial additional capital to fund expenses. For some of our product candidates, we may decide to collaborate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with pharmaceutical and biotechnology companies for the future development and potential commercialization of those product candidates. Furthermore, we may find that our programs require the use of proprietary rights held by third parties, and the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. Collaboration arrangements are complex and time-consuming to negotiate, document, implement and maintain. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements, and the terms of any collaborations or other arrangements that we may establish may not be favorable to us.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate collaborators, and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, competing or alternative products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. We may also be restricted under existing license agreements from entering into agreements on certain terms with potential collaborators. Even if we are able to obtain a license to intellectual property of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, including for example, that the collaborators may not&#58; adequately perform their obligations under the collaboration agreement&#894; devote sufficient resources to the collaboration to ensure success&#894; or agree with us on the strategy or tactical aspects of the collaboration.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any such potential future collaborations do not result in the successful development and commercialization of product candidates, or if one of our future collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, the development of our product candidates could be delayed and we may need additional resources to develop our product candidates. In addition, if one of our future collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization apply to the activities of our potential future collaborators.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Compliance</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies, and our failure to comply with existing and future regulatory requirements could adversely affect our results of operations and financial condition. Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to a broad array of regulatory requirements globally. We are subject to federal, state, local, international and transnational laws and regulations, including the operating, quality and security standards of the FDA, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;), and other regulatory authorities such as the EMA, and in the future, any changes to such laws and regulations could adversely affect us. In particular, changes in the FDA&#8217;s regulation of drug discovery and development or manufacturing processes could adversely affect our results of operations and financial condition. We may be required to register for permits and&#47;or licenses with the FDA, HHS, or other regulatory authorities such as the EMA, and there can be no assurance that we will be able to maintain or renew existing permits, licenses or other regulatory approvals or obtain, without significant delay, future permits, licenses or other approvals needed for the operation of our business. Any noncompliance by us with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable laws and regulations or the failure to maintain, renew or obtain necessary permits and licenses could have an adverse effect on our results of operations and financial condition.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the European Union, and other foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March&#160;2010, the Affordable Care Act (&#8220;ACA&#8221;), as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states, without specifically ruling on the ACA&#8217;s constitutionality. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, non-deductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new requirements to report certain financial arrangements with physicians and certain others, including reporting &#8220;transfers of value&#8221; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of the Center for Medicare Innovation at the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS is developing new payment and delivery models, such as bundled payment models. HHS moved 30% of Medicare payments to alternative payment models tied to the quality or value of services in 2016. Additionally, HHS had set a goal of moving 50% of Medicare payments into these alternative payment models by the end of 2018, but in 2019, it discontinued this performance goal and replaced it with a new </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developmental goal to increase the percentage of Medicare health care dollars tied to APMs incorporating downside risk, with a target of 40% for fiscal year 2021. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there have been several recent U.S. congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. HHS has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to use step therapy for Part B drugs beginning January 1, 2019, and in May 2019, CMS finalized a new rule that would require direct-to-consumer television advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product. However, this rule was struck down by a federal court before it went into effect. Although some of these and other proposals will require authorization through additional legislation to become effective, members of Congress and the Biden Administration have stated that they will continue to seek new legislative and administrative measures to control drug costs. In response to an Executive Order from President Biden, the Secretary of HHS recently issued a comprehensive plan for addressing high drug prices that describes a number of legislative approaches and identifies administrative tools to address the high cost of drugs. And Democrats recently included drug pricing reform provisions reflecting elements of the plan in a broader spending package in late 2021&#8212;such as capping Medicare Part D patients&#8217; out-of-pocket costs, establishing penalties for drug prices that increase faster than inflation in Medicare, and authorizing the federal government to negotiate prices on certain select, high-cost drugs under Medicare Parts B and D. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our products or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (&#8220;Right to Try Act&#8221;) was signed into law. The law, among other things, provides a federal framework for patients to access certain investigational new drug products that have completed a Phase&#160;1 clinical trial. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union (&#8220;EU&#8221;), similar political, economic and regulatory developments may affect our ability to profitably commercialize any of our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors and customers will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, if we obtain FDA approval for our product candidates, and begin commercializing those products in the United States, our operations may be directly, or indirectly through our prescribers, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal civil and criminal false claims laws and Physician Payments Sunshine Act and regulations. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may impact, among other things, our current business operations, including our clinical research activities proposed sales and marketing and education programs and constrain the business or financial arrangements and relationships with healthcare providers, physicians and other parties through which we market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business. Finally, we may be subject to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The U.S. laws that may affect our ability to operate include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe, or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services&#59; similar to the U.S. federal Anti-Kickback </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;) enacted as part of the American Recovery and Reinvestment Act of 2009, and its implementing regulations, and as amended again by the Modifications to the HIPAA Privacy, Security, Enforcement and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act&#59; Other Modifications to the HIPAA Rules, commonly referred to as the Final HIPAA Omnibus Rule, published in January 2013, which imposes certain obligations, including mandatory contractual terms, on covered entities subject to HIPAA (i.e., health plans, healthcare clearinghouses and certain healthcare providers), as well as their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information, to safeguard the privacy, security and transmission of individually identifiable health information from any unauthorized use or disclosure&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state laws and regulations, including&#58; state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and local laws that require the registration of pharmaceutical sales representatives&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws governing the privacy and security of personal information, including personal health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our internal operations and current and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. Further, defending against any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained orphan drug designation in the United States for troriluzole in SCA. We may seek orphan drug designation for other product candidates in the future. Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same drug for the same indication during that time period. The applicable period is seven years in the United States and ten years in the European Union. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that any future application for orphan drug designation with respect to any other product candidate will be granted. If we are unable to obtain orphan drug designation with respect to other product candidates in the United States, we will not be eligible to obtain the period of market exclusivity that could result from orphan drug designation or be afforded the financial incentives associated with orphan drug designation. Even when we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve a later drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of non-compliance. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to rules and regulations by various governing bodies, including, for example, the SEC, which is charged with the protection of investors and the oversight of companies whose securities are publicly traded, and to new and evolving regulatory measures under applicable law, including the laws of the BVI. Our efforts to comply with new and changing laws and regulations have resulted in and are likely to continue to result in, increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because these laws, regulations and standards are subject to varying interpretations, their application in practice may evolve over time as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to our disclosure and governance practices. If we fail to address and comply with these regulations and any subsequent changes, we may be subject to penalty and our business may be harmed.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential changes to regulatory legislation in the British Virgin Islands could lead to increased costs for us to comply with additional regulatory and reporting requirements.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the global regulatory and tax environment evolves, we may be subject to new or different statutory and regulatory requirements. For example, on January 1, 2019, the Economic Substance (Companies and Limited </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Partnerships) Act, 2018 of the British Virgin Islands (the &#8220;Economic Substance Act&#8221;) came into force and was amended on October 1, 2019 and June 29, 2021 and remains subject to further amendments, additional regulations and guidance on interpretation from the regulator. It is difficult to predict what impact the Economic Substance Act and its associated regulations and guidance or changes in the interpretation of these laws or regulations could have on us. However, compliance with various additional obligations may create additional costs that may be borne by us or otherwise affect our management and operation.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could lose market exclusivity earlier than expected.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or license patents in the U.S. and foreign countries that protect our products, their methods of use and manufacture, as well as other innovations relating to the advancement of our science to help bring new therapies to patients. We also develop brand names and trademarks for our products to differentiate them in the marketplace. We consider the overall protection of our patents, trademarks, licenses and other intellectual property rights to be of material value and act to protect these rights from infringement. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain the proprietary position of our products and development programs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the biopharmaceutical industry, a substantial portion of an innovative product&#8217;s commercial value is usually realized during the period in which the product has market exclusivity. A product&#8217;s market exclusivity is generally determined by two forms of intellectual property&#58; patent rights held by the innovator company and any regulatory forms of exclusivity to which the innovative drug is entitled.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents are a key determinant of market exclusivity for most pharmaceuticals. Patents provide the innovator with the right to exclude others from practicing an invention related to the medicine. Patents may cover, among other things, the active ingredient(s), various uses of a drug product, discovery tools, pharmaceutical formulations, drug delivery mechanisms and processes for (or intermediates useful in) the manufacture of products. Protection for individual products extends for varying periods in accordance with the expiration dates of patents in the various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent, its scope of coverage and the availability of meaningful legal remedies in the country.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market exclusivity can also be influenced by regulatory data protection (&#8220;RDP&#8221;). Many developed countries provide certain non-patent incentives for the development of medicines. For example, in the U.S., the EU, United Kingdom, Japan, and certain other countries, RDP intellectual property rights are offered to&#58; (i) provide a time period of data protection during which a generic company is not allowed to rely on the innovator&#8217;s data in seeking approval&#59; (ii) restore patent term lost during drug development and approval&#59; and (iii) provide incentives for research on medicines for rare diseases, or orphan drugs, and on medicines useful in treating pediatric patients. These incentives can extend the market exclusivity period on a product beyond the patent term.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Exclusivity &#8211; United States</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, biopharmaceutical products are protected by patents with varying terms depending on the type of patent and the filing date. A significant portion of a product&#8217;s patent life, however, is lost during the time it takes an innovative company to develop and obtain regulatory approval of a new drug. As compensation, at least in part, for the lost patent term due to regulatory review periods, the innovator may, depending on a number of factors, apply to the government to restore lost patent term by extending the expiration date of one patent up to a maximum term of five years, provided that the extension cannot cause the patent to be in effect for more than 14 years from the date of drug approval. A company seeking to market an innovative pharmaceutical in the U.S. must submit a complete set of safety and efficacy data to the FDA. If the innovative pharmaceutical is a chemical product, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company files an NDA. If the medicine is a biological product, a BLA is filed. The type of application filed affects RDP exclusivity rights.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Small Molecule Products</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A competitor seeking to launch a generic substitute of small molecule drug in the U.S. must file an ANDA with the FDA. In the ANDA, the generic manufacturer needs to demonstrate only &#8220;bioequivalence&#8221; between the generic substitute and the approved NDA drug. The ANDA relies upon the safety and efficacy data previously filed by the innovator in its NDA. An innovator company is required to list certain of its patents covering the medicine with the FDA in what is commonly known as the FDA&#8217;s Orange Book. The FDA cannot approve an ANDA until after the innovator&#8217;s listed patents expire unless there is a successful patent challenge. However, after the innovator has marketed its product for four years, a generic manufacturer may file an ANDA and allege that one or more of the patents listed in the Orange Book under an innovator&#8217;s NDA is either invalid or not infringed (a Paragraph IV certification). The innovator then must decide whether to file a patent infringement suit against the generic manufacturer. From time to time, ANDAs, including Paragraph IV certifications, are filed with respect to certain of our products. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, certain innovative pharmaceutical products can receive periods of regulatory exclusivity. An NDA that is designated as an orphan drug can receive seven years of exclusivity for the orphan indication. During this time period, neither NDAs nor ANDAs for the same drug product can be approved for the same orphan use. A company may also earn six months of additional exclusivity for a drug where specific clinical studies are conducted at the written request of the FDA to study the use of the medicine to treat pediatric patients, and submission to the FDA is made prior to the loss of basic exclusivity. Medicines approved under an NDA can also receive several types of RDP. An innovative chemical pharmaceutical product is entitled to five years of RDP in the U.S., during which the FDA cannot approve generic substitutes. If an innovator&#8217;s patent is challenged, as described above, a generic manufacturer may file its ANDA after the fourth year of the five-year RDP period. A pharmaceutical drug product that contains an active ingredient that has been previously approved in an NDA, but is approved in a new formulation, but not for the drug itself, or for a new indication on the basis of new clinical studies, may receive three years of RDP for that formulation or indication.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biologic products</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. healthcare legislation enacted in 2010 created an approval pathway for biosimilar versions of innovative biological products that did not previously exist. Prior to that time, innovative biologics had essentially unlimited regulatory exclusivity. Under the new regulatory mechanism, the FDA can approve products that are similar to (but not generic copies of) innovative biologics on the basis of less extensive data than is required by a full BLA. After an innovator has marketed its product for four years, any manufacturer may file an application for approval of a &#8220;biosimilar&#8221; version of the innovator product. However, although an application for approval of a biosimilar version may be filed four years after approval of the innovator product, qualified innovative biological products will receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative biological product was first approved by the FDA. The law also provides a mechanism for innovators to enforce the patents that protect innovative biological products and for biosimilar applicants to challenge the patents. Such patent litigation may begin as early as four years after the innovative biological product is first approved by the FDA.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the increased likelihood of generic and biosimilar challenges to innovators&#8217; intellectual property has increased the risk of loss of innovators&#8217; market exclusivity. First, generic companies have increasingly sought to challenge innovators&#8217; basic patents covering major pharmaceutical products. Second, statutory and regulatory provisions in the U.S. limit the ability of an innovator company to prevent generic and biosimilar drugs from being approved and launched while patent litigation is ongoing. As a result of all of these developments, it is not possible to predict the length of market exclusivity for a particular product with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Regulation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union and other geographies, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Union</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A typical route used by innovator companies to obtain marketing authorization of pharmaceutical products in the EU is through the &#8220;centralized procedure.&#8221; A company seeking to market an innovative pharmaceutical product through the centralized procedure must file a complete set of safety data and efficacy data as part of a Marketing Authorisation Application (&#8220;MAA&#8221;) with the EMA. After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies the MAA. It is also possible for new chemical products to obtain marketing authorization in the EU through a &#8220;mutual recognition procedure,&#8221; in which an application is made to a single member state, and if the member state approves the pharmaceutical product under a national procedure, then the applicant may submit that approval to the mutual recognition procedure of some or all other member states. After obtaining marketing authorization approval, a company must obtain pricing and reimbursement for the pharmaceutical product, which is typically subject to member state law. In certain EU countries, this process can take place simultaneously while the product is marketed but in other EU countries, this process must be completed before the company can market the new product. The pricing and reimbursement procedure can take months and sometimes years to complete. Throughout the EU, all products for which marketing authorizations have been filed after October&#47;November 2005 are subject to an &#8220;8+2+1&#8221; regime. Eight years after the innovator has received its first community authorization for a medicinal product, a generic company may file a MAA for that product with the health authorities. If the MAA is approved, the generic company may not commercialize the product until after either 10 or 11 years have elapsed from the initial marketing authorization granted to the innovator. The possible extension to 11 years is available if the innovator, during the first eight years of the marketing authorization, obtains an additional indication that is of significant clinical benefit in comparison with existing treatments. For products that were filed prior to October&#47;November 2005, there is a 10-year period of data protection under the centralized procedures and a period of either six or 10 years under the mutual recognition procedure (depending on the member state). In contrast to the U.S., patents in the EU are not listed with regulatory authorities. Generic versions of pharmaceutical products can be approved after data protection expires, regardless of whether the innovator holds patents covering its drug. Thus, it is possible that an innovator may be seeking to enforce its patents against a generic competitor that is already marketing its product. Also, the European patent system has an opposition procedure in which generic manufacturers may challenge the validity of patents covering innovator products within nine months of grant. In general, EU law treats chemically-synthesized drugs and biologically-derived drugs the same with respect to intellectual property and data protection. In addition to the relevant legislation and annexes related to biologic medicinal products, the EMA has issued guidelines that outline the additional information to be provided for biosimilar products, also known as generic biologics, in order to review an application for marketing approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Japan</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Japan, medicines of new chemical entities are generally afforded eight years of data exclusivity for approved indications and dosage. Patents on pharmaceutical products are enforceable. Generic copies can receive regulatory approval after data exclusivity and patent expirations. As in the U.S., patents in Japan may be extended to compensate for the patent term lost during the regulatory review process. In general, Japanese law treats chemically-synthesized and biologically-derived drugs the same with respect to intellectual property and market exclusivity. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rest of the World</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In countries outside of the U.S., the EU and Japan, there is a wide variety of legal systems with respect to intellectual property and market exclusivity of pharmaceuticals. Most other developed countries utilize systems similar to either the U.S. or the EU. Among developing countries, some have adopted patent laws and&#47;or regulatory exclusivity laws, while others have not. Some developing countries have formally adopted laws in order to comply with World Trade Organization (&#8220;WTO&#8221;) commitments, but have not taken steps to implement these laws in a meaningful way. Enforcement of WTO actions is a long process between governments, and there is no assurance of the outcome. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on licensed intellectual property in our business. If we are unable to obtain licenses from third parties on commercially reasonable terms or lose our rights to such licensed intellectual property, or if our rights are determined to be narrower than we understand them to be, we may not be able to continue developing or commercializing our product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of license agreements under which we are granted rights to intellectual property that are important to our business, including, for example, a license agreement with ALS Biopharma and Fox Chase Chemical Diversity Center, Inc., pursuant to which we were assigned intellectual property rights relating to troriluzole, license agreements with AstraZeneca, pursuant to which we were granted exclusive licenses relating to BHV-5500 and verdiperstat, a license agreement with Bristol-Myers Squibb, pursuant to which we were granted an exclusive license to BHV-2200, and a license agreement with KU Leuven, pursuant to which we were granted an exclusive license to develop and commercialize the TRPM3 antagonist platform. We may enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose on us, various development, regulatory and&#47;or commercial diligence obligations, payment of milestones and&#47;or royalties and other obligations, such as non-compete periods for certain collaboration targets and rights of first negotiation for development of certain programs. Typically, in our licenses, we have control over the filing, prosecution, maintenance and enforcement of the licensed intellectual property. However, in some cases, we may not control prosecution of the licensed intellectual property, or may not have the first right to enforce such intellectual property. In those cases, we may not be able to adequately influence patent prosecution or enforcement, or prevent inadvertent lapses of coverage due to failure to pay maintenance fees. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with any of our obligations under a current or future license agreement, the licensor may allege that we have breached our license agreement, and may seek to terminate our license. Termination of any of our current or future licenses could result in our loss of the right to use the licensed intellectual property, which could materially adversely affect our ability to develop, manufacture or commercialize a product candidate or product, if approved, as well as harm our competitive business position and our business prospects. Under some license agreements, termination may also result in the transfer of or granting of rights under certain of our intellectual property and information related to the product candidate being developed under the license, such as regulatory information. If our licensors fail to comply with their obligations under these agreements, such as, for example, by failing to maintain or enforce patents licensed to us, exclusivity relating to the products covered by the license may be diminished or lost. Our rights under license agreements could be determined to be narrower than we understand them to be. Also, if it is found that our licensors were not the original inventors of the licensed intellectual property, or were not the first to file patent applications, then we may lose rights to the licensed intellectual property.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing of intellectual property is important to our business and involves complex legal, business and scientific issues. Disputes between us and our licensors have arisen and may arise in the future. For example, disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues, including our right to sublicense patents and other rights to third parties&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our right to transfer or assign the license&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of termination.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop, manufacture or commercialize the affected product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It may be necessary or desirable for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would seek to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or payment of royalties and&#47;or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may not provide exclusivity for our product candidates for an adequate amount of time for us to realize commercial benefits.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States and most of the world, the statutory expiration of a patent is generally 20 years from the first filing date. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive products, including generic products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates may not provide us with exclusivity for an adequate amount of time for us to realize commercial benefits. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process, subject to a statutory maximum of fourteen (14) years from the regulatory approval and an additional six months of pediatric exclusivity if available. Similar regulations regarding patent term extensions, or supplementary protection certificates, are available in some countries such as the European Union, United Kingdom, Japan and Korea.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, we may not receive a patent term restoration, a supplementary protection certificate or extension if we fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain a patent term restoration, a supplementary protection certificate or extension, or the term is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may seek to invalidate our patents.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once granted, patents may remain open to invalidity challenges including opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation actions in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the patent owner may be compelled to limit the scope of the allowed or granted claims which are the subject of the challenge, or may lose the allowed or granted claims altogether.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic manufacturers seeking to launch a generic substitute of small molecule drug in the U.S. typically engage in patent challenges. We expect that as early as four (4) years after the approval of our products, one or more generic manufactures may allege that one or more of the patents listed in the Orange Book under our NDA is either invalid or not infringed (a Paragraph IV certification). We then must decide whether to file a patent infringement suit against such generic manufacturer(s). Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our technology, such as our compositions, formulations, or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. If, in the context of seeking approval for one of our product candidates subject to approval via Section 505(b)(2), we were required to file a Paragraph IV certification against any patents of a third party, we would additionally be at risk of an automatic stay if litigation is initiated, thereby potentially delaying our approval or market entry. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of resources from our business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a successful claim of infringement against us, we may have to pay substantial damages, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to claims of infringement made by third parties against us, we may file claims of infringement against third parties who infringe, or misappropriate, our patents or those of our licensors. This can occur as a counter claim in an infringement suit against us or as a direct claim against the third party. Our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable or claims challenging the scope of the intellectual property rights we own or control. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other risk factors relating to our intellectual property </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the risk factors described above, we consider the items below to be relevant for consideration in the assessment of the Company&#8217;s intellectual property position.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in intellectual property laws or regulations in the U.S. or other countries could negatively affect our business. Similarly, changes in the interpretation of such laws or regulations could have an impact on our business. For example, U.S. Supreme Court has ruled on several patent cases in recent years, such as Impression Products, Inc. v. Lexmark International, Inc., Association for Molecular Pathology v. Myriad Genetics, Inc., Mayo Collaborative Services v. Prometheus Laboratories, Inc., and Alice Corporation Pty. Ltd. v. CLS Bank International, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, decisions by courts may lead to legislation impacting our ability to obtain or enforce our intellectual property. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to enforce our intellectual property outside of the U.S. is dependent on the laws of jurisdiction in which the alleged infringement occurred, the ability to engage in discovery to obtain evidence and the availability of meaningful recoveries, e.g., damages and injunctions. The laws of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. As a result, our business may be harmed by limitations on our ability to protect our technology through the enforcement of our intellectual property in certain countries outside the U.S.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The U.S. government may seek to exercise its rights under the Bayh-Dole Act of 1980 in programs that have received government funding. This exercise of rights could require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party the U.S. Government determines that&#58; (i) adequate steps have not been taken to commercialize the invention&#59; (ii) government action is necessary to meet public health or safety needs&#59; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into confidentiality agreements with parties who have access to them, such as our employees, third party collaborators, contract manufacturers, consultants, advisors and other third parties. An unauthorized disclosure or use of our trade secrets can have an adverse impact on our business.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other innovator companies may independently develop alternative technologies to our technologies without infringing our intellectual property rights, such as, for example, by developing compounds that function according to the same mechanism of action as our compounds, but are chemically distinct from ours and are not covered by the claims of the patents that we own or control.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation involving intellectual property can be generally time consuming and expensive. Litigation or other legal proceedings relating to intellectual property claims is unpredictable and generally expensive and time-consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our valuation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations, Employee Matters and Managing Growth</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the management, development, clinical, financial and business development experience of our senior management. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or employees.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition for qualified personnel in the biopharmaceutical field is intense, and our future success depends upon our ability to attract, retain and motivate highly-skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement business strategy, which could harm our business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future profitability will depend, in part, on our ability to commercialize our product candidates in markets outside of the United States and the European Union. If we commercialize our product candidates in foreign markets, we will be subject to additional risks and uncertainties, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular economies and markets&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements, many of which vary between countries&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different medical practices and customs in foreign countries affecting acceptance in the marketplace&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tariffs and trade barriers&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or foreign governments&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer accounts receivable collection times&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer lead times for shipping&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is common&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">language barriers for technical training&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection of intellectual property rights in some foreign countries, and related prevalence of generic alternatives to therapeutics&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency exchange rate fluctuations and currency controls&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing foreign reimbursement landscapes&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertain and potentially inadequate reimbursement of our products&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign sales of our products could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations governing our international operations may preclude us from developing, manufacturing and selling certain product candidates and products outside of the United States and require us to develop and implement costly compliance programs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand our operations outside of the United States, we will be required to dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. We are subject to U.S. laws governing international business activities, including U.S. economic sanctions, export controls and anti-corruption laws, including the FCPA, compliance with which is expensive and difficult, particularly in countries in which corruption is a recognized problem. As a result, these laws may preclude us from developing, manufacturing or selling certain product candidates outside of the United States, which could limit our growth potential and increase our development costs. If our employees or agents violate our policies or we fail to maintain adequate record keeping and internal accounting practices to accurately record our transactions, we may be subject to regulatory sanctions. The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Violations of U.S. economic sanctions, export controls and anti-corruption laws, or allegations of such acts, could damage our reputation and subject us to civil or criminal investigations in the United States and in other jurisdictions and related shareholder lawsuits, could lead to substantial civil and criminal, monetary and nonmonetary penalties and could cause us to incur significant legal and investigatory fees which could adversely affect our business, combined financial condition and results of operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our clinical development progresses, we expect to experience growth in the number of our employees and the scope of our operations, particularly in the areas of clinical operations, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or unauthorized activities that violates (1)&#160;the laws and regulations of the FDA, the EMA and other similar regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (2)&#160;manufacturing standards, (3)&#160;federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad and (4)&#160;laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involve the improper use of individually identifiable information, including information obtained in the course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of product candidates, which could result in regulatory sanctions and serious harm to our reputation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have adopted a code of business conduct and ethics, it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert management attention.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share price may be volatile, and in the past companies that have experienced volatility in the market price of their shares have been subject to securities class action litigation. This risk is especially relevant for us because biotechnology companies have experienced significant share price volatility in recent years. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations may be materially adversely affected in the event of computer system failures or security breaches.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems, and those of our CROs and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyberattacks, natural disasters, fire, terrorism, war and telecommunication and electrical failures. If such an event were to occur and interrupt our operations, it could result in a material disruption of our development programs. For example, the loss of clinical trial data from ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, loss of trade secrets or inappropriate disclosure of confidential or proprietary information, including individually identifiable health information or the personal data of employees or former employees, access to our clinical data or disruption of the manufacturing process, we could incur liability and the further development of our product candidates could be delayed. We may also be vulnerable to cyberattacks by hackers or other malfeasance. This type of breach of our cybersecurity may compromise our confidential information or our financial information and adversely affect our business or result in legal proceedings.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including date concerning health, is subject to the EU General Data Protection Regulation, or GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing data concerning health and other sensitive data, obtaining consent of the individuals to whom the personal data relates to process their personal data, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global turnover, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Shares</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common shares may not be sustained, or be liquid enough for investors to resell our common shares quickly or at the market price.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares began trading on the NYSE on October 4, 2022. Although trading in our common shares has developed, we cannot assure you that an active trading market will continue to develop or be sustained or that any trading market will be liquid. If an active market for our common shares is not sustained, it may be difficult for our shareholders to sell shares without depressing the market price for the shares or to sell their shares at all. An inactive market may also impair our ability to raise capital to continue to fund operations by selling our common shares and may impair our ability to acquire other companies or technologies by using our common shares as consideration.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The trading price of our common shares may be volatile and may fluctuate due to factors beyond our control, and purchasers of our common shares could incur substantial losses.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share price may be volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our shareholders and investors may not be able to sell their common shares at or above the price paid for the shares. The market price for our common shares may be influenced by many factors, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">positive or negative results, including preliminary or topline results, of preclinical studies and clinical trials reported by us, strategic partners or competitors&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any progress or delay in the commencement, enrollment and the ultimate completion of clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">technological innovations or commercial product introductions by us or competitors&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully develop and commercialize any of our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments, announcements or changes in government regulations relating to drug products, including related to drug pricing, reimbursement and healthcare coverage&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in in-licensing or acquiring additional complementary product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning proprietary rights, including patents and litigation matters&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern relating to the commercial value or safety of any of our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financing or other corporate transactions, or inability to obtain additional funding&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements relating to our arrangements with AstraZeneca&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed expectations of the investment community&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in our operating results&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial estimates by us or by any securities analysts who might cover our shares&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by therapeutic drug product providers related to pricing of therapeutics&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant licenses, acquisitions, strategic partnerships or joint ventures by us or our competitors&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports or comments by securities or industry analysts&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to attract or retain of key personnel&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common shares, including sales by our directors and officers or specific shareholders&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market or regulatory conditions in the pharmaceutical industry or in the economy as a whole&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other events and factors, many of which are beyond our control&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors described in this &#8220;Risk Factors&#8221; section and elsewhere in this prospectus.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other market and industry factors may cause the market price and demand for our securities to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from selling their common shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our offerings or business practices. Defending against litigation is costly and time-consuming, and could divert our management&#8217;s attention and resources. Furthermore, during the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our common shares.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, the price of our common shares and our trading volume could decline.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common shares will depend, in part, on the research and reports that securities or industry analysts publish about us or our business. As a newly public company, we may not receive any research coverage by equity research analysts. Equity research analysts may elect not to initiate or to continue to provide research coverage of our common shares, and such lack of research coverage may adversely affect the market price of our common shares. Even if we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our shares could decline if one or more equity research analysts downgrade our shares or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our shares could decrease, which in turn could cause our share price or trading volume to decline.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our amended memorandum and articles of association (&#8220;Amended Memorandum and Articles of Association&#8221;) could make an acquisition of us, which may be beneficial to our shareholders, more difficult and may prevent attempts by our shareholders to replace or remove our current management and limit the market price of our common shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our Amended Memorandum and Articles of Association may discourage, delay or prevent a merger, acquisition or other change in control of us that shareholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for our common shares, thereby depressing the market price of our common shares. In addition, because our Board is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our shareholders to replace or remove our current management by making it more difficult for shareholders to replace members of our Board. Among other things, these provisions&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified Board such that not all members of the Board are elected at one time&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of our Board&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the manner in which shareholders can remove directors from the Board&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for shareholder proposals that can be acted on at shareholder meetings and nominations to our Board&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that shareholder actions must be effected at a duly called shareholder meeting and prohibit actions by our shareholders by written consent&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the ability of members to requisition and convene general meetings of members&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our Board to issue preferred shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preferred shares without any further vote or action by our members without shareholder approval, which could be used to institute a shareholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our Amended Memorandum and Articles of Association or BVI law that has the effect of delaying or deterring a change of control could limit the opportunity for our shareholders to receive a premium for their common shares, and could also affect the price that some investors are willing to pay for our common shares.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Substantially all of our total outstanding shares may be sold freely into the market. This could cause the market price of our common shares to drop significantly, even if our business is doing well.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of substantially all of our common shares in the public market, or the perception that these sales might occur, could depress the market price of our common shares and could impair our ability to raise capital through the sale of additional equity securities. Immediately following the Distribution, substantially all of our common shares became freely tradable, without restrictions or further registration under the Securities Act, subject to certain restrictions applicable to shares held by our affiliates as defined in Rule&#160;144 under the Securities Act.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not expect to pay dividends on our common shares in the foreseeable future, capital appreciation, if any, would be your sole source of gain.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our common shares. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. The decision to pay future dividends to shareholders will be at the discretion of our Board after taking into account various factors including our business prospects, cash requirements, financial performance and new product development. Accordingly, investors cannot rely on dividend income from our common shares and any returns on an investment in our common shares will likely depend entirely upon any future appreciation in the price of our common shares.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to &#8220;emerging growth companies&#8221; will make our common shares less attractive to investors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we continue to be an &#8220;emerging growth company,&#8221; we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies,&#8221; including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As an &#8220;emerging growth company,&#8221; we are required to report only two years of financial results in certain Securities Act registration statements. We may take advantage of these exemptions until we are no longer an &#8220;emerging growth company.&#8221; We will remain an &#8220;emerging growth company&#8221; for up to five years after the effective date of the registration statement of which this prospectus forms a part, although we will lose that status sooner if our revenues exceed $1.235 billion, if we issue more than $1 billion in non-convertible debt in a three-year period, or if the market value of our common shares that are held by non-affiliates exceeds $700 million as of June 30 of a fiscal year. We cannot predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and the price of our common shares may be more volatile than that of an otherwise comparable company that does not avail itself of the same or similar exemptions.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a&#160;smaller reporting company, and the reduced reporting requirements applicable to smaller reporting companies may make our common shares less attractive to investors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a &#8220;smaller reporting company&#8221; as defined in Rule&#160;12b-2 under the Exchange Act. For as long as we continue to be a&#160;smaller reporting company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies, including reduced financial statement and other financial information disclosure, and reduced disclosure obligations regarding executive compensation in our annual and periodic reports and proxy statements. We will remain a smaller reporting company as long as either (i) the market value of our common shares held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common shares held by non-affiliates is less than $700 million. Our public float is measured as of the last business day of our most recently completed second fiscal quarter, and annual revenues are as of the most recently completed fiscal year for which audited financial statements are available. We cannot predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and our share price may be more volatile than that of an otherwise comparable company that does not avail itself of the same or similar exemptions.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a BVI business company limited by shares and, the holders of our common shares may have fewer protections as a shareholder of our company, because judicial precedent regarding the rights of shareholders is more limited under BVI law than that under U.S. law.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate affairs are governed by our Amended Memorandum and Articles of Association as amended and restated from time to time, the BVI Business Companies Act (As Revised) (the &#8220;BVI Act&#8221;) and the common law of the BVI. The rights of shareholders to take legal action against our directors, actions by minority shareholders and the fiduciary responsibilities of our directors under BVI law are to a large extent governed by the common law of the BVI. The common law of the BVI is derived in part from comparatively limited judicial precedent in the BVI as well as from English common law, which has persuasive, but not binding, authority on a court in the BVI. The rights of our shareholders and the fiduciary responsibilities of our directors under BVI law therefore are not as clearly established as they would be under statutes or judicial precedents in some jurisdictions in the United States. In particular, the BVI has a less exhaustive body of securities laws as compared to the United States, and some states, such as Delaware, have more fully developed and judicially interpreted bodies of corporate law than the BVI. There is no statutory recognition in the BVI of judgments obtained in the U.S., although the courts of the BVI will in certain circumstances recognize and enforce a non-penal judgment of a foreign court of competent jurisdiction without retrial on the merits.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of all of the above, holders of our common shares may have more difficulty in protecting their interests through actions against our management, directors or controlling shareholders than they would as shareholders of a U.S. company. They may have greater difficulty securing legal advice about the law of the BVI than they would U.S. and state law, and the relatively less developed nature of the BVI&#8217;s securities law may leave investors with less certainty about the validity and strength of any claims they believe they may have against us. In addition, other differences between BVI and U.S. law, as well as the terms of our Amended Memorandum and Articles of Association, may result in shareholders having different potential influence than they would under various U.S. state laws with respect to matters such as officer and director actions, mergers and acquisitions, dispositions of assets, takeover efforts, and other corporate decision making. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholders in BVI business companies may not be able to initiate shareholder derivative actions, thereby depriving a shareholder of the ability to protect its interests.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While statutory provisions do exist in BVI law for derivative actions to be brought in certain circumstances, shareholders in BVI business companies may not have standing to initiate a shareholder derivative action in a federal court of the United States. The circumstances in which any such action may be brought, and the procedures and defenses that may be available in respect to any such action, may result in the rights of shareholders of a BVI business company being more limited than those of shareholders of a company organized in the United States. Accordingly, shareholders may have fewer alternatives available to them if they believe that corporate wrongdoing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has occurred. The BVI courts are also unlikely to&#58; (i)&#160;recognize or enforce against us judgments of courts in the United States based on certain civil liability provisions of U.S. securities law&#59; or (ii)&#160;to impose liabilities against us, in original actions brought in the BVI, based on certain civil liability provisions of U.S. securities laws that are penal in nature or that relate to taxes or similar fiscal or revenue obligations or would be viewed as contrary to BVI public policy or the proceedings pursuant to which judgment was obtained were contrary to natural justice. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no statutory recognition in the BVI of judgments obtained in the United States. However, the courts of the BVI will in certain circumstances recognize such a foreign judgment and treat it as a cause of action in itself which may be sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. court issuing the judgment had jurisdiction in the matter and the company either submitted to such jurisdiction or was resident or carrying on business within such jurisdiction and was duly served with process&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the judgment is final and for a liquidated sum&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the judgment given by the U.S. court was not in respect of penalties, taxes, fines or similar fiscal or revenue obligations of the company&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in obtaining judgment there was no fraud on the part of the person in whose favor judgment was given or on the part of the court&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition or enforcement of the judgment in the British Virgin Islands would not be contrary to public policy&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proceedings pursuant to which judgment was obtained were not contrary to natural justice.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The British Virgin Islands courts are unlikely&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to recognize or enforce against the Company, judgments of courts of the U.S. predicated upon the civil liability provisions of the securities law of the U.S.&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to impose liabilities against the Company, predicated upon the certain civil liability provisions of the securities laws of the U.S. so far as the liabilities imposed by those provisions are penal in nature.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The laws of the BVI relating to the protection of minority shareholders differ from those under U.S. law and, in some circumstances, may offer less protection.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BVI Act includes the following statutory remedies which minority shareholders in the company can rely upon&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the company or a director of the company engages in or proposes to engage in conduct, that contravenes the BVI Act or our Amended Memorandum and Articles of Association, a shareholder may apply to the BVI court for an order directing the company or its director(s) to comply with or restraining the company or a director from engaging in conduct that contravenes the BVI Act or our Amended Memorandum and Articles of Association.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the BVI Act, minority shareholders have a statutory right to bring a derivative action in the name of and on behalf of the company in circumstances where the company has a cause of action against its directors. This remedy is available at the discretion of the BVI court which will take a number of factors into account before granting or refusing a leave to proceed to the relevant shareholder, including whether such action is in the interests of the company, the cost of such action and whether there are alternative remedies that the shareholder concerned may rely upon.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A shareholder of the company may bring an action against the company for breach of duty owed to him or her as a shareholder. This would typically be relevant in a situation where a shareholder is aggrieved by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company for breach of an entitlement or right under the company&#8217;s Amended Memorandum and Articles of Association.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A shareholder of the company who considers that the affairs of the company have been, are being or likely to be, conducted in a manner that is, or any act or acts of the company have been, or are, likely to be oppressive, unfairly discriminatory, or unfairly prejudicial to him in that capacity, may apply to the BVI court for an order to remedy the situation. Again, this is a discretionary remedy and the BVI court will only award it if they are satisfied that it is just and equitable to do so.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A shareholder may, in certain circumstances, apply for liquidators to be appointed over the affairs of a company under the BVI&#8217;s Insolvency Act 2003 (as amended) (the &#8220;BVI Insolvency Act&#8221;.). Shareholders can also by resolution appoint a liquidator of a BVI business company under the BVI Act if the company is solvent or under the BVI Insolvency Act if the company is insolvent.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the statutory rights outlined above, there are common law rights for the protection of shareholders that may be invoked, largely dependent on English common law. Under the general rule&#160;pursuant to English common law known as the rule&#160;in Foss v. Harbottle, a court will generally refuse to interfere with the management of a company at the insistence of a minority of its shareholders who express dissatisfaction with the conduct of the company&#8217;s affairs by the majority or the Board. However, every shareholder is entitled to have the affairs of the company conducted properly according to law and the constituent documents of the company. As such, if those who control the company have persistently disregarded the requirements of company law or the provisions of the company&#8217;s Amended Memorandum and Articles of Association, then the courts will grant relief. Generally, the areas in which the courts will intervene are the following&#58; (1)&#160;an act complained of which is outside the scope of the authorized business or is illegal or not capable of ratification by the majority&#59; (2)&#160;acts that constitute fraud on the minority where the wrongdoers control the company&#59; (3)&#160;acts that infringe on the personal rights of the shareholders, such as the right to vote&#59; and (4)&#160;where the company has not complied with provisions requiring approval of the shareholders, which are more limited than the rights afforded minority shareholders under the laws of many states in the United States.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Having regard to the above, the protection available to minority shareholders under BVI law may be more limited than under the laws of some jurisdictions in the United States.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It may be difficult to enforce a U.S. or foreign judgment against us, our directors and our officers outside the United States, or to assert U.S. securities laws claims outside of the United States.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a BVI business company, it may be difficult for a shareholder to effect service of process within the United States upon us, our directors and officers, or to enforce against us, or them, judgments obtained in U.S. courts, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state therein. Additionally, it may be difficult to assert U.S. securities law claims in actions originally instituted outside of the United States. Foreign courts may refuse to hear a U.S. securities law claim because foreign courts may not be the most appropriate forums in which to bring such a claim. Even if a foreign court agrees to hear a claim, it may determine that the law of the jurisdiction in which the foreign court resides, and not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still be governed by the law of the jurisdiction in which the foreign court resides. Accordingly, it may be difficult or impossible for you to bring an action against us in the BVI if you believe your rights under the U.S. securities laws have been infringed. In addition, there is uncertainty as to whether the courts of the BVI would recognize or enforce judgments of U.S. courts against us or such persons predicated upon the civil liability provisions of the securities laws of the U.S. or any state and it is uncertain whether such British Virgin Islands courts would hear original actions brought in the British Virgin Islands against us or such persons predicated upon the securities laws of the U.S. or any state.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law, determinations by tax authorities or changes in our effective tax rates may adversely affect our business and financial results.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under current law, we expect to be treated as a non-U.S. corporation for U.S. federal income tax purposes. The tax laws applicable to our business activities, however, are subject to change and uncertain interpretation. Our tax position could be adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes in the interpretation thereof by the tax authorities in jurisdictions in which we do business. Our actual tax rate may vary from our expectation and that variance may be material. A number of factors may increase our future effective tax rates, including&#58; (1)&#160;the jurisdictions in which profits are determined to be earned and taxed&#59; (2)&#160;the resolution of issues arising from any future tax audits with various tax authorities&#59; (3)&#160;changes in the valuation of our deferred tax assets and liabilities&#59; (4)&#160;our ability to use net operating loss carryforwards to offset future taxable income and any adjustments to the amount of the net operating loss carryforwards we can utilize&#59; and (5)&#160;changes in tax laws or the interpretation of such tax laws, and changes in generally accepted accounting principles. We may also become subject to income, withholding or other taxes in jurisdictions by reason of our activities and operations, and it is possible that taxing authorities in such jurisdictions could assert that we are subject to greater taxation than we currently anticipate. Since 2017, the G20&#47;OECD Inclusive Framework has been working on addressing the tax challenges arising from the digitalization of the economy and has proposed a two-pillar tax approach with pillar one referring to the re-allocation of taxing rights, addressing issues such as where tax should be paid and on what basis (i.e., where sustained and significant business is conducted, regardless of a physical presence), and pillar two ensuring a minimum tax to be paid by multinational enterprises. We are unable to predict when and how the Inclusive Framework agreement will be enacted into law in the countries in which we operate, and it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate, could have a material effect on our liability for corporate taxes and our consolidated effective tax rate.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are or become a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. holders.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are or become a passive foreign investment company (&#8220;PFIC&#8221;) for any taxable year during which a U.S. holder holds our shares, the U.S. holder would be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Code, we would be a PFIC for any taxable year in which (1)&#160;75% or more of our gross income consisted of passive income or (2)&#160;50% or more of the average quarterly value of our assets consisted of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income includes, but is not limited to, dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations and subject to certain exceptions, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets and received directly its proportionate share of the income of such other corporation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe our common shares should not currently be stock of a PFIC for U.S. federal income tax purposes&#160;and do not expect to become a PFIC in the foreseeable future, we cannot provide any assurances regarding our PFIC status for any current or future taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies which in some circumstances are unclear and subject to varying interpretation. In particular, the determination of whether we are a PFIC and the characterization of our assets as active or passive may depend in part on (i) our current and intended future business plans which are subject to change, (ii) the application of certain &#8220;look-through&#8221; rules and (iii) the applicability of the &#8220;start-up exception.&#8221; Under the start-up exception, a foreign corporation that would otherwise be treated as a PFIC will not be a PFIC for the first taxable year the corporation has gross income (the &#8220;start-up year&#8221;), if&#58; (A) no predecessor of the corporation was a PFIC&#59; (B) the corporation satisfies the IRS that it will not be a PFIC for either of the first two taxable years following the start-up year&#59; and (C) the corporation is not in fact a PFIC for either of those years. The applicability of the startup exception to us is uncertain and will not be known until after the end of the two taxable years following such startup year. In addition, for our current and future taxable years, the total value of our assets for PFIC testing purposes may fluctuate considerably from time to time, and is dependent on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our application (which inherently involves an element of judgment) of the relevant valuation assumptions and methodologies. Under the income test, our status as a PFIC depends on the composition of our income which, in our current and future taxable years, we may not be able to fully control, for example, with respect to income attributed to us from entities owned 25% or more by us. The composition of our income and assets is also affected by how, and how quickly, we spend the cash we raise in any offering. Therefore, we cannot provide any assurance regarding our PFIC status for any past, current or future taxable years.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, a U.S. holder of shares in a PFIC may alleviate some of the adverse tax consequences described above by making a &#8220;qualified electing fund&#8221; (&#8220;QEF&#8221;) election to include in income its pro rata share of the corporation&#8217;s income on a current basis. However, a U.S. holder may make a QEF election with respect to our common shares only if we agree to furnish such U.S. holder annually with a PFIC annual information statement as specified in the applicable U.S. Treasury Regulations. We currently do not intend to prepare or provide the information that would enable U.S. holders to make a QEF election if we are treated as a PFIC for any taxable year, and U.S. holders of our common shares should assume that a QEF election will not be available.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see &#8220;Material U.S. Federal Income Tax Considerations&#8221; for further information. U.S. holders should consult their own tax advisors with respect to the operation of the PFIC rules and related reporting requirements in light of their particular circumstances, including the advisability of making any election that may be available.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mail addressed to us may not reach us in a timely manner.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mail addressed to the Company and received at its registered office will be forwarded unopened to the forwarding address supplied by Company to be dealt with. None of the Company, its directors, officers, advisors or service providers (including the organization which provides registered office services in the BVI) will bear any responsibility for any delay howsoever caused in mail reaching the forwarding address. Such risk will be borne solely by the Company&#8217;s shareholders.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Amended Memorandum and Articles of Association provide that unless we consent in writing to the selection of an alternative forum, the courts of the British Virgin Islands shall, with certain limited exceptions, be the sole and exclusive forum for certain disputes between us and our shareholders, which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended Memorandum and Articles of Association provide that unless we consent in writing to the selection of an alternative forum, the courts of the British Virgin Islands shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company&#8217;s members, (iii) any action asserting a claim arising pursuant to any provision of British Virgin Islands law or the Amended Memorandum and Articles of Association, or (iv) any action asserting a claim against the Company governed by the internal affairs doctrine, and that each shareholder consents to the exclusive jurisdiction of the courts of the British Virgin Islands over all such claims or disputes. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over actions brought under the Securities Act or the rules and regulations promulgated thereunder. Furthermore, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the forum selection provision in our Amended Memorandum and Articles of Association will not apply to actions or suits brought to enforce any liability or duty created by the Securities Act, Exchange Act or any claim for which the federal district courts of the United States of America are, as a matter of the laws of the United States of America, the sole and exclusive forum for determination of such a claim.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This choice of forum provision may increase a shareholder&#8217;s cost, impose additional litigation costs and limit the shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees, although our shareholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder and may therefore bring certain claims in another appropriate forum. Any person or entity purchasing or otherwise acquiring any of our shares or other securities, whether by transfer, sale, operation of law or otherwise, shall be deemed to have notice of and have irrevocably agreed and consented to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these provisions. It is possible that a court could find such a choice of forum provision to be inapplicable or unenforceable, and if a court were to find this provision in our Amended Memorandum and Articles of Association to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could have an adverse effect on our business, results of operations and financial condition.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because our common shares have only traded on the public market for a limited period of time, the market price and trading volume of our common shares may be volatile</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Distribution, there had not been a regular-way trading market for our common shares. We cannot predict the extent to which investors&#8217; interest will lead to a liquid trading market or whether the market price of our common shares will be volatile. The market price of our common shares could fluctuate significantly for many reasons, including in response to the risk factors listed in this prospectus or for reasons unrelated to our specific performance, such as reports by industry analysts, investor perceptions, or negative developments for our customers, competitors or suppliers, as well as general economic and industry conditions.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our historical financial results as a part of Former Parent and our unaudited pro forma combined financial statements may not be representative of our results as a separate, stand-alone company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The historical financial information we have included in this prospectus has been derived from the combined financial statements and accounting records of Former Parent and does not necessarily reflect what our financial position, results of operations or cash flows would have been had we been a separate, stand-alone company during the periods presented. The historical costs and expenses reflected in our combined financial statements include an allocation for certain corporate functions historically provided by Former Parent, including general corporate expenses and employee benefits and incentives. These allocations were based on what we and Former Parent considered to be reasonable reflections of the historical utilization levels of these services required in support of our business. The historical information does not necessarily indicate what our results of operations, financial position, cash flows or costs and expenses will be in the future. Our pro forma financial information set forth under &#8220;Unaudited Pro Forma Combined Financial Information&#8221; reflects changes to our operations as a result of the separation. However, there can be no assurances that this unaudited pro forma combined financial information will appropriately reflect our costs as a publicly traded company.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred, and expect to continue to incur, material costs and expenses as a result of our separation from Former Parent.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred, and will expect to continue to incur, costs and expenses greater than those we previously incurred while part of Former Parent as a result of our separation from Former Parent. These increased costs and expenses arise from various factors, including financial reporting and costs associated with complying with federal securities laws (including compliance with the Sarbanes-Oxley Act). In addition, we have increased corporate and administrative costs and expenses compared to those we incurred while part of Former Parent, even though we are now a smaller, stand-alone company. These costs may be material to our business.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act, or our internal control over financial reporting is not effective, the reliability of our financial statements may be questioned and our share price may suffer.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 404 of the Sarbanes-Oxley Act requires any company subject to the reporting requirements of the U.S. securities laws to do a comprehensive evaluation of its and its consolidated subsidiaries&#8217; internal control over financial reporting. To comply with this statute, we may eventually be required to document and test our internal control procedures, our management will be required to assess and issue a report concerning our internal control over financial reporting, and our independent auditors will be required to issue an opinion on the Company&#8217;s internal controls over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. If our management cannot favorably assess the effectiveness of our internal control over </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial reporting or our auditors identify material weaknesses in our internal controls, investor confidence in our financial results may weaken, and our share price may suffer. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to this Offering</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of the net proceeds from this offering.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways with which you may not agree. Accordingly, you will be relying on the judgment of our management with regard to the use of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the net proceeds will be invested or otherwise used in a way that does not yield a favorable, or any, return for us.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">You will experience dilution as a result of this offering, which may adversely affect the per share trading price of our common shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This offering may have a dilutive effect on our earnings per share after giving effect to the issuance of our common shares in this offering and the receipt of the expected net proceeds. The actual amount of dilution from this offering will be based on numerous factors, particularly the use of proceeds and the return generated by such investment, and cannot be determined at this time. The per share trading price of our common shares could decline as a result of sales of a large number of common shares in the market pursuant to this offering.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus contains &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward&#8209;looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;design,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would&#8221; or the negative version of these words and similar expressions are intended to identify forward&#8209;looking statements. We have based these forward&#8209;looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short&#8209; and long&#8209;term business operations and objectives, and financial needs. These forward&#8209;looking statements include, but are not limited to, statements concerning the following&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to develop and commercialize our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption from the Separation making it more difficult to maintain business and operational relationships&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unknown liabilities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk of litigation and&#47;or regulatory actions related to the separation or our business&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks and costs related to the implementation of the Separation, including any changes to the configuration of the businesses included in the Separation, if implemented&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future business combinations or disposals&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to diverting management&#8217;s attention from the Company&#8217;s ongoing business operation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ongoing and planned clinical trials, including discovery and proof of concept trials, the status of our ongoing clinical trials, commencement dates for new clinical trials, and the timing of clinical trial results&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical utility of our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to pursue research and development of other products&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into additional collaborations with third parties&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated future milestones, contingent and royalty payments and lease payments (and, in each case, their expected impact on liquidity)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of our products or product candidates, and our estimates regarding the potential market opportunity for our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position, including our competitors and competing products (including biosimilars)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated impact of interest rate changes on our financial statements&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and anticipated amounts of future tax payments and benefits (including the potential recognition of unrecognized tax benefits), as well as timing of conclusion of tax audits&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding future revenues, expenses and needs for additional financing&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the COVID-19 pandemic on our business, operations, commercialization plans, clinical trials, regulatory timelines and other plans.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward&#8209;looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward&#8209;looking statements we may make. In light of these risks, uncertainties and assumptions, the forward&#8209;looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward&#8209;looking statements.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward&#8209;looking statements as predictions of future events. We cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward&#8209;looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward&#8209;looking statements. We undertake no obligation to update publicly any forward&#8209;looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDUSTRY AND MARKET DATA</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus contains statistical data, estimates, and forecasts that are based on independent industry publications, or other publicly available information, as well as other information based on our internal sources. Although we believe that the third-party sources referred to in this prospectus are reliable, neither we nor the underwriters have independently verified the information provided by these third parties. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_28"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USE OF PROCEEDS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that our net proceeds from this offering will be approximately $233.1 million (or approximately $268.1&#160;million if the underwriters exercise their option to purchase additional common shares in full), after deducting the underwriting discount and prior to paying any offering expenses, based on an offering price of $12.40 per share (the closing price for our common shares on the NYSE on October&#160;19, 2022). We intend to use the net proceeds of this offering for general corporate purposes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_31"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIVIDEND POLICY</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to pay any cash dividends on our common shares in the foreseeable future. All decisions regarding the payment of dividends will be made by our Board from time to time in accordance with applicable law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_34"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAPITALIZATION</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Biohaven Business cash and capitalization as of June 30, 2022 </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">on a historical basis&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">on a pro forma basis to give effect to the pro forma adjustments included in our unaudited pro forma combined financial information&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">on a pro forma as adjusted basis, giving effect to the sale of the shares in this offering at the assumed price of $12.40 per share, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us and excluding any exercise of the underwriters&#8217; option to purchase additional shares. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information below is not necessarily indicative of what our capitalization would have been had the Spin-Off and Distribution been completed as of June 30, 2022. In addition, it is not indicative of our future capitalization. This table should be read in conjunction with &#8220;Unaudited Pro Forma Combined Financial Information,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; &#8220;Summary Historical and Unaudited Pro Forma Combined Financial Data&#8221; and the audited combined financial statements and corresponding notes included elsewhere in this prospectus.</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Historical</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pro Forma</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pro Forma as Adjusted</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,209&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,799&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,919&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt&#58; </font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current debt</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity&#58; </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment from Parent</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,998&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, no par value&#59; 200,000 shares authorized,  36,587 shares issued and outstanding on a pro forma basis&#59;  59,376 shares issued and outstanding on a pro forma as adjusted basis </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,228&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,348&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total capitalization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,998&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,228&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,348&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_37"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DILUTION</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you invest in our common shares in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public offering price per common share and the as adjusted net tangible book value per common share immediately after this offering.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our pro forma net tangible book value as of June 30, 2022 was $242.4 million, or $6.16 per common share. Our pro forma net tangible book value is the amount of our total tangible assets less our total liabilities. Pro forma net tangible book value per share represents historical net tangible book value divided by the 39,375,944 common shares outstanding as of October 14, 2022.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After giving effect to the issuance and sale of 20,000,000 common shares in this offering at the public offering price of $12.40 per share and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of June 30, 2022 would have been $474.6 million, or $7.99 per common share. This represents an immediate increase in as adjusted net tangible book value of $1.83 per share to existing shareholders and immediate dilution in as adjusted net tangible book value of $4.41 per share to new investors purchasing common shares in this offering. The following table illustrates this per share dilution&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public offering price per share</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.40&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net tangible book value per share as of June 30, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$              6.16</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in as adjusted net tangible book value per share attributable to this offering</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.83 </font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As adjusted net tangible book value per share after this offering</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.99</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilution per share to new investors purchasing common shares in this offering</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.41&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the underwriters exercise their option to purchase additional shares in this offering in full, the as adjusted net tangible book value per share after this offering would be $8.17 per share and the dilution in as adjusted net tangible book value per share to new investors purchasing common shares in this offering would be $4.23 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table and discussion above do not include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">9,110,000 common shares issuable upon the exercise of stock options outstanding as of October 14, 2022, at an exercise price of $7 per share&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">80,000 common shares reserved for future issuance of awards under the 2022 Plan&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">393,769 common shares reserved for future issuance under our 2022 Employee Share Purchase Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma combined financial information of the Company gives effect to the Separation and related adjustments in accordance with Article 11 of the SEC&#8217;s Regulation S-X. In May 2020, the SEC adopted Release No.33-10786 &#8220;Amendments to Financial Disclosures about Acquired and Disposed Businesses,&#8221; or the Final Rule. The Final Rule was effective on January 1, 2021 and the unaudited pro forma combined financial information herein is presented in accordance therewith.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma combined financial information presented below have been derived from our historical combined financial statements included in this prospectus. While the historical combined financial statements reflect the historical financial results of the Biohaven Business, these pro forma statements give effect to the separation of the Biohaven Business into an independent, publicly traded company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma combined balance sheet gives effect to the Separation and related transactions described below as if they had occurred on June 30, 2022. The unaudited pro forma adjustments to the combined statement of operations for the six months ended June 30, 2022 and year ended December 31, 2021 assume that the Separation and related transactions occurred as of January 1, 2021.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma combined statement of operations for the six months ended June 30, 2022 and year ended December 31, 2021 and the unaudited pro forma combined balance sheet as of June 30, 2022 have been prepared to reflect adjustments to the Company&#8217;s historical combined financial information for the following transaction accounting and autonomous entity adjustments&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issuance of approximately 36,587,038 common shares of the Company as part of the spin-off&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of our anticipated post-separation capital structure, which includes an anticipated cash advancement to the Company from the Former Parent equal to the remainder of $275 million of cash minus the sum of the amount of marketable securities and cash and cash equivalents held by the Company as of the close of business on the day prior to the effective time of the Distribution, subject to certain adjustments agreed to by the Former Parent and Pfizer&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the Separation and Distribution Agreement, dated as of May 9, 2022 (the &#8220;Distribution Agreement&#8221;), by and between the Company and the Former Parent, the Transition Services Agreement, dated as of October 3, 2022 (the &#8220;Transition Services Agreement&#8221;), by and between the Company and the Former Parent, and other agreements between the Company and the Former Parent and the provisions contained therein&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the one-time expenses associated with the separation of the Company&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the aforementioned adjustments on the Company&#8217;s income tax expense.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma adjustments are based on available information and assumptions that management believes are reasonable given the information that is currently available. The unaudited pro forma combined financial statements are for informational purposes only and do not purport to represent what the Company&#8217;s financial position and results of operations actually would have been had the Spin-Off and the Distribution occurred on the dates indicated, or to project the Company&#8217;s financial performance for any future period. The historical audited combined annual and unaudited combined interim financial statements of the Biohaven Business have been derived from Former Parent&#8217;s historical accounting records and reflect certain allocations of expenses. All of the allocations and estimates in such financial statements are based on assumptions that Former Parent&#8217;s management believes are reasonable. The historical combined financial statements do not necessarily represent the financial position or results of operations of the Biohaven Business had it been operated as a standalone company during the periods or at the dates presented. As a result, autonomous entity adjustments have been reflected in the unaudited pro forma combined financial information.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma combined financial information should be read in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our historical audited combined </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">annual and unaudited combined interim financial statements and corresponding notes thereto included elsewhere in this prospectus. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_43"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED PRO FORMA COMBINED BALANCE SHEET</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Historical</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transaction Accounting Adjustments</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pro Forma</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,209&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,590&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;A&#93;, &#91;B&#93;, &#91;C&#93;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,799&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,469&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,469&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,073&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,073&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,751&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,590&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,341&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,397&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,397&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,282&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,282&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,220&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,590&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,810&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity </font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,640)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;B&#93;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,473&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,473&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,850&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,640)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,210&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,372&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,372&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,222&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,640)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,582&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, no par value 200,000 shares authorized&#59; 36,587 shares issued and outstanding on a pro forma basis</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,228&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;D&#93;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,228&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment from Parent</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,998&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,998)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;A&#93;, &#91;C&#93;, &#91;D&#93;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity (deficit)</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,998&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,230&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,228&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity (deficit)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,220&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,590&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,810&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_46"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED PRO FORMA COMBINED STATEMENT OF OPERATIONS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Historical</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Autonomous Entity Adjustments</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pro Forma</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,183&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,701&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;E&#93;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,884&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,700&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,822&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;E&#93;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,522&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,883&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,523&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,406&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286,883)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,523)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299,406)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286,954)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,523)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299,477)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,365&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;G&#93;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,845&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300,319)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,003)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314,322)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;H&#93;, &#91;I&#93;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.59)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#8212;basic and diluted</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;H&#93;, &#91;I&#93;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,587&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_49"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED PRO FORMA COMBINED STATEMENT OF OPERATIONS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Historical</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transaction Accounting Adjustments</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Autonomous Entity Adjustments</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pro Forma</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,775&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;E&#93;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,486&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,911&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;F&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,172&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,046&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;E&#93;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,414&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;C&#93;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;F&#93;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,223&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,900&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,945&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,395&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218,900)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,550)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,945)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(247,395)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from equity method investment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,261&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,261&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.209&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,683&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;F&#93;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,892&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,470&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,683&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,153&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212,430)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,550)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,262)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223,242)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;G&#93;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;G&#93;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,796)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,550)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,483)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,829)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;H&#93;, &#91;I&#93;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.60)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;H&#93;, &#91;I&#93;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,077&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_52"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Pro Forma Combined Financial Data</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.12pt">Reflects the cash contribution from Former Parent to the Company for funding amount pursuant to the Distribution Agreement and subject to adjustments agreed to between Former Parent and Pfizer as described in more detail below.</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the effective time of the Distribution, Pfizer or an affiliate of Pfizer advanced to Former Parent $275 million, minus the sum of the amount of marketable securities and cash and cash equivalents contained in any accounts held by the Company as of the close of business on the day prior to the date of the Distribution, and Former Parent contributed such funding to the Company. The Company&#8217;s liabilities under the Distribution Agreement include payment of certain distribution related expenses (see Note (B) below for more information) of the Spin-Off and Merger, which amounts, estimated at approximately $5.8 million, are deducted from the cash paid by Pfizer to Former Parent immediately prior to the effective time of the Distribution. Former Parent and Pfizer also entered into a side letter, which provided that the Company funding amount would also be reduced by approximately $4 million in connection with the purchase by the Company of shares of capital stock of Artizan Biosciences Inc., and by approximately $7.4 million of transaction expenses allocated to the Company.</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the adjustments described above, we anticipate that the Company had approximately $257.8&#160;million in cash as of the Distribution date.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following adjustment has been recorded to cash (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biohaven Funding amount, prior to adjustments</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biohaven cash as of June 30, 2022</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,209)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Artizan funding amount</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other transaction expenses as agreed per the side letter</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,429)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution expenses - Amount incurred to date (of which $2.6M is accrued as of June 30, 2022 (See Note (B) below))</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,222)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution expenses - Estimated remaining amount (See Note (C) below)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,550)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transaction accounting adjustment to cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">234,590</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt">Reflects the payment of $2.6 million of certain expenses incurred and accrued by the Company as of June 30, 2022. In accordance with the terms of the Distribution Agreement, all costs and expenses incurred on or prior to the Distribution date (whether or not paid on or prior to the Distribution date) in connection with the preparation, execution, delivery, printing and implementation of the Distribution Agreement, the Transition Services Agreement and the Spin-Off registration statement, and the Distribution and the consummation of the transactions contemplated thereby, shall be charged to and paid by the Company, and shall be deemed to be the Company&#8217;s liabilities.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt">Reflects the payment of the remaining $2.6 million estimated Distribution expenses. The pro forma combined statement of operations for the year ended December 31, 2021 reflects the estimated Distribution related costs expected to be incurred by the Company subsequent to June 30, 2022. The Distribution expenses, except for $1.5 million in recurring costs for audit fees, are nonrecurring.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.12pt">Represents the reclassification of Former Parent&#8217;s net investment in the Company, including other pro forma adjustments, into common shares, no par value, to reflect the number of our common shares expected to be outstanding at Distribution date. The assumed number of outstanding common shares is based on the Former Parent common shares outstanding as of June 30, 2022 and a pro-rata distribution ratio of one Biohaven common share for every two Former Parent common shares, plus incremental shares of 1,031,503 for the Company RSUs and performance share units (&#8220;PSUs&#8221;) that fully vested upon the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective Time as stated in the Distribution Agreement and assumed to be issued by the Company on the Distribution date.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.24pt">Reflects the incremental compensation costs for the difference in the amount of salary and bonus and stock-based compensation expenses allocated to the historical statements of operations for the Company and the amount of compensation costs that the Company expects to incur based on actual current employees that are expected to transfer to the Company and based on current employment agreements in place and historical compensation cost amounts.</font></div><div style="margin-bottom:9pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following adjustments have been recorded to research and development and general and administrative (in thousands)&#58;</font></div><div style="margin-bottom:9pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:69.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary and bonus</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,701&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,775&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Autonomous entity adjustment to research and development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,701</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,775</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary and bonus</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,960&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Autonomous entity adjustment to general and administrative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,822</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,046</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Reflects the effect of a Transition Services Agreement whereby the Company will provide certain transition services to Former Parent, and Former Parent will provide certain transition services to the Company, generally for up to one year with options to extend, as necessary. The other income, net adjustment of $17.7 million reflects the Transition Services Agreement revenue that the Company would have recorded for services and resources related to commercialization and administration support provided to Former Parent under the Transition Services Agreement. Pricing under this agreement will reflect the Company&#8217;s costs plus a nominal markup. The research and development adjustment of $5.9 million and the general and administrative adjustment of $0.2 million reflects the costs that the Company would have recorded for the services Former Parent will provide to the Company. The research and development and general and administrative adjustments reflect the historical services from Former Parent to the Company under the terms of the Transition Services Agreement. The parties enter into the Transition Services Agreement prior to the Separation. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.12pt">Reflects the adjustment to provision for income taxes of $1.5 million and $0.2 million for the six months ended June 30, 2022 and year ended December 31, 2021, respectively. The adjustment was determined by applying the respective statutory tax rates to pre-tax pro forma adjustments and reflecting the impact of the valuation allowance recorded against deferred taxes, on a jurisdictional level. The Company&#8217;s post-separation income taxes will be impacted by many factors, including the profitability in local jurisdictions and the legal entity structure subsequent to Separation, and may be materially different from the pro forma results.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(H)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.12pt">The number of our common shares used to compute basic earnings per share for the six months ended June 30, 2022 and year ended December 31, 2021 is based on the number of our common shares assumed to be outstanding on those dates, assuming the distribution ratio of one share of Biohaven common share for every two Former Parent common shares outstanding, plus incremental shares of 1,031,503 and 610,253 for the six months ended June 30, 2022 and year ended December 31, 2021, respectively, for Biohaven RSUs and PSUs that will be fully vested upon the Effective Time as stated in the Distribution Agreement and assumed to be issued by the Company on the Distribution date. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt">The number of shares used to compute diluted loss per shares is the same as the basic Biohaven common shares as described in Note (H) above, due to a net loss reported in the unaudited pro forma combined </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements of operations for the six months ended June 30, 2022 and year ended December 31, 2021. The Company has not considered the effect of outstanding options and warrants expected to be issued by the Company as replacement awards to Former Parent employees transferring to the Company, since their inclusion would be anti-dilutive. </font></div><div style="margin-bottom:9pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s anti-dilutive pro forma options and warrants are as follows based on the Distribution Ratio, using an assumed Former Parent value equal to the Merger Consideration pursuant to the Merger Agreement and an assumed Biohaven value of the cash contribution per share from Former Parent to the Company for the funding amount pursuant to the Distribution Agreement and subject to adjustments agreed to between Former Parent and Pfizer (in thousands)&#58;</font></div><div style="margin-bottom:9pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:69.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,609&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,727&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,640&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_55"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of the financial condition and results of operations of the Biohaven Business (as defined below) should be read in conjunction with &#8220;Unaudited Pro Forma Combined Financial Information&#8221; and the audited combined and the unaudited condensed combined financial statements and corresponding notes thereto included elsewhere in this prospectus. This discussion includes forward&#8209;looking statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward&#8209;looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;design,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would&#8221; or the negative version of these words and similar expressions are intended to identify forward&#8209;looking statements. We have based these forward&#8209;looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short&#8209; and long&#8209;term business operations and objectives, and financial needs. These forward&#8209;looking statements include, but are not limited to, statements concerning the following&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to develop and commercialize our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption from the Separation making it more difficult to maintain business and operational relationships&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unknown liabilities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk of litigation and&#47;or regulatory actions related to the separation or our business&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks and costs related to the implementation of the Separation, including any changes to the configuration of the businesses included in the Separation, if implemented&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future business combinations or disposals&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to diverting management&#8217;s attention from the Company&#8217;s ongoing business operation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ongoing and planned clinical trials, including discovery and proof of concept trials, the status of our ongoing clinical trials, commencement dates for new clinical trials, and the timing of clinical trial results&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical utility of our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to pursue research and development of other products&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into additional collaborations with third parties&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated future milestones, contingent and royalty payments and lease payments (and, in each case, their expected impact on liquidity)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of our products or product candidates, and our estimates regarding the potential market opportunity for our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position, including our competitors and competing products (including biosimilars)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated impact of interest rate changes on our financial statements&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and anticipated amounts of future tax payments and benefits (including the potential recognition of unrecognized tax benefits), as well as timing of conclusion of tax audits&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding future revenues, expenses and needs for additional financing&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the COVID-19 pandemic on our business, operations, commercialization plans, clinical trials, regulatory timelines and other plans.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward&#8209;looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward&#8209;looking statements we may make. In light of these risks, uncertainties and assumptions, the forward&#8209;looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward&#8209;looking statements.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward&#8209;looking statements as predictions of future events. We cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward&#8209;looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward&#8209;looking statements. We undertake no obligation to update publicly any forward&#8209;looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation from Former Parent</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2022, the Board of Directors of Former Parent approved and directed Former Parent&#8217;s management to effect the spin-off of the Kv7 ion channel activators, glutamate modulation and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by Former Parent, or collectively the &#8220;Biohaven Business&#8221;. The Spin-Off was subsequently completed on October 3, 2022. To implement the Spin-Off, Former Parent transferred the related license agreements, intellectual property and Former Parent&#8217;s corporate infrastructure, including certain non-commercial employee agreements, share-based awards and other corporate agreements (the &#8220;Business&#8221;) to Biohaven Ltd, through the Separation. On&#160;October 3, 2022, each Former Parent shareholder received one of our common shares for every two Former Parent common shares held of record at the close of business on September 26, 2022, the record date for the Distribution. Registered shareholders received cash in lieu of any fractional common shares that they would have received as a result of the application of the Distribution ratio. Upon completion of the Distribution, we became a stand-alone, publicly traded company focused on the development of our Kv7 ion channel activators, glutamate modulation and myostatin inhibition platforms, which we believe have the potential to alter existing treatment approaches across a diverse set of neurological indications with high unmet need in both large markets and orphan indications.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The historical combined financial statements of the Biohaven Business have been prepared on a stand-alone basis and are derived from Former Parent&#8217;s consolidated financial statements and accounting records and are presented in conformity with U.S. GAAP. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial position, results of operations and cash flows of the Biohaven Business historically operated as part of Former Parent&#8217;s financial position, results of operations and cash flows prior to and until the distribution of our common shares to Former Parent&#8217;s shareholders. These historical combined financial statements may not be indicative of the future performance of the Biohaven Business and do not necessarily reflect what its combined results of operations, financial condition and cash flows would have been had it operated as a separate, publicly traded company during the periods presented. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where we describe historical business activities in this prospectus, we do so as if these transfers had already occurred and Former Parent&#8217;s activities related to such assets and liabilities had been performed by the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1, Nature of the Business and Basis of Presentation, of the Notes to the Combined Financial Statements appearing elsewhere in this prospectus for further discussion of the underlying basis used to prepare the combined financial statements. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transition from Former Parent and Costs to Operate as an Independent Company</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combined financial statements reflect the operating results and financial position of the Biohaven Business as it was operated by Former Parent prior to the Separation, rather than as an independent company. We have incurred and will continue to incur ongoing operating expenses to operate as an independent company. These costs include the cost of various corporate headquarters functions, information technology-related costs and costs to operate stand-alone accounting, legal and other administrative functions. We also incur non-recurring expenses and non-recurring capital expenditures. As an independent company, our information technology operating costs may be higher than the costs allocated in the historical combined financial statements. It is not practicable to estimate the costs that would have been incurred in each of the periods presented in the historical combined financial statements for the functions described above. Actual costs that would have been incurred if we operated as a stand-alone company during these periods would have depended on various factors, including organizational design, outsourcing and other strategic decisions related to corporate functions, information technology and back office infrastructure. We have entered into a transition services agreement with Former Parent, pursuant to which we provide Former Parent with, and also receive from Former Parent, certain services and resources related to corporate functions for a transitional period. During the transition from Former Parent, we may incur non-recurring expenses to expand our infrastructure. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transactions with Related Parties</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a Distribution Agreement and various agreements relating to transition services, licenses and certain other matters with Former Parent. These agreements govern our relationship with Former Parent and include the allocation of employee benefits, taxes and certain other liabilities and obligations attributable to periods prior to, at and after the Distribution. We have agreed to provide Former Parent with indemnities with respect to liabilities arising out of our business, and Former Parent has agreed to provide us with indemnities with respect to liabilities arising out of the business retained by Former Parent. These agreements also include arrangements with respect to support services and a number of on-going commercial relationships. The terms of these agreements, including information on the business purpose of such agreements, transaction prices, related ongoing contractual commitments and any related special risks or contingencies are discussed in greater detail under &#8220;Certain Relationships and Related-Party Transactions&#8221; appearing elsewhere in this prospectus. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company that combines a deep understanding of neuroscience, immunoscience, disease-related biology, advanced chemistry and expertise in global clinical trials to advance novel therapies for patients. Our experienced management team brings with it a proven track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia, and our research programs, built on a deep understanding of disease-related biology and neuropharmacology, are advancing novel therapies with target indications, including epilepsy, mood disorders, OCD, SMA and pain disorders. Our neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing our broad and diverse pipeline with at least five clinical trials currently underway or expected to start by the end of 2022. We have built a highly experienced team of senior leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with capabilities in drug discovery and development. In addition, we have several preclinical assets in our early discovery program, targeting neuroscience and immunology indications.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our recent and expected clinical-stage milestones&#58;</font></div><div style="margin-bottom:9pt;padding-left:2.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:20.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#f2f4f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Drug Name</font></td><td colspan="3" style="background-color:#f2f4f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indication</font></td><td colspan="3" style="background-color:#f2f4f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1H2021</font></td><td colspan="3" style="background-color:#f2f4f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2H2021</font></td><td colspan="6" style="background-color:#f2f4f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1H2022</font></td><td colspan="6" style="background-color:#f2f4f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2H2022</font></td><td colspan="6" style="background-color:#f2f4f6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BHV-7000</font></div><div><font style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kv7 channel modulator</font></div></td><td colspan="3" style="border-left:1pt solid #8c56ee;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Focal epilepsy</font></td><td colspan="3" style="background-color:#d9c6f9;padding:0 1pt"></td><td colspan="3" style="background-color:#d9c6f9;padding:0 1pt"></td><td colspan="6" style="background-color:#d9c6f9;padding:0 1pt"></td><td colspan="6" style="background-color:#8c56ee;border-left:2pt dashed #ffef87;border-top:2pt dashed #ffef87;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Start Phase 1</font></td><td colspan="3" style="border-left:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="border-top:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="border-top:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#58bd2b;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Troriluzole</font></div><div><font style="color:#58bd2b;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NCE prodrug of riluzole</font></div></td><td colspan="3" style="border-left:1pt solid #58bd2b;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinocerebellar ataxia</font></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"></td><td colspan="6" style="background-color:#58bd2b;border-left:2pt dashed #ffef87;border-top:2pt dashed #ffef87;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Topline</font></td><td colspan="6" style="background-color:#ffffff;border-left:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #58bd2b;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:1pt solid #58bd2b;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Obsessive-Compulsive Disorder (&#8220;OCD&#8221;)</font></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"></td><td colspan="6" style="background-color:#dbe9cd;padding:0 1pt"></td><td colspan="6" style="background-color:#dbe9cd;padding:0 1pt"></td><td colspan="6" style="background-color:#58bd2b;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Complete Enrollment</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#34a4e2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Taldefgrobep Alfa</font></div><div><font style="color:#34a4e2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anti-myostatin adnectin</font></div></td><td colspan="3" style="border-left:1pt solid #34a4e2;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy (&#8220;SMA&#8221;)</font></td><td colspan="3" style="background-color:#def2fb;padding:0 1pt"></td><td colspan="3" style="background-color:#def2fb;padding:0 1pt"></td><td colspan="3" style="background-color:#def2fb;padding:0 1pt"></td><td colspan="6" style="background-color:#34a4e2;border-left:2pt dashed #ffef87;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Start Phase 3</font></td><td colspan="3" style="background-color:#ffffff;border-left:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#fbc150;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BHV-1100</font></div><div><font style="color:#fbc150;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARM combo</font></div></td><td colspan="3" style="border-left:1pt solid #faac16;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Myeloma</font></td><td colspan="3" style="background-color:#feeac5;padding:0 1pt"></td><td colspan="3" style="background-color:#fbc150;border-left:2pt dashed #ffef87;border-top:2pt dashed #ffef87;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Start Phase 1</font></td><td colspan="3" style="border-left:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:2pt dashed #ffef87;border-left:2pt dashed #ffef87;border-top:2pt dashed #ffef87;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milestone Achieved</font></td><td colspan="3" style="border-left:2pt dashed #ffef87;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kv7 Platform</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BHV-7000</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we closed the acquisition from Knopp Biosciences LLC (&#8220;Knopp&#8221;) of Channel Biosciences, LLC (&#8220;Channel&#8221;), a wholly owned subsidiary of Knopp owning the assets of Knopp&#8217;s Kv7 channel targeting platform, pursuant to a Membership Interest Purchase Agreement, dated February 24, 2022. The acquisition of the Kv7 channel targeting platform adds the latest advances in ion-channel modulation to our growing neuroscience portfolio. BHV-7000 (formerly known as KB-3061) is the lead asset from the Kv7 platform and is a potassium channel activator with a preclinical profile suggestive of a wide therapeutic index, high selectivity, and significantly reduced GABA-ergic activity. In the second quarter of 2022, our Clinical Trial Application for BHV-7000 was approved by Health Canada, and we subsequently began clinical development. The Company is evaluating and has not yet finalized potential clinical trial designs, including trial size and primary and secondary endpoints.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the transaction, on April 4, 2022, the Company made an upfront payment comprised of $35 million in cash and 493,254 common shares of Former Parent, valued at approximately $58.8 million, issued through a private placement. The Company has also agreed to pay additional success-based payments comprised of (i) up to $325 million based on developmental and regulatory milestones through approvals in the United States, EMEA and Japan for the lead asset, BHV-7000 (formerly known as KB-3061), (ii) up to an additional $250 million based on developmental and regulatory milestones for the Kv7 pipeline development in other indications and additional country approvals, and (iii) up to $562 million for commercial sales-based milestones of BHV-7000. Additionally, the Company has agreed to make scaled royalty payments in cash for BHV-7000 and the pipeline programs, starting at high single digits and peaking at low teens for BHV-7000 and starting at mid-single digits and peaking at low tens for the pipeline programs.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Glutamate Platform</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most advanced product candidate from our glutamate receptor antagonist platform is troriluzole (previously referred to as trigriluzole and BHV-4157), which is in multiple Phase 3 trials. Other product candidates include BHV-5500, which is an antagonist of the glutamate N-methyl-D-aspartate (&#8220;NMDA&#8221;) receptor and its oral prodrug BHV-5000.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Troriluzole</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spinocerebellar Ataxia</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of its investigational therapy, troriluzole, in adult patients with SCA. The primary endpoint, change from baseline to week 48 on the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA), did not reach statistical significance in the overall SCA population as there was less than expected disease progression over </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the course of the study. In the overall study population (N&#61;213), the troriluzole and placebo groups each had mean baseline scores of 4.9 on the f-SARA and the two groups showed minimal change at the 48-week endpoint with f-SARA scores of 5.0 and 5.1, respectively (p&#61;0.76). Troriluzole was well tolerated with an adverse event profile similar to placebo. The frequency of subjects with any TEAE was 80.6% for troriluzole vs. 84.4% for placebo and the frequency of subjects with serious TEAEs was 5.6% for troriluzole vs. 7.3% for placebo.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-hoc analysis of efficacy measures by genotype suggests a treatment effect in patients with the SCA Type 3 (&#8220;SCA3&#8221;) genotype, which represents the most common form of SCA and accounted for 41% of the study population. In the SCA3 subgroup, troriluzole showed a numerical treatment benefit on the change in f-SARA score from baseline to Week 48 compared to placebo (least squares (&#8220;LS&#8221;) mean change difference -0.55, nominal p-value &#61; 0.053, 95% CI&#58; -1.12, 0.01). SCA patients treated with troriluzole showed minimal disease progression over the study period. Further, in patients in the SCA3 subgroup who were able to walk without assistance at baseline (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, f-SARA Gait Item score &#61; 1), troriluzole demonstrated a greater numerical treatment benefit on the change in f-SARA score from baseline to Week 48 compared to placebo (LS mean change difference -0.71, nominal p-value &#61; 0.031, 95% CI&#58; -1.36, -0.07). Notably, the f-SARA is a novel, 16-point scale developed based on feedback from the FDA as the primary outcome measure for this trial&#59; the scale was designed to assess clinically meaningful changes in function. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across all SCA genotypes, and SCA3 specifically, patient reported falls, as measured by adverse events, reveal reduction of fall risk in the troriluzole group compared to placebo.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk reduction of falls in the troriluzole group combined with the progression of f-SARA scores in the untreated SCA3 group compared to SCA3 patients on troriluzole demonstrates that SCA3 patients are experiencing a clinically meaningful improvement in ataxia symptoms on troriluzole treatment. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obsessive Compulsive Disorder</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced a Phase 2&#47;3 double-blind, randomized, controlled trial to assess the efficacy of troriluzole in adults with OCD in December 2017. The Phase 2&#47;3 study results were announced in June 2020. Troriluzole 200 mg administered once daily as adjunctive therapy in OCD patients with inadequate response to standard of care treatment showed consistent numerical improvement over placebo on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at all study timepoints (weeks 4 to 12) but did not meet the primary outcome measure at week 12. Troriluzole treated subjects (n &#61; 111) had a mean Y-BOCS improvement of -3.4 points from baseline versus -2.9 for placebo-treated (n &#61; 115) subjects &#91;difference -0.5 and p-value &#61; 0.451&#93; at week 4, -5.1 points (n &#61; 96) versus -3.6 for placebo-treated (n &#61; 108) subjects &#91;difference -1.5 and p-value &#61; 0.041&#93; at week 8, and -5.9 points (n &#61; 99) versus -4.9 for placebo-treated (n &#61; 102) subjects &#91;difference -1.0 and p-value &#61; 0.220&#93; at week 12. Troriluzole&#8217;s safety profile was generally consistent with past clinical trial experience with its active metabolite, riluzole. Treatment emergent adverse events (&#8220;TEAE&#8221;s) were mostly reported to be mild in intensity. TEAEs that occurred in at least 5% of patients in the troriluzole group, and more frequently in the troriluzole group than in the placebo group, were headache, dizziness, fatigue, somnolence, nausea and nasopharyngitis.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the strong signal in the Phase 2&#47;3 proof of concept study and after receiving feedback from the FDA in an End of Phase 2 meeting, in December 2020 we initiated enrollment in a Phase 3 program. The Phase 3 program will have an estimated total enrollment of 1,300 participants with a primary endpoint of change from baseline on the Y-BOCS total score at week 4, 8 and 10. The two Phase 3 randomized, double-blind, placebo-controlled trials that make-up our Phase 3 program for OCD are currently ongoing with enrollment expected to be completed in 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glioblastoma</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Global Coalition for Adaptive Research (&#8220;GCAR&#8221;) selected troriluzole for evaluation in Glioblastoma Adaptive Global Innovative Learning Environment - NCT03970447 (&#8220;GBM AGILE&#8221;). GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that tests multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (&#8220;GBM&#8221;), the most fatal form of brain cancer. Troriluzole will be evaluated in all patient subgroups of the trial which include newly-diagnosed methylated MGMT, newly-diagnosed unmethylated MGMT, and recurrent GBM. Troriluzole was selected for inclusion in GBM AGILE, which we believe was based on the existence of compelling evidence showing deregulation of glutamate in GBM. The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic potential of troriluzole in GBM and other oncology indications is supported by several recent clinical and translational research studies conducted with troriluzole and its active moiety. In July 2022, the Company and GCAR announced that enrollment has commenced in GBM AGILE for the evaluation of troriluzole.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BHV-5500</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing BHV-5500 (lanicemine), a low-trapping NMDA receptor antagonist. One potential target indication includes Complex Regional Pain Syndrome (&#8220;CRPS&#8221;). CRPS is a rare, chronic pain condition typically affecting limbs and triggered by traumatic injury. Accompanying symptoms also include chronic inflammation and reduced mobility in the affected areas. Other disorders of interest include post-herpetic neuralgia and diabetic peripheral neuralgia. Former Parent acquired worldwide rights to BHV-5500 and its oral prodrug BHV-5000 under an exclusive license agreement with AstraZeneca AB in October 2016. Current work is focused on formulation development.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Myostatin Platform</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taldefgrobep Alfa</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we announced that we entered into a worldwide license agreement with BMS for the development and commercialization rights to taldefgrobep alfa (also known as BMS-986089), a novel, Phase 3-ready anti-myostatin adnectin. Myostatin is a natural protein that limits skeletal muscle growth, an important process in healthy muscular development. However, in patients with neuromuscular diseases, active myostatin can critically limit the growth needed to achieve developmental and functional milestones. Myostatin inhibition is a promising therapeutic strategy for enhancing muscle mass and strength in a range of pediatric and adult neuromuscular conditions. Taldefgrobep is a muscle-targeted treatment for neuromuscular disease and offers the opportunity for combination therapy. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of taldefgrobep alfa in Spinal Muscle Atrophy (&#8220;SMA&#8221;). SMA is a rare, progressively debilitating motor neuron disease in which development and growth of muscle mass are compromised, resulting in progressive weakness and muscle atrophy, reduced motor function, impaired quality of life and often death. The Phase 3 placebo-controlled, double-blind trial is designed to evaluate the efficacy and safety of taldefgrobep as an adjunctive therapy for participants who are already taking a stable dose of nusinersen or risdiplam or have a history of treatment with onasemnogene abeparvovec-xioi, compared to placebo. The study is not restricted nor limited to patients based on ambulatory status or classification of SMA. We expect to enroll approximately 180 patients in this randomized, double-blind, placebo-controlled global trial.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Early Discovery Programs</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired the remaining approximately 58% of Kleo Pharmaceuticals, Inc. (&#8220;Kleo&#8221;) that we did not previously own. We have assumed Kleo&#8217;s laboratory facilities located in Science Park in New Haven, Connecticut to serve as the integrated chemistry and discovery research arm of the Company. We are continuing several existing Kleo discovery partnerships, including one with the Bill and Melinda Gates Foundation for the development of a Hyperimmune Globulin Mimic for COVID-19 and one with PeptiDream for the development of immuno-oncology therapeutics. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fox Chase Chemical Diversity Center, Inc.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into an agreement with Fox Chase Chemical Diversity Center Inc. (&#8220;FCCDC&#8221;) for FCCDC&#8217;s TDP-43 assets (the &#8220;FCCDC Agreement&#8221;). The FCCDC Agreement provides us with a plan and goal to identify one or more new chemical entity candidates for preclinical development for eventual clinical evaluation for the treatment of one or more TDP-43 proteinopathies. In connection with the FCCDC Agreement, Former Parent and FCCDC have established a TDP-43 Research Plan that provides for certain milestones to be achieved by FCCDC, and milestone payments to be made by the Company. The Company is evaluating and has not yet finalized potential clinical trial designs, including size and primary and secondary endpoints.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of Connecticut License Option</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into an exclusive, worldwide option and license agreement with the&#160;University of Connecticut for the development and commercialization rights to UC1MT, a therapeutic antibody targeting extracellular metallothionein. Under this agreement, we have the option to acquire an exclusive, worldwide license to UC1MT and its underlying patents to develop and commercialize throughout the world in all human indications. If we choose to exercise the option, we would be obligated to pay UConn milestone payments upon the achievement of specified regulatory and commercial milestones, and royalties of a low single-digit percentage of net sales of licensed products. The Company is evaluating and has not yet finalized potential clinical trial designs, including size and primary and secondary endpoints.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Artizan Biosciences Inc. License Option</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into an Option and License Agreement with Artizan Biosciences Inc. (&#8220;Artizan&#8221;), a biotechnology company focused on addressing inflammatory diseases involving the human intestinal microbiota. Pursuant to the agreement, we acquired an option to obtain a royalty-based license from Artizan to manufacture, use and commercialize certain products. Artizan will use the proceeds to continue advancing the preclinical research and development of its lead program for inflammatory bowel disease, which is anticipated to enter the clinic in early 2023, as well as to explore additional disease targets. In November 2021, we announced a collaborative therapeutic discovery and development program in Parkinson&#8217;s disease (&#8220;PD&#8221;), to exploit recent scientific advances in the understanding of pathogenic roles played by the gut microbiome in PD. In June 2022, we and Artizan executed a non-binding indication of interest which describes terms under which we and Artizan would amend the 2020 Artizan Agreement to eliminate certain milestone payments required by us in exchange for limiting our option to the selection of the first (ARZC-001) licensed product. The Company is evaluating and has not yet finalized potential clinical trial designs, including size and primary and secondary endpoints.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reliant Glycosciences, LLC</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into a development and license agreement with Reliant Glycosciences, LLC (&#8220;Reliant&#8221;) for collaboration on a program with Biohaven Labs&#8217; multifunctional molecules to develop and commercialize conjugated antibodies for therapeutic uses relating to IgA nephropathy and treatment of other diseases and conditions. The Company is evaluating and has not yet finalized potential clinical trial designs, including size and primary and secondary endpoints. Under the Agreement, Reliant was entitled to an upfront share payment and will be eligible to receive development milestone payments and royalties of net sales of licensed products.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BHV-1100</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, we initiated a Phase 1a&#47;1b trial in multiple myeloma patients using its antibody recruiting molecule (&#8220;ARM&#8221;) BHV-1100 in combination with autologous cytokine induced memory-like (&#8220;CIML&#8221;) natural killer (NK) cells and immune globulin (&#8220;IG&#8221;) to target and kill multiple myeloma cells expressing the cell surface protein CD38. BHV-1100 is the lead clinical asset from our ARM&#8482; Platform developed from a strategic alliance with PeptiDream Inc. (TYO&#58; 4587). This open-label single center Phase 1a&#47;1b study will assess the safety and tolerability as well as exploratory efficacy endpoints in newly diagnosed multiple myeloma patients who have tested positive for minimal residual disease (&#8220;MRD+&#8221;) in first or second remission prior to autologous stem cell transplant (&#8220;ASCT&#8221;). We expect to enroll 30 newly diagnosed multiple myeloma patients. The primary outcome measures are dose limiting toxicities following combination product administration (time frame&#58; 90 to 100 days post-combination product administration) and incidence and severity of side effects related to the combination product.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TRPM3 Antagonists</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we entered into an Exclusive License and Research Collaboration Agreement with Katholieke Universiteit Leuven (&#8220;KU Leuven&#8221;) to develop and commercialize TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders (the &#8220;KU Leuven Agreement&#8221;). The TRPM3 antagonist platform was discovered at the Centre for Drug Design and Discovery (&#8220;CD3&#8221;) and the Laboratory of Ion </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Channel Research (&#8220;LICR&#8221;) at KU Leuven. Under the KU Leuven Agreement, we receive exclusive global rights to develop, manufacture and commercialize KU Leuven&#8217;s portfolio of small-molecule TRPM3 antagonists. The portfolio includes the lead candidate, henceforth known as BHV-2100, which is being evaluated in preclinical pain models and will be the first to advance towards Phase 1 studies. We will support further basic and translational research at KU Leuven on the role of TRPM3 in pain and other disorders. The Company is evaluating and has not yet finalized potential clinical trial designs, including size and primary and secondary endpoints.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of the Results of Operations of the Biohaven Business</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Biohaven Business has not generated any revenue from product sales and we do not expect to generate any revenue from the sale of products in the near future. If our development efforts for our product candidates are successful and result in regulatory approval or additional license agreements with third parties, then Biohaven Business may generate revenue in the future from product sales.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. The Biohaven Business expenses research and development costs as incurred. These expenses include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;) or contract manufacturing organizations (&#8220;CMOs&#8221;), as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial materials and commercial materials, including manufacturing validation batches&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, travel and non-cash share-based compensation expense for employees engaged in research and development functions&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to compliance with regulatory requirements&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">development milestone payments incurred prior to regulatory approval of the product candidate&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payments made in cash, equity securities or other forms of consideration under third-party licensing agreements prior to regulatory approval of the product candidate.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biohaven Business recognizes external development costs based on an evaluation of the progress to completion of specific tasks using estimates of our clinical personnel or information provided to us by our service providers</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External direct research and development expenses are tracked on a program-by-program basis for our product candidates and consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs, and central laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses by program also include fees and certain development milestones incurred under license agreements. We do not allocate employee costs, or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to oversee the research and development as well as for managing our preclinical development, process development, manufacturing and clinical development activities. Many employees work across multiple programs, and the Biohaven Business does not track personnel costs by program.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will remain significant over the next several years as we increase personnel costs, conduct late-stage clinical trials, and prepare regulatory filings for our product candidates. We also expect to incur additional expenses related to milestone and royalty payments payable to third parties with whom we have entered into license agreements to acquire the rights to our product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of an appropriate safety profile with IND-enabling studies&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful patient enrollment in, and the initiation and completion of, clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of commercial manufacturing capabilities or making arrangements with third-party manufacturers&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">development and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisition, maintenance, defense and enforcement of patent claims and other intellectual property rights&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant and changing government regulation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintenance of a continued acceptable safety profile of the product candidates following approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel costs, including salaries, benefits and travel expenses for our executive, finance, business, corporate development and other administrative functions&#59; and non-cash share-based compensation expense. General and administrative expenses also include facilities and other related expenses, including rent, depreciation, maintenance of facilities, insurance and supplies&#59; and for public relations, audit, tax and legal services, including legal expenses to pursue patent protection of our intellectual property.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses, including payroll and related expenses, will remain significant in the future as we continue to support our research and development activities and prepare for potential commercialization of our product candidates, if successfully developed and approved. We also anticipate increased expenses associated with general operations, including costs related to accounting and legal services, director and officer insurance premiums, facilities and other corporate infrastructure, office-related costs, such as information technology costs, and certain costs to establish ourself as a standalone public company, as well as ongoing additional costs associated with operating as an independent, publicly traded company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain (Loss) from Equity Method Investment</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company&#8217;s acquisition of Kleo in January 2021, the Company owned approximately 41.9% of the outstanding shares as of December 31, 2020, and accounted for the Company&#8217;s investment in Kleo under the equity method of accounting. As a result, the Company&#8217;s proportionate share of Kleo&#8217;s net income or loss each reporting period was included in other income (expense), net, in the combined statements of operations and comprehensive loss and results in a corresponding adjustment to the carrying value of the equity method investment on the combined balance sheet.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2021, the Company acquired the remaining shares of Kleo it did not previously own.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net primarily consists of a gain recognized upon the Company&#8217;s determination that the value of the contingent value right related to our Kleo acquisition was immaterial as of December 31, 2021. The consideration transferred for the Kleo acquisition included contingent consideration in the form of a contingent value right to receive one dollar in cash for each Kleo share if certain specified Kleo biopharmaceutical products or product candidates receive the approval of the FDA prior to the expiration of 30 months following the effective time of the transaction. The maximum amount payable pursuant to the contingent value right was approximately $17.3 million. At December 31, 2021, the Company determined the value of the contingent value right to be immaterial and recognized a gain of $1.5 million related to the contingent value right in other income, net. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax amounts in the combined financial statements have been calculated on a separate return method and are presented as if the Company&#8217;s operations were separate taxpayers in the respective jurisdiction. Therefore, tax expense, cash tax payments, and items of current and deferred taxes may not be reflective of our actual tax balances prior to or subsequent to the Distribution.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company incorporated in the British Virgin Islands (&#8220;BVI&#8221;), we are principally subject to taxation in the BVI. Under the current laws of the BVI, the Company and all dividends, interest, rents, royalties, compensation and other amounts paid by the Company to persons who are not resident in the BVI and any capital gains realized with respect to any shares, debt obligations, or other securities of the Company by persons who are not resident in the BVI are exempt from all provisions of the Income Tax Ordinance in the BVI. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BVI has historically outsourced all of the research and clinical development for its programs under a master services agreement with BPI. As a result of providing services under this agreement, BPI was profitable during the years ended December 31, 2021 and 2020, and BPI is subject to taxation in the United States. As such, in each reporting period, the Biohaven Business tax provision includes the effects of consolidating the results of operations of BPI.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, we continued to maintain a full valuation allowance against our net deferred tax assets, which are comprised primarily of research and development credit carryforwards and future stock based compensation deductions based on management&#8217;s assessment that it is more likely than not that the deferred tax assets will not be realized. The Biohaven Business recorded an income tax provision during the years ended December 31, 2021 and 2020 of $1.4 million and $0.0 million, respectively, which primarily represents U.S. Federal tax and state taxes related to BPI&#8217;s profitable operations in the United States.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we completed the acquisition of Kleo. We recorded a full valuation allowance against our Kleo deferred tax assets and periodically review our position. Due to Kleo&#8217;s cumulative loss history, we determined that a full valuation allowance on these assets was appropriate. We will continue to evaluate the need for a valuation allowance on our deferred tax assets until there is sufficient positive evidence to support the reversal of all or some portion of these allowances.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months Ended June 30, 2022 and 2021 </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Biohaven Business for the six months ended June 30, 2022 and 2021&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,183&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,695&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,488&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,700&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,830&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,870&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,883&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,525&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,358&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286,883)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,525)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174,358)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,261&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,261)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,021&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,092)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286,954)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,504)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179,450)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,365&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,324&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300,319)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,545)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192,774)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expenses by program&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BHV-7000</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,438&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,438&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Troriluzole</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,642&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,683&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verdiperstat</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,121&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,482&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,361&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BHV-1100</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BHV-1200 (COVID 19)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,973&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,371&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BHV-2000</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,996&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,996&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated research and development costs&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel related (including share-based compensation)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,240&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,464&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,776&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical research programs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,224&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,320&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,835&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,934&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,901&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,183&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,695&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,488&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $247.2 million for the six months ended June 30, 2022, compared to $92.7 million for the six months ended June 30, 2021. The increase of $154.5 million was primarily due to increases of $119.4 million in expenses related to BHV-7000, $4.4 million related to BHV-1200, $7.0 million related to BHV-2000, $5.3 million in costs related to our preclinical research programs, and $22.8 million in personnel related costs. The $119.4 million increase in expense for BHV-7000 was primarily due to the Kv7 Platform Acquisition, which resulted in $93.7 million of expense recorded to R&#38;D during the six months ended June 30, 2022, and a $25.0 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million milestone payment accrued during the second quarter of 2022 which became payable in June 2022. These increases were partially offset by decreases of $5.4 million in direct costs for the Verdiperstat program and $3.0 million in direct costs for the Troriluzole program. Personnel-related costs for the six months ended June 30, 2022 and 2021 included share-based compensation expense of $37.3 million and $21.9 million, respectively. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $39.7 million for the six months ended June 30, 2022, compared to $19.8 million for the six months ended June 30, 2021. The increase of $19.9 million was primarily due to increases in personnel-related costs, including share-based compensation, as well as increased expenses related to accounting, legal and other professional fees. Personnel-related costs for the six months ended June 30, 2022 and 2021 included share-based compensation expense of $23.7 million and $15.4 million, respectively.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net was a net expense of $0.1 million for the six months ended June 30, 2022, compared to net income of $5.0 million for the six months ended June 30, 2021. The decrease of $5.1 million in net income was primarily due to the acquisition of Kleo Pharmaceuticals, Inc. in January 2021, which resulted in a gain of $5.3 million being recognized during the six months ended June 30, 2021 upon our remeasurement to fair value of the existing equity interest in Kleo.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Income Taxes</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a provision for income taxes of $13.4 million for the six months ended June 30, 2022 and an insignificant provision for the six months ended June 30, 2021. The increase in income tax expense was primarily attributable to the mandatory capitalization of R&#38;D expenses effective January 1, 2022 under the Tax Cuts and Jobs Act, offset by an increased benefit to the Company&#8217;s foreign derived intangible income deduction.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2021 and 2020 </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Biohaven Business for the years ended December 31, 2021 and 2020&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,486&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,460&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,026&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,414&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,046&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,368&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,900&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,506&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,394&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218,900)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,506)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,394)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from equity method investment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,261&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,162)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,423&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,209&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,209&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,470&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,162)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,632&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212,430)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,668)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,762)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,796)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,668)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,128)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expenses by program&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Troriluzole</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,637&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,101&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,536&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verdiperstat</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,664&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,036&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,628&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BHV-1100</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BHV-1200 (COVID 19)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,023&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,023&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated research and development costs&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel related (including share-based compensation)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,308&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,060&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,248&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical research programs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,592&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,158&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,678&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,239&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,486&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,460&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,026&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $181.5 million for the year ended December 31, 2021, compared to $98.5 million for the year ended December 31, 2020. The increase of $83.0 million was primarily due to increases of $8.5 million in direct costs for the troriluzole program, $9.6 million in direct costs for the verdiperstat program, $33.2 million in personnel related costs, and $21.2 million in costs related to our preclinical research programs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in personnel costs of $33.2 million was primarily a result of hiring additional personnel to support the expanding number of clinical trials and preclinical programs. Personnel-related costs for the years ended December 31, 2021 and 2020 included share-based compensation expense of $39.4 million and $18.5 million, respectively. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $21.2 million increase in preclinical research costs was primarily due to the following&#58; an upfront payment of $2.0&#160;million to Yale University in connection with the Yale MoDE Agreement&#59; an upfront payment of $5.9&#160;million to Moda Pharmaceuticals LLC in connection with a consulting agreement to further the scientific advancement of technology, drug discovery platforms (including the technology licensed under the Yale MoDE Agreement), product candidates and related intellectual property owned or controlled by the Company&#59; and a $3.8&#160;million upfront payment to Reliant Glycosciences, LLC in connection with a development and license agreement to develop and commercialize conjugated antibodies for therapeutic uses relating to IgA nephropathy and treatment of other diseases and conditions. The remainder of the increase primarily related to the rise in the number of ongoing preclinical research programs, including increased costs for outsourced chemistry and research arrangements.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $37.4 million for the year ended December 31, 2021, compared to $16.0 million for the year ended December 31, 2020 The increase of $21.4 million was primarily due to increased personnel-related expenses of $16.4 million, including share-based compensation expense, and a $2.0 million increase in expenses related to accounting, legal and other professional fees. Share-based compensation expense included in personnel-related costs increased $15.2 million, from $11.0 million for the year ended December 31, 2020 to $26.3 million for the year ended December 31, 2021, primarily due to annual equity incentive awards that were granted by Former Parent in the first quarter of 2021. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net was a net income of $6.5 million for the year ended December 31, 2021, compared to net expense of $4.2 million for the year ended December 31, 2020. The decrease of $10.6 million in net expense was primarily due to a $9.4 million change in gain (loss) on equity investment, primarily due to the acquisition of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kleo Pharmaceuticals, Inc. in January 2021, which resulted in a gain of $5.3 million being recognized during 2021 upon our remeasurement to fair value of the existing equity interest in Kleo. The decrease was also due to a $1.2 million increase in other income, net, which was primarily due to a $1.5 million gain recognized in 2021 upon the Company&#8217;s determination that the fair value of a contingent value right recorded relating to the acquisition of Kleo Pharmaceuticals was immaterial as of December 31, 2021.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Income Taxes</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a provision for income taxes of $1.4 million for the year ended December 31, 2021 and $0.0 million for December 31, 2020. We recorded a tax provision for the year ended December 31, 2021 for the U.S. Federal and state income taxes related to BPI&#8217;s profitable operations in the United States.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception as a business of Former Parent, we have not generated any revenue and have incurred significant operating losses and negative cash flows from operations. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. We expect to continue to incur significant expenses for at least the next several years as we advance our product candidates from discovery through preclinical development and clinical trials and seek regulatory approval and pursue commercialization of any approved product candidate. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. In addition, we may incur expenses in connection with the in-license or acquisition of additional product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have funded our operations primarily with proceeds allocated to our business from financing arrangements entered into by Former Parent and through the one-time issuance of contingently redeemable non-controlling interests. Prior to the Distribution, transfers of cash for general operating, investing, and financing activities and net cost allocation from Former Parent were reflected in net investment from Parent in our combined balance sheets. The cash reported on our combined balance sheet represents cash held by Biohaven entities at the end of the period presented. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we had cash of $23.2 million, excluding restricted cash of $0.8 million relating to collateral held by a bank for a letter of credit (&#8220;LOC&#8221;) issued in connection with leased office space in Yardley, Pennsylvania. We continuously assess our working capital needs, capital expenditure requirements, and future investments or acquisitions.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for each of the periods presented&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,722)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,053)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,840)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,957)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,250)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,697)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,874&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,791&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,447&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,242&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and restricted cash</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,098)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,449)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,588&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $126.7 million for the six months ended June 30, 2022 and primarily consisted of a net loss of $300.3 million adjusted for non-cash items, including share-based compensation of $60.9 million, acquisition of IPR&#38;D asset of $93.7 million (of which 35.0 million was paid in cash and classified as an investing activity and $58.7&#160;million was paid in Parent common shares), depreciation and amortization of $0.7 million, issuance of Parent common shares as payment for license and consulting agreements of $1.8 million, and other non-cash items of $&#8212; million, as well as the change in our net working capital. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $69.1 million for the six months ended June 30, 2021 and primarily consisted of a net loss of $107.5 million adjusted for non-cash items, including share-based compensation of $37.3 million, depreciation and amortization of $0.5 million, issuance of Parent common shares as payment for license and consulting agreements of $4.2 million, gain from equity method investment of $5.3 million, and other non-cash items of $2.0 million, as well as the change in our net working capital. The year-over-year increase in cash usage of $57.7 million was primarily due an increase in R&#38;D development spending. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $145.8 million for the year ended December 31, 2021 and primarily consisted of a net loss of $213.8 million adjusted for non-cash items, including share-based compensation of $65.6 million, depreciation and amortization of $1.4 million, issuance of Parent common shares as payment for license and consulting agreements of $7.9 million, gain from equity method investment of $5.3 million, and other non-cash items of $3.4 million, as well as the change in our net working capital. The year-over-year increase in cash usage of $69.9 million was primarily due an increase in R&#38;D development spending. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $76.0 million for the year ended December 31, 2020 and primarily consisted of a net loss of $118.7 million adjusted for non-cash items, including share-based compensation of $29.5 million, depreciation and amortization of $0.1 million, and loss from equity method investment of $4.2 million, as well as the change in our net working capital.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $36.3 million for the six months ended June 30, 2022 and was primarily due to our acquisition of Channel Biosciences LLC for $93.7 million of which $35.0 million was paid in cash and classified as a payment for IPR&#38;D asset acquisition under investing activities and $58.7&#160;million was paid in Parent common shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $1.2&#160;million for the six months ended June 30, 2021 and was due to $1.9&#160;million in cash acquired from the business acquisition of Kleo partially offset by $0.7 million in purchases of lab equipment to support Biohaven Labs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $0.9 million for the year ended December 31, 2021 and was due to $1.9 million in cash acquired from the business acquisition of Kleo partially offset by $0.9 million in purchases of lab equipment to support Biohaven Labs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $2.7 million for the year ended December 31, 2020 and was due to $1.1 million in purchases of office and lab equipment and $1.6 million in payments for leasehold improvements related to our Yardley office lease.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $109.9 million for the six months ended June 30, 2022 and was due to $109.9 million in net transfer from Parent for our general operating, investing, and financing activities and net cost allocations from Parent, excluding share-based compensation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $75.8 million for the six months ended June 30, 2021 and was primarily due to $75.4 million in net transfer from Parent for our general operating, investing, and financing activities and net cost allocations from Parent, excluding share-based compensation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $138.4 million for the year ended December 31, 2021 and was primarily due to $138.1 million in net transfer from Parent for our general operating, investing, and financing activities and net cost allocations from Parent, excluding share-based compensation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $152.2 million for the year ended December 31, 2020 and was due to $92.2 million in net transfer from Parent for general operating and investing activities and net cost allocations from Parent, excluding share-based compensation, and $60.0 million from the sale of contingently redeemable non-controlling interest by BioShin Limited.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase in connection with our ongoing activities, particularly as we advance and expand preclinical activities, clinical trials and potential commercialization of our product candidates. Our costs will also increase as we&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the development of our clinical-stage neurology assets, including the initiation of a Phase 1 clinical trial for BHV-7000 for the treatment of focal epilepsy and a Phase 3 clinical trial for taldefgrobep alfa for the treatment of SMA&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the development of our glutamate modulation product candidate&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to initiate and progress other supporting studies required for regulatory approval of our product candidates, including long-term safety studies, drug-drug interaction studies, preclinical toxicology and carcinogenicity studies&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate preclinical studies and clinical trials for any additional indications for our current product candidates and any future product candidates that we may pursue&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to build our portfolio of product candidates through the acquisition or in-license of additional product candidates or technologies&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to develop, maintain, expand and protect our intellectual property portfolio&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue regulatory approvals for our current and future product candidates that successfully complete clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">support our sales, marketing and distribution infrastructure to commercialize any future product candidates for which we may obtain marketing approval&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, medical, commercial, and development personnel&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional legal, accounting and other expenses in operating as a public company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our cash, as of the date of this prospectus, will be sufficient to fund our current forecast for operating expenses, financial commitments and other cash requirements for more than one year. Thereafter, we expect we will need to raise additional capital until we are profitable. If no additional capital is raised through either public or private equity financings, debt financings, strategic relationships, alliances and licensing agreements, or a combination thereof, we may delay, limit or reduce discretionary spending in areas related to research and development activities and other general and administrative expenses in order to fund our operating costs and working capital needs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We expect that we will require additional capital to pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for troriluzole, or our other product candidates, we expect to incur commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize or whether we commercialize jointly or on our own.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical studies and clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of COVID-19 pandemic on our business operations and funding needs&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of hiring new employees to support our continued growth&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other product candidates and technologies</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of public and private equity offerings, debt financings, other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of its existing shareholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we will be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates of the Biohaven Business</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial results are affected by the selection and application of accounting policies and methods. Significant accounting policies which require management&#8217;s judgment are discussed below.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation and Impairment of Intangible Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-Process Research and Development (&#8220;IPR&#38;D&#8221;) that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. If successfully completed, the Company would make a determination with respect to each project as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of acquired intangible assets is primarily determined using an income-based approach referred to as the multi-period excess earnings method utilizing Level 3 fair value inputs. The market participant valuation assumes a global view considering all potential jurisdictions and indications based on discounted after-tax cash flow projections, risk adjusted for estimated probability of technical and regulatory success.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates IPR&#38;D for impairment at least annually in the fourth quarter and more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&#38;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing the combined financial statements of the Biohaven Business, the Biohaven Business is required to estimate its accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of actual costs. The majority of its service providers invoice the Biohaven Business in arrears for services performed, on a pre-determined schedule or when contractual milestones </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are met&#59; however, some require advance payments. The Biohaven Business makes estimates of its accrued expenses as of each balance sheet date in the combined financial statements based on facts and circumstances known to the Biohaven Business at that time. It periodically confirms the accuracy of these estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors, including central laboratories, in connection with preclinical development activities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CROs and investigative sites in connection with preclinical and clinical studies&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CMOs in connection with drug substance and drug product formulation of preclinical and clinical trial materials.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biohaven Business bases its expenses related to preclinical studies and clinical trials on its estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Biohaven Business estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Biohaven Business adjusts the accrual or the amount of prepaid expenses accordingly. Although it does not expect its estimates to be materially different from amounts actually incurred, the Biohaven Business&#8217; understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses of the Biohaven Business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost Allocations</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biohaven Business has historically operated as part of Former Parent and not as a separate, publicly traded company. Accordingly, certain shared costs and share-based compensation expenses have been allocated to us and are reflected as expenses in the accompanying combined statements of operations and comprehensive loss. Management considers the expense methodology and resulting allocation to be reasonable for all periods presented&#59; however, the allocations may not be indicative of actual expenses that would have been incurred had we operated as an independent, publicly traded company for the periods presented. Actual costs that we may have incurred had we been a stand-alone company would depend on a number of factors, including the organizational structure, what corporate functions the Company might have performed directly or outsourced and strategic decisions the Company might have made in areas such as executive management, legal and other professional services, and certain corporate overhead functions.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our combined financial statements appearing at the end of this prospectus.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. As such, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, presenting only two years of audited financial statements, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation, and an exemption from the requirements to obtain a non-binding advisory vote on executive compensation or golden parachute arrangements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this provision of the JOBS Act. As a result, we will not be subject to new or revised accounting standards at the same time as other public companies that are not emerging growth companies. Therefore, our consolidated financial statements may not be comparable to those of companies that comply with new or revised accounting pronouncements as of public company effective dates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_58"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated on May&#160;2, 2022 as a direct, wholly owned subsidiary of Biohaven Pharmaceutical Holding Company Ltd. On May 9, 2022, we and Former Parent entered into the Distribution Agreement. On October 3, 2022, Former Parent completed the Distribution to holders of its common shares of all of the outstanding common shares of Biohaven and the Spin-Off of Biohaven from Former Parent. Unless expressly indicated or the context requires otherwise, the terms &#8220;Biohaven,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; in this prospectus refer to Biohaven Ltd. and its subsidiaries, including as a business of the Former Parent, to the extent the context requires. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Distribution, we now own clinical stage assets, including the Kv7 ion channel activators, glutamate modulation and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure previously owned by Former Parent and have proprietary rights to a number of trademarks used in this prospectus which are important to our business, including the Biohaven logo. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the &#174; and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company that combines a deep understanding of neuroscience, immunology, disease-related biology, advanced chemistry and expertise in global clinical trials to advance novel therapies for patients. Our experienced management team brings with it a proven track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia, and our research programs, built on a deep understanding of disease-related biology and neuropharmacology, are advancing novel therapies with target indications, including epilepsy, mood disorders, OCD, SCA, SMA and pain disorders. Our neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing our broad and diverse pipeline with at least five clinical trials currently underway or expected to start by the end of 2022. We have built a highly experienced team of senior leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with capabilities in drug discovery and development. In addition, we have several preclinical assets in our early discovery program, targeting neuroscience and immunology indications.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Candidates</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes some of our key clinical programs in addition to upcoming potential clinical development milestones for our product candidates. We hold the worldwide rights to all of our product candidates.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="octoberswimlane.jpg" src="octoberswimlane.jpg" style="height:168px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Kv7 Platform</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kv7 Platform Acquisition</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we announced that we entered into a definitive agreement with Channel Biosciences, LLC, a subsidiary of Knopp Biosciences, LLC, to acquire a drug discovery platform targeting Kv7 ion channels, adding the latest advances in ion channel modulation to our growing neuroscience portfolio. BHV-7000 (formerly known as KB-3061), the lead asset from the Kv7 platform is an activator of Kv7.2&#47;Kv7.3, a key ion channel involved in neuronal signaling and in regulating the hyperexcitable state in epilepsy. In the second quarter of 2022, our Clinical Trial Application for BHV-7000 was approved by Health Canada, and we subsequently began clinical development. The Company is evaluating and has not yet finalized potential clinical trial designs, including trial size, and primary and secondary endpoints. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kv7&#8217;s Role in Epilepsy and Other Central Nervous System Disorders</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epilepsy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of their fundamental role in health and their aberrant role in disease, ion channels in cell membranes represent a broad and important class of drug targets. Sodium channels and potassium channels form the ionic basis of the action potential in electrically charged cells throughout the body (see figures below). The Kv7 protein in particular forms a channel that regulates the flow of charged potassium ions (K+) across cell membranes, repolarizing nerve cells and resetting them for normal action potential firing. Kv7 channels include a family of channel subtypes, designated as Kv7.1 through Kv7.5, and they are formed by tetramers of identical or compatible subunits. Some of these channel subtypes localize in nerve cells (neurons) while others can be found in cardiac muscle, smooth muscle, and other tissue types. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Kv7 subunits, Kv7.2 and Kv7.3, are widely expressed in the brain, notably in the cortex and hippocampus, and together they form Kv7.2&#47;7.3 heteromeric channels that produce the M-current (IKM), a critical regulator of neuronal excitability (see figures below). Kv7.2&#47;7.3 channels normally perform a natural &#8220;braking&#8221; function by regulating the electrical excitability and hyperexcitability of brain cells. Dysfunction of these channels, due to genetic mutations or other factors, increases seizure risk, while augmenting the &#8216;open&#8217; activity of these channels has been demonstrated to reduce neuronal hyperexcitability and seizure frequency in electrophysiology laboratories, in animal models, and, most importantly, in patients.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.888%"></td><td style="width:0.1%"></td></tr><tr style="height:174pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:9pt"><img alt="business2a.jpg" src="business2a.jpg" style="height:219px;margin-bottom:5pt;vertical-align:text-bottom;width:290px"></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:9pt"><img alt="business3a.jpg" src="business3a.jpg" style="height:219px;margin-bottom:5pt;vertical-align:text-bottom;width:329px"></div></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">White, Role of Potassium Channel Ions in Epilepsy, Medscape.org</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are synthesizing novel Kv7.2&#47;7.3 activators as we seek to improve on the selectivity, potency, and other characteristics of ezogabine (Potiga in the U.S. and Trobalt (retigabine) in Europe), a drug approved in 2011 for the treatment of refractory epilepsy and voluntarily withdrawn from the market in 2017 because of poor tolerability and structure-related toxicities that limited its use, and ezogabine-like compounds while averting its negative attributes, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including off-target activity at a different brain ion channel, gamma-aminobutyric acid (&#8220;GABA&#8221;)A receptor (&#8220;GABAA-R&#8221;). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using a structure-based approach, supplemented by in silico modeling, we have identified structural features of our molecules critical to Kv7 activation. We have applied these analyses to the generation of proprietary chemical leads structurally distinct from known Kv7 activators, including ezogabine and flupirtine, the only other approved Kv7 modulator, approved in Europe for the treatment of acute pain. Our team has synthesized a large library of Kv7-activating molecules and are advancing them according to stringent criteria requiring improvements over ezogabine, including chemical stability, synthetic tractability, the avoidance of structural motifs associated with the generation of reactive metabolites and other unwanted, off-target activity, including GABAA-R activation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Epilepsy is the initial disease we are targeting with activators from our Kv7 platform. Epilepsy affects approximately 3.5 million Americans, or more than 1.2% of adults and 0.6% of children in the U.S., and more than 50 million patients worldwide, according to the World Health Organization (&#8220;WHO&#8221;). It is the fourth most common neurological disorder, and many patients struggle to achieve freedom from seizures, with more than one third of patients requiring two or more medications to manage their epilepsy. While the use of anti-seizure medications is often accompanied by dose-limiting side effects, our clinical candidate BHV-7000 is specifically designed to target subtypes of Kv7 potassium channels without engagement of GABA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> receptors. The lack of GABAA-R activity potentially gives BHV-7000 a wide therapeutic window and is expected to result in an improved side effect profile, limiting the somnolence and fatigue often seen in patients receiving anti-seizure medications. By adding BHV-7000 to our pipeline, we aim to bring this potassium channel modulator as a potential solution to patients with epilepsy who remain uncontrolled on their current regimens.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHV-7000 is a Kv7.2&#47;7.3 channel activator from a novel, bicyclic imidazole class with significant in vivo anticonvulsant activity and a wide therapeutic index. In the most widely used and highly-validated preclinical model of epilepsy, the maximal electroshock (&#8220;MES&#8221;) model, data for BHV-7000 and ezogabine were collected in independent experiments (see figures below), measuring the activity of both compounds in preventing seizures (ED50) and recording the neurologic deficit 5 to 15 minutes prior to the MES test to calculate the tolerability index (&#8220;TI&#8221;). The neurologic deficit is a behavioral index ranging from normal activity (score of 0) to a loss of righting reflex (score of 3). As shown below, BHV-7000 was demonstrated to have a calculated ED50 &#61; 0.5 mg&#47;kg with limited impact on behavior producing a TI &#62; 40x. In contrast, ezogabine was 40x less potent (a calculated ED50 &#61; 20 mg&#47;kg) in the MES model with a narrow TI &#60; 3x. The narrow preclinical TI for ezogabine is consistent with the clinical experience with the drug where side effects such as somnolence and dizziness limited its use at doses that prevented seizures in patients. </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business4a.jpg" src="business4a.jpg" style="height:237px;margin-bottom:5pt;vertical-align:text-bottom;width:672px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KCNQ2 Epileptic Encephalopathy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KCNQ2 epileptic encephalopathy (&#8220;KCNQ2-EE&#8221;) is a rare pediatric epileptic encephalopathy&#8239;first described in 2012 resulting from&#8239;dominant-negative&#8239;mutations&#8239;in the KCNQ2 gene. Epileptic encephalopathies (&#8220;EE&#8221;) comprise a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">group of epilepsy syndromes in which onset of recurrent and medically refractory seizures are associated with cognitive and broader developmental delay or regression. Early infantile epileptic encephalopathy, also called Ohtahara syndrome, and early myoclonic encephalopathy are the earliest-presenting of these age-dependent syndromes, clinically defined by onset within the first three months after birth. Although only recently described, heterozygous de novo variants in KCNQ2 are a highly validated cause of early onset epileptic encephalopathy, and KCNQ2-EE has emerged as a well-defined clinical entity with a characteristic neonatal presentation, including hypotonia, treatment-resistant tonic seizures, a profoundly abnormal interictal electroencephalogram (&#8220;EEG&#8221;) with prominent burst-suppression, and most often with moderate-to-profound global developmental delay, resulting from a defined subset of missense variants in the gene. KCNQ2-EE is thus both a seizure disorder and a developmental disorder caused by pathogenic, dominant-negative KCNQ2 mutations.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identification of genetic etiologies has created the opportunity to treat not just the symptoms of KCNQ2-EE, including seizures, but also the underlying causes, including attenuating or reversing the effects of the dominant-negative variants responsible for KCNQ2-EE. Developmental delay is an intractable feature of KCNQ2-EE even though seizure frequency tends to diminish after infancy and EEG organization tends to improve. Importantly, limited clinical evidence, including a case series of four infants with KCNQ2-EE, suggests that pharmacological augmentation of reduced Kv7.2 channel current with ezogabine reduces seizures and may improve developmental milestone attainment.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severe pathogenic KCNQ2 mutations disrupt the function of the KCNQ2 gene product, Kv7.2, a voltage-gated potassium channel subunit which, in addition to being a critical regulator of neuronal excitability, plays a fundamental role in early brain development. Kv7.2 polypeptides are co-assembled in either homotetrameric channels, or, in combination with Kv7.3 subunits, to form heterotetrameric channels. Both subunit configurations contribute to IKM. Significant reduction of Kv7.2&#47;7.2 activity or Kv7.2&#47;7.3 activity with loss of 50% of more of current density through these channels abrogate these functions, leading to neuronal hyperexcitability and impaired brain development.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its activity in the MES model, we explored the ability of BHV-7000 to reverse the reduced current density associated with KCNQ2-EE and support its use as potential treatment for the disease. Most encephalopathy-associated pathogenic KCNQ2 variants identified to date disrupt channel function in any of four distinct &#8220;hot spots&#8221; of the protein, including the S4 voltage sensor, the ion channel pore, and the proximal and distal regions of the C-terminal domain (see figure below). </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business5a.jpg" src="business5a.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Millichap, Neurol Genet (2016)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the effects of BHV-7000 on the function of Kv7.2 and Kv7.2&#47;7.3 channels poisoned by dominant-negative KCNQ2 mutations, four highly recurrent human missense variants representative of the &#8220;hot spot&#8221; domains </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were introduced into KCNQ2 cDNA by site-directed mutagenesis. Using lipid-mediated transfection, plasmids including the pathogenic variants were co-expressed with wild-type (&#8220;wt&#8221;) KCNQ2 subunits or wt KCNQ2 and wt KCNQ3 subunits in Chinese hamster ovary (&#8220;CHO&#8221;) cells. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The figure below shows the effects of BHV-7000 on current density of wt&#47;wt Kv7.2 channels and those formed by 1&#58;1 coexpression of wt KCNQ2 genes with either of two KCNQ2 pore domain variants (T274M, A294V), a C-terminal variant (R581L), or a voltage-sensing variant (R210H). In the control condition, all pathogenic variants produced a marked reduction in current density to below wt&#47;wt levels. BHV-7000 at 0.3&#181;M restored current density in mutated pore and C-terminal channels to or beyond wt control current density (**&#60;0.01). Similarly, application of BHV-7000 at 1 &#181;M restores function to mutated channels expressing the R210H KCNQ2 S4 voltage sensor domain pathogenic variant in the heterotetrameric (wt&#47;R210H) configuration, to above wt&#47;wt levels of activation.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business6a.jpg" src="business6a.jpg" style="height:230px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHV-7000 has been granted Rare Pediatric Disease Designation by the FDA for the treatment of KCNQ2-EE.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neuropathic Pain</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuropathic pain, as defined by the International Association for the Study of Pain, is pain caused by a lesion or disease of the somatosensory nervous system and includes a collection of heterogeneous conditions that are often chronic and debilitating and for which long term therapy is difficult. In the United States, over 20 million adults are estimated to be living with neuropathic pain. Pharmacological treatments for neuropathic pain vary according to patient needs, although recommendations such as the WHO analgesic ladder, United States Centers for Disease Control (&#8220;CDC&#8221;), and FDA guidelines are in use. Initial or first line treatment for neuropathic pain includes non-opioid analgesics, in particular, antidepressants, anticonvulsants, steroids, and anxiolytics. Second line treatment of persistent, severe pain may require escalation to opiates, often less potent ones at first, followed by more potent opiates for intense refractory pain. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thus, an urgent need exists for effective, non-addictive pain therapies. Flupirtine, a non-selective Kv7 activator, was previously approved in several European countries and indicated for the treatment of pain. However, the European Medicines Agency recommended withdrawal of its marketing authorization in 2018 because of the risk of serious liver injury. Selective Kv7 potassium channel activators represent a new approach in the development of non-opioid therapeutic options for neuropathic pain. In addition to leveraging reduced abuse and addiction risk potential of potassium channel activators, our Kv7 potassium channel platform addresses the complexities of channel subtype physiology through targeted pharmacology to overcome the limitations inherent in unbiased Kv7 activators and is intended to deliver a well-tolerated, highly effective, non-opioid treatment for neuropathic pain.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Kv7 program research was supported in part with funding from the National Institutes of Health (&#8220;NIH&#8221;) to advance the development of novel Kv7 non-opioid therapies for the treatment of chronic pain. The NIH funding is by the NIH Helping to End Addiction Long-term Initiative (&#8220;NIH HEAL Initiative&#8221;), which aims to improve treatments for chronic pain, curb the rates of opioid use disorder and overdose, and achieve long-term recovery from opioid addiction. The goal of our Kv7 program is to discover a small-molecule activator of the Kv7.2&#47;7.3 voltage-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gated potassium channel to treat neuropathic pain. Similar to our epilepsy program, we are targeting compounds with these characteristics&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biased for Kv7.2&#47;3 activation vs. Kv7.4 activation to minimize potential adverse smooth muscle effects</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selective against GABA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> receptors to minimize potential tolerability issues</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selective against Kv7.1&#47;KCNE1 (IKs) and hERG (IKr) to minimize cardiac side-effects</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potent and effective across animal models of neuropathic pain </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A fundamental program hypothesis is that creating Kv7.2&#47;3 activators with minimal activation of Kv7.4 and GABA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> receptors will greatly improve the tolerability profile of a successful candidate compound. Ezogabine has known effects on the GABA system, both directly as a GABA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> positive allosteric modulator, and indirectly by affecting GABA synthesis or metabolism, a pharmacology consistent with the dose-related increases in somnolence and dizziness reported in ezogabine clinical trials. Our program is directed to reducing this potential source of poor tolerability by selecting compounds with no or minimal activity for the GABA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> receptor.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axonal excitability and neurotransmitter release are altered in neuropathic pain due to sodium channel plasticity, increased voltage-gated calcium channels in the spinal cord, and diminished potassium channel activity in dorsal root ganglion (&#8220;DRG&#8221;) neurons. These changes in ion channel number, distribution, and function are common to many neuropathic pain subtypes. The functional density of Kv7.2&#47;3 channels is a key variable governing sensory DRG control of intrinsic excitability. There are some reports that demonstrate downregulation of Kv7 potassium channel mRNA, protein and function in experimental neuropathic pain models. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using human induced pluripotent stem cell (&#8220;iPSC&#8221;)-derived sensory neurons, we have assessed the physiological activity of these neurons by modulating Kv7 channels across three electrophysiologic parameters&#58; resting membrane potential (Vm), change of rheobase &#61; the current required to stimulate an action potential (&#8220;AP&#8221;), and the number of APs elicited by a suprathreshold stimulus (3x rheobase). We are currently evaluating the activity of various compounds from our proprietary series of selective Kv7.2&#47;7.3 activators in multiple preclinical models of neuropathic pain.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mood disorders</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 1 in 5 adults in the U.S. are living with neuropsychiatric illnesses that are, in turn, associated with inadequate treatment, poor quality of life, disability, and considerable direct and indirect costs. There is significant unmet need for novel and effective therapeutic options that are not limited by long latency periods to clinical effects, low response rates, and significant risks and side effects. Increasing evidence from animal models and clinical trials now suggests that Kv7.2&#47;7.3 targeting drugs offer the potential to treat a spectrum of these neuropsychiatric diseases including, but not limited to, mood disorders such as major depressive disorder, bipolar disorder and anxiety.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Glutamate Platform</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most advanced product candidate from our glutamate receptor antagonist platform is troriluzole (previously referred to as trigriluzole and BHV-4157), which is in two Phase 3 trials in OCD. Other product candidates include BHV-5500, which is an antagonist of the glutamate N-methyl-D-aspartate (&#8220;NMDA&#8221;) receptor and its oral prodrug BHV-5000.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Glutamate is an important neurotransmitter present in over 90% of all brain synapses. Glutamate plays an essential role in normal brain functioning and its levels must be tightly regulated. Abnormalities in glutamate levels can disrupt nerve health and communication, and in extreme cases may lead to nerve cell death. Nerve cell dysfunction and death leads to devastating diseases, including ataxia, amyotrophic lateral sclerosis (&#8220;ALS&#8221;) and other neurodegenerative disorders. Glutamate clearance is necessary for proper synaptic activation and to prevent neuronal damage from excessive activation of glutamate receptors. Excitatory amino-acid transporters (&#8220;EAATs&#8221;) help regulate glutamate clearance, and are responsible for most of the glutamate uptake within the brain.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mechanism of action of our glutamate platform is depicted below. Glutamate must be tightly regulated once released from a pre-synaptic neuron and acts as a signaling neurotransmitter to stimulate the post-synaptic neuron via glutamate receptors (e.g.,&#160;N-methyl-D-aspartate (&#8220;NMDA&#8221;), alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (&#8220;AMPA&#8221;) or Kainate receptors). Glial cells surrounding the synaptic junction are predominantly responsible for clearing glutamate through transporters, the EAATs. There are five distinct types of glutamate transporters. The figure below depicts the areas of modulation that are affected by our product candidates. (1) As depicted in the glial cell to the right in the figure below, troriluzole increases the activity and expression of the EAATs to increase the clearance of glutamate released from the pre-synaptic neuron. Troriluzole also is designed to inhibit presynaptic ion channels that may inhibit the release of glutamate from presynaptic neurons. (2)&#160;As depicted in the postsynaptic neuron to the bottom of the figure below, BHV-5500 blocks glutamate signaling that is mediated by post-synaptic NMDA receptors. Modulating glutamate also has the potential to be neuroprotective and increase the release of neurotrophic factors, including brain derived neurotrophic factor (&#8220;BDNF&#8221;) which are endogenous molecules that help to support the survival of existing neurons, and encourage the growth and differentiation of new neurons and synapses.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business7a.jpg" src="business7a.jpg" style="height:229px;margin-bottom:5pt;vertical-align:text-bottom;width:422px"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adapted from Glutamate abnormalities in obsessive compulsive disorder&#58; Neurobiology, pathophysiology, and treatment, C.&#160;Pittenger, M.&#160;Bloch, and K.&#160;Williams</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Glutamate Transporter Modulation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abnormal glutamate release or dysfunction of glutamate clearance can cause overstimulation of glutamate receptors which can lead to a dangerous neural injury called excitotoxicity, which has been associated with a wide range of neurodegenerative diseases. The FDA has approved anti-excitotoxicity drugs that act on the glutamatergic system by blocking NMDA receptors, such as memantine (&#8220;Namenda&#8221;) for Alzheimer&#8217;s disease, lamotrigine (&#8220;Lamictal&#8221;) for epilepsy and bipolar disorder and riluzole (&#8220;Rilutek&#8221;) for ALS. Although these drugs show the therapeutic potential of glutamate receptor antagonists and other glutamate modulators in the treatment of a range of neurological diseases, these approved drugs have serious side effects and other drawbacks that we have attempted to address with our development of troriluzole.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Troriluzole</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Troriluzole is a new chemical entity (&#8220;NCE&#8221;) and tripeptide prodrug of the active metabolite, riluzole. Based on its mechanism of action, preclinical data and clinical studies, troriluzole has potential for therapeutic benefit in a range of neurological and neuropsychiatric illnesses. Initial development has focused on its use in treating SCA, an orphan neurological indication that currently has no approved drug therapies and for which the active metabolite, riluzole, has demonstrated preliminary efficacy in two prior randomized controlled trials conducted by third parties. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ristori et al. reported a randomized, double-blind, placebo-controlled trial of 40 patients presenting with cerebellar ataxias of diverse etiologies, including SCA. Subjects were randomized to receive 8 weeks treatment with either placebo or riluzole (50 mg Riluzole tablets, twice daily). Statistically significant improvement in the riluzole </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treated group was demonstrated on the International Cooperative Ataxia Rating Scale (&#8220;ICARS&#8221;). The number of patients with a 5-point ICARS drop was higher in the riluzole group than in the placebo group after 4 weeks (9&#47;19 vs 1&#47;19&#59; odds ratio &#91;&#8220;OR&#8221;&#93; &#61;16.2&#59; 95% confidence interval &#91;&#8220;CI&#8221;&#93; 1.8&#8211;147.1) and 8 weeks (13&#47;19 vs 1&#47;19&#59; OR &#61; 39.0&#59; 95% CI 4.2&#8211; 364.2). The mean change in the riluzole group ICARS after treatment revealed a decrease (p &#60; 0.001) in the total score (-7.05 &#91;4.96&#93; vs 0.16 &#91;2.65&#93;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Romano et al. described results of a second randomized, placebo-controlled trial subjects diagnosed with a hereditary ataxia (including SCAs) randomized to receive 12 months of treatment with either placebo or riluzole (50 mg, twice daily). 60 patients were randomized. Statistically significant improvement in the riluzole treated group was demonstrated on the Scale for the Assessment of Ataxia (&#8220;SARA&#8221;). The proportion with decreased SARA score was 14 (50%) of 28 patients in the riluzole group versus three (11%) of 27 in the placebo group (OR 8.00, 95% CI 1.95&#8211; 32.83&#59; p&#61;0.002).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired troriluzole from ALS Biopharma,&#160;LLC (&#8220;ALS Biopharma&#8221;) and Fox Chase Chemical Diversity Center,&#160;Inc. (&#8220;FCCDC&#8221;), along with an estate of over 300 prodrugs. A prodrug is a compound that, after administration, is metabolized in the body into an active drug. Troriluzole is actively transported by virtue of recognition of its tripeptide moiety by the PepT1 transporter in the gut and is responsible for the increased bioavailability of the drug. Once inside the body, the prodrug, troriluzole is cleaved by enzymes in the blood to the parent, riluzole. To mitigate the limitations of riluzole, several classes of prodrugs were designed, synthesized, and evaluated in multiple in vitro stability assays that predict in vivo drug levels. Troriluzole is a third generation of prodrug development and the product of six years of intensive chemistry efforts.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Riluzole is currently only indicated for ALS and has a number of non-desirable attributes that have limited its clinical use. Key limitations of riluzole include poor oral bioavailability, difficulty swallowing due to tablet formulation, food reducing efficacy, liver toxicity, pharmacokinetic variability, and oral numbness.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prodrug design and selected administration pathway that was pursued with troriluzole is intended to address all of these limitations of riluzole. In addition, a prodrug can be engineered to enhance absorption and protect from diminished absorption when taken with meals. The troriluzole preclinical development strategy was based on optimizing in vivo and in vitro features, such as stability in gastrointestinal and stomach fluids&#59; stability in liver microsomes&#59; limiting off-target effects (particularly liver effects)&#59; metabolic cleavage in the plasma to release the active moiety&#59; and enhanced gastrointestinal absorption properties. In in vivo studies in rodents, the intended benefits of this optimization program were observed, including delayed peak concentrations and greater exposure.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After six years of chemistry development and preclinical testing, the resulting lead prodrug from the chemistry program was troriluzole. Troriluzole is chemically comprised of riluzole linked via an amide bond to a tripeptide that is a substrate for gut transporters (&#8220;PepT1&#8221;) and which contributes to its improved bioavailability. The tripeptide moiety is cleaved by plasma aminopeptidases, releasing riluzole and naturally occurring amino acids, which we believe are readily managed by endogenous metabolic routes. We believe that the estate of compounds we acquired, combined with our internally developed intellectual property, will provide a significant protection for our innovations. Troriluzole is stable in fluids from the gastrointestinal tract and expected to have a differentiated profile with regard to any liability for hepatic effects.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Clinical Program for Troriluzole </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1 Studies with Troriluzole</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, we began a Phase 1 randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (&#8220;PK&#8221;) of single and multiple ascending doses of troriluzole in normal healthy volunteers. 58 healthy volunteers were dosed with troriluzole and 20 were dosed with placebo. Both single and multiple doses up to 200 mg were well tolerated without evidence of novel, clinically significant safety signals or lab abnormalities. There was no apparent dose response regarding the frequency or severity of adverse events (&#8220;AEs&#8221;). In the blinded group, including subjects treated with both placebo and troriluzole, the most common AEs were headache (five subjects, two with moderate severity and three with mild severity) and constipation (two subjects). No pattern of AEs or lab abnormalities were apparent to provide specific cautions or to suggest cautions beyond what is appropriate for the active metabolite, riluzole. Commencing in December 2017, an additional single </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and multiple dose study was conducted to assess the safety, tolerability and PK of a 280 mg dose in 10 healthy young and elderly volunteers (eight active&#59; two placebo). The results supported adequate safety and tolerability and yielded mean exposures comparable to what would be expected from a 200 mg dose, a dose that has been safely used in clinic populations and associated with efficacy in a range of disorders in randomized controlled trials (Huntington Study Group Neurology 2003&#59; Lacomblez Neurology 1996). In addition, a bioequivalence study was conducted to bridge a commercial formulation with a Phase 2&#47;3 formulation in 32 healthy volunteers. The commercial formulation was well-tolerated and provided bioequivalent exposure with the Phase 2&#47;3 formulation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Troriluzole for OCD</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCD is a chronic neuropsychiatric disorder characterized by symptoms of obsessions (intrusive thoughts) and compulsions (repetitive behaviors) that can interfere with patients&#8217; functional abilities. According to the National Institute of Mental Health, the 12-month prevalence of OCD is 1% of the U.S. adult population, and approximately half of these cases are characterized as severe. First-line treatment for OCD includes cognitive behavioral therapy, selective serotonin reuptake inhibitors (&#8220;SSRIs&#8221;) and adjunctive use of atypical antipsychotics. Nonetheless, up to 60% of patients have an inadequate response to conventional intervention strategies and some seek invasive neurosurgical procedures to ameliorate symptoms. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also currently developing troriluzole as a potential treatment option for patients suffering from OCD. Despite the significant public health burden, no novel mechanisms of action have been approved by the FDA for OCD in over two decades. The rationale for use of troriluzole in OCD is supported by clinical data with its active metabolite, riluzole, in populations with OCD in open-label and placebo-controlled clinical trials as well as in preclinical, genetic and neuroimaging studies implicating the glutamatergic hyperactivity in the pathogenesis of OCD.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In multiple case studies, the use of riluzole in patients with refractory OCD has commonly been associated with meaningful improvement of symptoms. A small-scale randomized controlled trial in adults with OCD conducted by a third party showed favorable trends for the use of riluzole in an outpatient setting. Another randomized controlled third-party study demonstrated statistically significant therapeutic effects with the adjunctive use of riluzole as compared to adjunctive placebo in 50 adults with refractory OCD. These clinical effects are consistent with findings such as genetic associations of glutamate transporter genes with OCD and increased glutamate concentrations in brain and cerebrospinal fluid of patients with OCD. Taken together, we believed there was a clear rationale for advancement of troriluzole, a prodrug of riluzole, into a Phase 2 proof-of-concept trial in OCD.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced a Phase 2&#47;3 double-blind, randomized controlled trial on the use of troriluzole in adults with OCD in late 2017. Results from the Phase&#160;2&#47;3 trial were announced in June 2020. Troriluzole 200 mg administered once daily as adjunctive therapy in OCD patients with inadequate response to standard of care treatment showed consistent numerical improvement over placebo on the Yale-Brown Obsessive Compulsive Scale (&#8220;Y-BOCS&#8221;) at all study timepoints (weeks 4 to 12) but did not meet the primary endpoint at week 12. Troriluzole treated subjects (n &#61; 111) had a mean Y-BOCS improvement of -3.4 points from baseline versus -2.9 for placebo-treated (n &#61; 115) subjects &#91;difference -0.5 and p-value &#61; 0.451&#93; at week 4, -5.1 points (n &#61; 96) versus -3.6 for placebo-treated (n &#61; 108) subjects &#91;difference -1.5 and p-value &#61; 0.041&#93; at week 8, and -5.9 points (n &#61; 99) versus -4.9 for placebo-treated (n &#61; 102) subjects &#91;difference -1.0 and p-value &#61; 0.220&#93; at week 12. Troriluzole&#8217;s safety profile was generally consistent with past clinical trial experience with its active metabolite, riluzole. Treatment emergent adverse events (&#8220;TEAE&#8221;s) were mostly reported to be mild in intensity. TEAEs that occurred in at least 5% of patients in the troriluzole group, and more frequently in the troriluzole group than in the placebo group, were headache, dizziness, fatigue, somnolence, nausea and nasopharyngitis.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the strong signal in the Phase 2&#47;3 proof of concept study and after receiving feedback from the FDA in an End of Phase 2 meeting, in December 2020 we initiated enrollment in a Phase 3 program. The Phase 3 program will have an estimated total enrollment of 1,300 participants with a primary endpoint of change from baseline on the Y-BOCS total score at week 4, 8 and 10. The two Phase 3 randomized, double-blind, placebo-controlled trials that make-up our Phase 3 program for OCD are currently ongoing with enrollment expected to be completed in 2023.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Troriluzole for GBM</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical and small-scale pilot studies are underway to explore troriluzole&#8217;s use in the treatment of a pipeline of other indications such as some cancers whose spread is thought mediated by glutamate transmission, such as melanoma and glioblastoma.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with Johns Hopkins University, we explored the potential applicability of troriluzole for glioblastoma. The oncology collaboration Johns Hopkins was based upon the mechanistic rationale that some tumors over express glutamate receptors, the central role that glutamate may have in cancer metabolism and the effect of glutamate on the tumor microenvironment.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Global Coalition for Adaptive Research (&#8220;GCAR&#8221;) selected troriluzole for evaluation in Glioblastoma Adaptive Global Innovative Learning Environment - NCT03970447 (&#8220;GBM AGILE&#8221;). GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that tests multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (&#8220;GBM&#8221;), the most fatal form of brain cancer. Troriluzole will be evaluated in all patient subgroups of the trial which include newly-diagnosed methylated O6-methylguanine DNA methyltransferase (&#8220;MGMT&#8221;), newly-diagnosed unmethylated MGMT, and recurrent GBM. Troriluzole was selected for inclusion in GBM AGILE, which we believe was based on the existence of compelling evidence showing deregulation of glutamate in GBM. The therapeutic potential of troriluzole in GBM and other oncology indications is supported by several recent clinical and translational research studies conducted with troriluzole and its active moiety. For example, Medikonda et al. showed a survival benefit with troriluzole, alone and in combination with anti-programmed cell death protein-1 (&#8220;PD-1&#8221;) immunotherapy, utilizing a frequently used murine brain tumor model. C57BL&#47;6J mice were intracranially implanted with luciferase-tagged GL261 glioma cells. Mice were randomly assigned to the control, anti-PD-1, troriluzole or combination anti-PD-1 plus troriluzole treatment arms, and median overall survival was assessed. The troriluzole treatment arm demonstrated improved survival compared with the control arm (median survival of 36% vs. 0%&#59; p &#60; 0.0001), as did the combination anti-PD-1 plus troriluzole treatment arm (overall survival of 80% vs. 0&#59; p &#61; 0.0007).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company and GCAR announced that enrollment has commenced in GBM AGILE for the evaluation of troriluzole. GBM AGILE is a multi-arm, platform trial. The evaluation of each therapy in GBM AGILE proceeds in 2 possible stages. A therapy&#8217;s Stage 1 is an adaptively randomized Screening stage for evaluating the therapy within patient signatures compared against a common control. A therapy in Stage 1 will stop accruing patients if it reaches its maximal sample size, drops for futility, or evinces inadequate safety. If a therapy reaches an efficacy threshold for graduation from Stage 1, it will move into Stage 2 within one of the prospectively defined signatures. The maximum sample size in Stage 1 is 150 patients. For a therapy graduating to Stage 2 there is a fixed randomization, expansion cohort. The maximum sample size in Stage 2 is 50 experimental patients in the graduating signature. The primary analysis of a regimen&#8217;s effect on overall survival (&#8220;OS&#8221;) uses all patients in both its stages and all control patients in the trial in the graduating signature, suitably adjusted for any possible time trends.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Troriluzole for SCA</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the results of our Phase 1 trial with troriluzole and two third-party academic trials that have shown preliminary efficacy of riluzole in cerebellar ataxias, we advanced troriluzole into a Phase 2&#47;3 clinical trial for SCA. Initially, we had conducted a Phase 2b&#47;3, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of troriluzole over 8 weeks in subjects with SCA. In October 2017, we announced that troriluzole at a dose of 140 mg once daily (&#8220;QD&#8221;) did not differentiate from placebo on the primary endpoint of the mean change from baseline on the Scale for Assessment and Rating of Ataxia (&#8220;SARA&#8221;) total score after 8 weeks of treatment. After eight weeks of treatment, troriluzole treated subjects (n &#61; 63) demonstrated an improvement of &#8211;0.81 points &#91;95% CI&#58; &#8211;1.4 to &#8211;0.2&#93; on the SARA versus &#8211;1.05 points &#91;95% CI&#58; &#8211;1.6 to &#8211;0.4&#93; improvement in placebo-treated (n &#61; 68), p-value &#61; 0.52. In this trial, we observed a generally favorable safety and tolerability profile of troriluzole, with low discontinuation rates due to AEs. During open-label treatment over the 48-week extension phase, however, troriluzole did show slowing of disease progression in troriluzole-treated subjects in contrast to the measurable decline expected for a cohort of untreated subjects based on the natural history of the disease. As of June 28, 2022, in either the randomization phase or the open-label extension phase, two subjects had a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug-related serious adverse event considered by the investigator to be related to troriluzole. Based on our learnings from the Phase 2b&#47;3 study, including analyses from the open-label extension phase, we advanced troriluzole into a Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of troriluzole over 48 weeks in subjects with SCA. We enriched this trial with specific SCA genotypes, extended the treatment period of this trial to 48 weeks, implemented the use of a modified SARA scale (&#8220;f-SARA&#8221;), and increased the dose of troriluzole to 200 mg QD. Notably, the f-SARA is a novel, 16-point scale based on feedback received from the FDA as the primary outcome measure for this trial&#59; the scale was designed to assess clinically meaningful changes in function.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of its investigational therapy, troriluzole, in adult patients with SCA. The primary endpoint, change from baseline to week 48 on the f-SARA, did not reach statistical significance in the overall SCA population as there was less than expected disease progression over the course of the study. In the overall study population (n &#61; 213), the troriluzole and placebo groups each had mean baseline scores of 4.9 on the f-SARA and the two groups showed minimal change at the 48-week endpoint with f-SARA scores of 5.0 and 5.1, respectively (p&#61;0.76). Troriluzole was well tolerated with an adverse event profile similar to placebo. The frequency of subjects with any TEAE was 80.6% for troriluzole vs. 84.4% for placebo and the frequency of subjects with serious TEAEs was 5.6% for troriluzole vs. 7.3% for placebo.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-hoc analysis of efficacy measures by genotype suggests a treatment effect in patients with the SCA Type 3 (&#8220;SCA3&#8221;) genotype, which represents the most common form of SCA and accounted for 41% of the study population. In the SCA3 subgroup, troriluzole showed a numerical treatment benefit on the change in f-SARA score from baseline to week 48 compared to placebo (least squares (&#8220;LS&#8221;) mean change difference -0.55, nominal p-value &#61; 0.053, 95% CI&#58; -1.12, 0.01). SCA patients treated with troriluzole showed minimal disease progression over the study period. Further, in patients in the SCA3 subgroup who were able to walk without assistance at baseline (i.e., f-SARA Gait Item score &#61; 1), troriluzole demonstrated a greater numerical treatment benefit on the change in f-SARA score from baseline to week 48 compared to placebo (LS mean change difference -0.71, nominal p-value &#61; 0.031, 95% CI&#58; -1.36, -0.07). Notably, the f-SARA is a novel, 16-point scale developed based on feedback from FDA as the primary outcome measure for this trial&#59; the scale was designed to assess clinically meaningful changes in function.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across all SCA genotypes, and SCA3 specifically, patient reported falls, as measured by adverse events, reveal reduction of fall risk in the troriluzole group compared to placebo.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk reduction of falls in the troriluzole group combined with the progression of f-SARA scores in the untreated SCA3 group compared to SCA3 patients on troriluzole demonstrates that SCA3 patients are experiencing a clinically meaningful improvement in ataxia symptoms on troriluzole treatment. Given these findings and the debilitating nature of SCA, we intend to interact with the FDA and&#47;or EMA regarding the SCA3 genotype data in the first half of 2023. We have not yet decided on the format of such a regulatory interaction but we could seek advice through various formal or informal interactions with regulatory agencies or we could choose to submit an NDA if we believe that is warranted from the results of our ongoing post-hoc analyses. There are currently no FDA-approved medications for the treatment of SCA or any other cerebellar ataxia, and treatment is supportive. In general, multidisciplinary care provides supportive measures and the goal of this treatment is to improve quality of life and survival.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Glutamate NMDA Receptor Antagonism and BHV-5500 for Neuropathic Pain</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An NMDA receptor antagonist is a type of glutamate antagonist that works to inhibit the action of NMDA receptors which may play a role in degenerative diseases that affect the brain. BHV-5500 (lanicemine) was in-licensed from AstraZeneca and is a low-trapping, NMDA receptor antagonist with differentiating pharmacologic properties from other agents in development targeting this receptor. The unique property of low-trapping antagonists is their ability to uncouple from the NMDA receptor more freely than other agents, a property that is thought to contribute to their mitigated risk of dissociative effects as has been observed in the clinic. Lanicemine, binds within the NMDA channel pore and functionally blocks the flow of charged ions through the NMDA receptor complex.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuropathic pain is a chronic condition caused by dysfunctional or damaged nerves. Neuropathic pain can be a debilitating and common problem affecting approximately 10% of adults in the United States. Despite the availability of multiple approved drugs, including Lyrica, and guidelines for the treatment of neuropathic pain, treatment of this condition remains a major therapeutic challenge. Existing analgesics are often ineffective, can cause serious side effects and have abuse potential that limits widespread use. Increased NMDA receptor activity is known to contribute to central sensitization in neuropathic pain. NMDA receptor antagonists have been shown to reduce hyperalgesia and pain in animal models of neuropathic pain induced by nerve injury and diabetic neuropathy. Clinically used NMDA receptor antagonists, including ketamine and dextromethorphan, can be effective in patients suffering from neuropathic pain syndromes. The clinical use of robust NMDA antagonists, such as ketamine, is limited due to dissociative, psychotomimetic and abuse potential properties. Novel NMDA receptor antagonists, such as BHV-5500, that are not associated with the psychotomimetic effects and abuse potential could lead to better management of neuropathic pain without causing serious side effects.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Myostatin Platform</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taldefgrobep Alfa</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we announced a worldwide license agreement with BMS for the development and commercialization rights to taldefgrobep alfa (also known as BMS-986089), a novel Phase 3 asset. Myostatin, a negative regulator of muscle growth, is a key member of the TGF (symbol Beta) family. Taldefgrobep novelty in a field of myostatin inhibitors is based on the mechanism where it binds to myostatin to both lower overall myostatin levels, but also to function as a receptor antagonist to block myostatin signaling in skeletal muscles. Blocking myostatin activity and signaling has shown to improve muscle function and strength in a number of disease models for neuromuscular wasting. Clinical studies have confirmed that taldefgrobep improved lean body mass directly through increase on contractile muscle and loss of adipose tissue as demonstrated in both normal healthy volunteers and in patients with Duchenne muscular dystrophy (&#8220;DMD&#8221;). The mechanism of improving overall muscle size and function opens the opportunity for taldefgrobep as monotherapy or combination therapy in a number of muscle-targeted neuromuscular diseases. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Clinical Trial for Taldefgrobep Alfa in SMA </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of taldefgrobep alfa in SMA. SMA is a rare, progressively debilitating motor neuron disease in which development and growth of muscle mass are compromised, resulting in progressive weakness and muscle atrophy, reduced motor function, impaired quality of life and often death. The Phase 3 placebo-controlled, double-blind trial is designed to evaluate the efficacy and safety of taldefgrobep as an adjunctive therapy for participants who are already taking a stable dose of nusinersen or risdiplam or have a history of treatment with onasemnogene abeparvovec-xioi, compared to placebo. The primary outcome measures of the study will be efficacy of taldefgrobep alfa compared to placebo in the change in the 32 item Motor Function Measure (&#8220;MFM-32&#8221;) total score from baseline to Week 48. Scores range from 0-3 on each item, with higher scores indicating higher functioning. The study is neither restricted nor limited to patients based on ambulatory status or classification of SMA. We expect to randomize approximately 180 patients in this randomized, double-blind, placebo-controlled global trial.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">About Spinal Muscular Atrophy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SMA is a rare genetic neurodegenerative disorder characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk and progressive muscle weakness that is often fatal and typically diagnosed in young children. The underlying pathology of SMA is caused by insufficient production of the survival of motor neuron (&#8220;SMN&#8221;) protein, essential for the survival of motor neurons, and is encoded by two genes, SMN1 and SMN2. In the U.S., SMA affects approximately 1 in 11,000 births, and about 1 in every 50 Americans is a genetic carrier. Newborn screening is now available in 48 U.S. states and covers over 97% of all births. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taldefgrobep Alfa&#8217;s Role in Spinal Muscular Atrophy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the past three years, significant advancements were made to address the underlying cause of disease in SMA with the up-regulation of SMN1 and SMN2 expression which positions taldefgrobep as a potential combination </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapy to enhance muscle performance. Data from both an SMA animal model study that shows advantages of combination SMN therapy with taldefgrobep and the extensive clinical data in DMD support the advancement of taldefgrobep into a SMA Phase 3 study. Other indications in muscle wasting diseases will be a fast follow-on for taldefgrobep along with other life-cycle opportunities. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquisition of taldefgrobep alfa expands our neuroscience pipeline. The advanced taldefgrobep alfa anti-myostatin development program offers extensive human safety data, especially in the pediatric population, which we plan to leverage and build upon in our future development efforts. </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business8a.jpg" src="business8a.jpg" style="height:458px;margin-bottom:5pt;vertical-align:text-bottom;width:620px"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biohaven Labs</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired the remaining approximately 58% of Kleo Pharmaceuticals, Inc. (&#8220;Kleo&#8221;) that we did not previously own. We have assumed Kleo&#8217;s laboratory facilities located in Science Park in New Haven, Connecticut and formed Biohaven Labs to serve, along with the Pittsburgh-based Kv7 platform, as our integrated chemistry and discovery research arm. Biohaven Labs will continue to augment its discovery efforts through research partnerships, including research agreements such as with KU Leuven and the Fox Chase Chemical Diversity Center Inc. and research grants such as from the Bill and Melinda Gates Foundation and the NIH HEAL Initiative.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TRPM3 Antagonists</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KU Leuven Agreement </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we entered into the KU Leuven Agreement to develop and commercialize TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders (the &#8220;KU Leuven </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement&#8221;). The TRPM3 antagonist platform was discovered at the Centre for Drug Design and Discovery and the Laboratory of Ion Channel Research at KU Leuven. Under the KU Leuven Agreement, we receive exclusive global rights to develop, manufacture and commercialize KU Leuven&#8217;s portfolio of small-molecule TRPM3 antagonists. The portfolio includes the lead candidate, BHV-2100, which we are evaluating in several preclinical pain models and advancing towards the clinic in 2023. We are continuing to support further basic and translational research on the role of TRPM3 in pain and other disorders through our collaboration with Professors Joris Vriens and Thomas Voets, world leaders in TRP biology at KU Leuven.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Efforts to target TRP Channels for pain</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Nobel Prize-winning discovery of the capsaicin receptor TRPV1 in 1997, members of the Transient Receptor Potential (&#8220;TRP&#8221;) cation channel family have been elusive drug targets for the treatment of pain. Initially, there was much excitement and investment in TRPV1 antagonists due to promising preclinical efficacy and some evidence of clinical pain reduction. However, trials of most TRPV1 antagonists were terminated after the class consistently caused clinically-significant hyperthermia in study participants. Several companies then made efforts to progress antagonists of TRPA1, the receptor for mustard oil. Though Glenmark&#8217;s GRC 17536 showed encouraging results in a subset of diabetic peripheral neuropathic pain subjects in a Phase IIa study, it suffers from poor physiochemical properties and pharmacokinetics like many other TRPA1 antagonists. Due to the challenges with drugging TRPA1, only Eli Lilly&#8217;s LY3526318 remains in active clinical development. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TRPM3 is a novel target in the TRP family. Like TRPV1 and TRPA1, preclinical data and human genetic validation support TRPM3&#8217;s role in neuropathic pain. Unlike TRPV1 antagonists, TRPM3 antagonists are unlikely to possess significant thermal liabilities, and unlike TRPA1 antagonists, Biohaven&#8217;s TRPM3 antagonists have desirable physiochemical properties and good pharmacokinetic profiles. The figure below illustrates TRPM3 as a differentiated target for the treatment of pain in the TRP family.</font></div><div style="text-align:center"><img alt="business9a.jpg" src="business9a.jpg" style="height:291px;margin-bottom:5pt;vertical-align:text-bottom;width:672px"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adapted from Efforts to target TRP channels for pain, Kovivisto et al. 2022</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">About TRPM3</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transient Receptor Potential Melastatin 3 (&#8220;TRPM3&#8221;) is a novel druggable target in the TRP cation channel family. TRPM3 is functionally expressed in the human dorsal root ganglion, and several SNPs in TRPM3 are associated with altered pain sensation in response to UVB (see figure below). Additionally, people with TRPM3 gain-of-function mutations experience altered pain sensation (de Sainte Agathe 2020, Dyment 2019, Van Hoeymissen 2020). Knocking out or antagonizing TRPM3 in animal models attenuates the development of various pain states, including those associated with nerve injury, chemotherapy, and diabetic peripheral neuropathy, further indicating that TRPM3 is a promising target for neuropathic pain. Lastly, preclinical evidence suggests that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">antagonizing TRPM3 may avoid the on-target body temperature effects and dangerous lack of noxious heat detection that afflicted TRPV1 antagonists.</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:63.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td></tr><tr style="height:167pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:9pt;text-align:center"><img alt="business10a.jpg" src="business10a.jpg" style="height:206px;margin-bottom:5pt;vertical-align:text-bottom;width:400px"></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:9pt;text-align:center"><img alt="business11a.jpg" src="business11a.jpg" style="height:210px;margin-bottom:5pt;vertical-align:text-bottom;width:211px"></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vangeel et al, 2020</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lotsch et al, 2020</font></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Development of BHV-2100 for the Treatment of Neuropathic Pain</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHV-2100 is an orally-bioavailable small molecule antagonist of TRPM3. TRPM3 is expressed in the relevant human tissue types for neuropathic pain, and both preclinical models and human genetics implicate TRPM3 in pain signaling. BHV-2100 is our lead orally-bioavailable small molecule TRPM3 antagonist which we are developing as a potential non-opioid treatment for neuropathic pain. We are evaluating the ability of BHV-2100 to reduce pain behaviors across several preclinical models of neuropathic pain, including chemotherapy induced neuropathy, diabetic neuropathy, and nerve injury. First-in-human studies of BHV-2100 are anticipated to begin in 2023, complementing our efforts with our Kv7 platform. The Company is evaluating and has not yet finalized potential clinical trial designs, including trial size, and primary and secondary endpoints. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional research on TRPM3-mediated disorders</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the KU Leuven agreement, Biohaven is supporting further basic and translational research at KU Leuven on the role of TRPM3 in pain and other disorders. In addition to BHV-2100, we are optimizing other lead compounds for TRPM3-mediated disorders of the peripheral and central nervous systems.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TDP-43</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreement with Fox Chase Chemical Diversity Center Inc.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into an agreement with Fox Chase Chemical Diversity Center Inc. (&#8220;FCCDC&#8221;) for FCCDC&#8217;s TAR-DNA protein-43 (&#8220;TDP43&#8221;) assets (the &#8220;FCCDC Agreement&#8221;). The FCCDC Agreement provides us with a plan and goal to identify one or more new chemical entity candidates for preclinical development for eventual clinical evaluation for the treatment of one or more TDP-43 proteinopathies. In connection with the FCCDC Agreement, we have established a TDP-43 Research Plan with FCCDC that provides for certain milestones to be achieved by FCCDC, and milestone payments to be made by the Company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Development Program Targeting TDP-43 in Neurodegeneration </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TDP-43 is a multifunctional nucleic acid-binding protein that is implicated in neurodegeneration. Mutations in the gene that encodes for TDP-43 cause familial and sporadic ALS and frontotemporal dementia (&#8220;FTD&#8221;). Cytoplasmic TDP-43 aggregates are the neuropathological hallmark of ALS-FTD spectrum disorders. The Company is evaluating and has not yet finalized potential clinical trial designs, including trial size, and primary and secondary endpoints. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Mechanism of Action of Our TDP-43 Targeting Compounds</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TDP-43 is a nucleic acid binding protein that has several molecular and cellular functions. Salient TDP-43 functions implicated in disease pathogenesis are shown in the figure below. The most common motif identified for TDP-43 is thymine-gauanine repeats (&#8220;&#91;TG&#93;n&#8221;), which corresponds to the uracil-gauanine repeats (&#8220;&#91;UG&#93;n&#8221;) ribonucleic acid (&#8220;RNA&#8221;) binding motif. Interaction with RNA allows TDP-43 to regulate pre-mRNA splicing to inhibit the inclusion of cryptic exons as well as influence polyadenylation site selection. Cytosolic roles for TDP-43 include transport of RNA along neuronal processes and response to stresses, including those affecting proteostasis, which can trigger TDP-43 nuclear efflux and localization to stress granules. A multitude of these basic molecular functions contribute to TDP-43 autoregulation, including splicing and polyadenylation.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business12a.jpg" src="business12a.jpg" style="height:312px;margin-bottom:5pt;vertical-align:text-bottom;width:400px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mechanism of action of our small molecule TDP-43 targeting compounds is the disruption of nucleotide binding to TDP-43. Our compounds were identified using a high-throughput screening approach that measured inhibition of oligonucleotide binding to TDP-43 using Amplified Luminescence Proximity Homogenous Assay (AlphaScreen&#174;) technology. Screening was performed on a diverse set of more than 7000 compounds and identified compounds with sub-micromolar affinities that disrupt oligonucleotide binding to TDP-43, by binding to TDP-43 directly themselves (Cassel J. Biomolecular Screening, 2010, 15, 1099-1106). Several chemotypes were identified. Structure activity relationships were developed and refined with a focus on optimizing pharmacology, in vitro and in vivo efficacy (e.g, prolongation of survival in Drosophila, induced motor neurons, and TDP-43 transgenic mouse models), and safety profiles.</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bispecific Molecular Degraders of Extracellular Proteins</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular Degraders of Extracellular Proteins (&#8220;MoDEs&#8221;) are bispecific molecules that target pathologic circulating proteins and direct them to the liver (or other organ systems) for degradation by the endosomal&#47;lysosomal </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pathway. Our MoDE platform is being explored for use in a wide range of therapeutic areas, including indications in autoimmune diseases, cancer and infectious disease.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business13a.jpg" src="business13a.jpg" style="height:302px;margin-bottom:5pt;vertical-align:text-bottom;width:672px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody-based Galactose-deficient IgA (&#8220;Gd-IgA&#8221;) MoDEs</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IgA nephropathy (&#8220;IgAN&#8221;) is the most common primary glomerulonephritis that can progress to renal failure and is characterized by immunoglobulin deposits in the renal mesangium comprised exclusively of the IgA1 subclass. Patients with IgAN have increased serum levels of IgA1 with a hinge region containing truncated galactose-deficient O-linked saccharides (&#8220;Gd-IgA&#8221;) and can present with a range of symptoms, from hematuria or proteinuria to severe hypertension owing to renal damage. The clinical progression varies, with 30&#8211;40% of patients reaching end-stage renal disease 20&#8211;30 years after the first clinical presentation. Currently, no IgAN-specific </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapies are available and patients are managed with the aim of controlling blood pressure and maintaining renal function.</font></div><div style="text-align:center"><img alt="business14a.jpg" src="business14a.jpg" style="height:431px;margin-bottom:5pt;vertical-align:text-bottom;width:475px"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lai, Nat Rev Dis Primers (2016)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our MoDE platform to develop novel bispecific molecules for the treatment of IgA nephropathy (&#8220;IgAN&#8221;) that remove potentially disease-causing Gd-IgA in patients and prevent harmful kidney deposits. We have taken a published rodent format IgG antibody that recognizes Gd-IgA and converted it into a partially-humanized, liver-targeted degrader MoDE using MATE conjugation (see below) that potently binds Gd-IgA and causes its endocytosis in human liver cells. Further work is ongoing to progress this as a potential IgAN treatment. The Company is evaluating and has not yet finalized potential clinical trial designs, including trial size, and primary and secondary endpoints. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To broaden our internal efforts, in July 2021, we entered into a development and license agreement with Reliant Glycosciences, LLC (&#8220;Reliant&#8221;) for collaboration on a program with Biohaven Labs&#8217; multifunctional molecules to develop and commercialize conjugated antibodies for therapeutic uses relating to IgAN and other diseases and conditions. Under the Agreement, Reliant was entitled to an upfront payment and will be eligible to receive development milestone payments and royalties on net sales of licensed products.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multimodal Antibody Therapy Enhancer Conjugation Technology</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody Drug Conjugates</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are using the Multimodal Antibody Therapy Enhancer (&#8220;MATE&#8221;) conjugation technology to generate site-specific antibody drug conjugates (&#8220;ADC&#8221;s) from native IgG1 proteins that we believe will show superior stability in comparison with those using current industry-standard cysteine maleimide conjugation. Our expectation is that the enhanced in vivo stability and expected superior physicochemical properties of these ADCs will lead to increased therapeutic indices (more cytotoxic payload reaching cancer cells and less reaching normal tissues). Over </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 site-specific ADCs using the well validated vcMMAE payload linker system have been prepared and are undergoing biological testing in comparison with industry standard maleimide conjugated ADCs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary MATE conjugation technology uses a new class of synthetic peptide binders to target the spike protein of SARS-CoV-2 that are then selectively conjugated to commercially available intravenous immunoglobulin. We used published synthetic binders for SARS-CoV2 that had been designed to establish a much wider area and number of contacts with the spike protein than other agents like monoclonal antibodies. In February 2021, we announced that BHV-1200 developed with our proprietary MATE platform demonstrated functional binding and neutralization of the SARS-CoV-2 virus, including the strains known as the &#8220;English&#8221; and &#8220;South African&#8221; variants (also known as B.1.1.7 and B.1.351, respectively). The preliminary experiments conducted by Biohaven Labs and by an academic collaborator demonstrated that BHV-1200 substantially reduced viral entry into cells. We are currently evaluating BHV-1200 as a clinical candidate for the treatment of COVID-19. The Company is evaluating and has not yet finalized potential clinical trial designs, including trial size, and primary and secondary endpoints. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MATE Molecule for COVID-19</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business15a.jpg" src="business15a.jpg" style="height:285px;margin-bottom:5pt;vertical-align:text-bottom;width:548px"></div><div style="margin-bottom:9pt;text-align:center"><img alt="business16a.jpg" src="business16a.jpg" style="height:308px;margin-bottom:5pt;vertical-align:text-bottom;width:548px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BHV-1100</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody Recruiting Molecules</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antibody Recruiting Molecules (&#8220;ARMs&#8221;) are bispecific molecules that recruit endogenous antibodies to target cancer, virally infected cells, and disease-causing microorganisms for immune-mediated clearance. These molecules are engineered as modular components that are readily interchangeable, giving the platform tremendous flexibility for a variety of indications and therapy areas.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By recruiting antibodies to coat the disease cell target, ARMs mark it for removal by the body&#8217;s innate antibody-mediated immune mechanisms (antibody dependent cellular cytotoxicity and antibody dependent cellular phagocytosis).</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business17a.jpg" src="business17a.jpg" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:400px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Platform advantages</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to biologics, ARMs directly engage patients&#8217; immune system to destroy disease cells by connecting target disease cells with components of the immune system. However, unlike biologics, ARMs are smaller in size than an antibody potentially allowing for enhanced tumor penetration and biodistribution, and may offer manufacturing advantages including enhanced shelf stability. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARM&#8482; NK Combination Therapy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARMs provide target specificity to Natural Killer (&#8220;NK&#8221;) cell therapies without needing to design chimeric antigen receptors (&#8220;CARs&#8221;) or other methods of genetic manipulation. NK cells are a type of immune effector cell that can recognize and destroy non-self targets and certain diseased cells. NK cells do not target specific protein epitopes like T cells of the adaptive immune system. Our ARMs are being used to provide antigen target specificity to NK cell therapies (both allogeneic and autologous) with the goal of enhancing efficacy and safety. ARM NK combination therapy directs NK cells to a disease target of interest.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Clinical Trial for BHV-1100 in Newly Diagnosed Multiple Myeloma Patients</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated dosing in a Phase 1a&#47;1b trial in newly diagnosed multiple myeloma patients. Our ARM, BHV-1100, in combination with autologous cytokine induced memory-like (&#8220;CIML&#8221;) NK cells and immune globulin (&#8220;Ig&#8221;), is expected to target and kill multiple myeloma cells expressing the cell surface protein CD38. The trial is supported by compelling preclinical data showing that BHV-1100 enhanced recruitment of autologous CIML NK cells increases killing of multiple myeloma cells.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This open-label single center Phase 1a&#47;1b study assesses the safety and tolerability as well as exploratory efficacy endpoints in newly diagnosed multiple myeloma patients who have tested positive for minimal residual disease (&#8220;MRD+&#8221;) in first or second remission prior to autologous stem cell transplant (&#8220;ASCT&#8221;). We expect to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enroll 30 newly diagnosed multiple myeloma patients. The primary outcome measures are dose limiting toxicities following combination product administration (time frame&#58; 90 to 100 days post-combination product administration) and incidence and severity of side effects related to the combination product.</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHV-1100 Binds CD38 and lg to Create a Targeting Therapy to Kill Multiple Myeloma Cells</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business18a.jpg" src="business18a.jpg" style="height:298px;margin-bottom:5pt;vertical-align:text-bottom;width:570px"></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHV-1100 Enhances Recruitment of NK Cells and Increases Killing of Multiple Myeloma Cells</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business19a.jpg" src="business19a.jpg" style="height:324px;margin-bottom:5pt;vertical-align:text-bottom;width:570px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of Connecticut License Option</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we signed an exclusive, worldwide option and license agreement with the University of Connecticut for the development and commercialization rights to UC1MT, a therapeutic antibody targeting extracellular metallothionein (&#8220;MT&#8221;). Under this agreement, we have the option to acquire an exclusive, worldwide license to UC1MT and its underlying patents to develop and commercialize throughout the world in all human indications.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extracellular MT has been implicated in the pathogenesis of autoimmune and inflammatory diseases. MTs are a family of low molecular weight, cysteine-rich, metal-binding proteins that have a wide range of functions in cellular homeostasis and immunity. MT has traditionally been considered to be an intracellular protein that can be found in both the cytoplasm and nucleus&#59; however, MT also can be found in extracellular spaces, particularly in disease states involving chronic cellular stress where intracellular MT production is upregulated by inflammatory cytokines, and extracellular MT acts as a danger signal, attracting leukocytes and modulating the immune response. In preclinical studies, UC1MT has been observed to block this extracellular pool of MT and the resulting MT-mediated inflammation and immunomodulation. The Company is evaluating and has not yet finalized potential clinical trial designs, including trial size, and primary and secondary endpoints. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Artizan Biosciences Inc. License Option</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into an Option and License Agreement with Artizan Biosciences Inc. (&#8220;Artizan&#8221;), a biotechnology company focused on creating new classes of precision therapies targeting chronic inflammation and immune dysregulation by leveraging the human gut as a drug discovery tool. Pursuant to the agreement, we acquired an option to obtain a royalty-based license from Artizan to manufacture, use and commercialize certain products. Artizan will use the proceeds to continue advancing the preclinical research and development of its lead program for inflammatory bowel disease, which is anticipated to enter the clinic in early 2023, as well as to explore additional disease targets. In November 2021, we announced a collaborative therapeutic discovery and development program in Parkinson&#8217;s disease (&#8220;PD&#8221;), to exploit recent scientific advances in the understanding of pathogenic roles played by the gut microbiome in PD. In June 2022, we and Artizan executed a non-binding indication of interest (&#8220;Artizan Side Letter&#8221;) which describes terms under which we and Artizan would amend the 2020 Artizan Agreement to eliminate certain milestone payments required by us in exchange for limiting our option to the selection of the first (ARZC-001) licensed product. The Company is evaluating and has not yet finalized potential clinical trial designs, including trial size, and primary and secondary endpoints. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary drugs. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their safety, efficacy, convenience, price, the level of generic competition and the availability of coverage and reimbursement from government and other third-party payors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies against which we are competing, or against which we may compete in the future, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an experienced manufacturing leadership team that manages our relationships with third party manufacturers. We currently rely, and expect to continue to rely, on third parties for the manufacturing of our product candidates for preclinical and clinical testing, as well as for commercial manufacturing of our products if our product candidates receive marketing approval.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidates are small molecules and are manufactured in reliable and reproducible synthetic processes from readily available starting materials. The chemistry does not require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to develop and, if approved by the FDA, commercialize our product candidates in the United States, and we may enter into distribution or licensing arrangements for commercialization rights for other regions. With respect to the product candidates in our Kv7 ion channel activators, glutamate modulation and myostatin inhibition platforms, we currently intend to build a neurological specialty sales force to manage commercialization for these product candidates, potentially in combination with a larger pharmaceutical partner, to maximize patient coverage in the United States and to support global expansion.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Members of our management team and Board have deep experience leading neuroscience research and have been involved in the development and commercialization of drugs such as Abilify, Opdivo and, most recently, Nurtec ODT. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our chief executive officer, Vlad Coric, had been the Chief Executive Officer of Former Parent since 2015, leading Former Parent&#8217;s development and successful commercial launch of Nurtec ODT (rimegepant) in the U.S., which received FDA approval for the acute and preventative treatment of migraine in February 2020 and May 2021, respectively. Under Dr. Coric&#8217;s leadership, Former Parent entered into several strategic arrangements, including its Collaboration and License agreement with Pfizer, Inc. for the development of rimegepant and zavegepant outside of the United States.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or license patents in the U.S. and foreign countries that protect our products, their methods of use and manufacture, as well as other innovations relating to the advancement of our science to help bring new therapies to patients. We also develop brand names and trademarks for our products to differentiate them in the marketplace. We consider the overall protection of our patents, trademarks, licenses and other intellectual property rights to be of material value and act to protect these rights from infringement. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain the proprietary position of our products and development programs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the biopharmaceutical industry, a substantial portion of an innovative product&#8217;s commercial value is usually realized during the period in which the product has market exclusivity. A product&#8217;s market exclusivity is generally determined by two forms of intellectual property&#58; patent rights held by the innovator company and any regulatory forms of exclusivity to which the innovative drug is entitled.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents are a key determinant of market exclusivity for most pharmaceuticals. Patents provide the innovator with the right to exclude others from practicing an invention related to the medicine. Patents may cover, among other things, the active ingredient(s), various uses of a drug product, discovery tools, pharmaceutical formulations, drug delivery mechanisms and processes for (or intermediates useful in) the manufacture of products. Protection for individual products extends for varying periods in accordance with the expiration dates of patents in the various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent, its scope of coverage and the availability of meaningful legal remedies in the country.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market exclusivity can also be influenced by regulatory data protection (&#8220;RDP&#8221;). Many developed countries provide certain non-patent incentives for the development of medicines. For example, in the U.S., the EU, United Kingdom, Japan, and certain other countries, RDP intellectual property rights are offered to&#58; (i) provide a time </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period of data protection during which a generic company is not allowed to rely on the innovator&#8217;s data in seeking approval&#59; (ii) restore patent term lost during drug development and approval&#59; and (iii) provide incentives for research on medicines for rare diseases, or orphan drugs, and on medicines useful in treating pediatric patients. These incentives can extend the market exclusivity period on a product beyond the patent term.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents and Patent Applications</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have many U.S. and foreign patents and patent applications in our portfolio related to the composition of matter, methods of use, methods of manufacture or formulations of our product candidates which have been filed in major markets throughout the world, including the U.S., Europe, Japan, Korea, China, Hong Kong and Australia.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kv7</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we acquired Channel Biosciences, LLC. This acquisition included Channel&#8217;s Kv7 channel targeting platform and related patents and patent applications. The patents and patent applications are directed to the composition of matter of compounds that are activators of Kv7.2&#47;Kv7.3 and their use in treating diseases such as epilepsy. U.S. Patent 10,851,067 (the &#8220;&#8216;067 Patent&#8221;), issued December 1, 2020, specifically claims BHV-7000 and will expire in March 2039, not including possible patent term extensions. Ex-U.S. counterparts to the &#8216;067 patent are pending in Australia, Brazil, Canada, China, European Union, United Kingdom, Hong Kong, Israel, India, Japan, Republic of Korea, Mexico, New Zealand, Singapore and South Africa. If granted, the ex-U.S. patents will expire in March 2039, not including possible patent term extensions in countries where such extensions are available. In addition, U.S. Patent 9,481,653 (the &#8220;&#8216;653 patent&#8221;), issued November 1, 2016, claims a class of compounds including BHV-7000 and will expire in September 2035, not including possible patent term extensions. Ex-US counterparts to the &#8216;653 patent are granted in Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Ireland, Iceland, Italy, Netherlands, Norway and Sweden. The ex-U.S. patents will expire in September 2035, not including possible patent term extensions in countries where such extensions are available.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Troriluzole</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own a portfolio of patents and patent applications in the U.S. and foreign countries directed to prodrugs of riluzole, including, among others, U.S. Patent 10,485,791, issued November 26, 2019, which is directed to troriluzole and other prodrugs of riluzole. This patent expires in February 2036, not including possible patent term extensions. Ex-US counterparts to the &#8216;791 patent have been granted in Albania, Armenia, Austria, Australia, Azerbaijan, Belgium, Bulgaria, Belarus, Canada, Switzerland, China, Cyprus, Czechia, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Hong Kong, Croatia, Hungary, Ireland, Israel, Italy, Japan, Kyrgyzstan, Kazakhstan, Lithuania, Luxembourg, Latvia, Monaco, North Macedonia, Malta, Mexico, Netherlands, Norway, Philippines, Poland, Portugal, Romania, Serbia, Russia, Sweden, Slovenia, Slovakia, Tajikistan, Turkmenistan, Turkey and South Africa, and patent applications are pending in Brazil, India, Republic of Korea, Macao and Singapore. The ex-US patents and patent applications will expire in February 2036, not including possible patent term extensions in countries where such extensions are available. In addition, the use of these compounds for treating OCD, ALS, SCA, depression, Alzheimer&#8217;s Disease and other diseases are described and claimed in these patents and patent applications. We own these patent applications subject to an agreement with ALS Biopharma and FCCDC. In addition, we have filed patent applications relating to drug product formulations containing trorilizole and methods of using the formulations to treat various diseases, including, for example, the use of troriluzole with immunotherapies to treat cancer, including among others U.S. Patent 11,400,155, issued August 2, 2022, which expires in May 2037, not including possible patent term extensions. Ex-US counterparts to the &#8216;155 patent have been granted in Albania, Austria, Australia, Belgium, Bulgaria, Switzerland, China, Cyprus, Czechia, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Hong Kong, Croatia, Hungary, Ireland, Israel, Italy, Republic of Korea, Lithuania, Luxembourg, Latvia, Monaco, North Macedonia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Sweden, Slovenia, and Slovakia and patent applications are pending in Brazil, Canada, India, Japan, Mexico, Philippines, Singapore and South Africa. The ex-US patents and patent applications will expire in May 2037, not including possible patent term extensions in countries where such extensions are available.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we in-licensed patents from AstraZeneca relating to the composition of matter of verdiperstat, pharmaceutical compositions and various neurological diseases including muscular system atrophy. U.S. Patent 7,829,707, issued November 9, 2010, U.S. Patent 8,859,568, issued October 14, 2014, and U.S. Patent 9,580,429, issued February 28, 2017, are directed to compositions of matter of verdiperstat and other compounds, pharmaceutical compositions of verdiperstat and methods of treating diseases. The U.S. patents expire in December 2025 not including patent term adjustments and extensions. Ex-US counterparts to the U.S. patents have been granted in Australia, Brazil, Canada, Switzerland, China, Germany, Spain, France, United Kingdom, Hong Kong, India, Italy, Japan, Republic of Korea, Mexico, Netherlands, Russia, Sweden, and Turkey. The ex-US patents and patent applications will expire in December 2025, not including possible patent term extensions in countries where such extensions are available. U.S. Serial No. 17&#47;766539, filed April 5, 2022, is directed to novel prodrug forms of verdiperstat. Ex-US counterparts to the &#8216;539 application have been filed in Australia, Brazil, Canada, China, European Union, United Kingdom, Israel, India, Japan, Republic of Korea, Mexico, New Zealand, Singapore and South Africa. The ex-US patents and patent applications will expire in October 2040, not including possible patent term extensions in countries where such extensions are available.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MoDEs Platform, ARMs, MATEs</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a worldwide, exclusive license agreement with Yale University for the development and commercialization of a novel Molecular Degrader of Extracellular Protein platform. The platform pertains to the clearance of disease-causing protein and other biomolecules by targeting them for lysosomal degradation using multi-functional molecules. The platform is differentiated from existing approaches in that it does not rely on ubiquitin ligases, and it allows for a broad range of targets to be degraded. The patent portfolio is directed to the composition of matter of bifunctional degraders and their use in degrading circulating proteins and treating diseases. U.S. Serial No. 17&#47;046221, which relates to bifunctional small molecules to target selective degradation of circulating proteins, filed October 8, 2020, was filed in the United States, Canada, China, European Union and Hong Kong and, if granted, will expire in April 2039, not including possible patent term extensions in countries where such extensions are available. U.S. Serial No. 17&#47;768166, filed April 11, 2022, which relates to bifunctional compounds as degraders of autoantibodies, was filed in the United States, United Arab Emirates, Australia, Brazil, Canada, China, European Union, Israel, Japan, Republic of Korea, Mexico, Philippines, Saudi Arabia, Singapore, and South Africa and, if granted, will expire in October 2040, not including possible patent term extensions in countries where such extensions are available. U.S. Serial No. 17&#47;046192, filed October 8, 2020, which relates to bifunctional molecules to degrade circulating proteins, was filed in the United States, Canada, European Union and Hong Kong, and, if granted, will expire in April 2039, not including possible patent term extensions in countries where such extensions are available. U.S. Serial No. 17&#47;768145, filed April 11, 2022, which relates to engineered antibodies as molecular degraders through cellular receptors, was filed in the United States, United Arab Emirates, Australia, Brazil, Canada, China, countries of the Eurasian Patent Organization, European Union, Israel, India, Japan, Republic of Korea, Mexico, New Zealand, Philippines, Saudi Arabia, South Africa and Singapore and, if granted, will expire in October 2040, not including possible patent term extensions in countries where such extensions are available. PCT&#47;US2022&#47;017319, filed February 22, 2022, which relates to targeted bifunctional degraders, is pending in the United States Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing. The patent applications, if granted, will expire in February 2042, not including possible patent term extensions in countries where such extensions are available. PCT&#47;US2022&#47;019658, which relates to bifunctional degraders of galactose deficient immunoglobulins, filed March 10, 2022, is pending in the United States Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing. The patent applications, if granted, will expire in March 2042, not including possible patent term extensions in countries where such extensions are available. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired Kleo Pharmaceuticals, Inc. in January 2021. This acquisition included Kleo&#8217;s proprietary technology platforms which are modular in design and enable rapid generation of novel immunotherapies that can be optimized against specified biological targets and combined with existing cell- or antibody-based therapies. These include Antibody Recruiting Molecules and Monoclonal Antibody Therapy Enhancers, which complement the MoDEs technology licensed from Yale. U.S. Serial No. 17&#47;769924, filed November 19, 2020, which relates to directed conjugation technologies, was filed in the United States, United Arab Emirates, Australia, Brazil, Canada, China, countries of the Eurasian Patent Organization, European Union, Israel, India, Japan, Republic of Korea, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mexico, New Zealand, Philippines, Saudi Arabia, South Africa and Singapore and, if granted, will expire in November 2040, not including possible patent term extensions in countries where such extensions are available. PCT&#47;US2021&#47;024186, filed March 25, 2021, which relates to technologies for treating COVID infections, is pending in the United States Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing. The patent applications, if granted, will expire in March 2041, not including possible patent term extensions in countries where such extensions are available. PCT&#47;US2022&#47;015390, filed February 6, 2022, which relates to technologies for preventing or treating infections, is pending in the United States Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing. The patent applications, if granted, will expire in February 2042, not including possible patent term extensions in countries where such extensions are available. PCT&#47;US2022&#47;029533, filed May 17, 2022, which relates to compositions including conjugated therapy enhancers, is pending in the United States Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing. The patent applications, if granted, will expire in May 2042, not including possible patent term extensions in countries where such extensions are available. PCT&#47;US2022&#47;029535, filed May 17, 2022, which relates to agents for directed conjugation techniques and conjugated products, is pending in the United States Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing. The patent applications, if granted, will expire in May 2042, not including possible patent term extensions in countries where such extensions are available. PCT&#47;US2022&#47;030070, filed May 19, 2022, which relates to antibody drug conjugates using MATE technology for delivering cytotoxic agents, is pending in the United States Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing. The patent applications, if granted, will expire in May 2042, not including possible patent term extensions in countries where such extensions are available.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TDP-43</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have pending patent applications covering the composition of matter of compounds targeting TDP-43 in neurodegeneration. TDP-43, TAR-DNA protein-43, is a multifunctional nucleic acid-binding protein that is implicated in neurodegeneration. Mutations in the gene that encodes for TDP-43 cause familial and sporadic amyotrophic lateral sclerosis (&#8220;ALS&#8221;) and frontotemporal dementia (&#8220;FTD&#8221;). Cytoplasmic TDP-43 aggregates are the neuropathological hallmark of ALS-FTD spectrum disorders. U.S. Serial No. 17&#47;635421, filed February 15, 2022, which relates to compounds that target TDP-43, was filed in the United States, Australia, Brazil, Canada, China, countries of the Eurasian Patent Organization, European Union, Israel, India, Japan, Republic of Korea, Mexico, Philippines, South Africa and Singapore and, if granted, will expire in August 2040, not including possible patent term extensions in countries where such extensions are available. PCT&#47;US2022&#47;017116, filed February 20, 2022, which relates to compounds that target TDP-43 for the treatment of ALS and related disorders, is pending in the United States Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing. The patent applications, if granted, will expire in February 2042, not including possible patent term extensions in countries where such extensions are available.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IBD and Parkinson&#8217;s Disease</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into an option and license agreement with Artizan Biosciences directed toward the development and commercialization of novel treatments for inflammatory bowel disease (&#8220;IBD&#8221;) and other gastrointestinal inflammatory disorders, e.g., Crohn&#8217;s disease, in the U.S. Under the terms of the agreement, we have the rights to exercise an option on up to three product candidates. In June 2021, we entered into a separate worldwide, exclusive license agreement under the IgA-SEQ patented technology with Artizan to develop and commercialize certain of their compounds for use in Parkinson&#8217;s Disease. U.S. Patent 9,758,838, issued September 12, 2017, U.S. Patent 10,428,392, issued October 1, 2019, U.S. Patent 10,774,392, issued September 15, 2020, and U.S. Patent 11,299,790, issued April 12, 2022, relate to compositions and methods for identifying secretory antibody microbes. These patents expire in March 2034, not including possible patent term extensions. U.S. Patent 10,925,953, issued February 23, 2021, Serial No. 15&#47;507357, which relates to compositions and methods for treating an inflammatory disease or disorder, was also filed in the European Union, will expire in August 2035, not including possible patent term extensions. U.S. Serial No. 17&#47;253333, filed July 3, 2019, which relates to compositions and methods for treating inflammatory diseases, was filed in the United States, Australia, Brazil, Canada, China, European Union, Hong Kong, Israel, Japan, Republic of Korea, Mexico, New Zealand, Russia, South Africa and Singapore and, if granted, will expire in July 2039, not including possible patent term extensions in countries where such extensions are available. PCT&#47;US2021&#47;050048, filed September 13, 2021, which relates to small molecule </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inhibitors of bacterial toxins, is pending the United States Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing. The counterpart application is also pending in Taiwan. The patent applications, if granted, will expire in September 2041, not including possible patent term extensions in countries where such extensions are available. PCT&#47;US2022&#47;012472, filed January 14, 2022, which relates to compositions and methods for treating and preventing diseases or disorders using inter-species interactions, is pending in the United States Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TRPM3</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we entered into an exclusive global license and research agreement to develop and commercialize TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders. The TRPM3 antagonist platform was discovered at the Centre for Drug Design and Discovery (&#8220;CD3&#8221;) and the Laboratory of Ion Channel Research (&#8220;LICR&#8221;) at Katholieke Universiteit Leuven (KU Leuven). PCT&#47;EP2021&#47;082853, filed November 24, 2021, which relates to aryl derivatives for treating TRPM3 mediated disorders, is pending in Taiwan and the European Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing. The patent applications, if granted, will expire in November 2041, not including possible patent term extensions in countries where such extensions are available. PCT&#47;EP2021&#47;082865, filed November 24, 2021, which relates to heterocycle derivatives for treating TRPM3 mediated disorders, is pending in Taiwan and the European Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing. The patent applications, if granted, will expire in November 2041, not including possible patent term extensions in countries where such extensions are available. PCT&#47;EP2021&#47;082858, filed November 24, 2021, which relates to aryl derivatives for treating TRPM3 mediated disorders, is pending in Taiwan and the European Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing. The patent applications, if granted, will expire in November 2041, not including possible patent term extensions in countries where such extensions are available. PCT&#47;EP2021&#47;082867, filed November 24, 2021, which relates to heterocycle derivatives for treating TRPM3 mediated disorders, is pending in Taiwan and the European Receiving Office of the Patent Cooperation Treaty and all countries were designated for filing. The patent applications, if granted, will expire in November 2041, not including possible patent term extensions in countries where such extensions are available. U.S. Patent 9,194,863, issued November 24, 2015, which relates to screening methods for analgesic agents, has also been granted in Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Ireland, Italy, Netherlands and Sweden. The patents, will expire in May 2032, not including possible patent term extensions in countries where such extensions are available.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Myostatin</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into a worldwide license agreement with Bristol Myers Squibb for the global development and commercialization rights to taldefgrobep alfa, a novel, Phase 3-ready anti-myostatin adnectin. Myostatin is a natural protein that limits skeletal muscle growth, an important process in healthy muscular development. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patent 8,853,154 issued October 7, 2014, U.S. Patent 8,933,199, issued January 13, 2015, U.S. Patent 8,993,265, issued March 31, 2015, U.S. Patent 9,493,546, issued November 15, 2016, U.S. Patent 9,662,373, issued May 30, 2017, U.S. Patent 10,245,302, issued April 2, 2019, and U.S. Patent 10,406,212, issued September 10, 2019, are directed to fibronectin based scaffold domain proteins that bind to myostatin. The U.S. patents expire in September 2033, not including possible patent term extensions. Ex-US counterparts to the U.S. patents have been granted in Austria, Australia, Belgium, Bulgaria, Switzerland, Chile, China, Colombia, Czechia, Germany, Denmark, Algeria, Spain, Finland, France, United Kingdom, Greece, Hong Kong, Croatia, Hungary, Indonesia, Ireland, Israel, India, Italy, Japan, Republic of Korea, Lithuania, Morocco, Macao, Mexico, Malaysia, Netherlands, Norway, New Zealand, Peru, Philippines, Poland, Portugal, Romania, Serbia, Russia, Sweden, Slovenia, Slovakia, Tunisia, Turkey and Taiwan&#59; and patent applications are pending in Argentina, Brazil, Canada, Egypt, Singapore, Thailand, Uruguay, Venezuela, Vietnam and South Africa. The ex-US patents will expire in September 2033, not including possible patent term extensions in countries where such extensions are available. U.S. Serial No. 16&#47;607688, filed May 3, 2018, which relates to stable formulations fibronectin based scaffold domain proteins that bind to myostatin, was filed in the United States, Australia, Canada, China, European Union, Hong Kong, Israel, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Japan, Republic of Korea, Mexico, Singapore and Taiwan and, if granted, will expire in May 2038, not including possible patent term extensions in countries where such extensions are available.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of all license agreements that the Company has entered into. As of June 30, 2022, the Company has potential future developmental, regulatory, and commercial milestone payments under these agreements of up to approximately $123.9 million, $412.1 million, and $533.8 million, respectively. As of June 30, 2022 the Company has not made any developmental, regulatory, or commercial milestone payments under these agreements.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreement with ALS Biopharma, LLC and Fox Chase Chemical Diversity Center Inc.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2015, we entered into an agreement (the &#8220;ALS Biopharma Agreement&#8221;) with ALS Biopharma and Fox Chase Chemical Diversity Center Inc. (&#8220;FCCDC&#8221;), pursuant to which ALS Biopharma and FCCDC assigned to us their worldwide patent rights to over 300 prodrugs of glutamate modulating agents, including troriluzole, as well as other innovative technologies. Under the ALS Biopharma Agreement, we are obligated to use commercially reasonable efforts to commercialize and develop markets for the products covered by the ALS patents. The Company is obligated to pay up to $4.0 million in aggregate potential milestones under the ALS Biopharma Agreement, comprised of $3.0 million upon the achievement of specified regulatory milestones with respect to the first licensed product and $1.0 million upon the achievement of specified regulatory milestones with respect to subsequently developed products. We are also obligated to pay royalty payments of a low single-digit percentage based on net sales of products licensed under the agreement, payable on a quarterly basis.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ALS Biopharma Agreement terminates on a country-by-country basis as the last patent rights expire in each such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2016 License Agreement with AstraZeneca</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, we entered into an exclusive license agreement (the &#8220;2016 AstraZeneca Agreement&#8221;) with AstraZeneca, pursuant to which AstraZeneca granted us a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights, including BHV-5500. In exchange for these rights, we agreed to pay AstraZeneca an upfront payment, milestone payments and royalties on net sales of licensed products under the agreement. The regulatory milestones due under the 2016 AstraZeneca Agreement depend on the indication of the licensed product being developed as well as the territory where regulatory approval is obtained.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to pay up to $210.0 million in aggregate potential milestones under the 2016 AstraZeneca Agreement, comprised of development milestones with respect to Rett syndrome of up to $30.0 million, development milestones for any indication other than Rett syndrome up to $60.0 million, and commercial milestones based on net sales of all products licensed under the agreement that total up to $120.0 million. We have also agreed to pay royalties in two tiers, with each tiered royalty in the range from 0-10% of net sales of products licensed under the agreement. If we receive revenue from sublicensing any of its rights under the 2016 AstraZeneca Agreement, we are also obligated to pay a portion of that revenue to AstraZeneca. We are also responsible for the filing, prosecution, defending, and maintenance of patent rights licensed under the 2016 AstraZeneca Agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 AstraZeneca Agreement expires upon the expiration of the patent rights under the agreement or on a country-by-country basis ten years after the first commercial sale and can also be terminated if certain events occur, e.g., material breach or insolvency. In July 2019, Former Parent assigned its rights and obligations under the 2016 AstraZeneca Agreement to our subsidiary, Biohaven Therapeutics Ltd (&#8220;BTL&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 License Agreement with AstraZeneca</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we entered into an exclusive license agreement (the &#8220;2018 AstraZeneca Agreement&#8221;) with AstraZeneca, pursuant to which AstraZeneca granted us a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent rights, including BHV-3241. Under the 2018 AstraZeneca Agreement, we paid AstraZeneca an upfront cash payment of $3.0 million and issued 109,523 shares valued at $4.0 million on the date of settlement. The Company is obligated to pay up to $105.0 million in aggregate potential milestone under the 2018 AstraZeneca Agreement, comprised of regulatory milestones totaling up to $55.0 million and commercial milestones totaling up to $50.0 million. In addition, we will pay AstraZeneca royalties in three tiers, with each tiered royalty in the range from 0-10% of net sales of specified approved products, subject to specified reductions. Verdiperstat is currently being studied in the HEALEY ALS Platform Trial, which is the first-ever platform trial in ALS designed to evaluate multiple investigational treatments simultaneously, thus accelerating the development of effective and breakthrough treatments for people living with ALS. We are solely responsible, and have agreed to use commercially reasonable efforts, for all development, regulatory and commercial activities related to verdiperstat. We may sublicense its rights under the agreement and, if we do so, will be obligated to pay a portion of any milestone payments received from the sublicense to AstraZeneca in addition to any milestone payments we would otherwise be obligated to pay.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 AstraZeneca Agreement terminates on a country-by-country basis and product-by-product basis upon the expiration of the royalty term for such product in such country and can also be terminated if certain events occur, e.g., material breach or insolvency. Each royalty term begins on the date of the first commercial sale of the licensed product in the applicable country and ends on the later of 10 years from such first commercial sale or the expiration of the last to expire of the applicable patents in that country. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreement with Catalent U.K. Swindon Zydis Limited</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, we entered into a development and license agreement with Catalent, pursuant to which we obtained certain license rights to the Zydis ODT technology in BHV-0223. We made an upfront payment of $0.3 million to Catalent upon entering into the agreement and we are obligated to pay Catalent aggregate potential milestones up to $1.6 million under the agreement, comprised of $0.8 million in regulatory milestones and $0.8 million in commercial milestones. We are also obligated to make royalty payments of a low single-digit percentage based on net sales of products licensed under the agreement. In July 2019, Former Parent assigned all rights and obligations under this agreement to our subsidiary, BTL.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and license agreement terminates on a country-by-country basis upon the later of (i) 10 years after the launch of the most recently launched product in such country and (ii) the expiration of the last valid claim covering each product in such country, unless earlier voluntarily terminated by us. The agreement automatically extends for one-year terms unless either party gives advance notice of intent to terminate. In addition, Catalent may terminate the agreement either in its entirety or terminate the exclusive nature of the agreement on a country-by-country basis if we fail to meet specified development timelines, which we may extend in certain circumstances.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Yale University for Riluzole and Troriluzole</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to an exclusive license agreement (the &#8220;Yale Agreement&#8221;) with Yale University to obtain a license to certain patent rights and know-how for the commercial development, manufacture, distribution, use and sale of products and processes resulting from the development of those patent rights, related to the use of riluzole in treating various neurological conditions, such as general anxiety disorder, post-traumatic stress disorder and depression. As part of the consideration for this license, Former Parent issued Yale 250,000 common shares and granted Yale the right to purchase up to 10% of the securities issued in specified future equity offerings by Former Parent, in addition to the obligation to issue shares to prevent anti-dilution. The obligation to contingently issue equity to Yale was no longer outstanding as of December 31, 2018.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Yale Agreement was amended and restated, and assigned to BTL, in May 2019. As amended, the Company is obligated to pay up to $2.0 million in specified potential regulatory milestones. We are also obligated to pay annual royalty payments of a low single-digit percentage based on net sales of riluzole-based products from the licensed patents or from products based on troriluzole. Under the amended and restated agreement, the royalty rates are reduced as compared to the original agreement. In addition, under the amended and restated agreement, we may develop products based on riluzole or troriluzole. The amended and restated agreement retains a minimum annual royalty of up to $1.0 million per year, beginning after the first sale of product under the agreement. If we grant any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sublicense rights under the Yale Agreement, we must pay Yale a low single-digit percentage of sublicense income that it receives. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Yale University for MoDE Platform</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered a worldwide, exclusive license agreement with Yale University for the development and commercialization of a novel Molecular Degrader of Extracellular Protein (&#8220;MoDE&#8221;) platform (the &#8220;Yale MoDE Agreement&#8221;). Under the license agreement, we acquired exclusive, worldwide rights to Yale&#8217;s intellectual property directed to its MoDE platform. The platform pertains to the clearance of disease-causing protein and other biomolecules by targeting them for lysosomal degradation using multi-functional molecules. As part of consideration for this license, we paid Yale University an upfront cash payment of $1.0 million and issued 11,668 common shares valued at approximately $1.0 million. Under the agreement, we may develop products based on the MoDE platform. The agreement includes an obligation to pay a minimum annual royalty of up to $1.0 million per year, and low single digit royalties on the net sales of licensed products. If we grant any sublicense rights under the Yale Agreement, we must pay Yale a low single-digit percentage of sublicense income that it receives. The Company is obligated to pay aggregate potential milestones of up to $3.8 million under the Yale MoDE Agreement, comprised of development milestones of up to $0.8 million and commercial milestones of up to $3.0 million. The agreement terminates on the later of twenty years from the effective date, twenty years from the filing date of the first investigational new drug application for a licensed product or the last to expire of a licensed patent and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with the University of Connecticut</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we announced we signed an exclusive, worldwide option and license agreement (the &#8220;UConn Agreement&#8221;) with the University of Connecticut (&#8220;UConn&#8221;), for the development and commercialization rights to UC1MT, a therapeutic antibody targeting extracellular metallothionein. Under this agreement, we have the option to acquire an exclusive, worldwide license to UC1MT and its underlying patents to develop and commercialize throughout the world in all human indications. If we choose to exercise the option, we would be obligated to pay UConn upon the achievement of specified regulatory and commercial milestones, and royalties of a low single-digit percentage of net sales of licensed products sold by the Company, its affiliates or its sublicenses. We are not currently obligated to pay any milestones under the UConn Agreement, as we have not elected to exercise the option described above.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fox Chase Chemical Diversity Center Inc. Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into an agreement with the FCCDC in which we purchased certain intellectual property relating to the TDP-43 protein from FCCDC. The FCCDC Agreement provides us with a plan to identify one or more new chemical entity candidates for preclinical development for eventual clinical evaluation for the treatment of one or more TDP-43 proteinopathies. As consideration, Former Parent issued 100,000 of its common shares to FCCDC valued at $5.6 million. In addition, we are obligated to pay FCCDC milestone payments totaling up to $4.5 million with $1.0 million for each additional NDA filing. Former Parent also issued a warrant to FCCDC, granting FCCDC the option to purchase up to 100,000 of our common shares, at a strike price of $56.46 per share, subject to vesting upon achievement of certain milestones in development of TD-43.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FCCDC Agreement, we and FCCDC have established a TDP-43 Research Plan, which was amended in November 2020, that provides for certain milestones to be achieved by FCCDC, and milestone payments to be made by us up to approximately $3.8 million over a period of up to 30 months as success fees for research activities by FCCDC. In addition to the milestone payments, we will pay FCCDC an earned royalty equal to 0% to 10% of net sales of any TD-43 patent products with a valid claim as defined in the FCCDC Agreement. We may also license the rights developed under the FCCDC Agreement and, if we do so, will be obligated to pay a portion of any payments received from such licensee to FCCDC in addition to any milestones we would otherwise be obligated to pay. We are also responsible for the prosecution and maintenance of the patents related to the TDP-43 assets.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In aggregate, the Company is obligated to pay potential milestones of up to $8.3 million under the FCCDC Agreement, comprised of development milestones up to $3.8 million and regulatory milestones up to $4.5 million, as described above. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCCDC Agreement terminates on a country-by-country basis and product-by-product basis upon expiration of the royalty term for such product in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Artizan Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into an Option and License Agreement with Artizan Biosciences Inc. (the &#8220;2020 Artizan Agreement&#8221;). Pursuant to the 2020 Artizan Agreement, we acquired an option (&#8220;Option&#8221;) to obtain a royalty-based license from Artizan to manufacture, use and commercialize certain products in the United States for the treatment of diseases, including, for example, inflammatory bowel disease and other gastrointestinal inflammatory disorders, e.g., Crohn&#8217;s disease. The Option is exercisable throughout the development phase of the products at an exercise price of approximately $4.0 million to $8.0 million, which varies based on the market potential of the products. We and Artizan have also formed a joint steering committee to oversee, review and coordinate the product development activities with regard to all products for which we have (or have exercised in the future) the Option. We are not currently obligated to pay any milestones under the 2020 Artizan Agreement, as we have not elected to exercise the option described above.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, simultaneously with the Option and License Agreement, we entered into a Series A-2 Preferred Stock Purchase Agreement with Artizan. Under the agreement, we paid Artizan 61,494 shares of Biohaven Pharmaceutical Holding Co. Ltd. valued at $6.0 million, which were issued in January 2021. In exchange, we acquired 34,472,031 shares of series A-2 preferred stock of Artizan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a Development and License Agreement with Artizan Biosciences Inc. (the &#8220;2021 Artizan Agreement&#8221;). Pursuant to the 2021 Artizan Agreement, we acquired an exclusive, worldwide license under Artizan&#8217;s IgA-SEQ patented technology and know-how to develop, manufacture and commercialize certain of Artizan&#8217;s compounds for use in Parkinson&#8217;s Disease. Under the agreement, we are responsible for funding the development of the compounds, obtaining regulatory approvals, manufacturing the compounds and commercializing the compounds. We are also responsible for the prosecution, maintenance and enforcement of Artizan&#8217;s patents. Under the 2021 Artizan Agreement, we are obligated to pay Artizan milestones of $20.0 million for the first licensed compound to achieve U.S. marketing authorization and $10.0 million for each subsequent U.S. approval. In addition, we will pay Artizan commercialization milestones totaling up to $150.0 million and royalties in the low to mid single digits. The 2021 Artizan Agreement terminates on a country-by-country basis on the later of 10 years from the first commercial sale of licensed product in such country or the expiration of Artizan&#8217;s patents in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we entered into an Amendment to the Series A-2 Preferred Stock Purchase Agreement with Artizan. Under the Amendment, we made a cash payment of $4.0 million in exchange for 22,975,301 shares of series A-2 preferred stock of Artizan out of a total of 45,950,601 shares of series A-2 preferred stock of Artizan for a total raise of $8.0 million (the &#8220;A2 Extension Raise&#8221;). Along with the Amendment, we and Artizan executed a non-binding indication of interest (&#8220;Artizan Side Letter&#8221;) which describes terms under which we and Artizan would amend the 2020 Artizan Agreement to eliminate certain milestone payments required by us in exchange for limiting our option to the selection of the first (ARZC-001) licensed product. The Artizan Side Letter requires Artizan to commit at least 80% of the funds raised in the A-2 Extension Raise to a certain program and to raise $35.0 million of additional capital within a certain time. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In aggregate, the Company is obligated to pay potential milestones of up to $170.0 million, comprised of regulatory milestones up to $20.0 million and commercial milestones up to $150.0 million.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reliant Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into a development and license agreement with Reliant Biosciences, LLC (the &#8220;Reliant Agreement&#8221;) pursuant to which we acquired an exclusive, worldwide license under Reliant&#8217;s patents and know-how </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and sublicense under the University of Alabama&#8217;s patents and know-how to collaborate on a program to develop and commercialize conjugated antibodies using Biohaven Labs&#8217; multifunctional molecules for therapeutic uses relating to IgA nephropathy and treatment of other diseases and conditions. Under the Reliant Agreement, we paid Reliant an upfront payment in the form of issuance of common shares valued at approximately $3.7 million. In aggregate, we are obligated to pay Reliant potential development and regulatory milestones of up to $36.5 million. Reliant will also be eligible to receive royalties of a low single-digit percentage of net sales of licensed products. The Reliant Agreement terminates four years after the effective date if an IND had not been filed, but otherwise continues on a country-by-country basis on the later of 15 years from the effective date or the expiration of the licensed patent in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KU Leuven Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we entered into an exclusive license and research collaboration agreement (the &#8220;KU Leuven Agreement&#8221;) with Katholieke Universiteit Leuven (&#8220;KU Leuven&#8221;) to develop and commercialize TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders. The TRPM3 antagonist platform was discovered at the Centre for Drug Design and Discovery (&#8220;CD3&#8221;) and the Laboratory of Ion Channel Research (&#8220;LICR&#8221;) at KU Leuven. Under the KU Leuven Agreement, we receive exclusive global rights to develop, manufacture and commercialize KU Leuven&#8217;s portfolio of small-molecule TRPM3 antagonists. The portfolio includes the lead candidate, henceforth known as BHV-2100, which will be the first to advance towards Phase 1 studies. We will support further basic and translational research at KU Leuven on the role of TRPM3 in pain and other disorders. As consideration, we paid KU Leuven an upfront cash payment of $3.0 million and Former Parent issued 15,340 shares valued at $1.8 million. In aggregate, we are obligated to pay KU Leuven potential development, regulatory, and commercialization milestones of up to $327.8 million. In addition, KU Leuven will be eligible to receive mid-single digit royalties on net sales of products resulting from the collaboration. The 2021 KU Leuven Agreement terminates on a country-by-country basis on the later of 12 years from the first commercial sale of licensed product in such country, expiration of all regulatory exclusivity for the licensed product in the country, or the expiration of the licensed patents in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taldefgrobep Alfa License Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we entered into a license agreement with BMS for the development and commercialization rights to taldefgrobep alfa (also known as BMS-986089), a novel, Phase 3-ready anti-myostatin adnectin (the &#8220;Taldefgrobep Alfa License Agreement&#8221;). Under the terms of the Taldefgrobep Alfa License Agreement, the Company acquired exclusive, worldwide rights under BMS&#8217; patents and know-how to develop and commercialize taldefgrobep alfa. In aggregate, we are obligated to pay BMS up to $200.0 million of potential milestone payments, comprised of up to $200.0 million for regulatory approval milestones. BMS will also be eligible to receive tiered, sales-based royalty percentages from the high teens to the low twenties. There were no upfront payments to BMS related to the Taldefgrobep Alfa License Agreement. Under the agreement, we are responsible for funding the development of the compounds, obtaining regulatory approvals, manufacturing the compounds and commercializing the compounds. We are also responsible for the prosecution, maintenance and enforcement of BMS&#8217; patents. The Taldefgrobep Alfa License Agreement terminates on a country-by-country basis on the later of 12 years from the first commercial sale of licensed product in such country or the expiration of BMS&#8217; patents in such country or the expiration of regulatory exclusivity and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rutgers University License Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into an exclusive license agreement (the &#8220;Rutgers Agreement&#8221;) with Rutgers, The State University of New Jersey (&#8220;Rutgers&#8221;), licensing several patents and patent applications related to the use of riluzole to treat various cancers. In April 2022, we provided notice of termination of the Rutgers Agreement which became effective in July 2022. The Rutgers Agreement provided for payments by us to Rutgers of up to $0.8 million in the aggregate upon the achievement of specified clinical and regulatory milestones and royalties of a low single-digit percentage of net sales of licensed products sold by us, its affiliates or its sublicensees, subject to a minimum amount of up to $0.1 million per year. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and&#47;or sponsor to a variety of administrative or judicial sanctions, including imposition of a clinical hold, refusal by the FDA to approve applications, withdrawal of an approval, import&#47;export delays, issuance of warning letters and other types of enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical testing, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import, export and marketing, among other things, of our product candidates are governed by extensive regulation by governmental authorities in the United States and other countries. The FDA, under the FDCA, regulates pharmaceutical products in the United States. The steps required before a drug may be approved for marketing in the United States generally include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical laboratory tests and animal tests conducted under Good Laboratory Practices (&#8220;GLP&#8221;)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the submission to the FDA of an investigational new drug (&#8220;IND&#8221;) application for human clinical testing, which must become effective before human clinical trials commence&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board (&#8220;IRB&#8221;), representing each clinical site before each clinical trial may be initiated&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adequate and well-controlled human clinical trials to establish the safety and efficacy of the product for each indication and conducted in accordance with Good Clinical Practices (&#8220;GCP&#8221;)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the preparation and submission to the FDA of an NDA&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA acceptance, review and approval of the NDA, which might include an Advisory Committee review&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facilities at which the product, or components thereof, are made to assess compliance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing and approval process requires substantial time, effort and financial resources, and the receipt and timing of any approval is uncertain. The FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Human Clinical Trials in Support of an NDA</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies include laboratory evaluations of the product candidate, as well as in vitro and animal studies to gather information on the safety and efficacy of the product candidate. The conduct of preclinical trials is subject to federal regulations and requirements including GLP regulations. The results of the preclinical studies, together with manufacturing information and analytical data, among other things, are submitted to the FDA as part of the IND, which must become effective before clinical trials may be commenced. The IND will become effective automatically 30&#160;days after receipt by the FDA, unless the FDA raises concerns or questions about the conduct of the trials as outlined in the IND prior to that time. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can proceed. The FDA may nevertheless initiate a clinical hold after the 30&#160;days if, for example, significant safety risks arise.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the product candidate to human subjects under the supervision of qualified investigators in accordance with GCP requirements. Each clinical trial must be reviewed and approved by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an IRB at each of the sites at which the trial will be conducted. The IRB will consider, among other things, ethical factors, the safety of human subjects and the possible liability of the institution.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trials are typically conducted in three sequential phases prior to approval, but the phases may overlap or be combined. These phases generally include the following&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.58pt">Phase&#160;1 clinical trials represent the initial introduction of a product candidate into human subjects, frequently healthy volunteers. In Phase&#160;1, the product candidate is usually tested for safety, including adverse effects, dosage tolerance, absorption, distribution, metabolism, excretion and pharmacodynamics.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.58pt">Phase&#160;2 clinical trials usually involve studies in a limited patient population with a specific disease or condition to (1)&#160;evaluate the efficacy of the product candidate for specific indications, (2)&#160;determine dosage tolerance and optimal dosage and (3)&#160;identify possible adverse effects and safety risks.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.58pt">If a product candidate is found to be potentially effective and to have an acceptable safety profile in Phase&#160;2 clinical trials, the clinical trial program will be expanded to Phase&#160;3 clinical trials to further demonstrate clinical efficacy, optimal dosage and safety within an expanded patient population at geographically dispersed clinical trial sites. These clinical studies are intended to establish the overall risk&#47;benefit ratio of the product and provide an adequate basis for product approval and labeling.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.58pt">Clinical trials may be conducted after approval to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations, or when otherwise requested by the FDA in the form of post-market requirements or commitments. Failure to promptly conduct any required Phase&#160;4 clinical trials could result in enforcement action or withdrawal of approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2&#47;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> trial design, which we have used in our troriluzole development program, is often used in the development of pharmaceutical and biological products. The trial includes Phase&#160;2 elements, such as an early interim analysis of safety or activity, and Phase&#160;3 elements, such as larger patient populations with less restrictive enrollment criteria. The early interim analysis of clinical or physiologic activity and&#47;or safety allows the study to be stopped, changed or continued before a large number of patients have been enrolled, while still allowing all data from enrolled patients to count in the analysis used to support approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Submission and Review of an NDA</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of preclinical studies and clinical trials, together with detailed information on the product&#8217;s manufacture, composition, quality, controls and proposed labeling, among other things, are submitted to the FDA in the form of an NDA, requesting approval to market the product. The application must be accompanied by a significant user fee payment, which typically increases annually, although waivers may be granted in limited cases. The FDA has substantial discretion in the approval process and may refuse to accept an application if they determine that the data are insufficient for approval and require additional preclinical, clinical or other studies.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA has been accepted for filing, which occurs, if at all, 60&#160;days after submission, the FDA sets a user fee goal date that informs the applicant of the specific date by which the FDA intends to complete its review. This is typically 10&#160;months from the date that the FDA accepts the application for filing for standard review NDAs and six months from the date that the FDA accepts the application for filing for priority review NDAs. The review process can be extended by FDA requests for additional information or clarification. The FDA reviews NDAs to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMPs to assure and preserve the product&#8217;s identity, strength, quality and purity. Before approving an NDA, the FDA typically will inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing facilities comply with cGMPs. Additionally, the FDA will typically inspect one or more clinical trial sites, as well as the Sponsor of the NDA, for compliance with GCP and integrity of the data supporting safety and efficacy.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the approval process, the FDA also will determine whether a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) is necessary to assure the safe use of the product post approval. If the FDA concludes a REMS is needed, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sponsor of the application must submit a proposed REMS, and the FDA will not approve the application without an approved REMS, if required. A REMS can substantially increase the costs of obtaining approval. The FDA could also require a special warning, known as a boxed warning, to be included in the product label in order to highlight a particular safety risk. The FDA may also convene an advisory committee of external experts to provide input on certain review issues relating to risk, benefit and interpretation of clinical trial data. The FDA may delay approval of an NDA if applicable regulatory criteria are not satisfied and&#47;or the FDA requires additional testing or information. The FDA may require post-marketing testing and surveillance to monitor safety or efficacy of a product.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA will issue either an approval of the NDA or a Complete Response Letter (&#8220;CRL&#8221;), detailing the deficiencies in the submission and the additional testing or information required for reconsideration of the application. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical studies. If a CRL is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, withdraw the application, or request a hearing. Even with submission of this additional information, the FDA may ultimately decide that the application does not satisfy the regulatory criteria for approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved drugs that are manufactured or distributed in the United States pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims and some manufacturing and supplier changes are subject to prior FDA review and approval. There also are continuing, annual program user fee requirements for marketed products.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase&#160;4 clinical trials, and surveillance programs to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. The FDA may also require a REMS, which could involve requirements for, among other things, medication guides, special trainings for prescribers and dispensers, patient registries, and elements to assure safe use.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. The FDA has promulgated specific requirements for drug cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may issue enforcement letters or withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Corrective action could delay product distribution and require significant time and financial expenditures. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information&#59; imposition of post-market studies or clinical trials to assess new safety risks&#59; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market or product recalls&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical trials&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of product approvals&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section&#160;505(b)(2) NDAs</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an alternative path to FDA approval for modifications to formulations or uses of drugs previously approved by the FDA, an applicant may submit an NDA under Section&#160;505(b)(2) of the FDCA. Section&#160;505(b)(2) was enacted as part of the Hatch-Waxman Amendments. A Section&#160;505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness, but where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This type of application permits reliance for such approvals on literature or on an FDA finding of safety, effectiveness or both for an approved drug product. As such, under Section&#160;505(b)(2), the FDA may rely, for approval of an NDA, on data not developed by the applicant. The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved branded reference drug. The FDA may then approve the new product candidate for the new indication sought by the 505(b)(2) applicant.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical program for troriluzole for the treatment of SCA and the treatment of OCD is based on a regulatory pathway under section&#160;505(b)(2) of the FDCA that allows reference to data on riluzole for the purpose of safety assessments.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Exclusivity &#8211; United States</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, biopharmaceutical products are protected by patents with varying terms depending on the type of patent and the filing date. A significant portion of a product&#8217;s patent life, however, is lost during the time it takes an innovative company to develop and obtain regulatory approval of a new drug. As compensation at least in part for the lost patent term due to regulatory review periods, the innovator may, depending on a number of factors, apply to the government to restore lost patent term by extending the expiration date of one patent up to a maximum term of five years, provided that the extension cannot cause the patent to be in effect for more than 14 years from the date of drug approval. A company seeking to market an innovative pharmaceutical in the U.S. must submit a complete set of safety and efficacy data to the FDA. If the innovative pharmaceutical is a chemical product, the company files an NDA. If the medicine is a biological product, a Biologic License Application (&#8220;BLA&#8221;) is filed. The type of application filed affects regulatory data protection (&#8220;RDP&#8221;) exclusivity rights.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Small Molecule Products</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A competitor seeking to launch a generic substitute of small molecule drug in the U.S. must file an Abbreviated New Drug Application (&#8220;ANDA&#8221;) with the FDA. In the ANDA, the generic manufacturer needs to demonstrate only &#8220;bioequivalence&#8221; between the generic substitute and the approved NDA drug. The ANDA relies upon the safety and efficacy data previously filed by the innovator in its NDA. An innovator company is required to list certain of its patents covering the medicine with the FDA in what is commonly known as the FDA&#8217;s Orange Book. The FDA cannot approve an ANDA until after the innovator&#8217;s listed patents expire unless there is a successful patent challenge. However, after the innovator has marketed its product for four years, a generic manufacturer may file an ANDA and allege that one or more of the patents listed in the Orange Book under an innovator&#8217;s NDA is either invalid or not infringed (a Paragraph IV certification). The innovator then must decide whether to file a patent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringement suit against the generic manufacturer. From time to time, ANDAs, including Paragraph IV certifications, could be filed with respect to certain of our products. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, certain innovative pharmaceutical products can receive periods of regulatory exclusivity. An NDA that is designated as an orphan drug can receive seven years of exclusivity for the orphan indication. During this time period, neither NDAs nor ANDAs for the same drug product can be approved for the same orphan use. A company may also earn six months of additional exclusivity for a drug where specific clinical studies are conducted at the written request of the FDA to study the use of the medicine to treat pediatric patients, and submission to the FDA is made prior to the loss of basic exclusivity. Medicines approved under an NDA can also receive several types of RDP. An innovative chemical pharmaceutical product is entitled to five years of RDP in the U.S., during which the FDA cannot approve generic substitutes. If an innovator&#8217;s patent is challenged, as described above, a generic manufacturer may file its ANDA after the fourth year of the five-year RDP period. A pharmaceutical drug product that contains an active ingredient that has been previously approved in an NDA, but is approved in a new formulation, but not for the drug itself, or for a new indication on the basis of new clinical studies, may receive three years of RDP for that formulation or indication.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biologic products</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA, which includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, created an approval pathway for biosimilar versions of innovative biological products that did not previously exist. Prior to that time, innovative biologics had essentially unlimited regulatory exclusivity. Under the new regulatory mechanism, the FDA can approve products that are similar to (but not generic copies of) innovative biologics on the basis of less extensive data than is required by a full BLA. After an innovator has marketed its product for four years, any manufacturer may file an application for approval of a &#8220;biosimilar&#8221; version of the innovator product. However, although an application for approval of a biosimilar version may be filed four years after approval of the innovator product, qualified innovative biological products will receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative biological product was first approved by the FDA. The law also provides a mechanism for innovators to enforce the patents that protect innovative biological products and for biosimilar applicants to challenge the patents. Such patent litigation may begin as early as four years after the innovative biological product is first approved by the FDA.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the increased likelihood of generic and biosimilar challenges to innovators&#8217; intellectual property has increased the risk of loss of innovators&#8217; market exclusivity. First, generic companies have increasingly sought to challenge innovators&#8217; basic patents covering major pharmaceutical products. Second, statutory and regulatory provisions in the U.S. limit the ability of an innovator company to prevent generic and biosimilar drugs from being approved and launched while patent litigation is ongoing. As a result of all of these developments, it is not possible to predict the length of market exclusivity for a particular product with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Regulation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union and other geographies, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Union</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A typical route used by innovator companies to obtain marketing authorization of pharmaceutical products in the EU is through the &#8220;centralized procedure.&#8221; A company seeking to market an innovative pharmaceutical product </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through the centralized procedure must file a complete set of safety data and efficacy data as part of a Marketing Authorization Application (&#8220;MAA&#8221;) with the EMA. After the EMA evaluates the MAA, it provides a recommendation to the European Commission (&#8220;EC&#8221;) and the EC then approves or denies the MAA. Regulatory approval via the centralized procedure results in a marketing authorization for the innovative pharmaceutical product in each EU member state. It is also possible for new chemical products to obtain marketing authorization in the EU through a &#8220;mutual recognition procedure,&#8221; in which an application is made to a single member state, and if the member state approves the pharmaceutical product under a national procedure, then the applicant may submit that approval to the mutual recognition procedure of some or all other member states. After obtaining marketing authorization approval, a company must obtain pricing and reimbursement for the pharmaceutical product, which is typically subject to member state law. In certain EU countries, this process can take place simultaneously while the product is marketed but in other EU countries, this process must be completed before the company can market the new product. The pricing and reimbursement procedure can take months and sometimes years to complete. Throughout the EU, all products for which marketing authorizations have been filed after October&#47;November 2005 are subject to an &#8220;8+2+1&#8221; regime. Eight years after the innovator has received its first community authorization for a medicinal product, a generic company may file a MAA for that product with the health authorities. If the MAA is approved, the generic company may not commercialize the product until after either 10 or 11 years have elapsed from the initial marketing authorization granted to the innovator. The possible extension to 11 years is available if the innovator, during the first eight years of the marketing authorization, obtains an additional indication that is of significant clinical benefit in comparison with existing treatments. For products that were filed prior to October&#47;November 2005, there is a 10-year period of data protection under the centralized procedures and a period of either six or 10 years under the mutual recognition procedure (depending on the member state). In contrast to the U.S., patents in the EU are not listed with regulatory authorities. Generic versions of pharmaceutical products can be approved after data protection expires, regardless of whether the innovator holds patents covering its drug. Thus, it is possible that an innovator may be seeking to enforce its patents against a generic competitor that is already marketing its product. Also, the European patent system has an opposition procedure in which generic manufacturers may challenge the validity of patents covering innovator products within nine months of grant. In general, EU law treats chemically-synthesized drugs and biologically-derived drugs the same with respect to intellectual property and data protection. In addition to the relevant legislation and annexes related to biologic medicinal products, the EMA has issued guidelines that outline the additional information to be provided for biosimilar products, also known as generic biologics, in order to review an application for marketing approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Japan</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Japan, medicines of new chemical entities are generally afforded eight years of data exclusivity for approved indications and dosage. Patents on pharmaceutical products are enforceable. Generic copies can receive regulatory approval after data exclusivity and patent expirations. As in the U.S., patents in Japan may be extended to compensate for the patent term lost during the regulatory review process. In general, Japanese law treats chemically-synthesized and biologically-derived drugs the same with respect to intellectual property and market exclusivity. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">China</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain marketing authorization of pharmaceutical products in China, an NDA must be submitted to the National Medical Product Administration (&#8220;NMPA&#8221;) once safety and efficacy has been established in Chinese patients. For imported drugs, this means issuance of an import license. The applicant must submit evidence of foreign approval (certificate of pharmaceutical product), unless it is an innovative drug that has never been approved anywhere in the world.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In China, medicines of new chemical entities are generally afforded six years of data exclusivity for approved indications and dosage. Generic copies can receive regulatory approval after data exclusivity and patent expirations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">South Korea</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain marketing authorization of pharmaceutical products in South Korea, a marketing application must be submitted to the Ministry of Food and Drug Safety (&#8220;MFDS&#8221;). The application must contain data in South Korean patients, information regarding safety and efficacy, quality, a good manufacturing practice certificate, and a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certificate of pharmaceutical product in an approved country to show that the drug being imported is being sold in the approved country in accordance with the with the relevant rules and regulations in that country. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In South Korea, medicines of new chemical entities are generally afforded 6 years of data exclusivity for first approved indications and dosage. Generic copies can receive regulatory approval after data exclusivity and patent expirations.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rest of the World</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In countries outside of the U.S., the EU, Japan, China and South Korea, there is a wide variety of legal systems with respect to intellectual property and market exclusivity of pharmaceuticals. Most other developed countries utilize systems similar to either the U.S. or the EU. Among developing countries, some have adopted patent laws and&#47;or regulatory exclusivity laws, while others have not. Some developing countries have formally adopted laws in order to comply with World Trade Organization (&#8220;WTO&#8221;) commitments, but have not taken steps to implement these laws in a meaningful way. Enforcement of WTO actions is a long process between governments, and there is no assurance of the outcome. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage, Reimbursement and Pricing</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States and foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the availability of coverage and the adequacy of reimbursement from third-party payors. Third-party payors include government authorities, and private entities, such as managed care organizations, private health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication. Moreover, a third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. For example, the payor&#8217;s reimbursement payment rate may not be adequate or may require co-payments that patients find unacceptably high. Additionally, coverage and reimbursement for products can differ significantly from payor to payor. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. However, one third-party payor&#8217;s decision to cover a particular product does not ensure that other payors will also provide coverage for the product, or will provide coverage at an adequate reimbursement rate. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Further, some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they provide reimbursement for use of such therapies.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of products and services, in addition to their safety and efficacy. To obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our product. These studies will be in addition to the studies required to obtain regulatory approvals. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. Thus, obtaining and maintaining reimbursement status is time-consuming and costly.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and foreign governments regularly consider reform measures that affect health care coverage and costs. For example, the U.S. and state legislatures have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription products. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (&#8220;collectively, the ACA&#8221;) contains provisions that may reduce the profitability of products, including, for example, increased rebates for products sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plans, mandatory discounts for certain Medicare Part&#160;D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. The Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) may develop new payment and delivery models, such as bundled payment models. For example, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) moved 41% of Medicare fee-for-service payments to alternative payment models (&#8220;APMs&#8221;) tied to the quality or value of services by the end of 2018. HHS had set a goal of moving 50% of such Medicare payments into these alternative payment models by the end of 2018, but in 2019, it discontinued this performance goal and replaced it with a new developmental goal to increase the percentage of Medicare health care dollars tied to APMs incorporating downside risk, with a target of 40% for fiscal year 2021. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for our products.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, the focus on cost containment measures, particularly in the United States, has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if we attain favorable coverage and reimbursement status for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European Union Coverage Reimbursement and Pricing</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies, or so called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of the company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Laws and Regulations</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians, other healthcare providers, and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors are and will be subject to various federal, state and foreign fraud and abuse laws and other healthcare laws and regulations. These laws and regulations may impact, among other things, healthcare professionals who participate in our clinical research programs, and our proposed sales, marketing, distribution, and education programs. The U.S. federal and state healthcare laws and regulations that may affect our ability to operate include, without limitation, the following&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Anti-Kickback Statute, which prohibits persons from, among other things, knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federally funded healthcare programs, such as Medicare and Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal civil and criminal false claims laws, including, without limitation, the federal civil monetary penalties law and the civil False Claims Act (which can be enforced by private citizens through qui tam actions), prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment of federal funds, and knowingly making, or causing to be made, a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) which imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;) enacted as part of the American Recovery and Reinvestment Act of 2009 and its implementing regulations, which imposes certain obligations, including mandatory contractual terms, on entities subject to the law, such as healthcare providers, health plans, and healthcare clearinghouses and their respective business associates to safeguard the privacy, security and transmission of individually identifiable health information from any unauthorized use or disclosures&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal transparency requirements under the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, and other programs such as CHIP to report to HHS information related to payments and other transfers of value provided to physicians and teaching hospitals and physician ownership and investment interests&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Analogous state laws and regulations, such as state anti-kickback and false claims laws, that impose similar restrictions and may apply to items or services reimbursed by non-governmental third-party payors, including private insurers&#59; state laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other health care providers&#59; and state health information privacy and data breach notification laws, which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and some of which are not pre-empted by HIPAA, thus complicating compliance efforts.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Healthcare reform legislation has strengthened these federal and state healthcare laws. For example, the ACA amended the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes to clarify that liability under these statutes does not require a person or entity to have actual knowledge of the statutes or a specific intent to violate them. Moreover, the ACA provides that the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of these laws can subject us to criminal, civil and administrative sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment, and exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and reputational harm, we may be required to curtail or restructure our operations. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our future operations and business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative landscape in the United States continues to evolve. There have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. In March 2010, the ACA was enacted, which includes measures that have significantly changed health care financing by both governmental and private insurers. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states, without specifically ruling on the ACA&#8217;s constitutionality.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions of the ACA of importance to the pharmaceutical and biotechnology industry are, among others, the following&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, non-deductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new requirements to report certain financial arrangements with physicians and certain others, including reporting &#8220;transfers of value&#8221; made or distributed to prescribers and other healthcare providers and reporting investment interests&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of the Center for Medicare Innovation at the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA. In January of 2021, an Executive Order entitled &#8220;Executive Order on Strengthening Medicaid and the Affordable Care Act&#8221; repealed two previous Executive Orders delaying the implementation of certain provisions of the ACA. Concurrently, Congress has considered legislation that amend all or part of the ACA.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other federal health reform measures have been proposed and adopted in the United States since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011 (known as Medicare sequestration) and subsequent extensions, which began in 2013 and will remain in effect through 2030 (with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, with a subsequent one quarter phase-in of 1%) unless additional Congressional action is taken. Further, the American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments from providers from three to five years. The Medicare Access and CHIP Reauthorization Act of 2015 also introduced a quality payment program under which certain individual Medicare providers will be subject to certain incentives or penalties based on new program quality standards. Payment adjustments for the Medicare </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quality payment program were scheduled to begin in 2019. At this time, it is unclear how the introduction of the quality payment program will impact overall physician reimbursement under the Medicare program.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there have been several recent Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the costs of prescription pharmaceuticals in the United States has also been the subject of considerable discussion. The previous administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out-of-pocket costs of drugs. HHS solicited feedback on some of these measures and, concurrently, implemented others under its existing authority. President Biden continues to push for reforms that would address the high cost of drugs. In response to an Executive Order from President Biden, the Secretary of HHS recently issued a comprehensive plan for addressing high drug prices that describes a number of legislative approaches and identifies administrative tools to address the high cost of drugs. And Democrats recently included drug pricing reform provisions reflecting elements of the plan in a broader spending package in late 2021&#8212;such as capping Medicare Part D patients&#8217; out-of-pocket costs, establishing penalties for drug prices that increase faster than inflation in Medicare, and authorizing the federal government to negotiate prices on certain select, high-cost drugs under Medicare Parts B and D. While a number of these and other proposed measures would require authorization through additional legislation to become effective, Congress has indicated that it will continue to seek new legislative and&#47;or administrative measures to control drug costs. In August 2022, Congress passed the Inflation Reduction Act of 2022, which included, among other things, a provision allowing Medicare to negotiate drug prices directly with pharmaceutical manufacturers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Foreign Corrupt Practices Act</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;) prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and debarment from government contracts.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, Social, Governance and Human Capital</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance and Leadership</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment to integrating sustainability across our organization begins with our Board. The Nominating and Governance Committee of the Board has oversight of strategy and risk management related to Environmental, Social and Governance (&#8220;ESG&#8221;). Applying NYSE&#8217;s listing standards for independence, six of our eight directors are independent.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the management level, we have implemented a cross-functional Sustainability Working Group, which meets on a regular basis and report to the Board periodically. We have a Chief Talent &#38; Sustainability Officer who works closely with the working group and coordinates efforts related to the advancement of ESG capabilities across the organization.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Ethics</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to creating an environment where we are able to excel in our business while maintaining the highest standards of conduct and ethics. Our Code of Business Conduct and Ethics (the &#8220;Code of Conduct&#8221;) reflects the business practices and principles of behavior that support this commitment, including our policies on bribery, corruption, conflicts of interest and our whistleblower program. We expect every director, officer, and employee to read, understand, and comply with the Code of Conduct and its application to the performance of his or her business responsibilities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We encourage employees to come to us with observations and complaints, ensuring we understand the severity and frequency of an event in order to escalate and assess accordingly. Our Chief Compliance Officer strives to ensure accountability, objectivity, and compliance with our Code of Conduct. If a complaint is financial in nature, the Audit Committee Chair is notified concurrently, which triggers an investigation, action, and report. All incidents are reported up to the Board on a quarterly basis.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Commitment</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to protecting the environment and attempt to mitigate negative impact of our operations. We monitor resource use, improve efficiency, and at the same time reduce our emissions and waste.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to reduce the overall impact of our product on the environment, we have taken steps to enhance the sustainability of our manufacturing processes for our drug substances.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with our contract research organization partners, we apply various green chemistry methodologies to our commercial and development pipeline. We have especially focused on using biocatalysis, a technology that makes use of enzymes instead of chemicals to accomplish specific chemical reactions used to construct organic small molecules such as Active Pharmaceutical Ingredients. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also initiated work in removing hazardous organic solvents from certain reactions and replacing them with water. This green technology relies on the use of micelles to enable such reactions to occur in water where they would normally not occur due in part to the very poor solubility of most organic compounds in water. These greener processes not only create less waste, but the waste that is produced is much less hazardous, therefore reducing the environmental impact of the manufacturing process.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are systematically addressing the environmental impacts of the buildings we own as we make improvements, including adding energy control systems and other energy efficiency measures. Waste in our own operation is minimized by our commitment to reduce both single-use plastics and operating paper-free, primarily in a digital environment. We have safety protocols in place for handling biohazardous waste in our labs, and we use third-party vendors for biohazardous waste and chemical disposal.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Social Responsibility</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For third-party vendor selection and oversight, we have adopted standard operating procedures that apply to employees and subcontractors who on our behalf, oversee and conduct research regulated by the FDA. We retain ultimate authority and responsibility for the conduct of regulated research, manufacturing, and testing and we must ensure that contracted services are conducted in accordance with Good Practice Guidelines and all applicable regulations.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Human Capital Management</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We foster and encourage a workplace environment that holds possibilities for everyone, with a commitment to respect and acceptance without biases. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development and continuous feedback are priorities for our organization, which comprised 190 employees as of December 31, 2021. We believe each individual person is critical to our success and we invest in our people by supporting continuous training programs and courses. We encourage each employee to engage with their manager in developmental discussions designed to focus on feedback rather than a rating.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important part of our talent recruitment is our robust paid internship program for high school, college and graduate-level students. This program offers opportunities to students in the community and develops a roadmap for &#8216;entry-level&#8217; candidates. We evaluate the success of our recruitment program through metrics such as time to hire, offer acceptance rate, turnover rate and business results. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to provide an inclusive workplace to foster growth and innovation. Our Diversity, Equity and Inclusion (&#8220;DEI&#8221;) Plan &#8220;Roadmap to Belonging&#8221; will include training to build DEI capabilities for all commercial employees, cultural competence capability building for leaders, as well as traditional anti-harassment and anti-discrimination training for all. Pulse surveys and individual interviews for commercial employees are conducted to assess program effectiveness. Combined with an agile mindset, this feedback enables our leadership team to further enhance program offerings to address the diverse needs of our team. We have expanded our team with an inclusive mindset from the beginning. We are actively focused on increasing the gender, racial&#47;ethnic, and age diversity of our board composition and we have made strides to diversify our senior leadership, with the number of females in scientific leadership positions becoming a strength of our organization.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established both an office-based and field-based response to protect our employees from COVID-19 infection. In our offices, we follow health and safety protocols by providing mandatory masks for anyone entering the building, foot-dispensing hand sanitizer stations, and disinfecting wipes at each workstation. We purchased high efficiency air filters to ensure air is not recirculated in the facilities. We offer antibody testing and encourage employees to be tested for COVID-19 frequently.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information about Segments</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate in a single business segment developing a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a business company limited by shares organized under the laws of the British Virgin Islands Our registered office is located at P.O.&#160;Box&#160;173, Road Town, Tortola, British Virgin Islands and our telephone number is +1 (284)&#160;852-3000. Our U.S. office is located at 215 Church Street, New Haven, Connecticut 06510 and our telephone number is (203)&#160;404-0410. Our website address is www.biohaven.com. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in making an investment decision regarding our common shares. On September 16, 2022, the Company changed its name from &#8220;Biohaven Research Ltd.&#8221; to &#8220;Biohaven Ltd.&#8221;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Properties</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. headquarters is located in New Haven, Connecticut, where, as of December 31, 2021, we occupied approximately 10,000 square feet of office space, used for executive and corporate office functions. We purchased the property in December 2018. In December 2021, we purchased an office building in New Haven, Connecticut to expand our office space for executive and corporate office functions to support our continued growth. The building is directly next to our U.S. headquarters and is approximately 42,000 square feet. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we entered into a lease agreement in Yardley, Pennsylvania for approximately 21,000 square feet of office space to support expansion of our operations. The lease commenced on May 13, 2020, and has a term of 88 months, with the ability to extend to 148&#160;months. The lessor provided us a temporary space to occupy while leasehold improvements were completed prior to commencement in the first quarter of 2020.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we entered into a license agreement in Dublin, Ireland for approximately 1,000 square feet of office space to support our operations. Upon execution of the agreement, the licensor agreed to provide us a temporary space to occupy at no additional cost until building improvements were complete. The license commenced in January 2021, and had a term of 36 months. In April 2022, we entered into an addendum to the license agreement, in which the parties agreed to terminate the license on August 31, 2022. Pursuant to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addendum, the Company&#8217;s access to the space and its monetary obligations under the license ended on May 31, 2022. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, in connection with our acquisition of the remaining interest in Kleo that we did not previously own, we acquired the lease on approximately 10,000 square feet of the recently established Kleo chemistry and discovery facilities at Science Park in New Haven, Connecticut. The lease has a remaining term of 24 months from January 2021, with an option to extend.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, BioShin entered into a lease agreement in Shanghai, China for approximately 4,600 square feet of office space to support its operations. The lease commenced on April 1, 2021 and has a term of 36 months, with an option to extend. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, BioShin entered into a lease agreement in Beijing, China for approximately 1,700 square feet of office space to support its operations. The lease commenced on November 1, 2021 and has a term of 12 months, with an automatic renewal unless either party decides to terminate the agreement. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, in connection with our acquisition of Channel Biosciences, LLC (&#8220;Channel Biosciences&#8221;), we acquired the lease on approximately 20,000 square feet of office and research space in Pittsburgh, Pennsylvania. The lease term expires in October 2024, with an option to extend. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we assumed a lease in Dublin, Ireland for approximately 6,000 square feet of office space to support our operations. The new Dublin office lease replaces the Dublin office license that will terminate on August 31, 2022. The lease assignment took effect in May 2022 and the lease has a remaining term of 59 months from May 2022, with no option to extend.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we entered into a lease agreement in West Palm Beach, Florida for approximately 9,000 square feet of office space, which will be used for executive and corporate office functions. The lease is expected to commence in late 2024, following substantial completion of tenant improvements, and has a term of 120 months, with an option to extend.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we entered into a lease agreement in Cambridge, Massachusetts for approximately 27,000 square feet of lab and office space, which will be used for general office, laboratory and research and development purposes. The lease commenced on October 19, 2022, and has a term of 120 months, with an option to extend.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our current facilities are suitable and adequate to meet our current needs and we believe that suitable additional or substitute space will be available as needed to accommodate any future expansions.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of June 30, 2022, there were no such matters which we believe would have a material adverse impact on our business, operating results or financial condition.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies.&#8221; These exemptions generally include, but are not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to take advantage of some or all of the reduced regulatory and reporting requirements that will be available to us as long as we qualify as an emerging growth company, except that we have irrevocably elected not to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">take advantage of the extension of time to comply with new or revised financial accounting standards available under Section 102(b) of the JOBS Act.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will, in general, remain as an emerging growth company for up to five full fiscal years following the Distribution. We would cease to be an emerging growth company and, therefore, become ineligible to rely on the above exemptions, if we&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have more than $1.235 billion in annual revenue in a fiscal year&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue more than $1 billion of non-convertible debt during the preceding three-year period&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">become a &#8220;large accelerated filer&#8221; as defined in Exchange Act Rule&#160;12b-2, which would occur after&#58; (i)&#160;we have filed at least one annual report pursuant to the Exchange Act&#59; (ii) we have been an SEC-reporting company for at least twelve months&#59; and (iii) the market value of our common shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smaller Reporting Company Status</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 under the Exchange Act. As such, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not smaller reporting companies, including, but not limited to, reduced disclosure obligations regarding executive compensation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain a smaller reporting company as long as either&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">(i) the market value of our common shares held by non-affiliates is less than $250 million as of the last business day of our most recently completed second fiscal quarter&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">(ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common shares held by non-affiliates is less than $700 million as of the last business day of our most recently completed second fiscal quarter.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_61"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Directors and Executive Officers</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning our directors and executive officers, including their ages as of the date of this prospectus&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Officers&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vlad Coric, M.D.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman of the Board</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Buten</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimberly Gentile</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President of Clinical Operations</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruce Car</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Scientific Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-Management Directors&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael T. Heffernan</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory H. Bailey, M.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Hugin</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John W. Childs</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Julia P. Gregory</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kishan Mehta</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Irina Antonijevic</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vlad Coric, M.D.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Coric, age 51, has served as our chief executive officer and as a director since incorporation, and was previously the chief executive officer and a director of Former Parent. Dr. Coric has more than 22 years of drug development experience at Yale School of Medicine, Bristol-Myers Squibb, Biohaven and the Former Parent. He has been involved in multiple drug development programs, including marketed drugs or filed NDAs such as Nurtec ODT (rimegepant&#59; oral calcitonin related peptide antagonist), zavegepant (intranasal calcitonin related peptide antagonist), Abilify&#174; (aripiprazole&#59; partial dopamine agonist), Opdivo&#174; (nivolumab&#59; anti-PD1), Yervoy&#174; (Ipilimumab&#59; anti-CTLA-4), Daklinza&#174; (daclatasvir&#59; NS5A inhibitor), and Sunvepra&#174; (asunaprevir&#59; NS3 inhibitor). From January 2007 to September 2015, he served as a group director of global clinical research at Bristol-Myers Squibb Company, or BMS, focusing both in oncology global clinical research and neuroscience global clinical research. Under Dr. Coric&#8217;s leadership, Biohaven has developed a broad therapeutic portfolio comprised of early- and late-stage product candidates targeting neurological and neuropsychiatric diseases, epilepsy, bipolar and major depressive disorder, OCD, SCA and SMA. Dr. Coric also led Biohaven&#8217;s acquisition of its novel Kv7 channel platform and the sale of the Former Parent to Pfizer in 2022. Since July 2001, Dr. Coric has also continued to serve as an associate clinical professor of psychiatry at Yale School of Medicine. He previously served as the chief of the Yale Clinical Neuroscience Research Unit and the director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as president of the Connecticut Psychiatric Society. He also serves on the boards of directors of Vita Therapeutics, Inc., Pyramid Biosciences, Inc. and OLM School of Madison. Dr. Coric received his M.D. from Wake Forest University School of Medicine. He completed his internship at Yale-New Haven Hospital and residency training at the Yale Psychiatry Residency Training Program, where he also served as the program-wide chief resident for the Yale Department of Psychiatry, and chief resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. Dr. Coric was an honors scholar in neurobiology and physiology at the University of Connecticut where he received a B.S. degree. We believe that Dr. Coric&#8217;s operational experience with our Company gained from serving as our chief executive officer, as well as his extensive experience in the biopharmaceutical industry, qualifies him to serve as a member of our Board.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Matthew Buten</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Buten serves as our chief financial officer, and previously he served as the chief financial officer of Former Parent since 2021. Mr. Buten previously served as Managing Director of Foresite Capital Management from December 2012 to December 2021. Prior to joining Foresite Capital Management, Mr. Buten served as a healthcare portfolio manager at Catapult Capital Management LLC &#47; Millennium LP from June 2007 to June 2012. Prior to that, Mr. Buten was co-founder and co-manager of Sapphire Capital Partners LLP, a co-founder and a partner at Argus Partners, a Managing Director and Head of Healthcare Investment Banking for Needham &#38; Company, LLC and as a Director in Investment Banking at Smith Barney Inc. Mr. Buten holds a Bachelor of Science in economics (B.S.) from The Wharton School of the University of Pennsylvania. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kimberly Gentile</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Gentile serves as our senior vice president, clinical operations and prior to that she served as the senior vice president, clinical operations of Former Parent since February 2014. Before coming to Biohaven, Ms. Gentile served as associate director, project manager, global clinical operations at BMS from 2000 to February 2014. Prior to this, she was a senior clinical trial manager at SCIREX Corporation from 1996 to June 2000. Ms. Gentile received her B.S. in Psychology from Salem State University.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bruce Car, Ph.D.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Car joined Biohaven on August 1, 2022, having served since January 2020 as Chief Scientific Officer at Agios Pharmaceuticals, where the research focus was initially oncology and genetically defined diseases (GDD), later driving the portfolio to sole GDD approaches. Prior to Agios, Bruce spent 25 years at Bristol-Myers Squibb (BMS) and its legacy companies, working across all therapeutic areas and drug modalities. For more than two decades, he held roles of increasing responsibility in drug discovery, covering all therapeutic areas, drug platforms, India R&#38;D site, and different stages of discovery. In early 2017, he became the first head of the BMS Translational Medicine function, where he built a cohesive team of over 300 scientists and specialists covering biomarkers through data science and pharmaco-diagnostics. During his tenure with BMS, Dr. Car contributed to progressing approximately 250 internally discovered drug candidates and over 18 drug registrations. Dr. Car left BMS as the interim head of Drug Discovery. Dr. Car received a degree in Veterinary Medicine from The University of Melbourne, Victoria, Australia (&#8217;83), and his Ph.D (&#8217;89). from Cornell University, NY, USA. He holds specialty certifications in anatomic and clinical pathology. Dr. Car undertook his postdoctoral studies in immunology and inflammation at the Theodor Kocher Institute, University of Berne and ETH&#47;University of Zurich in Switzerland.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Management Directors</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Michael T. Heffernan </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael T. Heffernan, Lead Independent Director, age 57, has served as a director of our Company since September 2022, and prior to that served as a director of Former Parent since January 2020. Mr. Heffernan has over 25 years of leadership experience in the biotech and pharmaceutical industries. Mr. Heffernan is the Founder and Chairman of the Board of Collegium Pharmaceutical, Inc. (NASDAQ&#58; COLL), where he previously served as President and Chief Executive Officer from October 2002 until July 2018. In addition, he is actively managing Avenge Bio, Inc. an Immuno-Oncology company that he co-founded in March 2019. Prior to his time at Collegium Pharmaceutical, Inc. Mr. Heffernan served as President and Chief Executive Officer of Onset Dermatologics LLC, a dermatology company that he founded in November 2005 and spun out of Collegium Pharmaceutical, Inc. to create PreCision Dermatology Inc. in December 2010. PreCision Dermatology Inc. was later sold to Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International Inc.) in July 2014. Prior to that, Mr. Heffernan held positions as co-founder and Chief Executive Officer of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp., a public healthcare services company, and Chief Executive Officer and Chairman of PhyMatrix Corp. Mr. Heffernan began his career at Eli Lilly and Company where he served in numerous sales and marketing roles. Mr. Heffernan has been an advisor, investor and board member in a number of biopharmaceutical and healthcare services companies. His recent board memberships include&#58; TyRx, Inc. (sold to Medtronic plc), PreCision Dermatology Inc. (sold to Bausch Health Companies Inc.), Ocata Therapeutics, Inc. (sold to Astellas Pharma Inc.), and Veloxis Pharmaceuticals, Inc. (sold to Asahi Kasei Corporation). He is a member of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the board of Akebia Therapeutics, Inc. (NASDAQ&#58; AKBA), Synlogic, Inc. (NASDAQ&#58; SYBX) and Trevi Therapeutics Inc. (NASDAQ&#58; TRVI). We believe that Mr. Heffernan&#8217;s extensive experience as a senior executive in the commercial pharmaceutical industry qualifies him to serve as a member of our Board.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gregory H. Bailey, M.D.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gregory H. Bailey, M.D., age 66, has served as a director of the Company since September 2022, and prior to that served as a director of Former Parent since January 2014. Since co-founding the company in October 2016, Dr. Bailey has served as CEO of Juvenescence Limited, a life science and biotech company developing therapies to increase healthy human longevity. Dr. Bailey is a co-founder and has served as managing partner of MediqVentures since January 2014, the chairman and director of Portage Biotech, Inc. (OTCBB&#58; PTGEF) since June 2013, a director of Portage Pharmaceuticals Limited since June 2013, and director of Manx Financial Group since March 2018. He has been a managing partner of Palantir Group, Inc., a merchant bank involved in a number of biotech company startups and financings since April 2002. Dr. Bailey was a founder of SalvaRx Group Plc and has served on its board of directors since May 2015. Dr. Bailey was also the co-founder of Ascent Healthcare Solutions, VirnetX Inc. (NYSE American&#58; VHC), and DuraMedic Inc. He was the initial financier and an independent director of Medivation, Inc., from 2005 to December 2012. He has also served on the board of directors of AgeX Therapeutics, Inc. (NYSE American&#58; AGE) since 2018. Dr. Bailey practiced emergency medicine for ten years before entering finance. He received his medical degree from the University of Western Ontario. We believe that Dr. Bailey&#8217;s extensive venture capital industry experience and technical background, along with his experience with public companies and biopharmaceutical companies, qualifies him to serve as a member of our Board.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Robert J. Hugin</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert J. Hugin, age 67, has served as a director of our Company since September 2022, and prior to that served as a director of Former Parent since June 2020, served as Chief Executive Officer of Celgene Corporation, a biopharmaceutical company, from June 2010 until March 2016, as Chairman of its Board of Directors from June 2011 to March 2016 and as Executive Chairman from March 2016 to January 2018. Prior to June 2010, Mr. Hugin held a number of management roles at Celgene, including President from May 2006 to July 2014, Chief Operating Officer from May 2006 to June 2010 and Senior Vice President and Chief Financial Officer from June 1999 to May 2006, and served as a director of Celgene from December 2001 through January 2018. Prior to that, Mr. Hugin was a Managing Director at J.P. Morgan &#38; Co. Inc., which he joined in 1985. Mr. Hugin is currently a member of the board of directors of Chubb Limited. In the past five years, Mr. Hugin also served as a director of Allergan plc, Danaher Corporation and The Medicines Company. We believe that Mr. Hugin&#8217;s extensive experience as a chief executive officer in the biopharmaceutical industry qualifies him to serve as a member of our Board. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">John W. Childs</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John W. Childs, age 80, has served as a director of our Company since September 2022, and prior to that served as a director of Former Parent since January 2014. Mr. Childs is the Chairman of J.W. Childs Associates, L.P., a private equity and special situation investment firm founded in 1995, currently focusing on life science, real estate and consumer brands investments. Previously, Mr. Childs was Senior Managing Director of the Thomas H. Lee Company from 1987 to 1995, where he had broad responsibilities for originating, analyzing, negotiating, and managing leveraged buyout transactions, such as Snapple and General Nutrition Company. Prior to that Mr. Childs held various executive positions in the investment area at the Prudential Insurance Company of America, ultimately serving as Senior Managing Director in charge of the Capital Markets Group. He is currently a Director of Realm, LLC, a premium Napa wine company, Biohaven Pharmaceuticals, Pyramid Biosciences, OMAX Health, VeraDermics and Basin Holdings. Prior to their sale, he was Chairman of the Board of Kosta Browne, Sunny Delight and CHG Healthcare Services. Mr. Childs is also on the board of Delta Waterfowl, Waterfowl Research Foundation and the Wild Salmon Center, focusing on wildlife conservation. Mr. Childs has a B.A. from Yale University and a M.B.A. from Columbia University. We believe that Mr. Childs&#8217;s extensive experience in private equity, venture capital and life science qualifies him to serve as a member of the Board.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Julia P. Gregory</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Julia P. Gregory, age 69, has served as a director of our Company since September 2022, and prior to that served as a director of Former Parent since August 2017. Ms. Gregory has been Chairman and CEO of Isometry Advisors, Inc., a biotechnology financial, strategy and management advisory firm, since April 2016. Ms. Gregory formerly served as Chief Executive Officer at ContraFect Corporation (NASDAQ&#58; CFRX) from November 2013 through March 2016 and as a member of ContraFect&#8217;s Board of Directors from April 2014 through March 2016. Prior to her appointment as CEO, she served as ContraFect&#8217;s Executive Vice President and Chief Financial Officer from July 2012 to November 2013. Prior to her time at ContraFect, she served as President and CEO of Five Prime Therapeutics, Inc. (NASDAQ&#58; FPRX) from 2009 until August 2011, and as Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. (NASDAQ&#58; LXRX) from 2000 to 2008. Ms. Gregory has 20 years of investment banking experience, starting at Dillon, Read &#38; Co. and subsequently at Punk, Ziegel &#38; Company, where she served as the head of investment banking and head of its life sciences practice. Ms. Gregory served on the Board of Directors of the Sosei Group Corporation (TSE&#58; 4565.T) through March 2020, and as Executive Chair of Cavion, Inc. (sold to Jazz Pharmaceuticals plc. in August 2019). Ms. Gregory currently serves on the Boards of Directors of public companies Nurix Therapeutics, Inc. (NASDAQ&#58; NRIX), Freeline Therapeutics Holdings plc (NASDAQ&#58; FRLN), and IMV, Inc. (NASDAQ&#58; IMV&#59; TSX&#58; IMV.TO). Ms. Gregory obtained a Masters of Business Administration from the Wharton School at the University of Pennsylvania, and earned her B.A. at George Washington University. We believe that Ms. Gregory&#8217;s industry leadership and expertise in strategy development and implementation, investment banking and business development qualify her to serve as a member of our Board.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kishan Mehta</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kishan Mehta, age 36, has served as a director of our Company since September 2022, and prior to that served as a director of Former Parent since June 2021. Mr. Mehta is the Portfolio Manager of the Averill strategy at Suvretta Capital Management, LLC. Mr. Mehta has over a decade of experience in the healthcare industry. Since 2021, Mr. Mehta has also served as President and a director of four Nasdaq-listed special-purpose acquisition companies affiliated with Suvretta, Social Capital Suvretta Holdings Corp. I, Social Capital Suvretta Holdings Corp. II, Social Capital Suvretta Holdings Corp. III, and Social Capital Suvretta Holdings Corp. IV. Prior to becoming the Portfolio Manager of the investment strategy, he served as a strategic advisor to the Company where he advised the firm on various business development, corporate strategy, and capital structure decisions. From 2016 to 2018, Mr. Mehta served as a Portfolio Manager at Surveyor Capital, a division of Citadel, where he managed a beta and factor neutral, healthcare-focused long&#47;short equity portfolio. From 2012 to 2016, he was an Analyst at Adage Capital, where he focused on public&#47;private investments in therapeutics. Prior to that, Mr. Mehta had a similar role at Apothecary Capital, a division of BBT Capital. From 2007 to 2010, Mr. Mehta worked as a Mergers &#38; Acquisitions Analyst at Evercore Partners, focusing on pharmaceuticals. We believe that Mr. Mehta&#8217;s extensive experience in finance, equity investments and life science companies qualifies him to serve on the Board. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Irina Antonijevic</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Irina Antonijevic, age 57, has served as a director of our Company since September 2022, and prior to that served as a director of Former Parent since May 2022. Dr. Antonijevic is currently Chief Medical Officer (&#8220;CMO&#8221;) and Head of R&#38;D at Triplet Therapeutics, a company developing novel therapeutics for repeat expansion disorders such as Huntington&#8217;s disease, spinocerebellar ataxias and Myotonic Dystrophy. Prior to that, she served as VP of Translational Medicine and Development at Wave Life Sciences, CMO at vasopharm GmbH, developing a treatment for severe traumatic brain injury, and Head of Early Development, MS, Neurology and Ophthalmology at Sanofi Genzyme. Dr. Antonijevic has been a member of the supervisory board of 4SC AG since 2012, and of Paion AG from 2017 through early 2022. Dr. Antonijevic is board certified in Psychiatry and completed her residency in psychiatry and neurology at the Max Planck Institute for Psychiatry. Dr. Antonijevic obtained her venia legendi from the Berlin University and her PhD from the University of Edinburgh, United Kingdom. We believe that Dr. Antonijevic&#8217;s extensive experience in neuroscience research and drug development qualifies her to serve as a member of our Board.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Composition</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board is divided into three classes and has eight members.&#160;Dr. Vlad Coric&#160;is the chairman of the Board. There are no family relationships between any of our executive officers and directors. Each class consists, as nearly as possible, of one-third of the total number of directors, and each class will have a three-year term. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director&#8217;s successor is duly elected and qualified. Our directors are divided among the three classes as follows&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class I consists of&#160;Michael T. Heffernan, Dr. Irina Antonijevic and Robert J. Hugin, and their term will expire at our 2023 annual meeting of shareholders&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class II consists of&#160;Dr. Gregory Bailey, John Childs, and Julia Gregory,&#160;and their term will expire at our 2024 annual meeting of shareholders&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class III consists of&#160;Dr. Vlad Coric and Kishan Mehta,&#160;and their term will expire at our 2025 annual meeting of shareholders.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the number of directors changes, any increase or decrease will be apportioned among the classes so as to maintain the number of directors in each class as nearly as possible. Any additional directors of a class elected to fill a vacancy resulting from an increase in such class will hold office for a term that coincides with the remaining term of that class. Decreases in the number of directors will not shorten the term of any incumbent director.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These board provisions could make it more difficult for third parties to gain control of our company by making it difficult to replace members of the Board.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director Independence</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six of the eight members of our Board, except the Chief Executive Officer, who is an employee of the Company, and Mr. Mehta, meet the criteria for independence as defined by the rules of the NYSE and the Code of Business Conduct and Ethics for Employees, Executive Officers and Directors that is adopted by our Board (see discussion below under &#8220;&#8212;Code of Business Conduct and Ethics for Employees, Executive Officers and Directors&#8221;).</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Committees</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has established an audit committee, a compensation committee, and a nominating&#47;corporate governance committee. Each of the committees reports to the Board as it deems appropriate, and as the Board may request. The composition, duties and responsibilities of these committees are set forth below. In the future, our Board may establish other committees, as it deems appropriate, to assist it with its responsibilities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee reviews our internal accounting procedures and consults with and reviews the services provided by our independent registered public accountants. Our audit committee consists of three directors,&#160;John W. Childs, Julia Gregory, and Robert J. Hugin. Julia P. Gregory&#160;is the chairman of the audit committee and our Board has determined that&#160;all three directors&#160;are each an &#8220;audit committee financial expert&#8221; as defined by SEC rules and regulations. Our Board has determined that all members of our audit committee are independent directors under New York Stock Exchange listing rules and under Rule&#160;10A-3 under the Exchange Act. We intend to continue to evaluate the requirements applicable to us and we intend to comply with the future requirements to the extent that they become applicable to our audit committee. The principal duties and responsibilities of our audit committee include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appointing and retaining an independent registered public accounting firm to serve as independent auditor to audit our financial statements, overseeing the independent auditor&#8217;s work and determining the independent auditor&#8217;s compensation&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approving in advance all audit services and non-audit services to be provided to us by our independent auditor&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls, and auditing or compliance matters, as well as for the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and discussing with management and our independent auditor the results of the annual audit and the independent auditor&#8217;s review of our quarterly financial statements&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conferring with management and our independent auditor about the scope, adequacy and effectiveness of our internal accounting controls, the objectivity of our financial reporting and our accounting policies and practices.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation committee reviews and determines the compensation of all our executive officers. Our compensation committee consists of three directors, John Childs, Michael T. Heffernan and Robert J. Hugin, each of whom is a non-employee member of our Board as defined in Rule&#160;16b-3 under the Exchange Act. Michael T. Heffernan is the chairman of the compensation committee. Our Board has determined that the composition of our compensation committee satisfies the applicable independence requirements under, and the functioning of our compensation committee complies with the applicable requirements of, the New York Stock Exchange rules and SEC rules and regulations. We intend to continue to evaluate and intend to comply with all future requirements applicable to our compensation committee. The principal duties and responsibilities of our compensation committee include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and approving, and making recommendations to the Board regarding, performance goals and objectives relevant to the compensation of our chief executive officer, evaluating the performance of our chief executive officer in light of those goals and objectives and setting, or recommending to the full Board for approval, the chief executive officer&#8217;s compensation, including incentive-based and equity-based compensation, based on that evaluation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">setting the compensation of our other executive officers, based in part on recommendations of the chief executive officer&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exercising administrative authority under our stock plans and employee benefit plans&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing policies and making recommendations to our Board regarding director compensation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and discussing with management the compensation discussion and analysis that we may be required from time to time to include in SEC filings&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparing a compensation committee report on executive compensation as may be required from time to time to be included in our annual proxy statements or annual reports on Form 10-K filed with the SEC.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nominating&#47;Corporate Governance Committee</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our nominating and corporate governance committee consists of five directors, Dr. Gregory Bailey, Julia Gregory, Michael T. Heffernan, Irina Antonijevic, and Robert J. Hugin. Dr. Gregory Bailey is the chairman of the nominating and corporate governance committee. Subject to our compliance with the phase-in provisions below, our Board has determined that the composition of our nominating and corporate governance committee satisfies the applicable independence requirements under, and the functioning of our nominating and corporate governance committee complies with the applicable requirements of, the New York Stock Exchange standards and SEC rules and regulations. Upon the listing of our common shares on the NYSE, a majority of the members of our nominating and corporate governance committee satisfied the applicable independence requirements of the NYSE. We are permitted to phase in our compliance with the independent nominating and corporate governance committee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements of the NYSE, which requires all members to be independent within one year of listing. We will comply with the phase-in requirements of the NYSE rules, and within one year of our listing on the NYSE, all members of our nominating and corporate governance committee will be independent under NYSE rules. We will continue to evaluate and will comply with all future requirements applicable to our nominating and corporate governance committee. The nominating and corporate governance committee&#8217;s responsibilities will include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assessing the need for new directors and identifying individuals qualified to become directors&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recommending to the Board the persons to be nominated for election as directors and to each of the Board&#8217;s committees&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assessing individual director performance, participation and qualifications&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and recommending to the Board corporate governance principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">monitoring the effectiveness of the Board and the quality of the relationship between management and the Board&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overseeing an annual evaluation of management&#8217;s and the Board&#8217;s performance.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leadership Structure and Risk Oversight</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for the day-to-day management of risks the Company faces, while the Board, as a whole and through its committees, provides risk oversight. In its risk oversight role, the Board must satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed, including assessing major risk factors relating to the Company and its performance, and reviewing measures to address and mitigate risks. While the full Board is charged with overseeing risk management, various committees of the Board and members of management also have responsibilities with respect to our risk oversight. In particular, the audit committee plays a large role in monitoring and assessing our financial, legal and operational risks, and receives regular reports from the management team regarding comprehensive organizational risk as well as particular areas of concern. Our audit committee charter gives the audit committee responsibilities and duties that include discussing with management, the internal audit department and the independent auditors our major financial risk exposures and the steps management has taken to monitor and control such exposures, including our risk assessment and risk management policies.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board is committed to sound and effective corporate governance practices. The Company&#8217;s management and our Board reviewed our corporate governance practices in light of the Sarbanes-Oxley Act of 2002. Based on that review, the Board maintains codes of ethics and conduct, corporate governance guidelines, committee charters, complaint procedures for accounting and auditing matters. The Company is listed on the NYSE, and therefore, it has modeled its corporate governance practices after the listing requirements of NYSE.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Interlocks and Inside Participation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the members of our compensation committee is or has at any time during the past year been an officer or employee of ours. None of our executive officers currently serves or in the past year has served as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our Board or compensation committee.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics for Employees, Executive Officers and Directors</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted a code of business conduct and ethics (the &#8220;Code of Conduct&#8221;), applicable to all of our employees, executive officers and directors. The Code of Conduct is available on our website at www.biohaven.com. The information that appears on our website is not part of, and is not incorporated into, this prospectus. The nominating and corporate governance committee of our Board is responsible for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for employees, executive officers and directors. We expect that any amendments to the Code of Conduct, or any waivers of its requirements, will be disclosed on our website.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Employee Director Compensation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board will adopt a director compensation policy for our non-employee directors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we were not formed as of December 31, 2021, we did not have any directors or pay any compensation to non-employee directors with respect to service on our Board during the year ended December 31, 2021. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historical information concerning the compensation paid to or earned by directors of Former Parent may not be directly relevant to or indicative of the compensation that any such directors will receive (as applicable) as directors of the Company following the Distribution, but is available in Former Parent&#8217;s previous annual proxy statements filed with the SEC. Disclosure of the compensation that Former Parent directors received during the year ended December 31, 2021 is included in the proxy statement that Former Parent filed on March 11, 2022.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_64"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a newly formed entity, we did not have any executive officers or pay any compensation during the year ended December 31, 2021. Historical information concerning the compensation paid to or earned by named executive officers of Former Parent may not be directly relevant or indicative of the compensation that any such officers will receive (as applicable) as named executive officers of the Company following the Distribution, but is available in Former Parent&#8217;s previous annual proxy statements filed with the SEC. Disclosure of the compensation that Former Parent named executive officers received during the year ended December 31, 2021 is included in the proxy statement that Former Parent filed on March 11, 2022. Detailed information on the compensation arrangements of our named executive officers for 2022 will be provided in our 2023 proxy statement. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Management&#8212;Directors and Executive Officers&#8221; of this prospectus for the list of individuals who currently serve as executive officers of the Company.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Compensation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that equity-based compensation is an important component of the executive compensation program of the Company because we believe it is important to maintain a strong link between executive incentives and the creation of stockholder value. Accordingly, we adopted the 2022 Equity Incentive Plan, which we refer to as the &#8220;2022 Plan,&#8221; and the 2022 Employee Share Purchase Plan, which we refer to as the &#8220;ESPP&#8221;. The material terms of these plans are set forth below. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Equity Incentive Plan </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board adopted our 2022 Equity Incentive Plan, or 2022 Plan on September 29, 2022, and our shareholders approved the 2022 Plan on September 28, 2022. The 2022 Plan became effective immediately prior to the Distribution.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2022 Plan provides for the grant of incentive share options, or ISOs, nonstatutory share options, or NSOs, share appreciation rights, restricted share awards, restricted share unit awards, performance-based share awards, and other forms of equity compensation, which we refer to collectively as share awards. Additionally, the 2022 Plan provides for the grant of performance cash awards. ISOs may be granted only to employees. All other awards may be granted to employees, including officers, and to non-employee directors and consultants of us and our affiliates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Reserve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Initially, the aggregate number of common shares that may be issued pursuant to share awards under the 2022 Plan will equal 9,190,000 common shares on a fully diluted basis. Additionally, the number of common shares reserved for issuance under our 2022 Plan will be increased on January 1 of each year, beginning on January 1, 2023 and continuing through and including January 1, 2032, by a number of common shares equal to 4.00% of the total number of shares of our common shares outstanding on a fully diluted basis on December 31 of the preceding calendar year or such smaller number of common shares as determined by our Board. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reversion of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If a share award granted under the 2022 Plan expires or otherwise terminates without being exercised in full, or is settled in cash, the common shares not acquired pursuant to the share award again will become available for subsequent issuance under the 2022 Plan. In addition, the following types of shares under the 2022 Plan may become available for the grant of new share awards under the 2022 Plan&#58; (1) common shares that are forfeited to or repurchased by us prior to becoming fully vested&#59; (2) common shares withheld or reacquired to satisfy income or employment withholding taxes&#59; or (3) common shares used to pay the exercise or purchase price of a share award. Shares issued under the 2022 Plan may be previously unissued shares or reacquired shares bought by us on the open market. As of the date hereof, 9,110,000 option awards have been granted and no common shares have been issued under the 2022 Plan. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Employee Director Compensation Limit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the 2022 Plan, the maximum number of common shares subject to share awards granted under the 2022 Plan or otherwise during any one calendar year to any of our non-employee directors, taken together with any cash fees paid by us to such non-employee director during such calendar year for services on the Board, will not exceed $1,000,000 in total value (calculating the value of any such share awards based on the grant date fair value of such share awards for financial reporting purposes)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that (i) this limit will equal $1,500,000 with respect to the calendar year during which a non-employee director is newly appointed as a member of the Board (including with respect to the 2022 calendar year)&#59; and (ii) the independent members of the Board may make exceptions to this limit for a member participating in a special committee, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the non-employee director receiving such additional compensation may not participate in the decision to award such compensation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our Board, or a duly authorized committee thereof, has the authority to administer the 2022 Plan. Our Board may also delegate to one or more of our officers the authority to (1) designate employees (other than other officers) to be recipients of certain awards, and (2) determine the number of common shares to be subject to such awards. Subject to the terms of the 2022 Plan, our Board or the authorized committee, referred to herein as the plan administrator, determines recipients, dates of grant, the numbers and types of awards to be granted and the terms and conditions of the awards, including the period of their exercisability and vesting schedule applicable to an award. Subject to the limitations set forth below, the plan administrator will also determine the exercise price, strike price or purchase price of awards granted and the types of consideration to be paid for the award. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plan administrator has the authority to modify outstanding awards under our 2022 Plan. Subject to the terms of our 2022 Plan, the plan administrator has the authority to reduce the exercise, purchase or strike price of any outstanding share award, cancel any outstanding share award in exchange for new share awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any adversely affected participant. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ISOs and NSOs are granted pursuant to share option agreements adopted by the plan administrator. The plan administrator determines the exercise price for a share option, within the terms and conditions of the 2022 Plan, provided that the exercise price of a share option generally cannot be less than 100% of the fair market value of our common shares on the date of grant. Options granted under the 2022 Plan vest at the rate specified by the plan administrator. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plan administrator determines the term of share options granted under the 2022 Plan, up to a maximum of 10 years. Unless the terms of an optionholder&#8217;s share option agreement provide otherwise, if an optionholder&#8217;s service relationship with us, or any of our affiliates, ceases for any reason other than disability or death, the optionholder may generally exercise any vested options for a period of 3 months following the cessation of service. The option term may be extended in the event that exercise of the option following such a termination of service is prohibited by applicable securities laws or our insider trading policy. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability or death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months in the event of disability and 18 months in the event of death. In no event may an option be exercised beyond the expiration of its term. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acceptable consideration for the purchase of common shares issued upon the exercise of a share option will be determined by the plan administrator and may include (1) cash, check, bank draft or money order, (2) a broker-assisted cashless exercise, (3) the tender of common shares previously owned by the optionholder, (4) a net exercise of the option if it is an NSO, and (5) other legal consideration approved by the plan administrator. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the plan administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution, or pursuant to a domestic relations order. An optionholder may designate a beneficiary, however, who may exercise the option following the optionholder&#8217;s death. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Limitations on Incentive Share Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The aggregate fair market value, determined at the time of grant, of our common shares with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our share plans and the share plans of any of our affiliates may not exceed $100,000. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own shares possessing more than 10% of our total combined voting power or that of any of our affiliates unless (1) the option exercise price is at least 110% of the fair market value of the shares subject to the option on the date of grant, and (2) the term of the ISO does not exceed five years from the date of grant. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Restricted share awards are granted pursuant to restricted share award agreements adopted by the plan administrator. Restricted share awards may be granted in consideration for (1) cash, check, bank draft or money order, (2) services rendered to us or our affiliates, or (3) any other form of legal consideration. Common shares acquired under a restricted share award may, but need not, be subject to a share repurchase option in our favor in accordance with a vesting schedule to be determined by the plan administrator. A restricted share award may be transferred only upon such terms and conditions as set by the plan administrator. Except as otherwise provided in the applicable award agreement, restricted shares that have not vested will be forfeited or repurchased by us upon the participant&#8217;s cessation of continuous service for any reason. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Unit Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Restricted share unit awards are granted pursuant to restricted share unit award agreements adopted by the plan administrator. Restricted share unit awards may be granted in consideration for any form of legal consideration. A restricted share unit award may be settled by cash, delivery of shares, a combination of cash and shares as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted share unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted share unit award. Except as otherwise provided in the applicable award agreement, restricted share units that have not vested will be forfeited upon the participant&#8217;s cessation of continuous service for any reason. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Appreciation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Share appreciation rights are granted pursuant to share appreciation grant agreements adopted by the plan administrator. The plan administrator determines the strike price for a share appreciation right, which generally cannot be less than 100% of the fair market value of our common shares on the date of grant. Upon the exercise of a share appreciation right, we will pay the participant an amount equal to the product of (1) the excess of the per share fair market value of our common shares on the date of exercise over the strike price, multiplied by (2) the number of common shares with respect to which the share appreciation right is exercised. A share appreciation right granted under the 2022 Plan vests at the rate specified in the share appreciation right agreement as determined by the plan administrator. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plan administrator determines the term of share appreciation rights granted under the 2022 Plan, up to a maximum of 10 years. Unless the terms of a participant&#8217;s share appreciation right agreement provides otherwise, if a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than disability or death, the participant may generally exercise any vested share appreciation right for a period of 3 months following the cessation of service. The share appreciation right term may be further extended in the event that exercise of the share appreciation right following such a termination of service is prohibited by applicable securities laws. If a participant&#8217;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested share appreciation right for a period of 12 months in the event of disability and 18 months in the event of death. In no event may a share appreciation right be exercised beyond the expiration of its term. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2022 Plan permits the grant of performance-based share and cash awards, the payment of which are contingent upon the attainment of certain performance goals established by our Board. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance goals may be based on a company-wide basis, with respect to one or more business units, divisions, affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise (1) in the award agreement at the time the award is granted or (2) in such other document setting forth the performance goals at the time the goals are established, we will appropriately make adjustments in the method of calculating the attainment of performance goals as follows&#58; (a) to exclude restructuring and&#47;or other nonrecurring charges&#59; (b) to exclude exchange rate effects&#59; (c) to exclude the effects of changes to generally accepted accounting principles&#59; (d) to exclude the effects of any statutory adjustments to corporate tax rates&#59; (e) to exclude the effects of any items that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are unusual in nature or occur infrequently as determined under generally accepted accounting principles&#59; (f) to exclude the dilutive effects of acquisitions or joint ventures&#59; (g) to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture&#59; (h) to exclude the effect of any change in the outstanding common shares by reason of any share dividend or split, share repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common shareholders other than regular cash dividends&#59; (i) to exclude the effects of share based compensation and the award of bonuses under our bonus plans&#59; (j) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles&#59; (k) to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles&#59; (l) to exclude the effect of any other unusual, non-recurring gain or loss or other extraordinary item&#59; and (m) to exclude the effects of the timing of acceptance for review and&#47;or approval of submissions to the FDA or any other regulatory body. In addition, we retain the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of the goals. The performance goals may differ from participant to participant and from award to award. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Share Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The plan administrator may grant other awards based in whole or in part by reference to our common shares. The plan administrator will set the number of shares under the share award and all other terms and conditions of such awards. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes to Capital Structure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the event that there is a specified type of change in our capital structure, such as a share split or recapitalization, appropriate adjustments will be made to (1) the class and maximum number of shares reserved for issuance under the 2022 Plan, (2) the class and maximum number of shares by which the share reserve may increase automatically each year, (3) the class and maximum number of shares that may be issued upon the exercise of ISOs, (4) the class and maximum number of shares subject to share awards that can be granted in a calendar year and (5) the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding share awards. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the event of certain specified significant corporate transactions, the plan administrator has the discretion to take any of the following actions with respect to share awards&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">arrange for the assumption, continuation or substitution of a share award by a surviving or acquiring entity or parent company&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving or acquiring entity or parent company&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accelerate the vesting of the award and provide for its termination prior to the effective time of the corporate transaction&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">arrange for the lapse of any reacquisition or repurchase right held by us&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cancel or arrange for the cancellation of the award in exchange for such cash consideration, if any, as our Board may deem appropriate&#59; or </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make a payment equal to the excess of (a) the value of the property the participant would have received upon exercise of the award over (b) the exercise price otherwise payable in connection with the award, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the payment may be $0 if the value of the property is equal to or less than the exercise price, and payments may be delayed to the same extent that payment of consideration to the holders of common shares in connection with the corporate transaction is delayed as a result of escrows, earn outs, holdbacks or other contingencies and in compliance with Section 409A. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan administrator is not obligated to treat all awards, even those that are of the same type, in the same manner. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2022 Plan, a corporate transaction is generally the consummation of (1) a sale or other disposition of all or substantially all of our assets, (2) a sale or other disposition of at least 50% of our outstanding securities, (3) a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">merger, consolidation or similar transaction following which we are not the surviving corporation, or (4) a merger, consolidation or similar transaction following which we are the surviving corporation but the common shares outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the 2022 Plan, unless the plan administrator determines otherwise or as otherwise provided in an award agreement, in the event of a change in control, then contingent upon the effectiveness of the change in control, all outstanding share-based awards will become fully vested (including the lapsing of all restrictions and conditions) and, as applicable, exercisable and with respect to any share-based award subject to performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target levels. Under the 2022 Plan, a change in control is generally (1) the acquisition by a person or entity of more than 50% of our combined voting power other than by merger, consolidation or similar transaction&#59; (2) a consummated merger, consolidation or similar transaction immediately after which our shareholders cease to own more than 50% of the combined voting power of the surviving entity&#59; (3) a consummated sale, lease or exclusive license or other disposition of all or substantially of our assets&#59; (4) a complete dissolution or liquidation of the Company, except for a liquidation into a parent corporation, or (5) when a majority of our Board becomes comprised of individuals who were not serving on our Board on the date of adoption of the 2022 Plan, or the incumbent Board, or whose nomination, appointment, or election was not approved by a majority of the incumbent Board still in office. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amendment and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our Board has the authority to amend, suspend, or terminate our 2022 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. No ISOs may be granted after the 10th anniversary of the date our Board adopted our 2022 Plan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Employee Share Purchase Plan </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board adopted our 2022 Employee Share Purchase Plan, or ESPP on September 29, 2022, and our shareholders approved the ESPP on September 28, 2022. The ESPP became effective on the date of the Distribution. The purpose of the ESPP is to secure the services of new employees, to retain the services of existing employees and to provide incentives for such individuals to exert maximum efforts toward our success and that of our affiliates. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423 of the Code. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Reserve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ESPP authorizes the issuance of up to 393,769 of our common shares on a fully diluted basis pursuant to purchase rights granted to our employees or to employees of any of our designated affiliates. The number of common shares reserved for issuance will automatically increase on January 1 of each calendar year, from January 1, 2023 through January 1, 2032 in an amount equal to 1% of the total number of common shares outstanding on a fully diluted basis on December 31 of the preceding calendar year&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that prior to the date of any such increase, our Board may determine that such increase will be less than such amount. As of the date hereof, no common shares have been purchased under the ESPP. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our Board has delegated concurrent authority to administer the ESPP to our compensation committee. The ESPP is implemented through a series of offerings under which eligible employees are granted purchase rights to purchase common shares on specified dates during such offerings. Under the ESPP, we may specify offerings with durations of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which common shares will be purchased for employees participating in the offering. An offering under the ESPP may be terminated under certain circumstances. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payroll Deductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Generally, all regular employees, including executive officers, employed by us or by any of our designated affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, between 1% and 15% of their earnings (as defined in the ESPP) for the purchase of our common shares under the ESPP. Unless otherwise determined by our Board, common shares will be purchased for the accounts of employees participating in the ESPP at a price per share equal to the lower of (a) 85% of the fair market value of a common share on the first date of an offering or (b) 85% of the fair market value of a common share on the date of purchase. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Employees may have to satisfy one or more of the following service requirements before participating in the ESPP, as determined by our Board, including&#58; (1) being customarily employed for more than 20 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hours per week&#59; (2) being customarily employed for more than five months per calendar year&#59; or (3) continuous employment with us or one of our affiliates for a period of time (not to exceed two years). No employee may purchase shares under the ESPP at a rate in excess of $25,000 worth of our common shares based on the fair market value per common share at the beginning of an offering for each year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value pursuant to Section 424(d) of the Code. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes to Capital Structure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the event that there occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or similar transaction, the Board will make appropriate adjustments to (1) the number of shares reserved under the ESPP, (2) the maximum number of shares by which the share reserve may increase automatically each year, (3) the number of shares and purchase price of all outstanding purchase rights, and (4) the number of shares that are subject to purchase limits under ongoing offerings. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the event of certain significant corporate transactions, including&#58; (1) a sale of all or substantially all of our assets, (2) the sale or disposition of 50% of our outstanding securities, (3) the consummation of a merger or consolidation where we do not survive the transactions and (4) the consummation of a merger or consolidation where we do survive the transaction but the common shares outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction, any then-outstanding rights to purchase our shares under the ESPP may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue or substitute for such purchase rights, then the participants&#8217; accumulated payroll contributions will be used to purchase common shares within 10 business days prior to such corporate transaction, and such purchase rights will terminate immediately. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESPP Amendments, Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our Board has the authority to amend or terminate our ESPP, provided that except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#8217;s consent. We will obtain shareholder approval of any amendment to our ESPP as required by applicable law or listing requirements. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Awards</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2022, following the Distribution, we granted equity-based incentive awards designed to align our executives&#8217; interests with those of our shareholders in the form of stock options.  The awards were granted to the following executive officers and in the following amounts&#58;  Dr. Coric&#58; 950,000 options&#59; Mr. Buten&#58; 300,000 options&#59; and Ms. Gentile&#58; 300,000 options.  The options were each granted with an exercise price equal to the Company share price on October 3, 2022 and will vest in four equal installments, with one-quarter vesting on the date of grant and each remaining one-quarter on the first, second and third anniversary of the date of grant, subject to the grantee&#8217;s continued employment through each vesting date. As of the date hereof, the award values for each executive officer have not yet been finalized.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treatment of Outstanding Awards</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with and effective as of the Distribution, each outstanding option (each, a &#8220;Pre-Spin Former Parent Option&#8221;) to purchase common shares of Former Parent (&#8220;Former Parent Common Shares&#8221;) was adjusted so that such Pre-Spin Former Parent Option is an option to acquire Biohaven common shares (a &#8220;Biohaven Option&#8221;) and an option to acquire Former Parent Common Shares (a &#8220;Post-Spin Former Parent Option&#8221;), and each outstanding restricted stock unit (a &#8220;Pre-Spin Former Parent RSU&#8221;) was adjusted so that such restricted stock unit is a restricted stock unit in respect of Biohaven common shares (a &#8220;Biohaven RSU&#8221;) and a restricted stock unit in respect of Former Parent Common Shares (a &#8220;Post-Spin Former Parent RSU&#8221;), in each case as set forth below, except as otherwise expressly provided in the Merger Agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Post-Spin Former Parent Option was in respect of the number of shares underlying the applicable Pre-Spin Former Parent Option and at an exercise price equal to the product, rounded up to the nearest cent, of (A) the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise price of the applicable Pre-Spin Former Parent Option multiplied by (B) the quotient obtained by dividing (1) the volume-weighted average trading price of a Former Parent Common Share exclusive of the value attributable to Biohaven during the period commencing on the first trading day following the record date for the Distribution through and including the last trading day prior to the effective time of the Distribution (&#8220;Former Parent Per Share Value&#8221;) by (2) the volume-weighted average trading price of a Former Parent Common Share inclusive of the value attributable to Biohaven during the period commencing on the first trading day following the record date for the Distribution through and including the last trading day prior to the effective time of the Distribution (the &#8220;Combined Per Share Value&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Biohaven Option was in respect of a number of Biohaven common shares equal to the number of shares underlying the applicable Pre-Spin Former Parent Option multiplied by 0.5 (the &#8220;Distribution Ratio&#8221;), rounded down to the nearest whole number of shares and at an exercise price equal to the price, rounded up to the nearest cent, determined by dividing (A) the product of (1) the exercise price of the Pre-Spin Former Parent Option multiplied by (2) the quotient obtained by dividing (a) the amount by which (i) the Combined Per Share Value exceeds (ii) the Former Parent Per Share Value by (b) the Combined Per Share Value, by (B) the Distribution Ratio. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Post-Spin Former Parent RSU was in respect of a number of restricted stock units subject to the applicable Pre-Spin Former Parent RSU, with any applicable performance conditions deemed achieved at 100%.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Biohaven RSU was in respect of a number of restricted stock units equal to (1) the number of shares subject to the applicable Pre-Spin Former Parent RSU, with any applicable performance conditions deemed achieved at 100%, multiplied by (2) the Distribution Ratio, rounded down to the nearest whole number of shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the effective time of the Merger, each Post-Spin Former Parent Option, Post-Spin Former Parent RSU, Biohaven Option and Biohaven RSU accelerated and vested in full, except as otherwise expressly provided in the Merger Agreement. Biohaven RSUs will be settled in common shares, and Biohaven will settle the Biohaven Options into Biohaven common shares (by reducing the number of Biohaven common shares issued by a number of Biohaven common shares sufficient to satisfy the option exercise price).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board adopted the Legacy Equity Award Settlement Plan on September 29, 2022, or the Legacy Award Plan, and our shareholders approved the Legacy Award Plan on September 28, 2022. The Legacy Award Plan became effective on October 3, 2022. The Legacy Award Plan is intended solely to provide for the grant and settlement of the Biohaven Options and Biohaven RSUs issued in respect of Pre-Spin Former Parent Options and Pre-Spin Former Parent RSUs, as described in this section. The aggregate number of Biohaven common shares that may be issued under the Legacy Award Plan may not exceed 4,981,801, and the actual number of Biohaven common shares that will be issued in settlement of Biohaven Options and Biohaven RSUs issued in respect of Pre-Spin Former Parent Options and Pre-Spin Former Parent RSUs will equal approximately 3,535,571. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board may suspend or terminate the Legacy Award Plan at any time, and the Legacy Award Plan will be terminated following the settlement of Biohaven Options and Biohaven RSUs in respect of Pre-Spin Former Parent Options and Pre-Spin Former Parent RSUs into common shares as described above. Except as described here, the Legacy Award Plan has the same terms and conditions as the Biohaven Pharmaceutical Holding Company Ltd. 2017 Equity Incentive Plan, which are described in Former Parent&#8217;s Amendment No. 1 to Form S-1 filed with the SEC on April 24, 2017.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements and Offer Letters</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, or a member of its group, has entered into certain employment and individual agreements with its employees, including the employment agreements entered into between the Company&#8217;s wholly owned subsidiary, Biohaven Pharmaceuticals, Inc. and the Company&#8217;s executive officers. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employment Agreements with Dr. Coric</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., have each entered into an employment agreement with Dr. Coric. The employment agreements with Dr. Coric provide for an initial three-year </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">term of employment, with automatic one-year renewal periods, unless either party provides notice of non-renewal at least 90 days before the renewal date. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s employment agreement with Dr. Coric, if the Company terminates Dr. Coric&#8217;s employment, or if his employment is terminated due to death or disability, he is entitled to a lump-sum severance payment in the amount of $350,000. Further, all stock options held by Dr. Coric will be deemed to be fully vested and exercisable on his termination date, and the exercise period of such stock options will be extended for a period of two years following the termination date (or if earlier, the end of the term of the award). These severance payments are in addition to any severance payments due to Dr. Coric under his agreement with Biohaven Pharmaceuticals, Inc., as described below. In connection with the closing of the Merger and Dr. Coric ceasing to be the Former Parent&#8217;s Chief Executive Officer, Former Parent will pay Dr. Coric $300,000 in full satisfaction of its obligations under Dr. Coric&#8217;s employment agreement with the Former Parent, subject to Dr. Coric&#8217;s execution of a release of claims. Dr. Coric has agreed to donate the net after tax portion of such severance payments to a charitable organization selected by Dr. Coric.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the employment agreement between the Company&#8217;s wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., and Dr. Coric, if Dr. Coric&#8217;s employment with Biohaven Pharmaceuticals, Inc. is terminated without &#8220;Just Cause&#8221; (as defined therein), due to death or disability, or if Dr. Coric terminates his employment for &#8220;Good Reason&#8221; (as defined therein), subject to the execution and non-revocation of a release of claims against Biohaven Pharmaceuticals, Inc., Dr. Coric would receive (i) severance payments in equal monthly installments equal to his current base salary for 15 months following termination (or 18 months in the case of a termination within 12 months following a change in control), (ii) continued health insurance coverage for up to 15 months (or 18 months in case of a termination within 12 months following a change of control), reduced to the extent Dr. Coric receives comparable benefits elsewhere during the period, (iii) continued life insurance coverage for 15 months (or 18 months in the case of a termination within 12 months following a change of control), (iv) full vesting of all stock options, which would remain exercisable for 24 months following termination (or, with respect to a qualifying termination within 12 months following a change in control, with respect to all time-based equity awards, with stock options remaining exercisable for 12 months following termination and any performance awards continuing to be governed by their award agreements) and (v) solely upon a termination without &#8220;Just Cause&#8221; or for &#8220;Good Reason&#8221;, within 12 months following a change in control, an amount equal to 1.5 times his target bonus opportunity for the performance year in which the termination occurs, payable in equal installments over 18 months following termination. The closing of the Merger was deemed to be a change in control for this purpose.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Distribution, we entered into an employment agreement with Dr. Coric (in addition to Dr. Coric&#8217;s agreement with Biohaven Pharmaceuticals, Inc.) to replace Dr. Coric&#8217;s current employment agreement with the Former Parent. Under our employment agreement with Dr. Coric, he serves as Chief Executive Officer of the Company. As compensation for serving as Chief Executive Officer of the Company, Dr. Coric will receive a number of options as determined by our Board. If the Company terminates Dr. Coric&#8217;s employment, or if his employment is terminated due to death or disability, he will be entitled to the same severance and option vesting benefits as he was entitled to pursuant to his employment agreement with the Former Parent, as described above. These severance payments are in addition to any severance payments due to Dr. Coric under his agreement with Biohaven Pharmaceuticals, Inc., as described above. Dr. Coric will also be subject to one-year non-competition and non-solicitation covenants.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employment Agreements with Mr. Buten</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the employment agreement between the Company&#8217;s wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., and Mr. Buten, if Mr. Buten&#8217;s employment with Biohaven Pharmaceuticals, Inc. is terminated without &#8220;Just Cause,&#8221; due to death or disability, or if he terminates his employment for &#8220;Good Reason,&#8221; each in the absence of a &#8220;Change in Control&#8221; (as each is defined therein), subject to the execution and non-revocation of a release of claims against the Company, he is entitled to receive severance payments equal to 1.5 times the sum of the applicable base salary rate in effect plus his target bonus opportunity, payable in equal monthly installments over 18 months, plus he would also be eligible to receive a pro-rata bonus payment for the year in which he is terminated, to be determined and made at the sole discretion of the Board, equal to his target bonus opportunity, if any, which would have been awarded to him had he remained employed for the applicable performance period. In addition, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon such termination, Mr. Buten is entitled to continued health and life insurance coverage for the period during which he receives severance payments, reduced, in the case of health benefits, to the extent he receives comparable benefits elsewhere during the period. In addition, under his employment agreement, all stock options and other equity incentive awards granted to Mr. Buten would become fully vested and exercisable upon such termination, and remain exercisable for 24 months following the date of his termination (or, if earlier, the end of the term of the award). Upon termination due to disability, the amount of severance paid to Mr. Buten is reduced by any disability benefits he receives under Biohaven Pharmaceuticals, Inc.&#8217;s disability insurance policies.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under his employment agreement, if Mr. Buten&#8217;s employment with Biohaven Pharmaceuticals, Inc. is terminated without &#8220;Just Cause&#8221; or if he terminates his employment for &#8220;Good Reason,&#8221; each within 12 months following a &#8220;Change in Control&#8221; (as each is defined therein), subject to the execution and non-revocation of a release of claims against Biohaven Pharmaceuticals, Inc., he will be entitled to receive (i) an amount equal to 1.5 times the sum of his current base salary plus his target bonus opportunity, to be paid in equal installments over 18 months, (ii) a pro-rata bonus payment for the year in which he is terminated, to be determined and made at the sole discretion of the Board, equal to his target bonus opportunity, if any, which would have been awarded to him had he remained employed for the applicable performance period, and (iii) payment equal to his target bonus opportunity, to be paid in equal installments over 12 months. In addition, upon such termination, Mr. Buten is entitled to continued health and life insurance coverage during the period during which he receives severance payments, reduced to the extent he receives comparable benefits elsewhere during the severance period. All time-based vesting equity awards held by Mr. Buten as of the date of his termination will be deemed to be fully vested and exercisable on the termination date, and he may exercise such awards for 12 months following the termination date (or if earlier, the end of the term of the award). Performance awards will be governed by the terms of the applicable award agreement. Upon termination due to disability, the amount of severance paid to Mr. Buten is reduced by any disability benefits he receives under Biohaven Pharmaceuticals, Inc.&#8217;s disability insurance policies.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Distribution, we entered into an employment agreement with Mr. Buten (in addition to Mr. Buten&#8217;s agreement with Biohaven Pharmaceuticals, Inc.). Under our employment agreement with Mr. Buten, he serves as Chief Financial Officer of the Company. As compensation for serving as Chief Financial Officer of the Company, Mr. Buten will receive a number of options as determined by our Board. If the Company terminates Mr. Buten&#8217;s employment, or if his employment is terminated due to death or disability, he will be entitled to a lump-sum severance payment in the amount of $350,000 and all stock options held by Mr. Buten will be deemed to be fully vested and exercisable on his termination date, and the exercise period of such stock options will be extended for a period of two years following the termination date (or if earlier, the end of the term of the award). These severance payments are in addition to any severance payments due to Mr. Buten under his agreement with Biohaven Pharmaceuticals, Inc., as described above. Mr. Buten will also be subject to one-year non-competition and non-solicitation covenants.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employment Agreement with Ms. Gentile</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the employment agreement between the Company&#8217;s wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., and Ms. Gentile, if Biohaven Pharmaceuticals, Inc. terminates her employment without &#8220;Cause&#8221; or if she terminates her employment for &#8220;Good Reason,&#8221; as each is defined therein, subject to the execution of a release of claims against Biohaven Pharmaceuticals, Inc., she is entitled to an amount equal to six months of her base salary, to be paid consistent with the Company&#8217;s normal payroll schedule over six months. Ms. Gentile&#8217;s employment agreement does not contain differing severance entitlements before or after a change in control. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Offer of Employment with Bruce Car </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Distribution, we entered into an amended and restated offer of employment with Mr. Car pursuant to which he serves as Chief Scientific Officer of the Company.  Upon a termination of employment by the Company without &#8220;Just Cause,&#8221; due to Mr. Car&#8217;s death or disability or by Mr. Car for &#8220;Good Reason,&#8221; subject to execution and non-revocation of a release, Mr. Car will be eligible to receive (i) an amount equal to the sum of Mr. Car&#8217;s base salary and target bonus, payable in substantially equal installments over twelve months, (ii) continued health insurance coverage for up to twelve months following termination, (iii) a prorated target bonus for the year of termination, payable at the same time bonuses are paid to similarly-situated employees, (iv) payment of life </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance premiums for 12 months following termination and (v) accelerated vesting of shares underlying time-based equity awards that would have vested in the twelve months following termination.  Upon a termination of employment by the Company without &#8220;Just Cause&#8221; or by Mr. Car for &#8220;Good Reason&#8221; within 12 months of a &#8220;Change in Control,&#8221; subject to execution and non-revocation of a release, Mr. Car will be eligible to receive (i) an amount equal to the sum of Mr. Car&#8217;s base salary and target bonus, payable in substantially equal installments over twelve months, (ii) continued health insurance coverage for up to twelve months following termination, (iii) a prorated target bonus for the year of termination, payable at the same time bonuses are paid to similarly-situated employees, (iv) an amount equal to Mr. Car&#8217;s target bonus, paid in twelve monthly installments and (v) accelerated vesting of all time-based vesting equity awards.  Pursuant to the offer of agreement, following a termination of employment Mr. Car will also be subject to one-year non-competition and non-solicitation covenants.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Executive Officer Arrangements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation arrangements for our other anticipated executive officers generally provide for the following primary elements of compensation&#58; (i) annual base salary, (ii) an annual cash incentive opportunity, (iii) eligibility for annual long-term incentive awards, and (iv) severance entitlements. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detailed information on the compensation arrangements of our named executive officers for 2022 will be provided in our 2023 proxy statement.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitation of Liability and Indemnification of Officers and Directors</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the Amended Memorandum and Articles of Association, which became effective and contain provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by British Virgin Islands law.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amendment to, or repeal of, these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to that amendment or repeal.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Memorandum and Articles of Association provide that we will indemnify, to the fullest extent permitted by law, any person who is or was a party or is threatened to be made a party to any action, suit or proceeding by reason of the fact that he is or was one of our directors or officers or is or was serving at our request as a director or officer of another corporation, partnership, joint venture, trust, or other enterprise. The Amended Memorandum and Articles of Association also provide that we may indemnify to the fullest extent permitted by law any person who is or was a party or is threatened to be made a party to any action, suit, or proceeding by reason of the fact that he is or was one of our employees or agents or is or was serving at our request as an employee or agent of another corporation, partnership, joint venture, trust, or other enterprise. Our Amended Memorandum and Articles of Association also provide that we must advance expenses incurred by or on behalf of a director or officer in advance of the final disposition of any action or proceeding, subject to very limited exceptions.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in connection with the Spin-Off, we entered into indemnification agreements with each of our directors and executive officers that may be broader than the specific indemnification provisions contained under British Virgin Islands law. These indemnification agreements require us, among other things, to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses incurred by the directors and executive officers in investigating or defending any such action, suit, or proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The limitation of liability and indemnification provisions that are included in our Amended Memorandum and Articles of Association and in indemnification agreements that we entered into with our directors and executive officers may discourage shareholders from bringing a lawsuit against our directors and executive officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against our directors and executive officers, even though an action, if successful, might benefit us and other shareholders. Further, a shareholder&#8217;s investment may be harmed to the extent that we pay the costs of settlement and damage awards against directors and executive officers as required by these indemnification provisions. At present, we are not aware of any pending litigation or proceeding involving any person who is or was one of our directors, officers, employees </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other agents or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, for which indemnification is sought, and we are not aware of any threatened litigation that may result in claims for indemnification.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained insurance policies under which, subject to the limitations of the policies, coverage is provided to our directors and executive officers against loss arising from claims made by reason of breach of fiduciary duty or other wrongful acts as a director or executive officer, including claims relating to public securities matters, and to us with respect to payments that may be made by us to these directors and executive officers pursuant to our indemnification obligations or otherwise as a matter of law.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our non-employee directors may, through their relationships with their employers, be insured and&#47;or indemnified against certain liabilities incurred in their capacity as members of our Board.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our company pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule&#160;10b5-1 Sales Plans</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our directors and executive officers may adopt written plans, known as Rule&#160;10b5-1 plans, in which they will contract with a broker to buy or sell our common shares on a periodic basis. Under a Rule&#160;10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer when entering into the plan, without further direction from them. The director or officer may amend a Rule&#160;10b5-1 plan in some circumstances and may terminate a plan at any time. Our directors and executive officers also may buy or sell additional shares outside of a Rule&#160;10b5-1 plan when they are not in possession of material nonpublic information subject to compliance with the terms of our insider trading policy.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_67"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related-Person Transaction Policy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Spin-Off, we adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. The policy became effective immediately upon the completion of the Distribution. For purposes of our policy only, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our Board, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant shareholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our Code of Conduct, which became effective as of the Distribution date, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our audit committee, or other independent body of our Board, will take into account the relevant available facts and circumstances including, but not limited to&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks, costs and benefits to us&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on a director&#8217;s independence in the event that the related person is a director, immediate family member of a director or an entity with which a director is affiliated&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of other sources for comparable services or products&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit committee, or other independent body of our Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our shareholders, as our audit committee, or other independent body of our Board, determines in the&#160;good&#8209;faith exercise of its discretion.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Related Party Transactions</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as described below, there have been no transactions since January&#160;1, 2021 in which we have been a participant in which the amount involved exceeded or will exceed $120,000, and in which any of our directors, executive officers or holders of more than 5% of our share capital post-Distribution, or any members of their immediate family, had or will have a direct or indirect material interest, other than the compensation arrangements referenced in the Distribution Agreement and contemplated by the Transition Services Agreement, as described under &#8220;The Separation and Distribution&#8221;, and the compensation arrangements described under &#8220;Executive Compensation&#8221; and &#8220;Director Compensation.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transition Services Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into the Transition Services Agreement with the Former Parent under which the Company or one of its affiliates will provide the Former Parent, and the Former Parent or one of its affiliates will provide the Company, with certain transition services for a limited time to ensure an orderly transition following the Spin-Off. The services that the Company and the Former Parent agreed to provide to each other under the Transition Services Agreement include certain finance, information technology, clinical study support, human resources and compensation, facilities, financial reporting and accounting and other services. The Company will pay the Former Parent, and the Former Parent will pay the Company, for any such services received by the Former Parent or the Company, as applicable, at agreed amounts as set forth in the Transition Services Agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">United States Distribution Services Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a United States Distribution Services Agreement with the Former Parent (the &#8220;Distribution Services Agreement&#8221;), pursuant to which the Company shall continue to serve as the Former Parent&#8217;s distributor and agent for the distribution of the pharmaceutical product Nurtec ODT in the United States for a limited period of time following the Spin-Off. Under the Distribution Services Agreement, the Former Parent and Pfizer Inc. have agreed to indemnify the Company for, among other things, losses resulting from the conduct of the distribution business or actions taken at the direction of the Former Parent.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outsourcing &#38; Employee Transfer Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into Outsourcing &#38; Employee Transfer Agreements, one with Pfizer Inc., Bulldog (BVI) Ltd., the Former Parent and Biohaven Pharmaceuticals, Inc. (&#8220;U.S. Employer&#8221;), and the other with Pfizer Inc., Bulldog (BVI) Ltd., Former Parent, and BioShin (Shanghai) Consulting Services Co., Ltd. (&#8220;Chinese Employer&#8221;), pursuant to which the Chinese Employer and the U.S. Employer will, among other things, provide Pfizer Inc. with the services of, and remain the employers of, certain of their employees for a limited period of time following the Spin-Off. During such period, Pfizer Inc. or one of its affiliates will pay the U.S. Employer for employee-related expenses for its employees (including the cost of salary and wages) and will pay the Chinese Employer a service fee based on employee-related expenses for its employees (including the cost of salary and wages).</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended Memorandum and Articles of Association contain certain provisions limiting the liability of directors and providing that we will indemnify each of our directors to the fullest extent permitted under the BVI Act. Our Amended Memorandum and Articles of Association also provide our Board with discretion to indemnify our officers and employees when determined appropriate by the Board.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have entered into indemnification agreements with each of our directors and executive officers. For more information regarding these agreements, see &#8220;Indemnification of Directors and Officers.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_70"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL SHAREHOLDERS</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the beneficial ownership of our common shares that are owned as of October&#160;14, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common shares&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our named executive officers&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our directors&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all of our current executive officers and directors as a group.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise noted below, the address for persons listed in the table is c&#47;o Biohaven Ltd., 215 Church Street, New Haven, CT 06510.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Address of Beneficial Owner</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Beneficially Owned</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage of Shares Beneficially Owned</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Shareholders&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BlackRock, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,317,640&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Named Executive Officers and Directors&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vlad Coric, M.D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708,029&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Buten</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,796&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimberly Gentile</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,969&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruce Car</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael T. Heffernan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,428&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory H. Bailey, M.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(8)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339,221&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Hugin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,209&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John W. Childs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(10)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827,501&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Julia P. Gregory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,392&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kishan Mehta</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(12)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,912&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Irina Antonijevic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(13)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,785&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All current directors and executive officers as a group (11 persons)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,445,242&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The amounts shown and the following information were provided by BlackRock, Inc. (&#34;BlackRock&#34;) pursuant to a Schedule G filed with the SEC on February 3, 2022 in respect of BlackRock&#8217;s ownership of Former Parent common shares. BlackRock reported that it had sole voting power and sole dispositive power over 4,635,280 Former Parent common shares. The principal business address of BlackRock, Inc. is 55 East 52nd Street, New York, NY 10055.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 569,309 common shares held directly, (ii) 9,565 common shares held by 401(k) plan, (iii) 492,212 common shares held by The Vladimir Coric Family Trust, (iv) 399,443 common shares held by The Vladimir Coric Marital Trust (Elizabeth Ann Coric, Dr. Coric's spouse, serves as the sole trustee of both of the aforementioned trusts) and (v) 237,500 common shares underlying stock options that are vested and exercisable within 60 days of October&#160;14, 2022. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Number of shares beneficially owned does not reflect shares that such person may acquire in connection with this offering. Vlad Coric, our Chief Executive Officer, Matthew Buten, our Chief Financial Officer, and certain of our directors and their affiliated entities have indicated an interest in purchasing approximately $100 million, in the aggregate, of our common shares in this offering at the public offering price. Dr. Coric and Mr. Buten have indicated an interest in purchasing approximately $10 million and $1 million of our common shares, respectively. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no shares to each of Dr. Coric, Mr. Buten or our directors and their affiliated entities, and any of such persons or their affiliated entities could determine to purchase more, fewer or no shares in this offering.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 23,796 common shares held directly and (ii) 75,000 common shares underlying stock options that are vested and exercisable within 60 days of October&#160;14, 2022. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 95,969 common shares held directly and (ii) 75,000 common shares underlying stock options that are vested and exercisable within 60 days of October&#160;14, 2022.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 75,000 common shares underlying stock options that are vested and exercisable within 60 days of October&#160;14, 2022.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 15,178 common shares held directly and (ii) 31,250 common shares underlying stock options that are vested and exercisable within 60 days of October&#160;14, 2022.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 1,307,971 common shares held directly and (ii) 31,250 common shares underlying stock options that are vested and exercisable within 60 days of October&#160;14, 2022. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 12,959 common shares held directly and (ii) 31,250 common shares underlying stock options that are vested and exercisable within 60 days of October&#160;14, 2022.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of (i) 1,791,251 common shares held directly, (ii) 5,000 common shares held by the John W Childs 2013 Revocable Trust,  and (iii) 31,250 common shares underlying stock options that are vested and exercisable within 60 days of October&#160;14, 2022. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of (i) 16,142 common shares held directly and (ii) 31,250 common shares underlying stock options that are vested and exercisable within 60 days of October&#160;14, 2022.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of (i) 22,662 common shares held directly and (ii) 31,250 common shares underlying stock options that are vested and exercisable within 60 days of October&#160;14, 2022. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of (i) 2,535 common shares held directly and (ii) 31,250 common shares underlying stock options that are vested and exercisable within 60 days of October&#160;14, 2022.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_73"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF SHARES</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following descriptions are summaries of the material terms of our Amended Memorandum and Articles of Association. Reference is made to the more detailed provisions of, and the descriptions are qualified in their entirety by reference to, the Amended Memorandum and Articles of Association. Please note that this summary is not intended to be exhaustive. For further information, please refer to the full version of our Amended Memorandum and Articles of Association which is included as an exhibit to the registration statement of which this prospectus is part.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a BVI business company limited by shares incorporated in the BVI on May&#160;2, 2022, and our affairs are governed by the provisions of an Amended Memorandum and Articles of Association and by the BVI Business Companies Act 2004 (as revised) (as amended or modified from time to time, the &#8220;BVI Act&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As provided in our Amended Memorandum and Articles of Association, subject to the BVI Act, we have full capacity to carry on or undertake any business or activity, do any act or enter into any transaction, and, for such purposes, full rights, powers and privileges. Our registered office is c&#47;o Maples Corporate Services (BVI) Limited, P.O. Box 173, Road Town, Tortola, British Virgin Islands.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized Shares</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended Memorandum and Articles of Association authorize us to issue up to 200,000,000 common shares, no par value, and up to 10,000,000 preferred shares, no par value (each, the &#8220;Preferred Share&#8221;). Our Board may establish the rights and preferences of the Preferred Shares from time to time. As of October 14, 2022, we had 39,375,944 common shares issued and outstanding and no Preferred Shares issued. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are summaries of material provisions of our Amended Memorandum and Articles of Association and the BVI Act insofar as they relate to the material terms of our common shares.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Shares</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The maximum number of shares we are authorized to issue are 210,000,000 divided into 200,000,000 common shares, with no par value each and 10,000,000 Preferred Shares. Holders of common shares have the same rights. All of our outstanding common shares are fully paid and non-assessable. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended Memorandum and Articles of Association do not provide for pre-emptive rights.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The holders of our common shares are entitled to an equal share of such dividends, as may be declared by our Board subject to the BVI Act. Our Amended Memorandum and Articles of Association provide that dividends may be declared and paid at such time, and in such an amount, as the directors determine subject to their being satisfied that the Company will meet the statutory solvency test immediately after the dividend.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In respect of all matters subject to a shareholders&#8217; vote, each common share is entitled to one vote for each common share registered in his or her name on our register of shareholders. Holders of common shares shall at all times vote together on all resolutions submitted to a vote of the shareholders. Voting at any meeting of shareholders is by show of hands unless a poll is demanded. A poll may be demanded by the chairperson of such meeting or any one shareholder.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A quorum required for a meeting of shareholders consists of at least 50% of the votes of the shares entitled to vote present in person or by proxy at the meeting or, if a corporation or other non-natural person, by its duly authorized representative. Shareholders&#8217; meetings may be held annually. Each general meeting, other than an annual general meeting, shall be an extraordinary general meeting. Directors may call general meetings, and they shall on a shareholders&#8217; requisition forthwith proceed to convene an extraordinary general meeting of the Company.  Extraordinary general meetings of the shareholders of the Company may be called, for any purpose as is a proper matter for shareholder action under applicable BVI law, by (i) the Chairperson of the Board, (ii) the Chief Executive Officer, (iii) the Directors pursuant to a resolution of directors or (iv) by shareholders holding not less than 10% of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the votes of the outstanding voting shares entitled to vote at the meeting. The Directors shall determine the time and place, if any, of such general meeting. Advance notice of at least 10 days is required for the convening of our annual general meeting and other general meetings unless such notice is waived in accordance with our Amended Memorandum and Articles of Association.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Appointment and Removal of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In accordance with our Amended Memorandum and Articles of Association, any director may be appointed by resolution of shareholders and may be removed, with cause, by the affirmative vote of at least sixty-six and two-thirds percent (66 2&#47;3%) of the votes of the common shares entitled to vote. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfer of Common Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the BVI Act shares that are listed on a recognized exchange may be transferred without the need for a written instrument of transfer if the transfer is carried out in accordance with the laws, rules, procedures and other requirements applicable to shares listed on the recognized exchange and subject to the Company&#8217;s Amended Memorandum and Articles of Association. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Amended Memorandum and Articles of Association, our Board may refuse or delay the registration of a transfer of shares where it reasonably determines that it is in the best interest of the Company to do so. Without limiting the generality of the foregoing, our Board may refuse or delay the registration of a transfer of shares if the transferor has failed to pay an amount due in respect of those shares. Where our Board passes a resolution to refuse or delay the registration of a transfer, the Company shall, as soon as practicable, send the transferor and the transferee a notice of the refusal or delay.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On a liquidation or winding up of the Company assets available for distribution among the holders of common shares shall be distributed among the holders of the common shares on a pro rata basis. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Calls on Common Shares and Forfeiture of Common Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our Board may from time to time make calls upon shareholders for any amounts unpaid on their common shares in a notice served to such shareholders at least 14 clear days prior to the specified time of payment. The common shares that have been called upon and remain unpaid are subject to forfeiture. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redemption of Common Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The BVI Act and our Amended Memorandum and Articles of Association permit us to purchase our own shares with the prior written consent of the relevant shareholders, on such terms and in such manner as may be determined by our Board and by a resolution of directors and in accordance with the BVI Act.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variation of Rights of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other than with respect to the issuance of the Preferred Shares in accordance with our Amended Memorandum and Articles of Association, all or any of the rights attached to any class or series of shares may, subject to the provisions of the BVI Act, be varied with the consent in writing of all the holders of the issued shares of that class or series or with the sanction of a resolution passed by a majority of the votes cast at a separate meeting of the holders of the shares of that class or series. The rights conferred upon the holders of the shares of any class issued shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issuance of further shares ranking pari passu with or superior to such existing class of shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuance of Additional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our Amended Memorandum of Association authorizes our Board to issue additional common shares from time to time as our Board shall determine. However, under British Virgin Islands law, our directors may only exercise the rights and powers granted to them under our Amended Memorandum and Articles of Association for a proper purpose and for what they believe in good faith to be in the best interests of our Company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inspection of Books and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A shareholder of the Company is entitled, on giving written notice to the Company, to inspect (a) the memorandum and articles of association of the Company&#59; (b) the register of shareholders&#59; (c) the register of directors&#59; and (d) the minutes of meetings and resolutions of shareholders and of those classes of shareholders of which he is a shareholder&#59; and to make copies of or take extracts from the documents and records. Subject to the Amended Memorandum and Articles of Association, the directors may, if they are satisfied that it would be contrary to the Company&#8217;s interests to allow a shareholder to inspect any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">document, or part of a document, specified in (b), (c) and (d) above, refuse to permit the shareholder to inspect the document or limit the inspection of the document, including limiting the making of copies or the taking of extracts from the records.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where a company fails or refuses to permit a shareholder to inspect a document or permits a shareholder to inspect a document subject to limitations, that shareholder may apply to the BVI High Court for an order that he should be permitted to inspect the document or to inspect the document without limitation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company is required to keep at the office of its registered agent&#58; its memorandum and articles of association of the company&#59; the register of shareholders or a copy of the register of shareholders&#59; the register of directors or a copy of the register of directors&#59; and copies of all notices and other documents filed by the company in the previous ten years.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Shares</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended Memorandum and Articles of Association provide that preferred shares may be issued from time to time in one or more series. Our Board is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. Our Board is able to, without shareholder approval, issue preferred shares with voting and other rights that could adversely affect the voting power and other rights of the holders of the common shares and could have anti-takeover effects. The ability of our Board to issue preferred shares without shareholder approval could have the effect of delaying, deferring or preventing a change of control of us or the removal of existing management. We have no preferred shares issued and outstanding at the date hereof. Although we do not currently intend to issue any preferred shares, we cannot assure you that we will not do so in the future.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on the Right to Own Shares</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no limitations on the right to own our common shares.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure of Shareholder Ownership</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no provisions in the Amended Memorandum and Articles of Association governing the ownership threshold above which shareholder ownership must be disclosed.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Differences in Corporate Law</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BVI Act, and the other laws of the British Virgin Islands, or the BVI, affecting BVI business companies like us and our shareholders differ from laws applicable to U.S. Delaware corporations and their stockholders. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-Takeover Provisions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some provisions of our Amended Memorandum and Articles of Association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisions that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified Board such that not all shareholders of the Board are elected at one time&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of our Board&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the manner in which shareholders can remove directors from the Board&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for shareholder proposals that can be acted on at shareholder meetings and nominations to our Board&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that shareholder actions must be effected at a duly called shareholder meeting and prohibit actions by our shareholders by written consent&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">162</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the ability of shareholders to requisition and convene general meetings of shareholders&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our Board to issue preferred shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preference shares without any further vote or action by our shareholders without shareholder approval, which could be used to institute a shareholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, under British Virgin Islands law, our directors may only exercise the rights and powers granted to them under our Amended Memorandum and Articles of Association for a proper purpose and for what they believe in good faith to be in the best interests of our Company.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs of Claim</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Amended Memorandum and Articles of Association, in the event that (i) any Member or prior Member (&#8220;Claiming Party&#8221;) initiates or asserts any claim or counterclaim (&#8220;Claim&#8221;) or joins, offers substantial assistance to or has a direct financial interest in any Claim against the Company or its subsidiaries, directors or Members (including any Claim purportedly filed on behalf of the Company or any Member), and (ii) the Claiming Party (or the third party that received substantial assistance from the Claiming Party or in whose Claim the Claiming Party had a direct financial interest) does not obtain a judgment on the merits that substantially achieves, in substance and amount, the full remedy sought, then each Claiming Party shall be obligated, jointly and severally, to reimburse the Company and any such Member or Members for all fees, costs and expenses of every kind and description (including, but not limited to, all reasonable attorneys&#8217; fees and other litigation expenses) that the parties may incur in connection with such Claim. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BVI Corporate Law</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BVI Act, and the other laws of the British Virgin Islands, or the BVI, affecting BVI business companies like us and our shareholders differ from laws applicable to U.S. Delaware corporations and their stockholders.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mergers and Similar Arrangements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BVI Act two or more BVI companies or a BVI company and non-BVI company, each a &#8220;constituent company&#8221;, may merge or consolidate. The BVI Act provides for slightly different procedures depending on the nature of the parties to the merger. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A merger involves the merging of two or more companies into one of the constituent companies (to the merger) with one constituent company continuing in existence to become the surviving company post-merger. A consolidation involves two or more companies consolidating into a new company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A merger is effective on the date that the articles of merger (as described below) are registered by the Registrar of Corporate Affairs in the BVI, or on such later date, not exceeding 30 days from the date of registration as is stated in the articles of merger.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As soon as a merger becomes effective&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">the surviving company (so far as is consistent with its memorandum and articles, as amended by the articles of merger) has all rights, privileges, immunities, powers, objects and purposes of each of the constituent companies&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the memorandum and articles of the surviving company are automatically amended to the extent, if any, that changes to its memorandum and articles are contained in the articles of merger&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">assets of every description, including choses in action and the business of each of the constituent companies, immediately vest in the surviving company&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the surviving company is liable for all claims, debts, liabilities and obligations of each of the constituent companies&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">no conviction, judgment, ruling, order, claim, debt, liability or obligation due or to become due, and no cause existing, against a constituent company or against any shareholder, director, officer or agent thereof, is released or impaired by the merger&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt">no proceedings, whether civil or criminal, pending at the time of a merger by or against a constituent company, or against any shareholder, director or officer, or agent thereof, are abated or discontinued by the merger&#59; but</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">the proceedings may be enforced, prosecuted, settled or compromised by or against the surviving company or against the shareholder, director, officer or agent thereof, as the case may be&#59; or</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the surviving company may be substituted in the proceedings for a constituent company. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrar shall strike off the Register of Companies a constituent company that is not the surviving company in the merger. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BVI Act provides that any shareholder of the Company is entitled to payment of the fair value of his shares upon dissenting from a merger, unless the Company is the surviving company of the merger and the shareholder continues to hold the same or similar shares. The following is a summary of the position in respect of dissenters&#8217; rights in the event of a merger under the BVI Act.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A dissenter is in most circumstances required to give to the Company written objection to the merger, which must include a statement that the dissenter proposes to demand payment for his shares if the merger takes place. This written objection must be given before the meeting of shareholders at which the merger is submitted to a vote, or at the meeting but before the vote. However, no objection is required from a shareholder to whom the Company did not give notice of the meeting of shareholders or where the proposed merger is authorized by written consent of the shareholders without a meeting.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 20 days immediately following the written consent, or the meeting at which the merger was approved, the Company shall give written notice of the consent or resolution to each shareholder who gave written objection or from whom written objection was not required, except those shareholders who voted for, or consented in writing to, the proposed merger.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shareholder to whom the Company was required to give notice who elects to dissent shall, within 20 days immediately following the date on which the copy of the plan of merger or an outline of the merger is given to him, give to the Company a written notice of his decision to elect to dissent, stating&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">his name and address&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the number and classes of shares in respect of which he dissents (which must be all shares that he holds in the Company)&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">a demand for payment of the fair value of his shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the giving of a notice of election to dissent, the dissenter ceases to have any of the rights of a shareholder except the right to be paid the fair value of his shares, and the right to institute proceedings to obtain relief on the ground that the action is illegal.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company shall make a written offer to each dissenter to purchase his shares at a specified price that the Company determines to be their fair value. Such offer must be given within 7 days immediately following the date of the expiration of the period within which shareholders may give their notices of election to dissent, or within 7 days immediately following the date on which the merger is put into effect, whichever is later.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company and the dissenter fail, within 30 days immediately following the date on which the offer is made, to agree on the price to be paid for the shares owned by the dissenter, then within 20 days&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">the Company and the dissenter shall each designate an appraiser&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the two designated appraisers together shall designate an appraiser&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">the three appraisers shall fix the fair value of the shares owned by the dissenter as of the close of business on the day prior to the date of the meeting or the date on which the resolution was passed, excluding any appreciation or depreciation directly or indirectly induced by the action or its proposal, and that value is binding on the Company and the dissenter for all purposes&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Company shall pay to the dissenter the amount in money upon the surrender by him of the certificates representing his shares, and such shares shall be cancelled.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholders&#8217; Suits</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of the BVI Act, the memorandum and articles of association of a company are binding as between the company and its shareholders and between the shareholders. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the majority shareholders have infringed a minority shareholder&#8217;s rights, the minority may seek to enforce its rights either by derivative action or by personal action. A derivative action concerns the infringement of the company&#8217;s rights where the wrongdoers are in control of the company and are preventing it from taking action, whereas a personal action concerns the infringement of a right that is personal to the particular shareholder concerned.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BVI Act provides for a series of remedies available to shareholders. Where a company incorporated under the BVI Act conducts some activity which breaches the BVI Act or the company&#8217;s memorandum and articles of association, the BVI High Court can issue a restraining or compliance order. Shareholders can now also bring derivative, personal and representative actions under certain circumstances.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally any other claims against a company by its shareholders must be based on the general laws of contract or tort applicable in the BVI or their individual rights as shareholders as established by the company&#8217;s memorandum and articles of association.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, a shareholder has the right to seek various remedies against the company in the event the directors are in breach of their duties under the BVI Act. Pursuant to Section 184B of the BVI Act, if a company or director of a company engages in, proposes to engage in or has engaged in, conduct that contravenes the provisions of the BVI Act or the memorandum or articles of association of the company, the courts of the British Virgin Islands may, on application of a shareholder or director of the company, make an order directing the company or director to comply with, or restraining the company or director from engaging in conduct that contravenes the BVI Act or the memorandum or articles. Furthermore, pursuant to Section 184I(1) of the BVI Act, a shareholder of a company who considers that the affairs of the company have been, are being or likely to be, conducted in a manner that is, or any acts of the company have been, or are likely to be oppressive, unfairly discriminatory, or unfairly prejudicial to him in that capacity, may apply to the courts of the British Virgin Islands for an order which, inter alia, can require the company or any other person to pay compensation to the shareholders.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of BVI Corporate Law and Delaware U.S. Corporate Law</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is a summary of the significant differences between the provisions of the laws of the BVI applicable to us and the laws applicable to companies incorporated in Delaware in the United States and their stockholders.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder Proposals</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meeting may be called by the Board or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings. Our Amended Memorandum and Articles of Association allow our shareholders holding not less than 10% of the votes of the outstanding voting shares to requisition a shareholders&#8217; meeting. We are not obliged by law to call shareholders&#8217; annual general meetings, but our Amended Memorandum and Articles of Association permit the directors to call shareholders&#8217; annual general meetings, and we expect to do so in the future. The location of any shareholders&#8217; meeting can be determined by the Board and can be held anywhere in the world.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumulative Voting</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no prohibitions in relation to cumulative voting under the laws of the British Virgin Islands but our Amended Memorandum and Articles of Association do not provide for cumulative voting. As a result, our shareholders are not afforded any less protections or rights on this issue than shareholders of a Delaware corporation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder Action by Written Consent</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although British Virgin Islands law provides that companies may permit shareholder actions by written consent, our Amended Memorandum and Articles of Association provide that shareholders may not approve corporate matters by way of a written resolution.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment of Memorandum and Articles of Association</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Delaware General Corporation Law, a corporation&#8217;s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. As permitted by British Virgin Islands law, our Amended Memorandum and Articles of Association may be amended with a resolution of our shareholders or, with certain exception by resolutions of directors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Removal of Directors</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Delaware General Corporation Law, a director of a corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our Amended Memorandum and Articles of Association, directors can be removed from office, with cause, by a resolution of shareholders passed at a meeting called for the purpose of removing the director or for purposes including the removal of the director by the affirmative vote of at least sixty-six and two-thirds percent (66 2&#47;3%) of the votes of the common shares entitled to vote.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transactions with Interested Shareholders</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware General Corporation Law contains a business combination statute applicable to Delaware public corporations whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation, it is prohibited from engaging in certain business combinations with an &#8220;interested shareholder&#8221; for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or group who or which owns or owned 15% or more of the target&#8217;s outstanding voting shares within the past three years. This has the effect of limiting the ability of a potential acquirer to make a two&#8209;tiered bid for the target in which all shareholders would not be treated equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in the person becoming an interested shareholder. This encourages any potential acquirer of a Delaware public corporation to negotiate the terms of any acquisition transaction with the target&#8217;s board of directors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">British Virgin Islands law has no comparable statute. As a result, we are not afforded the same statutory protections in the British Virgin Islands as we would be offered by the Delaware business combination statute. However, although British Virgin Islands law does not regulate transactions between a company and its significant shareholders, it does provide that such transactions must be entered into bona fide in the best interests of the company and not with the effect of constituting a fraud on the minority shareholders. See also &#8220;Shareholders&#8217; Suits&#8221; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above. We have adopted a code of business conduct and ethics which requires employees to fully disclose any situations that could reasonably be expected to give rise to a conflict of interest, and sets forth relevant restrictions and procedures when a conflict of interest arises to ensure the best interest of the Company. Our Amended Memorandum and Articles of Association also import the provisions of the Delaware General Corporation Law which prohibits the Company from engaging in certain business combinations with an &#8220;interested shareholder&#8221; for three years following the date that such person becomes an interested shareholder unless (i) prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in the person becoming an interested shareholder, (ii) upon consummation of the transaction which resulted in the shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of the votes of shares in the Company outstanding at the time the transaction commenced or (iii) at or subsequent to such time the business combination is approved by the Board and authorized at an annual or extraordinary general meeting of shareholders, and not by written consent, by the affirmative vote of at least 66 2&#47;3% of the votes of shares not owned by the interested shareholder.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors&#8217; Fiduciary Duties</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components&#58; the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, a director must prove the procedural fairness of the transaction and that the transaction was of fair value to the corporation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under British Virgin Islands law, the directors owe fiduciary duties at both common law and under statute, including a statutory duty to act honestly, in good faith and with a view to our best interests. When exercising powers or performing duties as a director, the director is required to exercise the care, diligence and skill that a reasonable director would exercise in the circumstances taking into account, without limitation, the nature of the company, the nature of the decision and the position of the director and the nature of the responsibilities undertaken by him. In exercising the powers of a director, the directors must exercise their powers for a proper purpose and shall not act or agree to the company acting in a manner that contravenes our memorandum and articles of association or the BVI Act.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification of Directors and Executive Officers and Limitation of Liability</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BVI law does not limit the extent to which a company&#8217;s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the BVI High Court to be contrary to public policy (e.g., for purporting to provide indemnification against the consequences of committing a crime). An indemnity will be void and of no effect and will not apply to a person unless the person acted honestly and in good faith and in what he believed to be in the best interests of the company and, in the case of criminal proceedings, the person had no reasonable cause to believe that his conduct was unlawful. Our Amended Memorandum and Articles of Association permit indemnification of officers and directors for losses, damages, costs and expenses incurred in their capacities as such unless such losses or damages arise from dishonesty or fraud of such directors or officers. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation. In addition, we have entered into indemnification agreements with our directors and executive officers that provide such persons with additional indemnification beyond that provided in our Amended Memorandum and Articles of Association.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variation of Rights of Shares</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than with respect to the issuance of the Preferred Shares in accordance with our Amended Memorandum and Articles of Association, all or any of the rights attached to any class or series of shares may, subject to the provisions of the BVI Act, be varied with the consent in writing of all the holders of the issued shares of that class or series or with the sanction of a resolution passed by a majority of the votes cast at a separate meeting of the holders of the shares of that class or series. The rights conferred upon the holders of the shares of any class issued shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking pari passu with or superior to such existing class of shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dissolution&#59; Winding-Up</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&#8217;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board. Under BVI law, the liquidation of a company may be a voluntary solvent liquidation or an insolvent liquidation under the BVI Insolvency Act. Where a company has been struck off the Register of Companies under the BVI Act continuously for a period of 7 years it is dissolved with effect from the last day of that period.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voluntary Liquidation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the liquidation is a solvent liquidation, the provisions of the BVI Act governs the liquidation. A company may only be liquidated under the BVI Act as a solvent liquidation if it has no liabilities or it is able to pay its debts as they fall due and the value of its assets exceeds its liabilities. Subject to the Amended Memorandum and Articles of Association, a liquidator may be appointed by a resolution of directors or resolution of shareholders but if the directors have commenced liquidation by a resolution of directors the shareholders must approve the liquidation plan by a resolution of shareholders save in limited circumstances.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A liquidator is appointed for the purpose of collecting in and realizing the assets of a company and distributing proceeds to creditors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that in the event of a voluntary liquidation of the Company, after payment of the liquidation costs and any sums then due to creditors, the liquidator would distribute our remaining assets on a pari passu basis.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rights of Non-resident or Foreign Shareholders</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no limitations imposed by our Amended Memorandum and Articles of Association on the rights of non-resident or foreign shareholders to hold or exercise voting rights on our shares. In addition, there are no provisions in our Amended Memorandum and Articles of Association governing the ownership threshold above which shareholder ownership must be disclosed.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Money Laundering</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any person resident in the British Virgin Islands knows or suspects that another person is engaged in money laundering or terrorist financing and the information for that knowledge or suspicion came to their attention in the course of their business the person will be required to report his belief or suspicion to the Financial Investigation of the British Virgin Islands, pursuant to the Proceeds of Criminal Conduct Act (as revised). Such a report shall not be treated as a breach of confidence or of any restriction upon the disclosure of information imposed by any enactment or otherwise.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NYSE Listing</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares are listed on NYSE under the trading symbol &#8220;BHVN.&#8221;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer Agent and Registrar</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transfer agent and registrar for our common shares is American Stock Transfer &#38; Trust Company, LLC. The transfer agent&#8217;s address is 6201 15th Avenue, Brooklyn, NY 11219.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_76"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHARES ELIGIBLE FOR FUTURE SALE</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales or the availability for sale of substantial amounts of our common shares in the public market could adversely affect the prevailing market price for such shares. As of October 3, 2022, we had outstanding an aggregate of&#160;approximately 35.5&#160;million common shares, assuming no exercise of outstanding options. All of the common shares are freely tradable without restriction or further registration under the Securities Act unless the shares are owned by our &#8220;affiliates&#8221; as that term is defined in the rules under the Securities Act. Shares held by &#8220;affiliates&#8221; may be sold in the public market only if registered or if they qualify for an exemption from registration or in compliance with Rule&#160;144 under the Securities Act (&#8220;Rule 144&#8221;) which is summarized below.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule&#160;144</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under Rule&#160;144, as currently in effect, once we have been subject to the public company reporting requirements of the Exchange Act, for at least 90 days, a person (or persons whose shares are required to be aggregated) who is not deemed to have been one of our &#8220;affiliates&#8221; for purposes of Rule&#160;144 at any time during the three months preceding a sale, and who has beneficially owned restricted securities within the meaning of Rule&#160;144 for at least six months, including the holding period of any prior owner other than one of our &#8220;affiliates,&#8221; is entitled to sell those shares in the public market (subject to the lock-up agreement referred to above, if applicable) without complying with the manner of sale, volume limitations or notice provisions of Rule&#160;144, but subject to compliance with the public information requirements of Rule&#160;144. If such a person has beneficially owned the sales proposed to be sold for at least one year, including the holding period of any prior owner other than &#8220;affiliates,&#8221; then such person is entitled to sell such shares in the public market without complying with any of the requirements of Rule&#160;144 (subject to the lock-up agreement referred to above, if applicable). In general, under Rule&#160;144, as currently in effect, once we have been subject to the public company reporting requirements of the Exchange Act for at least 90 days, our &#8220;affiliates,&#8221; as defined in Rule&#160;144, who have beneficially owned the shares proposed to be sold for at least six months are entitled to sell in the public market, within any three-month period, a number of our common shares that does not exceed the greater of&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one percent (1%) of the number of common shares then outstanding, which will equal approximately 393,759 common shares (calculated on the basis of the number of common shares outstanding as of October&#160;14, 2022, the assumptions described above and no exercise of outstanding options)&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the average weekly trading volume of our common shares on the New York Stock Exchange during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such sales under Rule&#160;144 by our &#8220;affiliates&#8221; or persons selling shares on behalf of our &#8220;affiliates&#8221; are also subject to certain manner of sale provisions, notice requirements and to the availability of current public information about us. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_79"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section describes the material U.S. federal income tax consequences of the ownership of our common shares. This section applies solely to holders that acquire our common shares pursuant to this offering and that will hold such common shares as capital assets for tax purposes. This section addresses only United States federal income taxation and does not discuss all of the tax consequences that may be relevant to a holder in light of such holder&#8217;s individual circumstances, including non-U.S., state or local tax consequences, estate and gift tax consequences, and tax consequences arising under the Medicare contribution tax on net investment income or the alternative minimum tax. This section does not apply to holders subject to special rules, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a dealer in securities or foreign currencies&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulated investment company&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a trader in securities that elects to use a mark-to-market method of accounting for securities holdings&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a tax-exempt organization&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a bank, financial institution, or insurance company&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a person that directly, indirectly or constructively owns 5% or more of the combined voting power of our common shares, or of the total value of our common shares&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a person that holds our common shares as part of a straddle or a hedging, conversion, or other risk reduction transaction for U.S. federal income tax purposes&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a person that acquires or sells our common shares as a part of wash sale for U.S. federal income tax purposes&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a person that acquired our common shares pursuant to the exercise of employee share options or otherwise as compensation&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a person whose functional currency is not the U.S. dollar&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investors in this offering who are existing shareholders of our company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this discussion, a &#8220;U.S. holder&#8221; is a beneficial owner of our common shares that is, for U.S. federal income tax purposes&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an individual that is a citizen or resident of the United States&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a corporation, or other entity taxable as a corporation, created or organized under the laws of the United States&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an estate whose income is subject to U.S. federal income tax regardless of its source&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a trust if a U.S. court can exercise primary supervision over the trust&#8217;s administration and one or more persons are authorized to control all substantial decisions of the trust.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section is based on the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), its legislative history, existing and proposed regulations, published rulings and court decisions, as well as on applicable tax treaties, all as currently in effect. These authorities are subject to change, possibly on a retroactive basis.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion is intended to provide only a general summary of the material U.S. federal income tax consequences of owning our common shares. We do not intend it to be a complete analysis or description of all potential U.S. federal income tax consequences of owning our common shares. The U.S. federal income tax laws are complex and subject to varying interpretations. Accordingly, the Internal Revenue Service (&#8220;IRS&#8221;) may not agree with the tax consequences described in this Registration Statement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not sought, and do not intend to seek, any ruling from the IRS with respect to the statements made and the conclusions reached in the following summary, and no assurance can be given that the IRS will agree with the views expressed herein, or that a court will not sustain any challenge by the IRS in the event of litigation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds our common shares, the U.S. federal income tax treatment of a partner will generally depend on the status of the partner and the tax treatment of the partnership. A partner in an entity or arrangement treated as a partnership for U.S. federal income tax purposes holding shares should consult its tax advisors with regard to the U.S. federal income tax treatment of our common shares.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Holders</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax treatment of our common shares will depend in part on whether or not we are classified as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes.  Except as discussed below under &#8220;&#8212;PFIC Considerations,&#8221; this discussion assumes that we are not classified as a PFIC for U.S. federal income tax purposes.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxation of Dividends</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. federal income tax laws, the gross amount of any distribution we pay out of our current or accumulated earnings and profits (as determined for U.S. federal income tax purposes), other than certain pro-rata distributions of our shares, will be treated as a dividend that is subject to U.S. federal income taxation.  For a noncorporate U.S. holder, dividends that constitute qualified dividend income will be taxable to the holder at the preferential rates applicable to long-term capital gains, provided that the holder holds the shares for more than 60 days during the 121-day period beginning 60 days before the ex-dividend date and meets other holding period requirements.  For this purpose, our common shares are treated as stock of a &#8220;qualified foreign corporation&#8221; if our common shares are readily tradable on an established securities market in the United States. Our common shares are listed on the NYSE, which is treated as an established securities market in the United States for these purposes, in which case dividends that we pay with respect to its common shares would generally constitute qualified dividend income, assuming the holding period requirements are met. However, we can give no assurances in this regard.    </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. holder must include any foreign tax withheld, if any, from the dividend payment in this gross amount even though the holder does not in fact receive it.  The dividend is taxable to a U.S. holder when the holder receives the dividend, actually or constructively.  The dividend will not be eligible for the dividends-received deduction generally allowed to United States corporations in respect of dividends received from other United States corporations.  Distributions in excess of current and accumulated earnings and profits, as determined for U.S. federal income tax purposes, will be treated as a non-taxable return of capital to the extent of the holder&#8217;s basis in the shares and thereafter as capital gain.  We do not currently expect to calculate earnings and profits in accordance with U.S. federal income tax principles.  Accordingly, a U.S. holder should expect to generally treat distributions that we make as dividends.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain limitations and the following sentence, the foreign tax withheld, if any, and paid over to foreign countries will be creditable or deductible against a U.S. holder&#8217;s U.S. federal income tax liability.  However, under recently finalized Treasury regulations, it is possible that taxes may not be creditable. Special rules apply in determining the foreign tax credit limitation with respect to dividends that are subject to the preferential tax rates.  To the extent a reduction or refund of the tax withheld is available to the holder under foreign law, the amount of tax withheld that could have been reduced or that is refundable will not be eligible for credit against the holder&#8217;s U.S. federal income tax liability.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends will generally be income from sources outside the United States and will generally be &#8220;passive&#8221; income for purposes of computing the foreign tax credit allowable to a U.S holder. However, if (a) we are 50% or more owned, by vote or value, by United States persons and (b) at least 10% of our earnings and profits are attributable to sources within the United States, then for foreign tax credit purposes, a portion of our dividends would be treated as derived from sources within the United States.  With respect to any dividend paid for any taxable year, the United States source ratio of our dividends for foreign tax credit purposes would be equal to the portion of our earnings and profits from sources within the United States for such taxable year, divided by the total </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of our earnings and profits for such taxable year. There can be no assurance that no portion of our dividends will be treated as derived from sources within the United States pursuant to the rule described in this paragraph.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxation of Capital Gains.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a U.S. holder sells or otherwise disposes of our common shares, the holder will recognize capital gain or loss for U.S. federal income tax purposes equal to the difference between the U.S. dollar value of the amount that the holder realizes and the holder&#8217;s tax basis, determined in U.S. dollars, in the shares. Capital gain of a noncorporate U.S. holder is generally taxed at preferential rates where the property is held for more than one year. The gain or loss will generally be income or loss from sources within the United States for foreign tax credit limitation purposes. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PFIC Considerations.  </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our common shares should not currently be stock of a PFIC for U.S. federal income tax purposes and do not expect to become a PFIC in the foreseeable future. However, the determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies which in some circumstances are unclear and subject to varying interpretation. In particular, the determination of whether we are a PFIC and the characterization of our assets as active or passive may depend in part on (i) our current and intended future business plans which are subject to change, (ii) the application of certain &#8220;look-through&#8221; rules and (iii) the applicability of the &#8220;start-up exception.&#8221; Under the start-up exception, a foreign corporation that would otherwise be treated as a PFIC will not be a PFIC for the first taxable year the corporation has gross income (the &#8220;start-up year&#8221;), if&#58; (A) no predecessor of the corporation was a PFIC&#59; (B) the corporation satisfies the IRS that it will not be a PFIC for either of the first two taxable years following the start-up year&#59; and (C) the corporation is not in fact a PFIC for either of those years. The applicability of the startup exception to us is uncertain and will not be known until after the end of the two taxable years following such startup year. In addition, for our current and future taxable years, the total value of our assets for PFIC testing purposes may fluctuate considerably from time to time, and is dependent on the application (which inherently involves an element of judgment) of the relevant valuation assumptions and methodologies. Under the income test, our status as a PFIC depends on the composition of our income which, in our current and future taxable years, we may not be able to fully control, for example, with respect to income attributed to us from entities owned 25% or more by us. The composition of our income and assets is also affected by how, and how quickly, we spend the cash raised in this and any other offering. Therefore, we cannot provide any assurance regarding PFIC status for any past, current or future taxable years.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, we will be a PFIC with respect to a U.S. holder if for any taxable year in which the holder held our common shares&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at least 75% of our gross income for the taxable year is passive income&#59; or </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at least 50% of the value, determined on the basis of a quarterly average, of our assets is attributable to assets that produce or are held for the production of passive income. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Passive income&#8221; generally includes dividends, interest, gains from the sale or exchange of investment property rents and royalties (other than certain rents and royalties derived in the active conduct of a trade or business) and certain other specified categories of income. Other than with respect to stock of a domestic corporation that is 25%-owned (by value) by certain foreign corporations, if a foreign corporation owns at least 25% by value of the stock of another corporation, the foreign corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation, and as receiving directly its proportionate share of the other corporation&#8217;s income.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are or become a PFIC, and a U.S. holder did not make a mark-to-market election, as described below, the holder will generally be subject to special rules with respect to&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any gain the holder realizes on the sale or other disposition of the shares&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any excess distribution that we make to the holder (generally, any distributions to the holder during a single taxable year, other than the taxable year in which the holder&#8217;s holding period in the shares begins, that are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">greater than 125% of the average annual distributions received by the holder in respect of the shares during the three preceding taxable years or, if shorter, the holder&#8217;s holding period for the shares that preceded the taxable year in which the holder receives the distribution).  </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these rules&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the gain or excess distribution will be allocated ratably over the holder&#8217;s holding period for the shares&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount allocated to the taxable year in which the holder realized the gain or excess distribution or to prior years before the first year in which we were a PFIC with respect to the holder will be taxed as ordinary income&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount allocated to each other prior year will be taxed at the highest tax rate in effect for that year&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the interest charge generally applicable to underpayments of tax will be imposed in respect of the tax attributable to each such year. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special rules apply for calculating the amount of the foreign tax credit with respect to excess distributions by a PFIC. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are or become a PFIC in a taxable year and our common shares are treated as &#8220;marketable stock&#8221; in such year, a U.S. holder may make a mark-to-market election with respect to the shares.   If the U.S. holder makes this election, the holder will not be subject to the PFIC rules described above.   Instead, in general, the holder will include as ordinary income each year the excess, if any, of the fair market value of the shares at the end of the taxable year over the holder&#8217;s adjusted basis in the shares.  The holder will also be allowed to take an ordinary loss in respect of the excess, if any, of the adjusted basis of the shares over their fair market value at the end of the taxable year (but only to the extent of the net amount of previously included income as a result of the mark-to-market election).  The U.S. holder&#8217;s basis in the shares will be adjusted to reflect any such income or loss amounts.  Any gain that the holder recognizes on the sale or other disposition of the shares would be ordinary income and any loss would be an ordinary loss to the extent of the net amount of previously included income as a result of the mark-to-market election and, thereafter, a capital loss.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. holder&#8217;s shares will generally be treated as stock in a PFIC if we are or become a PFIC at any time during the holder&#8217;s holding period in the shares, even if we are not currently a PFIC.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, notwithstanding any election a U.S. holder makes with regard to the shares, dividends that the holder receives from us will not constitute qualified dividend income to the holder if we are a PFIC (or are treated as a PFIC with respect to the holder) either in the taxable year of the distribution or the preceding taxable year.   Dividends that the holder receives that do not constitute qualified dividend income are not eligible for taxation at the preferential rates applicable to qualified dividend income.  Instead, the holder must include the gross amount of any such dividend paid by us out of our accumulated earnings and profits (as determined for U.S. federal income tax purposes) in the holder&#8217;s gross income, and it will be subject to tax at rates applicable to ordinary income.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, a U.S. holder of shares in a PFIC may alleviate some of the adverse tax consequences described above by making a QEF election to include in income its pro rata share of the corporation&#8217;s income on a current basis. However, a U.S. holder may make a QEF election with respect to our common shares only if we agree to furnish such U.S. holder annually with a PFIC annual information statement as specified in the applicable U.S. Treasury Regulations. We currently do not intend to prepare or provide the information that would enable U.S. holders to make a QEF election if we are treated as a PFIC for any taxable year, and U.S. holders of our common shares should assume that a QEF election will not be available.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a U.S. holder owns shares during any year that we are a PFIC with respect to the holder, the holder may be required to file IRS Form 8621.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. holders should consult their tax advisors as to the application of the PFIC rules in the event that our common shares were treated as stock of a PFIC.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NO ASSURANCE CAN BE GIVEN REGARDING OUR PFIC STATUS FOR ANY CURRENT OR FUTURE TAXABLE YEARS. U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS WITH RESPECT TO THE OPERATION OF THE PFIC RULES AND RELATED REPORTING REQUIREMENTS IN LIGHT OF THEIR PARTICULAR CIRCUMSTANCES, INCLUDING THE ADVISABILITY OF MAKING ANY ELECTION THAT MAY BE AVAILABLE. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder Reporting.  </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. holder that owns &#8220;specified foreign financial assets&#8221; with an aggregate value in excess of $50,000 (and in some circumstances, a higher threshold) may be required to file an information report with respect to such assets with its tax return.  &#8220;Specified foreign financial assets&#8221; may include financial accounts maintained by foreign financial institutions, as well as the following, but only if they are held for investment and not held in accounts maintained by financial institutions&#58;  (i) stocks and securities issued by non-United States persons, (ii) financial instruments and contracts that have non-United States issuers or counterparties, and (iii) interests in foreign entities.  Significant penalties may apply for failing to satisfy this filing requirement.  U.S. holders are urged to contact their tax advisors regarding this filing requirement.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-U.S. Holders.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxation of Dividends</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid to a non-U.S. holder in respect of our common shares will not be subject to U.S. federal income tax unless the dividends are &#8220;effectively connected&#8221; with the holder&#8217;s conduct of a trade or business within the United States, and the dividends are attributable to a permanent establishment that the holder maintains in the United States if that is required by an applicable income tax treaty as a condition for subjecting the holder to United States taxation on a net income basis.   In such cases, the holder generally will be taxed in the same manner as a U.S. holder.  For a corporate non-U.S. holder, &#8220;effectively connected&#8221; dividends may, under certain circumstances, be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or at a lower rate if the holder is eligible for the benefits of an income tax treaty that provides for a lower rate. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxation of Capital Gains</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-U.S. holder will not be subject to U.S. federal income tax on gain recognized on the sale or other disposition of our common shares unless&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the gain is &#8220;effectively connected&#8221; with the holder&#8217;s conduct of a trade or business in the United States, and the gain is attributable to a permanent establishment that the holder maintains in the United States if that is required by an applicable income tax treaty as a condition for subjecting the holder to United States taxation on a net income basis&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the holder is an individual, is present in the United States for 183 or more days in the taxable year of the sale and certain other conditions exist.  </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a corporate non-U.S. holder, &#8220;effectively connected&#8221; gains that the holder recognizes may also, under certain circumstances, be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or at a lower rate if the holder is eligible for the benefits of an income tax treaty that provides for a lower rate. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Backup Withholding and Information Reporting.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a noncorporate U.S. holder, information reporting requirements, on IRS Form 1099, generally will apply to dividend payments or other taxable distributions made to the holder within the United States, and the payment of proceeds to the holder from the sale of our common shares effected at a United States office of a broker. Additionally, backup withholding may apply to such payments if the holder fails to comply with applicable certification requirements or (in the case of dividend payments) is notified by the IRS that the holder has failed to report all interest and dividends required to be shown on the holder&#8217;s federal income tax returns. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-U.S. holder is generally exempt from backup withholding and information reporting requirements with respect to dividend payments made to the holder outside the United States by us or another non-United States payor.   The non-U.S. holder is also generally exempt from backup withholding and information reporting requirements in respect of dividend payments made within the United States and the payment of the proceeds from the sale of shares effected at a United States office of a broker, as long as either (i) the non-U.S. holder has furnished a valid IRS Form W-8 or other documentation upon which the payor or broker may rely to treat the payments as made to a non-United States person, or (ii) the non-U.S. holder otherwise establishes an exemption. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of the proceeds from the sale of shares effected at a foreign office of a broker generally will not be subject to information reporting or backup withholding. However, a sale effected at a foreign office of a broker could be subject to information reporting in the same manner as a sale within the United States (and in certain cases may be subject to backup withholding as well) if (i) the broker has certain connections to the United States, (ii) the proceeds or confirmation are sent to the United States or (iii) the sale has certain other specified connections with the United States.  </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A person generally may obtain a refund of any amounts withheld under the backup withholding rules that exceed the person&#8217;s income tax liability by filing a refund claim with the IRS.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EACH HOLDER SHOULD CONSULT ITS TAX ADVISOR ABOUT THE PARTICULAR CONSEQUENCES OF OWNING OUR COMMON SHARES, INCLUDING THE APPLICATION OF STATE, LOCAL AND FOREIGN TAX LAWS, AND POSSIBLE CHANGES IN TAX LAW THAT MAY AFFECT THE TAX CONSEQUENCES DESCRIBED ABOVE.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_82"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDERWRITING</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are offering the common shares described in this prospectus through a number of underwriters.  J.P. Morgan Securities LLC is acting as book&#8209;running manager of the offering and as representative of the underwriters.  We have entered into an underwriting agreement with the underwriters.  Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of common shares listed next to its name in the following table&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J.P. Morgan Securities LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000,000</font></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters are committed to purchase all the common shares offered by us if they purchase any shares.  The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may also be increased or the offering may be terminated.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters propose to offer the common shares directly to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers at that price less a concession not in excess of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share.  After the initial offering of the shares to the public, if all of the common shares are not sold at the initial public offering price, the underwriters may change the offering price and the other selling terms.  Sales of any shares made outside of the United States may be made by affiliates of the underwriters.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters have an option to buy up to&#160;3,000,000&#160;additional common shares from us to cover sales of shares by the underwriters which exceed the number of shares specified in the table above.  The underwriters have 30 days from the date of this prospectus to exercise this option to purchase additional shares.  If any shares are purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above.  If any additional common shares are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriting fee is equal to the public offering price per share of common shares less the amount paid by the underwriters to us per share of common shares.  The underwriting fee is $          &#160;per share.  The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters&#8217; option to purchase additional shares.</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Without option to purchase additional shares exercise</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">With full option to purchase additional shares exercise</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per Share</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$          </font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$          &#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$            &#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$          &#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $1.0 million. We have also agreed to reimburse the underwriters for up to $30,000 in expenses incurred in connection with the review and clearance of this offering by the Financial Industry Regulatory Authority, Inc. (&#8220;FINRA&#8221;). In accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting compensation for this offering. The Underwriters have agreed to reimburse us for certain out-of-pocket expenses incurred in connection with this offering.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering.  The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders.  Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">177</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vlad Coric, our Chief Executive Officer, Matthew Buten, our Chief Financial Officer, and certain of our directors and their affiliated funds have indicated an interest in purchasing approximately $100 million, in the aggregate, of our common shares in this offering at the public offering price. Dr. Coric and Mr. Buten have indicated an interest in purchasing approximately $10 million and $1 million of those common shares, respectively. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no shares to each of Dr. Coric, Mr. Buten or our directors and their affiliated funds, and any of such persons or their affiliated funds could determine to purchase more, fewer or no shares in this offering.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreed that, without the prior written consent of J.P. Morgan Securities LLC, we will not, during the period beginning on the date of this prospectus supplement and ending 60 days after the date of this prospectus supplement, or the restricted period&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">offer, issue, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, or file with or confidentially submit to the SEC a registration statement under the Securities Act relating to any securities of the Company that are substantially similar to the common shares, including but not limited to any securities that are convertible into or exchangeable for, or that represent the right to receive, common shares or any such substantially similar securities, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common shares or any such other securities, whether any such transaction is to be settled by delivery of common shares or such other securities, in cash or otherwise (other than pursuant to employee stock option plans existing on, or upon the conversion or exchange of convertible or exchangeable securities outstanding as of, the date of this prospectus). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our directors and executive officers have agreed that, without the prior written consent of J.P. Morgan Securities LLC, they will not, during the period beginning on the date of this prospectus supplement and ending 45 days after the date of this prospectus supplement, or the restricted period&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any common shares beneficially owned (as such term is used in Rule 13d-3 of the Exchange Act), by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for common shares&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common shares or any security convertible into common shares, whether any such transaction described in the foregoing bullet or this bullet is to be settled by delivery of common shares or such other securities, in cash or otherwise&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicly disclose the intention to do any of the foregoing.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whether any such transaction described above is to be settled by delivery of common shares or such other securities, in cash or otherwise, or publicly disclose the intention to do any of the foregoing. In addition, without the prior written consent of the representative on behalf of the underwriters, (i) our directors and officers will not, during the restricted period, make any demand for, or exercise any right, or publicly disclose such person&#8217;s intention to make any demand or exercise any right, with respect to the registration of any common shares or any security convertible into or exercisable or exchangeable for common shares and (ii) we will not file any registration statement with the SEC relating to the offering of any common shares or any securities convertible into or exercisable or exchangeable for common shares. In addition, our directors and officers agreed and consented to the entry of stop transfer instructions with our transfer agent and registrar against the transfer of each such person&#8217;s common shares except in compliance with the below restrictions.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">178</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restrictions described in the preceding paragraphs are subject to certain exceptions, including, but not limited to&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transactions relating to our common shares or other securities acquired in open market transactions after the completion of this offering, provided that no filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of common shares or any security convertible into common shares is required or voluntarily made during the restricted period&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transfers of common shares or any security convertible into common shares to an immediate family member or a trust for the direct or indirect benefit of the director or officer or such immediate family member of the director or officer, provided that each transferee signs and delivers a lock-up agreement, and provided that no filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of common shares or any security convertible into common shares is required or voluntarily made during the restricted period&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transfers of common shares or any security convertible into common shares as a bona fide gift or charitable contribution, provided that each transferee signs and delivers a lock-up agreement, and provided that no filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of common shares or any security convertible into common shares is required or voluntarily made during the restricted period&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transfers of common shares or any security convertible into common shares by will or intestacy, provided that each transferee signs and delivers a lock-up agreement, and provided that no filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of common shares or any security convertible into common shares is required or voluntarily made during the restricted period&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if the transferor is a corporation, partnership or other business entity, distributions of common shares or any security convertible into common shares to limited partners, members, shareholders or holders of similar equity interests in the transferor, provided that each distributee signs and delivers a lock-up agreement, and provided that no filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of common shares or any security convertible into common shares is required or voluntarily made during the restricted period&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if the transferor is a trust, transfers or distributions of common shares or any securities convertible into or exercisable or exchangeable for common shares to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust, provided that each transferee signs and delivers a lock-up agreement, and provided that no filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of common shares or any security convertible into common shares is required or voluntarily made during the restricted period&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the exercise of a stock option granted under a stock incentive plan or stock purchase plan described in this prospectus supplement, and the receipt from the company of common shares upon such exercise, insofar as such option is outstanding as of the date of the lock-up agreement or the date of this prospectus supplement, provided that the underlying shares shall continue to be subject to the restrictions on transfer set forth in the lock-up agreement, and provided that, if required, any public report or filing under Section 16 of the Exchange Act clearly indicates in the footnotes thereto that the filing relates to the exercise of a stock option, that no common shares were sold by the reporting person and that the common shares received upon exercise of the stock option are subject to a lock-up agreement with the underwriters&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the disposition of common shares to us, or the withholding of common shares by us, in a transaction exempt from Section 16(b) of the Exchange Act solely to the extent required for the payment of taxes due with respect to the vesting or expiration of options or the vesting of restricted stock or restricted stock units granted under a stock incentive plan, stock purchase plan or pursuant to a contractual employment arrangement described in this prospectus supplement, insofar as such options, restricted stock or restricted stock units are outstanding as of the date of the lock-up agreement or the date of this prospectus supplement, provided that no filing under Section 16(a) of the Exchange Act reporting a reduction in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beneficial ownership of common shares or any security convertible into common shares is required or voluntarily made during the restricted period&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transfers to us in connection with the repurchase of common shares in connection with the termination of the director or officer&#8217;s employment with us pursuant to contractual agreements with us as in effect as of the date of this prospectus supplement, provided that no filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of common shares or any security convertible into common shares is required or voluntarily made during the restricted period&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transfers of common shares or any security convertible into or exercisable or exchangeable for common shares pursuant to a domestic order, divorce decree or court order, provided that each transferee signs and delivers a lock-up agreement, and provided that, if required, any public report or filing under Section 16 of the Exchange Act shall clearly indicate in the footnotes thereto that the filing relates to the transfer of such securities pursuant to a domestic order, divorce decree or court order, that no such securities were sold by the reporting person and that the securities so transferred are subject to a lock-up agreement with the underwriters&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of common shares, provided that (i) such plan does not provide for the transfer of common shares during the restricted period and (ii) to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the director, officer or us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common shares may be made under such plan during the restricted period&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transfers of common shares made pursuant to a written trading plan established prior to the date of the lock-up agreement in accordance with Rule 10b5-1 under the Exchange Act, provided that, to the extent a public announcement or filing under the Exchange Act is required of or voluntarily made by or on behalf of the director, officer or us regarding a transfer pursuant to such plan, such announcement or filing shall include a statement to the effect that such transfer was made pursuant to such plan&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a merger, consolidation or other similar transaction, occurring after the closing of the offering, in which all holders of the common shares may participate, involving a change of control of the company and approved by our Board, provided that, in the event that such change of control transaction is not completed, the person&#8217;s common shares shall remain subject to the restrictions contained in the lock-up agreement and title to the person&#8217;s common shares shall remain with the person (for purposes of the foregoing, &#8220;change of control&#8221; means the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than the underwriters pursuant to this offering), of our voting securities if, after such transfer, such person or group of affiliated persons would hold at least 90% of our or the surviving entity&#8217;s outstanding voting securities)&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transactions relating to common shares or other securities convertible or exercisable into common shares purchased in the offering, provided that no filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of common shares or any security convertible into common shares is required or voluntarily made during the restricted period.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">J.P. Morgan Securities LLC, in its sole discretion, may release the common shares and other securities subject to the lock-up agreements described above at any time.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares are listed on the NYSE under the symbol &#8220;BHVN.&#8221;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling common shares in the open market for the purpose of preventing or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retarding a decline in the market price of the common shares while this offering is in progress.  These stabilizing transactions may include making short sales of common shares, which involves the sale by the underwriters of a greater number of common shares than they are required to purchase in this offering, and purchasing common shares on the open market to cover positions created by short sales.  Short sales may be &#8220;covered&#8221; shorts, which are short positions in an amount not greater than the underwriters&#8217; option to purchase additional shares referred to above, or may be &#8220;naked&#8221; shorts, which are short positions in excess of that amount.  The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market.  In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares.  A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common shares in the open market that could adversely affect investors who purchase in this offering.  To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters have advised us that, pursuant to Regulation M of the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common shares, including the imposition of penalty bids.  This means that if the representatives of the underwriters purchase common shares in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These activities may have the effect of raising or maintaining the market price of the common shares or preventing or retarding a decline in the market price of the common shares, and, as a result, the price of the common shares may be higher than the price that otherwise might exist in the open market.  If the underwriters commence these activities, they may discontinue them at any time.  The underwriters may carry out these transactions on the New York Stock Exchange, in the over&#8209;the&#8209;counter market or otherwise.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions.  In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling Restrictions</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required.  The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction.  Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus.  This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in the European Economic Area </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In relation to each Member State of the European Economic Area (each, a &#8220;Relevant State&#8221;), no securities have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of securities may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">to any legal entity which is a qualified investor as defined under the Prospectus Regulation&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">181</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the representatives&#59; or </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation,</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided that no such offer of shares shall require us or any of our representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase any shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017&#47;1129 (as amended).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in the United Kingdom</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In relation to the United Kingdom, no shares have been offered or will be offered pursuant to this offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares that either (i) has been approved by the Financial Conduct Authority, or (ii) is to be treated as if it had been approved by the Financial Conduct Authority in accordance with the transitional provision in Regulation 74 of the Prospectus (Amendment etc.) (EU Exit) Regulations 2019, except that offers of shares may be made to the public in the United Kingdom at any time under the following exemptions under the UK Prospectus Regulation&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of representatives for any such offer&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">in any other circumstances falling within Section 86 of the Financial Services and Markets Act 2000, or the FSMA, provided that no such offer of the shares shall require the Issuer or any representative to publish a prospectus pursuant to Section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#8220;UK Prospectus Regulation&#8221; means Regulation (EU) 2017&#47;1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, this prospectus is only being distributed to, and is only directed at, and any investment or investment activity to which this prospectus relates is available only to, and will be engaged in only with, persons who are outside the United Kingdom or persons in the United Kingdom (i) having professional experience in matters relating to investments who fall within the definition of &#8220;investment professionals&#8221; in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, or the Order&#59; or (ii) who are high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as &#8220;relevant persons&#8221;). Persons who are not relevant persons should not take any action on the basis of this prospectus and should not act or rely on it.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in Canada</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in Switzerland</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectus under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectus under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither this document nor any other offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority, or FINMA, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in the Dubai International Financial Centre, or DIFC</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority, or the DFSA. This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for this document. The securities to which this document relates may be illiquid and&#47;or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document you should consult an authorized financial advisor.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In relation to its use in the DIFC, this document is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in the United Arab Emirates</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus has not been approved </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in Australia</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth), or the Corporations Act&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, available under section 708 of the Corporations Act, or the Exempt Investors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares, you represent and warrant to us that you are an Exempt Investor.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As any offer of shares under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the shares you undertake to us that you will not, for a period of 12 months from the date of issue of the shares, offer, transfer, assign or otherwise alienate those shares to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in Japan</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#8220;resident&#8221; of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in Hong Kong</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a) to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the SFO, of Hong Kong and any rules made thereunder&#59; or (b) in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong), or the CO, or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the SFO and any rules made thereunder.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in Singapore</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">to an institutional investor (as defined in Section 4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time, or the SFA) pursuant to Section 274 of the SFA&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section 275 of the SFA except&#58;</font></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.57pt">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section 276(4)(i)(B) of the SFA&#59;</font></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.8pt">where no consideration is or will be given for the transfer&#59;</font></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.03pt">where the transfer is by operation of law&#59;</font></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.57pt">as specified in Section 276(7) of the SFA&#59; or</font></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Singapore SFA Product Classification&#8212;In connection with Section 309B of the SFA and the CMP Regulations 2018, unless otherwise specified before an offer of shares, we have determined, and hereby notify all relevant persons (as defined in Section 309A(1) of the SFA), that the shares are &#8220;prescribed capital markets products&#8221; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SFA 04-N12&#58; Notice on the Sale of Investment Products and MAS Notice FAA-N16&#58; Notice on Recommendations on Investment Products).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in Bermuda</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, non-Bermudian persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in Saudi Arabia</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued by the board of the Saudi Arabian Capital Market Authority, or CMA, pursuant to resolution number 2-11-2004 dated 4 October 2004 as amended by resolution number 1-28-2008, as amended, or the CMA Regulations. The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an authorized financial adviser.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in the British Virgin Islands</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on behalf of us. The shares may be offered to companies incorporated under the BVI Business Companies Act (As Revised), or companies incorporated in British Virgin Islands, but only where the offer will be made to, and received by, the relevant BVI Company entirely outside of the British Virgin Islands. This prospectus has not been, and will not be, registered with the Financial Services Commission of the British Virgin Islands. No registered prospectus has been or will be prepared in respect of our common shares for the purposes of the Securities and Investment Business Act (As Revised) or the Public Issuers Code of the British Virgin Islands.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in China</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus will not be circulated or distributed in the PRC and the shares will not be offered or sold, and will not be offered or sold to any person for re-offering or resale directly or indirectly to any residents of the PRC except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in Korea</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea, or the FSCMA, and the decrees and regulations thereunder and the shares have been and will be offered in Korea as a private placement under the FSCMA. None of the shares may be offered, sold or delivered directly or indirectly, or offered or sold to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea, or the FETL, and the decrees and regulations thereunder. The shares have not been listed on any securities exchanges in the world including, without limitation, the Korea Exchange in Korea. Furthermore, the purchaser of the shares shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the shares. By the purchase of the shares, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares pursuant to the applicable laws and regulations of Korea.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in Malaysia</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No prospectus or other offering material or document in connection with the offer and sale of our common shares has been or will be registered with the Securities Commission of Malaysia, or the Commission, for the Commission&#8217;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of our </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common shares may not be circulated or distributed, nor may our common shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (i) a closed end fund approved by the Commission, (ii) a holder of a Capital Markets Services Licence, (iii) a person who acquires our common shares, as principal, if the offer is on terms that our common shares may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction, (iv) an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3 million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual, (v) an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding twelve months, (vi) an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months, (vii) a corporation with total net assets exceeding RM10 million (or its equivalent in a foreign currencies) based on the last audited accounts, (viii) a partnership with total net assets exceeding RM10 million (or its equivalent in foreign currencies), (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010, (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010 and (xi) any other person as may be specified by the Commission&#59; provided that, in the each of the preceding categories (i) to (xi), the distribution of our common shares is made by a holder of a Capital Markets Services Licence who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in Taiwan</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares in Taiwan.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in South Africa</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to restrictions under the securities laws of South Africa, no &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">offer to the public&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (as such term is defined in the South African Companies Act, No. 71 of 2008 (as amended or re-enacted, or the South African Companies Act) is being made in connection with the issue of the shares in South Africa. Accordingly, this document does not, nor is it intended to, constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">registered prospectus&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and&#47;or filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The shares are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions stipulated in section 96 (1) applies&#58;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 96 (1)(a) the offer, transfer, sale, renunciation or delivery is to&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the South African Public Investment Corporation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">persons or entities regulated by the Reserve Bank of South Africa&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">authorized financial service providers under South African law&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">financial institutions recognized as such under South African law&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorized portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under South African law)&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.8pt">any combination of the person in (i) to (vi)&#59; or</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 96 (1)(b) the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to Section 96(2)(a) of the South African Companies Act.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information made available in this prospectus should not be considered as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">advice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; as defined in the South African Financial Advisory and Intermediary Services Act, 2002.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to prospective investors in Israel</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the State of Israel, this prospectus shall not be regarded as an offer to the public to purchase shares of common shares under the Israeli Securities Law, 5728-1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section 15 of the Israeli Securities Law, 5728-1968, including, inter alia, if&#58; (i) the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the Addressed Investors&#59; or (ii) the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728-1968, subject to certain conditions, or the Qualified Investors. The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728-1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our common shares to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728-1968. In particular, we may request, as a condition to be offered common shares, that Qualified Investors will each represent, warrant and certify to us and&#47;or to anyone acting on our behalf&#58; (i) that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728-1968&#59; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728-1968 regarding Qualified Investors is applicable to it&#59; (iii) that it will abide by all provisions set forth in the Israeli Securities Law, 5728-1968 and the regulations promulgated thereunder in connection with the offer to be issued common shares&#59; (iv) that the common shares that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728-1968&#58; (a) for its own account&#59; (b) for investment purposes only&#59; and (c) not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728-1968&#59; and (v) that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#8217;s name, address and passport number or Israeli identification number.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_85"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALIDITY OF THE SECURITIES</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity of the common shares will be passed upon for us by Maples and Calder, our special British Virgin Islands counsel. Certain other legal matters will be passed upon for us by Sullivan &#38; Cromwell LLP, New York, New York, and for the underwriters by Ropes &#38; Gray LLP, Boston, Massachusetts.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_88"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPERTS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combined financial statements of Biohaven Ltd. (formerly Biohaven Research Ltd.) at December 31, 2021 and 2020, and for the years then ended, appearing in this Prospectus and Registration Statement have been audited by Ernst &#38; Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_91"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHERE YOU CAN FIND ADDITIONAL INFORMATION</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed with the SEC a registration statement on Form&#160;S-1, including exhibits and schedules, under the Securities Act that registers our common shares to be sold in this offering. This prospectus does not contain all the information contained in the registration statement and the exhibits and schedules filed as part of the registration statement. For further information with respect to us and our common shares, we refer you to the registration statement of which this prospectus forms part and the exhibits and schedules filed as part of the registration statement. Statements contained in this prospectus as to the contents of any contract or other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, we refer you to the copies of the contract or document that have been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the information reporting requirements of the Exchange Act, and we have filed and will file reports and other information with the SEC. These reports and other information are available on the SEC&#8217;s website at http&#58;&#47;&#47;www.sec.gov. We also maintain a website at www.biohaven.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of, and is not incorporated into, this prospectus.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information that we file with the SEC after the date of this prospectus may supersede the information in this prospectus. You may read these reports, proxy statements and other information and obtain copies of such documents and information as described above.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No person is authorized to give any information or to make any representations other than those contained in this prospectus, and if given or made, such information or representations must not be relied upon as having been authorized. Neither the delivery of this prospectus nor any distribution of securities made hereunder shall imply that there has been no change in the information set forth or in our affairs since the date hereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">190</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_94"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Audited Annual Combined Financial Statements</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_100" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Report of Independent Registered Public Accounting Firm</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_100" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_100" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_103" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Combined Balance Sheets as of December 31, 2021 and 2020</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_103" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_103" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Combined Statements of Operations and Comprehensive Loss for the years ended December 31, 2021 and 2020</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_109" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Combined Statements of Changes in Equity for the years ended December 31, 2021 and 2020</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_109" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_109" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_112" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Combined Statements of Cash Flows for the years ended December 31, 2021 and 2020</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_112" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_112" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notes to Combined Financial Statements</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">7</a></font></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unaudited Interim Condensed Combined Financial Statements</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_265" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Condensed Combined Balance Sheets as of June 30, 2022 and December 31, 2021</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_265" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_265" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_268" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Condensed Combined Statements of Operations and Comprehensive Loss for the six months ended June 30, 2022 and 2021</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_268" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_268" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_271" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Condensed Combined Statements of Changes in Equity for the six months ended June 30, 2022 and 2021</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_271" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_271" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">32</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_274" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Condensed Combined Statements of Cash Flows for the six months ended June 30, 2022 and 2021</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_274" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_274" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">33</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_277" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notes to Condensed Combined Financial Statements</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_277" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#ibbeb41436b1c46838ddd18c39bc90b9a_277" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">34</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_97"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_100"></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Biohaven Ltd. (formerly Biohaven Research Ltd.)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying combined balance sheets of Biohaven Ltd. (formerly Biohaven Research Ltd.) (the Company) as of December 31, 2021 and 2020, the related combined statements of operations and comprehensive loss, changes in equity and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;combined financial statements&#8221;). In our opinion, the combined financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2022.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hartford, Connecticut</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July&#160;1, 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_103"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A BUSINESS OF BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.)</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMBINED BALANCE SHEETS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,057&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,506&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,734&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,240&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,032&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,823&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,756&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,010&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,400&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,438&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,988&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,061&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,499&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and equity</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,775&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,758&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,160&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,119&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,935&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,877&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,435&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,841&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,370&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,718&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 8)</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingently redeemable non-controlling interests</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment from Parent</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,691&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,781&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,691&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,781&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,061&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,499&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these combined financial statements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_106"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A BUSINESS OF BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.)</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMBINED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,486&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,460&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,414&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,046&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,900&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,506&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218,900)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,506)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from equity method investment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,261&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,162)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,209&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,470&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,162)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212,430)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,668)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,796)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,668)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these combined financial statements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_109"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A BUSINESS OF BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.)</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMBINED STATEMENTS OF CHANGES IN EQUITY</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Investment from Parent</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,451&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,668)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers from Parent</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,998&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,781&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,796)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers from Parent</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,706&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,691&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these combined financial statements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_112"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A BUSINESS OF BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.)</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMBINED STATEMENTS OF CASH FLOWS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,796)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,668)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,639&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Parent common shares as payment for license and consulting agreements</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,929&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss from equity method investment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,261)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,408)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,073)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,419)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,594)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,882&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,855&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,939&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,840)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,957)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(938)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,097)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for leasehold improvements</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,600)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired in business acquisition</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,697)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers from Parent</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,052&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,242&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of contingently redeemable non-controlling interests</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,447&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,242&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (decrease) increase in cash and restricted cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,449)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,588&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and restricted cash at beginning of period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,506&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,918&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and restricted cash at end of period</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,057&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,506&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,594&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,758&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these combined financial statements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_115"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_118"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Nature of the Business and Basis of Presentation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2022, Biohaven Pharmaceutical Holding Company Ltd. (&#8220;Biohaven&#8221; or the &#8220;Parent&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;) and a wholly owned subsidiary of Pfizer (&#8220;Merger Sub&#8221;), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), which provides for the acquisition by Pfizer of the Parent through the merger of Merger Sub with and into the Parent (the &#8220;Merger&#8221;). In connection with the Merger Agreement, the Parent and Biohaven Ltd. (&#8220;SpinCo&#8221; or &#8220;the Company&#8221;) entered into a Separation and Distribution Agreement, dated as of May 9, 2022 (the &#8220;Distribution Agreement&#8221;). In connection with the Distribution Agreement, the Board of Directors of the Parent approved and directed the Parent&#8217;s management to effect the spin-off of the business, operations, and activities that are not the CGRP Business (as defined below), including Kv7 ion channel activators, glutamate modulation, MPO inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by the Parent, or collectively the &#8220;Biohaven Research Business&#8221;. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To implement the spin-off, the Parent expects to transfer the related license agreements, intellectual property and corporate infrastructure, including certain non-commercial employee agreements, share based awards and other corporate agreements (the &#8220;Business&#8221;) to Biohaven Ltd, through a series of internal restructuring transactions, which we refer to as the pre-closing reorganization. Descriptions of historical business activities in these Notes to Combined Financial Statements are presented as if these transfers had already occurred, and the Parent&#8217;s activities related to such assets and liabilities had been performed by the Company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To effect the spin-off, each of the Parent&#8217;s shareholders will receive one of our common shares for every two common shares of the Parent held prior to the spin-off. Upon completion of the spin-off, the Company will be a stand-alone, publicly traded company focused on the development of its Kv7 ion channel activator, glutamate modulation, MPO inhibition and myostatin inhibition platforms, which it believes have the potential to alter existing treatment approaches across a diverse set of neurological indications with high unmet need in both large markets and orphan indications.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spin-off would generally result in (a) the Company directly or indirectly owning, assuming, or retaining certain assets and liabilities of the Parent and its subsidiaries related to the Parent&#8217;s pipeline assets and businesses and (b) the Parent directly or indirectly owning, assuming, or retaining all other assets and liabilities, including those associated with the Parent&#8217;s platform for the research, development, manufacture and commercialization of calcitonin gene-related receptor antagonists, including rimegepant, zavegepant and the Heptares Therapeutics Limited preclinical CGRP portfolio and related assets (the &#8220;CGRP Business&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts may require additional capital, additional personnel and infrastructure, and further regulatory and other capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon formation and to date, Biohaven Ltd. has had nominal assets, and no liabilities or results of operations and has 100 common shares of no par value outstanding.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying combined financial statements present, on a historical basis, the combined assets, liabilities, expenses and cash flows directly attributable to the Business which have been prepared from the Parent&#8217;s combined financial statements and accounting records and are presented on a stand-alone basis as if the operations have been conducted independently from the Parent. Historically, separate financial statements have not been prepared for the Company and it has not operated as a standalone business from the Parent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combined financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combined financial statements of operations and comprehensive loss include all costs directly related to the Business, including costs for facilities, functions and services utilized by the Company. The combined statements of operations and comprehensive loss also include allocations for various expenses related to the Parent&#8217;s corporate functions, including research and development, human resources, information technology, facilities, tax, shared services, accounting, finance and legal. These expenses were allocated on the basis of direct usage or benefit when specifically identifiable, with the remainder allocated on a proportional cost allocation method primarily based on employee labor hours or direct expenses. Management believes the assumptions underlying the combined financial statements, including the expense methodology and resulting allocation, are reasonable for all periods presented. However, the allocations may not include all of the actual expenses that would have been incurred by the Company and may not reflect its combined results of operations, financial position and cash flows had it been a standalone company during the periods presented. It is not practicable to estimate actual costs that would have been incurred had the Company been a standalone company and operated as an unaffiliated entity during the periods presented. Actual costs that might have been incurred had the Company been a standalone company would depend on a number of factors, including the organizational structure, what corporate functions the Company might have performed directly or outsourced and strategic decisions the Company might have made in areas such as executive management, legal and other professional services, and certain corporate overhead functions.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax amounts in the combined financial statements have been calculated on a separate return method and are presented as if the Company&#8217;s operations were separate taxpayers in the respective jurisdiction. Therefore, tax expense, cash tax payments, and items of current and deferred taxes may not be reflective of the Company&#8217;s actual tax balances prior to or subsequent to the distribution.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the separation, the Company and Biohaven expect to enter into a transition services agreement whereby the Company will provide certain transition services to Biohaven and Biohaven will provide certain transition services to the Company. The Company expects to incur certain costs to establish itself as a standalone public company, as well as ongoing additional costs associated with operating as an independent, publicly traded company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combined balance sheets include assets and liabilities that have been determined to be specifically identifiable or otherwise attributable to the Company, including certain assets that were historically held at the corporate level in the Parent. All intracompany transactions within the Company have been eliminated. All intercompany transactions between the Company and the Parent are considered to be effectively settled in the combined financial statements at the time the transactions are recorded. The total net effect of these intercompany transactions considered to be settled is reflected in the combined statement of cash flows within financing activities and in the combined balance sheets as &#8220;Net investment from Parent.&#8221; See Note 9, Related Party Transactions for additional information regarding related party transactions.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity balance in these combined financial statements represents the excess of total assets over liabilities. Net investment from Parent is primarily impacted by contributions from Parent which are the result of net funding provided by or distributed to Parent.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash on the combined balance sheets represents cash balances from the standalone entities established to operate the Business and that will be contributed to the Company in connection with the spin-off.  The Company is a co-obligor, jointly and severally with the Parent on Biohaven&#8217;s third-party long-term debt obligations with Sixth Street Specialty Lending, Inc.  Biohaven&#8217;s third-party long-term debt and related interest expense are not reflected in the combined financial statements because the Company has not agreed to pay a specified amount of the borrowings on the basis of its arrangement with the Parent, nor is the Company expected to pay any portion of the Parent&#8217;s third-party debt, and the borrowings are not specifically identifiable to SpinCo. See Note 8, Commitments and Contingencies for additional information regarding debt.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_121"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the combined financial statements are issued.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through July&#160;1, 2022, the Company has funded its operations primarily with proceeds from Biohaven Pharmaceutical Holding Co., its Parent, and the Company expects the Parent to continue to fund its cash needs though the date of Distribution. The Company has incurred recurring losses since its inception, including net losses of $213,796 and $118,668 during the years ended December 31, 2021 and 2020, respectively. The Company expects to continue to generate operating losses for the foreseeable future. As of July&#160;1, 2022, the issuance date of these combined financial statements, the Company expects that its continued funding from Parent will be sufficient to fund operating expenses, financial commitments and other cash requirements for at least one year after the issuance date of these financial statements. Following the Distribution, the Company&#8217;s viability will be dependent on its ability to raise additional capital to finance its operations.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute its business plans, the Company will require funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through the sale of public or private equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s shareholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_124"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_127"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of combined financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the combined financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these combined financial statements include, but are not limited to, the valuation of intangible assets, determining the allocations of costs and expenses from the Parent and the accrual for research and development expenses. In addition, management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_130"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. Periodically, the Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_133"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash primarily consists of collateral held by a bank for a letter of credit (&#34;LOC&#34;) issued in connection with the leased office space in Yardley, Pennsylvania. See Note 8 &#8216;&#8216;Commitments and Contingencies&#8217;&#8217; for additional information on the real estate lease. The following represents a reconciliation of cash in the combined balance sheets to total cash and restricted cash for the years ended December 31, 2021 and 2020, respectively, in the combined statements of cash flows&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,057&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,506&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other current assets)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other non-current assets)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and restricted cash at the end of the period in the combined statement of cash flows</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,057&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,506&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_136"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s combined financial statements include the operations of acquired businesses after the completion of the acquisitions. The Company accounts for acquired businesses using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired In-Process Research and Development (&#34;IPR&#38;D&#34;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. Contingent consideration in a business acquisition is included as part of the consideration transferred and is recognized at fair value as of the acquisition date. Fair value of IPR&#38;D and contingent consideration is generally estimated by using a probability-weighted discounted cash flow approach.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_139"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in non-public companies in which the Company owns less than a 50% equity interest and where it has the ability to exercise significant influence over the operating and financial policies of the investee are accounted for using the equity method of accounting. The Company's proportionate share of the net income or loss of the equity method investment is included in Gain (loss) from equity method investment in the combined statement of operations and comprehensive loss and results in a corresponding adjustment to the carrying value of the investment on the combined balance sheet. Dividends received reduce the carrying value of the investment.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company owned approximately 42% of the outstanding shares of Kleo Pharmaceuticals, Inc. (&#34;Kleo&#34;), which was accounted for as an equity method investment. In January 2021, the Company acquired the remaining 58% of Kleo's common shares that it did not previously own and ceased accounting for Kleo as an equity method investment. See Note 4 &#34;Acquisitions&#34; for additional details. </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_142"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the respective assets. As of December 31, 2021 and December 31, 2020, the Company's property and equipment consisted of office buildings and land, office and lab equipment, computer hardware and software, and furniture and fixtures.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fixed assets have the following useful lives&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 years</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and lab equipment</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred. Property and equipment are monitored regularly for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_145"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&#38;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, the Company will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of acquired intangible assets is primarily determined using an income-based approach referred to as the multi-period excess earnings method utilizing Level 3 fair value inputs. The market participant valuation assumes a global view considering all potential jurisdictions and indications based on discounted after-tax cash flow projections, risk adjusted for estimated probability of technical and regulatory success.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates IPR&#38;D for impairment at least annually in the fourth quarter and more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&#38;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, in connection with the acquisition of Kleo, the Company recorded intangible assets consisting of IPR&#38;D assets of $18,400, which included an oncology therapeutic candidate and a COVID-19 therapeutic candidate which have entered clinical trials, and goodwill of $1,390. See Note 4 &#34;Acquisitions&#34; for additional details. </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_148"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors its long-lived assets for indicators of impairment. If such indicators are present, the Company assesses the recoverability of affected assets by determining whether the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found not to be recoverable, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, with the fair value generally determined based on the present value of the expected future cash flows associated with the assets.  The Company believes no impairment of long-lived assets existed as of December 31, 2021 or December 31, 2020.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_151"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_154"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and operating lease liabilities are recognized at the commencement date based on the present value of the remaining future minimum lease payments. If the interest rate implicit in the Company&#8217;s leases is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based on market sources including interest rates for companies with similar credit quality for agreements of similar duration, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and exclude lease incentives. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the term of the short-term lease and variable lease costs are expensed as incurred. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its real estate leases, which are accounted for as operating leases, the Company has elected the practical expedient to include both the lease and non-lease components as a single component. In addition, payments made by the Company for improvements to the underlying asset, if the payment relates to an asset of the lessor, are recorded as prepaid rent within other non-current assets in the combined balance sheets prior to lease commencement and on commencement, reclassified to the right-of-use asset. The commencement date for the Company's leased office space in Yardley, Pennsylvania occurred during the second quarter of 2020. In connection with the commencement of the office lease, the Company reclassified $2,850 of leasehold improvements from prepaid rent to operating right-of-use asset. As of December 31, 2021, the Company had restricted cash of $250 and $750 included in other current assets and other non-current assets, respectively, in the combined financial statements, which represent collateral held by a bank for an LOC issued in connection with the leased office space in Yardley, Pennsylvania. The restricted cash is deposited in a non-interest bearing account. See Note 8 &#8216;&#8216;Commitments and Contingencies&#8217;&#8217; for additional information on the real estate lease.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_157"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its operations as a single segment, the development of therapies targeting neurological diseases, for the purposes of assessing performance and making operating decisions. In 2021 and 2020, materially all the Company's long-lived assets were held in the United States.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_160"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, non-cash share-based compensation and benefits, third-party license fees, and external costs of vendors engaged to conduct clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development-related contracts. These agreements are cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Certain judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company's estimates. The Company's historical accrual estimates have not been materially different from the actual costs.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_163"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Cash Share-Based Compensation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s employees have historically participated in the Parent&#8217;s share-based compensation plans. Share-based compensation expense has been allocated to the Company based on a combination of specific identification and a proportionate cost allocation method. The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_166"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Business&#8217; equity on the combined balance sheets represents the historical investment by the Parent in the Business and is presented in net investment from Parent in lieu of stockholders&#8217; equity. The combined statement of changes in equity includes net cash transfers and other assets and liabilities between the Parent and the Business as well as the net losses after tax. </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_169"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the combined financial statements or in the Company's tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the combined financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The provision for income taxes includes the effects of applicable tax reserves, or unrecognized tax benefits, as well as the related net interest and penalties.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_172"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2021, the Company adopted ASU No. 2019-12, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)&#58; Simplifying the Accounting for Income Taxes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#34;ASU 2019-12&#34;). This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The adoption of ASU 2019-12 did not have a material impact on the Company's combined financial statements.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_175"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021 the FASB issued ASU No. 2021-04, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#58; Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides guidance on modifications or exchanges of a freestanding equity-classified written call option that is not within the scope of another topic.  An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument, and provides further guidance on measuring the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. ASU 2021-04 also provides guidance on the recognition of the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration. The guidance is applied prospectively and is effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Early adoption is permitted. The Company has evaluated the impact that the adoption of ASU 2021-04 will have on the combined financial statements. The effect will largely depend on the terms of written call options or financings issued or modified in the future.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_178"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Balance Sheet Components</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consisted of the following&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.820%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income tax receivable</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,911&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,032&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and land</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,297&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,858&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and lab equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,352&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,284&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,342)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,705)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,010&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a purchase and sale agreement (the &#34;Purchase and Sale Agreement&#34;) to purchase a building located at 221 Church Street, New Haven, Connecticut in exchange for 39,004 common shares of the Parent valued at approximately $4,871. The Purchase and Sale Agreement closed and the Parent issued the shares in December 2021.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $673 and $72 for the years ended December 31, 2021 and 2020 respectively. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, computer software costs included in property and equipment were $760 and $0, respectively, net of accumulated amortization of $211 and $0, respectively. Depreciation and amortization expense for capitalized computer software costs was $28 and $0 for the years ended December 31, 2021 and 2020. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Non-current Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets consisted of the following&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.820%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A-2 Preferred Stock Investment</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,981&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,216&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,438&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,988&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a Series A-2 Preferred Stock Purchase Agreement with Artizan Biosciences Inc. (&#34;Artizan&#34;). Under the agreement, the Company paid Artizan 61,494 shares of the Parent&#8217;s common shares valued at $6,000, which were issued in January 2021. In exchange, the Company acquired 34,472,031 shares of series A-2 preferred stock of Artizan. The Company determined that it was not practical to estimate the fair value of this investment as it represents Series A-2 Preferred Stock of an unlisted company. On a routine basis the Company will determine if additional preferred shares of the unlisted company have been issued and will adjust the carrying value of its Series A-2 Preferred Stock investment accordingly. See Note 6 &#8220;License Agreements&#8221; for additional details on the Artizan Agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.820%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,538&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,054&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,051&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,840&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Series A-2 Preferred Stock Investment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,571&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,225&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,160&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,119&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingently Redeemable Non-controlling Interest</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company's Asia-Pacific Subsidiary, BioShin Limited (&#8220;BioShin&#8221;), authorized, issued and sold 15,384,613 BioShin Series A Preferred Shares at a price of $3.90 per share for a total of $60,000 to a group of investors led by OrbiMed, with participation from Cormorant Asset Management LLC, HBM Healthcare Investments Ltd, Surveyor Capital (a Citadel Company), and Suvretta Capital Management, LLC (the &#34;BioShin Investors&#34;).  The BioShin Series A Preferred Shares contained both a call option by the Company and a put option held by the BioShin Investors. Due to the contingently redeemable features, the Company had classified the BioShin Series A Preferred Shares in mezzanine equity since the redemption was out of the Company's control. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company, Biohaven Therapeutics Ltd. (&#8220;BTL&#8221;), Atlas Merger Sub and BioShin entered into an Agreement and Plan of Merger (the &#8220;BioShin Merger Agreement&#8221;). The BioShin Merger Agreement provided for the merger of Atlas Merger Sub with and into BioShin, with BioShin surviving the merger as a wholly owned indirect subsidiary of the Parent, in accordance with Section 233 of the Cayman Islands Companies Act. As a result of the satisfaction of the closing conditions described in the BioShin Merger Agreement, on January 6, 2022, each Series A convertible preferred share of BioShin, no par value, other than Excluded Shares (as defined in the BioShin Merger Agreement), was converted into the right to receive 0.080121 of the Parent&#8217;s common shares.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_181"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2021, the Company acquired Kleo Pharmaceuticals, Inc. (&#8220;Kleo&#8221;). Kleo is a development-stage biopharmaceutical company focused on advancing the field of immunotherapy by developing small molecules that emulate biologics. The transaction was accounted for as the acquisition of a business using the acquisition method of accounting.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of the consideration transferred was $20,043, which primarily consisted of the issuance of a total of 115,836 common shares of the Parent to Kleo stockholders and contingent consideration in the form of a contingent value right to receive one dollar in cash for each Kleo share if certain specified Kleo biopharmaceutical products or product candidates receive the approval of the FDA prior to the expiration of 30 months following the effective time of the transaction. The maximum amount payable pursuant to the contingent value right was approximately $17,300. At December 31, 2021, the Company determined the value of the contingent value right to be immaterial and recognized a gain of $1,457 related to the contingent value right in other income (expense). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the consummation of the transaction, the Company owned approximately 41.9% of the outstanding shares of Kleo and accounted for it as an equity method investment. As part of the transaction, the Company acquired the remainder of the shares of Kleo, and post-transaction the Company owns 100% of the outstanding shares of Kleo. The carrying value of the Company&#8217;s investment in Kleo was $1,176 immediately prior to the acquisition date. The Company determined the fair value of the existing interest was $6,437, and recognized a gain from its equity method investment of $5,261 for the year ended December 31, 2021 as a result of remeasuring to fair value the existing equity interest in Kleo, which was included as Gain (loss) from equity method investment on the combined statements of operations and comprehensive loss.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the transaction, the Company recorded&#58; net working capital of $573&#59; property, plant and equipment of $1,257&#59; intangible assets consisting of in progress research and development assets of $18,400 which include an oncology therapeutic candidate entering Phase I clinical trials and a COVID-19 therapeutic candidate in the planning stage for clinical development&#59; debt assumed of $1,577&#59; and goodwill of $1,390. The goodwill is primarily attributable to the acquired workforce.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kleo&#8217;s employees, other than its President and Chief Financial Officer, were retained as part of the transaction. In connection with the transaction agreement, the Company filed a registration statement permitting Kleo stockholders to offer and sell the common shares of the Company issued in the transaction.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_184"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160; Share-Based Compensation</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_187"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parent has share-based compensation plans under which it may issue common shares or restricted common shares, or grant incentive stock options or nonqualified stock options for the purchase of common shares, to employees, members of the board of directors and consultants of the Parent. The Parent also has an Employee Share Purchase Plan (the &#8220;ESPP&#8221;) which allows eligible employee who are participating in the plan to purchase shares of the Parent at a discount. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation has been allocated to the Company by using a combination of specific identification and a proportionate cost allocation method based on employee hours or directly identified operating expenses, depending on the employee&#8217;s function. The amounts presented are not necessarily indicative of future awards and do </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not necessarily reflect the costs that the Company would have incurred as an independent company for the periods presented.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation under the Parent&#8217;s share-based compensation plans is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the award (generally three to four years) using the straight-line method. Share-based compensation expense attributed to the Company by classification included within in the combined statements of operations and comprehensive loss was as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,381&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,475&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,258&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,025&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,639&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,500&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_190"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;License Agreements</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_193"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Yale Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013, the Company entered into an exclusive license agreement (the &#34;Yale Agreement&#34;) with Yale University to obtain a license to certain patent rights for the commercial development, manufacture, distribution, use and sale of products and processes resulting from the development of those patent rights, related to the use of riluzole in treating various neurological conditions, such as general anxiety disorder, post-traumatic stress disorder and depression. As part of the consideration for this license, the Company issued Yale 250,000 common shares of the Parent and granted Yale the right to purchase up to 10% of the securities issued in specified future equity offerings by the Parent, in addition to the obligation to issue shares to prevent anti-dilution. The obligation to contingently issue equity to Yale was no longer outstanding as of December 31, 2018.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Yale Agreement was amended and restated in May 2019. As amended, the Company agreed to pay Yale up to $2,000 upon the achievement of specified regulatory milestones and annual royalty payments of a low single-digit percentage based on net sales of riluzole-based products from the licensed patents or from products based on troriluzole. Under the amended and restated agreement, the royalty rates are reduced as compared to the original agreement. In addition, under the amended and restated agreement, the Company may develop products based on riluzole or troriluzole. The amended and restated agreement retains a minimum annual royalty of up to $1,000 per year, beginning after the first sale of product under the agreement. If the Company grants any sublicense rights under the Yale Agreement, it must pay Yale a low single-digit percentage of sublicense income that it receives.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered a worldwide, exclusive license agreement with Yale University for the development and commercialization of a novel Molecular Degrader of Extracellular Protein (&#34;MoDE&#34;) platform (the &#34;Yale MoDE Agreement&#34;). Under the license agreement, the Company acquired exclusive, worldwide rights to Yale's intellectual property directed to its MoDE platform. The platform pertains to the clearance of disease-causing protein and other biomolecules by targeting them for lysosomal degradation using multi-functional molecules. As part of consideration for this license, the Company paid Yale University an upfront cash payment of $1,000 and 11,668 shares of the Parent valued at approximately $1,000. Under the agreement, the Company may develop products based on the MoDE platform. The agreement includes an obligation to pay a minimum annual royalty of up to $1,000 per year, and low single digit royalties on the net sales of licensed products. If the Company grants any sublicense rights under the Yale Agreement, it must pay Yale a low single-digit percentage of sublicense income that it receives. In addition, Yale University will be eligible to receive additional development milestone payments of up to $800 and commercial milestone payments of up to $2,950. The agreement terminates on the later of twenty years from the effective date, twenty years from the filing date of the first investigational new drug application for a licensed product or the last to expire of a licensed patent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, in addition to the development milestone payments noted above, the Company recorded $150 in research and development expense related to Yale MoDE Agreement following the initiation of a certain Phase 1 clinical trial. For the year ended December 31, 2020, the Company did not record any material expense or make any milestone or royalty payments under the Yale Agreement or the Yale MoDE Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_196"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ALS Biopharma Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2015, the Company entered into an agreement (the &#34;ALS Biopharma Agreement&#34;) with ALS Biopharma and Fox Chase Chemical Diversity Center Inc. (&#34;FCCDC&#34;), pursuant to which ALS Biopharma and FCCDC assigned the Company their worldwide patent rights to a family of over 300 prodrugs of glutamate modulating agents, including troriluzole, as well as other innovative technologies. Under the ALS Biopharma Agreement, the Company is obligated to use commercially reasonable efforts to commercialize and develop markets for the patent products. The Company is obligated to pay $3,000 upon the achievement of specified regulatory milestones with respect to the first licensed product and $1,000 upon the achievement of specified regulatory milestones with respect to subsequently developed products, as well as royalty payments of a low single-digit percentage based on net sales of products licensed under the agreement, payable on a quarterly basis.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ALS Biopharma Agreement terminates on a country-by-country basis as the last patent rights expire in each such country. If the Company abandons its development, research, licensing or sale of all products covered by one or more claims of any patent or patent application assigned under the ALS Biopharma Agreement, or if the Company ceases operations, it has agreed to reassign the applicable patent rights back to ALS Biopharma.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021 and 2020, the Company did not record any expense or make any milestone or royalty payments under the ALS Biopharma Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_199"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 AstraZeneca Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, the Company entered into an exclusive license agreement (the &#8220;2016 AstraZeneca Agreement&#8221;) with AstraZeneca, pursuant to which AstraZeneca granted the Company a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights, including BHV-5000 and BHV-5500. In exchange for these rights, the Company agreed to pay AstraZeneca an upfront payment, milestone payments and royalties on net sales of licensed products under the agreement. The regulatory milestones due under the 2016 AstraZeneca Agreement depend on the indication of the licensed product being developed as well as the territory where regulatory approval is obtained.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development milestones due under the 2016 AstraZeneca Agreement with respect to Rett syndrome total up to $30,000, and, for any indication other than Rett syndrome, total up to $60,000. Commercial milestones are based on net sales of all products licensed under the agreement and total up to $120,000. The Company has also agreed to pay royalties in two tiers, with each tiered royalty in the range from 0-10% of net sales of products licensed under the agreement. If the Company receives revenue from sublicensing any of its rights under the 2016 AstraZeneca Agreement, the Company is also obligated to pay a portion of that revenue to AstraZeneca. The Company is also required to reimburse AstraZeneca for any fees that AstraZeneca incurs related to the filing, prosecution, defending, and maintenance of patent rights licensed under the 2016 AstraZeneca Agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 AstraZeneca Agreement expires upon the expiration of the patent rights under the agreement or on a country-by-country basis ten years after the first commercial sale and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021 and 2020, the Company did not record any expense or make any milestone or royalty payments under the 2016 AstraZeneca Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_202"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 AstraZeneca Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company entered into an exclusive license agreement (the &#8220;2018 AstraZeneca Agreement&#8221;) with AstraZeneca, pursuant to which AstraZeneca granted the Company a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights, including BHV-3241. Under the 2018 AstraZeneca Agreement, the Company paid AstraZeneca an upfront cash payment of $3,000 and 109,523 shares valued at $4,080 on the date of settlement, both of which were included in research and development expense, and is obligated to pay milestone payments to AstraZeneca totaling up to $55,000 upon the achievement of specified regulatory and commercial milestones and up to $50,000 upon the achievement of specified sales-based milestones. In addition, the Company will pay AstraZeneca royalties in three tiers, with each tiered royalty in the range from 0-10% of net sales of specified approved products, subject to specified reductions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company completed enrollment in a Phase 3 clinical trial of this product candidate, which is now referred to as verdiperstat, for the treatment of Amyotrophic Lateral Sclerosis (&#8220;ALS&#8221;). ALS is a progressive, life-threatening, and rare neuromuscular disease for which there are currently limited treatment options and no cure. The Company is solely responsible, and has agreed to use commercially reasonable efforts, for all development, regulatory and commercial activities related to verdiperstat. The Company may sublicense its rights under the agreement and, if it does so, will be obligated to pay a portion of any milestone payments received from the sublicense to AstraZeneca in addition to any milestone payments it would otherwise be obligated to pay.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 AstraZeneca Agreement terminates on a country-by-country basis and product-by-product basis upon the expiration of the royalty term for such product in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021 and 2020, the Company did not record any material expense or make any milestone or royalty payments under the 2018 AstraZeneca Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_205"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fox Chase Chemical Diversity Center Inc. Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company entered into the FCCDC Agreement in which the Company purchased certain intellectual property relating to the TDP-43 protein from FCCDC. The FCCDC Agreement provides the Company with a plan and goal to identify one or more new chemical entity candidates for preclinical development for eventual clinical evaluation for the treatment of one or more TDP-43 proteinopathies. As consideration, the Company issued 100,000 of the Parent&#8217;s common shares to FCCDC valued at $5,646.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is obligated to pay FCCDC milestone payments totaling up to $4,500 with $1,000 for each additional NDA filing. The Company also issued a warrant to FCCDC, granting FCCDC the option to purchase up to 100,000 of the Parent&#8217;s common shares, at a strike price of $56.46 per share, subject to vesting upon achievement of certain milestones in development of TD-43.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FCCDC Agreement, the Company and FCCDC have established a TDP-43 Research Plan, which was amended in November 2020, that provides for certain milestones to be achieved by FCCDC, and milestone payments to be made by the Company up to approximately $3,800 over a period of up to 30 months as success fees for research activities by FCCDC. In addition to the milestone payments, the Company will pay FCCDC an earned royalty equal to 0% to 10% of net sales of any TD-43 patent products with a valid claim as defined in the FCCDC Agreement. The Company may also license the rights developed under the FCCDC Agreement and, if it does so, will be obligated to pay a portion of any payments received from such licensee to FCCDC in addition to any milestones it would otherwise be obligated to pay. The Company is also responsible for the prosecution and maintenance of the patents related to the TDP-43 assets.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCCDC Agreement terminates on a country-by-country basis and product-by-product basis upon expiration of the royalty term for such product in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded $1,746 and $1,500 in research and development expense in the combined statements of operations related to the FCCDC Agreement during the years ended December 31, 2021 and 2020, respectively.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_208"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UConn</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company announced it had signed an exclusive, worldwide option and license agreement (the &#8220;UConn Agreement&#8221;) with the&#160;University of Connecticut&#160;(&#8220;UConn&#8221;) for the development and commercialization rights to UC1MT, a therapeutic antibody targeting extracellular metallothionein. Under this agreement, the Company has the option to acquire an exclusive, worldwide license to UC1MT and its underlying patents to develop and commercialize throughout the world in all human indications. If the Company chooses to exercise the option, it would be obligated to pay UConn upon the achievement of specified regulatory and commercial milestones, and royalties of a low single-digit percentage of net sales of licensed products sold by the Company, its affiliates or its sublicensees.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_211"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Artizan Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, BTL entered into an Option and License Agreement with Artizan Biosciences Inc. (the &#8220;2020 Artizan Agreement&#8221;). Pursuant to the 2020 Artizan Agreement, BTL acquired an option (&#8220;Biohaven Option&#8221;) to obtain a royalty-based license from Artizan to manufacture, use and commercialize certain products in the United States for the treatment of diseases, including, for example, inflammatory bowel disease and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other gastrointestinal inflammatory disorders, e.g., Crohn&#8217;s disease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Biohaven Option is exercisable throughout the development phase of the products at an exercise price of approximately $4,000 to $8,000, which varies based on the market potential of the products. BTL and Artizan have also formed a joint steering committee to oversee, review and coordinate the product development activities with regard to all products for which BTL has (or has exercised in the future) the Biohaven Option.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, simultaneously with the Option and License Agreement, the Company entered into a Series A-2 Preferred Stock Purchase Agreement with Artizan. Under the agreement, the Company paid Artizan 61,494 of the Parent&#8217;s common shares valued at $6,000, which were issued in January 2021. In exchange, the Company acquired 34,472,031 shares of series A-2 preferred stock of Artizan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, BTL entered into a Development and License Agreement with Artizan Biosciences Inc (the &#8220;2021 Artizan Agreement&#8221;). Pursuant to the 2021 Artizan Agreement, BTL acquired an exclusive, worldwide license under Artizan&#8217;s IgA-SEQ patented technology and know-how to develop, manufacture and commercialize certain of Artizan&#8217;s compounds for use in Parkinson&#8217;s Disease. Under the agreement, BTL is responsible for funding the development of the compounds, obtaining regulatory approvals, manufacturing the compounds and commercializing the compounds.  BTL is also responsible for the prosecution, maintenance and enforcement of Artizan&#8217;s patents. BTL will pay Artizan development milestones of $20,000 for the first licensed compound to achieve U.S. marketing authorization and $10,000 for each subsequent U.S. approval.  In addition, BTL will pay Artizan commercialization milestones totaling up to $150,000 and royalties in the low to mid single digits.  The 2021 Artizan Agreement terminates on a country-by-country basis on the later of 10 years from the first commercial sale of licensed product in such country or the expiration of Artizan&#8217;s patents in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into an Amendment to the Series A-2 Preferred Stock Purchase Agreement with Artizan. Under the Amendment, the Company made a cash payment of $4,000 in exchange for 22,975,301 shares of series A-2 preferred stock of Artizan out of a total of 45,950,601 shares of series A-2 preferred stock of Artizan for a total raise of $8,000 (the &#8220;A2 Extension Raise&#8221;). Along with the Amendment, the Company and Artizan executed a non-binding indication of interest (&#8220;Artizan Side Letter&#8221;) which describes terms under which BTL and Artizan would amend the 2020 Artizan Agreement to eliminate certain milestone payments required by us in exchange for limiting our option to the selection of the first (ARZC-001) licensed product.  The Artizan Side Letter requires Artizan to commit at least 80% of the funds raised in the A-2 Extension Raise to a certain program and to raise $35,000 of additional capital within a certain time. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, the Company did not record any research and development expense or make any milestone payments related to the Artizan Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_214"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Moda Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, the Company entered into a consulting services agreement with Moda Pharmaceuticals LLC (the &#8220;Moda Agreement&#8221;) to further the scientific advancement of technology, drug discovery platforms (including the technology licensed under the Yale MoDE Agreement), product candidates and related intellectual property owned or controlled by the Company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Moda Agreement, the Company paid Moda an upfront cash payment of $2,700 and 37,836 shares of the Parent valued at approximately $3,243. In addition, Moda will be eligible to receive additional development milestone payments of up to $81,612 and commercial milestone payments of up to $30,171. The Moda Agreement has a term of four years and may be terminated earlier by the Company or Moda under certain circumstances including, for example, the Company&#8217;s discontinuation of research on the MoDE platform or default.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, the Company did not record any material research and development expense or make any milestone payments related to the Moda Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_217"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reliant Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into the Reliant Agreement pursuant to which the Company and Reliant have agreed to collaborate on a program with Biohaven Labs&#8217; multifunctional molecules to develop and commercialize conjugated antibodies for therapeutic uses relating to IgA nephropathy and treatment of other diseases and conditions. Under the Reliant Agreement, the Company paid Reliant an upfront payment in the form of issuance of common shares valued at approximately $3,686, which the Company recorded as research and development expense on its combined statement of operations and comprehensive loss. In addition, Reliant will be eligible to receive development and regulatory milestone payments of up to $36,500, and royalties of a low single-digit percentage of net sales of licensed products.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, excluding the upfront payment noted above, the Company recorded $167 in research and development expense related to the Reliant Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_220"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KU Leuven Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company and Katholieke Universiteit Leuven (&#8220;KU Leuven&#8221;) entered into an Exclusive License and Research Collaboration Agreement (the &#8220;KU Leuven Agreement&#8221;) to develop and commercialize TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders. The TRPM3 antagonist platform was discovered at the Centre for Drug Design and Discovery (&#8220;CD3&#8221;) and the Laboratory of Ion Channel Research (&#8220;LICR&#8221;) at KU Leuven. Under the KU Leuven Agreement, the Company receives exclusive global rights to develop, manufacture and commercialize KU Leuven&#8217;s portfolio of small-molecule TRPM3 antagonists. The portfolio includes the lead candidate, henceforth known as BHV-2100, which is being evaluated in preclinical pain models and will be the first to advance towards Phase 1 studies. The Company will support further basic and translational research at KU Leuven on the role of TRPM3 in pain and other disorders. As consideration, KU Leuven received an upfront cash payment of $3,000 and 15,340 shares valued at $1,779, and is eligible to receive additional development, regulatory, and commercialization milestones payments of up to $327,750. In addition, KU Leuven will be eligible to receive mid-single digit royalties on net sales of products resulting from the collaboration.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_223"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taldefgrobep Alfa License Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, following the transfer of intellectual property the Company announced that it entered into a worldwide license agreement with BMS for the development and commercialization rights to taldefgrobep alfa (also known as BMS-986089), a novel, Phase 3-ready anti-myostatin adnectin (the &#8220;Taldefgrobep Alfa License </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement&#8221;). Under the terms of the Taldefgrobep Alfa License Agreement, the Company will receive worldwide rights to taldefgrobep alfa and BMS will be eligible for regulatory approval milestone payments of up to $200,000, as well as tiered, sales-based royalty percentages from the high teens to the low twenties. There were no upfront or contingent payments to BMS related to the Taldefgrobep Alfa License Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_226"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax amounts in the combined financial statements have been calculated on a separate return method and are presented as if the Company&#8217;s operations were separate taxpayers in the respective jurisdiction. Therefore, tax expense, cash tax payments, and items of current and deferred taxes may not be reflective of the Company&#8217;s actual tax balances prior to or subsequent to the distribution.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company incorporated in the British Virgin Islands (&#8220;BVI&#8221;), we are principally subject to taxation in the BVI. Under the current laws of the BVI, the Company and all dividends, interest, rents, royalties, compensation and other amounts paid by the Company to persons who are not resident in the BVI and any capital gains realized with respect to any shares, debt obligations, or other securities of the Company by persons who are not resident in the BVI are exempt from all provisions of the Income Tax Ordinance in the BVI. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parent has historically outsourced all of the research and clinical development for its programs under a master services agreement with Biohaven Pharmaceuticals, Inc. (&#8220;BPI&#8221;). As a result of providing services under this agreement, BPI was profitable during the years ended December 31, 2021 and 2020, and BPI is subject to taxation in the United States. As such, in each reporting period, the Biohaven Research Business tax provision includes the effects of consolidating the results of operations of BPI.   </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, the Company continued to maintain a full valuation allowance against its net deferred tax assets, which are comprised primarily of research and development credit carryforwards and future stock based compensation deductions based on management&#8217;s assessment that it is more likely than not that the deferred tax assets will not be realized.  </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded an income tax provision during the years ended December 31, 2021 and 2020 of $1,366 and $0, respectively, which primarily represents U.S. Federal and state taxes related to the Company&#8217;s profitable operations of BPI in the US.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before provision for income taxes consisted of the following&#58;</font></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BVI</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,334)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,468)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,096)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212,430)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,668)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes consisted of the following&#58;</font></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax provision&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BVI</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign (U.S. federal and state)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax provision</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax provision (benefit)&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BVI</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign (U.S. federal and state)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax provision (benefit)</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the BVI statutory income tax rate of 0% to the Company&#8217;s effective income tax rate is as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BVI statutory income tax rate</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Credits</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.00)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.00)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.00)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.00)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets (liabilities) consisted of the following&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.820%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating loss carryforwards</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,573&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,590&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,577&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,246&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,023&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,326&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,192&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,224)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,970)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,102&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets and other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,102)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,102)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company completed the acquisition of Kleo and recorded a full valuation allowance against its Kleo deferred tax assets due to Kleo&#8217;s cumulative loss history.  The Company will continue to evaluate the need for a valuation allowance on all of its deferred tax assets until there is sufficient positive evidence to support the reversal of all or some portion of these allowances.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, and 2020, the Company had foreign net operating loss carryforwards of $39,281, and, $0, respectively. As of December 31, 2021 and 2020, the Company had federal and state research and development and orphan drug credits of $26,590 and $20,577, respectively, which begin to expire in 2030.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2021and 2020 were due primarily to generation of excess tax credits and the acquisition of Kleo as follows&#58;</font></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance as of beginning of year</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,970)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,592)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases recorded as benefit to income tax provision</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases recorded to Purchase Accounting and Net Parent Investment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,449)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,805)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,467)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance as of end of year</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,224)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,970)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company followed the authoritative guidance for recognizing and measuring uncertainty in income taxes for tax positions taken or expected to be taken in a tax return. The beginning and ending amounts of unrecognized tax benefits reconciles as follows&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period balance</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for tax positions taken during the current period </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases recorded to Purchase Accounting and Net Parent Investment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases for tax positions taken during a prior period </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period balance</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized tax benefits relate primarily to issues common among multinational corporations. All of these unrecognized tax benefits, if recognized, would impact the Company&#8217;s effective income tax rate. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December 31, 2021 and 2020, the total amount of accrued interest and penalties were not significant. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BPI files income tax returns in the U.S. and certain state jurisdictions. BPI&#8217;s U.S. federal and state income tax returns are subject to tax examinations for the tax year ended December&#160;31, 2018 and subsequent years. The federal tax return for BPI is currently under audit by the IRS for the period ended December 31, 2019.  </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_229"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Commitments and Contingencies</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following agreements are either current Company agreements, or those the Parent expects to assign to the Company upon separation, accordingly, all considerations paid by the Parent in association with these agreements are recorded in the combined financial statements of the Company.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_232"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parent&#8217;s leases primarily consist of office space that will be attributed to the Company in connection with the separation. The Company determines if an arrangement is a lease at inception. The lease term includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Real estate leases for facilities have an average remaining lease term of 5.75 years, for which none include the optional extension. The Company has made an accounting policy election not to record short-term leases (leases with an initial term of 12 months or less) on the balance sheet. The Company currently has two short-term leases with immaterial lease expense.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since most of the Company&#8217;s leases do not have a readily determinable implicit discount rate, the Company uses the Parent&#8217;s incremental borrowing rate to calculate the present value of lease payments. The Company does not separate lease components (e.g., payments for rent, real estate taxes and insurance costs) from non-lease components (e.g., common-area maintenance costs) in the event that the agreement contains both. The Company includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). The allocated operating lease cost was $264 in 2021 and $0 in 2020. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s lease agreements contain variable lease payments that are adjusted for actual operating expense true-ups compared with estimated amounts&#59; however, these amounts are immaterial. The Company had no sublease income and there are no sale-leaseback transactions. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets </font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,981</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,797</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,929</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,236</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.07&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.07&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities are as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; imputed interest</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,236&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_235"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Commitments</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parent has entered into agreements with several CROs to provide services in connection with the Company&#8217;s preclinical studies and clinical trials. Research Commitments entered into by the Parent and related to the Company are expected to transfer to the Company upon separation. As of December&#160;31, 2021, the Company had no material noncancellable research commitments in excess of one year.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_238"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company&#8217;s amended and restated memorandum and articles of association also provide for indemnification of directors and officers in specific circumstances. To date, the Company has not incurred any material costs as a result of such indemnification provisions. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its combined financial statements as of December&#160;31, 2021 or 2020.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_241"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parent entered into license agreements with various parties that are directly attributed to the Company under which it is obligated to make contingent and non-contingent payments (see Note 6). License agreements entered by the Parent and related to the Company are expected to transfer to the Company upon separation.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_244"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sixth Street Financing Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Parent and Biohaven Pharmaceuticals, Inc., (together with the Parent the &#8220;Borrowers&#8221;), entered into a financing agreement, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, and the lenders party thereto (the &#8220;Lenders&#8221;) pursuant to which the Lenders agreed to extend a senior secured credit facility to the Borrowers (the &#8220;Sixth Street Financing Agreement&#8221;). The Sixth Street Financing Agreement, as amended, provides for term loans in an aggregate principal amount up to $750,000, plus any capitalized interest paid in kind (the &#8220;Sixth Street Financing Agreement&#8221;) and is accounted for as third-party, long-term debt by the Parent. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a co-obligor, jointly and severally with the Parent on its third-party long-term debt obligation under the Sixth Street Financing Agreement. The Parent&#8217;s third-party debt and related interest expense are not reflected in the combined financial statements because the Company has not agreed to pay a specified amount of the borrowings on the basis of its arrangement with the Parent, nor is the Company expected to pay any portion of the Parent&#8217;s third-party debt, and the borrowings are not specifically identifiable to SpinCo. Pursuant to the terms of the Merger Agreement, at closing of the Merger, Pfizer will pay off or cause to be paid off the applicable payoff amount on behalf of the Parent.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_247"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of December&#160;31, 2021, there were no matters which would have a material impact on the Company&#8217;s financial results.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_250"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;Related Party Transactions</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not historically operated as a standalone business and the combined financial statements are derived from the consolidated financial statements and accounting records of the Parent. The following disclosure summarizes activity between the Company and the Parent, including the affiliates of the Parent that are not part of the planned spin-off.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_253"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost Allocations</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combined financial statements reflect allocations of certain expenses from the financial statements of the Parent, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including research and development expenses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and general and administrative expenses. These allocations include, but are not limited to, executive management, employee compensation and benefits, facilities and operations, information technology, business development, financial services (such as accounting, audit, and tax), legal, insurance, and share-based compensation. Some of these services are expected to continue to be provided to the Parent on a temporary basis following the Distribution under a transition services agreement. See Note 2 for discussion of these costs and the methodology used to allocate them.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These allocations to SpinCo are reflected in the combined statement of operations and comprehensive loss as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,929&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,482&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,928&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,646&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,857&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,128&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes these cost allocations are a reasonable reflection of services provided to, of the benefit derived by, the Company during the periods presented. The allocations may not, however, be indicative of the actual expenses that would have been incurred had the Company operated as a standalone public company. Actual costs that may have been incurred if the Company had been a standalone public company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by Company employees, and strategic decisions made in areas such as research and development, information technology and infrastructure. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5, Share-based compensation, SpinCo employees participate in the Parent&#8217;s share-based compensation plans, the costs of which have been allocated to SpinCo and recorded in research and development and general and administrative expenses in the combined statements of operations and comprehensive loss.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Transfers From Parent</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net transfers from Parent represent the net effect of transactions between SpinCo and the Parent. The components of net transfers from Parent are as follows&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General financing activities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,834&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,614&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate cost allocations, excluding share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,218&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,628&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers from Parent as reflected in the Combined Statement of Cash Flows</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,052&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,242&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,639&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,500&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Parent common shares as payment for business acquisition</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,673&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Parent common shares as payment for license and consulting agreements</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,929&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Parent common shares as payment for building purchase</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,871&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Parent common shares as payment for Artizan investment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash adjustments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,458)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(744)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers from Parent as reflected in the Combined Statement of Changes in Equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,706&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,998&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_256"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Yale</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;30, 2013, the Company entered into the Yale Agreement with Yale (see Note 6). The Company&#8217;s Chief Executive Officer is one of the inventors of the patents that the Company has licensed from Yale and, as such, is entitled to a specified share of the glutamate product-related royalty revenues that may be received by Yale under the Yale Agreement. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into the Yale MoDE Agreement with Yale (see Note&#160;6 for detail). Under the license agreement, the Company acquired exclusive, worldwide rights to Yale&#8217;s intellectual property directed to its MoDE platform. As part of consideration for this license, the Company paid Yale University an upfront cash payment of $1,000 and 11,668 common shares of the Parent valued at approximately $1,000. Additionally, in the fourth quarter of 2021, the Company paid a $150 development milestone to Yale following the initiation of a Phase I clinical trial.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021 and 2020, excluding the</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> development milestone payment noted above,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recorded $458 and $138 in research and development expense related to the Yale MoDE Agreement and Yale Agreement (the &#8220;Yale Agreements&#8221;). As of December 31, 2021 and 2020, the Company owed no amounts to Yale.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_259"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;Subsequent Events</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated subsequent events through July&#160;1, 2022, the date on which these combined financial statements were available to be issued.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kv7 Platform Acquisition</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company closed the acquisition from Knopp Biosciences LLC (&#8220;Knopp&#8221;) of Channel Biosciences, LLC (&#8220;Channel&#8221;), a wholly owned subsidiary of Knopp owning the assets of Knopp&#8217;s Kv7 channel targeting platform (the &#8220;Transaction&#8221;), pursuant to a Membership Interest Purchase Agreement (the &#8220;Purchase Agreement&#8221;), dated February 24, 2022.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the Transaction, on April 4, 2022, the Company made an upfront payment comprised of $35,000 in cash and 493,254 common shares of the Parent, valued at approximately $58,750, issued through a private placement. The Company has also agreed to pay additional success-based payments comprised of (i) up to $325,000 based on developmental and regulatory milestones through approvals in the United States, EMEA and Japan for the lead asset, BHV-7000 (formerly known as KB-3061), (ii) up to an additional $250,000 based on developmental and regulatory milestones for the Kv7 pipeline development in other indications and additional country approvals, and (iii) up to $562,500 for commercial sales-based milestones of BHV-7000.  Additionally, the Company has agreed to make scaled royalty payments in cash for BHV-7000 and the pipeline programs, starting at high single digits and peaking at low teens for BHV-7000 and starting at mid-single digits and peaking at low tens digits for the pipeline programs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to account for this purchase as an asset acquisition as substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, in-process research and development (&#8220;IPR&#38;D&#8221;). The IPR&#38;D asset has no alternative future use and relates to intellectual property rights related to the Kv7 platform lead, now BHV-7000.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Leases</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company entered into a sublease for office space in Dublin, Ireland to replace an existing license agreement for separate office space. The lease commenced in May 2022 and the lease has a lease term of 59 full calendar months, with no contractual option to extend at the end of the lease term. Upon commencement, the Company&#8217;s base rent per quarter will be &#8364;100 to be paid in advance, with no open market rent review until termination of the lease. The Company will also be responsible for its proportionate share of operating costs, including, but not limited to, real estate taxes, common area maintenance, and utilities.  </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a lease agreement for office space in West Palm Beach, Florida to support its operations, which will be attributed to the Company in connection with the separation. The Company expects to take occupancy of the premises in late 2024, following substantial completion of the tenant improvements. The lease term will commence on the date the Company takes occupancy of the premises and continue for 120 full calendar months, with an option to extend for two additional periods of 60 months each. Upon commencement, the Company&#8217;s base rent per month will be $105 to be paid in advance, with annual base rent increases of 3.00%. In addition, there is a rent abatement period for the first three full calendar months of the lease term. The Company will also be responsible for its proportionate share of operating costs, including, but not limited to, real estate taxes, common area maintenance, and utilities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_262"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_265"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A BUSINESS OF BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.)</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED COMBINED BALANCE SHEETS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:70.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.866%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,209&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,057&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,469&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,734&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,073&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,032&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,751&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,823&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,397&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,010&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,282&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,438&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,220&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,061&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,775&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,473&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,160&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,850&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,935&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,372&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,435&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,222&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,370&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 8)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingently redeemable non-controlling interests</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment from Parent</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,998&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,691&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,998&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,691&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,220&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,061&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these combined financial statements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_268"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A BUSINESS OF BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.)</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED COMBINED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:70.328%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.866%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br>June 30,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,183&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,695&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,700&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,830&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,883&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,525&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286,883)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,525)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investment</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,261&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,021&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286,954)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,504)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,365&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300,319)</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,545)</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these combined financial statements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_271"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A BUSINESS OF BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.)</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED COMBINED STATEMENTS OF CHANGES IN EQUITY</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Investment from Parent</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,691&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300,319)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers from Parent</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,626&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,998&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Investment from Parent</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,781&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,545)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers from Parent</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,896&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,132&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_274"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A BUSINESS OF BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.)</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED COMBINED STATEMENTS OF CASH FLOWS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300,318)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,545)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,930&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,278&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of IPR&#38;D asset</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,747&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Parent common shares as payment for license and consulting agreements</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,779&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,243&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) from equity method investment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,261)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,951)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,026)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,557)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,350)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,581&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,312&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,722)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,053)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,250)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(706)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for IPR&#38;D asset acquisition</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,000)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired in business acquisition</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,250)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers from Parent</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,874&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,396&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,874&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,791&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (decrease) increase in cash and restricted cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,098)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and restricted cash at beginning of period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,057&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,506&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and restricted cash at end of period</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,959&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,420&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these combined financial statements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_277"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_280"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Nature of the Business and Basis of Presentation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2022, Biohaven Pharmaceutical Holding Company Ltd. (&#8220;Biohaven&#8221; or the &#8220;Parent&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;) and a wholly owned subsidiary of Pfizer (&#8220;Merger Sub&#8221;), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), which provides for the acquisition by Pfizer of the Parent through the merger of Merger Sub with and into the Parent (the &#8220;Merger&#8221;). In connection with the Merger Agreement, the Parent and Biohaven Ltd. (&#8220;SpinCo&#8221; or &#8220;the Company&#8221;) entered into a Separation and Distribution Agreement, dated as of May 9, 2022 (the &#8220;Distribution Agreement&#8221;). In connection with the Distribution Agreement, the Board of Directors of the Parent approved and directed the Parent&#8217;s management to effect the spin-off of the business, operations, and activities that are not the CGRP Business (as defined below), including the Kv7 ion channel activators, glutamate modulation, MPO inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by the Parent, or collectively the &#8220;Biohaven Research Business&#8221;. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To implement the spin-off, the Parent expects to transfer the related license agreements, intellectual property and corporate infrastructure, including certain non-commercial employee agreements, share based awards and other corporate agreements (the &#8220;Business&#8221;) to Biohaven Ltd, through a series of internal restructuring transactions, which we refer to as the pre-closing reorganization. Descriptions of historical business activities in these Notes to Condensed Combined Financial Statements are presented as if these transfers had already occurred, and the Parent&#8217;s activities related to such assets and liabilities had been performed by the Company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To effect the spin-off, each of the Parent&#8217;s shareholders will receive one of our common shares for every two common shares of the Parent held prior to the spin-off. Upon completion of the spin-off, the Company will be a stand-alone, publicly traded company focused on the development of its Kv7 ion channel activator, glutamate modulation, MPO inhibition and myostatin inhibition platforms, which it believes have the potential to alter existing treatment approaches across a diverse set of neurological indications with high unmet need in both large markets and orphan indications.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spin-off would generally result in (a) the Company directly or indirectly owning, assuming, or retaining certain assets and liabilities of the Parent and its subsidiaries related to the Parent&#8217;s pipeline assets and businesses and (b) the Parent directly or indirectly owning, assuming, or retaining all other assets and liabilities, including those associated with the Parent&#8217;s platform for the research, development, manufacture and commercialization of calcitonin gene-related receptor antagonists, including rimegepant, zavegepant and the Heptares Therapeutics Limited preclinical CGRP portfolio and related assets (the &#8220;CGRP Business&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts may require additional capital, additional personnel and infrastructure, and further regulatory and other capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon formation and to date, Biohaven Ltd. has had nominal assets, and no liabilities or results of operations and has 100 common shares of no par value outstanding.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed combined financial statements present, on a historical basis, the combined assets, liabilities, expenses and cash flows directly attributable to the Business which have been prepared from the Parent&#8217;s combined financial statements and accounting records and are presented on a stand-alone basis as if the operations have been conducted independently from the Parent. Historically, separate financial statements have not been prepared for the Company and it has not operated as a standalone business from the Parent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed combined financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed combined financial statements of operations and comprehensive loss include all costs directly related to the Business, including costs for facilities, functions and services utilized by the Company. The condensed combined statements of operations and comprehensive loss also include allocations for various expenses related to the Parent&#8217;s corporate functions, including research and development, human resources, information technology, facilities, tax, shared services, accounting, finance and legal. These expenses were allocated on the basis of direct usage or benefit when specifically identifiable, with the remainder allocated on a proportional cost allocation method primarily based on employee labor hours or direct expenses. Management believes the assumptions underlying the condensed combined financial statements, including the expense methodology and resulting allocation, are reasonable for all periods presented. However, the allocations may not include all of the actual expenses that would have been incurred by the Company and may not reflect its combined results of operations, financial position and cash flows had it been a standalone company during the periods presented. It is not practicable to estimate actual costs that would have been incurred had the Company been a standalone company and operated as an unaffiliated entity during the periods presented. Actual costs that might have been incurred had the Company been a standalone company would depend on a number of factors, including the organizational structure, what corporate functions the Company might have performed directly or outsourced and strategic decisions the Company might have made in areas such as executive management, legal and other professional services, and certain corporate overhead functions.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax amounts in the condensed combined financial statements have been calculated on a separate return method and are presented as if the Company&#8217;s operations were separate taxpayers in the respective jurisdiction. Therefore, tax expense, cash tax payments, and items of current and deferred taxes may not be reflective of the Company&#8217;s actual tax balances prior to or subsequent to the distribution.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the separation, the Company and Biohaven expect to enter into a transition services agreement whereby the Company will provide certain transition services to Biohaven and Biohaven will provide certain transition services to the Company. The Company expects to continue to incur certain costs to establish itself as a standalone public company, as well as ongoing additional costs associated with operating as an independent, publicly traded company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed combined balance sheets include assets and liabilities that have been determined to be specifically identifiable or otherwise attributable to the Company, including certain assets that were historically held at the corporate level in the Parent. All intracompany transactions within the Company have been eliminated. All intercompany transactions between the Company and the Parent are considered to be effectively settled in the condensed combined financial statements at the time the transactions are recorded. The total net effect of these intercompany transactions considered to be settled is reflected in the condensed combined statement of cash flows within financing activities and in the condensed combined balance sheets as &#8220;Net investment from Parent.&#8221; See Note 9, Related Party Transactions for additional information regarding related party transactions.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity balance in these condensed combined financial statements represents the excess of total assets over liabilities. Net investment from Parent is primarily impacted by contributions from Parent which are the result of net funding provided by or distributed to Parent.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash on the condensed combined balance sheets represents cash balances from the standalone entities established to operate the Business and that will be contributed to the Company in connection with the spin-off.  The Company is a co-obligor, jointly and severally with the Parent on Biohaven&#8217;s third-party long-term debt obligations with Sixth Street Specialty Lending, Inc.  Biohaven&#8217;s third-party long-term debt and related interest expense are not reflected in the condensed combined financial statements because the Company has not agreed to pay a specified amount of the borrowings on the basis of its arrangement with the Parent, nor is the Company expected to pay any portion of the Parent&#8217;s third-party debt, and the borrowings are not specifically identifiable to SpinCo. See Note 8, Commitments and Contingencies for additional information regarding debt.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_283"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the condensed combined financial statements are issued.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through August&#160;10, 2022, the Company has funded its operations primarily with proceeds from Biohaven Pharmaceutical Holding Co. Ltd., its Parent, and the Company expects the Parent to continue to fund its cash needs though the date of Distribution. The Company has incurred recurring losses since its inception, including net losses of $300,319 and $107,545 during the six months ended June 30, 2022 and 2021, respectively. The Company expects to continue to generate operating losses for the foreseeable future. As of August&#160;10, 2022, the issuance date of these condensed combined financial statements, the Company expects that its continued funding from Parent will be sufficient to fund operating expenses, financial commitments and other cash requirements for at least one year after the issuance date of these financial statements. Following the Distribution, the Company&#8217;s viability will be dependent on its ability to raise additional capital to finance its operations.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute its business plans, the Company will require funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through the sale of public or private equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s shareholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_286"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Summary of Significant Accounting Policies</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies used in preparation of these combined financial statements for the six months ended June 30, 2022 and 2021 are described in Note 2 to the combined financial statements for the year ended December 31, 2021. Updates to our accounting policies, including impacts from the adoption of new accounting standards, are discussed below in this Note 2. </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_289"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Combined Financial Information </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed combined financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. The accompanying unaudited condensed combined financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete combined financial statements. The accompanying year-end condensed combined balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America.&#160;The unaudited interim condensed combined financial statements have been prepared on the same basis as the audited annual combined financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of June 30, 2022 and the results of its operations for the six months ended June 30, 2022 and 2021 and its cash flows for the six months ended June 30, 2022 and 2021. The results for the six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods or any future year or period.&#160; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_292"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed combined financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the combined financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed combined financial statements include, but are not limited to, the valuation of intangible assets, determining the allocations of costs and expenses from the Parent and the accrual for research and development expenses. In addition, management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_295"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&#38;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, the asset is classified as a definite-lived intangible and the Company will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates IPR&#38;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&#38;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, the acquired IPR&#38;D is expensed on its acquisition date, unless it has an alternative future use. Future costs to develop these assets are recorded to research and development expense as they are incurred.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_298"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022 the Company adopted ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#58; Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force), which provides guidance on modifications or exchanges of a freestanding equity-classified written call option that is not within the scope of another topic.  An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument, and provides further guidance on measuring the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. ASU 2021-04 also provides guidance on the recognition of the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration. The guidance has been applied prospectively and did not have a material effect on the combined financial statements of the Company.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_301"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022 the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820)&#58; Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify the guidance in Topic 820 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security. The ASU also introduced new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023. The Company is currently evaluating the effects of ASU 2022-03 on its combined financial statements.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_304"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Balance Sheet Components</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash primarily consists of collateral held by a bank for a letter of credit (&#8220;LOC&#8221;) issued in connection with the leased office space in Yardley, Pennsylvania. See Note 8 &#8220;Commitments and Contingencies&#8221; for additional information on the real estate lease. The following represents a reconciliation of cash in the condensed combined balance sheets to total cash and restricted cash as of June 30, 2022 and June 31, 2021, respectively, in the condensed combined statements of cash flows&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:70.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.866%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,209&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,420&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other current assets)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other non-current assets)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and restricted cash at the end of the period in the condensed combined statement of cash flows</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,959&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,420&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consisted of the following&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income tax receivable</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,097&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,911&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,073&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,032&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and land</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,297&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,297&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and lab equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,904&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,602&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,352&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,205)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,342)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,397&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,010&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $488 for the six months ended June 30, 2022 and $329 for the six months ended June 30, 2021.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, computer software costs included in property and equipment were $760 and $760, respectively, net of accumulated amortization of $338 and $211, respectively. Depreciation and amortization expense for capitalized computer software costs not material for the six months ended June 30, 2022 or 2021.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Non-current Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets consisted of the following&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A-2 Preferred Stock Investment</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,262&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,216&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,282&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,438&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a Series A-2 Preferred Stock Purchase Agreement with Artizan Biosciences Inc. (&#8220;Artizan&#8221;). Under the agreement, the Company paid Artizan 61,494 shares of the Parent&#8217;s common shares valued at $6,000, which were issued in January 2021. In exchange, the Company acquired 34,472,031 shares of series A-2 preferred stock of Artizan. In June 2022, the Company entered into an Amendment to the Series A-2 Preferred Stock Purchase Agreement with Artizan. Under the Amendment, the Company made a cash payment of $4,000 in exchange for 22,975,301 additional shares of series A-2 preferred stock of Artizan. The Company determined that it was not practical to estimate the fair value of this investment as it represents Series A-2 Preferred Stock of an unlisted company. On a routine basis the Company will determine if additional preferred shares of the unlisted company have been issued and will adjust the carrying value of its Series A-2 Preferred Stock investment accordingly. See Note 6 &#8220;License Agreements&#8221; for additional details on the Artizan Agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued development milestones</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,178&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,538&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,015&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,051&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,280&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,571&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,473&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,160&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingently Redeemable Non-controlling Interest</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company&#8217;s Asia-Pacific Subsidiary, BioShin Limited (&#8220;BioShin&#8221;), authorized, issued and sold 15,384,613 BioShin Series A Preferred Shares at a price of $3.90 per share for a total of $60,000 to a group of investors led by OrbiMed, with participation from Cormorant Asset Management LLC, HBM Healthcare Investments Ltd, Surveyor Capital (a Citadel Company), and Suvretta Capital Management, LLC (the &#8220;BioShin Investors&#8221;).  The BioShin Series A Preferred Shares contained both a call option by the Company and a put option held by the BioShin Investors. Due to the contingently redeemable features, the Company had classified the BioShin Series A Preferred Shares in mezzanine equity since the redemption was out of the Company's control. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company, Biohaven Therapeutics Ltd. (&#8220;BTL&#8221;), Atlas Merger Sub and BioShin entered into an Agreement and Plan of Merger (the &#8220;BioShin Merger Agreement&#8221;). The BioShin Merger Agreement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided for the merger of Atlas Merger Sub with and into BioShin, with BioShin surviving the merger as a wholly owned indirect subsidiary of the Parent, in accordance with Section 233 of the Cayman Islands Companies Act. As a result of the satisfaction of the closing conditions described in the BioShin Merger Agreement, on January 6, 2022, each Series A convertible preferred share of BioShin, no par value, other than Excluded Shares (as defined in the BioShin Merger Agreement), was converted into the right to receive 0.080121 of the Parent&#8217;s common shares and was removed from mezzanine equity.  No Series A convertible preferred shares of BioShin were outstanding following the closing.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_307"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Acquisitions</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition of Kleo Pharmaceuticals, Inc.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2021, the Company acquired Kleo Pharmaceuticals, Inc. (&#8220;Kleo&#8221;). Kleo is a development-stage biopharmaceutical company focused on advancing the field of immunotherapy by developing small molecules that emulate biologics. The transaction was accounted for as the acquisition of a business using the acquisition method of accounting.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of the consideration transferred was $20,043, which primarily consisted of the issuance of a total of 115,836 common shares of the Parent to Kleo stockholders and contingent consideration in the form of a contingent value right to receive one dollar in cash for each Kleo share if certain specified Kleo biopharmaceutical products or product candidates receive the approval of the FDA prior to the expiration of 30 months following the effective time of the transaction. The maximum amount payable pursuant to the contingent value right was approximately $17,300. At December 31, 2021, the Company determined the value of the contingent value right to be immaterial and recognized a gain of $1,457 related to the contingent value right in other income (expense). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the consummation of the transaction, the Company owned approximately 41.9% of the outstanding shares of Kleo and accounted for it as an equity method investment. As part of the transaction, the Company acquired the remainder of the shares of Kleo, and post-transaction the Company owns 100% of the outstanding shares of Kleo. The carrying value of the Company&#8217;s investment in Kleo was $1,176 immediately prior to the acquisition date. The Company determined the fair value of the existing interest was $6,437, and recognized a gain from its equity method investment of $5,261 for the year ended December 31, 2021 as a result of remeasuring to fair value the existing equity interest in Kleo, which was included as Gain (loss) from equity method investment on the condensed combined statements of operations and comprehensive loss.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the transaction, the Company recorded&#58; net working capital of $573&#59; property, plant and equipment of $1,257&#59; intangible assets consisting of in progress research and development assets of $18,400 which include an oncology therapeutic candidate entering Phase I clinical trials and a COVID-19 therapeutic candidate in the planning stage for clinical development&#59; debt assumed of $1,577&#59; and goodwill of $1,390. The goodwill is primarily attributable to the acquired workforce.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kleo&#8217;s employees, other than its President and Chief Financial Officer, were retained as part of the transaction. In connection with the transaction agreement, the Company filed a registration statement permitting Kleo stockholders to offer and sell the common shares of the Company issued in the transaction.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kv7 Platform Acquisition</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company closed the acquisition from Knopp Biosciences LLC (&#8220;Knopp&#8221;) of Channel Biosciences, LLC (&#8220;Channel&#8221;), a wholly owned subsidiary of Knopp owning the assets of Knopp&#8217;s Kv7 channel targeting platform (the &#8220;Kv7 Platform Acquisition&#8221;), pursuant to a Membership Interest Purchase Agreement (the &#8220;Purchase Agreement&#8221;), dated February 24, 2022.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the Kv7 Platform Acquisition, on April 4, 2022, the Company made an upfront payment comprised of $35,000 in cash and 493,254 common shares of the Parent, valued at approximately $58,747, issued through a private placement. The Company has also agreed to pay additional success-based payments comprised of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) up to $325,000 based on developmental and regulatory milestones through approvals in the United States, EMEA and Japan for the lead asset, BHV-7000 (formerly known as KB-3061), (ii) up to an additional $250,000 based on developmental and regulatory milestones for the Kv7 pipeline development in other indications and additional country approvals, and (iii) up to $562,500 for commercial sales-based milestones of BHV-7000.  Additionally, the Company has agreed to make scaled royalty payments in cash for BHV-7000 and the pipeline programs, starting at high single digits and peaking at low teens for BHV-7000 and starting at mid-single digits and peaking at low tens digits for the pipeline programs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for this purchase as an asset acquisition as substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, in-process research and development (&#8220;IPR&#38;D&#8221;). The IPR&#38;D asset has no alternative future use and relates to intellectual property rights related to the Kv7 platform lead, now BHV-7000. There was no material value assigned to any other assets acquired in the acquisition.  As such, during the second quarter of 2022, the Company recorded a charge to R&#38;D expense in the accompanying condensed combined statements of operations and comprehensive loss of $93,747. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, the Company recorded a liability for a $25,000 regulatory milestone payment which became due to Knopp in June 2022. The milestone payment was recorded as R&#38;D expense in the accompanying condensed combined statements of operations and comprehensive loss during the six months ended June 30, 2022.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the milestone payment noted above, the Company has not recorded any of the possible contingent consideration payments to Knopp as a liability in the accompanying condensed combined balance sheet as none of the future events which would trigger a milestone payment were considered probable of occurring at June 30, 2022.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_310"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Share-Based Compensation</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_313"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parent has share-based compensation plans under which it may issue common shares or restricted common shares, or grant incentive stock options or nonqualified stock options for the purchase of common shares, to employees, members of the board of directors and consultants of the Parent. The Parent also has an Employee Share Purchase Plan (the &#8220;ESPP&#8221;) which allows eligible employee who are participating in the plan to purchase shares of the Parent at a discount. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation has been allocated to the Company by using a combination of specific identification and a proportionate cost allocation method based on employee hours or directly identified operating expenses, depending on the employee&#8217;s function. The amounts presented are not necessarily indicative of future awards and do not necessarily reflect the costs that the Company would have incurred as an independent company for the periods presented.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation under the Parent&#8217;s share-based compensation plans is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the award (generally three to four years) using the straight-line method. Share-based compensation expense attributed to the Company by classification included within in the condensed combined statements of operations and comprehensive loss was as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.534%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.683%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,254&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,899&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,676&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,379&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,930&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,278&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_316"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">License Agreements</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_319"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Yale Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013, the Company entered into an exclusive license agreement (the &#8220;Yale Agreement&#8221;) with Yale University to obtain a license to certain patent rights for the commercial development, manufacture, distribution, use and sale of products and processes resulting from the development of those patent rights, related to the use of riluzole in treating various neurological conditions, such as general anxiety disorder, post-traumatic stress disorder and depression. As part of the consideration for this license, the Company issued Yale 250,000 common shares of the Parent and granted Yale the right to purchase up to 10% of the securities issued in specified future equity offerings by the Parent, in addition to the obligation to issue shares to prevent anti-dilution. The obligation to contingently issue equity to Yale was no longer outstanding as of December 31, 2018.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Yale Agreement was amended and restated in May 2019. As amended, the Company agreed to pay Yale up to $2,000 upon the achievement of specified regulatory milestones and annual royalty payments of a low single-digit percentage based on net sales of riluzole-based products from the licensed patents or from products based on troriluzole. Under the amended and restated agreement, the royalty rates are reduced as compared to the original agreement. In addition, under the amended and restated agreement, the Company may develop products based on riluzole or troriluzole. The amended and restated agreement retains a minimum annual royalty of up to $1,000 per year, beginning after the first sale of product under the agreement. If the Company grants any sublicense rights under the Yale Agreement, it must pay Yale a low single-digit percentage of sublicense income that it receives.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the Company did not record any material expense or make any milestone or royalty payments under the Yale Agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered a worldwide, exclusive license agreement with Yale University for the development and commercialization of a novel Molecular Degrader of Extracellular Protein (&#8220;MoDE&#8221;) platform (the &#8220;Yale MoDE Agreement&#8221;). Under the license agreement, the Company acquired exclusive, worldwide rights to Yale's intellectual property directed to its MoDE platform. The platform pertains to the clearance of disease-causing protein and other biomolecules by targeting them for lysosomal degradation using multi-functional molecules. As part of consideration for this license, the Company paid Yale University an upfront cash payment of $1,000 and 11,668 shares of the Parent valued at approximately $1,000. Under the agreement, the Company may develop products based on the MoDE platform. The agreement includes an obligation to pay a minimum annual royalty of up to $1,000 per year, and low single digit royalties on the net sales of licensed products. If the Company grants any sublicense rights under the Yale Agreement, it must pay Yale a low single-digit percentage of sublicense income that it receives. In addition, Yale University will be eligible to receive additional development milestone payments of up to $800 and commercial milestone payments of up to $2,950. The agreement terminates on the later of twenty years from the effective date, twenty years from the filing date of the first investigational new drug application for a licensed product or the last to expire of a licensed patent. Under the Yale MoDE Agreement, the Company entered into a sponsored research agreement (the &#8220;Yale MoDE SRA&#8221;) which included funding of up to $4,000 over the life of the agreement. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the upfront payments above, the Company recorded research and development expense related to the Yale MoDE Agreement of $2,000 and $150 for the six months ended June 30, 2022 and 2021, respectively. For the six months ended June 30, 2022 and 2021, the Company did not make any milestone or royalty payments under the Yale MoDE Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_322"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ALS Biopharma Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2015, the Company entered into an agreement (the &#8220;ALS Biopharma Agreement&#8221;) with ALS Biopharma and Fox Chase Chemical Diversity Center Inc. (&#8220;FCCDC&#8221;), pursuant to which ALS Biopharma and FCCDC assigned the Company their worldwide patent rights to a family of over 300 prodrugs of glutamate modulating agents, including troriluzole, as well as other innovative technologies. Under the ALS Biopharma </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement, the Company is obligated to use commercially reasonable efforts to commercialize and develop markets for the patent products. The Company is obligated to pay $3,000 upon the achievement of specified regulatory milestones with respect to the first licensed product and $1,000 upon the achievement of specified regulatory milestones with respect to subsequently developed products, as well as royalty payments of a low single-digit percentage based on net sales of products licensed under the agreement, payable on a quarterly basis.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ALS Biopharma Agreement terminates on a country-by-country basis as the last patent rights expire in each such country. If the Company abandons its development, research, licensing or sale of all products covered by one or more claims of any patent or patent application assigned under the ALS Biopharma Agreement, or if the Company ceases operations, it has agreed to reassign the applicable patent rights back to ALS Biopharma.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the Company did not record any expense or make any milestone or royalty payments under the ALS Biopharma Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_325"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 AstraZeneca Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, the Company entered into an exclusive license agreement (the &#8220;2016 AstraZeneca Agreement&#8221;) with AstraZeneca, pursuant to which AstraZeneca granted the Company a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights, including BHV-5000 and BHV-5500. In exchange for these rights, the Company agreed to pay AstraZeneca an upfront payment, milestone payments and royalties on net sales of licensed products under the agreement. The regulatory milestones due under the 2016 AstraZeneca Agreement depend on the indication of the licensed product being developed as well as the territory where regulatory approval is obtained.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development milestones due under the 2016 AstraZeneca Agreement with respect to Rett syndrome total up to $30,000, and, for any indication other than Rett syndrome, total up to $60,000. Commercial milestones are based on net sales of all products licensed under the agreement and total up to $120,000. The Company has also agreed to pay royalties in two tiers, with each tiered royalty in the range from 0-10% of net sales of products licensed under the agreement. If the Company receives revenue from sublicensing any of its rights under the 2016 AstraZeneca Agreement, the Company is also obligated to pay a portion of that revenue to AstraZeneca. The Company is also required to reimburse AstraZeneca for any fees that AstraZeneca incurs related to the filing, prosecution, defending, and maintenance of patent rights licensed under the 2016 AstraZeneca Agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 AstraZeneca Agreement expires upon the expiration of the patent rights under the agreement or on a country-by-country basis ten years after the first commercial sale and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the Company did not record any expense or make any milestone or royalty payments under the 2016 AstraZeneca Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_328"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 AstraZeneca Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company entered into an exclusive license agreement (the &#8220;2018 AstraZeneca Agreement&#8221;) with AstraZeneca, pursuant to which AstraZeneca granted the Company a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights, including BHV-3241. Under the 2018 AstraZeneca Agreement, the Company paid AstraZeneca an upfront cash payment of $3,000 and 109,523 shares valued at $4,080 on the date of settlement, both of which were included in research and development expense, and is obligated to pay milestone payments to AstraZeneca totaling up to $55,000 upon the achievement of specified regulatory and commercial milestones and up to $50,000 upon the achievement of specified sales-based milestones. In addition, the Company will pay AstraZeneca royalties in three tiers, with each tiered royalty in the range from 0-10% of net sales of specified approved products, subject to specified reductions. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company completed enrollment in a Phase 3 clinical trial of this product candidate, which is now referred to as verdiperstat, for the treatment of Amyotrophic Lateral Sclerosis (&#8220;ALS&#8221;). ALS is a progressive, life-threatening, and rare neuromuscular disease for which there are currently limited treatment options and no cure. The Company is solely responsible, and has agreed to use commercially reasonable efforts, for all development, regulatory and commercial activities related to verdiperstat. The Company may sublicense its rights under the agreement and, if it does so, will be obligated to pay a portion of any milestone payments received from the sublicense to AstraZeneca in addition to any milestone payments it would otherwise be obligated to pay.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 AstraZeneca Agreement terminates on a country-by-country basis and product-by-product basis upon the expiration of the royalty term for such product in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the Company did not record any material expense or make any milestone or royalty payments under the 2018 AstraZeneca Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_331"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fox Chase Chemical Diversity Center Inc. Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company entered into the FCCDC Agreement in which the Company purchased certain intellectual property relating to the TDP-43 protein from FCCDC. The FCCDC Agreement provides the Company with a plan and goal to identify one or more new chemical entity candidates for preclinical development for eventual clinical evaluation for the treatment of one or more TDP-43 proteinopathies. As consideration, the Company issued 100,000 of the Parent&#8217;s common shares to FCCDC valued at $5,646.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is obligated to pay FCCDC milestone payments totaling up to $4,500 with $1,000 for each additional NDA filing. The Company also issued a warrant to FCCDC, granting FCCDC the option to purchase up to 100,000 of the Parent&#8217;s common shares, at a strike price of $56.46 per share, subject to vesting upon achievement of certain milestones in development of TDP-43.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FCCDC Agreement, the Company and FCCDC have established a TDP-43 Research Plan, which was amended in November 2020, that provides for certain milestones to be achieved by FCCDC, and milestone payments to be made by the Company up to approximately $3,800 over a period of up to 30 months as success fees for research activities by FCCDC. In addition to the milestone payments, the Company will pay FCCDC an earned royalty equal to 0% to 10% of net sales of any TD-43 patent products with a valid claim as defined in the FCCDC Agreement. The Company may also license the rights developed under the FCCDC Agreement and, if it does so, will be obligated to pay a portion of any payments received from such licensee to FCCDC in addition to any milestones it would otherwise be obligated to pay. The Company is also responsible for the prosecution and maintenance of the patents related to the TDP-43 assets.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCCDC Agreement terminates on a country-by-country basis and product-by-product basis upon expiration of the royalty term for such product in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record any material research and development expense or make any milestone payments related to the FCCDC Agreement in the combined statements of operations and comprehensive loss during the six months ended June 30, 2022 and 2021.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_334"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UConn</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company announced it had signed an exclusive, worldwide option and license agreement (the &#8220;UConn Agreement&#8221;) with the&#160;University of Connecticut&#160;(&#8220;UConn&#8221;) for the development and commercialization rights to UC1MT, a therapeutic antibody targeting extracellular metallothionein. Under this agreement, the Company has the option to acquire an exclusive, worldwide license to UC1MT and its underlying patents to develop and commercialize throughout the world in all human indications. If the Company chooses to exercise the option, it would be obligated to pay UConn upon the achievement of specified regulatory and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial milestones, and royalties of a low single-digit percentage of net sales of licensed products sold by the Company, its affiliates or its sublicensees.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the Company did not record any research and development expense or make any milestone payments related to the UConn Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_337"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Artizan Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, BTL entered into an Option and License Agreement with Artizan Biosciences Inc (the &#8220;2020 Artizan Agreement&#8221;). Pursuant to the 2020 Artizan Agreement, BTL acquired an option (&#8220;Biohaven Option&#8221;) to obtain a royalty-based license from Artizan to manufacture, use and commercialize certain products in the United States for the treatment of diseases, including, for example, inflammatory bowel disease and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other gastrointestinal inflammatory disorders, e.g., Crohn&#8217;s disease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Biohaven Option is exercisable throughout the development phase of the products at an exercise price of approximately $4,000 to $8,000, which varies based on the market potential of the products. BTL and Artizan have also formed a joint steering committee to oversee, review and coordinate the product development activities with regard to all products for which BTL has (or has exercised in the future) the Biohaven Option.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, simultaneously with the Option and License Agreement, the Company entered into a Series A-2 Preferred Stock Purchase Agreement with Artizan. Under the agreement, the Company paid Artizan 61,494 of the Parent&#8217;s common shares valued at $6,000, which were issued in January 2021. In exchange, the Company acquired 34,472,031 shares of series A-2 preferred stock of Artizan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, BTL entered into a Development and License Agreement with Artizan Biosciences Inc (the &#8220;2021 Artizan Agreement&#8221;). Pursuant to the 2021 Artizan Agreement, BTL acquired an exclusive, worldwide license under Artizan&#8217;s IgA-SEQ patented technology and know-how to develop, manufacture and commercialize certain of Artizan&#8217;s compounds for use in Parkinson&#8217;s Disease. Under the agreement, BTL is responsible for funding the development of the compounds, obtaining regulatory approvals, manufacturing the compounds and commercializing the compounds.  BTL is also responsible for the prosecution, maintenance and enforcement of Artizan&#8217;s patents. BTL will pay Artizan development milestones of $20,000 for the first licensed compound to achieve U.S. marketing authorization and $10,000 for each subsequent U.S. approval.  In addition, BTL will pay Artizan commercialization milestones totaling up to $150,000 and royalties in the low to mid single digits.  The 2021 Artizan Agreement terminates on a country-by-country basis on the later of 10 years from the first commercial sale of licensed product in such country or the expiration of Artizan&#8217;s patents in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into an Amendment to the Series A-2 Preferred Stock Purchase Agreement with Artizan. Under the Amendment, the Company made a cash payment of $4,000 in exchange for 22,975,301 shares of series A-2 preferred stock of Artizan out of a total of 45,950,601 shares of series A-2 preferred stock of Artizan for a total raise of $8,000 (the &#8220;A2 Extension Raise&#8221;). Along with the Amendment, the Company and Artizan executed a non-binding indication of interest (&#8220;Artizan Side Letter&#8221;) which describes terms under which BTL and Artizan would amend the 2020 Artizan Agreement to eliminate certain milestone payments required by us in exchange for limiting our option to the selection of the first (ARZC-001) licensed product.  The Artizan Side Letter requires Artizan to commit at least 80% of the funds raised in the A-2 Extension Raise to a certain program and to raise $35,000 of additional capital within a certain time. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, excluding the upfront payments above, the Company did not record any research and development expense or make any milestone payments related to the Artizan Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_340"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Moda Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, the Company entered into a consulting services agreement with Moda Pharmaceuticals LLC (the &#8220;Moda Agreement&#8221;) to further the scientific advancement of technology, drug discovery platforms </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including the technology licensed under the Yale MoDE Agreement), product candidates and related intellectual property owned or controlled by the Company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Moda Agreement, the Company paid Moda an upfront cash payment of $2,700 and 37,836 shares of the Parent valued at approximately $3,243. In addition, Moda will be eligible to receive additional development milestone payments of up to $81,612 and commercial milestone payments of up to $30,171. The Moda Agreement has a term of four years and may be terminated earlier by the Company or Moda under certain circumstances including, for example, the Company&#8217;s discontinuation of research on the MoDE platform or default.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, excluding the upfront payments above, the Company did not record any material research and development expense or make any milestone payments related to the Moda Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_343"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reliant Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into the Reliant Agreement pursuant to which the Company and Reliant have agreed to collaborate on a program with Biohaven Labs&#8217; multifunctional molecules to develop and commercialize conjugated antibodies for therapeutic uses relating to IgA nephropathy and treatment of other diseases and conditions. Under the Reliant Agreement, the Company paid Reliant an upfront payment in the form of issuance of common shares valued at approximately $3,686, which the Company recorded as research and development expense on its combined statement of operations and comprehensive loss. In addition, Reliant will be eligible to receive development and regulatory milestone payments of up to $36,500, and royalties of a low single-digit percentage of net sales of licensed products.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the Company did not record any material research and development expense related to the Reliant Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_346"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KU Leuven Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company and Katholieke Universiteit Leuven (&#8220;KU Leuven&#8221;) entered into an Exclusive License and Research Collaboration Agreement (the &#8220;KU Leuven Agreement&#8221;) to develop and commercialize TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders. The TRPM3 antagonist platform was discovered at the Centre for Drug Design and Discovery (&#8220;CD3&#8221;) and the Laboratory of Ion Channel Research (&#8220;LICR&#8221;) at KU Leuven. Under the KU Leuven Agreement, the Company receives exclusive global rights to develop, manufacture and commercialize KU Leuven's portfolio of small-molecule TRPM3 antagonists. The portfolio includes the lead candidate, henceforth known as BHV-2100, which is being evaluated in preclinical pain models and will be the first to advance towards Phase 1 studies. The Company will support further basic and translational research at KU Leuven on the role of TRPM3 in pain and other disorders. As consideration, KU Leuven received an upfront cash payment of $3,000 and 15,340 shares valued at $1,779, and is eligible to receive additional development, regulatory, and commercialization milestones payments of up to $327,750. In addition, KU Leuven will be eligible to receive mid-single digit royalties on net sales of products resulting from the collaboration.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the upfront payments discussed above, the Company recorded $397 in research and development expense related to the KU Leuven Agreement during the six months ended June 30, 2022. The Company did not record any research and development expense relating to the KU Leuven Agreement during the six months ended June 30, 2021.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_349"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taldefgrobep Alfa License Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, following the transfer of intellectual property the Company announced that it entered into a worldwide license agreement with BMS for the development and commercialization rights to taldefgrobep alfa (also known as BMS-986089), a novel, Phase 3-ready anti-myostatin adnectin (the &#8220;Taldefgrobep Alfa License Agreement&#8221;). Under the terms of the Taldefgrobep Alfa License Agreement, the Company will receive worldwide </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights to taldefgrobep alfa and BMS will be eligible for regulatory approval milestone payments of up to $200,000, as well as tiered, sales-based royalty percentages from the high teens to the low twenties. There were no upfront or contingent payments to BMS related to the Taldefgrobep Alfa License Agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the Company did not record any material expense or make any milestone or royalty payments under the Taldefgrobep Alfa License Agreement.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_352"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Income Taxes</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a comparative summary of the Company&#8217;s income tax provision and effective income tax rate for the six months ended June 30, 2022 and 2021&#58;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,365&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.66&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded an income tax provision of $13,365 for the six months ended June 30, 2022 compared to a provision for income taxes of $41 for the six months ended June 30, 2021. The increase in income tax expense for the six months ended June 30, 2022 as compared to 2021 was primarily attributable to the mandatory capitalization of R&#38;D expenses effective January 1, 2022 under the Tax Cuts and Jobs Act, offset by an increased benefit to the Company&#8217;s foreign derived intangible income deduction.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_355"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Commitments and Contingencies</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following agreements are either current Company agreements, or those the Parent expects to assign to the Company upon separation, accordingly, all considerations paid by the Parent in association with these agreements are recorded in the combined financial statements of the Company.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_358"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parent&#8217;s leases primarily consist of office space that will be attributed to the Company in connection with the separation. The Company determines if an arrangement is a lease at inception. The lease term includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Real estate leases for facilities have an average remaining lease term of 4.66 years as of June 30, 2022, for which none include the optional extension. The Company has made an accounting policy election not to record short-term leases (leases with an initial term of 12 months or less) on the balance sheet. The Company currently has two short-term leases with immaterial lease expense.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since most of the Company&#8217;s leases do not have a readily determinable implicit discount rate, the Company uses the Parent&#8217;s incremental borrowing rate to calculate the present value of lease payments. The Company does not separate lease components (e.g., payments for rent, real estate taxes and insurance costs) from non-lease components (e.g., common-area maintenance costs) in the event that the agreement contains both. The Company includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). The allocated operating lease cost was $220 and $153 for the six months ended June 30, 2022 and 2021, respectively. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s lease agreements contain variable lease payments that are adjusted for actual operating expense true-ups compared with estimated amounts&#59; however, these amounts are immaterial. The Company had no sublease income and there are no sale-leaseback transactions. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases is as follows&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new operating lease liabilities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No right-of-use assets were obtained in exchange for new operating lease liabilities during the six months ended June 30, 2021. Operating cash flows paid for operating leases were immaterial for the six months ended June 30, 2022 and 2021.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets </font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,262</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,797</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,457</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,236</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.66</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.47&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.07&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities are as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining sixth months)</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,526&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,706&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; imputed interest</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,249)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,457&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_361"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Commitments</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parent has entered into agreements with several CROs to provide services in connection with the Company&#8217;s preclinical studies and clinical trials. Research Commitments entered into by the Parent and related to the Company are expected to transfer to the Company upon separation. As of June 30, 2022, the Company had remaining maximum research commitments of approximately $21,400, which are variable based on number of trial participants, and contingent upon the achievement of certain milestones of the clinical trials covered under the agreements. If all related milestones are achieved, the Company expects these amounts to be paid over the next five years.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_364"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company&#8217;s amended and restated memorandum and articles of association also provide for indemnification of directors and officers in specific circumstances. To date, the Company has not incurred any material costs as a result of such indemnification provisions. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its combined financial statements as of June 30, 2022 or December 31, 2021.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_367"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parent entered into license agreements with various parties that are directly attributed to the Company under which it is obligated to make contingent and non-contingent payments (see Note 6). License agreements entered by the Parent and related to the Company are expected to transfer to the Company upon separation</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_370"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sixth Street Financing Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Parent and Biohaven Pharmaceuticals, Inc., (together with the Parent the &#8220;Borrowers&#8221;), entered into a financing agreement, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, and the lenders party thereto (the &#8220;Lenders&#8221;) pursuant to which the Lenders agreed to extend a senior secured credit facility to the Borrowers (the &#8220;Sixth Street Financing Agreement&#8221;). The Sixth Street Financing Agreement, as amended, provides for term loans in an aggregate principal amount up to $750,000, plus any capitalized interest paid in kind (the &#8220;Sixth Street Financing Agreement&#8221;) and is accounted for as third-party, long-term debt by the Parent. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a co-obligor, jointly and severally with the Parent on its third-party long-term debt obligation under the Sixth Street Financing Agreement. The Parent&#8217;s third-party debt and related interest expense are not reflected in the combined financial statements because the Company has not agreed to pay a specified amount of the borrowings on the basis of its arrangement with the Parent, nor is the Company expected to pay any portion of the Parent&#8217;s third-party debt, and the borrowings are not specifically identifiable to SpinCo. Pursuant to the terms of the Merger Agreement, at closing of the Merger, Pfizer will pay off or cause to be paid off the applicable payoff amount on behalf of the Parent.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_373"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of June 30, 2022, there were no matters which would have a material impact on the Company&#8217;s financial results.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_376"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Related Party Transactions</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not historically operated as a standalone business and the combined financial statements are derived from the consolidated financial statements and accounting records of the Parent. The following disclosure summarizes activity between the Company and the Parent, including the affiliates of the Parent that are not part of the planned spin-off.</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_379"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost Allocations</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combined financial statements reflect allocations of certain expenses from the financial statements of the Parent, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including research and development expenses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and general and administrative expenses. These allocations include, but are not limited to, executive management, employee compensation and benefits, facilities and operations, information technology, business development, financial services (such as accounting, audit, and tax), </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legal, insurance, and share-based compensation. Some of these services are expected to continue to be provided to the Parent on a temporary basis following the Distribution under a transition services agreement. See Note 2 for discussion of these costs and the methodology used to allocate them.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These allocations to SpinCo are reflected in the combined statement of operations and comprehensive loss as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.420%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.820%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,724&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,674&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,377&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,778&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,101&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,452&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes these cost allocations are a reasonable reflection of services provided to, of the benefit derived by, the Company during the periods presented. The allocations may not, however, be indicative of the actual expenses that would have been incurred had the Company operated as a standalone public company. Actual costs that may have been incurred if the Company had been a standalone public company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by Company employees, and strategic decisions made in areas such as research and development, information technology and infrastructure. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5, Share-based compensation, SpinCo employees participate in the Parent&#8217;s share-based compensation plans, the costs of which have been allocated to SpinCo and recorded in research and development and general and administrative expenses in the condensed combined statements of operations and comprehensive loss.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Transfers From Parent</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net transfers from Parent represent the net effect of transactions between SpinCo and the Parent. The components of net transfers from Parent are as follows&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General financing activities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,703&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,222&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate cost allocations, excluding share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,171&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,174&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers from Parent as reflected in the Combined Statement of Cash Flows</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,874&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,396&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,930&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,278&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Parent common shares to repurchase non-controlling interest in a subsidiary</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Parent common shares as payment for IPR&#38;D asset acquisition</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,747&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Parent common shares as payment for business acquisition</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,673&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Parent common shares as payment for Artizan investment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Parent common shares as payment for license and consulting agreements</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,779&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,243&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash adjustments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers from Parent as reflected in the Combined Statement of Changes in Equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,626&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,896&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-50</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_382"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOHAVEN LTD.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Yale</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;30, 2013, the Company entered into the Yale Agreement with Yale (see Note 6). The Company&#8217;s Chief Executive Officer is one of the inventors of the patents that the Company has licensed from Yale and, as such, is entitled to a specified share of the glutamate product-related royalty revenues that may be received by Yale under the Yale Agreement. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into the Yale MoDE Agreement with Yale (see Note&#160;6 for detail). Under the license agreement, the Company acquired exclusive, worldwide rights to Yale&#8217;s intellectual property directed to its MoDE platform. As part of consideration for this license, the Company paid Yale University an upfront cash payment of $1,000 and 11,668 common shares of the Parent valued at approximately $1,000. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the Company recorded $2,000 and $150 in research and development expense related to the Yale MoDE Agreement and Yale Agreement (the &#8220;Yale Agreements&#8221;). As of June 30, 2022, the Company owed $2,000 to Yale, which is related to the Yale MoDE SRA.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-51</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_385"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:72pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20,000,000&#160;Shares</font></div><div style="margin-bottom:24pt;text-align:center"><img alt="picture1.jpg" src="picture1.jpg" style="height:57px;margin-bottom:5pt;vertical-align:text-bottom;width:327px"></div><div style="margin-bottom:25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Shares</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS</font></div><div style="margin-bottom:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">J.P. Morgan</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_388"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Not Required in Prospectus</font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_391"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Other Expenses of Issuance and Distribution</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is an estimate of the expenses (all of which are to be paid by us) that we may incur in connection with the securities being registered hereby. All amounts are estimates except for the Securities and Exchange Commission (the &#8220;SEC&#8221;) registration fee.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount to be paid</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SEC registration fee</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$31,429</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FINRA filing fee</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,280</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NYSE supplemental listing fee</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,400</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal fees and expenses</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting fees and expenses</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer Agent</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous expenses</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,891</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,000,000    </font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_394"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Indemnification of Directors and Officers</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">British Virgin Islands law does not limit the extent to which a company&#8217;s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the BVI High Court to be contrary to public policy (e.g., for purporting to provide indemnification against the consequences of committing a crime). An indemnity will be void and of no effect and will not apply to a person unless the person acted honestly and in good faith and in what he believed to be in the best interests of the company and, in the case of criminal proceedings, the person had no reasonable cause to believe that his conduct was unlawful. Our Amended Memorandum and Articles of Association permit indemnification of officers and directors for losses, damages, costs and expenses incurred in their capacities as such unless such losses or damages arise from dishonesty or fraud of such directors or officers. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation. In addition, we have entered into indemnification agreements with our directors and executive officers that provide such persons with additional indemnification beyond that provided in our Amended Memorandum and Articles of Association.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we have entered into indemnification agreements with each of our directors and executive officers that may be broader than the specific indemnification provisions contained under British Virgin Islands law. These indemnification agreements require us, among other things, to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses incurred by the directors and executive officers in investigating or defending any such action, suit, or proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The limitation of liability and indemnification provisions that are included in our Amended Memorandum and Articles of Association and in indemnification agreements that we entered into with our directors and executive officers may discourage shareholders from bringing a lawsuit against our directors and executive officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against our directors and executive officers, even though an action, if successful, might benefit us and other shareholders. Further, a shareholder&#8217;s investment may be harmed to the extent that we pay the costs of settlement and damage awards against directors and executive officers as required by these indemnification provisions. At present, we are not aware of any pending litigation or proceeding involving any person who is or was one of our directors, officers, employees or other agents or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, for which indemnification is sought, and we are not aware of any threatened litigation that may result in claims for indemnification.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained insurance policies under which, subject to the limitations of the policies, coverage is provided to our directors and executive officers against loss arising from claims made by reason of breach of fiduciary duty or other wrongful acts as a director or executive officer, including claims relating to public securities matters, and to us with respect to payments that may be made by us to these directors and executive officers pursuant to our indemnification obligations or otherwise as a matter of law.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_397"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Recent Sales of Unregistered Securities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three years preceding the filing of this Registration Statement, we have not issued securities that were not registered under the Securities Act.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_400"></div><div style="-sec-extract:summary;margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Exhibits and Financial Statement Schedules</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit <br>No.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022026549/exhibit11-sx1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Form of Underwriting Agreement.</a><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022026549/exhibit11-sx1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">*</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022022261/exhibit21-form101.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Separation and Distribution Agreement, dated as of May 9, 2022, by and among Pfizer Inc., Bulldog (BVI) Ltd. and Biohaven Pharmaceutical Holding Company Ltd. (incorporated by reference to Exhibit&#160;2.1 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022022261/exhibit22-form101.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement and Plan of Merger, dated as of May 9, 2022, by and among Pfizer Inc., Bulldog (BVI) Ltd. and Biohaven Pharmaceutical Holding Company Ltd. (incorporated by reference to Exhibit&#160;2.2 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022022261/exhibit23-form101.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Membership Interest Purchase Agreement, dated as of February 24, 2022, by and among Biohaven Therapeutics LTD., Knopp Biosciences LLC, Channel Biosciences, LLC and Biohaven Pharmaceutical Holding Company Ltd., solely for the purpose of Section 9.14 (incorporated by reference to Exhibit&#160;2.3 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022025893/exhibit31-8xk1032022.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Amended Memorandum and Articles of Association (incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Current Report on Form 8-K filed on October&#160;3, 2022).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022026549/exhibit51-sx1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Opinion of Maples and Calder</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.*</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0001935979/000162828022022261/exhibit101-form101.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Amended and Restated Agreement, by and between the Registrant and Yale University, dated as of May 6, 2019 (incorporated by reference to Exhibit&#160;10.1 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022022261/exhibit102-form101.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">License Agreement, by and between the Registrant and AstraZeneca AB, dated as of September 4, 2018 (incorporated by reference to Exhibit&#160;10.2 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022022261/exhbiit103-form101.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">License Agreement between Biohaven Therapeutics LTD. and Bristol-Myers Squibb Company, dated as of December 23, 2021 (incorporated by reference to Exhibit&#160;10.3 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022022261/exhibit104-form101.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ALS Biopharma Agreement, by and among the registrant, ALS Biopharma, LLC and Fox Chase Chemical Diversity Center Inc., dated as of August 10, 2015 (incorporated by reference to Exhibit&#160;10.4 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022022261/exhibit105-form101.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment and Assignment, by and among the Registrant, ALS Biopharma, LLC, Fox Chase Chemical Diversity Center and Biohaven Therapeutics Ltd, dated as of May 29, 2019 (incorporated by reference to Exhibit&#160;10.5 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022022261/exhibit106-form101.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Agreement dated May 9, 2017 by and between Biohaven Pharmaceuticals, Inc. and Vlad Coric (incorporated by reference to Exhibit&#160;10.6 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022022261/exhibit107-form101.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Agreement, dated December 8, 2021, between Biohaven Pharmaceuticals, Inc. and Matthew Buten (incorporated by reference to Exhibit&#160;10.7 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022022261/exhibit108-form101.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Offer Letter dated February 21, 2017 by and between Biohaven Pharmaceuticals, Inc. and Elyse Stock (incorporated by reference to Exhibit&#160;10.8 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022022261/exhibit109-form101.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Agreement dated February 1, 2014 by and between Biohaven Pharmaceuticals, Inc. and Kimberly A. Gentile (incorporated by reference to Exhibit&#160;10.9 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022022261/exhibit1010-form101.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Agreement, dated March 29, 2016, between Biohaven Pharmaceutical Holding Company Ltd. and John Tilton (incorporated by reference to Exhibit&#160;10.10 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022026247/exhibit42-sx8.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2022 Equity Incentive Plan (incorporated by reference to Exhibit&#160;4.2 to Company&#8217;s Registration Statement on Form&#160;S-8 filed on October&#160;11, 2022).</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022024448/exhibit1012-form10x12bax3.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Form of Restricted Share Unit Grant Notice and Restricted Share Unit Award Agreement under 2022 Equity Incentive Plan (incorporated by reference to Exhibit&#160;10.12 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022024448/exhibit1013-form10x12bax3.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Form of Share Option Grant Notice and Share Option Agreement under 2022 Equity Incentive Plan (incorporated by reference to Exhibit&#160;10.13 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022026247/exhibit44-sx8.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Legacy Equity Award Settlement&#160;Plan (incorporated by reference to Exhibit&#160;4.4 to Company&#8217;s Registration Statement on Form&#160;S-8 filed on October&#160;11, 2022).</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022026247/exhibit43-sx8.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2022 Employee Share Purchase Plan (incorporated by reference to Exhibit&#160;4.3 to Company&#8217;s Registration Statement on Form&#160;S-8 filed on October&#160;11, 2022).</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022024448/exhibit1016-form10x12bax3.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Form of Employment Agreement by and between Biohaven&#160;Ltd. and Vladimir Coric (incorporated by reference to Exhibit&#160;10.16 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022024448/exhibit1017-form10x12bax3.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Form of&#160;Employment&#160;Agreement&#160;by and&#160;between Biohaven&#160;Ltd. and&#160;Matthew Buten (incorporated by reference to Exhibit&#160;10.17 to Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.#</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022024924/exhibit211-biohavenresearc.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">List of Subsidiaries. (incorporated by reference to Exhibit&#160;21.1 to the Company&#8217;s Registration Statement on Form&#160;10 filed on September&#160;20, 2022).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="exhibit231-sx1a1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consent of Ernst &#38; Young LLP.</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022026549/exhibit51-sx1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consent of Maples and Calder (included in Exhibit&#160;5.1).</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1935979/000162828022026549/biohavenltd-sx1.htm#ibdd6bc299bfd4984887fe9eda84f19d4_115" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Power of Attorney (included on signature page of this Registration Statement).*</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="exhibit107-sx1a1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Calculation of Filing Fee Table.</a></font></div></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"># Indicates management contract or compensatory plan. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* Previously filed</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </font></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_403"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 17. Undertakings</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The undersigned Registrant hereby undertakes that&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#160;430A and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contained in a form of prospectus filed by the Registrant pursuant to Rule&#160;424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II-4</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_406"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Amendment No. 1 to the Registration Statement on Form&#160;S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of New Haven, Connecticut, on the 20th day of October, 2022.</font></div><div style="margin-bottom:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.961%"><tr><td style="width:1.0%"></td><td style="width:14.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.863%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BIOHAVEN LTD.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Vlad Coric</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vlad Coric</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No.1 to the  Registration Statement on Form&#160;S-1 has been signed by the following persons in the capacities and on the dates indicated.</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Vlad Coric</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director <br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2022</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vlad Coric</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer <br>(Principal Financial Officer and Principal Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2022</font></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Buten</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2022</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory Bailey</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2022</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Irina Antonijevic</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2022</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John W. Childs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2022</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Julia Gregory</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2022</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kishan Mehta</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2022</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Heffernan</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2022</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Hugin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.903%"><tr><td style="width:1.0%"></td><td style="width:23.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Vlad Coric</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vlad Coric</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Attorney-in-Fact</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II-5</font></div></div></div><div id="ibbeb41436b1c46838ddd18c39bc90b9a_409"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AUTHORIZED REPRESENTATIVE</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the United States Securities Act of 1933, as amended, the Authorized Representative has signed this Amendment No.1 to the Registration Statement solely in its capacity as the duly authorized representative of Biohaven Ltd. in the United States, in the New Haven, Connecticut on October 20, 2022.</font></div><div style="margin-bottom:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.961%"><tr><td style="width:1.0%"></td><td style="width:14.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.863%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BIOHAVEN LTD.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Vlad Coric</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vlad Coric</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized Representative in the United States<br>Biohaven Pharmaceuticals, Inc.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II-6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>exhibit107-sx1a1.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i24bd77d7795e444db598a7676880c981_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 107</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Calculation of Filing Fee Tables</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FORM S-1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Form Type)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Biohaven Ltd.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Table 1&#58; Newly Registered and Carry Forward Securities</font></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Security Type</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Security Class Title</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fee <br>Calculation <br>or Carry <br>Forward Rule</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount Registered</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proposed Maximum Offering Price Per Unit</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maximum Aggregate Offering Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fee Rate</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of Registration  Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</font></div></td></tr><tr><td colspan="27" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Newly <br>Registered <br>Securities</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fees to be <br>Paid</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Equity</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Common Shares, <br>no par value</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">457(o)</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 2.55pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$285,200,000</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.0001102</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$31,429.04</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fees <br>Previously <br>Paid</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$26,233.11</font></td></tr><tr><td colspan="27" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Carry Forward <br>Securities</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Carry <br>Forward <br>Securities</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 4.12pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total Offering Amounts</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$285,200,000</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$31,429.04</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 4.12pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total Fees Previously Paid</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$26,233.11</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 4.12pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total Fee Offsets</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 4.12pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net Fee Due</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$5,195.93</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Includes the offering price of shares that the underwriters may purchase pursuant to an option to purchase additional shares.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exhibit231-sx1a1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8ffd0fbd61764517bc1df158c6fa5efe_1"></div><div style="min-height:126pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 23.1</font></div></div><div style="margin-bottom:36pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We consent to the reference to our firm under the caption &#34;Experts&#34; and to the use of our report dated July 1, 2022, in Amendment No. 1 to the Registration Statement (Form S-1 No. 333-267928) and related Prospectus of Biohaven Ltd. for the registration of 20,000,000 common shares.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.160%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Ernst &#38; Young LLP</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Hartford, Connecticut</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">October 20, 2022</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>business10a.jpg
<TEXT>
begin 644 business10a.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   Z"@
M P $     0   =\     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_W0 $ #K_V@ , P$
M A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH __0_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** $/0U\K? #3-/N]?^),EU;13-_;C<N@8_<]Q7U2>AKYD_9X_P"0Y\2?
M^PX?_0* /H;^P=%_Y\+?_OTO^%)_86B'I80?]^E_PK7KXQ_;!^ GCCXN>#VU
M?X;^.]1\%Z_HL3R1&VN&BMIP!DK*%/Z]J .0^-G[47AKX4?M&^ ?@F--LGM_
M$Q/VV1XU#1;CB/''<U]S?V'HA (L("#_ -,U_P *_AH\=^-/B+?^.I]2\6^(
MKK5?$&D3M M[).TDBM"V 4<G.,CBOZ+?^"=?P3^-.L:3I?QV^*_Q-U+7+.]C
MW6&EK>/+!MZ9GR2"1Z4 ?K7_ &%HO_/A;_\ ?I?\*/[!T7_GPM_^_2_X5JXI
M: //_'#:7X4\'ZQXDM],MI9=-M99U1HU 8QJ2 >*_,;X:?M#?MH?%[PK'XY\
M!_"+PU=Z+<2RI"\EP$D81,5^Z1[5^EWQD_Y)5XK_ .P;<_\ HLU\M_\ !./'
M_#+>A9Z?:+K_ -&&@#2_9V_:!/Q-\2ZI\,OBQX'B\#^/-(42-8L%DBN(?^>D
M3XY%?3&L>(OA9X>U&'2-=U'2=/OI\>7!/)#'(V?16(-?GY^T9JU_HG[9'@W6
M?"0#7^GZ#?S7@3J(E0E=^.V>F:Y[X!?L>_"SXY?"V]^*WQ>\_P 3>*/%<MS.
M+V6=]]F Q")#@_+MH _4:XM/"EK"ES=164,4F KNL:JV>F">#FN?LM?^%VI:
MS)X<T^_TJYU2+[]K&\+3#ZH#FOQ#\8^*O%>O_LLZM\-=3U:>8^$?%D6CVM^)
M&\\VXDPN7SDE1QFO=?CG^S1\-?@;X7^'?Q/^'<$^G^+(=4L%FU#SG:6Y\XJ)
M/-)/S;J /U3\0W_P]\)6@OO%$VG:3;L<"2Z,42D^@W8S5O3?^$*UC3EUC2OL
M%Y8L-PGB$;QX'?<,BOS5T'X3^&?VK_VD?'EU\9#-J^C>#$MK2QTII66V5I8P
MSRE 1DDUR^EZ##^SW\9OB+\"/ T\P\&:QX9N-4@LI)6D%E.JD$1DDE5;TH _
M3]-:^&<NIPZ+%>Z4]_<+NC@5X3(Z^JJ#D_A70W6F>'+&VEO+RUM8((5+O(\:
M*JJ.222, "ORZ_X)X?LZ_#C5?A?H/QFU^S?4O%B75RT%Y-*[-$BN5"*"<;1Z
M5^I.OZ%IGB?1;SP_K4/GV%_$T,T9) 9&&"./44 ?'7AO]J[X3>/?C[9_!3X>
MV%OK436UQ-=:DD0$"/#@>7$Q&)/<CI79?LNQ1PM\18X4$:+XEN\*HP!PO0"O
M(M3\&^&/ 7[8'PQ\->#]-@TK3;70M05(8$"+U7GCJ?<U[%^S%_K?B-_V,UY_
M): /JBBBB@ HHHH **** "BBB@ HHHH **** /_1_?RBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **3-+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 AZ&OF3]GC_D.?$G_ +#A_P#0*^FST-?,
MG[/'_(<^)/\ V'#_ .@4 ?3E>=_%?0O$?B?X=Z]X=\)RQP:IJ-K)!#)+G8K2
M#;DXY[UZ)3=U 'Y4_#'_ ()5_![0?A/K'A/X@M_;OB?Q "\^J ;6MY#DCR!V
M )Y]:^F?V-?@-XU_9Q^'=[\,O$^J0ZQ86=X[Z;/&"K_9W[.#T(]J^N_,4':2
M,_6G!@>* :'4444 <KXY\/S>*_!^L>&[>40R:E:RP*[#(4R*0":_.;X5?LX_
MMN?!KP;%X \#_$;P[!H]M)*\7G:8995$K%N6)ZC-?J'2;A0!\6? G]D^^\!Z
MSXB\??%?Q/+XV\9^*(6M[F\D7RXH8&&#'"G\*\UY#H7[-/[5GP>M=<\"_!3Q
MSI9\':U/--"-3MVDNM/$Y.Y8B#@@9XS7Z99Q10!^>.J_L02I\"-*^%>AZXAU
M>/5(=5U'4)T)-U.K[Y#@=,]J]V^/7P.U?XM^!O#_ (4TW48K&;1[RTN7DD4L
M'%L02 !W.*^E\BC(H ^!_''[.'QH\+_%FZ^,O[//B:RT_4-9M8K;5-.U.%I;
M2<Q+A9%VG*M5GX;_ ++/CN"?QQ\0/BYXCM]<\?>,[%[$36\1CM;. J0L<2GG
M'K7WA10!\\?LO?!K4_@/\(]-^'6KW\>I7-E)*YFB4JI$CEAP>>]?0Q]J7-%
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M.MPEDHN;@74F3F1>AYZ4 :M%%% '-^=+_P )*838C9Y(/VGOG^[725@[+O\
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MS61\4/'_ .R+\9?#O_"*?$C7--UK2A(LOD2E]N]>AX%?3O\ PAOA+_H#6?\
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M+;W/]F"0)Y[[O,Z[L\X]JZRL/0Y=1EBF.HVZV[B1@H7^)<\'ZFMR@ KG;S[
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MDGB.&ZU'4M;E,-CI]C$9KFX91EMJ#L.YH ]_S29%?G^W[>-LHS_PJSQ8?;[
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ML+Q"UD-,;[= UQ%N7Y%&23GB@#9A_P!6@W;N!SZ^]2U'%CRTVC:,# /85)0
MAK"T4 /=C[7]JS*>/[G^S^%;I&:PM%:T+78M(&A/G'>6&-S=R* -ZBBB@#DM
M83.OZ2W]HBUPS?N/^>_'3\*ZVN1UDZ8-?T@75H\UR7;R95&5C..2?K774 %5
M;WFSF_>>5\A^?^[QUJU56^,8LYC*A=-IW*.I&.E %+0QC2[<?:?M?'^M_O>]
M:]9&A&V.EVYM(3!"1\J,,$"M>@ KG8A_Q4DK?;0W[D#[-_=Y^]715SD1L?\
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M49% &/K4BQVJ%K;[5\ZC;CISU_"M=>@^E9>L17<MJJV<PA?>I)/IGD5J*/E
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M3H *YB)]._X2B:--_P!L\@%N?DV9X_&NGK"1KP:Y(&MU%MY0Q+_$6S]TGTH
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M;-[4F9[;#R$?*R$XVTF5!I239_-M\:O$MYXJ^*/B'5KV?[2S74B*P;< J'
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M2/\ @G)XB_9H^-?@_P"*WP.OGU?2[29(M1M+AOWNQ^'=3W'?%?MF0>U)CN:
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M^']6URRGO;W5F0/+;6<9V[8,_P ;'OVK[-KY9_: ^"?C+QMKWAWXF?"C6X]
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M"<X\J3W/]!/&7QXX;Q7#>(PV$K*K4JQLHKI?J_0_:>PCE%]>F2Y$RLPVH/\
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M#3XTB@M5<&5@V.&QT-?L#;^9Y$?F_?VC=CUQS7XP:-X^_:PT[2_AA\4?B/\
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MTF#/Y0VGYO3WH J:.;MM.@-]&(I\?,JC !K4K*T58QID CG-RH'$A_B]ZU:
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M >OE(6Q^E?BA#\)?CIX[^%&I_MD6GQ1U"R\0QM<:K;:6C$6*VMM(?W)7W5:
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M'- #Z0]#2TAZ'% ',>%S9FWN39VS6R^<^X/U+9Y(]C745AZ)_:9BE_M39O\
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MTQVH U**** .6'V/_A*2/LS?:?)'[[^';Z5U-88.I_VX<[?L7E_\"W?X5N4
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M%M^QGXI/3XZ>(@#_ -/"U]Z>%M(DT'P]I^C37LFHR6<*1-<RG,DI48W,?4T
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M4G>VM[^1^G$OAS1O%?A/4O#UQ(UW:7QEC<OS@MP1^%?B!\?_ -D?QI\(3?\
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M ][<7$ES=Q2"&7[9&!Y*B3JH/J*_2"O#?C3^SQ\,?C[;:=:?$K3CJ,6ENTD
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M7\>_AQK>J^--)'A/5+&XDM);<M\\)7NPZBOJO24\K3K6+S?/VQJ-_P#>XZT
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M>G:_X1U#Q+X9\;ZO+JNDW&EQF78\WWHI0/ND'O7T/^Q]\-?&&D7?COXQ^/[
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M/RP*G_//Z]Z_7KX;_%_P;\5O"J:QH=U'/*]OYDUJ&!DCR.0PZBOYG/>OV?\
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M^- 'U9_PFW@[_H-V?_?]/\:QM>\7^"[G2YH7\0VEN#M^<3ID<_6OFS_A@KX
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M^_\  R7_ !H ^DM2\7>#)KRQ=O$5I$8W)"B=/GXZ=:V1XW\&C_F-V7_?]/\
M&OE-OV!_V?V(+6=Z2O(_TN3C]:7_ (8+^ 7>TOO_  +D_P : /JS_A-O!W_0
M;L_^_P"G^-07/C3P<]O*IUVS0%2"?/3CCKUKY:_X8*^ /_/I??\ @9+_ (TA
M_8*^ )X-I?$'C_C\E_QH ^@+?7/ FH>%9-$E\1VL\%W"\32?:$#%7!![^]?(
M6E_L?_ ?1(Y(='\?:A9PRNTACCU0!0S')P-W%=VG[!'[/\:[([.]4#H!=R_X
MT_\ X8*^ /\ SZWW_@9+_C0!WWPC\"_#7X0?;?[)\8R:G]NP6^W7RS;<?W<G
MBO0+;Q3X*7Q?=7H\3VKNT"@P>>FU1_>ZUX%_PP5\ O\ GUOO_ R7_&HQ^P+^
MSZ)#,+*]#G@M]KDSCZYH ^K_ /A-O!W_ $&[/_O^G^-'_";^#O\ H-V?_?\
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M1)XBM+@ M\YG3)Y^M?-9_8*^ /0VE\<_]/DO^-(O[!'P 10JV=ZH]!=R?XT
M?5O_  FW@[_H-V?_ '_3_&C_ (3;P=_T&[/_ +_I_C7RG_PP5\ ?^?2^_P#
MR7_&E_X8*^ 7_/K??^!DO^- 'T1_PEO@O_A)#=?\)):;_)QY/GIC&>O6NC_X
M3;P=_P!!NS_[_I_C7RC_ ,,#?L_;_,^QWN[IG[7)G'YT_P#X8*^ /_/I??\
M@9+_ (T ?5?_  F_@[_H-V?_ '_3_&L+Q%XN\&76FO$_B.TME+*=ZSID8/3K
MWKYP_P"&"O@#_P ^E]_X&2_XTU_V!_V?Y%VO9WK#T-W)_C0!]51>-?!RQHO]
MN69P!SYZ?XU)_P )MX._Z#=G_P!_T_QKY3'[!7P!_P"?2^_\#)?\:/\ A@KX
M _\ /K??^!DO^- 'U9_PFW@[_H-V?_?]/\:P=%\7>"[=KO;XCM)]\Q8YG3Y3
MZ#FOG'_A@KX!=K2^_P# R7_&FK^P1^S^I.RSO1N.3B[DY/YT ?5W_";>#O\
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M'OP$T9[IM'\>7]BMY*TTB1:F%4NQR3@-BN]7]@G]G] $6TO5 Z#[9)_C3_\
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MX& ?M<F<?G0!]7#QMX._Z#=G_P!_T_QH_P"$V\'?]!NS_P"_Z?XU\I_\,%_
M'_GTOO\ P,E_QI?^&"O@%_SZ7W_@9+_C0!].ZEXR\&2Z?<1MK]G$&1AO$Z97
MCKUINE>,?!L&GV\2Z_9RA4 #F=,M[]:^8V_8(^ # AK2^(/4?:Y?\:1?V"?@
M"JA5L[X = +R7_&@#ZM_X3;P=_T&[/\ [_I_C1_PF_@[_H-V?_?]/\:^4_\
MA@KX _\ /K??^!DO^-'_  P5\ ?^?2^_\#)?\: /H?3/%?@N+6M3G'B2TE:7
M9F,SIB/CMSWKRKX[_##X-_M!:1I^C>,_$*0P:;.+B(VUVD;"1>AR#GBN+'[
MW[/ZLSBSO06ZG[7)D_K3O^&"O@#_ ,^E]_X&2_XT <BO[*WP;1%C7XD:F%4
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MH+^$Q.&(SQGJ*YG]JWQ;KW@?X(ZYXF\-W9L=0M&@,<H_AS(H/X8KZ$MK:&%
M8XUC9@-Q  )('?%>)?M(7'@6'X2:S'\2K.>]\-W 2*\%NI9TC=@-^!SA>IH
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MVK\O_"7[9W[:=WX6UJ_OO 5CJ-UHD<OVR*-_+N;8H#\SQGG'?(K]5_BG\8_
M'P9T>VU[XAZDNEV%U,($E8$KO/0'%?!_QGA^#OQLEN/&_P "OB)8:-XXEM);
M4IYPBAOXY%QY<R'&3Z&@#U#]E;]L"3XRZ-H6D^+?#VH:;K]_"7>X: BSD9>N
MQ^E?<NIR/'IMW+&<,D4A!]PIQ7SS^RMX1OO!?P3\,>%_$?V9]7TZ I-Y+K(
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M\?['QW\8/&%K\!?"[Z=:^%G$4VK3F4?:D1&R(TB]\=:^T=#TBVT'1K+1+/\
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MPJIZU]N#- "T444 %%%% !1110!__];]_**** "BBB@ HHHH **** "BBB@
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MNA1A@@_A7Y@:9HGQ*_9_\;ZMI?P'\6:3XOT.^F>4>&[V[2.>T=CDK"V>F>U
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M;JNE:'J7B?2_&/A:!HH',L9BN(K9 %^4CJ0!7Z$@\XH 6BBB@ HHHH ****
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M]L7PO^RR_C/3M8^*,^H6WC*ZMML!TAI#=_9X_P"(K'SM'J:\1\!?LI7WB/\
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M#;HV5_*;="EP/X)1QQN'6O&[<?M-?L\?&7QSXCT#X?+XO\*>*;P70>VF N4
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M=Z_2H8S7XT^ /V6X?'4R?&K]F+XQ:A_;>F1O8H-4'G&!<Y:&56^9>G>OM_\
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M4*)U"%6QU4=<5[)\./V+M#A\1:9\4?B_K]]XU\8VY6X66XE(M[>4_-B&(<
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MCO+:3[LD3!T/T(S7QK^U_P##O7?&UWX'U#P?XET_0/$>C:AY]BFH?ZNYD'\
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M%K"ZUJMQJ(+1C""<YV$$'I0!A^#_ -LC]F_Q];+Y?B>VLI7X-OJ \AP>X(D
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MA6YKZ%KQ/2/V=/@OH'BVV\<Z%X4L].UJTSY=Q;QB-AGKTKVV@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /__3_?RBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]3]_**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>business11a.jpg
<TEXT>
begin 644 business11a.jpg
M_]C_X  02D9)1@ ! 0  D "0  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      "0     0   )     !  .@ 0 #     0 !  "@ @ $     0   4Z@
M P $     0   4P     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_W0 $ !7_V@ , P$
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MY=_X4C\<?^CB/$W_ ()O#7_RJH_X4C\<?^CB/$W_ ()O#7_RJH ^HJ*^7?\
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M@#_@J/\ \F*?$S_N"_\ IXLJ^_Z "BBB@ HHHH **** "BBB@ HHHH ****
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M-M19>=]0M;VZ6_';\G]S$W:U^OZ'VC1110,_-OX\_ CQ1K/Q&^)FMV'PZO\
MQO<>--*TY_#6K6NIVMI'X>UNTMYK3SG6YO;>2W:,B"=;FUAEE(+K@[0I_0KP
MW9ZKIWAW2]/UZ\&HZG:VL$5U=!=@GG1 LDNWMO8%L=LUM44XNR:[_P#!_P _
MGI<):M/M_P #_+Y=#X _X*C_ /)BGQ,_[@O_ *>+*OO^O@#_ (*C_P#)BGQ,
M_P"X+_Z>+*OO^D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!YS\8?^22>-_\ L!ZE_P"DTE?-O[!__))-9_[#MQ_Z2VM?27Q@_P"22>-O
M^P'J7_I-)7S;^P?_ ,DDUG_L.W'_ *2VM>96_P!ZAZ,_,<U_Y*S!_P#7JI^:
M/1_VF?&/B;P7X1TO4/"^H/IUQ/?")W0*2R>4[8^8$=0#7Q1_POKXO_\ 0SW'
M_?$7_P 17UE^V#_R(NC?]A(?^B9*_/&OW;@W 4*F!C*I33=WND^IP<88^O3Q
MLHTZC2LMFT>N?\+Y^+__ $,]Q_WQ%_\ $4?\+Y^+_P#T,]Q_WQ%_\17D=%?5
M?V3A?^?4?_ 4?,?VMBO^?LO_  )GVG^SK\4?'_B[XA_V1XDUJ6_L_L<TGENJ
M ;U*X/RJ#QGUKNOVUO\ DB4O_80M?_9J\'_92_Y*J/\ KQN/YI7O'[:W_)$I
M?^PA:_\ LU?BWB-0A3K3C3BDN7HK=SZ3,J\ZG"V-E4DV^6>[OT/;?@Q_R2#P
M1_V!-._])DKTJO-?@Q_R2#P1_P!@33O_ $F2O2J^6H?!'T/TS(_]RH?X(_D@
MHHHK4]0__]/]_**** /D+XK0>)O$.KV.MWOP=UGQ)*L'B3PY-;6FK:-##=:+
M?/ C&<75U$3'>K!'-&L96:+RRLFT,5?3_9A\(>(?#L'B74_&6C^);37+Y[*!
M[WQ1J6DZC=SVMG"4MX(SH[>2D<&YS^\02.\K.S.3D5_VCKS4OAUXD\)_'ZRO
MO#8B\+VVIZ3-9^*-5&AVL@U=K9UEM;]XITBND-IL"M&1)%)(H9"/FO?LTVFN
M>(9/&'QLU>_T*2'XBW5I<6]GX:U'^U]-A33[<6AE:^$<*W%U(4V3.D:J%BC0
M9*$FJ3T=OG]_]/YL*BV_KI_PR^2/H[7]0.D:%J.J@!OL5M--@@L#Y:%L$+R>
MG0<FOR"\'6WAG0;#PWXQN?@YH_A[XDZ];>&=3\.*GB"^U/PREQK-]'91W)TP
M2+#9BQEO#/#!$C@ D03AU9U_8;4KJ2QTZZO8K=[M[>)Y%ACY>4HI(1<]VQ@>
M]?EY\*_V;#\5?#7ACXE1?#_X5Z%X?\4K!JLEKIFD7T>H6\%VH+1K>V]S;K]K
M@1B$D$2^1."\:JPS4T_C=]M/UZ^??I;;5-5)^Y]_Z?E^-_)W_0#X.^.M3^(G
M@:+7=>LX;#6+.^U/2=0BMI&EMOMNCWT^GW#P.ZJYA>6!GCW ,$8!OF!KU"N7
M\&>#/#/P]\,6'@[P?9#3](TU66&(.\K9=C([O)*S2222.S/))(S.[LSNQ8DG
MJ*J;3=T0D%%%%2,^ /\ @J/_ ,F*?$S_ +@O_IXLJ^_Z^ /^"H__ "8I\3/^
MX+_Z>+*OO^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MSGXP?\DD\;?]@/4O_2:2OF[]@_\ Y))K/_8=G_\ 26UKZ1^,'_))/&W_ & ]
M2_\ 2:2OFW]@_P#Y))K/_8=N/_26UKS*W^]0]&?F.:_\E9@_^O53\T=%^V#_
M ,B+HW_82'_HF2OSQK]#OVP?^1%T;_L)#_T3)7YXU_0/ _\ R+X^K_,\;C7_
M '^7HOR"BBBOKCY(^E?V4O\ DJH_Z\;C^:5[Q^VM_P D2E_["%K_ .S5X/\
MLI?\E5'_ %XW'\TKWC]M;_DB4O\ V$+7_P!FK\,\3/\ >)?X5^I]?C/^24QO
M^&?Y'MOP8_Y)!X(_[ FG?^DR5Z57FOP8_P"20>"/^P)IW_I,E>E5\C0^"/H?
MJ.1_[E0_P1_)!1116IZA_]3]_**** /EGXWZ!KMO\5/A]\3-'\)P_$'_ (1Z
MTUBT_L07-G;W\4E\UHRZE8B_>*!Y(%@:"0&6-A'<$J_WD?)_97EC\3W_ ,0O
MBKI-CIV@:)XLU2$0:1INH66HB&XLH?*N+N[ETV6:T6[NLIYD<<CD)'&78N6
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MC_K^O\CX#_X*C_\ )BGQ,_[@O_IXLJ^_Z^ /^"H__)BGQ,_[@O\ Z>+*OO\
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MM=I?WM[;#4HX]/:_:>"6V,DLI^T*X0H?.!!)K]?YIHK>)YYW6.*-2SLQ 55
MR22>  .IKYD\,?'_ ."'B;Q#:Z]X0T+7-0NM>,5O#K=KX.UIK6ZBD8)&_P#:
M8L/):WZ$2F7RMHW;MHS4T])?=^'^?Z?>5-8:^?I_2_4^GZ*** "BBB@#X _X
M*C_\F*?$S_N"_P#IXLJ^_P"O@#_@J/\ \F*?$S_N"_\ IXLJ^_Z "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /.?C!_R23QM_V ]2_P#2
M:2OFW]@__DDFL_\ 8=N/_26UKZ2^,'_))/&W_8#U+_TFDKYM_8/_ .22:S_V
M';C_ -);6O,K?[U#T9^8YK_R5F#_ .O53\T=%^V#_P B+HW_ &$A_P"B9*_/
M&OT._;!_Y$71O^PD/_1,E?GC7] \#_\ (OCZO\SQN-?]_EZ+\@HHHKZX^2/I
M7]E+_DJO_;C<?S2O>/VUO^2)2_\ 80M?_9J\'_92_P"2JC_KQN/YI7O'[:W_
M "1*7_L(6O\ [-7X9XF?[Q+_  K]3Z_&?\DIC?\ #/\ (]M^#'_)(/!'_8$T
M[_TF2O2J\U^#'_)(/!'_ &!-._\ 29*]*KY&A\$?0_4<C_W*A_@C^2"BBBM3
MU#__UOW\HHHH ^"?VF]6^$_B7XH:-\/]5^+5M\.]>N/#VNZ?J<IGL,#1;Z73
M#=VC-<S(]G>W ,+VDH1OD29MK;4(])^ %W\*+[XD?$N?X4:O::II\,?A^UVZ
M4MN=*MH+6R:*"&*:WFE66=0K>:2(RD?D)L*JKOS?Q_T&WO/C-X"T_0=%\)Z;
MK?B&QUI9/$?B;37U*();"S?[!#:QW%HLUU.%65&DF!C@MIC&&&_'N7P?\.>*
M?#&E7NG>(M9\.ZK$95>W7PYHKZ+!#D'?YD;7UZ'9CC# I@#D'J*HNT&OZW_X
M?MU?74J:M?UT_P"&_+IIZAJEE%J6F7>G3!&CNH9(F$JEXRKJ5(=05)7GD;AD
M=QUK\T_@;\4;_0Y_!GPFT+]H#0-<T73YH=%L))O VIVMOJ,=D?+%E9ZU)J0L
M9Y3&ABA=&F9\!L2MDM^BGBJ^\-II_P#8/B+5(-,&OK-8P"6=())G:"21TAW$
M%I%B1Y,+DA49L84D?G=X=UO7M>\*>!OV>-2\=_#-_#F@7VAP?VSIOB'S=4U"
MTT.YAFLX[;2#"L=O=W#6\*,1>2K$69H@Y" *E\3^7Z_E^-PJ?!]_]?/\+'Z<
M4444@"BODG]HOXY>+_ .IZ9X>^&L-G<7MA<:1>>()KR-Y8[73-4U.+3+>%%1
MX\7%U(\KQ-DJB6TI9<M'GZVIVTN*^MCX _X*C_\ )BGQ,_[@O_IXLJ^_Z^ /
M^"H__)BGQ,_[@O\ Z>+*OO\ I#"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /.?C!_R23QM_V ]2_])I*^;OV#_P#DDFL_]AV?_P!);6OI
M'XP?\DD\;?\ 8#U+_P!)I*^;OV#_ /DDFL_]AV?_ -);6O,K?[U#T9^8YK_R
M5F#_ .O53\T=#^V#_P B+HW_ &$A_P"B9*_/&OT._;!_Y$71O^PD/_1,E?GC
M7] \#_\ (OCZO\SQN-?]_EZ+\@HHHKZX^2/I7]E+_DJH_P"O&X_FE>\?MK?\
MD2E_["%K_P"S5X/^RE_R57_MQN/YI7O'[:W_ "1*7_L(6O\ [-7X9XF?[Q+_
M  K]3Z_&?\DIC?\ #/\ (]M^#'_)(/!'_8$T[_TF2O2J\U^#'_)(/!'_ &!-
M._\ 29*]*KY&A\$?0_4<C_W*A_@C^2"BBBM3U#__U_W\HHHH ^)/VO-?\)V!
MLK76/A#X=^*NH:/X>\0^)B/$7DI%9Z;HPM#=K;-)97SM/.TT*K&J(K;<NZX7
M/7?LTQ:/HNI^,O!MM\-/"GPTU+3&TZXF@\*2K-;WUM>PL]O<NZ6%AW66-0RE
MP4<X"%&=?';_ !9O/&NB>'-)N_!'_"5W$?B"ZLDU/2]0NI/["2>UB&R2.9!&
M^V:%;L%@LKE/+7:AQO?LW_!S4O@QH.L:)>:-X5T6*_NA<I'X7LKFSC=BNUC/
M]IFF9B %6,*0J(-H & *I:1=^J_7^OG?Y*IJU;O^G]?)KY^E?$_3_$5WX6FO
M/!F@Z7X@\2:>3+IT6K3FUABF=&A>1)UMKMHY!%(ZKB+Y@Q1F56)KXO\ A]X
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MM@_\B+HW_82'_HF2OSQK]#OVP?\ D1=&_P"PD/\ T3)7YXU_0/ __(OCZO\
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MK*I\*[:_ET_7Y'Z[T444#/AO]K#Q[XJ^'-Q;ZYX1\>:]H.K[M-%K82:5:_\
M"(L);U8I6U35[G3S';ATWAU.HPR ;/*0NZ!_N2OGGXM? S7OB[_:>@:M\1-7
MT_P5K\ M=2T*VM=-\N6W*!)8HKI[4W,2S 'S"9&?YF\MH_EV_0<<:11K%& J
M(  !T '041^&W]?U_6@Y_%IV_K^OS/@/_@J/_P F*?$S_N"_^GBRK[_KX _X
M*C_\F*?$S_N"_P#IXLJ^_P"@04444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!YS\8?\ DDGC?_L!ZE_Z325\V_L'_P#))-9_[#MQ_P"DMK7T
ME\8/^22>-O\ L!ZE_P"DTE?-W[!__))-9_[#L_\ Z2VM>96_WJ'HS\QS7_DK
M,'_UZJ?FCH?VP?\ D1=&_P"PD/\ T3)7YXU^AW[8/_(BZ-_V$A_Z)DK\\:_H
M'@?_ )%\?5_F>-QK_O\ +T7Y!1117UQ\D?2O[*7_ "54?]>-Q_-*]X_;6_Y(
ME+_V$+7_ -FKP?\ 92_Y*J/^O&X_FE>\?MK?\D2E_P"PA:_^S5^&>)G^\2_P
MK]3Z_&?\DIC?\,_R/;?@Q_R2#P1_V!-._P#29*]*KS7X,?\ )(/!'_8$T[_T
MF2O2J^1H?!'T/U'(_P#<J'^"/Y(****U/4/_TOW\HHHH _%/X_>.OV7]8^,/
MBKP%8_#30O#VL6M]*NM>,/$?AJ]U-9+IVS,VGV5C!(UY)N+9EN)K>/=\RB93
M@_:7[$/AG]G/PIX+U_3?V?M3N]:,UZEQK5[>6$^G/->2I\I2W>VM(8HPH(2.
MWB"*.#D\GF=8^(7QXUN]\0_ W2K?7M/\::]XNNHEUO\ LPQZ9HOA'S5D2\M+
M\V[6DLK62^7$C.\PO)&WA53CV']GNV\7^&_$OQ#^&^J^(=6\8>'?"M[81:9J
M^N,LU^TUS9I/=VC7"1Q+<) S1LK[25,K1%CY>%NCI!^:7Z/[E>VFEUO="K*\
M_1O]5][^^SV29],74 NK::V+%!,C)N 5B-PQD!PRG'H01Z@BOC(?L7Q#PUH_
M@X?&3QY_8>@3VMS8V7GZ+Y$$EC();4!/[)P8X)%5HHFS'&438H\M-OTU\2M(
M\9:[X*U/2O .N6OAW6IX\0WM[9M?01KGYPT*S6Y^9,J&\P;"=V&QM/Y?_#7X
MF0:QHWP]^#WBG]I30]5AL9?#UI)9Z)X9OC<7DUC-"8((-9>YDCD2:: +]I$
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M''X7^$]:N?#VOZR;74+,J)8_LUP^TNH<?,D;*<JP/!K%_P"&D_@O_P!# ?\
MP$N__C->E#)L9**E&C)I_P!U_P"1Y\\WPD6XRJQ37]Y?YGN=%>&?\-)_!?\
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M )))XW_[ >I?^DTE?-O[!_\ R236?^P[<?\ I+:U])?&'_DDGC?_ + >I?\
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MOSSQ$_@4O5_D?H/A_P#QJOHOS.\HHHK\F/U,**** "BBB@#SGXP?\DD\;?\
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M95]_U)1^4G[1'_)9O$G^_;_^DT5>+5[3^T1_R6;Q)_OV_P#Z315XM7]%9/\
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M'_UZJ?FCHOVP?^1%T;_L)#_T3)7YXU^AW[8/_(BZ-_V$A_Z)DK\\:_H'@?\
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M7X_(517E=;?U_78[ZBBBI&%%%% !1110!\ ?\%1_^3%/B9_W!?\ T\65??\
M7P!_P5'_ .3%/B9_W!?_ $\65??] 'Y2?M$?\EF\2?[]O_Z315XM7M/[1'_)
M9O$G^_;_ /I-%7BU?T5DW^YT?\,?R1_/N<?[W6_Q2_-A1117I'FGZ0?LC?\
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M+&Z[E) 8*V57S\<KT9KRO^7^:/D/$?3(L9?^27Y'Z2_!C_DD'@C_ + FG?\
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MR+]G641N8U<^9A%4TG[*&D?M4^'_ -H[XF>,_BC\%O\ A$O#OQ6N[6^FO?\
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7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>business12a.jpg
<TEXT>
begin 644 business12a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" ++ Y0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUKJFO6>DVO\ 9MBUPWVBY?9&6"_=3/5N@')H [>BHTD!;:QYIQ= ,EJ '44
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M%_AOP/=W4EUX'\0-HNO+<6YC$=VL:2%5)^^NUU^84 =S12!U;D-2 KG_ %E
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MQH6G:?JD4=K90VLZ;)2T40 DD=."S9ZU/*RN:)X9^RE\#_VP/'WP1^%_[?\
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M^)/B]\%/%7B#XH^)_%6GV.L?M"6_CKPQJ7B2S$>J:O;V+J4GN8F ,7G.&.,
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MQ^RWI'[9O[-WB#]G/Q#XDN-)L_$!MO-U"UC#21>5<1SC /')C _&@:W/S?\
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MX=_\+0?_ !JO>*,T[LD\%/Q$_;JZ#]F?PY_X6P_^-4?\+$_;LW9_X9G\-_\
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MK@-3P7_A8G[=?_1M'AS_ ,+4?_&J4?$;]NT?\VT>&_\ PM1_\:KWFB@#P?\
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M-/$,?-_&O/7-?3/P\^)MIK<$96Y7<?>CR'8].HJOI]ZEW$K!P>*L4""BBB@
MHHHH X#]J/XO6OP%_9]\8?%^[1G&@>'[FZCC7J\@0[%'N7*C\:I?LD?#&+X4
M_L_^&?#[I_ITVGK>ZO.5^:XO+C][-(WJ2S'GV%>?_P#!564#]A[QI!G_ %BV
M*-[J;Z $?B*]JO/'O@?P+HVFP>*_%%CIOGVJBW6[N%CW[5&<9ZXR*!G145R?
M_"^/@SC(^)VB_P#@>G^--_X7U\&/^BFZ+_X')_C0(ZZBN1'QZ^#!Z?$W1?\
MP/3_ !I?^%\_!D_\U-T7_P #D_QH ZVBN1_X7S\&>WQ-T7_P/3_&E_X7Q\&O
M^BF:-_X')_C0!UM%<C_POGX,?]%.T7_P/3_&C_A?/P8_Z*;HO_@<G^- '745
MR/\ POGX,_\ 13-&_P# Y/\ &C_A?/P9_P"BF:+_ .!Z?XT ==17(_\ "^?@
MS_T4W1?_  /3_&C_ (7U\&/^BFZ+_P"!R?XT ==17(CX]?!@\#XFZ+_X')_C
M2_\ "^?@S_T4S1O_  .3_&@#K:*Y$_'KX,#K\3=%_P# Y/\ &E_X7S\&<9_X
M6;HO_@>G^- '6T5R/_"^?@S_ -%,T;_P.3_&C_A?/P9_Z*;HO_@>G^- '745
MR7_"^/@U_P!%,T;_ ,#D_P :3_A?/P9_Z*;HO_@>G^- '745R7_"^/@S_P!%
M,T;_ ,#D_P :/^%\?!G_ **;HO\ X')_C0!UM%<E_P +Y^#)_P":F:-_X')_
MC1_POGX,_P#13-&_\#D_QH ZVBN1_P"%]?!C_HINB_\ @>G^-+_POGX,_P#1
M3-&_\#D_QHN!UM%<C_POGX,_]%-T7_P/3_&E_P"%\_!GO\3=%_\  Y/\: .M
MHKD?^%\_!G_HINB_^!Z?XU>\/_%;X;>*]471?#?CC3;Z\:-G6VMKM7<JN,G
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M!!R>M+7/^$_%^F:IX<LM2O\ 6;59KBUCDD7[0O#,H/K[UI_\)%H '_(;M/\
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M7SM<_MG:IJFL'5O!_AB&\T%9"L;32-'<3J#AV4$8'.< ]<=J]K\#^-]#\?\
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M'BJ']M[Q3K&GKIO@5C\/VO)6MS<:"6?%_P#*W-YN5 P^\H"?WC3_ (*Z_?\
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M7"':\,J$95U/4?E4'B[0-&TS]H/P%+I6D6MJTFGZUN:WMU0D;+;@X S7E_\
MP3:^)FM_$C2OB*-6URQUB/2_&\EO;:]8Z&M@NIKY,9,_EK][<Q.'R=P />O6
M_'9Q\?\ X?\ /_,/UK_T"VK@Q-)4<1*"Z&T)<T4ST&OPY_:QEV?\%+?B]@_\
MS3#_ .DL5?N,>E?AG^UD2?\ @IE\7@3_ ,S5#_Z20USR.BC\3/MS]CFYDETZ
MW!;L*^V/"+$Z='G^[7Q%^QF2;"W'T_I7V[X/_P"0='_NU1G(V****"0KYG^,
M63_P5!^"!/;P+XP_]QU?3%?,OQD8K_P5"^"(!_YD7QA_[CJF14=SZ:HH!SS1
MG/2J)$;IR*_##_@XT!_X;PTT^O@"Q'_DQ=5^YSGC%?'?[=?_  1^^$W[=OQC
MM_C+XY^(NM:3>6^BPZ:MMIT<9C*1O(X;YAG),A_*OH^%<TPN49O'$5W:*36U
M]SCQU&=;#N,3PO\ X(L_L3?L\_'+]AW2O'OQ(\&RWFIRZYJ,4EPM_+'E4F(4
M85@.E?6P_P""87['9'R_#FX_\&]Q_P#%UT7[$?[)?A7]BCX&6OP+\&>(;W5+
M&UU"XNENKY0)"9G+$<<8!KV  @\M7)FF:U\3F-6K2J/EE)M?,THT>6DE)(^?
M?^'8/['W_1.9_P#P;W'_ ,71_P .POV/O^B<S_\ @WN/_BZ^A**X?KV+_G?W
MFGLJ?8^>_P#AV%^Q]_T3F?\ \&]Q_P#%T?\ #L+]C[_HG,__ (-[C_XNOH2B
MCZ]B_P"=_>'LJ?8^>_\ AV%^Q]_T3F?_ ,&]Q_\ %T?\.POV/O\ HG,__@WN
M/_BZ^A*#TH^O8O\ G?WA[*GV/GO_ (=@_L>G[WPXF_\ !M<?_%T'_@F!^QV!
MQ\.)O_!M<?\ Q=?008]<TJYZFE]>Q7\[^\/94^Q\J_%;_@FA\%;+P;<3_!3P
M*MMXB5E^QS76J3&,<C.=Q(^[[5X\O_!.[]HP2+YECH^T]?\ B8'_ .(K]"'0
M$\FF[$)P1FOS7B[PZR'C3-(8_,7)S@DE9VV=T?89#QEG'#N!EA<&XJ,M[J_D
M?.>B?\$R?V3I=(@EUSX>2&\,2_:F75KC!DQR?O\ 3-7E_P""8'['H''P[F_\
M&UQ_\77OY3;QM_2GJ<#K7Z+AZ^*PV'C2C-VBDEKV/DZEJE1SDM6[_>?/O_#L
M']C[_HG4_P#X-[C_ .+H_P"'87['W_1.9_\ P;W'_P 77T)16WU[%_SO[S/V
M5/L?/?\ P["_8^_Z)S/_ .#>X_\ BZ/^'87['W_1.9__  ;W'_Q=?0E%'U[%
M_P [^\/94^Q\]_\ #L+]C[_HG,__ (-[C_XNC_AV#^Q[W^',_P#X-[C_ .+K
MZ$HH^O8O^=_>'LJ?8^>C_P $O_V.SR?AS-_X-KC_ .+K@OVI?^"</[*'A+]G
M#QSXFT3P!-'>6'A6^GM9/[4G8*ZP,P."^#R*^PCZ5ROQN\!3_%7X1>)?AG;Z
M@MJ^O:'<V"W3+N$1EC9-Q'?&:UH8_$QQ$)2F[)K\&*5*/*TET/YP?^"?''[<
M/PO'_4ZV/_HP5_30.E?EQ^SM_P &]OB;X&?'7PK\8KC]H>QOU\.:Y!?R62:2
MZF7RVW;0<\9K]14W8R?2OH^,LUP6;8RE4PTN9*-GZW./+:%2C3:FAU%&1ZT#
MIUKXT]$*P?BB<?#;Q ?^H'=_^B6K>K!^*//PW\0#_J"7?_HEJ /P5_8CNVCT
M?1\?\^Z?RK]8OV6KEFTJV+<\#^5?DI^Q1_R"-';_ *8)7ZR_LK_\@VW'^P/Y
M"HB;UCZBTGFU!JU572/^/-:M'I5F!\R_%"3=_P %3?@^"/\ FF?BW_T?IE?3
M1.!G%?,7Q-Y_X*H?!\9_YIEXM_\ 1^F5]-LW':@J70%D#' IU?)/Q9^.GQ/_
M &1?VW]/UWXK^+)KCX1?$BUATRPGF/[KP]JZ<*'/\,<H.-Q/7Z5]865W#>VR
MW<$RR1R+NC=#D,/4'O6U2C.E&,GJGL_Z[&49\S:)J*%.1G-%8EB'.WI7S7^U
MLMP_Q6TT2;O+_L#;#Z9\YO,Q_P"0\_A7TG)DH<'M7CO[6O@2]UGPO9>-](A,
MEQH4S-<1+UDM9 !)CW4JC_137YIXNY/C,[\/\9AL+=SY;I+=\NK7S1[7#N(A
MA<XI3GM>WWZ'S;\.E,'A:#3)4*R6;R03*?[RN0:[[X<?M&^%?V<;;Q!J?Q&U
M-;/PW_8\VI"ZD;_57,(7=$!W:5#E?>)NN:\]>^_X1W7I+J7']F:D0WVC=_J9
M\8Y]G'.>Q&#U%:3? ;P-^TYXM\._#3QU:O>Z7!JJZI>6L;?++' I8*^/X"S*
M#ZY%?P]X)8[,<K\5,)."ER59<L[)OW6M4^UO/8_4N)X4<1D512>RNO7R.Z_X
M)F_"[Q/K.F>*OVR?BKI36_BSXK:D+V&&X7,EAI*<6EMD\@;3N(]6'I7U8B[%
MVU6TBRM--M4TZQ@2&&&,)''&H544#   [5;'%?Z98BO+$5G4?R79=#\1A'DC
M81CBO&OV]_@<W[0W[)_C+X96R?Z;<:4USI3*N2MW 1-"1_P-%KV4J#UILL2O
M&RE<YJ*525&M&I'=.X2CS1:/%OV!/V@=+_:*_9>\+^-K>3;J5M9#3O$%FQ^>
MTOK<>7-&P['<N1Z@@U[6IR,U\1?%_P &?$#_ ()U?'?5/VHO@KX5N]:^&'BZ
M\$GQ&\(Z;&6FTVZ/!U*!!U4_QJ/2OJWX-?&_X9?'3PE;^-/A=XSLM8L+B)76
M2VF!:,G^%UZJPZ$$ @UUXRA'F]M2UA+\'U3]"*<_LO<[&BF[U[FEW#UKA-1:
M*S?$OBO0?"6G/K'B+5[>QM(RHDN;F0+&I9MJC)]20/QJ^DPDB$B_Q#(H\P'T
M5AWGQ$\&Z?XPM/ %]XIL8=:OH6GM-+DG4331KU95SD@>M3>+/&.@^"M&N/$/
MB?6K73[&V7=/=7<P2.,>I)H<9]F!K45Q/A7]H7X->.-/OM4\*?$K2+ZWTN+S
M=0DM[M3]GCQG<W<#WZ5V%E?VM]:1W=K.KQR(&CD4\,I&01^%.491E:2L%R:B
M@'(ZT4@"BC/M10 4444 %%%% ' ?M6_\FQ_$+_L2]3_])9*_$C]B6X9-&T/!
M_P"7&W_] 6OVX_:LY_9C^(7_ &)>I_\ I+)7X?\ [%9/]DZ(/^G&#_T 5,C:
MDKW/UF_9:N&;1[?GLM?1^E$_9%![5\T_LL_\@>U_W5KZ5TG_ (]:KI<R>Y:H
MHHH$%%%% 'SA_P %5_\ DROQ;_O:?_Z7P5U?Q5U/QSX8^)/@+Q!X1\/6.H+?
M:=>:4WV^^,$<<SI%-&-P4\L(7 ]3@=2 >3_X*L9_X8J\7?[VG_\ I?!7L7CS
MPG/XL^&+6-AM%]%:PW.GLP^[<1;9(S_WTHH^T/H<S9O\>;'5KK7K#X*^$X[V
M]""\NDUQA).%&%#-Y66P.F>E8OC'X;>-_B!JD.N^-OV9/ >J7EN<PW5]J DD
M7'^TT.:]2^'OB6+QAX2L?$L2;?M=NKO$>L4G1T/N&R/PK<JHRG&5TV(\IL8O
MCIIUA-IVF_!'PE;P7!)GAAUHJLA(P<@18.1Q4NG3_'[2-(BT'3O@QX5@L8(O
M*BM(M=98TCQC:%$6 /:O4:*3E)ZW \&L?@WXBTK4;G6=-_93^'<%S>9%U-%>
M*&E!ZY_<]ZZ6]/QWU%K-]0^"7A.=M/D66Q\W7"WD2 8#)F+Y2!W%>J44Y5*D
MMV!Y'XOTOXR^/](;0?&OP%\':M9N<M;ZAK)E3\FA/-9ND?#GQYH6C)H&B_LR
M^ K>S5746T.H!4"OC<,>3SG SGKBO;J*(U*D8V386CV/']9\/?%KQ)Y \0_L
M]^"[S[+#Y5O]JU;S/+3CY%S#P.!QTXIVL:%\7/$%S#>:[^SYX+O)H(Q'!)<:
MMN**#D*,P\ $ X]:]>HH]I/N%CRM&^/2:N/$"?!/PHM\(/(6[77#Y@CSG9N\
MK.W/..E.TA_CYH23+HOP7\*V?VJX:XNA!KQ7S96^\YQ%RQ.,D\FO4J*F\@/#
M-0^%GC'4O%:^.-1_9>\ S:QN#?VE)?J9BP[[C#UK7;3_ (T2>'?^$.E^ O@]
MM)VX_L]M8S#C=G&SRL=>>G6O7**J52I+>0'F&HW/Q^UK29-$U;X,^%+BSDCV
M26T^NLZ.OH5,6#7.>%?A?XS\%/N\(_LO> =++7"S,UGJ 0[P<AN(>H[5[E11
M[2HE9,7+%[H\M>Y_:"GU6+6Y?@UX6:\@A:.&Z;7F+HC8+*#Y60"1TZ5D^//!
MGQ.^)UM':_$+]G/P3K$<+;H5U+51-Y9]MT7%>T44HRE&5T]1GB]IX)^).GV\
M-I8?LW^!88K?RS!''J04(8R2A \GJI)(]">*LWFB_&'4=97Q!J/P!\&S7T;*
M4O)-7W2 KG:0QASD9.#VS7K]%/VE3JPLCRNVD^/=CJ-QK-G\%/"L-Y=JJW5Q
M'KI#S!>%#,(LG Z9Z4[0Y/CUX=TF/0]!^"OA.RLX]WEVMOKA1%!.3@"+')/Z
MUZE12;N!X3%\)/%5OXAF\5VW[+'P]74[D,)[U;Y?,<'KD^1WS6]<6WQQO;"T
MTFZ^"'A&2VL9(Y+."36BR0-']PH#%\I7 P1T[8KUBBFZE25KMZ!9'E/B:#XY
M>,M'ET'Q9\#O".I64RXEM;S6S)&WX-%BLGP?\/\ X@> 4CC\$_LT^!-*\F0R
M0FQU(1E'(VD@K#P2./I7MA('!IKR+&NYJ%.<8\J8'EZ7/Q]BU:37X_@SX56\
MFB6*6Z776\QT4\*6\K) /:L+QQ\/O'WQ'NX=0\>?LU>!=6N+7F";4-3$K)SV
M+0YKTGQ1\6?!GA2Z73;W43/>NN8=/LHVFN'^B("1]3@>]8EK<?&7X@)(5LX_
M"-A)Q"TVV>^9?[Q492,^@^8BB,IQE=,+(Y:Z\:_$KX4Z9)=2_#/P3H]NVTR+
M%KQCWD !1M6'+'    /2JOPUUCXW_%_XPZ)X\\6_"F'P_H.A:??)#?2:@S2W
MDD_DA=L+(&50(R=S8/3BO2/"7P:\&^%,736\VI7Q;=)J6JS&>=VSUW-]WZ
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MZ+\,=8_:#OOVE?B/XY^)7BJUN/!^JL_AK3]/UJ6"+3K@:9'.7"J1D[MHP>
M>,DU]F_LCZ[K'CW]EOP+XI\4WLEY?ZEX5LY;ZXD;YI7:(98^YKEQ6!CAX<RE
M>SL].MKETZGM'8V=-^/?PPU[XP7'P/T7Q5#=>(K/1UU2ZL[=MXAMS+Y0+,.
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M\>:U:/2JND?\>:U:/2J.<^8OB;_RE1^#_P#V3+Q;_P"C],KZ=P/2OF+XF_\
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M(;FUCN()-R21AD8=P1G-,":BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIFOF;XQ?\I0/@C_V(_C#_P!Q]3+H..Y],T4450@HHHH **** "BBB@ HHHH
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M )!EO_N#^53]HZ*GP_UY'U%I'_'FM6CTJKI'_'FM6CTJCG/F+XF_\I4?@_\
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M0 4444 %%%% !6#\4?\ DF_B#_L"7?\ Z):MZL'XH_\ )-_$'_8$N_\ T2U
M'X&_L5_\@G2?^N*?RK]9/V5_^09;_P"X/Y5^3?[%?_()TG_KBG\J_63]E?\
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MAM&_Y ]K_P!>T?\ Z"*^>?\ @JQ_R93XN^NG_P#I?!7T-HW_ "![7_KVC_\
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M277AO1=0^==&M7^XY5N$<K]U1PBE3PQ('+6J.3]G#=G51IQA'VD]NGF>C_\
M!'O_ ()=7/[*/AVZ_:3_ &A;G^WOC%X\5KW7]1NQYC:6LIW?9D8\[NF]NYX'
M %?=J1[*(QA  *=713@J<5%&-2I*I+F8C*IY*_2OA+_@L#_P2_N_VL/#=K^T
M=^SS)_8OQD\#JMWH.J6S>4VHK$=PMG8?Q<?(QZ=.AK[NIKQEXV3/6IJ4XU(V
M84ZDJ<^9'Q#_ ,$?O^"I,'[:O@&Y^$GQL5-#^+W@YC:>)M"N%,,ET(SL^T(C
M8/48=?X6]C7V\K# ^:OS1_X*\_\ !.OXE>#/'EK_ ,%.?V$3-I_Q,\)R)<^(
M-'TV(!=9MEY>0J,;W"_>7^-?<5],?\$R/^"C?PS_ ."A_P !+7Q_H0CTWQ/I
MN+;Q=X;9OWEC=#@E1U,;$$J?3@\BL:-249>SGO\ F;UJ490]K3VZKL?3%% .
M>E&<=:ZCD"BBB@ HHHH **** "BBB@ K!^*/_)-_$'_8$N__ $2U;U8/Q1_Y
M)OX@_P"P)=_^B6H _ W]BO\ Y!.D_P#7%/Y5^LG[*_\ R#+?_<'\J_)O]BO_
M )!.D_\ 7%/Y5^LG[*__ "#+?_<'\JG[1T5/A_KR/J+2/^/-:M'I572/^/-:
MM'D8JCG/F+XF_P#*5'X/_P#9,O%O_H_3*^G:^8OB;_RE1^#_ /V3+Q;_ .C]
M,KZ=H*D%%%%!(4444 %%%% !1110 4444 %%%% !4<H#<8J2B@#Q_P#;#_8^
M^%?[9?PGOOA9\3M(6194WZ?J*1CSK*8#Y9$;L0?S'%?!/[(O[5GQK_X);_'*
M']A;]M2YFN/!-U,8_ OC1B3%'$6PBEC_ ,LSD J>8S[8-?JL1D8KQ3]M']C'
MX4_MG?".]^''Q+T]/-VE]*U2.,":QF[2(W7ZCN*X\10E*2JTM)K\5V9]CP]Q
M!AZ.'EE>9KGPM3_P*G+^>'9]ULT>LZ=K&GZKIT>JV%['-;S1AX9HV#*ZGH<C
MK7BL_P#P4(_9IMOVK+;]D%?''G>+;J$N%@7?;I+VMS(#Q*1SMQT_*ORMN/V]
M?VVOV$['Q3_P3ATF]M_%6L6MY_9OA/7;.0S7$$4OW511GYL,-JGE#QT K[1_
MX).?\$K8/V=HH?VDOVB"VK?$W6H3.ZW4GF_V7O.XC)ZRG^)L\=!WKGI8ZIB:
MBA2CM\79>7J>[F' ^7\/9?5QF9U[QFOW$8-7G>S4FOLQ2WON4O\ @YCPW_!-
M&\)'_,V:;_Z,-?9'[)W_ ";'\/?^Q*TS_P!)8Z^-_P#@YB '_!-&\Q_T-FF_
M^C#7V3^R=_R;#\/?^Q+TS_TECKJA_O4O1'YW/_=8^K_0]!HHHKJ.4**** "B
MBB@ HHHH **** .!_:K_ .38_B%_V)>I_P#I+)7X?_L5?\@O0_\ KQ@_] %?
MN!^U7_R;'\0O^Q+U/_TEDK\/_P!BK/\ 9>B?]>,'_H J9'11V9^L/[*W_('M
M?]Q:^D])_P"/6OFS]E;_ ) ]K_N+7TGI/_'K5KX3G+5%%%( HHHH ^</^"K&
M?^&*?%W^]I__ *7P5]"Z.^-'M?\ KWC_ /017SU_P58_Y,I\7?73_P#TO@KU
M'XL^'/B]XH^%2Z3\$?'=GX<\0,MN;;5-0T\7,:("I=3&2,Y7('/%$8J51)NU
M^H/X3J_%GB_P]X&\-7OB_P 5ZI%9:;IML]Q?7<V=L,:C+,<=@*\,_P"'KO\
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M4#JS$ >_2L.Y_P""FG[)_CQ(X_%'[8_A;P_8M\TMAHLTKW#_ .RTYC^4>NT
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M1D9_2@ =#N_,5Z7^H?#_ &?WLP_M/$]U^)^SG_$3!^SW_P!$&\5?^!,%-/\
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M\<M%U#P3)X.MFMO#=OH CN(XV@'E*9]W.WC/'.*_/G]K$Y_X*8?%W_L:H?\
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M36ZM)9WNNP*7BD4%6*EONLIR.Q!KY-^('[//P)C_ ."WGP_\'+\(?#HTFZ^
M>K75QIJZ3%Y,DXU(*)"FW!8#C.,XKI/V;/@/\$_'G[>'[3FD>._AAH.J6NG:
MAX;M["'4--CD6VA.EGY$##Y5]ACM6<ES1LT5M9GKWBKX7_L>>$_#"_$OQ?XY
MTVPT&^D6/3-8O/$(2UC9P2!!(6V@D XP3D=.*ZK]G;Q)^S)=V]WHGP(^(V@Z
M[<*%DU"33=9CNK@]@7*L6P,\=AFOR]\<+J6D?#'7_A!X,\(_\)7X-\)_MMZ9
MIW@7P[=7"BWGMVM%EEL4DDROE+,[=<A2Q'; ^L/AM\$OB7X/_:=LOVP?$'[)
MNF_"CPSX(\$ZK!JFC^$[R._O_$CS",HAAMD 81;&91RQ9L"O%P/#^1X'%>WP
M^&A":OJHI/75Z^IU5,5BJU/EG-M=K]C[D:2&*+?*X4*,LS'@5DWWQ&\#Z9X:
M_P"$QU'Q?ID&DJ3NU2:^C6W&"1]\G;U&.O6OBK]KK_@H_P"$?''PB\/^!_ U
MWXE^'I^(<]]:ZAX@\:>&;JPGTG3;8#[3(D10MYLFX1Q<=26_AKS3_@G5X,_9
M\_:B_P"">_PK^'FM>/(?$5WX)\5>(+NQ\#ZCJ8AC\1W27%X8()_-&9E6.5)>
M P4D%NE>\<O*?I5X6\6^&_&NE+KOA37K/4K.0_N[JQN4EC;Z,A(K28D+D5\4
M_P#!(&QUKP5K_P =OA;XL\$0^#M5TOXF?:F\#:?>?:+'1K6YM(I(!;R]&61/
MWA  VLV,"OM8=*%L*2L['@?QK_;T^&G[.G[47A3]GOXS.NB6?CS2))O"OB6Y
MDVVLM]#+LELY">(VVO$RMT;<0>171?M>?MA?"/\ 8T^ VK?'KXLZ]%#I^GVK
M-9V:2#S=0N",QP0C^)F/X#J>E?&O_!S=^SM<_%#]A2U^,.B0'^TOAWXBCOUF
MCR'2UF'E2X(Z8/EM_P !K\H?V1OVJ-/_ &P?VA_A/\&?^"DOQWU6Z^&?A&5;
M?3+6[DW0/-N'EK<OUV$X4R-DA1C@$FO/K8J5.HX/KL=]'"1K4E473='Z)?\
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M 9%8[MS,<&IY@:/T7K!^*/\ R3?Q!_V!+O\ ]$M6]6#\4?\ DF_B#_L"7?\
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MS^E_X$P]A1_E/E'_ (<J?\$YO^B 0_\ @QN/_BZ/^'*G_!.;_H@$/_@QN/\
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M0 4444 %)M!I:* "BBB@#\]/^#F?_E&E>?\ 8W:9_P"C#7V3^R=_R;'\/?\
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MK<, !]H?CKTKZ#A_(7GU:I34^7E5]CEQ6)^KQ3M>[/Z4KOQQX/T]E34/$UA
MSH'19KM%+*>A&3T-6]+UO2=9M_M6D:A#=0[B!);RAU)[C(-?S_\ _!7[6M:M
M?C#\/4M-6N(U;X0:"6"S, 28FR>#7Z9?\$#KBXOO^">.AW%U<222?\)!J(+R
M.6)Q*.YKHS+AS^S\GIX[VE^9VM;;?_(BCB_:UG3ML?;%% SCFBOESM"BBB@
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M2UC2=1@A==,U[0=0>WNK0G..5.&7/.U@14RYN70J/*Y:GRW_ ,'+FIZ=>?\
M!-6\@M;V&1O^$LTT[5D!./,-?8_[*.N:-#^S#\/E?4[?*^"]-!'G+Q_HT?O7
M\\?_  4L_P""5?[?O['-[(/%_B#7OB!X#N+H#3]>T^XGN(Q\WR">$EC$_( Z
MC/0]J^A?^"7W_!#W]LCX[KI/Q2_:S^*GBKP3X'54DM/#L>KSIJ%_&,;05W8M
MX^G7YL= .M>;"M6^L/W3TY4:/U5>_P!6?N[9ZC9:@GF65RDBYQNC8$9_"IJY
M/X,?!CP'\!O -C\./AQIK6NF6$>(UDF:61V/5W=B2S'N2:ZRO36J/*"BBBF
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M?O1>[2YK-[75M-SZHMU;9AOO5,,XYI @7[M+7L'YJ<#^U7_R;'\0O^Q+U/\
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ML!LX.2<=ACGZ/_9\_9H^'GP$TJ<>&?"^EVNH7Y5M0N-/L4A3 &%CC 'RQJ.
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M.,C-?B7^UE_RDS^+W_8U0_\ I)#7ERCRZ'90^(^U_P!C+_CQM_P_I7V[X/\
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M$O4__262OP__ &*O^07HG_7C!_Z *_<#]JO_ )-C^(7_ &)>I_\ I+)7X?\
M[%7_ ""]#_Z\8/\ T 5,CHH[,_6']E;_ ) ]K_N+7TGI/_'K7S9^RM_R![7_
M '%KZ3TG_CUJU\)SEJBBBD 4444 ?-__  58_P"3*_%Q_P!K3_\ TO@KZ"TY
M_*T2V?\ Z=H__017S]_P58_Y,I\7?73_ /TO@KZ%TF-)-'M0ZY_T:/\ ]!%3
MO(.A\@^,_$/[?7[8?CW6OAS\/-'N/@WX"TG4)+*Z\5:E&LFJZRJM@FT09$2'
MJ'.,@C&>E>I?LY_\$_?V=?V=9?\ A(]'\*'6O$TWS7GBOQ$WVN_N).[>9)G:
M<_W<5[D8XD;<5'Y5@?$/Q_I/@/1UO+B%[J\N)!#INFV_,UW,?NHJ_J3T49)X
M%=TL=4]G[.FN6/9=?5[LS]G&]WJ5/B)X]M/ VG1QVM@U[J=XWEZ5I5NP\RZD
MXX]E&<ECPHZ]@6_#CX=W6ASW'B_Q?=QZAXBU 8N[Q5PL$8.5MX>ZQK^;'D\U
M'\._A[J-GJ,WC[QY/#>>(KZ'RY)(4Q'90YR+>'/10>K=7(R>V.T VC KC--M
M ''%%%% !1110 4444 %(5!YI:* (Y;>*48>-6_WAFN9UKX*_#76[]M7F\+6
M]O>M]Z^L,V\Q^KQX)_'-=510!P+?#'QUH$WF^"/BKJ$<8.?L>M1K>1?]]'#@
M?1OPI=3\7?&WPI;?;+[X9V?B&%/]8OA_4%BN6_W8[@JC'V,J_6N]P#QBC'M0
M!Q>C_';P!?0J-6N+S1;C'[RSUS3Y;62-O0EUVMC^\C,I[$UU&DZ[I.N1"XTG
M48+J-AE9+>4,/T-376GV5[&8KRTCE5A@K)&&'ZUQ^J? 7X>W-_\ VSH^ER:/
M?'DW6B7#6K,?5@A"M^(- ';;AG&:*X.;P5\8-"(;PA\2TNXUY^Q^(+%9 ?;S
M(]KCZG/THO/B+\4?"\ E\4_""XOHXQ^^N/#=]'<8']X1R^6Q^@)/ID\4 =VP
M)'%>0:U^SWKFH?MI:3^TRNNVXT_3O ]UHDFFE#YK22W$<HD!Z;0$(]:[3PY\
M;OAGXE=H+;Q.EK<+P]GJEO)9W"'WBG5''Y5TUO=65Z@GM9XY5/\ '&P(JHU)
MT[N/704HJ6YX&O[)?BG[%\<M-C\=QV4OQ89SI=Y9HPETPM8_9@S<\L&^;C\Z
M\<\(_P#!/?\ :&\-'X;7.FP_"W1YOAWK5M>.VDZ5.LNM[(FB>2>7&X,59FV\
MY8\FON/$3'.!1LC;G;772S#$T4TK:]UY6_(B5.,CY3UO]@SQIJ?[$_Q$_9C3
MQKI_]H>-/%%_JEKJ+0OY5O'<7R7"HPZDA5P<=ZPOCG^PI\??B?'KWA!]5\ ^
M(=#UK3XK?2;_ ,5:7(;[PVPMUB8VSQKEP&!D4%AACZ5]D^6@.0M'EI_=I4\P
MQ5.3=T^NW73_ "$Z--GR9H_[''[1GP(\277B/]F_XA^'[B37_"6GZ3X@F\51
M3,Z75I!Y*7L>S.YBN,JV,D#FN[^"'[+?C[X:?%^'XG^,OB1_PD$W_"O;70;V
M\NHV^T7-TEP\SSGMM)? '48KWD(JC 6D**?X:)XZO.+3MKHW;5_\,.-*$3\_
M/%G[.'QL^ 7Q8^!_@7X=^+]'F\0-X\\9:S;75U;R&S>*YBDG^SRX^891]FX=
M#R.E>@>.?V#OC=\6OAG\0K[QQX[\/P^//'&L:3>PM9V\IT^QBTZ9)((.?G8'
M:=S>K5]>W.E:==W4-[<V,,DUN28)'C!:/(P=IZC(XX[5,L:KT6M/[1K>ZU:Z
MZV\[D^QB97@Z+Q5'X:L4\:-9G5%M4_M V&[R3+CYMF[G;GIGFOQ*_:R_Y29_
M%[_L:H?_ $DAK]S#TK\,_P!K+_E)G\7O^QJA_P#22&O-EW.RC\1]K_L9?\>-
MO^']*^W?!_\ R#H_]VOB+]C+_CQM_P /Z5]N^#_^0='_ +M6R)&Q1112("OF
M;XQ?\I0/@C_V(_C#_P!Q]?3-?,WQB_Y2@?!'_L1_&'_N/J9=!QW/IFBBBJ$%
M)N%+7(_&GX1Z1\;?A_>?#O7M?UK3;6^*&2\\/ZK+972;6##;+$0RY(YP>1Q0
M!UNY<XS2YYQ7YC_L<? F"V^*O[1?C7Q5\;OBAK$'P4\?NOA?3+KX@WS0RV]O
MIT=WY,RF0B0,^0=P/!QTKV;P9_P40_:B\9? #PS\:HOV7-%TB+QW>0?\(O)K
M7C1(K6SLS"\DEU?R[/W*Y4*B('9MPSBIYD4XL^T2P'!-,:-&7:&Q]*^&;3_@
MKKXON?A;#K&E_!72]<\6+\:(OAU<Z;H/B02Z?-=R6PG2Y@N2GS1[67.0""&Z
MX&=CQI_P4Z^)WPD\*>/-(^+7P+TO3_&G@KQ%HNF20V?B!I-):+5$#07<ER8P
MT42#<),IP1QUHYH] Y3[-&U>A]J54"MN'>OD7_AX;\5],^%S7VN?!W0[[Q=J
MGC6R\,^#5\-^+([O2->N+F(RK*EP%WQI$B2^8'0$>6=NX$$UOB%_P4%_:<^$
M'AZUT#QW^R"6\;7GQ%L?"VF6=EKA&EZK]KM99X[JWN9(QN1?**2 KE3GKQ1H
M'*?8VX9P31N'>O@<?MZ?$7X/>+_BQ>3_  9O=4\;6GC?P?H-_P"'?^$N>:P6
M^U*S/%J9$Q#&C<,0H#XW'!K&_:X_X*.?M9>#? 7Q"^"D_P ,]+\'_%#PC!H>
ML1WFG:\T]E>:/>WH@\Z"1H@V\2*T3JRC&[(SBCF#E/T1# G I:P_AW?^*M2\
M%Z7J'C73K:UU:>PB?4+>SN#+%%,5!958@;AGH<"MRJ)"BBB@ HHHH ***X;]
MIW5-2T/]FWX@:UH]]+:W=GX)U6:UN87*O%(MG*RNI'0@@$'U% '<!P:8X0G)
M;KVK\B?A/^V/^T1\/O\ @EAXX^"O[0'Q&U1O&$WP5_X3'X9^.OMSK<ZIIT\0
M:2(39W&YMI"5/.XJZ'W/8>'?VG?C-\-/^"M'@G_A(_B%JUQX#U?X7^%-'UO2
M[J^=K6&_U&VG,-T5)VAVFA"%^I+CDTN8I19^HJK$K<<,.>*?N7'%?F#_ ,+X
M^-OCW]OKXQ?$"P^*.K)X)G^%?BJS\%Z3;Z@ZVT;:3&D#WJ(#C>UR9\/U_=BM
M*W_9U\=?"S_@FMH_[=/PD_:@^(MGX[T7X;6OBN\&N>,+J_T_46CM5N)[>6WG
M9DVR*'48 ()&*5Q\A^E'EAG+ _\  33@H63.>U>-?%3]K32?@S^QJO[5_BO0
M+B['_"-V%]'H]FP$EU=70B6*W3/ +2RJN3P!R:\=\7_\%&_C5\!(]?T7]I[X
M$Z5H^MQ?#?4/&'A6WT'Q UU#?16:J9K.5VC4QS+O3) *D9HN3;4^RMPI:\I_
M8_\ C/\ %?\ : ^#]A\6OBC\*8?!\>O0PWV@:8NJ"ZF:QEB1XWGPH$<A#<H"
M<#&3G('JU4(**** "L'XH_\ )-_$'_8$N_\ T2U;U8/Q1_Y)OX@_[ EW_P"B
M6H _ S]BO_D%Z3_UP2OUE_97_P"0;;C_ &1_*OR:_8K_ .05I)_Z8)_*OUE_
M97_Y!EOG^X/Y5/VC:?PGU%I'_'FM6CTJKI'_ !YK5H].:HQ/F+XF_P#*5'X/
M_P#9,O%O_H_3*^G:^8OB;_RE1^#_ /V3+Q;_ .C],KZ=H*D%% (/2B@D****
M "BBB@ ILG*$4ZN#_:0^.OA7]G'X)^(?C'XRN-MIHNG/,L2GYIY<8CB4=V9B
M ![U4(RJ5%"*U8I2Y5=GR3J&FWG[7?\ P60AGA0W'A/X#>&5,C-S&=8NB2%'
M;=C!_P"V/TK[O@5EB4&OFK_@EY\$/$7PV^ ]U\3/B+;%?%_Q*UB7Q-XB,GWH
MVGYBA/\ N1X&/4FOI=1A<8KNS"I&594H;02BO.V[^\RHQ]WF[@5&.E?&W[7&
M@IK7_!53]F<;<&WTWQ)<%O\ <MXR!^?-?9+YV\5\=_\ !2;5V^"WQ[^ ?[4<
MT3?8/#WC271=<F[16NHQ>26/H U3EW^]676,E]\6@K_ O5'V(N,<"EJ"VN(;
MF)989%99%#*RMD$'G-3YSTKAZV-@HHHH **** "BBB@ HHHH ***1NG7% #+
MAE*[2?Q]*_-W_@HS^P/<>"V\<?M#_"?P-I_BJW\70N?$FFZA;FXO=)E<;7U"
MR_O%5RQASS@;<'BOMK]JSX1>+?C?\$]>^''@;XA7_AC5=0M?]!UK3I622"4$
M,.5(.#C!P0<$U^?7P8_9^U;XD?M36/[.'QY\:?$+PM?:'X?N)=<@F^(%Z;?Q
M'.758IK!C)N:+;N9EX92P!Z9KS<=[UJ<H7OL[['W?!L?JTJF-CB%'D^.%FVX
MK6^C76UK;/R/M?\ 8>^!O[*G@?X5:+XX_9P\/:;]FU+0[>#^WK:WVSWJ(N,R
ME@&W[@20W.[.>:]VB7;P*YCX-_"CPI\%_AYIGPU\%V\T>FZ7!Y=O]HF,DC<D
MEF9N68DDDGDUU2C!Z5W4:<:=)0ML?(YCBI8S'5*KFY)MV<M[7T%HHHK0XC@?
MVJ_^38_B%_V)>I_^DLE?A_\ L5?\@O1/^O&#_P! %?N!^U7_ ,FQ_$+_ +$O
M4_\ TEDK\/\ ]BK_ )!>B?\ 7E!_Z *F1T4=F?K#^RM_R![7_<6OI/2?^/6O
MFS]E;_D#VO\ N+7TGI/_ !ZU:^$YRU1112 **** /G#_ (*L?\F4^+OKI_\
MZ7P5]"Z.<:-:D_\ /M'_ .@BOGG_ (*L9_X8J\7?[VG_ /I?!7M7B#QSH_@/
MP9#K>N3_ ">3'';V\:[I;B5E 2.->K,QX %+[0^A-X]\?:3X%T;^UM5!D:20
M16=E&1YMW,W"1(.[$XZ=!DGBLGX?> M6DU=OB/\ $&2.;7;J';#;Q-NATV')
M(@C]^?F?JQ'H *A^'W@O6=6UMOB5\1U5]5E0+I^FC!ATB+'W%]9&S\[]2>!A
M0*[P *, 4Q   , 4444 %%%% !11FB@ HHHH **** "BBC- !1110 449HH
M*"-PQ110!GZEX9T/6H_*UK2;:Z7IB>$-_,5RE]\ /!RZA_:GA+4-3\.W6<^9
MHU\\:-]8R3&1_P !KNZ* .%NM!^-VB+YNA>,-*UI5'%OK%GY#'_MI#P/Q4TQ
M?BUXG\-PY\>_";6;<+_K+K1=NH0X]0(R)?\ R'],UWI /44;0.U '-^%?BY\
M-_&NY?#GC"RGE7A[5Y/+F0^C1/AU/L0#70"XC9=R?,/[PZ&LS7/ G@WQ)+YV
MN>&K*YDVX$DENI<#_>QFN8U7X&V=M+]L\ ^-]<\.W .56RO/.A/UAF#H1^ H
M [X'(S17#D_'G0+;]R^@^(!&.5E5[.9_?(WID_[JCZ5';_&\:8/+^(?P_P!>
MT!U^_,UB;RW/N);;?@>[JGTH [RBL+PU\1_!'C.#[1X4\6:?J"XY^RW2,PY[
MKG(/L16XC!E!!H 4]*_#/]K+_E)G\7O^QJA_])(:_<PGBOPS_:R_Y29_%[_L
M:H?_ $DAJ9&U'XC[7_8R_P"/&W_#^E?;O@__ )!T?^[7Q%^QE_QXV_X?TK[=
M\'_\@Z/_ ':MD2-BBBBD0%?,WQB_Y2@?!'_L1_&'_N/KZ9KYF^,7_*4#X(_]
MB/XP_P#<?4RZ#CN?3-%%%4(*#THHH ^=?A-^Q)J/PWN?C]-+XYBNA\:/$%QJ
M-N%M2O\ 9HEL%M-K<_/@KN[<<5P_Q&_X)S?$2_\ @W\$O!/@;Q[X<NM3^$-J
MT#6OBK1WN=+U8/;>07DA5@=Z_>0Y.#7UMX@UO2O#&B7GB/6[V.UL[&W>>ZN)
M3A8HU4EF/L *^1?V3O\ @I=K?[4'CJWATJ;X>0Z#?^,M0TBQAB\12G4S;6T=
MR5E\IE"N[F!7VJ0!&6/44M.I5Y'._#W_ ()4_%?PWXN75_$_QHT&YLO^%U:;
M\13;Z9X=^RA;B&R^S36B(K;4B(5"G&1@YR37HWQF_85^)_B[XA?$;XH_#+XQ
M6>CZEXRO- N+6SOM)6YM'73H&B>VND8_O8I0V3C!! YH^*?_  5'^ .A?%3P
M/\(/A!X^\.^+=:\2?$2V\-:Q8V>H$R6$<BR^9.FWB0HT84@$@%N<5Z1:_MM_
MLK7OQ8;X%VOQY\-2^+5NFMET>+4 7,P',(;[IE '*9W#GBE[I7OH^=="_P""
M6'Q)T_PYK/C&/XC>%]#\>3>.-,\4>'XO#6@-!H>F7=E!) !]F+;F\V.602,"
M"=PQTKMK/]A_]H7QYK>@_$'X^?M 6>K:]IGQ.L?$[V>FZ<\6G6EO:VDUNMI;
M1LQ9=QEWL[$DGM5+X;?\%+[OQ;ID7BKQ?IGA3P_I%OXZ\5:'J?\ :6N-'<O#
MI(^66V3!$K-U<9 4<CTKT?\ 9$_;Y^!/[87@K0=;\ ^,M-36M:T9]2/AG[<K
MW5O"CJCD@8R%9T!(Z%A1[I/O=3YS_;@_8Y^)'@_7/%7Q6^'OC?\ XFWQ.^-W
M@N^TSR]+:8:.;)6AWR#/[Q"3N/0 =ZZ'QI_P2_\ C%\<[?XG?$KXZ_&W1[CX
MA>./#^FZ)HUUHVD/'INCV5C=&ZB01.Q>0O,2SDL.#@5]@^"_'G@OXEZ=/J_@
MWQ!::K:6FH364\UI()%CN87*2QYZ;D<%3Z$5NA0.@I\J#F,7X=Z=XMTGP7I>
MF^.M3M+S6(+&--2NK"$QPRS!0&9$))52>@))%;=&.<T4R0HHIDSE%X]: 'T5
MX_X?_;P_9)\4_%3_ (4EH'[0'ANZ\4-?26<>DPWF6DN$)WPJWW'<;3E58D8K
MSO\ 9;_X*E? /XWRS^#_ (@>/O#OAGQ@?&VLZ#8^&Y-2_>3_ &.^EMHFRPP'
ME6/<$)!.> 11<#ZD&>XKG/C!X&E^)_PF\4?#:&_6U;Q!X>O=-6Z9=PA,\#Q;
M\=\;\_A7'>-/VU/V7?AU\3H?@UXW^.OAW3?$T\D<:Z3=7@5U:3_5JYQM1G_A
M#$$]J/&/[:W[*_P_\67W@3QI\>_#.FZQI<,LNI:;=:DJS6J1Q"5V=?X0(V#9
M.!@BEH!\_P#[2?\ P2+T7]H7_@G[X,_9#O/B"NF^)O _AZWT[1?&EM:G*[81
M%,K)G)BE0$%,^GI4WQ/_ ."5-[\1YO'.HGXI1V=]XC^'/AO0M!O8[$F32=2T
M=VDAOASR#(0=HQQD9YKVC5O^"@'['6B>"Y/B'?\ [17AG^Q5U>32UU"&^\U)
M+Q$21X4" M(RI(C':#@,*O7O[;/[*VF_#G2?B[?_ ![\,P^&];,RZ1JTFI*L
M-V8AF1$/4NN#E>H/&*7NE7D>.^#/^"8Q\":'X6T+1_B.K+H/P8U?P7=3S6A,
ME[=Z@WF2WS'/4REW*]3NZUS6D?\ !.7]L'Q=\!M#_9'^-?[66B2?#73=+L]-
MU+3_  QX5-M?:E96X0"W>=Y&VJX0!B!D@D5Z'\:/^"JG[+/PN\(>!_'VA?$'
M2O$>B^-O&T/AV'4=/U!1':.Q EEDR,_NP067 /(KVSXC_&_X6_"#PA'X^^*'
MC_2O#^BS30PQ:IJER(H6DE_U:[FXR>U'NAS2.9_:7_9>\-_M$?LT:M^SA_:<
MFC6MU8V\6EWUH@+6$MNZ26\B@]=KQIQW ([UX+XW_P""=7[07[12:]KG[3_Q
MH\/7VM_\*WU/PEX3D\.Z/)!;VBWJJLUY,KN2\A"*-H(4#.*]V\(_MO?LJ>.?
M VJ?$WPS\>O#=QX?T.ZCMM8U)KX1QV<KL%19-^"FYF4 D8.>*S_$?_!0G]C/
MPQX3TSQWK?[1OA>WTG6IIH=+O?MV];IH7*2E H+%58$%L;1ZU0>\>D?";P7)
M\./A?X;^'LUZMPVA:%9Z<UPJ[1*8($CWX[9VYQ[UT5?/NO\ _!1/X Z-^TAX
M!_9[L_&6EW\GQ \/W&JZ/K%CJ"20,JM&(4&,[C+O;:0<?(:ZSPQ^VQ^RWXU^
M*<WP2\*?'7P[?>*89Y(7T>WOP9&DCXDC0\*[KSN522,'(I70M3U:DRW]VO!/
M#O[?'P5\-_#RV\6?M!?%[P3X<N[Z^U&*QAL-<^T1W$=M<F$F,E=SR#Y0Z ':
MQ(YQ70:[^W-^REX>^&&E_&;4_CQX=7PQK5PT&DZQ'>>8EU(N=R(J@LS+@[AC
M*XYQ1=!9GKE8/Q1_Y)OX@_[ EW_Z):F_#;XE^"/BYX3L_'WPV\5V.N:)J$>^
MRU/3YA)%* <'!'H>"#R#P:=\4?\ DF_B#_L"7?\ Z):F+J?@9^Q7_P @O23_
M -,$K]9?V5\_V;;_ .Z/Y5^3?[%?_(*TG_KBG\J_63]E<_\ $LM_]P?RJ?M&
M\_A/J+2/^/-:M'I572/^/-:M$X&:HP/F+XF_\I4?@_\ ]DR\6_\ H_3*^FY7
M9(V91SMXKYD^)O\ RE1^#_\ V3+Q;_Z/TROIIRX0\9X_.@J1XK^R;^US!^T#
MJ7B_P+XLT!=!\8>"_$$UAK>@--N9(=Q\BX4D?-'(G(8<9!%>UK)NKY/_ &R/
MV8?BEX>^)=A^VU^Q[:PKX^T.#RO$'A^1]D'BS3QR;9^WFJ,['XY/L#7HG[)G
M[;OPD_:J\.L/#M]_9/BC3_W7B#P=JO[F_P!.F'#*T;8)7/1AP:[JV'C4HJO1
MUCU76+\_+LS&,GS6D>W YY%%-1@5R33JX30*0M@X-+FN=^(WQ(\%_"WPS=>,
MO'_BFQT?2[.,O<WU_<K'&B@>I/7V&2>U"C*4DD@O;<VK[4K73[>2[O+A(HHD
M+R22, %4=23V%?$-UJ6N_P#!4']I^WTS0#O^ _PRU@2W]XPVIXHUJ/[D:CK)
M!$<DG[I/KD8A\3_$_P"-W_!4O69OAK\"8]0\(?!2*?;KWQ FC:"\\0JIPUM9
MHWS+$W\4A X'X5]A?"/X1_#_ ."7@;3?AO\ #3PY#I>D:7"([6UA7 Z<L?5C
MU)/4UZ<8K+Z?-+^(]E_*O/S_ ",/>JR_NG26-J+.%8$1555"JJK@ #H*FHHK
MS-]3<*\]_:?^ GA;]I;X*Z]\&_%T.ZVUBQ:.&8?>MYQS%,I[,C@,#[5Z%377
M<*JG4E2J*<=T)KF5F?)_[!7[4?B2#4;C]C']IT?V7\3_  3&((6N?ECU_3E&
M(;V!CPY*8W '(//J!]6PW"2;E3^&O'?VK_V,OAA^U/HD,FN/=:/XETM_,\/^
M+-&D\J^TZ4<@J_=?53D&O&K3XG_\%+?V3;:+P[X]^#-O\:O#EJ-D/B;PQ<):
MZMY0^[YUNY"NP&/F3KWYKT)4:.,]^DU&3W3=M?*_Y&493IZ2V[GV5YF>U.KY
M<UO_ (*!^-KS1? *^"/V:/$$/B#Q]K%]IMMX?\5R?V=+926T>]GD)5LQD9^8
M>G&:+3]O_P ::U'I_P -O#7P66X^)UUXFO\ 1+[PK-K 2ULWLXUEFN&N-IS$
M8Y(F7"[CY@&!S7/' XKJOQ73]--RG5IGT_--Y3+Q09MJ;B,U\@^-_P!L'XDZ
MUK'@W5;3P?<:;KVA^)-=TWQ9X/@U /'<W%KISS+$LH&'1P4=&QGGD<5Z1X3_
M &X_ ?CK7_!NC>'+'SH/$_@:X\5:I=M< +H]C&% \WCJ9"Z#IS$W7%$L#B(Q
M4K73!5:;ZGNR7 <9 IK7:(VTC\:^'_V(_P!J/X@^(/VD%N/B+\2X-5T7XP6-
M[JOA71UO(Y#H#6T[".UVJ<KYEJT<AS_$K5W?[?VK?$#3O'W@T:C9>.V^&OV>
M[?Q5/\.5=KZ.ZPH@:18OWOD@;B=@ZCFM)8&K'$JE)[J]]>W](%5C*',CZE%V
M-PXZU)'(9!N KX7^&/Q_T#0/"GAN#1?VD]6\=:&_Q;BL=+N!,]OJ6F6S6\DG
MV+4EE3?(%*L1E58@KR<5WF@?\%#/B'J6I>"O$MS^S]]F\"_$+Q.=*\,^(&UQ
M3/Y>9-EQ-!L_=JXC+*-Q.",XJ99?B(WMK^'Y]0]I$^K=W.#3968+D"O KS_@
MI_\ L'Z>US#>?M.>&XY+.9X;B*2X<,LB$AAC;S@@]*\]\7_\%;O /C"\;PC^
MQM\)/%7Q9UV3Y87TC1YK?3HB>\ES,J@ >H&/>IAE^.J:*#7F]%][T!UJ?<]B
M_;6_:-T?]F#]GCQ%\4;R<'4(;)H-#LU^:2ZOI 5@C11RQ+D' !X%<O\ LJ?L
MWZAJG[.GPPOOVF[*36O'WA^SCU&;5=2;=>6MY)F1D\P<G:'V$=#MKC/@Q^QK
M\:?C%\6-/_:@_;O\16=[K&FGS?"_P_T>0MI6A,<$,V?]=./[QR,CBOK>)%"+
M@=*K%1H4Z/L%:3O=OS[(O#U:L9.<6UT""#R%V[LU)1D=,T9KC&%%%% ' _M5
M_P#)L?Q"_P"Q+U/_ -)9*_#_ /8J_P"07HG_ %XP?^@"OW _:K_Y-C^(7_8E
MZG_Z2R5^'_[%6?[+T3_KQ@_] %3(WH[,_6']E;_D#VO^XM?2>D_\>M?-G[*W
M_('M?]Q:^D])_P"/6K7PF!:HHHI %%%% 'S=_P %7#M_8G\7N1T_L\_^3\%:
M_P /9?C1XLU*+XHZ[\.=+U*%/D\+VS:YY:65N 4W[3$V9GP2S9X!"C SG'_X
M*O9/[$GC  ?] _\ ]+X*A\'_ !B\:>&_CQ\&O@SI=Y"NA^)O".N7>J0M#EVE
MMF0QE6SP!N;([U5.FZDFET5_N!RC&.I[(GBCXP%03\--+4D9*_\ "0'C_P @
MTV;Q3\:8_P#4?#+26YYW>)"/_:%>1_&_]JCQ)\&OVA?%6A:F8[CPWX<^#_\
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M^TK\?_AU\ YD?XR^'?$FI:;\6-$TG3_%6AW4$SZCI-U=QH1<11DK%+M9U.,
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M>^&M2U7]OK39O%YO;.XU[POXVU2SM;/5K5Y EPL"85X2 6*,">5 .<YKT?\
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MQX;L36+XDC^(/P-_8+^#O[6WPF^%^O:7\0_@W)=>$=<T/4-'DLIKV/4$-NX
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M%[?X@Z]+IOAJ;6M+>.ZL/#:3M(;9(F*M&LCRW&,\X*DBON^6-I!@'\Z:+;'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"_[(G_1&?BW_ .$M!_\ )-.X>SGV/O>BO@C_ (B%_P!D3_HC/Q;_ /"6@_\
MDFC_ (B%_P!D3_HC/Q;_ /"6@_\ DFBX>SGV/O>BO@C_ (B%_P!D3_HC/Q;_
M /"6@_\ DFC_ (B%_P!D3_HC/Q;_ /"6@_\ DFBX>SGV/O>BO@C_ (B%_P!D
M3_HC/Q;_ /"6@_\ DFC_ (B%_P!D3_HC/Q;_ /"6@_\ DFBX>SGV/O>BO@C_
M (B%_P!D3_HC/Q;_ /"6@_\ DFC_ (B%_P!D3_HC/Q;_ /"6@_\ DFBX>SGV
M/O>BO@C_ (B%_P!D3_HC/Q;_ /"6@_\ DFC_ (B%_P!D3_HC/Q;_ /"6@_\
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M/O>BO@C_ (B%_P!D3_HC/Q;_ /"6@_\ DFC_ (B%_P!D3_HC/Q;_ /"6@_\
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MBCE#VQ^9'_#'5Y_T#_\ QT4?\,=7G_0/_P#'17Z;_P#"BM+_ .?./_OD4?\
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M^@?_ ..BOTW_ .%%:7_SYQ_]\BC_ (45I?\ SYQ_]\BCE#VQ^9'_  QU>?\
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M)%?E: $\E?0?E1Y*^@_*GT4 ,\E?0?E1Y*^@_*GT4 ,\E?0?E1Y*^@_*GT4
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MH **"V*;O'<4 .HIN\4;Q0 ZBF[Q1O% #J*;O% <9H =11G/2C(]: "BBB@
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MO\4?$?Q+8V37U])%8:=%'J=R6GO;LJPAB4!54'EB0!T.+$WA']O#]J?]K_\
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MFEV^HWS7FI7$GP^NYI[VX8 &6661BTC8XRQ-?:PYYJ-I%SPU-RLKAS(^;?\
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MZ_8%BJ7D(ZHQ_CB/*-GG!!/TEX*\?V>LP*R7.=WW>: .XHJ*UN!<1AAZ5+0
M4444 %%%% '*_&SXEZ'\&_A1XC^*GB6Y6*Q\/Z+<7UPS?W8XV;'XXQ7!?L._
M"A?AS\%;/Q'J]FG_  D7C29O$7BR\QE[F^N0'^8^B)LC [*@%<Y_P54F=?V&
M?'%JLC*MU;V=O(%_BCDO(4<?BK$5[YX=M(K/0+&UA7:L5G&B*O8! ,4=1EZB
MBB@04444 5]5MVN]-GM4DVF2%E##MD8S7\JOQ[\,:MX,^.'B[PIK<3)=:?XD
MO(+A6ZAEF<&OZKY_]623BOQI_P""Y'_!*SQSI7C_ %3]LCX$Z'-JFCZQ)Y_B
M[2;.'=)I\P7FY"C[T;8RV.5/)X.:^JX3Q]'"8R4*CMS*R;[G#CJ<ITTXGY=9
MR.372?"3XN>/_@?XUM?'_P -]?ET_4+-LJZ'Y9%[HP_B4]Q7-X()1@5(XP10
M-OK7Z#F&7X+-L#4PF*@ITYJTHM7374\>C6JX>LITVXR6S1^DGP _X+._#C6[
M>/1_C_X9NM$O-N#JFFQ&>UD]V0?.A^@8?2O?-*_X*'_L:ZM;"X@^.FCQKC.V
MY$D3?DRBOQ=9-_O00,\''T-?RMQ%]#GPTSK'2Q&%E4H<SNXP:<5Z)K3[S] P
M7B+G.%IJ$TI6ZO?\#]AO&W_!4']C/P;9R7*?%#^U)D7*VND6,LKO[ X"_FP'
MK7QG^U?_ ,%8/B#\;-&O/ ?PIT:3PSH-XICN+B2;=>3Q=P2O$8/<*3QWKY%P
M#S7HW[.?[)?[0/[57BZ'P=\#_AM?ZQ-),%FNHX=MM;#/+R2MA5 '/7->YP7]
M%[PNX#QBS"K%UZD-4ZKND^_*M/O./,N.,ZS:+I1?*GORGG)+,^22=W'TK["_
MX)K?\$C_ (Q?MN>*;7Q9XPT>\\._#N%@][KTR;'O0/\ EE;@X+$\@OC"U^@'
M["W_  ;\?!?X)W=CX_\ VE]4A\:^((561=+6,C3K>3@YVGF4CI\W!]*_1#1=
M!T?0=,AT;0]-@L[6V4);VMM"(XXU'10H& ![5^O9MQ53C3=#!+ROLEZ(^=H8
M*3ESU>IS_P %O@K\/_@'\.=+^%OPO\.PZ7HNDVZPVEK"N.!U8^K$\DGDFNN_
M"D4;5VYI:^%E*4Y<TG=L]1)15D%%%%2 UU+=J_G;_P""W?[/$OP&_;^\57MC
M9>3I/BYDUS32J_*&E4"=1_VU#G_@5?T35^?/_!P)^QRGQR_9D7X[>%]+\SQ!
MX!E,\QCCW27&GN<2IQV4D/\ 0&O>X;QL<'F4>;:6C^9RXRG[2BT9/_!MK\9X
MO%?[)>N_"*YF_P!(\*>(7>%&;GR;@;A_X\K5^CBG<,BOY^O^""?[25U\$?VX
M-/\  FI:DT>C>.K-]+N(RWR?:0-T#GWR"O\ P.OZ X?]6,T<2866%S26FDM4
M&#J>THKR'4445X)U!1110 4444 %%%% '(?'?X.>"_C[\)->^#WC_3OM&D^(
M--DM+I%;:R;A\KHPY5U;#*PY! -?GA^RA\9?%7@ZZNOA7X[U9IM8\*:Q<:+J
M,LC?/*]O(8UD;W= K'_>]Z_3R093%?C+\6?$7_"'_P#!1+XPZ192;8V\;+/M
M!(^9[6!C^M*1K3CS:,_4WX3>.$UJPCD\[J!CFO2[:431!P*^3_V6O&4FHZ=;
MJ\_WE4?>KZET&<2V2G=_#3,Y%^BBB@05X%^W[XQOH?A[X>^!6@RS+JWQ6\7V
MOA>V:UD*R06TB2SWDV1R EK!-SZE:]]KYG^.V-3_ ."EWP%TFZ9FAL_#'B^_
MAC)^47"PV<(?'J$FD7/HYH&CZ!\%>#=!\!>%-/\ !GA33(;+3=+LX[6QLX(P
MJ11(H55 'H!7%?&WX(P?$6Y7Q++XOU:P:QT^1$@L;QHXV.=VX@'D]L^E>F 8
MX%4=?A>XTBZBC!9VMY JCN=IXKAS+#QQ6!G3:O=/0NE-PJ*2/F[]G7X0R>.?
M#J_$+4?'NN1W&GZH2D,>H2%'\K:P#98Y!/7VJA\#O@I?_%_P7J'BZ\^).O6=
MXFL75M;B&_D*KY;#:WWL_K7I7[*.CZSH_P )+RSU?2KBUF?4;@K%<1%&(V@9
MP>W%><?!SXG_ !&^$/@^^\&VWP?U&^GFU:ZN8;CRYE \QN 5$))/T//KS7Y?
M0P.%P6'P:Q*FH.$W+XF^?1)NW7>Q[4JTZCJ.$E>Z2VVZF9XL^)_CG6?@9?>&
M_%&NSKJ?A_Q9#93ZA!,R-<VYB<JY*D'.Y7!SUV9/6F>)IM ^'5QX?U[X5?'#
M4-8U2;4(TN+'^TFF7RRIR",D8+87!'5JO>)?@[XWT?X'3:IK&C7%QK?B+Q5#
M?WMG;0EFMH?+9%C(7T)+'T,AKWOPM\%OAGHJ6NIV/@C3X;J*-6686X+(V.HS
MG!![]<U6#RG.\RQ'[QVM"%I-RNM6TTK[VM>X5,1A:-/W==7HDNR[_A8Z:UUF
MS%E&]U=1HWE;I%,@^7C)[]J^9_%WQ^\6>/OVC/#=EX/N+BW\(V^M"SBNXY"B
MW]PLD7F';_$@5\#.!W[\>C:G^R+X0FU&^UG2?%6M6]Y<)<>7(U\SI&TR.K';
MW&'; SQQZ"O)?&'[*_CGX>^(?!OA;PSXUUB^LY+Z1(;J&%]NDMYD3F7@]3@\
MMZ=:^BX@J9[[.G"G2=E)-N,M79K?;2UVSEPL<*I-N2V>_I^:-[XQ7?CQ];\0
M>)_B3\4M0\'VMM--#X1T^UNL"_2+.) $.6+#83GD;\=J]?\ V9_%_B'QQ\&M
M%\4>*9#)>74+EI64 RH'94D..[*%/XUXYXF\7_$/PW<ZO\/OC7\+[[QMMF=?
M#NK6]C JI&RX#$_*1D8W;=SA@>",$^G?LE^#O%'@?X/V>E>*89(;B2XDGCLY
MOO6T3$;4/H>"Q'8L1VI9/*I+/FX.3BXOFYKZ._6^GI8,3%?5%>U[JVVJ_/[S
MU8=.E% /%%?=GEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M%  >1BOEW_@JY\';OQ3^SA<?';P:'C\4_"PMXBTN2!1NN;:(9O+1O5)( _']
MY5/:OJ*N9^,NFVFL?"7Q/I>H0"2WN/#U[%-&W1U:!P0?;%)CB[,^-?V7?VAX
M/%&F65]#J&Z.XA22,Y^\K $&OL3P+XE74[.-_,SQ_2OQQ_8&^)=ROA'0;:2X
M;]W8PK]X] N*_4CX ^)CJ&F0EIC]W/Z4HNZ-*D;;'N*MD9I:CM7#Q!AZ"I#T
MJC(\ _;[U>^\2^#_  Q^S7H5S(MY\5O%4.@WGV>0I+%I8BDN-0E4CE<6\+KG
ML9%KVOPOX8T'P5X9L/"7AC3(;'3=-M([:RM;=0J11(H55 '8 "OG?XS%]0_X
M*@_!"PFD8PV?@3Q=>1QYX$O^@1;L>NR1QGT8U]&:YKFF>'-&NM8UN^CMK2SM
MWFN+F9MJ1QJI)8GL  3[4=4D-VB?#_\ P<(?#/1/&_\ P3_O?%]]?1PW7A77
MK2]L?,ZR-(_DM&/<A\_\!K\E_P#@D[XBL/"W_!17X3ZKJ17RY/%D5JN[L\RM
M"G_CSBO7/^"PO_!5#4_VT?&#_!KX83FW^'OA_4F:"920VKS+P)F_Z9CG:OOD
M]J\9_P""7GPF\:?%[]O#X9Z/X+TV29M+\66>J:C,J_+;6MM,LTLC'H/E4@>I
M('>OTO*\+4P7#U6.(TNF_1-;?-GC5:D:F*7*?TPJ.,TM-0DKS3J_-#V HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@ HHHH **** "L'XH_\DV\09_Z =W_ .B6K>K!^*?/PU\0#_J!W?\
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M ?.'_!5C_DRGQ=]=/_\ 2^"OH;1O^0/:_P#7M'_Z"*^>?^"K'_)E/B[ZZ?\
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M_P!K+_E)G\7O^QJA_P#22&OW,/2OPS_:R_Y29_%[_L:H?_22&ID;4?B/M?\
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MA+;:ZUB;JXU9TU>6W6Y-N;M82-NW>"0F<D"OKS5KF'3[&6]N0?+BB9WVKG(
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MJ***LY0K!^*/_)-_$'_8$N__ $2U;U8/Q1_Y)OX@_P"P)=_^B6H _ W]BO\
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M&-; T<1'7I?U5SR\#+EJ2BSZ@HH%%? GJ!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 44'/:L3QY\0?"'PR\*WWCCQ[XEL])TG3H
M3+?:A?3".*%!U9F/2A)R=D&VIMT5F^%?$>E>+O#UCXJ\/WZ76GZG9Q75C=1G
M*S0R*'1Q[%2"/K6E1L 444A8 9H X3]J;_DVCX@?]B;J7_I-)7X>_L4 _P!D
M:'[V%O\ ^@"OW _:DD'_  S5\0 Q_P"9-U+_ -)9*_#_ /8H?.DZ'_UX6_\
MZ *B7Q(UIRY4S]8OV5SG2+4_[*U]):3_ ,>M?-G[*PQH]J/]E:^D])_X]:N/
MPF1:HHHH **** /G#_@JQ_R93XN^NG_^E\%?0VC?\@>U_P"O:/\ ]!%?//\
MP58_Y,I\7?73_P#TO@KZ&T;_ ) ]K_U[1_\ H(I?: LT444P"BBB@ K\U_\
M@YFNY$_93\$VR_<D\;9;\+>2OTHK\Y_^#EC1WO?V-/#6L(GRV'C:,R$#IO@D
M7^=>MD;2S:C?N<^*_P!WD?APB!F"XSNX-?U*?L>Z5;Z)^RU\.]*MU^2W\&Z:
MJ^W^CQU_+8/E;<K?=[U_4E^QUJT.M_LL?#O5;<Y6?P;ISK^-NE?4<:2C[.DH
MOJSCR_XI.^YZ91117P)Z@4CG"$T%CG%?.W_!0_\ X* _#7]@OX0W'BWQ/<1W
M>O:A&\7AK0T^_=3[>"WI&IY9ORYK2C1J8BJJ=-7;)E*,(\TC\^O^#F']HBPU
MKQ;X'_9JT>YCEDTF&76=89&!\J20>7"A';Y=[?3'K7L__!N#^S(/ 7[.6N?M
M$:SI[1ZAXTU'R-/::/D6-N2-RGT=V8^^T5^?7[*O[._Q]_X*\?MD7WC'QQ>S
M26EU?)?>,M=:,B*WMP0!!'V!VC8J^G/K7]!WPN^'_A7X4^ -)^&_@?2(['2=
M$L(K/3[6,<1Q1J% ^O')[FOJ\XJ1R_*Z>71=Y;R\O(X</&5:NZKVZ&\IXI:*
M*^0/0"BBB@ ILBAEP:=10!\]_P#!07]@'X:_MX_!RX\"^+$AL]<LU:3PWKWE
M[GLIO0^L;=&7O^%?AGH\/[3_ /P2'_;#L=6\1:+<6>J:'=X906%KK5CN&X(V
M,.CKW_A/TK^DZ1=P'L<UXS^V-^Q!\$/VU_AQ)X ^+?A]&FCC8Z7K,* 75C)C
M[Z-CITRO0]Z]S*,V^I*5"LN:E+?R\T<N(P_M/>CHT2?L8_MG_"+]M7X16'Q1
M^&&L1>;)"HU71Y)E-QIT^/FBD ]#G#=&'(KV0'/:OY]OBY^S?^W9_P $7?C8
MWQ)^&^KW<WAV6Z:.R\064+-9W\&<K%=)T5\=0>,YP:^]_P!B7_@X"_9U^-&E
MV7A;]HR1/ OB5OEFO)OFTV<]F67.8\^C# ]:TQV224?;X-\]-]MUZHFEBHOW
M:FC/T2SSC%%9?ACQCX9\9:9%K/A7Q!9ZC:S(KQ7%E<+(C*1D$%21TK4W ]#7
MS[4HNS5CLWV"BBB@ HHHH #TK\,_VLO^4F?Q>_[&J'_TDAK]S#TK\,_VLO\
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MU]]#IQ7S.,PM3!XB5&>Z_JYV4ZD:E-204445SF@4444 %%%% !1110 4444
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M.GZ3"P:ZOY<?+'&F<G)[G '>OF:-.I6J*$%=OL=DI1BKL^:O^"^G[5Z_ _\
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M83\-_P!F_P *Z;)"!LF724DD'_ G!/ZURXJC4Q$>562.S"5X8>7.U=]/^"?
M?_!J]^S9KWPU^ /C_P",OC7PG?:;J'B?7[>TL?[1M'AD:UMXV;<H< [6>4^Q
MVU]#_P#!5S]F3X":IX-\/?$S4?A=I<FO:M\5O#-IJ>J-$?.N8)+Z*)XV(/*L
MGRD>E?:5K9VME"MO9V\<4:C"QQH%"CT %<#^T1\ _#G[1/AC2_"/BC4KRUAT
MOQ1IVMPR6>-S36<ZS(IR"-I90#[5I2H^QIJ",:U:5:JYOJ> ^+IOB!\"/VLO
M!'[('['7A3P=X3\-:_H%YXD\47%U82.R^1<6T3")589=T;;SP, ]J\?\9_\
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M^2;^(/\ L"7?_HEJ8'X&_L5_\@G2?^N*?RK]9/V5_P#D&6_^X/Y5^3?[%?\
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MG&0QQ<5JM?/LT>?A^;#XGV;>A^U &.!10&!Z&BOSL]8**** "BBB@ K\*/\
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M7]I4G>G%^2/S-A1116@!1110 4444 %%%% !1110 4444 %%%% !@=:***
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M=%9FXX&T%B/7FOJC_@YJ\;R:C^TWX%\!1GY-+\&M=-ST:>Y=?Y15YC_P0%^
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M%Q:W'F:%XJT65OLMVH(/RL,?BC#\*_7W_@D!_P %1K?]N/P!+X%^)=Q:VOQ
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M $DAK]S&Z5^&?[67_*3/XO?]C5#_ .DD-3(UH_$?:_[&7%A;CZ?TK[=\'_\
M(.C_ -VOB+]C+_CQM_P_I7V[X/\ ^0='_NU;)D;%%%%(@*^9OC%_RE ^"/\
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MI[#J* <C-(&R<8J0%HHHH #TK\,_VLO^4F?Q>_[&J'_TDAK]S#TK\,_VLO\
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MPB\0ZKJ6E6L@+7GA'5FF)4<_-;,=V/\ @)'O7L?[)'_!Q;XH\'W$/P\_;6\
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MW?[1)9C[L:^VO^#9GXUPZ/\ $SQ[\"-2O43^UM-AU73XV;EY(6V2 >IVN#]
M:P_AA_P;9_''Q/\ "R3Q/\0OB]IVA^))K7S;'08[4S(C8R$ED!&">G&<>]?)
MO[/WC'XA?\$Y?V\=*U#QWITNGZEX,\1_8_$%FP(W6[827ZJ4;<.QX-?2UGEV
M999/!825W%;>FQQ1]I1K*K-;G],4;;NW2G5E^#?%&C^-O#&G^,/#U['<6&J6
M4=U9SQMD212*&5A]016I7YA9K1GMA1110 4444 %%%% !39<[,BG4V0;DP:
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MA5UN8%/T?YOUK]&QTXHKY_#YECL+_"J->5]#LE1IS^)'X2?M"_\ !'G]O/\
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M&S8M?S/_ +<WB;Q-;_MB_$N"#Q!>*J>--0"*MTX"CSVP!S7[H2_LV?MU*/\
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M[L74?+)^(S[U]24$ ]16V'Q%;"U%.E)IKL3*,9[H_!#]J?\ X('_ +8?[/\
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MQJ$+_P!Y?+R8R#ZXKULJXFS.6(4*D>=/LM4<]; T(QO%V/CG_@D7H/[%%_\
ML+?$#6+:+2Y?BO;>'=7&I?VJZ&Y2,V\GEFW#?P%>Z\YSFO"OV*1_Q*-#(.0;
M"#\?D%?/.F7_ ,+;;]J!7_9]NM<A\,SW4PL4UAE6X$11_D?9U&,=?QKZ'_8I
M_P"03H;'_H'V_P#Z *\WB?"RHXU5')OG5[/=>1U8"7/3<>Q^L'[*O_('M?\
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ME?Z.>%]:-?@#+IK_ )]1_!6/QO/(\N;5E_>8M &.!117WQY)',#C@=J_!?\
M:X_X)3?MX_$/]I_Q]XW\(? :^O-+U;Q7>W5A=+-&%EB>5F5AENX-?O4ZEQ@'
MO04R*]K),^Q60UI5**3<E;7^D<^(P\,1&TC^=$_\$<_^"B>TA_V=M0_[_P ?
M_P 57V'_ ,%C_P!@']K+]I#XJ?#O7O@Y\);K6K31?AK::9J$T4J*(;E9YV:,
MY(Y =3^-?K6J8Y--\K;WKUJ_&N98C&TL3*$;T[VWZZ=SGCE]&--QOHS\8O\
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M_%%(OIGHW0BO=0N>>E=&%\0,TH8>-.$8M))+?I\PJ971]H^:Z/YU&_X(Y?\
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MX TV[\0?#V>1I+?4K>,M)IH+']U.!T &,/T(ZXKY>^!/QH\9_L]_%?1?B_X
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MSB2MS+[A?4:!^4?@C_@V*\%6TD<OC_\ :5U"Z7@R0Z;HZ1_AEG/\J]]^'O\
MP0$_8"\&QQ'6/#&J:]-'@L^I:@VUS[JN!7V\$0=%I<#KBN&MGF:5OBJOY:&D
M<+0CM$\E^%_["_[)'P9\I_AW^S_X9L)H1\ERNEQM)]=S G->I0V,%L@C@@5%
M7[JHH %6**\RI4J5G><F_5FT8QCLA@3/!IX  P!114%!1110!P?[4W_)M/Q
M_P"Q-U+_ -)I*_#W]BC_ )!.A_\ 7C;_ /HL5^X7[4W_ ";1\0/^Q-U+_P!)
MI*_#[]B<*=)T/'_/C!_Z *B7Q(VIO1GZO_LK?\@>U_W5KZ4TG_CUKYM_97_Y
M!%KC^ZM?26D_\>M:1^$REN6J***0@HHHSSB@#YP_X*L<?L4^+O\ >T__ -+X
M*^A]'_Y!-K_U[I_Z"*\%_P""GOAW5/$W[%'CZUT6TDN+JTT7[=#!$N6D-O*D
M^T#U/EXKV?X<^([+Q7X!T/Q+I\F^'4-)M[B%EZ%6C5OZT#Z&W1110(^%O^#A
M7P-JOB__ ()]7^JZ8NY="\1V-]=*/^>>7C)_ R UXA_P;">,=+E^&_Q3\#"1
M1>6NMZ?>E.-S120R(#[X:(_G7Z4?'GX2^&OCM\(_$'PB\7VB3:?KVFR6DZNN
M=NY>'^JM@CZ5^//_  2C^''Q0_8-_P""N=Y^S?X^AFM8]6TN]T_<RE8M0A'[
MVWN$[$'8<=QN(XKZ; U:>(R*OA6_>C[R.&K&5/%1FNNA^VV?:B@=**^9.X**
M** "BBB@ I&'R$ 4M% 'YN_\%X?^";D?QS^';?M4?"C06?Q=X9M,:Q:VL?S:
MC8KR6P.LB#D=RN1V%4?^#?3]N^3XJ_"BZ_9-^(VL22:]X/A$OA^2X;+W.GY(
M,8]XC@8]&&.E?I5>6L-];26EW LD<B%9(Y!E74]01W%?&=]_P24\(?"W]L+0
M_P!KW]EK78_#-U#J!?Q'X;93]CO;>0_O@F/]6Q!S@<9 KW*.84J^6RPF)Z:P
M?;R.65&4:WM(]=S[0CDW#!7&!S3JCA5PBY_N\^]25X9U!1110 5\N_\ !9+X
MAW?PX_X)V?$75M.NFAN+W3XK"%U;!_?3(C#\5+"OJ*OBO_@OKI=[J7_!.+Q)
M)8ABMKK&GS7&T?P";!S[9(KNRV,9YA23_F7YF=;^#+T/&?\ @V3\%K8_ #Q]
MXY:+Y]0\2Q6ZR-U(BBSC\WK].AR,$5^>O_!MU#'%^PWJDZL-TGC*YW#/3$<8
MK]"@<UOGDN;-JOJ3AE:A'T&LN5P!7S+_ ,%&O^";/PQ_;U^&O]F:N(=)\5:>
MC/H?B&.$;XGV\1R$<M&3U';J*^G*:Z;^"*\^C7K86JJE)V:-)1C.-F?A[^P?
M^VS\<?\ @D=\=;K]E+]KO0M2@\&2:@1(S1M)]A+<+<P'/S1-W ]3WS7[8>#O
M&/AOQYX8L?&/A'5X;_3-2M4N+&\MVW)-&PR&!]"*XSX\_LG?L_\ [2^DKI'Q
MK^%^EZZL?^IFNK<>;'_NN/F'TS70_"/X3^"_@E\/=+^%WP]TK[#HNCV_D:?:
M>87\J/)(7))/<UVYEC,/CK55'EJ?:ML_/U,:-.=+1O0Z8'/-%%%>:= 4444
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M_C)+_P#$4I_X+(_\$RP<']K_ ,*_]_I?_B*(SE'9V%RR['TU17S+_P /DO\
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M*_\ ?R7_ .(HN'++L?35%?,O_#Y'_@F3_P!'@^%?^_DO_P 11_P^1_X)D_\
M1X/A7_OY+_\ $47#EEV/IJBOF7_A\C_P3)_Z/!\*_P#?R7_XBC_A\C_P3)_Z
M/!\*_P#?R7_XBBX<LNQ]-5Y5^VQ\"8OVDOV6?&WP8<?O-:T.9+/VN%_>1?\
MCZK7G7_#Y'_@F7GC]L'PK_W\E_\ B*;)_P %CO\ @F6ZE!^U]X5_[^2__$55
M.HZ513734F5.4E9K<^*_^#<?]I'3O!VK>,OV-/&\LECK1OFU'2[6X7;\T>([
MB+G^,$ X]CZ5^MT+AX]RFOYZ_P!M/]H#X&_ W_@I1:_M;?L4_%/2/$6G76I)
MK=S'ILS>6ERS'[3 W PKY)_&OUN\+_\ !9__ ()KZOX<L=5OOVI_#NG375K'
M++87C2++;LR@F-P$X9<X/N*]K/(TZE6&*IO2HKM=F<^&52,>1K8^J**^9?\
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MI1_P61_X)E]_VO\ PM_W\E_^(K[WF1Y7*SZ:HKYE_P"'R/\ P3*_Z.^\+?\
M?R7_ .(H_P"'R/\ P3*_Z.^\+?\ ?R7_ .(HYD/ED?35%?,O_#Y'_@F5_P!'
M?>%O^_DO_P 11_P^1_X)E?\ 1WWA;_OY+_\ $4<R#ED?35%?,O\ P^1_X)E?
M]'?>%O\ OY+_ /$4?\/D?^"97_1WWA;_ +^2_P#Q%',@Y9'TU17S+_P^1_X)
ME?\ 1WWA;_OY+_\ $4?\/D?^"97_ $=]X6_[^2__ !%',@Y9'TU17S+_ ,/D
M?^"97_1WWA;_ +^2_P#Q%'_#Y'_@F5_T=]X6_P"_DO\ \11S(.61]-45\R_\
M/D?^"97_ $=]X6_[^2__ !%'_#Y'_@F5_P!'?>%O^_DO_P 11S(.61]-45\R
M_P##Y'_@F5_T=]X6_P"_DO\ \11_P^1_X)E?]'?>%O\ OY+_ /$4<R#ED?35
M%?,O_#Y'_@F5_P!'?>%O^_DO_P 11_P^1_X)E?\ 1WWA;_OY+_\ $4<R#ED?
M35%?,O\ P^1_X)E?]'?>%O\ OY+_ /$4?\/D?^"97_1WWA;_ +^2_P#Q%',@
MY9'TU17S+_P^1_X)E?\ 1WWA;_OY+_\ $4?\/D/^"99Z?M?>%_\ OY+_ /$4
M<R%RR/IJBOF4?\%C_P#@F83C_AK_ ,*_]_)?_B*H>(O^"UG_  3/T"R:[C_:
MCT?46Z+;Z5:W%Q*WT58\T70^678^IVD11DM7YG_\%Z/VS].N/"]G^Q!\-_$D
M<FHZY)%=^.3:3*QMM/1]PM7QT:5@,CKM4YX-8/[6_P#P7IU?Q?H]QX)_8O\
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M_?L4?\,U:3_SZ1_]^Q2Y2_:2/RR_X8\;_H 1?^ XH_X8\;_H 1?^ XK]3?\
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M?^^11_PS+HO_ #YK_P!\BCE78.<_+3_ACZ3_ *%R/_P&'^%'_#'TG_0N1_\
M@,/\*_4O_AF71?\ GS7_ +Y%'_#,NB_\^:_]\BCD78.<_+3_ (8^D_Z%R/\
M\!A_A1_PQ])_T+D?_@,/\*_4O_AF71?^?-?^^11_PS+HO_/FO_?(HY%V#G/R
MT_X8^D_Z%R/_ ,!A_A1_PQ])_P!"Y'_X##_"OU+_ .&9=%_Y\U_[Y%'_  S+
MHO\ SYK_ -\BCD78.<_+3_ACZ3_H7(__  &'^%'_  Q])_T+D?\ X##_  K]
M2_\ AF71?^?-?^^11_PS+HO_ #YK_P!\BCE78.<_+3_ACZ3_ *%R/_P&'^%'
M_#'TG_0N1_\ @,/\*_4O_AF71?\ GS7_ +Y%'_#,NB_\^:_]\BCE78.<_+3_
M (8^D_Z%R/\ \!A_A1_PQ])_T+D?_@,/\*_4O_AF71?^?-?^^11_PS+HO_/F
MO_?(HY%V#G/RT_X8^D_Z%R/_ ,!A_A1_PQ_*.GAR/_P''^%?J7_PS+HO_/FO
M_?(H_P"&9=%_Y\T_[Y%'*NP<Y^6;?L?2M_S+L?\ X#BGP?L@S(V4T-%8?W80
M#7ZE?\,S:*.EJGY"G)^S3HZ_=M$_[X%'*5[1GYI>'_V1+]Y5\S3CU_NU[C\'
M?V27M)HW?2_3JG6OLW3?V=M*@8-]BC_[XKLO#7PETW32K"U7@?W*.4S=2YY[
M\%_@G!H4,?\ HFW'^S7O'A[2$L8 /+VX]J-'T&WLHUVHOTVUJ 8&*HS8#CBB
MBB@".YA\Z/97GWQ'\ Q:U;.OD;OE/;K7HM0W5G%=+AUH ^#_ ([_ ++\&L>=
MC3 RMGY3'D&OEGQW^QG;B[D=/#T74_\ +N/\*_7#Q'X!L=1#>;"K9']VN#UO
MX$:3>LS-9I_WS2Y32-2Q^2MY^QTP.!H4?_@./\*A'['<@ZZ!%_X#C_"OU2N/
MV;M)9MRV*_\ ? J/_AFW2R.;-/\ OV*7*7[61^67_#'C?] "+_P'%'_#'C?]
M "+_ ,!Q7ZF_\,U:3_SZ1_\ ?L4?\,U:3_SZ1_\ ?L4<H_:2/RR_X8\;_H 1
M?^ XH_X8\;_H 1?^ XK]3?\ AFK2?^?2/_OV*/\ AFK2?^?2/_OV*.4/:2/R
MR_X8\;_H 1?^ XH_X8\;_H 1?^ XK]3?^&:M)_Y](_\ OV*/^&:M)_Y](_\
MOV*.4/:2/RR_X8\;_H 1?^ XH_X8\;_H 1?^ XK]3?\ AFK2?^?2/_OV*/\
MAFK2?^?2/_OV*.4/:2/RR_X8\;_H 1?^ XH_X8\;_H 1?^ XK]3?^&:M)_Y]
M(_\ OV*/^&:M)_Y](_\ OV*.4/:2/RR_X8\;_H 1?^ XH_X8\;_H 1?^ XK]
M3?\ AFK2?^?2/_OV*/\ AFK2?^?2/_OV*.4/:2/RR_X8\;_H 1?^ XH_X8\;
M_H 1?^ XK]3?^&:M)_Y](_\ OV*/^&:M)_Y](_\ OV*.4/:2/RR_X8\;_H 1
M?^ XH_X8\;_H 1?^ XK]3?\ AFK2?^?2/_OV*/\ AFK2?^?2/_OV*.4/:2/R
MR_X8\;_H 1?^ XH_X8\;_H 1?^ XK]3?^&:M)_Y](_\ OV*/^&:M)_Y](_\
MOV*.4/:2/RR_X8\;_H 1?^ XH_X8\;_H 1?^ XK]3?\ AFK2?^?2/_OV*/\
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M8;;^Y0ME IR$J:B@!JHJ#"K3J** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 &,G.*,#THHH   . *38OI2T4
M %&.^*** #'M1CC&*** # ]*3:O3%+10 !0. *,#THHH -JC^&C'M110 8]J
M, ]J**   #H*-HQC%%% !M'I1M!&"***  @'J*-HSG%%% !0 !P!110   =!
M1M [444 &!TQ0 !T%%% !CVHHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>business13a.jpg
<TEXT>
begin 644 business13a.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0!J17AI9@  34T *@    @  @$2  ,
M   !  $  (=I  0    !    )@       Y*&  <    2    4* "  0    !
M   $\J #  0    !   ".@    !!4T-)20   %-C<F5E;G-H;W3_X0DA:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[
MOR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \>#IX;7!M971A
M('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)835 @0V]R92 V
M+C N,"(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O
M,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B+SX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2)W(C\^ /_M #A0:&]T
M;W-H;W @,RXP #A"24T$!        #A"24T$)0      $-0=C-F/ +($Z8 )
MF.SX0G[_X@(@24-#7U!23T9)3$4  0$   (087!P; 0   !M;G1R4D="(%A9
M6B 'Y@ & !X "  J #-A8W-P05!03     !!4%!,
M    ]M8  0    #3+6%P<&R^/^.2M^#8X"%KDT6&-W>]
M                          ID97-C    _    &)C<')T   !8    "-W
M='!T   !A    !1R6%E:   !F    !1G6%E:   !K    !1B6%E:   !P
M !1R5%)#   !U    !!C:&%D   !Y    "QB5%)#   !U    !!G5%)#   !
MU    !!D97-C          A,1C(W5#,U
M
M                    =&5X=     !#;W!Y<FEG:'0@07!P;&4@26YC+BP@
M,C R,@  6%E:(        //8  $    !%@A865H@        <W   #RM   "
M0EA96B        !="   M54  !.P6%E:(        "9>   -_@  O3MP87)A
M             ?8$<V8S,@       0NW   %EO__\U<   <I  #]U___^[?_
M__VF   #V@  P/;_P  1" (Z!/(# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M"PL+"PL+"PL+"PL+"PL+_]T ! !0_]H # ,!  (1 Q$ /P#^_BBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B_Q=_R
M4/Q(RKM5[V)@0?O$6ENI/YKM_"L>HH[JWU*:XUFSF^T0:A<3WD4G]Z*XD:2/
M\D91^%2T %%%% !7GGQ'F9-)A@'1Y>?P!KT.O-/B4?\ 1+5?]MC^E 'D5=EX
M#B,OB)&_N(S?T_K7&UWW@.>UL+BYU&\<(BJL>3ZN?_K4 >U44 YYHH ****
M/</@?<PA-8TY%"N)HIVQU;S$" G_ +]X_"O>*^8?@W>6EGXVN[#!,VHV(?/8
M+928Q]2;C].W?Z>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ,/=O^"AO_10O_*3IO\ \B4?\/=O^"AO_10O_*3IO_R)1_Q"_-?^?M/[Y?\
MR ?VC3[/\/\ ,_MLHK^)/_A[M_P4-_Z*%_Y2=-_^1*/^'NW_  4-_P"BA?\
ME)TW_P"1*/\ B%^:_P#/VG]\O_D _M&GV?X?YG]ME%?Q)_\ #W;_ (*&_P#1
M0O\ RDZ;_P#(E'_#W;_@H;_T4+_RDZ;_ /(E'_$+\U_Y^T_OE_\ (!_:-/L_
MP_S/[;**_B3_ .'NW_!0W_HH7_E)TW_Y$H_X>[?\%#?^BA?^4G3?_D2C_B%^
M:_\ /VG]\O\ Y /[1I]G^'^9_;917\2?_#W;_@H;_P!%"_\ *3IO_P B4?\
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M_P!%"_\ *3IO_P B4?\ $+\U_P"?M/[Y?_(!_:-/L_P_S/[;**_B3_X>[?\
M!0W_ **%_P"4G3?_ )$H_P"'NW_!0W_HH7_E)TW_ .1*/^(7YK_S]I_?+_Y
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M $4+_P I.F__ ")1_P /=O\ @H;_ -%"_P#*3IO_ ,B4?\0OS7_G[3^^7_R
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M_#_,_MLHK^)/_A[M_P %#?\ HH7_ )2=-_\ D2C_ (>[?\%#?^BA?^4G3?\
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MF?VV45_$G_P]V_X*&_\ 10O_ "DZ;_\ (E'_  ]V_P""AO\ T4+_ ,I.F_\
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M?\/=O^"AO_10O_*3IO\ \B4?\0OS7_G[3^^7_P @']HT^S_#_,_MLHK^)/\
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MN- =KP\GA?(*QW);UVPLH_O&OAW5=,U+0M4FT+7+:6QOK8XFMKA&BFC/HZ.
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M5V/]V-'-?!>O^'_$'A/6)/#WBNPN=*U"$ R6M["]O.@/3='(%89]Q7VN SG
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MK+&%]AN'2@#Z5KY<^%L/B7X9_%SQ%\+]7AFD\/ZJZ:IH%YY9,:EDVW%H[JH
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MAC V\# ^8\5%?,*5+$T<+._-4YK=O=5W<<8-Q<ET/RRHHHKN("BBB@ HHHH
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M@V6Q\1V)N!:Z5MDB:Y$2@HP1_G&6)&.2VWCJ*XWP]I7Q^_:,\'Z=?^.-0NO
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MC.,UZA^T;^V'^R5^PE\1G_9E^!_P9T'Q##H"1P:Q>Z@J&261U#M%YKQ2R2L
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MBGQFQU:2+4-@M=,M%/EA;4-%)Y0DD60A4 P<Y.T(@_&7]JEBW_!0[QJ6.?\
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M:_FX_:H^+O@SXZ_'77/B=\/?#=MX2T?46B^S:9;1QQK$(XU1F81A4+NX9V(
MR37ZU?\ !6MW'[(_[-,8)VG022.V196./YU^"%?6<&9?36'^OR;=23FKN3:L
MIM62O;IVOJSFQ<W?DZ:?D%%%%?;G&%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '_U?[^**** "N%^(WBX^#?"\NH6@1[Z<_9[*-^
MCW#@E<C()50"[XY"*Q'2NZKY/^*.N'7_ !L]B%)MM&411DDX:XE&Z5@,D,%4
MHBMP5;S%Z&@#SVRM%L;9;=7:0Y+/)(<O([DL[N0!EG8EF..22:M444 %%%%
M!117S_X!^*VI/\2M5^#?Q%0VNN0I]NT]]BK!?63<%H&#')B;Y75@K $'D9-=
M%#"U:RFZ4;\JYGY)63?ROKV6NR9SXC%T:#@JTK<[45?K)IM+YVTON]%JTCZ
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M*3Y:D6G9/731I-/T:::[IW%2K4ZL>:G)25VKIWUBVFM.J:::Z--/4****S-
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M.PD,2QL/0AC7DGB+_@XV_83TAS%H^B^+]6.>'@L;:-/_ "+=HW_CM?ME\/\
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M4'S4C65\*[ ;W;K]*^F? 7_!5;]NCX<^#+?P+H/C0S6=G$(;:2]L[:[GB1>
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MS:W&K>"_%!WI=P1233:9?@X*W 4,3#,&&V7 V%<-Q\Q^JJ*BGFBMH7N)CM1
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M]ET^V4H+O5)1#&%_ZY1DEMW8;P3P,9K\@;?]M'_@HS_P45\>3_!S]A[1=2O
M2$N+ZSB%K;VT;\;Y96(C@0\X,\I+= N[BOH+]@G_ ((A_M(?\% [S2_VB?VZ
M[^[\&?#R;;<Z;H, \G4;^%N5*QL"+6%Q_P M9 TTB_=4*5DK^TGX&? /X-_L
MT?#BQ^$?P(\.V?ACP]IPQ%9V2;06( ,DC'+R2-CYI)&9V/))-?1.G@,KTJ)5
MZ_;_ )=Q?G_._+8PO.IMI'\7_D?SA_L;?\&T'PJT.YC^*7_!0?Q'<_$CQ5<L
M)YM*L[B:'3(WZD2S_+<W)!QR#"G4%6'-?TJ?"SX/_"GX'>$(/ 'P;\-Z;X6T
M2V_U=EI=M':P@XP6*QJH+''+'+$\DDUZ-17CX_-L7C7?$5&UT6T5Z):(UA2C
M#X4%%%%>::!1110 45^07_!8GXE_&7P'\(/!N@_"SQ5/X.LO$WB%=-U;4=.F
M\C4O+,$LD,5O("KQB25 )'C(<?*N0K-7\]%Q+XV^)WB<VGQC^(?B'QG>>&DC
M71I[[59OM&G;P6\V)XW1A/N(S,29,*H+8  ^CRGAJOCZ+KTYI13MUO\ E^I]
M)E/#&(Q]%XBG-**=NM_Z^9_<I17X/?LQ_P#!:C]F'P[^S]I&@?M/>)]23X@Z
M!&^G:C&FCWUW)J+VKM%'=1R6UN\#?:459&^==KL00N*Y2?\ X.!OAC<>,%T_
MP]\)_%-]H9;;]J\ZSCOF]TM#*5(SV:=6QVSQ7%'(LPE*48T)/EWT9Q1R',93
MG"%"3<=]&?T&5Y;\7_@A\'?C_P"#YO 'QN\,:9XKT6?):TU2V2YC#8QN4.#L
M<=G7# \@@U^)_P /O^"YEQ>?%S2?#/QM^%5QX,\(ZY?16,&M?VF+N:T:X<)%
M)=0?9XT6/<1YI29_+&3\X!-?T!5SXK!8K!5(^VBX2W7_  +')CLNQ&$DH8FF
MXMJZOU1_+-^U/_P;@Z)X:\1#X[?\$P_&=]\,_&.G,T]OI=U=S-9,?[D%V-UQ
M!N&05D,Z/G:=BY-?+OPS_P""NW[4/[&GQ"M?V=O^"MG@&^T.]SY</B>TMP!-
M&IVF9XXLP7,8)^:6T;C&/+9LU_9W7B'[0G[-WP/_ &JOAI>?"+]H#PW:>)M
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M[_"*_'BOZ<_^"CGQ<\,?'C_@E-X,^,'A+38M'M=?UVUNI+.%0J0W9%V+H#
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M2^N-0N#UDN)&E?\ -B36+691]@^+O^"EWB[Q'XJN/ W@:S@T6>-=V]U^TR=
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M[.'[%WPL_8.L]2AU'Q%I;0ZEJGDMD1B*.7<2."JS3SL8]PR53)K%_P""Y/\
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M=Y=W]R]Y?2O--(<L\C%F8^I)R37[A_M7?!__ (6Q\,IGTR+?J^C[KJSP/F<
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MX97!_P"WJ>N[#?V-B<WPD,NC'E=.HI65M'%63_O6O?KKJ1+VL:4G4?56+/\
MP5__ &=9_&_[27@'XO?"2(7UM\7K:TL[>2(?+-?KY<<39'02P20[?78QH_X+
M&^,M#^%?A'X9?L+> 9?^)9X.TN&^O@O&^8(8+<N!T?:)9&SU\T&OOK_@E?\
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MG*I.-..[=E\R*M6-.$JDW9)-OT7H>A45PWPP\4+XW^&WA_QDCF0:MIUK=[B
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M@?4?!.LC$5]$55\9,<@Y1Q[JP!]^E?SW>)_#FK>$/$-[X7UV/RKRPF>&5?\
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M6UXNR9]GT57M+9+.TBLXR66)%0%CDD*,<GN:L5\\]]#Z9;:A1112&%?R$?\
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M$"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_LZ7\Q_ #17]_P!_PQI^R!_T2GP=_P""*R_^,T?\,:?L@?\ 1*?!W_@BLO\
MXS1_Q%3"_P#0/+[T']G2_F/X :*_O^_X8T_9 _Z)3X._\$5E_P#&:/\ AC3]
MD#_HE/@[_P $5E_\9H_XBIA?^@>7WH/[.E_,?P T5_?]_P ,:?L@?]$I\'?^
M"*R_^,T?\,:?L@?]$I\'?^"*R_\ C-'_ !%3"_\ 0/+[T']G2_F/X :*_O\
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MO_!%9?\ QFC_ (BIA?\ H'E]Z#^SI?S'\ -%?W_?\,:?L@?]$I\'?^"*R_\
MC-'_  QI^R!_T2GP=_X(K+_XS1_Q%3"_] \OO0?V=+^8_@!HK^_[_AC3]D#_
M *)3X._\$5E_\9H_X8T_9 _Z)3X._P#!%9?_ !FC_B*F%_Z!Y?>@_LZ7\Q_
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M_?\ ?\,:?L@?]$I\'?\ @BLO_C-'_#&G[('_ $2GP=_X(K+_ .,T?\14PO\
MT#R^]!_9TOYC^ &BO[_O^&-/V0/^B4^#O_!%9?\ QFC_ (8T_9 _Z)3X._\
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M_P#&:/\ B*F%_P"@>7WH/[.E_,?P T5_?]_PQI^R!_T2GP=_X(K+_P",T?\
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MH$NC0L#AA)K+K8 K[KY^X8Z8SVKHPE!UZ].BMY-+[W8F4K)L_GU_X-M]'O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY=VD>FQ"3?:30N<)*XVEBO.<9 (\,_X+]_\ !(K_ ()X?L7?\$_Y_C3^S/\
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MTOX\77]J) K,L6F1BU5<@?P+<& \\9QWQ7Z+_MZ_"+]J;Q+_ ,$XUU7]JO\
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M?9QZE8^/O!FE6^MW$=Y;K':W=C<"$B6UE$C&0*9T5\JN&)'8X_%/_@YH\<?
M[6?V)_A?#)J.GWVM:QXYT>^\--;R)+)-;".0SSPLI.ZW,3H&=3L):/G)6NW_
M ."PT,?[&'[;_P"SG_P5@L,VNC:-JO\ P@7CJ906']B:J)/*F=5&2MOON'YS
ME_*'7% 'W%^U]^U!\-?CEJ_QC_X)D?#>P\1Z]\2HOAU?:M<Q:"8+7R%O(Q%!
M"MY<2K'%=2&6)D#*0$<-DX('F6F?M=_#O_@D7^QI\#/V??VK)M:\7_$Z_P!#
MM=+M]!\,6SZUJ^HWMK$GVGR5+)O2)W"!W==_\(/('D/_  04\(:_\7/"WQ;_
M ."G7Q'M7AU[]H7Q9=7NG+-R]OX>TN1[>RA!/("MYB>C)'&>>*P_^"MGPK^$
M/QA_;<^"&A?#3XUW7P3_ &E].L]0G\%W[Z<]UIU]9S+(LMO-*ZK;J[%)$52[
M%@[(T+^8E 'Z#?L3?\%1_P!FG]NKQEXB^%7P]M?$'A7QQX4A6YU3POXLTUM+
MU:WMV*KYIBW2(4#.JMARREER &4G[M^(/C_P7\*? VK_ !+^(^IP:-H&@VDM
M]J%]=-LAM[>!2[NQ] H)]3T'-?SB?L)_M$_M5_#?_@K%=_L6_M^^&?A]XQ^)
MNI^#FU&U^)'A"QCBU4Z? Q*VVH2+%&ZQMY>1$8X0C[" ZNC#ZJ_X.--'\;ZS
M_P $@_BE#X)$K^0VD7%_'"I9VL8M1MVEZ D*F!(YZ!%8GC- ',:3_P '%W[!
M%_?V.KZMHWCS1O NIWQT^S\=ZCX=EA\-3R[BORW(<RXRISF$,H^\!@X_1O3?
MV[O@1J?[9-O^PY$]ZGB_4/"Z>+].NFB0Z9J&FNX0-;7"R$R-G<<; -J,0W S
M^?G[:_Q1_8_N?^""'B;Q#I][I3_#W5/AJNG^&HU=#$U\;,1Z;!$HZ3PW2Q_(
M!NC>,E@-C8_(+QS_ ,)9^Q9^RS_P3T_X*=_$."XMW^'MK:>%?%3"-GN!X<UZ
MV?[.73DD6]MYFU3SOD48!Q@ _I<^"W_!1S]FGX^?MA?$#]A[X>W5[+XW^&T!
MN-5$L"I:.J/%'*() Y9S%),B2 HN&.!FOFWQW_P7$_8=^&VE>(O%'BZ;7+?0
M?"WQ#7X9W^KBQ5[)=9V322NCB;+VT*0,TDBKN *E4;=7\I?PN\<^./\ @G/;
M_!;_ (+7>,8)KC4OCL?B+<>)X,,P>YU'S9](C)[K-,B2]@%7)[D?1_QV_97A
M^$7_  1<_8^\'_$FV^UZK\2OC/H'BCQ&+@;FN9?$4-[+B4'^+[(T,;@]U.?2
M@#]_O@Q_P7G_ &*/C'\<_"_P(GTKQGX/NO'4J0>&-5\3:(VG:9K,DI"Q"UE,
MC.PE9E5&>-%+,HR"0#^U5?SL?\'#NFV">"OV8]9CA5;JT^-_AJ&&4##1QR1W
M#,JGL"8T)_W17]$] 'X7_$;_ (.$?V&/A[XM\7_#NTT?QMXF\2>!M<U31-8T
MO0M$^V7%N-(D$5Q>,?.6);3>6"R,ZL=C?(,#.=XI_P"#BW_@GMIO@BP\??#N
MW\7_ ! LY-.75-57PSHC7;:#;L[IG4VDDACMF#1M\I=CM 895E9O)O\ @@]X
M5T*+X]_ML^,5MT_M"]^-.N6,LQ4;F@M[BX=$SC. TSG'3FO(/^" '@KPGIO_
M  2>^-MM96$,:7_BOQ=!< (/WD45E#$B,>I54X Z#)]30!^S?CS_ (*=_L9?
M#C]C/2/V]?$GBK_BW7B".(Z7<PV\DES>7$^\+:QP ;S<;HY%9"!L*-O*JK$?
M)?P=_P""]'['WQ2^.OAK]GWQ=X7\>_#;5_&<\=KH%SXST+^S;/4IYV"Q)"ZS
M2M^]9@J,Z*A8@%@2*_!#X'_M*Z9\&?\ @B7^QS\/-'^'_AGQUX_\<>.-6LO!
M]QXR4G1]$U"'7+I5O964JP9'FC"@.HVEF.X*4;5_X*KZ3^W1X(^-?[,FF_MY
M_&CPEXLUVZ^).CWNG^$?#&CQVJV,"3QK+>F[DVW9CW%8E1T".26SNCH _IT_
M;/\ ^"HG[,O[$/C+0_A3X[BUSQ9X[\2PO<Z;X4\(Z>VK:S/!'D&3R%9 BDA@
MI=UW[6VY"MC\V_VQ_P#@J!\"_P!MK_@DE^T+XP_9EU;6O#OBGP5ID5OJNE:E
M"^E:YI,TES&$,B*Y*A]K@-'(PR&4D,"*K_LPZIX?\.?\'(?[1^E_%9H;;Q'K
MW@[0#X/:X'EFXTR*UM?M:6I?[Y\Q,N$)),4AQA&QY'_P5+^,7[!OC/X5_MG?
M#[X!>&T;XLZ3X/TZ;QIXFLK=#:7"M<6B0VSW22-NG0!0R;%P8V!)92* .S_9
ME_X.%OV)?AM^SK\*?"7Q-@\;W-G:>']#T;5O&S:+-+H2:M%:01W*27<CB:22
M.7>)&2)\E6(+#!/W5\8/&_[/6K?\%:O@$D_C3Q0OBS5_"NL7>@:1I3QOX8U.
MR:WN7:>[;?EI%3<T)56!(0YKX]_:O\$^%=!_X-A(_#.EV,,5E!\*?#-RL2H
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M0]!_9Q_X)G>/OB[L7X7:/J/A1O$LETFZQB=["P:W>X)!78L<=P6#<%-W49H
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M9$5D==D*H&+$*%W$"OI+P-_P<'_L,>+/$F@VWB71O'/@SPMXINQ9:-XR\1Z
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MSJH_  "OGJOH#]G]2OPRB##'_$QU4_G?7%<YTGM%%%% !1110 4444 %%%%
M!1110!\W^'/V1_V>O"7[3GB#]LCP_P"'OL_Q(\4Z7%HNJ:Q]KN7\^Q@\K9%]
MG:4VZ8\B/YDB5SMY)R<K^U/^R1^SW^VM\*V^"?[37A__ (2;PP]W#?&R^UW-
MGFXM\^6WF6DL,OR[CQOP>X-?1]% 'P/^V9_P3'_8J_;[O](UW]ISP<NL:OH"
M&+3]3M;JXL+V&(L7\OSK:2-GC#$LJ/N56)*@$DUR'P9_X)!_\$YOV>O''@[X
MF_!CX9VOA_Q)X$DO)M(U2UOKT78>_0QSFYE-P6O-R$H!=&4(K$(%!.?TGHH
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M2:@]S<3+?0V$2P0(8)96MXPL:A3Y<:;OXLG)KZ-HH _&C6_^#?K_ ())Z_\
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M]O==-N/VG_!4&NZEHJ-'I^IP3SV.H6R,2=BW%M)%(T88EA&Y:,,2P7)S7/\
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M ,6]'BLU\41P%O#^D&>Y,<ANY]A6*6%$$J%V0*65\_+@_J-^QQ^S;X:_8_\
MV6O G[,_A,K):^#M(M[!YD7:+BY W7$^.QFG:24CU8U]*T4 >3_'/X'?"[]I
M/X2ZY\#/C5I?]M>%?$EO]EU&R\Z:W\Z(,'V^9 \<J_,H.4=3QUKC_%_[)O[.
MGQ _9UMOV3?'?A.SUGX>6>F6ND0:/?;[B..TLHUCMPLCL90\2HNR7?YJL P?
M=S7T110!^7_[,?\ P1H_X)P_L@_$RW^,7P0^',5IXFL"_P!@O[^^O-2DLE<%
M=MN+N>58\ L RKOP2-W-?7?@3]E3X"?#/X]^-OVG?!&@_8?'/Q%CLH?$.I?:
MKB3[8FG1B&W'DR2M!%L10/W4:%NK9/-?0M% !7YB_M0?\$<?^"=7[8OQ<_X7
MG\>OA\FH^)YTCBO;RTO[S3S?1Q*%1;E;6:)9=JA1N(W[5"EBH 'Z=44 ?'GP
M1_8 _8X_9T^'?C#X0_![P#I^E^%/'U[<:AKVC2&6[L+N:Z01RCR+EY8XXBBA
M1#&J1*HPJ 5\:^!/^" __!)[X=?$NT^*7A[X50R7FG7 NK2TO=1OKW3X)@=V
MX6MQ<20MDX.UU9!@848K]C:* /Y__P#@LKH7Q1U_X@>!M/\ B/\ LX1?M&?
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M:'_K^U/_ -+9Z^=Z^C/@;'Y?PX@4\_Z;J)_.\F-<AV'KE%%% !1110 4444
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M#^C2BOY^-4_X+;_&3XHZ]XOO/V"_V9/%'QJ\&>"=3N-)OO$UOJ<&F6US<VA
ME%E&8;B2Y W*RA/G96#%5!%>I2?\%O/@QJW_  2OU7_@J'X%\*:AJ6G:%>6^
MF:CX<GG2VNX+Z6\@M)(C,%D0A?M"2JP7YT(R$8E5 /VUHK\IO^">_P#P4@^*
M?[=_B[5Y=0^!'BCX<^!/[.35O#GBG7&Q;ZU:S2!8=D?DH$>1"90$DE78 =V&
M4F[_ ,%-_P#@J/X,_P""9-E\/]5\;>#]3\76_CO4[C3$CTF1!=0O!&KKLB8?
MOFD9PBH&3GO0!^IE%?B+\)?^"OOQ @_:3\%_LY?MP_ C6_@1-\3B8O!^J:CJ
M=OJEIJ%W\NRUF,$:"VN'+JHB8LX=U5@NX$^;?M)?\%R_%'PC_;%\??L/?!+]
MG_Q/\5_&W@8V%P8M#N<I<6%S:175Q<,$MYGB\@SQ1*I5A*[XW(<!@#^@.BOP
M=\6?\%HOB'XJ^+M]^S]^QK^SWXC^+OC+PGI]I<^,[:'4;?2K+P_>7,8=K"2[
ME25);J%O,B=,)F2-E3<5?;5U7_@K9+^T]_P3U^-OQ _9_P# GB#3/BI\.K*\
MTCQ'X/NKF/3M8T"XECD1KP2MC*6P6296 21C"RA58"@#][**_EQ_X)5_\%)X
MOV6?^",NF_'7]L3PMJN@^%_!\(AT?6GO(=0NO%]SJ-[=L5M(=RR+*L@VN)F&
M1ND+!%8CZ/T[_@MS\3/AGKWA#6OVY?V;_%'P6^'?CJ]@T_3/%M]J$%_!;SW0
MS"-0MTCBDL@P!)$A+A03M(5L '[POXI\,1^(U\'R:C:KJ[P?:5L3,@N3#DKY
M@BSO*9!&[&,CK6]7XT^)_&?[.L?_  7:\-^![WP9>S?$^7X3O=VWBA=29;.+
M2?M]RIM#9;=K2&0._G;LX;&.*^4/ G_!?3XL_'RR\3+^R=^RYXL^(M[X(U"[
MM-?^R:E#;VEK';R%(S'.T#M//*J,XMTBW 8P6R< '](M%?$__!/O]NCX7?\
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ME6BK;7/@[19?CU_P3K^-=O\ MC?L:7#1P60_XG>CX9[6:T)!ECEB!&^V?&6
M^:%@'0C *?W._P#!/C_@HG\!/^"BGP;@^)7PEO%M=8M$1-<T">0&]TRX8?=<
M<;XF()BF4!9 /X6#(O\ *=IM_%9Z7=6Z']_<'R\D9^3'/YU\(ZE\+?C5^RM\
M5;;]JC]AG5I_#WB33&,DVGVO^KFC.#(BQG*21OCY[=P5;^'D**_3,GX@H9I2
MA@<TGRUHZ0JO9KI&H_RE]_G^:\4\'3I2EC<MC>+UE!=/.*_./W=E_I+UXA^T
MU\--=^-'[-WQ!^#WA>:"WU/Q9X:U;1K26Z9E@2>_M9((VD**[! S@L55B!G
M)XK\G?\ @F#_ ,%R?@!^W59V'PJ^*3P> _BR (9=(N7\NTU&9>"UA+(>6)Y^
MSN?-7D+Y@4O7[HU6-P%?"571Q$>62_'S3ZKS1^>0FI*\3\EO@S^P;\7OAW\9
MOV;_ (B:UJ6CRV7P>^&#>"M92":9I9[\VUM#YEJ&@57@W0L=TC1O@CY,Y ]\
M_9I_9@\??!K]JKX^?'+Q/>:?/I/Q3U31;W28;621KB&/3;$6THN%>)$5F?E-
MCR KU(/%?=M%<A1^6O[1G[+O[4OAW]KVW_;>_8NNO#=WKFH>&?\ A%?$&@>*
M7N+:TN[:&<W%O<P7%LDCI/&YVLK+L:/C(->1_"_]@G]L@_M$_!+]I/\ :*\?
M:9XKUGP9KOC77/$,"2W(M[*+Q+IZ6EI8:.CQ'=;6S)D^<T388D;C@5^TU% '
MX[_#S_@F3XAO_P#@GO\ $_\ 8D^-&L64<WC[7->U2WO]*,EQ':B_O/M=F[++
M'"6:*14:1!@'!57YW5!X6_9V_P""H?Q?\2^$/!W[5/C3PQX=\"^$[6>'56\%
MW%XU_P"*99+<V\?VI;B*..&'YO,DC&X,^0!@J4_8^B@#^:#5O^"9_P#P5 \2
M_LA^&_V#-4\2_#N+P3X#U.PNK#58WU!=1U>UL;P3PPW">2T=MLC+,2@E+21Q
MIG:6DKZ)_:H_X):_'3]H'7_VH;[P]XHTC1[;XU2^")M%21[AP1X8@,=S;ZBB
M1J4BG?&TPO(2.6 QM/[K44 ?S_\ @'_@G1^UQ+^U+\&/V@M9\._"CX=:!\+;
M^],OAKP7%<P?:8-0M6MY[EI_LD8DF7Y?*A9%4+N)EW$BL3Q3_P $QOVSM6\*
M_%/X'Z?J?@U_!OBOXK)\2]%OI;F]BU%//U"*ZN+:XC6VDC&R*/$90G<_4@'Y
M?Z&Z* /R%\2_LM?MO_L_?M1?$;XY_L0WG@W5]$^+;6=YJ^D>,)+RU.FZM:1>
M0+FWDLXY?-BE7YI8WVMNP%('->?_  '_ ."6WQ/^"?Q3_9Z^(USXFT[7;OP!
MJWCCQ%XWO91);S:AJOB^S$6ZSB6)E*1R@*WFO&?+4, 2=@_;JB@#X2^#_P"S
M!X^^'_[>7QD_:BUF\T^70/B'I7ARQTZWADD:\BDT>&6.8SHT:QJK%QY>R1R1
MG(6ONVBB@ K\YO\ @H__ ,%+/@3_ ,$X?A!+XU^(EPFI>*-0B<:#X<AE"W>H
M3#@,>ICMT/\ K9B,*.%#.54_%/\ P4X_X+I?!C]CQKOX&_L[K%\1?C!._P!C
MATZSS<66G7+G8HNGB.9)0QP+6(F0L,.8\@G\WOV+/^"5?Q/^-'Q0;]N?_@J9
M>R^+?'.K2+>6GA^_(DAM0.8S=H/W?R#_ %=H@$40X8$_(OTF"RBG2I+&YFW&
ME]F/VI^BZ+O+[CGG5;?)3U?X(X7]B']B7XW_ /!0CXWC_@I=_P %*2U^+]DN
M?#/AJ="EO]G0[H&:!B?+LX\YAA.3,29)"P8F7^F*D50H"J, < "N5E\=>"X/
M%L7@.?5;5-:FB,T=B95%PT8R=P3.XC )Z= 3VK@S',*^85>9QM&*]V*VC%=O
MU9<(QIK5[_BSJZ***\HU"BBOF76OC+\0;;]H[3OA'H7AY;W0I;?S+W458EK=
MRK-EL?*H'R##<L6X.>*WP^'G6<E"VB;U:6B]=WY;F=6JH)-WU:6B;W]/S/IJ
MBBBL#0*^B/@1_P DVA_Z_M3_ /2V>OG>OHCX$?\ )-H?^O[4_P#TMGH ]@HH
MHH **** "BBB@#\AO^"J?_!'7X&_\%5+'PG=?$37]3\*ZYX/:X2SU#35CE$E
MM=E#+#+%(,-S&K(P92IS]X'%?>O[*7[-'PX_8Z_9W\*?LS_"07'_  C_ (1L
M_LEL]VXDN)2SM+++(P"J7EE=W;:JJ"Q"@# 'T)10 4444 ?QP_%C4/V ]-_X
M.)?CC/\ \%#E\)MX4/@31ET\>+XH9;3^T?)TW;Y8G5E\WRO,P0,[=W;-?J)\
M%_BI_P &[W@OXJZ#X@^ UY\(=*\9)=I#I%SI,%E#>K=7'[I5A>- P=]^P8.3
MG%?IU\2_V(?V+_C3XPN/B%\8_A#X*\6Z_=K&D^IZSH%C?WDJQ*$0/-/"\C!%
M 506X  '%<IHW_!.7_@GMX=U>U\0>'_@/\.["_L9DN+:YM_"^FQ30S1,&1T=
M;<,KJP!5@001D4 ?S0?\%QO!.N?\%=OVN[']A+]B[P[I^M^+O@KH^I:UXH\4
M2N8TMI9HOW6C),OR&2:14!5L[96 R@CN#7KWQ5_:Z^%O[8'_  ;;?$NR^&NA
M0>$=:^'V@V/AKQ#X3MT:(Z->:;=6RLBQ-EUA=4,D98D@;E9BZ/7]/'PX^!?P
M1^#FH:UJWPB\':'X5NO$ES]LU>;1]/M[&2_N<LWFW+0HAFDR['?(6;+'GDUD
M:3^S7^SGH&J>*M<T+P!X;LKWQVKIXEN(-*M8Y=967?O%\ZQAKD-O?<)B^=S9
MZF@#^5+]HCXK_![X^>%_^"9%]\,]>T[Q/9:1XU\.:7J!L9TG%KJ-E;:6TMM.
M%)\N:(E2\;X9<C(YK[Z_X+F?MC?&/X#?$CX!_L_?##Q7I/PJL_B;K-[%J7Q%
MUFP@O8]"BM/LZYA^T9BB=A.6>1BA4*N)$&]E_7SP;^Q#^QG\/+'2M-\"_";P
M?I,&A:J==TU+71+.,66J,$4W<&(OW5QMBC7S4P^$49PHQZ9\8_@3\%?VAO"#
M> /CQX3TCQCHAD6;[#K-G%>P+*N0KJDJL%< G####/!H _AZ_: OOAEX6_X*
MB?LC>$],_:DUW]I/Q'!X]TV?5[FYU""ZT/25N+NUC@2VCMC)!%/.PD\Q5F9@
MB)N RI/ZK?L<_'SX1_L0?\%B/VO?AY^V)XDT_P $7_Q)O-&\2^&]6U^XBL;.
M^TN".Y_=QW,S)%F,3*BKNR3'(/O(17[N^'/V&/V*_"/A33_ WAOX1^#;31]*
MU&+5[2S30[/RH=1@4K'=JIB(%RBDA9O]8 ?O5UWQS_98_9J_:<L+33/VB? .
M@>-XK L;3^VM/@O6MR^-WE-*C-'NP-VPC..: /Y-?^"L_P"U%X<_X*8_L-?M
M!R?L?^!7N/!_PF\6Z!=ZIXRT[88O$T422+=-&%A5G6R+K([EY,1;).$;CQG]
MK:[_ &(O$'[%L'BWQW^W+\3/BUH/C);&*+P%8ZCI]_K%W(\L;K%-ISD&%K=U
M#MYVP!D 4EB@/]MWP]^%GPR^$G@JV^&_PK\.Z;X:\/6:LD&F:7:16EG&K\L%
MAB54&XDDX')/-?/O@[_@GW^PK\//B-'\7? ?P=\&:-XFAD$T.I66B6D%Q#*.
M?,C9(AY;DDY=,,>YH _#'X >$$^'W_!=_P"#_@&./48ET/\ 9ETO3PFL+&FH
MJ+:Y:/%TL):,3C;B4(Q0/G:2,&ORR\,>'=9\2?\ !M1^U!!HEN]S):?%6ZNY
M$C4LPA@U'27E? [(@+L>R@GM7]RTGPC^%$OQ.3XVR^&-);QG%8?V6FOFRA.J
M+8[B_P!F%UL\X0[R6\O?LW'.,U2\#_!#X+_#'PKJ'@3X;>$-$\/:'J\T]S?:
M=IFGP6EI=370"S22PQ(J2/*H D9@2X&#F@#^37_@MA_P4N_8R^,O_!&72OA-
M\'?'ND>)O$WC2#P[LTG3[E9[VRCLY(;B9KR%"6MBC1",K,$8NV #S7USX?NY
M+#_@X7\#WT,+W+P_LYPR+#'C?(5O92%7.!D]!D]:_9GP]_P3L_8$\)Z?K6D>
M'/@GX%M+3Q&BQ:I;IX?L?*NXED298Y4,.UHUEC218R-@=0P&X U[_#\&?@_;
M_$:#XPP>%-'3Q=:Z<-(AUM;& :C'IX8N+5;D)YJP!B6\H-LSSC- '\7O[-7[
M6VN_MH?!OQA^T[^UO^VBO[/&BV&K:@'^&_@@66AZK:6\6&'EOQ>W$LH)5"L,
MSNR_>+91/EKX-:G::E_P:N?'\VLDK[/B7;[OM#[YQOO=$<>:<#+D$%C@9/-?
MV\7W[ G[#NI_%1_CAJ7P@\'7'B^2?[6^KRZ+:/=M<[@WGF0QDF;<,^;]_/\
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MG"'>S-Y8?9N).,FD^&OPA^$_P8T>Z\/?![POI'A/3[Z[EU"YMM&LH;&&:[F
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M[I\WBW7[];_[9?1R1RRQ64J*J?9(APBH73>)&5V!K^J+QK^P'^P]\1_".@^
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M:O9:Y>V(LI;?^P;:VLI[9[:1Y$5"QDG5%$3.A$9;.-A/]G_[!_\ R8[\&?\
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M3X'^?I7P^U+4OB5JT65$6@VQ2T$@Z!KJY\I"I_O0B85^9OB/_@HA_P %L_\
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M?O.WFV^["OG/]GWPQXFMG\5>/?'2NNK:]KM\5B?D6]G:2&V@C3('R%(1("
M^X-[U]&444L7*G0J48I>_:[ZV3O9>3=F_1>85L&JF(I5Y2?N<UET;DDKONTK
MI?XGUL%1R2Q18,K!=Q"C)QDGH*DKYZ_: _9YT7]H&RT:RUG5+S3!H]W]I4VC
M %\@ CGHPQ\C]5YX.:C"PI3JQC6GRQZNU[?+0WK2G&#=./-+M>WXGT+7T'\
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M\!?M7>"OV+]8GNY/'?CO3KW5K"WA@+0165BDCO+-,Q55#&)T15WN6'(5?FH
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M% 9H^H= 9$!!V.-P.S:0Q /U)HK\%?C-_P %QKSX?_M5^/\ ]D_X3?L]^/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?M#V_P +]%_M;X;Z[K-O,+_4;F6WNC%!*)U6YD#SQQ(!(2=P;8=K#&IXF_9
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MJ>FRQ2RX5,N%FV%BH9@H+Y<L3[G^PC^R9_P4I_X)_P#A?Q'\ =!_9)\)^/\
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MO&PKM^>NT^+/Q8_;P_;W_P""@FC_ /!-?1O']S\$K+X?^!=.\3_$K4?!TO\
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ME*Z#,87>%D93DH?:?V?_ -F;_@HS_P $I=*\6_LQ?"W]F_0?VCO =QJ]U?\
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M(/"_PNNOA-X,UR;P[I5GITNI7^@6,]U>26T2QO/-))"SO)*P+L6)))-?B_\
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MDE\,ZBOESVCM"V[KOA.QA^:U;BDKG)3TJOS.YHH'/-1LQ4Y/"CJ:@ZR3-,+
M\ \G@#U-=K\/_AK\1/BIJ']F_#W1KK5I,@,]O'F%!T^>4D1IU_B85^IWP!_X
M)T:?H]Q#XI^.\T5_.NUDTFV8FW5AS^^DX,N/[H 7UW UVX; 5J[]Q:=V>%FG
M$6"P,7[6=Y?RK5_\#YGSU^QS^R+??%?5(?B%\0[5XO#$/SQQN"IOW!X5>_DC
M'S,/O_='!:OV"O\ X:Q*O_$GFV #A''&/0$?X5Z9;6UM96T=G9QK%#$H1$0!
M555X  '  '05/7UN$PD,/#DC\WW/QK.<XK9C7]M5T71=$OZW9^7&B_&+Q_\
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MAX>&M*M;N2)M/TFT>0RSO:1+$KK/<,<2RO([%!L7:O%?5=%% !1110 4444
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M1IKS4M+/V/0+%=3\1:;IY 8M>6\H&<'_ $>19N/7'EY^E?:=?&_@F&67XAZ
M\8!$5S,[9ZA?LTR\>^2/PK[(KE.P^&&L+7299-'LLF&QDDM4+=2+=S%D\#KM
MSZ>G%)78?$'3KC3_ !MJ3S;5CN9$FA5?[AC123]9%>N/H ^:=2^*GQXOO$4N
MF^"_AQ*^E+(435-1U"&VWJO5UM?FEP3D*'*$C!..@^@=#FU:XT>VGUV%;>\>
M-3-&AW*KD<@'G^9^IK5HKKQ6(IU5!4Z,865GRN3YGW?-*6K_ +O*NR1QX/#5
M:*G[6O*HV[^\H+E7\L>6,=%_>YI=Y,*_([_@K5I;R^!_!NM(&/D:A<PD\;?W
ML8;GOG]WQCWK]<:_.#_@J1HZW_[-D&J!<MI^LVDF0N2!(LD1Y[#YQSWZ=Z\G
M'QOAYKR/IN':G)F>'E_>2^_3]3\.[/-Q;QS]B WXUJ3SW5U+YUP<DX'X*,"N
M>\-3^;IPC_YYG;^%=!7PQ^_!1110 4444 %%%% !4,TD<:EGXP"<_2I<CI4<
M6A>(O%M_#X7\)6CWVH7F52*,9(4<EB> JCN20.?4@4XIR:BMS.K5A2@ZE1V2
MZG#>&;*^U[QE8PZ<LGF&[CF+*#\B1N'9R1T  Z],XYY%?>OB3]C7Q9\8OB->
M>)/AG?6D4>M7(O'AN=P\CSU#ETV*P922<@[=K ]>E?57[+'[)!\ :1*]U$E_
MK6HQ^7>7&/W$,9ZQ(2!QW8]6/L *]X_93U!= \77W@K4HUBNUBEMSG[P-I/(
M%4=\;2Q_X#]*]VEEBA.G[=_%?3L]T?FN8<4SJ^VEE[M[.VN_,KV;L]M=CR7X
M?_\ !+[PIIT,4WQ,\47FJ2@?-%8HMK'GTW-YCD=N"IKZP\)?L8_LU>#I8KFQ
M\+6]Y/#]V2_9[LY]=LS,H/T6OJ&BO=IX.A3^""/B<5G6/Q'\:M)_.R^Y:%2P
MT^PTNT33],ACMX(AA(XE"(H] !@"K=%%=)Y8445DZQK-EHEJ;F\;_=4=6/H*
M *7BC6TT33&E4_OG^6,>_K^%?/9))R3DFM36=8NM;O6O+HX[*HZ*OI650 45
MXI\4G^-R^(?#X^%BVS:>;C_B9^=LR(\K_>YVXW?<^;.*]KKHJT.2G"IS)\U]
M$]59V]Y=+[KR,H5>:4H\K5NK6C].X4445SFH5[%\-X2NFW%P?XY<#_@('^->
M.GCFOH3PE8FPT"WC889QO;ZMS0!TE%%% !1110![-\$C<MJ6L$@^0L5JJG''
MF9E+#/\ NE..V?>O6_&UA=ZIX.U73M/&;F:TF2'_ *Z%#L/?HV*\\^"-I/;Z
M/JL\I!6:_P!T9&/N""$$<>C!NM>U4 ?"D4L<\:S1'*N P/L:?5>WM8].1M)C
M.X6#R69;U-LQB)_$J37F7@[XT?#[XA>)M1\+^"+J75'TJ0PW5U;P2/9)*H!,
M8N=ODLX##*JY([UO2PU:I"=2G!N,=9-)V2;LKOI=Z:G/6Q="E.%.K-*4W:*;
M2<FE=I+K9:NQZK1116!T!114<RR-$RPMM<@A6(S@]CCO0!)17RWIGQ-^)?PW
M\<VG@7XPZ;]KTG6+B.VTSQ!9$/%]HE^[!=1X4Q,S?+&XRK9"]>:^I*Z\5@JN
M'4)5$K35TTTTUZINS6S3U3T:./"X^CB)5(4F^:$G&2:::?HTKIK6,EHUJF%>
MM?!'4#-XFUO32W$%G8/M[#S)+KG\=N/PKR6O4/@O=I;>+]0L7;+7EG%(BXZ"
MV=@QS[^<OY5R'8?3%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<YKOC
M'PCX6"GQ-JMGIV_[OVJ=(<_3>10!T=%<OH7CCP5XI=HO#.KV6HLO)%K<1S$?
M783744 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD!'7*RRJ1^5=)X!^-WP8^*[,OPM\7Z+XE*+O8:5J$%YA?4^2[<>] 'I]%%%
M!7\KOPS_ &K/^"VW[9W[57[0?PS_ &2?%OPWT'PY\'_&U]X=BC\36%P)W@6X
MN$M\/;PS[R$@P[-M.>@K^J*OXI_V(?V8_P!MS]H']NW]M&^_9)_: E^"UMIO
MQ2U&/4;>/0K?6/[0DEN[TQN6FD0Q^6 PPH.=WM0!^O'["O[?G[:]I^W/K?\
MP32_X*/Z%X;C\<0^'AXGT'Q#X3:8:?J5BKA&5HYOG#Y\PJ^V'_5,I3.UF^S?
MV9?CK\5=,/QC\4_M@>._ O\ PCGASQG>V.A76E:C J:;I/F^7;6^J2,RI#>
MLJ.CD-O..I%?A!^R-X7^/?\ P3E_X+::5\-/VW-7M_C1XM^/^@2VNB?$#S)X
MK[3K>Q62:2T-FQ:&*&1[= 5C&%^5E?'F)7P?\:/^49/_  4I_P"R\O\ ^G^U
MH _MQA_:=_9KN?B4/@S;_$/PS)XP9M@T)=6M3J1;T^RB3SL^VRNX^(GQ/^&O
MP@\+R^-_BSXATSPOHMNRK+J&KW<5E:HS= TLS(@)[ GFOY$/^"J/_!,']D']
MF+_@BS8_M _";PM#I7Q+\&Q>&=67Q9#))_:UW?WUU;17,T]QNWN9&G:0 _*C
M ; N!7TM^T'X1T7]OS_@L_\ !+]F#]J2%]9^'GAGX4)X\30+IMMAJNM7,DD+
M321ICS%0;?D;C]TRXV.ZL ?=WB?_ (**^)-?_P""L7P7_9<^!_B+0?$OPN^(
M'A'5]8O+W3GBO_-N[%;HIY-U#(R!085W*,]_6OTF\??M7_LM?"GQ='\/_BC\
M2O"OAO7I0K)INJZS:6=XP<94B&:59"".1\O-?S=_\,7_ +/G['G_  <C?!B/
M]G+1;;POI/C#P7KFIW>C60V6L%W';7D+20Q#Y8DE1$^1 %W*Q &:^&OB#^RO
MXZ_9%^(/QQ'[:G[*+?M+^#?'_B75-77XF^&KA=0U[3K.YYP(PDLEL]N#O;(M
MPDF[+R1A" #^Z*&:&YA2XMW62.10RLIRK*>001U!K@/%OQ?^$W@'55T+QUXH
MTC1;YK26_%O?WL-M*;2#_63!)'5O*3!W/C:O<U\$_P#!'7Q5^S3XG_X)Z> H
M?V2/$?B#Q+X'TJ*XL;.7Q4T3:Q:O',[/:W/DI'&# 7V($!01!-K,N"?R@_X*
MA_LS?"S]KK_@NS^S)\$?C7!]N\,7GA35[V^L-Y1;T:>;FZ2!RI!,;R1*9%_B
M0,.^: /Z0_A3\=_@?\=].N=8^!_C/0O&5I92"*XGT+4;?48X9#T5VMW<*QQT
M)!KF#^U=^RVNK:;H+?$KPJ+[69Y+73[;^V;3S;N>%MLD<*>;ND=&^5E4$@\'
M!K\!/C/\"/A7_P $]O\ @MM^S-JW[&^AV_@_3OC39>(=!\6^&]#C6UT^YM]-
M@22&Y-LF(T*/*)"4"Y^SYQEGW?(G_!"O_@G?^RG\7_A9\4OVTOC/X-3QEXV\
M*?$O53X>^T7$ZI:?V'Y-[ (XXW5"SW,K%PZNK *",;@0#^K_ .)/[4/[,_P9
M\0VWA'XP?$3PQX4U:\57M[+6-7M;&XE5L@%(YY4=@<'! .<5X#_P46_;=\/?
ML*_L:^*?VH+8:;J]]IUI&^BZ?=7JVT>I7,[*J)&PRTF%8RE8P69$."!\P_"C
M_@B)^P!^R?\ MX?L7:Y^V3^VAX7L?BC\0_BUKVL2ZSJFM!II[5(IV@6&V((^
MS$!3(KP[' <*&"J@'YZGPQH]Y_P1P_;,_9?\:X\7Z+^S;\0KS3/ >I:DJW$U
MA;B^2W @D(^5@GF'*]!.P'RD  ']F/[,G[3G@7X[?LM>&/VBKS7]$:"]T.RU
M#6KFQNXVL+"[DMHY[F)Y#(XB\DO\RR/N08W'O7??"O\ :+_9\^.LMY!\$?'?
MA[QB^G_\?2Z'JEMJ!@YQ^\%O(^SGCYL<U_&O_P %"O"FF> /V>OV&?V,_@I\
M.I=3\%_%*&#Q7XJ\)>'9H](;Q5J-I8Z:3$\XP \@D<RDG+$HP^=4(Z3Q1\%?
MVE-%_:]^!O[0/['7[&.J_L\:IX4\06]KKMQ8:G8?9-8T2X9%N;>:WB:)7?RA
M)E\%V#$G)5"H!_3G\+/B9\?'_;-^,?AOXH^*O!\OPS\.V.E7&@Z?97<9US3B
M]LDEW)J<><PQL^YXF? ,>#TKVC6OVQ/V1O#9TD>(OBGX0L#KT8ETS[3KEE%]
MMC)*AH-TP\U2RL,ID9!'8U_/=X4_Y2G_ /!2#_LGFC?^F%*^8O\ @G5_P2L_
M8L^+/_!!K4/CY\4_!MKKWCSQ+X:\2ZH->NR\EY8RZ9)=PV2VK[@84A6WC8HO
MRNV[=N4X !_9RK*ZAT(*D9!'((IU?D9_P0<\7>(_&_\ P20^"FN>*KN2^NTT
MJZLQ+,VYO(LKZYMH$R>R11H@]E%?KG0 4444 %%%% '_U_[\YYX;:![FX8)'
M&I9F/0 <DFO@G1YKF[TV+4KY/+N;W-U.G]V:X)DD'_?;&OJGXS:@EG\.=0LW
M!;^T@FGX4X;;=L(G9?=(V9_^ U\TT %%%% !1110!\U:/\"]2\2^.[KXD?&?
M4Y=8F2:9-*TI'*:?86I<[/D7:)IG3!DDD!Y^4# !KZ4  &!P!2T5UXO&U<3*
M,JKV2222226R25DN[[MMN[;9QX' 4<)!PI)ZMR;;;;;W;;U?;LDDDDDD%%%%
M<AV'M?P4T@PWVK:^N"MQ';6Q]0T!E<C\I5/XU[[7CWP5MYX_#=Y>2',5U>N\
M7.<*B)$WT^=&XKV&@#G/%^CS>(/"VH:-:E1-<0.L+-T67'R-_P !;!_"OC>*
M6.>))X3N210RGU##(/Y5]UU\5ZYI<FBZ[?:7*4S%<RE4C^['$[%XEQVQ&R<4
M 9=%%% !7R1^W9J2Z7^RAXQF:,2>;;10@$9YEF1<_P# <Y'IC-?6]?GE_P %
M.M7?3OV8VT^-MIU/5K*VQ_>"EI2/_(>?PKGQ3M1F_)_D>CE$.?'4(_WX_FC\
M%_"\)2R>1NKMG\!Q72,=HS5/3H8[6UCA/&U1GZUB:]XECTE&A@P9SWQD1CZ=
M"?K7P9_1-.+E9(U=2U.QTV(/J$A0$9V 9<_AV'N<5]@?LQ?L>_$O]H>Q'C:^
M8^&?"[@^1<.I:ZO,?\\=PPL?4>9C!Q\H/6KW[#'[$][\;=3B^+?Q<MV_X16"
M3?;P2$AM1E0]^<^0I')_C(P.,U_0A!!!:P);6R+''&H5$4855'   X  KW\N
MRM3BJE9:=%W]3\^XMXL6&D\%@7>:TE+>S[1Z7[OIT\OCWX??LK:5\/;,:9X:
M@M;&,@"28;I9Y2.[NPW,?J:^C_"_@'1O#+"YC!GN<8\U^W^Z.W\Z[BJ]W=0V
M5L]W<':D8+$_2OI(Q45:*LC\IJ5)U).=1MM]7JSS+XQR:I=^!+[P[X=U*32=
M1U&/R(KN'F6!6(#NG(PX3.QNS8/:OFKP'\+/ OPWLOLOA6P2*5F9YKJ3]Y<S
M2/RSR2MEV9CR237JNL:I/K.H27T_\1PH_NJ.@K,KKCC:\:#PL9M4V[M+9O97
M[VZ7VN[6N[\$L!AY8E8R4$ZB7*F];*]W;M?JUJ[*][*Q117.>*_%.E>#=#FU
M_6/,,40P$AC:661S]U$1069F/  'Z5A3IRJ24(*[>B7=G16K0I0E5J2M%*[;
MV274Z.BO// GCO4_&^HQPW'AC7="LV?8;K5K,VJD8)W*&.<#_:V]>,U[+>IX
M8M89(K)YKJ8C"N?D0'UQU-:XK"U</5=&LK26ZT_0SPF*I8FE&O0E>#V>O>W6
MQSM%%%<YT!1110 4444 %%%<AX[\<^'OAQX8N/%WBB1H[.VVABBEV)=@H  ]
M2:NE3G4FJ=-7DW9)=63.<81<I.R1U]%8'A?Q/HWC'0;;Q'H,OFVMW&LB$C:P
M##(!!Y!]C6_2G"49.,E9H:::36P5TOA?0FUS4@D@_<18:0^H[#\:Q+*SN-0N
MDLK49DD.!7T/HFCV^B6"V<')ZLW]YCU-2,U5544(@P , 4ZBB@#BOB+\0?#/
MPL\&7WCWQA*T.G:>JM*R*7;+L$4 #J69@!]>:G\!^./#GQ)\(6'CGPG,9]/U
M&/S(792C8!*D$'D$,"#[BMG7-"T7Q-I,^@^(K2*^LKI=DT$Z"2-U]"I!!J32
M-'TKP_I<&B:';16=G:H(X8(5"1QHO0*HP ![5O>C[&UG[2^]].6VUM[WZWV,
MK5/:7NN2WSO_ )6-&H9[&#5571KEBD=_)':%@<8^TN(@<\=V%35M^$XH[KQO
MHEC.A>.:[);'8PQ23*>O]^-?7^M8&I]FT444 > ?&Z.Y6]T>ZX^S[;F(]/\
M6MY;+VS]U'[UX4=.T]K\:JT$9NE0Q";:/,"$YV[L9QGG&<9KZ1^--A/>:%I]
MQ&VU+6]\V3G^$PRH![Y9EKYZIIM;!8*S6UC25U4:&US&+QH_-$&X>84SC=MZ
MXK2KQWXK?!7PW\5+1)Y;J[T?5[4K)9ZIITS0W,$B9VG@[77D@JX(()'O6V&A
M3G5C&M/EB]W:]O.W7Y:F&*J584I3HPYYI:1O:_E?I\].]MSV*BN'^'%MX[L?
M!MG8?$NY@O=:M]\4]U;KY<=P$=@DNP8"%TVLRCA6) XKN*BM35.I*"DI6;5U
ML[=5>SL^ETBL/5=6E&HXN-TG9[J_1VNKK9V;]3*U?0]'U^W2TUNUCNHD<2*L
MJA@&7H<&M6BBLS4*S-8NY-.T]M7AC,SZ>T=ZD8&=[VKB95_%D K3I5)4AAVH
M ^Y4=9%#H0RL,@CD$&G5YO\ "&]DN_AQI44P</9Q&R8R'+.;5C#O)_VPF\>H
M85Z10 4444 %%%% !1110 4444 ?ST^/_P#@C#^UA;_M??%+]K#]EK]J6\^%
M4OQ5O;>[U'3K3PM#J!"VJ;8D:::^7?M+.01&GWN1Q7I?[-W_  1EU_P?^U5H
M/[97[:/QO\0?'GQIX/A>/PZ-2M$TW3].DE!!E2V26<;QDE=K(H;YB&8*5_<N
MO'? WQ_^#OQ+^)GB_P"#W@+78=5\1^ GM(O$%I KM]ADOD,D,<DFWRR[(I)1
M6++_ ! 4 ?E)%_P1K$7[._[4'P$_X6/G_AI'Q7J'B?[=_9'_ "!OM]P)_(\K
M[7_I6S&W?OAW==HZ5]6_&?\ 8('Q>_X)G_\ #NL^*_[/_P"*2TOPM_PD'V'S
M?^0;' GG_9//7_6>3GR_/^7=]XXY^B_&O[6/[-OPX^-WA_\ 9N\=^--+TKQW
MXJB6?2=$N)PEW=QNSJK1IW#-$ZKDC<5(&37T+0!^.?[27_!)#3?C7\!/@MX7
M\ ^/KSP/\5?@'IVGV7A7QU86@>139VT5O*LUHTNUX;CRE9HS(=AXW,I=7\.^
M&_\ P1O_ &C+_P#;:^&G[?G[5_[1%S\1O&G@&2[1[(>'X-/T][*:W:&&WMD@
MN%6W*/++)++Y;F8LHVH5+-]N>,_^"O\ _P $QOA]X^D^&/BWXV^%[;68)7@F
MC6[\Z*&6,[622>,-#&RG@AY 001VK] _"_BGPSXX\.6/C'P7J-MJ^D:G ES9
MWMG*L]O<0R#<DD<B$JZ,""&4D$=* /Y^=*_X(P?M:?L[>*_&6B?\$]OVG+WX
M3?#?QYJ=QJMYX<G\/6VKMI\]T )6LKB65&3Y55$*B-U15R[,H:OU3_8 _8?^
M&/\ P3R_9BT3]F;X675SJ5KISS7=YJ-X%$]]>W+;IIG" *H)PJ*,[8U52S$%
MCA?M"_\ !3K]@#]E3Q6W@+X^_%?0/#^NQX\W36G-S>0[@"OG0VZR219!!'F*
MN1R.*]^^ O[2_P"S[^U)X1D\>?LZ^,M)\9Z3#)Y,UQI-TEP(9<;MDH4[HWP0
M=K@'!SC% 'S'^TS^P8/VB_VS/@1^UP?%7]C_ /"DY]8F_LG[#]H_M/\ M:&.
M+'G^?'Y'E>7G_52[LX^7&:/V$OV#!^Q1XL^-'BG_ (2O_A)O^%O>.M1\:>5]
MA^Q?V=_:#L_V;/GS>=LW8\W$>[^X*B^('_!6G_@FW\*O'&K_  U^(GQC\.:1
MKV@W<MCJ%C<7!66WN8&*21N-IPRL"#[U[S^S[^V9^RA^U:MV/V</B)H'C26P
M7?<P:7?13W$"9 #R0@^8BDD ,R@$\ YH _/7]C?_ ((O_"?]CO\ ;]^)?[<_
MA[Q"=4_X3;[;_9&@M8""+0O[3G6XN_*F\YQ)O==L>V*+RXR4^;.:U_VOO^"6
M/C/XH_M3VO[=W[&/Q5N_@K\6_P"S!I&JWL>G0ZMIVLV48 1+JUE9%+@*B[V+
MC;''A R*P]\^(7_!6?\ X)N_"CQSJWPT^(WQC\.:/KV@W4MCJ%C<7!66WN(6
M*R1N-IPRL"#7J_[/W[>_[%W[56NS^%?V=OB=X=\7:M;Q&XDL-/OHWNQ"I :3
MR"1(44D L%V@D9/(H _/C]FW_@CMK/P_\3_%3X__ +3GQ5O/BI\9?BIX<N_#
M$_B:YTZ.RM=,L+J'RBEK91R%!C:F<.@*IM54W.6^]?\ @GS^R/\ \,)?L>^"
M_P!D_P#X2#_A*O\ A$(;J'^U?LGV'[1]INIKG/D>;/LV^;M_UC9QGC.![/IG
M[0/P=U?XY:G^S58Z["?'6D:7#K5SH[I)'.-.G?RTN$+J$ECW_(S1LP1OE;!X
MKV.@#\]_VP/VZQ\"_%^E?LW_   \-2_$[XX>*K9[K1_"EI,((;2S5MC:EJUT
M0RV.GQL=OF,#),_[N%';.WQ#P9_P2X3XUZ_:?&'_ (*C>)A\<?%<4JW5KX;>
M-[;P)HDG4)9:,S-'<M'DK]JU#SYGP"!']T?I]HGPQ^''AKQOKGQ,\/:#I]CX
MB\3+;)J^J06T<=Y?+9(8[<3S* \HA0E8PY.T' Q7<T 9>B:)HOAK2+;P_P"'
M+.#3["SC6&WMK:-8H8HT&%5$4!54#@   5J444 %?AU_P4J_9"\&GQGHWQY^
M!?P+\5W_ (^D6Y>\\??"75=+\/\ BK2S&8S'YL5Y<6D6K1S;G#03B=-JD%?F
M!'[BT4 ?QR_L(_MF?MMZ9_P68\+:'^UA\+?%VEVGQ \(W/@B_P#&NI>&+CP[
M:ZO+I+RZCH]S?6X\ZSBOHP;RUD-K=302?:8MFP J/[&J** "BBB@#R[XW^*Y
MO OP=\4>+[9BLVGZ7=30D=1*L;;/_'L5\@?\$SO!=MH'[/DGBPH/M/B#4)YF
MD_B,5N?)13[!E<C_ 'C7U)^TEH-UXF^ /C'1;(9FETBZ,:_WF2,L!^)&*^?/
M^"</B*VUK]E_3],@(WZ1>WEK)_O/(9Q^DHH ^[Z*** "BBB@#X?_ ."AG@JU
M\6?LR:MJ3QAKC0YK>^A8]1AQ&^#_ +CM^5>O?LI^+9_&_P"SGX/\0W3%Y6TZ
M.WD=N2SVV868^Y*$FN#_ &[_ !#;>'OV6O$[3D;[U(+2)?[S2S(#^2[C^%?C
MW\./VGOVL_V!K/1M6^*OAZ7Q%\(?$4<-W82P89[);I0Y$<O 1R26\F;"N<E&
M&6->[D'#^)SBM/#824?:J+E&,I*+FTU[L;Z.5G=+31,^>XCXEPN24(8O&QE[
M)R492C%R4$TWS3MJHW23=GJT?TA45XQ\#?V@OA'^T=X-C\<_"+6(M4M#A9HP
M=L]M(1GRYHC\T;?48(Y4D8->SUY.*PM;#594,1!QG%V::LT_-,]G"8NABJ,<
M1AIJ=.2NI1:::[IK1A117A'[07[2?P@_9B\%/XX^+>J)90MN6VMD^>ZNY%'W
M(8LY8],GA5SEB!S3PF$KXJM'#X:#G.3LDE=M^20L9C:&$H3Q.*J*%.*NY2=D
MEYMGME_?V.E6,VIZG-';6UNC22RRL$1$49+,QP  .23P*R_#'BOPOXVT2'Q+
MX-U*UU?3KG/E75E,D\$FTD':Z$J<$$'!ZU_/?)=?M@_\%;]?,%D)/A_\'+>?
M#,<G[6$/?[INI<CH,01D<_./FK:UX1_:'_X) ?$0^+_!$ESXS^#>L7"B\@E/
MSP,V%'F;1MBG P%E4".7A6 . /TF/AS3M]0GCH+,FKJAT_P.I\*JOI'RM?6Z
M_+)^*%7F68PR^H\J3LZ^SU_Y>*G\3I+K+SO;2S_HXHKR+X'_ !T^&?[1/P]M
M/B7\*]16_P!.NAM9?NS02@ M%,G5)%SR#U&""5()]=K\UQ.&JX>K*A7@XSB[
M--6::W31^JX7%4<31AB,/-2A))IIW33V:84445@;A17COQI^/WP?_9Z\+-XO
M^,&NVVC6AR(EE;=-.R_PPQ+EY&]E4XZG YK\O/AU_P %KO@9XR^,/_"$^(]"
MN_#WAFY;RK77+J96(D)P#<0(I\J,_P!X2/MX+ #)7Z3*>$,YS/#U,5@<+*=.
M"NVEIINE>W,_*-WY'R^<\:Y%E.)IX/,,9"G5FTE%O779RM?E3_FE9>9^TM%5
MK.]L]1LXM0T^5)[>=%DBEC8,CHPR&5AP01R"."*LU\XTT[,^G335T%%%%(84
M45^9?_!4?]JO7?V;?@A;:%X&G-KXC\82RV=K<+D-;VT2@W$J'M(-Z(AZ@ON'
M*UZ63Y57S+&TL#AE[\W9>75M^22;?DCR,^SK#Y1E];,<4_W=-7=MWT27FVTE
MYLPOVSO^"G?@']GF\N_AO\,(HO$GC"',<V6)LK%^XF92"\@[QH1C^)E(Q7\\
M/Q?_ &B?C'^T#KIU_P"*^NW&J.&+10%MEM!GM%"N$3CC(&3W)/-?-\4\DLAE
MF8L[$DDG))/4DUNV[U^^T>#,'E-'EI1YJG6;W?IV7DOG<_CSB'Q S3/ZS>(G
MRT;Z4XOW4NE_YGYOY)+0Z>WDZ&MR!MRUS-N_&*W;9Z^%SK#6;9R82I<T*]G_
M &=OB)??"?XY>%?B!8N4_L[48&EP<;H)&V3+G_:C9E_&O&*^AOV7_@1XI_:#
M^,&D^"?#]L\EJL\<VHW&TF.WM4;+LYZ#(!502-S$"OE*EE%\VQ[V6PKRQ=)8
M5-U.9<MN]]#^Q*BBBOE3^QPKQ;]H_P".7@_]F3]G_P :_M$^/WVZ-X'T2^UN
M\&X*SQ6,+2E%)_C?;L0=V( YKVFOGO\ :H_97^!7[:OP*UO]FG]I;16\1>"?
M$;6IU+35NKBS\_[%<1W4(,UK)#,H6:&-_DD7.W!R"00#^97]B'_@HUXR\)_L
M9>&/ '[/NK>#]*U?79+WQ-X\^+WQ,U--*\)0^(?$%S+J&HQ:;$\L-SK4MM-,
M]N'@>&S4Q*#<'I7ZV:)_P2E\ ?'C2K;Q?^W#\6O&/[0+ZE"ER+:?59-#\*,)
M!E'M=(T9[>V:,H1M-Q)=$@Y+G.:]U^"W_!);_@F7^SVL+_"?X%>"]/N;?:([
MR?28+Z]4(,#%U=++/P/^FE?H5'''%&L42A54   8  ["@#X0\'?\$L_^":/@
M'34TKPE^S]\.[2) !N_X1G3WE;'=Y'@9W/NS$US?Q _X)$_\$O/B9"$\3? +
MP-#.A+)=Z;HMMI=XC'NMS9)#.I]"'!':OT6HH _(:[_X)T?M!_L\ Z[_ ,$\
M?CIXB\.I;?-'X-^(-Q-XQ\+3(G*P+)=R'5;)#TWV]Z0HY\ML8/?? C_@HC?O
M\6-._93_ &YO![_!SXKZF7CT>.6Y^V^&_$YBQN;1-4VQK-)@AFLYTANXPP_=
ML 6K].Z\+_:/_9K^"?[6OPDU+X(?'_0;?Q#X=U0 M#,"LD$R?ZNXMY5Q)!<1
M'YHIHV5T;E2* /=*_G*?_@B=^V+X _:$^*_QP_9;_:TO?AI;?%GQ->>)-0TR
MT\)P7@22YFEECC::6_!?RA,RA@B;NNT=*_<?]G+X6^-/@I\&-$^%?C_QKJ/Q
M#U'1$DMQK^L1QIJ%U;B1S;BY,0"R31PE(Y)L!IF0R, S$5[=0!^*O['W_!'J
MY^"/[5,?[;O[5'Q@U_XY_$[3;"73=&U#5H%L;73()U9)#!;I+-ABDDB "01@
M2N=A8[AYSXT_X(>CQ?\ LQ_M*_LY?\+/^SG]H?QX?&_]H_V+O_L?.H17WV7R
M?M@^T_ZKR_-\R'KNV<;3^^%% 'YY?MV_L%+^VM^P+JG[#@\5_P#",_VE:Z/;
M#6OL/VW9_95S;W&[[-Y\.?,\C;CS1MW9YQ@^,_MF_P#!+:\_:$U/X9_&SX"_
M$*Z^%WQF^$UHFGZ+XNM;-;Q)[(1E)+:YM)'5)(G+,0"Q"AW5E=6(K]<Z* /P
M=_9V_P""/7QQ\#?M\^&/^"C/[2_Q]N_B=XXTC3KW3KVVDT*+3[1X+FWD@ABM
M1#<;;:.#S7<@1-YK$L0C,Q/GNE?\$8/VM/V=O%?C+1/^">W[3E[\)OAOX\U.
MXU6\\.3^'K;5VT^>Z $K65Q+*C)\JJB%1&ZHJY=F4-7] ?A_Q=X3\6F^7PKJ
MEIJ9TN[>PO/LDZ3?9[J( O#+L)V2J&4LC88 C(Y%=#0!\7?L ?L/_#'_ ()Y
M?LQ:)^S-\++JYU*UTYYKN\U&\"B>^O;EMTTSA %4$X5%&=L:JI9B"Q_!W_@K
M'\"O&G[1?_!</]FOX:?#;QO>_#GQ&WA'6;_2_$5A EU+8W=@+JXC8PNRK+&Q
MCV21LP#HQ4G!(/\ 5G7%:C\-?AUK'C?3_B;JV@:;=>)-(BDM['5IK6)[ZUBE
M!#I%.5,D:N&(958 @G/6@#\I_P!DS_@E]\3_  +^U4?VY_VY?BS-\:?B?INF
MOH_AV==,BT;3]$M)0Z2^1;0.R&65'92^$X=\AF.X>_?\$UOV"1_P3Q^#GB?X
M2#Q7_P )?_PD?BW4O%'VK[#_ &?Y/]HK"OD;//N-VSRO]9N7=G[HQS^A]% '
M\^UC_P $:OVF/V=_%_C#3?\ @G/^TE?_  >^'/CS4)M2O_"\N@6NLIIUQ<C$
MKZ=-+)&T&1A$"JKJJKF1RBD?1_@__@CA\ ? '_!-OQ?_ ,$Z_"FKZA';^.H9
MKC6_$TX$]_>:Q,8W^VR(QVG#PQ@1!@/+3;NW%I#^NEQ<6]I;O=73K%%$I=W<
M[555Y))/  '4UE>&O$WAOQGX?L_%G@_4+;5M*U&%+BTO+.59[>>&095XY$)5
MU8<AE)!'2@#\(+W_ ((G>/?B=^QMX3_9Z_:)^-]_KOCWX6:S%J7P[\=Z7I,6
MF7OAZWM8+>""T\I)F-Q&I@$K,94E9MGS_NP38\)?\$?/VB?BY^T7X%^//_!2
M3X_W'QGL_A?>#4/#>@6NA6VAV(O8RK)<70MW82L&1'*E,DJ%+E-R']\J* /R
MQTG_ ()H#3/VI_VD/VE_^$UW_P##0?AZRT'^S?[-Q_9'V.P%CYOG?:#]IW8\
MS9LAQ]W<>M=]^RK^P0/V9O\ @G'9_P#!/T^*_P"VQ::'K&B_V]]A^S;O[6DN
M9/,^R^?)CR_M&-OG'=MSE<\?HA10!\:?\$^?V1Q^PC^Q[X+_ &3QX@_X2K_A
M$(;J+^U?LGV'[1]INIKG/D>;/LV^=MQYC9QGC.!]ET44 %%%% !1110!_]#^
MVCXWZI'=:]I'AL!9!;)+J#X/SQ2$>3"2/[KJ\_XK7D]:OB?5Y-?\;:UJIPT4
M=R;*W;&&$5H/+93]+CSBI]&_"O&[KXS?#6R^)UO\'+G5$7Q%<P^?':;6.5P6
MP7QL#%06"ELX&<<C.E.C4J7]G%NR;=E>R6[?DNY$ZD86YG:^GS['I]%%%9EA
M7@?Q$\.?M%MKA\0_"GQ+I26ZJ%&D:K8L8'Y&6-Q$_FANN,*5YZ=Z]\HKJP>+
MEAZBJ1C&7E**DON:?WJS71HX\=@H8JE[*<I1ZWA*47?UBU?T=T^J9R7@K4?%
M>IZ&+CQG8I87P=E,<;;E*CHPY;&>>,FNMHHKF;N[G8%%%1S3+;1-</TC!8]^
M!S2 ^I_A1IDND^!;6VE8MOEN9U)SG9//)*G7_98<=J]%KEO VG7&C^"='TB\
M.9;6QMX7(_O)&JGK[BNIH *^2OB39_8?B!?XR1=I!=9Q@9*>5CWXB!_&OK6O
ME'XL0L/B9-<$\-IEFH'^[+<G^M '"T444 <9X]^(?@OX8>'7\5^/=0CTW3XW
M6,RR G+OP%"J"Q)] #P">@KY&_;O\'WOQ;_9LBUGP,O]J1V5U:ZL@M_WGG6N
MUE+IC)8!)/,&WD@5]:?$/X;>"/BMX;?PE\0+!-1T]W67RF9D(=.C!D*LI&2,
M@C@D=#74:1I.FZ#I5MH>C0K;6=G$D$$2#"QQQ@*J@>@  %:5Z="IAN37G=[[
M6M;2W6^]^FQI@L56P^+C7BE:-FM[W3UOY'\BLNKOJ5X-"\+1R7NHR-Y:QP(9
M'#=" J@L2/85^BW[)O\ P3B\2^+M0M?B!^T);R:?I,9$L6E2'%S='((,X_Y9
MH>ZGYV'!VU^YUMH.AV=XVHV=E!%</]Z5(U5S]6 R:UJ\+#Y+3IRYIOF/NLRX
M^Q5>BZ.%A[.^[O=_)V5OS\RI86%CI5C#IFF0I;V]NBQQ11J%1$48"J!P !P
M*MU'--#;QF:=@B+R2QP!7G>J?$2S@8Q:7%YY'\;<+^'<_I7LGP)Z17F'Q%U5
MDBBTB(_?^=_H.@_.O%/B7IO_  M/3DT[7+N]LA"2T3Z=>3V;(_!#?NI%#,I
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MVN+Z*WF>[T>XN(9)8UCN5:W!FA:)EWKM$MX22-N0 >9?L(_MD_\ !'K]F?\
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M\%1_VWX(\30:GXV\3>'-!ET/28-%$T7F)=J8;8.3$LZ[W1=X<1([E]J_>?\
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M?Q1M@!U]@1@@&@#Z-HK\??!'[3OQM_8^OH/A/^U!H]QJ>CP 16&JVW[QS&O
M"NQ"S*!T5BLB#KG@5]W>$?VP/V:O&=LMQIOC#3[8LN3'?2?8W4^A$^SD>Q-
M'TI17SKXH_:V_9L\(VQN=4\9Z9, "=MG,+QSCMM@WG-?"OCS]L+XM_M,:E)\
M)_V2=&N[>*X!CNM6G CD2-N"0P)6!<?QEBYSA0&Q0!!^U?XIN_VJ_CYH'[+/
MPZ<SZ?I-T9]8NHCE$=<"0YZ?N(RR^\C[>H%?JK<^#/"=]X2_X0+4=.M[K13;
M+9M93QK) T"J%",C @K@ 8-?/7[*_P"RWX:_9O\ "KIO6_\ $.HJIU"^P<''
M(CCSR(U/K@L>3V ^JZJ,G%J479HF48RBXR5TS\*_CE_P37^*/P#\92?M"?\
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M>'O$5K+!+"UI?16X&T%U"R*P0E60LO8D$$4 ?LY1110 4444 %%%% !1110
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MXJO*?B==1O\ <72[ I]6EN]W\E^GXU]85\I?%B=6^)<UMW33+-O^^I;D?TH
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M_L^6330INXE\VV+C*K/'\T3?\!<*?PK[GTC5+'7-)M=;TQ_,MKR))XG'\22
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MB#7UQX=\,>'/"&E1Z%X5L+?3;*'A(+:-8HU^BJ *W** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-D86E.E1C3J5'.26LFDFWWM%)+Y(^0?&'[)NC^/_ !UH?C[Q!>RPW6A.KQ)
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M>:_<;YODB7[D8/ ^OJ:\4\3_  ;^%_C"[CU/7=#LY+V"198[I8E2=74Y!WJ
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MIX6\:_\ !P5^U#XE^!S17?ANT^&4.G^([FQP]J_B$-9A5+)\AF5(YD;J=Z2
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M]GC4_"VFV:P0>$(F:.U B6"UB%N?--U#*JIL0>8LJ'(!4X[/X@?#WP\/CO\
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M^"OW[;?@OXIRQ6_Q&U;Q#8WVDI=@)=W'A_\ ?O']GW ,T21R6Q?;P08SR "
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MO]OT^)-'^#YU?1_$G@^6./6_#OB.Q;3M5L?.SY;20DNI5BK#*NQ4C# 97/Z
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M8[B62W2,L3\JQ@*#M7"\5^BE% 'XY>!/^" __!)[X=?$NT^*7A[X50R7FG7
MNK2TO=1OKW3X)@=VX6MQ<20MDX.UU9!@848K]!O%?[*7P"\;_M%^%?VL_%&@
M?:OB#X)LKK3M%U7[5<)]EMKU729/(25;>3<LCC,D;,,\$8%?0]% 'SQ^S7^R
MC\ OV0?!^J^ OV=M _X1[2=:U>YUV]@^U7-WYNH7@19I=US+*Z[A&OR*P08X
M49-'[-?[*7P"_9"\':IX _9VT#_A'=(UG5[G7;R#[5<7?F:A>!!-+NN9977<
M(U^16"#'"CFOH>B@#YG_ &L/V/?V<_VX/A0WP4_:>\-Q>)_#OVJ.^C@>66WD
MANH0RI-%+ \<D;A7=<JPRK,IRI(/Q7\3?^"&W_!,GXM>%?!_A/Q9\.V$?@33
MTTG1[JUU2_@O8[&-VD$$EPEP)9D#.VWS6<H&(0J.*_6RB@#\\O@3_P $H_\
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MPN(HY2&>,R6DL+.A*@A7)"G)7!))^[J* /S#_:N_X(X_\$[OVT_B,/B_\>_
M"WOBEHHX+C4[&^N]/N+J*-0BK<&VFC$QV )O<%]@"A@ *^P/V;/V7/V?_P!C
M_P"&%O\ !K]FOPM9^$O#=M*\XM;3<S2328W2RRR,\LTA  +RNS;5"YP ![Y1
M0!\@_MB_L&_LI_M[^"+'P#^U1X3A\2V>E3-<6$OG2VMU:2N ':&>!XY%#@+O
M7=L?:-P.!CY<^'__  0\_P""7GPSCT.?PI\+H8M3\/:U:^(K+5VU+4#JB:E9
M<PRF\^TB<HK?-Y!?R"P#&/(!K]8:* /GKP)^RI\!/AG\>_&W[3O@C0?L/CGX
MBQV4/B'4OM5Q)]L33HQ#;CR9)6@BV(H'[J-"W5LGFOF/]KO_ ())?L ?MR>,
MX_B7^T-X!BO_ !/'"MN=7L+NYTV\EA4!0DSVLL0F 4;%,H<JORJ0*_2&B@#Y
MN_9:_9"_9O\ V*_AHOPB_9B\*6OA30O.-Q+# 7EEGG8!3+--,SRRO@ ;I'8@
M  8  KU;XG_##X??&GX?:O\ "GXK:1;:]X<UZV>SU#3[Q-\,\,G56'8]U889
M6 (((!KNZ* /Q?\ "_\ P;X?\$C_  K'/';_  J^UM+-%-%)=:QJ<LEMY+B1
M%@?[6&B4/R=I!<$ARPXK[9_:_P#V /V0_P!O'P]I_AW]J?P7:^)AI#M)I]UY
MDUI>VC/C=Y5S;/%,JL0"R;]C%064D"OL>B@#X3_8V_X)J?L6_L#?VG=_LO\
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MD$@?(R&,  !0.*_8.B@#YX^)?[*?P"^,'QE\!_M _$70/[1\7?#)[R3PU?\
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M7X4\$:5:?#B>UFLIM $.^UEBG),GF!R6=W8[FD9BY;YMV1FOI&B@#\?/@_\
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M3GV^[&>OX<XK[6KY.^&=C:W_ (_L?M .^TBN+N(XXW*%A/T^6<U]8T %%%%
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MNO,SU4SRM.H_!)5_"O6Z "BBB@#XH\0Z0VFZ_JNF7I$I>\N96!&1MN7:91T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;"76FB01P03W,RVT*\9"Q1NJ$L1DE@Q)QS@ #/\ "-\UAK]NV?ED/EM]&_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:Y#L/L*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>business14a.jpg
<TEXT>
begin 644 business14a.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" -0 Z4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \[D_:&^','B*XT.7Q;8
M0ZG;WITV:.4LB1W((!A:0C8'R1QG/(KT2OSK\57FMZAIOQ-\'WZZ;I7PV\5?
M%:]TS5O$\H:6XTQRULZ?N^%579$C$A/RLV2.]>Z?$SXY>.5^+GBCP3X-M+V&
M#PMI5I<&:TT)]5:]N;A'>..0AU\J(+'C<,L220?EH'8^H**^<F^)WQ,\:_$#
MP/X7LFLO 5QK'@^37=4AU#3S=W-G=++'&8D!=1@%R/F["L31?VC/$7B3X8^$
M$FUB+3?'&I:GJ=A)!H^@RZG->I8SR0RRPP!PL:Y$;,TC84/@<D4!8^D-8\7Z
M/X?UG1-*U"_CM=1UJ:2#3[=\[KB1(S(ZKQU"*QY]*V*^.O#?Q/U?XN:_^SMK
MFO6D=GK,7BC7-/NDBC,:EX+2YBW;"24)"@E<G!R*]D^+/Q \30_%;P-\.O"U
MU;:-=>(+:^U&ZUJZMA<?9X+81@I'&6 9V:9>22  >* /8:*\'\0^,_B%9>-O
M!/PSCUO28/$6JVE]J5_XD73B4%M Z*B16[/@RMYB[LL0H!('2N)U/]H+XAKX
M9.BVLVBQ>,K'XA6_@JYU9[1WL[B&5-XN!$'!5]K+E-QPRD9P> #ZNHKY[D\0
M?%"Y^,UM\-X?&.E0"V\*IK5YK/\ 8@:6:X:[DB 2+S=JKM"Y!R>#CKQE?#/]
MHSQ5XN\0?#+2=2M]/@N-3U/7M&UIK>-BDTVGJ0LL!+?*K$9(Y[C/% 'TS17R
MWXB^.'Q*NM$\<7&@V!O(?#WCN;1+N;2--%W>6NE);1OYL=NS@32"20 _[))
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M\"K;_P"1Z /0J*\]_P"%2WG_ $4/QC_X%6W_ ,CT?\*EO/\ HH?C'_P*MO\
MY'H ]"HKSW_A4MY_T4/QC_X%6W_R/1_PJ6\_Z*'XQ_\  JV_^1Z /0J*\]_X
M5+>?]%#\8_\ @5;?_(]'_"I;S_HH?C'_ ,"K;_Y'H ]"HKSW_A4MY_T4/QC_
M .!5M_\ (]'_  J6\_Z*'XQ_\"K;_P"1Z )Y/@CX,N/"_C'P[/HZW&C>+;RX
MU#6+::9W$\\P42."6RA^12-N-I4$8-9>K?LY^#M5EL)U_MC3KZUTY-):^T[6
M+FWN;FS7[L,\JN&F4<X+DD9.#R:N_P#"I;S_ **'XQ_\"K;_ .1Z/^%2WG_1
M0_&/_@5;?_(] S9L?AGX=TWQ/I?B"VL6CU33-*.BVLOGR$):%E;R]I;!.47Y
MB">.M<E<?LR> Y+/28;6SU#2IM*NKV[L[W3=4N+>YB:\D,ETHE5]VR1CRI..
M!C&!6I_PJ6\_Z*'XQ_\  JV_^1Z/^%2WG_10_&/_ (%6W_R/0!2T[]F_P+HN
M@^'])TS3[K3K;0=4DUC3I+>_G$T%Q(6\PB0N6*N'<%22"&QBN@^('PKT#XE?
MV9+JT=U!J&ERM-8:EIUW):7=JS+M;RY8R& 8<%>A[BLS_A4MY_T4/QC_ .!5
MM_\ (]'_  J6\_Z*'XQ_\"K;_P"1Z!$.I?L_>#]2T71;!H=1@GT6:6XL-6@U
M.X34())<^:PN=_F'?D[@20>XX%3:?\!?!.EZ!I&CP:4XM=+UA/$$+M=2M-)J
M"DG[1+(6W2N2QSO)SQGH*/\ A4MY_P!%#\8_^!5M_P#(]'_"I;S_ **'XQ_\
M"K;_ .1Z .,\8? 6X\=?M'2>++^2_L-#3PK'I<%]I&JRV=RMS]JD=T_=,&*&
M-AUX_$5T^H_LX>!;WPSX8T2WTZYTBW\,S-<:1<Z5?36UU:2.&$C+,C!R7#-N
M))W;B3S5S_A4MY_T4/QC_P"!5M_\CT?\*EO/^BA^,?\ P*MO_D>@9GZ?^S=X
M,T/1;G3M'_MG1?M&IR:O)>:?K-U'<FZDC$<CF7S-QW*HRIR,\XSS3YOV<? W
M]@^&]+LK&\T;_A'%D32[_2[^:VO+=9"3*//1@["0DLP8G<>3SS5W_A4MY_T4
M/QC_ .!5M_\ (]'_  J6\_Z*'XQ_\"K;_P"1Z );?X(>%+/4?"=_!;WD5YX9
MCGAL9OMTS.T<^/.28LQ,RN0K$/GD U3\(_L^^$/ VM6E_H\>IVT%C))-8Z4V
MJ7#V%F\@8.T-N7V)D,W &!DX J?_ (5+>?\ 10_&/_@5;?\ R/1_PJ6\_P"B
MA^,?_ JV_P#D>@1Z%17GO_"I;S_HH?C'_P "K;_Y'H_X5+>?]%#\8_\ @5;?
M_(] 'H5%>>_\*EO/^BA^,?\ P*MO_D>C_A4MY_T4/QC_ .!5M_\ (] 'H5%>
M>_\ "I;S_HH?C'_P*MO_ )'H_P"%2WG_ $4/QC_X%6W_ ,CT >A45Y[_ ,*E
MO/\ HH?C'_P*MO\ Y'H_X5+>?]%#\8_^!5M_\CT >A45Y[_PJ6\_Z*'XQ_\
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MHL>=9^6/FD7ZYV$'A@S C!KSGX?_ +5%C)'#8^.X!HEV,+_;%NI:PE_VGZM
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MAD,".H(/6OT*C6C6CS1/E)P<'9D]%%%;F84444 %%%% !1110 4444 %%%%
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MG9G?&2DKQ=T%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW0_&%I)=:#K.GZW:QOY;S:==1W"*V =I9"0#@@X]ZUJ "BBB@ HHHH ****
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M]!5I5KFH8/#89N5&FHM[L]CZK*5O;3<DNG0AM[:.WACBB18HHU")&@PJJ!@
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MFTSX>_"Z3QCK7B*\N/#=E;W5OX9U*>$VMA>B+:6.R,.^S)"J\C!>W;'I6G?
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MX"CA1^OFXC%2C-8;#KFJRV7;S9]'E^64ZE&688^?L\-#>75^4>[>W_!+;_\
M"2_&;Q=)KWB2^^V7?*"15*V]E&3GR;=#T'J?O-U8UW/AK1K[Q+-)H/@F.."U
MMW\N_P#$$R;X+9A]Y4_Y[3_[(^5?XCT4[?P]^&]S\3K6%H?.T;P#'P)X28[C
M5AW$3=4A/>3[S_PX!W5ZQXQ\7>%_@OX9LK4P);)M\C3=$TZ,>;.0/N11CL.I
M8X ZDUQU*O\ 9R<,.^>O+XI]O*/]?\#CQ.(GGLHJI#V6$A\%)=?[T^[?;_@M
M^;^/K;PY\ _A7>:?IKM;ZEXAG%DU_*K3W5W/*,27$A4%G*1[FP!@ !5 R!7(
M^)O&-_X[TFV\/V%G<^'?!-O"EN;>=MM[J$:J%"R;3^ZB( RN=[=&VC(-.\OM
M5\7>(G\1:^T:7YC,-K8P,6AL(203&I_B=B 7?N0 , "K2K7F4<-RVG5=Y[_,
M^BI89))M678C@MT@C2.-%CC0!511@*!T '85.JTY5IZI7H'<(JU(J4Y5IZK0
M3<:%IZI^%/5*>JTR+C%2GA:D6.I M,FY$L=/$8J3;2A:";C OM2[:D"TX1T6
M%<BVTNWVJ;92^73L*Y!M]J7;4_ET>70%R#;1M]JG\NCRZ N5]OM1M]JG\ND\
MNBP7(-M)M]JG\NFF.E8=R H*:8ZL;332M [E8I[4QEJT5IC1YH'<JLE,*^HJ
MRT>*85I%7*S)4;)5ED]*8RT%IE5E]:C9*M,E1LM(NY7\-^)-5^&NNW&JZ3;M
MJ6EWK!]3T=6"M(P 'GP$\"4  %3PX Y! ->\63^"_CQX+F@9+;7M&F.R>UF4
MK+;R#LRG#Q2+V/!'4&O"V6J"-J7AO6E\1^&Y1::]"N&7_EE?1CGR)U_B4]F^
M\I.0>H/'4PT*DN=:2.*M0<DW#[CJ_$GA77_@;<+>37=UK/@V-@8=:R6O-+YX
M6YQ]^,=IAR/XQ_$??OAC\68/$T4-CJ4L:WS*##<*1Y=RN."#TSC\#VJUX)\3
M6/C_ ,&Z7KMI'FSU.V67R90"5W##1MZD'*GZ5XE\0OA3=_"F2;7?"MK-=^$=
MQFO-%ME+2Z9W::U4<M%W:(<KR4_NU])@L<JD5A\6]MI=O4_.L9@IT9O$X):O
MXH]'Z=G_ %Z_5U%>2?"'XP0>);6SLKV[CN#.BM9WZ,"EPI' )]?0]_K7K3,$
M4LQ"J!DD]!7=4IRI2Y9%8?$0Q,.>'_!7DQ:Q?%GC+1O!&F_;M:OH[*%FV1J<
MM),YZ)&@RSL?[J@FN1O/B9?^+KJ;3?A[9PZN8V,5QX@NB1IELP.&"L.;AQ_=
MC^4'AG4\5J^%/AC9:%J1UO5+J;Q+XH==KZQJ !:-3U2",?+!'_LH.?XBQYK(
MZ3%^R^+_ (I<W377@3PL_2UC8#5KU?5V&1;*?[JDR>I0Y6NX\->%])\':3%I
MFBV$.G6,9+"*%<98]68]68GDL223R2:U:* "BHY[B*UADFFD6&&-2SR2,%50
M.223T%?._P"V1=6UQH'PT$MG=:YIEUXNLEFT_33N>]B9)3Y:C<H8'C@L : /
MHRBOE+]GOQ4_A37OC2FG:-K&E:;I<EI=:;X#U>Y"7=LK1-OG5IG,<<4S@X <
MJOEMT/%=4G[8&DVOA/X@ZGJ&A2)J/@R&VGO++3;^&^BGCG($;1SQ_+M!/SD@
M; "3D"@9]!T5XKKW[2UIX3^'.C>)-6TJU^VZ[J2:7I%GIVLV]S;WLC@LKB[&
M(UCVJ[%FZ!3P3@5B-^V%ID?AV_N%\.7%_KUAK]CX?N-)TR^@N5:6[QY$D4X(
M1T(/L0000,4 ?0M%?.>J?M:ZIH<?C3^T/AIJ<4G@DQOXB6+48)!;P2H)(Y83
MP9LH2Q7"X"]3FM+Q]^UIH_A3Q1JNC:5I::\VC:=#J>I3/J<%ELCE4NB0+*09
MI2@W;1@8(&<D"@#WJBO%;S]I%]5\3:+HG@KPC>>+Y]7\.1^)K6X6[BM(!;.^
MQ0[/RK'C'!Y...M<A>_M4>(_$5Y\(;KP?X/^U:9XPFO(KNUO[N.&XBE@CEWV
MX)R%*M'N+\@@8&"<T ?3-%>??%[XLGX3Z/X>NO[!NM=O=;U>VT6VL;.5$83S
M!MI+.0-H*X)]\UYG>?M=7VDV/BN]U/X<ZE9VG@Z\2T\23KJ,#K9A]I62'O.N
MQU<X"X![F@1]&T5X%\0OVNM&\%>*/$NE6>E+J\/A>WAN-:N&U."U>+S(_-$<
M$4AW3R"(ARJX'( ))Q5OQ5^TT]CX@GTOPQX.O?%@A\,0^+&NHKR*VC-G(T@"
MC?R9,1Y"XYSU&* /<J0$, 0<BO!-!_:83QI)H-C<^%=0T'3?&>CW=_X=U&YN
M(G-TL4(D=9(T),3;&W $G('8\5Q/[-/QPU'PC\%?A':>(O"E]9^'=66WT6U\
M127L<I>ZD++$7A!WK'(PVJQ).2,@9H&?65%>,^$_C_JWC35/%8TSP!J#Z'X=
MO+[3Y]4DU"WC%Q<6V?DB1F!(8X&YBH7//2L;3OVN-.;3_'O]I:"UOJWA'0?^
M$BGLM/U*"^CN+;$F%2:,[1)F,J5/0D<D$&@#W^BO$=$_:8_XJ/1M/\5>$;WP
MA8ZYHUSKFF7]Q=Q7 DAMXTDF658^8W6-U;&3D>_%9_PX_:\T7Q]XB\*V,FD_
MV98^+!*=$NO[2@N)9-B&11<0(2UN7C4LH;/H<'B@#WZBBB@04444 %%%% !1
M110 4444 %%%% !1110 5X1^U--=V]_\))+"QCU*\7QE;&*TEF$2RG[/<<%R
M#M^N#7N]<=\2/AC8?$R'1!=ZCJ.E7.C:@FIV5WIDD:R1SJC*#^\1U(P[<%:7
MVHOLT_N:8^DEW37WIH\D_:@F\3:E\ 95GTS3?#UQ/K.GP7-E)(;V.6%KN)0-
MR>7U)&X$'*@COD9'AO\ M_PG^TIX^U?6YO#TUOI?A6QNKS^S]+EB=H4-RRK%
MNF;8P*\DY!   '6O9-4^#]OXD\*W&@^(/$FN>(+6:[M[P2WCVZ2QM#(LB*IB
MA0;2R#.03[BM:/X<:.GC36_$SK--?:QI\.F7<,KAH6AB,A4!<=3YK9YYXHU2
M?+OK_P"DV_,=TU9[:?\ I5_R/'/A;^T;XE\;:EX0GN=(AN-+\2H[M;V6EW<4
MFD*8VDB:6XD)CF4@!255,,PQN%4X/VDO%ME\$M#^(.IV>BN_B2Y@TW2]+L[:
MX)@N))WC\R:3>Q= B%MB(&R,!CG->K^"?@_!X#:RMK'Q+KTVA:?&T5CHD]PA
MMK="" F0@>15!PH=F"C'7 Q''\!_#$7PKT[P /MO]D::R2V5SY^+NWF24RQR
MI(!PZN<@XQV((S52M?3;3[KZKUM_PXEY_P!/_ASS/6/VDO%/ASP-X]U&71[;
M5;OP_!:7-CJ?]G76G65\)I1&T31RLSJZ'KAV!#*>.172ZA\0_'6E^,-;\(7\
MN@G4)/"T_B#3K^SM)E2V>.58FAE1I29>9%(<%,X.5%=/JWP7M?%'@W6_#GB3
MQ'KOB"WU?RA/-<SQHT:QN'41+'&J)RHR=N3W/3&]??#O2=0\;KXIG$[ZB-(E
MT0Q[_P!R;>25)&RN,[MR#G/3-1--JR\_R=OQL7!Q3O+^M5_P?O.4_9GUKQ/X
MD^"GA+6/%6I6NJW]_IEO<K<6\#QNP:,$F4L[!G)/)4*/:F>)OA'>:/J%QK?@
M*:WTZ[G<RWNA71*V%\QY+C:"8)3_ 'U!!_B4]1U/PS^'T7PP\*VWAVSU2]U+
M3+)1%9+?>67MX0,+$&55W #NV3[UUE&(IT\1>,E>+(I2E2LT]4?/US\6M'\/
M_N?%L5UX-OU(1K?5X6"%B<#RYE!CD!/ *MSZ5XC)^SM;^*M!U_Q)X1M&T'4;
MC5+F[TVTN%,,-_;,0=LD9_U>Y_,*/@$!ER,<5]O>(O#NF^+-%O-(U>SBO].N
MXS%-;S+E64_R/H1R#R*\:;^T_A;JMKHOB2YDU#0+J00:7XCEY8,>$MKL]I.R
MR]'Z'#?>^0QF5RPT'/#ZI[IGT.#S&<:JGS<LELT?$]K<&XC):*2WF1VBFMYE
MVR0R*<.C#LP((-35[5^TC\';[1M:NO'.AV<EYIUT%.LV=M&6DA=5P+I5'+*5
M #@<C ;IG'B,$\=U"DT,BRQ2#<DB'*L#W!KY>K3=-WZ,_>,IS.GF5!33]]?$
MNS_R?3[B2BBBL#VPKWK]G/XU:7I^@VGPX\7S_9(8S]GT34YB!"\7_+.V=_X)
M$^ZI/#*%&<C!\%J.XMXKN"2&>-9H9!M>-QE6'H1731K>RO&2O&6C7<\/-LJI
MYI14&^64=8OL_P#(_0S0?"XT<WJ3R)<P3KL\MEX*\Y# _7%5?@G>2:3I^J^"
MKEV>;PS<"VM6D.6>P<;[4Y[[4S'G_IESR:^>?V8/C)J5CX@M_ >NWLFH6%S"
MQT:\NGW30M&,M;.YY==O*$\C:5YXQ[CKEU_PBOQ2\*^(0=MIJA/A[4/3]X3)
M:.?I,&C'_7S[5]5E/L,*HT:&D'M]_P#F?A6;87$4*\X8GXX_BNZ^1Z_1117U
MI\V%%%% !1110 4444 %%%% !1110 4444 %>._M#?'^V^$&DQZ=IJ1:AXPU
M",FRLG/R0)T-Q-CI&IZ#JQX'<C8^.WQJL?@OX56[:)=0UV^9H=+TS=M,\H&2
MS'^&-1RS>G Y(KX6LK76?'WBJ[O]2O&U+7-2D\Z]OG7  ' 51_#&H^55'0>Y
M)KR<=C'1M1HKFJ2V1]5DN41QG-B\9+DP]/64GY=%^O\ FT2^']"O_&&N7NHZ
MG?2WEU<2?:-2U6Y(WR-CUZ  # 4<*!Q7MOPS^&EO\0[>#4=3C%A\.K4@V]O)
M\IUE@?OOW^S@CIUE//W1\U;X7?#&'XC7)L_+:/P'IDI2]FZ'5[A3\T />)2,
M2$<,1L' :O7-4OIO$&HI;VL>+=#Y=O!&,*JC@<#I7@9ECX\.X?V=/W\14T;_
M $7DNO=_@JU:?$V(C-KV>%I?PX>7\TE_,^G\J\[WZSQ1XJTWP?X)U3Q#(4?3
M-,LY+DB'@%44D*OY8 KY(M_[0UO4Y_$.OR?:?$-^H,[DY6W3JMO$/X8TSC Z
MG+'DUZW^T9J$>G>%_#7@:&57N-4NUN[U%.3]EMV$K$CL&F$*\]1N'K7FRKFN
MO#J?LHRJJTFM?Z]3JP=./-*:U2=D"K4BK2JM2JM=)Z@BK4BK2JM2JM,S;&JO
MK4BK3E6I53%,BXQ8ZE5?:G!:<%H)N-"T\+3U2GJE,FY&J4\1U(%IVVF*Y&$I
MVVGXI=M!-QFVEVBG[*=LI@1;?:EV^U2;*7RZ!$6WVHV^U2^71LH AVBC;4NP
MTFR@9%MINWVJ;;2;:07("E-*58Q3=M [E8I3"M6BM,9*15RL5IC1BK#)3&6D
M4566F,M6V6HFCH*N5&6F,M666HV6D4F566HV7\#5EEJ)EI&B9Z'^S'XF33K[
MQ!X*N)%0QS'5],1CC?!*?WZ+Z[)@S'T$R>E>R>*=<N-#MX)8(DD#/M8OG XX
MZ?YXKY$UKR[&.'5O[2;0[O37^T6^JHZHULV,$Y;@J1P5/# X-;EC^T[K_C/2
MH-)UVP;PUI$F5N/&EK8O<+*HQAXK0Y>$G_GHX9!C.,8-<F+H5:]"<</+ED]G
MY_\ !/$J451K\\H\T7T&?%&?2_AEJ[:SX>CDFMK\R75_X3L5WW%LP!9[RV4?
M=B)!\Q3A03N'.0?2/ACJ=[\9EMK3Q_JB_8&C5K/0=/F_T:[3&0;F88,[8Q\@
MQ&?1^M:/PK\#Z+I#1:KX2O;77K"\?=<ZU'=+<RW>1@F63)+''\/0=  .*\^\
M?^#W^"'B2&ZL2T?@;4[D"!E./[%NW;(CSV@D;[I_@8[>A7'=D.95<12^J9BG
M&4792:M?S]/G;]/ELUP/U>K]<P%G?645U7^?X_K]>VEI!I]K#;6L,=M;0H(X
MX84"HB@8"J!P !V%35POPO\ B OBS3_LEXX75;=?G'3S5_OCW]:[6ZNH;&WE
MN+F:.WMXE+R2RL%5%'4DG@"OHJE.5.3C+<YJ-:&(IJI3>C):Y7QE\1M+\&RV
M]DZ3ZGKEVI-GHVGIYMU<8XR%R J ]7<A1W-<XWC;7?B6S6_@55T_0R=LGBR]
MAW)(._V.(X\[_KJV(_3?74>#?A_I'@>.X:R26YU&[8/>ZI?2>==W;_WI)#R?
M91A5'"@#BLS<YF'X>ZM\0)H[[X@RPM8AA)!X4LG+6<7<&Y? -R_3(($8[*WW
MBOQF^$]]\2M/\+)HNM6WAV_\/:Q!J]K+<:>;N%FB5E$9C$D?'S=F[5Z510!\
MY^*_V2[_ ,?:;XPNO$GC47_BKQ"=/3[;#I8BL8(+.?SHK?[*9&+QNQ;S TA+
M XXQ6GX/_9Y\2>%-7\9Z]%XIT2'6_$5I9VJV]EX<6+3K58&;*>1YQ,B.KE3E
M@W)(;H![S10,^:+7]C6%/!\]JVL:;::\/%/_  EEE]BT@#2;*X\H0M MF\C9
MA=-VX;P2SE@00*Z>Z_9ZU/7M TVUU;6]%M+RU\2V&OXT+05L[8):N'%NJ"0N
M=V#^\=V(SP,<5[A10!XSXH_9W/B1_C,W]O\ V?\ X6+9VMI_QY[OL'DVI@W?
M?'FYSNQ\N.G/6L75OV8KVS\57FN^&M8T*&YU73K2QU%/$'A]=1426\?EI<V_
M[U#&^W@JVY3@$CCGZ HH \ZT7X1?V/\ %6U\9#5%<0^&8_#OV%+18@=L_F^<
M"I"KGIL"@#L>U<'8_LQZIX9\.^ 8="\46@USPCK-]J<%U?Z:SV]Q'=&821-&
MLH8$++PP?JO3GCZ!HH X7XG?#-OB0/!Q;4A8-X?\06FNL1!Y@N/)#CROO#;N
MW_>YQCH:XGQ9^S2?%'AGXR:1_P )%]F_X6'*DOG?8MWV#;!'%C'F#S/]7GJO
M7'O7N%% CP37OV:+U/'7B#Q%X:U;0K4^(X[?^THM>\/IJ30S0Q+$)[9C(NQB
MBJ"CAUR,XZYZF;X(B3Q[KOB1=75%U/PG%X8%HMFJB+8\K^?E6 Y\W&P* -O7
MG ]2HH \3TG]FP:;;_!^%O$!E7X?Z;=Z<Q6SVF_$]F+;>/G/E;<;L?/GI[UD
M^%/V9]<T_0_ OA37O%ECJ?@SP9>0W]C:V>EM;W5W+ 2UO]HE:9UPC$-A$7<5
M'0<5]!44 >(:C^S.NI?"/Q_X'D\1R1CQ5K-WJ_VZ*U ^SF:991$T9<^8@*[6
MY7<"1@5SD'[)>IWS>/+C5/$VCV]SXI\)GPJ+?0O#XLK6R7=(1,J"8ES^\.02
M.G! P!])44#/)?$O[/\ :^*]:\ 75_JA>Q\,Z-J.C7%F+?!OH[NVB@9M^_\
M=X$9.,-G=U&.<GX0_L^ZK\,+K0;*36= U#0-!@-O:-#X;B@U*X0+LB%Q<[V!
M*+CYHT0N1ENI!]PHH ****!!1110 4444 %%%% !1110 4444 %%%% !7/\
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M1M4-[%XFFU:[^T/$LC20D6>-BSJ2HW;RO&<9.*ZF/X ^)%_9I^)'P_-SIO\
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MN'NM4DGMO"KMNL-!!*1R1 _)+= ?ZQF^]L/RKD#!(S38(4AC2.-%CC4855&
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MK;P[8^$9->U71]4TSP<UW$T4C6$B22F=HLQ(]QM"G:6 VJ6)YKJ-;^$NL_M
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MRW^R/LB_J6'Y5X'7L?[7UX\_QBT2U)_=VV@>:H]#+<N#_P"B5_*O'*^1Q_\
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MQKFI*TD>+&WP64#ACV0?YZ5S]NNI>(-6GN;V8W^MZI<M<7<__/29SDD>BC@
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MYT^";6=.BF@M+UES)#'+M\Q5/8-L7/\ NBM6B@ HHHH **** "BBB@ HHHH
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M7<P=56=WJ=2UC[56FL?:NB: '/'-4-4FM]+L+F]NI%AM;:)III&Z(B@LS'Z
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M-C\--3NO#^K>&;?PW_8>J6GV1]:O&F;$DL;<QPQ(X4S-SC=MSM&>-;X,>.O
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MBO!?#?A/Q/I?[,WPEL1X+UO^W/A[XETZZUC2Q9%)YXX6D$CV^>)P!(K J3D
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M10 445QOQ*^*VA_"JUTF;65OIGU6]73[*WTZT>YFFG968*$09Z*WY4 =E17
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M?+Y=E(^4#@MFL3X5Z;)9^#;2\GU"^U:[U7%S]LU*027#6_W;6-B !\D(08
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M'_"+?$?_ *'[2O\ PF__ +IKT&B@#S[_ (1;XC_]#]I7_A-__=-'_"+?$?\
MZ'[2O_";_P#NFO0:* //O^$6^(__ $/VE?\ A-__ '31_P (M\1_^A^TK_PF
M_P#[IKT&B@#S[_A%OB/_ -#]I7_A-_\ W31_PBWQ'_Z'[2O_  F__NFO0:*
M//O^$6^(_P#T/VE?^$W_ /=-'_"+?$?_ *'[2O\ PF__ +IKT&B@#S7PGK'B
MO3?BE=>&-?UJPUNU;1EU**6VTTVCQOYYC(/[U]P(QZ5Z54'V&W^V?;/(C^U^
M7Y7G[!OV9SMW=<9YQ4] @HHHH **** "BBB@ KPK]I9@OB[X(DD #QM!R?\
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M ,'QOLOMGBGP4GW[!F,VHZ8OK"QYN(@/^6;?.O\ "6&%'U^6YQ0S"GS0E?\
MKJNA^8XK!5,-*TD>OT50T+7M/\3Z/::KI-Y#J&G72"2&Y@;<CJ?0_H1U!!!J
M_7OGG!7QG^VGXR.M>/\ 0O"<,F;71K<ZG=J#P;B7<D(/N$61O;>/6OL>ZNHK
M&UFN)Y%B@A0R22,<!5 R2?8"OS%UKQ1/X[\3:YXJN0PFUN]DO%5NJ0\) G_
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M'XW+/;0>+PTK5H]&G:<7TNMFNE][[Z'VXDBR*&1@ZGHRG(IU?)EOX/\ BK:
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M**** "BBB@ KR_XR?%+5_!>N>"/"WAJPM;OQ+XNU"6TM9M1W?9;6.&%IIII
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MNXVBSDW-L[@GW]JUM&T.ST&S%M90B-.K-U9SZD]S7=5Q',K4_O(YZ=+X=7^
MS0-#M_#VFQVEOEL?,\C?>=CU8T:QI_VR+S$'[U!Q[CTK2Q2XK"C5E0FIPW1X
MV,P\,=2E2K:J7]7/'?'EOXDL_#.OP>%FA:VULQKK6FS1,_F(K+ON( I!\[8N
MUE_C X^8#/0V7Q$T[1=<DL]4\9:+K.G36$%_;ZE;(+8*9&=3"4W'D;,\\C!W
M5UNJ:1]H;SX/EF') XS[_6N'L]%?PGXFU/Q-X9T[2EU[4(#!?VFI0@6]^ #@
MEP"T,G/WP"&'# \$>C6P\<1%U\*M>L?/^OZ[?,8?%U<MJK"XU_X9=)+S[/\
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M6<$275\$ X'/[J+CMB3%>'C,6IS=6J[=D=&7X2&"IJ"Z?>WU;]16%0,*WF^
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M'YZE;5V5[;/)I=TL?WS&V*_4*E%QAHKVN_P1\K&IS2^XY'4M>DFD9+8^7$.
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M=$OKK5_"EX?$06.PM[*_4MIUP[HL:73;R&7$@9G4)MV,,'@UW#:?(_+0QO\
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MF"#NZ=LYJ/2_&6AZ2WPXL[W5[2TN--\9ZI<W\,TH4VD3M=".67/W$;S8\,V
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M0>P!4 G\:\_URWO?"=XMIXCTN^\-W3G:D>JP&%7/HDG,;GV5C7V_9ZOXAFG
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M!7_(B_\ ;U)_2O0Z\]^!?_(BK_U\R?TKT*O;I? CXG%?QY^H4445J<H4444
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MEA\F:5?^!I\R_G7T$I1CT,:6/FNGW'FW_"2WO (CP.Q4_P"-2+XFNQCY8O\
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M,H\/:TNE36%Y=7DEM]IA6RLGF61=VTC<#A2#C[Q YZUM*VF.W,5W%_NR*_\
M-17&VL_A_P 5Z[-KMIJ]Q;6^E13Z>PO+)D620,"Y# GA2N.1U)Q71[./8BG4
MJ5)J-V6-%^*'B=/%4,&NVMC8V.J1$6$$0+M!*F28Y),X9W0[AC@>60,YKN5\
M47G]V'_OD_XUP=KH%YXLA^SLVDZK8R$203:==Y='4Y4X<*=P]5K(\;ZAXV\
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M*1_V-$=JYX&<\X%1_8/B?_T4.U_\$D7^-=GMI=M5RQ[&?//^9_>SB_L'Q/\
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M;36-2A7$]Q%"(BQ]2BL<?I]!6K_PDEW_ '8O^^3_ (U>^+GA3X=Z#\.M)O\
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M$] 1S7CFJ>*/$NO,3JGBO7;W=]Z,7SV\9^J0[%(]B*SHXUAC6-%"(H"JJC
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MR0QSQJ['DLJR[,]]M<Y\5;@:'XGT?6+F$)I,MK-IT]Y@_P"CL[HREFS\H;!
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M791^$\O$_&%%%%;G+8**** L%%%% 6"BBB@+%/6-+CUW1[[393MBO()+=F]
MZE<_K7Q3)X;_ +2\"V2:E(MM;Z9;W>FZJ\C!/)$8:-W/_?)-?<5?'GQN\$ZD
MOQDG\.;43PKXBE/B"7:_S2[/*2:W*^C3%9">A#D5YN.I\T%+L?3Y!B94:\J<
M?M+^OP;/0OA'XT7QQ\.= U?SA+<RVD:W7RE2EPJ@2*5(R#NSP?45VBS5\_\
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ML[2;-S[OE48RWR!@-I^:KVH?#N#Q-K'A^]A\/7&EZEH:--/=:_>#4H+^[)4
M!"[!H=HD_AC(\SA017<Z+X>L]&L[.".-9Y+5"J74R*TQ+$LYW8X+,23C YZ5
MKK7F3E*H^:;NSZ"EA848J,%9=EH<%?>!3>>,E\6:EX4T#6[B:-K*;0H\06T5
MML'EB*1D)#K("Y; /SG&,"F^![S6+6S\[7K(1>&;_4I[+1KZ*Z:=H'C<H;>6
M20;BI=)%C=N6*D'!*Y]#!KS3XA>$?"MK+I4WB*34+#PB^H-<ZH]E<S[(9-K-
M&ZQJ3L+3;261<YQ_>)HA)T9*=/1HFOAX5*;A)73W/3--GLT80_:+B!P?EW(&
MP?3((_E6U%JUS<6\D5MK:SQY,;?/NVD=1\X(!'I7@'AGQ+J/Q-N+O2!>W6G6
M>GL\9O)('MKW5X4<KYB9'[O'RB3;EPQQ\N:]&A:+PWX1O8=&LXX);.TEDMK>
M->&<(2#CN2>N>37IUH*M'ZQ27JNS/'P=9X6HL%B'_A?==O5'F_AWP]#XQ6XU
M;662*RM;FZ9-.6$16EL8W8*JQ1*%:3Y3EF!^8D\5U8^"W@ZZTB[NET"P\S>&
M5WM8W5LDY'RK@G'3=SP>]>;ZC#>:A\+]'32@TP"J]T+<'?-D;C(W]XEF)-=M
M\ EU'0='U1]5\ZVT^9T%I!.K<R88$A2#Q]T9XKZ)8>,*"EIIT/O/8\M%2OMT
M*6GW@^'>I/IFI6[C09KC=87SL7%F'  ADW<A-V=K9(&[!Q@5U>L:X=-OO[.B
ML-1U"_:/S&AL("S1H<@,S$A5S@XRV3CC-8_Q(L_^$RU33?#2*$?Q!=K;2RS3
MACL\II)L#H,I%(!_M.*[2/1+3X5^'-<DMH[B.V@6?4&M[F5G";8\[%W=$ 3
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MZME8?\"SG]:^>(];\'6.S3['3]/GE8XCL;&V6XE<^BQQJ6)^@KIM(^&7B?Q
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MB<!Y9""0&8$* I)P3C S6$_Q^^'&J7$]S'::Y>2QR-&RPZ-<@2.IP1RH /\
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MT-,U#XD^&O%7B:W;5K2\CU1+'3BJND$431(A"MP&)W,6ZY..PKVRV_=PQCN
M*\"\<>'[WP_\1M LQ!-=:5Y>HW%G):023R1+(T3/&\<:EL*Q)# $8;G&,GS,
MTE5J*I*CJ]?U(]C4I8&G""U27Y?YGK.N:3X<\0>%=0\6^#K;^P_$.C(9Y$5!
M&954%C'*%XD1@".>1U&"*Y:Q;Q7+J^L>)3X=ANK'41";6.VOU-Q]D1,QG85
M+$R2-C=GY@.U2>';?4-0T'4=%TFTOD&KA8;[5;BTDMX;>W!.Y8A(JM)(P) (
M7:,Y)XP?0[B]M-"LH\G%O"HB41*9-H   ^7/;'6N3+O;*@G65GV.S+?;QBI2
M5F<4?'FB+:6DXNV=KI"\-O%$\DY )!S&H+#!!!R.""*ET[Q=I>HWJV2R36MX
MX+);WEN\#R =2H<#=^&35KP+:Z'HUYJ":587:7.H7,MY<74UN079B6QN_NC/
M Z?G3_$FH:'XOTN?3+R66TESNM[B6-HW@F7E)$8CA@<']#P37J\RWZ'TGMJZ
M>L"S//':P2332+%#&I=Y'.%50,DD^@%<YX1UU[77O$.O3Z?<6OAFZM8)AK%Y
MMA"B)7! 1CO*$-D''K[51F\&^./''@:Y^TZK9Z+J%S;M$EC%;">$L."9),YP
MV,X7H&'6NE^)-L_]C^&X;M3_ &?_ &Q9QWW'R;/FV _[/G"']*I>\U'N<&/Q
M:C1E**ORIO[CC_B9\2KW4/ ?B..WT);:RN-+N0DFI7J6\[H8F^=8<$XQR Q4
MGTKT'P+XGM?$6BQ)''-:7EG''%<V5TNR:%M@(R.ZD<AAP:E^-OPC\+V/PI\?
M^,;VUOM3NY-(D6&WC)"V\GEE1(,=@<$YX S7$_#M;J/4/!QG#+>R>'I1>;A\
MWDB6/[*7_.;&>PKMJT8*GS0>Q^?99F^.JXU8;%QC:?,UR]$K6OZGH^I7)15B
M3[S=<5P'BS7_ !(+2WN/#]B9M'75(]+O-5W*9?,.2T=JC@HS#;LWM\H=@,'!
M(WO&FL2Z-H>LZC"56XM[9V@,G"^;C;'GVW%:Q_"/@O3O#^N7'AZU\1WOBW1]
M%,5W9W#7TDEO%/)O9T9 WEM(K9?(X'F X!K3$3>'I0H0T;5V>CA8?7L54Q-3
M5)N,5T26[]64_P#A$[;4O'2:_8Z?J_B30K*".%]*\674D37LK;S*Z*?EC*9C
M ^7:3N'&,U<\-^ ]0\*-XAO-%MM!TFZ\2^:;ZW:S\U;(OE5:V<;3N6,A2#\K
M$ \8Y]!+?C3:\BRZGTWLH]3F=/\  ZZ98V>E0:M??\(Y:W*WL>BMY9@^T#G?
MNV[\;B7V;MNXYQ6-'X<C^%MY=ZCH6FH^@73^9?Z?:Q#S;=O^>L('+)R28NV2
M5[@]]NIN>]5<T44MB"QU"VU6R@O+.>.YM9T#Q31-N5U/0@U,S5Q^H:/>>$;R
M?5= @:YLIG,M_HL>!O)^]-!V63N5Z/[-R>ATG6+/7M.AOK"=;BVE'RNN1@C@
MJ0>00>"#R#2+16O)-0T#7K3Q+HL7VB_MD,%S8[@HOK4G)CR> ZGYD)[Y!X8U
MZ'I/BSPW\3(U;3=21-0B&);.8>7=0_[,D3888.>>GH37&LU9&M>&M(\1!?[4
MTNSU#;]TW4"R%?H2./PKSL7@:6-BX5.HU%QESP=F>KW%YH/P_@.H:UJ]K8K@
MA9+N58A]%!.6/L,GVKS'QEXRNOBJ/[/MH)].\'Y!G:Y0QSZI@Y";#RD'3.?F
M?I@+G.7IO@O0-%N#/8:+8VMQT\Z.!0__ 'UC-:K-66$R^C@XJ%-:('"527/4
M=V-8_@*C8U'>7D%C;O/<S1V\"<M)*P51]2:KV6J6FK0^=974-W#G'F0N'&?3
MCO7I,WL3L:C8TYCBH6:I-$BGJNGV^K63VMRI:)B#E6*LK @JRL.58$ @CD$5
M!=0ZAJDUG)K.O:GKJV1W6L5]*I2)L$;]JJ-SX)&YLD9J\YJ!VK.5.$I*<HIM
M;/L:)#':HF-.8UFW&L0IJ":?!'/J&IR#*:?80M/.WOL4$@>YP/>K*;45=LFN
MKB.UADEF=8XHU+N[=%4#))KU7X#>$Y=-\(2Z[>0F+4O$$HO65QAHX -MO'^"
M?-C^\['O6!X-^!.K^*KJ"\\90QZ7HR,)!H22"2>Y(.0+AU)54SUC0G/0MC(K
MVSQ-J]GX5\/ZAK%^WE6-A ]Q*5'\*C. .Y/0#N2!7'B%SQY$>5B,5&348/1'
M@OQ?UO4M>^+'A/PYI-Y<:;I^BS?VIK&I6T4<C0EHW6*-1("N\J7QD'!=6_AJ
M]<2>(+R1DT[Q5XB=/22&RD/XA;85U7P3^%MSK^G/XD\3(4N-4G;4)[<'EY'_
M (,_W$4*@]=F>]>]6=A;:? L-M!';Q+P$C4*!7TN'R_"86E&%6FIRZWZ>1\3
M6Q6,Q<W*E/DATMN_,^5UTSQXJ_)XF\0*OHNG6V/_ $15>X\*:AJ5Q;W>NS:S
MK&IV1WZ=?3 0OI\A^])$L:*NXCY26#94D=":^MZ3 ]*ZHTL'%W5")BXXQ_\
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MHPOBCQ H]%M[,?\ MM7U;M'H*9)-#"\:221QO(=L:LP!<XS@#N<>E3[# _\
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M-U/J-[>%[N[O7W2SLJ*JDX "@#@*H 'XFO<?#_\ R"X_JW\S7*[1Z5U?A_\
MY!<?U;^9K.IRI6@K+L>EA>;F]]W=M^YHT445S'IA1110 4444 9^O?\ (-D^
MJ_S%<M74Z[_R#9/JO\Q7,;:ZJ7PGGXCXAM%.VT;:V.<;13MM&V@!M%.VT;:
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MJD>N:=XA\/W%O;ZQ91R6YBO49H+J!RK-&^WE2&52K#..>"#2V>A^(-<\3?\
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M8W-K-#;V>FJ65H9&X7=D;SSG>VW! KURUMH;&VBM[:*.WMXE"1Q1*%5%'
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M (S?"&Z^*%QX1U"TU"PM[_PY?/?1VNKV'VVPNF>(QD2P[U)VYW*<Y!KCK?\
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M-M.4;E#*0RD9!!R"/6EV&F S;1MI^PT;#0%AFVC;3]AHV&@+#-M&VG[#1L-
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M;ICWJ3X;_"'Q/\,_L.AZ;XQMV\#6%S)/;:;)I0-Z(G9F%LUP9-OEJ6X(C#X
M&>]+4I\G0YC2_P!JM)OAQJWQ!U7P;?:+X-LP\5O>37T,DU[<BY^SK$D0^Z&<
MX#L0!SGCFMKP3^T1;^*M4U[1I]&BA\0:9I7]L1V6G:O;WL5U"25V+."J)(&
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M!>V,<T9.#<6[X ]RIKBO#6L>*M1_X3&Y,VC2:1H*+=02ZN9-.N[JT96*RM&
MZJ2R$8^7JO /%/A\=^(&\!Z7XKE\'R0Z=J=[#IMOOU. -]JEE\E(W3.Y3YG!
MXR,'TKTHU<'O%RAY:-?B*.*S>BN1N%1>::?X:'=77CNYAN)(HM&O)PIP)!@*
MWN*H7&O>)-47;'#!I49_C9O,DQ].E8/BK7/%G@OQEX?\-:MX=LHI]<D:*UU1
M=3'V ."HV.Q0.K991C;SFF:7;Z_KWQ2UOP7K?B2S\+/9JL5I/HL:W'VNX,:2
M21"2=-NZ-74E @8\\\&HGC,)&#J<TI+RLORU-?K.:5/=2IP??63^YZ?>7KN3
M1_!L+ZIK6I1Q.W#7E]* 2?1<]_8<UF:OXDO&\3:-I6LZ;KGA3POJ4,EQ+KGV
M,M<M$I (2%<R1!LX\QTRH(.T=:Y:^T5/"=CJW@CQS8Z5=ZQ-?HZ>--:N?+EN
M;,.''EB3C=@;=L;#&3D#OVWAG3M0\;:M#'X4O+_Q'-'#]CBUG4YWGL-,M]V2
M%D/^M/ PJEB=H!8"L9XZ52GRTK1@^W7YF5++HJI]9Q$G.?\ -+_VU;+]#!\&
M^$;[7[>Q\$>'-7UR2R6^FNK&UO9#Y&GV8E;R[V5&7>'VDE$9L,Y!V\&OL30_
M#MEX7T'3]'TZ+R;"Q@2W@CSDA%&!D]SQR>YKS[3=#MOAG9MHVC/*9Y")K_4Y
ML&YO9B.7=OIP%'"C@<5T?A?Q'=7%U]DNI#,&!*.WW@1SCWKXFIGN%EB_J5G>
M]K]+_P!:'L2P=65+VRVWMU]3R7XK::OA[XG7$T0VV_B'2VGD7' N;?;&6^K1
M.@_[8BN+^$;X^%OA#/3^RK;_ -%K7??':[6Z^('A^S0[GM-*O;J7'\(=HXTS
M]?GQ_N&O._A,W_%KO"/_ &"K;_T6M?1TG^[1K0NTK^9VOPA\0> O#_@_6K7Q
M9<Z;9:Y]JN'U9-2VB2X#.VQP&Y=&CVA<9&!MZC%<UX)C:W\-6Z>5+!;[Y3:P
MS@B2.W,C&%6!Y!$>W@\@8!Z5K36T,TD<DD$<LD9RCN@)3Z$CC\*>S5YV$P$,
M)5J58N[F[_C?Y_Y'H2DYI)]!S,:S-0^VV6JZ+K6G01W=[I%W]I6UF?8LZLC1
MNF[!VMM8X.,9 J\STQF-=]6G&M"5.HKIJS)5TTT6/''CJ_\ BAJ&@B309M T
MW2+AKUC>31///,89(E51&S (!*Y)+9)QP.:KL],+4PM6>'H4\-#V=/8IWD[L
M<S4SPIX5_P"%D>/KC0KG4KG3=-L;&.[DCLI/*EN6=V4#?U"+LYVX)+#FFLU9
MU]IHN+RWO8+J[TW4;<,L5[83M#,JG&5W#JIP/E.1Q6>,I5*]&5.E+ED^OS_"
M^Q<;1=VKE[Q!X?;P%X^U#PS'J,^J6*V4%_;R73!YH0[R(8F8#YAF/<"><-@Y
MQFHV:J=CIJ6,EQ,9KB[O+E@]Q>7DS333,!@%G;DX' '059+ 5="$Z=*,*DKM
M=2BKJ&FV>IJ@O+2"["'*^?$KX/MD<5#JVDVFM:?)8WD"RVS@#9TVXZ%2/ND'
MD$<C%6Y) JDDX Y.:L^%/"/B/XC6_P!MT9+72O#^2/[>U7<8Y<<$P1*0TH_V
MB54]B:V;LKMV2(J3A35Y]3BK/6+SPW>1:7K4QN+>5O+LM688\P]HINRR>C=&
M]CP=K3[?4?&VN#P]X9*SZD__ !\WH&^#3HSUED(XW==J=6..P)'K?A_]G/P?
MK2R0Z[J^I^,&4!I;>YD^S6AY[0Q!05SV<L?>M"&^T_\ 9KTIK+5E2#P"'Q9Z
MO%#F6T=CA8+D*,R$G"I+R3D*W.&.<*T*T>:BU+TV/-JXQPO!)KU.@AL?#WP<
M\ Q1/,+#1-+APTTOS/(Q.2QQR\CN2<#)9FK@/A[X%OOV@/%R>,/$EF=/\)6+
M-'I^F,!OG/0EV'4GHQ' &8U/+DGA7POJ_P"TQXHBU_6XIM+\!Z?*?L-CNP\[
M#@DD=7/(9AP@RBG<68?3UG9V^FV<%I:01VUK @CBAB4*B*!@* .@KTL'@8T)
M>VJ:S?X?\'\CYBOB'6]R/P_G_P #\_0E1%C14151% 5548  Z #L*6BBO6.0
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K>TG_ (\4^I_G6#6]I/\ QXI]3_.LY[&]'XB[1116!W!1
M110 4444 4M6_P"/%_J/YUP7C3Q5+X/TA+V'1-2U^6298$M-,6/>"V?F=Y'1
M(T&.69@.1ZUWVK?\>3_4?SKPWX[?"?5?B9<>$+O39M,N8]!OI;NXT/7/,^PZ
MB'B**)/+R<H3O7((R.E;0V.6HKRU,N3]JCPTWA[0]1LM$\0:G>:QK$^@0Z19
MVL3W<=]$C,\3@R! ,(?G#%>0<XYI=#^/&MZO\:SX+G\!:QIUBNC6NI27%PUM
MYELTKD,TN)R!&N-IVAFW*WRXP3SO@']F/6O"=UX7N+G5M&SI/C"]\32P:=;2
M10F*>W>(01*?NE2PZ\8%=]J7PYUN/XY+XSTZ73I](U#1DT75+6[>1)XT25G$
MD)4$,2'((;'KFJU,[1Z&3H?[3_A?7=7TV**PU.'0M4U)M(T_Q%,L(L[FZ#,H
M0*)#,JLRE5=HPK$8!Z9Q=>_:,L_%'P_^(&H:7I?B[P_I.@VVHQ3^*X;.U(AG
MM7,<@MTDE/F/D$KE=IQR1S5'X9_LQW7P[U#2=-&E^"M2T+2]0:[AUJZT]VU9
MHM[/'&1P@D0D?O=QX4?+FM^/X!ZFO[/OCWX>'5K,W_B.?5Y8;W8_DPB\F>1
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M*94TZPM/#6E:E<:3;S+=,]Y-- X5W>/;M5"2V,,3Q[T@Y3T6BGT4PL,HI]%
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MAWPTP/D:I?)'<[>OV= 9)1^*(1]":^SO&6H+'+'I=JJP6ENBCRHQA1Q\JX]
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M>F58<@_0U/IUC::3:I:V5O%:VZ9VQ0H%49Y)P.YKD_MWCS_H%>'_ /P-F_\
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M[Q[J<GC6^4AQ8.GDZ9$WM #^\_[:EA[5[?;6T-G;Q6]O%'!;Q+MCBB4*B =
M . *].E1HT-:4+/N]7_DOE]YS3YZO\>?-Y*ZC_G+YV7D>2_#_P#9OT?P[J$&
MM^)KMO&'B.([XIKN():6C?\ 3O;Y*J1_?8LWO7KV*6BM_,71);(3:*-HI:*
M$VBC:*6B@!-HHVBEHH \<_:5U?6M-L?A]9:)KE]X>?6/%]CIEW=:>RK*UO(L
MOF("P(&<#G'! ->)>*]6\9>$O"OQRU:U^(7B6>3X=:E$=%AN+I71XFCAE:*Y
M^7,P/F,N6.0,8YYK["U/0].UHV9U&PMK\V=PMW;?:85D\B9<[9$R/E<9.&'(
MR:IW7@GP]?6NL6USH6FW%OK+!M3BEM(V6^( 4&8$8D.%4?-G@#TI-%QDD?-/
MQ"\7?$'QA\9O&?A_2;R^TNST'1+2\T];'7(=+57E1F:\E$BGSXU8;=I^4;3G
MK1XO\9>.?"FJ>%O&7BW5)]0\+0Z=I<.K1>#M:C3^S+Z20!II(,$7,$V],8.0
MN=HZ5]$^*_ACX0\=RV<OB/POI&NRV8VV[ZA91S-$O]U2P.![=*35/A;X-UO7
M+'6=0\*Z/>ZM8A!:WL]E&TL(3[@5B,C;V].V*-1\R['RY\;/C1K]IJ7B?Q3X
M0U76[6U\/^(['0Y&O=5MXK$R>?"D\$=CMWRAA(3O8AL@D?**N>-M8\8W7A?]
MH#Q9;^/O$&GW7@O7KA-$LK6=%M84BA@DV.FW]XK;R-K' R<=37TAJGP?\":Y
MKL^M:CX-T&_U:XV^=>W.G0R2R%2"I9BN205&">>!6O+X-T">SU>SDT33I+36
M)&EU*!K5"EZ[ *S3+C$A(502V<@#TI68^96V/";CQ9??$#XN>*M%USQ3?>%=
M$T'PQI^K6EGIE[]A-V\\<CS7#R?>9(V14"@X&>>2*YCX1_&77I)_A/J&OZ_>
MW^EW/@#5]:U0G$C7,D$\(68@#YG"%L8ZYKU;XP_"'4_'6HV,NG:3X'U*VMK,
MVUN/$NDM--82$G]["ZGE0-O[L@#*@YKIOAG\(]&^'/@[POHXM[?4[[0M,_LR
M/59K=//:-L&4 XRJ.PR4!QP/2C4+JQ\^?"WXF>*+KXQ?#B#^TM9E\.>-M(U2
M_:UUW6+>^GF6.)98)EAA4"VQG;M!(/3J#7=?LW:Q>:#^Q?H&J:9;?;M1L=$N
MY[>V'/F2H\Q5,?48Q7JOAWX1^!_!^IIJ.A^#]#TC4(V=TN[+3XHI4+C:^UE4
M%<C@XZBMCPYX4T;P?9SVFA:59Z/:S3O=206,"Q(TKG+N54 ;CCDTQ.2>QX+\
M/-2U+3_@[IGQ#7Q_J?BKQ3?^&KK5/[%GO(Y+34;H6[2A(K?&4\MAMVQX.,AL
MUR/P=USXEZY8^"/$%WK#7^E>(M'NI]7&I>(;>Y2]+6K.KV=JJAHFB?@HN<+D
M-R,U]+:#\,/!_A77+K6=&\+:/I6K76[SKZSL8XIGW'+991GD\GU/6DT'X6^#
MO"^N7.M:/X5T?2]7N=PFOK.QCBE?<<MEE&>3R?7O0',CY@^"++'<?LMR-(L:
M+X5U=&D8@*K".+@GU&#Q[5W/[._B3Q%I/CZ\\'>.K_5-4\4W.EMK%OJJ:JM[
MI&J6HGV?:+=  ;=OWB+Y?3 X)YKV2W^%/@RSAL88/"NCPQ6-X^H6B1V4:BWN
M7^_*@ ^5CW(ZU+X5^&GA+P->7EWX=\-:5H=U>8%Q-I]G'"TH!R 2H'&<G'3)
MHU!R3.DVBC:*6BF9B;11M%+10 FT4;12T4 )M%&T4M% ";11M%+10 FT4;12
MT4 )M%&T4M% ";11M%+10 FT5KZ=_P >J_4_SK)K7T__ (]5^I_G42V-J7Q%
MFBBBLCJ"BBB@ HHHH K:A_QZM]1_.LBM?4/^/5OJ/YUD[:UCL<U3<2N*^)GC
MZ3P?96MAI4,=]XHU4M%IMFY^48^_/+Z11@@L>YPHY85O^+O$MGX+\+ZKKU_O
M-GI]NUQ(L8RS8'"K[DX ]R*\";QGI/@Z2[\2^-=7MW\7:LBE[&S)N)8(AS':
M6\2 N57/) ^=MS'MCS\?C/JM/W5>3V7ZG1A</[>>NR.OTF'2_ACX3O[_ %34
M<I'OU#5=7NS\]Q*1EY7]S@!5'0!5'05\D_$OXDZI\9-4:YU+SK3PZC?Z!H;,
M0@3M).O1Y&'.#D*#@<Y-:7Q8^(^N_%"ZB2[TV[T+PO:R"6#3[E"LEQ(/NRW&
M/E&.JQ@D#J23TXS.>>M?!5L3.W+?5[L_9,AR&-.V*Q4=?LI]/-KOV73UV9'"
MD,:QQHL<:\*B  #Z 4[;2T5YI^A60FVC;2T4 )MHVTM% ";:-M+5SPEX;U;X
MD:ZNB>&(UN;HG_2+Y@6MK%.\DK#C/H@Y8\<#)&E.$JDN6*.7$XFCA*;JUI6B
MB;P)X1UCQ]X\TZQT>QM[RTTZ07FH7%Z";6W88,*R 8,A+?/Y8()V#)4'-?2/
MB/P?HN@V*:EXG:^\>:Y/*L%E9W; BYN&^Y#!;+B- >>QPH+,>":ZO0?#'A[X
M(_#_ .S1RF#3K%#-<WDHW2W,K?>D;'+.[8 4>H4#I71?#'P1>W6H_P#"9^)[
M8V^LSQF/3M,D(/\ 95LW\)[>>XP78=.$' )/T6#P,Z\U!:16[_K^K'X;F^:_
M6ZTL1);Z)=E_6OJ3? _X40?"GPG)#)#;KKFI3->ZD]J/W2R,21#%Z11@[%'3
M@G^(UZ+2[:-M?=1BHI16Q\4WS.[$HI=M&VJ)$HIVPG-<]-XIG_X2N/1+30M2
MND4!KK4VC$5I;J1D .Y!E8\?+&&Q_$5H"QOUS\/C2VO/%4F@VECJ-S+ #]JO
M5M66UMSMR%,C8#,>.$W>^*7_ (1 S>*_[<NM9U*X$0Q:Z:L_E6D&4VLQ1,>8
MQY.9"P&> , UT&WWH'H<]9^&]07Q1<:O>^(;VZM\%+72HE6&UA4@9+ ?-*_!
M^9FP,\**W^@P!@=:=MHVT"$HI=M&V@!**7;1MH 2BEVT;: $HI=M&V@!**7;
M1MH 2BEVU2UK6M.\.:=+?ZK?6^G64>-]Q<R!$&>@R>Y]* +E8FL>,]&T+5M/
MTJ[O5&J:@VVVL8E,DSC."^Q02J#NYPH]:B\0V_B34+[3X=$O+'3=,;]Y>7LT
M9FN" 1B.*/A1N'5V)QV7O6XME MX]TL$:W+H(VF"#>4!)"ENI +'CW- [&'<
M:'K%YXLAOI->DM]$M5!BTJSA"&:3!#-/*22ZC/RHNT=VW<8Z"EVT;:!"44NV
MC;0 E9VO>'=*\5:;)IVM:;:ZM82?>MKR%94/O@C@^XYK2VT;:!GS=XX_8M\.
MW2RW?A#6+OPI( 6^Q2J;VQ]<"-B)$_X ^!_=-?/$WP9^)FC^&['6-3\(W%Y9
MW4(N=^D9FDA1AN42P'$B,%(R,'G-?>_B[7K[19-$MM-M!=W>I:C':G>K%(8L
M%I9&(Z;44X]R*Z+'.0:\K$99A<1K*-GW6A]/@>(\RP%E"IS1726J_P _Q/S,
MT7QQ=:==/;6>I/%<0G]Y93Y62/V:)P&7\0*WK;Q5837PO+K36L=1SDZEH\S6
ML^?4E""3]2:^\O%_PX\+>/[80>)/#^G:TB_<:\ME=T]T?&Y3[J0:\;\1?L2^
M$;UGD\/ZSK7AIR<K"LPO(%]@LP+8_P"!5QQP>/PBMAJUX_RRU7ZK\CU*N:9)
MFCYLRP?+/^>&C^]6?WMGFOAWXT>)--V+8>,X=5B''V/Q1:!VQZ">,HX/N^_Z
M5Z!I_P"T%K$*J=6\%M.AZW&A:BEPF/7;((V/T ->=>(/V//B%H^6TK4-#\2P
MC)VLTEC-CL,$.C'\5%<'J'P[^)/@UBUYX,\162CEIK",7D8]RUNSX'UQ4RKU
MEIBL+?S@_P!-?T.=Y/EU;7+\QY?[M5?^W>[^I]+1_M$^#Y/^/U]6T5NXU#2Y
MU ^I16'XYK7TSXF>%?$DGEZ7XGTJ^E[PPWL9E'U3.X?B*^/(/BW?Z6QCN=0$
M94[634(3&1['<!6C_P )_IOB*,+J&AZ5K$8_V4E'Z@BN*K_9M96=2=-_WHW_
M "#^P\\I:TJ=.LN\)V_]*M^9[AJ5G#\:]7U[1-8U>&QTG3;IK,:+ L1O9L*#
MY\CR!FC1L_)Y84X&=QZ":']FOPW;V\<-KJWB2W6-0J8U:23 '08?(_.O"H1\
M.V8M-X'TR)F&#MTV!A_(5J63>"+<?Z&]]HQ[?8;R[M0/PB<"M(8+#M)8?&Q2
M[/W3AG'-L.W[;+ZO_;JYOR/9K?\ 9HTUV'F>+O$SQYYC\^W7/MN$(8?@:ZO2
M?@[X;\"0?;M!T-+O601_Q,=0=KNZ7W5Y"2#],5X59^)4LUQ8?$7Q#9+V5K\2
MC_R-&Q_6M6#X@ZY /W7Q0N6'_3>*U<_^@"NF66U:M-P6)AKU4E<X)8ZM&2=7
M#5=.CA(]E^QZ[J$V2MVSD\LQ*BN[T*SNK+34BO)O.FR3G.<#TSWKYF_X65XD
M/_-36_"UMO\ XFJUQ\0]:F/[[XIZDOM:"UC_ /:1KS\OX<C@)NJ\0I-]YJQ6
M(S.KB8J$<-/3M3E_D?5=]8V^I6LEK=V\5Y;/]^"XC$B-]5((-<1-\+? &@R2
M:BWA?0;(I\[7$UK$J)[_ ##:*^=[[Q/;7B_\3'QYXDU!.X_M.6+_ -$*E<G?
M:]\,K6Z$MY;V^HW0^Z^H,;J7\#,S-FO9EA:.TL3!>CN80CCY:PP55^;@TOO9
M[C\8/C#X2N?"-YI&C>,M,DU&0QQ_9].G>5I(0X\R%7@5_++(&7=VSVZC@+/]
MH+Q2EC:Z;X-^%*VUA OE1M?7AM8(5'0JOEY8?D:Q=)^(B:DWV;POX3U7567A
M8]-T^1P/P1"*Z_3O _QE\48-EX*MM"B8?+/KE]'"/^^$,D@_%!41R_ /XIRG
MZ1:_%V1JY9C'>E"G_BJ1?_DL;R(8_&WQ=U6,>?JOAWP_GJ+#3WG=?^!2R,I_
M[Y%9&LZ;<W6I6VK>*?'>K75]:Q/%'+%/'88C?&]<0*A*G X)(XS7I.D_LH^,
MM:P_BGXA+81GK:^'[3!'J/-D//U"BN]\-_LD_#709$GN]'F\37:G=YWB"X:[
M4G_KD<1G\4->A1P^'H_P:&O>3_2.GXG+6=2KI6Q&G:G&W_D\_>7W,^4/!_B+
MPSXFOYX/"OA#4/%.OVLK1R);VQO7C8$X8W#EE ;J#N'Z&O9=!^!OQ1\:%9-6
MO-.\ Z<W6-!]NOROI@$1H?<L<?W37TS?:7/9^'[BT\/?8]+NUA*6FZ#_ $>-
M@/E#(N/ESV';I1X:OM0U31+6XU73#H^I,I%Q9^:LJHX."5=?O*<9!.#@C(!X
MKN=2K)<KE9=EHOPU_$X(T<-3?-"FG+O+WW^/N_=%,\X\%?LQ>!?"-W'J%U93
M^*=93D:EXAE%TZGU2/ C3_@*"O6?3T' I=M&VHC%15DC:<Y5'>;NQ**7;1MJ
MC,2BEVT;: $HI=M&V@!**7;1MH 2BEVT;: $HI'=(\;Y%3/3<P%-^T0_\]XO
M^^Q_C0 ^BF?:(?\ GO%_WV/\:/M$/_/>+_OL?XT /HIGVB'_ )[Q?]]C_&C[
M1#_SWB_[['^- #Z*9]HA_P">\7_?8_QH^T0_\]XO^^Q_C0 ^BF?:(?\ GO%_
MWV/\:/M$/_/>+_OL?XT /HIGVB'_ )[Q?]]C_&C[1#_SWB_[['^- #Z*9]HA
M_P">\7_?8_QH^T0_\]XO^^Q_C0 ^BF?:(?\ GO%_WV/\:/M$/_/>+_OL?XT
M/HIGVB'_ )[Q?]]C_&C[1#_SWB_[['^- #Z*9]HA_P">\7_?8_QH^T0_\]XO
M^^Q_C0 ^BF?:(?\ GO%_WV/\:/M$/_/>+_OL?XT /HIGVB'_ )[Q?]]C_&C[
M1#_SWB_[['^- #Z*9]HA_P">\7_?8_QH^T0_\]XO^^Q_C0 ^BF?:(?\ GO%_
MWV/\:/M$/_/>+_OL?XT /HIGVB'_ )[Q?]]C_&C[1#_SWB_[['^- #ZU]/\
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MC.,L<<^E8&HZYJ\?B6TTNP\/7%W:G:]UJLTR16\*$\A.2TC_ .R !SUJ75?
MNBZYXBL]:U*U:_N[(+]ECN)6>"!@21(L6=GF<_?()&!@BM^BX'-7G@6QU+Q1
M;Z[>S7MY<6N#:6LERPM;9P"#(L0PI<Y/S-D^F*Z'8:DHH CV&C8:DHHN!'L-
M&PU)11<"/8:-AJ2BBX$>PT;#4E%%P(]AHV&I**+@1[#1L-2447 CV&C8:I>(
MM6DT'2)[U-.O=5EC V66GQAYI6)P H) '7DL0 .20*RKKP^?'WA."T\5:<;
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M\>?#KEY[2ZY=*#]0CK7N]%6L+AX[4U]R,Y9ICI_%7F_^WG_F>26/[*?PHL5
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MTZO/OA?_ ,C+\2/^QA_]L[:@#T&BBB@ HHHH **** (+S_CW;\*SMIK2N_\
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MG8%'.21BMKXA?%KQ-X=\3?$B^@M+/1]4TOX;0:W$C6D4D]M=EY2R-+MRZJ5
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MH 9+RAJ#8*L2?=-0U2,Y;C=@HV"G44Q#=@HV"G44 -V"C8*=10 W8*-@IU%
M#=@HV"G44 -V"C8*=10 W8*\:^*FGZG'\0H+UYB=&?3!#%#YG G$I+-M[?*1
MS7L]>.?%"UUJ;X@PL3_Q(O[+41!F4#[1YIW8'7.W;[5C6NX,[,(TJR;.:I.!
M3VMI8OO(1^M,X[UYEG'<^DYHR6CN<E\7D%]\+?%4?WWBTZ6ZCXS^\B7S4_\
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M"&\R-T$?R.IR/NFO6PRYN3WM5T\O^&..IIS::'>>"?'7@'P3H!TL^-](NO\
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M_P"'[W5_B#?:OJ+:B\<UA;27US8R6Z;<,?*AD18HVXV1%=R*.3D[5]IT_P"
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M7GWPO_Y&7XD?]C#_ .V=M7H->??"_P#Y&7XD?]C#_P"V=M0!Z#1110 4444
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M1UCW;(U3<=QV@#)]3[UOFU*GF\J;J>ZHWT76_P#D89/B*N41J*'O.5M^EO\
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M8_&#6?%EC8Z)JNCIH,UO'OU:'R)+E)H_,201'YD4CD!P#@@X% 'IE>??"_\
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MN TP57^T74DW3.,;V..O:O/I_P!I;6+6(R3:5HT48P"SHX R<#^/U('XT_\
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MJ_B:_P#!=_X9U"6PBT]+K5O$;:I<SH':1TVAF18U;!4[MQRWRBO4_"?@S0?
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MV_NQS+\I/^R<$^E>VQSR0MN1BI]CBF:U:Z=XJTNXTW6K&.]L[A=DB2+D,/\
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MY&WK716/[+-G#X/FLK?QCJD^J7'BY?&\>MSPPO(M[M08V!0AC(4_+C^+KP*
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M9AQVXP,^I]<5]R5IBOBB[6NBN$FUAJ]+VWM%"HTG:W2/WZA1117$?<A1110
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MQ)I'AO\ :"MY-7U6QTJ.7PNRQM>W*0AR+M<@;B,_A77_ /"TO!?_ $-^@_\
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M%8-CR]UU<V (5[A0& PK!B%).1Q]%_\ "TO!?_0WZ#_X,X/_ (JC_A:7@O\
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MP+(5!Z@;@<52_P"$&\-_]"_I?_@%'_\ $UN44 8?_"#>&_\ H7]+_P# */\
M^)H_X0;PW_T+^E_^ 4?_ ,36Y10!A_\ "#>&_P#H7]+_ / */_XFC_A!O#?_
M $+^E_\ @%'_ /$UN44 8?\ P@WAO_H7]+_\ H__ (FC_A!O#?\ T+^E_P#@
M%'_\36Y10!A_\(-X;_Z%_2__  "C_P#B:/\ A!O#?_0OZ7_X!1__ !-;E% &
M'_P@WAO_ *%_2_\ P"C_ /B:/^$&\-_]"_I?_@%'_P#$UN44 8?_  @WAO\
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M_H7]+_\  */_ .)H_P"$&\-_]"_I?_@%'_\ $UN44 8?_"#>&_\ H7]+_P#
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MT/)P!CK5/X:_%+0?BMI-Y?:(]RC6-T]C>V5];/;W-I.N"T<L; %3@@^A!!%
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M%XPL/#BPZSIMWJ33+IMQJFE36MO?M%GS%AD=0&( )P<$@9&: /4**\-_8O\
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M1D$$'TQ3]'\2Z3XAM[>?2]3L]1AN(1<0O:SK()(B<!UP>5R",].* /E7Q%\
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MF!7D5] PS)<0I+&P>-U#*R]"",@TVZNH;&VEN+F:.WMXE+R2RL%1% R22>
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MX+\0/J%M=>,+.9KV2[.Z[MH94V6\39_BBA$2[>Q4CB@"SX[_ &C/$GPE\,^
M=)UY_#?_  EOBF1A%J$SW"Z=9VT<*R--,,&1W.=H5< LPY S7/W?[9VM1?#_
M %+4(]*TR2\TGQ!!I&H^(8(;J?1X;26,R+J 0 2F,8\MES\K<EL<UZ5JW[/N
MLZ_H?@RXOO&FSQQX1G:33/$5KI:)&8VC$3PS6Y<B163@_,#GD8(K<'PW\=IX
M=:(?$II==DO6NI;B?1(&L7B,>S[-]G!#",?>SYF[=DDD'% $]E\3+O\ X43>
M^.#=Z%KMU;:7<Z@EQH4[R6%SY:NRE&;Y@"%&1R0<C)QFO,K#]HCQ_H?ASX;^
M,O%V@^'XO"?C"[L;"2WTJ>=[S39+O"P2,[?)(I=E#* I7=U;%=&GP;A^#W[,
M?C;POIUQ+K%Q/8:K>RR+;B(2W$ZR.PCA3A%RV%1>E<G\(?V?]=\4_#OX4GQA
MXSO-3\-Z%;V&K6WAV338[>7[5'&K0K<3 Y=8FP0-JDE1N)Q0!#:?M2>-+7PO
M\0O'VKZ%H-MX \':IJVEO#!<3-J=_):S-##L!'EQAGV [B>I( J'P;^U?XI\
M1ZY;:#%;^%O$&LZSI%U>:8N@O=&*SO(HO,2UNVD495_NB5=O*GY>E>G:/^S?
MH=M\+_''@75;VXU;2?%FJZEJ=T^T0R0F\G:8JA!/*%AM;K\H-:/PZ^&OB_PG
MJ%BVO?$*;Q)INGVAM;>R32H;0R\*!+<.I8R. ,#;L'))!H XC0?VJHO$_@_X
M;ZMI^G1_;/$%M<ZCK-M(6SI=I9QDWK$#G<LNR)0V,E^>E</\/OVW+[Q;JG@R
M^GM=!GT3Q5J45A%H^F27$FK:9',Q6"><E?*=<[=X7;L#@Y;!%>N?#O\ 9F\-
M?#SQG\0=?AEFOT\7.P:PN!^YL89"SSPP@'A997>1NF21Z"J_PW^ WB'X:+H>
MBV'Q#NY?!&B2EK+2&TR'[281N\NVENB3NB3( PBM@ ;N* T/,_\ AJ;XD_\
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MQ)I=A!K?C[XJ>.-0T[3QJ$ABAABM7EB02LH+>7#!:LP4<DL<<FOHOP+\+(/
M_CCQ[XDCU"2[D\67MO>26[QA5MC% L(52#\P(7//K7C^A_LSZC)_PD&@R7<^
M@+H7BQ_%/@WQ-:".1H3<AGFA>$GYE5FF1@V-RR#!ZT 'C+]I[Q7\+=(^)^F^
M*=#TF?Q=X3\/#Q+82Z;)*+'4[4L4^ZY+QLCC:PR0<@@UZW\.]:\=W7A:^U?Q
MM9Z!93R1"ZLK/199I?*C,>XI,\@ 9P>,H *\_P!>_93;QQH/Q$_X2KQ=/JOB
MCQGI"Z'+J\%BL$5A:*25B@@W' W$L2S$L<=,5[5>67V/PM/:(3+Y-DT0..6P
MF.E 'S-H7[4?Q#C^"_@WXNZ_X=\.Q^#=8>T%[I^GSSM?6L,\@B%P';Y"%9@Q
MCQD+GYB>*['4OC5X]\6>(?'D7P\T30;G2/!<WV.Y?6YYEFU.Z6(2R10>7\L0
M4,%WONRW\('->:?LX?L]^(O'7[-GPKTGQ7XOO4\(6]K::A/X7?3$@N&>)O,2
MWDGSN\I7"G;L#$#!8BO7->_9YU:/Q)XPU#P9XYN/"%EXOVOK%D-/CN\3"/RV
MGMF9AY,C( #D.N1NQF@#@?$'[8]W>-\/+O1H]%\+>'_%FB+JD.L^,!.+5KHR
M;/[/\V+Y8I!@G>^0<C"FNED_:)UH_M#3^ +F3PWX<LXIK9;2+6S<)<ZW#)&'
MDFLIA^Z)4DJ(R"Q*\E015_Q=^S'-J7PYMOAYX=\5#1/ BZ/'HLND7FE17Q$:
M[@9HI&*LDS!N6;>,@$ $4>*OV9KSQ<V@Z1?>,I+CP5HM[97UGI<VF1->PFU"
M>7&EX""J$H"QV%SDC=@T!H>">)]:-]9^&9O"'A;3-,U.W^,UW;):&YE6"[N5
M1U-Q,YW,I;[S!1_#@#FNG_:1^*GB>X^#_P <?ASXXL-*AUZT\&R:W9W^AM)]
MFNK5V,3 I)ED=' '4@ALC%>H7?[*R#23'I_BJXL]6A\97'C2SO9+))8XKB4G
M,+Q;AO0 D?>4U+JG[+T?C32?B WC+Q+-K?B'QCI']AS:C;6BVT5C9C)6.WAW
M-@;V+DLQ+$#IB@!N@?'X^&/''BGPEXLM+?2]/T7PS;^)-+U"-F_TVQ6+%P6!
M_CCD4@A>Q4]Z7XD?$#7IOV2=2\6ZKH^GVFLWNDK<2:-=1&XM\3$!8)%)!)*N
MJM[DUY]\8OA=9?%+XB_"+P+=ZA<:QXF\/,9?$6I65F]K"^E"-6>&;&5VSND*
MA Q_B..*^COB7\/;'XG^"[[PW?W%Q9VUR8W$]H5$D;1R+(A&X%3AE'!!!'%3
M)75BHOE:9XY?>(/&]G\5+[P5X9UG3?#OA31/"5MJ$P_LY)&LI,NB1PC(!4K$
M?OYVA>!SD=?X3^(_C#Q)^S'8>-;'2(-5\:76A"^@TZ,%([B<IE0 3T/!VY[X
MS740_"?2%USQ-K%Q/>7=]XBTZ#2[YI)%5?)B1U&P*HVD^8Y//4\8I;'X9QZ/
M\.-.\(:5K^L:9#IL,4%IJ5O)$+J-8\; ?W>QA@!2"F".O/-5*[C)/=_YRO\
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MHV<C.:\E\._%3X@^,O"/P"\-0:GJVKV_B*VU:[O;F'73IUYJC6\K+%#]MP7
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MC;7OAK\<]*T:R\7^(]9L/$7@;4M4NK?6=0>Z"WD#0^7-"#Q$?WC J@"]..*
ML?5M%?'>G?%77I?V8?V<M5/BBZ;7->UC0X+ZZ-V?/O5<GST<YRX/\0_.N8U2
MZ\4WGP.^,_Q';X@^+8M=\*^+=;&D00:H\=I!#;7I5(6A'RRQE?EVONP.!B@+
M'W717QAXH\5?$'XJ?';Q;X=M1J_]FZ%HFFW%C::+XG&A'=<P>9)>-A"9PKDH
M V479RI)->B>-OB#\1?A_P#L4WWBC4KO3[CXA6.BYGU*Q9;BV$FX)]J!4;6
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M'C&X^!/PZ\>?\+)\7KX@UOQX/#URW]ILT"V,VJ3VC1K"P*;E105=@64XP<
M 'Z!USWAOQUIOBK6O$6EV4=ZESH5TMI=M=6<D,;.R!P8G8 2+@CYE)&>*\=^
M"$FJ>%/VA?BCX$;Q#K.N^']/T[2M3L5UR^>]FMI)Q.)565R6V'RU(4G P<=:
M\K^+WQ+\7Z=X _:;GL/$VIV-WHOB32+32KB&X(>PCD:R#K%_=!\Q\CH=Q]:
M/M>N(^*/Q2M?A>OA,W5C-??\)#XAL_#T7DN%\F2X+!9&SU4;>0.>:^>?B;J_
MB?\ 9Y^*!C\/>)?$/B9=3\%ZUJDMAKU^U[&;RT6-HYHD;B/.]LHF%(&,"N9\
M9>'8$\&_LW>*9/'FN>)]3UWQGX?N[G^T-5:>VO)) TCR1P$[8@C$@"(* #@Y
MH ^XZ*^2X_B=K=O\%_VG]0N?$MS%J&@^(]9M=,N);K;)8QK;0F!(B3\@#,2H
M'<\5#\.[K6OC=\2=8T+Q+XSU[1-.T#PIHMS8VND:K)82W$MS;EYKZ5T(:7#*
M% 8E00V0<T ?75%?(7Q.U[QGK7QT\,_#G2-0UC7] M?"*:LDUAXC71KC5[@S
M-$TK7,:9DV*JL43:,R9.1@5E>(M-^,__  K?POJ.K:A<^(X- DU0ZOH_ASQ4
M+/4KRS#@6MQ]JB""66%0RNAVJS<X)XH ^TJ*^:/V@?BE-<?L/W/CCP7KNJZ6
M;NPTJXLM6DD\N]CCENK92SM_?*LP;L<GM6=XXFU7X/\ Q=\!V'AWQIKNNV?B
MC3-6&IV.JZH][Q!;"6*^BW$^3M8X/E[4.Y0 ,4 ?5%8GCCQ1%X'\%>(/$<\#
MW4.CZ?<:@\$9 :18HVD*@GH2%Q^-?%VCZIXJ\+_LT_#GQG)\0_%%QK7CS4-)
MT;5]:U+43+#I-I/,V^>")OW<3@!8_,()^;.<UTOQ4FU/X:^*O'/@'3/$FL^)
M?#FL?#;5]5NK+6K][^;39XXV1)5ED)<)*&(V$XRA(QTH ^AO"?QJT;Q0OA&/
M[+J%G=^(_#Z>(H5:UD>"& HC%))P-@<>8/ESDX) J+X*_%R?XS:%-K\/AF\T
M3P_*[?V9?7EQ"YOXP[H9!&C%H^4SANH8&O _ NL:IJ&J_![PFNL:A::!J'P=
M:>>UL[EH@9E2T5905/#JK, W49->;^%M4\2?#_\ 9A^"6F>%]3UG;XUUL6.H
MS-K!MVAB7SV$%O.X86OFL@7<HSD\<F@#]"J*^'/B'??%?P#\,?&]K<:YJ'AR
MPDUSP[!H[CQ&-5U73OM%]%%=1O.5#&-E92@DW?><9(XKO/B)IZ^'?%&A?"W0
MM6\?^)M:DM+K7[AY/&#6&(2RQ[Y;L@R$*P)6*,;1DDC% 'TY?:M9:6ULMY=P
M6C74RV\ FD"&60YPBY/S,<'@<\&LG3?'.G:KXTUGPO#'>KJ6DP07%P\MI(EN
MRR[MGERD;'/RG(4DCC-?#4=QJGQ>^&7[.VJ>)?$&L3:BOC^;19+RUU-E9HX_
MMJ)*9$P&EQ&JB8 $@G^]7I_C_P")WBOX8^(?CX-'U2^U%?"O@_2[C2X;^5KE
M;>4I,KW!#?>;"AV)^]LYH"Q];T5\HO-JGPI\6? Z]T/QYKWBP^,[P6&K66KZ
MDU[#?0O:O,UW$C<0F-E4_N]J;6P1TKS+PGJWB[3?V6_AE\79?B#XLU'Q5/K-
ME!<17>J.]E/;RZ@;=X9(/N.-A^\P+Y_BX& +'WW7-_$CQYIWPO\  .O^+=7$
MATS1;*6^N%A&7*(I8A1ZG&/QKRW]HKQ'JI\>?"KP5!K=YX9T/Q1J=Q#J.I:?
M-Y%Q((H&DCM8YAS&9&'5<,0I (S7@7QTN-3M? /[3?P[;Q)K&O\ AGPYX=M=
M6L;J\OWFN;2:6.4R6<LY.Z6,^6K;')(#$$X(H ^S?AWXHU7QCX7M]5UCPW<>
M%KJ?YEL+FZBN'\L@%7W1DKR#TZ@@UTU?/_QB^W_"_P#8W\2SZ!KFK0ZE9:()
M[;4[B]>:[B=MIR)6.>,X'H.*X#_A#=:C^.W@CP@_Q&\;2Z%XF\+3ZGJD?]M2
M++)=0F/:\4@^: 'S#E8BH.T<8H ^OZ*^!?\ A;7Q$F^'/P_\)6^LZGJ1U#QU
MJWARZU=M3%G?7%M:-(8(&O"IV22;0N\#<VW .3FNYE\*?&RX\'>,-!LM6^PK
M#JVGW.DZ7>>+3<:G)!M+7=@U^JB2/?A6C8Y8!B"V.0!8^P:*^.X/C18^)/AQ
MX0\'Z;;>/H/%>J>(K[23HTOB%8;Y)[-3)<V\VHL6;R55EPR'>P  /7/#Z%X\
M\=:II5IX2G\7ZWI36WQ67P[]KMM6^V7D=BUL)&MFNBO[[#%@&8$C(_NB@+'W
MY2$X!-?%GCCQ]XK^ >H?'O2=!\1ZQJ]IHOAS3=8TV3Q!=OJ$FG33R2QS2*\F
M6,:JH?820-A]376S6;_#WXR_ FTTGQQXBUO_ (20WQU4:EKLUW'?QI8M(DGD
MLYC0;\$%%4=J /H;P+XXT[XA: -8TN.]BM#/-;[;^TDMI=T<C(WR2 -C*G!Q
M@C!%9'Q2^*=K\+5\)&ZL)K[_ (2+Q#9^'HO)<+Y,EP6"R-GJHV\@<\U\P>%_
MBIJWB;X6^!?#-Y?^*==\7>)O$.N?9(]+UL::\]O9W$F])KMLLD:H\>%CPQV@
M#@$5R]AXMU_Q%X-\':=X@O[C49?#_P =+'2[>6[O_M\L<",Q6)[G ,Q0L5WD
M9/>@+'W_ $5X#^T%KFL:A\7_ (2^ 8M;OO#7AOQ)+J$VI7VFW)M;BX:WB1H;
M1)EPR;R[,=I#$1X!ZUPGQVU#Q+\.9OAUX"\*>*-<US3O$?B*ZM[ZZN=>$-["
ML=N)8]/6^96>/>V<%LR$#:&YH ^@OC#\4K;X/^#?^$AN[&;48?MMK9>3 X5M
MT\RQ!LGL"^?PH\'_ !0MO&'C[QOX6AL9K>?PM-;0S7$C@K.9HO,!4#D8''-?
M*'Q.L?'FC_!KQIIWBR4G1;?Q/H4FCVUYK@U:_LU:YB,T4\^T,5W;63?EMKX)
M.!75:AHWBC7O&W[2^F^#=9CT'Q/<7FBBSNI;@V^[]PI:(2#F,R*&0.HRI;(Y
M% 'UY17B7[+?C-->T/Q+H=S8^(=(\0^']3^RZKI?B+53JDEK(T:.HBN2S&2)
ME(9<DD;C[5[;0(**** "BBB@ HHHH **** .,^,WA&^\??";Q?X;TUHUU#5=
M+N+.W:9MJ!W0JN3V&37._"?]G?P9\.+30=1@\+Z9:^*++3X[:2^A0MLD,:K*
M8\\)N(.2H&<\UZ?>WD&G6<]W<R+#;01M++(W1%49)/L *\^\%_M">!/'^L3:
M5I&KS'4([,Z@MO>V%Q:-/; @&:+S8U\U 2/F3(Y'K0 R/]FWX7Q:TVK+X'T<
M7YNUOQ+Y'"7"OO$J+]U'W $E0"3US6[/\)_"-QXTG\6OH5M_PD5Q;FTGOEW*
MTT14IM< [6^4D9() -<?X:_:P^%OB_4-!M=*\2M<C77$6G71L+F.UN)2,B(3
MM&(_,X/R%MW;%<I^TE^TMX9\,_"WXGV.A^(KF#Q1H^DW<*WUA9SR0V5]Y+&.
M-KE4,22[MORLV02,B@>I[ GPO\)Q^&]!\/KX?L1HN@RP3:78B(>59O#_ *EH
MQ_"4[>E9.J? 7X>ZWXJ;Q)?>$M-N=9>9+F2X>+B65,;)'3.UW7 PS D>M87C
M+QIJ/A_]GG3_ !$GB>R\-ZC]@L))-:U:R>\A1I/*#%XD(9BQ8CCH6S5_QE^T
M=X \!>(M0\/ZOK,W]N:?;1WESI]EIUS=S) X8K+MBC8E?E.2.G&<9% ')?'3
MX5ZGXR\76^IP?#7PCXWBCL?L]O=:I?26=W;R;F)64A&$L!RIV=00W!R,:OPW
M_9MT#0O@7X4^'WB^RL/$YT>/S&F\HHBW)=G9X3PR8+D @@X%;^J_M!> =)\/
M^'=9;7EO;3Q$GF:1'IMM-=W%\H&YC'#$C2$*/O?+\O?%9NL?M2?#+0=&T+4[
MWQ(8[?7#<KIT:6-P\\[VY431B)8RX=2R@H5#9/2@#I-/^#?@C2]#TS1[7PQI
MT6FZ;J*:O:0"'(BO4.Y;C)Y,@)SN))K5NO GAZ^UV]UFYT:SN-4O;$:9<W4L
M(9YK4,6$+9ZIEB<'UKB=:_:=^'/A^:**^UR>*1K.'4+A5TVZ?[#;R@-')=;8
MS]F!!S^]VD=ZU_''QQ\&_#R.P?5]2G<7ULUY --L;B^+6ZXW3$0(^(QN'S'C
MF@1-X'^"7@7X:ZA)?^&?#-CI%X\7V?SH5)9(LY\M"Q.Q,@?*N!P.*KV/P#^'
MNFP:A!;>%-/CMM0OHM3N+?:3$US'(98Y0A.U6$C%OE Y.:K:U^T/X!T.QT&[
M;6GU&+7+1M0T]=)LI[Z2:V4+NGV0H[+&NY<LP !..M/\8?M!>!? UW:6FJ:O
M*;RYLAJ2VME87%W+':GI/*D4;-''_M. .#Z&@9:\6_ OP!X[UX:UK_A33M3U
M38L3W$T?,J*<JL@! D /0."!7._M'?""Y^,'A7PGHEG;V,UEI_BC2]3O;6\X
MBDLX)MTT>W!!RF0%Z&M77/VB/ .@S:3&^M2:@VJ62ZG;?V393WX-HS!5N&,"
M.$C)(&YL"H/C]\>-+^ O@.+Q)?6-SJ8N+F&U@M[:-SN:1U7<S*K;0 2>>N,#
MDB@#>\%?![P7\._[1/AWPY9::^H@)=R(A=YU P$9F))4 D!<X'I57PA\"_ '
M@'7/[8\/^%-.TO4@C1QSPQG,*L<LL0)(C!/4( #7D7C3]H2RT/X__#VX?6M1
MMO!VJ^'=1F.G_8;CS+JX2:-4Q;>7YK.!OP-O3)Z5Z=!^T;\.[CP"OC)/$<?]
MA->'3@S6\HN#=AMOV;[.4\WSL_\ +/9N]J .<^+7P;EN? _B+POX \-Z38CQ
MM.Z:[?S3>6ENLF!+<"+:PDD*EL ;?FP2:]%7X9^&3X?\,Z+-H]K<Z=X;DMI]
M*AFC#"TEMTV0R)Z,HS@^])X!^)WASXFV=Y<>'[]KHV,_V:\MIX)+>XM9< [)
M89%5T)!!&X#(.17/VO[1'@6^U/5K*VU.[N#I8NOM-U#IET]KNM@3<(DXC\N1
MDP<JC$Y&,9H ZEO 'AQK[Q%>G1K0W?B*&.WU>;RQNOHTC:-$E/\ $ C,H]B:
MP]?^!'@#Q/I>BZ=J7A73Y[31;<6FG*J&-K6$*%\I&4A@F !MSCBKT?Q9\)S>
M%?#WB2+68IM%\02V\&EW42.XNGG_ -4J@#//N. "3C!KC="_:V^%7B6[T6'3
MO$YN(]9G%I97GV"Y6UDG)($)G:,1K(2,!68'IQS0!W=C\-?"NER>'Y+/P_86
MK^'XY(=*,, 7[$CKM<1X^[N Y]:LQ>"- AU/6]131[/[;K:1Q:G,8@3>(BE$
M63/W@%)&#V->-WO[4FC^(O$WQ0\$Z=;ZE8:MX=L"+6_-I/MFF:UEE8Y\O$00
MH "Y <\KD8JI^SC^T[X5\2> /AOHVL^);BZ\6ZQIT,?VJ[M)Q#>78CS)&MR4
M$3R\'Y0V>#Q0!ZIX'^"?@7X:ZA)?>&?#%AI%X\7D>= A+)%G/EH23L3(!VK@
M<=*L:_X!L/L7BZ\T71=';Q#X@MEBNI-2A+07K1QE(EN-O+( 2O'8FL+6OVD/
MAWX>\376A7WB$1W=G<1V=Y<):S/:6<[XV13W*H8HG.1\KN#R/6KX^./@]_'4
MOA&'4+FYUF&Y6RG^S:?<2VT%PR!UADN%C,2.5(.UF!Y'K0!XA\/_ -EN6;XF
M:#KFJ^ ?#/@;0=$L+VUDT_2;^2]?4I+F+R2I9D7RX%C+X3U;H*^H-.TBRTG2
M;;3+*UAMM.MH5MX;6- (TC5=H0+TP ,8KRC1OCAI7AG3_$U]XI\76>LQ1>*K
MC0["#2-)N//BD7!6R\I0[SS*,Y=!@\GC%>BZ/XYT76O"*^)X;S[/HGDO.]S?
M1/:^4B9WF190K)C:<[@,8H Y;4OV<_AGK'AC2O#EYX+TJ?0=+WFRTUHOW$&]
MM[;4!QRW/UKL])\,Z7H/A^'0["RCMM)AA,$=HN2@C.<KSVY-<1X2_:-^'_C?
M5HM,TK6Y'O;BV>\M([FPN+;[="@RTEL9(U$Z@<YCW<<UYI^R/\1I?BUK'CCQ
M%?>)=>U"]_M>]MH=)NH)(=.M+-)ML'E*T2CS-HY^8MR=PH ]MT/X7>$O#5QH
ML^E^'["PFT6S?3]-DAB"FUMW(+1)Z*2HX]JCD^$O@V7PW=: _AO3VT6ZO3J4
MUB81Y4ER9!*92/[WF -GU%8%U^TC\.[+Q1+H,OB$"[AO5TV:Y6UG:RANF( M
MWN@GDK(20-A?.3CK6A>_'3P-IK>+4O-?AM)O"K1KJ\,\<B26_F &/"%<R!\@
M*4#;B0!D\4"-&[^%7A"^T?Q-I5QX=L)M.\33-<:S;-""E_(R*C/*/XB51!]%
M%:,O@O0IO$%CKLFE6KZQ8VDEC:WK1@R0V[E2\:GLI*+D?[(KS6S_ &GO#UY\
M<[GX:BQU*.ZAL8+D7K6-QM:65RHB*^7\@ P3(Q"Y..H-6?#G[5GPP\76^HW6
MD^(I+VQTZTDO;J^33KH6\4<;['!E,>TN&(_=@[CG@4#U+^E_LT_"[1=3CU"R
M\#Z1!=Q78OH9!#GR)PV\21@G$9W<_*!71M\+O"3>&M:\/'P_8'1-:N)[K4K#
MRAY5U+,^^9W'<NW)/<UD>$?CQX'\;1:Z]AK)MFT.(7&I0ZI:S6$MK"5+"5TG
M1&"$*QWXQP>:@\'?M#> _'5Z;;2M8F#&T>_BDOK"XM(I[9,;YHI)HU61!D99
M21@@T :'C+X)^!?B!-93>(/#-CJ,]E#]F@F92DB0_P#/+<I!*?[)./:NGM?#
MVEV.AQZ+;Z=:PZ1'!]F2P2%1"(L8V;,8VXXQ7#^"_P!H;P#\0M:M])T/7&GO
M+R*2:Q\^SGMX[Z-/OO;22(JS =<QEN.>E?/7PS^*GB_5--^ ;W?B&^N'UKQ1
MK-IJ+/)G[5#$+CRT?CD+M7'T% 'TGX-^!O@'X>WD]UX>\*Z=IEQ-";9GCCW$
M0DY,2[B=J'^ZN![4GA#X%> / .N?VQX?\*:=I>I*CQQW$,9S"CG+K$"2(P3U
M"  TY_C=X*C\ :GXV;7(QX8TV>2VN[_R9-L<D<ODNNW;N.)/EX%>?_#OXG2Z
M?\1/CO<>)M:E'ASP[J%F8//RR6D+6BNX0 9Y8YP,DDT >F?\*E\&_P#"-C0/
M^$;T_P#L47W]I"Q\D>5]I\WS?-Q_>\SYL^M<-^TI\"XOBK\+_'=GH&GZ?#XS
M\0:3'I:ZE<?(7B242+&[@$[0=Q'N:V]%_:,\ :YI/B;48=:EMHO#5F=0U6'4
M+"XM9[:VVL_G&&6-7*%4;#*I!P<5K_#7XP^%?B[;WUQX5OI]2M;0Q[[I[*>"
M&3>"5,;R(JR# /*$@=Z (?!/P0\#?#[6'UC0?"^GZ7JTD/D-=0H2R1DY*)DG
M8I/.U<"FS? GX?W&BZKI$GA/3GTS5+W^T;NU:/*/<YSYP&?D?/.Y<'.3UKDK
M/]L?X17T=C-#XLS:7V\6MXUA=+;SR)G=$DACVM+P?W8.X\8!S73^%_CYX&\7
M>'_$.LZ?K3)9^'B1JR7EI/;3V7R[QYD,J+(,KR/EY[9H MZ#\$O GAE-/73?
M"^GVQT^\;4+9_+WNERR;#,68DM)M.W<22!TK0D^&7A.;6->U23P]I\E_KUNE
MKJLS0*3?1*,*LHZ. #CGM7":A^U9X#A\(^+-:LKJ^O+CPY9K>W6E3:;<VUVR
M/D1,(Y(@Q1F&/,"E1U)XIFD_M7> I/AGH/C+7-0F\/66JM%;I'=V5P#]I>(2
M>2G[L&3C@,HPQX')Q0!T.A_L\_#?PY8ZG9Z?X.TR*VU*V^QW4<D1E\R '(B^
M<G" X(48 (''%;7@7X7>%?AG'>IX9T6WTHWKB2YDC+/),P&%W.Q+' X )X[5
MPFA_''3M:\::AJ,7B>-_"L/AD:P-#DT*[AU&)1.R-=,64,4(1E\O9NR,].O9
MZ'\8/!_B:X\-0:1KD&IR^(K-]0TU;56D\ZW4 M*<#Y%!(7+X^8[>O% $_P#P
MJGP?_P!"[I__ "%O[=_U(_X_R,?:?^NG^U6K!X3T:U\47?B.+3;>/7;JVCLY
M]05/WLD*,S)&6[J"S$#W-<'^U%XIU;P3^SUX^U[0KV33=8L-*EGM;N( M%(,
M88 @C/U%>7?'#]J#0+#]G.^O?"WQ$TD>,_LEGY!L[R&2X,K2Q"3"<Y)!?/'K
M0![U<?"_PM=>.H?&<FBV_P#PE$4(MQJ2[ED:, @*V#A@ S8W XSQ3(_A/X.A
M\':;X33PYIZ^&]-EBFL]+$(\B!XY/,C95[%7^8>].T'XC:#J]YKNEPZDLVJ>
M'8;=]7BV,#;>;#YR$G&#E/F^7-<O?_M-_#?3]/\ #MV_B!ID\16;W^DQ6MC<
M3S7L*D!FCC2,L2,_=QG&3C - C4\0? 7X>^*O$S>(-6\):;?:O(T;RW$D7^N
M9/N&50=LA7MO!Q4_QD\*W?C+X?W^D6>@Z'XE:9HR^D^("RVMQ&K@LNY02CX'
MRM@X.#BN5T[]KCX4:M-I"6GBD31:I.EI!="QN1;I<.=JP2S&/9#*3QLD*MDC
MCFMOQO\ M"> _AYK5SI.M:U(E_:0K<WL=G97%T+*)ONR7#1(PA4X)RY' STH
M&><?!']G23P_XZ\6>)M:\+:)X7TO6-'BT./PWI]RU\)(@SO-+<3,J[V?>%VX
M.%7KS7I>H?L^_#O5-!T;1KKPI8RZ?HR-'I\?SA[5&^\B.&W!3T*YP1Q5'Q=^
MTO\ #CP3J&G6.H^(?-O=2LDU&RM].LY[U[FV<X66,0H^Y?<=!R>*EU#]HSP!
MI/BQ/#MYK,UMJ#7B:=YLNGW*VJW3@;(&N/+\I9#N VELY..M :G1V_PP\)6=
MIX=M;?P[I\%MX=D\W2(8H%5;)]I4M&!]T[689]S3IOAKX6N(/$L,N@V+Q>)?
M^0RC1#%_\GE_O?[WR +]*\\^"'BO6->^+WQTT[4=1GO+'1_$%G;:?;RME;:)
MM.MY&1/0%V9OJ35F\_:X^%&GWLUO<^*E@6WOGTVXNWLK@6MO<J2#%+/Y?EQM
MD<!F&>,9R* .D\4_ GP!XU731K7A6PO3IUL+.U?84>.  #R=RD$QX ^4DCCI
M6W9_#WPUI^J:/J5KH=C;7VCV3Z=I\T,(4VML^PO%'C[JGRTX']T5S_@GX]>!
M_B!=:U;:3K+)=:-"MS?0:C:364D,+ E9MLZ(3&<'YQE>.M0^"?VAO 7Q#UJ#
M2M$UMIKRZA>XL_M%G/;1WT2?>DMWE15F49&3&6XYZ4"+7BKX#?#WQQXD?7]>
M\):;JFKR0BWENIXLF:,9VK(,X<#)QN!QVJQ_PI7P+YNA2#POIP.AV+Z9IP$6
M%M[1TV- !T,94XVG(KP[]H?]J+0;CP';1^!O$UY'J<GB72K"/4;2SG2VN =0
MA2XBBN6C\J3Y/,!"L>,UZO8_$N#1_%WQ-DUSQ9IT^A^&Q:2/8PV$L<^E(\ =
MA-)R)BY^9=@X! ZT#+GA/]GOX<>!M8M-6T+P=I>FZG9E_LUW%$3) &7:RHQ)
M*J02-HP.>E=9X3\):-X%\/VFA>']-M](T>S#"WLK5-D<89BQP.V68G\:\\D_
M:>\"S>%?%FL6-W>W4WAJT^UWNERZ;<V]XJLI,9\F2,/L?:0'VE>N3Q5?P;^U
M)X+\1?"?2/'.IW4VA6U]':JUI<VLYD^TS1AQ;PCRPUPW) ,08'!(H [6[^$_
M@Z_T'Q%HEQX<T^;2?$5T]]JUFT(,=[.^S=)(/XF/EID_[(K3N/!>A7?B2'Q!
M-I5K+K4-D^G1WSQ@R+;.P9X@?[I95)'M7'P_M&?#R7P9XA\4OX@6VTGP\RIJ
M_P!JM9H;BP8D!1+ Z"5,[AC*\@Y%48_VH_AU/I=O?P:K?W$5U>/8V<4.CWCS
M7DB1^8Q@B$6^5 GS&1 5 [T"-KPK\!?A[X)UHZMH?A+3=.O]CQI)'%D1*_WU
MC4DK&&[A0,U'H/[/OPY\-3:A+IW@_3(#?6K64ZM%YB&W8Y:%58D*A/55 'M7
M46_C#2+GPB/$XN_+T0VAOC=31O'MA"[BS*P#+@ Y!&?:O/$_:F\ 7FC^(+RQ
MO[VXN=&TXZK+I\VF75O<RV_198XY(@SH6P-Z@J,C)% S;\)_L^_#GP-J46HZ
M%X0TW3K^**2WCNHXR94B< /&&))"$ #:.!C@5L1_"SPC#X5T7PTGAZP70-%E
MAFT[3Q"/)M7A;=$R+V*GD>E>,7G[;GAFS^!V@_$+^Q]3DDU1[*!M-^R7"B&6
M?86'FF+:ZH')W+P^W"G)%=SKW[4OPW\,W6G6>H:S=PZCJ%DNH6NGKI-Y)=2P
M&5HMXA6(O]]&!!&0!D\<T!J>9_'G]GW7/B7KGBN.S^'G@N[N=<M_LEKXMN+R
M6*>T0QA/,N+?81-)'EBA!_NCC!KW3PS\*_#_ (=M]*=M.M;S5+'1(M .HRQ
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M_P!G314T*4:IX9U[1[S5;4/&#9QQ12K*['=@[2P!VDGGO7U-10%SX;M_V?\
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M:867>;9(#:7/F.IC13'N#<KAV[\'Z;HH ^5OV;_@/XJ^$_Q$\)#6+03VFF>
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M,8SS6/-H'C+XJ6OP<\,3?#_4/!TG@_5+/4M6U2\>$6T M8RGE6C(Y,OFG Z
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MX 48^0G/2JV@_M*WEYIN@'4/#\,-_?\ C.;P?<);71>*-XQ(3.A*@LI\O[I
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M71=?TJWNY/$5]I=W=W$@9(=(L3;00(!C:-S,SDG)+,>_ %$=KRW_ . OUO\
MU8<M[1VU_-V_"W]7/#-9_;4TNQ_X2'5[8:"_AK0M1DT^>WN-:2/5[H1N$FF@
MM<<JK9PI(9@I([5V?B+]H>;PUXWN?"-QX;GGUW44BF\+)!(3%K4;#YSOVXB,
M7+2;NB889SBF^'_@AXB\!WVJ6'A;7M'MO"^HZG+J?E:CI)N+RR:5_,FCA?S
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M[Q+^S;JGQ#T_QQ>>*/$EJ?$WB;2X=&CN-/L&6TTZUCD\S:D;2%G9GRS,6'8
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M55U73WDM[Z.WSY4ZJDJM'(NYQC<00<<8S41Z<W:/W\KO_P"3<O\ 5QR\O/\
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MY)&"JH]23T%2U\B?M??#&^\+_LO?$5&\?>)=:M%2SN(K/4;F.62/]^B.K2!
M[QMG=M/ *\<<5TVN+K]Q\</"WPAC\;^(-/T+_A';GQ%<ZN+E!J6I2BX6)+99
M]GRJ@8N=HR1C)H ^E:*^-_\ A)/BWXF\'^-?#'A[5;[Q1=>"/&2V%Q?6=U%9
M:EJVEB(2/ D^W8+A"P5F &[:1\I-4=>^.^M>*=(^$'AGP3=>,+FT\076JPZM
M)<36UOKRR6.W?9&:3;&K[G.6!W%8^"<DT!8^UJ*^>/AEXB^,WAS0==M;_P &
MW7B9(-5V:2-:UNTBOULFB5B+B2/<CNLFY1W*E2:JKKWBOXM?'ZY\&:OJ^I^
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M&H&0^)OV=?AWXLC\/I?^'5C7P_:O9:6-/NY[+[+ X4-&GD2)\IV+P?2KVB_
MWP)X=T73-)TSPW:65AINI+K-O'$7!%ZN<3NV[=(_S'ER<]^@JO\ \*]\7?\
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M4F,[MI5N&"C(KJ_^%>^+O^BI:Y_X+--_^1J/^%>^+O\ HJ6N?^"S3?\ Y&H
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M_P"1J/\ A7OB[_HJ6N?^"S3?_D:@#K?%7A72/''AW4-!UZPAU31]0B,%U9W
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MJ6Y/&?>N;\)?LZ^ ?!.K:9J.EZ/-YVDHR:7'>ZC<W<.G*R[2+:*61DA^7CY
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M.ZOKBZN#"Q4F,O+(Q*C:, ].<8R:=_PKWQ=_T5+7/_!9IO\ \C4?\*]\7?\
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M[T^\N$T1G?3;YM4NA?VI?AMET)/. (P"-^" !C@5+_PKWQ=_T5+7/_!9IO\
M\C4?\*]\7?\ 14M<_P#!9IO_ ,C4 -;]GWP$OA.P\.VVA?V=IUA</>6KZ?=S
MVUS%.X(>47$;B4NV3N8L2W?-)<?L]_#ZY\$Z?X3;PY"FBZ=<F]LUBFE2>WN"
MS,TZ3JPE$I+,2^[<=QR3FG_\*]\7?]%2US_P6:;_ /(U'_"O?%W_ $5+7/\
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M7@D=#BI_^%>^+O\ HJ6N?^"S3?\ Y&H_X5[XN_Z*EKG_ (+--_\ D:@!UY\
M_ 5]X$T?P=)X?C70-&=9-,ABGE26R=22'AF5Q(C#<WS!LX)'2DT[X!^ ]+TW
M3;*+05DCT_5X]?AEN+J:68Z@@(2XDE9R\C@,1\Y(QVX%)_PKWQ=_T5+7/_!9
MIO\ \C4?\*]\7?\ 14M<_P#!9IO_ ,C4 ;TWPZ\.7'B?5/$,NE0RZQJFGKI-
MY<2%F\^U4LPB92=N,NW;)S4/P[^&7A_X5^'_ .P_#EO<6FE!MT=M/>37*Q#
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>business15a.jpg
<TEXT>
begin 644 business15a.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0",17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        #<     0   -P    !  .@ 0 #     0 !  "@
M @ $     0  !*B@ P $     0   FD     _^T .%!H;W1O<VAO<" S+C
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MW0 $ $O_V@ , P$  A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M*  ]*CJ0]*CH __0_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TJ.I#T
MJ.@#_]']_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2HZD/2HZ /_TOW\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD@U.R?2_"]GJLMU8:3<NV+J+SY%C"JR98!3C<,=JN?&[7+7Q%X#\(^'OVRM
MD\)ZKJ^O2Q:7KGANY5[;1I$5?*FFN"[;-^6R,'A<\$9HDMN7K;\;:+H$7O?I
M?\%N^MNY[K\-_P!I?Q1K/Q,@^$GQ9^']_P"!]>U&TDO=,<SK?6=U'$"77SHU
M"JX /'/(QP<5V'P4_:%TCXLZ?XAOM1M8?#O]B>(;O0(UN;M&^U/:G&]<A,%O
M[O./6OC#X:^,/&/PI_:)\'_"?PS\4_\ A;GACQ-#<FYAF9+NZTJ.)"5D-PC2
M%1WY?! .0.#7C/A/X4^ O%?P _:"\>:_8"]UK1=>UUM-NGE<?8GMV,BO"H8*
MK%C\QQD@ 4Y32CS]%%O[I)?D[=A1BW-4[ZN27WQ?ZJ_<_;+4-3TW2;8WNJ7<
M%G;C ,L\BQH,]/F8@<UY=\:OBQ;?"/X3ZU\4K>S76X-)@2=;>*<1B<.ZI\L@
M#@?>SG!K\KO$FJ:[XX\4_ 70/&,.GZ]H-SX%CO+>Q\1:A)8:7>ZD$9':695;
M?,BJFU6')/O6K+8WVC?L@?'+2H]9TB_T"WU1#I=CI%]+?P:26F7SK032HN45
M@NW&1UHK1<8SL]K_ (2Y?^"%)J3A=;V_%7/M#QE^U9J6F>)O O@;P-X33Q!X
MB\9:/'K;VTNI164-E;NBN5:612#( 3@$#...M?8T#2O#&\R>7(R@N@.X*Q'(
MSWP>]?D19?"[X>Z]^U7\'+'5]'@N8=:\ 6^KWR,S@3WMI:CR9CA@<IL7&,#C
MD5^OE:SBDOG+\&U^AG%MM>D?Q2?ZA11161H%%%% !1110 4444 %>#?'7XFZ
M]\-=-TN[T&*WE>]N'BD%PK, JIN&-K+SFO>:^0OVN/\ D!^'_P#K\E_]%FOC
MN/\ '8C!Y!B<3A9N,XI6:W7O)'GYK5G3PLYP=FO\SW;X3^+=2\<>!M/\2:LD
M4=U=&3>L(*H-CE1@$D]!ZUZ/7B'[.O\ R271_K/_ .C&KV^O5X8Q%2OE&%KU
MI7E*G!MOJW%79O@IN>'A*6[2_(****]PZ0HHHH **** "BBB@ HHHH ^??VE
M/CJ/V>_AX/'AT9M=+7UO9"U2<6Y)G) ;<4?ICIBO-?$/[8>A:)^S9I/[04.C
M/=/J\L5M%HRW 647+R-&\1DV'E I8_+TKGO^"@OE_P#"G="6;&Q_%VB*P/0J
MTX!'Y&OAF#1=3F^+M_\ LQW4)_L/P)KGB+QB&/W6MI;-I8$Q_=#/QVS62DW&
M?>^GHE%O\&W\C644G!^6OJW)+\4E\S]8/A5\;M.^(OP2M/C3J5E_8EE-9W-[
M/;R3"7R8[8N&S)M4'(3/05YE^S;^UIIG[15IXF73]!FTC5-!43P6$LXD>\M9
M WE2J=B[0S *>#@GJ:^$+KQOJUO^P1\-?A+X21[SQ'\2II-+MK6!@)I;83N]
MP%]-X 3/09K4T_Q%XW^"7Q^^'7Q&\5?#ZY^'OAJ\L+7P1J+37<5S#<A5VPS,
M8@H5E/S?-U/>NIQ3K2@MMEZVO?[[+YLY5)JDI==WZ7M^5W\CZ&UO]M#XP>'/
M%6C>"=;^"&H6FN>(?-_LNS?5H=]T(?OE2(L#''4BNM\:?M:?$3P9_P (+HEW
M\*KQ_%GC87OEZ$=1C6:W:U<!07\LJV]3N[8%<]^T(Z']LWX X8?,FID<]1\O
M2N&_;<MK6]_:"^#%G=^)G\&Q2KJ(;7(I4ADLN4^=7D(49Z<G'-91U4?-M?<;
M35G*W2*?WGU+\+/C#\:/&?BU-#\;_"._\':6UO+*VJ7&H17$:R(/DCV(BG+G
MC.>*R9?C[\2;'QQXC\(ZGX$M(HO#&F'6;RZ36%?-D_F>2R)Y R[^7RN?E]36
M#\!=(\.Z#XW=K;X^W7Q(N+JT>*+1KJ_M9P"I#&9$B<L64#TQBO;]7^#NFZOX
MI\7>*9-1GCE\6Z!%H$T2HI6".+S,2H<Y+'S#P>.**B?+>/9_?K;\;!!J[4NZ
M_2_X7/!?"_[95GXG/PQMH/#$T5[X]NY;6_@-TI.C;&"*9#L_>;RR[1\N0:^W
M*^2?#W[(G@[PWXEM_%%CJUX;FWOM&OE5D38#I$(BV*,_*+@J'DQW%?6U7+EZ
M=W]VG_!,X\U]>R^_6_Z!1114%A1110 4444 %%%% !1110 4444 %%%% !16
M%XGU^T\+:!?>(KY'DM["$S2+$ 7*KV&2!FOGD?M7^!",_P!G:G_WQ'_\77@9
MMQ1E65U(TLPKJ$FKI/JCEKXVA1?+5E9GU'17RY_PU?X$_P"@=J?_ 'Q'_P#%
MTO\ PU?X$_Z!VI_]\1__ !=>5_Q$3AO_ *#(_C_D8?VM@_\ GXCZBHK@?AY\
M0](^).CRZUH\$\$,,[0%;@*&+* 21M)XYKOJ^JP6-H8NA'$X:7-"2NFNJ.ZG
M4C4BIP=TPHHHKJ+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJE?:E
MIVF1B;4KJ&TC8[0\\BQJ3Z L0,T 7:*R[+6]%U)S%IU_:W3@9*P3)(<?12:L
MIJ%A+=R6$=S"]U$ SPK(ID53T)4'< ?<4 6Z*S)M;T:V:=+B_M8FM0&G#S(I
MB#="X)^4'MG%7?M-M]G^U^:GD;=_F[ALV8SNW=,8[T 3456M+RTOX%NK&>.X
MA?[LD3AT;'HRD@T37EG;2PPW$\<4EPQ6)'<*TC#DA03ECCL* +-%4;W4]-TU
M5;4;N"U#G"F>18PQ]!N(R:GENK:&W-U-*D<"KN,C, @7U+$XQ[T 3T57M;NU
MOH%N;*:.XA?[LD3AT/T*D@U%!J6G75Q+:6MU!-/#_K8HY%9T_P!Y0<C\: +M
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z5'4AZ5'
M0!__U/W\HHHH **** "BBB@ HHHH **** "N'\<?#3P!\2K&/3?'OA^PUVWB
M.Z-;V!9#&3UV,?F7/?!&:[BOG[]J7QUXF^&OP&\6>-O!]RMIK&EVL<EK,\:R
MJC-*BDE&R#P3UJ*DE&+E+H7"+E)174]+\$_#?P%\-]/?2O >@6&A6LIW2)90
MK%YA'0NP&YL=LDXIFG_#/X?Z5HVK^'=-T"PMM,U^2:;4[6.$+%=R7(Q*TJ]&
M+C[V>M?&WC;]H?XHOH/PG^&GPV2SN/B+\1]'MM0GU&]CS:V-OY*O-<&)>"2=
MQ Z *>#P*Z'P]:?MD?#KXA>'[;Q+K.E?$KPMJTWD:L\%O%IMSI8X_?+DJ'49
MZ<DXQ@'%;2@W)QEW:OT=OTO\C&,URJ4>RE;KKM\_Q/LK0=!T;POH]IX?\/6<
M.GZ;8QB*VM;=0D448Z*JC@#FN7\4?"OX<^--<TSQ-XK\.V&J:MHSJ]A>7$(:
M:W9&WKM;KPW(!R >:[J>>*V@DN9V"11(SNQX"JHR2?H*_,+X,?M;_$;Q7^T!
M#;>+#''\-O&]]J>F>$Y/)2,B?3V4*?,'S-YG3D]6XZ5,6Y5%%;[_ ->;Z%22
MC3<GMM_7DNI^A]A\._ VEIKL>G:'96Z^)I'EU@1Q!1?/("K--_?+!B#GUK)U
M#X._"W5?!UK\/M2\+:9<>'++FUTV2W4P0');,:X^0Y)Y7!YKG?B'^T+\*/A9
MX@A\+>-=7:RU6YL7U"WMDMIIGGB5MF(_+1@TA88"#YCZ5X]XX_;-^'5I\#=?
M^+/P\G.KW6ESC3H[&Z@G@>/49/N1W*;=\2X!.XX4XQG-0VN5OI_D[+\=/4M)
M\R77_-7_ "U]#Z@\&^!/!OP\T@:#X'T:ST33PQ?R+*)8E+GJS8Y9O<DFK?BC
MPGX9\:Z/-X?\7:7:ZOIL^/,MKR)9HR1T.&!P1V(Y%?&TG[1$OC'P3\)O%NA>
M,8/#<GB'7+73-5BN-)N)!J%SY:F>S@!0F(%V^64G;CHQKE_"'[8VF>$O'WQ5
MT7XQZQ*]KH/B+['HUM9:>\\L%BBMYCR>0C'RU.,N]:2CJXRZ7_#E_P#DE\OD
M1!^ZI1\OQO\ Y/\ J]OL/P)\%OA/\,IYKOP#X5TS1+BX79+-:P!964_P[SEM
MOMG%:EG\,/A[IVB:OX:L?#]A!I6ORS3:G:)"HANY+C_6M*O1B_?/6N5\1?M
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M.AZA+I=Y+Y,D<8NH#B1$9U42!>[+D>]>B4?U]^OX[A_PWW:?@%%%%( HHHH
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ML7Q=XE\,_ _5].\&6-Y?Z[XE9-$LTLXFE>/[8=DDIV [0D>[YCT.*^&/B/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 445"UQ;H2KRHI'4%@#0!-14'VJU_Y[1_\ ?0H^U6O_ #VC_P"^A0!/
M14'VJU_Y[1_]]"C[5:_\]H_^^A0!/14'VJU_Y[1_]]"C[5:_\]H_^^A0!/14
M'VJU_P">T?\ WT*/M5K_ ,]H_P#OH4 3T5!]JM?^>T?_ 'T*/M5K_P ]H_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH XS0_^1M\2_P"_9?\ H@5V=<9H?_(V^)?]
M^R_]$"NSJI @HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\5Z"/^7D?]\G_"C_ (2O0?\ GY'_ 'RW^%>,T4^5!S'LW_"5Z#_S\C_OEO\
M"C_A*]!_Y^1_WRW^%>,T4<J#F/9O^$KT'_GY'_?+?X4?\)7H/_/R/^^6_P *
M\9HHY4',>S?\)7H/_/R/^^6_PH_X2O0?^?D?]\M_A7C-%'*@YCV;_A*]!_Y^
M1_WRW^%'_"5Z#_S\C_OEO\*\9HHY4',>S?\ "5Z#_P _(_[Y;_"C_A*]!_Y^
M1_WRW^%>,T4<J#F/9O\ A*]!_P"?D?\ ?+?X4?\ "5Z#_P _(_[Y;_"O&:*.
M5!S'LW_"5Z#_ ,_(_P"^6_PH_P"$KT'_ )^1_P!\M_A7C-%'*@YCN-&\2Z+'
MXI\12M< +(UF5.T\X@ ]*Z[_ (2O0?\ GY'_ 'RW^%?/.F_\A[6OK:_^BA70
M4-!<]F_X2O0?^?D?]\M_A1_PE>@_\_(_[Y;_  KQFBCE0<Q[-_PE>@_\_(_[
MY;_"C_A*]!_Y^1_WRW^%>,T4<J#F/9O^$KT'_GY'_?+?X4?\)7H/_/R/^^6_
MPKQFBCE0<Q[-_P )7H/_ #\C_OEO\*/^$KT'_GY'_?+?X5XS11RH.8]F_P"$
MKT'_ )^1_P!\M_A1_P )7H/_ #\C_OEO\*\9HHY4',>S?\)7H/\ S\C_ +Y;
M_"C_ (2O0?\ GY'_ 'RW^%>,T4<J#F/9O^$KT'_GY'_?+?X4?\)7H/\ S\C_
M +Y;_"O&:*.5!S'LW_"5Z#_S\C_OEO\ "N?U'XH^"]*N_L=]>/&P4,7\B0Q@
M'U<*17G-.#NOW6(^AIQ4;^]_7YB;?0]6TGX@^"-<E^SZ5K=E<2XSY8E ?_OE
ML&NO!!&1R#7S3?:7I>J+MU.SM[L#IYT2N0?4$@D'W'-5K*VU[PVWG>#]6EME
M7G[!?,]U9/[#<3+%Z95B!_=K3DIRV=O7_/\ X N:2W/J"BO-O!_Q&L_$-W_8
M.KVYTC743>;.1@R3H.LEM*.)4]<89?X@*])K*<)0=I%QDFKH****@84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I
M4=2'I4= '__1_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XS
MXA?\BAJ/^XO_ *&M=G7&?$+_ )%#4?\ <7_T-::!G9T444@"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#CO&W_(/L?\ L)V7_HT5V-<=XV_Y!]C_ -A.R_\ 1HKL:;V
M****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '/>(M:71[3,>#<2Y$:G]2?85XW)))-(TTS%W<Y9CU)K6U_46U+5
M)ILYC0^7&/15_P 36-5I$-A1113$%%%% !1110 4444 %%%% !1110 4444
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M*** "BBB@#G]-_Y#VM?6U_\ 10KH*Y_3?^0]K7UM?_10KH*; ****0!1110
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MBBBO*.D**** "BBB@ HHHH *RM2_X^]%_P"PQ9_^A&M6LK4O^/O1?^PQ9_\
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M*-3NDPHHHKA-@HHHH **** "LK4O^/O1?^PQ9_\ H1K5K*U+_C[T7_L,6?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#^E4J0LJC+L%'JQ 'ZT 7O[0N_\ GH?TH_M"[_YZ']*HJRL,HRL/52"/TI:
M+O\ :%W_ ,]#^E']H7?_ #T/Z52HH N_VA=_\]#^E']H7?\ ST/Z52HH N_V
MA=_\]#^E']H7?_/0_I5*B@"[_:%W_P ]#^E']H7?_/0_I5*B@"[_ &A=_P#/
M0_I1_:%W_P ]#^E4J* +O]H7?_/0_I1_:%W_ ,]#^E4J* +O]H7?_/0_I1_:
M%W_ST/Z52HH N_VA=_\ /0_I1_:%W_ST/Z52HH N_P!H7?\ ST/Z4?VA=_\
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M2]7=0-(_L^,]9;^18@/?:"6/X5^GU,[RZ$.>5>-O\2/F8X+$2?*H/[F>8D@
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MPO\ A1XOTW0;[P!X_P##^A+X>U2%I-2N[*_NYM2U&]8J3+<2N$9BY!)(8;>
MN!Q7=>)?B]JL?BVY\!_#OPQ<>*M9TVWAN-487,=E9V N 6BCDGER#,ZC<$4$
MA<$]:ZCX<_$*7QU!J=MJ>BWOAW6=$NOLFH:?>8?8[()$>*9/W<T3HP*NOT."
M*F*T:6UOP\O*_P")4GLWO?\ 'S^1N^#/!'AGX?:*OA[PE:&RT])'E$1EDFP[
M\L=TK.W/UKK***;;>XDDM@HHHI#"BBB@ HHHH #TJ.I#TJ.@#__1_?RBBB@
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M1HHD#  8>0.YP.>/2N\U/P%\/-.TJ]O+G2K.WBAMY7::>2143"G!+-)@#->
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MU>]AM'U&X%I:+*VTS3LK,(T'=BJDX]!4V3T>ST_%:?/;YCNT[K=:_@]?EO\
M(^.;+P9\0_@[\3/!'B;4KFUU;0[ZRC\%7L6DV#0?9H%5I+&>4*7W+'*K(6.
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M0O&*P6\+DO(0"Q &/0$UZM3L%^@4444@"BBB@ /2HZD/2HZ /__2_?RBBB@
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M1O8&Q)<2C[T,;#I&O1B.6/'2OHGXV^-Y? GP_OM0LGV:C?$6%D>ZRS @N/\
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MJP&!E'F93QV((KVZAM,:5@HHHJ2@HHHH #TJ.I#TJ.@#_]/]_**** "BBB@
MHHHH **** "L[4H99X56)=Q#9_2M&B@#E/[/N_\ GF?S%']GW?\ SS/YBNKH
MH Y3^S[O_GF?S%?!O[;>M3VUOX6\(\J)Y+C4IESU\D"*//XN3^%?H[7Y5_MN
MS2/\6-+@8_)%H<94>[SRY_D*^JX,H*IFU._2[_ \S.)N.$E;K8^.Z***_<CX
M8*_3[]CO2;H_!ZXF5"4O-5O70^HV1Q_S4U^7[L$1G/\ "":_;?\ 9^\+2>#O
M@[X8T:X39<&R6ZG'0B6Z)F8'W&_'X5\)X@5U' 0I=92_)/\ S1[V00;KREV1
M^*^IVKV.JW]C*"'MKRYA8'J#'*RG^54J]F_:%\+2>$/C+XFTXH5AO+D:E;DC
MAHKP;R1])-X_"O&:^PP%=5\-3K1VDD_P/'Q%-PJR@^C85WOPL\0R>%/B5X9U
M^-MJP:C#'+SC,,Y\J0'VVL:X*G(YCEBE7[R21L/J&!%:8JC&K1G2ELTU]Z)H
MS<)J:Z,_>PZ?=@G$9Q2?V?=_\\S^8KH+"5IK&VF?[TD2,?J5!JW7\UM6T/T@
MY3^S[O\ YYG\Q1_9]W_SS/YBNKHI <I_9]W_ ,\S^8H_L^[_ .>9_,5U=% '
M*?V?=_\ /,_F*/[/N_\ GF?S%=710!RG]GW?_/,_F*/[/N_^>9_,5U=% '*?
MV?=_\\S^8H_L^[_YYG\Q75T4 <I_9]W_ ,\S^8H_L^[_ .>9_,5U=% '*?V?
M=_\ /,_F*/[/N_\ GF?S%=710!RG]GW?_/,_F*/[/N_^>9_,5U=% '*?V?=_
M\\S^8H_L^[_YYG\Q75T4 <I_9]W_ ,\S^8H_L^[_ .>9_,5U=% '*?V?=_\
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M,!PJYY$<8X0?4GDFO:J_#N*<[68XOFI_!'1?J_G^5C[?*\%]7HVE\3W/A?\
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MTGC/*'/U'<5Z/!,EQ$LT9RK#(H EHHHH **** "BBB@ HHHH **** "BBB@
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M;2;HR1?9Y#EH^GNO_P!:@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** $) &3T%<C>7!NIR_\(X4>W_UZV=4N-D?D(?F;[WT_^O6!@^M
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TJ.I#TJ.@#__1_?RBBB@
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M+_%FBW^H7VH^#[/P1X4TW1M/D2""9KN[NX%^WL%E$B@1A1%G .2>U94?P_\
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MIJ7;1MH C 8$$'D5TUI/]HA#'[PX8>]<[MJU:2^1+N)^5N"/ZT =#11UY%%
M!1110 4444 %%%% !1110 4444 %%%% !56^@^TV<UOU\R-E_$BK5% 'SN5*
M$HW!4E3]1Q174>+-,:PU)IT'[FY.]3V#?Q#^M<O6A#"BBB@04444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5EWXWZCH$(^]+K-HJ_50[G]%-:E1^&[-]?\
MB%90QY-KX<B:^NF'3[5<*8[>/ZB,NY'HRGO6M'XK]M29;6/HRBBBN8V"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (4NQ_[K?D: LQM%.V/_ '6_(T;'_NM^1H"S&T4[8_\ =;\C2;'_ +K?D?\
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M,D<A(^5B 2 <'%?-WQE\%ZOKOQ)T[Q+:>']-^(NG:5I+6USX4NKY+:XM))Y
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M+/5C%*R-<6UO&)EM?,!!"3.H5@",@$5*]YJ/=)_>XK_V[\"G[J<NS:^Y2?\
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M*(\"DP*EP*,"@"/ JW:2;6\L]&Z?6H,"C&.0: -BBHH9/,3)ZC@U+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %(0#P1FEHH 9Y<?]T?D*/+C_ +H_
M(4^B@!GEQ_W1^0H\N/\ NC\A3Z* &>7'_='Y"CRX_P"Z/R%/HH 9Y<?]T?D*
M/+C_ +H_(4^B@!GEQ_W1^0H\N/\ NC\A3Z* &>7'_='Y"CRX_P"Z/R%/HH 9
MY<?]T?D*/+C_ +H_(4^B@!GEQ_W1^0H\N/\ NC\A3Z* &>7'_='Y"CRX_P"Z
M/R%/HH 9Y<?]T?D*/+C_ +H_(4^B@!GEQ_W1^0H\N/\ NC\A3Z* &>7'_='Y
M"CRX_P"Z/R%/HH 9Y<?]T?D*/+C_ +H_(4^B@!GEQ_W1^0H\N/\ NC\A3Z*
M&>7'_='Y"CRX_P"Z/R%/HH 9Y<?]T?D*/+C_ +H_(4^B@!GEQ_W1^0JK+ING
M3R>;/:P2/_>>-6;CW(S5VBFFUL U$2-0D:A5'0*,"G444@"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M #TJ.I#TJ.@#_]3]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,QIDC]X2.,\>]$G97?G^&K^X<5S;>7XNR_$]:HKYIL?VCXH;32=9\:>"]?\
M#&A:RULMOK%V+>>SC-YM\@SF"9WB60L &9< GG%=)XE^-$^G^*=2\)>#O">K
M>+KS0HX9-6>P:"&*T^T*7CC#3R)YDK(-VQ1TQSS3:MN):['N5%<GX'\9Z/\
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MY%>P9*EHFR58=5=?O*P[JP!'I5NG)+F:T$I*]C8HHHJ!A1110 4444 %%%%
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M\BG=(!D#*YZU](T6T3%=7L%%%%(84444 %%%% !1110 4444 %%%% !1110
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MF*?1_P#MS=OT-;^\VNJ_2W_!.ET31=+\.:/9Z#HENEI86$*6]O!&,)''&,*
M/I^=?E^]KX%DT?XCZ#XH\0^-=,UN[\1ZX]OHVE)J+6ER'DW0 6Z0M;RK,<;@
M3AQG=Q7Z.>'/B7\/?&"WC>%O$FF:JNGQB6[:TNHY1!&<_-(58A5X/)P.*A\,
M?$SX;>--0FTWPEXCTG5[VW!:2&SNHII54'!;:I)*@]QQ[TI1<I-OJG^+3O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB1HGBV\GU+5_ =[<-8RW#F2>\L]2S+IOS'EB78PC_<Q7I/@B[N-$\!Z?\/\
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MWQKU$CS]*M]/4]6NKJ,8_!"YKZZCG^6T=:N(@O\ MY?YGY9F.28^MI2HR?\
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M[1HMPJP_%W4-<FSM(73)48+<'YO]6V<>OM6K2Y[+;_[:/Z7[:&<'^[;EO_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M*  ]*CJ0]*CH __4_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TJ.I#T
MJ.@#_]7]_**CHH DHJ.B@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B
M@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B
M@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B
M@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B
M@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B
M@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B
M@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B
M@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B@"2BHZ* )**CHH DHJ.B
9@"2BHZ* )**CHH DHJ.B@"0]*CHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>business16a.jpg
<TEXT>
begin 644 business16a.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0",17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        #<     0   -P    !  .@ 0 #     0 !  "@
M @ $     0  !">@ P $     0   E(     _^T .%!H;W1O<VAO<" S+C
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MW0 $ $/_V@ , P$  A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH __0_?RBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "F/(D8W2,%'J3BHKFYCM8FED. H)_*O)-1
MU:YU&9GD8A,_*O8"@#U7^T]._P"?F(?\#%']IZ=_S]0_]]BO%B]-+B@#VO\
MM33?^?J'_OL4G]J:;_S]0_\ ?:UXB7%1%J /<O[6TO\ Y^X?^_B_XTG]KZ6/
M^7N#_OXO^->$LPSFH2U 'O@U?2R<"[A)] X/]:T%96&Y2"#T(Y%?-K-72>&_
M$5QI=VD,KE[61@K*QSMSW% 'M]% ((R** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^7_UZY'3_$FC:KK>I^';"<R:AHZP->1;& C%RI:/#$;6W '[I..];Q5AU!%
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M37-,L8K;4-:>*34+A =]R\*[(R^21E5X&,4 ?-?C&/Q%XS^,.B?"GQ/XGO=
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MP(Y!!KA;'2[W5&D^S022PVX62Y=%++%%GEF(Z#MDUW/TK]?HVE='R4[JS/V
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M87"3A">@;825S[UV5?D_^RAXB^"K?'W6;^Q\.ZW\*_&4^E2+=>%;@XTJXAA
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M=HX2TN9-\9A(_P!8^.JCD5W_ %?+&D[V_P"WO*6FW=+[_0P]IBEH_P O-?\
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M?_&37[SPCIEAK7AW7[2QCU5=,\0V9L;BXTZ8X2ZA!9@\1XYSG'-;?QJ_:#\
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MQH ^0/BI^R9!\3_V?O#?PRO+VWM?%7A.RM$TO6D#[(;JW15?D#S/*DQR,9!
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MDVO@J ^9X<\*/#J.M,.4N;X_-:VOH0G^L<?05]"=.!0 4444 %%%% !1110
M4444 %%%% !117EGQC\3W?AGP-=KI/.K:L\>E::@Y)NKP^6I&.?D!+9[8H \
MS\,^#_#7QG\4^)/'GB_3X]4TN&Z_LC1(YBQC6"S)6:50"/\ 6RYY]!7??\*
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M'A?0_P#GTC_(_P"-=!10!B)X<T.-@ZV461ZC/Z&ME$2-0D:A5'0*, ?A3J*
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M=E[*Q4@'VH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /_7_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S=0T71]
M6 75;&VO O07$*2X_P"^@:GL["QTZ$6^GV\5K$.B0HL:C\% %6Z*KGE;EOH*
MRO<\]U_X4?#CQ1<27FN>'K*YN)?]9+Y?ER/[LT94D^Y.:KZ/\'?AAH,JSZ9X
M<LHY%.59T,Q!]O,+5Z5172L?B5#V:J2Y>UW;[KF?L*=^;E5_0:B+&H1 %50
M !@ #L!7PM^W8UT/"'A94+?9SJLOFX^[N$#;,_CTK[KKQ/\ :!^&\GQ/^&>H
MZ%8JIU*WVWNGD_\ /Q!\P7/8.,K^-=N08N&&S&E6J_"GK\]+_+<QQU)U,/.$
M=['XJXSZ@@@@@X((Y!![$=C7WC\/-&T;]J?X>/X?\47!MO&WA.,0VNK!<O-:
MO_J_-&?WBY&U^X.".2<_",D<L,CP3QO%-$[1R1N"'1U.&5AV(/!KZ%_9>\;Z
M-X#^*<>I^(M1BTS2[FQN8+B>=]D>0N] ?<L.*_9N(L/.>#=?#NU2'O1:W\UY
MW73J?(9?42K*G4^&6C_KR.?\8_L]_%OP3=20W^@W%_;H?EN].4W$+C. ?E^9
M2?1@#7E>A^)M=\'>([?4_#U[-IFI6C,@FB.&5F^0QG((.3PP/XU^L_Q$_:!^
M'=W\-O%%SX(\5:==:M;Z9.UO'%,!*7*X&P'!)&>,=Z_(( [-K$OG[S,<EB>I
M)[D]ZCA/.,5BDZF/HKW6E9I^]ZI]/P9R\295"IAYX;#5I0<TUS1:O'T??\C]
MB/#?P[^)NKZ!IVJ:G\2=9MKN[MHIIH8H+1TC>10Q56\LY S6CX3N/%G@WXG_
M /"#^)_$-WXAL]8TIKW3[B[BBC:.>V<+-'^Z50048-S7S/\ L<?&*]%\WPH\
M0W)E@:(S:,\IRT>SF2#)Y*X^91VY K[,^(/P_N_&4^CZKH^LRZ#JVAW$DUM>
M10K/E9D*21LC$ JP]Z^(S#&5*>.JY?FG)&G-2M)4XKENKP:<8<UE)).UW:ZU
M-(Y%&AA:6,RMU)U8.-TZLWS*Z4TU.?)=Q;:O97ML>ETUT612C@,K @@C((/4
M$5X>/AQ\5#G?\3[P^FW2K48_4UM_!KQ)K7B3P9GQ)/\ :=6TR^N]-O)MH0R2
M6LA4,57@%EVG KY?%9-"GAI8K#XB%11:3Y5--<U[/WH1TTMIY'T&#SVI4Q4<
M)B<-.E*2DTY.#3Y;77N3E9^\GKTOV..U3PWKWP>U&X\5^ +:74?#%RYFU;P]
M%RUN3RUS8CL>[Q#ANHYKVKPUXFT/Q?HUOK_AVZ2\LKE<HZ=01U5AU5E/!4\@
MUO5YMI7PWL/#WC6X\6>'+J73K;44<ZEI<8'V2YN#]V<+_P LY!_$5^]WKPSZ
M ])HHHH **** "BBB@ HHI"0H))P!R2: /!_B^7\5ZYX9^%-L24U>Z&HZIC^
M'3K$ARK>TLNU??FO=T18T6- %50  .@ Z"O!_A0#XO\ %/BCXJ3@F&]N/[(T
MDGM86+%6<>GFR[FXZXKWJ@#Y_P#VG_%7B?P7\&-9U_P=J(TG5XIK&&WO619%
MA-Q=11,S*X*E0KG.>U>#^+_&'Q-^$6K>)O"C>,;OQ.+KX?ZCXGM;R\B@$^G:
MA8';F/RD53!,3E%8'!&,FOHW]H3X<ZG\5_A5JO@32?(\_49K/<+EBL30Q7,<
MDJDKS\T:L!CO46A?L[_"O0=-US3H-,FN!XCL?[,U":\O)[J=K':5%LDLKL\<
M*@G"J0* /G.VO/C!9VOPR\ ZE\1+Z34/B49=4U#6VMK:.:SAMK..8V5BNSRU
M,KOG<X9@ <5YK\5+_P ;:YX=\2_#'Q!XMO-0?P1X]\,V]IK,4<"7-Q!J31R)
M'<@)Y9GM6.0RA<D#<*^_/%?PC\!^-/#6F>%==L&>TT7R6TR2&:2"ZLG@0(CP
MSQLLB,%&,AN1US7/?\,]?"AO -]\-Y-(9](U*X%[>.]Q,UY<788.+B2Z+^<T
MP8 A]V1CCB@#X^\8_%#XU:QXQ^(-GX5N_$T<?@&9--TW^R[:QDL)9[>W69Y]
M5>X*N1,>HCV*J<@YK9\6_%[XB6L/Q$\16TT6E:G8_#30M;@2**&3[-J%Q)+Y
MF)=I:1.. 690.@KZ8\2_LT?"+Q;?#4=:TRY>66V@M+WRKZYA348+8!8TO5CD
M47. ,$R9)'!)KIM6^"?PUUK^V5OM'0IKVD6^A7R1N\:/IUH288556 0(6."N
M#0!X3X%U+XG>$/C'X/\ "_B?QC=>*;#QGX9N]2NX;RWAB6UO;00MNMO*52L;
M"0@HQ;IG-?9=<<_@+PL_B/1O%C6>=4T"RFT^PFWM^ZMIPHD3;G!R$7D@GBNQ
MH *\3^*?QX\"?"ZPODO[Z*YUFV@+PZ;$2TKR-_JU<@$1AB1R<<<U[3(Q2-G'
M\()_*OPY\13W/B*^U2\U&0R7.H7,TLLC<DR%R0?PP/PK[#A#AVGFE6;K2:C"
MVBZW_30\G-LPEA81Y%JSTN]_:[^-]W?M>PZA8V<;-N6UCM%>)!_=W,=S>YR,
MU] _##]M6VOKN+2/BC8QZ?YA"KJEGN-NI/\ SVB;+(/]H%@.^*_.9EDBD:WG
M4I*G#*?YCU!HK]+Q?"N65Z?L_9*/FM&O\_G<^<I9IB82YN:_J?T'6EW:W]K%
M?6,R7%O.@DBEC8,CHPR&4C@@BK%?GQ^Q)\0]3N1J?PVU&1IK:TB^W:=N.3"A
M8++$,_P;F#*.V37Z#U^+YQED\!BYX6;O;9]T]C[#"8E5Z2J+J%%%%>8=(5XU
M\5/CKX!^$D*Q^(+IKC4Y5W0Z;: 27+CL6&<1J?[SD"MCXP^/A\,OAUK'C!(Q
M+<6D02UC;[K7$S"./=_LAF!/L*_$;5M6U77]4NM<UVZDO=1OI#+<7$IW.[G^
M0'10. .!7V/"O#"S)NO7=J<7;3=OMY>9Y.9YE]72A#XF?;.J?MT^*I+HMHOA
M:QAM1]T75R[RD>^Q0HX],U]3? G]H'2/C'8W4%Q:C2=9L"GGVID#QR+)G:\+
M'!89!!!&1^-?CAQ72>&X9X)O[6B=X9%P+>1&*.N#G>K#!'.,'VK[S&\$9?7H
M^SP\>271ZO[TWJ>%1SJO"?-4=UV/WRHKR7X&^*[_ ,9_##1M;U60S7FQ[>>4
M]9'MW:,L?=MN3[UZU7XSBL/+#UIT)[Q;3^6A]A2J*I!3CL]0HHHK L**** "
MHYIH;>)Y[AUBBC4L[N0JJHY))/  J2O)OCU_R1/QUSC_ (I[4N?^V#T =I;^
M,_!]Y<1VEIKFFS3RL$CBCNXG=F/0*H;)/L*Z6O@#]GOP9IS6G@K4;_X&6.BQ
MPZ7:72^)OM-C+()([8.EP(T8S;I6 /3(+<UW'@#QU\?_ (AV6F?%/1[SP_'X
M3U;6+BU70YX6CN8M,BN)+87'VPOAKC<F_P K8%(.T'- 'V/7-R^,O"$-PUG-
MKFFQSHQ1HFNXE<,#@@J7R"#VKY0T#X^>.M9A\*^ ]EFOCVY\7WN@ZXHA/DPV
M&DLTUS=+%ORHEMC%Y9)(W/WKY-L;_P +^&_!_P 1_$OB?X+)XTL(_&?B&.;Q
M"[6NR%7NRH\XD_:(XH21ND PH.10!^O<E]90F!9KB)#<L$A#.!YK$9 3)^8X
MYP,\4ZWN[2[\S[+-'-Y+F*3RV#;'7JK8)PP[@\U^?$7A;6/!GA3]FGP[KVIQ
M:O=VWB96-U;S&XA,<UM<R1)'*<F1(XV5%8]0OI74_"GXH>#_ (4V'Q)UGQE/
M/;VMW\1]8MXFM[6:Z8R".)\%84=@, \D8H ^VWU"PCFDMI+F%9HHO/DC9U#I
M%TWL,Y"Y'4\4R/4]-F>WCBNX':[0RP*LBDRQC!+( ?F4 CD9%?"WB/6+'Q#\
M:/'FO:6S/9ZC\&UN8&=&C8QR7$[*2C ,IP>A (K$^%F/^$V_9H_[)WJ?_I-:
M4 ?HE117-^,'\01^%-7D\*>7_;*64[6/FC<GV@(2F1W^;'%5&/,T@-J^NX["
MRN+Z4,R6\3RL%&6(12Q 'KQ7PO=?M(_!7XT^%M2\'?$ZRN/"UM>PM-8W&H;6
MC?;DQS0S1;@DZ'!"G#9XYYKQ[PC^TS\=--M(YK^XTSQ/;ME9[74(#972.IVR
MQ&2+* JP*X9.*\GLU>07,LUG'9)<7EQ<Q6:/YR6R3.7$:O@9"DG!QTQ7WN6<
M+2A*7UG?1QE%[?UIT,9UDMBOI327FDQ+>GSPZO&7D3'GQJQ59&0]/,4!L'UJ
M73=*T[2$>/3H!"LC!FP2<D< <DG ' '0#I6C17W!QMG7>!OBI\1OA=H.K^%/
M!PL[G3-4,DMI]L9E?2[B;B1X@H(D0GY@AQAN^":YSX8>(+?X4?$#1?%U[IMY
MKEMIUA?0XM=AG:\NN3*V\@#>2V6SQFJE%<<L!0DJBY;<_P 5NI:K2T,_XE^(
M/$7Q(UF]\6^)E6+4=9NK.PL[56WQV%H9U$<*GH6)^:1A]YOI7[36L)M[:& G
M)CC5,^NT8K\5=7M[J:VBDL0K7-I<V]Y$CG".]M() A/8-C&:^F/'7[6GC7Q%
MHQT_P;H[>$M\7^FZKJ,L<TL Q\_V:-"5)'9W( ZXKYSB#)JV)]C1PL5RQNO)
M;'12J*S<F?<EQ\1O MKXOM_ -QKEFGB&ZC,D6G&4>>R@9^[V..0#R17:U^;?
M[*'P>OO$/BB/XT:]%.FF6IF?2)+PEKO4[J4%9+Z9F^8H!D19^H&*_22OBLUP
M='"UO8TI\UEJ_/JD;)W"BBBO,&%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ?_T/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /C;]HG]FC1O&-GJ?CSPC&]IXCB@>>6WA7,6H.@
MSAE_AD(&-PZ]QWK\KY[*_M+YH=4A:":,?)&ZLI'9CA@#D=.E?T,U\<^(OA-X
M=^,_C7XCZ9JY^SW=F^EQ6%[& 9;:98&8X'\2-D;U[_6OU'@_B=4L%7HXQ-JF
ME)2OJES1ARVZKWK]U:WI\+Q#@:ZS+"SH3M&HY0<+*S?)*:ES;I^[:VSOTMK^
M5K(C\.H;ZC-5F1K?]Y%DQC[T?H/5?\*]O^(/P%^)WPXN95U;29;VQ0G9J-@A
MFMW4=S@;HSCLPKRRQTC5M3NX[#3[*XN+F5@BQ1Q,6+-T&,=Z_0:&.P]>G[6E
M-./>_P#5CEG1J0ER2BTSK?A/JD^D_$OPOJEGEI(M3MRH7DL';:1]"#S7[L5^
M:'[/G[+7CC3?%^G>*OB!:)IEGI,@N8;8R+)+-*#E 0I.U5SDY^E?I?7Y'QSF
M&&Q6+A]7DI<JLVMM]CZO)</4I4I>T5KL*^=X-*^*'@#Q1XFN_"V@6FOZ-KE^
M-2C3[<MI/!(Z*LJA77:02N1R*^B**^<RW-)813BX1G&:LXRO;1IKX7%IIKHR
M\TRF.-=.:J2A.#;C*-KJZ:?Q*2::?5=CQG0/BOJ-YXKL/!OBGPKJ/A^^U*.>
M2VDF>*>WD^SKN<!XV)X'J*]FK\\_VD_C;XB^'?QLT)]/T^WFCT&Q:>+S]P^T
M?;@4E&X= H7 QG!KZQ^#WQB\,_&/PW_;6B$P7=N1'?6,A!EMY2.A]5/\+=Z^
MDXCX;JT<#ALVHT5"E4BF^5N24FW;=MI./+NWK=>1\WPQQ)"OC<5E->LYU*4V
MHN45%N*C&^R46U+FV2TL_,];HHHKX@^Z"BBOFSXM_M,>#/AE=+HEGMUK6C+Y
M4MM#($BM3U_TB7!"$]EY8^E9U:L*<>:;LCORW*\7F%=8;!4W.;Z+]>B7F]#Z
M3HKYV^$7[2'@OXI/_9,C#2-<$C1I93.&6XVC):WDP!(!W'# ]J^B:*=6-2/-
M!W0LQRS%8"N\-C(.$UT?]:KS6@5Y+\:?$=YH7@B:PT<_\3?7Y8]'TY1RWG79
MV%@.OR)N8GMBO6J\$ /CKXX;N7TKP%:[?5&U6^7_ -"BA_(M6APGK7A/P[9^
M$O#6F^&M/4"#3K:.W7'\10<M]6.2?K70U'-*D$3S29VQJ6.!DX'/0=:Y3[5X
M@UT$6$9TFS8<7$ZYN7'^Q$>$^K\^U &UJ>MZ=I"@WDO[QSB.% 7ED)Z!47+$
MUS.HOXEU33;JX9CHMJD$CJ$(>\?"DC)Y2+_QX^N*Z+3-!T[2F::!#)<R?ZRY
MF/F3R?5SV]A@>@I^O';H>HMZ6DY_\<:@!=">631K&29R\C6\99FY+':.3[FM
M6L[1UVZ39*.UO%_Z"*T: "BBB@ HHHH *_'/XL>#[CP+\0=9\/RH5A^T/<VC
M'H]M.2Z$>N,X/H17[&5XC\:?@QIOQ8TF(QRK8ZU8@_8[PC*[6ZQ2 <E&_,'D
M5]9P?GL,MQC=;^'-6?EV?R_4\K-L"\31]SXEL?DA?:?;7R#SU.Y/NNIPP^A_
MITKZ<N_V/99/"D'C32_$\<%@VG+J-Q'?0,'B3R_,< Q[MV!TX%>:^/\ X2>/
M_AS:)=>)+**&">X%M%<1S+(C.06R #GH.XZTRX^+'Q,NM$G\.7'B.[ETZYM6
MLI+=UB*&!EV%1A 1\O'6OUG'_6L=&G6RFM%1N[O=/;R>J/EL.Z5!RABX._0\
MH\ _$3QC\.-8DUWP??BTFE7RV5HEDCDB#9"N&&<' )P0:_7WX&_%^P^,/@]=
M96-;75+-_L^HVBG(BFQD,I/)1QRI^H[5^,-YI<U@H8?O(1@;QQCZC^M?4O[&
M?B.72/BQ)HQD(@UJPEC9,\&6#]XAQW(&[\*\7C'(Z-?!SQ*C:I!7OU:6Z?R.
MW*,;*%54V_=9^L-8_B'7])\+:)>^(M=N%M;#3X6GGE;HJ+_,GH!W)Q6Q7PQ^
MW%XNGL/">A^#+:0H-9NWN;D D;H;0 A3Z@NX/_ 17Y-E&7O&XRGA5]IZ^F[_
M  /J<77]C2E4['S%\9/VFO%_Q5M=0\.6EO;:;X:NF7RK=XO-NF6-PR.\F0%8
ME0<*, <9-4/A=^SAXQ^*_A^+Q)H6HZ=#:M+);S"5G\R&6,\AE"G(((88[&O
MH+>:YD\N%2S?H![U]#?"[XN>/?A/H]UHWAN6R,-Y<?:7%S TVU]H4A<.G! Y
M]Z_;J^5U\-@_8Y,E&5^NS[WOU/C(8J%2MSXQMH\\\3^ $\(^*]4\-W]R+YM+
MN#;LR*4C=D R<'DC/3.*149BL<8R3A54#GV  KJ;V;Q3\1O%6IZQ!IKW5]>O
M]KG2QC9E!.%9MO)4%OYU]5_ ?]G75SJUOXP\?6ALX+1Q+:V$W^LED'*O(O\
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M?;2W5HHVB"9HU+H .@4\8[=*ZF@ HHHH **** "BBB@ HHHH **** "BBB@
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MTZ[K>VR/*P&5UJ=95*RM%'U77YW_ +=ND7K2^#]=1";53=V3/V6638R GMN
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MQC$>/;S'W,1^ -=710!SMMX4T&W<2O;"YE'_ "TN6,[9]1O) _ "NA50H"J
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH __T_W\HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^:?C7^
MS#X(^+X;5$)T77\<7]L@(EQVFCX#_P"]U'O7TM177@L=B,)4]MAIN,O+^M3#
M$86C7CR5HIKS/P\\5_#&Z\"^);_P=/J+>?HT\3+/!'M$C%0ZN5<9*G.,=#@\
MUEMJ,]EB/6H_+7<"EY!GR]P/RDX^:)@>0>@/0U^P?C_X,^ /B5,E[XCL6%_$
MGE)>VLAAN G8%APP';<#CM7S#XQ_9(72[*YU7P_XG5+2VC>::/58=RI#&I9L
MRQ\G@=UQ7S&;8?&8K$SQ51\S>I_3' OB1P]@\LHY95BZ3BK/3FBWU>EWKOLN
MU['DFL_ME>)?"OPNG\+2#[7XNGB\C2]5&&3[,?E:XF'_ #UC'"]G;!]:\G_9
MB_9^?XF:@WQ*^("R7.@Q7+R017!+/J]V&R\DK'EH5;[W]]N.E>!?#?P-=?&3
MXHVOAJR AM;^X>6YDASY=OIT!R[)G[H=1\O3EO6OV^TC2=-T'2K/0]&@6UL;
M"%+>WA085(XQ@#Z]R>YYKNPZFJ:51W?]:?YG3Q55P/#=.I@<EAR5<1[TVMXQ
M>T5UC?5VZ:^5KT:)%&D42K&D:A41 %5548"@#@ #@ <5YU\1?$>LZ:FE^&?"
MI1-=\1W+6MK/(NY+6&-=T]P5[F-?NCNV*](KQWXFS#0/$7@[QY<@_P!GZ5>S
M65^^.((=001K*?\ 95\ GL#6S/RG"Q3JI-7WLN[L[+[[$?\ PH[PPT'FRZKK
MCZO]XZM_:$HN/._OA ?+ SSLVXQQ6S\//$.MW,VJ^#?%TB3:[X>D19+E%V+>
MVDPS!<A>Q8<.!_$*],X(!!!!&00<@@]Q[&O))@(/CM:F X:[\,RBY [B&?\
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MR/Q)XBAO;?4EA6WDN-/NGMFGA0DJDNW(8+DXX!YZUZ)X'^'_ (0^&^B)X?\
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M<!E(]"#P:YUO"ME 3)H\TVF/Z6[_ +H_6-LKCV&*Z>B@#DTG\5Z:,7<,.JQ
MG]Y;GR)L=LQL=IX_NM5JS\4Z/=3M:22-:7*8W072F%QG_>X/X$UT55KJRL[Z
M/R;V".=/[LBAA^M %@$$9'(-+7*'PN;27S]"OI[ XYA)\ZW)]3&YR#]&'TH;
M4O$>FE1J.GB^B)PTUB<LH]3$^&/_  $F@#JZ*Q+#Q%H^H-Y<%PJRC@Q2_NY
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M^%OQ$WW%UX"\(:OI&GZ@P8F^TMB)+64L>"0GR]>V.U 'W#_PV/\ "B'X1/\
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MSBI.:;3YI\T7TU5DVO)M^=SXG&@?&Z+Q-:>%_B5XMM-8TJ[@>[N;2S@\HM'
MRA5=L [7<@8'49JS\;?$,F@>!+B.U?R[C4I%LT*\$(W+X_X",5ZMXA9G^)>H
MAQ]S2K0)[AI)"<?B!7S/^TK/(+30;8?<:2>0_P"\H 'Z$U[65152I1C)+OHK
M>?\ E]QY&-Q<L34=622?DK+[CY1[8%%%&*^[.(**** .B\(ZS/X?\3Z7J]NV
MQH+F/=[HQVL#[$&OTEGG$7EE8Y)%ED5!L7.T-_$WHH[FOS1\.Z;+K&OZ=I<"
MEWN;J) !_O D_@*_3-OD4A 6V*< =3M' _&OF<_Y>>#ZZE1%JCH$)O?BEIJ@
MG&FZ5=7##MNG=8A^F:I^']4N]9TM+^^T^?3)6>13;7&/,4(V QQV;J*6&^_X
M1WQSHNO-_P >NH Z-='^Z9F#P-_W\&T_6OGJL)<DX+>S*/HNBBBOD "BBB@"
MI<Z?87DL$]W;0SR6K^9 \D:NT3]-R$@E3CN,&F-IFFO>C4VM(#>!#$+@QJ9?
M+/5=^-VWVSBO/O'OQ+MO GB+P9X?GL9+M_&.K'2HY4=5%NPB:7>P/+#"XP.:
MZA/&W@V34X=%CUW36U"X++#:K=Q&>1D.&"INW$@\$ 4 :\&DZ5:V;Z?;65O#
M:R%B\$<2+$Q?[V4 VG=WR.:DL=/L-+MEL],MH;2W4DK%!&L: GKA5  S]*\+
M\._'6U\5_%SQ!\.M#L;>32O"L0&JZQ)J$";+ADW[([?/F.B8VR2<*C<&O8M#
M\4^&?$UO+=>'-6LM4A@8I+)9W$<ZHP[,48@'ZT 3W'A_0;N_CU6[TVSFO8L>
M7<R01O,F.FURI88[8-+J.@Z'K#I)JVG6EZ\8(1KF!)2H/4 N#@5R6J_%7P#I
MOA[7?$D6N6%];^'+:6YOUM+F*9XA$I.U@K'#,1M&<9/%,T/XK>!M8\$:3X^G
MU>RT[2]8@BFADN[F*,!I%#>66+;?,7.&4'(.: .HA\+>&+>">VM](L(H;D!9
MHTMHE24#D!U"X8 ],TEIX4\+V%PEW8Z/86\\?*2Q6L2.N>.&5013]1\3>'-(
MTI==U75+*TTUPI6\GN(XX&#_ '<2,P4[NV#S7%_#?XGZ;\2;OQ1!I<&R'PWK
M$FDBX65)HKK8B/YL;)D;2'XY[4 =4?!?@YF+MH6F%B=Q)LX<DGG/W.M7-1\-
M^'=8\HZOI=E?>0,1?:;>.7RQZ+O4[1]*KZAXO\*:1JEMH>JZS86>HWG_ ![V
MD]S''/+GILC9@QSVP.:74O%OA71]2MM'U;6+"RO[S_CWMKBYCBFE]-B,P8Y/
M P.30!OHB1(L<:A$0!551@ #@ #L!3J^<_'W[0NG^!-1\::?/HUQ=GP;8Z1>
MR,DJ*+@:M.(%5<_=,9.3GKVKT7XH?$2W^&?P]U'Q_<V4E]%IZ0.;:-PCOY\J
M1C#-P,;\_A0!Z/17G_BGQ[;:%H%_?Z5%!JFK6-K!=MI0NX8)O+G95!=I"%C&
M&)!; .,#FO++G]HS3[75+_2Y-%N"VG^,]/\ !SL)D(:6_@$PG'^PG0CJ>HH
M^DZ*\]T+Q_976G7FH>*!:^'A;ZC>V40N;Z!UFCM&QYH=6VC<OS%#\R]ZZ>S\
M3>'-0T<^(;'5+.XTM59S>Q7$;VP5?O$RAM@ [Y/% &W16!HGBOPOXE7?X=U>
MQU,;/,_T2XCG^3.-QV,<#/&?6M^@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#__7_?RBBB@ HHHH **** "BBB@
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M327.DZDX"W$]B547"CIYB$$%AV;KCUKL_ 'PE\ _#.%E\)Z7';W,RA;B\?\
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MW!$4*D*JI&F20JCJ237K5 !1110 4444 %%%% !1110 4444 %%%% !1110
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M/FP<<@-U(!Z5F:UK5EH4"R70:2>5A';VD0W3W$I^ZD:=22>_0=35C1?!NO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]/]_**** "BBB@
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M^.XI>'JXC!X.M*ZG4]Z%VN:/)/=)W<5+E;OIW/8?"?@+PAX'@>#POID%CYH
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MMU3L_P FOPN?,/Q*\8ZCXZ\'WUMX1\*ZM*=/VZE%J=]&+&*UELCYH= YWNV
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MY15KKHK]8NUXNU[[[Z?H!1117PQ04444 %%%% !1110 4444 %%%% !1110
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M-_;2![QS</+'\^ WW0PX(VKCUKTRRU*PU%-]E.DH'4*?F'U4\C\17G(P.%X
MX '8"H7@B=Q*5VR+TD0[7'XC!K[/ 9M+#TXT7&\4K=F?'X_ 0Q-65:]I/7N>
MM45YS;:WK%EQO6]C'\$ORR8]G'!_$5T]AXCTZ^80NQMIS_RRF&TD_P"R>C?@
M:^BPV94*VD79]F>#B,MK4M;77D;]%%%=YP!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!_]?]_**** "BBB@ HHHH **** "BBB@
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M.(QD.:G&2<EW2?\ 6G4_%^[19-2TZQ08CAWW3#T$8V)^9)K] _V->-)\7?\
M81M?_29:\ LOV1/B]%XH\M9++R\&&?5+JX,L4UN"2A6%0'5@?X<@<G)-?>/P
M8^%%O\)_#D^FM=_;]0U"?[3>W*KY:,X4(JHI)(1$  R<GJ:\++<'5A6YYQLD
M?O?BAQKD^.R66"PE93J3E%V5W9+75[+;;>_2Q[!7B/[1W_)%_$O_ %Q@_P#1
M\=>W5S/C+PMIWC;POJ7A752ZVNI0&%VC.'0Y!5E]U8 CMQ7O58N4)175'\_Y
M3BH8;'4<14^&$HM^B:9^*5T/(UFQN1PMPDEJWIG[\?\ [-7W'^R+XUO8M3U/
MX=W&Z2T>)M4L_P#IB^X+.GLKDAQ[EJ_._P 9ZC<:?K5WX<OK:7S-'OGC;=F&
M7S("5#''1L<^E?K%^RUX!\.^'OA[9>+[*[75M4\00+-<WY))6/)*VZY^Z(B<
M-ZL"364N$\SRWV>*Q,;0EUO?Y/SZ_J?MG&_BGPSGF5XC+<))SJJ2<;JUGUDO
M):KOKMU/IZBBBND_ R*>""ZA>WN8TEBD&UT=0RL#V(/!%>37_P !_A3>QN(-
M M].F>7SA<Z?FTN%D_O+)$5(^G3VKUZBNW!YEB\(^;"U90?]UM?D<&.RO!XV
M/+BZ49K^\D_S/FBX?Q]\-/&/A?PKIGB)_$UCK]W)$;+58PUW;6L*[I95N4P6
M6,8 #@Y) KZ7KYDT'Q5H$WQT\1WOC&[72KZRBCT?0;:^!@$MLO[R>>&1\(_F
MR<#!S@"OIH$, RG(/((KW^*HU(RPZK02FX)RDHJ*DY>]T23Y4U%M;M.[/G>$
M)TY1Q+HU&X*HXQBY.3@H^[;5MKF:<DF](M62%HHHKY,^Q"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP+Q)8G3/$=Y;@8CN,747
MIA^' ^C#/_ J]AU+7;:Q<VT(-Q=8SY2'[ON[=%'Z^U>4^+UO;@0:U=RAC;L4
M=$&(XX9>N.YP<$D^E?)\5^RJX1P3O*+O_G^!]9PNJE/$WEI&2MZ]OQT^8WPO
MK]_I<LNAVRILNBT\#R'Y8V'^L4*.23]X#ZUTS0M-+]HO)&NIO[TG1?\ =7[J
MCZ"O+E>:[EC72E:>YAD5XVC&45@?XG^Z!C@\]*]9/-?/97C:U7#*E4;Y8Z+T
M_P" >UFV&ITJWM8JTI;]_7Y_B[B9I**6O0/,$HHHJ6AB4M%%(!*0CTI:6@".
MBG$9Z4W!H+3#K124<FDQB]>M I"*6I: 3V[4TC%.QZT?2D%QE%.*\Y%-H*W"
MBBDH 6CK245+0%*]TZRU"/RKR)95'0GAE/L1R*HZ?HEMIT[7,<DLKE/+4RMN
M*)G.!^/<\UM\TA%9NG!R4VM3:.(J1@Z:EH^@VBBBK:,PIDB)*NR10Z^A&:=2
MT@)K._U+3,"SE\V(?\L)R67'^R_5?U%=?IWB*QOV$$F;:X/'E2\$G_9/1OPY
M]JXJHY8HYDV2J'7T/^>*]/"YM6HZ-\R[/_,X<1E]&MJU9]U_7]=SUBBO-['6
M-2TO"9:]MA_ Y_>H/]EC][Z'\Z[?3M5L=5B,EG)DKPZ,-KH?1E/(_E7T^$S"
MCB%[CU[=3Y[%8"K0U>J[_P!;&C1117<<04444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% '_]#]_**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** ,+Q+XFT'P?HMSXA\2WL6GZ?:+NEGF.
M%&>@'<DG@  DU^)/Q2\0:=XW^*WB#6_#(N;RUUB]\^TW0L)'!15VA 68X*\>
MH[5],_MN>-KG4O&.E^ (9"++2K9;^XC!X>YGR(R?78@. >YS7QGI.JWNA:K9
M:WI\C175A<1W$3J<%6C8']1Q]*_7N"\D>&PWU^_OS6BZ6Z??;[CY3.,:JE3V
M'1,ZNU\(^*-#CBU?6M*N[&SNMT,$MQ$T:R2*-Q W $_+STJY_2OL/X]?&_P!
M\0/!EMX9TJ";4M25;>[CO8L1VMK<;067<PRXP2K  ?6O%_@C\-XOBAXM_L?4
M+N.S@LU6YGCY:2>$'#+'QC.>N>@-?49?G-19=+&YA3=/EOIY=//7Y?<>7B<'
M%XA4:$N:Y]T?LN^'IM$^%EK=7"E9-4GENP#Q^[)VI^@KZ,JK8V5KIMG!I]C&
ML-O;1K%%&O1408 'X5:K\%S'&/%8JIB9?:;?WGW.'I*E3C371!1117&;!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?F!^V1\$]2M/$S?%+P_:/
M/I^H(JZH(EW&"=  )6 _A<=3V/6O9?V&-0U"?X;ZOIESN-K8:JPM2V=N)8U=
MPI] Y/3N:^N?%UVUAX5UB^C@-R]O8W$J0A/,,C)&Q"[<'=DCI7D'[.VM>#A\
M-]%\/Z+J-G)J-M;AKZU1A'.ES*2\@:-MKY#$C..U?ICSNKC.$9X:I1YG3G"*
MDNBLW=Z:6LHWOK?RU_,I97'"\84ZT*_+&I"<G!]7>*M'76]W*UM.7ST^@***
M*_,S]-"BJUY>6FGVDU]?S);V]NC22RR,%1$49+,3P !7S)J7[8GP0L#<I#J-
MU?26[;46VM7;S^<$QEMH*CU.*[,+E^)Q-_J]-RMV5S*K7IT_XDDCZ&\0>%_#
MOBNQ;3?$FG6^HVS#&RXC#X^A/*GW&#7A7P]TFXT+XL:OX7\'ZG>R>$]$L8UO
M;.[E-S%%J%P=R16[OEE"1#++G@D"JGAG]K3X3>+)SIMK>3:5J$JLMLFK1?9X
M9)<?(#*"ZJ">Y(K-\ ^,+OX4:1+9_$3PYJL%WJ5[/?WVM6<8U"RN9KA]V_?#
M\Z(%VJH*G %?8Y3@<RIX+$X646Y-)1INVK;UG&+W<4K7BKIR3Z'PW$%; 1S#
M"XJ=HI-N55)Z**TA*:V4FT[2?*U%KJ?6%%<UX9\8^%_&-JUYX8U.WU&),!_)
M?+QD] Z'#(?]X"NEKX>O0JT9NE6BXR6Z:LU\F?<8?$4J]-5:$E*+V:::?HUH
M%%%%9&P4444 %%%% !1110 4444 %%%% !1110!6BO+.=S'!/'(PZJCAB,>P
M-6:\I\0Z/96&L*;9/*6\1YOW?RM'*A +*1TW;L_4>]=AX8U2>_M9;>\;?<6C
MA&?&-ZD95OJ1D'W%>90S#FQ$L-45I+\?Z1ZN)RY1PZQ-*5XOONNGYZ'34453
MOK^UTZW-S=OM4< =68]@HZDGTKTI225V>9&+D^6*U+,DB1(TDK!$499F. ![
MFN*OM>N;_,6EDP6_0W)'SR?]<P>@_P!H_A5&\N;O5I ]Z/+@4YCM@<CV,A'W
MF]N@HS7SV-S1RO"CHNY[F%P$:?OU-7^"_P _R]2*&&.!"D2X!.2>I8GN3U)J
M5E5U*. RL,$$9!'O24N?6O%:/2OU&Q110((X$6-!T5 %'Y"G"EHI W?5B8I,
M4ZDH ;13B*2A,L2BEI*30!2=Z6BI&)0:** &$8HI]-(H*3$SW[T8I*7VI%![
M4@HYHZ4FA!01FCO14C&8Q14A&>U,(Q0-,;2T44AA24M%#0#<9ZTA%/I*D$QE
M%*124-%!1112 *B*8E6XB9H9D^[*APP]O<>QXJ6BA-I\T79AY'1:;XG*E;;6
M0L;$@+<+Q&Q_VO[A_2NQ!!&1R#7E3*&!4@$'@@\C%6=.U.\T8A(]UQ:=X"<N
M@]8R>W^R?PKZ+ 9W:T,1]_\ F>+C,I4KSH:/M_D>FT54LK^UU& 7-I('0]?5
M3Z$=01Z&K=?2QDFKH^?E%Q?+):A1113)"BBB@ HHHH **** "BBB@ HHHH *
M*** /__1_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#\>_VMK>:'XZZN\JE1-96+QD_Q+L8<?C7S6Y_=L?8
M_K7ZK_M2_ 75_B;#8>+/!R)+K>F1M;RVS,$^U6S'< K'C>C<C/!!(K\WM5\"
M>)?"NN_V/XNT^73+B%5F,,P&Z16^Z5P2"OJ03Z5^Z\)YG0Q.!I4827/%6:ZZ
M:7]#XG-<-.G6E-K1N]_4MV<1AM(8C_!&HQ[XKZU_9'\/W=]\0+KQ"JD6VF6;
MQL_.#)<8 7TS@9KP?P/\/_$_Q!U1-,\.6CS;B/,G(Q#$O=G?H,>G4]J_5?X9
M?#O2OAIX7@T#3L23']Y=W&,-/,>K'V'11V%<_&^>T</@Y8*$KU)Z6[+K?]"L
MEP,ZE95I+W5^+/0Z***_$C[0**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *X#Q-\+O 7BYO.UK1X&N1]VZA!@N4/JLL95P?QKOZ*Z<+C,1
MAJGM<--QEW3:?X'+C,#AL73]CBJ:G'M))K[F>*_ "_O]0^&]O)J%W/>O#?:A
M;1RW+F27R8+F2.,,QY)55 R:]JKYG\*Z5\8_A9I<FA:?H6F>)=+CN[JYC>"\
M:UNRMS,TN"LBLF1NQP:] \)?%&37O$I\'Z]X>U#P[JYM&O8XKLQR1RPHP1FC
MDC8@X)'85]1Q#E%3$8S$8_!N,Z3E*7NRBVHWO=QOS+S]W0^1X9SFGAL#A<NQ
MZG"LHQB^:$TG)*UE-KE=WM[VIX3^VWXHO-(^'&G>'+.1HUUZ_$=P5.-UO;KO
M9#[,Q7/TK\KA\EUST= %^JGD?K7ZA_MR:)<7G@+0M=B!:/2]4V38&=JW*$!B
M>P#(!^-?F#+&LJX.00<@CJ#ZU]UP,H+*DX;W=_7_ (:QOG;E]9=^R'D!AAAD
M'L:^T/V6_CYJ7AO7+3X<>+;IKG0M1<06,T[;FLIVX5-S?\L7/&#]TX[$U\D6
MGAKQ/=:&_B./3+B?3(93;R7D,9DA60 '#;<E."#SQ[US\\G[IE3+.WRKMX(8
M].>V.M>]F.!PV84)8>K9^?6+[^J."A7J8>:J07_!/VE^"UK;ZGJ7C/Q[##'&
MFN:U)!;&-0H:TT\>0C<<'<P8Y[YKWFOS!_8]^,&E^%M2N_ OBZ]EMH]7EB_L
MUI&W6JW'(92Q^XTI(QV)'J:_3ZOR7CK!O#YQ4A&7-#W5%V:O%122U[)6?FCT
M^!Y57DU+ZS3]G5]YSC=.TG)N3NM+2;NO)A1117R!]:%%%% !1110 4444 %%
M%% !1110 'I7F=OK_B#39[C3KKRKMX)& ,N8WV,24.1D,"O?%>F5D:IH=AJV
MU[E2LJ#"2QG;(H],CM[&N''4*TXIX>5I+[F>A@,11IMQQ$;Q?X'G-Q<75]=-
M?7[JTFW8JH,)&G7 SR<GDDUK^%KZUM=0NX;I_*DNC&("W"NJ ]&Z9R3Q^5;$
M/@W3@X:[FGND'_+.1OD/^\ !G\:Y7Q1I5MH2B2$>=9SL0+7J\9Z[D[[!U/\
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M04444 %%%% !1110 4444 %%%% '_]+]_**** "BBB@ HHHH **** "BBB@
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MHO\ WT*//A_YZ+_WT* ):*B\^'_GHO\ WT*//A_YZ+_WT* ):*B\^'_GHO\
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MMV"&^TM+\QER./FSP.PXK*TKPKK5]*UW*9-,$X*S75PRW&J7"<C;NYCMT/\
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M5GDEOYVD.2'*_P#?/%>JZM]R/ZUXYJ3_ /$PN?\ KJ_\S0 PO32]5B_>FEZ
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MG6L8#0O"_(5. O#<T ?H<%). .?2LK3-:T?6I+V+2+N*\;3KEK.[$3;O)N%
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M0^KX=/7=OR['W>1Y!4P=9UZ\E>UDEY]R.Z+B$N@)9"KKMZY4@C'OQ7MK^-]
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M44 %%%% '__5_?RBBB@ HHHH **** ,?5ONQ_6O$M4?&HW7_ %V?^=>VZO\
M<C_WJ\-U3_D)77_79_YF@"J7I-]1TM '(>._'GA[X<^'9O%'BB62&QA=8_W2
M&1VD<X55 QR3Z\5^6GQV_:!U7XNWL&GZ=%)I>@V#F2"WW_OII#QYLI7'..BC
M@>]?II\4?AQI_P 5/"W_  B>J7<UE;-<PW#R0!3(?*.=HW @9]:^$?VI?A?X
M+^&'AKPIIOA"Q^S^=<7)N+B0[[B<J@P7<\G'8#@5];PQ+!JK%33=5MV[)6W]
M?O/I^'I815(J2;J-NW9*Q[E^Q4\DGPQU0R.SG^V).68L?]6GK7V%7QW^Q1_R
M3#5?^PS)_P"BTK[$KR,]_P"1A5]3R\Y_WVIZA1245Y)YAWWA3_CPF_Z[?TKH
MY8XYHG@E4-'*K(ZGHRL,$'Z@USGA3_D'S?\ 7;^E:.OW4UAH&JW]L=LUK8W,
M\1(R \<3,IP>N"*:5W8&>3Z7^S9\!-%OH-2TWP/I4=Q;2":%FC,BI(#D,J,2
MH(/(XZUZ'K7@7P?XCO;C4==TFWO;J[TV31YY95RTFGS,'>W/^PS $CVKX.^"
MW[:]AI7P$^'WC'X[3ZAJ?B'QQJ&IV-H^D:>)3+)9R82/R8BIW,"%7:I)/6M#
MXM?MDVFM_LT^/?B5\%I;_0O$W@O4K#3KZTURP6*[L9)YU5A) Y=?FCW8[C'K
M7J/)L4JOL^7[7+?I>]M^USE6-I./-?I>W7N?:WB3X<>!/&'A^T\+>)M%MK_2
M]/$8LX'!'V;R5V(8G!#(548!!'%5;7X4?#6Q\&3?#RV\.6"^'+@EYM/,0,<L
MC')D<GYFDSSO)W9[UX?\)_VM/A]\4=9/@"VAUK2?$Z>'EUF(ZOIS6<6H0K &
MDN;0,27C#Y89"A@..*^3)OVP/'7A_P #_!3QI<>)IO$&F^)_&.K:9X@G@T5(
M;J]L[1L);P6J&1A(I^52C N?2E3R?$SDX6L_._9OMY,)8RDES7T_K_,_1"U^
M"/PEL_"6H>!8?#%E_8>K2++?6KJ7-S(GW'DD8EV9.-ISE>U=?J/@_P ,:OX8
M_P"$+U73XKO0S!%;&QERT9AAQL4Y.2%VC'/:OCGQK^U[X5\4_ OX@^+OA]JF
MJ>"_$/@F6VM]1AUG2 ^HZ8\\@52]D\@#K(. =_'?M5#PO^UQK>J?M1Z1\")]
M(O;C1YO#5E</J,>G,)KC4KJ%)?M4AW%8;'!^\!C<2.U*.48EQE+EMRWO\DG^
MJ&\72NE?>WXGVW-X7\.W.MP>)+C3X)=3M;*33H;EURZV<N"\//&QL#(KC?"O
MP5^$_@C7F\3^%/#%CIVJ$.J3QJ285D.7$(8E8@W<(!FJ_BSXR^#_  5\3/"'
MPK\0+>0:IXX$XTBY$(-B\UORT+R[LK*?X5VG/K7S7\7/VK-%O?AQXA\0?#+7
M+[0#X5\9Z=X7O=8ETI+ZWN+B64+-#;HT@WJ?NM)P4/0&L:& KU7%1CH[:]-7
M;\RZE>$+W>Q](6OP$^#-CKQ\3VGA'3HM3-XNH+<*AS'=JV[S8USM1RW)*@9/
M6M67X0_#&?6[_P 1R^';-M2U2\M]0O)\$&:\M&W0S,,[?,0\AL9]:\:U;]L'
MX8:3\6[GX)#3O$6H^)=/N;:UO38::;BU@%Q&L@N))5?Y(1GYF(&#P :I^%?V
MU/A)XH^(&B^!%TSQ+IJ^(]1ETS1=7U+2WM=,U*Z@8AD@E9MQR1P2@'KBG_9N
M*Y>;D=K7^7<7UFE>W-Y'N7B_X1_#3Q[K,'B+QAX?M=3U*VC\E;B3<&:('<(Y
M-I D3/.ULBI=.^%/PXTB&QM]+\/6=K%IEO>VEFD:86WM]1_X^HT&<*LW\0'X
M5X9^S5\5?&_Q&\<_&O0_%UXEU:>#?%ZZ3HZ)"D1@M#"7*,5 +G<.K9-6_B;^
MV'\(_A7XPU'P9K,&N:I<:!%#/X@N]'T]KRRT2*<@(U]*K 1YR"0 2!2>7U_;
M.C"-Y))Z>:3_ %^\?MX*'/)V1Z#J/[.WP/U:X@O-0\'V$D]K9Q6$,@WHR6D&
M?+B!5A\B9X%377[/WP7O?[.^U>$[*3^R8/LMKG?Q &+")_F_>(&.0KY KSSX
MA_M>_"CX=^)M/\(3VVN:_JFKZ(GB#3(=!T]K_P"V64@W Q[6!SM^8[@% ZFO
M$OC7^W;I.@_!KP7\4OA!I]YJL'B_74TUWN;%G:RCMY MW"\8; O"/EB0DAB>
M*THY5BJKBHP?O;/^O1DSQ5**=Y;'V1+\'?A=-HNC^'6\-V:Z;X>NS?Z5;HI1
M;*Y9MQ>$@@KD]0#CVI=3^#WPOUGP['X3U+PY9RZ5#=RW\,&TJ8;J=BTDT;J0
MZ.Y))*D9S7AFO_MJ?"W0_'L?PS&A>+;[Q'+;V-T;"STDS2Q17Z[T,P$G[LQ@
M@2;L!3QS6G_PV)\'_P#A5T'Q8!U0Z=<>(_\ A%$L!:K_ &E_:OF^28C!YF.&
MYSN^[S6;RW%))\CUM;Y[%+$T[M<VQ[;8?"_X>:7I.CZ'IV@6=O8:!>#4=-A1
M,"WO!G]^#U,G)RQR3FNBL_#NAZ=K6I>(K&RBAU/6?)%_=*,27 MUVQ;SWV#@
M5XM^U+X^U7X8? CQ#XYTC66\-7M@MJ4U#[$NHM;F:15(-LS*KD@[3\W%<'XQ
M_;*^&7PYUUO FM6/B/7/$ECH%AKES#HVEFZ\ZVNH%E>8!7 0(,O)NP%!P":*
M. K58*=)7O?;RM_F@GB(0=INQ]?T5^>/Q6_;HTW1+OX.7_PTTR^UKP[\1KK[
M1=W::>\UQ]B1C&UM;1A@#=A_OJ<[4&0:]7^)'[:?P=^&GBW4/!]]:^(-8NM$
MABN=>FT;3'O+?18Y@"OVV0,/+8 C<!G'UK1Y3B_=M!ZW_!V=^VI/UJEK>6WZ
MGUO17,:=XT\*ZOX.A^(6G:G;S>'+BP_M1-1#?N39A"YD)[ *#D=<\=:^;OAS
M^VI\'/B9XRTSP=I%OKVG?V\+AM#U75-->UTS55MLF0VTY8@@!2<L ,"N>G@Z
M\U*4(-J._D:2K0BTF]SZXHKY+\*_MJ?!3Q9XXL/!]C_;4%IJ^IRZ-I?B&ZT]
MX=#U'4(3A[>WNB<,^00,J 37R?XW_:G^-FA^ /C5KEAJ\$=]X-^*&F^&=(=K
M2(B#3+@@21,I7#L?[S98>M=E')L3.7(URO3?3=V_/<REBZ:5T[^A^LE J&V=
MI+2VE<Y:2"&1C_M/&K']34U>4=(E+110 E+110 4444 %)2T4 %%)2T %>*?
MM$/=)\(-<^R[@6-LLFW_ )YF9-V?;IFO:_:OA/\ :(^+VL76MW_PZT";[-IE
MJOV?49$ ,ES*P!:/=_"B< XY+9KZ'A?+ZV+S&FJ*ORM2=]K)HX,SQ$*6'DYO
M?3[SY0^E<EK=ZMQ*+2(Y6$DN?5^F/PKZ,^ OA[P5XB\>VWA_QKY\L5T#]B"R
M;4:=.?+D/WB&&<8/48[U#^U5:?">V\9>;\.KI7U5<0:K8VD8^Q(\8VAA*#M6
M7  95# ]20<Y_;,1G,8X]9=R2NU>]M/Z\^^A\93P;=!XCF5KVMU*W[(\MU%\
M;M,%N#MEM;M)L<XC\LGGVW**_7^OSK_8>\(Z'=2:OXYDNTDU:V'V$66/GMHY
M,,9">_F8PI'8'/-?HI7Y!QOB85<TDHKX4D_7?]3ZW)J;AAE?KJ%%%%?(GJGR
MI\6OV4/!OQ&U.?Q)I%R^@:Q<G=</"@DM[A^[21$C#GNRD9[YKYMF_8=\>I<;
M(-=TR6'_ )Z%9$;_ +YP?YU^GM%?18/BO,\+35*G4]U;72=OO//K99AJDN:4
M=3XH^&W[&?ASPUJ,&L^--1.N36Y#I:QQ^5;;QSE\DLX![9 />OM955%"( %4
M8 '  %+17F9AF>)QL_:8F?,_R]$=-##4Z*Y::L%%%%<!N<3J/@/1+V9KBW\R
MRE<[G,!PK$]RARN?PJE;_#G2U8&]NKFZ7NA(C4_78 3^=>AT5YD\FP,Y^TE2
M5_0]2&=XZ,/9QJNWX_?N<OK$D.CZ9'I>E(L#S_N85C  C7'S/C_9'/UQ6$EO
M"EN+4(#$JA=K#((]\TZ6Y_M+49[_ #F)";>#_<0_.W_ F_0"I*\C'5E4J>[L
MM$>EAZ;IP][XGJ_7_@?YG*W?A*Q?+Z:[63GG:GS1$^Z'@?ABN;NM-UFP/[^T
M-PG:2U.[/U0X8?K7IU*,BO!Q&58>KK:S\CV:&;XBGI)\R\_\]S \/6,EAIB+
M<+MGF9II0>H9SP#]%P*VZ>>::0:]"E",(*$=D<-:K*K4=26[$I*6BM#(2OG7
MXY_$Z7X9>*/AM<WFJC2M!U/6[FVUEVC,BR6ZVLCHIVJSC]X ?E&:^BZ\=^)'
M@'5_%_C7X<Z_8_9FLO"NL7%_J"3M\S0RVTD*B-=K!FW,,@XXJZ/*I^]MK^1E
M6YN7W=SS.V^/.B^-?CKX3\*_#OQ$FHZ-/HNM7.J6\<+H#/ BM;L3*BM\OS8V
M\>M;WPB\<>*?$O[.3>-]:OC<ZV+/6I?M155.^UGN$B.T +\JHHZ=JZK7OAWJ
M-_\ &CP?X_L([2'2M#TG5[&]0?NYVDOU01[%5<,!M.22,>]>*6'PV_:&\%>#
M]9^#W@Z'PY>^'+^6_CT[7+RYEBN[&TU&1W=9+94*RR1>8VTA@#WKH_=RBE'3
M;?Y_\ Y_WD9-O7^D>:^)_CO\4?#NF? [Q0FIM/8:GH9UCQ;'Y2?Z7;(T*RR=
M/E*"0M\N*]8^+_Q:\7Z=\=OAYX(\%7PAT1[ZS'B%U57%PNI$BUA#$$C*(S\$
M<5OWG[/C2ZAX'T42PW/AKPYX-U3PO>M*Q6>5KV&.-'1,$$94L>1CCK7%^#OV
M>OB)I&A^%;CQ+?V.I>(].\7V>LZI<B5@LFFZ9 ;:TB0E,EUC )! &YFY]=.:
M@[/3K^-_R_R,U&JM-2U\:?C%XZ\-?$II_!\V?"GP\AL;OQE"(PYN4U281B,,
M1E6MX<RG';K5_P#:'^*GQ"\"^,? -Y\.A_:FESV^H:KJ^FQJK-J&FVD:R.8C
M@GS%C)= ,9J3P[^RMX:\0:7XAU;XR6HU+Q1XJU"^N[Z6TO;@01PS$I;0@*R*
MXAB"_>7KFKOP_P#A%\2-'U7X8WGB^XL+L>!++6M*N9HYF=[FUN%\NR8*4&6\
ML 2 GC'!-1>BK6UM?YZ?Y_H5:J_F='HWQ.E\5_&KPW9^&M3%UX2USP7/K<,:
MA=LDWGHJ.3]X,JDJ5SP<YIOQ+\3^-=<^*.A?!;P)JO\ PCKWNEW&N:QK"0I/
M<PV<+B)(;99 4621SRY!V@<5S?P\_9\U?X<?'K4_&NC7D+>";G3+F+3].9SY
MVGW5[,LL\428QY#.N]?FX)(Q7;_$SX?^,YO'6@_%OX8O82>(=&M+C2[O3M39
MHK;4=/N"&*>:@+121N R-@CL167[M37*^GX^9?[SD=^YC#3_ (Q_#O2O&AU3
MQ&/$V@VN@SWVC:I>)''JMK?Q(Q,,JQHL<L> &5S@@\8KP7X8_$*R\4:7X6NM
M5_:#O?[;U2.T>XTE;.VP;F7!:WS]GSR?EZ_C7N]OX+^-'C#_ (2S6?'U[9:4
M-5T&XT;2/#>G7,D]E#),#FZN9F5=\S$[1A<*M<YX#T/]HCP9X8\/^%G\%>"9
MTT:UMK-KO^TI1,ZP@*9,?9OO8R>O6M(RCRN]K_+_ "_(F2E=6O8]$^%WBSQ#
MX@^(7Q3T75[HSV?A[7+6TTZ(J +>&2V#LH(&3EN>:+'Q9X@F_:.UCP/)=$Z)
M;>$;34HK7:,+=R7)C:3=C=RO&,XK@[3PK\>? _Q"\>>(/!.B^'-7TSQ=J4&H
M0MJ.I36TT7DP+$59$A8<D'O5C6O"OQQT[XM?\+2\):/X>OGU'PO::/?6E[J$
MT"P7,,IF<Q,D3%TSP"<$^E9N$6V[K5?CH6I222:>C/J6BN;\*7'BNZT*WF\;
M65EI^L,6\^WT^=KBV0 _+MD=58Y'7(KHZXI1L[';&5U<=124M24'6CK112L
MS%'(XI_:FFEZE7$HQZ4M%#'<2DI:*EH!***6D,0C-,J2DX(IC3&4E.((I*"[
MB4M%%)JX!1S125  13*DI",]:!W&44446&%%%%(8E)C-.I*35A#.E%/II&*-
M!IB5%-$LT9B8D9P0PZJPY!'N#R*EHI;#.V\/ZHVHV92XP+JW/ES =SV8>S#G
M]*WJ\KANWTR\CU./.U1LN%'\4)/)^J'YA[9KU)'61%D0AE8 @CH0:^URO&?6
M*7O?$M_\SY7,L)[&IS1^%_U8=1117I'FA1110 4444 ?_];]_**** "BBB@
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M %3/^PN!]<U[E7\_\28^&,S&I6I_#LO.RM<^\RZ@Z.'C"6X4445X1VA1110
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M4M% $7D0?\\U_(4>1!_SS7\A4M% $7D0_P#/-?R%'D0?\\U_(5+10!%Y$/\
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M-<_E7IY17]EB%%[2T_R.',:/M*#[K7^OD>A4445]D?)A1110!__1_?RBBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,BH-^ Q SUP"*_.\CQ^+PU9_58\S:VU?ST['W6:8+#8FC;%.R3O>Z5OF^_\
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M_P  ****]4\H_]/]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZHXS I,#BEI!VK\_/KP &*3_ !IPZ4G^- (,"C S2T=Z 0@ HP,B@4'J* 0
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;:R+^-+T_4\S-_P"!\U^3.GR:,FDHKZ@^:/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>business17a.jpg
<TEXT>
begin 644 business17a.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_X1<417AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   !(     0
M $@    !    1TE-4" R+C$P+C(X   R,#(R.C$P.C Y(#(R.C4Q.C,X  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   "9     @$#  ,    8 0   P$#  $    &    !@$#  $    &
M%0$#  $    #     0($  $    > 0   @($  $   #N%0        @ "  (
M /_8_^  $$I&248  0$   $  0  _]L 0P (!@8'!@4(!P<'"0D("@P4#0P+
M"PP9$A,/%!T:'QX=&AP<("0N)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R
M_]L 0P$)"0D,"PP8#0T8,B$<(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\  $0@ F0$  P$B  (1 0,1 ?_$
M !\   $% 0$! 0$!           ! @,$!08'" D*"__$ +40  (! P,"! ,%
M!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()
M"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T
M=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%
MQL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$!
M 0$! 0$        ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P !
M @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:
M)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#
MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3
MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ]_HHHH *
M*** "BBB@ HHHH ***P_$*:M-$G]C38E1)-R!@-^0 !ST(R6'NH'0T ;E%<S
M##XB6SU$3,SS-(K6Y1E&(=_S(,G_ %FT'#'C++TP:K79\5202P6MN\<0AS$[
MS(TN[L&;.,]<]1TYZY .OHI!T&:6@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YS7-;6T@:5]QB#;$13@R'
MW]NOX>M<FOBR82+BR@"*?E R"/H>WY5H^*8&ETJ*9.5B?)_W3QG^5<;7I4:<
M>41Z7I>IBXMUNK6:5U)^:.20MSW7D\&NCC=98UD0Y5@"#[5Y[X/#I!=R,<1E
ME SZC.?YBNXTTDV?.-N]MN/3/^.:Y:\%%Z#+E%%%<X!1110 45BZAXJTS3=5
MCTZXD<2L 68+\L>>FXUM53C))-K<2:84445(PHHKGU\3)<Z-J]S;Q[+K3UEW
M12'/*AL'CL2I'X&FHM[ =!165X<U.35M%BN9POG99)-HP"0<9_$8/XU8GU>P
MMM1AL);A1=3?=CP3],XX&>V>M-Q:;0$R7EK),84N86E!9=@<%LC&1CVR,_45
M/7-W'@ZVGOY[O[3(K3$EDV*5R6RWY@*I]E'0TZ/PE D#1R7<LN5QO91NS@C)
M/?KCGM@5('022QQ*&D=4!8*"QQDDX ^I)Q3JY1?!43RS?:+IGA:1'5-HY"E&
MVG/\.4P%Z &FR^#9%NEGAOW<LZ>8)>  I)W  <O@[<\<#KZ@'6T50T;2DT;3
M([*.5Y53^-SR?<^_K[YJ_0 4444 %%%% !1110 4444 %%%% &'<VRPR&!P&
MB=?EW#@CG*^^!_.L67PQIDDF\)(G.2J/Q79RQ1S1E)%#*>QK)N["XAMIY(YE
M;RT9E!7YFP.!Z?C71"K;J"5]#-\E+...&&+;$.@'0<9[G\?6KUE=26:MYTH6
M,[659L(JJ6)8@\DG!!P?45=ET^W\O[1$K,R@,.KY'!("DXR<54,BB(;KE521
MRAF!"B3&U278+\K@@@ >E)R4D!HVMZLX*N464,5(1BRYR1@,0,GY>1VJU6$'
M9/,),1>&<2,EP3(\+.W0%>VT\?7FMF&0RQ[C&\9R1M?KP<9_'K64E8"2J&K7
MMS86T<UM:&Y/F;74$@A<'G@$]<#IWJ_6?KEW<V.BW=U:1"2>-,HI_G^ Y_"D
ME=V0-V.7\2Z!>ZD_]IVMFK78'E2Q, -R8'S+G^(9(SGG'%:MMK"PV-C97.HP
M1:H4 :.4Y+-R K'L2<9[UR^CGQ+KM[;7J7UUM0@2N6"Q+@GHHX;C';K4GB73
M+Z+6[AQ9PZA;F E"5VM;@\ LPQT.2"2>YXQ7=[)NU*33L<[FE[YZ+'O\M?,Q
MOP-V.F>]-N)XK6VEN)W"11*7=CT  R37"Z1:^(+*SCL]5N9[>"0D1LIWLAXP
M"5YZ]L],^E:%SXKBT@);W$R:EN^4F%=K?J=K=^A'0^AKE=.TN5.YTI7C<BU?
MQ3=VE_;W5A/;76G3QG:F.=R_>!/53RO7/?BN3N[Z6\O;JY"FV^U']Y%%(=I'
M<$\;@3SR.YJ.[-I+?S3V=K]FA<Y2,D$J,#(XZ#.>.@JK=W*VEL\SC(7H/4UW
MTZ48K;4S;-;3M;U'2HI(K.<+'(VXJR!L'&,CTZ#VXJ]H-[I%A)-JVJW,L^H!
MR43821QRV>F3SR2 !QQ7G#:W>F7<'4+G[FT8_P :Z'3;X74<-RBJ)(I%8JPR
M-RD'D=QTJITDT_,>J/9K>_AN+&"[),,<RAE$WRD9Z ^]6:X*PTK4/%]PFHZK
M,HL%8A(5X#@'! '\(R""3DGGH,5WM>94BHNUR@HHHJ "BBB@ HHHH **** "
MBBB@ HHHH *:TB(&+NJA1DDG&!3JS;_1+74=0M;R8N)+8Y3:1U['\#SQ^/%
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MP98$')],5E>"O%46O:CJ]C:/%-86 @%M/'N(<,GS#+=<,IY]Z[&J]W$KV$T
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MAV+RR?P*1@#=[#)..Y QTJSIBZ5H%X^EH%BE$,<KW$K*&F+,R@9ZDY!XZ#(
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MKL7%NZ%7 !#'&*U(K7R-/2T#9)38#CJ36[4;+4Q3=S5HHHKG-PHHHH ****
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MH **** "BBB@ HHHH **** "F21++C=U'0CJ*?10!76T /S32./0X'\@*?)
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M4T94                                  #VU@ !     -,M;&-M<P
M
M#61E<V,   $@    0&-P<G0   %@    -G=T<'0   &8    %&-H860   &L
M    +')865H   '8    %&)865H   'L    %&=865H   (     %')44D,
M  (4    (&=44D,   (4    (&)44D,   (4    (&-H<FT   (T    )&1M
M;F0   )8    )&1M9&0   )\    )&UL=6,          0    QE;E53
M)    !P 1P!) $T 4  @ &( =0!I &P =  M &D ;@ @ ', 4@!' $)M;'5C
M          $    ,96Y54P   !H    < %  =0!B &P :0!C "  1 !O &T
M80!I &X  %A96B        #VU@ !     -,M<V8S,@       0Q"   %WO__
M\R4   >3  #]D/__^Z'___VB   #W   P&Y865H@        ;Z   #CU   #
MD%A96B         DGP  #X0  +;$6%E:(        &*7  "WAP  &-EP87)A
M       #     F9F  #RIP  #5D  !/0   *6V-H<FT       ,     H]<
M %1\  !,S0  F9H  "9G   /7&UL=6,          0    QE;E53    "
M !P 1P!) $T 4&UL=6,          0    QE;E53    "    !P <P!2 $<
M0O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_" !$( B8#E0,!$0 "$0$#$0'_Q  >  $  @(# 0$!
M!@<%" ,$"0(!"O_$ !P! 0 !!0$!               $ 0(#!08'"/_:  P#
M 0 "$ ,0   !]_
M
M
M
M                     >6!9QACKF[QYAF]Q+S04WL+Q
M                                     /*DTE+I+[-F"KC5X^R)GIT;
M*@                                                   %5F(.^8
M<O(TY+^*W.^6R2H
M     _"GMW2%[5@9;N8DA@I!#9Z,L;65^P
M                         #Y-:.MIE\U<'EI56SIUZK0UU9Q#KTKT4NIM
M!QM>W:                                                   % =
M+3EF5UKW]NJ'3V_%0^J-O.6NV.T-WX8^-387F*@
M                             <56JG<TR]CS:] L^:@!^T;U\9?<&KK#
M)--DN+KE<0                     "&GG^18]#":&%,:?A(S'&FYN\1\Y#
M('5)L                    =&]JYW-,5D:"]Q8  +>U-=[N-O')KZ7AS]0
M                 /DCN=),   5H?SVFR)4A;AM2:N&!/HN(@!$B2'7*--G
MSVB                    !J3W=,YC>;'H-GZ  6+KZ^@_#WB,6TV;Y&H
M      Z-]O=LN_0      0^2P.99T!JAT+S2](P>['BV?D  ,(:IEDE$EG'3
M+2-82!&PI-RM3]/-LW5+>-N0                   #"YFNO9TF$:OGKW..
MO9X #9?G;MH><KE+*XC!38OEJ@       4=O8/DM[MQ&S?+[+T]\4[+Z5
M   U:Z!YA>EX/<OQC/I5U31;TF![#>+S[/@!^&D_64E\5M5SM0
M                 ()/I6/2URN-7<ZFAW:68C, D,=Z \/?S6OBJ4:=>>@J
M       !HIZ!H?,WUOE;96^N_P ]=_9NIE@     =*YX5>WQ-Q>)DXK(H3MM
M=OOY;L]MN<#S6[ZS6+N(.P_&S?3_ ,[R
M<=6I?<TL2+48?)2AMW2MI])!@;%:&[K7,EC=>JHYE-B>:K>V@J      .@=P
MI:?@\D?<^*LNVDVC9?5GPCN-5"4E]G.  #X/*?TFS:CF;]LN<>./K<>';N-Q
M$IMLP4.5L[R4BK-K94731+*YR7ZV^89<KC
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M75+M]-')^"L=G&V YW8>@/EWIM4;.7G<.+8G3<O^E<S7DAZK@B&UP6-9A^@
M##5N^3-4M_08[72_9[Q^3KONZ>:?I\2<:K-[%^3Y@
M        *^V-*'ZES6TKB-WN_/(<)^E"]!3@N=:ZF3Q5X*IE"5)N*9/$[ME=
MA^<J   ! Y^#Q,]_X2;ZN5!^GU<[BY/4GP/N_%3Z X3:GB-U6FVB4MT,#9WS
MWT?:CCN_K';:2:Z7M[]UG(7MKN6IS9V^1WLD"=V8@!TU=9Y$VNLF83BS%L['
MA92EL=IDLO0R*>Z#!QQ<_K1Y3(O#5                             !I
MKO?1MQ=%YWRK1KOT=))&0V;2Y=)77GHZ7IH:R*,KK9*IV]-O..N   &N'3:W
MR#]YX>RXU\ZULC?'ROJ-E>/V^C?IO#>=_O\ \_R3B/6KCX_L+0Y3U:Z.0B[7
M1-%2*OF3ZIOXOL=?\S-'-KX_V #6G/-JW+G $[LQ;6QH Z*LTYG8>K7FU^<Q
M                              *&V/32'%CMB'SHB\JFO'24GVNKJMUM
MOHQYK?HAW]N[O"W:[]);??/5D,>H   Z5]NBWIW-9N-EW5\XZ'FI4:4>\_.V
MYOAGT%HM]!_->^?SM]-\-;_/"EDQ-62Q^YMUV[B),+\  '0K72B5L_FH ?AN
M;$UN<I;#K\GK=XUL+?UH                              5Q+W^MN]G;
ML\OR0H;?TFL%U+TGBM*^XMNO178W+3)8U3S8.ZW'SLG9<     !0/H_E^OWI
M'EN&GZ[T8^8?K,1PA9(JM->LIJ%Z!#D&?  !![LNI\J> !^&W<77RZW'BJUW
M4\UV6[O*5                              %4SNAT7[:/Z"\)9A,V:U(
M&CUJZ>VU-36(S%<;.E]<]76_IZ9; U#W?-X++B]C_,.K   U\]*\KR,67']E
MJ\I$F=3-@CFTU%]^<^HS#2;W03Z.^8-O/%?=[ YOJ136S>7_ *9@Z.VB9>EH
M  C-U^GDK8_H .Q2FZL36]M3!UNA=V7T)\VF;Q\C4
M      8LRA "?&L_9:?7SK]3MWYYO[@T,_\ 3Y5T,ZKU:J=_YM/(,G?_ (?3
M9"RX"EMW2Y=+7"YJ>/GI?*^>/;\WN?RVY]X/'^V  '%?9I)[W\Z=;+B^J5[>
M'-<_"^ASCG^BDNJV^8A;#0WZ(^9=\OG?Z:%.;-Y,>N0Y=ECP&_+F-?F[EB)[
M+%8EN'Z!^&H<G812_( -A\$.X<4?X+!Y+9;6<U=<NL6;
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M_K-7YJ^Q\CA)<3:C<>&W;SNZOCSSTNU^.[>=\]TP   TW] \^V(Y/K+ U>U
M\^O4_+(/L];C,V#U0\3]L&G/?\!I7Z7Q&V7.2=Z/&/;0/);T_%7\ZGLOY+FU
MG[/B,CBS;,\=V( H[;/)WV'7S>S&  !"JY=PO/YU+;JS9WG+]V^3J
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M+NNYCR 0F4\4O;(,B68&))L"3#A=,W2LR2W+'@5<TUA7>VOB\KFH
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MWESZK#X\.3V#\DD6C #2KJZ:V=#9ZT>9Y //?MK;!@5W'YBH
M                      @^RUOCY[?Y7B9NA]T?G'Z$ UC.B:HG3,L;; PQ
MER/&KAP@VG)*84S1##68'X;D'V7&:<^H^7;5<1V^@O6[&NYV7U9\UR3B(
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M3NUQ/;2,                                      ZAJ\90 'P<YF3
MGZ=8[(.L8DZA(CL  CIFSY.D9,^S@/PFY7IT3-'. =HV. !C3IF8.8
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M1 ]MJ()Z!Y_76WU6$DQMR?$/;<9@D5 7X:_DC)01D[QO2
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M9LLLAQ5IF#LGZ<9*"O3].L<YGSY,:<6VU]A384CL=2^G4IDG&IV,JAR0
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M..L62<-%T74X-E#XY4'(X[HE+PRJ)FYZ5$3RW6QHML
M               /PJO>:OKR(LACY,5ELB4JSZMNS^"[ZI6!;&-)HV3.8+NO
M<@\^/(8N;*XKL99? ,$C(:;9<M*Y R9?!'"I3#  P4G#:^S@Q%2/X[\GJY_[
MCOZIT-G"F<Z%G,N+\HBDO%.(6:51,PZ5]L2D+;Y_<=NRX
M                   =6^V+S(_4OMP>PU\MBY !!YF.QM)MH5LH.<IA[=MP
M'R4KBS]K6;#8Q6&;")')\+AOLQF.^!QI,@U4_/$0V4*PYT"7Q\@%;R<</T^U
MF\G#*I<'+XKP!7.QC<^"3GXV;(8,T[ULS]
M          *?Z+2S2+=16^U]);^!<.DF[ \[LA&+\O3DQ)G#S="^V.R<4PAY
M_P!.*M,1;)Y+:_,F'FL-X'4NMC=^2=:R?$-MJL[@OHCH-?\ 1>W/[#FI6(R*
M?BDOCW=.^E?["-/-?(R%EPB>:ML:';@
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MSW_/_JHW0X7>3B#(B,S#9&@W62Q9
M ,$?)7YB#*&0.\9*?%Z\S7]ZRZK=K$IG>0;?TLVV=1,$#EVY>VS]-)>\T/5O
MI9VHE[=<=N1!YT><09%-;J#JYUVI$VU^?=+A]Z*[V4:Q-;)ALW!J-V6FY[:[
M>\9NI/%RQ"9AZ=:SB%ETL[G10V?@DD3+NWPF^[-M89,PVYSF]^Z5
M                          &MA%37,VK-G%*AZ/1S2)E  PN:S,:_8Q'8
MPIA@I&9.*'S<%G:N7V+:\:E2;:-;^IE<5::W]-K(U+P[%\SM)?#S<=:4_M8]
MR:F2 H5"(YV6BR>SFB<U*P+81IQ D=ZRX1/-6V-#MP
M                (25.8<NHGA!]E"QDV!G\&0#$9;*RV.*PM7-Q^6R$[*#<
M>GE\M*CK74ATA+=?-^9,'OV7  0N7BL/2;>![K4RV+D $'G8,7?7-8+X[*P2
M6-DE\3,.*M(5+LM/0;C)XL@
M$3FQHQ/A?-UG#6L#V<*Y--,YZ5&(S64_MXEH:?8*5@FQBRZ)D^;K<9FQY7%=
M-(6<"%S<&"R5ET&1&)>)=9DK:# Y[+!U^?*XKP,9DLK78X9OK9O<Q9;"U4[D
MI4                                       "K-WJY-9C_0 <-:8&N;
MKWVR;'CYJ5 Z-]M=[&/*(4F%SXUA0,V<P9 (G*Q9_7['NXK\'L=;W+:ZP]5J
M<5FLV:Y7:RF+FBLK%8>BW.3Q9
M      *EZ'2RZ-=4VWAT7T&OLW52]@.=V(@D[#EL5TEC9,=DMZ-]N?P9!B<M
MGY&FXR= E47* !$Y6/'KYY%KKYT6MUZZ;6BS]3+VYXW<C%8Y5@ZN<
M                                 !3?3:"7P\VA/H?.]:^GX;K<)O9G
M"SP2?'G<"1$Y>'3/N-'C\MNS7*;6[M%/%,[B)<VGEX?-9JIUVHQF6S9_E-M-
MX.<5AM(MGZN5K[T6MUYZ;6BT=1+VWX[<C!TD61J-@
M                     !4/1Z.4QK]"/0^=Z]]/PW5X3>S2%G@\[!.(.?7W
MH];KSTNM$P@YMV.%WPK/:1;,U<K7;I=90'1ZX6/JY6X/%[H02?'G<"1T+[=9
M.JU6*S6;,\MM9-%R]2^GW$G337RP
M        *HWNIE>*VI]O#HKH-?9FJE[ \[L16^RC3[7R*^V,;4+M=*+IT,_9
M_E=J*:W,.Y=-,H7H-=KCU&L%JZ>9MGQ^X%0[:+;6JD\E*@ 0>9CN+F]W]*@
M                                       8W+CK'?:>:1,@ Z-]N.LD
MX:7$G$3)7NQC8"1CMO3S.:E>I=;AJ2>O*AR.-DUVZ768G+9L7S6SSN#)\F#I
MGP$V)/8>0 1:3CE6KV<KA20
M    ,-GQ5UN=9\9<'V?-M^7AR[)U&QC\K! -SJIG$R =2ZV*YKKAY_<5YM8'
MS)AYG#> (+,QW#SF[XKJ5KN-;Q9<)3ZLRS?63Y!%S@
M                        #AK3ANIW++@!C<N. ;77]+-BY+;LS%DV!JYW
MZ"#[&'&-A!_+\?[2O-BSV1IMED<60
M                       #\4_50
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MX=*WD>V38=1E<V @!RT$JPC"\<<<0RV+(A&]/C9<6(UD@Q"&V6RB')5WR?\
M@YG&%8P")CCHK+?',+$?\Y;I+B%O>QQ"74,O/8Y$0S9O)A[TR1160F/9( *?
MS%2*),7\#LF?&%\,8X\\T.T?=GU."W8]M81P\B-S.,*PHA283&,8P00T*R?<
MI!]8]MFF51$L/+C=.MY'E.'%H!$(/-+X.^Z*\%)"G-\7\<YDYL$=AE'EM<==
M;8;S:P<.ISA6'$^-3X@I6)9I#$MPR4! R.2P4RAQMSIQAEWB%YC%A/>OE>&'
MB1[6;O%>,&3!DD=84J/G/P.:SXI;EX-7A/5,,6S)=2./#:N7DE:6^JF4L>9Z
ML*?+F>3ASI9W0?F>KX;YB4-H0VCEH-?92MY]W'*W)D..NM^:AFT*993YJU<G
MLXS+I<=2D<AX5T$GU@G P52A$"G&(M2DH3*R3TJ9P$U^.*'?04/R=^*(U.<*
MQ^!3R? 5R\L*P_U3V%.S74QC_,\O(R\HZJ@RB)KJ<^#DMR<&4-)=5P,=,?Q2
M<*2$YXFN6)D=R-ZB2_12'#?]/_/),OT(.<Y5GJ!5A43RM8_Z2!S_ (J42M<9
MC^.JXE2(/D]_LHOQP+^!2X69".CB_7"2(#$F(=698%0L!+F+A(9F'&ZC0L2P
MT02Z\,2.R6P?3I$=8]4FGUP\0/#C=/\ C?/X2(.8V756<I'JQJW&6FV&N!@O
M2SQ;33$ERP#N$QO4>(X:9R'C4R;Q(R CS!&SAI.-=C'^H-E;$7RL?_@(C(,K
MRPP;T41R%A2)A]"$MHY-X\T7\$D&'(@MMQ#S?LD7W27!AVA!Y8)\<@4I@UCV
M'ONE.F0K#L7XE(<]BE82FO#>GBY-.6ICIZ"BWG%UB,5D*.$CT_'X<KJ/!#G^
M+YMQ\8<I)=<CR, UH49SBUX;3"#Y!CYH)PEL,QD\=24K3FOPN5MMMLHZCDXE
M93\%?B"XU3<X#G."Q58>F(MCADT3E$<Q+81\K)5ST$BUPI$O'D"V)E;6)N'S
MQ4_%\7,S,LX# /#-?(0L\*KWGH='D8W+3N'4K5A"4Q\RIL2$.-=QC&,2,4-)
M)D8DN,:]AA#*>(EI12)$*P&.H00UQYKTV>+=0C.'BWR&ZWYG/IV&YBOQ[>78
MZ:BRH^8"DL=/D,"HQDN>RPPT,S^#.,LO)57H)>3<QD$,''K\[V%#N1KK"8\U
MF5=402PPR,UWG&%8D(U$-D:-+E%XQC&)&<&"7\;$5SY=(\."GB!LONCN!A'R
M7,UZ6X8%)M$QL,+'>R3@$/I"9EC&UL9A6 @F@&/9-P3)_(R/R:)\C/7P6N18
MSGX4-G,I(\L-J6(]\ZE\K@;8XZ]U$._+R(3"W!N$%#"(9L$*^O\ GI:$.HKS
MN6<2TB1EX$ >/:[?89):CWEPQ,H>F-"C0E"M..-LMF7A"5A7AM2T+0ZCB_A'
M3 ZO6S/'WV!F_J^!\8Q8QC?3*E1TY^"'R ,4(3(@!KX00P(PY8H%H/&<*QR<
M)4)$@BI"#/?R*#_?/<0^HJ+Y8GLC+:;PTU(&MQP9IQ,B1RJ3CHY/4H6B'D(P
M-0C#SS8[4G<#R7&++-L+@YQB9:Y("8-#9.5-E<N\@Y\>J0>XM/)MGSHNO8_Q
M"E82F9EGY<OD7)/Q13+K9#/)[.6H].<*3^![>\?].9SZ_'EJM<;:KF;'8>$!
M.?*9 JVUQ='FBK0;9O\ 9\_R8/ZH1QIQASF$J7F-&R&!RV?%75VRKY3TQE6'
M\_SR10@B3Y=R5-@=0!*Q)CJ%&PQ)<NK2DRG5':4HWA?P])7',.0<QXOE/=;\
M7R/D_P##Y&'_ *3\#DHT"8"*BX\Y85!IT=(!ZSH@"G*/335SL*0X/4Z\'4Z[
M8&5/PPSZ2A^3E89E5?1\YXX.K,QB^E,?-I*(*R7'RT>F3CWF'1G>5>)<//Z5
MG_N/EU%4]'=5T19DQU&D)5.\G(AN8#+C) %8,1(R+D1%LQ ?)UW+47$,_+GU
M8PI,W#OQ!7(N+(EBF6D,-<GL9=CTXPE/X-LYXC,677*EK5R=O\W,5>@YSF=S
MC&<1/P#7[3S4 "PH*P0BDYAY3DA$1\IANFPR%M--,-\4I*$BY6Y+<6A#B).E
MD(6/4)IY<1##0['%*PA(32Q\^['^2FYP-[XC$LF,.LM$-YJ<%E0XPXC70F,R
MDQ^#V&OQMGBH_6L8T4G5,6L6(KX<*7R8CGB. R#)R>S#A8]D:4;(-^:SB^$R
M1SC ,\."M"TN)Z=>:80A#UB5/!+(C12&RQ_;*Y<*67'CF 1Q;OC]DE+99S'
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M(&TD =^ 01<&X_UTC]"/S_P6?*33PMP6;;^TIM[\?GL]N)::> Z9HGCX78$
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M!)L-^$A5=IZQ]P\.=XE?N;M_CAE*FQYHY#&>T'>,>4);CAG>4V V<%'YXC@
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M4+W4[/PV8\@?Z55+;[*HOOTXCH:>,ZM)D?TY29"/#5L'J'U+9NGF>8FZ)>*
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MMD;?[-BCN&*F/H)^DM\C.>L?U<VZY^S+Q/I#;OYI(8Y?/6Y&X[F'K'YWP**
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M1SVN_6;^'JYF94%W95'VC:_AA98G\V12>RXO[.=T#J5/'<>*D;0P[P<05/\
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MA*.=CM7HQVL1[@+DXAB6%-*^)/%CW_ES%M(+'<H)]F*)-%+$#O8%SXR,7_\
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M3N?N:!^\]OPPE'/+\^PA3]5$=3D=C2[+=X4>O$<:1($C4*HW ?UO[3_^AO\
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M&:HD&K"-2!E3EG=F"B^@U)X;8714N&4L5!31A84OUF"EY':Y9I3;KLW"_99
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MQY#;"L.GQ?$*7#:9HUGJY-W&TI*QALK/UB Q&B]AUVQ_H_6=':J.CK6A>26
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M%501Y&Y!XER.GB+*W@U_Z[Z'=)H! F$XA*L31G+1SR'*CHQT@D8Z*RM?=L;
M@A.(%\H8%6 96!# ZJRL-0>1!&V#X-18,LGF:$/.Q:61F)+*6+)';@(XP<J:
M7YDDD["13W;=-XABN*1+APBJ*FC@\WJXXY$%1FSM(HW396D6-6()3.5)(<+;
M;HBU-084M#42TU-7)++-4P25$ EM*UX789^!AR6'$"Q.A%\5Z44M(LD.&_\
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M5FR\%!L.&W1FKBHJ'S.O!H7F?SNG>H4Q)502J@#H[ *UBEN/HVMSVQ/I-A]
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M16@F7>TLQ^ECYJ?TT7LRIQ!'I#JGCM6TC4<QC)#QL!)#*/1EA;5''?;1AZK
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M%[FCZP_U'@?+72F2FPR_'<27\498[_NJ/)@3@TCIS28W\' *G[F'N\N/N!#
MG-I2WN52/XL/)%??0VX[Z+_S%VQ)2M?5@\Y2W[RJ1_':CMYW2YN&_BO^\/\
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ME0>+&VV*2"2OJ"INJ,L*?9A18A\<E_U4H7%30R4O&>D+5$':\+6\XC'>A E
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M46[=M$L62V88YD;EG6Q'#(][BV#[[3 ,@UVC-I-BNF>7KU>..:N"0&(DCYR
MADF5XF0M!8CD5DE@<'E+&V3(R-P8, 0"3MT?AA4N_P J5+/9\(:DJV)I/V$C
M3BW+BHYL/1TDQ7I+T>H8IA\V$='*V$SWXH;&4M<XM\HI$A)>/+>U-990'[.G
M/2<NDU_ >BT/2##NDW1G \&PZ!):<-?";>"Q7J4='%(;4D7_ $%-#;BF=JN^
M<!)XNKDLA-.*PM=)XZL"3I40QU5E6)5D6M&<RD"N"(5)[,>D?YCK-?-NBO2.
MPS0<_P#HV^V;R56\-(XR0GAJK%DXM6S;*W DARX2CA*/A(./W',>[;JV!],,
M3J4\BJUIW-A8E/A#K+!,O#0J;6)9)Y;EVY*9[MV<ZIK$K$L68DL>\S-Q8DDY
MD^7SNB^ 8K8ZKA%VPTDYST];FB#/'2U'( V&1*X\1OSI[97:*O!&D,$$:10Q
M1J%2..-0J(BC@%50  /#;5C.,4,/X9A+%B-9F_8AS,K?<AVAPFCC<;W+#[JN
MLD%B".:7V8TFEC6,N_)%S[9X+F?Y[_RCPFN;C-#'6QG#D.4MJM"6,-JKGP-N
MJ&8;L_31=@<5&9EIS"32=,L9!2>!_&.>%LGB=3P(8<^1/SIHUGDJEXG068B!
M)!FI&]0MP#)S&?#AL[F"I-1&'U8ZV,J\<EZZX^E65DYIJU2<,DU9$9ZLEEPJ
MI5JPXY?SK8WB%-S+'AN"Q2MN3-/D!UV> Z8:W%D9]1RR&G#^CEZS'AT"F"/#
M%$\<,V\KKNDW(DS$A*OI?-3J+\>T=L"P/",,:[7LR2-+-,[[R1WF42!#&N36
MI"^H @*%55"Y<J5*K0AEC>O':F-C>!YP\A3<5]'!673Q;)SK91H\\,L4:L9D
MQ%NT]L,8ZX$2R;ME4KZUM67%AEI<\=NC'2-[;X2\<(>:KH9\O7AS-2?4AB>0
MQ H[*<XV0^QVDPN]=9;1T"31$\B5]YEHZQ(HRCU Y^) [3 +QV#*<U8 @CD0
M>((^/^:QZ7"*F&RXOCLV#S8A'C$ESJ5Y,&*+7B2:LQGPJRD2@U<1I(9J]E(Y
M=#\=ND]3I/A^&3Q]++,,E[!X[=W&:J5ZU5:R"SB6)JER_=F8/9GM,D961D$.
M6Z5MJN*PU+MR[AX(PR3%\5Q'%UPL$%?^CHL0LSQU&T$H)(E$@3LAP/1UC%L(
MK3VM.GKD>JO;T^36*[1R.!R&\+9#@,MJ5[#J BPC$</L4\36".6W>I&G(MF/
M%M3;V>2EZ_JF(HC:P[X=(D4@1]-FAT7>"M0K-N?E)XM_9MS+]*T4<HW<$$;>
MK76CRNRNS;L:1L)'Q2*ZHYP6Z5?=MQXC.!8)%SY9AN&SVEAZI?IRBOB5/5K6
M*9DUQR0N0#)6G3M1,0&!5XV&J,_/Z/X/A>*SX#0OP3V)\2K]EY)XY-"U]]WE
M1!H9E5ESWRESI7:).E0'2/ SDKWZR(N(UU.7K<QNTFR'$I,%U^S/JX'I%;JX
MA3NUXJ MP=I>L5;\;HU/5"^4T$YF*PY%0=,CKQ5CGA[2Y[PU(-6?/N#(GWE<
MO\RL;LT4D3B6O8CX2UYER*NA^(!YCD""" 0F&2=*$@JQKH-^M&$Q*>,<!KF$
M8D#Y<W5T8GFY)VEQ#%II;TQ[4UO$9GE:1O?F2TC$\E)<^6V&6\-PZ/"^C.#X
MC!<FQ1HA"]EJL@D$-32N<LDC*%R4[N$9R2R;P+&=C>QS$(*,''1O#G+,P]B"
M!<Y9G^S&I]^6SX?A=FS%?5#*E3$*KU);$*]Z6MJ+)*HYD!MX!Q* <?YY^4:<
MDF$XRHR7$*?#>^278/HK<?\ 6C7EP#C:7!L9B2OBL"[R.2+/JN)U?]KIY\LL
MO7P'M0G[/IWMVS%6C)R!D/%S]5$&;R-[D4G;U5;&)_(Q8/>(;X%HE&SUZ717
M'+BS(T3&S%#AT&AP58/)9F5@"#EV03M#1EL5NCF&1KH%3#)'N8B4))96OS#1
M$6).;PAVXG)MJ]22:##4LN<FDWLUFW+PWEBQ(JR2R'CVYI3I7EF!D-L+Q-K\
ML2UHU'J-+I8K-(MA3&WYMB>4JYYJ1PS53M2JXM:CAGG(:NKQ/,4&>[$[LJ/N
M4U=G>,1X^ 8C#;U_"TQ622P13]7 3#H02O,D\RL(SEIT!<B[9'DI(PRRV%Q8
MI\K!9JU:]&NYC3=++O)E=).VNM555&>H\\ALMQ*W4WAE:K+74YQHT84C=')?
M5E&4J,AI[OAM+BD&))7@NO&]R*2)GD4JB1L:[ Z3K5.3Y:&\2.&T,"9Z((HX
MESXG3&@1<_?D/\WUC%\1JT(CW38D"L^7Z.,9R2'W(C'86L'L1X[<FE,$-2 O
M!NV5=336]_&DL-=>':$3-*S!(P>TRZA3P98\_HMU9/#RWF_!^_3]VS8?BT,>
M#X@L,DT<AFSH6XX5+S;J:32898HP9&BEYH"T;OI8"*=\3CCJ1/2@2U-':@IB
MG7:3%K\BVY8%J2"S;K85555E+2[M@@8*<K&(=&NE5"E?N2!K%/%(+]/#K5C(
M*9JMYZ@2!Y=(U*V<+R=L%"[$J!3PU('R*W3BU>2L4/YQ=P)9V7RRBS.V)8(F
M+W8)(7I23-A]BQ1BG8U(Y8Y0(G61T1IIHXC*>.3'2I)&T%+I+9?$\)=UC:]/
MVK^'ACEOGD49VZZ<Y=YG.J9LKOIT;(EO$%:>:**:"M5CDM3SI8(6N4$"N@ZP
M2-R9'C63FIR!.TD.&X+:L"!MW8>_(,-:.P #)7ZNZ23:XLP'9E5-7<+CM;"I
MB=2?!)7*K!-9DBFHSNW#=K;B.43Y\A92$/GV6)X>F7"L9K+-$W:AF&0LTYQW
M;%67O12+XY=F1<XY R,5V3#\7U8CT;ML4P[&!'J5 ?\ 5[2=K=R(._"W9=.W
M7+#6B[Z,21QR:7>*"4BO,.\N:\>SX@+P\LM@H&0   '( < ![@/G936Z\9\F
ME7/\,\]LHKM9SY"5<_P)!^9T>P'%V(PIXK%QX YC%Z:!7<5BZY')] #!2&W>
M\52"V>T56I!%6K0(L<,$"+'%%&HR5410%4 >6W58\L4Z0V.%/!X&S<9\IKC*
M&ZO /(^ME/"-"-3*<?Z5V.O7W_T:E_J6&Q>Q!!!GNQIYD '4^;R-))VML,EH
M+G5Z.5;4]^S'W!O(I*ZPEAP.J681QKX[N<C@O\](N]:I?J/UC#;\7TM6PO\
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MYRU",\Y(')_S(AFMUHICRCDF17X\N!/C[]DZ1=&;;4L6B WB+QK8G"..XLQ
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MJ%PZAV/RNNL>;2,[9Q,,S(S2:!Z2#R(R/P.V.1I]''CE](O+0LSJN7NTJO\
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M7HLR11K-#9R+1DZ62SI$<4B_61NRLB<_:4\QLTTSF6S+VIIFYLWD/JHO)%'
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MVFV%62[/*>JI.[(%A76TC+I50&[  X:B3[]O6/-+[I)"5_ :<_OVR4  <@.
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M/VE0D;"QOY=_JU[W6VK5S\^7NY9<,LME"O'!D.)B3M.?,Z]67P784[NDR/\
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MQ'=7Y<>K7ITNR2VK$H$E6=;Z"=35TQK'E62-8@!_/[369XJ\2]Z29UC0?>Q
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M1R*'519CWP4\1J1LAGEX:MEZ]!U2DK!I(V=6FLZ3GNLDS"1'VR3FP[(''/8
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MBKP(L4,*+''&HR5549 ?^>9XGC^H^F:*.53[,B*Z_@P(VU-A-'/_ *O&/X
M;;Z"A7$SL(:E>M7B6:S8?A'$NE0>?%V/!$!8\MCB.(N+.)R+EJYPTHSQZM37
MDBCVY?I)3F2<C\V3%<.C)]K$</C^CO1+Q>6./NK=C7-E< ;T9H_$[16HH:\L
M<Z+(CF&,DAAGXKGGYCP/#9<#H_DZM%OL3LP91M7JL=*5XF4=F>WV@&'%(@S<
MR-D@@C6*&)=*(O  ?\R>9)XD\3Q^858!E89,I&8(/,$'@0?$'9[=9&^3Y#Z^
M,'5U-\^#H#_JYSRR_-<!W<LECZO-7I$J9[$Z[LO'F#NX$/;8R<B^055.?$\-
M@!R R'P&W5HDDOX@W<HU<FE_;F<Y1UX_MRL/L@[:I+=7"U/*&M"+DRCR>>;*
M+5^Q&1[]L_\ *#$]7[-73_8W.6S5_E*M<0O&^BS6ZO(=TX<+O:_8XD#/5'L(
M<0K2493W"^35Y?ZJPOJS^RVEO=LSU$BCKJ=(LV=865O'<H@U.H^N<E)X#/;A
M/0;XB=?^3;18?#-3>[-VV6$2NM6OXV;#R!0B^$:9%Y6[HX$[&3C8N/\ 2W9N
MU,Q\0GZ&/R1,N',GYDLN''J=E\G>).Q5M21G4AEB'828'N6$ 89D-FI.WJJ2
MNZNT,V<\4?5YTX.EB-CK0CO=@,KH0R$Y[15X&2;'L7?=+8TYB!%&<LJ@\5K5
M(^Z/SDI7/GP$$6IN)>660ZIK$S<9)IGYO(Y\^7(<!\T7(8DZ]!Q XQBVB_F9
M'C*NLF7"&=3KC;+FG#:.SAV-XI70YH]6T8K;59D[,M=^L(SAHV&DYL<^8X';
M*7'[V7]!#5@/]I8B=A.\4EVR.(L7Y7MR*?--Z2D?[B#+]2Y\5=M5:LTM'"T]
M@"-M-NZ/-IY!ND;]%'P[WHDH8;IWT?9GM, XB?QCB0]EG7D[-FJMV0"0=MY\
MIW-?//>D#^QW/NT[1TL4*$RD)#<R"=L]U; &2=H\!(-(S[P\?3BN'2<*\/\
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MU=U&23+FDRCR$BY'3]ELU]VVIEL2C]')-V/OT*I(^_98H8TBB0:4CC4*BCW
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M$D9<\3D,L^.G,G9*F)UVPZU)PA9FUT[)\J]K@NKRBDTR?'YFXA1KN(R#U-&
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M[M:@Y?=R_53&KOU[W4HS_18>FZR'N,[2MZ.J546:[D"VKZ*N#RU@<7D/,)F
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M$01D;$L1Y, X$24>.HYA^=,,UE<!,P9VL%&4"KC9H(^EN!! X3?P4"A*R"G
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MS. PS5E1[SO:!59;&V!X'(#:!DHG@ ( #HH\:@2G<6K=?58$PI"G5Y&[SLT
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M!^<4(BT(,<4M;J2B B*43G; 1+< ^A@D8AK4]L=(30PE9+PWKD1!*>04(?(
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M 5X\3*E)F<AM0LP!R>C"\D4D,B10!+*S@X"28)Y4.A)/$.01#XRLL4TJ!30
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M/@[-)88CU,V6((\<8^3%!?<S@&61#T5 LP40Y889X  [$:3!KI(N'3%=5,H
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M?A)Z& ](B8'\"-!GZQFW0N??WB(G#T1D@0D4@ -/@#8+(_-VNEEVR5<\&9-
MG!$3>H<Z4.[/E1]^%:%4*#<>R>&3U@0PDR$* UV"((Q)E$6S+CW\'7=-#QQ0
M._I-]*T<@O!12L0 CV5\Q3C,9&46=!#I(+=OFTHPY"CKD<6D?H1E=(7"QOF0
M?+X;3'*B/L()]%SIYO%3:\2$#+--E7@-1P2;$[ )]?#E@(8#'V -7)!'BQ&T
MWS2:]L ]+SJ!%WQCVBYX/")O'L%'&'=S0@\\%?OD=>SK::G&)8U+'QQFW?2Q
M!PTNN@8&'%$P6(GF; *JK?AUNK0YD$+(*!J<O,@N?8(>)W%>(S)P(0(MV-L
MNI$LC^W9B ^,#-)WK@"H0,I80#('9ZLA\81 !R'ALC#D@%&\6H:9,5MTJ[V!
M]Y@:9!2G>F-&B/=X(\WR< >1,<D>%S0HPOPU[J 4X10& ]!%VP&O <89)S]-
M,](?K$,4P;9X$'LD6HPP[TE$5HIV".@,'@D]S&%\K[CP]AL<G\Y)Z>*;+5V
M']G]!_S6T9/_ +<?$US"79T\+/;T>0 8N:E@]:W9T>7-Q5VK]'W]\,X# JEN
MA.VI;'RT-BWM$.@$.1#7GG4:ZO\ ]Q^O%.PLNH-3RL+) \EIT%0$ZE "(R4S
M/C^).H1_AP$2FY- [D._ $ "&T1#SO=4;R\P$F(>N-[@'=/![?RB?\@7WK!
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MT+(.5X1C0 _ J#'/&T4T-68FM.3@2;"JD$1A^-;BN$"K0I!8-:$E*"J;%74
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MQWN18R:(P#=DS;DYW]Y[KY4S*-(_UE]4=-8FL_D&;[#_ 'C'AO=Y^3S5^JK
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MD<,P)HU!!^WE$^$@'>D#L'[$K*,2@W&(7B6;YCC0OR)E5"YJ\8TICVCEC-_
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M57_,$VKM0KE%_6$'1_\ RO\ _]H # ,!  (  P   !
M
M
M
M                                                  "  00
M                                               22 00
M                                            ""202
M                                        3G:(X
M                                     )#WU)8
M                                   R0"40
M                               "*P !0"
M  22""0 0                    *8  # 0                  *   2"
M ""0""                     +P  8#         .       "#3   ""00
M"000                    ) @ !<0        =/@      !;("3@
M                     "P1 !GG         _$      ;@6 <D
M                   2 <9YE:       09<"2   ;2(4$+4
M                 4@ !0.]$       20"    4!  0,;
M               '@ #7RD5X    2 =$8  #W8   #8F)
M             ,@>84<2/     ,]?FW6$8<  #. 24X
M           ,7 24+MX    2H6^4US98  + 0#?S
M          7@8-^M$   !Z.C"JJ8M0 !   #A
M       #,"E%(7@   +3@4T$2%   X ",#
M     . 3LW,U      ".@20<  8  2"\
M  "1@&@T?$   $Z4[V )(  "P !(=@                          "0SP
M(B< *9.   #Q45B@  [V !@ 4?(                          22"^5M9
M   0>1  1O\  (FE@  H%NS ?                           @D5ZX(E
M   'Z #] %E 6B  S     Z                             MC=#%
M 'P ](&7 !V8  A   &?P                             &N;(I0  $J
M@$U -( F#^ "H   @                               "@#WA   $D #
M4"0$$G4  7I]",@                              GQ\?<K   $ @ $8
M   N  &&#.,8                              #IQ#X6   $ $@D $ @
M D "C0?!]H                              ]^YV%D $D @$ @@$$$@@
M$$0$8 /                                   -( @@D$@@ $  $D62
M                                       ',@ $  D$$D D @!=
M                                   DD 9@   $ $D$@@@@J
M                                  $ $   DD@@DDD$@!
M                             $   @  $@  $ @$@@ $  $
M                            @@$ D@$ $$ D@$$D@ @\@$@
M                        @@$$D@ $ $$    $$ @D9@
M                     $@@D@@  @ $@D@@$   '<# $@D
M                   @ @   @$  DD@ @D@ @ 'X$$D
M               %UN 'MN $D @$ D $ $ ']
M            &\#Y%$$-D@@DD@ @$@@$$?.X
M         &X  *@  K@@ $$D@D  D%P  X
M       H1^"TK]$HD$ D$D@ D@  KX$
M    "! X%$ (#  @ $@ D$@@_L'HM
M  X0% $0& P@ $ @$$  $%88' P                                '
M-!0&K4 C $ D$@D@$$ "%@H@                                 &TP
M'K@  T  @@$@ @@ 6EOP#                                  1*T%)
M/R+;, @@  V9$$'E@-0                                  %.@@ IX
M 7X1Q8#X ;*  ?F@                                    @\L XW 8
M2 ']Z9H#$2 0                                 $@  Q& X ZG S#U
M"X0$&S8F$(                                   $&^@O!  #!$ H#!
M (FI 8G                                 $ D@N"0 OQ& 88'  .P!
M.@6'(                                   @'8  U@S ]!Q@K@/ BR;
M (                                   D$!X ]0= "+  '\  $>P!K
M                                     "?+0 9065 %KJ1C 'ZE
M                                    %@ %<0 \RH$XVG_%X
M                                  @M $@B [0$ G' @"
M                               !@$@H<% 0$4 (X! @
M                             D0G % (%  @%&E A
M                          #!L $X" 08$ Q  %8
M                        :  X8.88,OHWX &0
M                      T0E!D \%@ @47[(
M                    &0 #?R@&7I8
M                          8
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M9MRX]OV_+5F[MDW(7;&^>-.TM,G(0^''GP:$BNSTQX>=Y<Q\:(A-M!=?FO\
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ML^-+X@&4J!L5PP[6YTJ"_)D*&+0ID/$13 X81X6^=F:.P#=I*=ZZ.$R !!-
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MC$V#W%=V5K'^@O@>N(C$F%9!]1N%OKDL!G6^ TBGFN^0)JC6I*\2?'NJ$HG
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M6I8>H@4H2JATW@3,N4:;Q 4EF,T+46.X,;%@0K]1,FDE6<J4/#<ZA6\34D)
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M6-&X&25U'H$+K A,4P !@T(^>"-!JN !U]&>,O\ /M[Z)@D+#O=]EGC;6'@
MK;=GEZ#G.QJB;7&X!RF!&88N[RB*.$43R;Z)2B !NMW,@!]UF-] "@F<"OV,
MSA,]]I0J#1QW3?!68VFJI1N$CN,,Y-PR6.@%G+\S@'C$>\.-_P#/J_!UWE>0
M@R H2FX-6(20RL!A-Q.3WZ2L0 (DC UO6Z@D'QL4.F]3G A0K29&%M).[M/.
MAT0] 7[#JER(*E+.YO-4LI99<SN;S7P^^'^]"TSKA 1YH5*"4/*2#VRAV2#3
M-W+.D+.EIV!HR%K_ %4$1*.$=DZ=)'%C$@0@)617U0" FX">XB/R?T$$1!$0
M!01!HH41$11$=-IB%4B&VE7"IOI=603Y;&YE?RO6GA.S&538]WX/;0%S9;O$
MG)#,3R\^EL;$/NT_,+[)I9&>3\V/RU^6C&9$\1A=L7[D?/HYS@.!(=$3C;+Q
MH,@ #X2_OMQ_GA>M@\RD1QR+CDSG7(2@,]LG>QO9C4<4ZF;*;4GCC6*&),:4
M+=H'$M8MEBRNT0SULD<,2N=Z9"6U>0(7S00$CUP 4AK?0Y*GEA<R8+T&"Y[K
MX? )D$%W%W1]V*1$CE4>5;Q+8S+C_@(,8*NP*NT M?!N^-2U57R3N_? )@\Z
M@"P4=7L[<]'F^L$,Y&=)^2'W=/!T7[G_ #T1G5O\9(FS?Y-  !L$^W\YOOJW
M('[!'GP<:3)XP]JS_,8_SS%&41B+K@C$(E.1(:445Y7"2*P:0&-\!0.)SE5=
MR8  R9+"38TE"UY(#0'55!XZ%*T]3 ^2N4^"@B B9 -AAIPZB  .C -7J;I6
MDZ9X#T7>0P8EPYE%O$T&?V@D@AV0# AJ6S 0VTJ1 -P/]]<"N *KL':\&D;:
MV*&0V#G]6%P:Q!MW@GEX?N,.=O4&2@1^2:FZI:A*^W 'E^A.=%KF.(GM/WT
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M6RY+#9!QTCSKB7$&Y7W5?.3G3;&%@M!V:DX;G NEP!Y<+M<GV"^,FFC"2*=
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MQH8 >!\I%.&N3?0)G@P&\ P>>5RU]% 5 "H@&57@#*\&L,S/$!UD$@:M47T
M ( 4!%'(F'0TB60;I<?5/N[LISZ<+N(O#8O,%T[LN[I-B; ;!<Y5<^B@*L I
MV@%7X!=1J+0R6&\(2I#&;'I4P+'CCK;2KNK-JWUVP*S<S8974X3ZKSP4%8F'
M("><?8,<6A^8G"83(XT\VM,GN(E.'<X32K:/ _M;'DN_P:$@^Q@O*]KRJO+Z
MMF6K##B*M6M,*!N_!HV=2)&[8F.:():,H"!$PB;UR"B.9]#X)&#=^ 9;@/=0
MSHA@,K6(M"6%99!:RPW!O!W C.+3G4P4+'N^3#O2C$S-"U9B+V B7*QB4T(!
M!,B"'8%'X?5X5Y1!\L^QEX-(B<$KC&(5;X#%4A, 0DK81)$9 CC69L_S;CY*
M' 1^JV6V^"JS#L-TMI=3A1C! "64"21'&L6R*N#F^P$ 5(;OI5+02-J,<@FX
M@K<EU"/*MD9=LX!@!0'0&#^Y'&4R;DCH*42N4,ABBH@FBZ\)*0?97VE6YP/1
M0* 94 #=4@?+I HVHHD$6%&=Q%(:$J-N%[1E515%6OX.BD)$A]1CO)>M8@3L
M8>*&^7(9L8UO_#M[G>+XLSG;66I0Y:I> W3+B8T=PA7<7C#<P16970(2P #V
M  ^WJD$(E3"\CDYH[[W0.%]UE :Q0+!I0W4 H C<)AB%PTWSPD#N%5 C=1(@
MY1.QWT+U+# Q!B1S@A!ETLX\D3(0(<//MQC5<%NR%3:VC]M-4N )Q8$JJ@*K
M*ME@(-"\8#)_3 5#Z#[@;I5,0*>ZL7CO3,Z8$XPX 86[<CC+;'8^+\A^34Q[
M\]92[F$PB[)<:F2,PL(L6X7R: 9*8.\0RG.=X%NA<J[-WK(<NV#OK%2,3%%L
MK"&@-#0[R[\YN6RJW< 0/5.5MKN<;HN$$]J:8M";8LP>8CL%G5TF)3^<1WB[
M/G!P<R,I["^YH!     &P!@#\);^&$6#)!F9!V=_4"("!02(CN)IZ551< Y,
ML :W8:-BI,0:*<)4,T6*B"8\% -@;!]& .(A'R<KH1'(W35V+P"Q8@<J$R=#
M(%>1WNE,Z#3<' 65$$!;6IFFYMR!G:+RM<6&P?1B.#C>63(F01N#1)RE"N8M
M:=LK;8K>ILG+0@9,B.=C0C553N=#=J2M@&C76!F&P!NJH ;J:<'P V(D1<L!
M+NZI!9$9CF4+>)SN;W)]#0NX!>0S  /(^E2]FAE>P0;!!QK9-?XE'.RQ\GX4
M>L4? PO"S'/H"P@+E-!$&4&ED,K(:4P#T'9)T>]TP0KAH$PH0%D,!2GJ(XEB
MS?!CCXR$SNMFD>[:-SA8\#V]*PJQ#!Q65]OW-.1ML+/9(OP>K/) AN0IP(1(
M\7.JXL=VH2/M'CQH5M6CO^6QC$% ]43<3W]7DU*0FY@U(@S) :ZOV!'2!#@Q
M1*GEZ$ 9!W<BI-J6^_MZK6@YVA?R"/W\^KM^,]@_@Q. Q^%&J*M0W*+GG 9=
M _M]_/V:1=49RU7C@V/$-O5 U5SNIGGL!=\WTL6[*YE^>W)BFU]%1D#=J,O
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M4J)E&38./J<BG-<A'(F';..(D8 %6UH(5NEP/ O5 [.JJ#OD,K'#NZ.>^4I
M\'#(<H3I [0(20KQ:.")E:IA2I6*')9P:,L)PAER"4IT%XZG=;(8(43A G/.
M"0R+ 54-8,A@X "A0(@Q$<B)$<C_ %E*$0U0BP4VJQ8M0XZ9!'4K89,-Z/RI
M(F4Q:!E+$L&$3)#(G$%8MRH*FS@4;(=K*6!*N2OKPE@5;C=8 HI@KQ*0+E:'
M870B94:(UY9',K*!4&%0D8=5/Z.$1,<!E)10H1$41&<(",6D5<Y3HQ8 <A6,
M#8\$0'1/VX'5"0PS=8]((BD'!25%2=XCW16,KSKON# (J(E&%<?YG.J12*WF
M=P>P4VTV\4792PC1/Q'(]4Q 0&/,1YB1S*HFP[Y01.R*?/$Q1F) 6()008F=
M<PANXR +&"K 784Z3D-+8ZB"7%"X-JAM23,Q".$BP$$OH[2FI,S@T$$]TL$5
M:1HHI012KU41D"M"JD@%*'&]&Z18T8(T(T.>'ZVW;K O&@@190HQRF'1T50Z
M/Z>E#W,&D0+W)[\6FN#%F@VI("@1P#$@2G!LMWU^;P#T,1TQM/H-*G O29Y(
MJ88:#0&B_P"[R;4 &58) <31U-(Y'#G.\DYO'#%_H/1!EZ*G:MNIJC0#83)7
MBR4Z#*E)8*$(B7'+%8\D >\(%C2@6F(&:"!995,,!GFM^F:*S58VIV!=)Q!2
M0!#4FP5=46F+PQAD% H)"Y284BZ:?6:2_#_/QQ':/D^/^_X<2;]3&,IG"D%)
M3)#8%$E-)"J91>UX.0CTJ'*Q;-3%D5X<WP\##(IHBN&:#@%%)Q# 737J2W_F
MAJIP[[ YK= "U(2&&J^[*4\$+L\(*U"J\-EK%,[2<#V-L<8E;7"!N*KE:^7T
MVRJ"+$D#L[$1Q.$5ZYQ1C,*$&VE87EK;,^%'!0'AD@TFD%@HK [0X9&%-SGN
MT)@ !($-4A'&T09\Z4A"&]\T%%:2[L@%:3)35!LB)&09#66@I?L0*A060O\
M2;&-!3V)6:[0V3@HBC@J-.4#'4 CEZ&)VA>Z5H(\%?,L*PJ@@.LDKOEU[ZA
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M@-9C@Q&#$8Y&=)V/?+%]['VJ&M@AP/(##>D#H.PCX7G5]=?= @6+G)T7B@5
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M)V-_ME,C&#N7QU"C>_M @_'+M1KSRJUR=2*?Z#R3#2L8I7HNPB7G8ZD*<"P
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MJ!0X]X\/0PB:05&$1X8*(%@ 4)%<Y1HA>,\+<C/147E?L\C($L*Q+5F**A4
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MF</)Q3DM3*K'$H#   >@)J9!50 #:J'';E "BNMBIL5IS>O2%&%-/9\/7VY
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MDO(H7C'.\5()EP*':$2P BIJSN#*XP#0H,   _6%32GW_P#RO__$ "T0 0$
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M*)+LH!9"93!V?:V!%:=UW("4BIM8A. 0/@>/05<#J"S1@/N90* !54  JJZ
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MV98<#DLR@J18U4$X@B(!(B41TB.D32/)EGY^NP(4>'@EWTO];]4WA7^K2$
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M""NQ+I@8,MER*D/72B4VE70+A.3G%2JL4Y%2(J1#Z^C3FJJ@)" ^"*H@1H!
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M"#OJ1A$^JGY1C--[:>Q#2C]+P_AP]%0!]A_A:=1)J>.A\! LIT &KHE=&/\
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M\!5*H\[ 'A*$.T7A6_$R."DZ5@[B[*KV"L<2,J(HZ1B>DSAIR</K^]8)W%6
M*] 0[1;)^@9U.'2TE0YOP4@UMJ;2^4+\DBX/8*B" R0P+Z76'1$:>JY$VA1L
M4\!8*>G(Z[,BTB#E[:MD@SQ"I$DP'QFE5\5&DE?)2JS*&-!1U234?(CNDEJ>
M &C,&P<&\).!AKQ/, [B"YJV5K('?#@)>A5 !;V:5KC/"5Q<= 9\H'(1Z.G1
M@-)V+H7XFO$S4%1Q+V>!#=6PMM"J ?8@$,30<APC8CH(C-'@7PIL5(6_+(.<
M(&C34.H3&PB-8^(#=V%)2-%#OL#<D:,$Y*K&XAG+07Q PE +K 5PTKG?L4SU
M7S4)S(2]"3: E.E( A*HF*S6LD(K#@9$<H^AG";YY-"NI>5,%"6@R&D1/$0;
M5;OH% H(!&F,(&:Q.N?G=[QAO&]2A)G>A?&+UN125-OQVI>?!@J,TJ(;0;$B
M&P";,5[WC@4W27=;K?"/2&[%=ZM:\ K3B#*:B-&@RS?.1\;V"&:,93<DCQA-
MS5$:? FYV. @ \B"?TXP*)T#2I<]GG>FIL828[-O0BT#[7%15-5<J""L(.RV
MQCM= *V$@(&5*@T+3T!1 5_PG$A15VGJI@F[\]Q\XR$30>'P!"$,%=J*%LU&
M)746'JBSY>)? 9^D*2?GDR)MQY6(EC):E_TW>3P R +\YS. )1+2F3L#)R,K
M:CO $X,9L:L9U=#\Z1Q4 JT8V%;@(\?QKT^".SH@!GTXAQN[^C<FHT)L\%9Q
MR%5F>+R@@647$^6X3^P?L0(F8KVWA:3;:4/QMS7PA1_= @88BHMX90MZ/F*7
M:W52<0;FA-@;U$9=Q6#?,B!:,8SVAC(!(R.=?CZU]JF.J%="*OR>C:ZN3JXU
M?C5A*S_^( ER' @[TE.H@E,ITCP59XJ88@,E0R!C0E@NNQ6)J.M3PH,&BM/C
MD?>%TO&(D(D-B%$>Q$3'W._%0@U5QP\WY?%.J%RVV@$WEZ@:8@%*$U!IK6M>
M"2%@(_#188-L;\'X9TDHFQ!A+R#Y>%=P1BB 'AGR^ QIR;,E0FVSC0EE46+2
MY9S9C:&21/&[D*7P55;:7"),9HKCPE3#]$6MU_[R8%R'46/0( 1!X>\I#0FM
MNAW?3U;JY.KC1^(3P\-X[P@V=HI#;LM/J)J>/_"FWP/])O2;F7V>PY[WYVOS
M]B*[*,4>\JGH5I.RR4?:(A @%/ O@*56MLL>-B3^5J,_]%)^\EJU['(A]&@B
M,$[R8FER2D9U8P,&-54/>YS+!RG.MV7"*/([,3XS]4J[W6.Q0[\)\\2XZ0(%
MA09WX:]I*!(WMZUV) EEJ"QW1%8B\!D.N4]Q1,0K1H<7=',+R)"T"#(,EO'"
MF<C&Z"Z@L%OY4"4)@((!C2XWAOZT7"&$ZL![GGP3V:>*3ZT$+#1MGB?W$0#X
M,?RB<E\AB]R^N0)M;G.%/$H1!1I=#5YT1A23P@R!+4Z,4H69^!;5!^!7^UB3
M:!DMB/0'XFT9%5PQ+D!:M7>R)3XY4T9Z[)L' 0L=,9H?E85-2&0H[S(9 TTH
M%TGETH.G)BHY5CR_GT/B"WJ3ZE2**L0@,$=/%T?M[' KH"^(P#@\"OW12-(E
M!D%?P*'P(_7V/ NU$_!N/+;O]J05P=T4[/M!<%$T_P!V?+)1@]BE%444@%D;
M%G10?:20=(HXLM?6,&""13M-]20X'K8>]A%U1PJ[?D,F%%'^0E0(NDRK-&K5
M1&? 9*1FIL0VA@I"JI9%G;@0FQ)O507">R/QE4W26H8P*R;MWM#%T([XQ9[#
MX-&CJCH$HF"2P@='J6QL61B#(->-*&7NEX5+&%:/8[2TZ4)'4MXYP-3E@"F*
MQB7$G% #H5%X#*06+T%@!PU:JIB(HB(Q'2)R)TGBZ3K0= : X2[B.*H%8(.A
MZ' ?!#RP$R0H)XW3-U>#"<^ '&:!/:AH9"98,$.H04-%VE?7<:=V[[8.P)C^
M>TYWL-'22#1K*C248^07X&:@ 9_OT'*]![7@^<#/9(UGRE&5^!]CP0'BVU:%
M<RN-(@H4(&F=W%8:7"N)\R[I.'YX&[%ACH,NIYV9,YEB=>Y]\C#MYIN'!@6I
MMQ?1,'$&ZYW228H"^ O#5$D7"M ) .Q;S6U:"4YW6U;*EQ<+7 R-$HH6,"K0
M>1*HS3#8* T71UA##18^2?W$.JH3UI$]$839]ZYD I'R@;RHG 0"1B\"X$1G
M"1-Y@&>,(GU5Z*!*1+K 0H"()7EN)"YJR8K48T$PWD5Z0C>\'TVO>D'-^P<R
M$2->2Z4ZT@N(!BJHZ,N<'-/+:<D$Z?J8&-#6("&-\+U26DR [%+)1X*]<$!1
MD :,ZMS?W01E0>F2"5<FJ:S8-:/V_9^S;E!NX:)M7+0B4 V<(:QA[I"DH$,A
M&W#D_L@>W/I,3HH&;"LF"CF9,=H,#%L&DETQ7W4$@FH.2GE;Y$K=7W28!L0"
MTF<)K,N2J$I(A$'&=/()D R2,#@99 W2EM["C: (*&WJ-RJR& J.02,#0X H
M: 6DI:82#V?@"D.Q3X"44OLB,7Q8MM99+7.,.T@^%C)'G\<^;.'C[(W%C/:0
M<S&R,%%<0CW4Y H>\MWP'OS8>W3W&@;HUN!%2S:O?D&.$%5@\7=+C3/V$//3
M5O>"(]$X= 8E0DS0%"K*W>+E*2HYQ;C>;0(/6V$$?0-W;2P*SCD& 5P4!N+J
M0OI\6(NE_?F:7^**<F]XW;K7RDX]!*@ZL%D"S1!QV@ >OM(:USAQ=AABYU
M9PX<!@      'TO)>.9!U*0<-$02W+#*PQ2@4$!X &A!C_&O4&61EK>] 8%
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M3NG>L6E<#+Z0[Y7XXSCGQI7!R1TI"3LC(Z=N-"IV@YF"Y&,5IT"1HH:0#!\
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M807S1S9QQU2D%3D5O[4%IOR%MNB0PB0X<^5TM".M U^,>"B:Y]>F"JM!< *
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:4 Q557+2QB_>"FU'VA_^8 < ?C7_ ,5?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>business18a.jpg
<TEXT>
begin 644 business18a.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_X1O817AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   !(     0
M $@    !    1TE-4" R+C$P+C(X   R,#(R.C$P.C Y(#(R.C4S.C,V  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   "%     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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MMC<+J5H\EK!)S#;N Q()R,Y.5 ^G7CI74+'=;%#W?S 8)2,#/YYHC@F0L//
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MQO\ 8GTK.O+)K&&26W:/RARL3G;C_9!_D,5WTY):,\0P=;T<ZK&LL8$=TF0
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M.2N(E;<G&02<\^_ KT6!PEVRG/SJ,8&>1G/T[5+33:9;BU9]PDTY9)DD^T7
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M+ .CBV7<@PIR<K]/3K2C2K)69U@ =A@N"<]N_P" HHH ;_8VG;0HLX@HZ #
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M8VUS
M       -9&5S8P   2    ! 8W!R=    6     V=W1P=    9@    48VAA
M9    :P    L<EA96@   =@    48EA96@   >P    49UA96@   @     4
M<E120P   A0    @9U120P   A0    @8E120P   A0    @8VAR;0   C0
M   D9&UN9    E@    D9&UD9    GP    D;6QU8P         !    #&5N
M55,    D    ' !' $D 30!0 "  8@!U &D ; !T "T :0!N "  <P!2 $<
M0FUL=6,          0    QE;E53    &@   !P 4 !U &( ; !I &, ( !$
M &\ ;0!A &D ;@  6%E:(        /;6  $     TRUS9C,R       !#$(
M  7>___S)0  !Y,  /V0___[H?___:(   /<  # ;EA96B        !OH
M./4   .06%E:(        "2?   /A   ML1865H@        8I<  +>'   8
MV7!A<F$       ,    "9F8  /*G   -60  $]    I;8VAR;0       P
M  "CUP  5'P  $S-  "9F@  )F<   ]<;6QU8P         !    #&5N55,
M   (    ' !' $D 30!0;6QU8P         !    #&5N55,    (    ' !S
M %( 1P!"_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\( $0@!GP,: P$1  (1 0,1 ?_$ !X  0 " @,! 0$
M       &!P4( P0) @$*_\0 '0$!  $% 0$!              ,! @0%!@<(
M"?_:  P# 0 "$ ,0   !]_
M
M               "(4K^5LF"[\!^@
M   %(TIV:5Y+J3HCY^E0DNM=R2EA674U'?UI(\H6U+'*(Y0(OI\64;C*  &M
M<4FLUM,!G8G=CDP.#F6[NM3Z 8&<  (QJ,:3[?) JNVZI;[)3;61RP]*.:/1
MWQ^>"YZ5LFV\   #BCNU,FCDEMW[2LVLK%\B#K02_4MOS#+B+[%U.[='LQ9*
M              !JS#+KW?'QW4X+K)=;??.1BZUP9,YLLHZZ7<*6"BH,C#0R
MV3DXMN3Q[ P3B*:7%UE\AYS:?V;IL]LI]9+:S.ZW'74G%*X2E>>E:^MNF.1C
M1>*2QHY*BGCN*BI+:3JV3/RQRO6V:M>-<ULCZST,IW&3R7UUOBDU4FCO.Z*)
M6W6[<BF-DU+FX.T44E]VR"E//M-4G$:N3[C)V?\ 8.D '!#)Y;9>/(89;7K;
M/L?*^,_75)A9?>S()/BY&(OCAU75F@]%89P               ->[;OBMM:W
M4M^*2ELC&MF.7(*8NM<M6EA6UEJOZ 4AYWI=?_,=%M![%TMG]ALM'(9H?E8T
MTD@X(9^W#+$J74;E8VPBG/;7DQ\B(RV[,SX]%XL])26[M74L?E</57Q;F;T]
M(W5U^@[BNY9*]K;WJH51=!2]]OW%+U<O&EN'D3>:*V[9*5\^T]2\-JY-N<C9
M[V'I /FVNE-U+04ZU4IM5#6EB*Y^^E.679:B8VW=.^SL7VR:VMNTN
M        %!6W5/1U9HMH,>:NLG#H"#+MR^/7B2S.8^3NQE8DZAG  KOEM?8G
M4[  5];6L+5?Y6-/(<C\K24UI!H9?B:&=PWUSE0[9PS "ON7P+!ZC/%;6UK>
MZW)$;)&1>ZV50SQ#+P]I\?(_:TY50  !K59?4.1C5UCY%V2P=.#(QLE.MD8V
MQ\4M3P2U]=2>765)+%,C>J.8                         1BVZMUO#+%,
M[;XE;)@;X\_%?@Y+?NRDDFLN..4           =13I   ^3Z  !WU>R
M        #X,,H  ,494  ':,DJ                    /P   CZD@5   _
M0                "*J2I4     =53K   'X?H  .<[BH'24X0 #\/T '*=
MY41N:R%9$76N    8BC+U    #[HD$5T\Q9?M4             "*J2I4
M  <1Q@  XS#J9Q4  ?9S '"?  .HITC,*@#Z.<ZU:5-G0?-0   %72Y$YAQ\
MQ4     )SC22N"0             "*J2I4        #C,.IG%0      .FIT
MS,*@ #$26UEF0@   "E?0/.;2\^]&S%7U1\U    "507SK&E
M  BJDJ5         XS#J9Q4      #IJ=,S"H  Q$EM99D(    I7T7R^P/.
MO3XCOL'0OTSGO4[Q3L/FH   "4P7SO&E              BJDJ5
MXS#J9Q4      #IJ=,S"H  Q$EM99D(    H?N>(U0[OG)QRW;W5S6SV%YG8
M    "4P7SO&E             %#;?/QV)9L5AX8        '&8=3.*@
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MO3GN@L75[0   #63?;7JLG'[CG^.=8N%<!^$<R*8.:G!"O\ Y:L\P*@
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MX74'J<#C5LS1YON9\]]V /*3V+D]0N^T?Y1:L5GN)\R^E@   #"*=.J3TJ
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MZAU!\^^C.W=&!'X\W5_3^C<5+L/9ER^?5[6[GS/] -N/0/G3;WT3YJV+Y?J
M!K+UMLFON'7NIQ5K \VWS][B'\/D_0?H-G.=DVQYF3 :^VZ^?N  $+V&/YO^
MW\1@<V*N<V*"35]NOF_T&=Z^?Q$^BN!C.YP=A-!F87)B]#/%^SNGF]D
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M-1#LNDQQ*X""W9/EK@    !Y(^T<AK9UVJ[\$EGZC*]%O!>UCU:WY+',HY
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M*          (Y2JMN/I=\K8[=3*VW96E>.ZV&DQI7CNIVK;NO=;-*5
M      'X1TX#5JE,Y6G<MNLNMM+W7R.L4/LOD-MVPDL?U;?DU(-FPXN^@  _
M2HLVEN850   !CZ29"L8'W19N'-E++@           -8;K:EMK($6+72^>+I
MXF3$9&]U\?9LD             &,(#C3ZF9N'VHY..CI7URET-BQW0:ET4OL
MGRZ(1W;-26V5;?EZTP<MG7K0         ?2N=BNR-MP
M            '"8L^**J4B]U,I:RRY=9*Z5A5MV!)/2O3G@MFR7M4KRF4/T$
M5HB-]F5MN^X[^A)9'RR5?JE:_NCZ:^SK4$I7)2QS2.^$5MLY<
M                    !^'1/D&O5*1:RO4OCQ<MLOLKG%\#MN^Z5LLTTRL/
MT\QLO\J'.=H%56*'ECS$,UQU12]6TD%NX^1T9X<9:J.^^]XE7Q5D.7%$8)<?
M-!NY',                               !UC@  -9;:0JMWS;?5,^/\
M.'D1C8X/JCBY7Y4 !W#D                                      !4
M^9!+\.;[I7X%78,J 8%3EI=SUMPE*\]:=HSBO3.B  ?9@I8_N2D]QI0
M                        !4=%DUHMO[4D73MORI@S.   J')AU\]D\)K[
MJ>0^K;IAHNBW!\(^AY&    #"TIU:U'[16V3=KKC]%LU%J9Q+@QS*AM/%F%+
M6ULV^/[CE^YX>O%?F*UUZHZQ*+K5+KG..C]K3Z5P*F?5_ 0.MLYMNYZT^E0
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MLD]E^3NMJ]=)Z4^JTFRL&K;,++X3);G8[\?)'F[;N4Q<4D2RL>Y;+LE;<
M             -<Z6]".3!2TX9<7J09O0DQXI%)8<\&1BFC$L-B0SUG#/JMF
MX>^5MNRMDXJ')AT_^BOEV7:+?_5*P+I^6WX^9?J[4SW_ .;\'L-;OM\Z_3O<
M@R-)?>OG2F^Y\^NO@O1=R_#?H+4SV7PR);K1<,$\3VNGN+S7UJE=UA37DN[V
M9Y#>R2*HCF5#:>+,-78KJ_GCM6) Y&,I=?M;8<<5K"6RQJ:'#XV5D\K"LR+(
MZ<N+54&5+;X\03N>#"X^3-U:MAO^\W&V4LNGEEX
M   H[/QYC#;&]MI!(M5N,UBYLH  .&^/FLD HGT+S/\ ,'86-Q?>  #BK2,Y
MD%N860                                    !Q5I^')2H'Z?H    /
MPXP  8:6S.17_0
M
M                              .A'?2T\'8LNP5RS+;H I=%&M%]+OCO
MCU:26ZE3W6V5%)]WV1"*3%312:EV4I7/5MKVE\^K;#%('9++KH8[6G+;?<-R
M:4J                                   !6EMU+RP2*)7UTLII;BZ7S
M_)QH)#/CX)I5EXO%%/#IL>8X61%,[%D.-/\ =DD4R<>312_M]D.BGNN?&@$,
MOW=7ANANA=-++ZWNI<=*@                 #\
M                             !__Q  W$  ! P0 ! 0$!0,$ P$    %
M P0&  $"!Q 1$R 2%!4P%C,T0!<A,350"#)@(C9!<",E)H#_V@ ( 0$  04"
M_P"XSIT9&QGKHSUW_"I)/0L5.LYU'UFZL]BJ)W,V&3QSF,223&25H5.M]JB'
MN"D\9(% L^CA8)ZV&]1E&RA46L2VD 8HI[!:/GX4NS/B.+0T,?/>[;@DB<@4
MFUY(DBYD1,)"GGK\HP+M([+<Y-KR(EX](.XF8&A\.,PE3>'"%]KL6#.3;$81
MIUC-!BYHO/@@F4(;2B[A^CMP/D,BTF:RD?[.>7@Q#;;:%:RV<(QC"^S@[8%+
MIH(A()]LD"P(X;,#YR6*[*$2LF=V(F+*OMGII$B&UPS4*^V@(9'/OYQ LIG(
M1VN]A#@PK54F9(N-<3HL*GFNI,71AD9+!3PG4\@CE-M?R).1?@_+DAT0A:P.
M4'HP5+$R&HI V?@(:\UD0U8-=BH!PN="8WBQ(>A,VY08\4H;M2-*L$-B0=UC
MCL_7^>><KCJ=-)Y#GQ0?.(B5(D-K1!(-E/HFW=B-FQT@:QEL=5P![0'%&025
MQR2*/MD)M2*<]B;LA%9"C*0+HBP97V02'/&GKX.L<L<\:VI&2<MBJNK)4Y$C
M]7,0TW@VK3PA O#R:KV0Z^)'C.6MYD22U_'R8-CPECJ7MU?4]KT&?[&5*=BN
M-\DXMJ>6#%%]*KJQLQK<H^V67A!+.*F8F5>M<-<2.\D@&OY*$-/P$YCTD7!;
M&%2]]KJ5LX,4UI+W4H_@91*R[0_A.LA J3;8]+O.#LB 1[#9AX9=;:$,18+[
M&B2!/':4-\B/V)%"2H4X,D+/L4UW$U5(]%09"4B8> ".Z#ZN+CR:NG#>4?-Z
MN*$\".MI,N79:O*-TVVJ#B; -'I/,,R6K)"YLMK&2KOA^M).T*_@V>] !1%X
M)ES>&%'KV-,#+>2:O&NQT3-1@-(,YU$P8-M^&T0I!%-LC)#KD5<I(I>%88R.
M3MGV6Q'F Z/2/$M&$MC/\HE^(#]NL[V:Y0ATBE9\*^B$ERE+6I67DPQ7XKV/
M0:13EV4XWY\FD[F^,IQVG#?(NML0IE938$63,@-M,Y#@-VC"2M1Z>1N3O",O
MV UF\;VJ+*/VVSH8ZP5VG$46!#:,*&.K3J,WM_ 2B($"9DIJDD2;/].6<L9$
M$N>C.,'SL^STBK@TPUPLUP-:K/C!DP@YUK'XR#0C4?[1L;:"RW9*3GPX"=F9
M3&'4(FTD/$C)"6H281/+Y/Q$]!F'4KEA(85_$)<>_P IZ%L3B$Q/R0OV2".M
M)$EPD8%4Q8A$9(7:?"IYPZO!"F3^\)5RB1;5[!=0M!\7+MSK/KYW3PO?'##"
MWL$H$\>&V^FW>*>QHS*'!A'4UD)6.U.^9V?:FOB UJ.EBTN=Q3)U.D]6Y6;C
MM)78C)7K(A(T/PVE#\J'ARSC:_\ *&1#(\+0B3Y5X+@(EC@O'6JI7*$-,\ >
MN1XC)U$7*3C#7 U 4CKYJV,QN'MXVK]PJNBA;U!C7J#&O4&->H,:]08UZ@QK
MU%AS]08UZ@QKU!C7J#&O4&->H,:3526Q^\OSY>$E7A)5X25>$E7A)5X25.UR
M3;'PDJ\)*O"2KPDJ\)*O"2I*SSQ?R.'[I_%%OE^XHNBC7G6=>=9UYUG7G6=>
M=9UYUG7G6=>=9UYUG7G6=>=9UYUG7G6=>=9TFX05OQS<MTK^=9UYUG7G6=>=
M9UYUG7G6=>=9UYUG7G6=>=9U@Y;*9<'C[H5FNLI7/*N>5<\JYY5SRKGE7/*N
M>5<\JQOEZASRKGE7/*N>5<\JYY5SRKGE7/*N>56SSM3<BIA>U[96^]+?+]S+
M##*NBC711KHHUT4:Z*-=%&LD4O",12]-Z*-=%&NBC711KHHUT4:QPPQ[+IIY
M7Z*-=%&NBC711I=%+H#T4O(=%&NBC711KHHU9-/&]*Y]-*][Y7]D?*$"$HQ^
MO]P6K?)/[TM\O[/+^T9^V^^X^0/^@[GWTGM#O RF./U]<K^V*^;]Z6^7]GE_
M:,_;??<?('_0=S[Z3VI7XA[E)FXL6F$D2CHL48D3>77_ %]D5\W[TM\O[/+^
MT9^V^^X^0/\ H.Y]])[6PR+!F %;,S"YETR.PW,(@3:+I^T*^;]Y.3A$0GE*
M/,Q_[/+^T9^V^^X^0/\ H.Y]])[6R(89D#INQF1!B1 '8I&1LWE@#*-'F\E$
M&C*8=(40Q*,.QV[;,&L;E(N5MJ%?-[YA*KQ6P*4B)*M7.U*.VJ*^.>&=_?FH
M;U41 ,$?A/C<Z3?2WW\O[1G[;[[CY _Z#N??2<93L1I&GX0RS/C*EJI!!_'R
MF95AP4Q\:<8;+9&[VME8]K0<4<1P"VC8F5X+N#PMC88/XNG&#1J/%8R1\BBB
MW2H5\WLO>V-L<K96<.6[1&83:&'L&+9BT;2ME)7+?6;9[FAL\;EF'BD73C#0
MP:& &&.5LL?9&;$:NWG P98 F*B\ID](0L*W2Q"D!U-)RJQNE+8PO:#I!WI?
MW\O[1G[;[[CY _Z#N??2643RSX;*&I(R'4&=\HR7E4>!*IJ")&-Q5M"C-YL,
M4R^)RE?%RB5 )&);2!28-G&5FTQ>5Z/)$J'*O1LJXY;;CMG[1]>8ET\,$L.
MKYO9+R3Q@/@Y=>%A)7)GFPRF3-IDG'9'*(9FU_J :>5<;$FB[IQ(IHX3BF\;
M^8D&+S9&,<:25JA[,B@&3Y=CL)LQ%Y?&16D(XCYKC_PJ&$+W6BL<7L@U.QVX
M"0LI V]W+^T9^V^^X^0/^@[GWTAF)J-3R4P&V5Q>-,V^Q2D4M@^+J#X6R .7
M^,=P(0P0QBZ75QM;"U<ZS334K&UL;<"@Y LQBY)=TTHP;;",$V8@9(=3/'#(
M[:<Q.ZHPV),XT*^;V[A(^FZY23Q13[<\,5,='RM9NYHJY<,AD<V8&D"O?(Y
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M"B?UX<[<^S6SN]EJA"F;9OUE:ZRM=96NLK765KK*T?$-I&,*0F3"E@4JD %
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MYD6ED#:HJ$XHH'9F80X01;HMDN58W\-^)LPS #&4R$/56TH$NC&,G"W"(S
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M=I& R.-T;K)&W5'1E=67X$.A*L"/B#CC4+BTX&;<!*X(A4C.7^9'[J_$GIG
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M>K-?F\+7HK%BNFJ:=J.S>D+"":G;L>G>QY0_DG.;?*43EPQ%MD8V@#@=OO\
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M=K6'GK6I+,*\ZN:LRRU.3S?1S)DDB]NFV6*5AOYD3A'3!OTUNP&/M(OJA?\
M=?Y'^RW8_+HW<<2+)$[1ON5T)5E/<$<5+<M2=)HSU4]03T9?BI_(_P#Q'4 B
MO8CM0I-$<JX_BI^*G\U/0_WCH0?J^B.W%<^CN&O#CFZ+KNH0W4'O :DD%FI.
MP[[9-DL*M^]"5STQ]8!)  ))(  &22>@ 'Q)XH^&6=5DO2&,$9\O%CF?I)(<
MA3\U4$C]X'BM3@IQB.O"(D)^ .7/;+.?4Y^'4G'88X_+X]L?G\N,'KT/3O\
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M'/PE899_U5, ?(MGN/JU2_KE/Q9XVJ4[%UH_%,^G^%M*]<KPZ-JZ:#HUL7H
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M9[9X\05*L$-0PUX8B]L*QC0*67;[IQW'Y<?9NG_\QJ_^A7@ * J@!5   [
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MD56R@DRP'<<+[/8,#">6QN^(K))&@;YK(DSK*.F\-TQP"5R.O5%1MWX@)IK
M)_/F3N<_$;1\.IZDG '7.!V'7X=^@[?ZN_U)W^MCG[CND2-)(=J("S'Y ?\
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M%E@U.YIIV25[1U34-)2K+"-2UR+4ECKK Z6Y(U6G$M?EV3S-4\;^(Y)==TP
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M61A)''*N=DJ+)&Q5EW(W9@& ./X?EPG<_H/]_P!V.K7BGL68X8TL6N5YF95
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M6>H=OM%W3;Z46&*'J%WFE_)9J,I&_P I3J56 ]/,-:6X^\'X K955!R1L^1
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M^J2QUR017$VHB:C&RY*[XJ_[/;N6 9C1L=[/J$YQS8I-*-6"N#UBO;+8$G7
MC)L2U[7FE.Y FWWH(T:QOD\ZQ/,D^VJTU=^@)J+%)%,\?^3C=2-\?I+YR59N
MO%GF,L;QG+)IVO5@ ?4L]NM#Y0C/0!F6=%?/H=SG:'+<.O[3E85GK:9O;>8^
M9Y:[J!L1%AU,AKM2<[L+.D*P,Y)V\)^TL/C:LDY=1M"+^SC5FCC'[)))%>7:
M<$L[.53=L7_$A!RF!T:.:5B?2$2&2O&6Z]TW6%#OT6(E _[0<9ZJ/B\O)4?$
MRGW4Q\"_]7G',_J]W!Z;L_A5F/S]!(< =V="#O09=.[*!QD88Y&$BBG<YZ+#
M/MY,I/;9+O38W9MPQWX((D6(_M7=XEC_ !&5"5>+'?F@J?9^_@%MNWKP.KE
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MD6U=N"4])MT]34Z\,9&?>#:DSV)M_JY2E$S(P1H6-18!MWKX?GTG/X1-*M\
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M):-;<(ZF,-(DD+=8Y ADCD\%_1UX9\#0#[*J<[477;8UBV%EU";( 94? 6K
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M]GA4ACD6XY2\M@T=B0M\LI1U91EYH46S234U-5)&N[Y*F".=1EZW"R!3:XS
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M,#EPB@--)6XU!1U#=YJ9<].Z.62TLKA;D#F6S#U\?^";L(1;XF:QV_GU=_\
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M?3TER^9658T2S9\LG,2Y+\!-J&EA+0E:VKJYJAV\V!B 6GQ%6-A:,T3O'!$
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MZ23&&,A9,4FPF:6+XHH:FB@CCRR=[JQ5S3R%BVHQ6*&..P(0+&MB%#'F)O\
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M"APC$TK)*/'(:NI58:F/3IUC(:0ZL,8(!\%);V<-\*78/<_R@BMN?YK7=/\
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M06CJ 9 !T5[^< ^\AA^UY9+?$V(W\)Z$K^UJ./\ NW^1[B01N"-B".A!\"/
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MJ3J5@!GA"Y)",J^D#Z(]7$?93LQ%(DL79[!XY8G62.1*"G5XY$8,CHP2ZLC
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M,\EU.H:C))EON5R#(-@!;CME2T@P:>2I6FBJ$R&C>PUFESK>**P5R&3-FZJ
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M[_\ #C7^S^__  XU_L_O_P .-?[/[_\ #C7^S^__  XU_L_O_P .-?[/[_\
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M@I@#<["28'K'P>UGP$ D?R=B:Q(S+V?D*M8^DIU=U/53XCC^5OP$_P#1N/\
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MJ9*6<6L&,;665?7',F66)NC(X(\M/3U%7/%2TL,M34SN(X8((VEFED;HD<:
MLS'U <=H>QO:3LLE)+CF&24D58MX9A)%/%J6N:>62!Y$AJ5&Y@D(<BY7,%:W
MYCL[V8Q3M-4O!A\86&#*:NNFN*:E5NF8C>29A?3@2[MU.5+L*3L-@^"H#I=_
MJQZ556*K6;UPT^\4*^K9W];\8O3^EMMX>'NVXQ>G]+;U\4A:&O:/Z$Z-?]M.
M93^%Q]_DIE,L-5 F\KZ$L:>,@@UM1$'TG"S9PHW94?*"1;RQAN[::66H3$JJ
MIC[SYRD ;N;4\AC\X&4/"QE0)G<*H'-E(\UK2, =/4[1-%K<[VK*S VI&?-F
MO))#3U1#&[(48DJY4EP\E(Z,&-;)AV#JM2S;I)2T#Q543R7S:BU++,_5:P\K
M,YC4%I U?6N"!!+78K,9-UETZD3:31N%/>HYR846GG4-2JTF5XA!"Y0!9:DO
M$9(G?!II(P0.\P4=;.U?3=1F>6"2"T<F6.=8LC.,@'"DZ50)'U#+6":G&_F8
M1 L<NQ TN\S .(!Z&D9&"O,1Q2W,&%4TGF101)2U,AW#00RRN)Z7+<M-,KK:
M-PNG+F+G+OQI=YP^"@8]W*8E6U$DK[A89<16I5HU2[-)IQ75>7F==Q8\"438
MJ:XC17OE:9E?G#X?/'*%[KE-TKI6ETY& C,07YUH6)- =.GB5[H%PF2EJ(WY
MI#7FM2H3N;+M%0;22-$I2++I((]11P%*Q57*29<2I7D49<\]!%%0:\()(&27
M3J(S$[*DK6U.7*PS*)$>5=:(U57(JV+:1EPZ6F@J%@(5(8Q4M&Q@4,Z-'WI4
M1E ?*]ID+DS/3TB4TBO;NZQ&MS0"LYI(Y$,U/-J@,I*Y$9^YP!T='G6H7*B+
MVAJIYIE0I'-2Q?%[5$*Q^D1- 9:<4K@)>HSFRM(R1 "E@C9;E<--'%'L.[U,
M=?-+,0UP(EK:5Z18ZI#F"T>B^F&%T;(E02^:I=J&.6H (-3I832T]9,IL#IU
M%6DK.&RM,P661+VM2\IIP?-RQ8J:NIG/2>A,M.QAVWEO2QS4/=7&3,VH>29Y
M%I;1BA3T(Q@4T%2GAWW4IY(DDM\Y(K(^23FR@%0X4Y>*3(LLHE%D;%<!JR2.
M1Z>FED%5>VY*>9=T(YT46S%<O$9L(=6Y6.;%PB%1)I=YAPTTLH5MA'F3$(D*
M<U.]09%14+,&/FZ9"<SQTZ1NV9I&+!G(#RM\\\:%(M2UB(P 7MG;_(@8$27.
MZS1P*!S%WDADGR[=),L3%8K%Y%!9=@>#L';;+'%KNUQE$(MFDOT*I<:A%].X
MSY> ";#ZSB,>',?1O?H'N,C&RR$V0L>/J#QDDFB0>+2T^H)XP/K1:,N<=5TV
MOT/ (:-I@1I(B2M)T412 ,DI)_5,"+2^A?;-?;@\JJY! =Q$NQN93:T66V82
M\P.F1GL0<MC?CQ?-942DGJ]0D9"E/54=)( WH[/6 LU\JZ;J=^GTZ53RI4U!
MI]0](Y!!+/E=?2#D1@",@.=1"!8[V.WVHC,/;$LB1-(/LI+(D3GZ,AR-9KCB
M(:I'@K34,:'J9(Z^FJJJ*:)1O(-.FN%&[J^=>53PGG$U(^9,B29ATTWRY9 ?
M&,YE&<74,RJ2&('#S!(ZJ7*2E*]#"Q'TJBOF*)$/5IPJ]1(QZ#20 F6ZR1Y*
MF>E5A))!/W=LOC(7R(H'7,^S!/2"L&(RD'A.>!9NGGZFFD0]8YZ9P"I]:O#)
M!4(VUUF"VS*WD^,'F1:>L&K3BP\T%AEC^VFF$21EZVG60-TNNS#!,5G[+]H<
M/Q:(+-)A-<DQ6UUJ(-TF50WHF:FD?3/I([*0;KQ\->#0XMAV"=O,+<U%(]+3
MTE4P)9>Y5=Y\.J@+V3+++)33VMSR19MP?+\!O9]5GQ3MI7MH46&P5%#1R.2D
M9<Q"7$JESL&BI:8+'O==21SZ4>QJ/@\^&2)Z=LV%]HX!(M)*XCAQ0PHS:4L)
M^:Q2C9+.]*Y,L%V%H2!*>U_8''^QL_Y?!WC#W?+38M2JS4DN_*LOTJ6<^,,U
MKF^DTJC-QV5['8YVPK>ZX33>:C9>]XA/F2AHT/C-+8W<CT((P\TGT4R@L .P
M_P "]!<_\,=JIX?L?&$V<>'IIA&&D^/-/.H_XR19>R_PIX7VR[WV:[=45!#%
MB<C)1R@,F'LKMYFCG9W+TU3$;=TKPZYI+9C%+E:3X1/@TK^QM0U;1ZM=V>FD
MM#5VS34+N>6EQ *+ _1AJ0!%/L#DE.GY.RGP>=I>U[J]#2&FP[-:3%JT-#1J
M+C,(=C)5R#ZE.K@':1HQOQ2=CO@L[#Z&'=I*RAQ/%\2RT[/BO-IZH(SI20ED
MPJ GT:RH<2J2"*D"]OA#^"RK[+F3%\&U<0[.N<Y(\[4X6'W5:DK\[2;C1K5V
MM99\K97E\G9[LQCG:FL[E@=#)5.MM><^;HJ13].KJF\W$/$)=I7Z1QL>,&[-
MP=F,#HL&A5"]/"#5S(MN]5SB]34DD!FSR;1YA<0K&NUK<8A#Z7&*P7!^_C&(
M  Q-@-]SMP*=14:WJN$M]K8G\.GDIXT;/-*S"*GR,1&<LCR.2(HT8@Z98JS-
M)8Y$1BH+91Q4U\E2H1HX%4=&$2M.0.F>J<-42'UEY#??P-O(&!65P>6%9&D;
MP585SS&_B(5YI;7TU!+Y0#P_FRROR,FCG#;%>\OIP7]6K)R)]9MAPG,M0[71
M86IXUN+O++4C,B*FQMEV\7,A$8CZL&Y=._ZT,8[;YPE]0BU]H\K:A_5V.?+;
M@(QD,(!,@R\H_P XN>, ]&,J\T2@DRK9D# @\%@"JWYFOE'4FPS-L/!0+L>B
MC<D#A%+R5*$912Q0N[>D6:H#M$JJ-BA10[2YLH66(H),QRA@URIS6S]-]XS9
MU%O2=>IC6[VYLN7?AN4,S;*D*U+-]$0.Q192>F0NK)?P=64\RD<("\BQ92LC
MU,M,H/CI89#B8?\ 9ECG2*/UNRDV1KA2'TP+9WAII2MQ9.])FCN_HE'(98I=
MDER\G4#@?-*[71FJZRDTB#GST>F9&(MTM)=MO-A27(X?S>S\MR@%R+'5*B.Q
MZ$29UR$&S!E*D@CA59LJ*#SZCJO3F4>=Y?"7+'=D($I5+Y2%X+ #,2 N@M5F
M\.[MHY9K]--N\06;H=6,#=AP%8O"EB!-WD!B/1:EHZBL=&'4/E@"E#9DU49A
ME(OF73ULPTKQC/<!?/&T1)^K*?FG]"3Z!/"HS,J*I+OFRK8YB4])+=1(+7TC
M:0C<*1OPGG%+Q\R@9KCIDS9"X^L@<A"ZW0,0M[D<)YQ]-.9^7E&YN]\B_MR6
M.FGIR6.0'B23)3SU*@R)!%+*V7Q$5PUC]4.-(N+HLAR$YMN)HQ"TBEP2E=6T
M5K'F-$L#/+[$(G%[[);F.XX960Y6!!V-CZB 5(]892&4C9E(()!_R'!YJ3.?
M^<(ZL6ZA$PC$:#V<^M5QN/ (KF^8*I=,T4<8M=,-Q^C/JU<5;$6@8?87OD>L
M>H(?*'VO6?E!KRFW>HL)CCS?1[BE<LH>U^4]YCTP+[*UPMEN[J]2LIS!(<2Q
M:MCZ%I(\2[\R*XZ(\,E9YRS.KHHR96)MTCB  S0X3AM&H/S;5-!-@<]G'_)I
M&PN56VSY9$Y+ELIE"3F?<M4UBN4E;ECC[CB=)SU%F'>G&(R9:EHUCSQ4\1 $
MKM&(C' @^F8<0RI(+><E[04&)TXEC4MEIYHL/?.MS(5G20IYTA=0BI[T 29,
M1IJR2-GYHXZ:FQ2(!9;'4JG?$F.L4146&(V8E@L8T<BJ0RM'B*RL1ETWKZK#
MZE=-;G-'#\7HL@NIEDGGF7+LI@*PFB](K2M@5^EV7"\*K:":WA=Y:A'B']&&
MS%6 !@!B%&&W[O@@PQK=-;\@.9+_ *G-2R-X-=E.2Y-C$TM)BE*N4.U?A6)(
M6N%:"-5IYA>W,\3T\?*+D"I1CREBJ2"HKERBT<?:AL4!:R2K%434\TKSE[(L
M$*1FTT;R%X\U-E#;\1-^23-T-9BM55(I])8((:>@C>WT1/)3SN =RBH_1P?+
M6_SJ;_LO_@1<?!!BU+VD[.XS\'N,'51:6=Z)6W9L-JS:>.*_ZS#ZQDJ8;>@)
M5(VCX/P =I@2%QO!"H)REDKPQ7P+ 0$!B-R 2 =@3Q_X .U'_/6!_P!C$/\
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M!Q8P0&)R<Y&3LM(E-4-04V-T@I2QL\'41'6#HM,F8+3P%S949'"5H[7"X46
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M0M&4>?MCL,_-8,>L@(8_'(S''*(3@>7L)D,!FE9"_P X5.8K]^_>H#8L,N4
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M/5,W8;CNGB<>S&VZ&6\!;OU$UO$Y&RN]2L^"=5W6#JO2TD.(R63 "B&9 *%
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M8&R:C>HN V>'V]2.G(Z1.GJU[?N3?Y./ZW[^I?\ >N-_^*#]Z%_%G_=QC_\
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MW.U>U@Y$GEC<A;<%O#15>YCZN*G*K(PJ6:*B\-",A*NI"H\,UT;1A^3R)M+
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MEO:AJMQIZQ=W*E9KDR)@2N9*"&ADJ-U?-6.E&+?@-.K:M6A5 KM5GZ=-U"W
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M1*1U+3VMD?(%A:WJ$Y.-EE)(='3,ESN67>(F1U&?K#I/S&6;+00A4;F-9.T
MCU=Y_'VB([S/:.%V:S0>AL;EM7.X#CU=I_'VF)[Q/:?E5G<)(#E:Z^D^L?9.
M5J1W\,WX.'_ G/V1K$B,\6<E:=Y.\GQ,9*K;\VS3;';I]/L3>H7FHV#JR?-T
M@M8AN<<*\+3N]$*->RMCLG&/0$PM[%:BA++$D3@4<SL@]QP7JE52^@EHQH.>
MO( [I74[O2VW,L[9ZD.V]1X, US,1M =HZ7L"3,J8E6>OE<<HSSD5;"9/)-J
M$D@&+;+<NMC7?$:U_-D"T(!=/DY>;J($XA]>0;#5D,@NR-);47O%5RD'BF 8
M -#4NNL=)7E;]:_3H5:MH".ZJ*AV7."%K2M1+6YBM9ES?,A,2"Y@M^D?(W^3
MC^M\RD=7EG*\P4K$O7=/#$MEVD<!'AM*12!N6\]PFX&#%?2"G76(XBOD'/+(
M4LIED6J5UK'9'%;KSGUL=D&-](VPJJU10Z=1:EBS7,AIQRSRDDX)IW)YCR01
MZU4\<#$T(9\/$WG3*XGU^$*?=^X5+M*V_'Y+'OBUC\A6F(?5?$2,S$%$@Q;
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MQ9S;>R?4P>R_C9JV#4&>P%30"PF69 D1JQ[65Y"-P2^H*5P<%7+J"L1@5B,
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MKM$!F?5)S[])TB)XC[F,M/PWMF)_C1NC7@06(@ 1 B QH(C'JB(CU1\AM84
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M>KW\;(,)/;NV;HW;==-VWU[=>VOJU[<6$W;>VQ4K4KCZZUL:X*V0R$8NH[:
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MV\<S8E.(O7N9D'R$BIS.Y]1Y8:S2PN(=9L6;_50Y#E0MUAYT:NF8)O0D"@I
M6,R')CLGA*_,'.[GXRM6Q;U6W9R_6MX'-JI,M+1>6C&Q9QDS8@+&,:^=BNCO
M<%;(<Q8\6V\?RQAJ>-M6'+O%CGQD>8VNI5WR9GXBECK>.I/N#'IUCL!S5[N.
M9=N#??RV6O81_*G,X'6Z7+U:FJB+0*RQXV\7X"TB]>-51)QE8MPKTI&T Y;R
MD8B$9$.<^<;.8OC*(M%@\C/,,T8LNALFZDTF8LDTXDQ071*$J(#D<NVI@)O#
ME^6,'CAO*&F.UN/YH&YD*MAS'ILJZV,8'3D8(' DU;Q)8#.3C&8F5\LCS/BL
MH>)H4\9:1<K_ +5V4;%BOA;3E4;,5LQX>Q:J-%<N8'C5+?82.]=:TN[7W7<C
M9KU+_@H=3J6;C75ZPHQVZI30(%N104QT45F-7JETNW^)+*,E:HT*U:E1M%;L
MWT++??MV:B5'5+1JQ8ROM0\IV6'$2%QU%EK7JTL[CK-FT#C0E;XZA^&@Y>O;
M.DA82*V&RJ>VR*P)DJV#)<&?[9L1(+Z1$46@(>F_78\9C6#K=IAED-U=,Q,.
M8$Q/#)G(5-$WJV,;/6#0,A<\/-6F7?M8L1;K2I?M'UU:>W'#:E/.8VQ80AUE
MJPM+\U%8MEIN^9A9#5+S;6TI\-.D/Z>L<7<BC.8YE+';/&V/$"(UX;V01P6A
M;+,^;4,8D;1>;7EI=N,16Q]JOD*^3=E:[KR+*^AC6XK&CDWKNP6A+9T"'<L]
MAIW;FQ$<.RU/(5<E5JY#$T;LU[(!X0,M?117==+-/N0>M+Q=$=.PM1PAA3':
MH5'*4[/CG6:]45MCJ-L4U]:VB%3HP75U>E:HQ%@+T.1VS$SX&G"+B_!8VX%_
MQ]=%-GE#F!G+Q5P:S6)L(LI9M7Z[#HBHO1I<3BJ69H6<C'7^Y%6 )LS49*K0
M#IV-M4XF+"0F6H];0&._&4JQ0=D#PO*61YNR72<"815JGT:52-XENLY-J[4*
MUD!2NJQA[M1&:'E/.XK$W+V*IY?R?=O(7816NJ6Q75U*(B9D]B]=)=,3*A*(
MXYBQ15RJ7N7<@JI843(;#ZERHJ[CLBHH$?0W$,*-DQN4Y#U3);8(N'93E\II
M98H(ONQK\A3M_&N^+C'V*:6^Q+,:VL:I+J;':2HW5B@ZZ\O0D="GTE5_X)R/
M8O#6E[&?59 %VT+C+<GY 839"PZS7B8T+Q5?1-ZOKZRU6L'JU^H#-O:?EQ_*
MU,>M:O.3;L@,;C@89TZ"!^#+#YD_CL ?<? /';D,&V5E86/4;C^J41U%MCZ3
M'V8+4!L#HIVD3JWV(^XF]"\ ZOQEF1&TKXDOZME/^>3K[NH*RG;QXG)O]*<3
MX:DK0[ELH]RE:QH$3[;F;5![RUTB=(_N5RTEO\/P2MGQ]DLI?B/=V2DO\A$^
M=6YAY-MW6LQRQ*TOL=T9 ?2VDB P-BNR-?$TMDZ!KMAB]P@-2UTZ>=4&K:NN
MBK@C[5BCNG68][:\S+$^OSU^?\A!=L^(OZ:AC*DBVW/PZO?96"?PWD.L>P)^
MKAU_ 5+N/Q5#<\1QOF]3ISKM*RV!/).B/:JH'IS&L2B?>O%Y;ITL\/F1'T:,
MC(>LJ\%]%9[>EJ3WUU).X=P+XG\4<>*RUL*XSKTDQY]JS,?5KHCSV3\2[+'Z
MYCQ>RKI/:YDC54<Z^&I+F8K5XB)D1VAYS-O:6D9=]?E&K2KOMV63H%>JEEAQ
M3/P6H2+]&G'[:>8EQ3MC6=7QF+W0=A/BAV.M79"9!1]'52:T$1CO,V[9@1^2
MKCJ0)*YDY>L2M!+:E:HA8S=MV$Q(S9$(:I*ZN\(L/L*%C 3#2CK(MY1K"UDE
M,OO#&P11H4U\-7).)JCW\T$5!V]IUDHW?)&&;EJ090NT4R=$,WRJ7PK\"+!(
MB7C7DNN2?2BN0\[A5MF6H!6?CF9=+SLK%3,6GH=6^)S.V:B_%5][M=@]9>L^
M='#,=5MT&8VIAXR^1S;;\5ZZ 99=40BNDT3XMA.5HR>LB!ZR(3XEC-@SEO+5
M'R?%GP4OZG?QNF[P?0T\1XK9Z3P_2ZW2]+LZ?G<4!/.XS7*+6ZA,6ED#TN/I
M);O&9 %N=JE3&D L=!)"98,C'B\K=11KRP5";RTZC3UVJ2$:L<TH@BA:A,]H
MD6W:)3&%Y>Q4ULE.6Q=C,S>"\((5028J7-: 2_QMAS)/T.^O"EI:1MWC"B+'
M7L[C:MX"@&5GV5@Q1DB+*P;K.BF.1,,0#)$K$=DPR>W%8J&4IVHMKN-KPML;
MV!CV+5>]'.AC--KE+LB8B:28$'$;HXZ#)(ZC'<KII9%!K=6N?MI.\-9J]O>$
M5@HFUS-2WB0],9GA#<IE,9CFV"N]-/E!-K5%.^^@=GJI\WH@Q/W4R8A=)DRF
MP8D$SQG0ON7CZ^$O4*'BWN$EWVY#&5<HGP@+B6,+I6=L+"&&<+-HQT^\>6O*
M%3R3%>;<Y'KK\'%8>Y.)^O3%8:3OF9C9I,%I,3Q U<YB)MW[BZ<]-JQ<^YM!
M==;IT@M6B2UTS=H%B" *ILU&.*MB,I1Z%V+957387"W#0!K+Q"<E$;:8(:5D
MITA$++J;=.,>[%V%9<+N>QN!/PKA@JCLEOZ3W R(/I;0WAYL=</.211WXO@G
M.XTYQ:G6+^ED-M>O7+98L2<S &BN<;+#ED:D,\QI"7;A25<Q8LVOMC26$61W
M399MZ(3^!%B3"*K3VJM28C7-DE$<'AJ^7HNR@2X)I@Z)9+*WWRH)]ACJW?Q"
M5D34:%U0#:6E:ED\M1HVK>V4)L/$#(39T@8>OT*C;Z(&NV+-OHQ*3[<9&DK)
M5+.3QM6Y9;CE/'KE-%$O?7"9\PGK&/3*&28B)W. 8XM6[_\ <A%8<'H=IHLF
MPS.82KFU(0"AEC&H39E;! 2F>BQT1"HF81=HV$VZEE8MKV:[!:ERR]DUL"9$
MHG[)^SU_XC\JI;2BM_[%^C>3>K_[.<RW,S<\T4F'I*[P&KYW=\3#.D,0<PR'
M4(C_ .D+*\VEH3HF:-W$7<>I?T'>Z)V%[XGT?2@M'%,0,U:?5QG41^Q==Y(D
MAEVSRG:\-HX9\-KX#5)2PM(=,[9Z$^Z:*IPQ8U_,O*7,K[C+5P;:YP2,$B]C
MU5!I2MA-+#]6K:.RL=CNFU(G&_C!84[E%$T,?SK2N6%=8_.YE79BL: E*^L
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MST49$P[P>X=/#WNWF68TAA:=;2?3#^USG3=3OUR\,O(VXZ,RP.W0R>[2%._
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M.UO2\9TNOX'Q?3\'X_H>E\#XCQ?3\[HZ<(H)N)=4FAE[]W)ZN"K33B7T*\L
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M<3P@T!"D&(4WD><8?:&PQB5PHH$8^!QT'7U)N,L>&#=NQ^ \T#X@8<5W$?\
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M(41PQ;VIXG7Z:IY]),+%E]#%OT"=P@ I0_HP=7 "R![!_L#[NC-'S",^N&\
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M@8)=#2]G:\HV=Z91"OH7H:1[K]+LV;-FS9LV;-FS9LV;-FS9LV4;9U%OJO\
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M>(S:80Y:;IZ!7_X%9MX,=E['H?WRY#(89*;_ *V.JO?+R-"#'+9XN@"CQWG
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MX0@8*N.*=Z:@9ANSP$M2DB,C#*I#*R+EHR!IQL+V1Y=(^?M;GE6(^QX(L4O
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M 0 "  ,    0
M
M      HD                                   #"#'&R*8 (  $ON(
M $  2^-     [9:;V'               &7E%_\ \F!\!7!!>B8;> @KO>H!
M]@ %D!*!,0               !"POP'  SA+>B9_T-_IYK?Q%P%0 ;(>HH^"
M               !!W[X>  *  7<QI<  @-%@@\0   "KYD2WR
M                "]$\^           !6VVVVVW              )__P#[
M_P#_ &                    !   &  !                  @     &V
MVV^VVWP VVWVV^!';;;;7;;;;:[P              @     (  !,  !
M'P (,@    <     !               @         $       .P  *
M,$     @              @         $       .P  *    !QX@   !@
M            @         $       .P  *    !_P      8
M  #T         !       #L  "@  0 -.'D " 8   9#6       "0 4
M   !       #L  "@!07 5(%P +@8 #\?Y;-@   0@,;I<       !
M #L  "P#VR!OAE0 ;@8  @>%>\@    EF 1K$      !       #L  "FX@=
MX1X D#"\8  (@ !8"   !82A[&<&@  SH>@"\    #L  "CY0L< 7@%HN(8
M7,    T@  TT0LE#0L  "0( !#8    !0  "@'?@0"WV4H]080;\ G$ /8"+
M< 2   S<  #:R 8L,        "@ #H !V  ,P4<,\ 7^(@"< " &,#) ("22
M3,6R6P&222222221P 1BBK8T !<-)#@),HQ 6^ # <$?+D<, $ 3#4,0@ /
M*   "*>@383@ 3:PVBRLD(9N\D H  D+(8LP )C]X#FISX #CV,I8S/(#<:<
M0"]":! !J,X+&7 4 $ %\.4;\,+Z@MP "84  !OF^G+_ *K C,:\%1G$LP L
MAG""J9$ !X!Q #   !& "  "$+   $P      $828B%1A'$-#0/T$0.BV%F(
M ) :$ %U     !4((      $   #$3P$ D6"!1?)@L "$+ #;  ?+]%%*F@
M   '[S/       D  HJ-5)X  !-FCN R  V8    %80"$@$C      ["50
M    D  H6Z*0Y $JF<<V OK    B  ' FF' ''      87       DD  H <
MT[Z&.U8"S& "D48$D7X   !XC[,?      9W      $  $ H!O1WP\D8( [V
M  90H"J!     8A8 G.(WJ          DDDD@H]@F? P:F; #F   #>+
M     X  F<!80         @   @HH .)P3#'!  &   #XQ         0
M            DDDDAH  +[   8'@ &     C     " 'T9J7
M E_@%VI(   &   A#8             GG23G0@             $1=*[ M
M C       7            "+O90              YV-_ "%?_\ _P#_ /\
M_P#_ /\ N                              )/363_3(( ,>K&XJ[P
M                            !(!&RY(.P( SE&O0"@
M                   ))(U0^I)(
M       'UH !0>4( ! T                              !?/!   /"B
M))))). H&, FPPGI.X9!GP                  !"[_  J@ H#L!8  "#WN
M"X=0SAR?<I;#D                 #4XY(>Z*,4#'-J0'P3=.B +*CMO69.
MH254                !--&T'\X#_L10A7WF!Z,# ;)HEU2IDL+/0
M                   !)P  < .R227@
M         T 0    "   7
M
M                                      ;42\+X:EH&#A>X
M                            #=I3+9T8GC9[2X
M                                                  #_Q  M$0$!
M  (! @4#!0 # 0$!   !$0 A,4%1$"!A<9&!L? P0*'!T5#A\6!P@/_:  @!
M P$!/Q#_ /8U#==S+=<36?"1Q6YI=4FH"P;L=@/_ (I@[ K&PK!;-52:)MSV
MC"(G0<B#V+$D*'#/YA&IM*199(1K2;T(%**$0"5@AVWH0<3 )R@@*FSCRB8'
M=C092[#J!30"KG'C(XOT0Y6&'9E;"" WU$6PT%J)HQK6E/V3(O:[<@PO."*
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M-I@K(:27NI!L#B&0( K.P,HU*G+.CABL1)L40"5$D;S.,2L0ZH'E:]D+ZC;
M+2!"CO,"6-*<01M(+!S:T-MD1%SI_P"!KB'<RXB IP!B(*#$1-:A^SA+:3*_
MP1'02-C:S#F\V#O39-ZZSU.N+$IO2!_>N ALLJIL)ID-ZM+5:.0X4*8W6*ZF
MNJI5>IR'+F<=C(G@UPV#<C5LSM#6 0[AZ(."Z%Z0Z>9Z#E4RH))6=/Y4BB&
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MY<KW?ERO=^7*]WY<KW?ERO=^7*]WY<KW?ERO=^7*]WY<KW?E_P!S4:.KR/\
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M !M7EPHZJN#B)[504M,YKD._B;''YZC),4J%Y71T9A$YKHC$!QN,2@,N9@!
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M$;,&W<%#T@-H8XOHD'J QZ)5R*>1TN* P4B $3V=*8J=I!%D$<PBX F4'F2
MJ0'^22KKZ5LL":U)="O*ZV W+$$H3HW8 @?Z^[U\O1_CMW^O7C?F%$32;, "
M?7WRP=>3W./7X_ZP:#W!\[Z$A#5<,-6(K6@XPTH.I]GHCU'3UR'%P5E(62H"
M (%S>#&G2H+@-NB@D.2/%,2Z( M (12B>"CWQ3M4. (BZ8" +?E3)8,,B>"
M<L#-P;:=8#CL%@8()U7%V6#5.0.EZ]^N6$648 18R1>OH_9_PO,*#N_G&_%
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M=6>WD01$HB(\(Z1]$TYI<!B)+O V]80X#X,5X:GHF]>_;O\ 7"@4;$4=8[(
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MSMXI1$$1$2B)$1TB:1TFL$2"E.X%2]46JQ4/'&4T-.]!\R7%YP H$# 0)B
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M&57?[I30,:V>3!?9#,5TC7+*&M:'%E0U%%^G$\U(+-K6-0.,X:C@R^GC?C2
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MW^,K9-3GU[3\]N*'+< =(QI3(C>K@6V];-"(P7B?+76N.(> WIAI5*L%#BA
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M,>NGJ$<".Q.HXBOA5'\)Q'?^>^_B?7#B)]=/7_/%#D?/; - OOJ/:?GURZI
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M;6<V84%IE)C-( &#?*)BS6X(\_B0<5,P22LWXX6! P$(:6 X""%:!A+'I<0
MNBXI8D*2'(3%"T.7I\2RRL-+18Z]1(=0E#D2E&.S* (1D'U\@D3G(K)B=.V"
MI!=H!: Z7&._)",5)42(=3DP<NZ$ 11.'170H"Z*D%>J0'*C.'(U+Q!IIMR-
MC279K>41"2MD%"O *A5E0YS@KHI72A2NZ('*)X'%P!PCN1?!L%C$,8Z*Z*%>
M*T#W48=8SC'0+H8+H8L/#&X;F^,=2ZNEU;(=Z0CA08N/%=*I2F@T-T7R< J
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MI.)3%;&TD*J:I*4I;2;+DR@1L 6IKG"K 4$@!+<H[I1*!=8E4&A7.([9 !W
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MX=M8,U1JFT(A1F_78PQ75@. L@M!J495W(^%@0H9XS0',"40!CM "T)8+)%
MQB%;&YX(I@4K#,F08M]*+$'F*T0HDP%I*Z,>:A"-AUUO"1.NN\ -#PDU([9S
M[#IK#\1)83KZ=PATV<@ \41O8AP/K+W?,2@L Q2/(X>Q&!M"@LJ1U*\HZ'+
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M:,FT  O%!_?NM :=D504M5'7NL*U3:L<JH-+<A@!+K.C_P#"O__$ "T1 0$
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M$IB#KEM*)$@>"50T'>+'&T"!TQ<^AT,F7*.@* F"6F:PL-L2WLAH522^H !
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M?9/X70O;#38-I*=1: 0/$/!!;]<[1!>@B" 8@8:%KE$60.J@J."7B]G5Q8C
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M%BE)J1*-(AU,N.<5$"Y"X;D78X81D))!W[?F<X.0%8"C#HF3B\B&HJZB!AY
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M2PXOA2RE[4OQE4["<A_Z##OXK-4 33 6:$G@E$[DPAX[4[8?LH^M\$GAW6^
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M3"#A]$Q]"NNZ?8P=6)I=LX13WW@9&HK"ZU%?8' G.$RV@*@I*I!85 L!X*!
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M(/@KY$9"\([WV RH*3#:1!4/ZH:1X@MTV'DDP@P0\/1S%1B0IQ]?(D=5>AV
MT   ##Z++70'57['*@+AM51T)DHPM&=PY0F1I -ANJZ .0N*11Q*EAH8044>
M7'F7M.,4P L%C8G[QDQ"D(0)$&4,_P!S*7_K #C6L_3]7CN!B:[^55$E<M>Q
M6*11BR0(Q9P'1/AW GL+IP !(B"79$4?G^$ZPU'0-_=Z!U89'ZR$-<U)WQ\$
M4?,6IO(D;,H\CJ2JBA$BB0;0H=;B@;25TS2#%$@%BJKV5.<4!]Q&H04B.'1
M- =A.XUK9$*K; #W)L!J(?2;P(@JCPE&+N<<GDN(1;DIZ;$'W/ GE2;T/=8-
MNS:]A="4HFFVC*=L"NWQ-[4=@3E4(VB!UP+O)H)EZ\;PVX4=#N,6XJKH (
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M8,EPKX!0!PV!5\P0+DGP "8N6"8 !  (B#FFH-K#;!6.RT\M>X3ZZ)_OZ?V
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MUV\G# S8%0+ 93'C'O0=:*V2GN_C#(,L;*<*M<IKL(2U59AA;2BDH"L'$N8
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MH X!Q9H\]2;T9W(1;>RHZA4,AN#:$W-8$(PRQKG@Q&I0B6XU3/V#VI4-D&1
MOD)1P"H!K=1NWVW=P$G58Q0W24:^621RJPC%C3;O4P@Q3,NE-J8!2(F< 4$5
MV)84'I.7-2<,1*C@0 $VGR"I O*/E&IO+J0!5H($K+?0$SR37NW=G; . IV
M"+8!L 2J$0M@CV4 ;3$AME&!GK<-N:5MU?%20,B1J00/M(!!->H:MM*"@#7
M<F\=0TZ)(\*=(.A_A>T0'=*X!6U0#T60NAM@(HUA":A9!5(W0Z3$*"8>(2!@
M*@-#"*,45PG00:G-$TD;-!UQ495U*HWQA3"*\?2"&E'(S*UN+I(\#J4+%-)5
M8O,A#&X@K#[%F%&D&O)%X>(GFMHJ/+;;WJ%#JQTJ,WU3MJ=_!S!H-9$7"2Z4
MLBVC&AG<%4B$>I%I=DZ6ND#P6SI!'1TCL8*"7<,"?QB00H8,$0G#+6W*5T(B
M &VWBJ"S+8<Z 4()X6LQAV62:TY<P/BW4#HJ$Z1OD*B&) (JR[L6EO HE]=T
M@U#T 6(#&-5?R*DZ]P83L@C5PXD1*4"V"QFH$VJ E)%AQ$F7+E.X\<: 4XK$
MM:3K("6P0-IU\53%MVU"!(4 8Z%CE)? \]*SE%QG8U+M"1UW^ [=LLX4AA>\
M_N?[Q\UHH#C?*#-(<]N9BBQDG<*^XT#>FN_!PS@@9/*''2*DL0B- \*Z;$ "
M> ,"1GVP5E^:,!"T]C1>SNGU!P( /TT9$0P)KPY^IG,6Y/4R#09ND"B32JZ%
M<59*DA*;($:] %M-)4Q<:]R""5#3/C[C*D)LK9G"\- R =\,HC=;I?4A04IA
MWE+[T @*K(SL5"Y*)T$O%M)LX&$(\2"@("(0-#8I9B(AO<KC@$V+4:*6(5$]
MAA:07>")+-3=$7JPC7<U: 18"*2H;@#.$(8&WB362148I#1&)368!( &YUU\
M][T#ZVH0@D:4TXFTAKU0ZT)8F",B"F]&(PF#'8S3& "#YN[J1LS)R-D#E2N%
M DA@O^"*KJ;2D&CP,ZD)Y%(DG-%& JZ(#)P\JE7=(AL:(4O@DP*$+86FQ<*;
MT#@%NA&U:"JNA)D P.1X1N*3$>1'E#9%(8;\3@4NC%XC^0**@/<F2DX>67HK
MMLF]"LHUM)I4R;"L(."#81!EU 8(*N)>ZN*=-,*#MV5P3#,BW"^7CG/'-5M1
M21ZB5H)BQ:\/[>"YAJ&WV^JA&-8P$!9*3$%0* "L./UO/6<IVS3>;@"XEQUH
M&I&%9"">&F@I11,(Z\CY%1V&S S.PSB%VMG.XX)YFOR?M5[^2" !  R<QE@4
M61TADH.9OXB3K,B=F7-N645Z_)8;=@$EKR#^:^9VB-JN/@FF!HB9$3:E<(<$
M![G=V5;D)K (-XI$"+>0R=L*@9(1T/82C;QQ'H!??EQ=@<<=%U7FT0]:CV'E
M>FL.KMPP]%L&JC^HK8%95?8/L$.AYAK-3'*3"X=J>SF6!ZS?- N3F 3F#6%5
M 6U=>2M#Q+>"8*7 (DA$3@6AE:-TO%EZ6=#?!PL&I V3&13QQV"F\W *>"YH
M+V]W4!35Z;7P@=XWR "\49!X&T0UZD04!$WB43.FEPR-!*\)>8F2K%(#PY_%
MT#W+ZP*$9*'YXL8TN'5C'2=S ;U8&-=>1X4(AL)61@<A*K?0!"C%C<?6,B*
M'$;Y@@R*VX5D%4!82<(!J\,WKF #8L0#580"(.(/)+-PZ"3;0G$CB#@0@Q):
M6<R23"B&30LRX18B<D^B/\DF"ZJ&TJI*++*9O*DJJATJ:%->+ER6,"IB*8($
MNP4OF&-\B)0"& (JH5?(72TYVA4@52,,+ UVBICR)7:$9\P1M B"P!H70 N;
M]QJ)@P*\9(D%_P",'G-4D=P(CZCB*H<HI]UJ_3)QX*$(N(M&TZ8JJJJM5VJ\
MJ]5__A,'4 V 5IJPM<-I@DHS DH&G&$!DD! YPAMTD@XRP2(EYUOB4HVHSSU
MO2;&J=%6E!5F'N9U5(9(X^"%)8*D*KQ.0.**R\22+*AWY51$VQ!)80GLU/RM
M9O\ #@5J!TV'"B@F8T1H-E TK ("@50708UIW1"#O*8#O%55ZV=M2BX1K&3B
M@D*8*,,YI.&.5..G&2<14KX0-/$9=R FA&O"5'V2%V$6C#[&DFHY1A@- % G
MA!+9Y83A 0+1L*HK&H-5<%]WFF#38835+W%$ %-@Q9*PC+"+(H092(AF0-;4
MO2M(&!%R.H0B0F(5!4L4$ AI8.EP=QL<I+$ 0@^1;"D )E.!NA2*@V8U<IO_
M !++)G4T !/QXA0I#@)1T ELA6(X9515B0_ZJ"IQL[,RC#B29&*YI$':J?5N
M*2*A%!9!!K+P:B=/ !%RAK4=ZPMN, @G@/KH2/1(@D 1,(%%24:' A)) 7,.
MB#1"DC[#.)Q"^3KHKJVGS$-#C1S0#<B$X<P#)J6=54M1L)*D, Q-0"\Z,4Y\
M]MT^.P.@%HP":R>;)X<*<0*(F3;2=@9 F6$L('*ZP2$ (*&=81895*LQ[K6F
M*CP,*M?M_P *$UJ-F#J:--AL'1-U\U4^!ZM5DHFC)-K%;;<ED )C%:3IZ 1R
M&":DKZ[1J:6!5<>IB"@"<G4#LX8S)IB>2KVFD6@$!_\ !=__Q  M$ $!  (!
M P0! P0# 0$!   !$0 A,1!!82!1H=&1,''Q0%"!\&"QP>%P@/_:  @! 0 !
M/Q#_ /8SFNV>.9+$S@- ;WG\%P E8I;'!'A'::>XQ/W$1]DCE%0124I2\4Y+
MVO.4WOCGQ^__  <2^5T$2!F+X.N=-*RK&J/),U-J"5Q5<RV\15? JY+RPHU@
MMUW-ZVXQC,"$-DATQ%=<5V]+J9 ON%F015.\/FE7G$E[8"6P-AYV54*"2:-S
ML'TMIA.=!603<3$5 Q89^#V:H09AMV*$#+$#'[BUL2U J^W"5\G#.0(^@$/V
MZSMDTCU*Z+ZCW2 >_P#$S8JWVJ8\FH6@Z]8+X.7"LBMEA(7K>'-DI@ _I^;]
MPWP:$J;.T#<EPH[5%^+GJ/&YB*V]H*D!AZ+-O5:CBP4Y0&-4W7GL.I#"7U\W
M)NVJ;L1E>,CV6[J4ORH+*LG6VD?!@BP("2!CQ3Q)8X2"B^ZFO4KVW":"K)0Y
MPG 3]*H\%]W=*%*4A4J&,%H@_M[-9I8S[N*] -17KLD"!L 2.S6^FPJT02:W
M""#AV<O#@A-3GDEZ\)WWEB28*%LH "I^QR%=1Y;IP-9'M1WVXC:84S)=@% .
M(AP@K-)HV?MS(M-_^P/1[BK<>X:P/JPD^)RAIE29 P$]MR(7S)+A-HSY#U:C
M.*Y\*[A,(FF6Q/S'N62H]VU' M'PY^7!21 DW+Y#<)ED0%5#$6V09Q3"T ^&
M\ZKBCV\ZJ#@$)O1"Y+@RR" ]*4+ 2IW\2V&(@EE369&#H"M$:2UXFZR-5:_%
MA83M*ICH$5$NY'7A' "9>2Q8)+2@+WE<[].<#VD&@2"3DWTIK%;W"C@ZH'[B
MC) !RH3)&F.SV2MG*N]+1\S9JPPUUM@$:2$)@"'S6,:M6S\0NDU% "JJLF^8
MC.UG#BTP:^@4;MH)&9"V_P :N4ML)S"@Y20,52I,8E5;H4Z0A#1\2 .'3Y">
M8$P\OE+AJ,!1_!R6:>FL.EU%4/TR@\BI%R05+2(-J-'.V20A8V$JFEK*&"&#
M3B90 *J, JO:!O'4V5)"V_0# N*94#2PR:42.Y!-@35\=<\P3:.>Z==#BD^Y
MS1<KFX\.WEXST@I#KI*.LP!PW("-%,-\@NC"8G+N.2CUU&/5W30S_3#K/YP,
MD+4X[[E8S0=!LX51=)<#;&1L^DY'"OL CH*C"L>,;&L7A"Z3W#-D91<RP&ET
M=EC%4F9]P^N@Z^#D5'G8#KIUPP>8HF@#%^22PXH%#X-UCEH+9L^'SN>3_#R1
ME'RKER95HEQDX^>U[@)]P.N\C4*MM]YP8T2G'LS*YA:_V(0\?)5[8K()RV08
ML"H[(06DBV+3A<U"HDU2 L 8#LM(*^HTC^G]BA/N=F6[0KDC?-T21@(EYNC?
M=WC7>R]CH/4+C:78')5-T<^X1'!),&W#:U.FS,T&7$ @0B B>R-$_?T##;Y8
M/IQ.<( .H)%UQS0T2+M8HS.^>FU7.5A%,5Q$''L=H@NO!:4BHGTQ%L](>\9T
M[PT3*VK"[%\4 43@Q9*CZ?R/A B(63C=YE-Z.[W#8].9Z^X(\M["Q>0'-Q M
M!MKC$KK697L(X>-&<V7JUF1*4$NI'&QJW'Y2:<")4UQ!'3N@ PKX'"IAK87J
M(DLUO'3,P>@7HO>M,4VM#06H%EJ9.6C8%L8!#^%Y(A2(X4$.D:S"=!$UWBXU
M9D *2.^7:0JK*3^-+X."8X*[WPXO\1E^UW 96.8M.9WIF&8FRQ3"GNR\MARQ
MUVP(.Y 1'Q%J$CK/)FL29TQ$;(@,, JO$77MDP&=2Q:*-1B "8SK\,V^G1"P
M+ZX(CHCE/*?]V_M2R'0'!"=&&=NQ<-$AU04!0HBAI)$%*("UTV5S(',@=F0L
MZ>X(Z Z D:':-B"11B$O+0E!&<AT:IZ36@<&.N1S8+:.OL_>1%9@;VU&+)+(
MD5F015"RWD32*L"I(]A<NJ$ +B+,CUV[,MS?* $E6$$W)QBR%%$VUIMD&>!4
M,<SBVEG)]"/CX5+?]B0 <3Z@83OV)IU]Y<'" =9G@X!D%D'>3HRB-K.++HE
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MOL>$W2@UTX-JS*K,BMSCQM5&;H&<E5,:<@!M =/FT6A*\2:3F ZOZ D>V]+
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MS8!/B1*1B3F%+!08<DH]:V411$11'D32/D<TC>7>+!ZYY%"3&**R5P))CA4
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MN80CQK73VJ-WD_05%6#QXR2/UJ6E)TKTC@];$"=:J5T2#B3@ '0;VZ#')HJ
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MQ?+]YXOE^\-VV+? \A^^_P# O#K/%XK4"3: O&9"V!CQ;%+Z+HQ&LM[&L(Y
M#\+CAB,^0VL9-S68:E)#VS"R.N9P:(V%M[.F)53Z4R$_.T(_(A5S6Z)>V%)D
M#)"4:]7A3#&]2$;"E/6  L0\41DZ6P6Q@CY:!"K&)FZ/9$4]?^]WF/5XAIE?
M<^P'G.;7JA.];T057_P+@KH4%4*(^0T\D.R9'Q^3[R/C\GWD?'Y/O(^/R?>1
M\?D^\19O<'Z&+?N&_;_=T^5!+,Y^+EZ62OX5]4*H$JM1LZ1M3M_3A0^[PJ0\
M.+VO/!3[9H!R"FM*<'A][O\ ?(^/R?>1\?D^\CX_)]Y'Q^3[RO>;$041HF^1
M*>3)#' ''@VZ-F];.1_X>43?C>H\?ENL#@U<]E>5>=< 0  .@'Y]V-5VJNV\
M_C\BQT7 8E ;$$2AL=1Z]VP+-/\ GG ["!X38^AZQG4LL6VV%65]+;M'A8T&
M%=?6(6(1VB"_3F42=(W"?7\8#\6@QBYB0Z:BH4%!%04+ *\@_P"U?^O14J5(
MKHJL);LT4>'DK.7/]I_\P1J5 R"4;7L8N_E48?W\0*,C [<F>6C._P#DU<H!
MSPZJ>:\7K/?H7+]%0)+H%!N$LW:MMH0Q"S*&:W*10&X:"Z%W"$?&NO6R--_\
M>_P2,A.4[N4D4U32JH$#NQ951L  **@*J =]T8._/)X[4BXUJR9"CX_)]Y'Q
M^3[R/C\GWD?'Y/O(^/R?>1\?D^\CX_)]Y'Q^3[R/C\GWD?'Y/O/_ *2]WMU.
M.7"D_8!7_!@O/[#[HI:44A%<</[52 \:BL58 AB,.IKKTAA^T<TK!D"0X- T
M-@'?6FB4)#]?+O$&GF$9H"JGK(HZ3J2Q[ICX,JQ@?]C7M(R5"HPE>UQNX3_<
M\,T'0!M9EX(1@8$+ /,IO]P2!6(U^]6#6GE@=B(DO/>X1)V&>8:KZ27H8*HT
M' F^.]SE5P+ 1%2:4=U$UKU=YI#.,7%A[.$B=X$)A* !-@ZPHJ G?W9 E[MA
MK<[471 \:Y"#4'WA>0,Z$QD0(X783]RJ@<BC*@O_ -57PWAYIO\ ##8V* U.
M9',MP P&_P 0I*X64"*(_P!HK-_F# I<P0&8S8>YGQ2*QEJ9$T+-()FVZLV/
ML%]OZ$O/]@7**(JP?P?TB49P1R(A!S3@JO!$;W95C?Y.TG(X\:.'DB2JW"&G
MIIW'"H4''-,HPQ(FQ,3]U7E&2TV!.GC0,.M[J0U7P"Y'8_'"=7R@6-QI1!CR
M H8T'#6%55:NU>5]WHK=-Y-,L+$S;B&U&H(.!0B88)'5-Z#U0 L:-8*@2AGS
M.8[=]>1(!_LO=T.^2)L$NE"DK,'8-0Z4ISW  ^]MUSGE:+DI1457E9S;HY+S
M^/<_PYOH!GM AV6I;ICI%AF&,JN\!& #_@(EY7""@11Z4:R7$ZLD)?\ D2WP
MU.ABIW,,$LB/2F'H@X9MNJ#>$HHCB&=H6<2U.T69WG%@[^ N>@LZ/L^BIJ 7
M%)D%FK9[,0755F]!L.7-68@N2B#)C3+Z!.!8\,9D+RA@YNAG/O3)B9S\QBQ
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MV #\'Z:"(@B1$HGLCI,7VL^[ZFC1HT:-5C</T)V0"E88'^H!L'@(     _\
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%A^L__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>business19a.jpg
<TEXT>
begin 644 business19a.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_X1Y217AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   !(     0
M $@    !    1TE-4" R+C$P+C(X   R,#(R.C$P.C Y(#(R.C4X.C Y  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   "1     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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M&\Q6<3$DE>I'&0#V[U8L;./3[.*UB+,D:[0SX+'ZGO5BILVM312C"5XZ^O\
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M&]EL;A98CQ_$N>&'I78VFJ6EYM6*4;R,[#P141DF=%;#RI[:H[:P\2VUGI\
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MDU2Z1<C2KESZ+C_/^>](VK7(!(TB[.,^G^U_@/SJ**S5%:+?J;;P"'<@E>^
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M'/TS6EG(S4,5P9)-A@E3C.6'%3T %%%% !1110 4444 %%%% !1110 4444
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M #D .&%C<W!-4T94                                  #VU@ !
M -,M;&-M<P
M            #61E<V,   $@    0&-P<G0   %@    -G=T<'0   &8
M%&-H860   &L    +')865H   '8    %&)865H   'L    %&=865H   (
M    %')44D,   (4    (&=44D,   (4    (&)44D,   (4    (&-H<FT
M  (T    )&1M;F0   )8    )&1M9&0   )\    )&UL=6,          0
M  QE;E53    )    !P 1P!) $T 4  @ &( =0!I &P =  M &D ;@ @ ',
M4@!' $)M;'5C          $    ,96Y54P   !H    < %  =0!B &P :0!C
M "  1 !O &T 80!I &X  %A96B        #VU@ !     -,M<V8S,@
M 0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #W   P&Y865H@
M;Z   #CU   #D%A96B         DGP  #X0  +;$6%E:(        &*7  "W
MAP  &-EP87)A       #     F9F  #RIP  #5D  !/0   *6V-H<FT
M  ,     H]<  %1\  !,S0  F9H  "9G   /7&UL=6,          0    QE
M;E53    "    !P 1P!) $T 4&UL=6,          0    QE;E53    "
M !P <P!2 $< 0O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_" !$( AD#KP,!$0 "$0$#$0'_Q  >  $   <! 0$
M             0($!08'" ,)"O_$ !T! 0$  @,! 0$            ! P0"
M!08'" G_V@ , P$  A #$    ?O&
M                          0+T >9K0MQ(GBO@7PVD0
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M!]C%8,O'Z!>8[/YW^IZGK[H][G;M-;7.WCW=UV77&TL&;7SC7YXYD===)O\
M#?HNNWSUNWKK:P>94R6O)QJ./+[>?//17;AS        O9>0   6<O ,=S9;
M/PX^W#A ]#Y*>VZ/1/8X=X]=GYM[;5W7U^>PY>'JX]J^>[+XZ>ZZ3Z#^:[#
M]C%6SE[\>7ERX>DO:_G>RX6]'H+BQ?/KY)@V?LQX+OYU   (4      ")F),
M 68O(*<Q1)95>L:UV\.P]7*-?[6+/M7+.LJ0)B !$DI&M]S#LK3S"8D-+=A@
MW5U^>!$$M>L(4A258E4"!!5B%1ER*RY*   +,7D QPMQ!/2+!EXVSE+9DX^D
MNN-K%LG5RS1DF+G8,G'46]@VYI9KKPY6')PN_#E9N?'*\.3&<W#VCVBAY3/M
M;+"%1B!&H1&V$+"Q2!$2D@*2J!"Q3VC+;8@%O(GN"4B>P
M      !$F    +8GNOH"!(>P           0H          G)B(
M                      !*4!              "%    (4A0  1/5<"(
M                             (&+12V%  0H  !"@ "%   $"( "%
M    NY?"(                               *,Q2)Z0H )%%  1"H@
M 0H!"D*   0I"B%(4 0B-5:90L0                               41
MBL3V% &A8TPFR%W;9D!6"51$J@A84A2% 2*+ B !(M  0L*  $*JS*"(
M                           *(Q5)Q$*BL#7*<\QGM7$U\G8#D2!&6%10
MJ%$@L4 !1!"QA1(+$@D95A2%!"@A2%@A:PR@B
M        "B,5)P  (5['(CCUJY     A0     "%       JS*"(
M                       *(Q8F$*  )[+R(X]:N0"%          (4  0H
M   JS*"(                        ,>R[M]Q:EBR[5]Q:OHX@   "B,5)
MP   >QR(X]:N0    )8M?M;%K]IG?8>6@H    (4      "K,H(@
M              T-W':[0Z[7RG!I#A7V6]U9Y?:Y^[_5VUU.UN7K.GL>7:YM
M[WL^KO.]$  !1&*DX   3V7D1QZU<@   (IJKJ/=\)_/_P!1X7H^E^A_TG\A
MRN4DL4]+PB061RC%RRZ.2[?39!L=17Y=7TO"$LKD!18]BMR:X   JS*"(
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M)T*)R0FCXVUV))>[+4=C.0 HL>S\9OB']&_JE]<_"NU.W\* 0H  (4  $*
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M4!]DJ@?,HO4F];+ =BN0    (4     1.?TP1)3>2[,64     JS*"(
M,%W,&<:>?17IO,\T^P\?MOHN^^7GYS_I328LX$JT\R;.WO-:GQ=Q==?8@4/#
M/LC>\YWE]R_">S<W2;!ZOM-C=1VXH-C5YJ^J?(.I/D?VD#PO/4/;YK]AU:'(
MUQV<Q'N+<L;8NC;/EEKR/G%[W'Y@ 4@9OJ7Z'^%R:SWITIXGM,NU^N]'$41B
MI.#2AP['U.J!,#T.1''K5R         $ASBXXN1.@ES=8  !"@  "K,H(@
M   Q78Q7C%SN7#D.7=#W7R3^;_K^ND     NV;3^P_UG\18;EULFY7=^C@T'
MZOR\V3'OKR'K !K'M)@O82U96Q^LO.'L)=,:^8;L#2LQRWZ/ARMZ3B  ,@P7
MO_Q'/+M6Z;['/:-+<ZF\TV1I=8*(Q4G!C:<3R]^4 /8Y$<>M7(    $*  *9
M.9TLYZ'2,N26@A0      *LR@B     "GLP;>U=@Z&V/G=Y']"<(^5^Z0
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MJ3@@?'@^JYF)SW)B!TA7-*=<N0  & )S,G7RWI0        $*(4   59E!$
M  &I>]Z++-#>YVZ[W7R>^6_LZ\<(  *'CGX,\S]VM?#; $"X<]?M;T/Q;,,_
M4   8YB['[L_4/PWLC=\S:-C!>=?8&F?1=)\K/L'E+CU_9]S?-?H_87E^KUE
MN]QANQMTV_YK3N_Z#?/5=!I??]%F;SENV&"Y^WZ Z'J=T]%S^</NO3?1KPOG
M*R8@ !1&*DX.8X^*-?I,)3D@\XSJ\=?G8+D ,23A0RE-L2],5!2%      (4
M  $*   *LR@B    #A?S'W#YT^._0\J@ #3>A[#D[H_JY2 H%3RQ9WL]%NGL
M/%[H[#QH %%QS?H+^L_@+GKUGD[EAS;U\UZ757>:6ONPU^./6]5>*^HOR7U0
M^?\ [;MNQ/)RX\,7+GHM[L[RW0\4^H]7V7YCS-7,7+'H>[S;4P;QZGJ].]GV
MVU>NZ^MXX0 !1&*I,1EH;..X[2HJ1;[)R&G6JQ(+&.:+Q_'%SQ?I(X9?K9.2
MPL$BL)(VP2*P2*D*0L)(VPDBL+(RPLC*L*0L$BL$BL)(VU:90L0    :^U._
M^%?R_P#<=UYZH &*X>TXO\_]ELF+?[>]-\0K>6#)\W6X-K]W?<FCS!TGT_5&
MAZP>EQ]^>G^"W7GJ@"T\-OZH?<?P#2>M^;XMNZFG/4=IA.UCV!TF[UYX#OK1
MV6MU=X7O!B&?L<OP==9LFUSYW>]TYT'3\5>J]'V9Y;H*F8\+V=[%]G)MSK>M
M    HC%2<&&'QO3[B+ 0L]EY$<>M7( 8Y)R'9T4NU5 (4      A0      *
MLR@B   "2SCOW_@=M=%WGS*\;^DM0_-OT2 *7CEX6\Y]QQW#V7I>&^NU\%[W
MA<N>OF&QTV :OH-6Z'J,)UN\"SO3TOPC(<O7@ 4G)]&_7?GOM_UGPGXH_??"
M[-Z/=^HGR7U/ ?TGSW//NNC^QOY\]]D>IE         %$8L3",>K\_A^@DO8
M!['(CCUJY (4          A0 !"@  "K3*%B    <!?4?EW07E?57GP_U;XA
M?-/VQ?\ )H :BTO6\C=%]:2[^[;P'T+]9^?=+]=[+/-KH;1PV\3U^UG3YQ^/
M_1Q-C[GG.S>_^-Q  !:^&S];_?\ Y.ZE[SY>!R9Z_J?EQ]H\=])_F/I.T_FW
MHP        !1&*DX-1)\FE^X9 !/9>1''K5R    !"@     $*      !5F4
M$0   "V9L-SPYL<P]C^?/Y-^_<OS]2!I;K_9<I])]5@M5RQ5_/7VEO>5M?#:
M\YRP75[ZY<];%,':]6]U\KW/V'C9D   B=Q^H^(_1SV'YU \K.5/7=5T)Y[?
MRS1S@        "B,5B<"OCV?84@)%OL<B./6KD$!0"%  (4 A0  2+0 A1"@
M !"JLR@B     :FT/5_#;YC^W<BR]>!B^'L^$O-_=(2Q('5'>_*NA>V^?;:W
MO*_(7P/ZXHN&PL^@?I_@-SYZP   L6YI_7;Z9^-NI7FQ,H           HC%
M2=!S-+\7S]'50)R$GI;R(X]:N0!$+0 "%  ("@  A0$*$$BH  (6K,H(@
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M   07$<';5_+7R#+H   "UX]KZ,_>_Y^X=]"^/\ 1WD?7=/>,]D
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M6/D=\Q_9NC^K]M[7@  A0     Z(^J?ESL_W7YTPWL>O[;^<?1@
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MY9JX8^E?-=Z>:]+O/S7I0  !8,W/0F;(LWS@X7W#PQ4K"_DIK<B;&/0D)B<
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M8J     ,#VLO(7:[=5PX]!:&OHS2PYJ6DS M1:S"3V,N.IB[    HC%2<
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MS0H!"@ 0$1JK,H(@                               HS$ST0H "%A0
M    0OF3D2!$2+8$0 03S7U      !61D]1
M      ! P<]",* 0 I"D*  0I"@$*  0I"D*0I"D*(5"D*0%9 7,B
M                         2% 1                       !4%20(@
M $AI4V468O9*>1CA6&?@L1?0   "RE07( MI<C"R<O![%S!8B4QHK#. "TE$
M9&4AY%P      /,G($0" (D0  "    (@@1  )2) $P !*1(@E! B3 @1
M+:?(8Z3-?&_24U@88=!FCHJRV50R9%;7&OC+CH8Y(-LIBRY":\,B,9,N-WFA
MDWVO,A0QYUM(Q KC8462M/E1'>E<5EG2[KU,<^QK1/I;;FX     /CK'458(
M;/+X:8*4W^8&7DJC$2<\0;8-$&-QN*S5YF:XDF\EY6CJ&L!*$OA<XIJVD:++
M0;&C6M5<9?67&,&R2^'(R7@W(N(E<:8BZUGAW*"!$   \3 #(BH+.92#&RZF
ML3Q2YK;"L-AD07,M11%Y*(]CW*$P\OA0%X(%28J4YFY4%M+F3%O,B+*:]-AE
M:0+47T]P     <Q&Z#$S9!:RS&&&3'@6PKBS%G*TD,L+4519BT%(7TV88*6,
MNY3F0IX+8C)#%S*#*C5A?2H.>CHP\C;YIDMAM(TJ;",>+^6$W>"!$   M)\R
MB])0K839QEI@4;7J8UPF5+A98SH Y>,L,/3*)<;,W*:MSIIF7IRN#8VQ6ODK
MI;O5ICJ*N1Y-[VZD*LN:>RVPWN<V1>*O<?2>@      !P=&2UL UN6)*I;\8
M 590IN!<4,Z*9.+C-%[^.)C 8[,K%3548M77IHLLYD<6&M\E@BAK1$=!V:^,
MM73!<2BCH"NH      0(@  $"S%649[EJ-=FW3R($#W/ @7 MY,64\BYEX*$
M]"I)CP*4J3!#,B8N!3&!&;$A7DA0%2>95%,7@       @<Z1?*O!B9EAK\O,
M1J[%G-BFO3:1KDG/<D,H+$9"87%/4YFAKDK3+#%#/06TQ@V(:H-KFN3)BR%*
M;;+Z     0(@                                Y62^2Y)6+&*&9&2F
M"1EU6$MYL,QPH##4W(NKDVJNNHNM$ORV@]2^QA=4YLXUI&8F(U[F0%K*TQP\
MB]%:8T5I[EN**,JJY&(QE=;N ($0
M49(>Y*2D01! \SW)CQ)R0]CR )3U) 3GF"4]#T+:513E<2D2!XD"!Z'F"K)P
M>1*58! B
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M/FI)K]:S*DX8NR*25\1MQX=CCX+?3L.@14G% ]F:*A[-NX0=M^U/Y-*?9?\
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MSRQMGC&&^QHL$?:ODQ%N]UQ.EF>+XY(@3;5\E$D()KF2:]I^SDL7G$Q@FP)
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M'M=[(C[L'^ _!#B"B$6%)*?AN/@M]/P?K1'><7%%.KB/'3*BEGS0D-?Y%]@
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M-PP0L[F$(0$AI##Y B,,025.0LCAAUPL*&.,U1@U=WF+&*/%$$5;KC1:SE!
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M*6BSLAL)+7H!(DMK<!FFQ@\?&*)P2/8-0^N@0E_((:)D#ISK*-+74A %5V0
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MR?DU;*1/3SF:/4&OZW>.IL#>PZE=KXIH*H0F19%CGFFDDEUJ3V=PJC:X6]W
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M<[;WW'@,4)C]-?E1&%>1?05WWT7>^^H,1]X+?7Q6H.>QF@DF1X],)4%@KE5
M&WJV(:Y(MV@=^Z.DO-1M-%<K'VBP.Q#-R[]=T%MB;C;K^H44THGIX5D<1-50
MLR!B%9M:BY ZXXKVK*;_ /#'_P"8?D>F06)U'2':/5;8E!J8@]ZJ+W/L.&J(
ME9D+;I&9FVOV%W)_'#5<*K&Q9CS?44*2Y[6GU1T[1M[\)*DAD52=43:7!V(/
M4? ]Q[\354-/82,=1W"J-36\;#NZ_<<12I,NN,ZE_$'P([NH/M!!Q)*D6G62
M-;!%V[\1RI+JT$G0VAMNC >9)4D+JC:C&VA[?5?KI]_F-1$LP@)M(=-MMKM<
MJ+^) )^&(ZF*5VC1B62]]MK!M)L?8PMAF"*SMLJ@EC[%%S@3QL5&KM.K,%(-
M[)L;]PL01UWL;8CD69=::K7(W!!NI(.V)9XX.7S#IYL@B3:]W;H/_'S33QP
M&0D7OT%^FY/L P:F%95AU=MM-K#;M@E+GNOI)^'FWQ'*DP+1DL 2O2VX\V^-
M_P!?R+)46%*^>/FRN.93Q'U%'U6;N+-W7V7POCB&+,=<517<I8V+1P11,6$8
M%B;W N3?=N_X?(>6.,@.ZJ6Z7[][?S('O(QS4U\O4.9]G>_2_NZ;V\PEC(N'
M6Q;2#>UV\![3@.K$A6N5]8>'L_ _=AG5%U.P51U)Z;]/O.+WWZWL<,ZH-3G2
MOB?PP9X@%8R+ID]0WV;QM[N_SAU9F0,"R>LM]Q<7%_>/D^D0:^7SDU_9U=][
M6\+WVM>]]NOF:HA77JE1>7;F7/J%O5U>&KN^G>-)%*.H93W'V;@^PCJ",0TT
M,%S&EBVQ))8VO>USW>S]2O;<;$=",,[N;N[.1T+,6^&_GDORWM?5H?3XWTFV
M&B66DHDWLTS:BO4%F(8^_??XXC699*J.;<Q44\0.]V"@:3[;J18]_O!Q3(]&
M:6ID^<BD0QDG<P_9(-["R@G:VVL"[$7C_P#253IMI,$9<CO?:U_[O3XXEE2E
MKFFJ 1&\6E)-.H DIV=@3?8CV7'<3:ID+4J-%%R(6F;F[LJLNW:8H RBUQ<?
M66REAI)3688+G4HJUY?K&R6'1F[3"_2^_6^^);B&:[%%]+D)OJ"'8$:V3M*/
MOO<[7%QECZZ;U6 5M()+$,+#="W:T^_>]\*IB7,%C,BOZ2;V+%O1M7K>\MU)
MWTG[.,O(](E6F9WH^4INY<_/7[B_LO?_ +M.*Z-SF#31^M%%3LMS8 \S22WL
M4-?X'$$+1I4-_O):97:U^]T8[#M6()]^]N_ F$SJ$9F"Y;*K[,!K6/M#?8F_
M?OOA4C$]*[EAJ@V(9M)<&8"UMCW=-NUX-C6.70B=Y$C9JKFD%PVGF;>KOUL-
MK]C4>[%Y&AI+ZFC&9KZ.6N28;;$WWZWZ[=0-L1M.:P%G(G]((9;R%C%?H4/S
M8C[M0[5OW;'&;0\_T9/&5@?B+#_+IB!)7J:::7<F18K ]%$ %CXD7%SW-?PQ
M#SS.M*5;13O*VO4;-I",@M>_UA[.VPMX4CR^EI=FYS2,)5U2ZM-]N8A!15TZ
MK:?K%2;6 .XA0.72F-3-SRMP=-ETW*[@>L??[;#!+F%51I33M7(D#$L'Y;!P
M;-ZVD#25O];KO<8EB,*5+HTUZ>:,0 RN0!(Y#MN>T;?R&V^]>]ZE[%E>/18E
MY 3L">4J]C2.I+]/J[G9#=$/BJG[P/UX3S  ":4 = )'V]V^&DD?UW=[=-3,
MW\S\C-5=I(N6;,(I3[[%6L?9M?X8IFF:J:9RP,@E(3JJO&IC^^]]_9B*K=_0
MEYQ+M))S1J&K2&4+K'6V^U^M[X*W2G)F:(>DD:@0+;QG5<^'\L3S21BJ9)#'
M\^HUCP^=W\+;#;IL?$XDD?E5<7I!JHUY+K(;$@F1-KKL>IM;;L^-\2U54)F"
MNZ"$1!%#HJ,"BWUH_:DVW[.POOMBONU&3ZK'E'L]QNIV]W=CY\E(W8VIN8#;
MJ_-D/4?#?[6)YZB.62E5I-4[0F!Q]17/;MX!;:;>PGJ<5-34I42*LK((.7I&
MM%4W]9I$;M27':[/2_:L,232Q29E+'LY%*+VOIU(MSM_H8$\J<^)*IZE?1Q+
MS;@LCE@+*RC;W;^L/ X'I?0UL^](E2?5]<H6T*;=E=N[<[XGJ9S! 1-(CM$6
M?0R1=KMZ69WZ^HUT )/L)&(7EEHBV_.,<P%_6U#6%O:W:Z;^.(6H!31B0:I.
M8W97]-JNR^(;U>SUW]4=K;%3550J)M#LG)9 B%T6,KWET/;D[._9Z=^V*SKF
MU[;M0$_\N)ZF:.H8\]^6A5=,;I9-NC1,-3G[Q?<M8@#P]MC]_P"Q8H4@#*E]
M+.TFDVLI;<A=NA._CYMO9]PM]W3$<*1M*ZW+S-J=CUV%E7;ZJCICW[^_?'\O
MP^[&W^AT]V/@/N&/PQ\!]V/=M[ML?=YO@/N&+#V?</P\,/!')+%*WK0ZM %K
M=H6-\6'@/]>'ACX#WV%_O\WW8AID@+L"S/);4[F[&W0?ZW-A?ICX#WVW^_'^
MN@Q\!_K^6/NQ\!]P/^7[$*J2"R@D @$BY /4#V'OP(XUMI1!I]6P&U]S;WX$
M$"MJ6&)6)OJ" &_C?#0PLNEHHV6^K25%M7C;QQ/2QS)H[*=L,2%]:U]C]^!#
M"JE%BC"DW*A0%)[B1WX:&%F5VBC9EV5F4$K[ <,JL+,H8>#"XVQRHC?YM-[7
M[(WMTOXVQZ+>I%2\FO1<1)I $=^F_?;>WOWO88:&%V#O%&[#U6902/<<<N.[
M'0MWV?;U_8WCM^&%@@12BQ1JC>LH4 -[_''+C^PGJZ.@]4=%_AMT&#! P4-#
M&P3U 4!"_P .%55%E 4> V&.3#S.;RH^9]O0-7WX:&%W#O%&SCHS*"P]QP88
M3JU11GF6UW4'7IZ:O'3W>&#!"SB1H8V<=&*C4/C_ /E9V'AA>GW_ -MEZ?VV
M7I]_]G:++JW,6=*.G>=D74^FP"WV4%F(74Y[*+?4[;*"<.C1LR.I1T8JZL"&
M5E-F5@=P0=B#T.*/+ZS,&=:2!IC& 7M8 7V478@:G.R+?4YV4'#*R,R.I5U)
M5E8696!L00=P0=B/U9?I,DRBKS_.,LR6@0R5F:5D-'"H%[&5P'D/[D4>J5_W
M5..->%:W@CB;,^&LQ8/-02+RJ@#3'64LBAX*J('ZDBGI<Z2"#OBX\1_8N&+*
MH:..JS.6N3TJIDIH31PQRK3\E(Y'GJ!)(C2#YP 10_.6!;?LC%=1/0S"-GCF
MBDC2>FJ83>&JII1>*>(FQTL.JD!D<,C ,I\^9<Y*#(J*"_YY/+6L$VYM3Z3'
M34MR-RT #:1]4R:A;&?LK9Q7Z=[2A'-[WFCC2.<W[R9E>Y[S<XJ2_P#1V\9(
MT9PC3%38J/1?S=C;<6E#E#W-TWQG3<V:DJC^EK,LH*J?Q,\D($C'VN5UGQU7
M\U'2O6U,=/&54O<M(YM'%$BEY9I#W1Q1JSN?!<1C**ZGS5*&GJ$.5TT=5'F,
MT_\ 7;U4-,R/2<O13K+S=< $K2+I >Y) _4AT^_Z(FW^7M]@\3[L91Y.^(LR
MI%S6N6EX9R$[_ESB289;2.O_ ++#(/2JUOLK3PN6QY".".!:)I^+<OS6HSBO
MHI)LMI<US 4^69>\C*!52Y103/Z64C_1"LJ>66NVA!>^/+I!2P</KQ709/PC
MG]9E<D<&9QYK#%6U)RN1M*/3O!513**:<]M1JNDMQ8+C^G&0R_UKR9\'R7N2
M::;.**]_#15R@? 8_I+Y.YA^<^3-HNESEW%==%;QLM123=?:V/RAY))OTG#'
M&M#UWI>(,OJ0/#:>E0GXVQR?)!-ZM;Y0,O.WZ2BRBM4>/Z.IC8_<,?D3R8R_
MH>/,\INMA7\)R&W@"U+4S??;']$>#I?ZMY4,F'2WIV39U2_>13.!]^/^C^AD
M_JGE$X#J/ 29C44;>S:IITM?VX7R79W-_4L\X+K][#T;BG++GX22H?OP?))Q
M\1>#*:6L%B0:+.,KJKV-MN74G[L2^3#RAP^MP?G3V_X$"U'_ ,IVQ4<(<6TO
M]8X8S^'O)?*ZJUO>(R,2T&80DB;+Z^$CJ)**J0C[XL-=?65U_B1U_F!C6GVE
M^\8U#N(^_P"1+1U<%/25<U/+'2U_.-%4.C+%5"G?ESF%R+/RG.EK=#^V:5Z6
MII9<KKI###)(*BEJPI?T*L"Z-;HO:>GG2T50%[0"HZCLD&LRJLH^&\MDG>EJ
MXHZ^NC@J:*<5,<5-+RV2)V'Z/75+52(C6*DD&UQ?S4D])2\,K6L*67-:;,)4
MRIY#JJ*!95C](DCBOI*ONR/(K".5 RB^"2Q+,222223<DG<DD]2>\XX?>$YC
M#15<:3Y?F$D=/6T\M]$J:OF]P0R.CV*.I#+<^)QQ$K1YUF$)V6"=H(D&RQP1
M66&-1W*D>D#S</9=49BF=10&.&^45"&LG;1!3%WC:TC_ %1-%'-&3W1EW/94
MX=J7+\O;+**;TF6IECFS.M562*4P_H*.F5[.:>!R9'D8#GS!&4:(U+?J2]/H
M(89JF9*>FAEJ:B0A8Z>GC>:9R=@$BC#.V_@,0^3>?+H8J[CK.:'@NCE77%1U
M7Y[Q'5)UM39+3EI8RPZ&J,2^./Z9<,\-CE<"<-1FL7LGBGBM8LSS1C_Q*'*]
M\NR_Q0N)Y$]^,WSO.,_JC6YWF5;FE5W25DS2\L?9AC-HH$'0)"B*!M;%V[F<
M>P.P'W VQJ;[;_%W_D3\NV"B'JBGWJ,+V/4)3^!BG_PD8AS3-*>QI\TS2"W3
ME9C61V_PS#$'&O&5+M3\5\11#P&;UI7_  O,P_#$?E/\H45K<6YM(/"H:"I'
MATJ(),#RK\<=)LPRZK'0BLR#):B]O&]$+X_Z4,ZD_K60\$UH-[\_A:C4F_B8
M'AM\!@>4"@D_KODYX%J>ES#1U]"WWPUC#?W;8_I=P--_6O)7E:WO<Y?Q#FM/
MU\!(DH%L?EGR53?IN!>)*2]KFAXJCDT^-A4TF^,DR?R8<59QEV1972^4"CS#
M-:E*6G42Y37(K2'UY#JB<10K=Y7MLHOCRK>2NBK/)?2Y3D,"^F<#TOI.4V4<
MVJIX4_ZRB:WK25:ZJCPY@-K[8!N+_P#F/>.X^(_:T]7EN7KEE+59;'+0UM!'
M4U&8QLXS%)Y)98YI(&ORFCHRB7I63YQ2;L&9<9A1/054E.SK(HTR0S)ZD\$J
MAX9D_=DC(:W<;KU'FX:S:G@,^4YF;Y3F2F.75TIYC8+.#]2]E#./498I3M&0
MU0L:3SQT\O/A25UBGL5YL8:ROI.XU#>V+8TCP&+>&(WDADCEC;2\;K(C6]5T
M8,I^! -L5=345U1+5U<IEJ)SJEDL%U-:U[#;V8L,1U%1!'-%#/+%'4+IGC1R
M$F4=TB_6'^1(Z$@W\<#?IO?I;$M/EN7:(LTJ*DUCZ"U#E\22S4JO;3Z3)(PC
M69E((IEO(+C58FPS*C_)]=4T?,$H@< 2 6U!E5Q<?58!@'7N<$?J"]/O^5P5
MY'LUXQX%XBXII%F-?3310\.40LJYF:9_^L_6L#LPC@:X DB>YL<'@SAKAJS\
M=\2H:T#4>%^$VBS/- ?^%79E_4,O/U7"M+(F_?B?RCSY?"]#P+DU#P71%2CU
ME-^?<1U:]-55G50K21LWUEI%B4'H<3S35,TE153S5-1*2TM142O-/(3N2\LA
M9V^)_5N$.,,VX'S?\N9&E"<Q6GEIHY:ZE%4L"3[2-"C,NB5E[',ZZ20,?_22
M\IW3G9$0;JRG*$*E3L5(YFX(-B.\8JJAJNJJ:MXXHGJIY:AXX$Y<"/,YD=8H
M]]$88G2H/9&W[42BK)8C41TE3) M]4R02O$+=;R*I06[[G;S15%)/1_D[,DE
M:!':6CJ:?3Z30S/82: _8EIYK#GP-:Y42(0XWXBRST2FR6HIIS6Y><LIZ2&K
M*Z6:2 ,661/]V>V="DWTK8[CS'?8?14<_H=73U6@2<B59>6W1BO3[C9AW7 O
MMBF?*Z"4YES9\XS5I'GB]*I^124M4[%S4S(SN];.CMJC!*P!QJ93I Q)))-(
M\LK%Y)'9Y'8W9G8W9B?$DW^GO[,+T^31TZUE92TDE3%11U-1%!)63FT-+'(X
M62HD(!.B%"7.Q)M:V.'N/O))PUD>5Y!EW&61BBRNCBI$',F^>*K::63YCM-/
M)K=R>NK'E)R_AV@XPS8\*9G1YID-?*<QHI:)F9*;THEYJ)]:JP:"74J];QZ3
M?^P]?F,5 $UJ9'?U8UV-N]B3T'\\4V<PU$PB:-HBVR,Q!!;P-NGL^5))F5=!
M03Y-6SPUN74PI9<M@G,+ND<CNE71QZA'4M()--3#8S:U#JLBO99J',LTRM\T
MFRFIIZ^CJ135[+2/3I61O&TBU8IRB$31%"E684*'4LKA.T3BASR.#**_)ZZ%
MZJGF7F4(4@&FJ[^L";V0^OM];5L=>UCWGY=QBXQ<>?IO]_ZB.GRM*^ ^X8L!
MT%O[#YZLIKQLQ!C01[&W?>W=?5B6">"15="KG2R]>^Q%OC]QZXCORTU>MH75
M[["_X^< L0J@LS$!0!<DG8  =23T&)<CS*%)7,,<OH_]92FJ::JFIK>MZ1#3
MRR2PA>CLZ!4.S$' )!!!((Z$;$>XXR_/,SRR?G4U5)W:XI6,L,H'U9(W)!]A
M%F4[JP.*A^'>(8)JG4F1YO'&TLB-_4ZLJ"S:/WVMW:9[G=:D[@;[_=_KV_*O
M\F]O/32TE.TDM73RU:I&3!31N8UFG)[*SR*1)' O5N5\X^RJR>MC*9ZZLE%3
M7Y;EM+P_&'%9(<MAID,5F(AHJEE%5/7E]*PM%)),OK2D1ASAM.IM-PMSI!ZA
M;[7]MOIEZ?V.XB:02TPN0FAR+;=NXO\ $"V%EJ*F6(M(\DFI%4DD]"+8%["_
M6PO[_/&[1.DB'2\;JZ,.JLA#*1[B </25%56_EGAV=8J]Y#43T'/2"J@J6WF
M:GYK*E91S,2>6"TB*QCEC*V9N(,IJZ1J:ODHA2Q5]/#/*D)5Z>FK'7Y^ &,L
ML>IP94C) 59.6EQ&;8.^WR-[^SZ$>9))(9(YH7:*:)UDBD0V=)$-U93W$'<8
MJJ^MKWYM;5SU4FYU3RO(02;FVHFUR;FUOIQT_:XF4S/#N&0*V_1@W>ONZ'X>
M/ZO7T,=?#RV.EE.J-Q]5O:.\'OQE>614Y:1WYLL;LH^R"/K#O_\ '&:9J:4\
MB"QFM=F/1 >FW>Q]NV(ILRKHIU24L$TNW16/[H(M[].%EFB;4DKH1X,?QWW_
M )8HYO2*6&8D$N@+$;#5T/X^;)>(I<N5J*KC%=E,W9FHY;-H5O6:#7LI[REP
MK-V@8Y+2#/J7*:>6&;)ZT5-/5J9!3L#SJ3?]'*??LH:TH^L&73(X'R2=_H1T
M\P[_ *=>G^O']KR*><S)ZZQI(OML75D_O+M[])[L(P=5=>C"X^5G6:)DN5UF
M9R1F5*2,.8U(4N6=4"@G87+C<XR[,HZ_*Z;-&1J2&HIA5:9RH,4177J=@=-M
M/:U7MIW-L1RQS(LD,B2QMNKQL'1A[&4D'Z266*"-YII$ABC4O)+*RI&BKN6=
MV(55 ZDFV,LXTX:SM*TY/FU+F$E#JYT,3VEV.E9$1PK20.WJ3H&B;J&.)*VM
MJYA:60,S#1'&2H'AL.MN\GWX2J@$L%-%-IFVCFD"EEUV[04G8LS[$[@'?K?&
M;954M,9X TZN!K%_G P%KVVN+>'3%)EN9,QT(]/=&!9SI!O]6W??']'*NEEH
MSF@:"DJXEJ$>G:.666GU%6Y5V$?-4@JR.P*'U@,1Y;1O2:\CJ):R&E5!/2S0
M&*OI4<Z4DDB4NDT+/V3/ [*K%0^DL,=-CL<' %OIU\T4M' YDK4GDB"[)3LB
M,S]P9Y-E2U[D GP&(8\OS*FKIZ*"LHVH(5G<U$B3TLH,J1\D3*D92H.O5&EC
MK"MTM],.G[7.U1'^]&X_PE3_ -K ^:ET_4E)9?9)U=?[WKCVZOE9IET&;9?5
MY=4W$-7$8F*^LO1E=?:CA6'NQE65<7YKEU5D]!FL!X?BK*C+?291:1X('L_(
M '-Y#7MHOUNE[7QD^5T^2Y;2Y;37,5+'IU'UI')+22-[7<EK=PV[O,N843U;
MT"54+5L:<R2F#@S(GVF3J!N.N)N(XX>):7ATTLFNHIFJ?2M:Z+ $A0GK=5L2
M2/9?S<=9GF>3Y**[*WY<D=9 )W,8E"P,'#74[:=6@%MK$C??&:\=991Y&*^A
MJZ2MK9(X.12ZSJ>5RO,$B+VX]"Z[[;, -[XRNHJ:O+J*JJX5IZFHIXYI84)*
MQ-(NK1VNUL"+WWO?Y/E/XMX;S/AO,>&LNS2AS//:ZOR[+:;*::I#3/6?E*G^
M:J$0W$'8:.>_9LVD]<4U)G]7Q+EF;5_#>6\*PY)E=7E+TL,D-3-FOI21K\TU
M,J)'E].\2O2F3YPG5L,0O10T+RQ!$K3$VQ:\@)[)*>&V^UL973M/5Q['1&W,
M=N[;>U_$GSP9C-#":5T@JZ347]%K(A/"KGJ\?JR1-X\J1 W5@V*7B"HRV0R9
M31Y?E3.JI,:2!M4Z*0VB1YI)6Y9<!RJ%-P+DVQ_2Z&J 7-LBRVM\9(X_1GZW
MU=C=GMV;F0;8SB;))S3R912U5(Q,OI451()$O<&(PVOI%M5UN2+#S7Z>WY#=
M/-;'M\WX=/DKYJ:H>EF$JQP2]EETU$2S1V;]Q]K@C8]1]^*O,ZVL18II0(%.
MI:>&.." 'QY4*HK-X,^IAX_3+T_7V_[_ .6 =QTZCN'ZO)M+ ?WG3_$M_P#L
MXD3F(5Z'JK?98;J?@?O&V(GUK<BS Z77P<=1[N\>((/R%5G8(BL[,;*J@LS'
MP &Y/NQQ;%FV0<-YAFT^69C3QB,4U-/-1544+5E7\S31K*\00R,[71-5WTD+
MCA_*7R3)LORZ:-XIXJ='J5E1HY/2)_GIBRN%8$R.?6%[6\_$7">85.:)G_#U
M<F7YIRN3.'!Y<Z@:0UP#VM/98,I5@!WC'!.5S5.;YKG&=5<E7G675#Y8T;6T
M0#2#S%V%UD3]$  JK?J3YIH8JB*2">-)H95*212*&1U/4,IV(QPAPQD=35YS
MF+T$3^BYY54^7HUVA@AIRFG3&3I8JY-BVKN'=YZ_,Z#*TCDKZJ*E2:5((S*U
MM<KFRJ/\ST4;L0, @BX-P=P1T(\<9[Q9Q1-Q-5<*\&Y7E-=4T&605V95V:5D
ML$-&U8[I3QJL 8O)I7F:#UWN-(QP1P-1<.9)ET.8466U>>0O/5U>9"FBDF-;
M55$M1(T53)'SK1F31&;@A5%K8SB"5*IY]),<FG2X%P"% (-NG3;&<G,:+(<X
MS6AI9)IZ#+ZBH@4)<M*B'2P5K:UB_2R6_P!VK=3C@_.JN/B+A_+\MXP/&4&=
MY3/79]#+R"N3-!#&Z55.U,BFGY]3*:7T.>['UMBOR41Y&"1HTCMLJ(I9F/L5
M;D_#%51UE&4%533T^M0\?-C9-0-_$;';=39AWJ,>'R6[O/\ Z^&+^:Y^0/-3
M9;75:--3T[21AM&H-&MV'4*&<,Q_A!Q+#+ YCFC>*0=4D4HP^# 'W'O^F7I]
M_P"N7Q?P'WXL>\_=BPQI'^K_ /?^KS[<IOLS)^-T_P"UYBI68.HNLG9D'@1Z
MLG_9;V$?9Q1YMG66<92Y)FM0E91YL)*J@9!8TH[6B,#JJ6C,;J3;5\X#N1YO
M)SY.ZKCBLGFGG.6\/99H;-<T*ZB-6Z4=(IVEK)AZJ](U[;BU@V49?P]PQ"M-
MPOD5#0A1I;,:N".NS6I(VYDM3.'T%NH2,*$O88SR./B>DBH.(43.*&"MI,QB
MHZU1)31UU!*)Z*I6*P7F4\HUQ]U^H.,SBRCB*$TW$^1Y=G$1&GG^CQTN8Q=V
MN"M@"2*X[BUQCB?R%2R"6OX#K_RK$+NV0U[)3YQ -R4II"5AKP.BV,<EA<ZB
M;8KJ"NRRIDH\QI*BAJX25EIZJ%X)D(-MTD"FVVQZ'J"1YLCRC,JGRE_D7**.
M:MJ>+<O$M'20#M35^7;3Z=15-1@(9B6&E1<V&,M_V?\ /719.(,_R3A\G?T;
M7)F=8OBLD5+9(WZ[<UO\L5WD"IDI:B6@XYH:BIB@FD2GGRFLAY\D<3.L*2"5
M@&D8:%N+7(QP9Y)?*#EW U'GM5PQ7K3UU1F-;+'&O.KZ56K)54U]"EZJG=D0
M.-49^;*L2 <,I4E6!5E)5E86*D;$$'<$'8@]/-QE5Y?2<9\+5&>*E=DE*ZRU
MF7!KDH)@9#+&#?2XTV[V52!CB*7@?CS/QEU/75OHDL,CQT=#)4T4+HH_J[3P
MF.1#&MCI32"%MK[L<-<&</<)"J_(E&T#UQC-5--43U4\W)!$8::HDDD*IJ:R
MZK7)\Q /47]^/+)FE$N49?DZYE+Z;59SEOI&0Y=,XS'-LL:7364W+I[S)$8F
MYUR%#F+2">F,JR3)LF@CARG+*/+HUB2-134T<+\M0-*R.J\Q[=^MF.K<[^?*
M:.*JEJ9)TGGBH:.6M>DI1>JK.4R**>&P)!8R!I'569(5D91< BEKL_K9&CH,
MJR_+:$V$QFRY5HXH1U-96UJZYK+U[1F?HB$V&*GBZ*C,D&09904<8.DU7)UO
M.R6!F5'VC#LNN,&[HI"D[8K\TS#-'$E?5S5)%]/,:ZI?[*^JOP&!_+SV/F;Z
M(8.PPF79=5)$ZYQ+0SZ!S8JJGE>(2=Y@EIWV4]0KQZOWCBNG@%#24*UDF9S4
MTLSM72QM'IBD"!*2'F,TKQ(RM)JD/K.0H ^EW\<#I^LW&-\6\<6'ZW4?HF/V
M2C?X74G\!YN):'B"LAICP_F,=#/3S&61)0=-2--EC9P'L@N24*,'-KVTXI^"
M^)9JJ3/:_/8X\_2WH;11B:E1 "#%,&5/FG!*Z(D 6Y/:.*/BN:BJ(LMXJI/R
M35R.L4&8*=64UC,0JLE0=J<L2"5E("WNQ48RC*J;AOAG(.'*)HG2GH8,PS">
M JT=;F>81+423\Q"5E6.-TBB8$KH *_(!*D,I*L-PRDAE/L(W&,Q7+,^A6FX
MFR;+\_B06CEK(M-=".GS-=%IG7;879L1< >2ZGEY\7!TLD@-Q'59W7STH-[[
MP%[,O[I[ML5%!D\U3E-7#D634$V0^DC))*&AAIYLL%8@CJO1JA5YP-1& LI9
MVUCSP55332<VGGEAD^TCD$]UCW$>PW&.*>"N%^.XI#7P09'Q"1^;\04,*QPU
M$GU4S:ECTQRHYL#4(%E3J#:]_*'2\2\(\2U/ L.7D\0QQQS25K ME5-0U O3
MY@E1;14K,G:A1-[C2XU KC+.$LNI*>H%>JYO75^^8UM<HEDJ&.^E0U^5"I]1
M$M;J3?&6Y%E&4:CEV7TU*S^L\:#F'V:S=[>R]O/6UM+EU)4U];,M/1T<$E34
MSO?1%!"A>21M()LJ@G8$^ )QP4\?$?'?$/&5#E%2F0UV4Y?39?FV94RP2U=9
M2OHDERY);SBCEI[?.@(KE%[S8>>.62%UDB=XY%-U=&*L#["+'%375M6 *BJG
MFMT$LKL/N)(_#S#VX([_  Q:]C@CSGI]#:_F/</$V_U[<#)LU*AO0*FQ&H#E
MD.1XB,_.'X+AE9&*.K(RFS*P*LI'4$'<'V'Z8=/U:X_\L7/A;WXMX_K\PO#*
M/_5O;WZ3;"FZJ?%1_+S^3;A3+>,^-,DR3.:"FS/*&G>KS.BJXEFIYZ.BB>HE
MCD1@05?0%:_<;=^&$*DI311T]-'\W34\*A(:>FB^;@@B0;)%%$J(BC95 'TF
M>\-9?QWDS\.Y@(X\P17?A[-BB\ZBK0I*4DLGKO151^;:,M9"0R6.^*O+YLMJ
MJNCS"-X*BBJ9J2:#I)SX'*2IN-@K#U[;@C2#?'-7NAB \"&8_%BU_NMC2DH/
M+&B0"_+O=6 ZZ"=[@;Z3?;H?-GU=EM92YQP\9%J*^HRJJC;+EU":6.IIG0:2
M5T[J]R03I&YQP/2567<*9)EU8'%3E]&E$_,MJ(IR8XSM]7EA OLZ_*ZC;'^C
M@X'JXZ6&";>=AW_+ QT\U).*:KIZ@J6$4FLJITMT(NC6.ETOK0VL'"X?+\OF
MD:H'$<Z:F+_G5)5-6+<WW:&1HG;P82(">X8S2KBJI(.299134L5,U74!14UC
M1W^?G"D@,;A%&IB(T74Q:Y^F7I]_\_U.XQO[L6\=_P!A$7!'B",1SQ1PP<V1
M(]>B--;A=4C;*BZCN['HHW/=Y_\ 9_H;9CQ1GS#;+,B:D@?_ -IS2980H\#R
ME<^['3;Z1"5=&4D,KJ01U!!!!'QQY1,PGS/C;B.LJ @E?,74B-="?-HD>JWV
MGTZG/>Q)Q1Y/!/21R2B9))89I4<.-/8!T]@*W9/?K96\!A25=2.JL/P/^ML3
M#3+(!T#'^>.(&S+A+BFFXXHJ6FS*G,<='5T55LC%U$(CLI$A$H"E62Y5P;BW
M6AEXFXMXK3B*OR]^'<MIH1%3Y33M+%'.UB%!B8AI1J/,DDD6VP08T1)L[EF[
MUC ('L+DV/\ =#>_&B)]D<ANY9 !?V!@2/\ %;WX?YL,7[.@$M?N"[G[L5>>
MO5U45)2@K"TL:NU[/(&=5ZC=5WO8;GZQ&ZXZ?RQUZ;8_$^88)^21X8_#Y%L
M6Q<7MYCU'Z@.GZA?&Y]F+?L7.LYI,BH'S"MYIA1D2T2&1RSFRBW0#K=F(46Z
MWMCCK.,ES3+<I3*:WTK,_3HIJ!*=R7CUGM<U1;0^HH$##F!QMMJQ3\SD0\[]
M-RH^;_[S0-?_ #7\WDJRALD\G4$\JZ*KBK,WS*Q];\G4*^CTA/?IEEYK@="+
M'Z;RK\*5-'FLO$%)"TE!7Z6JFC4GT:I "L7 Z)(+'5X]<"HF50JSRJHO95E<
M*+]; -8>VV.%^':KB+,H*:/5%3<P&HJS&SI$M[[ ?I&)^J/CC._(5Q-2T\E?
MD-;0<40HAFFIZ!FAS2->K?F$X5Y2/" R-;ZN.+(Y*G/N&^'Y(W1AF$F95T$B
ME'CCRY399$:S*3*64JPZCV80Z(I''K$B-3X!@2Q'ML-/][&6T4-9'7&5^68(
M5>-RVF-&+6U2;$E1[,5E))13&&0J_95U=-U='%U(OOO[<9D__5TTQ]80RQ,?
M'LV0^^QM[;8RLQC,X3(RK&)O68V "MJ!)_NX66-]TD1OX6!_E@[7OCNV[^AW
ML>_KBFR'-JNFEJXJ.04T,3RM-+:)"(Q=EC,FGF/;HJ DX4]_CO@CY \]ABV+
M#Y.20T=14U$=3%Z1/Z+(<LIGEY$%3F (,<-1,+%4==0501S'TIK4L#A\U@68
MTV;</QT>DZ)#0+5TM9 1L2(ZJ6HBJ"O>AT<RVT@QF-$<OJY:4OS FED>Q4O'
M(BR1LR-VD8HPU(VZM<'I],O3[_Y_2,;8#$_Z]N-_=BW[(G@AJ89(*B-)H95*
M212*&1U/4,#_ *!W&^)N .&V@JDI:/T.HG%X:N*24RTDJG7')!J>RZ7M<=ZC
M3<8X;SFIDDGR'.K)GF6@!FZ)F-+TBKH+^MJ6W- Z-OXV\G?D^S#C?-%U*])P
M_0LLV<YM(I6"&G5KM!"YL):R< I%$A)!.MK ;U<T,LD<=+$*>BI((J*@IQT@
MHZ9!%"G\6D:F/>Q-_E7Q<=Q^7+%'/&T4R+)&X*NC@,K ]Q!V.*CR<\*5$W/_
M "9"CDZB$N$_PAM/X8RW)<NRJ,1T=/'$!TTJ!;W 8CD>)UEB=HY$-T="593X
M@C'E4\EE+Q369GY4J&>7^DV4Y+3T6993'!"E)6Y9!-))4YQ$4M(<R4/'Z4"N
MEX8BP)=L1C7')&/6VD4=[:;A@/$Z3<#V8I*Z>CYO)Y9$RA9!(@<%0;VL?QQ4
MU,M7*T\Q!<@+V1I4*NRJH'0 =,9I \U ]&OZ60:G!VMJ9>S?N;0._H3B7A_,
MX^T(F8W_ -V5;\5:_P#RW]F(,OS/GK$J2H[=Y5Q:WBSJ OO)V]O3&29:V49.
M<S-/+GE?+5&CA@=9JFCH>5$DIJ:BG0F25I#($IE<K$S1RLWJA,9=F.=4<C9I
MGC0"G%/(M)E=314:M63E2L)CI4@5Z:"G<B22H;2QTB+M%AC,>(LVS3LU-4RP
MVL*>#YJ +MV2JG4Z[;"5I+=UL'8@_ _0DV^3[O\ R\T7$&<0H(UK7=5%D,\<
M-2Z#J DE1'+(@'U0K#3W6Q++)/(\LSO++(Q9Y)&+.['J68[D_3#I](03A01^
MQJZNILMI9JVLD$-- NN60@G2+@=!N3<@ #?%%7T>8TZ55#4155._JR1-J'N/
M>K#O5@&'AY^%/))Q=Q5"E>M-%D^3O_\ 6N</Z) Z][4T3#GU/B.7'I8>JQQ0
M>0[@RD"G-^)<US68#MQY31Q4M,6[],U27D(ZV.D>[%3Y%_)++F&39JN09Q/F
M&2UD=7!/59RP2J1 =5#70P1J)J"<D--!<:B+!@"<25;-!%1P04U!E\'Z#+J"
M!*:CB]O+C UOXR2:F/4F_P K*LMFS6L2EAV'K32V[,40.['V]RKWG%%D664,
M2QQTL3D#M22HLLCGO9F<'K[+#V8JL@RFL4B6BA!/1XU$3K[BEM_??&><+3Y:
M&J:4M4T8W>X^>A'BUO70?;&X^L/HLID6.OIQ( T%0325*-NLE/5*8)48=ZE7
M.V.*LJ.0<39YE NOY,S6MIHCT/*BG?DGXQ:#C.<^RS):-J_-+H@(1>1^FGE/
M1$C]5G.Y)V %R<</<14^>TCUM+0U%(%F:)/3 2[* "LJ#2$LP.Q%P",0YC05
M=144U/74M354UC500U$4L\!;ISHT8O'<_; W\\=9-1!Y(JJ6E%OG'BF>&ZC?
MM%&6X'<#A<TIZR5OSDR2D[M*S:G/2^M]V^^_FR[(:<Y74YQG$DE-1\MTH%7:
M6IJ3<(Z*?6C5AL.CV+$B-22O3?K])UZ??BNJLKH:?)P<ABEI*NB#S5T57,E8
M]7'(\=4BR$&'7#\VXAD4 AQ<Z1?%;21PB"II9?2*"L0R4LY70_9;3)!.F_+J
M8&[$J=+V9>RP_4%Z??\ M/-:C*$A]&SB6D2"J##E5C*L<P3M,+/L=.Q\?#'"
M^<0Y+FW$#Y=0YC6\.O4!(C0Q-4+3NI[,FCUBK+K T[Z-);NQ1<9\.5IT+F45
M/-WP5H:DE7O[2S!1_P V/);Y-\NHLMHN,^**6*OJ*]%J>&\EFLU.8.L>;Y@O
M22-B-5)3G9["1[[ 5594UKB2IE,FD:42P6*)1LJ0Q+9(T4;*%&P^7EN3U^:L
M12Q?-J;//(=,2GPO]9OW5N?&V*?@0;&KKF/BL$84>[4]S\;8R[*Z/*X>321Z
M =W<]J21O%WZGV=P[O.P# JP!# @@[@@[$6[]L<3Y%^3)_2J9?S&=N@Z4\I^
MI[$;JE^GJ]WT+3FF5JD135!IE:H%/3+KJ:@P@R<BG0D!YY=.B);C4Y47&/*)
MQQQ'Q)QKQ%F>6\ YQDXK,P:3T3B.:&BJJ5N7%'HJ84[2R74R.H]4,!OCC"DX
MMJ::CS/-J7+WI,LK(ZAJ#+S+,^@D:WF9AVX](T-I'9#%NE\5V9\->4NH6ERN
M7,\FCI*:%ZFB@/HOS>D0RPPRQ.++J)&I5U $,-\57DGRFE%%4<'UU7PCFU('
MBDS2B9JF:NI9_P"L1Y@M2[K52D_.1SR7=)0#N-L-P3QQPY5";@[BE\P3,T$.
M<?TKD:MY%0#MF]&$6W- )5J,!(F[/4#LYDW'N39MD_"^=\;0TV4YU45-7!Q:
ME/!29BDM)"99LF<2WHT2621'@=[EH@8KW6V.&\\S6MDXAR:NS7\O4V1YL(*3
M/ECBC2OCDIXW:G8P?,R344FI9&BNAUK8[88,EK@@V# =#OT/QVMCA^/(VGR6
MGS*>KK:FMY'-IZ"->33,VZQ5,TN\SD+>9( N@-;F$],_SJ;-ZKH(:.EO#1TJ
M>I%&O9U6&Q=@!<]%6R+L-R,5--4T<G)JX'IY"BR!9!;4CBZL.H((MW_0TM/)
M65,%)$8TDJ)$BC>9M$0=S9=3'I<[#Q-L9AEU3EE7-1U:Z98FM??1(G5)8R>L
M<BD,I]MC9@0,4F8"*"2BK*:.ORZ9A))2RLR%)0++44LZ?.4U0HVUILZ]F16'
M2IJ:(4<-!E\$\5/'/+5,U5.)YFFE54TJ55%2-44; 79KLQO^H+T^AZ_LK..'
M,HS[D?E2F-0:?7R?G)(].NVKU&%[Z1UQEV6T.4TRTF7TT=- N^B,=6/5G8]I
MV/>S$G' 'D_R/R@<8Y3DN=9925N6ZY*W-%EA0ELOHHS/4)KMJ E"B(V/1S;?
M!6FB6*FH::*BRZCACH\MH8!IIZ'+Z<<NEI(%^K%%$ %'O^730/55$%-'Z\\J
M1K_>.Y_NB[?#%%20T--%2P*%2) OO/>S>+,=R?'Y5530UD$M-4('BE4JRG\"
M/ @[@]QQG.43Y/5-$X9H&-Z>>W9=.Y2>@D7HR_$;?091'S<TH4[O28W;^&(\
MQC\ I..,LR.<<6<1YF6+"MSK,9E8F]XS52"+?_W86WLQUV.X/48BI*6!F>"F
M@A=_6:*)$9O>54$^?/\ +,KS/+Y$S7+J/,H80TL<59"DR)+I*B10X.E@&ZK8
M]V.'*"@REX*/+Z.FHZ)#*_H\"!(4UW>233XD]HL;GX8K*FGK*V,B.T>I8B]R
M-8U>L1W 7]]L4L5'D:-+!5)79H\30P20(ZTF7QR+H>5'E5))JMDNL;!$2 $L
M-3VMC)J 5=5%-4R0TV705$'IE75.(J9 S]F(L;ZGFMH"(KL 2[ ("<<651J\
M]K3:T=.RTL(_]3 H5#_?]>XZWOBV.(\HI\HK((*9I6AFHX:D&9@SWD+JW0"R
MW3LCPQ88X:RJES2LJ$K YIZ>AJ:AN6Y1@Z+\V;C>VLBXQ;P)_P##PQOB@R>H
MS"BS&MAFC_ZMC666GTN9I(V/K)8:; !V.]P(V.VV+80A71CT#*3;K8&^V,QS
M.I_+U509M.];E.9R1S4DDMF>D@JU!H:RBDM=!!J$4T0)20)+%(-0.*B%Z:>:
MGDMK@EDA>W35$Y1K>RXV_4;#PPO3Y7WXO[,6\?V;_L_RQKQS40M82U?#F=T]
M.3U,Q@1PJ_O,J-MUVP.@]WR^#*$U&8M5LOS5'&;-W<Z4:0![534?C]!-!%4(
M8YXDEC/5)%#J?@UQB;A7))K_ )F(R;[Q.\=O@K:?PQGO"CY=$U91.\U,F\L;
MV,L*_;##UT'UM@5Z[CY7I1R_*^(\U7U\KX<S>KB(ZB;T9HT;X%[X))))W)))
M/B3UQQIG%3DF05591[5):*GBD(N(3.VCF^%T%RM]M5L<)T=91Y+3>G9@^8S5
M(],YSG5H%2!)R@YNSA;^L3U) L+>:JS"EH[":2S'HBC4]O<.GQMA,PH*Z*6/
MF;%"&1AI8@_9^T;]+;W[L)EZP4M0ZNQGD31&I%M(9AV;B_;8=FVWA;&793-S
M5FJ4Y:1FZQGUF8=+CN4>?.*>:>GX:R:E77Z;3O5Z5Z2U=7.T+22=WYM"FDL?
MT<88FV,ZG2HS.I:,AD0I C@6UBGC6'7[=6B]^_KC*J9*S,:2GEORI)?G .IC
M0&1U'@65"H/=?%1F<W$-)6U-6L8JLKDA6!XD$8_)LLCQ+3NJ^N:>4IHD/;(D
M<,3YLLKHLB]#@:+FS<10&&ID+$>A4$\O*@>$#K.\T9D)>ZB-=-NT3B>(P3S0
M$W,,LD1(Z$QN4)^-O-15E;E^39O5Y=.]/4K-EL4LL=M8I)7J.:MC<&.1UC66
MXM:R-L^]=RZJGHLUAB2#TU98ZJ&(!88ZZF;1/RE^I',K1U"H.S'S="[*/-!F
M4?)AILPH8,RBI'YE'SGFBEICJUF-)H'1VIG<:GIWU1ZKLH4DDU$[U,\U1);F
M3RR3/86&J1B[6'<+G8=P_4AT^_Y)P>I]YPO_ '?R_9W"V?U'"_$.4Y_2[RY9
M615!3_BQ Z9X3W6EA9TWVWOW8J'I*N.DS?+'$N59U3IF.7R#NCFWD@;PDIY=
M43J=P1T^5E.4U.;U(@@&E%L9YR.Q$O\ FY^JOCN;#&79?3Y93)2TRV1?68^O
M(Y]9W/>Q_P##N\U7QUF>2^4[.LNS2J4<)QY/ ( R1**/-DRS\K&\NA9#Z72P
M5FE7D8%T"H!W^3OC_.Z_E47$<3SYAFV<<2/!;E0KEE%EU#09C3T+HD:F1A'6
M"/4>V&!UL^*WRD\25,@S#)($]'K*3@^2'+JIX/S4YKQ#79;5GG\D\QZF.G2(
M'I"#S56X-Z3RC9O'^94>1U>?5KMQ-73\^OHJ+T.DR3,_1)(%=*;1-NW+H[J'
MDLHF<7+X_P"EE:.HS2O;\\H\RJ.&(.'**IE@R^*F;,LIDK*TUM<Z.((H70\U
MV$QU )$MCC@WBNGXPR89K!3O2LE34T51 SK,J5-))RY#!4( E13OL\$ZA1)&
MP.D&X\\B+(CHX#*ZLK#Q#"Q'W;8KJ?T6LJJ8=()Y(Q_"&.G_ );?)I/1I/2J
M&NOZ!FM%5976D=5IZR,Q&0>V,D/\,>4V"H\FG$4G"];339GFTT8J\I@H%,J9
MCET[.M)7B8#EPP2Z"&UG6CJZZ.S?#<.9SQ*IDXHK324K=J')<M:T<3?4>JJ"
M#SY$.^G=0>A'3%%P3G=#-2@\5U7Y,RZ83P4ZHP.E"6Y;*9#'IM<$69=SI48K
MLWJ:B4\B1X85/8"'2S?O,>N_6V*ZDJ5Y53/(LC5"KW]M2%&Q]PMC(J=C5&6W
M9C0@MW7;HH_GC,YXJ:#F,+RDCE =2R$-U^R._&7YRE6_)E00RGU+&Z/[!?<'
MV=_GBS;,(*4T<504@M(H 2/F(DOZ6.*<KSHHY?\ >QQR*C_6!\U#5-15E-5J
M Q@E232>CJ#VD/L=;J??B7\FT5/7)E]3)4',YHW*/"T1HZ6-S,*>1FVEF,I6
M[1WCT1WO=K#&BCJI<HS66LIXXLMHXH*JD9_SR2>CDE>!8(?]Y'4:TO)ZL6E]
M9Z8FD,TLLS>M+(\C>]V+'\3YJ"M]#DDYD2U-+4PO35E*Y*K/3O8E0PN8Y$95
MDAD )21%-F74IJZBC]&IJ#+HJB.DIWGGU5<D<M1)/4E=99HD1 B)''&@ N=)
M=MVL/U1>GW_S^58?Z)_9I-@3X G;KMX8B\H^0/6>B2K74P,I@%344Y2#F*Q0
MACJ+( VQ)6P[[8S'BO(<L.B>OCDG/JTM)>JJ6ON+10ZR+]Q:P]N/]G;RAYSQ
M-)7\!5N1U%'DZ4=9G?#N9YE.L58E;!H:HRV"BL6:GK8M<XN]XY$;;M;?(@AD
MJ)HJ>(:I9I%C0>UC;\.N,KRZ'+*.*FA4;"\C]\DA]=V/M/3P%AYG=(U+NRHB
MB[,Q"JH\23L/CC/> .%L_>OJ,T,[_EJLR2JE*U:1H9\G1HZ):8\LZ1/#))%4
M*"YGC=U4I?%;Y-LDJI&GAK,YRZK.:YAFHK<OK4IZF.3-*6&BKJ:-C3R(M)-!
M!&.68RZ,-:2@C'_1APQ!EZY>E1FE/'Z'E&703"NC6IB_(V839GE\D,C0&]4*
MN9R[,KB1+*4ZDU/DJ23.J%Z;-LVHLHARO.X*N:EKUAS2JK,[S"*JJDED]$:)
MJ25%DN%1)8G(,3*;,)_)CPW(A%,:_+Y4ERF>AJ:*I6.;+)LFHVH:22A,D,JK
MKIV9:E9UJ%J"Q+ 8X?R&DX=R\9?235E2O.FJ9JFOJ&JJNHJ*A^9-++*0JW9N
MB1I'$@ 6.-1YST.,VE$V9U\JFZM52Z3[%;3_ -GY4T&5YC324&>9319Q0S1\
MIDJ84]+ACOJ'H5<!Z32E&[:".0(&N=.YQQ_Y'WR:EJ.(>$YYLVR"&[UE'* <
MVR9/M5"(+5-(O3TJ-1I&\J@7?#J'5D/1E*GW$6Q54$M+,\:QR&._S<EKZE[M
MP/AC+\LEG:]2CI3[FS$@L>ZW>/:<0P14Z".) BCN'>?$GO/MQQ &UT[6.C2X
M]E[B_P!XP*>>#D53 I#S%*R^X^'7N/OQ#-'41K+$X=&Z$?C[0?8?V O3[_VI
MY1:W+8\O_(:4;39K7%):%(*?U&YN\P=5W;5<%%N6+=O;'#/#]'E&6T5Z&FAS
M#T>(U<PC4S&<K=[RM=P038A2%OW8X S63)>->&,QC;3R<YHD?>UX:B9::<'Q
M!BE>X.QQFD ILRKX%]2.JE"?P%M2_@?D<&4XFS<RL+^CP.X]C.0@/P!-O/Y4
MP#Y/N*P38-E,RD@V(#%0=_CBHJ\QK8.#^%:F:=&\F_$W#]/FLYN/3)JS.J6A
MX::Y_27RAI:INMV9;]=ZCR@\84U-G]+&%FS/@++,[;B!VHQR<PK)ZOD<-RHB
M^I"<M+YK,J&S\G2Q"$X?BKB&K6FBS&HCS<95Q)PEF>7OS\LEK'J)UJ96HI_R
M+--2\B=T62E4L*@(6252=)Q)Y0.**7*5KH.)*+.*G.>%*_.YX(Z&G1>%J^":
ME6&,B-BWHXDGDH)(*WYYYH2ZGJHFS[C?*:[,A/Q3'7P9!GG!],T#Y320?E&'
MB<1&KBJ9(WU1+3<TBC,(#[ RENF,F\H&>5?'.3TRYL:O)\YSOB'*_1YZ;+J6
M$199'*8#0TZ3-G$<D,D.B6>OC2.I[1B3S\09Y3Y;22HDBO6RHR0Q*064MMS'
M'U53KO:YL!C\3WGQ/>?ETE7)13B>.S"Q2:)AJBG@?LRP2KT>.1"5(/CCRM\)
MTW"G%LJ9<FC)\XIXLXRM/JPPU5^;2@_^S3AT'@F@=WR,YC>2B;1]1U=K==(N
M#_._NPSR/&(V=BBG4BDW -M[>_'#A;D3_8Y@T^^W:_R_8"]/O_G^U&IX'E2=
MX8FGB4K'*R*9(U;=@CD:E!MO8B_FR@,<VRL+ZQS&B"_Q>DQV_'&>_P#I:L_B
MCO\ Q<I-7X_(X(D"YG/'_P 6EV_N."?P/GG@AJ8G@J(HIX)%TR13(LL3K]EX
MW#*P]C C#9;E[M([4-&7FD@ED<TL):26EMZ+*Y*7>2FTKR':[16'+*V&*/*L
MDX,H\\S3-\TYWY6JS5YQFN<20#G#EK2TM(;+''R*:F5::G@"DD:_69SCAR3@
MS,Z-I>&(\CFHXJP32#+J6EB6&NCW262%(D:&I4&\<CHL@4]@Z<5?]#LD>K6J
M@R++WKJ>6MK@]+1PFKIH9(UEJ*GYL<]$EECU-+KM(X/4X]!R^;6YHZ.3GM!*
M[&GA;FM3V]&D<E.VT  Y+-<Q;:"N(LBR2&J:NARC+(JUY>>U7'04J5+3$$&4
MSK$)3(02->K5N=]S?'$/$U745,U)12&GI87:(O&;23LILQU]52_JA;$VN3@D
ML26)8GJ222?>3N?H?]H*2/G\$4MQZ3!P_4R3#ZRQU-:6IPW?ZJ.1[#M\CKL=
MQA\FHFD+Z76][HK66Y[P.[%/3Q4L8BA72@^\GQ)[S^P!T_:W M V9\9<,4*B
M_/SS+KC]R.ICFD_Y(VQFTPGS3,)5]5ZN;3_"K:5_ ?(R:L] S2CJ+V02B.7_
M -W+V&_F, @BXZ'Y'E+AY<_!V;UE%-F&09+Q"*S.Z>&!ZODQO15%/1YA+21J
M[SPT%9)'-(%CD,=Q)H.G'%>>)7BJS#@O*:O*\IJ,ZR6DXFXJBI\PRZ/-**.*
MINBK2TXS04E([Q15>8T]/J"R\M2RW.*I<\S#)>;6^G9J!P]Q9!E]6U%F!DDH
M!G.4^AQ:ZJ/TJI"J'%-/.B3U$*!^79;XI+BFIP=OF8[WV/JCN\]:G*K*N/[%
M3,N_LD;Z',\TRW(,JS/B+.VJH\BR*F.89Q/14LE;40T4; .8J:+MRNQ.E5%N
MI8[ XXO\HF7>4SB.OXARRJBEH#RZ7+:8,!+29;2CE4L<T.SQR%;R2!AM(["Y
MM?!(&YV'M_8J]/O_ )_M3-N-X,DS=\OS#+ZQ*0"'3F<:EH+RK<@@J ='?I<F
MU^SMB*6.>*.:)Q)%*BR1NNZLC"ZL/80<>0BB%3Y0:.K9;ID^7YGFI)Z*\%,T
M4?QUS"V"=1+'JQ+'^]N?Y_)X7S9<QH$C=AZ52@13*>K*-HY1^ZPZG[0/C\@V
M[\:5 T@"W2W=;%A;8#P^1FLBS9GF$J>J]7,1[M9_G;Z!$>1TCC4O)(P1$479
MF8V  \2<>6OC):.$>3[*)PV@I4<55,+;5%9;5%E.I?6@I!9IUZ--93ZK#&9<
M'Y56R^F4O-RC,?66NRUO1Y"W6\J+\W,+]SK\<-2YWQ#Q(_"V:9Y*:;*HGD>>
MF04TE6+(4+H#9IK-9G-P!<@;XX<X?_H]33TWI]57K+/S$:J:YB2P C47('>6
M(MJ)Z?L1>GW_ ,_D6)O8$Z1<V!-E'5C:]E'>38#Q_:''7$U#505_"U+2559F
MLCQ4^E804C=N7(KHUV9FL0!91U-V OB@X4XDIZ*A6+BNMHVCIXP]&T$51! V
MG]"G:2ZQ^KVM73;;'D!X;X[_ *39EF5/QU#'E^5Y7S,[RZ7(:5VSG+9Y>4U!
M%4"351.9>7+Z2G:'+TV-_E45=4Y?4I54KZ)4^*NOUD<?65OPZC&4<3T&9*L<
MCK2U71HI396/C%(>RP/<ILWL-K_0<1YPF5T3*C U=0K1P)?=;[-,1W*@Z'[5
MO;]!##+42I#!&TLLC:411<D_Y =2>@&YQQ[Y3,OX*BJ,FX<J(<QXMD1X*O,H
MB)*+A\,-+Q4K;K49E8D%Q>.G/B_9Q++)/+)--(\LTKM)++(Q=Y)')9W=C<LS
M,26)W)-_-G/"%/F>:T><TU7/EU?3R0\Z2 V])@B-^6UB"CE>QK%^R;,IV_8J
M]/O\]'0UV8SBERZBK,PJF#,M-0TT]94,J"[LL%.DDI51NQ"D*-SC_9E\AD68
M\(\89WQIE4U-)Q70U?#&64F84KPU5'EMOSK,%@J$CEBFEJ^68'LI*4Y%]+[\
M3^3OB_A/.<[R>NR#.I$R.LJ::3,8LJKI:"6F@<\NM%9' U/R9(=,IDYFA;M<
M[?L\00"0S"&(2MZTHC7F'WO;4?O\W^S[,/ROQ71_7JN&974=Y]%J89&M\&^@
MI,ZS2BL*>ME51_NW/,C_ ,+Z@,0\;9JFTL5+-[2KH?\ E:WX8IN.XS85="Z>
M+P2"0?X&"G_F.*'.LMS$?FM4C/WQ,=$H_N-8GX7'F) %R; =3C-N*J#+U:.!
MUJZO<+'&;QHW=S9!L!^Z+MW;8K*VHKZAZFJDURR?X57N1!]5%[A]!Y4^-9^#
M,DH\FR>40\0<24LE16UL; SY;DY8Q1PTY4WBJ*Y@^J39DB4Z;,582RJBR3SR
M!54-)++*U@!ZS.[L?>2Q.,OXJR'-:PT%!7I4U(5WT)'+I*Q^L1(4"$#Q#;]U
M_P!CKT\_DQRKB;/>.N'\EX2S',,HS?,ZKT5LSRRIFI*FARUM\RJ#40,LB1)2
MAR^]CL,4%/'04-'0BHEJ!1TT%-Z153&:IGY,:Q\ZHF<EI)I-.N1V)+.2<?[8
M&5\6T639?Q?PYQ#GE)DP5LBXJR>AS.IBR^6FJRWHE;-1QR\IU9M=)5$QZ2AA
MU]<=-A^T/(MFJ97Y0\F$S:(,T%5DTS'H%S"%HTO?QG$0]YQ-$T$LL#BSPR/$
MP/<48C_+Z($@@@D$=""01[B,0Y]G%.+1YA46 L!(1+;_ /4#'\<5.:YC67%3
M6U$JGZAD*I_@72OX?0T-.:JMI:8?[Z>.,GP4L-9^"WQY2>$LAKN/>*Z_):S.
M\LAESO,.2:;-ZJ12!.RNRBH:;3%)*KRK$A"('TJ H QQCDN>Y=D%2Z\0YAF=
M#JB6JI*B*(R<@N+OST^=*HVG6MK,-WVOCA&/AEZ&EFR5*)JB&EC2HDC5?3$9
MU'-%0?TEV<-ZW9-NSM;]CKT\]/555')SJ.JJ:.< J)J6>6GF"MLRB6%D<*W1
MA>Q'7'Y?X@_^T&>__N^8?_Z,39QG-3$\%3G&;5,$FSP5.95D\,@!N-<4LK(U
MB+@,IWW_ &C2U,U'4T]73N8ZBEGBJ(''5)H'62-O[KJ#B/-(.(\JR?BFDMRL
M\HHY:A0;\C,X5$684[>#+,I;W-^JT=2,OCS/-20!E&39IF.H] \%))R_CS"H
M'MMB21I9))7-VD=I&)ZEG8L2?>3AT216CD571P5=' 964[%64W!!'4'8XRW)
M,KRAZE\MI(Z0U;(TXCU:69-6DA6)">L=ELOL_8Z]/O\ VL2 "20 !<D[  =2
M3X8\@?E47,<_J?)MR$EX=KI)IZ7B.:<Q4^7<21QA8:"D!&BHCS(#DRL&54F"
M$7+XDCDAD>&5#'+$Q21&ZJR[$?Z[OU3C[,/R/Y-^)JF^F7-GHL@ICTOSY/2*
MJWC:GB-_XM_V4O3[_P"?[5XASCBJ+,5RSA_)UDO"*@YA4'53E;V9!NJHP.Q#
MG438J-.^*7,\\XOK6X:S-ER04<9?.(Z<LM5F"JX7DP$_HHFN#*58W5MB188R
M^E@RJ&GI\OC%)%2Z>0(>P8V0@JX8=KF:@&UWU:NU>^/)YY0*7CRC@R?-IXJ;
MC.CA6&">5ECBXDIXELG:-E7-8T%F4_UBVI;DL%>.2)VCE1HY$)5T<:64^!!_
M4MSL-R38 =2>X?'NQ_M*?EY>(<DRWAOB.<-D^4129SPW5E6R*3-:IY)Q(ND<
MR+,/1)8XI9BQ55T+8$-BCXSIHW-'Q#32Y!F"*Q*U()I*@+U:DJ@"D@(W"FSV
M]N(?*7DLU8E.M+F7)EF$$-6*>\<LC-I4*H.KM$_Q6WM^R%Z??^ULAR#-4XES
MCB'..2DLNJDHXZ<W1Z<$:9=^T $554-VKZB?-'))#(DL3O%+&P>.2-BCHZFZ
MLC*0RLIW!!N#B#_:+SF"LX5X1SC+Z+-ZVLS.F6MXCGYWI^7<,Q-:OGJ(Z<J*
MVI1;>B/+NQ5@^HV.*6&GS6E_*'#]?29_EQ[7/RZ0231 ]!54G]8IW\59.O3!
MV)!V(Z@[$>\'<?']0S+.:#A#):GBO-M)CIM4>443[/FN:V/(BC4[M3P-:6ID
M'955ZWM?-<SK,ZS*NS;,)3-6YA4RU53*?K2S.6;W*+Z5'<H [L<=9=-F7#==
M%30B:HCY<Z+H#2%8I%>017W#Z 3V=VMIWOC@FJRS,LAHEIJ,1'+N73S)+ .Q
M6Q*#)+&Y7M,S?.%Q9U+:38CY:(7;2-NI)/15&Y8^P#'-5-HD7^.0:F;VV.R^
MX?''-5MI46WVXUT./;MLWN.'0HUK@]X(Z,IZ$?KR]/O_ )_MC,N+>'\IJ#2U
MN8Q1U"B[1*LDK)['Y:L$8_98@^(QPA#)F,E?Q75CY_-G,5"EP?1<KIW*PQBW
MJM*RZY!UN!?J<95G.;9'5+6Y/F-9EM4ANLU'/) ^WCH(##V,"/9C*/+YQ'"$
MAXCRS*N)8@ IGGB]"S&WCZ72:0[^V6)K]^*SR_>3R&IX?I)\KXBRRJS[-XLL
M;MT]=0Y=$\;/+F$DB@5,T,%EU0)$LC*UPUP1BA_)F<KKX?S_ "7/%/JQT=;'
M'5D>VCJ#%.+^&F^*BEJ:5M%3!- WA*C)]Q.Q^!^@GDI:*&GJLSS'+<GHZNJ6
MAI:S.*Z#+J:HK'#,M+!+4,HFG958A(]1[)O;!S3A17Y;<;\*A_ 9CJ7_ !JA
M3\<1S9'4?U7BSA2H/@N=4R-]TA7!IJ906?/.&XXQN9&S[+]('CM*3^&.,?*#
MPGPUE&9#*\YI>(>)_0ZA<IH\OC:HRJ',='YM)F56W+CEIE>Q>* N7]5K XF\
MI_$/E0B@S/B.:),PRT'+9\KI(_1J#+9X.S*E+2#LQ+,1S=1N[@B[$ >>.&*$
M,(HTB#.TC"-0@9V]9R% NS=YZGY<?Z.?QY8^[6NK\/PQE4$4]45E$3(L3OHE
M8JK$= MBNIOW=0'CC.:>F@FIS3*JK+!J=48,JR [C9FT^T7.)/T4'CI;_#K.
MG\/UW?Q_#%CXXW\?PQOXXW\?PQOXXW\<6/CC?QQOXXW\?PQOXXW\<;^.-_'\
M,;^.-_'\,;^.-_'\,;^.-_'\,;^.-_'&_CC?Q_#&_C^&-_'\,;^.-_'\,;^.
M-_'\,;^.-_'\,;^.-_'&_CC?Q_#&_CC?Q_#&_>?U$[@CI[1U&*/@7(J1<P:K
MA;-9*V665YZT"6>-&N=$3*+A[DGF*!(Q(\ ,>36*IAI,YC=9XZ*/-'2BBJ0R
MR(%!Y@*O8C;E:OWK^?-_SOC7AJDO=**DK\S91;LO801D^^Y'\L1R21,'BD>-
MQT>-F1A[F4@C'#_E>X[X?"0IF[9I0K8'+\Z09E3%!]13/>>(=WS,J''"OE/X
M3XQDCH*N)>$\_ETI$DLW-R*OF)L$BJ'M)0R2&P2.;4E^R)&.*FFGI)GIZB-H
MIHSVE/AW,IZ,K=58;$=/DT5/Z764M+TY\\<9/@K-VC\%OCRXYM_TBYWFN554
MC#(\HJI:'(*>)K1T'H+M#'7P*#I]*F=6FDEW9@_+OHQPYG%2DTO#F>$)F] E
MX9SV8\THE]2JB)ZN%MSEZ@[G<-B*:&8$PRQRA38F-U< ^!*DV.+GQ\V<UD'!
M_$:9NS6RW/8VBS*GCL9$JZ=;Q5L<6Q;4OS<I'4G<],9'Q9DO$#R19?4-SXQJ
M:GG0Q3%.]U4DAU'?I)*]X'T*/H;5UZ@@]&4[$'WC!B5MXG!'V78(Z^S<@-[P
M=^\# A"[RNJC[*,'=O8-)(7WD[=P.)'UM>UA8!5'15'0?V9XRSZ?(,H-12)S
M*VHE2EI;J65))/\ >,.AT#H#L6M?;%?2<7<-K%Q?59E3UL_+AAJX9%[24\K!
M_1_45=.HV)CT,C;C4,9?6)F%#25L>R55/%.H\.8@:WP)MY_)3Y0Z?B*BBX(S
M[,HCQ/1PRS<+&IE'IN;Y;2QF2LRP:CKGEH8E,\!-VY(9;_-_)RF9*2JDS"4V
MARNBKLRF8]%2DI99-_9>P]O=BJF-14U%0>L\\LQMTO+(S_YX\H2>G9UPUE)*
MTB54CALQM:1%E=86B5[KV;&[(38LR7QE_ 9R7-J.NR?-JJ"E0'T^FF/--5ML
MHL%CTN?6U+JCMJ0W\^;Y545?'^62UE%+7Y5Z%V/F]=-2NNH%I[C1;G=K2U[W
M78VP>%LH_+%/G<<)IZNFC**M,1!#(3<:Y8XP-;!25ZZ2+:@;#Z(16 :1Q&#N
M ;ER/'2-P/ FP/=CEHWZ.4$]RN"A/N)[-_ %@3@@J2""".H/4?V99%<:757'
M@P##[CBMH*/,J9Z2N@2III+:XI+Z3;<="#MW6.V(((J6&*G@010PHL<4:]$1
M195%_ 8JZVDH(345M3#2PC8R3.J+?P%^I]@N<5_&.3T]!Z515,>:3S/Z/1T=
M&XDFJ*IO4CTKVD7H7<BRK[;8\G8S3A7B;+N/:^03\34U0D\2=8,OI";2Y=3C
MH%F@9H:A^K!F%SN6DGH\RI:'/LJ.O*<\@6MHV'^Y=_ZS1R?9EI9M<;+[//[.
MI.P ZD^ '>?9CRL\40<*\,U'#<,JGB/B6%$K(4/;RK)+ZV6>WJ5&8, HC/:$
M(8L!M?&:9)EN<FD.84XG-%.*B#<K9_LL1NT;;%DO8E1X?30@%[L+A%:0CQT*
M6M\;8RZG6OKHX9V:TNLLR[-<*2+7! &UO=BMH)*/0S-%)%,7$;Q-J7L,05)^
MT._XX<ZXD<^LI,;'[5A=2?:%VO\ V<SSA;+>(*BAGS#GL*(M\RDK+#.K;Z)$
MZ>MOK6SD=C5;I/EV79-Y0<F@R%%!D4^GTB_.)2AU?4REM1C)A^=ZW4V(/;MY
MO)SY3ZG@WFY3F=.^;<+ULG,J*$/IJ*&H.WIV6R-V8YK?I8C:.< :K$;Y;G_!
MF?(LV2\6Y5VQ?T'-I?R9F$5_JR)-9&L;C6C%3:XQ55?#V6J9,TXMX:HHUW-L
MQCJI#;ZL<5/K9V/<!CRK^7L<)QY+4^3:1I_1,V1.(,YS;+HW@FR^I0TRC+J6
M5^93M33-Z1Z5(MV(2PM>];F%9FU5/F5?535M96.9YZJ=S)+,\F^MF/X 6519
M5   _4(F"OVO5(*M_"PL?YX@FFR^I29 I= V@L-4;JPMJ'2X(Q5UTU:(HV2-
M%BU<N.%-(U.;LUM^T2=\2=A$BZL"7D]C';3[U'K>W^SHRZA6M;,A2PBN>(0-
M5!!S3$#?26_S]:UEO;;Y.<T,69Y57T,VD)4TLJ:F-E5M-T<D[ (X5K]UL<*<
M795/EN79?79C3QYK$GH<D4CV,CP,84<.>P><JJZ]K>_ZBLKJ-.S+]EQJ'POT
M^%L<]K614C]L:V._MW(^!_M'Q_Z<>&:U*!9GEE>"-T@5FE:%WLZJ$[6YTAK?
M5OW8_H!E-;PW34\-(M!F;4]/,*R0-Z1'4E5:3G6-R/6'+%M)M;<7QEU//24%
M)2U-0:N:G@CBDJ2NDS%%TZR-]R!OXG?_ /BV_P#_Q !<$0 " 0($ P4#!@@*
M!P0&"P$! @,$$0 %$B$3,4$&(C)181 4<2-"4H&1H14@,V!B<K'P!R0P-$!#
M4%/!T19S@I*BLN%C@\+Q)35$1823-E1D<'20E*"CL\/2_]H " $" 0$_ ?\
M[]E&IE4<V95'Q8@"_P!N).S-2C20I6T$M5'&932+(PGT!=9V(MX2#SQ)0RQ4
M--7LR<.JDEB1-]:M$;,6Z6^'UXGR&J@2L8RP.:&*">:--6HQ5 NK+?F%WU?#
M$U!+!0TM=(R!*QG6&+?B%8]FD/31?;ZQB+**R6@GS+2(Z:$ J7N#/WM)X7F
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ME2LC:N&PBON-M7>MM<?'!RRI2GKJB33'^#YTIYXVOKUR$@%=K$;7OY;C'!E
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MDZ19Q :6.Z_S59N_P!S*E.=N=S?<[YI4:A-,V:4DN4R2TC4U @620HA34B(
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M515QEKN,ZQ--3_-LS#Y1 -C&.?+XU69Q>Y=H!0U(CCDK(O=HT(76CK:J:-"
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M_ %*/R=7FL7ZF82G_G#8_ TR_DL[S=/UI(91_P 48Q^#<V7P=H:C_O:*G?\
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MP4M*O9\@.BNE34&INP!%PNEF].':Q.VUL4M?0YA3RRP3QRP+Q8IC<=W3=6U
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M]78_9;V9[%/[IEM)%%(^F-ZJ;2I($DQV!]=(O]>"I4V8%2.8(L?L/]FWQ?\
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MHJ7 (72D>T2R'H)/W.)<EH9%LB-$>CHQ;[0UP1]F*B%J>:2!B"8V*W'(^O\
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M::JD>GCD9O<W1'/":F'Y.RH1;3WOI[W_ +*=$D&F1$D7Z,BJZ_8P(Q[K2?\
MU2E__3Q?_P#.%IZ="&2G@1AR9(8U8? A;CZO[1=%D1XW%U=61AYJPL1]AP\#
M4<]11/XJ:0JI/SH6[T3#T*_T5TXIA@_OZB"'ZFD%_NP!I 4<@ !]6$=XW62-
MF1T(9'0E65AN&5A8@@\B,9EGF:YPE,F95DE6*176 R:=2J^G5<J!K\(W:[>O
MYN@$D  DDV &Y)/( =2<=MNQ397DT':&LJN!F[\,)D:QZZB;+6-WJZH\Z<P[
M-&I&IE)O:V%(8 J;@BX/Q_HF4Q>\9Q1)T@XE4X\M T)_QL/[*_Z?VKV=R?LI
M+ES9GV@SAHK3-3C+Z?NSAK75VV9W#"[ H-('B-]L565Y'V/H5[2Y8KYV:QQ'
MD\E2$:ER]F0MQY@+<64;B(,!8C< W.*ZLJ<RJ)JJNE>IGJ"3*\IU:K_-L=@@
M&P4=T#8#&;Y0^5R-44ZL^72-J90"S4;'GZ\$]#\SK@$,+@W!Y$;_ -#_ (.J
MG(!EU9%V@R8/'65;&DSJD)7-*>%56/39NY+2B12XBL"QOOBL[%U+QBL[.U,6
M?Y>[ !J8A:NG+;!:NE)#QF^Q8=V^)OX,\ZAHY*AJO+>-# :B:D]XM)%&HU,6
M8C3L.O(G8'\WL_[094_9G)^SV3"9XXM-76R5 LZ5%FO$/FD\1F9BO<"Z0.OL
M(# JP#*18@BX(/,$=1BD_@]HZK+<^S\U,]#1T%*PI:2()HK,XE_FM/&9/!&>
M<X7D"MK"^)"\#\*KBDIIN6F464_J/X7'P/\ 08*:7,*E*&"]WWJ)!R@@^<S'
MZ3#9!YG$$,=-#%!$-,<*+&@_146_\_7'83,H<L[24,M5,8::3B0.VLK&&EC9
M(C+T*!R/%LI.K:V.VU)F>6Y]6M4UAE&8ZZF%XISWJ.5B(XI$4]U57Y/0;JP7
M4-C^/!"9Y!&"%YLSMX411J=V]%4$G!J8XN[2PQV']?.@DED_2"GNQ ]% ) \
M1O@54<O=JH(])_KJ=!%,A^E8=V4#JK#X&^)X3!(4)#"P9'7PR1MNKKZ$?8;C
MI^:V6]D>T.;4XJJ++I9*9C99F:.)7WM=.(ZEU'TE!7R)..U\J9='0=E*0G@9
M2@EKGL5]ZS2H4/-(;\UB5@D9Y;D#EB>F@J4,=1#',A^;(H8??R^K%1V4HV):
MCFGHV^BK<6+_ ')+V'ZI&,N[!YW7T^<U4550O!DV7-7N7#QR5!#A$ID%]"22
M7-G+%=MQB7C4^U72U-,?^TC8I_\ ,6ZX5T?=&##]$W_D(*>JJFE2CI:JLD@A
M:HGCI()*AXJ=+!YI%C!T1K<79K#?' KK7_!M=;_4V^Z]\,E4GCH*Y?\ X9S^
MR^-4AV%-6$^0II;_ /+C)\HJ:RNH_?Z::EROWB'WUV;AU34NOY84R68K)HO9
MF L>6^,W[)T79*NDI<MUR9?6*M=0UDK<26JI9QJC,DOSFBN8VZ!@=M_;)-+,
M5,TCRE46-3(Q<JB^% 6)LJ]!R'X]-^0KK>+W=;?J\>+B?\%[^E\=E:&FK\T,
M56E++#'333<*KE:-)&4=T(%DBXLG41F15/4X[8Y?EM#59>V6)%%'54 FJ(H9
M%DCCJ ^E@ LDHC/FFMK>9YXJ/YK07\7"E^.CBGA_5IY?FJ-B#SL>1Y'XXK>W
M>>U9R]*29<JCHHHXD@HB8H)&7;7*K7!2UAPV)C47/4X_A+EIIJO)I5>GDKI,
MK1ZV2F*-&Y8CAD,FQWXNG?PV'MRC^*=BNTU7:SUM7E^6JQOWDN9Y OPL-_C@
MJ&%F 8>1%Q]AQ5]G\KJKL:?@2'^MICP7OY]WNG_:4XK\CK\O#2QGW^E7<E5M
M4Q+YL@VD ZE=_085U=0RD$'K^+(W#C=_HJ3]G+'8>HG[*FES&EL:N:,-7AQ<
M5<4UFDI9O.+3W0OS2 W/':/)J5X(NT61 OE%>]IJ<;R976MXZ20#E&6OP6Y6
MLHVTXEAFA($T4D1(N!(C(2/,:@+CVY+1S]L.S<F3JM\RR*59<MJ)+K&])4-:
M6CDFL0N@C7$#R'+F<9YV2SKL\B2YA3KP)#I%1 _%A#]$=K HQZ:E ;H3_(P3
M&"0. &%BKH?#)&XTNA]&4D??@TJ2'522HRG^JFD2&:/]$ERL;@<@Z-=NJK@4
MBQ=ZKEC1!OPHI%FFD_17AEDCOU=V%N8#'%1,9Y-=@B@!(XQRCC79$'P',]3<
M]?S9[&9#!G^;B"K?AT5-$]556;0SQQ\HU/,:SL2-PM[;XH*SLAVE:;LA2Y;4
M4-/Q)9J2:-^Z]1"I7WCQLVJVX634KKL;$XS"C?+ZZKH9#=Z6HE@8^?#8K?ZQ
MO[<[R"I@X^<T5)*V6(4&9R1QG@4<TS:(9G8=U!.QT$?2WZ_BS*9$$2^*:2.%
M1YF1PN$70B+]%57[!;'\'K^XY)VES8!JMZ6-",NO>-VB1IEE:.S=ZXLK@7"J
MX&,Q[>C.LIK*'.,II9ZIR#05,(X0I3?Q&Y>34@\.DA9-UD%O;E&:T]'_  ?Y
MG%1UT=!FOOWRGRG#J:E'TD+!;OWX/=NMK6;<7P.U6;_@>IR2285%)4N'9JD&
M>>, AM$4DA.A2P#7L6!OI(!/\D*4*JR5,R4ZN+HK!GE=?I+$@)"GHSZ%/0G
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M-?KV5JI.UY#CTVHSD@/R78.9(]@ISM45"O&*$U=-U[@V*\4+&1*O7*!5,UY
MIGC4*_1J4PY/(:G(&T"H2:<R0G,8%+ *<4$DOP[\EI4LJ3RISOA>WZ/1I[3L
MB=0L@3SNY#GCK4HL%TPW3:-?)BH\1Y82E4RFO3T2O9<!($-DGEZ Q4&A=3;&
MZ[+3"=9?-#BN*33(\*;4\E4FD9LG95DZ3V8;=;@...4%^9R8)N<WM,(5ELZC
M@\36V49C^3I]&8D_A73,RPV\OS84&,518DHS"J5:D2'7Z]TA;$4MU 99U" J
MJ\<9)EMY,K[$K)/A6<J6;6H])?69)A?C3,*9":O>HLL1U!C4SP#@B\[X\*3G
MX,U^*F9/"YERIQ($F$ZU4'*.X30O2=H551 &;JZ0*NS>Q*BIAK+67\@DU1H^
M3I0T.H4^AR\P'(JLAQ7WX$9"DC%HCV]=]^J.ZWUXZ$55%,>"6H3:=4Q;A^!Y
MRG5*7+8>3HU322*+$ENN<1E=7L'UB3CC+=.DE5H-!+)M3;G56 !(QT@9#SD>
M!(D?-H+KJM.&R7S@#:W'$K(M7R]5/PBR7FC+=,:>B0'$BUNB0ZLST6IP%:%
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M3AB52HV7:+'I<UW?F4YJGQPARGD+6CDAA T.F)(A"IHNE>6(E0J&7Z/.G0!
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MAUL'0_-<$3'[)(J8@TEN802'JG!W:- -1EU"GJ[IDQT;8\H#>@MR]A0M%N.
M;IT"-"!&Q!$98!LM"<A,D367KU*O'X2EQFQ-]UYN*T;OS$<GM7EW[>8&G@ET
M0C4$5;+AM4JM3FS5.[#4-]476O\ 51X_4;'UE9L4[18*I9UKE;K.S'*2[2VG
MS9A,( ;A,"Q$T'*(>SQ+RA)P3CCHU-I,>#3ZG#6PI$2/($7@6Q'J3=%T;ZNL
M5[]^(M*G5(XSV7440876B5*!J4FGF>.AS6"H+FJZB*63LK@R;;C1WYIZCMH;
M<E&G[7%3U82+)?9 I(D",FZ &Z!HH%H%5NO!53AWX!J)'D- U-0FY WZ/T1'
M+W)SLD.U=%$N-^%O@I\E.3$HVR]2/-\%][?R2/&ECGOE(_ZH?)M>_K8J$WSF
MHYHTGI=<\FVB>O45_P!6(Q-,19J/,@\=GD9>%QY-PQ<%T50E%2MJ0OU8F'/,
M&FY6UM0&G-T&2#5K>(K( FXBB*BVEK#=5O\ "[]0ONPGL3[OAETD:K5*&LI&
M_P#:E%?2+4HNTX+JK'?420->C;<X+=LB3OQ3!'-WAFETY,PTZFT^?6:O$>H5
M9>F2JG"BG)A@VDCQ7*J%*D0D(EUF2H2B(_#F<H 9I*IUS.M K>7RC CN3'J*
MC45BIK71*\978+34BZ2TZ2R?1RI_:/&0<LG0JI#D9%S-FVK5JL2(VW2WH,Y9
MR0G850U6G%5NF-'M!<QV2Z0@V2ZJWX4Z8 JZJMA^!%.+0"G< U*?64!L.I>U
M:^";EOC*DAFK-HOR1:1D7WAKDI''49'JM(X=R0$X#>R<ORA5[DXJO<B>E5Y(
MGK7"PY->8GU/D-'H+;M=JIG_ %:1*8+^V2KP\N;2>E4Q_P"2N0@R["/L5O/\
MQ(SBBO\ .,T"G*[*);<4"3(;]>$//_A KU;:7B5#RZOX*T#_ '9MP5Z;)#N7
M>D=9.>-&7\O4JEKWO,10*6:_G.3'=R29+WDKEU7%U557U_*![?W?+/N)_,/0
M9/L2//C/'_P 6$7TI?$$LG5MBD2H<E7WFWQ+1.31I!HW4%Q$:&Y$39,F+BZ;
MJFE,/9MJV;66,XM:4IIQV$DP&VQ%16/)$VVO(."JAML-B@:B)=:K; 4?PB4W
M\'IZW&/6&M3V7ZGI3M,RD1>C.%:^R]WKYG!,5S-4A55)DMR%21+CT:CPC5F.
M#?YN^2$^=NTI<?B*)(A"O!1)$5%]J+P7!2<L5JHY>=-;N-0G=4!Y?^=@.ZHZ
M_P!T4QL.YR9;;5+*[$H<!B5;U/('5+UIW\<.2ZE,FUF<]979E5D'+=)4X]5'
M/)MHB\D 13'[N[X-N2PT^"]S@H7N7FB^A4P'0'WZ[EU%_&,O3GB<>CM><=(E
MN:C:,4XI'<4FCY6Y8B4[P;1CJ%6J#".2YTQDV8660)5!Q:CJ3K36B0D",.I"
M)$5-:+;$P:PV.9*K5TO6JK56QD.S37BH-HYJZ/& OFFF[6X*JWY&M$H\* ;G
M;=::3>)/S5>+4YI] ZM/J^%^7*<%F-&:-]]TKZ6VFQ4C-;76PBE^"*OHQ6LS
MQ::^-(ETZ''AU&<PC1R),<M)G"$_*I&<9_G+"A:4]-OB$VZ .-DEB!P4,23U
MB5T7&UER33J!-<DLHD@D:B[HW74P#J#='#6RHB(JE91\[$YL9\"6^S28[;#*
M B.A5MDU-Z3QX,R#T$V!(G5OW<T8S(XQXX%QPU9 V-\8BDB,FZVRMDN6M!)$
MMIT]^/PJ@2G6ZA18NL8_#;?:9/=/CVD+0I\.(FED7%"KW2'F=AL'Q::7J&JK
MJ(/2&EQ%153F'!<1Y\DI#<B/H2[)V1P0+6(E=%M9?."RVQ;$QIV&3##!-I&D
MJX)#+0AN9("<0T+PX\\3(/#6ZWJ95>Y]OKM?\267U+@FW!43 E Q7F)"MB1?
M6B_(-Q0148"SDM[N:81>/'\]SL@G>JX;9:% ;: 6VQ3S0!-(I[L4>$J]6=7:
M>TYZVP<W#_59...C+5:>+@]31TIKJJG#2JZM**G*RKA" D(22XD*HHJB]Z*G
M!4^%WZA?=A/8GW?#5\S,PQJ$J$D1B%#-S:9>FU"8Q B)(=_FHPO2!-\[I9M%
MXISQX.,V2,FP=S-=5C4ZJK%KM1>C4+.-3;*1&E42BNN="?IS<@I9*[MZF"=W
MVQ;)2)?@M=;>B_#%KK9.Z_# ?6'[\2O[89Q_SZ9^2DXX0MM@ES<,D !3TD96
M$4]:K@H$:INYCJHKI\4Y4B/Y@FZ_S#Z")Q6%OPO(DM(G?C_8>4*7DF ?9JF=
M)O3ZFH]QM4&E%M@5N.B5-X+P),"YG[.F9<W=ZTJ/)_!W+J+^;XLI.R3P=WXR
M\ZJIVKX2/E^ATNCM(EOQ"&RR9>LWD'=,E[R(U5>_''Y</;^[Y:K B75:=,TI
M^FD<R#_B1,1G4Y.1V3^TV*_#F)YQIIYUZ.$*&CS8N(,R:Z$=AP4+D;:FI@2=
M9%&^(['/99;!57FI(*:E7UJ5U7Y0<RTY". ZK;>9:6/ )\&]EE@/(9L-%W .
MW6%%$KHJIB'XCVI9SX;,\91W6+%A21U,/.""H3KKR?-1Q(56Q*9"(\=;E9J*
MN<[M]'9:3ZK(,Z-/J/6OI5<-1ZJ82(S[@M-5 01EQETULV$QL/):'"Z@2&D
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M>Q#ITI-TU!V./SY-(A65;=W#%.KF8J?1G*?0Z@$LZ515D2G1 [";\@G!\JT
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M8_L5/CN_4+[L)[$^[X<R)FVH56E4';A],G404.ILETZ/T7HH+U35R3M-D)6
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MJKBS!9;@U/HX@1*] DL-R!46BD-[;;A$OQ0^L/WXE?VPSC_G\SXN?_[.2_\
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MTMH+K:B7N3X)@,17#B5.2$GIW#H[#1 V+Z.EYK@:%TA:YZDMAID>RTV#8_5
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M^A/2OJ3X3A4[,%$GS&D,G(D.J0I$H!:^<56&GB=LW_.+IZGG6PU/6HP4@OJ
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MRPB=#G1=U%V8B<YCU,Z[QO-ZD1K4G9&^&WFC1QIT4-LQY$)<47\DRQ&MJ:I
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MHT*4L*4Z%T3JLRA5DOTD^))J$YX8\.&R<B2^?8:9;349E;N%.*XF1X4IN0]
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MD[JMHRZ!')Z+#5L!$52VUMIAQ(<?9.LY.J,NI/[KQ2)3[U9 5,GS,C'0'49
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M5*I.SAD2VHT^BU;Q6ZS$1H@5Z-(<$E S6X-E?B:6QER/ CQH$^HY=<KU1?\
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MJ)A-N,PW9M64T,MC9E2UJTEA2S:GUE#LZN-KX9:?@0GFHQ:H[;L5AP&"_.9
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M2:2F)&9240VM99&C=5+<+*7+A^0Q' *K[%.JI5FFT\JM*6FTZ<;CCKIQ(E]
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M &SN_P!L[O\ ;.[_ &SN_P!L[O\ ;.[_ &SN_P!L[O\ ;.[_ &SN_P!L[O\
M;.[_ &SN_P!L[O\ ;.[_ &SN_P!L[O\ ;.[_ &SN_P!L[O\ ;.[_ &SN_P!L
M[O\ ;.[_ &SN_P!L[O\ ;.[_ &SN_P!L[O\ ;.[_ &SN_P!L[O\ ;.[_ &SN
M_P!L[O\ ;.[_ &SN_P!L[O\ ;.[_ &SN_P!L[O\ ;.[_ &SN_P!L[O\ ;.[_
M &SN_P!L[O\ ;.[_ &SN_P!L[O\ ;.[_ &SN_P!L[O\ ;.[_ &SN_P!L[O\
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M)%H'Y@:>.'O<+O84=FN+HO'[9;&A-@008NK#TR*E*9C!P !.+F[;33);FG+
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M0G31/3_Q5;P9SPH5&-^IMC$CO56>IK[?6_C0< .Z[C'7T3Z;X1<#JNL!' E
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M2Y.76O20A'24R4$4*,'X_P"E%()=:TS8TU%)HX 0N,QGH>LQN(Q_]. +6B>
MDJ< YQ&XL1)X%N)QZOO^&("R,P?E"X9)V-;AO7N"4<\6I,]7!P&S(6J5T %N
M2D&&NTJY+DBU3)AOG3J%1:A'G:(B/GJX4141Z07@I^F$37V%F7".CHZV#L;<
M#6%UR9WA%K[ZH(\>Z\GR0!"BRTT#':'H!]U!CQS%+?XK6,0](%Z]JR0X"@WM
MW51G"\>(Y>.W;ICP+5)Q<4LBC",>FI8Y-&4H\D,D\N[S3@V3T 8@@;Z4^Z1"
M'!R^)XUM[8<*D,"0:M"1+D501X@.4.FJR(&DY!L,J@^9 1J4XFV!MB'!0R!
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M9(8D@CC !( &1C^?_O\ ($1T5P'%>6.OH4(C3^S[C@1#ZTNK=?G.Q_[SO?\
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M>29X'9I(^EV3;#SG:*K\Y8,(<O96\DAF4(IDO(@X$'YPFQP8-?U/Y3^V.O\
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MO*>05_ADT7Q.:?(+J@8^;T.>9**JSJJ]:LJ]7R/RG[8Z\TH/%S]W.M+C'3#
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MH(0R1DT(':"SY ,&6O$?:45UX/$^/ 2Q19+[J<;:Q)4I,M3'085$HG3ERY+
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MN)I[-R, *3R*5NR9%$KM_1?E/VQUY<2(7"Z0!9X[!AO*A[AOHZPBB,J?4DH
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M1N0C[ >0;(WC@@5XMU=+5-6?0BET)PA5R,H1(Q\UJ^8)*8R*C!CS2$)T)B2
M  _C6=_Y/'04;.Z^'-$7D]0P(^Z:ZN;,&SZOT=VY/ZJ9^4_;'7F*%"1F(MCG
M4ZY6W]O/\K]!#>AWJ?67W8BH$(PCN%,^C7T(F=J\N5.J*ZB4U!TT37UD!T6
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M<YSB0@3:1)-%! 0 : H/L?6^@\&;UVM!, "X K '-7)A&0*601EX$PL6+
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MX\\B-F,?[6"U:ME_VI07#L)2B^6+UP+ $X3&!H@1G$A,S,&VI]8XY5"RAZ8
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M $   " HR6NEYZK8%5;RK@!MYF(5#T)[!*),B28D?A-! #)6RBT547*L&E7
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MON!RQ6?$L0G73<.L'); QQ0J+T!R3LV? W5N<O(A((&7<R/(/X+ZS@V0#"K
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MIS0NLE ?K(A%*.XUE:/"L>(I)V>:-S[RPTP>OW3S(1+6S$-F0QY4"<:RHVQ
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M:J+M.&F.@P$X!HLAJS= ([/@@6,.T !>$:9AC<VQ_/)K@Z2*8I\9'5)")Q(
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MD"VJ=PLSG!0FD"!XR9#26[)D*Y/X1AD&S4#$",QN?H=?\'*,4)389H99M,N
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M)))))))))     "  !          !0          (
M              (              @    @@  %(
M             B  $   $  "   !  "       (
M           )@@ .0  H    @ @@   @@00 ,*
M          )J  FC:@4 B*" &1 (.  $0( $
M         !2Z(6<P:H0@822!8@8*B" 0""+
M        !(  $(P    "      *
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M )X&(P (             0  (       "           3-J-]$(.??\ Q0@
M2!0 "8    @@     "@  $           D  .$     (F;:70*#G-W>_*< 6
MK*@B,&K ("A@ @@"#H@BU BC@      !   , 1A_  => ,'V;R#Z8/FAD 2@
ML 6,@@@ @B@@  @BB  B @@@      #- #:@? &"FT8@ .KAA& "OU*L"(.2
M*6( *(("P$((* 0( YP@ ) @     !#P>M@A>/ASA[ $_,<@46I_NST 0!8"
M,\     @     #-P            ")(@ 11*.#$!4 %I="$W_P#/\V6 $ &
M A          C3   !           6 320280@I 4  1^_V!-K/#U] $ N@
MC     (  %_;@(              U N*($,(+K3KZ>BK.\$W_;&"  A$ZHYE
M #(,(8"MMH( 91*)) 10(      4 R22280 )8APX'S306&'HE0C $ B 3C
M    +%L!   (              R&L  _*(0161;*A@R!$^V@$Q5 $$@ (A
M@  -L     @  !         V SG>RS6::2TRC\X%0G PVZP1B  D(.(7K()8
M ((,(9%(())!1(())0    2.8$. *8M  ""B<OURLI'*T+F+  D @ ;K   %
MM         "!         O-22"'0 PJ $"(X ]V!1HC9G?   $ P "[  @N(
M(      (  !          [  &91X4B\%$:R$!8&Q O"P    %JO(8OIB.R(H
MXHH((XZJJ((HHX(     K" EXKP)0Y" '\:YX'%H]'     $ % 1B  ;( (
M     (            $7@$1!Y"#0! ""FB\           @"@  C "
M    "  !    (    '7"0ET&PW#D720N %L          $ H !C     (
M   (            $$* [TUE1ND$6$" %[          F2$ 8A 2 "  " "
M  8 "!   0      !J0>RW:V/ &":$?            $)R@#C !8  (  )
M ( 0%   (       H@U=6/\ KV&"CUX0           )6#2J0@%R#J.K@"R"
M % 2B"$$""     <(@CE0&,. !DB<-@           !  !!!@/K>A;O0 1
M"             P" #LY=IR  !)H             )   "(P,Q8#*9
M   0         !2@A@HAOB@A@V8             !"  $8@&*&$,EI 0  "
M  0          X!#@ !#   @#Z             )   &(P("! !)(
M@0         !&TD   ND@!!0              !   "8P( -!$K]    "
M0         .\M+OOS;'++RW0             )ZZJF:J! DI:3FH0J:(*X@;
M:IL"     )Q/K@@!FDD%DK@  %E         !(   8P    "      "
M         !>ED0 "AY0D!P  .>I))!)    ) @ (_.__ /LNUGOM_OLOCOGG
MGP        K ;L )*7CAT   "*^ 20"2    0       0  P      @  0
M         #BZB:11[D"L    8P         0      "0 "3(    !@ #Z
M         "?K:IV#,     "YV0""20    0      #*@ \P     @  L@
M          3#5P@       DJ0000    "%( )@!!<@(!A0 L (!X$(H! 5
M         "  8        %0         0@@E\@@MD-+Y5-]-[YSAEH@AED
M           :8                 " 6  @  2 "J93/B;S6^$ $  3
M                              0@ !$      @00,0 "R      !
M                             "82;:::02::2:02::::::6::90
M                            2   0         0  "   0        ""
M 0 "       0 0  0 " 0      " "20     "0    "    0 22     022
M2!:> 0 B02"B8030( R9P     #  "2"00":F$82# 2::"24@!2     " 22
M242"  00 22"2""0"000     "2""020"0 0 20&2 "0"0"""2     "60#2
M&2""Y*%#"J:."& ((       !""P2$"&P3 8 #0*8F0:          " 02 0
M"2"2  2"202 02         30 #0 0220302 " ""000
M                      "H"0*0"0@C0P! !:00"  "(3
M                        "2""0002"2 002"220 02
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MPBP % "\(@IOS=J-=[<<R,Q"+"0Y<,2^?^V]_&YX'[YSS=^B/',-" A"5\#
M"K!6)7J=&2^%F[$+8O331@H9$%64B0 5:'AE(A*PBD$S,!#E0.)9.CK0!%[#
M6ET8!18;C!,,D91RK)YH%1B@B29.32)BA+,+@P;7"]2$'!*BA(N;DB,! $TL
M<=C3 "!5 F58,:8;//) H3$3PX))A"8O#$$Y2/0C"@$!.8AOE4 +L#I1"D&
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MSX=[GBT;Y;XDPH"S>^M2=.410(.H'ZC$JQ%V#Q2,2$B6@2%.U2QMD/"K)P$
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M4<#2H8SLMQ5@%_YC"G@I8(1,'88X)<N)"!Q"D(+)90D #$Y0$81YG("L 6+
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MO#K_ +ONAK&/F@$7,$S#2\222SS$R1D3)$\15MJF>2ED(":3+"?2DHDY0C$
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MPH+<)T_;4@1>5'IC/!)B\0S^.IGU!RX91-T.SV>]3A?'EF(6,69PG*VM))#
M&UG*;Z3?;9#R%A;28N.?GK1 +&#$8!:9D]8UF@$7J03U.=^]YQ:B+)A.N0)A
ME?\ E3S.;[YV\VK&$QD:&DOS4VF3KEC'\^:&/;?IN.#E@:W0708PPV$,:64
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MSZ-8Q?\ ?3/EVJT,=2/C'Y[UWTWTHVQQ].1;J]=2E(\K=<K9]*'"%$=(;*T
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M<2Z1LQK@)<IPSDL5<.0KA%2\IH^_W>O/QSWZ3O,7+HDL-RD&(8=RA5 -V I
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MM[W^T^WT[RZ^ OAS$125TE2!B%B%U59557%6Z]5]ZY9'EX@V&ESRV"P)4AE
M*<@<C'S2P8E&+1EX4Q:L6H)5X.D">NDDL!8+0*"Q&FN/?_KO]7_+>OAWO?EP
MWO">O#W,D9OGUXZ@D;YRG4\4):E7S!_ !Y*6@U)0-;+2UCW, 1H,@B(PC-H<
MQ,=376M>O3.>4XDZQUX8^S6YSZX8U>.>KZ_,'"/CTHZSCX+]?CI;W\=^7G^?
M[7^[_E_3_6%P4!A (+0 NK 8<+S%ST=12&6S$98T-AU#/4UX;\^!UC+LXY;C
M6.&%\\G,YFCS*#6H0)1@!@Z!EH4.0>92UP5P^@9ZTG.:! U2%:!8C%HL);^Q
M9%I;9B7@J!<(@!C=;!'I41I <9<],W54&#1&V.OB"9N9@ ZLJOCPIDT)9X \
M+;XHT\/%1I'0!U:5FHCQA0AGOF(,R1/_ &;W/CZ8^4]8.(Z)7.<7'\XQLV$0
M(X5X57&8HT?6YS!_2PNWI3K4?0-5P(!+>      @ ( ,(# K"9IWWZZ?R:WT
MF5S]O;"L,L=#9YUOR<-\^&]^W^G?>GB\R_*_O;R?^8]J[ RNY YF$4GH@T*:
M1V)R\%\#R\2)GE9C!0(FHF%%;9 @M83K$$6884$H"J#.LIH2H+<"6QXM_5-J
MB<$MC&8+= 7*BY$08T)6?X8@JI'D6MI#@342&[J#!O<"\1*9/_N7Y??UZ\-[
MM]Z\=[WY<#?Y8DY\.1F][M]Z=:V?MK< ) WH0 18X4$MPR&C0$4 -8   (03
M>[;UK^WMV[;FM_%9<,?YN*UW.^<<=[QWEPW?>\*PY_'0"_OU\=^7G^5O<<-[
MCA^[MOKPPU??T/%O<5?[O^7]*WO?E_M@/A:"_,/K%/)#K2+!BK'$4DCAOSK>
M]_%&]P[YQXW?+K0QWL].&][^?&4X_95VL66*<K6F8/VE 3-0KFM Q:B:B*X@
M$%$2EVB7#0$P)\>(,?\ ?O>WP],?*>L''J8Z-7#'USR\).9'+'_K\R_*_O;R
M?^9$S$ !*$  55 "6U-Y*>(&2HH>9R;J.(:E'6XX*$L^#^??[U\._GA? GGV
MUY< FQXRDTF4F1NUA1;  R'_ (-_J_Y;UX;W;[U\'3$R^_N.E&_RQ)SK?]TK
MW!ZKZYOQ6S]M;AL\/K_?C^\-Z5K'::U=N,;RJ?5@WYT9\V_MRR,>_*M8QY\-
MWWO"M[C^\-[-M;]=][<-^N^]N%^7G^5O<<-[CAO<<,-7W]"M-^6OAWN*O]W_
M "_I6]Q_K%-VZQ+&V,W7-2XQQG48C0.!8HDI9GL"T@0:8EC4([0;(IP"P1%:
M3//BCV89'T2XHUULWMWWTK77+Y/69RBO/O:CWM:O2V\]-YUD^N^H>E6_.^'E
MG1WYQIA3'3EI?#RHQSC!BV. NB\/F"-=H5]7Y?=0G<,+VGWD\ZWN^_6C372_
M/XJVNF6;EO&@@!  E# &:F!FVJ*>UG3<?+JAG0DB+<J9 *R0LH*5>6@8*:T(
M7#D</^Z2U\<.>]:P@NY?J[FF^<;]-:PBRX?V=^O#\.WYPABW*5^:U.6/G[5A
MSE\K9^7L5"PQF5[W7?+J-/2;[:Y?WQ;^_.I3*;QV<9?/KA3>2YS&^_NL\[\L
M+9T$6FV1IO*LXQQOD&7UZ\.4*,S?*/G[:;_E;?+UWI23J=,:WOO[\,(-9OA&
M_6[7I?SP?RM"->W]?FOS?>*SWO7IWX3?#O\ &^6M).N,V^>5?N^]^..I#DX]
M>7+E1D:&.!OVKTN_)^UG$98_&_GAGAW^/!F9!ZY>1\FG^C,,8Y3A/.G)M!&E
M+EO:[>(<#!CTM%0$' $1*8%JYA'0,0H;;0;B";E*H4$PLW$*$$N@:O,B(9@$
MS_PZ#&+]X?6/CMOTIT)TPNSHA*%\9!1P&\JQ"G(AV(V%'F<M=ZB<<()@4$6;
M#5N=$W,!H\1) 1@86$R2O2"[3*CB2+CB"1N1*$26Z=BX)<PHS%(M,,Q#)A0P
MX)S4)DX,F7_+>_I^G[PV>&>OD^UX+</<]RMG#9XKWWY\+\C3/ZX;WNW/AO>[
M<_#O<UO>[<^&][MSX7Y&N?UXM_?#;PV\-O"_W_?S_A6?=<42/EZ R("- 05^
ME!"91;2 $J$0:2A2#U3=YJHF#A<Y"BIEE,I1EM[[*(>A"31E#(3:C 5R+CR"
M)JXFH@C>+:.;"@N"VGILW'@YZ=>(6DR7VN'J# +WL@C"HQ)A<RBVB<W(C2O?
MR ///*@QQJA9+ !*";85")<DS5ZZ#L 4U:]!3^JP=$@*,X-'L;&)04"XH"KX
MYV=#U]L7BY)RFHDZ!IV%U7&HE44 ;<= D#5[,3FW53+@/L@QH2#*,.#O<D=?
M\;]LOG_'T_PO?I;UJ-/%OB"<-,/8(SH"Q;=))2<LI/+I491ZK>F[<ZB>",K>
M][_/+*-/O*WI?ITJ+Y$96O\ 7\J+;.=I\L*EGD8@UF^)@1WFHMLQO;+ESJ-+
MRC+E>SA?#F%1I8^3[Y^E1I8N646M-[WW:-+&9B\7MC&,?E1.XY0>_:/N]1;;
MSY.5]X\J#..QU_+=;U%MG/Z84$[CL>_U,>146V<\7EA4/$$9AC?,<$BV)C,U
M%MF<\W(][WY5$<$Y6MC)GI9RY5$2R>G+K.,>M!G$]+8]=-:BVSGB\K^]1I;/
MQ'K43+(SLGE%1G'ET^9OD=ZC3POS<KX;SJ,XGI;'>OJU$\$1?-/I:HTM,,IF
M8UBSE;FU%MLWY-S'::A8".E\YMVU\ZC2\O7\Y%\ZC2GI;#TOUMZ1IQ[O/?>T
M1P3R.GO>>7G4:>%\5^5\-] RC?(R\\^.]^>\O]1<&0F!(1(ZF)SHQADB8*$B
M])(5(.N.;#"YQ03.W7B&2@4Q+:* ,3=A@BTO3Q9,9%!""(B)-2E[$L%03"X8
M4&+4RK4@&#6%*JDA4"($-% ER,R:X5X7,4$DR!% H@QR2:E/SW+'L2:)K(#!
MYR(41@' ,!*Q5;TWO$D#,4:4(4FBJ>7!']G0NR@:P*6P*D2>10@L"0:A(B+_
M (,0 1@87DR).3#E5UUO>6L))%@>XD6K4P74U=,V10EH(T1X$#!\@Q<U7/\
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M " :  4  J5!6R@B;2F8O] KI%83KO8/1:D<54@0+\0 IUMH>V\KQ12BIF*
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MOSS:W6+9E<C0'=6G LR0H]R+,L5@+V9<+B,66'UH7 1RFJ&.Q+.FK2;>0$Z
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MJPY.8Z9!1L@U!L\N"]$A;D"4%)(0Z!QX:%AF"F+M,(;D31H%U"2W2C &N-4
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MQW029!P-"%,@ 4QJ' 2Y-P:$8T%A)/&)="E58E8V8GA3*2C 1#XX9(U5(0A
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M;[L9^+S'LM1_'U^([Z5G]=,S[SUKSXY<X]OMAKG^8[]ZC?YY>:C6Y1D@NO>
MO)B$G_P.OWW/UN]R<7/CX'UO+G;Z)T]_;M)RKDW-([\S<>>'VWES5KWQ=]?U
M$??_ (-[W\_\R#X3L,M44",D$I$F?:T63Q/K"$G_ )?%T;A!'%F"U-(0B#FP
M%,ZAA !3!!38$BT),^,6G%:ZG*8\4=8B?-CS'QZ5$39";'5\1U=7W-/6.6F/
MOVK%NG*+Y^<N:GNY;>/=WBL:Z?)<^WO5_&F^Y3TO5S)K:W6/;7E6V:.O?JWY
M]O$S7C6+G>?MU[4==W^8S3:V^;[S7QIUYQ3RG$AI[5/-@-= E^,O[I$&5?(V
MO#1&J2'6NVI!D"@F]<!2=,!!AA)B24$?^XDRX@C&2>??3AU>H=K?,<-?A[Y^
M-WKON]M\ZU]S?GWK\Z=[?OB^MCX^V.'/O]M>N?%3IS^W'G/]-YH(-!C3G^)<
M5J^-^VE%OZ_.>/\ //*M[FN\9^&WDCUK)RY3I1K/;N:?-;*OYT^U=ZTTGVG^
M_1^7??GP^^>!,.)?2<>ECASB)QYSZ7^K2<VTU[?:ISTS1[N>]7BT3[5O\_Z]
MZDB%ZZCBZ'<"?*X/Y$>&0@(@HB(EFDRGPQR+9RW%YM"#Q-W:6F[-B'!;-689
M(<,R)S$D>73U@UGE;&3J_;I7+<;_ #YS.)CO?//+\VMIO>_ACTW_ #7G8K>]
M_>M;??R^=9MFU9R_+YU_/2NOWUSK^9Q3U6=9FVOO/KGG69ZWW-_>_6O/6\[O
M:_VO6?[^>?SZ5R9O\:[ZSYTT[ZYOW=6=,16$-!3.M ASE0M"P9<4= ">:Q*R
MI6[4T7;'>8A'D("0D9BS1M\"5 !<MCZ@MR-8?)DI&(5B 5*?7K4M"19Q3'!)
M-89VQ)E!-=8$4F*")%^'ANEY5QN"2K_D^^>L8^MOO\U8Z:OYX.?!\'^G]\\_
M_,)>(4UR:U,M(0"*/@&X 1 7"2!""I="A[T$%75#UI (E+Q=+SI""P5?P@X^
MYA0H6!(T'0(E3+88%8U1TEBB.IP9:(7,X07%;^-_SA?QIO[^-."(7G+'M.OK
M]VMG7/>^"N^]QGI2*5[&(W<480:T/&LR&2A!F>AOG<3YRF>DFYY7==:$"0P9
MMT0#;5Z+:ER0QK0!$]BEYP*-H7191&,9%E'B++8V-&@!0V!0#ZY>'65A%R$K
M/6M-9^<:)W +" *07#V(%&T8%MR+,*^1B,)SUR76C%KK;ZL_[[[&S<3]&S@Z
M9SI]^E6Y:<]?QT]ZU+>GCOX8YSU(O)V1^?-6M9ZWM\>CI?S;4?#W]L=:M;/4
MTZ[Z]+VO:^E_9_-$6DY9>VMO?G5KR<XOG$3R,XFK<GU_7VTR8JW7'/7TWSJU
MK.+W,^F_FVW7T]O>K3KZY[=<^V8JU[=K[MRUT5S5IPZ9<]+>;QB.56C#.E_F
MK:#I,OM;'?.*DC%[Q?+Z;^%)L.-77>>>D5;DZ:YO?3EBVG62W)]8?C]]:MRM
MWOIT[]NM6G#$&7?VFUZM>W:_S;X_EIP^7VMU]3E7.U]+_-M?;K5IUUR^GVMS
M[U;D^OZSI[][2P,=7?*<:YJT89[V;]K,>_K5N3CGK^.G7/*W+WOGM%QY:&:D
MQ%W%\==<_P JW7//3TSU]JM?/2=_B]^]HN,]&WQX]ZM.&.KN/S>K<GUR7Z9Q
M^*8TGR[CM5_/K^/^!6 @,$P,P-1PG*EM&S+"U"8]$4M3.D6L+A%,RDP CBR$
M7AB%(864W0(;+31LLB8Y((^E*@70P.8"?R-:1&)AF9E#KP]:0T2)K#T1FXB0
MCAFQ4;U].5:V^_E\ZS;-J9U==7G>>SS,UUQRTQ?>N*G#)PSD*(Y*GJ\J)>)9
M*#)E$:!I&H)A FTEI33 TA4QS^=[P#TY@G6H.1Z<+B)F'I8"K4 !4IIDI]D4
M09%M C!#_!*KEV00\,H)<4%RG3>DD.7AE+! ;XIH@HA],KRY:+6S"E$I^J7(
M-TS%U0+#_P /6>WM/Y^OOU]/YG_S%6)5@@E6 F G!=L6N\%;HD8!*W'!TCP4
MP>1T:MHT44BS@+$<,0Q#$A$0EB8EB>):\>I44AI"$R&GE,\_V<+]==_FM]\\
M_;\Y.91QFPW)B;PQ$N*(7!DY@_LJ]4#F88"36^A*1RTAZZ7-,P@J>,Y3!!6,
M5,:.C+73;_E"3G TB P_XD08P-C4#/<L1I*:LP'-D3H_@J%.HXP60H!$=$_Y
M=Y^-E;\;W:?HV5C3P?5O?XMJUUW'#OP[]?3>?IVWQOVKTG=M]XX;_%;*[WX=
M_IW=<^_K[4>^L<^&WAOTJ;]]^F/+6=/7GO\ 7T[WSK;5_/K^/^0F,8,=+*)9
M3.M7@%19X)-!L$$4<U'WNB31*0*P 8 * #[!VR!8]4#5J6Q*U=;&D18H9 A2
M02W$'$K% I"NOA]6BVYEEJ-;W:[$^).]^SGK;DSJZZL\KZVQ?72N;@)9F C5
M7 =7E>D3 D-A"GCP)*(5&*"/0 B*@% 2!P%1556557FMU_UNQAN";D"]0V:*
MOMY1\$L;NV0(/*N@[A  RC5@(?)LRYMJ*V4R-H/^/M_@$8^N.7X]?S7\ZQUF
M[?>O#M]$8Z,_/Y_Y/&YV_O\ [BZ'F -+$RD))#&T+Q%$G4@BV*EBX#7GNEDY
M1G%+X$8+U.0MNP,\28 ,-[H1W@/+HR#5+13-?>_08F(L2% -%>5,3RB-0,F5
M9557_@AL-!D!9JI!JE06AX$F!WB;02)5[I(F;*)5;)6(9)#0;3@Z(Q(4&AN_
MY?UK\;,UWCIOK^N&_7]\.\?BO&.WM?3Q7?C^=7X^(M^:_.K\?$6_.NG(Y]OO
M6RN^N_CA;6-3WQ]GK4_C?FW>K?;[1]JGG:\7B^_7A^\N^O;ERV:?FM]ZW\[]
M>'>+\.^WA[[VUO?SPQ;O$MWYMN*])UX>E]SK]^%M8GYC\>W"S&'4_)4^->'X
MYWWB\O#?6OGYKTGU_%?WY^<?\[[5L)S9BRI.""U?0902A)GR+I%40E*01P,Q
MY+3$YN;"_P#"=294662.O Z5"TL'D+0A@&\WQ:8M2JJLK=7*\W_D^]\S4'*N
MGWX=/OPQ_?S7;OW],[:@.AG?*H.58J#EP^W[WYJV/O?\U!_+5CI45@\:].?W
MHC)KO^^]6/Q]MX.E0<BH(C2M.5O3S;[<-^N=\Z_E];3Y_M1FP1CR=+E\XIY'
MOKT;K\^:R6+6T<6^VF%LUDOKH]=*Z1[6[;^S%L>.?//HYK.]/PQ5L>+_ +S:
MF/,:6?6U?;?[OI5KZ:<O2-/WP@W;XJV^OYJ/YI';&WG5L/:^OKFHX1O'#.X;
M.XK;4'(T]L5;6M]][Z_]3=KVEHD6]L00128O8]&I2 -S A 4,@A,K@@ ! +'
M_D;\;W::WOV^CM^/\>_T=HS?Q;['BIBN6][Y0]2'K_.6W6O$_P!S5^_O>QTL
M7GM.9J2U\S&^U'>=/)G?2MGMOS1.OM5O?W/Y6(Y7]<_F9K>]_%;Y[D].O!N)
MSJ(F[>/QI[\-O^6/OI6FGR?:?_A-[Q7?Z\_(V]29JQTU?S_R6.0>G_/N-\O3
MV_\ @\=N'>.F_$_R:WOVK9OQN.$G/>Y]'DU[]O[IK4CA'A)S.$]3IZ3^^U;W
MZUUW%9K?CA)S-[]SG1Z]JD<(U)F;<ZDY[,^G#R:[\:_;A\_;]36:[5I]]*G-
MS\=^$G,YYTY\)ZFOM^->!XG6-].'I.[QXX27N;V^CRJ?3G]ZDY]?'/A)S.'D
MTWYT^]?:O3F_GVKT/?MRKML_?_X'O?K]$G.L_P#V&][[?1VXS?%N>[UKK;WG
MY\?GAY_']^K;PWN_U;_-.'6MG";2VY].(1:M[W\5KOKOQZ;].&/C\<>^->5;
MW^N%YS;E&]GBNI>UN3/\\3UKO_K?M?O)[;Y_5XZ16]^G'Q^OHW^.'WKD!&W'
M6T]JY==[CA?>_P"].,AO?/CZ#RX7UMRY[[./I=.O7SY_LUFB,&^_[O7?QOO]
M.][^]>?WUIMQW^/OZ?\ %!F+\_\  O[^S'_G8K'U;W^O\_MQWOTX[^?S]'VX
M?;_@@Y=/'+_@[\==QMGVK7>OWM]>][_>_;C,X];6ZWYZ62IG\Z:_BKR8#7\%
M;O6_Q6L3I>WO[-OQPZ1:-G#7?X^_BL=@R[]9Z=>%[Z<M\O1ST>%_?7ET_?TX
M]NO3]M8MI7VOVT_7GU_O;3\Y_E:Z=.?7[?\ #OIZ[>E;[[\UO>]:Q,_3KZ6]
M?G[<<<=[W;V>-^[U[_BB];G[;Y5F(P[WCZ-?OI7;I/;9QZ=,\]_S7AVO9\XC
MZ=_G?.M<-XG\WMI>+UF^G_R 1S\OU!&\OT[^/Q[O^,!OEBOUOX]/_HK_ )<?
MGAO>*,$\-[]JOJ^T?G_'>_O['.GM/VK>]VX?K^^.,XZ[V?0,^J>EJF\/CJ;?
M[6][^;?3^]^)K>WA??OOQUX7T\]N!@U]//3OQYZ=_GM6G7_]Q__$ "L0 0 !
M @0%! ,! 0$!      $1 "$Q05'P$&%Q@9&AL<'1(##A\4!@4/_:  @! 0 !
M/Q#_ -J,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!
M@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,
M&#!@P8,&#!@P8,&#!@P8,&#)CD^8_ [MY ("L>14OZA6XDH HQ%()<8$CPO(
MSP'W XM'P@^&;>BS_1S!D\SM9_>M F",+38ZS]IY%/0M?DLE[,#/&)*>C/*<
M''/+6MR_-;E^:W+\UN7YK<OS6Y?FMR_-;E^:WK\UN7YK<OS7L/-TQK<OS6Q?
MFMR_-;E^:W+\UN7YK>OS6]?FMR_-;E^:W+\UN7YK<OS6Y?FMR_-;E^:W+\UN
M7YK>OS6]?FMR_-;%^:W+\UN7YK<OS6Y?FMR_-;E^:W+\UN7YK<OS0X%+@#+T
M!_4$%U%!NKF;8[TYLI%:"PH0NI!>]&A"OE_DU(]J)@7?F[U86D.]%P/IK=<=
MI;78H& 8X?[/;&]8-DD;E&@QCDV&%0Q/J'S6Y?FMR_-;E^:WK\UO7YK<OS6Y
M?FMR_-08[7G6Y?FMR_-;E^:W+\UO7YK<OS6Y?FMR_-;E^:W+\UN7YK<OS6Y?
MFMR_-;E^:WK\UO7YK>OS6Y?FMF?-;E^:W+\UN7YK<OS6Y?FMR_-;E^:WK\UN
M7YK<OS6Y?FMR_-;E^:V9\UN7YH&0-4)Y%K&[>Y^ RP9C '%O%O@YU=]0QC@Y
MSU+7O7,G*6+=<$LZU./8Q/OTZL7Z%5""@5MB(,EV%*B%$(\85F,0;X0QH6)
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M8WVAV5",O74%X@D0*,%[I3P*XN.WI$O#ODI#DJY4B)%I$^,#YY?(OJ]9]I0
MW1@JA_C9=AGM3 ,J7NQ+",BQ586C4+@"#?KG$8E5IG(1D_1N-LC$#BVGZWKV
M_2!N".IM4@2Z%""0DGG]" RMC8&BZ;"$4Z3@+(N)$LTHT%UN.1G"50D1D"5/
MKI*\F3A<'HU@ZU3,O0_RU)P'V2U/D^XG2JR7!=2L6ORO(X*0D0 :09"+&1L.
M1QI5;" EP27#/#!U\SI$Q%/1!&:L8BWZ1AEJ0%IL)=GE*@A6V6-]>#65&_\
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M"B#!60.@L(_#U#5?=Z"(9D 0-H4X/B(# -$ @<B9Q+3J2QT;F)8['.=/ZES
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MXVL-P81O(YL)[ (Y-V^'K&J;-+%&165,)<1E+;*H61@R( ;(*#-Q$O>L?O\
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M5I8RH*AOZRH=E!09A"TPL\+2SOA(3+N$L-!DFP")QW]4#H!        $ !8
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M#O'MCP]:WO=JE&1A&R6\814+JIZ%L5^8J<**;3LVEA)0ZZ)]"!$RI6 $2'J
M*B"4AQ(14-P!$XRMH) 1W/$G\A:TPZ';.+J?@88T*FKN/$B(70)!6',E6T%&
M2:W*8F/Z%G*:K>*MT5PA]OI4&I"H-)4]0KR(<%?/PU5ECQD,3 +!4TJ>@!R
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M@R(,\C%*?)I4:547FD*0(^$\),+4^QPMD0D*MG=#9H>Q0?M( /G1&:A,G0F
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M360AWVI_OZH@\FW.C,!9"G%V#29UEE/<ZCU8RORG'+&,N40W8QI%8"K8#%5
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M")\&-WX&S<8R/-DY2X/2Q,S KE;OZ:^DA<HKM.V8@7.LK(%  $<J!P;(0!$
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MHH;A(Y(CB,PFDS!1^"'YR0)@,&*C2YX$%\7T5PFXVNX15N6@<K2)TZ1)W7/
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MN'K>CNN4>M?4^L1USZ=N&][*WO#A]:=-S]\((*/ XL+'+(FF-%$M(7,V/!8
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M19P;=K**FX6H%%\Q6(@TRD)[5\/0.$3BC2$5 ^3YB&L4CKXJ :LNU$:@4A.
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M6'Y_YP_F^W^<>OX0\;M[G[F' >PGL=P@@62' JUGF92$PHUG*%X(= RD7%I
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M<26DU)((W"JYP.Q#@8A<KED,.L?$ WAQ)5(,!-E1ZQ!(,,9IA(BE[(]:9?\
M/=>J1G3Q6YJ*I2Y@'$,P4$(XA@20 5"@R>FXP&"!  KLM,='>F[TS>]$I&/B
MH$5)@V:MVXS2D&%($I  "@D A$$A2#$RL<266*#498=*$"(6PRR:!"+ABI$6
M0 H20,2'Z-XU_I]XM!1M["$DX%$T!;;]"5%6,+YUS)#)^4AXU=GJ1$1HM*EO
MEZ7OC2!$0+_GO^?/XOG?/\F\G+WHJM_D:8C(CD3G]-/&[>Y^^<I*T8 @B<!F
M0!8#A=C*K!O*9'S5\T93FCB-"\%MG41-/K @0Q 1+"D @*$1!$2$1LB61LE
M;K@'3BJ::2D2+:*6N=G/ZASKK>UN7IU];UO?O7O:-Y[YTSF)*%L N%E%,J<%
MO@4&0"Q4 +* 6J29UGY,I%=GA:HU=J52VG,8UG$6HP1!;3,TYN)7'*I1>BC#
M8!?TM0U@ )=_?G 841/)!H#R(8A[U$76:&B-1,)SG_C^T=6SGQ]O^3O2M[T[
M<-[CCA6/X;W' P*#@0EQK& E4E6?UPG5RZ7:D">I@$GGUZB(KO=MY5CP)0$J
M "RJP!U::RQ0V1V$*,))VRPO!,IP@=(=H(!A>(#CAF<IUK>.]\N/3[MZ>?3A
MO?\ :Z\O3AUY>G#3&U[,5[ZUO'<_A)@OD#0S+$I,%7-XA0<(/D9E(YP98U(=
M%B#5_&W/E?WUW?C3QNWN?\,(2[3(+  )4(+@U)O@L!D!(%%!((2UK1>@OU)A
M+BN8AR?OCW.1H"^9 JNZ<X:;!SS1S!DKA/T#<9,(+"X<!7#A3!GTW+2!P0$5
M2!RH )6H&D4X# "DSDG@.S!-6VXAR (DS0S8  <@ .7[6N8R!,FZ=627"D<:
M?OOU4:,"FW0VH3E("QD$.NXJQB.]$1C 6,Z]4I(Z5PA@TXR38E%0T'U#!#U_
M%"F*I<I)BD_/D#AISY$=S5>NIP*#^''VBHTM,$8(UY",>JF"[DJP$7^J#.[@
MYX R 1'(8!^-VROTY R\Y:J$G]&\:^'OOO2M[]_/XS@6Y83_ &M[Q_1>/"%L
M!<A2@K<*V>R]%^H*)2-BC:@.[[@];WYK>]^*(L0@Q0J"RX!D7(0"Q3V')1H;
MM/8("22))"(C'Z(B@1$1SO!-G1(?R^-_WQ^+&%K^OY6 9O26PJQ$[AQ.7#NQ
MJTQLPW18U +V%FH'CO?I^-/&[>Y_R"5**W*-HZ@3H[R1'FP2VC( E*J#46P5
M9AH '2'B"&: 6\16#(S,"95"8K=Z1!L+UO72DBL0J>T=_&/C. YW_@]/#B%7
MI"1+V'DM(#5@&2KT>R('1++,<)=HS=H0E2BOP+.'JE,5M,7@WR!D]5D.#"JA
M0RG+"L"<"-@&6,0'& ;$WC)5K,6 V"X!]D/U'LVO^(?V<)R=F(A/A4B5Y%;;
MKXA8LTGI@=+,DJ%)"#5@G*8:Y,-5B#P$3$T$B/@#].U:JB>_8&)$^N-8TXSZ
MKAC[%L/3#>].U6WI6]Q3RQBT[PGA;QZ'"V].%MN!?'[^JWI]>G:FTXDYSAIC
M\'6@Z^=Q[<J\98L8O#'#4Q<I[?7;A;>E09WY;(WA5MN&$&SWX;G3"U];6K[U
MY[^J].&+!&-Y<#[Z\+>OKOXY<.^]/6NM;[VMWWC6F-KV8KW<];KSY]FW+>.Y
MK?I/MPZ1S\>^'"34QCOIUK?3?M4[\V[1P[YX][F??TK>/7>RN7SZ:_S#E;GR
MO[Z[O7C//1C_ '3A3QNWN?\ +8] BZ;$C^/3@R;KUN8BEHZ(-32,)H2C2!8!
M+..'_ L;V$9S1 H(<(JX N""JD" R%( F   " "      @_X]H<V^6/#VP9Z
M>7+S5O7[GO/S6_/X199+:OM\U=TY1IWUS].._/!^??\ L?BX["2\T!/*]XOI
M26M1N!(B=)U$ C1$#+.6[*6%"XH2Z2][()(1I=<CPQ%.W?83!OC !SV27V)*
M274DL9RJ+)P-9#IPXU06CD/CWU9)=M,70+Y@&.>U(ERLL'A:,H-X8%MUM9*0
MIH3[OL24^L]$ZS[EFN3GR-02=,'MC#(%R  S9CRXZ]A30%Z_YI!)+0%2P$+F
M5VYC(R R #4!(*V[A?3+E1!:3>+QI [=HA!7/-V)!1;A^&6Y_#>_/#/M_ON?
MC3QNWN?]1-P82#!8<Q\I*"AK\?GRAMTI+/-L,@:2]%#/_B[5JH$V<$\N"><I
MZ;:BW7%YQ$\N&43ECAWK^X\ C5ZXUCQB/ >*RB<L<.]1$QBF..&#46B6]U+,
MZ\IX@\NABPHVQ8*:.F,Y$ITB8$L!G[%\=6*+A40YF;ZW#/2R0_@FO(_.CN$J
M _6Z#M"%-7XH>%4SHZT:$?0$F;MA]4C%@X3=YH3 ?A%-6@*4.E]NBL[*W:#5
M%E!]D4R:O49#[%Q=Y5(Z<C %_:^9.8D?6'V#2;A C)J=#TFZ1/\ ,?NL @:X
MOR A\4)(EP51^K_I- LRZR#H];($L)BK*1R'U1VBV)?L1INBJ@Y56Z1P2=3I
MO;^"3V9X).N,V^>51I:\^LOFDG7&;?/*HM&ORW\^E1AC;+[X1YL)MY5C=O<_
M\#=46.,X1]!H+R31A#%&\N'RP=L=_9^77TMOGK^N#&T^M0-XOKO;G49QW_OB
MHC*)]:!$3&0* 7Z04](,(QO$68Q?,;*MIZ:X]*@T/'"/O>O"#P[.F?).45'+
MI\U Q8MARX01$6TBVYIC3TG#=O2G*4I/+,B(! XBJJJJJK*JLJKBJRK=9?T[
M^OQ2#F5I@/#B5C=O<_\  B:*M@B@\D4H#P_QB\GLH,$($BA *$"$ C@B(SDC
M4.,,:Q4M&_*)?2]0Z/BH<&=,(Z=V_P 5#H^&HZSG;QYJ'1\-(Z-[8)XJ'1\-
M(Z-[9E0Z/AJ',=,(V]*1T3G%2+0WY0KVCO4.CED[OE4.$,]-+^T5#HY9.^E)
ME#IIX]/-0Z/AJ6CZE0Z-N34.CZY5#>R=L*APA\)S_P!]:AT3M4.$.[_[4.0V
MQL[*AT?'9];?VH7)\;U]:APA\0[]ZAT;<FH='URJ'1MR:1T=<S#X]*AT?%0X
M0](>F&E0Z/BH='QV?6W]J'1YV:AT?'GUM4.CXJ&<'7!]JAT?#4.C..=0Z/BH
M=&<<Z5HWY8\JAR&VD_% H J8 *G0"Z\@FKL8Q=>%T"A)D&*:QNWN?^"$&<%E
MS!'Q:HU9S-Q$L#,>6;'XU*E2INKMU9\*GLG*TY.$3[KTJ;JC@J<XXRI4W5L8
M\*FZMC'\JE2)4J;JV^OPJ5*F1N_9EPJ;JG@B;JGBJ5.M:WOQ1*E2INKO[.%3
MYK.=75PB;J[\%3<6ORCA4W%K\HI:<[*HF"5B*9H.'9X8W;W/T6ZQ<OF7BR#
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MXXG@#GC][W\4]&157 WCU HP2Z,@D PH"BP#3U/*E*0^C6>^H+[6_EGJV(_
MXVF]J(=Y:?0%30,EMD\O<?:)AI+*7U[9)F3OYHJ=]%U5M@TN"(K^GPAP9G'/
MJ\10KK"A""Y9DH+W=-3]MWA*?\<$,$.#-;:22S4I]GZC::A*L2BK'$*9ZK!M
M3B9 S,S^<I$'T$,TJJ(7,5)N],4?/4T0/,P_ABL9\LI3%VJ.76^LB4_'4*JL
MA:9>01Q0Q4@EQ5-QT@']$YHYP-2('HSC"-9%F%_QSZ0FY"/ * 3+WAL0#0\]
MS02'%OY@L90<T=6RJ@QUH:8=[['WH_*I0''P1R:6J*DL]F_=XR>^E@3X 7"
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M/J'O^1N-(_$+5*(0:)2.;X2'8%3375NZQ98,5956Y'"Y'F@8@@$>XCC %4S
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M # IEARDH46S%E9VBJ)<2T0"PE+%K$HO/'\=)GA<9*@?@B3=-WUPH,UQ(3N
M&M"^6WM FZA*4EM6+^\D ,-D<LQM0S0B*@$(<+((LM0V[ %J!:9(CLI%,3(#
MX!5@ )( *A7<)'5T%9D,1N,=[MN[QNH9R57"=*0".T)R<J( QNK  _@!P 2
M03C T)4R7DD2(!A365<^I9",IP'SP]Z0 I9.00<80\CJ5M*PE1Q2KM7)\H#
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MV5:NE8*L36#0Q41K&Z43FL4(-((,-;MTVUONY6;RQBT=%9"E++ K:/\ E(5
M_DG!LI#!0.,NM(^+R4J0J)P&:2FFA1XALM$/\>>C 3J44X2.)(EP04S=1E!'
MAC<<"^TJUXB2J:(1"]);%';V)Y9EI27T* $ETRK$.0#2$M;;24H]TD6KO"^C
M3Z0LOO+T6ZFD'ATK@;M,DF(9</6=D.-"X"P4<#OPSAPI"A=&!2,G03UHGLAD
M;\GIUQZ:>$U+8<DB>0UTF&0G(-6*&DRQ"3N0K"88RFK(4=5J4Q,M6*A!<T1J
MP*:@%D29Q&K1;D>Q%33OL8VBA([ ,)2G;LC--NE0?%.VI=06V+SU%#[IE<Z]
M ?3U"KN5/%1.+&3Z*_"&*@DN9=A BJ.T]WAC4!:2,5>58L,V/0EM-8L^*O5;
MBBY2?-0NSI;4=APRA6H.HO&8B!"%6?M!V+L\025-883UX6GZ,U&*I_X68 +(
M*2&H!D-W;.RQ;PA,28\/*5<()D&L0XT,NIIU)1AU!2;*#[338S-!T&J-ZC A
MHPRE_CC=O<_\&"@V6!6>*%E(BK*O1D2)033DHN94?58)J#S)!22QBS ]$.(
M*B $<H)P*7;B,Q3@8T8/2AGD[XH!(I)I&*E'.6JI4:IJ(  4.1Q)AQ)1 E !
M52X \/47<@-D2,40715:M! U2 &*51AH9UO_ )00  VS88"%"@)902V(+'P#
M$$C$\--)+%> S$B)D2BI U'%:<)]$M!-W2&8R64*[):\$!"E3DZ1<!3Q2N)!
MX1T/&TL;)7+*:U&3 @[EF""X@  '!\FO@@<!,%10\$S\BHE11 6J)>+S!5?"
MS[%,IH__ '$B@ .Q4+"8;X;+=9?GN4[E\(IY.U@*5>]6T;@2>2^/$;BRHKI4
M"-II5.(%;"-]+#G"A+; L*I&HA*\T,T2-H*(3)Q*7VPL6&"ECT(1!3BEN1S:
M3N(!9("@8E@A"@U)?1Y38MRSJ06)Y19K:S -[N+$YRBZM&!L(6%H4%  <&I
M0$J,$K(M%10@+ R,)$(#00K2(4&Q99=Q*;L4M8H5WF"K#3S88K1L$)MR50TY
M2[7*2FG!K8(&8#=1$:^/,R185<*-G[U'.G T=TFE4N_5%6P-#1 0M3D21.LP
M01A(9<O!WZ'(5+$S)+ED HA8P"Q% 7X193UANW@R% A).)_#&[>Y_P"VQNWN
#5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>business2a.jpg
<TEXT>
begin 644 business2a.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $2 6@# 2(  A$! Q$!_\0
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M?'WB+0[3X8_#N2VT[4)[6)IM!!=E21E!8AP,X'I7/1_MGWC9S\,/AN/^Y?\
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MQ^UY.?\ FF7PZ_\ ! /_ (NOEJ/5GJ['J?J<4?5Z7\HOJ=#^1'TVO[7%P?\
MFF/PZ_\ ! /_ (NE_P"&N)^_PQ^'?_@@'_Q=?-L>HKC/F&K<=XDBYWYH]A2_
ME#ZG0_D1]$C]K:8_\TQ^'?\ X(1_\74B_M92,0/^%9_#O_P0#_XNOGA9 R@@
MU-&PQR:/84OY0^IT/Y$?0G_#5TO;X9_#O_P0#_XND_X:NG_Z)E\.S_W !_\
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MT9'_ -$V^'__ ((5_P#BJ\76/@<U+M(Z5'L8=A_5:'\J/95_:)0_\TV^'_\
MX(5_^*I?^&B(_P#HFW@#_P $*_\ Q5>-#)]Z-IH]C#L'U6A_*CV3_AHA/^B:
M^ ,?]@)?_BJ<?VBH?^B:^ ?_  1+_P#%5XSM/I3]F.]'L8=@^JT/Y4>RC]H>
M#O\ #;P"/^X$O_Q5 _:'@W8_X5OX!_\ !&O_ ,57C14'J:3A>XH]C#L+ZK0_
ME/:%_:(M3U^&W@+_ ,$:?_%5/'^T+IS=?AQX%'_<"3_XJO$=K8/3%,VFCV5/
ML'U6A_*?<_P'U?P3\4-&N)M3\"^$[>]2Y\I4M='A52NT'/(/.2>]%>9_LA,P
MFF7)Q]H7C_@(HKRZB2FTCYO$14:LHQV/SX_: OBOQP\>J&Y&N7@_\C/7!C4F
M'<UUW[0TNWXX?$#. /[=O/\ T>]>;M>)MR&_"OIH)\J/NZ<%R1]$;?\ :C#W
MIPU3IU_*L'[8O;I3/[0'3-5RLT]F=3#J09>OYU(VH;<8.<UR?]H!L#H*!J?;
M!/XT<K#D.K_M#Y@<XQ4BZBK=#^=<D-17<5/!I7OQ_"YHLP]F=<-2PW;\*=_:
M0[UQ7]J>7ZY]2:<NLMVS^!HY6+V=]CM!J ()I1J"'TKD4U9SD 2,>N$4L<?A
M3/[:(Q@;O7;19D>S.R-\BTG]H)7%OJSG) )]LTS^UGX)5@#]T^H]?I3Y67[.
MVC.W^V(W-3_V@O\ ?KA%U1FQN8@DXQFI&OF1@KEHF;HLBE2?S%3:SLQ<JV.X
M75EX!?OS4\>K8Y5N*X6*_P A?FZ_C4C:DR[?F;;WV_SHE%$.%MST.+664+\W
M6K4>MMCEA7FL>I2QG(?(/\1S5J'7I,D'K[<TN7E#D/2H]8+X&<U;CU,]Z\VA
MU\YQY@##[W!PH[$GM^-7H]<?@[B>,_*"3^E3YB<;'H(O/,;KC-2M..A.:X>'
M59'VOYA/TK1@U7<PR^#[T[$69U:7&T"I?MQ' KGK?4DEXWGV!XJTMTH(^;_&
M@1N+>G R.:E^W>U8JW*LQ&<>E.6^0\$LK9QAE*_EGK2N*^MC8^V9IPG)ZYK&
M^W(IX)XZ\5+_ &DO9A[?Y% ]3:BN"%ZU+'>-CK6"NI*O>G_V@ 0P)QVHN)I'
M3PW1;J?SJS'*=W!%<O%J$DG13P<5:CO''4'\/YGTI/5&=F=/')4WVC<#MY-<
MW'?R*H.[C%3PZE_MU%GL%K'2*_RCL:7=[_I6$NJ#N]2QZHG3?1RL1L;O?]*=
M^-92Z@I(_>+^=6%N W\7ZUCU N<'J:/DJNK%OI]:DVCN>:=F!+YBA>M1&X0=
MS^5&U3QBG>0GI2LP/IC]D%@UQ,1_S\+_ .@BBG?LAJ%N9@HP/M"_^@BBO'K?
MQ&?)8K^/(_-K]H><M\=OB$HZ#7KT?^1WKS;:#FO0OVB#_P 7Y^(7/_,>O?\
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M49]3\1:5XUU'P_87%]*J6$=C')'&P/S;"3D*6)('8<5\W4X@RW#3E3J5;6_
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M\$P8Q'X7U$#_ *"A/_D-**^;Q'\61\/C5;$37F?(G[0#'_A>'C[//_$\O/\
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M?#M^(^G]I?\ LBT54_X)@L6\+ZCDY_XFA_\ 1:T5\SB/XLCX+'?[S/U/DO\
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M/P!;=\ ? +=,Z?\ ^S-7NOP'_P"2;^W]IW/_ *$*_F//?XV(_P 3_,]S-O\
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M\OI3-9;'Z3_L_P#_ ";[X _[!_\ [.U>\_ 7GX<+[ZI<_P Q7@O[/Q_XQ\\
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M=JC^RNJYI$*3'+)MXJ190HJKY;+C-/(/:F5S=S]'_P#@F*V[PSJ!_P"HH?\
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MW'THU*Y7W.H7P3!NX\:>%_\ P*?_ .(J:/PG;;0?^$R\,/\ [EQ(?_9*XV9
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9^Q_A110!O^$[."*\!2"-#D?=0"BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>business3a.jpg
<TEXT>
begin 644 business3a.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X25D17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   "0     0
M )     !    1TE-4" R+C$P+C(X   R,#(R.C V.C,P(#$S.C$X.C Q  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   #      @$#  ,    8 0   P$#  $    &    !@$#  $    &
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MM=E\/FW:I)]!7F8NO5Q7H'POF$NJ7'S9P%_K4U%[I%9>XSQSQ03_ ,)7J_\
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MTR_FLKJ,)<0-MD4,& /U'%>@?"(8U2Z_X!_6G4^$=?6FV>5>)V/_  E>K_\
M7Y+_ .AFH=-UO4='6X&G7<ML;A0DC1'#$ YP#U'/I5GQ.G_%5:OQ_P ODO\
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M498YX"<5G@&JH.?*U-W:8\.Y\K51W:8;32;6I^:!GUK4W&X/<4X,13LDT_%
M"+*5%/$@/6F8IO.>E K(ZW3PK1:8W&%CF_4$?UID !6U7^[82)^84_\ LU-T
MT_Z#;L?X44?FX%%K&WG!><B1;<?4B/C]*\*HO>E_7<^;JKWY?UW'R)N$J@<?
M9$B_)6_PJ6=5EDE)Z-<PG\$P/ZTEM*AN;<.1B::?_OE _P#C5;[? ;7<9%4K
M9^?C/+.SX ^O J5%O9$)-O1%F&3;)-<'_G_:7_R%4-FFUK3=TANI)?SWX_\
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M'3N^B6W_ '^E_P#BJ/[1T[_H"6W_ '_E_P#BJR,B@8-%@LC6.HZ</^8);?\
M?^7_ .*H_M'3_P#H"6W_ '_E_P#BJR^*:<46"QLQ:O902K+%HUNKKR")I?\
MXJJU[?6MTO[K38+5]VXM&[G/M@D@5G&D)Q2Y5>XN17N39H(XJ/=3@]4587 Q
M3-OI3\YI<"@9"01VJ_!?V,4")+I$$KJ,&1II 6_ -BJI3-,,6: :N:$FJV4A
M7=HUL=HVKB:487L/O4O]J:>/^8';?]_Y?_BJS#%BDV8ZU*BEHB5!+1&J-8T[
MOHEM_P!_Y?\ XJG#5=,/71+;_O\ 2_\ Q59(C4U8L-.^WW\5KYJQ"0G]XW1<
M G^E.R"R1?\ [2T_MHEM_P!_Y?\ XJE&J:>.NB6W_?\ E_\ BJ@G\/WMO%?3
M<>592".0O\K$G'1?Q%9@(S0D@23V-O\ M+3O^@);?]_Y?_BJ<FJV43!XM'MT
M<=")I?\ XJL8 $4_8,4G%/1B<4]&7;B_MKB-E73K:!R1B2-GR/P)Q^E5,TPH
M#3L8Z4))*R",5%61*N#7IGP?Q_:EWC_8_K7ENX]J]/\ @X2=4O,_[']:FI\)
MG7^!GFWB;_D:=6_Z_)?_ $(UEUJ>)C_Q5.K?]?DO_H9K*S5K8T6PM+29HS0,
M6ES244QW'@TNZH\TX=*!W)0:,^]19QQ2[L4 34N:B!IX/% #L4A% -+F@!-M
M%.HI -R:<&-)28H E#$T[-04H<B@":C;GM35<4\$4"(S'4EO/-9W"3P/MD3H
M2 ?8\'@C%* #2E<T 3-K-^\=TCW#$739FX&7Z=_3@<#C@52VJU2&,5&5Q[4
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M6B 'Y@ & !X $@ 1  UA8W-P35-&5
M    ]M8  0    #3+6QC;7,
M                          UD97-C   !(    $!C<')T   !8    #9W
M='!T   !F    !1C:&%D   !K    "QR6%E:   !V    !1B6%E:   ![
M !1G6%E:   "     !1R5%)#   "%    "!G5%)#   "%    "!B5%)#   "
M%    "!C:')M   "-    "1D;6YD   "6    "1D;61D   "?    "1M;'5C
M          $    ,96Y54P   "0    < $< 20!- %  ( !B '4 :0!L '0
M+0!I &X ( !S %( 1P!";6QU8P         !    #&5N55,    :    ' !0
M '4 8@!L &D 8P @ $0 ;P!M &$ :0!N  !865H@        ]M8  0    #3
M+7-F,S(       $,0@  !=[___,E   'DP  _9#___NA___]H@   ]P  ,!N
M6%E:(        &^@   X]0   Y!865H@        ))\   ^$  "VQ%A96B
M      !BEP  MX<  !C9<&%R80       P    )F9@  \J<   U9   3T
M"EMC:')M       #     */7  !4?   3,T  )F:   F9P  #UQM;'5C
M      $    ,96Y54P    @    < $< 20!- %!M;'5C          $    ,
M96Y54P    @    < ', 4@!' $+_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" $0 6H# 1$  A$! Q$!_\0
M'@   00# 0$!             P$"! < !08("@G_Q  < 0 " @,! 0
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M*M81%F3TH><G8S&T2J<IMHP]H5VUCXU;WY7L/4\U] W*\'\E_HGL],Y&8
MX:0&%;0'%S&1!,K%&(6"!IBM6@8SE&P!I2/C:Z.F/B3D6Y+99"@:VR3E6E,D
M]^QFN-*X\PF.1EQF0$'<$RV_:"GFMX>Z-)RGT<<EY_\ *?WOLM(W9D2R W#(
M;!,)4&Q*M",-K'L82,=@+ QQBR+&QQE XJ!B41DQ&4J\,AL5ULG+(D9&1,R\
M]]MJD/87'F*E,8Q&T*P%ML*-B*:X]X:GG/I:Y3AOE7[KURH+<R$[0G S(QGA
M@"!H) )Q9 @TE@-D51R+B(**P&*)4;74W7HVT:*KP5K"#'NRC6YTVZUP)"-2
MXDHEJ B(8)74@&5R,GNK3\O]*7*^>?+'W/KM.VY;&& "'"7Q&@"P.(&]K54=
M[ 9  X$#(K1495&$8+@H*Q(B/52K#*L5BUHSMAUE#QF2\W(DM8L6R%&V,6VT
M#0.9*5N!T)(&]V:#E/I Y7SGY8.Y]=I^W+*TRP($6'UL-L]3IM+N=JA8A4UL
MDD1"""$0(Y8PKQ8PI$0TI%7*@6QL!M:83U.KT7/WMJ)RVQ4LVDLDK7/LM6R)
M%N5(LNF*I5L.!+!*SW'IN4^COE?.OE;[GURF+<L4,5UDR,6<>RS?+O+;%T7.
MTOVO9ZOJ.NU.PVK(D ,2$"/:1%B,"/8DRHC"& -$*$FRQL/:W'>>Q]/I.]U^
M!3FYW_>:[4UYLMIE<:O-LFY>7J++=U;E<CN>A+;F/9WN8A[HU'*?29RGG7RZ
M]SZY3=N7TM-78QB]$E%3Y6PX@S+5\K\DMKC.(IOI]_M]]TU4=YZ,)X20+-%!
MSA%)R@GNC-$$MU\1'!D20!Q$ITN+CO.=-I]#;?-<]3^^WULZ/35AM=GU>)A<
MCD9/7X&@JS:[^X=;J_+/H_KLO:[A^3GN6Q^2>[='RGTC\GYU\M/<^Q5#;E[Z
M*.\KQ.ABBEK\WJ%?O_*/(K(Y'BZCZCK-MOMY6O?>D9$G*CBM",S1H"!S<V#E
MY0L9K-2&D+]82,BQ%HN?A/,-#I=%;>BY^JMWO[8Y_G:LZ;HNOP=?RF?O>RU.
MEKC;[#O,#"H;T/U/4;CH.(LRSS9)F/<^GY'Z0>3\[^4#O/9*@MR\:'#F*CB)
M#VKY/X_:'*<;1/2]=LNAZ6HN\]"(QA0H*#AI .8P"J(,H*#"R&$4!%=W^?>7
MZ/0<Q=VFYBEMGN[ST/.TMUO:V)@:_C,K.[;%JJ[:9_?XF'YL]']9B;;;/&PL
M*'N;3\M])?)^=_*-WOLM06YC6'E!!I!9EBVMY#XU:'*\C370=,[I.GIWT/TE
M(%1'RR X7&,>U]*.F'$H"@<) JD,:+A\V\NC\SP-TZ/24SE[*YM)H*>ZKK>Y
MP\#F[\WJ+6KG/V5I8N!Y6]4]G%N.D#"0BD!'N+3<Q])W)^>_*YWOL50VYBM&
M"H2T<%BVQXUXW:/+<C5V3G=3M-IYP]1]9B9NP)&.![5KKVF-3U_/\I7??^D-
MH1S" @& @THHGE<M2XN \UW/G/D%A:_%KK)R^TU6MY79[78X^O%LML^Q.%SM
M]9&NYWS;[/\ 0//;KK#VULDCEOM+2\I](')^=?*QWOKM0VY:M* @(*L-<7AO
MAUU\5Y]PI;M[<FFO6/7M5MMS.P\*7AZW7Y^3M-9A=AS?+^8?>?H"17$@E *#
M@(0A* -HM7B/-[)\G\:GK.VP]; OF.]\^M>;V&UVDKJ,S,CT5\QZI[%;VWVG
M$Y.99E6%Y(SNA]=ZGG?HVY/SGY9^]]<J.W+QI>!A'E8F:\_G7YWMWB>*TN5F
MU!Z-Z-0?N/N :U&TK-R()8UD<#P=;>@=DZO)6)4% @3P4&%( L'B/._0ODGA
M]6[3==I5KZAZWO=#L=AT2W<=M=GTV-1IK'&]O>[/,+N.JX^VWL8IHU\OV[J>
M8^COD_//EL[WU^I+<LC201$K4AC/Z?\ G;YVK/K.UX3T#N=3DY6HVNS&6#E4
MB_!Q0E@\%PM:^A=HZN_"5!X. PD\)94%3M.+\\L'A?///OI_K6JSMW'S\\=L
M(+(2N:L2Y;8X&!NM?K.;W_3A)8.VQ?;.FY?Z+>3\_P#EF[WUVI;<LC+.$)6K
MP9#V!P?GG =UZ"LJUVC3>QA &#("3%@\=R-==)OHV;L DC! 0,((!R9B1W',
M<=7NUW MGFJ7O+2-,<!@P&!M,'#W.IYG3=!V&$LLF.'M;3\O]%/)^?\ RM=[
M[!4CY5[4ZK2*;A3167FK?M>!\[XWTCO4A\ ;,T&@.90"1)M;KNSY[G:=['M=
M>SL".\B'CA@-0[":>UY7D.2WW2;J[(+*!F0A))4'RHF@6.G8<7P7 ];W6AS]
M@X0X>PM3S/T(\IP7RG]Y[)7]EWJ_7\]Q[76%1B^9=GO(E:$P\-=AG$)0@I.
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M2$W*!WDCN$8-8W":@*H0[F1L0V(%4":@*H034(P2PE9#(^#&!CK\@@9" _\
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MZ"%-_P#[N5XDE7=E@[^\H]V,5%D?(RFRNN@5;(V+/P#2D<!D132C]/("?SG
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M]ZZ8_P!,C ST)0V&2!*R,C/^N!CJ1@E$",9+IC(U(:A5,%^T$K V(QKD:#7
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MW(Q[<A[<A[<1[<![<![<!!.&:L2>Z=LLJ?\ _\0 5A$  0(#! 0)! L-!@<
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M=>.KJ42=A1&BA%2*]@I7L%1WA,F(9"B3$,;-S_-/F(8"9,0RK\.)DHDY!ER
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M)@O<D8YHPV5&'-R3HH<+I H.A$L)!+17J6AAW0V@IU+B\*MZ@JA+!KKP&/\
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MR5U75=5U<*!]PM\DC\&PR64+#RU*J54*H]Q>*!0=TJ@5 @TIP(_NZE5*HKJ
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M%'&-HC_IH/U";%I8MF?G9GZTJR(]9FV_S4/_  %0\>#]F_I$?Z]0'4X0Q/S
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M&F&$&BZ8 S4R%3$QUC"<7 D O'$MLNE8WPA&2DI@5OB0&BT+B&24X8\1V*!
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M&2CH[1%H4=CE!WM4S[7.8$B!VPFK \+,8@A&XXQ<H!=#A2NP;BW%X8&SDZ'
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MJCQKG#@@#8*PK&3IF4S'XE0D%VXM7#V/,?@C4YSIJBY;(O&^S4L8G8LJVZP
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M&E7L2=0[@C'#IXM,@ 87 J'68%.'Y58QQOX:Z)K8L?A.&BV>$<31>%58QN"
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MP6%T2Y='0AQ<_;9;A>PC1'XQZ!\4V*BO,+(IJH@V0,<45VS8Q!*G(B @DJZ
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M6>$,J\3D&Q3+IJ&;E,BBKG04:N"JD,4+9,^;)3]1Q$O(XL>Q>OC#(MEFP.N
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MUD^:%8O]TDS]?6\](R#(Q".FHB9(ZZ*3E(!,&4<Z#@BJ2VGYZ9@IDB9I(/)
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MWA-(P@+$;.!Q30">!1;JB:L05K:C]]0W&E-\\Y ^WUD=5/B5;Z?X$-PH)/C
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MT[R7[RCD?>\ ;;6>1^91AJ*YKU8(IR0$R#VA@)L<<^P^KW.SHAZH<,5KJ1*
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MDR+IJ7) ;$(JI"0(I(,*80&*":#*2WG3+.L6HCA-B8O99UB7!.+ZQ1VB74,
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M, P!&DL0@ Y#!:%1%49Q !NQ-P1!R-@@&1O#B'! :"$&%%&2U0(B. DE@6#
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M9"=M=XTI.H6&!:YH;1YH>P]P0YNWZW]*4,(R" 9$BVF?-,#9W;^70[\E"]"
MV^'U%)JPEP:7X^PTVY$CI.31X\F]0D@N6[>SNDLTT5*3K^A[4$FU?;ZBL#H>
MU8[$L/J\9_R@3!T?VUT>?Y71Y_GY_5^J_=^Z4'7BYYI;A>N>NGY5@3_C4/*+
M^GS]FFB S?I/C5QYI"P%YZ7GMGEZTJ_K]7X._)1@\OKSQY-ZC7)S^TVT\TAE
MB.#YI Y+:.+<3Z=4I2D),_OX\N]7$RW?=OGB]&";ZV/[O7-X/B@3/K]*Y7V?
MGP;5SOL_/@VI!R9OUXZ]VF$3C6UYGBI'?G'9%?3U:S>GL5F]/8KZ7YXZ]N*0
MBD3??G^]N*14VDR_MR=VK^7NSKSR=VN?WY_GGBB;.O//\\\4L19D%\G3<CJN
M].%&LY9\:^:X/>F)MINU L:L;[-#T]*+ ;5&QB6.LM^U9PS#OSO_ +^5FW??
MN4-7Q&G']\%.4WG[I1LM'W6N;P?'_ L&*3)UG:OO;_@HS;6W\]J60R#'J%(0
MIR0^O\FB%_9TWZI6VCSZW.>\<U 8CIQB?NE<W@^*YO!\5+5]+6[4""GEWJ!,
M6G7/O4,! .,U)M\;Z1BWEWHT)Z7VGC[-3;W>8^M'M2%N,^OUCQ4C!-YW^LM)
M;@Q?7-W23=*4*(SN[\.W#4*VK[8SHG'OZ6)E[=>>&KF?'7GAHYSH5%CQC]U#
M+(#SGK&/?:I0SF^"^'<S,>:FS(MT:0C'^U@=#VI]Z5]VEHQ$T7W39TZ]/3F*
M^E_BOI?XHFA&>?Y0*P?^/-X/BN;P?%?2_P 5]+_%*N\8<?JEE7>C%YTZ0YOF
ME:%YUQB^(-J31UOG;6U,R.?3TU\@5/;WYYX\F]3V]^>>/)O4(LXTCGK2QG\=
M7C^UM$X^NVG<H(9'_)]=]+RU81;7[\^.:9S$3?O]OCFE'V=L\W]:0+Y<YYI&
M1Q]_M90+\=>>:L1'CKSRTWK&NF\\\J;VWWN>Q73Y_K2)+3&(UOF.9\TL6X_W
M?TQSQ01=+$/=;'WCF\->6T&>C]M2:>7YJ#3R_-1%_;9HCHZ])TH+IC<QZ[4D
MI&I1="&_6?MZ84&G6[?%1H1Z\_[V/4WD>K?MBN+R_P#)>)GG.>;=JQLM^V\F
M],6KT.=9Y\&U1R/ZUOL^E9W)MCS>@KGG_*4LOAIM8S%LYJ?\NO//@VI;^K3K
MSSX-J@,,2[</&][QZ4@&[.-<9>G$:Q4MZ ;3$3NETXJYDEA?6%WXM,<TP3=S
MJ3YW/-* 4=;Z1'ZVG?%*.S3]Z<OFDWO<Y=W,[RTI!$QC[/O0^(<R\\NW>*C(
M@'G%^F)KO,9YGZU'=;;0>EYFBQDO%F]V],S#;2Q4FO@^*"T\NZ_N@"Q2GZ,*
MXO+7EM!GH_;^11DI1@(E#/\ *!S=)'EYTO!';2A9%L<I,MP.OFG PPWU/[[T
MA9FW&?MMNE2-[;/29TJ0OZ'>;_\ -K/KOG2;15[3[&??77>D8M8A[?=MJ8R6
MGIY_3Z4YCY_?[GBE,>A_9];U]+?-?2WS7TO\TP/]^7V:V9KCU#7&N*3=&)>S
MR-Q^E0J,RB+))TN-^*E<ADD]CH\;\TE(BUH.K:^^D:Y,4L,@D;3IG7@IDB;@
M'K"3Z6I\%]?7-N*2W>I+>9,YR=[4P;Z6S9VZWIA"VO&VO#Q4&>!MOEQV]:B(
MU_WC@:EN-]><<:?\_0X?CRVC"]E^ZB8">(S'Z[^M)5,%TGI].]9Q;:#FXXV\
M6H,3E<G>,=*#4TG6#P-H[S0"H"2P(N;@@XO%)Q J"  C6 $]ZCU!AS$ZS07-
M$49O9.<V>K,V*(*B2#4D5OS?[F#GU>>>GGBOI7GGIYXKH\_RNCS_ "K;1$<4
MVB3/4Z4.\W\1XJ3#DD7>34Y\4/JSSB-:1I,YTQU?L%<?GK\^#:N/[?Y\&U?2
MWS7TM\U"L7_WIMY:D+F=)SCFT>:8EBP5(F;$+/K:K="02PI*[N%PO2J"%Q)[
M(AP/%8#5 79743?G4ZT>A,<!64=[* ^!,+I3$PKS%%9*I<L1&H.QS4:B!$1+
MY 0Z[U,H.ADQ!O?,3M33$53A>QCU;7FI-A>)=QGH;\5HKU=(2$W]6H#23G:=
MJ$;GY^AP_'EM#86R_=')Q"WGBM[F_BIM29SZC7?Q?:EX!*VQNZQ]L\44DX9T
ML3]UF3K*4B(VO+GUOOG6H"&O?2W>TR;:4.$&SF?]]M)J:8&,Z>OD+]C6@HPQ
M>2UJZ>U0C@'1DS]Q4EXWOG>N)W_E<+OU_GGBMP1UTO\ SS7(>>>.GGBN0^S&
MG3S22 )YZYG]49,C(ZXB=LSI12FON=GQIJT#;N]](_,_Z*G_ $:<4SZQN_NE
M-X;SKEM:\VN%.J@[UE?T]FCF1(PDO!'W/68TJ#DO[!_6: 3 /0(N3IO2D,\1
MMNNBZ7;T"VJ@P,F\>]',M\[WDO$:Y+Q14WT=+:^YYZT@TUY<$!5NQ8J]P #:
MX;3$R,T@% 60Q@>B'>BV+YF\ZAB76^^:D0D8P^CK$4^1G6>O'Y^AP_&/Z^2?
MX<5*F,H[V_O6C!3,LXRK$S.8UI$T4SRE.[?/:IDB6211(X4*Y0FB- P((2)F
MVN7K+QUJ6E!>HK.O'3-0F40Q+&'I8H E#5:R<W!FEM*6YN]<FQW*F=AARRP.
MFT3ZT%@.@5*);M(M/%M*2($)$7<;NU!4GW;?WP5R>ZN3W5S_ +<US_MS633U
MU8D/4^Y2#".-[_JD,O8_9-<WD^:)B6VOV:,$Y@G\))#K3TR;$P'3['%7MB4K
M-L/W_*?0)R,*2:1M!:D53*Q2Z/ZMF^]*FR$W#&T7L6JQ"RD5D"65^]:=XE;S
M*19UF;3VH$6$O#)SUIS:6%!+NNK&2U+"4Z%L*&,S)19E"A++-E;LL\31"B-B
MNXXSB>)IAWCN1 &)BYP5>0=<I?\ 44^#$%\<[N"7Q7%Y?FD!MHZOS2L:%G>>
MP?CRVC"]E^Z5-L-KF[N=N*5C$G>SL:2>:43%W^]#76<5&;;[<O\ "M;G7O\
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M039?>F2F_B7O7%Y:\MHPK8?W2,G*/-Z6;=]^Y^"Z&]"5RA'1)8UO^^UTN@!
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MCH\_RNCS_*92.;]](]*&0=_S]/0K%]U:ZO']KJ\?VNKQ_:ZO']J%7=CK.:+
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M7WTOK00 ,0P0NR"\ FB9<!-J$2(C)$(LV[Z:10999%N6&E]Q]=J7,RRW,KC
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MM05C!)/2?2.MMHFD%-$[\\=//%?3//'3SQ4_T:%(:F,M)$_??W*Y/'RH%8*
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M4@9O"1(VJ>C;3&-*YO!\?YLE6W0U?6A3(SDEQ[8IS&.;W(;]9;SDJ18QFXT
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M<.+KTNW](\T(&(H-7'E-/GL;@EUAR]2EYJ8#BRVO8C2VE$X(>(YB;3Z>O_?
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M!,AX(?*F+32LN59LOS;/MS4>R,>T(>EYK_O?NA$A+K._F+\<T @5I$[D(?\
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M8!E$@,(1%"02@#0&<BMAFD8A@.MA23#$ $"X$$BD #7BA$RLMH0L 1%BHH
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M 21#((,(*]Z(6!4UT@^)QU#FUJ (([3]IG,WXOHVPN0V\3VGWJ;3T/9IEA#
M1[2MS:E/86UXO@_7C%)VMS^MMZ34(MI'K%N=N[67=FQ]5^+??^8UP<A;S?\
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M]?6K>C=$[6B^VO.E/UK6B,9+B&I?$I58OAH$M&4 5?)(A1'P#M;=$1E4J2C
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MZVWOMFE,GQ34()DT=7KLS'+-+8I:Q2MN2TRK>ZX%0M["-%9XLBK9\3WYVYA
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M.OO//"FE*Y5ZKZJ(_P"5G;_FS2"#-9M?K_?6O^S_ "GT4"FVL^]3_BTM4Z"
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0)W(T4L90:UI)8MN(XK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>business4a.jpg
<TEXT>
begin 644 business4a.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $\ WT# 2(  A$! Q$!_\0
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI!WI: "BBB@
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MZ*\9&"C $$>F*556-555"JHP% P /2@!54+T 'TI:** "BBB@ HHHH ****
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M=W2,I$7E*?W"Q#*@G[U?2*V,@&3JFICY<_\ 'TQ[X]:?UCR/J/[)7_/S\/\
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MT3YL_P""A'_)MEW_ -AW1?\ TXP5](0_ZI/]T5\W_P#!0C_DVR[_ .P[HO\
MZ<8*^D(?]4G^Z* 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 45\V?M3?M$Z_\*]8T_1/#T4,%S-!]IEO+B(2#!8@*H/'8Y_"LKPO^W?X
M5T_P3#)XL=Y_&+2^1#H&AP-<WE[TVR+"OW5.0"20 <]JPC6A*HZ:W1X%'/,'
MB,PGED&_:05WIITOKY7/JBLKQ)XJT7P?ILFHZ]JUCHMA']^ZU"X2",?5F(%?
M%OQ8_:4^-UUIEIJ2:#:_"_P[>2&**&=UN]7D^4GY^/+A_ %O>O,O@+X-\.?$
MKXE7I\=Z3=^/=6>W:ZAU7Q#=RWJP%6^X4<E%!R-N .0:/;053V74)9W@X9DL
MJ;?M6K[:;7M?O;4^J-<_;R^&,,T]KX4.M_$?4(6V-;^$M+ENT!]YB%B ]]]>
MI?!_X@:U\2O#<VKZSX-O_!1-PT=M9:G/%)/)$ /WC"-F"Y.1MSGBO/[R2T\'
M^';RYLK&*WM[*W:06]K&(\A1G: !7D/P;_:S\6ZI\0=*T6_M+>]TG4;H0"VM
MX<20;B?F5ARV#USVS1.M"G)1ENRL=G6$R[$4<+7;YJKLK+SMK\]#[8HHHK<]
MT**** /DW]J__DY'X"?[^K?^B%K2\8^"M#^(&@S:+XBTV'5=+F*L]O-D?,#D
M,"""I![@@UF_M7_\G(_ 3_?U;_T0M=97GU?C9]CE_P#NL?5F1X'\$Z%\/=#B
MT7PYIL.E:7"'9;>')^8@DL6))8D]R2:V&ZT^'[Q_W6_D:8W6LCNZFEX)L_[1
M^(6D1D9CM8Y;IO9@ J?S:O<Z\G^#EG]H\0:_?X^6%(K,?7!<_P#H0KUBNV@O
M=OW/F<UGS5U#^5+\=?U/'OBY\3?B?X+UXP^$OA;#XOT1+832ZI-KT%B(VYW*
M5<9P  =W3FO/OV?_ -KSQ3\;/B1+X;E^&W]EZ;:>8M[K5IJ@O+:!U4E5#K&$
M8DX'#=ZYO]N#POK?B#6M+&I?%70?!O@IHTQHFK2R1B\F!)8N(_F=<8XZ#GUK
MN_V<=%^(=G'HLL6O^!;_ .' A81P^%K(QAOE^0JW3KUSS7G^TJRQ/(F[+_#_
M ,.EYGU\<)E]/(UB*E*FZDD[.]6-GZW<93_NI)+N]CZ+HHHKV#\W"BBB@ HH
MHH *Y7QAXAU_PW=075CH/]N:1L_TE;64"[C.?O(C8#C';.:ZJO$OCSX;M_$_
MB/1K9]7T=+C[._EZ7K5S+!&<M_KHRC#+CI@^@K*HW&-T>5F=:I0PSG2^+2VJ
M77S3^ZSN<[HDVO\ CKXH2:CHVIR/!'?),[RZH\+6ML"-T$EBR9S@,-Q/.<YK
MZ,DC6:-D<;D8%2/4&O.;?PCX2L=%T*?7]1L;K5-)C0KK#7"Q2DKS]_.2O;!)
MR*[K1=<L/$6FPZAIEU'>V4N?+GB.5;!(.#]0:FE'EO=ZLY,JHRP_/&K).<_>
MW^_3I:]KWE?OLCS#6OV4OAMX@^&>A>!+S193H.ARM-IODW<L4]J[%BS)*C!A
MG>P//(-5?%?['?PE\9:7X:T[4/"D:67AZV^PV,5I<2P#[-D,8)"C R1E@&*M
MG)Y[FO:**W/H"*UM8K&UAM[>-8H(4$<<:C 50, #V KYL_85_P"1<^+'_91=
M:_\ 0TKZ8KYG_85_Y%SXL?\ 91=:_P#0TH ^F**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O-_C'I_@!K*WO
MO&FFPZI,F8[.W*L\\C'^&-5.23Q[>M=/XZ\9V?@3P[/JEV#*P(C@MT^_/*W"
MHON3^0R:\;TC1[W4-4D\1>(I!=:]<#Y5ZQV<?:.,=L=SWI-*6C,JE*G6CR58
MJ2[-71Y?\2/A_;7W@#Q+JMGX<T_PA8:?IUUJ%M9Q!IKAWCA9E,C%MJYVC( S
M[TG[-NBZ?:_!_P )ZQ;V<=OJ&JZ7#<7DL>?WKL"22"?4UZ+\7#_Q:3QU_P!@
M"_\ _2>2N'_9T_Y('\/O^P+;_P#H-<5:$4TTN_Z'NY+@\-1525.E%.\=DETD
M:7A_X.^"O"OBN[\3:1X;LK#7;LN9KV)3N)8Y8@$X4D]=H&:[;_EG_P  _P#9
MJBJ7_EG_ , _]FK ^G,W6F9=)N@G^LD3RD_WF^5?U(KZ%T.Q72]&L;11M6&%
M$Q] *\(M+/\ M3Q!H5AU6>^0M_NIF3_V05]"UTX=:MGAYM/W:=/U?Z?YF=XC
MO;_3?#^HW6E:?_:NIPV\DEM8F41?:) I*Q[SPNXX&3TS7RA\1/VROBC\)[.W
MN?%?P6M-*6Y<1P0_\)5;RS3,3CY(D0NW/H*^JO%L.IW/A?5XM%O(M/U=[25;
M.[G7='#,5.QV'< X)^E?G_\ #'P7XCM_BK?7&G?%SX=>-/B+<2,OGZLLEW=1
M%>"D.[Y5Q_L5S8VI5BXJFVK^GY/5_@>WPSA,%7IUJN-IPFH:V?M+_P#@4'RQ
MCW;4GV1]Q?!_QIK/Q"^'^F:_KWAN;PGJ-XK.VESR%WB7.%))53R.<$"NTKFO
MAW;^*;7PI:Q^,[RQOO$ +>?/IL1CA89^7"GVKI:]&G?D5]SXS%\GUBI[-)1N
M[6;:M?HWJUZZA1116AR!1110 4444 %%%% !1110 4444 %%%% !24M)0 5Y
MYXF^ ?P_\3W[WU]X>M8KV0_/<6S- S?780#7HE?+OQJ;P]<?&2]C\967BC6-
M(CT^'['!HT,QB@D.=V2A&21SUXZ5SUI1C&\DGZG@9U5H4</&5>E&HFTO>V6^
MK=I6VZ(]V\&?"WPCX"WOX?T*SL)7^]/&NZ0_\#;)_6NKKS;X!KX83P;<#PGI
M^KZ;IOVQ]\.M)(LQDVKDCS"3MQCVZUZ36E.W*FE]QWY?[/ZM!THQBFMH_#\M
M%^2%HHHK0] ^;/\ @H1_R;9=_P#8=T7_ -.,%?2$/^J3_=%?-_\ P4(_Y-LN
M_P#L.Z+_ .G&"OI"'_5)_NB@!]%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5S?Q!^(WAKX5^%[KQ#XKUBUT32+8?/<73X!/95'5F/91DFOF+X[?
MM7>+?!?Q.O=#T2.VM+'3)%219X!(UR=H8DD]!S@8Q]:I>"?AK>?%36-/^)GQ
M/U)/%>M2#[1HVDB(QZ9HT9^[Y4))W2XQF1LGTK"G6A4DX1W1X& SS!YEBJV$
MH-\]+>ZTWL[?,RO'5YXM_;$U/3KBUT+_ (5Y\/[.3?!J^JV^=:U-#VCB)Q!$
MV <OECD' KT[X?\ PE\*_#&.1M!TJ*"^F ^T:E* ]U.<8^:0C/X# ]J[#.:2
MM>6*?-;4]6.%H0K/$1@E-Z-V5WZO<R_$OA?3/&&EOIVK6B7=JQW;6X*MV(/8
MU5\(>!=$\"V<EOHMBMJLAS))G<\F.FYCZ5O44<L>;FMJ-X6@ZRQ#@N=*W-97
MMVON(Z+(C(ZAD8896&01Z5J?"OX)^#O"-T=?TS1XX=3D9PLK,6$0)(.P'[N1
M697IGA#_ ) <7^^__H1H<8R:;6P5<-0K3A4JP4I1U3:3:].QM44451TA1110
M!\F_M7_\G(_ 3_?U;_T0M=97)_M7_P#)R/P$_P!_5O\ T0M=97GU?C9]CE_^
MZQ]620_>/^ZW\C3&Z^U/A^\?]UOY&J6K7/V/3;J<#)2,D#U..E9=#OBN:5D>
MI_!BS\KP>;MA\][<RSY]5W%4_P#'0*[RLCPCI?\ 8?A?2K#_ )][:.,_4*,U
MKUZ5-<L4CXG%5/:UYS6S;/EC]J'X-W7B?5?&6N^5H]_/J'AN#3M'BU*XCBEB
MN4N=[B,R$*H9.K>V*[7]DWP3>>$?"&MW%^=+L[G5M1-Z=%T6Y6>UTW**OEJR
M\;CMW''&37E?[2GAVPN_C\FH^)/AAXA^(^A'1(H(/[.#^59S"1V8@ @,6!&?
M3'O7KW[+]GX=LO"NJKX=^'^J?#VW-T#)9:JA5YFV_?&2>.U>53C%XINUM^_W
M[?J?>XZI5CD$*;E=/E>T;+9<OQMZ65_<3O?6SU]HHHHKV#\X"BBB@ HHHH *
MQ/%7@G0?'%A]CU[2;75+;J%N(PQ7Z'J/P-;=<!\>);J'X2^(C9S7<%QY  :Q
M1FFQO7<%"\Y(R/QJ)V46VKG'C)0AAJDZD>9)-V[V5[:F;I_[-OPTL;Q9T\-V
MT[HVZ-+B5Y43Z*S$5Z9;6L-G!'!;Q1P0QC:D<:A54>@ Z5\K_#2'X5KXP\/G
M3O#7C6WUKSX_*GOX;GR5E]7);;C/7C%?5E8T7&2;BDO0\C)98>I3E.A2A#7[
M#O\ ?[L?U%HHHKI/HPKYG_85_P"1<^+'_91=:_\ 0TKZ8KYG_85_Y%SXL?\
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MRW;OW_X;7R_S/O<1.,<CC'VB=U&WP;WU22]]./5RNG\XGM5%%%>J?!!1110
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M888E")&@PJJ!@ #L *^:_P!A7_D7/BQ_V476O_0TH ^F**** "BBB@ HHHH
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MDLE9^\^;WFNEH-/SO8^X:***]4^!"BBB@ HHHH **** "BBB@ HHHH ****
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M0!+\=/\ DB7Q!_[%[4/_ $FDKYJ_9L_Y-\^'/_8#MO\ T&OI7XZ?\D2^(/\
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MW))Y8D_C6S7M*]M3\RJ<BDU3=UTOH_U_,****9 4444 %%%% !1110 4444
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M;=4M='^%VOW5]90:C9+"!/:W!(62,NH8<<YP21CN!7<UXG\:M9\4:YX_\/\
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MOESX#LZ_LS^ 5B_UTFA6L48]690 *XL1NOG^A]-DZYHU%YQ_]N/JKX1V)LO
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M0@B.0CYO++=".F0*]B55C554!548  X H =1110!P_QT_P"2)?$'_L7M0_\
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M3>&/$5Q?^-'6!K*X6_,ESJETS*/(DB)Y#DE2I'R=>-M1G6?CJMFEP?@Q9DL
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MJN9K32TCU)'1Y(H_,<.P'R#;SGO76?\ "5^/O^A$M_\ P<1?_$T >@45Y_\
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M7+N56]F498\DX'4U]'4 %86I>!/#NLZS:ZM?:)8W>I6H<0W,T"LZ[@ W)'/
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M99@.FYP,M^)K0KQW]CV;6KC]E_X:2>(#,=5;1+<R&XSYA7;\A;/.=FWK7L5
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M:W,B^C2 ;B/QK<HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\'=0N+3Q)J-]H^C7,>K18N;RV9PP8%/DC(0G><XP>#CG>TG]N6Z\5>%_ O\
MPCOP[O=4\;>)[^^L?^$=:_CC6T^QL5N9'G*X*C'&!R30!]6T5\B^'_VLM=^-
M.D^##X?TZ7P;J-_XJU'3+ZSN&2XE%OI\+2S9.,#<RA/;/!KG?V3OVZKCXC>
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MY'FTS2+/3YY%"R/:PA"P]..V:UKA'D@D2-_*D92%DQG:<<'%245L>R?*FJ_
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M>W<]UIFIWMZ86TD3,6,<T>"9@C$X*$$CK6;I/P%\2_!R.QOO",5GXN-QH_\
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M*-IR!Q7H^:0R(IP64'ZT +2TE+0 4444 %%%% !1110 4444 %%%% !1110
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M%\@?.3NX'/%-T+X,^"O#.EV.G:;X>M;:ULKY-2@'S,XNE!"S,[$L[@$C+$T
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M@RDECG!YS0!\_:U\>M5A\7:/K?B"TB&I^#8_$5MJEMI4C"UO)+:"&16BW$D
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M[%FVJ !DGDG ZFK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 )12T4
M)12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4
M)2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "
M?Q4M)_%2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>business5a.jpg
<TEXT>
begin 644 business5a.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +2 [X# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \;_
M &J?A/KGQC^&J:%H#VZ7PO(Y\W3;5VKG//KS6S^SI\/=5^%OPFTCPYK30OJ%
MKO\ ,-NV4Y8D8->ET5T>WG[+V/2]S'V4?:>UZ[!1117.;!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1124 +1110 4444 %%%% !1110 4444 %%%-P<4 .H
MIN=O%(S;>2<4"'T5F7FN6=BK&:Y08[9K#NOB1I=NIV%IB/[M1SQ74Z(8>K4^
M&+.OHK@F^)@DYCLI".W-0_\ "S9?^?-ORJ?:1.K^S\5_(>AT5Y]'\3CD;K.0
M^PJY#\3+3.)H)(O3FG[2/<3P&)BKN!VM%8%AXPTW4&PEP$;^ZQK:BF6505<,
M#W!JE)2V.*=.=/2<6B6BF]*,YJC,=131UZTZ@84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT.::S4X\UEZCUKU7X1_'G1/BO&\,&;;4(_O0-P2/:N:&)I5)<B>I[.*X?S'
MT/K-:E:'D[_>>G[J6F8VT^NIZ.QX,=_(*,444%D5Q"EQ&4D *UBZ;>2>%-81
M59OLLS88-T%;K?>JGJE@-0M60CYQR#1UN5&2LZ<]I'>Q3>9&C*0RL,@U,*XK
MP+KC/YFF7!/G0_=)[BNT%=<9*2T/G*U)T9N#Z#J***HP"BBB@ HHHH ****
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M8Y\93]K051;Q.[HI,TM=9\^%%%% !1110 4444 %%%% !1110 4444 %%%%
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MX^(XBRO&35:I":;WV/O_ /B%^<4VH4ZM-KIJ]7VV/TJ'[>7P0:15'C&$$_\
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MYC6_@6SUJ806EA#;W" F.X2,*8CC[V17"_#OX9Z;H=QJE]J CUK5IKAA+=7
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MOMGQPF91A5<K]3@5ZS\8(UD_9A8,-V%@Q^#"O(?V9U"_&)2!C=R??B@#[?\
MXOPIU)_%^%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M4->U6/0]$O]1E
M($=K \QS_LJ3_2@#\XOCI,B?%;QS"WWYKX;??YA7TUXZW?\ #(.LEN";)?\
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M1X1I?PCOY==6&.&>XFLKER<QD#)<G\:^J/B]X1N-8^"&J:%8#R7>S",,9(&
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M86/147C_ 'J]9_94/_%&W7_7BW\JZHQ4$?/XG$/$5>;H?*K$G4/#O_87D_\
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M0!]A_P 1IU-_B-.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1^QI:17XF'^UUC_A:^M_]@=/_0Z]5_93_P"1+N_^O%OY5YW^V%I\<7Q4D?\
MY^=( ;\&KTK]DN'S/#$\>,J;4J?SQ6QYA\FL?^)AX>_["\G_ *&:^TOC5_R;
M#K'_ %Y?UKXZUO3UL/%RVXZ6VO[$]@237W'XXT>/6OV?]4M)P=K:<S?ES0!\
M=?"K_DKGAC_KUB_]!%>N_M2_\ED\+_\ 8-G_ )5Y5\*80OQ.\*'J[1[3_P !
MX%>V?M4:3&?B!X+OF^5C;31-^- 'R[X>_P"//1?^ONY_G7T'^Q+_ ,A+4_\
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MGC.,-V_6OSZU+]DSQ;X;U.70[VP-S%&Q6*Y!P&&>#7ZR;/>LK7O#]MK<#13
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAXA:)Q^\U6.H]=#];M[?W31O;^Z:_)/_ (;2^/\ _P!!VU_\!EH_X;2^/_\
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M0EAJCE2J+KNF?HY^S?\ #T?#SX8:;9NNVYG7SI,]?F&<5ZI45O&BP1H@PBC
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M=']AXK>3BOFB'C*.RU/UZ9MHY95^IJG?:Q8::A>]O;>!!WED _K7X_7?Q/\
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M_:^^.W_/Y'_W[/\ A2-^V!\=]O%W&3_US_\ K5^E'_"M_"__ $ K+_OR*/\
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MS3NSGI)U*SK6LNAU*YQS3J**\,] **** "BBB@ HHHH **** "BBB@ HHHH
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M^_8I#\#? W'_ !3UI_W[%=]MI-HH&<YIOP\\-Z2H6UT6SB Z8B%:8T#3<?\
M(/M_^_8K0V^]+M]Z++L!0CT/3XVW)8P*WJ(Q5Q(4CZ(J_08I^/>EI@-(..#B
MC:?6G44 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 57DA69'CE =&&"I'&#5BF&@/)GP]^TW
M^Q0FL:E/KOA&R!DF)>2!>,,>I%?,$WACXJ?"]FTZRU#6M,1N?*5G*CZ5^O%U
M>0:?"9KJ>*VB'&^9PBC\37GOCCXJ?#/P];O=>(-9TAA&.3YB2-^0->WA\TQ,
M$J3BIQ[-7//J86'-S1ERGYIV7QV^.'@N$QVOB.XPW5KR(L?UJY8?MA?'W2)C
M-)KMO<QCGRI+8'-?4GB_]L+]G!+@02P0:J__ $SM#Q7+7G[6'[-5Y"87T,(I
M_NVQ!KU88A5%>>!3^\Q5*=[*J>,?\/ ?C=Z:>?\ M@M'_#P+XX;<F+3QZ8MU
M-=[?_M _LUMD6>B3RR-_TR.*R/\ A;'P,U!]QTZ:W3^Z(CQ7.\10O_N/YGJT
M\OQ$H\TJT8HYB3_@H)\;X\973?\ OPM0?\/#?C;NPL=@Q]K=:[RW^(_[/$?,
MMM-(?^N1K1B^+?[.L?":9(?^V)J/:0EI]1:^\[%A:4-ZRD>:M_P4 ^.TX"I;
MV0!_B6W%0/\ MM?'>\;YWMUS_=B KUJ/XT?L]J57[!,@)Q\L1_.NLTOQC^SU
MJWDB*]B1I3@"1,8-83G2BKO!O\3>+<=(3BODF?.%Y^UA\<-4C\B+5HH"W5FB
MK#G^(?QB\3-_IOB:7GJ(%(K[BT_PO\&;BX06]YITDIZ+)*H_K7?:3X%\$J@-
MC9:7*.S1LK?RKF>,P\%>.$2];FO[^2_B_<DC\X%A^)[$,-;U-AZ@M2R6OQ-D
M4JVNZLF>."U?IX/"NE1XVZ9;B/U$=*?"^CL.=.MSZ?(*R_M2/_0/#[A*GB?^
M?\C\N;?X&^*O$S%[B^UR]D<Y*-*^VM*/]C[Q+J"C?IUVZ>DC$Y^M?I];:7:6
M:@06L40_V5%6L^G'X5G+-L1M3M%>27^0UA[ZU)N3\S\XO#?[".ODB0V$%HIY
M)903780_L4S6TBF5HXP.NV*ONSZFD9!(-K $'VKFEF6.>U:2^9TK#X5JU2C&
M1\V>!?V3/AY#;JFL&=[HC!.XJ*](TO\ 8U^&,C"5+66=5[";BN_NM%M;E2&C
M 'JO6LQ=)U#36WZ?=.H7^ G@U@\36E_$DY?-F%3+,)/^$N7U+^A_L^^ ] 96
MM= MRZ]#*H:NNM?">C6>!#IMK&/:(5@Z'X[?S5M=33RI.@DQP:[".7S%W+AE
M/(8546GJF>96P]3#RY9+_(?;V\5NN(XT0#H%7%28/K0M.JC$;@YY-+2T4 )1
M2T4 )2,N12Y%-9N*0SRK]I_P7%XY^"?B6R9-\T5LTT)QDAE'&*^-?^">OC23
M2?'DNB7#_)+&8SENK#BOM3]HOQY9?#GX-^)M7OG  M6CB4G[[L,!17YX?L0V
M-YJ/Q<TR\,;*]T[7/EC^ $YYKZ? R;R[$1FM-+>MT>5B8VK0G'<_5I>F*=3!
MW^M/KY='J"T4450!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 E?/?[:7P3E^,/PQ)LW8
M7^E/]JC0?Q@<D5]"U%<()%V,NY6X*GH16]"M*A4C5ANB)Q]I%Q?4_.S]E?\
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M[-1X1UN73-0_LJ[<N&&48]O:OE70?^"@^ALH77?#]W9S#K]G7*YIOB#]OCP
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M\_[_ /?NOK:BJ^N8C_GX_O8OJ]'^5'R3_P .\_"G_/\ O_W[H_X=Y^%/^?\
M?_OW7UM11]<Q'_/Q_>P^KT?Y4?)/_#O/PI_S_O\ ]^Z:W_!/+PGY;*+^0$]]
ME?7%-/>CZYBE\-27WL/J]+;E/R^\0Z#XE_8F^,UG=V,SOHMTZ].(YD)Y!'J*
M_2+P3XNM?&OAG3]9LWWPW<8<8[''(KYU_P""A_ARRU+X&2:Q/M6XTR</$YX)
M)XQ4G[ /BJ?6OA?-87#%S:. F3T%>UC9_7L%#%S^-/E;[G+1BZ-9T^C/J513
MJ:O;Z4ZOFCT@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*+V/3?AOX3NYW\NW@UVVDD?^ZH;DUZ7IO[87PHL]%L_-\76Y>.!-RCD\*.U
M'EW_  3SM],U2R\<>*Q<B'Q)KFHO<:AHK#:]CDY"E:^QU^Z*^)?V-67QQ^T9
M\5?B#H5C-8^$-0"06\DD1C6XD5N6 -?;5 "T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?]G4*GQT>5^4U8?UJK3V?,?H+_P\R^%7_/OK/_@+_P#7H_X>9_"GO;ZS_P"
MO_UZ_/(R:H3G^QH?P(H\[4_^@/#3_L7#>?WQ%_:%7^0_0S_AYI\*?^??6?\
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MO@S2U##,LD:NC!T89#+R#4M>8CI%HHHI@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #6Z56N[A;2&2>:58H(
MD+N['  '4FK,GW<XS7QQ_P %%/CEJ'@KP;8^"?#\WDZOK[;)Y0?FB@[D5M0H
M2Q-54X=2)S5.+DSR7]K;]N1_B-#J?P]^''G10"0P7^N9PNT=53]:XS]EW]D/
M5OB$;:XN8VM-"602S7DJG?<'OU[&M7]CO]E]/'VKQ7FHVLD>@69WO(X_X^'Z
MGZ\U^F6CZ/9Z'IL%C86Z6UK"NU(T&  *]G%8J&%@\'A'I]I]SBIP^L/VD]NB
M,?P7X!T7P)I<-CI=C% D2A=X49/O73;0>U 4#I2UX!Z FT>E&T#M2T4 )BEH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***3(H 6BDS1D4 +129HR* %HHHH *8QYQ3Z8?O4;:AKT/"?VM/@.
MGQL\ LELBC6=/_>VSX^8@?PU\F_L[_M/ZE^SG=R^#_&FGSG2%EVB;!#0'/7Z
M5^E.!@\5XQ\:/V8?"WQ>ADFFMEL]4/2XC4#=]:]K!XVE&D\+B8<T']Z."MAY
MN:JTGJ;_ (0_:%^'WCB-)-+\46+;ER%FE$9_4UWMGJ5KJ2>9:7<%VA_BAD#C
M]#7YQ>,/^"=OB/3YWETQOM<2G*B*1E;^=</+\+?C=\)YL:3J>MZ="AX5'++6
MCR_!U/X%=>C)>)J0TJ0?R/U?4'TI<>U?DX_QB_: MV,7_"2ZD"O4LAS_ "I/
M^%T?M _]#/J'_?#?X5/]DM;5H_>5]<I]4_N/UC:-9%PR!A[BJDVCV4P.^TB;
M_@(K\J?^%T?M 8_Y&?4/^^#_ (5#/\8/V@;A&3_A*=43<,9"'_"C^R7_ ,_8
M_>4L=&.US]-=9T'PQ$Y:\OK6Q('*M<+'C\S7E?B;XL_!WPO,]MJ/C&VBD4X/
ME2;_ -17P':_ WXJ_%"X:?4)O$&L/(<M*\A537HG@O\ X)W^++Y3)=VL5F&Y
M_P!*8LW\ZCZA@Z>M:NODKG3#,L7:U)/YL[_XC_MS?#WPY?&P\*Z7?^*MIYN8
M6**/SKRC7?VV/'&O97P_X>BTKT-R0YKW_P"'_P#P3NL=/E\SQ!J*F,?\L;4<
M'ZU[?X?_ &1OASH+)*ND+<NHZRTN?+*/\*DY^;=OP-/KF83^*=D?EM=R?%+Q
MQJL]]-XAU:.24D^3:AMB_3%-F^'?Q-NT\J;7]?D0\%2'Y_2OV0TCX>^'=!7%
MAI%K".F1&,UK_P!CV"_\N4'_ '[7_"M/[4BOAHQT,)K$5/BK,_&K3OV5_&GB
M01>=IFI:AN/'F%AGWKLQ^P=XR95/_".R@D=/,K]:8X8XR L2(/\ 94"ILCTJ
MO[:Q2^"R7DD<_P!3A/XVW\S\C_\ A@OQAW\.RG_MH:0_L$^,#_S+DN/^NAK]
M<<^U&?:C^W,;_,ON0OJ%'S/RF\-_L"^+I[@H-$^RCNTK9KOM"_X)Z^*?M*AV
MM+-<\NRYK]&^:3FL:F;XRHK2G]P_J=+S/BNQ_P""=%LUNOVWQ"?.ZGRU( KH
M=!_X)]^'M-N/,O-6FNUQ@+T%?6AXH7YNHKSGB*LE9S?WLZ(T:<=D>.Z3^ROX
M$TNQCMVTR.4J.68<FKG_  S/X#_Z \/_ 'S7J]%8W9KRQ6R/*/\ AF?P'_T!
MX?\ OFC_ (9G\!_] >'_ +YKU>BD.R/*/^&9_ ?_ $!X?^^12_\ #-/@7_H$
M1?\ ?->K44!RKL>4?\,S^ _^@/#_ -\TO_#-/@3_ * \/_?->K44!RKL>4?\
M,S^ _P#H#P_]\TO_  S3X$_Z \/_ 'S7JU% N5=CRG_AFCP)_P! B+_OD4']
MFGP(>ND1?]\UZM13NPY8]CRC_AF?P'_T!X?^^:7_ (9H\!_] >'_ +Y%>K44
MA\J['E/_  S1X#_Z \/_ 'R*/^&:/ ?_ $!X?^^17JU% N5=CRG_ (9H\!_]
M >'_ +Y%'_#-'@/_ * \/_?(KU:B@.5=CRG_ (9H\!_] >'_ +Y%'_#-'@/_
M * \/_?(KU:B@.5=CRC_ (9G\!_] >'_ +YI1^S3X$7D:/%G_=KU:B@.5=CY
MR\7?L4^#]?\ .>V9[*5AP!T!KYE^,'["/B'PK8MJFCS+J A.]/LX*R)CO7Z2
MMRW(IDJ[D*E=ZD8*GO7HX;,,1A&N1W78Y*F%I5G>UF?!/[(G[5T_A6ZB^'WC
MV>=I/,*6^I7)(*GH$.:^]89$DA1XY/,C895P<@BOD#]L;]EF'Q)HS^+O"EJ(
M-8L_WLT<0P7 YR,>E5_V./VJ&\1B#P+XH/E:E;CRK:=SCS,=CGO7H8S#PQM%
MXW#*W\R['/1K2P\_85ODS[,!IU-4C(%.KYT]4****8!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #6[5^8/[=#SZM^
MUAI5O*^Z*/3D2-#T!+BOT_;M]:_,/]M%<_M?:=_UYQ_^ABO<R9?[2WV3_(\[
M'NU'YH_03X,^&;;PK\.M$M+>!8CY"LY0=21G-=P.>V*P_ W_ "*.D_\ 7LG\
MJW:\.[EJST(Z)!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HINX4@D!]: 'TF0.M9VM>)-+\.V[3ZIJ%O80J,F2XD
M" ?G7C/Q _;7^$OP^7-SXEBU*7IY>FXF/TXJXTY5':*N)M+5GN^X=<TG%?$&
MO?\ !4/PK"SKH7AF_P!3QT\Q"F:\UUG_ (*6?$'5KL_V3X+MM,M1]WS9<L?S
MKT*>5XRIJJ;2\]#"6(I0WD?I2:2OS$NO^"@GQ;NH62'2[&WD/1^#BN-U;]H?
MX^>/7Q_PD,D,1/$=C!T_*NE9/77Q22^9A+&T5HM6?K:2!W%1M<1+P98P?=A7
MY&O??'>ZA9)-?UPQR<96%@:J6?P:^+FL@S_VAXG=V.2QED']:3RVFOBQ$%\P
M6*;U]G+[C]>_M4(!)GC ]=XK*G\<>'K:1HY=;L4=>JF=>/UK\H6_9]^+\BE6
MOO$K(>H\^3_&M#1?V,?B5JL+RLNJ L<[IKIP3^M/ZCA8_%B8_),/K,^E-_<?
MJ5_PL+PU_P!!ZP_[_K_C1_PL+PS_ -!ZP_[_ *_XU^8__##_ ,2?[M\/^WMJ
M/^&'_B5_T_?^!34?4\%_T$K[F/V]3_GVS]./^%A>&?\ H/6'_?\ 7_&C_A87
MAH_\QZP_[_K_ (U^8_\ PP_\2O\ I^_\"FH_X8>^)7K?_P#@4U'U/!?]!*^Y
MA[>I_P ^V?IQ_P +!\-?]!ZP_P"_Z_XT?\+ \-?]!VP_[_+7YC_\,/?$C^[?
M'_M[:C_AB'XE_P#3]C_KZ;_&E]3P7_02ON8>WJ?\^V?I[#XX\/W#!(]:LG8]
MA,O^-7?.L=04'S;6X0]\JP-?EG-^Q/\ $VWC+HVHC']R[?-9<G[.WQ=\/2%H
M+[Q!$8^0%N'8?SI_4,++6.)C\[H/K,U_R[?W'ZLMX;TB5MQTVT8^OE+2?\(O
MH_\ T"[3_ORO^%?E;:Z_\?/!L@>WUO5E\OIY\)8?K6FO[4?[0]J!&=;#8_YZ
M68S3_LB4M:=6#^8OKD%I)69^H'_"+Z-_T"[7_ORO^%'_  C&C_\ 0+M?^_*_
MX5^8'_#5G[0W_09C_P# ,4']JO\ :&Q_R&HQ_P!N8I?V/6_FC_X$@^NTC]3;
M:UM[1 D$"0+Z1H%J;=S@FORRL?VO/C[I<ZW%WJ,-W ART36P4-[9KM=-_P""
ME?C;3;?R]0\"6]]./^6JSE0:<LEQ?V4I>C3''&46[7/T7W#IWIRL,5\!Z;_P
M4_O"P_M3X?O;KW:*8MBNYT/_ (*9?#RYA']K6&HZ?)W582PKGGE6-IJ[I,VC
MB*4M%(^Q-PZ9I:^;M$_;^^#^MM@:O<VC?]/%N5_7-;H_;7^$1X_X2B/_ +Y_
M^O7)+"UX[P?W,T]I#N>Z45YCI/[3'PPUBU6>'QGI2*>TTX0_D:ZFQ^)?A34[
M=9[7Q%IL\+='2Y4C^=8NG..Z9=TSI:*R+/Q=HFH3"*VU6TN)?[D<RL?YUK!M
MW/:LPN+132VWM1Y@H&.HIJN&I=U(!:*3=1NI@+12;J6@ HHHH **2C(H 6BB
MDS0 M%)D49% "T4F11D4 +129I: "BBB@ HHHH **** "BBB@"":%9HWCD4/
M&P(93T(/45^:O[6?P1U?X+?$ >./#^ZWT>:X\\-"/]4^<X^E?I@:Y;XC^!++
MXC^#=2T'4(EDANHBJ[AG:V.#^=>GE^->#K*3UB]UY'+B*/MH6ZK8Y3]G'XLP
M?%SX;Z;J@D5KZ-!%=+GD.!UKU0$'I7YK?LM^,M0^ OQ[U;P-J,I6R>Y:W97.
M!G/#"OTFC=2NX<J>0:>986.$K\L'>,M8^C)PM5U*?O;K1DE%(K!NE+7EG8%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 -9MM?FK^W;I9T?]IS0-3(W17%E'^!#BOTHF&5Q7PG_ ,%&O"][<:]X0UFV
MM7>&-Q%+.JY"#.>:]K*)J.*2;W3_ ".'&+FHOY'V5\-;U-0\":)<)]R2V0C\
MJZ:O+_V<+BXG^$>B-<!@?* 4,,'%>H5Y$U:32.NF[Q3"BBBH+"BBB@ HHHH
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M^4UZ+8_\%//!LENIN_#.JV\_\2 @C^59RRG&1^Q?TU-8XFG);GVC17Q]I_\
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MC0-6C^T,/FLYB%E'_ :]*7[W2OGYPE3ER25F>A&7/JMB2BDI,4BAU%-VTHH
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MI8K]5S/8.V)(SWX]*].C)YSQ7R=2$Z4G&<;/L>Q&4)QYH.Z):*2EJ"@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $K(M/%F
MBWVL3Z3;:M9S:I ,RV23J9D^JYR*V*_)#XJZUXH^&G[:GQ!^)/AEF>#P[<K+
MJENI)$EN2 <C\Z /UEO+VWTNUENKN>.WMHEW232N%5!ZDGI3=)U>QUW3X;[3
MKN&^LYAF.XMW#HX]B.#7BOQ8\<:;\3/V2?$GB32IEFL=2T1ID*MTR!D'T.:I
M?L#H(_V3_ 2CH+5__1C4 ?0=%%% !1110 4444 %%%% !1110 4444 %%%%
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** $Q32II]%+S CVFF-#O\
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M_P"\;_&L_P"R<9_(:?6:7<_1#?[4GF5\%:;_ ,%0(U4#5/!5S$_<6X+"M/\
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M37H4</\ 5*#YKN[?^1%.G*=7VLM-#L(6WQAO6GTU!M4"G5XIW!1112 ****
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MW3=/T_7O%;M<:BX69;7^&/N!7V'96,.GVL5O;QK%#&H5548&!4R1K&H"C '
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M.X_X)EZS'"S0C3I9.RL0*_2*C ]*/[9Q_P#S]_!?Y!]1P_\ +^+_ ,S\QO\
MAW#XJR1_9FF_]]"E/_!-KQ1)C.G:;Q_TT K].:0KFC^V<?\ \_/P7^0?4</V
M_%_YGYPZ'_P3E\3(Q6?[#9Q_],R#7:Z!_P $XC).@U;6(HK9>=L,8)-?=&VC
M:*SEFV.EO59?U.BNGXL^2[/_ ()X^%H6Q<:S<S1YSM5 O'IUKV#X<?LU^"_A
ML-UEIZ7,_P#SUN &->K45PU<16KZ59M^K-X4H4]8HB2W6-0J@*@Z*HP!3E3;
MWI]%<YJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'YC?\%&%:;]H32E9BR)IT952> ?6OLO]D+08
M-%^"VE&(#?<#S7/O7QM_P42./V@K#_L&QU]M?LL_\D6T'_KD*^DQ^F7X9>IY
MM+_>9GKM%%%?-GI!1110 4444 )2T44 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'YG_P#!1BRDM_CCI5VR'R);%$#=LBOL_P#9
M7F2;X+:!M;=B,#BO!O\ @I1X#N]3\,^'O$]G#OAT^9DNV Y"D<?K6Q^P/\8-
M*U;P<WA.ZNUBU6W?=%"YP67VKZG$TWB,HI5H;TW9_,\V+5/%._4^PJ*;Y@SC
MO2U\L>D+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!@^,_!]AXZ\-7^AZI"L]E=H496&<>A_"ORE^*'P_\1?L
MR_%QVL&FB2WE\ZTNT4X=,Y"DU^N^*Y+X@?"_0/B5I+6.MV:7"XPLA4;E^AKV
M,MS%X&4HSCS0ENCDQ%!5EIHSP_\ 9O\ VU/#_P 7I;?0=6C.C>(E0*!,PV3M
MZJ>U?3BMNK\JOVE/V==7^!?BR/5="^T?V46WV]W%G=&V>Y%?3W[&?[5B^/\
M25\+>++Z./Q';?+!-*V/M"#ISZUV8W+:<J*QN#=X/>/5&5'$/F]E4W/KFBF*
MQ/\ C3A7S1Z M%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %,:3:3G@8SDT^OF#]MCXM
M:WX>TWP_\._!TQM_%_C"X%K!./\ EC$3AGS0!] 77C3P]9W2V]QKEA#<'CRV
MN4!_G6O#*EQMEBD66,CY70@@_B*^0/#?_!-?P9#X1-MXAUO5]8\2S19?5FNG
M#)*1R5&>@-:W[&^@_$?X2^)/%/PY\71WFI^'=/D$FCZW/EA(AZJ6/>@#ZQHJ
MC<Z@;>41^3*^?XE'%7%;<!]* '4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5\5_M2L/#O[97P6UV_&-+D1[)97^ZD
MK.<<^M?:E>8?'[X$:+\??!IT35'DL[J"03V6H0'$EO*.C T >FG!'KZ5P>F_
M&CPMJOQ1OOA_;7S3^)+.$3SP*N41<9Y/K7BVC_ W]H/P_H7]C6GQDTN6V1/*
MBFNM,+S*O09;UQ78_LW_ ++UE\"YM6UG4=5E\3>,M8???ZS..6_V5!Z"@#W7
M;12T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>business6a.jpg
<TEXT>
begin 644 business6a.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %* <X# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK-KH'B%[#PX%T[5&;1KA'M)FTA[9 49 Q1I'4>8H*8.2PK-\*^'?&?@3X?\
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MA_M(_LQ^!?#?@K0M2\$_#C3K77K?Q1HKK/H^G9GCB%]"96^09"A-VX] ,YH
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MMX''[&<%P5TU]/03:M8&SDRA0-)%]Y@<Y8;@3D\B@#[E\%W&M77A/2)O$?\
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M/F/<4G[5WB:70_'7P5LIM6UK3=$U/7[F#48]$EF26X1;*5T1A#\[*'"G ]*
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MC*&^TN\L]:OI+[-U! +B*Y5I&)C.U)E8+PVY./E%?1= !1110 4444 %%%%
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M$MAN86%[:),5?+#) =TP>N :]^L]/M=-65;6WCMUED:5Q&H7<YZL<=2?6K%
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MEQ_KY/\ >-1T /@_UT?^\/YU[)H__((L?^N"?^@BO&X/]='_ +P_G7LFC_\
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M\%%O^27?#S_LH>@_^CFH ^K**** "BBB@ HHHH **** "BBB@ HHHH ****
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M">4N!@L& & >/EZ Y]:ZZ@ HHHH *^4_^"BW_)+OAY_V4/0?_1S5]65\I_\
M!1;_ ))=\//^RAZ#_P"CFH ^K**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "N8\77WBRTN+=?#FE:??PE297O;EHBK9X  !S6AXF\
M6:/X.L8[S6K^+3K6200I)-G!<@G:,=\*3^%<S_PO;P#_ -#19?\ CW^% '.>
M&_B%\2?$TFKI!X5T2(Z;?26+[]28[V0 EAA>!SWKUJS>>2TA:YC6*X9 9(T;
M<JMCD ]QFO%/AO\ %SP;H]SXM>[\0V<(O-;GN(=V[YXR%PW3H<'\J[JS^-?@
M?4+R"UMO$EG+<3NL<<:[LLQ. .GJ: .WHHHH **** "BBB@#X5_:X_Y+%>?]
M>\/_ *+6O%J]I_:X_P"2Q7G_ %[P_P#HM:\6H *^E_V(_P#D9/$7_7HO_H8K
MYHKZ7_8C_P"1D\1?]>B_^AB@#Z\HHHH **** "H[C_CWE_W3_*I*CN/^/>7_
M '3_ "H \4N/]?)_O&HZDN/]?)_O&HZ 'P?ZZ/\ WA_.O9-'_P"018_]<$_]
M!%>-P?ZZ/_>'\Z]DT?\ Y!%C_P!<$_\ 010!<HHHH **** "BBB@#/U[5TT/
M2;R\8PEX())ECFF6)7*J3@LW"CW/ S7S%XD^"?C#]I6SANOBEKGAKPIX?D0,
M-)\+117-]Y.2<-J4@S&<8R80 >>:]*_:2^%NG_&+0]*\-ZQX,E\5Z3.URTUQ
M!J1LWL&%N_EL,$%][$)CH,@D<5\E6_[.T>FZ=!;/^RI,\,:BW$DWQ$"^81\N
M#^\QDXZ?I0!]4?!_X+I\,=>T2Y\ >*KN^^&=QIDJ7.EZA?O?J]QN0P7%M*Q)
M7(\W?R0V4P!BO<*Y/X3Z0F@?#7PSIL?AN/P>EK810KH,,PF2P"J!Y(<<-MZ9
M[UUE !1110 5\I_\%%O^27?#S_LH>@_^CFKZLKY3_P""BW_)+OAY_P!E#T'_
M -'-0!]64444 %%%% !1110 4444 %%%% !116!XT\=Z%\/=%EU37]3MM-M4
M5RGVB9(S,RH7*)N(W.0IPHY- &_17!Z9\<O!&K> 8/&,/B+3TT26%)?,ENHU
M9&>(2B%OFPLNTCY"<YXK3^'/Q,\.?%;PO8Z]X:U.#4;*ZMX;G;'(K20B6,2*
MDJ@G8^UAE3R* .IHHHH **** "BBB@#P7]LW_DE=C_V%8_\ T5+7Q-7VS^V;
M_P DKL?^PK'_ .BI:^)J "NC^&__ "4+PQ_V$[;_ -&K7.5T?PW_ .2A>&/^
MPG;?^C5H _3"BBB@ HHHH **** /A7]KC_DL5Y_U[P_^BUKQ:O:?VN/^2Q7G
M_7O#_P"BUKQ:@ KZ7_8C_P"1D\1?]>B_^ABOFBOI?]B/_D9/$7_7HO\ Z&*
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M_85C_P#14M?$U?;/[9O_ "2NQ_["L?\ Z*EKXFH *Z/X;_\ )0O#'_83MO\
MT:M<Y71_#?\ Y*%X8_["=M_Z-6@#],**** "BBB@ HHHH ^%?VN/^2Q7G_7O
M#_Z+6O%J]I_:X_Y+%>?]>\/_ *+6O%J "OI?]B/_ )&3Q%_UZ+_Z&*^:*^E_
MV(_^1D\1?]>B_P#H8H ^O**** "BBB@ J.X_X]Y?]T_RJ2H[C_CWE_W3_*@#
MQ2X_U\G^\:CJ2X_U\G^\:CH ?!_KH_\ >'\Z]DT?_D$6/_7!/_017C<'^NC_
M -X?SKV31_\ D$6/_7!/_010!<HHHH **** "BBB@#,\3ZC:Z/X;U:_OX#<V
M-K:2SSPA-YDC5"67;WR 1CO7P[X(A\1>+-2U&^NOA]\(;6TU;P<?$_A_3TT6
M-X[7$J@)=W)7!RF02HPI/M7U?\:?B1X@^&^CV=UH/P]U3X@FX=TN+?3;F&$V
MR!<[W,I *GD<>E?G4WA/P;XLM7^(5C^S%\6%\)M TCZ;I_B(1Z;<6QR[A;</
MN:!L[BJ$*?2@#](/@1XQL/B%\&?!?B72])AT&PU32K>ZATRW51':JR ^6FT!
M=HZ#'&,5W=<E\)-8M/$'PO\ "NI:?HJ^'+"ZTV"6WTE&1ELXR@VQ Q_+A1@?
M+QQ76T -?.UMHRV.!7Y[_'Z'Q#\<OAGJ?P=T#]GC5_ _BB^UV/;JHLH5TJT5
M9@S:@+J/ / .,#<<U^A5% 'A?QY_8]\"_M,>&?">D>/CJ5T/#J,+>73[LP%G
M=$5RQP<Y\M:^-?VF/^"?WPI_9JTKX>^,/!D6LIK)\<:-99O[_P Z/RWGRWR[
M1S\HK]/J^4_^"BW_ "2[X>?]E#T'_P!'-0!]"^+K7Q=<:QX:;PW>Z7:Z9'>[
MM;CU")WEFM=I^6 KPK[L'+<8%?'W[?O[?'BO]D+XH>#-)T70-,US2M2TR:]N
MX;UW21W\PH@5U^Z%VYZ'.>V*^Z*_'?\ X+<_\ED^'?\ V )/_2AZ ,GQE_P6
M3\=>,--UO29? >AVVCZII,^FO;K<RM(DDJLIF$F.<*V-N.W6G^#/^"S'COPE
M8VNFMX"T*]TJSL;6RM(#<RH\?E1A&=GP=V[ .,#&.]?GE10!^X?_  3W_;P\
M6?M=>.O'6E>(="TS2;/3+:*^LOL+.6C5F"&)BWW^06W<=<8KZY\"VOC2UT/4
MU\77VD7NK->W#V4FEPR1PI:D_N$<-R7 ^\1P>U?E9_P1#_Y*I\2_^P+;_P#H
M\U^O] '%^'++Q]#\,6MM;U+1+GQ[]GF"WUG;R)8><2WDL8R=VT IN'?!INI6
M7Q D^$_V6QU+0XOB+]A1?M\L$AT[[5QO?R\[]A^; Z\BNVHH XWQO9^.[KP;
M9Q>%-0T6R\4++;FYN-2ADDM6C##SPJK\P)&[;GID9JSXUM?&%S?>&SX5OM*L
M[2/4HWUE=2A>1YK( [T@V_=D)Q@MQ74T4 <CXN7Q?%XBT6[T6\TJ#PW;QW+Z
MQ;W<3M=3?NCY/DL#M7#X+;NHXKY-D_; \>*[ '3\ X_X]A_C7VIK/_('OO\
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MS<"CJ_W1&%R".N375U'<?\>\O^Z?Y4 >*7'^OD_WC4=27'^OD_WC4= #X/\
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MU?;/[9O_ "2NQ_["L?\ Z*EKXFH *Z/X;_\ )0O#'_83MO\ T:M<Y71_#?\
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M//BM\3O%T-]?ZAXA^'UFFO>#)/%&AQ6]@KV6DOYP$<=Q.6S-A"%=AMP<X'%
M'UM\*QX=7X;^&QX1G:Z\,?88O[-F>1Y"\&WY"6?YCQW;FNJKAO@;X[?XG_!W
MP;XMEL(],EUG2K>]>SB^Y$SH"57C[N>GMBNYH **** "OE/_ (*+?\DN^'G_
M &4/0?\ T<U?5E?*?_!1;_DEWP\_[*'H/_HYJ /JROQW_P""W/\ R63X=_\
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M1Z3_ -!2S_\  A/\:/\ A(])_P"@I9_^!"?XT :-?RX>-/\ D<==_P"O^?\
M]&-7]/W_  D>D_\ 04L__ A/\:_F \9D-XPUT@Y'V^?!'_71J ,>BBB@#[R_
M9)_Y(AIW_7Y<_P#H8KV.O&/V2[J"+X):<LD\,;?;+GY7D4'[X[$U[#]NM?\
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MS_\ !E>__'Z^FZ* /F3_ (=I_LU?]$NL_P#P97W_ ,?H_P"':G[-7_1+K/\
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M &:O^B76?_@ROO\ X_7TW10!\R?\.T_V:O\ HEUG_P"#*^_^/T?\.U/V:O\
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M'2?$T?AQ/#DUJWV^X5MJK<B;S!]]FW*NS&U3\V>: *7_  [5_9K_ .B76?\
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3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>business7a.jpg
<TEXT>
begin 644 business7a.jpg
M_]C_X  02D9)1@ ! 0( '  <  #_X1WJ17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   ")!0  ,@
M (D%   R    1TE-4" R+C$P+C(X   R,#(R.C$P.C$P(# U.C4U.C(U  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   "*     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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M[_!A]8I]S=?POH\AA+6G^IP4 D8 8+$<9YY=OSK3M;:*SM8K:!-D,2!$7.<
M# %<?_PGK_\ 0/7_ +^__6KH-!U@ZU9R3F 1;)-F V[L#Z>]73Q-*I+EB]1P
MK0F[19Y?XZ'_ !65]](__0%KG8X1 'ND2621 6$:-C<>N*Z3QP/^*PO?I'_Z
M M8L+^4C-C)Z >I["JGN?,5+K%RMW.OTB*'4;14FC/E3*"5;J,_U%==I=U=2
MZ'?6TKF2[M-\._N_RY5OJ017*Z @MXHD+?+&@!)]A76^&%:6SN-08$"\F,B
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ML<XE.7(^Z"!Q6HB*BX48%>7A\)[-\TCDITN5CJ***[C<**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *9)#%*K+)&CAA@AE!R*?10!SBZ)J
M<;DB73Y!U4O;@$-D'J!ZY/\ GBQ;Z1<B]CFNA8R*N0V+<!B",=<<?_K^@VZ*
M &1PQPJ5BC1 3DA0!S7!^,;&Y?Q%!+;6LTB/#EVCC+#<"!SCV KOZ*J$N5W&
MG9W/,!I<DJ_OM-E8YS\T)Z_E39='.WY=+D&.1B%O\*]1HK7V_D7[3R. \(Z?
M<'Q#-+<VLT:11!E:2,J"Q)&!G\_RKOZ**RG+FE<AN[N%%%%2(**** "BBB@
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M(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_X@*P24-#7U!23T9)3$4  0$
M  *@;&-M<P0P  !M;G1R4D="(%A96B 'Y@ *  H "@ W  IA8W-P35-&5
M                                ]M8  0    #3+6QC;7,
M                                                      UD97-C
M   !(    $!C<')T   !8    #9W='!T   !F    !1C:&%D   !K    "QR
M6%E:   !V    !1B6%E:   ![    !1G6%E:   "     !1R5%)#   "%
M "!G5%)#   "%    "!B5%)#   "%    "!C:')M   "-    "1D;6YD   "
M6    "1D;61D   "?    "1M;'5C          $    ,96Y54P   "0    <
M $< 20!- %  ( !B '4 :0!L '0 +0!I &X ( !S %( 1P!";6QU8P
M   !    #&5N55,    :    ' !0 '4 8@!L &D 8P @ $0 ;P!M &$ :0!N
M  !865H@        ]M8  0    #3+7-F,S(       $,0@  !=[___,E   '
MDP  _9#___NA___]H@   ]P  ,!N6%E:(        &^@   X]0   Y!865H@
M        ))\   ^$  "VQ%A96B        !BEP  MX<  !C9<&%R80
M P    )F9@  \J<   U9   3T   "EMC:')M       #     */7  !4?
M3,T  )F:   F9P  #UQM;'5C          $    ,96Y54P    @    < $<
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MB,J:1;!IL?W_ )-*/? @%E\^F-6U;A-G]0./_3,Y5O9(SO!R
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M!Q&;UNEYC] ^E.G=3^P <@ $*+B20 $/B\'2'C?/_E;N=V+H>0I7-5
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M^6E=7OK+I+?37ZGA?L/3M<(C1\&6<XQCZ8DT\8OBZ[V<V;ZZN%^8
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MYU3N=BG==BGL9X4^%2HNI;<J^+2OK.-*@/0[587#FGQN6=MRY;G9_P!UNYJ
M               &,3"U5+5?")F;Z4R'2ODGO^Q2GWRK='^/9519OK3XF%ZQ
M:) R&HIQ2OU<                  @!@RJMJRC:RF#R?V^9H]@E)GXV_-*P
M?+],G:5KWI+K^!S<                      X*"M>+J_2I3YK7MLMK+*+@
M                _\0 ,A   00" 0(#!P0" @,     !0(#! 8  0<1%106
M(! 2$R$T-D F,#%0(S(7(B0E0__:  @! 0 !!0+]Q4F,A?B(^>)C9XJ-GBXN
M;G0DZ0I*]?UCQ49&Q=MK2<N5A$.7D1;XADN5(*@M1K=&D.R%Z;1(N,(T)K]I
M Q 2;=658T="OXAUMS7]))LX2,[HR9E9N/;9._+\AW/)X!6V:^"CXAMMO7(J
M^E[2O%=%Z#DHLV>[O+'O>QU?WU!J2E6G0XA_'*E6G,35!C6=C(M:TQ;F-]SL
M4?/-@IO(TN-,;_,+&&QN) 2B>1H<6$UZN07=+OC:LES&X3 E-9&3G$X=3_Z^
MH/:?K%G'FR&>,OZ,CDK[-SN?)#[H)RV^.]F]=<E5<1(<5/+5_&W&WF_R9\U@
M=#KX]_6O7UPK,2;NS*<7$9DM#A88E%=1A%GXT?BB<F74,L-$E%BZZE8UYNGG
M5*3UUKT=,83Y9*?DV'7C9O['(ES2$B"!_@HS+6&NYM!:S$(QJ\ZWC[>4PZFH
MV+6]*U^S88&R(8/.T3%^@X:B !YGDLU/P-R49'X$L< ['_ =U[]V]6]ZUELY
M.:CN#QBT/,,X;.3F)T=N^[RL6'1]AQO'V<GCVI;5=NQBH:&6$*7C==;_ &:=
M]M^CDW[7"R&(Q.WH2BS<;_3V7D$R).;Y5DAWM\MEX,2-RX9)N.\T.N/B>8"2
M]6J59(MPE<S$((9_E<A'D+YM>3 F\O.12<KE>RC'*]R*6L1+VJ^]_2>L@JNQ
MSMIL%PR".8B-LL8TUCBF@5Z1)2Q$IW4I8UHQQK'6,W$VXH=$A#=#3;X[;+R'
MFNOKIWVYZ#XADV/+<?$8>X%0E2'*O7WQ663F.(%(IOU/>E#^1ZV5-Q^2:\X_
MOE.NR<>Y)HL/ )\996U0XB]>'8QROAG9NXT=3BHL96-L,M>A7WMZ+K=X]8:\
M-+GRFVNN--8TWB$80$P"T8G2*Z*2Q&8AL[Q2<<;Q"=="4F5+E1%I@QF+T1!$
M(,^*2B0"PXGOVFKM5J]CO.-';<HG(U.EA4+2XGT*2E>FF&&-9.XZIQ*6F@U-
M)%GC"EL-_P#&=*U%;XTIK33G&U,=<@"!XQWU\H\F&:9/G\B\C%51UFIA(.5O
M8O*CR:T7DY9SS-<##VY,MY">NVD8VG$:Q.O9=(A:;60YF$]$S>+UB]=-[6WD
ME6W-[0E>J := '4--M^QYYJ.T8M!^Z.+K8@=HN^W$QA0%[0DO::NNO<W0W5H
M5I:?3R&2(Q;+WLSG>S.:-&>KC-A^'^L?>EHM4-CK;_A[3;DIDD+%#<[V9SO9
MG.]F<"J6X(YWU^I%M^^B&&>4Y6WV'XS@*-8(7'EBF%(7+SJW4[U_C:QO$8G>
M)5G7)ZDVRRKJ-=E91R4[XF]XK>+WCN\<S_Z3^J)TR8395G),N1,7,A1AT0I_
M)-IM[#"TAA8R<DK =9;=1$U_XGIOX(S/L?E6R9Y5LF>5;)FAMLTQO5P]WW+;
MMAWS4O&U7"/A45:RSWE6R9Y5LF>5;+@=MQH5SIK]1],AZ^=+"0@Q4'_L.0F/
MRCR:'5/%0Y'BF4*Z8VO$.8EW-.ZSXN%X4^O''KDS)AUZ',KT://C365.8XYB
MW,<7B<#C9!PV+425"RP_+DLS_)/)NOG(<1'C"F%L#-IR+]+^'SE]Q9$_VJ_^
M=P'_ #0=*/6=:4K3:J),'O,$67]Z<VG$OXE_-2,U)SQ/3/$],\1A>OC>\ :R
M9N#;].E)&PB>I\=Y]IA(D86LSP !# 1(Y.#+D]K;[KR:P[#T1?:EL$\G=-:?
MD02#6MI6G>LB_2_A\X_<?Q6O>VF3*6)0AI!B?*:A5P%&K87V':4!/Y-XUL@[
M),6R#L[PPG:#$)6:*1<[E&SN4;-E(N%Y[#P^JRXA4#-V**$P_'5Q>V'XO!P5
MS8<G8].E:0N<,C3Q%KV;-LD@KC@J=(]T\0B$$N/)BIDOUV"42A+:=Y%^F_#Y
MQ^XY O;Z@\9R-@W..X??+OBB7N$D+0XGV3)L4>RN(-G8Y4JR[FZ+4']:X^IN
M\\A5'6Y-7HD&3'!U391^"^+SP$KN\F:\Q-P?'GQ]DH\^2Q(C?$2W(L14>V!,
MI:8 %$K C9:#-JADEV".P&<([]D7Z;\/G'[C/,E'8(V7(;V5,CAL\#R#Y<;&
M<LSU$'3]5FLCD0&H6'$J4+%NQ;'B3-:LK0FQ,"S,6+'A,0!<(;N9#BQ'V?AS
M&672Q!EHE''R.OL&#.VX5%,%V-:Z:&L$8[,E3H%X4/C$!MYDSO!EG9;$Z[DI
MCYXMQ^'#\?U Q/DRLB_3?A\X_<>1/Y<AK);H?'\&W 4<8!*_-9E!7)$9F-'9
MRS$@\DO\:O@FDW@,R5@D0,]G8\X[;!-D9DE)5D:COS6G"L%*>FNFL(#(Q1GT
M+VKW![LY4$>0AE8O*3FYUB*?S<P1+NL2S0F>.ZB$GQ).1?IL<<0TDUR0#&X%
MY("$L0\VZG][G+[CR)_L-_G@Y[:1)F4Y)FK*:1/)6"Q#($7E&R-9_P LB%%[
M!;F)J8#^MF9YI;$IMHFDE,+3 A5NT2;+)X_+BA%;<NE=;U)Y-JT;)/,(_J]R
MP27CO)%J6N!RP7C*KUN&V%#$:<W/Z8A"&TJ=[[?B>3,U#&,R/>UO6\B_39R9
MO]+!&(<F?9QX\84XX6OPI?DHA!(QN3H2'V^68B(FN70CKLCEROMJ&\O"'V[E
MRM(J)XWSD4$O(Y%/)F5/E&-9KAZ.<_N.:X\VB(3(HP X\Y&XE<VU;+X<%CIT
MZ#'),QILAN-X/2MRH([NB!FL&?&BF234F65W%*I,VN*Y#D5>*N3)[8[O-!&\
M0';UFAO3/ =,7$QZ-K(,UT),K9?O(O"\S0X738BF:V3R;A5G>\>;CL,Z_P"J
M(GTN702^:!MZL-/EK;,61^BCGH:3AOC65:)<#BLJE<#B<@]LIQ"%@]LXE8(R
M(W&(<!-)<9%ASSO$,J4F#Q6T?C2^+H[*;Q65K=N]/8T.)CS$3.==_J.2WM^.
MV,EOX$;VRSQ,C;MKL\EV:9#FGX+#TR1/61+"0K+M[%2#@Z:(,Q2L*$V49@PT
M2&G93]C/51PLJETUV(QX+6>#UGA-9N-K%LX\WK)"=9-UKW>.H4@K7&T^XBZ(
M6Y4Z^M#E2)Y-_EQMI]OM@[-[R+]+[) Z+)U'K8YE>DZUJ3QB%D%8G#8"$TOB
MH:\7$<-Z2'G\2"2+IFD##L!OB(&RR1XG@STL<2DHAV'Q"'BKWQ(&VTWQ$%1$
M  8]>C9SO]R:WD+?S=)Z&QN,ZLY6*W>!;P<S%<UD=>7Q?ZKU:2D:N<5,HD67
M=+K^HH48#22]S'U-1V*/-@$ZU[F;1FTXO6L>R0YK)+NL4TZ1D &8%0#8XA#S
M;7Q:.3*9/W\];^6U8MQ*$Q/I?3R&4)1+)WTWG?3>=]-YN-;=*:7:GXB9%G6_
M[EHZ):MRT3"%A@O=]-YWTWG?3>!E*<$<Q4BV6,M(J5Y@X*K%Y(+HG%"0DK+3
M5H=GA%:\7KDB)-2K1RGQS4I=AYD(/4NA0:NM.\,"F34"BUDY5!ZML[2+%BP(
M_-XZO2=/SV4X[-;5J7+R-&FFI%)H,6O)=89?]MAKHNS#S%/N]7R<::UMB9(F
M;'\?\@F5!^#!:%(1IM'IY !F9]B\K67/*UESRM9<W*M?5M%STG;%NW-2Y9T+
M1JRHT0!V2<_Y6LN>5K+GE:R8';6R*]1$7!*L6CB\C$6S/<8>BSNN1Y77&G>N
M)5FMXNI[W-8J,1S/DG2E89F_"TV;THB:<')?%#2!B54PX(5%D.[88&S')\+T
M.,,NXAM#>OV.GXUFI02SM'JH=J3T DES467K>,NZWI*LWO\ ZU7Y5Y2L>=UK
M+%_D3(BQTRH"6YR(8^>+?X^[@I_^GDQV);-VX^>$*'$??R))ZXT[UR2\MJ+Q
M^2?)U-USIJ7)Z84G:TF%1BLJ"T/=VT(8E24!H6HS/]1O6E:Y!I79Y8V;IQ,D
MRV,CQ[L"=TNWATY'LD JZ1FZ1J@4Y=DG31C$J*Y3W7E0Q$>*G6NFOZ.U"IYF
M!+'\@"F&F^2(SBV.2U,M1N5)S5:9M+#Q. R4@265C2[TB;X;9(TPKNIOW8<^
M0]J"/=.E!8Y@5!_J+&!9L8]GCHNQ(7Q^3=U7JVX"<]G(BO@\AQ'M:Q$C71R3
MK)CVMZX@0F;9?Z]<6,XKPD7/"QL\+&SPD7&X[#/])__$ %$1  $" P0&! @'
M#@4#!0    $" P $$042(3$&$R)!46$4,G&!!Q4C0I&AL? 0(%)4=)+1)# S
M-#5 4&)RD[*SP>%#1(+2\253@Q9C9'/R_]H " $# 0$_ ?OBEAL5=6AL<5*"
M1Z5&D=+E!ATJ7_?-_P"Z.ERGSF6_?-_[HZ9*?.Y8?^9K_='3I/YY*_OVO]\)
MG9-:@E$U+*56@2E]HDGA0*)KRCGQ[_T?IPA9LC86EM0(VEN71B8G)14LQ+OJ
MFV'%.)";K;H4H85QINB7K,*<3K"BX,SDJ)B1<2WK=>C%)-+]#@.%84MQ;B4:
MR[?(3M*H!4TQ/#G%AV/,26D]DI7.RKH<6APZJ82Y6OFT!Q@9;L.'Z/\ "0YJ
M[#K16*P,/VA'22H(!O&[W =\&:=;4JXNM[<,\><6JE]EJ26I#B=<VO:J0DX#
MG2)A>T0I9-!Z(T&=4=++(VW#]TH1Y3'"OFXF-_Z/\*TWJ;*EVLBXX:=U(:<*
M@H'&IKG2)9@S*PEL[3:"<<?)CK*PWB+23:TW+RH>JN7824-)Q\FBM<MP))5V
MU.^)AE574JQJ<*>R-$R&M*+(<. 3.MIA)O)!X@']&U&-</Z_!X8K2#DW(6:V
M05M7G'"#D%@4PB5;K1-:BG#?PB4:=:6'&S=*DE*J88<.^)Q^:9\B'KP4VFI(
MXC*)AK8(&"CB5'&L2RNBVE*3-::IU#M.Q5,XD'0_)2CP-=:PTH;_ #!O_,AC
ME&.\4CWQ_.3V5BW;9EK"L]R>G%A%$JU::XE6[?%I3SUOVL_/NDDN+5<KN:J;
MGJB3EO)D)&W>NCMSBS99@S$KTE=&DK2'.^+2;EES+IEB5,U*4*.>R2(?8%,1
M$[+=9:<*8C]G_F/!II*BT+-19<RK[ME11-3B6]P]&[^WYC:$\S9\L9E\**$J
M2*)S*C6@]43^EL[,J*)1(EFZ];_$/"IW?Z8DM+)V5(3-#I#5<5GK]@/LK$A/
M(M!A+Z$E*%"NU[G\X[!AW1I#I19NCS"G)IY)>(\FPDU43NP%:=\:0Z16EI5/
M*5-**)-*O(L@[--UX;S$I*4HVG+=%D6,VM"9J;)0V%)0,@._CG%IZ,-6:VW,
M*E4.R;R %VC+>4;:6L52E2DW@%TW8&+2LMN7N*97K&L"E5,XF&<00,*81-2V
M!B6?FK*FT3LDM;;S2@K8.8&)"AO2=\:*^$:S[70B5M%0DK0H$"\0&G5#"MXX
M G@3"&G7$WF4EY%*WF]H'F"*CN@IH<:A7R3]^TJ%;(<%:'7-4[<:19+K+<VR
MIZ7#QUR47'.K52@F^>(%:\XM]-RU9M"+J4)>5@D !..5!@*1HM7Q6UMWMI7M
M_-ACV0XXAEM3CJTMMIQ4M1HD <^R-+?"9+RB5R%C_=#^*5/H5LH[#C6)N9GK
M7F%/SKZG5*54UJ>Y/ <HEI-)IAEZH:E@$(NC$$5/ORBSU>0E%H81,='<2M3*
MTWD+\TWTY$8[ZQ/.6<E4[)OSKZY:;E>DL6=9A*9&7GD( ;#K:#<PQK6+32$R
MC;!H%I%>X\86BJ!7L[8>8!!PB8E :C'/<;I(X5YQH?X.[5TRM-F6DF7$2B70
M7YJA"64I-5$+^5SK&C^B,GHY8\O9[+BG@RT 7IA5];I H34Q:>C#,ZEQ]DH;
M>37>!7NAYM;#KC*QMMJ*5=T<#3.-U?4(&7Q*CXT]),V@P9=^NK*@K T-1ECW
MQ/Z(S32JR;NM3>O)2=E0ID+V_P#M$IHM/3"K]HKU=?, OE0XJ5SYXQ(R3%GR
MB)9D4*36_7T^G_C\VM*TI:RY=4S-K#320<R-JFX=L:6Z=SML+<E91U;,@"H!
M -"NN\G,PS+IP)JI2C7_ /1W=T2\J*[20#P&42\N.$(:  %(E7WY8U;50#K<
M*<^^&[2?=O74MM*N%>L0.NH90XZX\HJ4LKQ-2K.OV1UMF%MBD/,CY)5QIN'&
M/ ?I%9C4@Y8[I0U-H=6M"10./)4=G:S53,UB8>=?4VE(!"E8)WA/=EV1;TW9
M%@6:]/6K-(9#:+W6IYM>^$>$BQ=([6=E64)E;JBB7</^9QZU>>8[8[^SF>43
MEG3D@&%S;"I<32-<S4I-]O*HHHT[#0\OB%24XJ4$CB300Y:=G-JNKFF ?VQ]
ML-S$N]BRZTODE0/QAWB*GW,;\?1]_P!*=-K+T64AJ>J7W6RXA 2HA5,-PXQ/
M^&N;<);D)*XI1HTNJ<>&'6B2\*>D<P&]8$H=2XH*"FUY99Y18VG;SY0B>ET[
M>;B!AC$O-,32 ME5016F_P"!QQ+3:W%FB4)4HD\ *QIMI.Y;<X[JKPLZ644-
MHO'RBP<SW@PTC6$N<?5P$2S0I_:&6\H:;P!]_?U0A,*&!]G$<(L[5=+0'$DM
MW?P:<_Z_VB8EWBXLMRQ2U>->RL;/5 *4C.O'X'!>J*TKOI$E:+]CSC<_(+6W
M-RRJUR0KEA&COAX88E7#;TI=FTI\FID?AL,,ZW23F3A'A'\(EK::3EU2W&Y"
M\=5*H40@)W7Z=8Q*N.2R@IHD.)<O)IFFX:]N,:#:1>/+-HZ?NJ6V7$YD@8:S
M_5"EJ72\I2KN O**J#@*Y#X ,>V)R<1*H-T5<QK[_P!8MBTYYZ_11" #45IA
M%JR[LQ>(>6VH&]UE'$]7 &L-/Z269=F&9UY*4I"JES8KPNG&+%\*L[+J2S:C
M FDX!3S>%.VN,61I58MLHO2\TA*L/)J-%U.['[,8&(%#6N(KO&?QM*9Z:EK1
M4&7W4#5MFZDF@)2-T"V+3/\ FGALCSE1XVM+YZ]]8QXUM-1N],="?.5?. WP
ML6FI#1EK67,.+%4-H+@-T8D[0 P$5M]2DU>F3?ZMU?V<.<.FVVD:Q4T^0C/R
MA-V@KE%ZVRG6AR;*,+Q+F*2J@3>%< HD7<-\)&D!#H,S, H""4WRHT62$TI7
M'Y0KA#T]:\LZ&WYA\%/6VCU>4"UK1W3CU-U5&/&UI?/7?K&/&MH@I"YQ\BJ?
M/5QB445RS"BI1):037FD>N/#4#XTLVE/Q)8Q%?\ $.,)5JGFUW4J+2KV._&O
M=%D6VA2D(3)I<6ZKSU!S/<!3"D2S4RTKRK6I0[MH01N.\<!%@OE@IWIX&#BV
MEP9+W<#&F#ZY?1VTG$5"DL84P.) AZ]JUWC1)7>IPKO],,BNZ@PISB7RAD]6
M&E4 A*^Z,L:]N%??'?$A9TRMEM-F2;DW/.(UB[B+ZFV@=I5.6>Z)VR^CR[T_
M9]K2]HRTJ&4S\N^$RLVV^X/*MM,$E3P;74*4,L]\6DRV&V9A("4O8W> I4'M
MY05 ##&%+I#RR H#SLZXP\12Z<J4JG ^F'SD$U%WG[\(1B^+F:<^Q>=8\%RW
M$VS.M#!.I!/ IO9\HDV)!YN95-SJY5;;15+(#!>$PYN05!0U8_6-?@;3LJ7\
MF+2<4M2SNK@(M&N./=QBVUK16ZM23>J2DW3R]$6*PNV)QJ2F9_H[;M0'75;*
M33"]7#'*+3L]=F3<Q+%QIW5K*4K:H4*_6O#"+/4_+S;*FG5-N*=1>*2147LO
M1%GDJD)$UQZ,R5$XDU;'QM);.G)FTKS##SB"V@7PDD A(@6+:Q*D]#F+N0V%
M GU1XBM7YE,_5/V1XCM85I)/X@@U;)S[H;E+::#5VSW?)(4@>3.(4"(/CPI
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M >,:*6>Y/S3*4@W$T4>'I[(:1JVTM_\ ;$6:]0E/'V0K ]L$&B4<8MA2Q/N
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M*Q R$.K65'.&;Q5&()W0W-K!H<H0^%1G[K3JU9Z3MIQMF=?;3JVJ(0NZD;/
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M=U/<T'+N^"Q\^$4Y#N]:G5^< 4_6*=G5'7C'W105)  )BG'/\HH(IZU.OO\
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M(O\ N5YXUCGTCG]QC6N_2.?WJ\\%2E8J)4>)))\L#?U_(?\ _\0 6Q   @(
M! ,$ P@,"@<&! <  0(#!  %$1(3(3$&%")!(S)1$!4S0E)A<8$@)#0U0V)S
MD9.4H=(6)4!04W)ULK31,&."@['!\$14DJ*CLP=VA+4F565TI,+#_]H " $!
M  8_ O\ 2<)[$"2D:\-I45]/;L)W:?5CX>']*G^>/NB#]*G[V/NB#]-'^]C[
MIK_IH_WL$M<JJ/:;$0'[6P'1E=6&JLI#*P]H(Y$?1_-OVQF-&#\M;@C_ +[C
M!_CO+WT\H;"SGZA!O)^K&56:TMF</EA1C%EN8L3M6^.2]TU?JO-=1\^,UR:'
M+LXKS928^);MT)(*,RRHKKPYWVE9O%\!(HDT\0Y8A=%B+36%@XDY800A@29)
M-GB/J[4 *[F(&[!A-2P='@4V(@.!I898D?;-PYAZ5MNW:Q"^(G#L59M@+;8T
MWNVWGHB#FSGR7SQFC)EN=4UKV^XD7<KL)(YCD3>Q5$?@@Z\D<[L9-#+8MP\/
M+:B^ERG-XUY0KKXFHA"-?,-IC[]4$_+3< _6)@A'UX]#F^62D] E^LQ_,)-<
M:QR)(/:CJX_\I/\ ,O=N^K;M].Z9='+F-G=\EXJ23F(_EN'C^+^S5M4Z"?.+
M=;*T^G@1]^NZ?UJT>OS8'$S+)\L3S6E0GS";Z.-<G@BY>WNOU8'?.T>?SGS6
M">KET1^@4*D$P_3GZ<;YZDUUSS+YA?S"\2?G%JS(O[,>AR;*X_G%&MN_\7#W
M?MQMC1(U]B*%'YAIC(/FRF8_XT?\\?3_ -<_GP58*X/56 8'Z000?HQV@@AN
M5;9J9@J+%%+#,U:(0QC;L34Q+Q0P .FC@Z<_<G^=X/KTF3K[<9.?_P!-I_\
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MH6,LG"C1 HU8(TAZD(H"(2=3Y<L"L$0,K+$#M82:R^)?MF'J'+:+N?0G4:'
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M%UY#S/L'F<=HNU9U[K%_$^7ZCDRQ\-6=#[.#!&?IF;#(ZAT<%61@&5E8:,K
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MLD9\TA3OYS"E,)O"=:ICJ.9/&/%KIM\&):T/9>RU9)A&M]+L*1LFHUF$9?B
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M?FX4-KG[1AS].+F91P\:K.ROK#XGCVHJGB)U\NHU&,R['<"R<RN]HJV:Q.B
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M31QM*."?C Z:'F?9B'+<L@KT,OKF0PPHRI&AED:23F3U,C$\_;[NIQS<8\+
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M_]H # ,!  (  P   !      %UK3                    "22J7:\02
M              ;3*&KYE2!(               22  #I;.>#* 1
M      "  "#G\F1)(  :  ;9@      "    1Z(8>22  !   1A       "0
M #DL<:!4M   3 "&!802  2 "2 +T8B.R'"I4@ < "8\""   " "0#;A8\QM
MBL7H #@ ,_);)())(:W2-:+1=2>D1V8B0Y@ !R_[Z?7U)02 ?Q(>GBE _P![
MJJ   N\#]JTOZA+PLF?HA4,N2EFPP  Z?;[;Y7=/)]<U$FK4+PU=NEP
M   "%UDB_*^1]90HK*Y.X          4$FL,(JQ;K F9"**;         %M0
MHY_RS]?'K'(_AZ8 @       $0HE,8&+&%P$6"8)#$ZH      %:;. /DTDK
M>94["Z?<G"$DD D@ ##ZB;BGN]_*P'XKU"$UN@@$ D 'Y[N]M=23'P#BF)LN
MHYWY04G,F4$.>V!R8[Z$%ZL<@=I  ! O>,!!FRX'R\J.?O&TKPL?Q@  *$WL
M& ^X?!T/#6S.ACOI'_5%   J"_HZ7H  $X2>V98$,H
M [;&&/Y"                 $D2J+:/#/P                "F2#"(UV^
M                   T4DW:2                      $LWF
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M5XZS:A&04.88N<F33P? (=7$%60@L2\R;)3!#8>T"4Q7&('AQB\JT1WG?R\
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M,'Q28<8_'1R&8=:/B?MS#P:NC^>N)L7K=N;KUS)I3X7^=\1EPPSJ-.][T6G
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M>,L4PQ4+![:[KZXKEO\ .?Y]O]'4@CA&Y.]<>N:KCNT3N_XUP&2Z'L)@ &/
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MCWW\3_1^/_G[C[X[ YA=YO-YOZ'],._Z%EO\Z\G[('^7,FCY3_<O_P 3_\0
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M'%%EB!T#426X,'*5+ ,R=GNSN/!D @DJSPB^):GDP!2*=)42$&>[&"S-<7B
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M01@ DC<+QO;80W"0H,E)2L!F=D)D6\":$(HG7<OJW!1G3)YY_K\*$JGB$JH
M[7"],X6(B1$9&0DI#.(TPC%8;$(K%(B=Q>-84E2B;3 //T_^\==[O'49^V[Y
MM[C[_P Z_G&M=>Y//K#:>V-.ZBGQ'QU7C(ZC*-E1DB%$A>V(M);DMP(I(/<_
M&$TT'&(! <D@":]\T=2I#NX ,GWW,9(]EY2:+7L J:J,#(@5*EDE(.:)4N-Y
M0P3BMG2;W"ML>^&^@&V)PQ-HLJC9YQWUVH"R;D%VE( ='-5\44@)%3+\X%;
M4S#"2!-<-8N=FYB-" E%$(>:QF!>HB]>>SSXR: :!>ML*I;H?B*@IU)[QYNH
MBW%01MHDL[J@@W;7'$R02(^7!XZGK TM@W&VH?EGMUD&U"!!)LAJ(Z\:P4*P
M2GL-<:BH3GC66MW_ !UK&#+[>)G05#Z??'6B'U&5!#EMN(FJPL(:)'(S,>=!
M<QSC4&3A!H>I2)L]];9QP5-D1S4/BM>>)9([$F4\HR;F^N>]X2)S=M,L(;X^
M8XG^OPV%I9'&7@2;Z<CY@71@RRB)PA4<!B*$24I$JED+W$XLLE":3$2J/3WK
M_P"^Q+KM;+_$>_61@*D]Q;Q9?[K'2E[/9B;\[G=;PB"KCT]2]5X/IY&)1'1^
MJV-U6 [(2,/PI9$"S-;VTT+$D0(( 20DQ$:4?5?R$@*DEB^"PX$B]9D6D&62
MUMXQ F&>[?OZK/L0D(@&8$:8AVS3ZX%'"@-AE"3+2.)OSD]OVC"9A#J*CIK%
M0!73-Q$E*)')Z8\648%6F%"T)J.J@2'D"*E*%%99N2IV,9HA"SBQMDGH]JR'
M4@)FQ(]] 1;L=X1Q0P"?=AM>B]?0)I"(A@<2)%.?;$4BR ++CT^LVOH902LT
MLWT^:XU',Y0J0/#2R\0>_+@G%2"&&R0UXXU,84H229<6[D5B/4T\8\O"G[I]
MEQ3Y1,\RA&M0W^,JK>H74\\_[OJRDU"?;B.[F/C$$D5ZG+UQ?'ID8#H]MP[Y
MUK?H8$6!7AG<%-=WZ\F.3Q,V343P!<2U176&O]#^C)I<%4-\0D"4@)>3RT:$
M0PW"+C<:P#8/-)6<MM&=+-8I*D%!(13&8[7P83!.X!\O+[__ &7SML\[_'UR
MB[A,>8?MS3/-7A$;RE-MQ7-<G_,)D5.A>Y]YN?&,3=,&U:>1*3?SGBU%"6]!
ME&H\.'HC1S%5,D, 6B(K(B8V.AE"%(1+J"((V-V%!.0#4:7E]8P'=9B"SD6X
M]%X=Q/.$T)H$*86-^/.$4+=B&.%%27EEOC(\])"5 I9Z/<,F9%5  JYY7_%N
M"EF*E-10R@ UNW>.1(I%0;E1ZEJ([Q IP*EH$I5U/K.+(19"(M\>T^/&*82]
M% W[7\<X>"*W](Y^/MG-$W')7I_/QCPO$Q$_+Q\W]I:B:PC['[Z3D!9"L0!;
MF">MGSCD0J)DE4C8-+%S$.QE6(X/H!+Y[YU7.*2ICZ!!?K/I.2DEH9)GS=>/
MCY)"38ZA+GSK4FB[K(*BAUS$SZ8$)9*V>ZSN<XVU_P#8WYB8F>,DE99MC8#Z
M\<>N1I(V=7]"/3T_H 0$2+RC^(A62+1#' D>,61$C%U0$$<'IJLD# L"8/*)
MSU[[J)DJG<"'X4V0EQ>\%C@]?6*6?SUB#A^'\F4*!0HE)Y0FIVZ"W!N(>;B"
MO,T=3^')8)I5.^TYY#B8]+P"I$ 4Z'67?TY_)^(>7+B:GKH\\3'2WK(WJA>O
M0]< SNE-/'IB 6Z\/\8P"!$FY$_2<0,+#$Z=?&#XOO/Y_>")O;^3;4S]?&43
MQ.O7:=<N*3#"!WN)KME-+O1B"B%"GMP!YOHB8<!BB%2A;=2R\//5M9R)F+:(
MW<^."9DF<G0=$]HD>(CQOUR90J1&)AFQY"Z;C1S$3MT64BRB-LA"0F&<5#2&
MX_C%!?(D]_;;.&15%34=2SZ'O-QD1;S)SXIIY?2*R8"^;G9]4BO>/0&FJ*X'
MR?L<X#5->_KOTF9Q$$L)5/?*_P#><&%4D3T[U[?7)KNC9\Q&&9=+]?\ 77/O
MAH#G]^V\U%$"):3<<''@N:QRQ&2@BD4<U.C0[XGT)1=RJF7$ZJ'S& &+^G-\
M%8DB=D>SO-#4V3R7K[\W3B@DIF/<3XK[YL<,US##+H!57U/OE/U_&1)%;$*]
M]%T;W&,&N#UM)U^Z_N@H;)<Q0)>;Y(N5BBYU7F#IZPV6\9^^_O?ZT10.JX0L
M*P>;LZDIH2L*["UL.AU(Y$15Q(#:HE2:.!U()!%(I=YA#$,7909K0Q0R2RMA
M(WO%)D3 GL:(K&C1%PAT%FTE,)=R(+)!&/:H+:'3S+]:K/WGC\_I\9*F(Q8D
M-@IG0!UO$FL'0**6]P/;&\&@"FI&T1#_ %K?>)0-RNHM>)G37SY6N0E_*+T>
MQ&$-&4#8=-B\>_T:#$M4N]8Y27#0 B#V;W3/KA< M(%!?GBYU[X.)R. W:/G
M:5O45A0066%Q/,\\48T,B0CNRK%%EEDY=68\X!!/(ZD65C[\F*+J-G[]?^9'
MM8!-P8A9+9^C?+*&ERPD'N 10I5FY;QB2!1C2&SZSZ96"96!B9^WT],J)?HQ
M/H_.,NXA!U$5^#\\N/K0C]_?OE.>%L*0-MVSEL?@&38][G?.@Q0,R)979Z]!
M?PS.-<L@#LHF5)<PFBM0E6"2JC+!PNCF-=X,10\V#?O^,?K<O?[^^<!%I$GD
M]/???=&&P!$@=^L-1,SU3K#2#.XXVS#4'CG5&/0"VA >NH]+V8.K;$Q PI!>
MJ1YF=T8_=@J:?$#Q%\)>YR  &:ZC^Z3R1"$*1TSS4DE92V(@!)/6V7CXWC='
MBU_+S^E :6,(068'#MK?JA<81D&>(*7(@ PB%!EF2A",GQ,UC9J$R\!$@%(F
MQ6=F9D9&U&BUH.4$**C#"@V1D22JI= D28T4  IB1/0VP1!@"XP   I16SVY
MHO"8LU7=-<;8Y\5K")=-&0"5VA5>'*N59HH& TE>_=0S,UU'IY\9^_LXBZ8]
MI][SREZFOJ9?/VC\N!O0_;IF9./VD2,DFP1!2;?C"6A3"%ZND1 U'I&=3".9
M":PE%D"F1QQ*@LNDTG"'H'K.(LHV ?%>N^87((7<&M5]O7CO%M+)J%=,/7.J
M^N3\"D<%_P 5QO%H/M"9ZW/SZ'*Y#L3!(B>%[_7<X(0DPI?-!/YR58LI9DB)
M'B7CS6[QS+AH,70"<D \VY(;5!2S1H@!<3Q> G"2B0X,+";DXG(F-!B[M)0S
M.R4>#4(RM3?OJ(R6SS'QAH)3RAC1?,^TOU2!;"867K[_ /+_ *W+?TU]?UQ)
M^1^&<69CRD,W///G> &@/0C-TV=.I[]<X@(/;^/I_>G!/4&3KQ[1D)("[I9<
M^\PY!T?!FT@*W&WAUJ=CMR&@K,MI9=LMVWXXJL#6T2PT)>8^>MVN0*H)-445
M)IYO\=(J6 - 7Z^/UXP*"!*$3$Q\3^P8+:.$E6A2.ZW@'!\9#H^#$'_MQU)%
M80FU/:KXC^]TQOC&+IJ]ZL:_Y\9=D%07T^*AKU[Q4Q0]BM,;Y;I=SA N2XC#
M=/",>GOFQ!YT";T^E^:33@)U%6Z5\_68_.04A*\2FGX>IBI/1P3$^TNG7FL4
MRN%4G)RZ@)DN)I)\S#J)>3-<D2*%NO-'@WQY7Q(!)20(EO$)K%U!\K(@!-\V
M)=Y4(1 %J M*E0@/-83ID7M-,%#)4-!&%="RE@EC"W%<O?>($)U2))GXGGVQ
M1S%QQ <2!7^NLZ_?S_'^%]T]&/MBI&+[!MM,)$%A'QFW7XH@ITE0;\X@=#93
MLF9ZWSQWC"N1K4GK=,:]\N(L,[8_.^?S& HN"%B"89(ZL@YR2Y \41] G@_Y
MB .>J3Y]B>O;<!RLE FB@)3!/<*P,(Z#,T*^UF_?-!8*F<5(J)7N4VDXBFHR
MFXKIXKVI[B< ,(B4*B@*NY4F\@Z/\//A_?V/]7B@QR_#PG4?%X(!Y^$J1F Y
M -1T819EPL-3YWJ2(..G#I$8)D(> GDXCNL)$(9'<C41S\]^,!)&7 TMUQ>N
M3ZQA0+2#(@D1/8R#7,$9=<3:!'"L6(_ Q:N<;A(0DF% 62,[>K1H)<A =PX2
M=_BL-,D6Q4B6=<)XXPFR@ +]@-_B]X,2 B"".*]8_>\$&YEG_!C' ^N238WQ
M)Q^UX>\GQ^'^,GQ^'C[^_OD^/P_QB&0"!ZM_U>O^8*2X-/G%<K8-O!FY)B]"
MR[,<QBV088EB>>-)V+A(W2\&QF9BQ;EJ9[RY\$$10::DJ_9Q'=3-26\:AH+(
M#@QY&4&PD'S42;J?;%Q)(HNX3MMEE\]1&$Q<>W[_ *Q\1/$X^9[<_(_X;2/3
M.>E^_OU?&(3/(E1SQZ>=^O"RS$<1_3TR=QK)!4QF?/@GF7"!>UR225,U'U Q
M,9CX=G46QS/TG%IS]'YC]7BW,3D:.EU$Q/+[QSAFS-W7HR^F_)A) A;?6)O_
M !R37V4^I>, BC2:9X29*N8;(QL5NBS(ESZM?T67_2K^\_7 M%Z!AAX<&/=+
MA2S-ME_[W_@__\0 *A ! 0 " @$"!00# 0$      1$ (3%!46%Q@9&AL? 0
M(,'14.'Q0##_V@ ( 0$  3\0_P#FZ'VPT0#6P#&8QN@8*2;K!I)Z[Z[YY>.&
M*/)>_P#/_P!8!= >1^YG77KZ8[OB!?GWY8>Q)+#I\-;I0._2 3&4763H14T7
MG_%+/R!IY^.OCEXU[^CV>:>)@AT!0  *JT MKJ>*G=K0.G.RIQ.;K 2M5$+A
MN,ULV@PF#O:P*UC$M-GBL@)<JRZ<9R I  Q8!/15"F!Q?VBMSIS*0"'#S"C(
M(WCV[H?XB6##QH^*\A,D(0"A/I"ZQL0G87P]?),N\2*1=-:N?"_3C%1$5%#I
MU!ZWBSY7O^O]^F6S7/?7'S^A_@@*@ J4 "J2  JKQBL%I?+!HBH"$B4@H%1!
M 1ZMM LBR[LBDH450G40:PN0-#X4J-=%.%*G3J%@0#>0)\1F 5D"\V)>K:8J
MD5P   .AH T< !.L"KG!00D,-B@*O>L2@8$P X1 ML+<  ">@57!MGH)$DDP
M-M!0]PJ8/:F%"5VM3OI=%TT4-!FB";(I JD 062(;@244*Y74@KSI.I)Q,6?
M4(L,/B.;9++OS4;=U*.[<C..23;!L[$#A,!(:GL(#_PB'"6L@=YU:J5S9P$T
ME'3P*SBI"-$(.C&L@P_"H0 +#4U4E;RXES 8<"012O(P1O9J=+.V<?\ K4)7
MGC\^^!$Q#F*Q=H1#EXYMLVI]"2N3D6V^Z_CMVZ0)4']SPWQ^<X"RIAEV%X#:
M:W*W!:.P!7@-:'QN\[W.Q-4#23"%W;A3@U6;VA%BKXJL82!0=;YWK3I$X&O/
M&*L;/#15.SGT\'MF]%MVI1?5-&HCI <#0F&-5X)X&88Z,#D1X&H].(T,*'9R
M9.DAW(]/#6+L7G>LLUNB1B[;?1O6'Z@TV%,Z!4')5=2+4G#;"*H!2F+%84M&
M20Y(8+4QN#Q6]*R('" _^H&^LE59D&71*;.&TIN-!CK>!UC! .9^Y0\$OQ]P
MUKZ8@- "H  %6NH&U8 +8;4&)4<D\#=51#K!!FF;=3B>_P 8._07Y;"QD2H.
MLT7#EM=A3KHE*4".M*K7OQZ]'F<<9MVAXJIC8429-EWQ (26AQ;Z#"Q%FY-1
M&G<.]1Y]:'*,P/W:E!^P@N<+BC@&4KPX<,+"N$:X!A9F3!!9KO+(-CQ(!O8+
M.+^V7PZ11UH@H1CK+LF\"W'(C&/U@KR37G=U3X7D9^U9_P!#[XDG=NRNSV'_
M )LN<5AZ;MX?'5W_ 'P:*B3\[X^/L*_^!T/Y^'GOQO!GE0]!<KB/('L+TJF[
MSOD4F]&H?O!M[YZ%U(+]M_7&95=)&67.K[2P8&!S1CTB@N"K:!HFAK@>(OPO
M#-X50I5K,8:F5*T.]#WC4RX$&+L9)OT6*O ;\;7TV)OCB,20EEL"KQ";==F/
M USCJ8-F=&02)"Z39R8J+""$ST#X$^W7IQ@#@_/S\WD6S?GY_P J^^0\?F_[
M?W'H?=*>PP,R08'<Y U*C.=4$/[6#_,@+V"\1#,##^%,E-H43EJ971KD900<
MP*#K4!]BC('(D25G@'!UZ>/_ +K!?& UIIUPN FO8#@T>G%UJ3S];^U0Y9^?
M'C -V=4G<'(("L-XS34R%8RZ,1H0N&_0<R8.X@,(A8C8#5 X Y0B5X\<SE"E
M*/D2N;):KV Z5,F^+HK%: CD(A<SJEJX4NGJ-2>!-HKIYGW."=\(O'-_$[;,
MMS0-J[E\%B@*\BJ<K&A19$A$8P))9+X6'Q0-2K*)648&XD4)P&;.\.#V_./W
MI22V"/"78WTN$XI/P">="EV &=_J\/J3YXC9SKWX?["%AAQ'S-A*%&8CP#,$
MVKN]S"I<C6]+C6^_*O&B;CHW%B]?K28$WGT8;8^PU+81O8/#3#SE&&2GV&08
MU$ $#Q/A#+-S@IZXJ$S ?5KT$^@H:5R9H_M7D]U//I7BJWY9@05F 8.>,6>
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M\'RB)WP1ML]5QR8B*T.D"/#$A;"8I1<7%!N=5]"BU4\8J1NS40=T18YD'_$
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ME@N+H$(AG+75G( 1'(\[/3M._A>3$Z7>ZK2Q1YO$2PPTFALB-N6=&[XK.08
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M.>1H\GB_M(=('=F 6H[S^T\7@N,:&.SCB$BRBH%7 5Q>?CQS\OEG%\??U_\
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M/]^\IJ6QVW",I)941EY.7_L0*T%]1,M%8I/V5>SI"4M[0P7O6".#1S8X8PV
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AUP+&+\M[MC@F[_D,L0I32IJD!: $%,^/^_\ G^#_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>business8a.jpg
<TEXT>
begin 644 business8a.jpg
M_]C_X  02D9)1@ ! 0  > !X  #_X0",17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        !X     0   '@    !  .@ 0 #     0 !  "@
M @ $     0   RF@ P $     0   E8     _^T .%!H;W1O<VAO<" S+C
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M^!OY:_\ XU^D-%']I?\ 3F'_ ("'U3_IY+[_ /@'YO?\)7_P6]_N? W\M?\
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M^!OY:_\ XU^D-%']I?\ 3F'_ ("'U3_IY+[_ /@'YO?\)7_P6]_N? W\M?\
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MA7WA7P?\;_\ DH/PA_[':+_TVZA7WA736_A4_1_FS*'Q3]?T1__1_IO\6?\
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M:2R;\="*Y/X]:-^Q)X=^&\K^*OVA_B#X\L]1:.#^P]+\36^K3W.]@0&MS'L
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MGQX^*WQ/_8'G^-/CG5?MWB9++6)1>>1#'A[5IA$?+C18_E"K_!@XYSS7SO\
M\%#?VUOV;O&_['&H>%O /B>PUW5/%*6R6UI:N))H521)6:9/O0E0N,2!6R<
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M590110QQ7<GEAXI5@@DW1MP1)N! /J&KGOB'_P IL-&_Z[0?^D#59_X*O_\
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M:_-[Q9_RF]3_ +(:/_3^:_2&O2S+_ES_ ((_J<F$_P"7G^)A1117FG6%%%%
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M](:]+,O^7/\ @C^IR83_ )>?XF%%%%>:=84444 %%%% !1110 4444 %%%%
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MRO;:_D%%%%9&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SO\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G?XW_\E!^$/_8[1?\
MIMU"OO"O@_XW_P#)0?A#_P!CM%_Z;=0K[PKIK?PJ?H_S9E#XI^OZ(__5_IO\
M6?\ *;U/^R&C_P!/YK](:_-[Q9_RF]3_ +(:/_3^:_2&O2S+_ES_ ((_J<F$
M_P"7G^)A1117FG6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5E90RG(/<5_"%_P7>_;YN;7P9^S-^QKK-SXXLO#VH1:3JGC:;0PT+ZU87$,
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MA736_A4_1_FS*'Q3]?T1_]#^F_Q9_P IO4_[(:/_ $_FOTAK\WO%G_*;U/\
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M"'B=]+>PO?$6@:7>VLKW?V;RT9E1%9S(5W<.KDO&Q/5?&/\ X+7>);_]AO\
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MI@?4!<VLKSP1FWMRP5Y0S#8 S+M  '/]9%Q;6UY";>[C66-NJN P/X&OD/\
M;B_8X\'_ +</[.]_^S[XIU6ZT&WN)X+JWN[)58PSVQ)CW1M@/'SRF5SQ@@C-
M>9BLDJQPU:G2:E=345;5<\N9J[E;OLHMZ-R35SZG*/$W#SKY9#&4Y4E1EAE4
MG%Q<90P[CRMP5)57*T5_R^:3NU'6R_GG_8[^,WP7\7_M+?!_QI^U-\9=7\0:
M_P"$].DTOP)HVJ>%9- MVO+N)8=LMV/,BDD(*HIW;2P4[LG#?*/QW_; ^,G[
M3'[*?Q6T/]HGXH>(X/B,E[<6\?PQTS05CLK:PLYTD=KF86K/Y<*AG,CS*R[
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MNL@8'S5,99N&/W66OG&\_P""9GP2N9=;TZWU_P 3V?A_7Y9;BYT*UU+RM/\
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M97$%M_P6[CDN'6-3\#@,L<#/]OFOT7_M;2_^?F+_ +['^-?F%\75#?\ !:J
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M:$!:>]N$TR%;78P?<7&P(-V[&<'*@YC]6?[:TC_GZB_[['^-']M:1_S]1?\
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MC;>7'(P6V^SO<SK;B11-=)"L'*_=R!1RH.8_7[^VM(_Y^HO^^Q_C2?VWH_\
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M_P"ADL__ $GNJ^CX1_Y'.%_Q(\O._P#<*W^%GU_^R>C']F'X>D'_ )EW3?\
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M&W[=WP.\:_L\Z)^TC=W.I:+I6LB&);>;3+\W?VN6(3&&*#[,)[C:N2'BC9&
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M\7/@K^VGJ7PQ_:D_9\\.7?Q%\#?#?Q;?O<+8Q+!_:NVV>W6]T];AXDNXK&\
M+H^TF6/?%N:(9_6KP[<>%_'7AZU\2^&+R&_L+Q?EEB=94)Z,I*%AN5LAAG@B
MOK,9[#&\LI0Y5TTW_0\BBZE&Z3N?QZ? +P+I_P"V9X(^'O[ EAX:O?!EOH7Q
M'UKXN^/M&%A+IUOX-@%U<Q:=H%@9U"OY[LS.T8*>6788SBOZUM?UN2RCAMUY
M!CR<>IZU\3?ML?$O5O@O\)M3USPC<20:K<ZQI&CZ:MN TTTVH:A!;B&+<"H=
MT=P&;A>O&*]S^(7CGPWX,\.ZEXQ\87L6G:3I%M->7=U.VV*"W@4O(['LJJ"3
M]*]?+<LI89<J=^K;\]ON.3$XJ=5W:\CX%_:;3]KWXY?'B[^ G['?CFT\&WFC
M?#_6-?O;N6TANXDU>XG@MM)@NGD20P),INI4*(SDPDD,HY] _P""0/P_^%W@
M_P 1_$_PIXP\'W>C?'KP9=V6D^,M7U;6Y?$MYJME>PK=V-U;W\T<.+2X4LPA
MC@@6.1&4IP#7S9^S!^V#^S_\,?VA_P!H?]H'XY>((/ASX/\ $=KX&N]*&K/]
MG&L6,EMJ"P:C%'G<9[PP2Q+"5$XCMDWJ. /OS_@DA\ ]:TGX'C]L[XUC4Y_B
MS\;K:'5]>EU69VDM=-$L\NE6$4!PEO%;6LZCRU4'<6R>P^.SO%SJXF<>9\J>
MBZ'LX*DH4D[:GZL"WSTR:>D0ZBL76O&/A?PU_P C#=K9+_>ER%_/I^=4+'XI
M?"R^3-IXCTQ_I=1Y_P#0J\8ZSKA 3ZT[[/CC%<??_%KX1Z3&9M4\4Z1;*.29
M;Z%0/S85X9XP_;T_8L\!HY\2_$S0%*?>CMKI;N3C_8@WL3[ 4 ?4GD$CD4GV
M?!Y%?F5?_P#!5[X(^(KIM'_9Z\)>+/B9?'A%TC2I8X2?>28(P'N$-56\7_\
M!5WX\CR?"/A/P_\ !C2)O^7O6KC^T]3"GNL2 JK>TD0^M 'Z5ZUJ&B^'-,EU
MKQ%=PZ?:0#?)<7,BQ1(!W9G( 'U-? WQ&_X*@_L3?#N].BVWBT>)M3#;4M-
MMI-19V]!)&ODY]C(*YK1O^"5_@;QEJD/BK]KSQOXA^+>JHP;R-0N7L]+C;TC
MMH6^4#V=0?[M??WPY^"GPB^#]BNF_"GPQI7AV(#!_L^UC@=A_M.HWL?=F)H
M_-Y?^"@OQM\;CS/@E^SKXVUB!_\ 5W.JHFEPMGON(E7]:4_'/_@JIKG[[1O@
M#HFF0GI]O\2VTC?BJO&1^*U^L[PNWWSD^]0M!CG]: /R@_X6O_P5LMAYDWP8
M\*70'\$7B"&-L?5YL5"W[7W[=OA(E_B9^S-J<T2??DT#5H=3;'<A(D;/TW5^
ML1B] ?Q%)Y)Z&@#\K= _X*N_LSQ:JGAWXRZ?XC^&NHN=OD^(]+EB3=_OPB4
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M>(?V@_V0O"'Q4\9W0O-:O8[J.^EP%W3V]Q+&W X (4$#L*^S/)'7:<U\4_\
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MDC@C::5@%4$DDX&!5QE+$+7YW?M _%WQ-X_U*^^%G@'S=/TJRE,&KZIG#?*
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M[>%?!6D^$?#]IH>GQB*UL(([>%.RQQ*%4?@!44\!0IQY5&RU_P 3OW?3Y?\
M#U/$SD[WO^1\E?LL_ /3_P!E_P  R>%FU>Z\1ZUJNH7.M:]KM^JK=:KJU\^^
MXN9%0!5W'"HB\)&JJ.F:^H=5\5M<VOV=/2L+Q#)"]T4C[&O)/B7\3OA[\'?!
M&H_$KXJ:S:Z!H.DQ^;=W][((H8ER ,L>Y)  &220!S7O4\/2C",FK)?@CSIU
M)N35[MGC'[9.M?#T?L]^*_ 7C^W?5?\ A,-(U#1K/1X&"W>JW-S Z);6^2,R
MN2-O(QU[5U/_  0B^,/[3_Q4_9<\1^#OVG=7MO$MS\-_$3^$=.UJ&-4DNTTZ
MUM_M"2-&3'-]FN6DMUG7'FB/)&<D_D)^TY^V%9?MZZ=<? ;]DSPIXD^('A$J
M#+KFBZ1>26FH>(H]DFG:9#>+%LM!'*R7-W=2%5CBC**<EB/ZG?V'?V9]._8]
M_9#^'?[-%A]F=_!^A6=A=W%K$(4N;U(Q]IN"HZM-,7D9CDLQ)))-?%<38NE6
MG%4VG8]S+*,X)\RM<^EOLX)SQ^(K\?O^"VD/E_L@Z8W'_(TV73_KVNZ_97RR
M>3@_A7X[_P#!;Q-O['NEG&/^*JL?_2:[KGX1_P"1SA?\2#._]PK?X6?;/[&D
M.?V2/AD3_P!"OI7_ *31U](F''0<U\__ +&$9_X9$^&)SC/A?2O_ $FCKZ5,
M0/<&O*S/_?*W^*7YL[,)_ I^B_(QV@_(^M-,7&,5LF+Y<@Y_"H7C#'/]*X3H
M,?[/SP*B:'Y>P^AK9,'8=:C,)Z#OQ0!R\]N?X17X;_\ !9GPAI%MJW[/WQS\
M9VEKK7AKPQX\32=2TG4HEGL&/B&!K6WO)(W!C,EK.J>674@>8<8/-?O%- =N
M/7FODC]MCX+_  _^/'[)GQ$^%GQ0^QQ:+J>@7YENK\'R+)X86DBNV(^9?LTB
MK,&4Y79D5M39X>/I.[6NJ:^\^"YO-\4O+I/B1$O[1RNZ&X421G805^1@5^4@
M%>." 1TKT504C!/:OBG]@#QKXY^)G[(OP_\ B'\1=.ELM3O],6-GF+$WL5LQ
MACO4WJC^7=(@G3<H.UQFON"5XQ%G& .]?4T9IP31^#XK#SHUJE*H]4W^9X)^
MT)^T)X3_ &9OA'JGQF\9VUY?6>DO;1K:Z?'YUU<3W<R00Q1*2H+/)(JC) YZ
MU^<_[*?[/7_!3'X.^%?&GQR^!W@^\LOAM<>-)M3TWX4>)K.&#Q+/I5\5>]FM
M;K[2$@<3O))#!-NW@'YAN%>S?M4_#SXB_M"_M/\ P9_9+TC4(;?PEXWU)]=\
M1)(@\Z.R\)3V]YB%^NZYFEAB8'[JKD=Z_II2'8BI&/E P/PKR<=B9>TM%['Z
M!PQE-+ZE[2M%2=3H]K+1:=[WUW1_/5X.^!W_  5N^,6@:G\;M-U7P]\.)9=9
MN!HGP_\ %FEEW.CJ2D37]_97,SQ7+CY]D<;*O0]<"V_[*_\ P6EL;NVU)/%?
MPFU,ZFQ6YM'M=3@@T@*00\4@8R7FY<AE818;!!Q7]!OE;A@C\*C-HQ/RC%<G
MUJI_,SZ*.181JWL(_<CX/_85_9!U?]DCX=ZYH?BK7H/$6O>+/$%_XFU>[L[3
M[!9_;=18-(EO 7D*1+@ ;G9B<L3DU]SQP?XU>2U*]>M6?*  [@5R2G<]_"87
MDU,Y8AM--\C/0GZ5IF('TI-G8C@>M0>F9?E%><FJSXZX_"M&5<'/XUS'B+6]
M-\.Z7-JVJS+!!"A=W<[0H'<FKC&[/.QF)4%8L7,HAC8],"OQ2G\0-IQ\7Z9<
MR?Z3%KESYLA;[Y8@K^0(%>W^-_VE?B5KD.J?$#P;<)%H&DW&V*V\HL]Y A'F
M.">0.NW [5^/WC;QO:?%+QW-X-6>ZALKK4;V^2[4O!YI=05P>,E">GH*]"A!
MQ=VCX?-L7"O3=*+]3U_Q'+JFIQM)#<&W>>Z@MVE'WD25PI*^^.E>W_%SX0-^
MRSK"_$V"676]*U."W@N)IYA]HB<G&0/X@<] .*^4/#.C_&BVT6?0I[[2[J.>
M/[/OD5A(!VDS_?'7ZU[5XMMO$6K16%S\0/$,WB"+2H@+:WEC5(U< #<0,[B.
MV:UDI.5T<6&G0A1<)6N=/K7C&RN[Z&)&^^0??FOI3]BSP?8?"SXI/H=[;B]?
MQ DMY97>=TD*9RT3 _=&3D$=:_-VUN=4O]9FO[=#(8%:15[94$XK]L_V$?A/
MIVD?#VQ^)^K%[O6M9@$LD\A+>6CG(C0'[JCIQ6=9Z'7E--\S['Z!6\1*@"M)
M$.,'L*;!%E0:NK$2,^]>=-W9]_@X-014V[3G'Y=*:40CZU>$8QU--VX.0,^]
M0=AC7:$6TF!C"DU_&=_P7WT+0OB9J/PT^'_C"W%]I.L?$SPYI]Y;EF02V]RT
MD<B;D(8;D8C*D$9X(-?V<Z@O^B2E3_">*_BV_P""YFG-K/BCX8:2TTMM]J^*
M/AF'SH&V2Q^9(XW(W.&&<@]C0!]RZE^U7XGO=0U#P%^S#\/M5\<3^'IVTZYO
M&9=/TF"6WD\ET%U.<SF(JP<0+(PVX/)%5KGXZ?MN>#/!MW\0_B3\+='32=+S
M/=PZ;K3W.H&U5\,\5O\ 90&=$S(4+@D< YXKA_V!])^,O@_Q%XC^">E:CI&H
M?#CP'?OI*W4MH]KK%Q?A1+.S!9)$<%Y,M,^UY&R0N#FOU4ELRJ'8,$#(-?(8
MW.\30KRIZ:,]_#Y?2J4E+74^1_AG^UY\&OBGXMA\&>%;R]6]O()+BS^VV%S9
MQ7<<.WS6MY)XT27RRZ[]A.,CL:^P]%<2,  ,\5^</A:];X@?MV^-=7O_ -_;
M^ ]%T[1;1+F4%[>ZO@;NXDMX@>(YHGMU>1@"6CVCA:ZKXK?'#5/%WCK2?V<_
M@9K5U9:Y>:G]FU[5+&R>X_LNRCA>20I-(AMDG+^7'ARS)OSL)KZO+YRQ%.$V
MM6?(YU7AA5-MZ1);:RUG]LO]HHW5[I]Y_P *J^'=\T%KNDBCM]5\0V4DJ332
M1$&22"U($<8. 9=S$$!2,CQI^Q;XS\"^)=6U3X5^+]7TC1-6U9[_ $S3='S;
M1Z1=WKF6>00H?L]S TI+-%-'@(Q52#@U]^?!#X9>"_@I\.+'X=^"!*;.SWN9
M;B3SIYYI6+R2RR'EY)'8LS'J37K$48GRI'%?2+#P@E"4=3\?K9WB:U:6(HU.
M5;)>7^9^)GQ#_:=_::_95\:Z9'^T5H]GXD\#W\CVT_B'0[0VUQ;2I"TYD>S:
MYG>2)4C<RLJKLQD BOSG_;#_ &<OVC[SXM:@?A5<WQ\.^.[^SU2;Q8MY"]SI
M]E%%@V_DR!6;YMIC8!B8R0QXK^D7XY_"SPE\0-$DT7QEID&IV<J2(8YUS\LJ
ME' (P5W(2I((."17X_?#W4_$-K\:/$O[*\6H)XGTGPU:F[MKI%F,^EI)(?+L
M+N20LLCK&RF)@VXH/F&>3YN/R^%E+[)]IPKQ75J2=*6E1+5]T?C;\:_V;_$?
MPH\/W7[4EYK%MXB\:>&[I+QGGMWBMFL53R/LL2AW,0S(96?)!?)(P!CZ5^#W
M[1_AZ+QU<>./%%K<Z;8I8II]I<DF=;NZCF=9[>!(=XE9&VD#[YW9 P:^W_B+
MX6?P_9WMUJ<!>UMH999D*[@\<:EF7'(.0",=ZXS]A._^'WP,_8F\*^(O%TMC
MI4.IQRZW/(=D<:&_D:53(_ +JK!2WM7-A.'*.83<)OE26Z^7_!/T7#\35\+#
MFA[S;ZDWQ:\?#XP?!RVTCX:ZQ':6WBO48M"N[IXRT]HET)$D4V[E'$FY0A5@
M"H)/:ODKXL3?%W]CH7.K_$WPY:>)Y-1MY=/\-ZAHBNDTETL6?L\]NTC"/>$!
M616+,%"MAL9^V+#]L+]BZ6[/QPL_!"7ES9Q37E[XCETP1/;P1C8LJS,@,K29
M 0(2Q7)^OJ/PL_:Y_8^^+GC;1?'\.KZ=JES&D\6F[K@+)$90#*!"Q!60*F&R
MNY0"..:]?#\%Y?'#RH3GS2;NGL[?J&)XQQU3$1Q$%RI*S6ZOW/QJ\&?%;X>V
M.B:A\4?AG:^(/'/Q&NM&B,T=Y;/>?V(RY"6MT\:(EJB.S,Y8[V4%BQXKU[X#
M_$KXQ?#CXUP?$C6[NS\6:/KFKV6@:MJ"6@6RMYW!$8M)DW>1'&I"?O'?S2<G
M:3@_T2VWB#X-WZ7FL^']%MUN;]5\VY@"!I<#Y2[+RV >,YXK\I_VF_$\/@7X
MK^'/"?C25&^'M\\][<Z!X>LFGU*66VVRPS7"1*2;<R@AMBCY@F203CJI<+4,
M%!UE-MK^D>#G6;5<PHRI5(JUGHN]OS/W7\#1I'ID5PT2J" >!4GQ"^/WP=^$
M?V.'XI^)=,\/'4'$=J+^YCMS*Q.,+O(SS7R%^R;^V5\._CM\++/QEH=O=:;;
M/)+;"WOE1)XV@8H0RJS <CIG([\U\9>*[3P7^TO^V+\3[SQ(EGJ>E:#HUIX4
M6UC5;B.:UN8S<2/)-N)BG#RNAC0*R@*22<8Y\QQBP]'VUKGY/P[P[4S#'2P=
M1\C2>MNQ^S/C#5["YTTM RNK@,".00>X-?AS^U;KWA;]IWXIV/[#_@6ZN+C5
MVO[/5?$4]G+Y*:=IML^]T>9?F6:;*JB)\X#;B0*\Z_:$^)GQ-_8O\$:-?^#_
M !YKFKV#ZA#:6&B:E;P7X>)"'EB>[?9,%$(?9EF<L% W=*E\ >&?VFK#XRO^
MVMX7\-:"]YXOTN/3;_PFMT;&>W@C/F6\\EU)&4DN-S/YR[1P1M+$5C1S2CB*
M:<+VZG?5X*QV7XF4JC3:3<6GUZ7O]_8_9[PS^SG\+;?X?P_#.UTJV708K3["
MMB4#0FWV[-A4\%2O!SUKX9\;?\$J_@;!>I;VQU>^\.1L9$\-7=_)/HZOV/E-
MERJCA8C(8AV6G?L\?MO?'WXE3W\UY\)+^&QT.^GT>^N+;4;:99-0M79)3:F1
MHEGME("^:&5MV1MXS7ZK^%M>N_$6C6U]K%F;*XF0/);NRNT3'^$LI*DCO@D>
M]>C&-.HKK8^7JU,5@JCA*5I=;.^ORZGXX>'/^"3_ ,.Y-4\2ZO!#-X<74+B*
M;16T*ZGLAI:1Q(K".!7^S'?(K.RM$48-A@:\BMO^"4=K\-X];M],^(M]I$>N
M6\MK?)INEV%I'<PR*0PG3RW5OE)!*!."<8K^B&XGL;*VWR,JJ!TK\B_^"E7[
M2OA[X(_ +Q+XHN[*?5+N^L[G3["QML[[B::)E/S $*J*2[,<<#CG%<U3#TN5
MRE'0]#"YQF$ZD*-*L[R:7?RZGYZ?LVZK=>)+#Q/X%:\MM9TOP5J\FBZ;K%E
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M&G@WPMXGT'6K:>ZUG7[6"T@U;PJT,"$S7<%Q<3:>P,P ?8DHDW@YBR<UY3\
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M\+>,_#-QX/\ %NFVVHZ5=@"6SN$#PO@Y'RXQD'D$8(/(KAO!OPZ\&?#C1?\
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MU% &:81G)Q41C 'O[UI[$Y XJ#RSD9% %':S<8S3#'U&,'%7B@8YZ4GE9[T
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M>(_&=_X+UWXE6O@_['K<OA^/0KBWN]2DTR5+>UC6/6(S#)EX'<L["+,B[&+
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MSI&1C_BJ[+_TFNZ^CX1_Y'&%_P 2/)SO_<*W^%GWY^Q-_P F>?"W_L5=(_\
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MQQZT@C;N:1N5?*(/ !_2F8!-7"K+VS2<^E %7#=2#BEXZBK!..HQ2!>X'XT
M1M'@9SFL77=)35=+FLIE!5U(Q]1BM_(I2,\4 ?R#?\%B_P!EOQFEA'\3_A'%
MY?C;P/?#Q)X=D57#27%HQ:2U8Q S-%=1;HGBC9/-)56.*^9U_:(\ ?\ !3'P
M-I>G_!V]U30O!\NF./%3HBV=[)J%P/+.FC>LA58@)#.Z$A@R!'(R:_JG_;(^
M"=OX^\*/J5JG[^!21@#/6OX>O GP*TW]BO\ X*577AS5Q/9>#?BE+<:AX=CM
MKR2&WMM8MT#75N]I J1;71B8S("BHBJ"SD@:T+<Z3V/*SE36$G4I?%%?\/\
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M_LJV^V274<@E69IO+WF42 /OSNW@-G(KW^DY%,1XR/V</@ -<\1^*/\ A!]
M.H^,/*_MVZ_LZ#SM3^SG,7VIMF9BA *E]V"!Z5U5S\+OAI>:1X@T"\\/:;+8
M^+/,_MNW>UC:+4O-A6W?[4A7$VZ!%B;S,YC4+T %=Z"5Y%2!E*[>F:5V/<@1
M(X8UBC 55&  ,  5^,?_  75_P"3.='_ .QKLO\ TENZ_:4(HYK\7/\ @NNN
MW]CK2/\ L:[+_P!);NOHN$7_ ,+.%_Q(\K/%_L%;_"S[[_8D!/['/PM'_4JZ
M3_Z31U].&/.<'%?-'[$D2G]CGX6'_J5-(_\ 2:.OIXQL.G->7F3_ -LK?XI?
MFSMPB_<4_1?D0B,]_P"5.52.6IV2/O"E'S$ 5Q7-[,*:RANM2>42>32^5CH:
M7,'*5C&P/'2FE7 SBK)1QVS3#QPQQ3N%CXD_;P_98E_:C^"ITCPO/_9WC/PY
M<+K'AG44;8]OJ-O\R+O[+)@*>P.UC]VN7_8R_;2\/_'+X'7VO_%&2+PYXK\$
M%K'Q=8W;>4UG<V^5:4AL$1R8+*>QRO4&OT#ZKS7\?_\ P5\M?C!IGQIU;QM!
M\.M3\!:;XAL_[+U;5;>Y%Q9Z[%&ZO$TOD@QQN-B\%]Y &0#G(!_7LCK*@D0Y
M5@"".X-$TZJOM7QC_P $_/CN?VA_V0?!?Q(O)O.U$V*V6H-G+?;+,F&4GTW,
MA8>Q!KZTO+D)DYJDKG/7JJ"))KK:2<X'UJH+Z.4!HV#+TR.17X2_M,?&+XS_
M +:?Q7\??LL?#+Q%+\-_AEX!U!="\7:[ILP'B+6+V:TANC9Z>=I2SMU2X037
M))E8Y2-5&6KP#2/ GQV_8Z\>6_C#]@76X;KP]=61MM:\'^.M;U*^LKF>)@8K
MJTNI?M<MK<%=R2#!B<8.T$9K6-)M72/#KYG3ISY)SL_P^9_2RL^3UQ5I)RZX
MK\)[7_@L7XS\+6,6H_&?]G;Q]HUG9@QZMJ&EBRUFVMY<[0T"6URUS<0LW21(
M,C(+*.<?8/[(O_!3/]F#]L+7W^'_ (&N]1T#QG;VK7LWACQ)8RZ5JRVRL%,R
MPS >9&"1EXBZC(R0:F4+;G70QC>J::\FF?I!A64 #FHG0CH#4$$ZM5P=QGI6
M;1ZE.HI*Y#C*[\_A2=?:K'8MZ5&VUCZ&D:#*0C-.VGN:3!'/7% !2'U%+AB<
M8Q2[6[F@!A&1ZTPIQP,'ZU/L([TQOER#0! 4;OBD*GJ1^=6MC=N::#GC% $
M#GTI=CGTJ=OE..M(2* *W+9 IHC#'Y1Q5DKM&.:^!/VJOV[=#^"?B^R_9[^"
MNB3?$GXS:[$9=-\)Z<X7[/!T-YJ5Q@I96:' ,DGS.?EC5FXH ]D_:D_:)^!G
M[,/PMN/B'\=]6CTW3WD2UM8$!FO+^[E.([:T@0&2>>0\+&BDGKT!-?R@?ML_
ML!?M&?MRZ3<?%?X\6^H?"3PP\BW_ (4\-V+K)K%I-$&^SW^IS %4N!DL+6%Q
MY8.&DW\C^C#]FK]A/6]&^(L'[5_[:>N0?$CXS/&XM;E8C'HWAN*;[UKHUJY/
ME #"O<OF>;&68 [:^X_B1X"TWQ[X?GTJ^C#%U(&?H1_6@>FQ_#+_ ,$Y/VM_
MB#XWT_7OV6/VI3%IGQ7\%.89()1Y<VJ:> /+O44?NVW9PYB9E/#_ "JZBO%O
M^"@_PW\$Z3X1TB;2=,CTC;?_ &:"ZLG6Q2WN)?FAEN)$*L8877SB#NW.J@CG
M-?=O_!6;_@F?\2=;U[0/CE\#Y!I?Q ^'MT=0T6=QY<5ZBD,]I/*I601R<@?.
M$^=U; <LORA\'/VP/"O[2WA#4UU2#_A$O&?AX/;>(-$U$8DTZ[0$%F#;2\)8
M$J_&0,'# @>G0K*I'DEN?G6<91+ XI8O#I^S;U2Z/_)_\ ]E^"OB_0_%.GVD
M^E:I!K42(L;7<#K(LCJ "<KD9)YQ7Z >#;FQA54A4 XK\/?V,?$L/B[Q)XE^
M+3I8V)U>^6TDL=/.41K',1FDX7]Y-]_I]S;DGK7ZBS_$6Q\/1I-&WS=A77!W
M2/E\=1<*K@CZYOM?CTVW:>8X %?&/QB^*FD:/X=UKQ;>H\]MH]G<7TR18WLE
MNA=@NX@9('&2!FO/OBY^TA'HG@K4/%%VK&STR/S;HHR@I$OWV^8J/E'.,Y/8
M$\5\5>./C#X&_:&\"7GP*^ U]#XJUKQC;-;7-Q;.6MM*LI,"6XN9!C:0IQ''
MG<[<8QFIJ58Q3U*P&5U:TXWCI?5EGX;?L\?%3XL?$S2OVCOBI<Z1I&G7_P!A
MU%= T^!II?\ 1%G^R_:+G>(Y) +@LS!#RJA3@9/Z(ZM?Q#%NAX_K6"EW%X<T
M6UT2"3?]EA2$-@#(10N<# '2N:AO9+J<!CP:\FI*Y^G8/"V226BV/4_#=M$\
MH9>M>R6FE.\2@=ZXCX?^%;N]E250<<'-?6>C^#2(E$BUB>VE96//M$\/.^-R
M_A7J.F^&Q@$KVKN-*\,QQ 86N^L=&"A?EH&>?+X;C>,!UXK&O/ UE*^3&/RK
MW:/3U' &33Y-+C8X*T ?,TW@>VB^98A5(^%UB(V)BOI*XT123\M9S>'P>JT
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MQ_HDH\F6?PC#+%J-O*/NN]I.Y$D<AX8QR90GH5Y'UOX#_P""K?P2M+N/P_\
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M5]G_ +*G['?P<_9!\(76A?#B&ZO]7UJ476N^(]7F-WK.M7G>>\N6 9V))VH
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MXUUJ\N9YIO(FN;AO-.^W$IA;RR=JAE.%4"ON^_U"STF)K72HDA!QD1*%'IT
MKP#]A/QK^S7XS^ &C^!_V??&-IXDETNW#7R#%O=I-.SL[26K8>$.X<JI7&!Q
MD<U]23> KU92\BD\]*YY2/7H89N6J/%KE[N>0R,N<UU7@_P]?ZI?)A#C([5[
M!HOPZN+N81M'P:^H?!/PUT_38UDV#=61Z\(**LCI/A;X92SM(EE3G S7T39:
M)'P=O%<OH>F?9"NP8 KUJP0.HVCGWH+*$&F"+M^5:D=KV'%:*P8Y[U,(EQSR
M: *RP@#Y<GWI3$,<@U;P*0X% &<8$/W?_P!=1-;8]:\R^,WQ^^"O[/7A<^-?
MCGXJTOPII0<1+<:G<I;(TC!F5%+D;F8*VU1R<'%?AIKO_!1O]M3_ (*4>)+W
MX$_\$@/ ][::<ERL%Y\3-<B6'3[5(Y#N:"*2.16$B["ID!EVEAY&<, #[Y_;
MW_X*4_ 3]@W2[30O%?G^(O'6NQ,="\+:8AEO;R0G9'NVY$4;.<;V&3AM@=AB
MO%_^"=G_  2!_:0_;'^+&F?\%!/^"Q)6]N;5S=^$OAZR@66EQ2-YB-=1#@L.
M-L3EGP 96)^4?HQ_P36_X(;_  >_8Z\1K^T+\>=9N_BY\:+Q%-UXIUYFN6MB
M %"6:2EC&JJ-H<DOC@;5.T?O)%"$38@PHH HVMG#9P);6R!(XP%4*,  <  #
MH!5H)GJ<58$>3ECQ4@51TH @QC&!3"@/08JX 1V)H/H: /EC]H--OCGX08_Z
M'>+_ --NHU]H5\:_M#*!XX^$./\ H>(O_3;J%?95;U_X=/T?YLFE\4_7]$?_
MUOTT_P""P&E^&I_^"JO@SQ/XQN5M]+\.?#NTU296!99&BU*^2($ '.V9TD Q
MU05^:USX\LO%NG^-KKP/J/E>,OB+K<&AZ;;,K17-II<?^BI/L<*V%B$]UD<
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MP!_$?[WK7X-QOF6<XZ'L\34M3;NHKI;9L_1,APN!H/FI1]Y+=GY]_P#!4?\
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MA)D)&9#&HR?:_P!D?]AKP'^R_/J7Q#US5+WQY\4/%"@^(O&FME7U&^?KY40
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M 5ZQY1 X ^E!4J/FH JX4=*D1-PR>*E '\-.523Z4 1[ #G'%2*A/0 >]3!
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M-Z>1:6%I%=HHGVW=P&FD\MM_D*>0#FO=OBK>?#CPQX"^*ESJ_B"]TG3K%O\
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M\H2ZCF8I.Z@98PF/>3P%YKXYLM4^*?A3PWX>\%?#W5UE\5M:OJ,MIK^;E9X
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MOQI_X+GE3^QSI&/^AKLO_26[K]CA$ZCY3Q7XU_\ !<K</V.=)##_ )FNQ_\
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MK*3Z&NF2YHV/"HU/J^(C4[._KY']9'P5^)NA?&;X4>&OBQX6D2>P\2:;;:C
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MRU+6M/@T"Z^QJ)K?3--GN8A<AGC) )C! *$_*,X&*];\9>-/"VC?$KP?X?\
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M1D2.>3()VAJ].^-/[%7C7QS9_MGWL/@ZUO[[XJ:3:6?AF200&2^^R:!;6T:
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MP[T+Q.G@[Q-=75OX*D$FKR:YNO%9YHUD^SQ31[&#QJ5 7:^6< \T ?;VB?\
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MC.*@9649JQ10(^4/VD<_\)C\( ?^AYA_]-FHU];U\G?M*_\ (X?"#_L>8?\
MTV:C7UC6^(_AT_1_FR:7Q3]?T1__TOT+_P""W";_ /@I)X='_5-K3_TZ7M?G
M$;-+F)K>YB66*0%71P&5@>H(/!'L:_2;_@M<F_\ X*3^'QC/_%M+3_TZ7E?C
ME\?+[Q/::9X1TOPKJDVCRZSXIT[3KBX@5&D-M,DS2*H<, 6"@ D'!P<'H?5S
M#:C_ ((_J<6&_P"7G^)GL%GX<T'2M.71M+T^VM;-&#K;PPI'$K A@P10%!#
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M2Y^+'P>^+M_^UG^U_KNBZOX_NM'30-)TKPY;-#I.@Z9O\UX8I),232.X7>[
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M" . -M?;VB>"V&"4.:[#X%?"BS70;KQK>QM-JFK7$AN+IBQ$Z1,1&8U;&R,
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M4GVB1,\_6@#[G\/:I^S?\9->_P"$O\"ZV+/4Y"\K7%C=ES()%*D21.SH0,Y
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MHU]8U\F_M)G/B_X0$=/^$YA_]-FHU]94Z_\ #I^C_-GHTOBGZ_HC_]3]-/\
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M;9%5@2A]".Q^M?@)\+O@=XN_9_\ $K>./V9/$UWHEW<&0ZC8ZS-<:IIMZKH
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M]Z[F2TV+E#D5CW-H1P/7% '+&=H^,9Q35U.5?ND@$5J368 P16+=6S9P!^-
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M<&-Y26:52F)!Y:*S90CD#D#FNEUBXT?0--FUWQ%=1V=C:J7EFD. %';U)/0
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MCW+D?UKZ\_X*\L4_X*>Z&1_T2^V_].UW7QPLCD=<'O7JYAM1_P $?U.+#?\
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M1"<MP.]>2?!OPW<^"OA%H^B70(N8[2)9L_\ /5AND_\ 'B:Z/5[@V]D\LAX
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M-T>UF'\-DL.^=E]@/- /]XUURZC#H6B^(/']E$PM;81Z-H=G]T3/$?+0@?\
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M P)S7I**:N;0=CFKN=B#@_A7':E<,,GK77W48"]>37':A&R9)&<548%3J:'
MZE,Y4\X_QKS;40Y)QS7IFH6Y8G)Z"N+OK4YR*Z(1//JU.AY;?VPDSQ7)7EC(
M"6 KUBYT]L=/_KUS\^GJV05K>)YU1W/&KVT=6Z<'BLB2VE4'"\5ZU<Z.-Q;%
M8LVEAEZ8SVK5,Q:/+9X6(VGCCK6/+;+SD<5Z3>Z:4'(QFL&:S4'!%40<)-9
M#+#K5)K'?UQ[5W36@Z 9JJ;103QTH XG[$_\0XQ5.>U=3N KN'M.W2J,]D-N
M<=:"&<8BE>",5.4RO(QWK?&G,0<\T&RV\8S0(Y5[;<V2/I49M%!';O74/;8/
MO562 J<<T <I<6H8<@CUK+DA$2$@=Q_6NSE@XP1T]*Q-3B5+7<.N\9_(U]'P
MC_R.<+_B1Y6=_P"X5O0Y":S+MN SG-<EX#N/%7Q>^("?#K]GFPM_$&KVC2/?
MW5Q(\.FV A(&)ID1\R%CA8T!;@YQBO6K:U+&%UQD[<5^@?\ P23T33+#]D2
MJH$,&MZW;6:G'G);07LR1B;''F@#YN_KS7RW%6->&J5YI;SDOQ9[63895HTX
MO^5?DCZL_9:^&4G[-_[/.A_!Z^OUU.[T_P"T37-RB>7&UQ=S/<2^6I)(C#R$
M(#D[0,U-XWUM;W=&3FN[\0>?\QB!Q7E-_ID]RQ8CK7Y$Y*=251O5L^YBN6*@
MNAY#='$N0.M0W,/FP<CMWKK-3T&>*7D<?TK*N[?R( K?7FNA2L[D6/+;FV$<
MAWCJ37Q!^UW^SW8^,?#.H?%GP3=2:%XPT/3[B2VU&U"[IDC0L(+A2I$L1(&
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M@UX9XT^,VA:!I6@Z[JZQ$7]M?SW21C>WV>%Q#&T8ZGSY"H1<?-GVK)U'Q/\
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M6'$L4GI\CJK<]0*^ JXJ>*Q"G5VTV[7/U_"X"G@,)*G0WLWKU=O^ ?E=\"=
MUR'X;>'O ]G9M;7:[KJXCC3:L-YJDPF"'T\B$N[9Z?*.M>^W5QJ/CZ>TEL)#
M"OC#5F@LA%A?(T_3<L;@ <&1Y K;FSPP'2G?L[_%JX\3?!'P_P",/$$P^W7D
M=M#<^6N UQ. !P/[_P![Z&N[NO#EYH5[!K'@HQ13:1I,^FZ9;2$^5%-.P)D+
M<GC:O'7BOT6FK1L?B]=WDV4]"UWQ!!HQO;V__M6YN]0N=,L(GB6 2RVK29RR
MEA\RQG!X&>M>B>%M2M/$^GRW$]L]KLF>VF@N0N5D0X92,D'GCO7,Z5I-C\/;
M:V\0:VAET/P+HLDMN<@M=W\P)EDQUSP%&>[M710^"Q8_"K1_ =ZB7GB3Q?>>
M;*I_AFF?[1<S<$%5A4D*01@E1WJS$P=;_9J\/3S-KOPRO;CPAK"_/&]BV+1Y
M.O[VW^XP/\6 #BH9OC;XF^$U_#9?M6^$[+4-,,;Q0:W8VQO;1D;&Z.6-U9X]
MV,X(*G'M7N,FCZKX?U>Z\._#N[MH;;2+BWT^4:HTLT4UY=+O"+,"\BNH(!!!
M'..#7T-\/Y=-U+6;KX<^-9;2#7[54,UJA;RY8I1E6C\U$,BGD$@'!!!HL--H
M]\_8[\=?!#Q+H47BKX-06,5G>PQ6YDT\>7&RP A%9!@!D!QR-V.#T%?HW97F
MP*X/85^/>@_L/^&[+6[WQU\ _%>H>!=6O9#/MT]DFTR6X4;=TEJRE3NQAMK*
M:]H\._M6_%/X+V46A_M?>#KO1X[6=;67Q5IJK/H<@<[8Y6*L9( Y(W!UPI/)
MH$?J!#J@V;2<YJK+>S"4;"<&N"T_7+#4K>*]TV=)X9E#H\;!E96Y!!'!%=;:
MSQ+\[&@#J(=0NPHZ\]:LC69T()SQ7)SZCMP4[52DU.X9"2.E 'JUCXB0X5VQ
M]:Z6V\0[!NCDQ^-?-C:NZR;5R,U/)KEW;@#=D4 ?6^F_$*\TUM\4I4CT->T^
M&?CM<0X2\82+ZYP:_-23QK<1GELBHT^(K0/RV/H: /VM\._%+0-7VQK,$<]B
M<5ZA;7T-R@:-@<^E?AOH?Q?,4B_O<<^O-?3'@G]H#4++8$GW)QD,<T ?IV".
MHI^58;6&1WKYP\*_'C0M218[\^4WKVKVC3_%6F:B@DM95<'T- [G/:[\'/AM
MXE>235])MYFE.68J,FNRT;PYH_AS3X],T6W2W@B&U408 %7(KJ&49!'-3>:!
MR,TVY/2X:/=#&A&<&D6)!V_*IED5OK[TR:41INI:D<D;WL/!5!SQ[581T8<5
MQM_K4<;<M3M.UN*<A=V:31:=CLZ*ABE5U'/6IJ@L^4_VF/\ D;OA!_V/,/\
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M#&!D&O2;VV!R*P'MCG!K4R9PQTS/%4Y[%E^8#K7=_9 S'CM566V"C!'6@AG
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M5^)'QM_;6^-G[17@K5O"_P"SSX6BTKPSXAAGL;7Q#J=UY%Q]FE4QM<QVH4N
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M^R%\*OB]=?L\> ?A9X4NF7P+XZTJPO\ 4;_S]MWI*R*#J%K;C.XB^)4PL/\
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M-IXJ_:#\0W/C^\TT2_8X-1@A2PM7FV[WBME4C<0H 9V<@=,5V@"Q+Y<8  P
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ME@^R:E)I-M%9S3VS$;XB\: [)%RC 8^5CC!P1](V*I!&D<"B-5 5508"J.
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MR:=T4?V>/BAX5^#GQ"\3>"/BKK%O9R:W<6=]8:E>_N9+^::,0O'O/RNR-&N
M#QOP !U_8'PS<206PR>#7X\>'[;2S^T1X!NO%-C!J6FSF^L[=)R"EMJ#(LT4
MX1OE9MD+HIZJ3QU-?KGIUZL2>6_:OA,[HQIXG1;K^K'ZUPOB9UL#[SO9V\_F
M=E->2/R.E95X)IT^3OWK+FUFV@1I7(55&23P !7DGBSX_P#PI\'745EXH\3:
M7ITLT3SQK<74<9:*(99AD\@#J:\F,7+2"N>].<(J\W;U/3+FP98MS/SZ5R-S
M=JR&/.[/&:^+/%_[<?ASQ3J-AX6_9JFTWQEJ=XMP]PQN'BM[..(*%>1U1_O,
MWRC W8.*\A_9F_:'TOP3X+T3X8?&.+5M*\1W%S-%<WFI6THLI;Z:1Y"L=RP\
MO:QSY8SC& *ZGEF(=/VG*_ZZG##.\$JZH^T5^_3TOU9Z=^W%K'@VS^#LN@Z]
MI5IKFIZW,NGZ1972JQ-W/\@D7()41 EW9>0HKYR\+^'+GPEX.TKPQ>7!NYM/
MM(;:29NLC1J%+<^I&:T_&OB,_%+]JC4M=T]/M6D>#]-&CQW#;?+34)G\Z?RL
M$EB8S&K-QC&.:Z2[C#Y)ZU]CDN%='#+FW>I^<<3X^.)QLN7:.GK8Y.6$=5/M
M7#>+M?FT$:=8:9:K>:GK5['I]A#*XBB:>0$YD<\*BJI8G!)Q@ DBO2I8R'P*
M\(^.^J:#)X*N/ <OV>ZUG7 L&FV<D8EFDED=4W1#!V, QQ+CY#SVKU)NT6SY
MV"N['VYX5_X)X>'+_1UUSXQ^(=4OO$%RQ><Z7>/:6<2L?]3%&/X O!9LLW7(
MKZ<L_!'A7P#H%MX8\(6$=E8V48BAAB&%55X'_P!<]37O_A/0I;?PQ86!5@+>
MWBCPS%V&U0.6/)/'4]:I:]X?41EG'7FOB*N.JSDU*1]+#"PC%61\C:O>3Q,5
M48%<+K5EIWB33)M&\0VL5[9SC$D,Z!T8>X/\^U>Z^)]"C4D*!C->:RZ:58@#
MBA-/4'$^,XO@M\2_@]?76N_LQ:JL%M=?--HFH9F@W#O"Q(*GVS7T!\)OV\-%
MT#2;;PO^T?'+X>\0QRF"56MY/L\G.%=' *A2#SD\5Z(ED\+9Z8K ^)'_  JN
MZ\(7%G\7S8KITB,";TJH(5<G:QP00,].:]+"X^<))/4XZV$C)76C/I:Y^'VD
M3>)(_B?\.[AH=4DW/-&UQ)]FO4E'2126"[3AE9%R,8Z&N(U'7/%OC;5+[1O'
M&G>5K?@N)]4LK"WD\RQU":1&%K(795)\MU8;& PW/I7Y-_ [QK^TI\+-+3Q/
MX!NH]4T'5#]HM= U6=Q+:6Y/[L).XZE,$@C Z#UK],/@]^TEX5^..DW_ (-^
M(%I#I>O6O^CZAIC2[RJGE2KC:65AR"M?3)W5SQ9*SL=!!:6/A#1K'1?%X=M(
M\*6 \1:W.1DZAJMP6**3T8J^6QD_,4':J5M!J7P_\)V6HZO;M<^)_%UZ]V;*
M(X_?3_,RY/W4@CP&;T'J:LW2:1\'IH--TZROM9\+ZM.1-;,[WRV$L8\R,Q1%
M7<QLR\_.=K8P!4VLZU9^-A/\6_!NH+/'<VL>EVLNT@Z>AD9KN5@P^5P!@@C(
M*J#Z4Q&#KEGX0OKE+*ZG6&'3-1BO;NWB(6&:[)_=B8@?,=Y#8SDG&:K :EIO
M@&T\,^-9DCL)KJ;6O%>I!LF<QOY@A4?>8.VU>G"+M[US>L;[[3M.'ABQ:#2X
MKI;?1;:X!#7U\^2UW.#\QBC 9QGESSW%=+>V6I>&]?TOP-97K:E.D4E]JUS<
M8^2+G:3T"[GSM'95- $6H>*=>\307Y,30>)/B B6^EZ=T.F:;;@JMU+_ '74
M,7SUWE4'2N[T3XJ>)?ACK&JKJ.OWOBW2_#UM$MT1;PH8YG)^4RAE#NJ@%@!_
M$*\^\,:7HNHQ:MXOT*\NTN/$&8WU!6 F6*/*JL!92%C')7 (.=W)YKG+\^'?
M"L<?_"0V6-*TR01:'H:.)9=3O6Y,\N"2[%NF_.WEVYZ 'V5J>J_#_P#:+\!Q
M^$_BII'[JZ"7:6,\RBXC4$^7*K1.2I/8JW'>N0U+Q/\ &?\ 9OTJUF^%\=WX
MW\*6Q N-,GD,VIVR9^]!(>944?POEO>ODL:7<Z^-.UCQA=3K=:=>M;_;["4Q
M3O=W;[GMXF[V\'(((()!QC%>Y:7\;)_"WC"7P5XV5K9&D5-.OEW/#<*0/D=P
M,),IX*G&>HH _1KX._M!>#_BUX/L_&O@V\6XMKM-P!X=&'#(Z]593P0>AKZ(
MTWQC'=P[,XK\0IOV;OAH/%TOQ"^'FH:GX0UZ>5[AYM,N2MO+*_),MNV492>2
M!BO6O"'[5_B7X1Z\OA?]I^W@L+.<*+/Q#8[Y+"8YQMFRH,#_ .]\I[&@#]6=
M2OA=MF,@^]9D%PT; 2=^]>?:;X@MM5L(=7T:=+JUG021RQ,&1E;H01P0:ZK3
M[_[0H24?C0!TPDBEXQFC[%@DIWK$G::*3='VJ[;ZG(!EADT 6RA4[2O2E\@'
M[IIG]IJ_!%1)?P!]O;T% &S8WLEJV">,XKTK3-;<*IS7E*21RX*&M:RN_+;'
M- 'O%GK*L 2WYUL17D<C+(K%''1E.#FO%[;4,8&:Z:SU4X"]Z />='\=Z_JG
MQA^$7AC5)/.B3Q>LB,>ORZ=?C^M?MQ7\^W@2_-S^T5\(XLY_XJG/Y:=?5_03
M6]?^'3]'^;(I?%/U_1'_T_T*_P""W3B/_@I'X>8_]$VM/_3I>U^==G<!\ U^
M@_\ P7(;;_P4=\.GI_Q;>T_].E[7YIVEZ$ SUKU<PVH_X(_J<6%6M3_$ST8+
M#>V<EG>*)(9D:.16Z,C J0?4$'!K"U'X5_"OQ/:V%GX@\/V-Y%I=NMI:J\0_
M=VR !8>,9B  _=ME..E+::EE!&#WK?L[K)'(SWKSCLB2ZO\ "#X1^,;YM1\3
M^&]/O97MA92>;""LEN%*K&ZC"NJ*2$W [!]W%=OK'PI^%_C'7[7Q7XI\/V.H
M:C9HL<5Q/$&<1H251O[ZJ22JON52<@ U6L9RV #R?2NZT^3?@#M64WJ=--#(
M?A7\,[G1X_#TVA6;V4>E?V$L#1#8--^7_1L?\\OE7Y?85Z!JOA?3/$$K:D<V
MNJ+975A;ZC"JFXMHKS8TGEEPR_,T4;$,I!*+D&J]F06#$Y]ZZJS((R/7^E8W
M.R*/G?X5?LL>&OAYXXM_'EQ<VUS=Z='<I916.F6^EP1M=A5EFE2W'[Z<HNP.
MQ"JI;"@L37T)XL^'?@;X@KIZ^-M*M]3.EW"W=HTZ9:"=1C>C#!4D'! .&'!!
M%='; G!/(/\ 2MJVBXWOT[5$F=5.!PG_  I'X0ZCXY7XG7_AK3I?$"R).+UH
M 9/.0 +*1]TRJ  LI!D4  , *]FD\-Z%XD-HNO6D5V+"ZBO;<2KN\JY@)\N5
M?1D).#[U7M8LJ,@\]/6N[T&R9G'%82FSMIPML>B^#OAEX$UF/7=.UK1[2YM_
M%T7V?6HY(P5OXC"+8K-_?'D 1\_P#%?1/Q6_9\^ _P 5/$EIXJ^)7A#2M<U&
MULS8I<7=NLC_ &9LGR7[/&K,S(KA@C$LN&.:XKP/9&)X@!SD5[[?3F2\6-O0
M5CJY*PJB78Y71OV>OV>]3\8Z;XOUGP;I-QJFE1VT=K<-;KN1;( 6P8#"R?9\
M+Y/F!O*(!3:0*Q?B-^SU\!]?^)#_ !D\5^#]*U#Q' T317\]NK2M)!@Q.X^[
M(\6!Y3NK-'@;"N*]:TII3JD<<8..])\4V^S^3:J<$#<?J:ZEL<=DZAXE)\&_
MA)XT\+:OX5\2^&]/OK#5=0;5[N&6$,)-08 &ZW?>6?  $JD..Q%>?:'\"OAA
M\//%FF^*_"6GQ:8FB:?=6-A86R+':PM?RK+=7&T#+7$_EQJ\C,6*J>?F;/T%
MX2_X]YY6/0=:XE8Y=:UHVR<A3S6#D[M(J22/*/'GP$^$7QHOO[7^)/ABQUF[
M$"6L=Q<1?Z0D*.SJB2J1(@#.Y^5AG<P/!(K6\4?!;X%R?#BT^%GB/POI=WH>
MGA!8Z6+=4M[,Q A&@"!3"ZAB \95AD\\G/JWB36+;PQ;"SML&=AC/I7BE[J<
MES(9ICN8\\^M9-MFL(+L<=:?#;X8Z!I6CZ#X>\/V%C9>'KI[[38;>%8TM;J1
M)(WF0 ?ZQTFE#.<LV]B222:YKQ+\,OAKXEM=8L_$.A6-[%X@F@N=22>%7%S-
M;(D<,CY',D:11JCC#+M&""!7>37!=23^)K$NIB1UY K6%S5V2."\*>!/ WPU
MT5O#_@#2K;2;,RF9X[=-OF2L "\C'+.Y  +N2Q  SP*Y[5/AS\/]4NM>O=2T
M:SFF\46:6&L.\2EKZUC1XTBF./G14D=0#T#$5WUS+D8SQG)K'EE)))X'6NB)
MRU'T/+_%OP>^%/C2TTS3?%/A^RO8M%7R]/5H]OV:/"CRXRN"(R%4-'G8P4;@
M<"N6UG]GCX#:YH]CH.J>#]*DL]-26.TA%NJ)%%,YDDC 7'[J1R6>,Y1B>5->
MVE\'>.YJ@[XZ\D<5H<<M[G"W7PX\ W'C*R^(TVD6O]NZ?;?8[>^5-LL=O\V(
M\K@%%W-M!!"[CMQDYH^'_ 7@?P=/:R^$])MM.DLM/ATJW:! IBLK9F:*!?2-
M&9BJ]B37=NXP>><8K-D<Y)'7M51U,WW/E?XJ?LX>'?&FE:1H&@RV&EZ;HV_[
M/IUUI-KJ=DC.^\R)%. 8Y<Y&Y7QCJIKKOAK\.M$^$G@>W\%^'Y9KF..:ZNY[
MBX(,US=7LSW%Q,^T*NZ6:1W(4!1G    KU:\E89-<_<NW4FKW,),R[ARQ(]^
M:YZ]E_='/'6M6>0J7 [\UA7A#(Q?FM8HQD<Y=.0N:YR5\/G/M6W>8*L5]S7.
M3<2D]35$$_F\8(IDKAE J"/>!@\@>M*7!7GMSZ4&9ES8)4#K68_#>U:LJ\^F
M!5*:V,2>9F@#*?@YZCFFA\G+?A4A'S%3W_QJHY;;QQB@ 8A1@?KZ52>3:,+R
M:DE8%L#I46[YMOKS04D4)UR<YQBO._B$N-!5AWG3_P!!:O1I>IR?QKSSXAG_
M (D Q_S\(?\ QUJ^CX1_Y'.%_P 2/,SS_<*W^$GTU?\ B36C#KY*?RJ&Z4D'
MUJSIG.B6G_7&/^55+F38G'8=*\K,_P#?*W^*7YLZ\+_ I^B_(Q+A?FW=*SY%
MS\Q_&KMP[,=OM5:3E2*X38A(*/4SRJ(^>W>J+R%.#^!]JH7-P<%<T 5M0N "
M<#IFN7GN 1Z9JU?3EOJ:QI6/WOS'UH J7<CLF1V_E6(\A<E6XZUO@%T\L#OU
MK+N+8+F0#\* .8N^-Q^E83Y& 376W,!;D8Z\5S\T!/4?C0!E$[F& :0 L<8Q
M5LQD _3%1Y'7-  BE3\IK6B+# Z^M90//'-:MO\ =(/0T ;<)41XQS@5.8]R
M8ZBJEJY/) XK30*'].: /-_B?X=N_$OPUUW3-+##4%LYIK!X\B6*[B0M"\9!
M!#AP,$$'FON7X+_''PW\5/AK8>+-*OHI)4MXTU!0V&MKA4!D20-@J5/7=BOF
M%&\J7(Y [_6O'/&WP'\&^.O$,WB&[O=2T_\ M"-(-2M]/NFMX=0BCQM6=5Y;
M  7(()7@G%>7F66QQ:CK9KJ?09'G4L!*3M=/IY]&;>L?&GXU?M0PW/A[1[>Q
MTGX?2:G-#-JD%P[W6I65JY7RTC*+L29AAGW'*@XX-26W[+G[.MK+YD?@[3G/
MF"5?.0S89>@'F,V%']T?+[5ZMH&EZ7H>EV^AZ';QVEI:1K%##$ J(BC 4#L!
M70LRQ@,3P/TKKP^$IT8J--6//QN8UL34=2K*_P"GH4[.QT[34\C2[>&U0  +
M"BHN!T&% _"LCQ+HVA^,M&F\.^*K.+4+*X $D,R[D;!R#CU!Z'J*TIYBBX&*
MS7N5+=:Z'%/H<2FUU.7\/^$O#?@O25T/PEI\.G62$L(H%"+N/4GU)[DY-+>1
M\D@YR,&MB>X!.T<KW_&L2>8,Q Z9IDW,.9"5)'TKS:^TGQEH'Q'TGXK?#MK0
MZI80O93VUZ62&XMI&#XWH&9&1AD':002*]2E *@'\*SI!D].E3.*E%Q81;3N
MC]1?V6OC9;?&;X<IK][:+I]_:W5SI]]:K()1%<VDC1.%? W*2N5.!D$<5[#X
MP0B$M%R*_#'P;X]U#]FGXI/\4-*@FF\.Z\%M]>MH-[F&4,S)>)&,@D[BDN "
M1M;L:_3_ .%'[4'PK^.KWVD>#-0:XN=.2)YXY(GA8)-G8P#@94[2,C(R*^+S
M#+9T:CE%>Z?287%QJ1LWJ1:[Y\DC+MZ5RBZ3)(<[<YYKWPZ%!>3_ "\YKI[/
MP-;2)EJX75Y=#JY+GS4OAYGC)VU\-?MJ:?;ZGH6A?">Y@@V>++J6WGN94#O#
M;6RB:18B?NO(0J@CH,GM7Z*?';5?$'PL\ W_ (P\(:,_B"YTX"5[&%L32P@_
M/Y0P=SJ/F"G&0#S7X[?$KXI_$?\ :N\.:;)'H^G:-H9O(-1L[[[69[V-(G##
M8L:[5D904?+X )'->MEE&=6:FMD<.-JQA%QZG<2MY6(8V)$:A1GDX KRGQOX
M"T+Q9J$.N227&G:M;#;#?V,AAG4>A(^\/8UZPT?ODD]:S;FV#*0>U?6I65CY
M][G,>&/VCOC%\$IUTOQ2EYXNT4 >7?0H#=1D=5E0?>'HPKZL^&GQ4_9Z^.NB
M75II-Z;&YOKEIYH4GDM+B.\<!2Y0,IW< X(()YQS7RS<0/$V5X(KS#Q9\+_"
M'BX2WMQ:K;:DP!BOX1LGBD4Y5P1C)!'>F(_5;Q'JGCSX?>%-'\4^)(+;Q!'H
MD2"]NE9EG0OA&G5=N& &"PR"!G%59_#;WJOHTMXMX-7F:]\0:D"%400@%;<<
MY56&!C^X#GDU\(^#/VJ?CE\)],CL_BGIEKXDT*W"QW-Y;.?/\D\%WA8'=@?>
MQ7VA?6W@?X[Z);>-_A-J,*#48GM;WR'V)=6LBD%7V@X93C!P6 R* +<&MV^I
M:=)\8?$#266@6"%=%TV+*&<'Y$D<#[S2G B3HH(/7IU.C:9-86FDW/BPVY\0
M26I^?:OG+N&7"'&0!GG'%>;ZC/?6)L-8^*UN-+M]#D>.STZW_>V\]Q&A*2A^
M-WR B-2HPV>^*I7GB/5XR/#NF.)_%WB*/=<3$9&GVC=3[! <(O\ $W)[T ;N
MH:-K'A.T76M)@_M"'0K<IHU@AW&2YE&TS2G@$Y/X+N/4UCZ!HES-KFB_"RPN
MFF.E,-;UZ[!YFNYBQCC_ .!,2Y'90H[UK6^MVFC:M=:9I#23V.@V\.E6\ ;+
M75_* VW/^PN,GMSZ5H^(-)E6WUWP_P""YHK+Q#J$,+W;H27B\X",2?544[/<
M"@"O;^,=8;7=;\5:5JF-!L+A;?RYT#)/.H",(9,KL7S"$Y# MFN[T#XM^&/%
MSOX-UZUFAEN4,<UC?V[!7&.5RPV./H2#VKQ3Q!$GAZ'3M+U:S,/A_0GCCTW3
MK?YY]4O0/D) Z(I^;GO\S8 JKXNL_%.E>#-%\%W=^X\2:[J8N%\AB6MP7,LA
M7GE(@=O/!''>@#O;'PW\5OV=+NW\4?L[ZI>:GH%O,#=^$[AA+'Y#M\WV1SAD
M9<Y5"<<8K[V^"G[6O@'XL74VBVC3:=K-IC[3IE_&8+J+W*-@E?1AD5^=UQ\7
M)/!,.EZAK]_%?:9--/97-_#&4"7,9^7*@M\IVN&(R 175^+?"'A+XNMI?C"V
MU"XTW5; ;K'5]-<+.J-U7)!#H>ZMQ0!^SL.LPW,8E0@Y]ZMQWBR+CJ0>@K\?
M?AG^U7XB^%&OM\+_ -H">0CS=FF:^T6RUO86^[YC+\D<HZ,#@$]*_1WPEXZL
M=1*3Q2JZ2 ,K Y!!Z$'O0![%)<;&^88%94ETJRDCCWHN=1MIH_W; YK#6Z7S
M,$T =M8WA=>M;45[M;!/OBN @N1$>O!ZUJQ7RL 5_*@#T&WO\\+WK>M;YL\'
MVKRF.^V=\8KH+/5<_+D9H ]P^%5YY_[2_P )(\_\S.?_ $WWM?T;5_-#\%+Q
M9OVI?A(@Y_XJ5O\ TWWM?TO5O7_AT_1_FR*7Q3]?T1__U/ZTOVP/^"6/[-W[
M;/Q4L?C%\6[[7[/6-/TJ+1HSI%ZEK&;:*:6<;@T3DMOF;)W8P!QQFOE[_B'\
M_8I_Z#_C?_P<1_\ R/7[CT5Z%/-<7"*A&H[+8YI8*A)N3BKL_#H?\$ /V+5^
M[XA\<#_N,)_\CU*/^" W[&2_=\1^.1_W&4_^1Z_<"BK_ +8QG_/U_@3]0P_\
MB/Q$7_@@=^QRGW/$WCL?36E_^1ZF7_@@M^R$GW/%7CT?36U_^,5^VM%+^V,9
M_P _'^ _J-#^0_$\?\$'OV2!T\6^/_\ P>#_ .,5(O\ P0C_ &35X7Q?\0!]
M-='_ ,8K]K**/[7QG_/Q_@'U*C_*?BN/^"$_[*2]/&/Q!'_<>'_QBGC_ ((6
M?LK#IXS^(0_[CW_VBOVEHH_M?&?\_'^ _J='^4_%T?\ !#']EL=/&OQ#'_<?
M_P#M%6$_X(=_LR1_ZOQU\1E^GB C_P!HU^S5%+^U\9_S\?X?Y!]4H_R_F?CG
M%_P1._9V@P8?B%\2DQTV^(V'_M&K!_X(M? $MO/Q&^)I/K_PDK9_]$U^PE%'
M]K8O_GX_P#ZI1_E_,_']/^"+_P !HFW1_$GXGJ?4>)7'_M*F7/\ P1;^ 5XV
MZ[^(_P 3I3ZOXE=OYQ5^P=%/^U\9_P _'^ OJ5'^4_'E/^"*_P"S_$I2/XC?
M$U0>H'B1A_[2ID7_  12_9Z@<RP?$3XEHQ[KXD8'_P!$U^Q-%+^UL7_S\?X#
M^IT?Y3\<9_\ @B9^SI<OYES\0?B5(WJWB-B?UAJO_P .0OV:O^A\^(__ (4)
M_P#C-?LM11_:^+_Y^/\  /J='^7\S\:/^'('[-/3_A//B/\ ^%"?_C--/_!#
MS]F4]?'7Q&/_ ',)_P#C-?LS13_M?&?\_'^'^0?4Z/\ +^9^,9_X(<_LQ'KX
MY^(O_A0?_:::?^"&W[+YZ^-_B+_X4'_VBOV>HH_M?&?\_'^ OJ5'^4_&#_AQ
MK^R]_P!#O\1/_!__ /:*3_AQG^RY_P!#M\1/_!__ /::_:"BC^U\9_S\?X!]
M2H?RGXO'_@AE^RV>OC;XB?\ @_\ _M%-_P"'%_[+!Z^-/B'_ .#_ /\ M%?M
M'11_;&,_Y^/\ ^I4/Y3\63_P0K_94;[WC/XA'_N/?_:*C/\ P0F_90/WO&/Q
M!/\ W'1_\8K]JJ*/[8QG_/Q_@'U&A_(?BG_PXB_9,_Z&_P"('_@]'_QBF'_@
M@_\ LE-P?%WC\_\ <<'_ ,8K]KZ*?]L8S_GZ_P !?4:'\A^)I_X(-?LBGKXK
M\??^#Q?_ (Q49_X(*_L@'KXI\>_^#M?_ (Q7[;44?VQC/^?K_ /J&'_D1^)'
M_#A3]C_I_P )3X\_\':__&*7_APK^Q__ -#3X]_\':__ "/7[;44?VQC/^?K
M_ /J&'_D1^(Y_P"""?['QY/BCQX?^XVO_P CT'_@@E^QZ>#XH\>'_N-K_P#(
M]?MQ11_;&,_Y^O\  /J&'_D1^(G_  X._8Z_Z&;QW_X.E_\ D>D_X<&_L<'K
MXF\=_P#@Z7_Y'K]O**/[8QG_ #]?X!]0P_\ (C\0O^'!?[&_7_A)?'7_ (.E
M_P#D>C_AP5^QL?\ F9?'7_@Z3_Y'K]O:*/[8QG_/U_@'U##_ ,B/Q!_X<$_L
M:GKXD\=?^#E/_D>H)O\ @@!^Q9<IY=QXA\<2+G.&UA",_C;U^XM%..=8Z+YH
MU6F)Y?AVK."/P[7_ ((!?L7(@1/$/C@*. !K"8'_ )+TT_\ !O\ _L5GKX@\
M;_\ @X3_ .1Z_<:BD\YQK=W58U@,/_(C\-_^(?S]BG_H/^-__!O'_P#(]'_$
M/Y^Q1_T'O&W_ (-X_P#Y'K]R**/[8QG_ #]?X!]0P_\ (C\-3_P;\_L3'KKW
MC;_P;Q__ "/3#_P;Z_L1'KKGC7_P;Q__ "/7[FT4?VQC/^?K_ /J&'_D1^%Y
M_P"#?']AYOO:UXT/_<6C_P#D>F_\0]W[#G_09\9_^#:/_P"1J_=*BC^V,9_S
M]?X!]0P_\B/PN_XA[_V'/^@SXS_\&T?_ ,CTA_X-[OV&SP=9\9_^#6+_ .1J
M_=*BC^V,9_S]?X!]0P_\B/PJ/_!O5^PP>NK^,O\ P:Q?_(]-_P"(>?\ 85_Z
M"WC+_P &D7_R/7[KT4?VQC/^?K_ /J&'_D1^$W_$/)^PD>NJ^,?_  :1?_(U
M)_Q#Q_L(_P#04\8_^#2+_P"1J_=JBC^V,9_S]?X!]0P_\B/PE_XAX_V$?^@I
MXQ_\&D7_ ,C4X?\ !O+^PH.FJ^,1_P!Q2+_Y&K]V**/[8QG_ #]?X!]0P_\
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MW=M)]Z&;58I(V^JM;$'\JTM/_P"" O[&.DVT=GI?B/QS;0Q*%1(M91%51T
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B$O&81GY9&Q@@BOU1HHKDQ&*JUY*5:5VM#:E1A35H*Q__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>business9a.jpg
<TEXT>
begin 644 business9a.jpg
M_]C_X  02D9)1@ ! 0  ?P!_  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      !_     0   '\    !  .@ 0 #     0 !  "@ @ $     0   WF@
M P $     0   8(     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_W0 $ #C_V@ , P$
M A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *)'_P"5_P#^X*_%BBJ_U6P7\GXO_,C_ %IQO\_X+_(_:?\ X?!-_P!$C_\
M*_\ _<%'_#X)O^B1_P#E?_\ N"OQ8HH_U6P7\GXO_,/]:<;_ #_@O\C]I_\
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M@\''2C_5?!?R?B_\Q+B?&_S?@O\ (_:'_A\$_P#T2/\ \K__ -[Z/^'P3_\
M1(__ "O_ /W!7XL5IMHNM)I$?B!]/N$TJ69K9+PPN+9IT4.T2RXV%PI!*@Y
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M#J6CD 8;E(89'(((H?"^!3MR_B_\Q_ZSXVU^;\%_D?LE_P /@G_Z)'_Y7_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO^C7:;@9)E.'#%O+)QC*G=X3:?ME/;Q7'@T^ M,7X;2Z,-$3PY%/<Q;(1/\
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MXAT_7-)O=$U"QN7DB2>RO@HE421$.C?*,,.0,XYY'12PF(>'G3J7OTUU_/\
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M1@)A#;O(@F;>3@_+D]/3;CQ1I-YX(EGN]6@FO)?@)#:NSSHTC7*WJ8B))R9
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MA[J\,(D=4,DC3VQ")D_,QP<*.3SQ7T]H7CI%_:\_9TE.N)'INE>$/#UJS?:
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MLCI7[?A\13JP52E*\7LT?#5*<H2<9*S0M%%%;$!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]/]_*C-24A4
M&@#^+.Y_X^9_^NC_ ,S4'%?TUR?\$W_V1Y)'E;PE/N<EC_Q,[[J?^V]-_P"'
M;G[(O_0I7'_@SOO_ (_7Z53XQPZBERO^OF?G=3A"O*3ES(_F7#8Y!P1[UHZ1
MJ)TG5;+53;PW@LIXYC;W"[X)O+8-LE3C<C8PP[@D5_2O_P .W/V1?^A2N/\
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M%W/Q3Q;QV&K5J,:4DY).]O/;7[RQ1117HGY %%%% !1110 4444 %%%% "$
M@@C(/:O,?$WP_BNM][H@$<QR6B/"M_N^A_3Z5Z?17E9ODN'QU+V6(C==^J]&
M=F"QU3#SYZ;/F/3]3UKPMJ1FM7>UN8CAE/0CT93P17T;X0^)6F>( EG?$6=\
M1C:Q^1S_ +)/\C^M9NO>&M-U^+%RFR8#Y9%^\/\ $>QKPO7?#.I^'YOWR[X<
M_+*H^4_7T/UK\O@LUX;J.=!^TH=5T^?9^>Q]2WA,SBHU/=J?U]Y]IYIU?+WA
M'XHZAHVRSU?-Y:# #9S(@]C_ !#V/YU]$Z/KVE:[:BZTNX69#U /S+_O#J*_
M8>&N,\%F<%[&5I]8O?\ X/R/C<SR6OA7[ZNNZV-BBD!S2U]8>0%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_U/W\
MIN3C-.IF<<4 ?C--_P %>;&*:2)?AA(PC9ES_:RC.#C./LM1_P##WVR_Z)=)
M_P"#=?\ Y%K\4[@'[3-_UT?^9KO;+X0?%C4M/@U73_!FLW-E<QK-%-'I]P\<
MD;@,KJRH05(.01P17ZK#AO \B<H_BS\PGQ'C>=J+V\C];_\ A[[9?]$OD_\
M!LO_ ,BT?\/?;+_HETG_ (-U_P#D6OQ2N+:XLYY+6[B>">%BKQNI5U8<$,I
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M^+[W7O$^JW;:CJ^NW]W=R$EI/M,L8&>RI&RJ@] H%6X/%WCJT&VR\5:M"N,
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M>Z5[V\]=#'O?@9X&C^,?P!\#PQS_ -E_$;0O#&H:H/-.]IM5F=+@QM_ -JC
M'2O0OBW#\/="_8STK0-,T.>.]M/&VLV5O=-=;MLUL4$DKKM^97A 0)GY6^;)
MZ5Y]X._;$D\,P^!M5U+P#HVN>*_AY:0Z=I6KW)G$B6,!;9&\22+&SQJY6-R,
MIG(&[)/F&M?'RX\1?"/5OA5K/AZSG6[UVYUZRO\ =*MQ97%XR>>B -L=&12H
MW XW9ZA2,EA\3*<'-:1:Z^NOXHU^L8:,)J#U:?3;;3\&?1O[(<6LR?L]_'=?
M#_BR+P/?^;X6\O5YIY;5+<?;)]P,L(9QY@RG Y+8/%>T>$_B'H]O#\+?A9XP
M^(T/Q4\:7'Q'T'4+6ZA\^X33;-)XTD0W5PJLQD8D!5X&3T[_ )N>%?BMJ?A;
MX6^.OA9;64,UEXZ?2WN)W+>;"=*N&GCV8(7YRV&R#QTKFOA[XPNOA[X\\.>/
M;"!+JX\.:C::C'%+G9(]I,LRJVW!PQ7!P<XJL1E3J2J2;W=UM_*EOON*AFD8
M1IQ2V5GOW;V]#]6_BYHNF_!WPA\8/'?[/NJV_B#QW/XDO8?%FI09-UH>GZA-
M),L5HN/E7<1'-,IR'5NFWY/RW^%GAJP\=?$KP]X7UP7TMGJU['%<#3XOM%ZR
M,<L(4/!<^IX'WCD UZ1X&_:2\6>!?C#XE^+-C8VMVOB^743JNE7 9[*ZM]2D
M:62!USDJK,"ISG@<]<\9\,_BQ?\ PF^+FF_%GP?IUO%-I-W-<6]E+ND@6*=7
MC:').\J(W*@[MW0YSS6F$PE6E3G'=M:/KMM\NGJ9XK%T:M2$MDGJNF^_SZGW
MCXZ_93^':_#77?$\?A*]\#ZGX9U72(/L\VMP:G/>V>HWJ6C&XAA+?9G&X,,$
M G(YP:R_%WP(_9KO/%WQ>^#G@S2M8LO$'PZT74=:@U>>^$L4SZ<L;R6QM]@
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MA_X'S?XU^<'Z&>S?\-P?LH_]%'T__OB?_P"-T?\ #<'[*/\ T4?3_P#OB?\
M^-UXR/\ @E_^RO\ ] W4/_ ^;_&C_AU_^RO_ - W4?\ P/F_QH ]B?\ ;<_9
M/D&V3XBZ>P]#'.?_ &E3E_;?_9148'Q&T\#_ ')__C=>-_\ #K_]E?\ Z!NH
M?^!\W^-+_P .O_V5O^@;J/\ X'S?XU/*KWZCN>R_\-P?LH_]%'T__OB?_P"-
MT?\ #<'[*/\ T4?3_P#OB?\ ^-UXU_PZ_P#V5_\ H&ZA_P"!\W^-)_PZ_P#V
M5O\ H&ZC_P"!\W^-4(]F_P"&X/V4?^BCZ?\ ]\3_ /QNC_AN#]E'_HH^G_\
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M.?\ T:7EC$>I ^4\G%4?A+^TSXW^(WQZ^%.F^.+^PT7PMH.O0W:6EM#!I]A
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M\C#_ %+K?SK\3^62BOZF_P#AA/\ 93_Z)]8?D_\ \51_PPG^RG_T3ZP_)_\
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M_P"NE#^1_@3_ *FU_P"=?B?RS^:X3R@QV'G;GC/TH61T4JK$*W4 XS7]2_\
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MMAZ3$L.F?&'3=4C1<*+S08$?CIN=6)8^I-4C:_MVZ8V$O_".LKC^.*>W.?\
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MQ:A_X$R?_%5R]S_Q\S_]='_F:@K]RHX>'(O=6Q^*8C$U.>7O/<Z__A8/CO\
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M]/;E7W!]:J?S/[SK_P#A8/CS_H8M0_\  F3_ .*I?^%@^._^ABU#_P "9/\
MXJN/HH6'I_RH/K-3^9G7_P#"P?'?_0Q:A_X$R?\ Q5+_ ,+!\>?]#%J'_@3)
M_P#%5Q]%"P]-?90?6JO\S.O_ .%@^//^ABU#_P "9/\ XJC_ (6#X\_Z&+4/
M_ F3_P"*KD**/J]/?E7W!]:J_P S^\[#_A8/CS_H8M0_\"9/_BJ3_A8/CO\
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MAA^SI\1OBII$OB?2A8Z-X=AF^S'5=8NX["R-QMW>4LDG+/CLH.,')KPZY/\
MI,^?^>C?S-?:_P"T"+Z7]F+]GVZ\.QR#PDFGZI%*4!\L:S]L)NO-QQN;&8\\
ME0V.,U^U5JTXQI0@TN;2[]+GXY2I0E*K*>O+K;YGSA\4OA!X[^#NL6VC^.+%
M;?\ M" 75E<PR)/:WENQ(66":,E74]1T.""0 1GS"OT@^ WPW\=ZEH.C>+?C
M+IS>)?"?AKP=XG\0^$=$OG,D=Q/I[1;D:#[WE2/(' Z. I'&*]0_9ZTWP?\
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MU2ZU">U^UQ1'B-)@J2A5P#CG.3EU\WY)./)ULM=WI_F*AE"G%2Y^EWILM?\
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M_P!Z221B\DC8[N[%C]:^2XUS7#U:,:-*2D[WTZ&^&@U=LZ:BBBOS8ZPHHHH
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M_P 57]7,OB+P]#*\,VJ6L<D9*LK3(&5@<$$$\$5'_P )-X9_Z"]I_P!_X_\
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M_P!>JG:(?ZI87^=_@?RE?\,J?M(?]$ZU?_ORO_Q5'_#*G[2'_1.M7_[\K_\
M%5_5M_PDWAG'_(6M/_ B/_&D_P"$F\,_]!>T_P"_\?\ \53_ ->JG:(?ZI8;
M^=_@?RE?\,J?M(?]$ZU?_ORO_P 51_PRI^TA_P!$ZU?_ +\K_P#%5_5L/$WA
MG_H+VG_?^/\ QH/B;PS_ -!:T_[_ ,?^-'^O53M$/]4L-_._P/Y2?^&5/VD/
M^B=:O_WY7_XJC_AE3]I#_HG6K_\ ?E?_ (JOZM?^$F\,_P#07M/^_P#'_P#%
M4O\ PDWAG_H+6G_@1'_C1_KU4[1#_5+#?SO\#^4G_AE3]I#_ *)UJ_\ WY7_
M .*H_P"&5/VD/^B=:O\ ]^5_^*K^K7_A)O#/_07M/^_\?_Q5*/$WAG_H+6G_
M '_C_P :/]>JG:(?ZI87^=_@?RD_\,J?M(?]$ZU?_ORO_P 51_PRI^TA_P!$
MZU?_ +\K_P#%5_5J?$WAG_H+VG_?^/\ ^*H_X2;PS_T%[3_O_'_\52_UZJ=H
MA_JEA?YW^!_*5_PRI^TA_P!$ZU?_ +\K_P#%4?\ #*G[2'_1.M7_ ._*_P#Q
M5?U;'Q-X9_Z"UI_X$1_XTG_"3>&?^@O:?]_X_P#XJC_7JIVB'^J6%_G?X'\I
M7_#*G[2'_1.M7_[\K_\ %4?\,J?M(?\ 1.M7_P"_*_\ Q5?U;#Q-X9_Z"UI_
MX$1_XTG_  DWAG_H+VG_ '_C_P#BJ?\ KU4[1#_5+#?SO\#^4K_AE3]I#_HG
M6K_]^5_^*H_X94_:0_Z)UJ__ 'Y7_P"*K^K4>)O#/_07M/\ O_'_ (TI\3>&
M?^@O:?\ ?^/_ !I?Z]5.T0_U1PW\[_ _E)_X94_:0_Z)UJ__ 'Y7_P"*H_X9
M4_:0_P"B=:O_ -^5_P#BJ_JU_P"$F\,_]!>T_P"_\?\ \52_\)-X9_Z"UI_X
M$1_XT_\ 7JIVB'^J6%_G?X'\I/\ PRI^TA_T3K5_^_*__%4?\,J?M(?]$ZU?
M_ORO_P 57]6O_"3>&?\ H+VG_?\ C_\ BJ4>)O#/_07M/^_\?^-+_7JIVB'^
MJ6%_G?X'\I/_  RI^TA_T3K5_P#ORO\ \51_PRI^TA_T3K5_^_*__%5_5L?$
MWAG_ *"]I_W_ (_\:3_A)O#/_07M/^_\?_Q5'^O53M$/]4L+_._P/Y2O^&5/
MVD/^B=:O_P!^5_\ BJ/^&5/VD/\ HG6K_P#?E?\ XJOZMO\ A)O#/_06M/\
MP(C_ ,:3_A)O#/\ T%[3_O\ Q_\ Q5/_ %ZJ=HA_JEAOYW^!_*5_PRI^TA_T
M3K5_^_*__%4?\,J?M(?]$ZU?_ORO_P 57]6P\3>&?^@O:?\ ?^/_ !I#XF\,
M_P#07M/^_P#'_C2_UZJ=HA_JEAOYW^!_*5_PRI^TA_T3K5_^_*__ !5'_#*G
M[2'_ $3K5_\ ORO_ ,57]6O_  DWAG_H+VG_ '_C_P#BJ4^)O#/_ $%K3_P(
MC_QI_P"O53M$/]4L-_._P/Y2?^&5/VD/^B=:O_WY7_XJC_AE3]I#_HG6K_\
M?E?_ (JOZM?^$F\,_P#07M/^_P#'_P#%4H\3>&?^@M:?]_X_\:/]>JG:(?ZI
M87^=_@?RD_\ #*G[2'_1.M7_ ._*_P#Q5?T'_L#^$/$_@3]EGPEX7\8Z;-I&
MK6LVJ-+;7 VR()=1N)$) S]Y&##V-?4Q\3^&A_S%K3_O_'_C6O;7%O=P+<6L
MBS1.,JZ$,I'L1P:\W,^(YXR"IR2T=]#T\KR2CA9N=.5VT6****\,]X*0TM%
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M* /P5^+MU<K\6/&RK,X US4P &/_ #]25Y[]KN_^>[_]]&N[^+W_ "5KQO\
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M[O\ ]]'_ !JO11SON',RQ]KN_P#GN_\ WT:/M=W_ ,]Y/^^C4*(TC!$!9F(
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M*'_OVO\ A1_9&D_\^4/_ '[7_"M&B@#._LC2?^?*'_OVO^%']D:3_P ^4/\
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M/7I%,]V+G4$19K=[?SV !4H03'DDX/:O3?#E-:N;_IVMZ_,[?['@MY?U_F?
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M$Z^8A;<#D>8%##NN>]<EXUT/0]=_:$O_  S8>;;V&H^(OL4A.W>AFNA%*4P
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M1*\OE*$3<Q;:@Z*,] /2D2XN8X9+>.1UAFP74,0K;3E<CH<=17IWQ(\$Z/\
M#WQ)I7AN>YEN+E+&SGU5!M!@N+A?,DACX_@1EY.>3^%?3/Q1^''P[U37=1\5
M7DEYIVA^%-$TE[R.!8]\SWB)'9QQC'!;#>8Q[X(K&GE-27M/>5XNS^YM_=8R
MC@)RYM=5_3_(^&;:ZN;.=;FSF>"5>CHQ5A^(YJ_+J>N@I<37=RIE/FJS.XW$
M?+N!)Y('&1]*]*^(7@7P]I7AOP_X\\%W,\^B:^UQ%Y5T%\ZWN+9@'0E>&4A@
M5/7 KW"X\-_#/7?"?PDTKQ?=7MOJ&LV+6<'V-4VQ"2\=1-(6!W?,V,>@-%'+
M*C<X<R323WT=[6_,=/!2;E%NUK?.]CXU6XN$BD@21A'*074$[6*],CH<=JN2
MZSJ\\(MYKZ>2(+LV-(Q7;_=QG&.!Q7TKX8^"GAI[K4]-U2+5=>O['5[O2VBT
MV-4CACMG\OSI))!MW,1D(#TZU2\?_ >R\-V7B.'PY>SZEJOAK6;6QGA95&;7
M4(E>VE 49W%V\MNV>E']CXA0Y_U_KS8?V?64>8^:$D>)UDB8HZ$%6!P01R"#
MV(J9+V\CN3>QSR+<$DF0,0Y+=3NZY/>OLI_V:O#]@NKZAOU+7;?1KB#3&M[
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MN6W);Y,QXW$CJ"/>N>608E.T=KV_%ZF3RJLG9'QZ-0OUNA?+<RBY7&)0YWC
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MV>[OLM_Z1I#,ZT;V?F>K_$/XAZ?XQT'P]H6G6$EE'H,VKR!I'#ETU&\-RB\
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M,_Z&F;_ORM'_  P3IG_0TS?]^EK]#**/]5,!_P ^_P 7_F']AX7^3\S\\_\
MA@K3/^AIF_[\K1_PP3IG_0TS?]^5K]#**/\ 53 ?\^_Q?^8?V'A?Y/S/SS_X
M8)TS_H:9O^_*T?\ #!6F?]#3-_WY6OT,HH_U4P'_ #[_ !?^8?V'A?Y/S/SS
M_P"&"=,_Z&F;_OTM'_#!6F?]#3-_WY6OT,HH_P!5,!_S[_%_YA_8>%_D_,_/
M/_A@G3/^AIF_[\K1_P ,$Z9_T-,W_?E:_0RBC_53 ?\ /O\ %_YA_8>%_D_,
M_//_ (8*TS_H:9O^_*T?\,$Z9_T-,W_?I:_0RBC_ %4P'_/O\7_F']AX7^3\
MS\\_^&"M,_Z&F;_ORM'_  P3IG_0TS?]^EK]#**/]5,!_P ^_P 7_F']AX7^
M3\S\\_\ A@K3/^AIF_[\K1_PP5IG_0TS?]^5K]#**/\ 53 ?\^_Q?^8?V'A?
MY/S/SS_X8)TS_H:9O^_2T?\ #!6F?]#3-_WY6OT,HH_U4P'_ #[_ !?^8?V'
MA?Y/S/SS_P"&"=,_Z&F;_OTM'_#!6F?]#3-_WY6OT,HH_P!5,!_S[_%_YA_8
M>%_D_,_//_A@G3/^AIF_[\K1_P ,$Z9_T-,W_?I:_0RBC_53 ?\ /O\ %_YA
M_8>%_D_,_//_ (8*TS_H:9O^_*T?\,$Z9_T-,W_?I:_0RBC_ %4P'_/O\7_F
M']AX7^3\S\\_^&"M,_Z&F;_ORM'_  P3IG_0TS?]^5K]#**/]5,!_P ^_P 7
M_F']AX7^3\S\\_\ A@G3/^AIF_[\K1_PP5IG_0TS?]^5K]#**/\ 53 ?\^_Q
M?^8?V'A?Y/S/SS_X8)TS_H:9O^_2T?\ #!6F?]#3-_WY6OT,HH_U4P'_ #[_
M !?^8?V'A?Y/S/SS_P"&"=,_Z&F;_OTM'_#!.F?]#3-_WY6OT,HH_P!5,!_S
M[_%_YA_8>%_D_,_//_A@K3/^AIF_[\K1_P ,$Z9_T-,W_?I:_0RBC_53 ?\
M/O\ %_YA_8>%_D_,_//_ (8*TS_H:9O^_*T?\,$Z9_T-,W_?I:_0RBC_ %4P
M'_/O\7_F']AX7^3\S\\_^&"M,_Z&F;_ORM?:WPY\'IX \$Z3X.CN#=)I47E"
M5A@O\Q.2!]:[:BNW Y-AL-)RHQLV=.%R^C1;E3C9L****]0[0HHHH **** "
MBBB@ HHIK.B L[!0.23TH \@^,'QAT3X-:?H6L>)+6633M8U2VTR2YCQY=H;
MG(667/\  ",&O8<U^>_[;_Q+\%>+?A;J/P0\*7<?B'QMXEN;.WL]/LB)Y(Y(
M[A)#(Y3(0($.23UZ\9K[N\.V5[IN@:;I^I2_:+NVMH8II/[\B(%9OQ()KT<3
MA%"A3FU:3;^[2S_%KY'+2K<U245JE;]3P#XYW$W@CQEX ^,<SO\ V+X=N+S3
MM7"@D166JHBBY<#^&"6)"Q(X5B>U?1UE?66HV<-_I\Z7-M<('CDC8,CHPR&5
MAP0?44EY9VFH6LUC?PI<6\Z%)(W 9'5A@A@<@@BOGR;]EWX9B4MI$NJ:+;LV
M[[-8:A-!;CN0L8.%!]JSC4I3A&-1M-=;7T*<9QDW'5,^C!)&7,88;@,D9Y /
M?]*\0^.'@SQ/XNT_P]<^&K>#4_[!U6'4+C3+ES%#?QQQNJQL_."DC+*N002@
MR*Z7P'\*/!?PT-W<^&X)EN+Q56>>YGDGED6/)&YI">F37A&G_$/XX?%Z\U7Q
M+\'#INF^$]*N9;2REU&-Y&U>2!BDLB%2/+AW JC=3@FM,+2?.YTWHNKTW^_^
MM2:T_=Y9+5]CZ<A\0QVD?_%0QII DNDM+?S95(G>104"'CEF)4#KQ7030P7"
M>7.BR)_=8 C(]C7RQI?@3XO?$CX@^'O%7QDM;#1](\'NUU9Z=I\[7"W6HLI1
M;B5F PL2D[%]3FOI^_U&RTR$S7LPB&&(!^\VQ2Q"KU8X!.!DUCB*,8-*+N^M
MMC2G-M.ZLCPW_A+/&7C+XNZKX)\,7<.CZ+X*:P?4Y&C$EQ>27<?GB&,'A(O+
M(#/U+9 Z&NW^(_A;3M>T=KK4I]56"RCD+6^E7#PR7"OC*E5(WGCC)'4^M>/W
MVLP-^TCH-_X(M[FYEO[.;3O$0%O)';QVT<1N;.X>1U56=)#Y0 R<2'.-M?5'
M!Q6N)?(X..FB]?/[]UY6(I>\I7UU.$\ ZOX<U3P\EAX8MGTVWT8BP:SEC$4E
MHT2*5B9 2!A&5AR<@@U\Y:9?SZ#I3Z1\(HY]=L_#>C7\37\T"O%=ZW-/"L,P
MDX,LF_SFE*_+CH37T-IGA;7-)\:ZQK=I>0_V/K4D=U/;F,^=]I2WCMN'SC85
MB0],YSVJ7P%X/L/AEX)M?"MC(TUEI0N#$6^_Y32O*JGU*AL9[XJ?K%.FI3;O
ML[?)WOZ#]E*32_KR.&?X?^'O =F/&&KW]YKNM6$3""YU"=IBMS*AC9XD/RH7
MW$?*.%) XKS'P#927?B2"09VVP:1C^! _4BF^,?&=_XKNU,G[JTB)\J(=O<^
MIJ7PKXIMO#<,J&T,LLQ&YPV.!T%?S#Q'QGALTSFC4JSM1I;-IZO?1+NTOD?J
M.69)4PN"G&"O.?3M_2/H2BO)V^*$('R6+9]W%95U\3-2E!6VMXXO0G)-?95_
M$+*H*ZJ7]$SQX<.8MO6-OF>VGCD]JY?5O&&BZ2I#S":4?P1G)_/H*\.OO$VN
MZF=MQ=.0?X5^4?D*T-$\#^(]>=3;6K1Q-_RTD^5<?C7S>(\0L3BI>QRN@W)]
M6K_@OU9Z=/AVE17/BJB2)=<\<:KJX:&(_9K<_P *GD_4TGAKP/K?B>0/#'Y-
MMU,SCC\/6O:_#GPHTC2RMSJA^VSCG!XC!^G?\:]4BACA010H$11@ # %>AE?
MAIB\956)SFI?^ZGKZ-[+Y'-B^)Z5&'LL%'Y_U^IROACP7I'AB$"TC\RX(^:9
MN6/T]!78445^SX+ T<-25&A%1BNB/B:]>=23G4=VPHHHKK,@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#_]+]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/2OS@NM+U[]I/]H?Q
M]\-_''BN]\/>'? TMLMKH=C(;:2_AECR;EY!AF0G^[TR!TK](*\+\<? CPQX
MO^(OAOXK6ES<:+XF\/2*#=VC;&N[0'Y[:<='C89'/(!.*]/+,5&DY-Z-K1[V
M?]:')BJ#FE;:^J[FC\-O@+\*OA,K-X)T""SNI.9+IAYES(3P2TK98DU['11D
M5P5:TZDN:;NSIA!15HJR/@EO&OBOPW_P4#/@[6=4F/AWQ3X862PM&?\ <">%
MLG:IXWYBD/'.&K[U!R*^0OVJ/@%XA^*<'A[Q_P##.]72_B#X(N#<Z9.YPDJ,
M07A?V)48SQU'0FO'K?\ :K_::\)+]E^(?P1O+A[?:))M/?<LF."RCYNIZ5[U
M3!K%TZ<Z#7,E9JZ3NNNN]T>=&O[&4HU+V;NG9L_1QE#*589![50TG2=,T'3H
M-)T>VCL[.V7;'#$H5$&<X '3FOGOX$_M1> OCK<WVAZ=#<:)XCTL;KG2K]?+
MN$7NR@XW*#UX]*^D9'6)&D=@J("22<  <DD_2O$Q.'JT9.G45GV.^E5A-<T7
M<\T\:?&7X8?#VY2R\7^(K73[J3[L!8O-CU*(&8#W(KG_ !UX5\-_'OP'8W_A
M;73#+#*E_H^K63Y,%S%G:X]1U5U/4$@UXU\#?'?PE^*7Q=^(:^!_""SPV,JF
MY\0RHLL5Y=%BKQ1EP2 .2,<8Y[BM^Y^!WQ-\'ZYJZ_!/Q;;>'/#GB&8W,]C<
MVOVC['</_K7L^0$\S[Q4\!N17J?5H4:BBY.$U9Z[:^E[?U>QQ^V=2-[7B^Q(
M-+_:R\20Q^'-3U'1/#%O#A9]6L5:XN;@*,9CAD^2(MU.<X[5#:WOQF^"GB/3
M+;Q5J,WQ!\&ZS<Q6;7OD*FH:;/,VR-Y%C&)(68@,0,KUZ9K8T3XI?!WX*60\
M#>*OB"-3UA)6EO+B\D:>7SI2-QD,:LL0ST4X KZ.L=2TW5M/BU33[F*ZLIU$
MD<T;!HV3J&##C%*O7G#25-<C_NVOYI[E4Z<7JI>]ZW/+_'_Q!U3PO\0?AWX-
MTVWCE3Q=>WT5R\A(,<%G:/,=F/XB^T<]LUZ\0'7:1D$=*\+\<^#?"GQXT?3-
M7\->('M-1\,W\LNG:MI[AGMKJ,-!,H)^5U925<<@_A7(^ ?&'Q&\'_%^/X,_
M$S5[?Q"NKZ5+J>E:A'"+>8_9I5CFAF1?E)PP<,/<5S/"QG27)I**=UUW>OW?
MD:^V<9N^SV9Z_J/PO\*W[/(D#6[N2<QG R?:N3F^"MDQ)M]0D4?[2@U[B#3J
M^#Q? ^4UWS5,/&_EI^5CWZ.>8NGI&H_S_,\'C^"D(/[W4FQ[(*V[+X.^'K<Y
MNI9;D^Y"_P J]=HK##>'^3TGS1PZ^=W^9I4XAQDM'4?RT.7TSP=X<TGFRL8U
M;^\PW'\S72!53"H, =A4E%?4X;!T:,>6C!17DDCRJE:<W>;N%%%%=)D%%%%
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M:\O-0TG3X+2YU&0RW$D4:J\KGJSL!DD^]6]6TG3M=TRZT;5[=+NRO8VAFBD
M9)(W&&4@]B*]REF>'@E!4$X];ZR?>SZ>1Y\\)5E>3J._2VW_  3(\%^,O#WC
M_P ,:=XP\*W:7NEZI"LT$J'JK#H?1@>".Q&*IW/Q#\$VOC"T\ 7&M6R^(;Y'
MEALO,!F=(QN8[1TP 3SVKX03]CCXS_#^\O\ 0_@5\4I?#?@_4)GF%C,ADDMC
M(<L(FZ#VKW3X%?LF>#/@[J\GC;4KVX\4^-+D,)=6OF+R+O&'$0/W0<D>N*6(
MP>$A&4XU;]DEK\[Z#IUJTFHN%N[_ ,CP/]M/2+;X/^.OAU^U'X:A^S7>DZM#
MIVKB$!/M5E< G$F.ORJR9/\ >'H*^B/VPO$FM:+^R_XXUWPI(XNI-/14DBR6
M$-Q(D<C@CIB-F.>W6O3/C1\(O#WQQ^'M_P##KQ1++!8W[PR&2$@2(\$BR*5)
M]Q@^U=RWAO29O#0\)7T"W>FFU%G)%,-ZR0A-A5L]<CK3CF<.7#RFKR@]?.-T
MTOS$\)*]1+127X[,\,_9*\.^#/#G[/W@RW\$/%-:W5A#<7$T9!,MW,H:<N1S
MN#DKSTQBO?M:TU=8TB]TEII+=;R&2$RPMMD02*5W(W9AG(/8U^9WA_1-=_8W
M_:3\+_#SPY?/?_#?XIW,L5O82L6;3[M<9,9/\(+K]5//(K]$/'WQ \*?#+PM
M=^,?&E^FGZ79 ;W;DEFX5%'5F8] *SS/"R595*;YE/5/KOU\TRL)53IN,E;E
MT9B>$/@]\.? _AX>&M#T2W^R,N)6F19I9V(PS2R."SLW<DUY-<?LG^$/.N;#
M2->UG2/#=[(9)M&M+MH[,[OO*O\ $BGGY5(%<CI7[;'AG5=5M+.+P-XFCLKV
M9(8KMM/?83(P56*XR!DCGTK[64Y&:BL\7AI7FVFRH*C55HJ]C!\,^&- \':'
M:>&_#-C'IVFV2!(H8EVJH_Q/4GJ:Y^]^'.A7_P 2-,^)]P7;5=)TZXTZ ?P+
M'<NCNV/[WR8^A->@45YRJR3<KZO]3JY%:UA *6BBLR@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /_4_?RBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQJ@C50%7H , 8Z8%24U<XYIU?)GLA1110 4444 %%%% !1110 4444 %%%%
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M?XW/J:Z[ H!%+7@SFY-R>[/12LK(****D84444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]?]_**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>octoberswimlane.jpg
<TEXT>
begin 644 octoberswimlane.jpg
M_]C_X  02D9)1@ ! 0 !2@%*  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      %*     0   4H    !  .@ 0 #     0 !  "@ @ $     0  $!B@
M P $     0  !%D     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_W0 $ 0+_V@ , P$
M A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'1_PV=\=/^@A9_\ @''7RE11]?K?SO[P_P"(A9Y_T&U/_ F?5O\ PV=\=/\
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M=\=/^@A9_P#@''7RE11]?K?SO[P_XB%GG_0;4_\  F?5O_#9WQT_Z"%G_P"
M<='_  V=\=/^@A9_^ <=?*5%'U^M_._O#_B(6>?]!M3_ ,"9]6_\-G?'3_H(
M6?\ X!QT?\-G?'3_ *"%G_X!QU\I44?7ZW\[^\/^(A9Y_P!!M3_P)GU;_P -
MG?'3_H(6?_@''1_PV=\=/^@A9_\ @''7RE11]?K?SO[P_P"(A9Y_T&U/_ F?
M5O\ PV=\=/\ H(6?_@''1_PV=\=/^@A9_P#@''7RE11]?K?SO[P_XB%GG_0;
M4_\  F?5O_#9WQT_Z"%G_P" <='_  V=\=/^@A9_^ <=?*5%'U^M_._O#_B(
M6>?]!M3_ ,"9]6_\-G?'3_H(6?\ X!QT?\-G?'3_ *"%G_X!QU\I44?7ZW\[
M^\/^(A9Y_P!!M3_P)GU;_P -G?'3_H(6?_@''1_PV=\=/^@A9_\ @''7RE11
M]?K?SO[P_P"(A9Y_T&U/_ F?5O\ PV=\=/\ H(6?_@''1_PV=\=/^@A9_P#@
M''7RE11]?K?SO[P_XB%GG_0;4_\  F?5O_#9WQT_Z"%G_P" <='_  V=\=/^
M@A9_^ <=?*5%'U^M_._O#_B(6>?]!M3_ ,"9]6_\-G?'3_H(6?\ X!QT?\-G
M?'3_ *"%G_X!QU\I44?7ZW\[^\/^(A9Y_P!!M3_P)GU;_P -G?'3_H(6?_@'
M'1_PV=\=/^@A9_\ @''7RE11]?K?SO[P_P"(A9Y_T&U/_ F?5O\ PV=\=/\
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M=\=/^@A9_P#@''7RE11]?K?SO[P_XB%GG_0;4_\  F?5O_#9WQT_Z"%G_P"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9>1[Y]:Y*HE%IV9RXG#5*-25*K%QDG9IJS3[-,****1B%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWPRU&R6]U=422&+4_M3RB'<PQ&TK\J"QR!G&>V:_/#]LWQ4_B#XTW6E*^8-
MM8+11VWNOGN?KF3:?]VOG_X>^)Y/!?CK0?%<;$?V7>P3OCO&KCS%_P"!)D'Z
MUZU?-8QK_ M':_4_7\^\7<)A\^E%X*$G3ER>T?QI)VE9VZ7=M?S/T<_;K\#?
MVGX,TCQ[:QYFT2X-M<$#_EWNL;23Z+(J@?[YK(_8#G+>'_&%KVCNK1_^^TD'
M_LM?:/Q$\*6_CWP'KGA*7!75;22*-CT60KF)_P#@+A6_"OB;]@.-X[#QNCC!
M6:Q!'H0L^:Z:E'EQL)KJG^"/J<TR/ZMQQ@\;!:5HSO\ XHP:?X<I\W_MAQ"/
MX^:ZX_Y:PV3?^2T:_P!*^L_V"Y]0D^'WB&&9F-G%J0\D'[H=H5,@'_CI(_QK
MN_BY^RGX7^+GC-_&-QKMUIUS(D45Q%&D<JGRE 7;G!0[<9SN]<5WSW7PQ_9C
M^&D=F\XM-/LE=HXW<-=7MPW+;1QOD<]< *H_NJ.(H8.=/$2K3TCJ>?D/ ^+R
M_B3%9YC91AATZDD^9:J3>_:U[N_5*USY\AN[5/V\9HK;AY-.\N;'=Q8JX_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^!?_ -A1]0K?R,/^(<Y[_P! =3_P%GR-17US_P ,3?&W_GGIW_@7_P#84?\
M#$WQM_YYZ=_X%_\ V%'U"M_(P_XASGO_ $!U/_ 6?(U%?7/_  Q-\;?^>>G?
M^!?_ -A1_P ,3?&W_GGIW_@7_P#84?4*W\C#_B'.>_\ 0'4_\!9\C45]<_\
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M;^1A_P 0YSW_ * ZG_@+/D:BOKG_ (8F^-O_ #ST[_P+_P#L*/\ AB;XV_\
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M]._\"_\ ["CZA6_D8?\ $.<]_P"@.I_X"SY&HKZY_P"&)OC;_P \]._\"_\
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MR;"T:T7&48)-/=,****ZCZP**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__5_?RBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /%OC3\$?"WQGT#[#JJBTU6U4_8K]%S)"QYVMTW
MQD_>4GW&#S7XQ?$#X>^*/AEXDN/"_BRU-O=0\HXR8IHR?EDB;C<I_,'((!!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &N
M<(Q'H:Y;[9=?\]6KJ7^XWT-<;0!9^V77_/5J/MEU_P ]6JM10!9^V77_ #U:
MC[9=?\]6JM7@/QD_:3^&GP*O]-TWQX]VDVJQ22P?9H/.!6-@K9.X8.2* /H?
M[9=?\]6H^V77_/5J^"Y/^"B/[/2?=_M>3_=LE_K(*VM!_;Z_9QUJXCMKG5;S
M2#(P4->6<@0$\#+1>8 /<\#O0!]M?;+K_GJU'VRZ_P">K5S^A:_H?B?2X-;\
M-ZA;ZII]R,Q7%K*LT3C_ &70D'WYKY?\>?MK?!+X<^+M3\$^))=174](E\J<
M16F]-VT-\K;AD8(H ^P/MEU_SU:C[9=?\]6KX'?_ (**?L^*<*FL/[BS3^LH
MKN?"'[;_ .SGXOOH]-7Q$VCW$S!4&I0/;1DGUFPT2_\  G% 'U_]LNO^>K4?
M;+K_ )ZM5.*6.:-)H7$D<@#*RG(8'D$$=0:^:/BM^UK\(_@UXL/@SQI)?)J*
MP1W&(+;S4\N7.WYMPYX- 'U']LNO^>K4?;+K_GJU?"7_  \+_9V_Y[ZI_P"
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M;+K_ )ZM5:O-OB-\7_AK\);!-0^(6OV^CI+DQQN6>>7'7RX8PTC@=RJD#N:
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MW_G]E_.C_A(]=_Y_9?SK$KG/%WBC2_!/AG4?%FMEQ8:7"T\QC7>^Q>N%XR:
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MV7\Z^._#/[8WP8\6>(M,\,:5-?\ VW5KF*U@\RU*H99F"("0QP"2.<<5]4T
M;?\ PD>N_P#/[+^='_"1Z[_S^R_G6)10!M_\)'KO_/[+^='_  D>N_\ /[+^
M=8E% &W_ ,)'KO\ S^R_G1_PD>N_\_LOYUB44 ;?_"1Z[_S^R_G1_P )'KO_
M #^R_G6)10!M_P#"1Z[_ ,_LOYT?\)'KO_/[+^=8E% &W_PD>N_\_LOYT?\
M"1Z[_P _LOYUB44 ;?\ PD>N_P#/[+^='_"1Z[_S^R_G6)10!M_\)'KO_/[+
M^='_  D>N_\ /[+^=8E% &W_ ,)'KO\ S^R_G1_PD>N_\_LOYUB44 ;?_"1Z
M[_S^R_G1_P )'KO_ #^R_G6)10!M_P#"1Z[_ ,_LOYT?\)'KO_/[+^=8E% &
MW_PD>N_\_LOYT?\ "1Z[_P _LOYUB44 ;?\ PD>N_P#/[+^='_"1Z[_S^R_G
M6)10!M_\)'KO_/[+^='_  D>N_\ /[+^=8E% &W_ ,)'KO\ S^R_G1_PD>N_
M\_LOYUB44 ;?_"1Z[_S^R_G1_P )'KO_ #^R_G6)10!M_P#"1Z[_ ,_LOYT?
M\)'KO_/[+^=8E% &W_PD>N_\_LOYT?\ "1Z[_P _LOYUB44 ;?\ PD>N_P#/
M[+^='_"1Z[_S^R_G6)10!M_\)'KO_/[+^='_  D>N_\ /[+^=8E% &W_ ,)'
MKO\ S^R_G1_PD>N_\_LOYUB44 >E>&/%[F06.L2;@Y^25NQ/9O;T->G5\SUZ
M/X4\5^5LTS4W^3I'(?X?16/IZ'M0!ZC1110!X9?>(-:CO;B-+R1561P #T )
MJK_PD>N_\_LOYU1U'_D(77_75_\ T(U2H V_^$CUW_G]E_.C_A(]=_Y_9?SK
M$HH V_\ A(]=_P"?V7\Z/^$CUW_G]E_.O*?B/\1?#GPL\+R^+_%1E73X9(XF
M,,?F/NE.U?ER.,U\Y/\ MT_ M1E7U-_I:#^KB@#[C_X2/7?^?V7\Z/\ A(]=
M_P"?V7\Z^(+/]N;X$W,WE33:C:+_ 'Y;3*_^0V<_I7T=X(^(_@;XCZ=_:G@G
M6;?5H5 +B)L2QYZ"2)L.A/HRB@#U'_A(]=_Y_9?SH_X2/7?^?V7\Z^>/BM\?
M_A]\&KW3[#QH]TDNI1O+#]GA\T;8R%.3D8.36E\*/C5X'^,UKJ-YX*DN'32W
MCCG%Q"8B#*"5QR00=IH ]U_X2/7?^?V7\Z/^$CUW_G]E_.L2OC^;]N'X&03/
M!)+J(:-BI_T0]0<'^*@#[;_X2/7?^?V7\Z/^$CUW_G]E_.N=M;F*\MHKNW.Z
M*=%=#C&589'!YZ5/0!M_\)'KO_/[+^='_"1Z[_S^R_G7Q-<_MP? JVN);<W%
M_(8G9-R6N5;:<94[N0>QKV;X4_&?P1\9;&_O_!<LSIILB13+/'Y3@R LI R>
M#@\^QH ]S_X2/7?^?V7\Z/\ A(]=_P"?V7\ZQ*YCQ9XS\*>!=)?7/&&JV^DV
M*''F3N%W-C.U%^\[8Z*H)/I0!Z%_PD>N_P#/[+^='_"1Z[_S^R_G7P?JO[>7
MP4L)&CL;?5M2P<!X;:-$/O\ OI8VQ_P'--TW]O3X*7THBNK36-/!_CFMHF4?
M]^IG;_QV@#[R_P"$CUW_ )_9?SH_X2/7?^?V7\ZX#Q7XKTKP9X7U#Q?K7F+8
M:9 ;B;8FZ0(O7"\9/M7R_P#\-S? G_GMJ/\ X"?_ &= 'V__ ,)'KO\ S^R_
MG1_PD>N_\_LOYU\0?\-S? G_ )[:C_X"?_9UZ9\+/VC?AM\8=<NO#W@Z6Z:\
MM+8W3B> Q+Y2NJ$ALD9W.O'_ ->@#Z3_ .$CUW_G]E_.C_A(]=_Y_9?SK$HH
M V_^$CUW_G]E_.C_ (2/7?\ G]E_.L2B@#;_ .$CUW_G]E_.C_A(]=_Y_9?S
MK$HH V_^$CUW_G]E_.C_ (2/7?\ G]E_.L2B@#;_ .$CUW_G]E_.C_A(]=_Y
M_9?SK$HH V_^$CUW_G]E_.C_ (2/7?\ G]E_.L2B@#;_ .$CUW_G]E_.C_A(
M]=_Y_9?SK$HH V_^$CUW_G]E_.C_ (2/7?\ G]E_.L2B@#;_ .$CUW_G]E_.
MC_A(]=_Y_9?SK$HH V_^$CUW_G]E_.C_ (2/7?\ G]E_.L2B@#;_ .$CUW_G
M]E_.C_A(]=_Y_9?SK$HH V_^$CUW_G]E_.C_ (2/7?\ G]E_.L2B@#;_ .$C
MUW_G]E_.C_A(]=_Y_9?SK$HH V_^$CUW_G]E_.C_ (2/7?\ G]E_.L2B@#;_
M .$CUW_G]E_.C_A(]=_Y_9?SK$HH V_^$CUW_G]E_.C_ (2/7?\ G]E_.L2B
M@#;_ .$CUW_G]E_.C_A(]=_Y_9?SK$HH V_^$CUW_G]E_.C_ (2/7?\ G]E_
M.L2B@#;_ .$CUW_G]E_.C_A(]=_Y_9?SK$HH V_^$CUW_G]E_.C_ (2/7?\
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M.L2B@#;_ .$CUW_G]E_.C_A(]=_Y_9?SK$HH V_^$CUW_G]E_.C_ (2/7?\
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MS\K#'-%:GCJ:YI\R7S"I'$P5Y77WGN?_  G?C#_H+3_]]4?\)WXP_P"@M/\
M]]5\7?\ #8'P=_YZW_\ X#?_ &5'_#8'P=_YZW__ (#?_95K]5S'M/\ $OV.
M+[2_$^T?^$[\8?\ 06G_ .^J/^$[\8?]!:?_ +ZKXN_X; ^#O_/6_P#_  &_
M^RKOO#OQX\ ^*/"FM^,M*>Y.G^'P&NM\.UP",_*N>>/>HJ4<?!7ES+[R94\3
M%7=_Q/I/_A._&'_06G_[ZH_X3OQA_P!!:?\ [ZKXN_X; ^#O_/6__P# ;_[*
MC_AL#X._\];_ /\  ;_[*K^JYCVG^)7L<7VE^)]H_P#"=^,/^@M/_P!]4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX^_M253XHT3P[J=IJ2<9D;['+Y5R .TP!)Z .& X KX+_8! /[26D'TLK_\
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MK/+6J'Q7T^_S.K *H\)^Z^+_ ()]4R_L.Z(P_<>*[A#_ +5JC?R=:^@OAO\
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MZ%YO",Z4:Z6I].4445\.?-A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'I7PF_Y'2V_P"N<O\
MZ :^LJ^3?A-_R.EM_P!<Y?\ T U]95^D\)?[J_5_DCZ_(OX+]?\ (__0_?RB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH :_W&^AKC:[)_N-]#7&T %%%% !7Y'_\%/V_XF'PZ7TBU0_FUM7ZX5^0
M'_!3N;=XC\ V_P#<M+]O^^I(A_[+0!XE^RG^R9I'[0^B:UKVK>(Y]'32+J.V
M\F"W61I Z;RV]G&/3&TU^A/@+_@G[\!_!U^FJ:PE[XJFCP5CU&5/LRL._E0I
M'N^CEE]J\C_X)CS;O!WCBW_N7]HW_?43#_V6OT_H IZ?I]AI-C!IFEVT5G9V
MJ".*&%%CCC11@*B* % '0 8K^>G]M5MW[3WC@_\ 36S'Y64 K^B*OYSOVQ)O
M/_:6\=/Z7<2_]\6\2_TH ^O?A;^P-\/OB=\'?#GCB'Q'JFFZSK=DMP^1!-:I
M(V1@1B-'V@CH9,^]?!'BKP]\0OV<OBO/HYO'TWQ#X<G1X;JU8A9%(#QR(2!N
MCD4C*L,$$JPZBOW@_9)D\S]G#P$WII^/^^9'']*^-/\ @I9\-$EL/#7Q:L(O
MWD#G2;U@.2C[I;=C[*PD4D_WE% 'W7^SY\7K3XW?"O2/'42I%>R V]_"G2&\
MAP)% Y(5LAU!).UESS7Y0_\ !2!L_'O3A_=T"T'_ ),7)KHO^"<7Q1.@?$+5
M?A=J$V+/Q/ ;BU4G@7MHI8A1_P!-(=Q/KL45QW_!16;S?V@XT_YXZ-9K^;S-
M_6@#ZG_8L^!?P>\?_ >QU_QCX3L=6U-[V\C>XGC+2%4?"C.>@'2OL/PY^S?\
M#O".OV?BCPUX/LM.U33W+P3Q;PT;$%20-V.A(Z5^*OP@_;'^*?P4\%Q^!?"5
MEI,^GQSRW >\@FDFWS$%AE)T7'''RUZ'<?\ !1?]H&88CAT6#_<LY#_Z',U
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MQA=89=#CU*1%/1Y?M$AB3_@;LJ_C0!\:?MH_$/\ X37XQ7.BVDN_3_"T8L$
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MY\.KB[NO!.AP:1+?*J3-#N^=4)*@[B>A)KT*OQFG_;K^.4IS'_9</^Y:,?\
MT*0U^R5J\DEM#), )'12P'3)'.* )Z^$/^"@:@_"C07[C6XQ^=M/_A7W?7P3
M_P %!9@OPQ\.P?W]85O^^;>4?^S4 ><_\$[<?;?'A[^7IO\ .XK]/*_+K_@G
M?-MUGQO!_?M[%O\ OEYA_P"S5^HM !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[1$TR6VCM_LL31<R+(9 VYWSC"X_&OKV@ HHHH **** "BBB@ HHHH ****
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M*R<M""5WKN'.,C->LZY9_M=>)=*GT/Q!8>,-0T^Z $L$]M>O&X5@P#*5P<$
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MU*NA#*PPV.",U^0?P?\ VC/'?P2TW4=+\(VMA<1:G*DTAO(I)&#(NT;=DL8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG@  P. *X>(\;35.&$I.ZCO\M/\ ASGS;$048T*?06BBBOD3P0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#TKX3?\CI;?]<Y?_0#7UE7R;\)O^1TMO^N<O_H!KZRK])X2_P!U
M?J_R1]?D7\%^O^1__]']_**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*[NB@#R;_A0?P+_Z)SX;_P#!19__ !JC_A0?P+_Z)SX;_P#!19__ !JO6:*
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M*A)7T^R@M6D4'(5C$BE@#S@UV5% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5Q/C3_ )"T?_7"/^M=M7$^
M-/\ D+1_]<(_ZT <C1110 52U'3=.UBQGTO5K6*]L[I2DL$Z+)%(AZJZ,"K
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.;]U;)ACW?>#$8D?H!D9W5^U(    P!3(88;:%+>WC6**)0J(H"JJC@  <
M=JDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)U[_D#W
M7T3_ -#6M:LG7O\ D#W7T3_T-:X<T_W:K_A?Y'-C?X,_1_D>8T445^.GP 44
M44 <'+\*_AA/*\\_A#1Y))"69FT^W+,QY))*<DFN\  &!115SJRE\3N5*;>[
M.,U'X<?#S5[V74M6\+Z7>W<YW233V4$DCGIEG9"2<>IKL41(D6.-0B(   ,
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M3M' X''%6]#\,>&O#$4L'AK2;328YR&D6T@C@5V' +"-5!('K6Y10ZLK<M]
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M#^S<1_S[E]S/I2BOFO\ X;"_9H_Z'_3_ ,I?_C=+_P -@_LT?]#_ &'Y2_\
MQ%']FXC_ )]R^YA_9N(_Y]R^YGTG17S9_P -@?LT?]#_ &'Y2_\ Q%'_  V!
M^S1_T/\ I_Y2_P#Q%']FXC_GW+[F']F8G_GW+[F?2=%?-G_#8'[-'_0_Z?\
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M_P# 7_D?0E%?/G_#5G[/'_0\6/Y2_P#Q%'_#5G[/'_0\6/Y2_P#Q%']D8O\
MY\R_\!?^0?V1B_\ GS+_ ,!?^1]!T5\^?\-6?L\_]#Q8_E)_\11_PU7^SS_T
M/%C^4G_Q%']D8O\ Y\R_\!?^0?V/B_\ GS+_ ,!?^1]!T5\^_P##5?[//_0\
M6/Y2_P#Q%'_#5?[//_0\6/Y2_P#Q%']D8O\ Y\R_\!?^0_[&Q?\ SYE_X"SZ
M"HKY]_X:J_9Z_P"AWL?RE_\ B*/^&JOV>O\ H=['\I?_ (BC^R,7_P ^9?\
M@+_R#^QL7_SYE_X"SZ"HKY]_X:J_9Z_Z'>Q_*7_XBIHOVH_V?I3A?'&GC_>9
MU_FHH_LC%_\ /F7_ ("_\A?V/B_^?,O_  %_Y'OE%>5Z;\<_@QJ[+'I_CG19
M9&Z(;^!7/T5G!_2O2+'4=/U2 76F745W">CPNLBG\5)%<E7#5*?QQ:]4<M7#
M5*?\2+7JK%RBBBL3 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +[%'V^P_P"?B/\ [[% %3^R8O[YH_LF+^^:M_;[#_GXC_[[%'V^P_Y^(_\
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M^Q0!Q/\ PKVP_P"?J3\A1_PKVP_Y^I/R%=M]OL/^?B/_ +[%'V^P_P"?B/\
M[[% '$_\*]L/^?J3\A1_PKVP_P"?J3\A7;?;[#_GXC_[[%'V^P_Y^(_^^Q0!
MQ/\ PKVP_P"?J3\A1_PKVP_Y^I/R%=M]OL/^?B/_ +[%'V^P_P"?B/\ [[%
M'$_\*]L/^?J3\A1_PKVP_P"?J3\A7;?;[#_GXC_[[%'V^P_Y^(_^^Q0!Q/\
MPKVP_P"?J3\A1_PKVP_Y^I/R%=M]OL/^?B/_ +[%'V^P_P"?B/\ [[% '$_\
M*]L/^?J3\A1_PKVP_P"?J3\A7;?;[#_GXC_[[%'V^P_Y^(_^^Q0!Q/\ PKVP
M_P"?J3\A1_PKVP_Y^I/R%=M]OL/^?B/_ +[%'V^P_P"?B/\ [[% '$_\*]L/
M^?J3\A1_PKVP_P"?J3\A7;?;[#_GXC_[[%'V^P_Y^(_^^Q0!Q/\ PKVP_P"?
MJ3\A1_PKVP_Y^I/R%=M]OL/^?B/_ +[%'V^P_P"?B/\ [[% '$_\*]L/^?J3
M\A1_PKVP_P"?J3\A7;?;[#_GXC_[[%'V^P_Y^(_^^Q0!Q/\ PKVP_P"?J3\A
M1_PKVP_Y^I/R%=M]OL/^?B/_ +[%'V^P_P"?B/\ [[% '$_\*]L/^?J3\A1_
MPKVP_P"?J3\A7;?;[#_GXC_[[%'V^P_Y^(_^^Q0!Q/\ PKVP_P"?J3\A1_PK
MVP_Y^I/R%=M]OL/^?B/_ +[%'V^P_P"?B/\ [[% '$_\*]L/^?J3\A1_PKVP
M_P"?J3\A7;?;[#_GXC_[[%'V^P_Y^(_^^Q0!Q/\ PKVP_P"?J3\A1_PKVP_Y
M^I/R%=M]OL/^?B/_ +[%'V^P_P"?B/\ [[% '$_\*]L/^?J3\A1_PKVP_P"?
MJ3\A7;?;[#_GXC_[[%'V^P_Y^(_^^Q0!Q ^'ME_%=R'Z*!2_\*]L/^?J3\A7
M;?;[#_GXC_[[%'V^P_Y^(_\ OL4 <3_PKVP_Y^I/R%'_  KVP_Y^I/R%=M]O
ML/\ GXC_ .^Q1]OL/^?B/_OL4 <3_P *]L/^?J3\A1_PKVP_Y^I/R%=M]OL/
M^?B/_OL4?;[#_GXC_P"^Q0!Q/_"O;#_GZD_(4?\ "O;#_GZD_(5VWV^P_P"?
MB/\ [[%'V^P_Y^(_^^Q0!Q/_  KVP_Y^I/R%'_"O;#_GZD_(5VWV^P_Y^(_^
M^Q1]OL/^?B/_ +[% '$_\*]L/^?J3\A1_P *]L/^?J3\A7;?;[#_ )^(_P#O
ML4?;[#_GXC_[[% '$_\ "O;#_GZD_(4?\*]L/^?J3\A7;?;[#_GXC_[[%'V^
MP_Y^(_\ OL4 <3_PKVP_Y^I/R%'_  KVP_Y^I/R%=M]OL/\ GXC_ .^Q1]OL
M/^?B/_OL4 <3_P *]L/^?J3\A1_PKVP_Y^I/R%=M]OL/^?B/_OL4?;[#_GXC
M_P"^Q0!Q/_"O;#_GZD_(4?\ "O;#_GZD_(5VWV^P_P"?B/\ [[%'V^P_Y^(_
M^^Q0!Q/_  KVP_Y^I/R%'_"O;#_GZD_(5VWV^P_Y^(_^^Q1]OL/^?B/_ +[%
M '$_\*]L/^?J3\A1_P *]L/^?J3\A7;?;[#_ )^(_P#OL4?;[#_GXC_[[% '
M$_\ "O;#_GZD_(4?\*]L/^?J3\A7;?;[#_GXC_[[%'V^P_Y^(_\ OL4 <3_P
MKVP_Y^I/R%'_  KVP_Y^I/R%=M]OL/\ GXC_ .^Q1]OL/^?B/_OL4 <3_P *
M]L/^?J3\A1_PKVP_Y^I/R%=M]OL/^?B/_OL4?;[#_GXC_P"^Q0!Q/_"O;#_G
MZD_(4?\ "O;#_GZD_(5VWV^P_P"?B/\ [[%'V^P_Y^(_^^Q0!Q/_  KVP_Y^
MI/R%'_"O;#_GZD_(5VWV^P_Y^(_^^Q1]OL/^?B/_ +[% '$_\*]L/^?J3\A1
M_P *]L/^?J3\A7;?;[#_ )^(_P#OL4?;[#_GXC_[[% '$_\ "O;#_GZD_(4?
M\*]L/^?J3\A7;?;[#_GXC_[[%'V^P_Y^(_\ OL4 <3_PKVP_Y^I/R%'_  KV
MP_Y^I/R%=M]OL/\ GXC_ .^Q1]OL/^?B/_OL4 <3_P *]L/^?J3\A1_PKVP_
MY^I/R%=M]OL/^?B/_OL4?;[#_GXC_P"^Q0!Q/_"O;#_GZD_(4?\ "O;#_GZD
M_(5VWV^P_P"?B/\ [[%'V^P_Y^(_^^Q0!Q/_  KVP_Y^I/R%'_"O;#_GZD_(
M5VWV^P_Y^(_^^Q1]OL/^?B/_ +[% '$_\*]L/^?J3\A1_P *]L/^?J3\A7;?
M;[#_ )^(_P#OL4?;[#_GXC_[[% '$_\ "O;#_GZD_(4?\*]L/^?J3\A7;?;[
M#_GXC_[[%'V^P_Y^(_\ OL4 <3_PKVP_Y^I/R%'_  KVP_Y^I/R%=M]OL/\
MGXC_ .^Q1]OL/^?B/_OL4 <3_P *]L/^?J3\A1_PKVP_Y^I/R%=M]OL/^?B/
M_OL4?;[#_GXC_P"^Q0!Q/_"O;#_GZD_(4?\ "O;#_GZD_(5VWV^P_P"?B/\
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M^Q0!Q/\ PKVP_P"?J3\A1_PKVP_Y^I/R%=M]OL/^?B/_ +[%'V^P_P"?B/\
M[[% '$_\*]L/^?J3\A1_PKVP_P"?J3\A7;?;[#_GXC_[[%'V^P_Y^(_^^Q0!
MQ/\ PKVP_P"?J3\A1_PKVP_Y^I/R%=M]OL/^?B/_ +[%'V^P_P"?B/\ [[%
M'$_\*]L/^?J3\A1_PKVP_P"?J3\A7;?;[#_GXC_[[%'V^P_Y^(_^^Q0!Q/\
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MH_X4EH__ $$9_P#OE*]@^WV'_/Q'_P!]BC[?8?\ /Q'_ -]BC^P,'_S[_/\
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M?\_$?_?8H_L#!_\ /O\ /_,/[+P_\AX__P *2T?_ *",_P#WRE'_  I+1_\
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M /01G_[Y2O8/M]A_S\1_]]BC[?8?\_$?_?8H_L#!_P#/O\_\P_LO#_R'C_\
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MO\_\P_LO#_R'C_\ PI+1_P#H(S_]\I1_PI+1_P#H(S_]\I7L'V^P_P"?B/\
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M)+'*,QN''J#FGT?V!@_^??Y_YA_9>'_D/%/^%):/_P!!&?\ [Y2C_A26C_\
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M$U9KHPHHHK,S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \$^,W[2WPC^ SVEI\0-4>+4+Y/-AL[:)I[AHLLOF%1@*FY2H+,,GIG!QW
M?PU^*7@3XO>&8_%WP]U5-5TUW,3,%:-XY5 +1R1R!75AD'!'(((R"#7X%_M\
M7$\W[5GC2.5RZP+IJ1@GA5.GV[X'MN8GZFOK[_@E1<3M;_$VU9R88VT9U3/
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MN>)O^@K=_P#?^3_XJM[^R?\ 9H_LG_9H^IA_97D8/]N>)O\ H*W?_?\ D_\
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M_D_^*K>_LG_9H_LG_9H^IA_97D8/]N>)O^@K=_\ ?^3_ .*H_MSQ-_T%;O\
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M/_BJ/[<\3?\ 05N_^_\ )_\ %5O?V3_LT?V3_LT?4P_LKR,'^W/$W_05N_\
MO_)_\51_;GB;_H*W?_?^3_XJM[^R?]FC^R?]FCZF']E>1@_VYXF_Z"MW_P!_
MY/\ XJC^W/$W_05N_P#O_)_\56]_9/\ LT?V3_LT?4P_LKR,'^W/$W_05N_^
M_P#)_P#%4?VYXF_Z"MW_ -_Y/_BJWO[)_P!FC^R?]FCZF']E>1@_VYXF_P"@
MK=_]_P"3_P"*H_MSQ-_T%;O_ +_R?_%5O?V3_LT?V3_LT?4P_LKR,'^W/$W_
M $%;O_O_ "?_ !5']N>)O^@K=_\ ?^3_ .*K>_LG_9H_LG_9H^IA_97D8/\
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M\51_;GB;_H*W?_?^3_XJM[^R?]FC^R?]FCZF']E>1@_VYXF_Z"MW_P!_Y/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** 'QR21,'B8HPZ$'!KJ--\8ZS8$++)]JB'\,G)
M_!NOYYKE** /?-&\06&M1_Z.VR51EHV^\/<>H]ZW*^;;>XFM9DN+=S'(ARK#
MJ*]O\-Z]'K=IE\+<Q8$BC]&'L?TH Z.BBB@ HHHH __4_=WQ9_R*VL_]>5Q_
MZ+:OY)J_K9\6?\BMK/\ UY7'_HMJ_DFK]!X(^&K\OU/T'@CX:OR_4*4=:2E'
M6ONS[\?3EIM.6@!U%%%7$J(5)4=24RA1UI],'6GT %%%%5$KH*.M/I@ZT^J&
M]ARTZFK3J!A11130T%25'4E4RPJ2HZDI@%%%%!<1RTZFK3J;&/'2EI!TI:L$
M%%%% T/7I2TB]*6@?4<M.IJTZK104444RHD@Z44#I10-#EIU-6G541A2CK24
MHZU0#Z4=:2E'6@:'T444T6%%%%65$DHHHH"(\=*6D'2EJNQ044450#QTI:0=
M*6@;)****OH6%.6FTY:8T.IXZ4RGCI06+1115H I1UI*4=:8#Z>.E,IXZ4%/
M86BBBKB4%.7K3:<O6F-#J<O6FTY>M-%CJ***<0%'6GTP=:?5%Q"BBBJZC1(.
ME% Z44T HZT^F#K3Z8T=KX"^(?C'X9Z_%XE\%:E)IM['PVPYCE3.2DJ'*NA]
M&'N,'!K]F/V=OVK_  M\:(8O#^M"/1?%R+\UJ6_<W6T99[9FY/J8R=P'3< 3
M7X958M+NZL+J&^L9GM[BW=9(Y(V*.CJ<JRL,$$'D$=*^>X@X8P^80]]6GTEU
M^?=?TCYWB'A?#YA#WU:?277Y]U_2/Z?**^!OV4?VM(OB(MM\.OB/.L/B=%V6
MEXV%34 H^ZW83@?@_;#<'[YK\!S7*JV#K.A75FON:[H_G[-<JK8*LZ%=6:^Y
MKN@HHHKSCS0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _G%_
M;S_Y.O\ '/\ W#/_ $VVM?7W_!*?_FJ/_<$_]OJ^0?V\_P#DZ_QS_P!PS_TV
MVM?7W_!*?_FJ/_<$_P#;ZOT[,O\ D3K_  P_]M/T[,O^1.O\,/\ VT_7RBBB
MOS$_,0HHHH \W^*GC+3_  1X.U'6]3F\BVM;>:XGD'5+>!"\K#WVC'XU_*5\
M4OB'K7Q7\?:QX[UQCY^IS%DCSE88%^6*)?9$ 'N>3R37[F?\%*O&EQH/P7U#
M2K=MC:S=6>F9!P0K%KI\?[RQ;3[&OY^H(\FOH\EH+E<^Y^A<'8)<DJSW>GR_
MK\BS;P;B*Z:SL2V.*@L+;<17=:?9# XKZO#T+GZEE^!YBO:::..*W8M-&.E:
MUO:A0.*TTA KVJ>&1]AALO26QZY\$?V9O''Q[76#X+N+"W_L/[.)_MLLD6?M
M/F;-FR.3/^J;.<=NM?0*_P#!-SXW;"QU;P^#_=^TW.?_ $EQ7LW_  388I??
M$"$='CTQO^^3<C^M?!6H_$GXE6VMW4\7BS5EFCF<"07]P'&&/??FO&<L34Q-
M6E2DDHVW5]T?'RGF&(S'$X7#5(QC3Y=XWOS1OW[FS\6/V5OBU\&[(:OXMTI)
MM)+!#?6<@G@5F. 'Z.F3P"Z@$G .>*\?\*>#;WQAXHTCPEI9CCO=:NX+*!IB
M5C$MQ((T+D!B%W,,D _2OV?\&^,?$/C;]B3Q'K_Q78W,SZ5JD4=Q<*%>Y1$9
M;:0YP"YDPJMCD@'D\G\I_@VWD?%[P/.O6/7=,8?A=1FM,NQ=2I3JJHES0;5U
MLSJR#-*^(H8F.(2YZ3<;K9V7]?\  +/QJ_9S\:_ >[TJS\9RV4[:PDLD#64K
MRJ!"5#!MZ(0?F&.#7B'V!?[M?J5_P4A;?XE\$1?W;2\/_?4D?^%?FGY8]*Z\
MHJRKX:%6>[_S/3X3Q,\9E]+$UK<TKWMZM'M_Q;_90^(?P9\(V'C7Q7/IT^GZ
MC<1VL8M)I))!)+$\J[E>-!C;&W()YJ?6_P!DCXC:)\(HOC5+<:;=:!+:6M[L
M@FD>Y$5T45<H8@NY"XWC=Q@\G%??/[=EPTW[/O@93TFU"SD/U%E-_P#%5>_8
MUU[3OBU^S]XA^#&OR;GTQ)[(@\L++4%=HW&>Z2&0#TPOM7AK,ZRPD<2[:2L]
M.ESXN'$F,65T\QDDTIVGI]F]M//_ #/QD^P+_=KT?X5?![Q)\8O&,'@CPGY"
M7T\4LV^Y9DA1(EW,695<C/ ''4BLWQ!H%_X9UW4?#FK1^5>Z7<2VLZ_W9(7*
M,/S%?I1^P'X1L/#'A[QE\;_$6+>SM87LXIF&-L%NHN+M_<<1@$=U85[>:8E4
M,.ZL=^GJ]C[/B;,(X/ 3Q-.SEHH^;>WKW/SF^*?PDUSX1>,KKP+XFFM;C4;-
M(GD-H[21CSD$BC+*ASM()&.]>=_8%_NUZE\1?&%]\1/'6N>-]2&V;6;N2XVD
MY\M&.(XP?1$ 4>PK3^$7A_P?XE^)&A:%X^OETSP_>3%+NY:9;<1IL8@F5\JN
M6 &3QS75"+C2YJFZ6MOQ/3I4Y4L*JF(5Y*-Y675*[LOR/&OL"_W:/L"_W:_6
MBY^!'[!]ID2_$ -C_GGJT$G_ *!&:W?!?[+W['/Q$U&?2?!'B6^UB[M8O.EC
M@O 2L>X+N), &,D"O)EGM!+F<)6_PGRM3C;!0@YRI5$EUY'8_'K[ O\ =H^P
M+_=KTWQ;H%A:^/M9\.>%%DN[.'4[FTL 3YDLL2S-'#R -S,,= ,GM7Z"Z1^Q
M[\&?A=X1LO$O[2/BI[&]O< 6MO*(HD?&XQ+M2269U'WF3"CT/!/?BL;1HJ+G
M>\MDE=OY'N9IG.$PD(2JW;G\,4KR?R\C\K?L"_W:/L"_W:_5GQ=^Q7\,/''@
M6;QO^SKXADU&2)7:.WEF6X@N&CY:)7"J\4OH'SS@$*#NK\QG@:-VCD7:RD@@
MC!!'4$56!QE+$)^SW6Z:LT7DN;83'QDZ%[Q=FFK->J.?^P+_ ':/L"_W:_33
MX;?L<^ ]%^'UO\3OVB?$#Z#97B1RQ6D<B0>6DHS&)G979I'!SY: %>Y)R!W#
M?L>?L_?%OPK=ZQ\ _%DK7UK\H\R7SX/,(RJ3QLBS1[NS=N3M;&*X9YWAHR:U
MLG:]M/O/&K<9Y;";3YG%.SDHMQ3[7/R3^P+_ ':/L"_W:[/7=!U+PWK5]X>U
MJ VU_IL\EO/$W5)8F*L/P(Z]Z^LOV:_V4'^,FG77C?QCJ3:%X1L7=#*FU9KA
MHQF0HT@*1QQC[TC C.0!P2/2Q->E1I^UJ/0^AS+&X7"4/K->5H_?>^UN]SX:
M^P+_ ':/L"_W:_7/0/V:_P!C/XE74_A3X?\ B^ZFUN)&*^5=AG;:,EE26(+*
MH[^7V[CJ/@?XV?!K7_@CXXG\':Y(MU&46>TND4JEQ;N2%<*<[2""K+DX(/)&
M">7"9C1K3=-74NS5CS<IX@P>+K/#Q3C-*]I1<6UW1X)]@7^[7ZY_\$UB+;PC
MX[3'"7=H_P"<4G^%?E5Y8]*_4[_@G:VSPK\1@/X7LV_\AS_X5R\24E]3E\OS
M1YGB+ADLIJM=X_\ I2/R4-B"<D4GV!?[M;WECTH\L>E>[[)'V_U6)]9^%OV!
M/C'XO\,Z1XLTR]T9+/6K2"]@66YF$@BN(UD3<%@(#;6&0">>];W_  [B^./_
M #_Z%_X%3_\ R/7Z@_"_4[[3_P!F/PWJNGL%N[+PK;R0EAN DALP4)'< J.*
M_+2+]NO]H:,Y?4K&3V:RB_\ 9<5\;A<7CL1*:I<MHNVI^097FN=X^K6CA7"T
M)6U3\[=^QXG\:_V9_'/P%71W\:3V$XULSB#[%+)+C[-Y>_?OCCQ_K%QC/?I6
M)\*/V??B1\9[Z2U\#:29[>W(6>\F/E6L)(SAI#U;'\*AFQSC%>RZK\0?B;^U
MWX\\%^!/%$EJ)DN9889+:'RO+CN-C7$CC<=VR.'< ,=#ZU^M_B[Q!X#_ &6/
M@S]JTZQ$>FZ-&EO9VB,$DNKF3A0SXY=SEY'P3@,V#C%=>-S*M0A"DTG5EVVW
MT/5SCB'&8&A1PLX*>*J7T6RU:3^?RZWV/SEB_P"":'Q%-IOF\5:0ESC[BK<,
MF?\ ?V _^.U\M_%[]F3XH_!1DG\8:8LFFRL$CU"S8S6K.>BEL*R,<<!U4GMG
MFOH!/V]/CTOB#^UGGL'L-^?[/^RJ(=F<[1)_KLXXSO\ ?%?JE\/?&O@O]H[X
M3KJTUBDVF:S'):W]A,0_E2KQ)$Q&.1PR,,'!5A@].3$8W'81QGB4I1?;H>7C
M\WSK*G"MF$8SIMV?+T\MEK]Z\S^;G[ O]VO1?AS\%_B!\6-4;2? 6B3:G)%C
MS9!A((0>ADE<A$S@X!.3C@&O6?$WP$U?3OVA)O@;I+EY9M02"VF<9_T68"5)
M7QC.R%MSX[@@5^R6H7'PX_90^#+W%I:>5I6C(BK''M%Q>W4F%!9N-TDC<LW\
M*@X&U0!Z>:9O&E&"HKFE/;YGT7$O%4,-3HPP<.>I5LXKR>S?KT6GKH?F98_\
M$V_C'<6HFO-9T.TE9<B(SW#D'T8K!@?@6KY>^,OP(\4_ WQ+;>%?&$UG<7EW
M;+=H;*1Y4\IG>,$ET0@ED;C%?4^M_M_?&_4-1>YTB'3-*M Y,<"VYF.S/ =Y
M&)8@=2H7/8#I7S;\7_BUXF^-?BN/QCXLAMH+V.UBM EJKI$$B+$$!W<@DL2>
M<<\5IE]+'>TOB+<OD=&0X3.O;IYAR<C3T6Z?3^M3RGPSX0U#Q;XBTOPOH\8>
M^U>YAM( V0OF3N$7<1G R>3C@5]J?\.XOCC_ ,_^A?\ @5/_ /(]:7[!/PX_
MX2KXO2^,+N+=8^$K<S D9!NK@&*$'Z+YCCT*BOU/\._%C2_$'Q@\5_"F K]H
M\-V5E<9!RSO/N,P],1AX1]6.:\W.\VJTJKIT$O=5W_7W'SO&?%.*PN*EA\"D
M^2/-*ZO:[2_5?>?SD^(_"5_X5\0ZGX8U>,)?:3<S6DX7) E@<HV"<9&0<'%>
M@?!OX%>*?CCXFNO"G@^6T@O;2S>]<WDCQQF))(XR 41SNW2+QCIGFOI?]NWX
M??\ ")_&J3Q';1;;+Q7;I> @847$8\J=1[Y57/N];7_!/1C'\<-2 _Y::%=*
M?_ BV/\ 2O5JXR^"^LT][7/J,3FSEDSS&A;FY+_/JOD[H^9/C5^SCXU^ ]UI
M5IXTELIVUA)7@-E*\H A*A@V]$(/SC'!S7A_V!?[M?J3_P %(6W^)?!$9Z+:
M7A_.2/\ PK\U/+'I6^4595L/"K/=_P"9V\)XF>,R^EB:UN:5[V]6C!^P+_=K
MUKX-_ KQ3\<?$UUX4\'RVD%[:6;WKF\D>.,Q))'&0"B.=VZ1>,=,\UP?ECTK
M[L_X)ZL8OCCJ*C_EIH5TI_\  BW/]*O,YNEAYU(;I&_$=66%P-7$4K<T5=&)
M_P .XOCC_P _^A?^!4__ ,CU4OO^"=OQML+*XOI;W0V2VC>1@MU/DA 20,P
M9X[FOL7]LC]H+XG_  :\4^'M-\"7D%M:ZC9R32K+;I,3(LFW.7!P,=A7QW<?
MMS_'J\L+G3KRYTZ:*ZB>)R;,*VUU*G!5A@X->!@YYC6IQJQ<;,^$RBMQ#C*$
M,52=/EEZWWL?.GP;^!7BGXX^)KKPIX/EM(+VTLWO7-Y(\<9B22.,@%$<[MTB
M\8Z9YKZ9C_X)O?&]_O:IH"?6ZN?Z6QK7_P"">K&+XXZBH_Y::%=*?_ BV/\
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M!=YQV0GSF]%?VK[>_:!^).C_ +,GP0T_PAX/<0ZM/:KIFDID;XUC0+)=-ZE
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/YQ?V\_^3K_'/_<,_P#3;:U]??\ !*?_ )JC_P!P3_V^KY!_;S_Y.O\ '/\
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M;8Z>8]/ADSD/]E&QV7_9,F\J>XP>]?H!XLT"3]I;]CC0F\)$WFM:7;VDR0Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V-"TM]7U
M**T ^3.Z0^B#K^?05G6UM/>3I;6R&21S@ 5[AX<T*/1+/8<-<2X,C?T'L* .
M@ "@*HP!P!2T44 %%%% '__7_=WQ9_R*VL_]>5Q_Z+:OY)J_K9\6?\BMK/\
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M^??X_P# -?\ B,57_H'7_@3_ ,C^9_\ X0_QA_T [_\ \!I?_B:/^$/\8?\
M0#O_ /P&E_\ B:_I@^R6O_/%/^^11]DM?^>*?]\BC_72?_/O\?\ @#_XC%6_
MZ!U_X$_\C^9__A#_ !A_T [_ /\  :7_ .)H_P"$/\8?] .__P# :7_XFOZ8
M/LEK_P \4_[Y%'V2U_YXI_WR*/\ 72?_ #[_ !_X ?\ $8JW_0.O_ G_ )'\
MS_\ PA_C#_H!W_\ X#2__$T?\(?XP_Z =_\ ^ TO_P 37],'V2U_YXI_WR*/
MLEK_ ,\4_P"^11_KI/\ Y]_C_P  /^(Q5O\ H'7_ ($_\C^9_P#X0_QA_P!
M._\ _ :7_P")H_X0_P 8?] ._P#_  &E_P#B:_I@^R6O_/%/^^11]DM?^>*?
M]\BC_72?_/O\?^ '_$8JW_0.O_ G_D?S/_\ "'^,/^@'?_\ @-+_ /$T?\(?
MXP_Z =__ . TO_Q-?TP?9+7_ )XI_P!\BC[):_\ /%/^^11_KI/_ )]_C_P
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M(?XP_P"@'?\ _@-+_P#$U_3!]DM?^>*?]\BC[):_\\4_[Y%'^ND_^??X_P#
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M2U_YXI_WR*/]=)_\^_Q_X ?\1BK?] Z_\"?^1_,__P (?XP_Z =__P" TO\
M\31_PA_C#_H!W_\ X#2__$U_3!]DM?\ GBG_ 'R*/LEK_P \4_[Y%'^ND_\
MGW^/_ #_ (C%6_Z!U_X$_P#(_F?_ .$/\8?] .__ / :7_XFC_A#_&'_ $ [
M_P#\!I?_ (FOZ8/LEK_SQ3_OD4?9+7_GBG_?(H_UTG_S[_'_ ( ?\1BK?] Z
M_P# G_D?S/\ _"'^,/\ H!W_ /X#2_\ Q-'_  A_C#_H!W__ (#2_P#Q-?TP
M?9+7_GBG_?(H^R6O_/%/^^11_KI/_GW^/_ #_B,5;_H'7_@3_P C^9__ (0_
MQA_T [__ ,!I?_B:/^$/\8?] .__ / :7_XFOZ8/LEK_ ,\4_P"^11]DM?\
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M/^@'?_\ @-+_ /$T?\(?XP_Z =__ . TO_Q-?TP?9+7_ )XI_P!\BC[):_\
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M\\4_[Y%'^ND_^??X_P# #_B,5;_H'7_@3_R/YG_^$/\ &'_0#O\ _P !I?\
MXFC_ (0_QA_T [__ ,!I?_B:_I@^R6O_ #Q3_OD4?9+7_GBG_?(H_P!=)_\
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M^,/^@'?_ /@-+_\ $U_3!]DM?^>*?]\BC[):_P#/%/\ OD4?ZZ3_ .??X_\
M #_B,5;_ *!U_P"!/_(_F?\ ^$/\8?\ 0#O_ /P&E_\ B:/^$/\ &'_0#O\
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M_$T?\(?XP_Z =_\ ^ TO_P 37],'V2U_YXI_WR*/LEK_ ,\4_P"^11_KI/\
MY]_C_P  /^(Q5O\ H'7_ ($_\C^9_P#X0_QA_P! ._\ _ :7_P")H_X0_P 8
M?] ._P#_  &E_P#B:_I@^R6O_/%/^^11]DM?^>*?]\BC_72?_/O\?^ '_$8J
MW_0.O_ G_D?S/_\ "'^,/^@'?_\ @-+_ /$T?\(?XP_Z =__ . TO_Q-?TP?
M9+7_ )XI_P!\BC[):_\ /%/^^11_KI/_ )]_C_P _P"(Q5O^@=?^!/\ R/YG
M_P#A#_&'_0#O_P#P&E_^)H_X0_QA_P! ._\ _ :7_P")K^F#[):_\\4_[Y%'
MV2U_YXI_WR*/]=)_\^_Q_P" '_$8JW_0.O\ P)_Y'\S_ /PA_C#_ * =_P#^
M TO_ ,31_P (?XP_Z =__P" TO\ \37],'V2U_YXI_WR*/LEK_SQ3_OD4?ZZ
M3_Y]_C_P _XC%6_Z!U_X$_\ (_F?_P"$/\8?] .__P# :7_XFC_A#_&'_0#O
M_P#P&E_^)K^F#[):_P#/%/\ OD4?9+7_ )XI_P!\BC_72?\ S[_'_@!_Q&*M
M_P! Z_\  G_D?S/_ /"'^,/^@'?_ /@-+_\ $T?\(?XP_P"@'?\ _@-+_P#$
MU_3!]DM?^>*?]\BC[):_\\4_[Y%'^ND_^??X_P# #_B,5;_H'7_@3_R/YG_^
M$/\ &'_0#O\ _P !I?\ XFC_ (0_QA_T [__ ,!I?_B:_I@^R6O_ #Q3_OD4
M?9+7_GBG_?(H_P!=)_\ /O\ '_@!_P 1BK?] Z_\"?\ D?S/_P#"'^,/^@'?
M_P#@-+_\31_PA_C#_H!W_P#X#2__ !-?TP?9+7_GBG_?(H^R6O\ SQ3_ +Y%
M'^ND_P#GW^/_   _XC%6_P"@=?\ @3_R/YG_ /A#_&'_ $ [_P#\!I?_ (FM
M/3_AK\1M4D$>G^&-3G)[K:2[1]6*X'XFOZ3?LEK_ ,\4_P"^11]DM?\ GBG_
M 'R*3XSGTIK[R)^,5>WNX=?>_P#(_"7P;^R-\3/$$L<OB3R?#MF2"QE<33E?
M]F.,D9]F=:^\/AE\%O!'PKMC_8-L9]0D7;+>SX:=QW . $7_ &5 SQG)YK[J
M^R6O_/%/^^11]DM?^>*?]\BO"S#/<1B%RS=EV1\3GW&^89@O9U9VA_+'1?/J
M_F['S?17TA]DM?\ GBG_ 'R*/LEK_P \4_[Y%>.?(GS?17TA]DM?^>*?]\BC
M[):_\\4_[Y% 'S?17TA]DM?^>*?]\BC[):_\\4_[Y% 'S?17TA]DM?\ GBG_
M 'R*/LEK_P \4_[Y% 'S?17TA]DM?^>*?]\BC[):_P#/%/\ OD4 ?-]%?2'V
M2U_YXI_WR*/LEK_SQ3_OD4 ?-]%?2'V2U_YXI_WR*/LEK_SQ3_OD4 ?-]%?2
M'V2U_P">*?\ ?(H^R6O_ #Q3_OD4 ?-]%?2'V2U_YXI_WR*/LEK_ ,\4_P"^
M10!\WT5](?9+7_GBG_?(H^R6O_/%/^^10!\WT5](?9+7_GBG_?(H^R6O_/%/
M^^10!\WT5](?9+7_ )XI_P!\BC[):_\ /%/^^10!\WT5](?9+7_GBG_?(H^R
M6O\ SQ3_ +Y% 'S?17TA]DM?^>*?]\BC[):_\\4_[Y% 'S?17TA]DM?^>*?]
M\BC[):_\\4_[Y% 'S?17TA]DM?\ GBG_ 'R*/LEK_P \4_[Y% 'S?17TA]DM
M?^>*?]\BC[):_P#/%/\ OD4 ?-]%?2'V2U_YXI_WR*/LEK_SQ3_OD4 ?-]%?
M2'V2U_YXI_WR*/LEK_SQ3_OD4 ?-]%?2'V2U_P">*?\ ?(H^R6O_ #Q3_OD4
M ?-]%?2'V2U_YXI_WR*/LEK_ ,\4_P"^10!\WT5](?9+7_GBG_?(H^R6O_/%
M/^^10!\WT5](?9+7_GBG_?(H^R6O_/%/^^10!\WT5](?9+7_ )XI_P!\BC[)
M:_\ /%/^^10!\WT5](?9+7_GBG_?(H^R6O\ SQ3_ +Y% 'S?17TA]DM?^>*?
M]\BC[):_\\4_[Y% 'S?17TA]DM?^>*?]\BC[):_\\4_[Y% 'S?17TA]DM?\
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MM?\ GBG_ 'R*/LEK_P \4_[Y% 'S?17TA]DM?^>*?]\BC[):_P#/%/\ OD4
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MTA]DM?\ GBG_ 'R*/LEK_P \4_[Y% 'S?17TA]DM?^>*?]\BC[):_P#/%/\
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M)]DB/4O][\%Z_GBO:%54&$ 4>@IU &+H^@V&BQ[;5=TC#YI&Y8_X#V%;5%%
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M:U_X%O7GG]E>U']E>U']G1_E_ /[!I_\^U]R/0_^&F/VB?\ HH6M?^!;T?\
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MB?\ HH6M?^!;UYY_97M1_97M1_9T?Y?P#^P:?_/M?<CT/_AIC]HG_HH6M?\
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M[D>A_P##3'[1/_10M:_\"WH_X:8_:)_Z*%K7_@6]>>?V5[4?V5[4?V='^7\
M_L&G_P ^U]R/0_\ AIC]HG_HH6M?^!;T?\-,?M$_]%"UK_P+>O//[*]J/[*]
MJ/[.C_+^ ?V#3_Y]K[D>A_\ #3'[1/\ T4+6O_ MZ/\ AIC]HG_HH6M?^!;U
MYY_97M1_97M1_9T?Y?P#^P:?_/M?<CT/_AIC]HG_ **%K7_@6]'_  TQ^T3_
M -%"UK_P+>O//[*]J/[*]J/[.C_+^ ?V#3_Y]K[D>A_\-,?M$_\ 10M:_P#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;C:Z.AVLK \@@C!%?6GP$_9 \4_&31F\9:OJ*>&O# +A+J6/S)9_+.',:%D
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MX..><5Z5^S9;7&E?M$^"[6\B:"X@U5(9(W!5T<;D96!Y!!X(-?=__!2"0_\
M"'^#;?L]_<M_WS$H_P#9J]'%8R4,93P\4K27SZGOYEFTZ.;8? 0BG"HFV^O7
M;6W3L?CC%I332)#"ADDD(5549+$\   <DU]1>%/V(OV@_%EC'J4/AK^S;>4
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MYO\ L]?2C^SU]*Z3RQ1Y8H]C$/J<3F_[/7TH_L]?2ND\L4>6*/8Q#ZG$YO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBD[G2?%$<T$T)8^6)HXVEBE"]-X*;,^C'VKV7_@HA\/M5DUCP]\4+*%I]/\
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MV@#I'/=-YFSZ^6L9/U%=]=+^TJ;AORN_IT_$]['0C_K'AW2^+DESV[=+_/\
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MPKVGPIX>_L>V-Q<C_2YA\W^PO]W_ !H ZJ.-(HUBC&%0  >@'2GT44 %%%%
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M:JEUCM=0_NYQCMF121[$5^,3I5X1AF3ZR?W[_B[_ ''XM*E7A&&9OK-_?O\
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M_>-^H692!U*VQ!7T+&OR_B:$\QQ_U2C_ ,NXM_.U_P#)'Y=Q/">8YA]4H_\
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MHH<9JVM/\?\ @'W]+QABE[V'_P#)O_M3^:C=2[O>OZ5_^%;_  __ .A=L/\
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M _XC'3_Z!W_X%_P#^:C=[T;O>OZ5_P#A6_P__P"A=L/_  '3_"C_ (5O\/\
M_H7;#_P'3_"C_72/_/K\?^ '_$8Z?_0._P#P+_@'\U&[WHW>]?TK_P#"M_A_
M_P!"[8?^ Z?X4?\ "M_A_P#]"[8?^ Z?X4?ZZ1_Y]?C_ , /^(QT_P#H'?\
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M  K?X?\ _0NV'_@.G^%'_"M_A_\ ]"[8?^ Z?X4?ZZ1_Y]?C_P  /^(QT_\
MH'?_ (%_P#^:C=[T;O>OZ5_^%;_#_P#Z%VP_\!T_PH_X5O\ #_\ Z%VP_P#
M=/\ "C_72/\ SZ_'_@!_Q&.G_P! [_\  O\ @'\U&[WHW>]?TK_\*W^'_P#T
M+MA_X#I_A1_PK?X?_P#0NV'_ (#I_A1_KI'_ )]?C_P _P"(QT_^@=_^!?\
M /YJ-WO1N]Z_I7_X5O\ #_\ Z%VP_P# =/\ "C_A6_P__P"A=L/_  '3_"C_
M %TC_P ^OQ_X ?\ $8Z?_0.__ O^ ?S4;O>C=[U_2O\ \*W^'_\ T+MA_P"
MZ?X4?\*W^'__ $+MA_X#I_A1_KI'_GU^/_ #_B,=/_H'?_@7_ /YJ-WO1N]Z
M_I7_ .%;_#__ *%VP_\  =/\*/\ A6_P_P#^A=L/_ =/\*/]=(_\^OQ_X ?\
M1CI_] [_ / O^ ?S4;O>C=[U_2O_ ,*W^'__ $+MA_X#I_A1_P *W^'_ /T+
MMA_X#I_A1_KI'_GU^/\ P _XC'3_ .@=_P#@7_ /YJ-WO1N]Z_I7_P"%;_#_
M /Z%VP_\!T_PH_X5O\/_ /H7;#_P'3_"C_72/_/K\?\ @!_Q&.G_ - [_P#
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M $#O_P "_P" ?S4;O>C=[U_2O_PK?X?_ /0NV'_@.G^%'_"M_A__ -"[8?\
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M/_ =/\*/]=(_\^OQ_P" '_$8Z?\ T#O_ ,"_X!_-1N]Z-WO7]*__  K?X?\
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M>C=[U_2O_P *W^'_ /T+MA_X#I_A1_PK?X?_ /0NV'_@.G^%'^ND?^?7X_\
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M_/K\?^ '_$8Z?_0._P#P+_@'\U&[WHW>]?TK_P#"M_A__P!"[8?^ Z?X4?\
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MO^?&/\J / J*]]_X1O0O^?&/\J/^$;T+_GQC_*@#P*BO??\ A&]"_P"?&/\
M*C_A&]"_Y\8_RH \"HKWW_A&]"_Y\8_RH_X1O0O^?&/\J / J*]]_P"$;T+_
M )\8_P J/^$;T+_GQC_*@#P*BO??^$;T+_GQC_*C_A&]"_Y\8_RH \"HKWW_
M (1O0O\ GQC_ "H_X1O0O^?&/\J / J*]]_X1O0O^?&/\J/^$;T+_GQC_*@#
MP*BO??\ A&]"_P"?&/\ *C_A&]"_Y\8_RH \"HKWW_A&]"_Y\8_RH_X1O0O^
M?&/\J / J*]]_P"$;T+_ )\8_P J/^$;T+_GQC_*@#P*BO??^$;T+_GQC_*C
M_A&]"_Y\8_RH \"HKWW_ (1O0O\ GQC_ "H_X1O0O^?&/\J / J*]]_X1O0O
M^?&/\J/^$;T+_GQC_*@#P*BO??\ A&]"_P"?&/\ *C_A&]"_Y\8_RH \"HKW
MW_A&]"_Y\8_RH_X1O0O^?&/\J / J*]]_P"$;T+_ )\8_P J/^$;T+_GQC_*
M@#P*BO??^$;T+_GQC_*C_A&]"_Y\8_RH \"HKWW_ (1O0O\ GQC_ "H_X1O0
MO^?&/\J / J*]]_X1O0O^?&/\J/^$;T+_GQC_*@#P*BO??\ A&]"_P"?&/\
M*C_A&]"_Y\8_RH \"HKWW_A&]"_Y\8_RH_X1O0O^?&/\J / J*]]_P"$;T+_
M )\8_P J/^$;T+_GQC_*@#P*BO??^$;T+_GQC_*C_A&]"_Y\8_RH \"HKWW_
M (1O0O\ GQC_ "H_X1O0O^?&/\J / J*]]_X1O0O^?&/\J/^$;T+_GQC_*@#
MP*BO??\ A&]"_P"?&/\ *C_A&]"_Y\8_RH \"HKWW_A&]"_Y\8_RH_X1O0O^
M?&/\J / J*]]_P"$;T+_ )\8_P J/^$;T+_GQC_*@#P*BO??^$;T+_GQC_*C
M_A&]"_Y\8_RH \"HKWW_ (1O0O\ GQC_ "H_X1O0O^?&/\J / J*]]_X1O0O
M^?&/\J/^$;T+_GQC_*@#P*BO??\ A&]"_P"?&/\ *C_A&]"_Y\8_RH \"HKW
MW_A&]"_Y\8_RH_X1O0O^?&/\J / J*]]_P"$;T+_ )\8_P J/^$;T+_GQC_*
M@#P*BO??^$;T+_GQC_*C_A&]"_Y\8_RH \"HKWW_ (1O0O\ GQC_ "H_X1O0
MO^?&/\J / J*]]_X1O0O^?&/\J/^$;T+_GQC_*@#P*BO??\ A&]"_P"?&/\
M*C_A&]"_Y\8_RH \"HKWW_A&]"_Y\8_RH_X1O0O^?&/\J / J*]]_P"$;T+_
M )\8_P J/^$;T+_GQC_*@#P*BO??^$;T+_GQC_*C_A&]"_Y\8_RH \"HKWW_
M (1O0O\ GQC_ "H_X1O0O^?&/\J / J*]]_X1O0O^?&/\J/^$;T+_GQC_*@#
MP*BO??\ A&]"_P"?&/\ *C_A&]"_Y\8_RH \"HKWW_A&]"_Y\8_RH_X1O0O^
M?&/\J / J*]]_P"$;T+_ )\8_P J/^$;T+_GQC_*@#P*BO??^$;T+_GQC_*C
M_A&]"_Y\8_RH \"HKWW_ (1O0O\ GQC_ "H_X1O0O^?&/\J / J*]]_X1O0O
M^?&/\J/^$;T+_GQC_*@#P*BO??\ A&]"_P"?&/\ *C_A&]"_Y\8_RH \"HKW
MW_A&]"_Y\8_RH_X1O0O^?&/\J / J*]]_P"$;T+_ )\8_P J/^$;T+_GQC_*
M@#P*BO??^$;T+_GQC_*C_A&]"_Y\8_RH \"HKWW_ (1O0O\ GQC_ "H_X1O0
MO^?&/\J / J*]]_X1O0O^?&/\J/^$;T+_GQC_*@#P*BO??\ A&]"_P"?&/\
M*C_A&]"_Y\8_RH \"HKWW_A&]"_Y\8_RH_X1O0O^?&/\J / J*]]_P"$;T+_
M )\8_P J/^$;T+_GQC_*@#P*BO??^$;T+_GQC_*C_A&]"_Y\8_RH \"HKWW_
M (1O0O\ GQC_ "H_X1O0O^?&/\J / J*]]_X1O0O^?&/\J/^$;T+_GQC_*@#
MP*BO??\ A&]"_P"?&/\ *C_A&]"_Y\8_RH \"HKWW_A&]"_Y\8_RH_X1O0O^
M?&/\J / J*]]_P"$;T+_ )\8_P J/^$;T+_GQC_*@#P*BO??^$;T+_GQC_*C
M_A&]"_Y\8_RH \"HKWW_ (1O0O\ GQC_ "H_X1O0O^?&/\J / J*]]_X1O0O
M^?&/\J/^$;T+_GQC_*@#P*BO??\ A&]"_P"?&/\ *C_A&]"_Y\8_RH \"HKW
MW_A&]"_Y\8_RH_X1O0O^?&/\J / J*]]_P"$;T+_ )\8_P J/^$;T+_GQC_*
M@#P*BO??^$;T+_GQC_*C_A&]"_Y\8_RH \"HKWW_ (1O0O\ GQC_ "H_X1O0
MO^?&/\J / J*]]_X1O0O^?&/\J/^$;T+_GQC_*@#P*BO??\ A&]"_P"?&/\
M*C_A&]"_Y\8_RH \"HKWW_A&]"_Y\8_RH_X1O0O^?&/\J / J*]]_P"$;T+_
M )\8_P J/^$;T+_GQC_*@#P*BO??^$;T+_GQC_*C_A&]"_Y\8_RH \"HKWW_
M (1O0O\ GQC_ "H_X1O0O^?&/\J / J*]]_X1O0O^?&/\J/^$;T+_GQC_*@#
MP*BO??\ A&]"_P"?&/\ *C_A&]"_Y\8_RH \"HKWW_A&]"_Y\8_RH_X1O0O^
M?&/\J / J*]]_P"$;T+_ )\8_P J/^$;T+_GQC_*@#P*BO??^$;T+_GQC_*C
M_A&]"_Y\8_RH \"HKWW_ (1O0O\ GQC_ "H_X1O0O^?&/\J / J*]]_X1O0O
M^?&/\J/^$;T+_GQC_*@#P*BO??\ A&]"_P"?&/\ *C_A&]"_Y\8_RH \"HKW
MW_A&]"_Y\8_RH_X1O0O^?&/\J / J*]]_P"$;T+_ )\8_P J/^$;T+_GQC_*
M@#P*BO??^$;T+_GQC_*C_A&]"_Y\8_RH \"HKWW_ (1O0O\ GQC_ "H_X1O0
MO^?&/\J / J*]]_X1O0O^?&/\J/^$;T+_GQC_*@#P*BO??\ A&]"_P"?&/\
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M_P#=J7^%?DA]?6G[$3%?VBM ']ZWOA_Y+2'^E?)=?6/[$@/_  T9X=QVAO\
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M?I'7\Z\;?\C2M\O_ $E'\W\<?\C6MZK_ -)04445\J?*!1110 4444 %%%%
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MKVH^H1_E_ /[!I_\^U]R/4/^&JOVF?\ HI>O?^!LG^-'_#57[3/_ $4O7O\
MP-D_QKR_^RO:C^RO:CZA'^7\ _L&G_S[7W(]0_X:J_:9_P"BEZ]_X&R?XT?\
M-5?M,_\ 12]>_P# V3_&O+_[*]J/[*]J/J$?Y?P#^P:?_/M?<CU#_AJK]IG_
M **7KW_@;)_C1_PU5^TS_P!%+U[_ ,#9/\:\O_LKVH_LKVH^H1_E_ /[!I_\
M^U]R/4/^&JOVF?\ HI>O?^!LG^-'_#57[3/_ $4O7O\ P-D_QKR_^RO:C^RO
M:CZA'^7\ _L&G_S[7W(]0_X:J_:9_P"BEZ]_X&R?XT?\-5?M,_\ 12]>_P#
MV3_&O+_[*]J/[*]J/J$?Y?P#^P:?_/M?<CU#_AJK]IG_ **7KW_@;)_C1_PU
M5^TS_P!%+U[_ ,#9/\:\O_LKVH_LKVH^H1_E_ /[!I_\^U]R/4/^&JOVF?\
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M^RO:C^RO:CZA'^7\ _L&G_S[7W(]0_X:J_:9_P"BEZ]_X&R?XT?\-5?M,_\
M12]>_P# V3_&O+_[*]J/[*]J/J$?Y?P#^P:?_/M?<CU#_AJK]IG_ **7KW_@
M;)_C1_PU5^TS_P!%+U[_ ,#9/\:\O_LKVH_LKVH^H1_E_ /[!I_\^U]R/4/^
M&JOVF?\ HI>O?^!LG^-'_#57[3/_ $4O7O\ P-D_QKR_^RO:C^RO:CZA'^7\
M _L&G_S[7W(]0_X:J_:9_P"BEZ]_X&R?XT?\-5?M,_\ 12]>_P# V3_&O+_[
M*]J/[*]J/J$?Y?P#^P:?_/M?<CU#_AJK]IG_ **7KW_@;)_C1_PU5^TS_P!%
M+U[_ ,#9/\:\O_LKVH_LKVH^H1_E_ /[!I_\^U]R/4/^&JOVF?\ HI>O?^!L
MG^-'_#57[3/_ $4O7O\ P-D_QKR_^RO:C^RO:CZA'^7\ _L&G_S[7W(]0_X:
MJ_:9_P"BEZ]_X&R?XT?\-5?M,_\ 12]>_P# V3_&O+_[*]J/[*]J/J$?Y?P#
M^P:?_/M?<CU#_AJK]IG_ **7KW_@;)_C1_PU5^TS_P!%+U[_ ,#9/\:\O_LK
MVH_LKVH^H1_E_ /[!I_\^U]R/4/^&JOVF?\ HI>O?^!LG^-'_#57[3/_ $4O
M7O\ P-D_QKR_^RO:C^RO:CZA'^7\ _L&G_S[7W(]0_X:J_:9_P"BEZ]_X&R?
MXT?\-5?M,_\ 12]>_P# V3_&O+_[*]J/[*]J/J$?Y?P#^P:?_/M?<CU#_AJK
M]IG_ **7KW_@;)_C1_PU5^TS_P!%+U[_ ,#9/\:\O_LKVH_LKVH^H1_E_ /[
M!I_\^U]R/4/^&JOVF?\ HI>O?^!LG^-'_#57[3/_ $4O7O\ P-D_QKR_^RO:
MC^RO:CZA'^7\ _L&G_S[7W(]0_X:J_:9_P"BEZ]_X&R?XT?\-5?M,_\ 12]>
M_P# V3_&O+_[*]J/[*]J/J$?Y?P#^P:?_/M?<CU#_AJK]IG_ **7KW_@;)_C
M1_PU5^TS_P!%+U[_ ,#9/\:\O_LKVH_LKVH^H1_E_ /[!I_\^U]R/4/^&JOV
MF?\ HI>O?^!LG^-'_#57[3/_ $4O7O\ P-D_QKR_^RO:C^RO:CZA'^7\ _L&
MG_S[7W(]0_X:J_:9_P"BEZ]_X&R?XT?\-5?M,_\ 12]>_P# V3_&O+_[*]J/
M[*]J/J$?Y?P#^P:?_/M?<CU#_AJK]IG_ **7KW_@;)_C1_PU5^TS_P!%+U[_
M ,#9/\:\O_LKVH_LKVH^H1_E_ /[!I_\^U]R/4/^&JOVF?\ HI>O?^!LG^-'
M_#57[3/_ $4O7O\ P-D_QKR_^RO:C^RO:CZA'^7\ _L&G_S[7W(]0_X:J_:9
M_P"BEZ]_X&R?XT?\-5?M,_\ 12]>_P# V3_&O+_[*]J/[*]J/J$?Y?P#^P:?
M_/M?<CU#_AJK]IG_ **7KW_@;)_C1_PU5^TS_P!%+U[_ ,#9/\:\O_LKVH_L
MKVH^H1_E_ /[!I_\^U]R/4/^&JOVF?\ HI>O?^!LG^-'_#57[3/_ $4O7O\
MP-D_QKR_^RO:C^RO:CZA'^7\ _L&G_S[7W(]0_X:J_:9_P"BEZ]_X&R?XT?\
M-5?M,_\ 12]>_P# V3_&O+_[*]J/[*]J/J$?Y?P#^P:?_/M?<CU#_AJK]IG_
M **7KW_@;)_C1_PU5^TS_P!%+U[_ ,#9/\:\O_LKVH_LKVH^H1_E_ /[!I_\
M^U]R/4/^&JOVF?\ HI>O?^!LG^-'_#57[3/_ $4O7O\ P-D_QKR_^RO:C^RO
M:CZA'^7\ _L&G_S[7W(]0_X:J_:9_P"BEZ]_X&R?XT?\-5?M,_\ 12]>_P#
MV3_&O+_[*]J/[*]J/J$?Y?P#^P:?_/M?<CU#_AJK]IG_ **7KW_@;)_C1_PU
M5^TS_P!%+U[_ ,#9/\:\O_LKVH_LKVH^H1_E_ /[!I_\^U]R/4/^&JOVF?\
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M_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\
M"1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!
MM_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6
M)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^
MR_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z
M[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='
M_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[
M+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'K
MO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_
M\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)1
M0!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_
MG6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\
MS^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'
MKO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT
M?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _
MLOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[
M_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\
M"1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!
MM_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6
M)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^
MR_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z
M[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='
M_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[
M+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'K
MO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_
M\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)1
M0!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_
MG6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\
MS^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'
MKO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT
M?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _
MLOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[
M_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\
M"1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!
MM_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6
M)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^
MR_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z
M[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='
M_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[
M+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_\)'K
MO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)10!M_
M\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_G6)1
M0!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\ S^R_
MG6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'KO\
MS^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT?\)'
MKO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _LOYT
M?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[_P _
MLOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\ "1Z[
M_P _LOYT?\)'KO\ S^R_G6)10!M_\)'KO_/[+^='_"1Z[_S^R_G6)10!M_\
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MK:S_ ->5Q_Z+:OY)J_0>"/AJ_+]3]!X(^&K\OU"E'6DI1UK[L^_'TY:;3EH
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M@(]7'K7Z2>./A[X,^).E1:)XYTJ+5[&"9;A(I2P42JK(&^4@Y"LP_&LGX1^
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M9['"V:PQ.%BK^]%)/Y=?F1CI10.E%?1'TB'+3J:M.JHC"OZ$OV7D\O\ 9_\
M Z^NGH?S9C7\]M?T._LUIY?P%\"KZZ5;G\QG^M?"<?O_ &:G_B_1GP/B"_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.W]V)'VD)N&-J*I..2 ",V_@7^U9X ^.UU-X:6TDT77-C,+&Z995N(@,N8I
M 'VC.Y2H..0" <>*\YQ7)[?V'N?C;^O(^.EQ?F?L?KRP7[G>]];=_3SY;'\^
M7]GKZ5UNA?##QSXILVU#PSX;U+5[5',336=G-<1B0 $J6C1@& (.,YP1ZU^A
M/[;?[->B^!6A^*G@.T6STF_G$.H6<0Q%;SR9*2QJ.%CD(*E1@*V,<-@?07_!
M.J3_ (LYKUO_ '->F;_OJUMA_2O1Q.;P6$6*I*_2S/?S#BNC'*EF>&AS*Z5G
MI9]4_0_)0_ 3XQ",S'P%KXC');^R[K _'RJX/4_#&IZ)=&QUFQGL+E1DQ7$;
M1.![JX!K]K_&O[=_ASP'\0M;\#ZUX3NY8]%NI+5KFWN(W:0QG!81.J 9]-]?
M0VFW_P &_P!I_P  &X6"W\1://F-XYTVW%I,5&5/\<,J@\,I''*D@@G@GG=>
MDE.O0M%]4_Z_0\2KQEC<+&%;&X.U.5M4[[_>OD['\W/]GKZ4?V>OI7TK^T+\
M%KOX(?$>[\*&1[G3)U%UI\[_ 'I+:0D -C WH04;'4C=@ @5X=Y8KZJA[.I!
M5(;,_3L%[#$4HUZ3O&2NBSH7PP\<^*;-M0\,^&]2U>U1S$TUG9S7$8D !*EH
MT8!@"#C.<$>M= ?@)\8A&9CX"U\1CDM_9=U@?CY5?K7_ ,$ZI/\ BSFO6_\
M<UZ9O^^K6V']*L>-?V[_  YX#^(6M^!]:\)W<L>BW4EJUS;W$;M(8S@L(G5
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M[[W_  /RH_L]?2ND\,?#WQ7XTO3IOA#1;S6KH8+1V<#SLH/=M@.T>YP*]I^
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MQ6894@@'G. ?FO\ X*%?#/POH5_X=\?Z):16-_K,EQ;WPB 03M&JNDI48&\
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M+#4_BG^7_!V^\^%O^"A7QD_L3PS8_![19\7NN!;O4=IY2SC;]W&?^NLBY/\
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M;K( 87[/=?O J^T;%H_^ UY]\-OB'XC^%GC+3O&WA>;R[RP?)0Y\N:)N'BD
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M*B+[E(T8GZ;A]:RCC>(N7V?LE?OI_G;\#&&-XCM[/V2OWT_SM^!]B_"[X2^
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MRS/()3G)21"=K(<D%2,8/&*_3#1],G^*7[ (T?0U6>^L]/8>4G+^9IEWYI3
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M=P/5L@$_[(':O7_V#?&>AZ+X_P#&_P -8IU\K49?M6FDG_6+:/(CJ#W)C96
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M,VQ+RW7_ %7ELQP9%'RE,Y( 901D+Z%\6?V,_A'\39+G5K"W;PQK=P2YNK$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1@]*_+JBM<7EE*M4C4GO'8Z<UX9PN,KT\363YX;-.W6_YG["_#7]LK]GK2?
M6A>#]2%_8)I%C;692YLO-5C!&J%OW+2 @D9R<'GI7477[;_[./AV"7^P5N[H
MXSLL[#R=Y'0?O?*'YU^*5%>7/A7#2DY-O7S_ . ?,5?"[+9S<Y2GJ[M<VGY7
M_$^GOVC?VF=?^/=[:62VG]C^'=-8R06?F>8SS$%?.E;"@MM.% &%!."<DGYA
MHHKW<-AH48*G35DC[G+LNH82C&AAX\L5T"BBBMSN"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5G_@G-_R+GC;_K[L_P#T7)7Z1U^;G_!.;_D7/&W_ %]V?_HN2OTCK^=>-O\
MD:5OE_Z2C^;^./\ D:UO5?\ I*"BBBOE3Y0**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#]G_ /Z$;3O^^&_QH_URH?R/\ _XB_@_^?4OP_S/Y[=U&ZOZ$O\ AF#]G_\
MZ$;3O^^&_P :/^&8/V?_ /H1M._[X;_&C_7*A_(_P#_B+^#_ .?4OP_S/Y[=
MU&ZOZ$O^&8/V?_\ H1M._P"^&_QH_P"&8/V?_P#H1M._[X;_ !H_URH?R/\
M /\ B+^#_P"?4OP_S/Y[=U&ZOZ$O^&8/V?\ _H1M._[X;_&C_AF#]G__ *$;
M3O\ OAO\:/\ 7*A_(_P#_B+^#_Y]2_#_ #/Y[=U&ZOZ$O^&8/V?_ /H1M._[
MX;_&C_AF#]G_ /Z$;3O^^&_QH_URH?R/\ _XB_@_^?4OP_S/Y[=U&ZOZ$O\
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MJ'\C_ /^(OX/_GU+\/\ ,_GMW4;J_H2_X9@_9_\ ^A&T[_OAO\:/^&8/V?\
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M_P  _P"(OX/_ )]2_#_,_GMW4;J_H2_X9@_9_P#^A&T[_OAO\:/^&8/V?_\
MH1M._P"^&_QH_P!<J'\C_ /^(OX/_GU+\/\ ,_GMW4;J_H2_X9@_9_\ ^A&T
M[_OAO\:/^&8/V?\ _H1M._[X;_&C_7*A_(_P#_B+^#_Y]2_#_,_GMW4;J_H2
M_P"&8/V?_P#H1M._[X;_ !H_X9@_9_\ ^A&T[_OAO\:/]<J'\C_ /^(OX/\
MY]2_#_,_GMW4;J_H2_X9@_9__P"A&T[_ +X;_&C_ (9@_9__ .A&T[_OAO\
M&C_7*A_(_P  _P"(OX/_ )]2_#_,_GMW4;J_H2_X9@_9_P#^A&T[_OAO\:/^
M&8/V?_\ H1M._P"^&_QH_P!<J'\C_ /^(OX/_GU+\/\ ,_GMW4;J_H2_X9@_
M9_\ ^A&T[_OAO\:/^&8/V?\ _H1M._[X;_&C_7*A_(_P#_B+^#_Y]2_#_,_G
MMW4;J_H2_P"&8/V?_P#H1M._[X;_ !H_X9@_9_\ ^A&T[_OAO\:/]<J'\C_
M/^(OX/\ Y]2_#_,_GMW4;J_H2_X9@_9__P"A&T[_ +X;_&C_ (9@_9__ .A&
MT[_OAO\ &C_7*A_(_P  _P"(OX/_ )]2_#_,_GMW4;J_H2_X9@_9_P#^A&T[
M_OAO\:/^&8/V?_\ H1M._P"^&_QH_P!<J'\C_ /^(OX/_GU+\/\ ,_GMW4;J
M_H2_X9@_9_\ ^A&T[_OAO\:/^&8/V?\ _H1M._[X;_&C_7*A_(_P#_B+^#_Y
M]2_#_,_GMW4;J_H2_P"&8/V?_P#H1M._[X;_ !H_X9@_9_\ ^A&T[_OAO\:/
M]<J'\C_ /^(OX/\ Y]2_#_,_GMW4;J_H2_X9@_9__P"A&T[_ +X;_&C_ (9@
M_9__ .A&T[_OAO\ &C_7*A_(_P  _P"(OX/_ )]2_#_,_GMW4;J_H2_X9@_9
M_P#^A&T[_OAO\:/^&8/V?_\ H1M._P"^&_QH_P!<J'\C_ /^(OX/_GU+\/\
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M;J_H2_X9@_9__P"A&T[_ +X;_&C_ (9@_9__ .A&T[_OAO\ &C_7*A_(_P
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M?_\ H1M._P"^&_QH_P!<J'\C_ /^(OX/_GU+\/\ ,_GMW4;J_H2_X9@_9_\
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M_"-Z%_SXQ_E1_P (WH7_ #XQ_E0!X%17OO\ PC>A?\^,?Y4?\(WH7_/C'^5
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M_"-Z%_SXQ_E1_P (WH7_ #XQ_E0!X%17OO\ PC>A?\^,?Y4?\(WH7_/C'^5
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M_"-Z%_SXQ_E1_P (WH7_ #XQ_E0!X%17OO\ PC>A?\^,?Y4?\(WH7_/C'^5
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M_"-Z%_SXQ_E1_P (WH7_ #XQ_E0!X%17OO\ PC>A?\^,?Y4?\(WH7_/C'^5
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M_"-Z%_SXQ_E1_P (WH7_ #XQ_E0!X%17OO\ PC>A?\^,?Y4?\(WH7_/C'^5
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M_"-Z%_SXQ_E1_P (WH7_ #XQ_E0!X%17OO\ PC>A?\^,?Y4?\(WH7_/C'^5
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M4U:=3 4=:?3!UI]!<3]6?^"<W_(N>-O^ONS_ /1<E?I'7YN?\$YO^1<\;?\
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M\U^F ?D7^$#DGYB2(M7OX7)E:]3[C[O+>$4TI8AZ]E_F?KGK?_!6OQG-,?\
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MH7_DU_\ ':/^'KWQB_Z$W0O_ ":_^.U^:O\ 9K>E']FMZ4?V12_E#_5+"_\
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M9K>E']D4OY0_U2PO_/M'Z5?\/7OC%_T)NA?^37_QVC_AZ]\8O^A-T+_R:_\
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M ([7YJ_V:WI1_9K>E']D4OY0_P!4L+_S[1^E7_#U[XQ?]";H7_DU_P#':/\
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MO_)K_P".U^:O]FMZ4?V:WI1_9%+^4/\ 5+"_\^T?I5_P]>^,7_0FZ%_Y-?\
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M]D4OY0_U2PO_ #[1^E7_  ]>^,7_ $)NA?\ DU_\=H_X>O?&+_H3="_\FO\
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M7_DU_P#':/\ AZ]\8O\ H3="_P#)K_X[7YJ_V:WI1_9K>E']D4OY0_U2PO\
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M#_PL*_\ ^?6+\V_QH_X6%?\ _/K%^;?XUY]10!Z#_P +"O\ _GUB_-O\:/\
MA85__P ^L7YM_C7GU% 'H/\ PL*__P"?6+\V_P :/^%A7_\ SZQ?FW^->?44
M >@_\+"O_P#GUB_-O\:/^%A7_P#SZQ?FW^->?44 >@_\+"O_ /GUB_-O\:/^
M%A7_ /SZQ?FW^->?44 >@_\ "PK_ /Y]8OS;_&C_ (6%?_\ /K%^;?XUY]10
M!Z#_ ,+"O_\ GUB_-O\ &C_A85__ ,^L7YM_C7GU% 'H/_"PK_\ Y]8OS;_&
MC_A85_\ \^L7YM_C7GU% 'H/_"PK_P#Y]8OS;_&C_A85_P#\^L7YM_C7GU%
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M;?XUY]10!Z#_ ,+"O_\ GUB_-O\ &C_A85__ ,^L7YM_C7GU% 'H/_"PK_\
MY]8OS;_&C_A85_\ \^L7YM_C7GU% 'H/_"PK_P#Y]8OS;_&C_A85_P#\^L7Y
MM_C7GU% 'H/_  L*_P#^?6+\V_QH_P"%A7__ #ZQ?FW^->?44 >@_P#"PK__
M )]8OS;_ !H_X6%?_P#/K%^;?XUY]10!Z#_PL*__ .?6+\V_QH_X6%?_ //K
M%^;?XUY]10!Z#_PL*_\ ^?6+\V_QH_X6%?\ _/K%^;?XUY]10!Z#_P +"O\
M_GUB_-O\:/\ A85__P ^L7YM_C7GU% 'H/\ PL*__P"?6+\V_P :/^%A7_\
MSZQ?FW^->?44 >@_\+"O_P#GUB_-O\:/^%A7_P#SZQ?FW^->?44 >@_\+"O_
M /GUB_-O\:/^%A7_ /SZQ?FW^->?44 >@_\ "PK_ /Y]8OS;_&C_ (6%?_\
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M/^%A7_\ SZQ?FW^->?44 >@_\+"O_P#GUB_-O\:/^%A7_P#SZQ?FW^->?44
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M:I9)-%(H9)(VG0,K*>"",@@]173AY1J4562T:N>C@*E/$8..,C&R:O;J>/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA*^02QE17JN,IN?VN97>_P K6_4YG]HCX8P_"GXOZ[X.T[+6 D6XLAR2+>Y
MD1.>24R4SWVY[U^BVOZKIW[$G[/ND6&B6-O<>--?(661QD/=%-\TKD$%XX,A
M$4$#E3W;/S9^V9J.EO\ M1:9]J4&"P@TM+H>H\PRMG_@#BO7O^"D.GWCV7@+
M545C:0R:C"YQ\JR2B!D&?5@C?]\U=2H\1]4I5=I*[\[+0WQ%>6/_ ++PN*^&
MHG*7]YQC=7]7OZE']FW]LWQKXL^(5EX$^*;6UY:Z])Y%M=1Q+ T-P^?+1@F%
M=)#A!QN!(Y(S7SG^V9\)M,^&'Q;>7P_"EMI'B* 7\$$8VI!(6*31J. %WC>
M. & ' KPWX207=U\5?!L%@"UP^LZ>$V]=WVA,'\.M?</_!1R\MW\5^#-/4?O
MX;*ZE<]]DLB*OZHU=2P\,/F$(T5923NEMIU/2CE]+ 9_1AA(\L:L)<T5M[NJ
M=OP_X=GYM;:_4;_@GFVWPK\2?]G[$?\ R'<5^7=?J!_P3V_Y%;XE_P"[9?\
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M=\7Z-N_LMC';6A<8+0VZ",/C@@2,"X!Y ;!YK]A?A^GVC]D[2(NN_P )!/\
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MYA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK6]5_P"DH****^5/E HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /YK?VU_^
M3HO'O_7U;_\ I+#7W=_P2M_Y 'Q$_P"OG3?_ $">O@C]LV1Y?VGO'[.<D7L:
M_@L$0'Z"OT _X)81H/"OQ E ^9KVQ4GV6.4C^9K].S?_ )%*](_H?IV;_P#(
MI7I']#]6Z***_,3\Q"BBB@#Y5_:?^&*?$GP%XA\)D '7K)DA9CA5NX</ S'T
M$BH3[ U_,L+*[TR^FTW4(FM[JTD:*6-QADDC.UE([$$$&OZ_M:TJ+6-/DLY/
ME8\HW]UAT/\ 0^U?A=^W+^S9J&AZ[=_&'PM9DV\[#^VK>->891@"Z '5)!CS
M#V;YSD,2/>R/%J$_9RZ_F?<<%9K&E5>'J/26WK_P3X,TK'&:[JT^Z*\]TJ4<
M5WEG("HK]'PLM#^A\KFN4V4J2H4-3=:[SWXGZI?L4>*_ASIOP/\ $OA?QCXH
MTW1;C5M4NT,5U>P6\Y@EM((]ZI*P.,[@#@C(/H:Y[_AF3]C_ $=UGUOXMI<1
M@[O+BU*P!8>A"([8/MBOS.HKPI9-+VLZD*KCS;VL?$U.#ZJQ-7$4,5*'M'=I
M)?FS]+/B%^TW\(/AA\-KWX1_LW6CL;M98I=0*NL2><-LLJO+^]EF(X5B JC!
M4D*%KY?_ &3-:T/P]^T#X5UGQ)J%OI>G6QO3)<W4J00H6LYU7=(Y"C+$ 9/)
M(%?.=%=5+*J<*4Z46_>O=O5NYZ6%X6P]'"5L-!N]5/FDW>3;5KMGV!^V[XE\
M,^*_C1'JOA35K36;,Z7:H9[*=+B(2*\N5WQEER 1D9[U\Y?#BYL[/XA^%[O4
M)DM[6#5+)Y99&"I'&LZ%F9CP !DDGH*XRBNC#X14Z*HIZ)6/1R_*HX?!QP<9
M72CRW/T7_;_\:^"/&4W@:3P=X@T_76M%U(3_ &"ZBN?*#FVV;_*9MN[#8SUP
M:_.BBBEE^#6'HQHIWM_G<C(,GC@,)#"0E=1OJ_-M_J?L3\._VG_#&F_LMQZW
MJ6NV*^,]"TR:RALI;F+[9+/#^ZMW$+-YC!@(V8A><,>U?CU+++<2O/.YDDD8
MLS,<EF)R22>I)J.BL<!EE/#RG*'VG?\ X!RY%PU0R^=:='_EY*_IV2\E=A11
M17I'T1^BG["7PBM;O4]0^-_BM5BTKP^)([%I>$,X3,TYSQMAC. >FYB>"E?*
M/Q]^*ES\8OBAJWC%F86!;[/81MQY=G"2(Q@]"W+L/[S&OLOXR?'7X4^'OV:=
M/^$GP5UU-1DN$AT^X,<4T$@ML&2YE82HAS.XPPQR':OS.KP<KI3JUIXJJFGM
M%/HE_F?"<,X:MB<76S3%0<6_<@FK-176S[O]3V/X#?%>Z^#/Q,TSQK&CS6:;
MK>^A3&Z:TEP)%&2 2I =02!N49XK](/B=\*?V>?VH;NV^(GASQW::/J<L2)<
MR(\3-*B !?/MY7C=)$4;03CC&00!7X^45T8W*_:5%6IS<9K2Z[>:/1SCACZQ
MB(XS#U72JI6NDG==FGO_ %Y6_5?QG\3/@_\ LO?!Z_\ A?\ !W64USQ3JRR"
M6ZMY5F:.:9=CW$LD>41D48CC4Y!P2/O,?RWTO4[_ $74[36=+F:WO;&:.X@E
M7[R2Q,'1A[A@"*H45M@<OC0C+7F<M6WU.O(^'Z>"A-.3G.;O*3W;_P NR/V,
MO?%/P&_;)^&^FZ;XKUR#PYXHL '"22I#<6MP0!+Y2RD+-#)@=">-N=K#C'\$
M>'OV=_V/++4_&.H>+HO%'B:>!H84A:,SE#AO*AMXW?9O91ND=L #&0,@_D71
M7F_ZOV3I1JM4W]G]+]CYQ< \L)8:&)DJ#=^33ULI;V\CKO'OC/5OB'XRUCQM
MKC9O-7N'G89R$4\)&I/\*( J^P%?J+X!^+/P@_::^#5O\+OB_J\6E^(K2.-'
MDN9EMWDG@4K%=V\LGR,Y!.]#SDL"NT@G\C**]#'97"M",4^5QV:Z'O9UPS1Q
M=*G"+<)4[.#CO&WZ>7D?K9X!^#W[.G[,VL/\2_%?CZWUN^L5<V,9:(/&74J3
M';Q/(\LFTX!^Z,DX!P1^>/QS^*U[\9?B3J?C:X1X+64K#90.<F&UBXC4XXR>
M7;'&YCCBO(:*G!Y9[.HZU2;E*UKOHO)&>4<-O#XB6+Q%5U:K5KM)679):+S_
M .'N5^HG_!/1,^%OB3_M?8A_Y#N*_+NOU5_X)UP&3PKX^X_UL]HGY1R_XUR\
M2NV#G\OS1YWB1*V3U?6/_I2/RJI1R<4E%>\?<G[M_'/XM?"+5_@IXQT;2?&V
MB7MU<:3<QP00ZC;22R2>6=BHBR%BQ.  !FOPDHHKRLIRJ.$@X1E>[N?+<*\+
M4\JI3I4YN7,[Z^AZ;\&=%\.>(?BEX:TOQ??VVFZ(]XDEY->2I# ((0971Y'(
M5?,"[!D]6 K]7_VK/CI\/V^!OB#2?!GBS2M6U/5Q%9+#97T%Q*(I7'G$I&[-
MM\H,I.,#(K\4Z*6.RF->M"K*7P]/F1G7"E/'8RCBJLW:G9J/1ZW_ !T^X*_8
M3]B_XV>!M.^"L'AKQKXGTS1;O1+VY@ABO[V&VD>WD(G5U$KJ2NZ1E!''RXK\
M>Z*US3+8XJE[.3MK<Z^)N':>9X;ZO5E;5.Z\O^'/TGNM5^&6A_MWZ3XTTOQ-
MI3^'M2CFOI[R.\A:T@N)+&>%U>8-L5GE4-@MG+CU%=9^WE\0?A[XP^&^@6?A
M/Q-IFMW<&K+(\5C>0W+K'Y$H+,L3,0N<#)[FORLHKD61Q]K2JN3O!)>MK_YG
MDPX*@L5AL5*JVZ,5%;:VOO\ >?M%^R9\3OA9X<_9Z\-Z'XC\7Z/I>H)]O\^V
MNK^WAF3S+R8KNC=PPRA!&1R"#7XNG@XHHKIP.6QH5*E1._.[_G_F>GDG#<,%
MB,1B(S;=65VGTU;T^\_8;]D;]I[PUJWP^_X1/XG^(++2=4\.!((;C4+J.W%W
M:D$1X:5EW21XV-WQM)R2:^*_VTO$/AOQ1\;[G5_"NJ6NL64EA:*9[.9+B+>J
MD%=\9921QD9XKY-HK'"Y)3HXF6(@]^G34XLLX+P^$S&>849-<U_=Z*]KV^:"
MOUE_8-\=^ O"OPGUC3_$WB33-)OI];GE6"[O(8)6B^S6ZJX21U8J6# '&,@^
ME?DU173F>7K$TO9-V/2XER&.985X6<G%-IW7D?NMXD\$_L>>)?$EWXY\477A
M^\U2\8///-JZ^6[!0H+1_:!%T 'W:X[XF_MC_![X6^&_^$=^%K6VNZE;1>39
MV]BFW3[; PI>1=J%!U"Q9)Z$KG=7XM45X]/A>%U[:I*26R>Q\C0\,Z+E#ZWB
M)U(QVBWIZ==/2QM^(_$6L^+M?OO$OB&Z:\U+4YFFGE?JSN>?8 = !P  !P*_
M<+XX?%OX0ZM\%O&6CZ5XVT2\NKC2+J*""'4;:2620Q$(B(KEBQ.  !FOPBHK
MTLPRB&(E3;=N3:WR_P CZ'/^$Z6/GAYN3C[)W227E_D?>/[%W@KX,>*H/%2?
M%A]*N)IS:P6-K?7"0S8&]I7BRROSE!N0]B*^QY?V1_V4(&&I36L<=J#G:VK3
M"'Z;C+N_\>K\1Z*Y\9D]6I5=2%=QOT7_  YP9OPCBL1B9XBCC9TU*WNJ]M%;
M3WD?N#\1?VD_@I\!? Y\+_#VZL=0U&P@,6GZ9I[>;#&S=&FD3<J@$[W!;>YS
MW)-?D7\+?BKXE^%'CZS\?Z&_G743,+B*0X6ZAE.98W//WNH/.& ;J*\RHK?
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M4<Y+:Y>5<"*CBHXS%XB56<=K[+\7^84445] ??A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :NA
M:'J'B;6['P_I,?FWFHS)!$O;<YP"?0#J3V'-?N!X:T*T\+^'M-\.6'_'OIEO
M%;H>Y$2A<GW.,GWKX]_93^"MQHD0^)OBBW,5Y=1E=.A<8:.%Q\TQ!Y#..%]%
M)/\ $,?;M?FO%.9JM55*#TC^?_ /YP\3^)(8O$QPM%WC3O=]Y=?NV];A1117
MRI^7!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(Z_G7C;_ )&E;Y?^DH_F_CC_ )&M;U7_ *2@HHHKY4^4"BBB@ HHHH ****
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MX%_W+_\ \"6H_P!;L+V?W?\ !#_B+.6=I_<O\S\3MU&ZOVP_X8&^!?\ <O\
M_P "6H_X8&^!?]R__P# EJ/];L+V?W?\$/\ B+.6=I_<O\S\3]U&ZOVP_P"&
M!O@7_<O_ /P):C_A@;X%_P!R_P#_  ):C_6["]G]W_!#_B+.6=I_<O\ ,_$_
M=1NK]L/^&!O@7_<O_P#P):C_ (8&^!?]R_\ _ EJ/];L+V?W?\$/^(LY9VG]
MR_S/Q/W4;J_;#_A@;X%_W+__ ,"6H_X8&^!?]R__ / EJ/\ 6["]G]W_  0_
MXBSEG:?W+_,_$_=1NK]L/^&!O@7_ '+_ /\  EJ/^&!O@7_<O_\ P):C_6["
M]G]W_!#_ (BSEG:?W+_,_$_=1NK]L/\ A@;X%_W+_P#\"6H_X8&^!?\ <O\
M_P "6H_UNPO9_=_P0_XBSEG:?W+_ #/Q/W4;J_;#_A@;X%_W+_\ \"6H_P"&
M!O@7_<O_ /P):C_6["]G]W_!#_B+.6=I_<O\S\3]U&ZOVP_X8&^!?]R__P#
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MW?\ !#_B+.6=I_<O\S\3]U&ZOVP_X8&^!?\ <O\ _P "6H_X8&^!?]R__P#
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MW+_,SJ>+66I>[&;^2_\ DC\3M \.>(/%6H)I7AO3YM1NWZ1P(7('J<<*/4G
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MI/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\
M"O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >4
M45ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J
M3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_P
MKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^
MI/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\
M"O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >4
M45ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J
M3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_P
MKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^
MI/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\
M"O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >4
M45ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J
M3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_P
MKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^
MI/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\
M"O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >4
M45ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J
M3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_P
MKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^
MI/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\
M"O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >4
M45ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J
M3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_P
MKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^
MI/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\
M"O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >4
M45ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J
M3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_P
MKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^
MI/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\
M"O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >4
M45ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J
M3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_P
MKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^
MI/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\
M"O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >4
M45ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J
M3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_P
MKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^
MI/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\
M"O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >4
M45ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J
M3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_P
MKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^
MI/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\
M"O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >4
M45ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J
M3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_P
MKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^
MI/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\
M"O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >4
M45ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J
M3\A0!Y117J__  KVP_Y^I/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_P
MKVP_Y^I/R% 'E%%>K_\ "O;#_GZD_(4?\*]L/^?J3\A0!Y117J__  KVP_Y^
MI/R%'_"O;#_GZD_(4 >445ZO_P *]L/^?J3\A1_PKVP_Y^I/R% 'E%%>K_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSC_T3W2?^_'_ ->C_7>A_(_P#_7G#_R/\/\ ,_F:HK^F7_AE']G'_HGND_\
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M]'^O6'_Y]R_ :X]P_P#S[E^'^9_-4M.K^E/_ (94_9T_Z)_I7_?G_P"O2_\
M#*O[.O\ T3_2O^_/_P!>G_KWA_\ GW+\!_Z_8?\ Y]R_#_,_FN'2EK^E#_AE
M;]G7_HG^E?\ ?G_Z]+_PRM^SK_T3_2O^_/\ ]>J_U[P_\DOP_P P_P!?</\
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MTK_OS_\ 7I?^&6OV>/\ H0=*_P"_/_UZ:X_P_P#S[E^'^8_^(@X;_GW+\/\
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MW_H0]+_[\_\ UZ/^&7_V??\ H0]+_P"_/_UZK_B(F&_Y]R_#_,K_ (B-A?\
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M $?\R+IG_?G_ .O1_P 1(PO_ #[E^!7_ !$O"_\ /N7X?YG\\E%?T.?\,R_
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MY?'O_0MZ=_WU-_\ %4?\-R^/?^A;T[_OJ;_XJC_6+"]W]P?VO1[_ ('[9?\
M"4:!_P _J?K_ (4?\)1H'_/ZGZ_X5^)O_#<OCW_H6]._[ZF_^*H_X;E\>_\
M0MZ=_P!]3?\ Q5'^L.%[O[@_M>CW_ _;+_A*- _Y_4_7_"C_ (2C0/\ G]3]
M?\*_$W_AN7Q[_P!"WIW_ 'U-_P#%4?\ #<OCW_H6]._[ZF_^*I_ZPX;N_N#^
MUZ/?\#]LO^$HT#_G]3]?\*/^$HT#_G]3]?\ "OQ._P"&Y?'O_0MZ=_WU-_\
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M?U/U_P *_%+_ (;B\>?]"YIW_?4W_P 51_PW%X\_Z%S3O^^IO_BJ/]8,-W_
M/[6H]S]K?^$HT#_G]3]?\*/^$HT#_G]3]?\ "OQ2_P"&XO'G_0N:=_WU-_\
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M?U/U_P *_%/_ (;B\>?]"WIW_?4W_P 51_PW%X\_Z%O3O^^IO_BJ?]OX;O\
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M_BJ7_AM_QW_T+FG?]]3?_%4?V]AN[^X/[4H]S]J?^$HT#_G]3]?\*/\ A*-
M_P"?U/U_PK\5O^&W_'?_ $+FG?\ ?4W_ ,51_P -O^._^A<T[_OJ;_XJC^WL
M/W_ ?]J4>Y^U/_"4:!_S^I^O^%'_  E&@?\ /ZGZ_P"%?BM_PV_X[_Z%S3O^
M^IO_ (JC_AM_QW_T+FG?]]3?_%4_[>P_?\!?VK1[G[4_\)1H'_/ZGZ_X4?\
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M_P#[ZF_^*H_MW#]_P#^TZ/<_:C_A*- _Y_4_7_"C_A*- _Y_4_7_  K\5_\
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M-_\ %4?\-N^.O^A<T_\ [ZF_^*H_MW#]W]P?VG1[G[3?\)1H'_/ZGZ_X4?\
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MWU-_\51_;>'[A_:5+N?M%_PE&@?\_J?K_A1_PE&@?\_J?K_A7XN_\-M>.O\
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MK_H7-/\ ^^IO_BJ/[;P_?\ _M.EW/VC_ .$HT#_G]3]?\*/^$HT#_G]3]?\
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MPH_X2C0/^?U/U_PK\5_^&W_'7_0N:?\ ]]3?_%4?\-O^.O\ H7-._P"^IO\
MXJC^WL/W_ /[4H]S]J/^$HT#_G]3]?\ "C_A*- _Y_4_7_"OQ6_X;?\ '?\
MT+FG?]]3?_%4?\-O^._^A<T[_OJ;_P"*H_M[#]_P#^U*/<_:G_A*- _Y_4_7
M_"C_ (2C0/\ G]3]?\*_%;_AM_QW_P!"YIW_ 'U-_P#%4?\ #;_CO_H7-._[
MZF_^*H_M[#]_P#^U*/<_:G_A*- _Y_4_7_"C_A*- _Y_4_7_  K\5O\ AM_Q
MW_T+FG?]]3?_ !5'_#;_ ([_ .A<T[_OJ;_XJC^WL/W_  %_:E'N?M3_ ,)1
MH'_/ZGZ_X4?\)1H'_/ZGZ_X5^*W_  V_X[_Z%S3O^^IO_BJ/^&W_ !W_ -"Y
MIW_?4W_Q5']O8?O^ ?VI1[G[4_\ "4:!_P _J?K_ (4?\)1H'_/ZGZ_X5^*W
M_#;_ ([_ .A<T[_OJ;_XJC_AM_QW_P!"YIW_ 'U-_P#%4O[>P_?\!_VI1[G[
M4_\ "4:!_P _J?K_ (4?\)1H'_/ZGZ_X5^*O_#<'CO\ Z%S3O^^IO_BJ/^&X
M/'?_ $+FG?\ ?4W_ ,51_;V&[O[A?VI1[G[5?\)1H'_/ZGZ_X4?\)1H'_/ZG
MZ_X5^*G_  W!X[_Z%S3O^^IO_BJ/^&X/'G_0N:=_WU-_\71_;^&[_@']J4>Y
M^U?_  E&@?\ /ZGZ_P"%'_"4:!_S^I^O^%?BI_PW!X\_Z%S3O^^IO_BZ/^&X
M/'G_ $+FG?\ ?4W_ ,71_;^&[_@/^U*/<_:O_A*- _Y_4_7_  H_X2C0/^?U
M/U_PK\5/^&X?'?\ T+FG?]]3?_%4?\-P^._^A<T[_OJ;_P"*H_M_#=_P%_:E
M'N?M7_PE&@?\_J?K_A1_PE&@?\_J?K_A7XJ?\-P^._\ H7-._P"^IO\ XJC_
M (;A\=_]"YIW_?4W_P 51_;^&[_@']JT>Y^U?_"4:!_S^I^O^%'_  E&@?\
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M[ZF_^*H_X;B\>?\ 0N:=_P!]3?\ Q5+^W\-W_ /[5H]S]K?^$HT#_G]3]?\
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M/!_S+>G?]]3?_%4?\-Q^//\ H6]._P"^IO\ XJC_ %@PW?\  /[6H]S]KO\
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M7_A*- _Y_4_7_"C_ (2C0/\ G]3]?\*_$K_ANCQ[_P!"WIO_ 'U-_P#%T?\
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M_P#6+'_\_P"7WL:S?%?\_']Y](_\-4_%_P#Y_;7_ ,!4IP_:H^+V/^/RU_\
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MGOBS_P _EM_X#)2_\-._%C_G\MO_  &2OGI>E.'6G_K!CO\ G]+[V-9MB?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4_[4#ZZ>%?V"_P#=I1H+8^Y7NG_"/C^Y^E.'AY?[M+^U ^NGA?\ 8#_W*/[
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M!O[E']@-_<KW;_A'U_N?I2CP^IZ+^E']I^8OKIX3_P (^W]VC_A'V_NU[O\
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M*/#J_P!VC^T06-/!/^$>;^[1_P (\W]VO?/^$=7^[1_PCJ_W:/[1']</ _\
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M/_A'G]/TH_X1Y_[M?0R^#KQHA,MK(8ST8(=OYXQ57_A'0/X:YWCS+ZV>!_\
M"/-_=H_X1YO[M>^?\(Z/2GQ^&7F8)%&78]E&3^E/^T$5];/ /^$>;^[1_P (
M\W]VO?F\-E&*.A5AU!&"*;_PCH]*/[00?6SP/_A'F_NT?\(\_P#=KWS_ (1T
M>E*/#H'\-/\ M 7UL\#_ .$??TH_X1]_2OKSX8?"J'Q_XVT[PO<7 LX+EF:6
M3*AQ'&I9@@/5B!@<'UQ@&NJ^+/[.FN_"^Y6Y+#4M&G;;%=HNW:W9)5YVMZ<D
M'L<Y [(>VE1=>,;Q3LV=,?:.FZJ7NH^&?^$??^[1_P (^_\ =KWW_A'A_=I?
M^$=']RN3^T#G^MG@/_"/O_=I?^$??^[7OO\ PCH_N4O_  CB_P!VC^T 6*/
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M\P#ZTCP#_A'G_NT?\(\_]TU[_P#\(XO]VD_X1Q?[M+Z^)XH\!_X1Y_[II/\
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M +IKWO\ X1Y?[M'_  CP_NTGF(?7#P/_ (1Y_P"[1_PCS?W:][_X1X?W:/\
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M?\(\O]VI>9!]</!O^$??^[1_PC[_ -VO>/\ A'A_=H_X1X?W:/[3%]=/!_\
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MQHUOG*@YVVZ@YXK\KA9KFOU/\&G_ (L_I1]-'3](*_,4+S7U_&T_W6%_PO\
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M+;C&0A1=D?'H#BOR_D=Y9&EE8N[DLS'DDGDDFO5S+&1R>G3H8>"<VKMO^O\
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M3EZ4T]: $HHHH ****F0!1114DR"BBB@D****  ]*CJ0]*CI( I1UI*4=:;
M?11168"-TIE/;I3*3)D%%%%02%%%% !1110 4444 %%%% ##UIR]*:>M.7I6
M9#%HHHH8@HHHK, IAZT^F'K5R Z;P;XHO?!OB2R\0V)):V<;TS@21GAT/U'Y
M'![5^H&G:A::MI]MJEB_F6]W&DL;#NCC(/Y&OR8K[K_9N\3-JO@^XT"=]TVC
MRX7/7R9LLOY,''TQ7Z'X>YHX5I823TEJO5?YK\CZ[A3&N-1T'L]5Z_\ #?D?
M1-%%%?KQ]\%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y:?&[_DJOB/_ *^!_P"B
MUKZ/_9(_Y WB+_KX@_\ 0&KYP^-W_)5?$?\ U\#_ -%K7T?^R1_R!O$7_7Q!
M_P"@-7X5PU_R4,O\53]3\RR?_D;2]9?J?7E%%%?NI^FA1110!7O+6*]M)[.;
M_5SHT;8_NL,'^=?RS7&DW.C:Q>:->J4N+">2"52,$/$Q5@?H17]4-?@M^VC\
M,)_A[\=]3U6"(KI?BTG5+=^WFR'_ $E<_P!X2Y;'976OE.*Z#=*-1=/U/"SV
MDW!3['A?A^ %EKV_1( %6O'?#N/EKV[1L;5K\<S*3N?G>->IV-L@"BKZCO56
M#I5P=*^;D]3R6>O_  %7=\6_#P_Z:3'\H)*W/VD=\?Q8OG4D$P6Q!'_7,"N2
M^#>OZ-X6^(^D:]X@N/LMA:^>9)-CO@O!(B_*@9CEF'05]-^+==_9E\9ZNWB'
MQ!J;W%V45#L6\0,J<#Y505]QE6'AB,IEA_:QC+VE_>DEIRI'TN"I1K8!TO:1
MC+GOJ[:6/(OV?O'?B^V\>:9X:2]FN],ORZ26\C-(B (S;T!SL((R<=1P:;^U
M!:V=O\31):JJR7-C!)-CO)N=,GWV*M>AP_%_X*?#>"1OAIH+W=_*I7S6#IP>
M<-+,6DQG!V@8..U?*/BCQ+JWB_7;OQ%K<@EN[MMS8&%4 855'95  '^-&:XN
MG1RU8%UE4GS7TNU%6V3?Z>9.-Q$*>#6%=3GE>^FJ2\F?9/Q!#I^S%HA4E2+;
M33^87_&OAOS9?[Y_.OK3QM\3? FK? K3O!NG:EYNL6]II\;0>3,N'@""0;V0
M)Q@]&Y[5\CUQ\7XFG4KTG2FFE"*T=]==-#'B"M"=2#A)/W5M\S[F\ !G_9AU
MHGDFVU$_EN_PKX9KZW\%_$WP)I/P)U#P9J.H^5K$]KJ$:P>3,V7GW^6-ZH4Y
MR.K<=Z^2*KB7$4YT<(H23:@D[.]GV?8,YJPE3H*,D[15_(^YO#4__"VOV>;W
M0I/WVJZ)&8D'5R]J \!'^^GR9[G-8'Q;NE^''P@\/?#&T.R]U"-9+S'7:I\R
M3/?YI3@>RD5YK^S]\1M*\ >)+Y?$5T;72M0M\.^QY,31G,9VH&/0L.G>N5^,
M/C.#QUX\O]9L93-8($@M6(9?W,8ZX8 C<Q9L$ \UZV*SRD\L592_?N/LWWY4
M[W^:TN>A6S.F\$JB?[QKD?>W?YHB^&7CG2O >JW>HZKH<6NI<0^4L<K*H1MP
M;<-R..V.E>H^(OVA-'UK0-1T.S\%VMB;^WE@$HE1C'YBE=P @7D9R.:^9**^
M6PN?XJC1]A2E:.O1=?-JYX5#-:].G[*$K+T77Y7/MCX&>!F\'>$+GXI7NGRZ
MGJES"QL+6%2\@B;Y05 !PTAZG^%.>Y%<1X.\,_%'6OC!IGC+Q9HMY%ONQ+-+
M)$R1QH =JC/15& *X?P]\?/B%X9T6TT'3)K?[+9)Y<?F0AF"YR 3GG%>I?#7
MX]?$'Q3XYT?P_JDEL;2]F*2!(0K;0I/!SQTKZ_!8_+:JPV'C*<>5K1)6<KK5
MN_R\D?08;%8.:HT4Y+E:TLK.7=F9^T7X)\5W_C:^\36>F33:5!:0L]PH!10B
M_-DY[=Z^;-'!.KV('4SQ?^A"OJ_]HCXG>*=,UZ_\!6CQ)I5U:1;QY>9#YG+?
M-GVQTZ5\HZ-/!:ZO8W-RVV&&>)W.,X56!)P/:O"XIC068S]DW?F?-?O?IY'E
MYXJ2QDO9M[ZW[WZ>1]5_M:@_VIX</;R;G_T)*X_X7?&O0O ?A*7PKJNAOJ4=
MS/)-*=Z;'$BJNTHRD'A1U-2_M$>/O"/CJZT.3PK??;19I<"8^5)%MWE-O^L5
M<YVGI7S;73GN<RHYK5Q&$FG>ROHU:ROW1MFF8RIX^I6P\D[]=&MD?=GAK7_@
M!\4[H: _AZ#3+^<'8CP1VS2-Z)+ 1D^@)!/85\[_ !H^&"?#3Q!!%82M-I>H
MHTEN9/OJ4(#QL1P=N00?0CO7+_#/0=9\0>.='M=$C9IH;F&=I .(DB<,TC'L
M%Q^)P!R17O?[5^NV5UJ^A^'H&#W%A'---@YV^>4"*??"$GV(]:[:^(CC<JJ8
MFO32G%I*25KWW7G9'16JQQ.!G6JP2E%I)I6OY'R17VMX2M$^"7P9O?%]\HCU
M[7E7R58?,ID!\A,'^ZI,C#\#T%>)_ OX??\ "=>,HY+V/?I6D[;BYR/E<Y_=
MQ'_?(Y_V0:W/VC/'G_"4>,/[ L9-VGZ%NBX/#W!_UK?\!P$'T..M<.3P^IX2
M>92^)^[#U>\ODC#+8_5\/+%RW>D?7J_D?/;,SL7<EF8Y)/))/<TVBBOCT?/G
MV3J?_)IMG]4_]+37QM7V;JBX_9.M/;RS^=Z:^,J^LXL^+#?]>H?J>[GN]'_!
M']20=*[[P;\3?&?@20?V!?LMMG+6TO[R!O7Y#T)[E2#[UV?P$USP9X>\4W>H
M>,[F."%[1H81+&TB,\C*3G:K 84$<\<U]1S7'[-MRQO)/["SU.%C4DG_ & !
MG\JUR+(Y5*:Q-+$QA*^U[-?CU-,KRQS@JU.LHR];,[CX6^/D^)/A1==>T^R3
M)*]O/'G<GF(%)*$]5(8=>AR.<9/R/X2TFST;]I<:7IRJEM!?W?EHOW44Q2,%
M'LN<?A7N/B'X_?#7P?I!T_P:J7TR(P@@M8O*MHV/3<<* N>2$!/TZU\I_#3Q
MC96'Q7L_&GBZZ\F)YKJ>YF",WSSQ2#.U QY=AT''TKZG/<UH2J8.C*JISC*+
ME)6LM5?7;S^1[>9XZDYX>G*:E*,DV^G]?Y'V=\<?B)KWPYT/3]0T"."26[N#
M"_GHS@ (6R K+SD=\U\9>)/CA\2?$]NUG=ZJ;6W;.Y+51!N![%E^<CVW8KUK
M]H'XF>!O&_AK3K#PQJ7VVYM[OS77R9H\)Y;*3F1%'4C@5\EUX?&&?598N4,/
M6O3LOA>FVNQYG$.:3==QI5/=LMGI^ 5^H_Q/3_BU&O+Z:<_Z+7Y<5^@'CSXV
M?"[6? ^MZ-INL^==7=E-%#']GN%W.R$*,M&%'/<G%:<&XNC2H8I59J+<5:[2
MOI+8?#E>G"E74Y)76EWOHSS_ /9+'^G>)6]([4?F9*\Y^)OB+4_!_P =M4\0
M:0^RYLYX7 /W74P)N1O]E@2#]:W/V=O'_@_P*VOMXJO_ +";T6HA_=2R;O+\
MW?\ ZM&QC<O7%>9_%_7]'\4?$75]=T"?[3871@,<FQDW;($1OE<*P^93U K+
M$XV$<EP\:=1<\9WLGJM9:VW[$5L3%9;14)+F4KVOJOB/T(TR]\/_ !3\,:3K
M]IRD=Q;WD>>7@N+=PS(?0\%#Z@Y'!%>&?M8#_B3>'V]+B<?FBUXS\"OBE#X
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MG\J\IKZD^"N@-I^A3ZU.NV34G&S/7RH\@'\6)_#!KZS@G!2K9C3MM'WG\O\
M@V/?X:PSJXN%MEK]W_!/:****_H@_70HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_\ S[R?]\&C[!?_ //O)_WP: *E%6_L%_\ \^\G_?!H^P7_ /S[R?\ ?!H
MJ45;^P7_ /S[R?\ ?!H^P7__ #[R?]\&@"I15O[!?_\ /O)_WP:/L%__ ,^\
MG_?!H J45;^P7_\ S[R?]\&C[!?_ //O)_WP: *E%6_L%_\ \^\G_?!H^P7_
M /S[R?\ ?!H J45;^P7_ /S[R?\ ?!H^P7__ #[R?]\&@"I15O[!?_\ /O)_
MWP:/L%__ ,^\G_?!H J45;^P7_\ S[R?]\&C[!?_ //O)_WP: *E%6_L%_\
M\^\G_?!H^P7_ /S[R?\ ?!H J45;^P7_ /S[R?\ ?!H^P7__ #[R?]\&@"I1
M5O[!?_\ /O)_WP:/L%__ ,^\G_?!H J45;^P7_\ S[R?]\&C[!?_ //O)_WP
M: *E%6_L%_\ \^\G_?!H^P7_ /S[R?\ ?!H J45;^P7_ /S[R?\ ?!H^P7__
M #[R?]\&@"I15O[!?_\ /O)_WP:/L%__ ,^\G_?!H J45;^P7_\ S[R?]\&C
M[!?_ //O)_WP: *E%6_L%_\ \^\G_?!H^P7_ /S[R?\ ?!H J45;^P7_ /S[
MR?\ ?!H^P7__ #[R?]\&@"I15O[!?_\ /O)_WP:/L%__ ,^\G_?!H J45;^P
M7_\ S[R?]\&C[!?_ //O)_WP: *E%6_L%_\ \^\G_?!H^P7_ /S[R?\ ?!H
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M>7#]F/X4#_ETN?\ P)>G?\,R_"G_ )]+G_P)>O0_^%J_"_\ Z'#1O_!A;_\
MQ=+_ ,+5^%__ $.&C?\ @PM__BZY_P"PLL_Y\P^Y&/\ 9>"_Y]Q^Y'G?_#,O
MPI_Y]+G_ ,"7I?\ AF;X5=K2Y_\  EZ]#_X6I\+_ /H<-'_\&%O_ /'*/^%J
M?"__ *'#1_\ P86__P <H_L++/\ GS#[D']EX+_GW'[D>>?\,S?"K_GTN?\
MP)>C_AF;X5?\^ES_ .!+UZ'_ ,+4^%__ $.&C_\ @PM__CE'_"U/A?\ ]#AH
M_P#X,+?_ ..4?V%EO_/F'W(/[+P7_/N/W(\\_P"&9OA5_P ^ES_X$O1_PS-\
M*O\ GTN?_ EZ]#_X6I\+_P#H<-'_ /!A;_\ QRC_ (6I\+_^APT?_P &%O\
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M_P#!A;__ !RC_A:GPP_Z'#1__!A;_P#QRC^PLM_Y]0^Y!_9>"_Y]Q^Y'GO\
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MA_T-^C_^#"W_ /BZ/^%J?##_ *&_1_\ P86__P 71_8>6_\ /J'W(/[,P?\
MS[C]R//O^&:OA9_SZW/_ ($/1_PS5\+/^?6Y_P# AZ]!_P"%J?##_H;]'_\
M!A;_ /Q='_"U/AA_T-^C_P#@PM__ (NC^P\M_P"?4/N0?V9@_P#GW'[D>?\
M_#-?PL_Y]+G_ ,"'H_X9K^%G_/I<_P#@0]>@?\+4^&'_ $-^C_\ @PM__BZ/
M^%J?##_H;]'_ /!A;_\ Q=']B9=_SZA]R#^S,'_S[C]R. _X9K^%G_/I<_\
M@0]'_#-?PL_Y]+G_ ,"'KO\ _A:GPP_Z&_1__!A;_P#Q='_"U/AA_P!#?H__
M (,+?_XNC^P\M_Y]0^Y!_9F#_P"?<?N1P'_#-GPM_P"?6Y_\"'H_X9L^%O\
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M\+O^?6Y_\"'KOO\ A:?PQ_Z&_1__  86_P#\71_PM/X8_P#0WZ/_ .#"W_\
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M$/1_PS;\+O\ GUN?_ AZ[[_A:?PQ_P"AOT?_ ,&%O_\ %T?\+3^&/_0WZ/\
M^#"W_P#BZ/[$R[_GU'[D']FX3^2/W(X'_AFWX7?\^MS_ .!#T?\ #-OPN_Y]
M;G_P(>N^_P"%I_#'_H;]'_\ !A;_ /Q='_"T_AC_ -#?H_\ X,+?_P"+H_L3
M+O\ GU'[D+^S,)_)'[D<#_PS;\+O^?6Y_P# AZ/^&;OA=_SZW/\ X$/7??\
M"T_AC_T-^C_^#"W_ /BZ/^%I_#'_ *&_1_\ P86__P 73_L7+_\ GU'[D']F
M83^2/W(X+_AF[X7?\^MS_P"!#T?\,W?"[_GUN?\ P(>N]_X6G\,?^AOT?_P8
M6_\ \71_PM/X8_\ 0WZ/_P"#"W_^+H_L7+_^?4?N0_[-PG\D?N1P?_#-_P +
M_P#GUN?_  (>C_AF_P"%_P#SZW/_ ($/7>?\+3^&/_0WZ/\ ^#"W_P#BZ/\
MA:?PQ_Z&_1__  86_P#\71_8N7_\^H_<@_LW"?R1^Y'!_P##-_PO_P"?6Y_\
M"'H_X9O^%_\ SZW/_@0]=Y_PM/X8_P#0WZ/_ .#"W_\ BZ/^%I_#'_H;]'_\
M&%O_ /%T?V+E_P#SZC]R#^S<)_)'[D<'_P ,X?"__GUN/_ AZ/\ AG#X7_\
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M"_\ Y];G_P "'H_X9P^%_P#SZW/_ ($/7>?\+2^&/_0WZ/\ ^!]O_P#'*/\
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M_P ,Y_#'_GUN/_ AZ[K_ (6E\,O^ANT?_P #[?\ ^+H_X6E\,O\ H;M'_P#
M^W_^+H_L?+_^?4?N0?V=A/Y(_@<+_P ,Y_#'_GUN/_ AZ/\ AG3X9?\ /K<?
M^!#UW7_"TOAE_P!#=H__ ('V_P#\71_PM+X9?]#=H_\ X'V__P 71_8^7_\
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M?\+2^&7_ $-VC_\ @?;_ /Q=']CX#_GU'[D']GX7^1?@<-_PSK\,O^?6X_\
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M_P ,\?#3_GVN/_ AZ[?_ (6C\,_^AMTC_P #[?\ ^+H_X6C\,_\ H;=(_P#
M^W_^+H_L? ?\^X_<A_4,+_(OP.(_X9X^&G_/M<?]_P!J/^&>/AI_S[7'_?\
M:NW_ .%H_#/_ *&W2/\ P/M__BZ/^%H_#/\ Z&W2/_ ^W_\ BZ/['P'_ #[C
M]R#ZAA?Y%^!Q'_#/'PT_Y]KC_O\ M1_PSQ\-/^?:X_[_ +5V_P#PM'X9_P#0
MVZ1_X'V__P 71_PM'X9_]#;I'_@?;_\ Q=']CX#_ )]Q^Y!]0PO\B^Y'$_\
M#//PT_Y]KC_O^]'_  SS\-/^?:X_[_O7;?\ "T?AG_T-ND?^!]O_ /%T?\+1
M^&?_ $-ND?\ @?;_ /Q=']D8'_GW'[D'U#"_R+[D<1_PSQ\-?^?:X_\  AJ/
M^&>/AK_S[W'_ ($-7;_\+1^&?_0VZ1_X'V__ ,71_P +1^&?_0VZ1_X'V_\
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M<-_PSI\,_P#GVN?_  (:C_AG3X9_\^US_P"!#5W/_"TOAE_T-VC_ /@?;_\
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MX'"?\,Y_#+_GVN?_  (:C_AG+X9?\^US_P"!#5W?_"TOAE_T-VC_ /@?;_\
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MW/\ X$/1_P ,X?##_GUN?_ AZ[S_ (6G\,?^AOT?_P &%O\ _%T?\+3^&/\
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M_P"&;_A?_P ^MS_X$/1_PS?\+_\ GUN?_ AZ[W_A:?PQ_P"AOT?_ ,&%O_\
M%T?\+3^&/_0WZ/\ ^#"W_P#BZ/[%R_\ Y]1^Y!_9N$_DC]R."_X9N^%__/M<
M_P#@0])_PS=\+_\ GVN?_ AZ[[_A:?PQ_P"AOT?_ ,&%O_\ %T?\+3^&/_0W
MZ/\ ^#"W_P#BZ/[%R_\ Y]1^Y!_9N$_DC]R.!_X9M^%W_/M<_P#@0]'_  S;
M\+O^?:Y_\"'KOO\ A:?PQ_Z&_1__  86_P#\71_PM/X8_P#0WZ/_ .#"W_\
MBZ/[%R__ )]1^Y!_9N$_DC]R.!_X9M^%W_/M<_\ @0]'_#-OPN_Y]KG_ ,"'
MKOO^%I_#'_H;]'_\&%O_ /%T?\+3^&/_ $-^C_\ @PM__BZ/[%R__GU'[D']
MFX3^2/W(X'_AFWX7?\^US_X$/1_PS;\+O^?:Y_\  AZ[[_A:?PQ_Z&_1_P#P
M86__ ,71_P +3^&/_0WZ/_X,+?\ ^+I?V)EW_/J/W(/[-PG\D?N1P/\ PS;\
M+O\ GVN?_ AZ/^&;?A=_S[7/_@0]=]_PM/X8_P#0WZ/_ .#"W_\ BZ/^%I_#
M'_H;]'_\&%O_ /%T?V)EW_/J/W(7]FX3^2/W(X'_ (9M^%W_ #[7/_@0]'_#
M-OPN_P"?:Y_\"'KOO^%I_#'_ *&_1_\ P86__P 71_PM/X8_]#?H_P#X,+?_
M .+H_L3+O^?4?N0?V;A/Y(_<C@?^&;?A=_S[7/\ X$/1_P ,V_"[_GVN?_ A
MZ[[_ (6G\,?^AOT?_P &%O\ _%T?\+3^&/\ T-^C_P#@PM__ (NC^Q,N_P"?
M4?N0?V;A/Y(_<C@/^&;/A=_SZW/_ ($/1_PS9\+O^?6Y_P# AZ[_ /X6G\,?
M^AOT?_P86_\ \71_PM/X8_\ 0WZ/_P"#"W_^+H_L3+O^?4?N0?V;A/Y(_<C@
M/^&;/A=_SZW/_@0]'_#-GPN_Y];G_P "'KO_ /A:?PQ_Z&_1_P#P86__ ,71
M_P +3^&/_0WZ/_X,+?\ ^+H_L3+O^?4?N0?V;A/Y(_<C@/\ AFSX7?\ /K<_
M^!#T?\,V?"[_ )];G_P(>N__ .%J?##_ *&_1_\ P86__P 71_PM3X8?]#?H
M_P#X,+?_ .+I?V)EW_/J'W(/[-P?\D?N1P'_  S9\+O^?6Y_\"'H_P"&;/A=
M_P ^MS_X$/7?_P#"U/AA_P!#?H__ (,+?_XNC_A:GPP_Z&_1_P#P86__ ,71
M_8F7?\^H?<@_LW!_R1^Y' ?\,V?"[_GUN?\ P(>C_AFSX7?\^MS_ .!#UW__
M  M3X8?]#?H__@PM_P#XNC_A:GPP_P"AOT?_ ,&%O_\ %T?V)EW_ #ZA]R%_
M9N#_ )(_<C@/^&;/A=_SZW/_ ($/1_PS9\+O^?6Y_P# AZ[_ /X6I\,/^AOT
M?_P86_\ \71_PM3X8?\ 0WZ/_P"#"W_^+H_L3+O^?4/N0?V9@_\ GW'[D<!_
MPS9\+O\ GUN?_ AZ3_AFOX6_\^MS_P"!#UZ!_P +4^&'_0WZ/_X,+?\ ^+H_
MX6I\,/\ H;]'_P#!A;__ !=']B9;_P ^H?<@_LS!_P#/N/W(\_\ ^&:_A;_S
MZW/_ ($/1_PS7\+?^?6Y_P# AZ] _P"%J?##_H;]'_\ !A;_ /Q='_"U/AA_
MT-^C_P#@PM__ (NC^P\M_P"?4/N0?V9@_P#GW'[D>??\,U?"W_GUN?\ P(>C
M_AFKX6?\^MS_ .!#UZ#_ ,+4^&'_ $-^C_\ @PM__BZ/^%J?##_H;]'_ /!A
M;_\ Q=']B9;_ ,^H?<@_LS!_R1^Y'GW_  S3\+/^?6Y_\"'H_P"&:?A9_P ^
MMS_X$/7H/_"U/AA_T-^C_P#@PM__ (NC_A:GPP_Z&_1__!A;_P#Q=']AY;_S
MZA]R'_9N#_DC]R//O^&:?A9_SZW/_@0])_PS3\+/^?6Y_P# AZ]"_P"%J?##
M_H;]'_\ !A;_ /Q='_"U/AA_T-^C_P#@PM__ (NC^P\M_P"?4/N0O[,P?\D?
MN1Y[_P ,T_"S_GUN?_ AZ/\ AFGX6?\ /K<_^!#UZ%_PM3X8?]#?H_\ X,+?
M_P"+H_X6I\,/^AOT?_P86_\ \71_8>6_\^H?<@_LS!_\^X_<CSW_ (9I^%G_
M #ZW/_@0]'_#-/PL_P"?6Y_\"'KT+_A:GPP_Z&_1_P#P86__ ,71_P +4^&'
M_0WZ/_X,+?\ ^+I?V'EO_/J'W(/[,P?_ #[C]R//?^&:?A9_SZW/_@0]'_#-
M/PL_Y];G_P "'KT+_A:GPP_Z&_1__!A;_P#Q='_"U/AA_P!#?H__ (,+?_XN
MC^P\M_Y]0^Y!_9F#_P"?<?N1Y[_PS3\+/^?6Y_\  AZ/^&:?A9_SZW/_ ($/
M7H7_  M3X8?]#?H__@PM_P#XNC_A:GPP_P"AOT?_ ,&%O_\ %T?V'EO_ #ZA
M]R#^S,'_ ,^X_<CSW_AFGX6?\^MS_P"!#T?\,T_"S_GUN?\ P(>O0O\ A:GP
MP_Z&_1__  86_P#\71_PM3X8?]#?H_\ X,+?_P"+H_L++?\ GU#[D']F8/\
MY]Q^Y'GG_#-'PK_Y];G_ ,"7H_X9H^%?_/K<_P#@2]>A?\+4^&'_ $.&C_\
M@PM__CE'_"U/A?\ ]#AH_P#X,+?_ ..4?V%EO_/J'W(/[,P?_/N/W(\]_P"&
M:/A7_P ^MS_X$O1_PS1\*_\ GUN?_ EZ]"_X6I\+_P#H<-'_ /!A;_\ QRC_
M (6I\+_^APT?_P &%O\ _'*/["RW_GU#[D']F8/_ )]Q^Y'GO_#,_P *_P#G
MUN?_  (>C_AF?X5_\^MS_P"!#UZ%_P +4^%__0X:/_X,+?\ ^.4?\+4^%_\
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M%_WVO^- %NBJG]H6'_/S%_WVO^-']H6'_/S%_P!]K_C0!;HJI_:%A_S\Q?\
M?:_XT?VA8?\ /S%_WVO^- %NBJG]H6'_ #\Q?]]K_C1_:%A_S\Q?]]K_ (T
M6Z*J?VA8?\_,7_?:_P"-']H6'_/S%_WVO^- %NBJG]H6'_/S%_WVO^-']H6'
M_/S%_P!]K_C0!;HJI_:%A_S\Q?\ ?:_XT?VA8?\ /S%_WVO^- %NBJG]H6'_
M #\Q?]]K_C1_:%A_S\Q?]]K_ (T 6Z*J?VA8?\_,7_?:_P"-']H6'_/S%_WV
MO^- %NBJG]H6'_/S%_WVO^-']H6'_/S%_P!]K_C0!;HJI_:%A_S\Q?\ ?:_X
MT?VA8?\ /S%_WVO^- %NBJG]H6'_ #\Q?]]K_C1_:%A_S\Q?]]K_ (T 6Z*J
M?VA8?\_,7_?:_P"-']H6'_/S%_WVO^- %NBJG]H6'_/S%_WVO^-']H6'_/S%
M_P!]K_C0!;HJI_:%A_S\Q?\ ?:_XT?VA8?\ /S%_WVO^- %NBJG]H6'_ #\Q
M?]]K_C1_:%A_S\Q?]]K_ (T 6Z*J?VA8?\_,7_?:_P"-']H6'_/S%_WVO^-
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M5.46XR5F/7I3AUIJ]*<.M0)#Z4=:Z+POX3U[QEJ+:3X=MA=721M*4+I'\BD
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M?B-_T"A_W_A_^.5,LEQG_/F7_@+#^SL1_P ^W]S/+J*]1_X4S\1O^@4/^_\
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M?F%*.M)2CK63,Q]%%%9@(W2F4]NE,I,F04445!(4444 %%%% !1110 4444
M,/6G+TIIZTY>E9D,6BBBAB"BBBLP"F'K3Z8>M7(!*[_X6?\ )1?#W_7Y%_.N
M KO_ (6?\E%\/?\ 7Y%_.NO+/]YI?XE^9TX/^-#U7YGZ:T445_2Q^QA1110
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MLM_0T?V6_H:]J_X1L?W:/^$;']VCZ^@^LH\5_LM_0T?V6_H:]J_X1L?W:/\
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MT?V6_P#=KVS_ (1H?W*/^$:']RG]>0?64>)_V6_]VC^RW_NU[9_PC0_N4?\
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M612CK7D9SQ'7QT(1K)>[?8\_,<XJXF,8U+:=A]?HO^SE)O\ A;9+_<GN%_\
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MJUY^6X*6(KPHQZO_ (?\#EP6'=:I&FNI];6BZ7\/?!<$=W($M-)MT5W'\3<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4]DE?_/\BZ.4TH48UL55Y>;:R/@G6?A[XE\.J'U[1[O3D8[0UQ \:DGG 9@
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M=])NEOY!N6W,#B9EP3D)C<1@$].QK[3_ &3SLE\3Q_WELS^1F_QJK\7?$/\
MPC/QXT37R<)806WF8Z^4SR"0?BC&L89/3^HT\9.;7-*S\E=J_P"!$,OC]5AB
M)2W=G]]CX[O_ (?>)=+MFO-3T6\L[=2 9)K>2- 2<#+, .36#_9"?W:_77XG
MZ&/%'P]UO2XAYCRVS2Q8YW/%B5,?4J!7Y=QVS2R+%$NYW(50.I)X %9<1Y.\
M#5C",KJ2W_KY$9OE[PTU%.Z:*-K\./%5];QW=EH5]<02C<DD=M*Z,/4,%((^
ME0V'@#Q%JL3SZ7H]W>1QN8V:&WDD57&"5)4$ C(R.M?JC>W,/PR^%_F,0#HF
MGI&OHTRH$7_OJ0C\Z\R_9>E9_!&IASN8ZG(Y)ZDM#%G^5>T^%H+$4L-*H^:2
M;>FUOZ?W'HO)(JM"BYN[3;\CX)_X59XS_P"A<U'_ ,!)O_B:IW_P^\1:3;&\
MU31[RS@! ,DUO)&@)Z#<R@<U^@_BC]HO3/"_B._\/3Z+-,UA*8C(LJ@-CN 1
MQ^=>3_$[XZZ/X\\'W'ARSTVXM)IY(GWNR,N(VW$<'/;TKAQN79?2C/EQ%Y1O
MI;JNAS8G!X6$9<M:\ETMU/C+^QX_2M'3?".HZS,UMI%C-?3(N\I!$TK!00,D
M*"<9(&?>M[RQ7T=^S ?+^(-X!_'ILP_\BQ'^E>#E5+ZQB(46[<SL>7@J?M:L
M:;=KGSBOPH\</]SPUJ3?2RF/_LE8VH^"]7T<@:OIMQ8EC@>?"\63_P " K]-
M/B9\9+7X;:O9:9<Z6]\+N'SBZ2A-HW%<;2IST]16KX)^)O@SXH6T^G6Z8N-I
M\VRNE4EH^A('*NO//IW XK[!\-X255X:&)_>+HU_PWX'OO)J#J.C&M[W:Q^4
M?]C1_P!VMO3? >OZO ;G2-(NKZ%6*%X())5#  D$JI&<$<>]?47QY^$UCX/N
M(?$OAV+RM+O7\N2$<K!,<D;?1& .!V(QT( ]?_9=;'@74HO[NHR'\X8O\*\?
M!9#4ECG@J[LTF[HX,-E<GB7AJCL?G;=^'+C3[E[._MGMKB(X>.5"CJ>N"K $
M5:TOP=JVMS-;Z-IT]_*HR4MXGE8#U(0$U]"?%#3&\0?&V_TE7V-?WMM;!O0N
ML<>?PK[0UB]\-_!WP.]W8:>196(1%BA #N[D*"['N3]YCD_H*UR_(?;5*W/4
MY84VTWZ7_P BL)E7M)U.:5HP;U/S4?X+_$-(_,;PQJ&,9XMI"?R S7'7GAJZ
MTZY>SU"V>UN(\;HY4*.N1D95@".*^[[;]JFT>8+>>''BBSRT=T';'^Z8T'ZU
M\U>/_$$7C3QGJ7B*UC=8[Z1?+1P-X155%! )&<*.A-<>:4<%3IJ6%K.3OLU;
M]$88VGAH04J%3F?H>/)H?FNL<49=W( 4#))/0 5WEK\$_B)>0"Y@\-WIC(R"
MT)0D>P;!_2OOOX4?"O1?AYH:Z]K<<9UAXC-//)C%LF,E$)^[M'WF[G/.,5R^
MI_M/>'+35'M=/TJ>]LT8K]H\P1E@.ZH5.0>V2#[5Z]/AZC1I1J9A6Y'+9+?^
MN^FG<]&&54Z<%+%5.5OH? .J^#-5T*Y^QZU836$_79/&T;$>H# 9'O68-&3^
M[7ZV!?!7Q?\ "0D9%O\ 3[G(&X;989 .<'JCK[?J#S^>/CKP9=>!_$]YX>NF
M\P0,&BDQCS(FY1ORX/H017GY[DDL)&-:G+FIRV?]?F<F:9=*@E4A+FB^IQB_
M"SQJQPOAO42?:SF_^)I)OA;XTMXS+<>'-0B0<EFM)E'YE:_5OQ5XD_X1CPI>
M^)OL_P!J^QPB7R@VS=D@8W8..OH:\5\%_M&:9XGUZUT'4M(?36OI%BAD6;SE
M\QSA58;$(R<#(SR><#FO<Q7#N#HU(T:N(:E+;3^E^)Z-;)\/3FJ<ZK3>VA^<
MSZ((V*/'M93@@C!!'8UL:=X#U_6(#<Z3I%U>PJQ0O!!)(H8 $@E01G!''O7W
ME^TMX2T>;PY!XKC@2+48)TB>10 98W!X;U((!![#-7OV7SCP-J,7]W49#^<,
M7^%>=3X=DL?]2J3TM=-?Y')#*']:^KRETO<^$_\ A5'C?:7_ .$:U+:._P!C
MFQ_Z!7.7?AFYT^8V]_:O;2CJDJ,C#\" :_177OVBM+\.>)M0\/7^C3.EA,T)
MECE5BVTXSL(7'_?5>FVMQX%^+GAKS?+BU2QDRK+(N)89,<C^\CC/4'W!(KMA
MPYAJSE3PV(O-=&OZ_4Z8Y/1J-PHU?>71H_)3^R$'\-=+!\-?%ES#'<VV@WTL
M,JAT=+65E96&000N"".017I?Q-\ S?#_ ,4S:,6,MI(!-;2-U:)B0 >VY2"#
M],]Z^_/!-\++X7Z)J#*9!:Z3 Y4=6\J <#ZXKS<FR-XBM4HUI.+@<F79:ZM2
M=.H[.)^7O_"KO&?_ $+NH?\ @)-_\361J7@[5=&=(]8T^>Q>0$H)XFB+ =2
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M&0"0#\O8T\UP^$I4U+#UN9WV_4>-I8>$;T:G,[G!#X7>,V.!X<U G_KTE_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=?[]_P!NK]3OXG_WKY(?2CK24HZU\?$^?1^I?A@Y\-Z2?^G2#_T6M?FAKO\
MR&]0_P"OB7_T,U^F'AI=OAS2E]+2 ?\ D,5^9^O#&N:B/2YF_P#0S7Z5QU_
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MCT!/"CV P!7UQ\<=7O+7PQ'HMA%))+JDF'**6Q%%AFY'3)*CW&:^0?[*U/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME@/;*Y^IKXE?1-9BU+^QI+&=;\-L\@QMYN[.,;,9SFOT;^"/@.X^'W@KR=7
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M&O5Q%+ YOA*N)IT^2I!7?W-^CO;?=?GW5:>&Q]"=:$>6<=7^?S_,\X_96/\
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MY &:Y^&\94QE/'2E\<UM\I+_ "1CD^(GB(8EOXI+]&C\NZ_1#]G3/_"L+/\
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MZBOT**P6<T:DU3Y*L5>__!Z_/4^L7U?,:<I<O+-=?ZW^9\U_LJ'_ $WQ&/\
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M5*3G3C1L[[W\_0SJ^A?V:#_Q<.;WL)O_ $..OGJOH?\ 9F4GXA7!_NZ?,?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,6]!_P!-8<GCZJ6S]!7H9-QE6KXF%&M%)2TTOOTZ]SLR[B*I5K1IU$DGVO\
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MTHKWZO&>.G%PDU9Z;'KSXBQ,HN+:U\@KUKX-^.M&^'WB>YUK6XIYH9K1[=1
MJLP9I(VR0S*,80]_PKR6BOG,'BYT*L:U/='CT*\J4U4ANC[W'[2_P\(R8;\>
MQA3_ ..5R7B/]J'3Q;O%X3TJ5YV&%EO"J*I]=D;,6_[Z%?&M*.M?25>-L?*/
M*I)>B/7GQ)BI*UTOD:VLZSJ?B#4Y]8UBX:ZN[EMSNW4^@ Z  < #@#@5[_\
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M-7'8E*I/675_UV/.IJ>)K)3EJ^K/H?3U'PE^#/F78$=[;VS.P[FZN#\J_P#
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M^[]0HHHKZ$]8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWE;\[H^CGG."K>]7I._E_P .CZJ\*? 3P-X9NH]0F275;F([E-R5,:MV(C4
M''^UGUJ+XI?&72/!MG-IFBS1WNN/E BG<EN?[TA'&1V3KZX'7X\U?XI?$+78
M_(U+7;AHSU6,B%3[$1!01]:X,G/)K#$\74J5)T<NI<E^O7_A_-LRK9_3A3=/
M"0Y?,LS32W$TEQ<.9)96+.S')9F.22?4FHQUI*4=:^$N?+O<?2CK24HZU41H
M_5^S7;:0+Z(H_2OS+\9+L\8:XG]V_NA^4K4]?'GCE0%7Q%J( X %W-Q_X]7.
M3337,KW%Q(TLLK%W=R69F8Y))/))/4U]=Q'Q'3QT(0A!KE[GT&<9O'$QC&,;
M6$7I7TC^SEX9%]K]YXFN%S'IL?EQ$_\ /68$$C_=0$'_ 'A7S<O2MO2_$?B'
M18V@T?5+JQCD.YE@G>)6;&,D*0"<5XF48NGA\1"M4C=1UMY]#S,OQ$*5:-2:
MND?=/QLUIM&^'FH"-MLM^4M5/M(<N/Q0,*^ EZULZEXE\1ZS MMK&JW=]"C;
MU2>>250P!&0&8C."1FL9>M=O$.<K'5U4BK)*UCJS;,?K-3G2LDK#J<O6FTY>
MM>&CS46+:XFM+B*ZMV*2PNKHPZAE.0?P-?IOHFIQZSH]CJ\7"7L$<P'IYBAL
M?AFOS#'6NEM?%_BVRMX[2RUN^@@B&U(X[F5$4#L%#  ?2OI^&\_6!<^:-U*W
MX'M9/FJPSES*Z9WGQJ\/C0O'5U+"NV#4E%TN.FYR0_\ X^"?QKW_ . %I]F\
M!M/C_CZNY9/P 5/_ &6OC?4=8U;69$FU>]GOI(UVJT\K2D#K@%B<"KVG^*/$
MVEVPL]-U>\M+=22(X;B2- 2<G"JP')JLOSNC0QT\4H/E=[+M<,+F5.EB95U'
M1WT]3T_X^2%_'I4_P6L(_5C_ %KQ=:MW^I:CJMP;O5+J6\G( ,DSM(^!T&YB
M3@546O'S'%JOB)UDK<SN>=C*_M:LJBZL]F^!FM'2_'$5DS8BU.)X2.VX#>I^
MN5P/K7U)\1]=;P[X+U348VVS&/RHB.H>4[ 1],Y_"OS^MKJYLKB.[LY7@GB.
MY)(V*NI'<$<@UK7WB7Q'JL'V75-5N[R'(;9-/)(N1T.&)&:]_*>)7AL'/#V=
MW>S[7_X.IZN!SKV.'E1MKK;RN8XZU(.M1CK4@ZU\H>(MC[A^"K%OA[8 _P ,
MDX_\B,?ZUXK^T!!Y?B^SG'26R3\UDD_IBO)K'Q-XDTRW%IINJW=I I)$<4\D
M: GDX52!S5/4-6U35Y5GU6\FO9$7:K3R-(P7.< L2<9/2OK,=Q#3K8"&$Y7=
M):^A[V)S:-3"QH<NJM^!]+?L_>'1%9W_ (GF7YYV^S0D_P!Q<,Y^A; _X#6Q
M\?M8:S\+VNDQMAM1GRWO'"-Q'_?16OENS\3>)-,@%IINK7=I I)$<4\D: GD
MX56 YJKJ6MZSK'EG5[^XOO*SL\^5Y=N[&<;B<9P,XJH\1TX9?]3IP:;5K^NX
M?VO".$^KPCK;?\S,HHHKY$^>"MSPUJ[Z#X@T_6$)'V2=';'= ?F'XKD5AT4J
M51PDIQW14)N+4ENC]-@5=0RG<K#(]"#7Y\>/=!'AOQ=J6DHNV&.4O$.WER#>
M@_ ''X57C\9^,$0(FNWZJHP +J4  =A\U8E_J%_J=RUWJ5S+=SL #)*[2.0.
M!\S$GBOK.(N(Z6.I1C&#4D]_S_0]W-\WAB8)*-FBG7H_PD7=\1-&'^W(?RB>
MO.*LVEY=Z?<)>6$[VT\>2LD3%'7(P<,N".*^9P5=4JT*K7PM/[F>-AJJA4C-
M]&F?H#X^7=X(UT?].4Y_)":_/6NAN/%WBN[@DMKK6KV:&52KH]S*RLIX((+8
M(/I7/5['$N=PQU2$X1M96/1S?,HXF<915K!1117S1XTC[?\ @DFWX>V3?WY9
MS_Y$(_I70>(_ASX4\5Z@-4UNV>:X5!&"LCH-JDD<*1ZFOARR\3^)=,MUL]-U
M:[M($R1'%/(B DY.%5@.35O_ (3;QG_T']0_\"I?_BJ_0</Q=A5AH8>M1YE%
M):VMH?54<_H*C&C4IWLEVZ'UX/@K\.QUTYS_ -MY?_BJF3X-_#A/^83N/O//
M_P#%U\>_\)MXS_Z#^H?^!4O_ ,51_P )MXS_ .@_J'_@5+_\527$V6K_ )A%
M]T?\@6=8/_GPON1]8^)?AEX"T[PSJU[;:0B2V]I/(C;Y"59(V8'ECT(KXCKI
M;CQ?XLNH)+:YUN^EAE4HZ/<RLK*PP006P01U!KFJ^<SW,Z&)E%T*7(EZ?H>/
MFF-I5I1=*'+;T_0*4=:2E'6O"9Y8^BBBLP$;I3*>W2F4F3(****@D**** "B
MBB@ HHHH **** &'K3EZ4T]:<O2LR&+1110Q!11168!3#UI],/6KD E=_P#"
MS_DHOA[_ *_(OYUP%=_\+/\ DHOA[_K\B_G77EG^\TO\2_,Z<'_&AZK\S]-:
M***_I8_8PHHHH ^8?VMQGX2D^E_;']'K\[_AT,_$'PP/^HI9?^CTK]$OVMC_
M ,6D?WOK;_V:OSM^')Q\0O#!]-4LO_1Z5^,\:_\ (UAZ1_-GYWQ'_OT?E^9^
MUU%%%?LQ^B'Y,_$3XJ_%G3O&&NZ!+XIOXDL+VX@40RF#Y(Y&5<>7M[ 5;3]H
MSQU9?#VS\':7?SIJ DF>YU&60R7#([;D2-V)88R<MUZ 8QSC?M&6JV?QH\31
M(NT-+#)^,MO&Y/XDUV_[-GP8T;XEWNH:YXIW2Z5I;)&+=&*&:5P3\S*0P50.
MQ!)(YP#G\&IRQ\\?4PM"H^9N4=6]D]?38_+H/%2Q4Z%*;NVUOTO_ , ^?U\8
M>+5NOMJZW?"XSGS1<R[\]<[MV:_8#X;?VI:?#K09O$UX]Q?&QBFN9KALON=?
M,.]C_=!P2?3FN/U']G3X.:E;BW;P[';E<8>"26-QCW#<_CFN2_:H\73^%OAB
M=)TUS#-KDRV>5XQ %+2@>Q "'V8U]MD^4ULHIU\5B9\R2TLW^OR/I,OP%3 1
MJ5ZTKJW1O^NQX?\ &']JG5KV]N/#_P ,Y?L=C$61]0P#+,1P3#D81/1L;CU&
MVOE(CQKXUGEN2-0UV9.9'_>W3#W8_,1^-0>$?#EUXO\ $^E^&+)@DVIW$< 8
M]$#GYF/LHR?PK]G_  OX8T3P=HEKX>\/VRVMG:J%55'+'NS'^)FZDGDFOF\L
MP&*SRI.KB*K4%]WHE^IX^"PM?,Y2J59VBOZLD?C;H'C?QMX,O!+H&KW>FRQ-
M\T:R,$)7L\;95OHRFOT/^ O[0</Q)8>%_$Z1VGB&)"T;)\L=VJC+%5_A=1RR
M]",D< @<Q^UI\,M/O_#7_"Q=,MTBU'371+QE !FMY"$5FQU9&*@'KM)R< 8^
M O#FNWWAC7M/\0Z:Y2YTZ=)T(.,E#G!]B.#Z@UBL5BLDQJHRGS0T=NC3ZVZ/
M_+L9JM7RW$^S<KQ_-?HS]7OV@-7\2>'_ (6ZIKOA6]>PO;%X',D8!8QM*L;#
MY@>S9_"OS:LOC)\1QK5CJ.J>)M2N(;:XBE>+[3($=4<,5*!@I! Q@C%?I[\5
MA!K/P@\33QC=%-I-Q<)GT6(R*?T%?C?7H<?XFK2Q5.5.;2<=KNUTV=?%5:I"
MM!PD[-=_,]N^)7QY\=?$#5II8M0GTO20Q$%G;R-&H3/!D*D%WQU)XST %=#^
MSEK'C35/BIHVDVVM7JV6Z2:YC\]S$T42,V'0DJ0QPO3O7U+\*/V:O .G>%;#
M4?%M@NLZM?0I-*96;RHO,4,(T12 =H."QR2<XP.*]@\*_!_X?>"?$$OB7PMI
M8L+R:!K=MLCM'L9E8X1V(4Y4=,?K75EW"V8U*]/&8BKU3:N[VWMV^1OA,CQ<
MZL,16GU3>KN?)W[3GQ)^(W@WQ_%H^@:Y/I^GW%C#<)'%M7!9G1CNQNY*>M9W
M[+?C3QKXI^)US!X@UZ^U&"/39Y/*N+B22/<)(E!",Q4$;NH%1?MH0*OB[P]<
MXY>Q="?9)2?_ &:LC]C9<_$O57]-(F'YW$%<=3$5O[?5)S?+S;7=MKG-*K4_
MM3D<G;F[GUK^TNH;X)>)!Z"T/Y7<-?EOX.&?%VB#UOK;_P!&K7ZE?M*''P3\
M2G_9M?UNHJ_+7P<=OB[1&]+ZV/\ Y%6HX^_Y&-+_  K_ -*8N*?]\AZ+\V?L
M5\1;[4M+\ >(]4T>8V]]9:?=3PR  E7BB9P0&!!Z=Q7Y:2_M ?&.;[_BBY'^
MZL:_^@H*_5/QXBR^!O$4;_=?3KL'C/!A;M7XE5W^(6,K4JM+V4W%-/9M=3IX
MLQ%2$X<DFKI[,_:GX:7^H:K\//#6J:M,US>7FG6LTLC8W.TD:L2<=SFO//VC
M_%/B3P=\-VUOPM>M87B7<"&1%5CL?<",,".3CM7H_P .(?L_P\\+P#_EGI=D
MOY0(*\B_:M7=\';T_P!VZM3_ .1,?UK[/,ISCEDY)OF4-^NW<^BQDI+!2:>O
M+^A\5^&?CC\7-3\4:/97'B:Y>.XO+>-EP@#!Y%!! 7H<U^DWQ4U6^T/X<>(]
M7TR9K:[M+&:2*1?O(X7Y2/<&OR+^'Z[_ ![X;0_Q:G9C\YDK]I[ZQLM3LYM.
MU*!+JUN$*2Q2J'1T;@JRG((/O7RG M:OB,/B%.;;>B;;=M&>'PQ4J5:-52DV
M^EWY,_(;_A?/Q@_Z&F[_ #7_ .)H_P"%\_&#_H:;O\U_^)K]3[?X;?#NT_X]
MO"VEQ8_NV4 /_H%?%O[4OC+PEIJK\-_">FV4-UE)=0G@@C1HP,,D(95R&)PS
MXZ# [D#R\VR'&8.@Z]7%O397EJ^VYQ8_*\1AZ3JU,0_O>K^\\"_X7S\8/^AI
MN_S7_P")K]4?AS>:CJ/@#PWJ.KS&XO;O3K6::1L!F>2)6).,#/-?F/\  KX/
M7?Q4\1[KU6AT#3F5KR4<%SU$*'^\W<_PKSUP#^G/BW6+3P%X$U/5[2)8X=%L
M7:"(#Y1Y28B0#TS@5ZO WUE4ZF+Q,VX6TNV]MV=O#/MN2>(K2?+TN^V[/ _C
MK^T=!X N)/"?A!8[S7@!YTK_ #0VN>@(_BDQSCHO&<]*^!-6\7?$#Q_J.S4]
M2OM9N9B2L(9W'N$B3Y5'LJ@5R5]>W>I7MQJ-_*T]S=2-++(QRSNYW,Q]R3FO
MUA_9_P#AKIW@'P'87+0)_;&K0I<7<V,O^\&Y(L]0J*0,#@MD]Z\+#SQ>>XJ4
M7-QIK6W1+IIU;[O_ (!YE*5?,Z[BY<L%_7WGY:QW/BOP=?A8Y;W1+V/D &2V
ME7/?^%A7U]\%?VH]334+;PQ\3)Q<6MPPCBU%@%>)CP!-@ ,AZ;^HZMD<CZM^
M+_PUTWXF>#KS29H$.I0QO)8S$ -'.!E1N[*Y&UATQSU K\=71HW:-QM9200>
MH(K#,,/B\CQ$71J7B_N=MTT98NC7RRM%TYWB_N?DT?N]7Y-?M.*%^-OB$C^(
M69_\E(J^_P#]G[Q-<^*_A-H5_>N9+FW1[61FY+&W8HI)[DH%)/K7P%^TZ<_&
MSQ /1;/_ -)8J^GXZQ,:V64JT=I2B_OBSV^)JRJ8*G46S:?X,^EOV+Q_Q2/B
M$^M\G_HH5]2>,_&&B^!/#EYXGU^4QVEHN<+@O(YX5$!QEF/ _,X )KY;_8O/
M_%(^(5]+Y#_Y"%>=?MC^+[B\\3:7X*@D_P!%T^ 74JCO/,2JY_W4''^^:Z,%
MFWU+(Z==;VLO5M_\.:X?'_5LLC46]M/6[/)OB%^T+\1/'=Y*(;^31M,)(CM+
M-VC&P_\ /1UPTAQUR=OHHKSJ?P_X_AL_^$@N=-U..TQN^UO#,(]O7/F$8Q[Y
MKU#]G.T\!CQN^N>/[^UM+32HO-MX[MU5);ACA3AOO!!EO8[37Z&2_&OX1;62
M7Q3I[*P((\T,"#VXS7R>691_:--XG&8KE;>EVOU:LO(\'!X#ZW!UL16LWMK_
M ,$_.;X<_M _$#P%J$/G:A-K&E @2V=U(9!L_P"F;MEHR.V/ESU!K]4_#FOZ
M9XJT*Q\1:-)YMEJ$2RQ-T.&[$=B#P1V((K\?OBU#X5A^(FM?\(5/'<:++*LM
MNT/^K'FHKNJ\# 5RR@=@,5]X?L?ZI<7OPONK&=B5T_49HXO9'2.3'_?3,?QK
MUN"<UK0Q4\!5GS15[.]]5V?9GH<-XZI&O+"SE=:V^7;R/JNBBBOU4^X"BBB@
M HHHH **** "BBB@ HHHH _+3XW?\E5\1_\ 7P/_ $6M?1_[)'_(&\1?]?$'
M_H#5\X?&[_DJOB/_ *^!_P"BUKZ/_9(_Y WB+_KX@_\ 0&K\*X:_Y*&7^*I^
MI^99/_R-I>LOU/KRBBBOW4_30HHHH **** /E7]H;]F'0?C)%_PD6C/'I/BV
MW0*ER0?*ND4?+'< <\=%D +*."&& /S UGPAXN^'.LMX?\9Z;+IMVF2H<921
M0<;HW&5=?=21^-?O36%XA\,^'O%FG/I'B;3H-3LWY,<Z!P#ZKGE6'8C!'8U\
MGGW"E+%WG!\L_P 'Z_YG@YID4,1[T=)?F?BE87891S701R@BOO7Q!^Q[\/+^
M5[CPW>W>ALQR(PPN(%^BR?/_ .1*X23]CO687(M?%$$J=B]LR'\A(W\Z_+\9
MP)F,)>[#F7DU^MF?$XCA?%Q?NQOZ-'R8&IVX5]9K^R)X@'_,Q6W_ 'Y?_P"*
MIX_9&U\?\S%;?]^7_P :X5P7F?\ SY?WK_,YGPYC?^??XK_,^2<BESFOK;_A
MD?7_ /H8K;_OP_\ C2_\,CZ]_P!##;?]^7_QI_ZF9G_SY?WK_,2X;QO_ #[_
M !7^9\D45];_ /#(^O?]##;?]^7_ ,:/^&1]>_Z&&V_[\O\ XTEP7F?_ #Y?
MWK_,?^KF-_Y]_BO\SY(HKZW_ .&1]>_Z&&V_[\O_ (T?\,CZ]_T,-M_WY?\
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MIF9_\^7]Z_S'_JYC?^??XH^3,BC(KZS_ .&2M?\ ^AAMO^_+_P"-'_#)6O\
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M_%?YA_J_C/\ GW^*/E3(HR*^J_\ AE/7?^@_;?\ ?E_\:/\ AE/7?^@_;?\
M?E_\:/\ 5#,?^?7XK_,/]7\9_P ^_P 4?*F11G-?5?\ PRGKG_0?M_\ OR_^
M-'_#*>N?]!^W_P"_+_XT?ZH9C_SZ_%?YA_J_C/\ GW^*/E6BOJO_ (93US_H
M/VW_ 'Y?_&C_ (93US_H/VW_ 'Y?_&C_ %1S'_GT_O7^8_\ 5_%_\^_Q1\J4
M5]5_\,IZY_T'[;_OR_\ C1_PRGKG_0?MO^_+_P"-4N$<Q_Y]?BO\P_U?Q?\
MS[_%'RI3P17U1_PRGKG_ $'[;_OR_P#C1_PRIKO_ $'[;_OR_P#C1_JEF/\
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M]Z_S%_8&+_D_%'RWD4M?4?\ PRMKG_0>M_\ OR_^-._X98US_H/6_P#WY?\
MQH_U2S#_ )]?BO\ ,:R'%_R?BCY:HKZE_P"&6=<_Z#UO_P!^7_QH_P"&6=<_
MZ#UO_P!^7_QJO]5,P_Y]?BO\Q_V%B_Y/R_S/EJBOJ7_AEG7/^@];_P#?E_\
M&C_AEG7/^@];_P#?E_\ &C_53,/^?7XK_,/["Q?\GY?YGRV.M.R*^HO^&6=<
M_P"@];_]^7_QH_X99US_ *#UO_WY?_&C_53,/^?7XK_,%D6*_D_+_,^7<BC(
MKZB_X99US_H/6_\ WY?_ !H_X99US_H/6_\ WY?_ !H_U4S#_GU^*_S'_8.*
M_D_(^7<BC(KZB_X99US_ *#UO_WY?_&C_AEG7/\ H/6__?E_\:?^J>/_ .?3
M^]?YA_8.*_D_(^7<BC(KZB_X99US_H/6_P#WY?\ QH_X99UO_H/6_P#WY?\
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MO\P_L3%?R?E_F?+^11D5]0?\,O:W_P!!VW_[]/\ XT?\,O:W_P!!VW_[]/\
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MF']AXK^3\O\ ,^7F(IN17U$?V6];/_,>M_\ OR_^-)_PRUK?_0>M_P#OR_\
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M_?E_\:/^&5M<_P"@];_]^7_QI?ZI9A_SZ_%?YC_L+%_R?E_F?*^11D5]3_\
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M %/S+_GU^*_S$^'\9_S[_%'RC29%?5__  RAKO\ T'[;_OR_^-'_  RAKO\
MT,%M_P!^7_QH_P!3\R_Y]?BO\Q?ZO8S_ )]_BCY0R*,BOJ__ (90UW_H8+;_
M +\O_C1_PRAKO_0P6W_?E_\ &C_4_,O^?7XK_,/]7L9_S[_%'RAD49%?5_\
MPRAKO_0P6W_?E_\ &D_X9/U[_H8+;_OR_P#C2?!V9?\ /K\5_F+_ %?QG_/O
M\4?*.11D5]7?\,GZ]_T,%M_WY?\ QH_X9/U[_H8+;_OR_P#C4_ZG9E_SY?WK
M_,7^K^,_Y]_BCY1R*:>M?6'_  R?KW_0P6W_ 'Y?_&D_X9.UW_H8+;_OR_\
MC1_J=F7_ #Y_%?YA_J_C/^??XH^3Z*^L/^&3M=_Z&"V_[\O_ (T?\,G:[_T,
M%M_WY?\ QH_U.S+_ )]?BO\ ,3X=QG_/O\4?)]&<5]8?\,G:[_T,%M_WY?\
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MVB@#YR^P7_\ S[R?]\&C[!?_ //O)_WP:^C:* /G+[!?_P#/O)_WP:/L%_\
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MTC^9^<\2/_;H_(_;FBBBOVD_1C\G_P!J#;_PNO7<==EIGZ_9HZ^C_P!BX_\
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M9Y[6_P"?C^]F/]J5/YW]Y]"_\-X?M*_]!>S_ / "#_"C_AO#]I;_ *"]G_X
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MM'_"/'^[3_MNM_S\?WL?]I5/YW]Y[]_PW9^TE_T%[/\ \ 8/\*/^&Z_VD_\
MH+V?_@#!_P#$UX#_ ,(\?[M.'AUC_#3_ +;K?\_']X?VE4_G?WGOO_#=?[2?
M_07L_P#P!@_^)H_X;K_:3_Z"]G_X P?_ !->!_\ ".-_=H_X1QO[M+^W*W_/
MQ_>/^TJG\[^\]\_X;K_:3_Z"]G_X P?_ !-'_#=?[2?_ $%[/_P!@_\ B:\#
M_P"$<;^[1_PCC?W:?]MUO^?C^]A_:53^=_>>^?\ #=?[2?\ T&+/_P  (?\
MXFC_ (;K_:3_ .@Q9_\ @!#_ /$UX'_PCC?W:/\ A'&_NT+.JW_/Q_>/^TJG
M\S^\]\_X;K_:3_Z#%G_X 0__ !-'_#=?[2?_ $&+/_P A_\ B:\#_P"$<;^[
M1_PCC?W:?]M5O^?C^\/[2J?S/[SWW_ANO]I+_H,6?_@!!_\ $T?\-U_M)?\
M08L__ "#_P")KP;_ (1QO[M'_".-_=I_VU6_Y^/[V']I5/YW]Y[S_P -U_M)
M?]!BS_\  "#_ .)H_P"&Z_VDO^@Q9_\ @!!_\37@W_".-_=H_P"$<;^[1_;5
M7_GX_O8?VE4_G?WGO/\ PW5^TE_T%[/_ , 8/_B:7_ANK]I+_H+V?_@#!_A7
M@O\ PCC?W:/^$<;^[1_;57_GX_O#^TJG\S^\]Z_X;J_:2_Z"]G_X P?X4?\
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MW?TH_MJM_P _']X_[1G_ #/[SWG_ (;J_:1_Z"]G_P" $/\ A2_\-T_M(_\
M07L__ &#_P")KP7_ (1P_P!W]*7_ (1QO[M/^VJO_/Q_>+^T:G\S^\]Y_P"&
MZ?VD?^@O9_\ @#!_\31_PW3^TC_T%[/_ , 8/_B:\&_X1QO[M'_".-_=H_MJ
MK_S\?WC_ +1G_,_O/>?^&Z?VD?\ H+V?_@#!_P#$T?\ #='[2/\ T%[/_P
M8/\ XFO!O^$<;^[2CPZV/N_I1_;57_GX_O8?VC4_F?WGO/\ PW1^TC_T%[/_
M , 8?_B:/^&Z/VD?^@O9_P#@##_\37A'_".-Z4?\(XWI3_MFK_._O8?VC4_F
M9[O_ ,-T?M(_]!>S_P# &'_XF@?MT?M(_P#07L__  !@_P#B:\(_X1QO2E_X
M1QO[M']LU?YW][#^T:G\S/=_^&Y_VD?^@O9_^ ,'^%'_  W/^TC_ -!>S_\
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M^E/^UZO\[^\/K\_YF>Z?\-R_M(?]!:T_\ (?\*3_ (;E_:0_Z"UG_P" ,/\
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MG_X P?X5X-_PCC?W*3_A'3_=I?VU5_Y^/[V)YE4_F9[U_P -U?M)?]!>S_\
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MO^&[OVE/^@Q9_P#@!!_A1_PW=^TI_P!!BS_\ (/\*^?_ /A'S_=H_P"$?/\
M=H_MRM_S\?WL7]IU/YW]Y] ?\-W?M*?]!BS_ / "#_"C_AN[]I3_ *#%G_X
M0?X5\_\ _"/G^[1_PCY_NTO[<K?\_'][#^TZG\[^\]_/[=W[2O\ T&+/_P
M(/\ "C_AN[]I7_H+V?\ X 0?X5X!_P (^?[M)_PCQ_NT?VY6_P"?C^]A_:=3
M^=_>?0'_  W=^TK_ -!>S_\  "#_  H_X;N_:5_Z"]G_ . $'^%?/_\ PCQ_
MNT?\(\?[M)Y]6_Y^/[V']IU/YW]Y] ?\-W?M*_\ 07L__ "#_"C_ (;N_:5_
MZ"]G_P" $'^%?/\ _P (\W]VD_X1YO[M']O5O^?C^]B_M.K_ #O[SZ _X;O_
M &E/^@Q9_P#@!!_A1_PW?^TI_P!!BS_\ (/\*^?_ /A'F_NT?\(\W]VE_;U;
M_GX_O#^TZO\ ._O/H#_AN_\ :4_Z#%G_ . $'^%)_P -W_M*_P#08L__   @
M_P#B:\ _X1YO[M'_  CS_P!VC^WJW_/Q_>+^U*O\[^\]_P#^&[_VE?\ H,6?
M_@!!_P#$T?\ #=_[2O\ T&+/_P  (/\ XFO /^$>?^[1_P (\_\ =H_MZM_S
M\?WA_:E3^=_>>_\ _#=_[2O_ $&+/_P @_\ B:3_ (;P_:6_Z"]G_P" $'_Q
M-> 'P^W]VF?\(\W]VE_;U;_GX_O8?VI4_G?WGT%_PWA^TM_T%[/_ , (/_B:
M/^&\/VEO^@O9_P#@!!_\37S[_P (\W]VC_A'F_NT//JW_/Q_>P_M2I_._O/H
M'_AO#]I;_H+V?_@!!_\ $T?\-X?M+?\ 08L__ "#_P")KY^_X1]O[OZ4?\(^
MW]W]*7]O5O\ GX_O8?VI4_G?WGT#_P -X?M+?]!BS_\  "#_ .)H_P"&\/VE
MO^@Q9_\ @!!_\37S]_PC[?W?TH_X1]O[OZ4?V]6_Y^/[V']JU/YW]Y]")^WE
M^TJC!FU6R<#LUA#C] #7I7A;_@H]\5M.EC3Q=X<TO6;=?O&W\VSG;_@9:5/R
MCKXP_P"$?;^[^E-/A]O[M7#B&O%W51_??\QQS>JM5-G[5_#']MKX-?$=H=.G
MEN/#VKRX46M\JA7<]HIE;8W/ !VL>RU](?\ "=:%ZR_]\?\ UZ_F\?06'1:^
MNO@1^T-K'A"XMO"/CZX>\T-RL<-U(2TMGV 9NK1#T/*CIP,5]+E7%L9R5/$:
M>?\ F>S@<_4GRU?O_P S]B?^$ZT+UE_[X_\ KT?\)UH7K+_WQ_\ 7KQ6*6.:
M-)H7$D<@#*RG(8'D$$=0:?7VQ]*>S_\ "=:%ZR_]\?\ UZ/^$ZT+UE_[X_\
MKUXQ10![/_PG6A>LO_?'_P!>C_A.M"]9?^^/_KUXQ10![/\ \)UH7K+_ -\?
M_7H_X3K0O67_ +X_^O7C%% 'L_\ PG6A>LO_ 'Q_]>C_ (3K0O67_OC_ .O7
MC%% 'L__  G6A>LO_?'_ ->C_A.M"]9?^^/_ *]>,44 >S_\)UH7K+_WQ_\
M7H_X3K0O67_OC_Z]>,44 >S_ /"=:%ZR_P#?'_UZ/^$ZT+UE_P"^/_KUXQ10
M![/_ ,)UH7K+_P!\?_7H_P"$ZT+UE_[X_P#KUXQ10![/_P )UH7K+_WQ_P#7
MH_X3K0O67_OC_P"O7C%% 'L__"=:%ZR_]\?_ %Z/^$ZT+UE_[X_^O7C%% 'L
M_P#PG6A>LO\ WQ_]>C_A.M"]9?\ OC_Z]>,44 >S_P#"=:%ZR_\ ?'_UZ/\
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M9?\ OC_Z]>,44 >S_P#"=:%ZR_\ ?'_UZ/\ A.M"]9?^^/\ Z]>,44 >S_\
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MH)"BBB@ /2HZD/2HZ2 *4=:2E'6FP'T445F C=*93VZ4RDR9!1114$A1110
M4444 %%%% !1110 P]:<O2FGK3EZ5F0Q:***&(****S *8>M/IAZU<@$KO\
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MN_Y*KXC_ .O@?^BUKZ/_ &2/^0-XB_Z^(/\ T!J_"N&O^2AE_BJ?J?F63_\
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M9R!&"<_@:^"Q:KZ5AG>%E@ZD(<_-S14NV_0RS*@\/*,>:]TG]YYY_P (^O\
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M:O(\GJXR,JLI*%..\F5EF75,0G4<N6*ZL_(RY\$ZG9Q">[L)H(ST:2)E7\R
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MM?\ R.3+,)/$5'3O:Q^37_"/K_=H_P"$?7^[7Z._M6Z?"=)\/3QQJNV>=3@
M?>53V^E?%7V5?2L,YP\L)B)4'*]K:[;JYEF%*6'JNE>]CS?_ (1]?[M+_P (
M^/[M?JI\#/#VG>"_A8FM:RJ0B^\S4)GD .R(@!/PV*&'UJ;]H?PE#K?PZN+R
MUA43Z3*ET-H )091QQV"MN/^[7O_ .K%7ZI]9]IKR\W+;I]_Z'J_V+/V'MN;
M6U[6_P""?E+_ ,(^/[M'_"/K_=_2O2?LJ^E'V5?2OCEBF?.^V9P6G^#[O5;V
M#3=-MFN;JY<)'&BY9F;@ "O>_'O[,T_P]^'MMXHU?48WU:2YCCDM4P(TCD4\
M*QY=P0,X&,9QD#)^C_V8O -I;VMU\0-0C_>LSV]H6Z(BC][(/J?ESV 8=Z\&
M^+?CBY^(7BNXO?,8Z;:,T5E'T41 _?Q_>?&X]^@Z 5]-+#T\/@5B*^LY_"NR
M[_UW7R]KV,*6&]K5UE+9=O,^9?\ A'U[BG+X=#$*JY)[ 5]B?!?X*IX]G?6]
M=WQ:):OMVJ=K7$@Y* ]0H_B(Y[#G)'UMJ/B3X5?".*/3&^S:5(R96"WA+3,H
M[OL!//JYY]35Y9D52M1^L5JBIP[O^E^96#RN=2G[:I-1CW9^1,OA>2#'GPM'
MGIN4C/YU%_PCR?W:_534?CU\--5T34(8KQEN/L\IBBGMWP\@0[0"%9<D^I%?
M$7P_@CC\=^')",A=2LR0>X\Y:Y<QPE*C4IPHUE-2[=/Q?Z&&+P\*<XQIU.:_
MX?B>$?\ "/+_ ':/^$>7^[7[/>-/%>A> -%_M_5;622 2+%BW1&?<^<<,RC'
M'K7*>#OBGX$^)MS+HMO;.MP$+^1>1)B1!UVX+J<9Y!P?;%>]4X8IQJJA+$I3
M>RM_P3U)Y+",U2=;WGTM_P $_(S_ (1Y?[M+_P (\OI^E?</[1?PX\/>%[[3
M=<\/VR64>I&5)H(QMC#Q[2&1>BY#8('' XY-==^RGI<0A\27DL:L&:UC7(!^
MZ)2>OU%>+1RBJ\=]1G*S[[]+^1YU/ 5'BOJTG9]_E<_/'_A'U_NT?\(^O]VO
MUQ^-GAV'7/AEK,=K$OF6T:W2%0.D+!VZ?[ :OS@LM)EU"\@L+5-\]S(L4:^K
MN0H'YFL\\RZ>"K1I<W-=7O:WRZBS/"2PU10O>YY;_P (^OH*7_A'U]!7[;:1
MHMAI&E6.D11HRV<$<*DJ,E8E"Y_2O@+]H>PCC^*%\RJ%$D-NP &!_JPO]*]+
M.L@G@Z"K.=]4K6_X+.G,<JEAZ2J.=_E_P3&O_P!DG4Y? 6F^*O#=ZNHZA-:K
M<7%F "&WC<! Z\,54@$'J0<'H*^8G\-^4[1R(4="001@@CJ"*^YOV=OB+>:/
MK47@?4YB^FWY(M@QSY,YY 4]E?D8_O8(ZG-;]I+P#:Z-XBM_%6G0B.WUG<)P
MHX%RO);VWJ<_4,>]9XS#4JN#6,PNEM)+]0Q%&G/#K$4-+:-'Q!_PCZ>E'_"/
MIZ5Z5]E7TH^RKZ5\S]:9XGMV>;#P^G]W]*7_ (1]/[H_*O2?LJ^E'V5?2A8I
MA[=GFW_"/I_='Y4?\(^G]T?E7I/V5?2C[*OI3^LL/;L\W7P^O]W]*=_PCZ_W
M/TKTA;5?2G?95]*'B6'MV>:_\(^O]S]*7_A'T_NC\J])^RKZ4?95]*%BF'MV
M>;?\(\G]T?E2_P#"/)Z#\J](^RIZ4OV5/2G]:92K,\V_X1Y?2C_A'U]*]*^R
M)2_9$I_6F/VS/-/^$?7TI?\ A'E_NUZ5]D2E^R+3^M,/;,\T_P"$>7^[1_PC
MR_W:]+^R+1]D6G]9D/VS/-/^$>7^[2?\(^OI7IGV1:3[(E+ZTQ>V9YI_PCZ^
ME'_"/+Z5Z7]D2D^R)2^M,/;,\U_X1Y/0?E2?\(\G]T?E7I7V5/2D^RIZ4OK3
M$ZS/-O\ A'T_NC\J3_A'U_N?I7I7V5?2C[*OI2>*9/MV>:_\(^O]S]*:WA]?
M[OZ5Z9]E7TIK6J^E"Q+#V[/-/^$?3^Z/RH_X1]/[H_*O2?LJ^E'V5?2CZRP]
MNSS;_A'T_NC\J0^'T_NUZ5]E7TH^RKZ4GBF'MV>:?\(^GI1_PCZ>E>E?95]*
M/LJ^E'UIA[=GFO\ PCZ>E)_PCZ>E>E&U3TH^RIZ5+Q3%[=GFO_"/KZ"D_P"$
M?7^Z*]+^RIZ4AM4]*'BF+VS/-?\ A'U_NT?\(^O]VO2?LJ^E'V5?2I^M,?MV
M>:?\(\G]W]*/^$>7^[7I?V5?2C[*OI0\4R?;L\T_X1Y?[M'_  CR_P!VO2_L
MJ^E'V5?2E]:8>W9YI_PCZ>E'_"/IZ5Z3]E3TH^RIZ4?6I"]NSS;_ (1]/2D_
MX1]?05Z5]E3TH^RIZ5+Q3#V[/,SX?7^[1_PCZ_W?TKTDVJYZ4GV5?2FL5(7M
MV>;?\(^/[M'_  CX_NUZ3]E7TH^RKZ5+Q3#VS/-O^$?7NM)_PCZ_W:])-JOI
M2?95]*7UIA[=GF__  CZ_P!VC_A'U_NUZ1]E7TH^RKZ4?6F'MV>;'P^O]VD_
MX1]/[M>DFU7TI/LJ^E3]:8G79YO_ ,(^G]VC_A'U_NUZ1]E7TH^RKZ4?6F+V
M[/-O^$?7^[^E'_"/I_=KTG[*OI3?LJ^E)8MB==GG'_"/I_=H_P"$?3^[7H_V
M5?2C[*OI0\6P]NSSC_A'T_NTW_A'T_N5Z3]E7TI/LJ^E+ZU(3KL\W_X1]/[E
M'_"/I_<KT?[*OI1]E7TJ?KDB?;L\X_X1]/[E,/A]<_=KTK[*OI3#:KGI1]<D
M'MV><?\ "/K_ ':/^$?7^[7HWV5?2C[*OI1]<D'MV><?\(^O]VD_X1\?W:](
M^RKZ4AM%]*GZTP]NSSC_ (1\?W:/^$?']VO1_LB^E)]D7TH^ML/;L\Y_X1\?
MW:/[ ']VO1OLJ^E'V5?2E];8O;L\X_L ?W:/^$?7^Z*]&^R+1]D2AXMB]NSS
MG_A'U_NBD/A]?[M>C_9$I#:)Z9I?7)![=GG']@+_ '*/[ 7^Y7HWV1?[M'V1
M?[M'UR0O;L\Y_L!?[E']@+_=KT;[(O\ =I/LJ^E3+&2%[=GG/]@+Z4?V OI7
MHWV5?2C[*OI2^ML7MV><_P!@+Z4?V OI7HOV5?2C[*OI2^N2#V[/-O[ 7^[1
M_8"^E>C?95]*3[*OI1]<8_;L\Z_L!?2C^P%]*]%^RKZ4?95]*/KD@]NSSDZ"
M/[M)_8(_NUZ,;5?2C[*OI2^N,GZPSSG^P1_=H_L$?W:]&^RKZ4GV5?2AXQA]
M89YS_8"_W?TH_L!?[OZ5Z+]D7TH^RKZ5'UR0GB&>=?V O]W]*/[ 7^[^E>B_
M95]*/LBT?7)"^L,\Y.@#^[2?V /2O1OLBT?95]*/KDA/$,\Y_L$?W:/[!']V
MO1?LJ^E'V5?2E]=8?6)'G/\ 8 _NT?\ "/K_ ':]&^RKZ4GV5?2D\8Q?6&>=
M?\(^O]VC_A'U_NUZ+]E7TH^RKZ4OKC#ZP><G0%'\--_L$?W:]'-JOI3/LJ^E
M+ZY(/K#/._[!']VD_L$?W:]%^RKZ4GV5?2G]<D/ZPSSO^P1_=IO]@K_=KT;[
M*OI2?95]*7UR1+Q#/.O[!7^[1_8*_P!T5Z+]E7TH^RKZ5+QC%[=GG/\ 8*_W
M133H*_W:](^RKZ4TVJ^E'UQB>(9YC)H"\_+6+=^'Q@_+7LC6BGM5">P5ATK2
M&.=RXXIGO?[,GCVYN]/F^'VLREYM.3S+)F/)MP<-'S_<)!7_ &3CHM?6=?FM
MX3O'\*^+]*\01'8+6=3)[Q/\L@_%"17Z4U^W<$YN\3A7"3UAI\NGZKY'Z7PU
MCW6H<LMX_ET"BBBOLCZ(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;?\ $\S'8*NJ/M55YX)]&]'Z%:;XZ?%B?[_B&49_NQ0I_P"@QBO;OV?O%'Q
M\8^*+O4-?UJXN-)TN!FE60@1M))P@/ Z ,WM@5\=Q123RI!"A>20A551DDG@
M #U-?9WBE(O@G\$XO"\3!=>\1;EG*GD&11YQ!]$3$8([D'UK?AS&XF=66*KU
M9.G35W=O5]%OU9ID^)K2FZ]6;<8*[U>O9?-GRUX]U]?%7C/6/$"$F.\N7://
M7R@=L?\ XX!7([12T5\C6K2J3=26[=_O/GZE5RDY/=GV3J?/[)]H/^N8_P#)
MTU\:@8K[)U/_ )-/L_JG_I::^-Z^FXK^+#_]>H?J>UGKUH_X(_J?2_[+NBV]
M_P".;O59U#'3+1FCR/NR2L$S_P!\[A^-=Y^U7XBO(H-&\+0.4M[G?<S@?QE"
M%C!]@2QQZX/:O//V8=>MM+\>7&E73!!JUJT<9/>6-@X'XJ&_&O;?VD_ 6H^)
M="LO$6CQ-<7.CEQ+$@W,T$F"6 ')V%<X'8D]J^ER^G*?#U2.'^*[O;?=7_\
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MLT4*V C5HW48]/P_4^AO!I_XL_I1]-'3](*_,7:*_3?PJPB^#6G.> NB(?\
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MZ2 *4=:2E'6FP'T445F C=*93VZ4RDR9!1114$A1110 4444 %%%% !1110
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MP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0=*CJ0=*8QZ]*<.M-7I3AUH ?3EZTVG+UIHI#J<O6FTY>M4BD/'6GTP=:?3
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M&N85![$JA)'X9'YU^%\-I_ZPS_Q5/U/S/)U_PK2]9?J?7-%%%?NA^F!1110
M5%/!%<PO;SJ'CD!# ]P:EHH ^#OC[^R[IGBJYD\2:(PL-5(XN O[J8#HMP%&
M=PZ"0<XX(/ 'PEJ?A+Q9X&N_L7B;3Y+7G"2XW0R8_N2#Y3],Y'<"OW<95=2C
M@,K#!!Y!%<%K?P^TC58Y$A"QK*,-$ZAXF]BI_P#U>U?*9WPE0QEYQ?++OT?J
MCPLSR&EB/>6DC\>+*[5U'-;<<H(K[ZU?]F_PU<2-*-"@W'^*UD: ?]\JR#]*
MY_\ X9NT-#\NEW(^DQ/]:_/J_AOC.;W)1:]7_D?)U>#\3?W9+\?\CXL#>]/W
M"OM,?LYZ,/\ F%W/_?X_XT[_ (9UT<?\PNY_[_'_ !K!^'&/[Q^]_P"1E_J?
MBN\?O?\ D?%611D5]J_\,[:/_P! NY_[_'_&C_AG;1_^@7<_]_C_ (T+PXQ_
M>/WO_(/]3\7W7WO_ "/BK(IRD5]I_P##.VC_ /0+N?\ O\?\:/\ AG?2!_S#
M+G_O\?\ &G_Q#G']X_>_\@_U/Q7=?>_\CXNR*,BOM+_AGC2/^@9<_P#?X_XT
M?\,\:1_T#+G_ +_'_&C_ (ASC^\?O?\ D'^I^+[K[W_D?%N12AAFOM'_ (9X
MTC_H&7/_ '^/^-'_  SQI'_0,N?^_P ?\:/^(<X_O'[W_D'^I^*[K[W_ )'Q
MANHW5]G_ /#/&D?] RY_[_'_ !H_X9XTC_H&7/\ W^/^-'_$.<?WC][_ ,A_
MZH8KNOO?^1\8;J-U?9__  SQI'_0,N?^_P ?\:7_ (9XTC_H%W/_ '^/^-4O
M#K']X_>_\@_U0Q7=?>_\CXPR*,BOM#_AGG2?^@9<_P#?X_XT?\,\Z3_T#+G_
M +_'_&E_Q#G']X_>_P#(K_5'%=U]_P#P#XOR*,BOM#_AGG2?^@9<_P#?X_XT
M?\,\Z3_T#+G_ +_'_&J_XAWC^\?O?^0?ZHXKNOO_ . ?&(;BEW5]F_\ #/.D
M_P#0,N?^_P ?\:/^&>=)_P"@9<_]_C_C1_Q#O']X_>_\@_U1Q7=?>_\ (^,M
MU&ZOLW_AGG2?^@9<_P#?X_XT?\,\Z3_T"[G_ +_'_&C_ (AWC^\?O?\ D'^J
M.*[K[_\ @'QENHW5]F_\,\Z3_P! NY_[^G_&E_X9ZTG_ *!=S_W]/^-5_P 0
M\Q_>/WO_ "#_ %1Q7=?>_P#(^79O'GBZ?PZOA*74Y6T=0JBVX"85MX'3/##-
M<INK[-_X9ZTG_H%W/_?T_P"-'_#/6D_] RY_[^G_ !K6KP%F4[.<XNVFK>W;
M8TGPKC)6YI)_-GQD"*?NK[*_X9ZTK_H&7/\ W]/^-+_PSWI7_0+N?^_I_P :
MR_XAYC^\?O?^1'^J.*[K[W_D?&FZER*^RO\ AGO2O^@9<_\ ?T_XT?\ #/FE
M_P#0,N?^_I_QH_XAYC^\?O?^0?ZHXKNOO?\ D?&N10"*^RO^&?-+_P"@9<_]
M_3_C1_PSYI?_ $#+G_OZ?\:?_$/,=WC][_R&N$<5W7WO_(^.-U&ZOL?_ (9\
MTO\ Z!ES_P!_3_C1_P ,^:7_ - RY_[^G_&C_B'F.[Q^]_Y#_P!4L5W7WO\
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M^%!Z?_T#;C_OZ?\ &C_A0>G_ /0-N/\ OZ?\:/\ 4/&]X_>_\A?ZK8CNOO\
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M0FG_ /0,N/\ OZ?\:/\ A0FG_P#0,N/^_I_QJO\ 43&=X_>_\@_U8Q'E]_\
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M/^@;<?\ ?VC_ (4+8?\ 0-N/^_M'^HN-[Q^]_P"0?ZLXGNOO/DC=2;Q7UO\
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MC_A0EA_T#;G_ +^__7H_U$QO>/WO_(/]5\3W7W_\ ^1-XHWBOKK_ (4'I_\
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M]_\ P#XXW4S(K[*_X9[TO_H&7/\ W^-'_#/>E_\ 0,N?^_QI?\0\Q_>/WO\
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MYQ_>/WO_ "#_ %/Q7=?>_P#(^*LBC(K[5_X9VT?_ *!=S_W^/^-'_#.VC_\
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MG_2OL3Z$P:*WO^$8U_\ Y\G_ $H_X1C7_P#GR?\ 2@#!HK>_X1C7_P#GR?\
M2C_A&-?_ .?)_P!* ,&BM[_A&-?_ .?)_P!*/^$8U_\ Y\G_ $H P:*WO^$8
MU_\ Y\G_ $H_X1C7_P#GR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A&-?_ .?)_P!*
M ,&BM[_A&-?_ .?)_P!*/^$8U_\ Y\G_ $H P:*WO^$8U_\ Y\G_ $H_X1C7
M_P#GR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A&-?_ .?)_P!* ,&BM[_A&-?_ .?)
M_P!*/^$8U_\ Y\G_ $H P:*WO^$8U_\ Y\G_ $H_X1C7_P#GR?\ 2@#!HK>_
MX1C7_P#GR?\ 2C_A&-?_ .?)_P!* ,&BM[_A&-?_ .?)_P!*/^$8U_\ Y\G_
M $H P:*WO^$8U_\ Y\G_ $H_X1C7_P#GR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A
M&-?_ .?)_P!* ,&BM[_A&-?_ .?)_P!*/^$8U_\ Y\G_ $H P:*WO^$8U_\
MY\G_ $H_X1C7_P#GR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A&-?_ .?)_P!* ,&B
MM[_A&-?_ .?)_P!*/^$8U_\ Y\G_ $H P:*WO^$8U_\ Y\G_ $H_X1C7_P#G
MR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A&-?_ .?)_P!* ,&BM[_A&-?_ .?)_P!*
M/^$8U_\ Y\G_ $H P:*WO^$8U_\ Y\G_ $H_X1C7_P#GR?\ 2@#!HK>_X1C7
M_P#GR?\ 2C_A&-?_ .?)_P!* ,&BM[_A&-?_ .?)_P!*/^$8U_\ Y\G_ $H
MP:*WO^$8U_\ Y\G_ $H_X1C7_P#GR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A&-?_
M .?)_P!* ,&BM[_A&-?_ .?)_P!*/^$8U_\ Y\G_ $H P:*WO^$8U_\ Y\G_
M $H_X1C7_P#GR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A&-?_ .?)_P!* ,&BM[_A
M&-?_ .?)_P!*/^$8U_\ Y\G_ $H P:*WO^$8U_\ Y\G_ $H_X1C7_P#GR?\
M2@#!HK>_X1C7_P#GR?\ 2C_A&-?_ .?)_P!* ,&BM[_A&-?_ .?)_P!*/^$8
MU_\ Y\G_ $H P:*WO^$8U_\ Y\G_ $H_X1C7_P#GR?\ 2@#!HK>_X1C7_P#G
MR?\ 2C_A&-?_ .?)_P!* ,&BM[_A&-?_ .?)_P!*/^$8U_\ Y\G_ $H P:*W
MO^$8U_\ Y\G_ $H_X1C7_P#GR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A&-?_ .?)
M_P!* ,&BM[_A&-?_ .?)_P!*/^$8U_\ Y\G_ $H P:*WO^$8U_\ Y\G_ $H_
MX1C7_P#GR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A&-?_ .?)_P!* ,&BM[_A&-?_
M .?)_P!*/^$8U_\ Y\G_ $H P:*WO^$8U_\ Y\G_ $H_X1C7_P#GR?\ 2@#!
MHK>_X1C7_P#GR?\ 2C_A&-?_ .?)_P!* ,&BM[_A&-?_ .?)_P!*/^$8U_\
MY\G_ $H P:*WO^$8U_\ Y\G_ $H_X1C7_P#GR?\ 2@#!HK>_X1C7_P#GR?\
M2C_A&-?_ .?)_P!* ,&BM[_A&-?_ .?)_P!*/^$8U_\ Y\G_ $H P:*WO^$8
MU_\ Y\G_ $H_X1C7_P#GR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A&-?_ .?)_P!*
M ,&BM[_A&-?_ .?)_P!*/^$8U_\ Y\G_ $H P:*WO^$8U_\ Y\G_ $H_X1C7
M_P#GR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A&-?_ .?)_P!* ,&BM[_A&-?_ .?)
M_P!*/^$8U_\ Y\G_ $H P:*WO^$8U_\ Y\G_ $H_X1C7_P#GR?\ 2@#!HK>_
MX1C7_P#GR?\ 2C_A&-?_ .?)_P!* ,&BM[_A&-?_ .?)_P!*/^$8U_\ Y\G_
M $H P:*WO^$8U_\ Y\G_ $H_X1C7_P#GR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A
M&-?_ .?)_P!* ,&BM[_A&-?_ .?)_P!*/^$8U_\ Y\G_ $H P:*WO^$8U_\
MY\G_ $H_X1C7_P#GR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A&-?_ .?)_P!* ,&B
MM[_A&-?_ .?)_P!*/^$8U_\ Y\G_ $H P:*WO^$8U_\ Y\G_ $H_X1C7_P#G
MR?\ 2@#!HK>_X1C7_P#GR?\ 2C_A&-?_ .?)_P!* ,&BM[_A&-?_ .?)_P!*
M/^$8U_\ Y\G_ $H P:*WO^$8U_\ Y\G_ $H_X1C7_P#GR?\ 2@#!HK?7PMK[
M' LG_$@?S-:MIX%UF<C[24ME[Y;<?P"Y'ZT <77H?A;PE),Z:CJB;8EY2-AR
MQ[%AZ>W?Z=>KTCPCI>ELLSC[3..C.. ?9>@_4UU5 !1110 4444 ?__0_?B6
M*.:)X95#)("K ]"#P17EW_"C_A'_ -"K8_\ ?O\ ^O7HNKRR0Z5>S1,5>."1
ME(Z@A20:_(3_ (7A\7/^AJOO^_G_ -:O8RKA-9FI.T?=_F5]_P#ACX'C7C7"
M91*DL52<^>]K6TM;OZGZ;_\ "C_A)_T*MC_W[_\ KT?\*/\ A)_T*MC_ -^_
M_KU^98^.'Q;Q_P C5??]_/\ ZU*/C?\ %O/_ "-5]_W\_P#K5ZW_ !"Q=H?=
M_P  ^&7C)E/_ $"R^Z/^9^FG_"D/A+_T*MC_ -^Z/^%(?"7_ *%6Q_[]U^9W
M_"[_ (M?]#5??]_/_K4X?&[XM8_Y&F^_[^?_ %J7_$+5VA]W_ '_ ,1DRG_H
M%E]T?\S]+_\ A2/PF_Z%:Q_[]TO_  I+X3?]"M8_]^Z_-/\ X79\6?\ H:;[
M_OY3A\;/BQC_ )&F^_[^?_6H_P"(6KM#[O\ @%?\1BRK_H%E]T?\S]*O^%)_
M"?\ Z%:R_P"_?_UZ7_A2?PG_ .A7LO\ OW_]>OS6_P"%V?%C_H:+W_OY_P#6
MIX^-7Q7_ .AHO?\ OY2_XA>NT/N_X _^(PY5_P! LONC_F?I-_PI3X3_ /0K
MV7_?O_Z]'_"E/A1_T*]E_P!^_P#Z]?FY_P +J^*W_0T7O_?S_P"M3A\:?BM_
MT-%[_P!_/_K4?\0P7:'W?\ ?_$8,J_Z!9?='_,_2+_A2OPI_Z%>R_P"_?_UZ
M/^%*_"G_ *%>R_[]_P#UZ_. ?&GXJ_\ 0SWO_?S_ .M3O^%T?%7_ *&>]_[^
M4GX8KM#[O^ /_B+V5?\ 0++[H_YGZ/?\*6^%/_0KV7_?O_Z]'_"EOA5_T+%E
M_P!^Z_.,?&CXJ8_Y&>]_[^4\?&;XJ8_Y&>]_[^4O^(9+M#[O^ 5_Q%W*O^@:
M7W1_S/T:_P"%+_"K_H6++_OW1_PICX5_]"Q9?]^Z_.<?&;XIY_Y&:]_[^4\?
M&7XI9_Y&:]_[^4?\0R7:'W?\ :\7,K_Z!I?='_,_1;_A3/PK_P"A8LO^_='_
M  IGX6?]"S9?]^Z_.S_A<OQ2_P"AFO/^_G_UJ</C)\43_P S->?]_/\ ZU+_
M (AFNT/N_P" ->+>5_\ 0-+[H_YGZ)?\*:^%G_0LV7_?NC_A37PM_P"A9LO^
M_?\ ]>OSP'QC^*)_YF6\_P"_G_UJD'QB^*&/^1EO/^_G_P!:D_#1=H?=_P
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M?\+>^)G_ $,=Y_WW_P#6I?\ $-EVA]W_  !KQ6RS_H&?W1_S/T _X4]\,/\
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M2_\ "J?AS_T+]I_WQ_\ 7KXG_P"%H?$'_H/77_?=.'Q/^()_YCUU_P!]U/\
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MS/N'_A5/PY_Z%^T_[X_^O1_PJGX<_P#0O6G_ 'Q7PX?BG\1,_P#(?NO^^_\
MZU)_PM3XB?\ 0?NO^^__ *U'_$.8]H?=_P  7_$4,M_Z!W]T3[D_X53\.?\
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M(W_0P7?_ 'W_ /6H_P"(;Q[0^[_@"?BIEG_0,_NC_F?=7_"J?AS_ -"]:?\
M?%'_  JGX<_]"]:?]\5\*_\ "UOB-_T,%W_WW_\ 6H_X6M\1O^A@N_\ OO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\G?CK_R5OQ+_
M -? _P#1:U],_L>?\@3Q)_U\0?\ H#5\S?'7_DK?B7_KX'_HM:^F?V//^0)X
MD_Z^(/\ T!J_8L__ .1)'TA^A_)W _\ R64_\=7_ -N/LFBBBOQT_K$****
M"BBB@ HHHH **0D*,L< 56-]9*<-<1CZN/\ &@"U153^T+#_ )^8O^^U_P :
M/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/
M^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_O
MM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM
M?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153
M^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L
M/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+
M_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\
M&@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/
M[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#
M_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F
M+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?
M\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W
M153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/
M^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB
M_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM
M?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[
M0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^
MT+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+
M_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^
MU_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\:
M+=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^
M?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_
M )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?
M\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH
M_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5
M/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_
M +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8
MO^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +
M=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P
M_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L
M/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7
M_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U
M_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/
M[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?
MF+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F
M+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"
MW153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :
M/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/
M^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_O
MM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM
M?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153
M^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L
M/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+
M_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\
M&@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/
M[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#
M_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F
M+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?
M\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W
M153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/
M^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB
M_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM
M?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[
M0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^
MT+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+
M_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^
MU_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\:
M+=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^
M?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_
M )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?
M\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH
M_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5
M/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_
M +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8
MO^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +
M=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P
M_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L
M/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7
M_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U
M_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/
M[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?
MF+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F
M+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"
MW153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :
M/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/
M^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_O
MM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM
M?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153
M^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L
M/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+
M_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\
M&@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/
M[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#
M_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F
M+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?
M\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W
M153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/
M^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB
M_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM
M?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[
M0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^
MT+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+
M_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^
MU_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\:
M+=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^
M?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_
M )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?
M\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH
M_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5
M/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_
M +[7_&@"W153^T+#_GYB_P"^U_QH_M"P_P"?F+_OM?\ &@"W153^T+#_ )^8
MO^^U_P :/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_OM?\: +
M=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7_&@"W153^T+#_GYB_P"^U_QH_M"P
M_P"?F+_OM?\ &@"W153^T+#_ )^8O^^U_P :/[0L/^?F+_OM?\: +=%5/[0L
M/^?F+_OM?\:/[0L/^?F+_OM?\: +=%5/[0L/^?F+_OM?\:/[0L/^?F+_ +[7
M_&@"W1547]BQP+B,G_?'^-6596&Y3D'N* %HHHH **** "BBB@#_T_WHUS_D
M"ZA_U[R_^@&OPSK]S-<_Y NH?]>\O_H!K\,Z_3?#WX:W_;OZG\Z>/'\3">D_
M_;1XZ4X=::.E.'6OT;H?@$1]/'2F4\=*@LEIXZ4RGCI06.568X4$GVJP(I<_
M<;\J^B?V6HC)\1KIQTBTZ9OSDB7^M?H-7QF><5_4Z_L?9\VB=[V_1GZWP=X8
M?VM@EBWB.35JW+?;SYD?C@00<$8-.7I7N?[1NCOI?Q.O+K&(]3AAN%].%\IO
M_'D)_&O#%Z5]+@<4J]&%9?:29^>YSEDL%BZN$D[\C:OWL]'\UJ/6G4U:Z3PC
MHDGB3Q1I6A1C/VVYCC;'9"PWG\%R:UK5%&+E+9')AJ$JM2-."U;LO5F((I<?
M<;\J=L=0-RD?45^O]?)W[529TOP])_=FN!^:I_A7Q>5\8?6<1&A[*U^M[]+]
MD?K_ !+X4?V?@:F,^L<W+;3EM>[2WYGW['QB.M6!%+G[C?E4,;,CJZ$JRG((
MZ@BOTT^%?CN#Q]X4M]29@+^WQ#=H.,2J/O ?W7'S#\1V->QGN;3P<%45/F6S
MUM;MT9\GP5PM2S:M/#SK^SDE=>[>_?JMOZV/S1((.",&E6OJ#]I+P.UAJT/C
M>Q3_ $?4-L-SC^&91A6/LZC'U7WKY?6NO+<?'$T8UH]?P?8\KB#(ZF78RIA*
MNO*]'W71_/\ #8D6I1TJ):]C^"7@U_%OC2VEF3-CI16YG/8E3^[3_@3#IZ U
MIC<3&C2E5GLCGRK+:F,Q-/#4OBD[?\'Y;GDWE2_W&_*CIP:_3WQMXLL?!7AN
M[U^](/DKMBCS@R2M]Q!]3U]!D]J_,N]O)]0O)[^Z;?-<R-+(WJSDL3^9KR<D
MSF>,C*;I\J7G>_X(^JXSX2I93.%)5^>4M6N6UETZO?7[BN.M2#K4UA8WFI7D
M-AI\+7%S.P2.-!EF8] !7V=\//@%I&DPPZIXR07]^<-]FSF"+T##_EH1WS\O
ML>M=&:9O1PD>:J]7LNK.#AOA7%YI4Y,.M%O)[+_@^2/D/3=$UG5RPTFPN+TK
MP?(B>3'UV@UNR^ /',*"23P_?A3W^S2''UPO'XU]ZZWXZ\"^"56PU*_@LFC
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M4445\N?I 4444 %%%% !1110 4444 %%%% !1110!^3OQU_Y*WXE_P"O@?\
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MRG]*/]6*?=_A_D'_ !$3$?RQ_'_,_:__ (:=^ W_ $.%K_WQ-_\ $4?\-._
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M0_LI_2C^RG]*/]6*?=_A_D'_ !$3$?RQ_'_,_:__ (:=^ W_ $.%K_WQ-_\
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M?X?Y!_Q$3$?RQ_'_ #/VO_X:=^ W_0X6O_?$W_Q%'_#3OP&_Z'"U_P"^)O\
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M /AIWX#?]#A:_P#?$W_Q%'_#3OP&_P"APM?^^)O_ (BOQ0_LI_2C^RG]*/\
M5BGW?X?Y!_Q$3$?RQ_'_ #/VO_X:=^ W_0X6O_?$W_Q%'_#3OP&_Z'"U_P"^
M)O\ XBOQ0_LI_2C^RG]*/]6*?=_A_D'_ !$3$?RQ_'_,_:__ (:=^ W_ $.%
MK_WQ-_\ $4?\-._ ;_H<+7_OB;_XBOQ0_LI_2C^RG]*/]6*?=_A_D'_$1,1_
M+'\?\S]K_P#AIWX#?]#A:_\ ?$W_ ,11_P -._ ;_H<+7_OB;_XBOQ0_LI_2
MC^RG]*/]6*?=_A_D'_$1,1_+'\?\S]K_ /AIWX#?]#A:_P#?$W_Q%'_#3OP&
M_P"APM?^^)O_ (BOQ0_LI_2C^RG]*/\ 5BGW?X?Y!_Q$3$?RQ_'_ #/VO_X:
M=^ W_0X6O_?$W_Q%'_#3OP&_Z'"U_P"^)O\ XBOQ0_LI_2C^RG]*/]6*?=_A
M_D'_ !$3$?RQ_'_,_:__ (:=^ W_ $.%K_WQ-_\ $4?\-._ ;_H<+7_OB;_X
MBOQ0_LI_2C^RG]*/]6*?=_A_D'_$1,1_+'\?\S]K_P#AIWX#?]#A:_\ ?$W_
M ,11_P -._ ;_H<+7_OB;_XBOQ0_LI_2C^RG]*/]6*?=_A_D'_$1,1_+'\?\
MS]K_ /AIWX#?]#A:_P#?$W_Q%'_#3OP&_P"APM?^^)O_ (BOQ0_LI_2C^RG]
M*/\ 5BGW?X?Y!_Q$3$?RQ_'_ #/VO_X:=^ W_0X6O_?$W_Q%'_#3OP&_Z'"U
M_P"^)O\ XBOQ0_LI_2C^RG]*/]6*?=_A_D'_ !$3$?RQ_'_,_:__ (:=^ W_
M $.%K_WQ-_\ $4?\-._ ;_H<+7_OB;_XBOQ0_LI_2C^RG]*/]6*?=_A_D'_$
M1,1_+'\?\S]K_P#AIWX#?]#A:_\ ?$W_ ,11_P -._ ;_H<+7_OB;_XBOQ0_
MLI_2C^RG]*/]6*?=_A_D'_$1,1_+'\?\S]K_ /AIWX#?]#A:_P#?$W_Q%'_#
M3OP&_P"APM?^^)O_ (BOQ0_LI_2C^RG]*/\ 5BGW?X?Y!_Q$3$?RQ_'_ #/V
MO_X:=^ W_0X6O_?$W_Q%'_#3OP&_Z'"U_P"^)O\ XBOQ0_LI_2C^RG]*/]6*
M?=_A_D'_ !$3$?RQ_'_,_:__ (:=^ W_ $.%K_WQ-_\ $4?\-._ ;_H<+7_O
MB;_XBOQ0_LI_2C^RG]*/]6*?=_A_D'_$1,1_+'\?\S]K_P#AIWX#?]#A:_\
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MRG]*/]6*?=_A_D'_ !$3$?RQ_'_,_:__ (:=^ W_ $.%K_WQ-_\ $4?\-._
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M0_LI_2C^RG]*/]6*?=_A_D'_ !$3$?RQ_'_,_:__ (:=^ W_ $.%K_WQ-_\
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M?X?Y!_Q$3$?RQ_'_ #/VO_X:=^ W_0X6O_?$W_Q%'_#3OP&_Z'"U_P"^)O\
MXBOQ0_LI_2C^RG]*/]6*?=_A_D'_ !$3$?RQ_'_,_:__ (:=^ W_ $.%K_WQ
M-_\ $4?\-._ ;_H<+7_OB;_XBOQ0_LI_2C^RG]*/]6*?=_A_D'_$1,1_+'\?
M\S]K_P#AIWX#?]#A:_\ ?$W_ ,11_P -._ ;_H<+7_OB;_XBOQ0_LI_2C^RG
M]*/]6*?=_A_D'_$1,1_+'\?\S]K_ /AIWX#?]#A:_P#?$W_Q%'_#3OP&_P"A
MPM?^^)O_ (BOQ0_LI_2C^RG]*/\ 5BGW?X?Y!_Q$3$?RQ_'_ #/VO_X:=^ W
M_0X6O_?$W_Q%'_#3OP&_Z'"U_P"^)O\ XBOQ0_LI_2C^RG]*/]6*?=_A_D'_
M !$3$?RQ_'_,_:__ (:=^ W_ $.%K_WQ-_\ $4?\-._ ;_H<+7_OB;_XBOQ0
M_LI_2C^RG]*/]6*?=_A_D'_$1,1_+'\?\S]K_P#AIWX#?]#A:_\ ?$W_ ,11
M_P -._ ;_H<+7_OB;_XBOQ0_LI_2C^RG]*/]6*?=_A_D'_$1,1_+'\?\S]K_
M /AIWX#?]#A:_P#?$W_Q%'_#3OP&_P"APM?^^)O_ (BOQ0_LI_2C^RG]*/\
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MB;_XBOQ0_LI_2C^RG]*/]6*?=_A_D'_$1,1_+'\?\S]K_P#AIWX#?]#A:_\
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MRG]*/]6*?=_A_D'_ !$3$?RQ_'_,_:__ (:=^ W_ $.%K_WQ-_\ $4?\-._
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M4M?AE\.?C'\3_A9<1GPSJTC6*$;K&X)FM&'<>63\F>Y0JWO7ZF_!/]H/PO\
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MI?+\S[SPV?\ PKT_27_I+,#]H8_\3C2!_P!,)/\ T*OGL=*^@OVAO^0UI/\
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M]U^Y^AKTJ' ]3V:GB*JAY?YZH^?QGC+A_;NC@</*K;JM+^:5F[>MCZ8_;6B
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MZ:Z-K&F^(-*M=;T>=;FRO8UEBD7HRL,CZ'U!Y!X/-?.9SD-?!22J:I[-;?\
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M'_"/G^[1_P (^?[M?JU^US\._ ?ASP3H=]X6T"RTJXN+[:TEK D+-&87.TE
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M_P#"/G^[1_PCY_NU]V_M2Z=X,LOB2/#W@S2;32X-)MHX[@6D21*]Q)F0Y"
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MT.1VKGR;-J&-E*$59KN=W%W#&,RBG"M5DI1D[75]'TO?OT]#YL_X1\_W:/\
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M_NU^E7['?@7P?XHU#Q1%XJT:TU<016C0BZA281[FE#;0X.,\9^E</^U=X/\
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MY?PA^!7P\M?AGX<7Q+X7TZ^U.6T2>>6XM8Y)2TY,NUF9225#!?;&*^1/VO?
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MR^E']G+Z4?4D']LR[GDO_"/G^[1_PCY_NUZU_9R^E']G+Z4?4D']LR[GDO\
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M[VQCL8955@P#+.O 8<&OG?\ 95\:CPI\24T:Z?99>(D%JV>@G4[H#]2<H/\
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MT(Y'%9=?J5-QY5R['\U5^=3DJE^:^M][];^9^P'P!.?@[X6]K7'Y.PK\A=0
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M* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ*
MN0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0
M^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6
M/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2
MCRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CR
MQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ
M5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-
M10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10
M%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R
M'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'R
MQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ
M4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>
M6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/
M2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2I
MJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R'RQZ4>6/2IJ*
M N0^6/2CRQZ5-10%R'RQZ4>6/2IJ* N0^6/2CRQZ5-10%R QCZ5!)""*O4TB
MDT-297T(MI_B32=0BX>VNX)5/ND@/]*_5*OS*\,:<VI^*-(T^,9-Q=P)] 7&
M3^ K]-:_+>/TE4I+K9_H?TIX&RF\/B6]KQ_)W_0****_/C]V"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-I2,!MKL#@XX/2OSMHHS+)EB<,L-.;TMKWL+A_BV679C/,*5)._-[NME=W_
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MF$^9=28Z$DDJ#U;  VJ<?F@22<GDFN#A^G+$8JKF,E92TCZ+K^'YGM<=5Z>
MRW#9#"2<X>_4MTD[Z?*[^5A****^Q/R8**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\^7]_P#P _X@/4_Z"U_X!_\ ;'X<[QZT;QZU^XW_  BGA?\ Z ]G_P" \?\
MA1_PBGA?_H#V?_@/'_A1_P 1"C_SY?W_ / #_B ]3_H+7_@'_P!L?ASO'K1O
M'K7[C?\ "*>%_P#H#V?_ (#Q_P"%'_"*>%_^@/9_^ \?^%'_ !$*/_/E_?\
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M\^7]_P#P _X@/4_Z"U_X!_\ ;'X<[QZT;QZU^XW_  BGA?\ Z ]G_P" \?\
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M &Q^'.\>M&\>M?N-_P (IX7_ .@/9_\ @/'_ (4?\(IX7_Z ]G_X#Q_X4?\
M$0H_\^7]_P#P _X@/4_Z"U_X!_\ ;'X<[QZT;QZU^XW_  BGA?\ Z ]G_P"
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M &Q^'.\>M&\>M?N-_P (IX7_ .@/9_\ @/'_ (4?\(IX7_Z ]G_X#Q_X4?\
M$0H_\^7]_P#P _X@/4_Z"U_X!_\ ;'X<[QZT;QZU^XW_  BGA?\ Z ]G_P"
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M &Q^'.\>M&\>M?N-_P (IX7_ .@/9_\ @/'_ (4?\(IX7_Z ]G_X#Q_X4?\
M$0H_\^7]_P#P _X@/4_Z"U_X!_\ ;'X<[QZT;QZU^XW_  BGA?\ Z ]G_P"
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M &Q^'.\>M&\>M?N-_P (IX7_ .@/9_\ @/'_ (4?\(IX7_Z ]G_X#Q_X4?\
M$0H_\^7]_P#P _X@/4_Z"U_X!_\ ;'X<[QZT;QZU^XW_  BGA?\ Z ]G_P"
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MK;7-$N6M+ZS??%*H!*MC'0@@\'&",5^V7_"*>%_^@/9_^ \?^%'_  BGA?\
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MQZU^XW_"*>%_^@/9_P#@/'_A1_PBGA?_ * ]G_X#Q_X4?\1"C_SY?W_\ /\
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M ]G_ . \?^%'_"*>%_\ H#V?_@/'_A1_Q$*/_/E_?_P _P"(#U/^@M?^ ?\
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MK1O'K7[C?\(IX7_Z ]G_ . \?^%'_"*>%_\ H#V?_@/'_A1_Q$*/_/E_?_P
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M_A1_Q$*/_/E_?_P _P"(#U/^@M?^ ?\ VQ^'.\>M&\>M?N-_PBGA?_H#V?\
MX#Q_X4?\(IX7_P"@/9_^ \?^%'_$0H_\^7]__ #_ (@/4_Z"U_X!_P#;'X<[
MQZT;QZU^XW_"*>%_^@/9_P#@/'_A1_PBGA?_ * ]G_X#Q_X4?\1"C_SY?W_\
M /\ B ]3_H+7_@'_ -L?ASO'K1O'K7[C?\(IX7_Z ]G_ . \?^%'_"*>%_\
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MQZU^XW_"*>%_^@/9_P#@/'_A1_PBGA?_ * ]G_X#Q_X4?\1"C_SY?W_\ /\
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M ]G_ . \?^%'_"*>%_\ H#V?_@/'_A1_Q$*/_/E_?_P _P"(#U/^@M?^ ?\
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MY%'V2U_YXI_WR* /F^BOI#[):_\ /%/^^11]DM?^>*?]\B@#YOHKZ0^R6O\
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M[Y%'V2U_YXI_WR* /F^BOI#[):_\\4_[Y%'V2U_YXI_WR* /F^BOI#[):_\
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MY6]4GS3LS\F?BQX\3XE>-[WQ;%:-8QW20HL+.)"HBC5#\P ZD$].]?8O@/\
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MU.7PNXHQ>.>)PN,J*HZ35I*VJ=UTW6ET_,O4445\:?K84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'Y._'7_DK?B7_KX'_HM:^F?V//^0)X
MD_Z^(/\ T!J^;_C]:7-I\7/$(N(RGG2QRH2" R/&N"/4=OJ#7TQ^Q]:SIX:\
M07CH1#-=Q(C8X+1IE@#[;A7[!G\E_8D?2'Z'\H<$4Y+C*IIM.K_[<?8-%%%?
MCY_5X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M_]']Z-<_Y NH?]>\O_H!K\,Z_=#5HI)]*O8(5W220R*H'<E2 *_([_A0?QA_
MZ%:Z_P#'/_BJ_1> \72IQJ^TFE>V[MW/P'QLRS$XB>%>'I2G92O9-V^'L>1C
MI3AUKUP? /XPX_Y%>Z_\<_\ BJ</@)\8,_\ (KW7_CG_ ,57Z!_:F&M_%C]Z
M/PV/#68_] T__ )?Y'DE/'2O6_\ A0OQ@_Z%>Z_-/_BJ</@+\7\?\BO=?FG_
M ,54?VGAO^?L?O1:X;S'_H&G_P" 2_R/)Z>.E>L_\*'^+W_0L77_ (Y_\53A
M\"/B[C_D6+K_ ,<_^*H_M/#?\_8_>B_]6\Q_Z!I_^ 2_R/):E'6O5O\ A1'Q
M=_Z%BZ_\<_\ BJD'P)^+G_0LW/\ XY_\54/,\-_S]C]Z+7#F8_\ 0-/_ ,!E
M_D>44]>E>K_\**^+G_0LW/YI_P#%4H^!?Q;'_,LW/YI_\52_M/#?\_8_>BEP
MYF'_ $#S_P# 9?Y'E2TZO5A\#/BU_P!"S<_^.?\ Q5._X49\6O\ H6KG_P <
M_P#BJF69X;_G['[T6N'<P_Z!Y_\ @,O\CRH=*D'2O4Q\#?BR!_R+5S_XY_\
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M_F7KC_QS_P"*IW_"FOB?_P!"]<?^.?\ Q5#S##_\_%]Z+608_P#Z!Y_^ O\
MR/-J<M>E?\*;^)W_ $+]Q_XY_P#%4X?!SXFC_F7[C_QS_P"*J'F&'_Y^+[T6
ML@QW_/B?_@+_ ,CS6I!VKT?_ (4Y\3?^A?N/S3_&I!\'?B9Q_P 4_<?^.?\
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M)OB+_P! *?\ \=_^*H^OT/\ GXOO1<<CQO\ SXG_ . O_(\_IR]:]!_X5/\
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M_H 3_P#CG_Q5-9AA_P#GXOO0GD&._P"?$_\ P%_Y'F]%>D?\*B^)/_0 G_\
M'/\ XJC_ (5%\2?^@!/_ ..?_%5?]HX?_GXOO1/]@8__ *!Y_P#@+_R/-STJ
M.O2S\(?B3_T )_\ QS_XJF?\*A^)7_0 N/\ QS_XJC^T</\ \_%]Z)ED&/\
M^@>?_@+_ ,CS>BO2/^%0_$K_ * %Q_XY_P#%4?\ "H?B5_T +C_QS_XJC^T<
M/_S\7WHG^P,?_P! \_\ P%_Y'F]1UZ9_PJ'XE?\ 0 N/_'/_ (JF?\*@^)?_
M $ +C_QS_P"*JHYCA_\ GY'[T+_5_'_] \__  &7^1YM2'I7I7_"H/B7_P!
M"X_\<_\ BJ0_!_XEX_Y %Q_XY_\ %57]HX?_ )^1^]$/A_'_ /0//_P%_P"1
MYG17I7_"GOB9_P! "X_-/\:/^%/_ !+_ .@!<?\ CG_Q5']HX?\ Y^1^]"?#
M^/\ ^@>?_@,O\CS6BO2O^%/_ !+_ .@!<?\ CG_Q5'_"G_B7_P! "X_\<_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '$^+?ASX)\<F%O%6DQ7SP?<<EHY .N-\95L>Q./:NCT?1=)\/Z
M=#I.B6D=E9VXVI%$H51[^Y/<GDGD\UIT5O+$U)05-R?*ME?3[CCIY?AX595X
M4TIO>5E=^KW84445@=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% '__TOW\HHKX7^)_QX^(?A;Q[K'A_2+F!+.RE5(PT"LP!16Y
M)Z\FOD.,N-<'D6'AB<:I.,I<JY4F[V;ZM=CW^'N',1F=65'#M72OJ[:72[/N
M?=%%?FV/VE_BKG_C[MO_  '2G?\ #2WQ4_Y^[;_P'2OSC_B8?(?Y:G_@*_\
MDC[#_B$V:?S0^]__ ")^D5%?F[_PTO\ %3_G[MO_  '2E'[2WQ4/_+W;?^ Z
M4O\ B8C(?Y:G_@*_^2#_ (A)FG\T/O?^1^D-%?G!_P -*_%/_G[MO_ =*/\
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MK?\ [\)1_P -"?$K_GZM_P#OPE'_ !,CP_\ R5?_  %?_)!_Q![-?YH?>_\
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M "0_^(.YM_-#[W_\B?>E%?!G_"_?B/\ \_4'_?A*/^%^_$?_ )^H/^_"4O\
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MS\P?]^%H_P"%\_$3_GY@_P"_"T?\3(\/_P E7_P%?_)"_P"(09K_ #0^]_\
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MK\0O^?F#_OPM'_"]?B%_S\P?]^%I_P#$Q60?RU/_  %?_)!_Q"+-/YH?>_\
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M1/MJBOB7_A>/C_\ Y^(?^_*T?\+Q\?\ _/Q#_P!^5H7TALA_EJ?^ K_Y(/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?,'Q6^->M^&?$LGAOPW%$IL@GGRRKOW.ZAPJ@$
M  \YYSZ8Y]-^$_Q!D^(&@RW5["L%]9.(Y@F=C9&59<YQGG(R<$>F*^.?B[_R
M4C7?^NX_] 6O>?V9/^03KO\ UWA_]!:OY)X&\0LVQ7'%; UZ[=%RJQY>B4.;
MEMV:Y5=]=;G[UQ-PG@*'#5/$TZ:51*#YNK<K7O\ ?MT/I^BBBOZV/P4****
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MNNUZ)+]#[.APE@[65/\ /_,^M!^W+\1#_P P.R_[^3__ !5._P"&XOB)_P!
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M '\F_P#BJ/\ AN+XA_\ 0#LO^_DW_P 57S1_PCK_ -W]*/\ A'7_ +OZ4?\
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M =E_W\F_^*KYH_X1U_[OZ4?\(Z_]W]*/^(EYA_T$/\/\@_U.PG_/I?B?2_\
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MYH_X1U_[OZ4?\(Z_]W]*/^(EYA_T$/\ #_(/]3L)_P ^E^)]+_\ #<7Q#_Z
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M[^E'_".O_=_2C_B)>8?]!#_#_(/]3L)_SZ7XGTO_ ,-Q?$/_ * =E_W\F_\
MBJ/^&XOB'_T [+_OY-_\57S1_P (Z_\ =_2C_A'7_N_I1_Q$O,/^@A_A_D'^
MIV$_Y]+\3Z7_ .&XOB'_ - .R_[^3?\ Q5'_  W%\0_^@'9?]_)O_BJ^:/\
MA'7_ +OZ4?\ ".O_ '?TH_XB7F'_ $$/\/\ (/\ 4["?\^E^)]+_ /#<7Q#_
M .@'9?\ ?R;_ .*H_P"&XOB'_P! .R_[^3?_ !5?-'_".O\ W?TH_P"$=?\
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M/M=U_P ]G_[Z-'VNZ_Y[/_WT:KT4 6/M=U_SV?\ [Z-'VNZ_Y[/_ -]&J]%
M%C[7=?\ /9_^^C1]KNO^>S_]]&J]% %C[7=?\]G_ .^C1]KNO^>S_P#?1JO1
M0!8^UW7_ #V?_OHT?:[K_GL__?1JO10!8^UW7_/9_P#OHT?:[K_GL_\ WT:K
MT4 6/M=U_P ]G_[Z-'VNZ_Y[/_WT:KT4 6/M=U_SV?\ [Z-'VNZ_Y[/_ -]&
MJ]% %C[7=?\ /9_^^C1]KNO^>S_]]&J]% %C[7=?\]G_ .^C1]KNO^>S_P#?
M1JO10!8^UW7_ #V?_OHT?:[K_GL__?1JO10!8^UW7_/9_P#OHT?:[K_GL_\
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MHT?:[K_GL_\ WT:KT4 6/M=U_P ]G_[Z-'VNZ_Y[/_WT:KT4 6/M=U_SV?\
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MG_[Z-'VNZ_Y[/_WT:KT4 6/M=U_SV?\ [Z-'VNZ_Y[/_ -]&J]% %C[7=?\
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M/M=U_P ]G_[Z-'VNZ_Y[/_WT:KT4 6/M=U_SV?\ [Z-'VNZ_Y[/_ -]&J]%
M%C[7=?\ /9_^^C1]KNO^>S_]]&J]% %C[7=?\]G_ .^C1]KNO^>S_P#?1JO1
M0!8^UW7_ #V?_OHT?:[K_GL__?1JO10!8^UW7_/9_P#OHT?:[K_GL_\ WT:K
MT4 6/M=U_P ]G_[Z-'VNZ_Y[/_WT:KT4 6/M=U_SV?\ [Z-'VNZ_Y[/_ -]&
MJ]% %C[7=?\ /9_^^C1]KNO^>S_]]&J]% %C[7=?\]G_ .^C1]KNO^>S_P#?
M1JO10!8^UW7_ #V?_OHT?:[K_GL__?1JO10!8^UW7_/9_P#OHT?:[K_GL_\
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MH#_>C;\& -?$GQT\4?\ "1>.KBU@?=:Z0/LJ8Z%U.93]=WR_117U5\&?$_\
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M6?[M3_PK\C^+,;_&GZO\PHHHKM.8**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _.?XN_\
M)2-=_P"NX_\ 0%KWG]F3_D$Z[_UWA_\ 06KP;XN_\E(UW_KN/_0%KWG]F3_D
M$Z[_ -=X?_06K^%?#7_DX53_ *^5_P#V\_I[C+_DDX?X:7_MI]/T445_=1_,
M(4444 %?FW^WY\<KGPSH]K\(O#=P8K_68O.U!T.&CM"2JQ^QE(.?]D'U%?I)
M7\W'QT\;3?$?XP^*O%;N9(;J^ECM_:V@/E0CV^103[YKX+Q#SF6%P7LZ;M*>
MGRZ_HOF?4\)Y<J^)YY+2.OSZ?YGE,$!<XKJM/TTR$<57TRS,C#BO5M"T??M^
M6OY=S3,531^UX+!N;*6F: 7P=M=U9>&P0,K78:3HBA5RM=O:Z6J@?+7YGF7$
M+N[,^SP>4JU['G,/AL8^[5L>&U_NU]5_ FTCA^*6B,ZAE)N 01D<V\@KZ.^(
M/QMO/ _BJZ\.66BP3I;+&?,:0J6\Q%?H%XQG'4U]1D&1X7%93+-\?CO8P53V
M=O9N=WRJ2VDNC?3IOJ>+FN9UZ./67X7#>TDX<_Q*.EVNJ_JY^9'_  C:_P!V
MC_A&E_NU^I?A'Q+X,^-]A>Z5K^@Q17=N@+*V'.UN-\<H564@_0C/4\U\2^(_
M#D>@>(M2T9'\P6%S+"KGJPC<J"?J!7)Q=P^\NPE#,<)BE7P]6Z4DG%W6Z<7J
MO^!TTOT9!FWUNO5PE>BZ=6%FTVFK/JFMSP[_ (1I?[M'_"-+_=K]*?VF;:VE
M\):.R1JI:\R"% ./*:OBW["E<''V5U,CS*67NMSV2=[6W5]KO\SIX6QT<SP<
M<6H<MVU:]]G;>R/*/^$:7^[1_P (TO\ =K]*/%,%LW[-=J/+7>;2Q4-@9R)8
M^_T%:'ANUMOB/\!9-%BC5KVUMC:X &?.M,-",]?F 3/U-?;Q\.:L\4L%3Q5Z
MDL.J\5R_%>_N?%OIOKZ:'S;XOA&A]8G0M!5?9-\VVWO;;>7XGYC_ /"-+_=H
M_P"$:7^[7J_V%*^C?V;/":7GBR\\031AH=,@*+D<>;/\H_) WYBOSCA+#8C-
M\RHY=2E9S=KVO9;MVTO9)O<^OSZM2P&#J8NHKJ*V[O9+YL^&_P#A&E_NT?\
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MDFN?[7,W>_V>O3JQW&=?"X66)Q6!E"THQ2<K7NI.Z]WIR_B?DU_PC2_W:/\
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M.&G4^&#LW\VY+;K;1=S\PK\<2K59PRO"2K1AO);?*R?RZOL?E#_PC2_W:/\
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MU?["E'V%*/[;GW#^SHGE'_"-+_=H_P"$:7^[7J_V%*/L*4?VW/N']G1/*/\
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MT_A'Q7J.A$'RX)"82>\+_,ASW^4@'WS7V7TD.%N2O1S>FM)^Y+U6L7\U=?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?G/\7?\ DI&N_P#7<?\ H"U[S^S)
M_P @G7?^N\/_ *"U>#?%W_DI&N_]=Q_Z M>\_LR?\@G7?^N\/_H+5_"OAK_R
M<*I_U\K_ /MY_3W&7_))P_PTO_;3Z?HHHK^ZC^80HHHH R=?NI;'0M1O8/\
M6V]M-(F/[R(2/U%?R_VJ&23<QR2>IK^I&:&.XADMYEW1RJ58>H88(K^975-
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ME;=I QC<V:^K_@3_ ,DRTP>CW'_HYZ^%M4US6=<D2;6KZ>^DB&U&GD:0J.N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&%4 8"J.P X%8M%>=Q/Q]C\UI0PU51A1@[QITXJ$$^]EN_5NVMMV=>2\+X;
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ME.78C*Z$(2I5K\W,I.UX\KM:2Z=T]B,[X-PN.Q='&U)2C.G:W*TMG=7NGU]
MHHHK\[/K0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** )(8);J>.VMU+RRL%4#J2> *^K-%TR/1]*M=-CY$" $CNW5C^)
M)->>^ /"$ECC7-43;.P_<QGJ@/5C[D=!V'Z>K5_=GT?/#NKEF$GF>,CRU:R2
M2>\8;Z]G)V=NB2ZW1_,GBMQ;#&UXX+#N\*>[Z.6WX;>K84445_1A^1!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M $'K_P  ?_R0?\1NI_\ 0,__  +_ .U/RVW>]&[WK]2?^$?T#_H&VW_?E/\
M"C_A'] _Z!MM_P!^4_PH_P")6:W_ $'K_P  ?_R0?\1NI_\ 0,__  +_ .U/
MRVW>]&[WK]2?^$?T#_H&VW_?E/\ "C_A'] _Z!MM_P!^4_PH_P")6:W_ $'K
M_P  ?_R0?\1NI_\ 0,__  +_ .U/RVW>]&[WK]2?^$?T#_H&VW_?E/\ "C_A
M'] _Z!MM_P!^4_PH_P")6:W_ $'K_P  ?_R0?\1NI_\ 0,__  +_ .U/RVW>
M]&[WK]2?^$?T#_H&VW_?E/\ "C_A'] _Z!MM_P!^4_PH_P")6:W_ $'K_P
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MWHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\
MD@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#
M;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (
M_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9
M_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K
M-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_OR
MG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[
MWHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\
MD@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#
M;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (
M_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9
M_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K
M-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_OR
MG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[
MWHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\
MD@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#
M;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (
M_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9
M_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K
M-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_OR
MG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[
MWHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\
MD@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#
M;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (
M_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9
M_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K
M-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_OR
MG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[
MWHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\
MD@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#
M;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (
M_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9
M_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K
M-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_OR
MG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[
MWHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\
MD@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#
M;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (
M_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9
M_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K
M-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_OR
MG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[
MWHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\
MD@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#
M;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (
M_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9
M_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K
M-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_OR
MG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[
MWHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\
MD@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#
M;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (
M_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9
M_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K
M-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_OR
MG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[
MWHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\
MD@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#
M;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (
M_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9
M_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K
M-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[WHW>]?J3_P (_H'_ $#;;_OR
MG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\ D@_XC=3_ .@9_P#@7_VI^6V[
MWHW>]?J3_P (_H'_ $#;;_ORG^%'_"/Z!_T#;;_ORG^%'_$K-;_H/7_@#_\
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M:_\ /%/^^11]DM?^>*?]\B@#YOHKZ0^R6O\ SQ3_ +Y%'V2U_P">*?\ ?(H
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MI#[):_\ /%/^^11]DM?^>*?]\B@#YOHKZ0^R6O\ SQ3_ +Y%'V2U_P">*?\
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M7_GBG_?(H ^;Z*^D/LEK_P \4_[Y%'V2U_YXI_WR* /F^BOI#[):_P#/%/\
MOD4?9+7_ )XI_P!\B@#YOHKZ0^R6O_/%/^^11]DM?^>*?]\B@#YOHKZ0^R6O
M_/%/^^11]DM?^>*?]\B@#YOHKZ0^R6O_ #Q3_OD4?9+7_GBG_?(H ^;Z*^D/
MLEK_ ,\4_P"^11]DM?\ GBG_ 'R* /F^BOI#[):_\\4_[Y%'V2U_YXI_WR*
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M#"34F^S1_P!T8+G^8'^>*]/L-/L],MQ;648C0=?4GU)[FKM% !1110 4444
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M /PRYX;_ .@S=_\ ?$?^% _9=\.#_F,W?_?,?^%?4%%'_$&^&?\ H"C]\O\
MY(/^(AYS_P!!#^Y?Y'S!_P ,O>'/^@S=_P#?,?\ A2C]E_PX/^8S=_\ ?,?^
M%?3U%'_$&N&?^@*/WR_^2#_B(><_]!#^Y?Y'S%_PS!X<_P"@S=_]\Q_X4?\
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MD_E5NBBOT2G34(J,=D?)3FY-R>["BBBK)"BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _]']_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH __2_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /_T_W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#_]3]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>picture1.jpg
<TEXT>
begin 644 picture1.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      !(     0   $@    !  .@ 0 #     0 !  "@ @ $     0   4>@
M P $     0   #D     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_W0 $ !7_V@ , P$
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MW6$2/4/$&C6-[<B,83SIX5>3:.REB<#L*_C=K^O#]DW_ )-C^%G_ &+>F?\
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M6_AA_P"P=.R0OEX:X<>KR'.T^R8QTR>M9?[17Q!N?&'CJYT>WE/]EZ$[6T2
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M\>>$K2#4-<T>>&TGB243*N]$#@';(5SL8="K8.:^Y_&/_);M"^D7\Z^D)/\
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M^(__ "*\O_76+_T,5W$?^K7Z"NZOFSGA8T.7ROZ'#0R>,,5+$<WR]1]?GO\
M\%-? OBGQU^S'.OA2PEU*70]5M-2N8H5+R"UBCFBD=47)8)YH9L=%!8\ U^A
M%%>7AJ[I5(U%T/5Q5!5:<J;ZG\M7_!/GX>>*_&_[2F@7VA6,DMAHD5]-?76T
M^1;I+9S0Q[WQ@%Y'557J>3C )']"G_"I]=_Y^;?\V_\ B:]%\ ?\>.I?]?\
:<?S%=Y7H9CFDJU3F2MT/.RS*HT*7+>_4_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
